
===== DOI 10.1016/S1470-2045(25)00726-0 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">41449152</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1474-5488</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>1</Issue><PubDate><Year>2026</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The Lancet. Oncology</Title><ISOAbbreviation>Lancet Oncol</ISOAbbreviation></Journal><ArticleTitle>De-escalation of adjuvant radiotherapy in HPV-associated oropharyngeal cancer.</ArticleTitle><Pagination><StartPage>e1</StartPage><EndPage>e2</EndPage><MedlinePgn>e1-e2</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1470-2045(25)00726-0</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1470-2045(25)00726-0</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Petkar</LastName><ForeName>Imran</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Guy's and St Thomas' NHS Foundation Trust, London, UK; King's College London, London, UK. Electronic address: i.petkar@nhs.net.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Oncol</MedlineTA><NlmUniqueID>100957246</NlmUniqueID><ISSNLinking>1470-2045</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>I declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>26</Day><Hour>0</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>26</Day><Hour>0</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>25</Day><Hour>22</Hour><Minute>55</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41449152</ArticleId><ArticleId IdType="doi">10.1016/S1470-2045(25)00726-0</ArticleId><ArticleId IdType="pii">S1470-2045(25)00726-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1016/S1470-2045(25)00725-9 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">41449154</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1474-5488</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>1</Issue><PubDate><Year>2026</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The Lancet. Oncology</Title><ISOAbbreviation>Lancet Oncol</ISOAbbreviation></Journal><ArticleTitle>Retraction and republication-De-escalation of adjuvant radiotherapy in HPV-associated oropharyngeal cancer.</ArticleTitle><Pagination><StartPage>e2</StartPage><MedlinePgn>e2</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1470-2045(25)00725-9</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1470-2045(25)00725-9</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>The Lancet Oncology Editors</LastName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016425">Published Erratum</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Oncol</MedlineTA><NlmUniqueID>100957246</NlmUniqueID><ISSNLinking>1470-2045</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumFor"><RefSource>Lancet Oncol. 2025 Sep;26(9):1127-1129. doi: 10.1016/S1470-2045(25)00408-5.</RefSource><PMID Version="1">40907508</PMID></CommentsCorrections></CommentsCorrectionsList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>26</Day><Hour>0</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>26</Day><Hour>0</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>25</Day><Hour>22</Hour><Minute>55</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41449154</ArticleId><ArticleId IdType="doi">10.1016/S1470-2045(25)00725-9</ArticleId><ArticleId IdType="pii">S1470-2045(25)00725-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1016/S1470-2045(25)00618-7 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">41449162</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1474-5488</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>1</Issue><PubDate><Year>2026</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The Lancet. Oncology</Title><ISOAbbreviation>Lancet Oncol</ISOAbbreviation></Journal><ArticleTitle>Tumour genetics and thyroid cancer staging.</ArticleTitle><Pagination><StartPage>e7</StartPage><EndPage>e8</EndPage><MedlinePgn>e7-e8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1470-2045(25)00618-7</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1470-2045(25)00618-7</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xing</LastName><ForeName>Mingzhao</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong 518055, China; Division of Endocrinology, Diabetes and Metabolism, Department of Medicine. The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. Electronic address: mxing1@jhmi.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Oncol</MedlineTA><NlmUniqueID>100957246</NlmUniqueID><ISSNLinking>1470-2045</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>I received royalties through Johns Hopkins University for a licensed US patent related to BRAF mutation in thyroid cancer.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>10</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>10</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>26</Day><Hour>0</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>26</Day><Hour>0</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>25</Day><Hour>22</Hour><Minute>55</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41449162</ArticleId><ArticleId IdType="doi">10.1016/S1470-2045(25)00618-7</ArticleId><ArticleId IdType="pii">S1470-2045(25)00618-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1016/S1470-2045(25)00563-7 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">41449163</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1474-5488</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>1</Issue><PubDate><Year>2026</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The Lancet. Oncology</Title><ISOAbbreviation>Lancet Oncol</ISOAbbreviation></Journal><ArticleTitle>Correction to Lancet Oncol 2025; 26: 1227-39.</ArticleTitle><Pagination><StartPage>e9</StartPage><MedlinePgn>e9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1470-2045(25)00563-7</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1470-2045(25)00563-7</ELocationID><Language>eng</Language><PublicationTypeList><PublicationType UI="D016425">Published Erratum</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Oncol</MedlineTA><NlmUniqueID>100957246</NlmUniqueID><ISSNLinking>1470-2045</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumFor"><RefSource>Lancet Oncol. 2025 Sep;26(9):1227-1239. doi: 10.1016/S1470-2045(25)00324-9.</RefSource><PMID Version="1">40907518</PMID></CommentsCorrections></CommentsCorrectionsList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>26</Day><Hour>0</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>26</Day><Hour>0</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>25</Day><Hour>22</Hour><Minute>55</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41449163</ArticleId><ArticleId IdType="doi">10.1016/S1470-2045(25)00563-7</ArticleId><ArticleId IdType="pii">S1470-2045(25)00563-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1016/S1470-2045(25)00715-6 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">41449165</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1474-5488</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>1</Issue><PubDate><Year>2026</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The Lancet. Oncology</Title><ISOAbbreviation>Lancet Oncol</ISOAbbreviation></Journal><ArticleTitle>Correction to Lancet Oncol 2025; 26: e477-87.</ArticleTitle><Pagination><StartPage>e9</StartPage><MedlinePgn>e9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1470-2045(25)00715-6</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1470-2045(25)00715-6</ELocationID><Language>eng</Language><PublicationTypeList><PublicationType UI="D016425">Published Erratum</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Oncol</MedlineTA><NlmUniqueID>100957246</NlmUniqueID><ISSNLinking>1470-2045</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumFor"><RefSource>Lancet Oncol. 2025 Sep;26(9):e477-e487. doi: 10.1016/S1470-2045(25)00326-2.</RefSource><PMID Version="1">40907526</PMID></CommentsCorrections></CommentsCorrectionsList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>26</Day><Hour>0</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>26</Day><Hour>0</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>25</Day><Hour>22</Hour><Minute>55</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41449165</ArticleId><ArticleId IdType="doi">10.1016/S1470-2045(25)00715-6</ArticleId><ArticleId IdType="pii">S1470-2045(25)00715-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1016/S1470-2045(25)00712-0 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41319667</PMID><DateRevised><Year>2025</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-5488</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Nov</Month><Day>27</Day></PubDate></JournalIssue><Title>The Lancet. Oncology</Title><ISOAbbreviation>Lancet Oncol</ISOAbbreviation></Journal><ArticleTitle>Gavi hits HPV vaccine milestone early but concerns surround future funding.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S1470-2045(25)00712-0</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1470-2045(25)00712-0</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kirby</LastName><ForeName>Tony</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>11</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Oncol</MedlineTA><NlmUniqueID>100957246</NlmUniqueID><ISSNLinking>1470-2045</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>11</Month><Day>30</Day><Hour>18</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41319667</ArticleId><ArticleId IdType="doi">10.1016/S1470-2045(25)00712-0</ArticleId><ArticleId IdType="pii">S1470-2045(25)00712-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1016/S1470-2045(25)00535-2 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">41449157</PMID><DateCompleted><Year>2025</Year><Month>12</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>12</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1474-5488</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>1</Issue><PubDate><Year>2026</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The Lancet. Oncology</Title><ISOAbbreviation>Lancet Oncol</ISOAbbreviation></Journal><ArticleTitle>International consensus recommendations and alignment of terminology for the histopathological diagnosis of extranodal extension in head and neck squamous cell carcinoma: an HN-CLEAR initiative.</ArticleTitle><Pagination><StartPage>e33</StartPage><EndPage>e44</EndPage><MedlinePgn>e33-e44</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1470-2045(25)00535-2</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1470-2045(25)00535-2</ELocationID><Abstract><AbstractText>Histopathologically detected extranodal extension leads to upstaging and treatment escalation in head and neck squamous cell carcinoma. There is considerable variation in the prevalence of histopathologically detected extranodal extension in comparable studies. The Head and Neck Cancer International Group, which includes 23 organisations managing patients with head and neck cancer, identified several challenges in evaluating histopathologically detected extranodal extension. Thus, the Head and Neck Consensus Language for Ease and Reproducibility (HN-CLEAR) and its global stakeholders prioritised developing diagnostic criteria and uniform terminology for histopathologically detected extranodal extension. The histopathologically detected extranodal extension working group established by WHO, International Collaboration on Cancer Reporting, American Joint Committee on Cancer, Union for International Cancer Control, North American Society of Head and Neck Pathology, and American Academy of Oral and Maxillofacial Pathology committees undertook consensus deliberations using scanned whole slides and a PRISMA literature review-based scoping questionnaire. The guidelines were tested by 30 additional pathologists across six continents and strengthened with prescriptive diagnostic criteria and unifying terminology based on the inter-rater concordance analyses. This Review generates practically useful consensus diagnostic recommendations and aligned terminology for addressing the gaps in the histopathologically detected extranodal extension literature. The recommendations can be used globally and cater to all levels of medical resources, practices, and experiences, thus ensuring equitable patient care.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Ruta</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, NSW Health Pathology, Sydney, NSW, Australia; Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fielder</LastName><ForeName>Timothy</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, NSW Health Pathology, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bal</LastName><ForeName>Munita</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Head-Neck and Gastrointestinal Pathology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiosea</LastName><ForeName>Simion I</ForeName><Initials>SI</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Pittsburgh Medical Center, Presbyterian Hospital, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dahlstrom</LastName><ForeName>Jane E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Anatomical Pathology, ACT Pathology, Canberra Health Services, Canberra, ACT, Australia; School of Medicine and Psychology, College of Science and Medicine, Australian National University, Canberra, ACT, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kakkar</LastName><ForeName>Aanchal</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pathology, All India Institute of Medical Sciences, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiss</LastName><ForeName>Katalin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laco</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The Fingerland Department of Pathology, Charles University Faculty of Medicine in Hradec Kr&#xe1;lov&#xe9; and University Hospital Hradec Kr&#xe1;lov&#xe9;, Hradec Kr&#xe1;lov&#xe9;, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mittal</LastName><ForeName>Neha</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pathology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pasricha</LastName><ForeName>Sunil</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Oncopathology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Samra</LastName><ForeName>Spinder</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Tissue Pathology and Diagnostic Oncology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Sydney, NSW, Australia; Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zidar</LastName><ForeName>Nina</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Institute of Pathology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bullock</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology, Faculty of Medicine, Dalhousie University, Halifax, NS, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chernock</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pathology and Otolaryngology Head and Neck Surgery, Washington University School of Medicine, Saint Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faquin</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Anatomic and Molecular Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richardson</LastName><ForeName>Mary S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hayes</LastName><ForeName>D Neil</ForeName><Initials>DN</Initials><AffiliationInfo><Affiliation>Oncology and Haematology, College of Medicine, University of Tennessee Health Science Center, Memphis, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Shao Hui</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Jean</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Mathematics and Statistics, University of Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alsugair</LastName><ForeName>Ziyad</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Pathology, Institut de Pathologie Multisite, CHU Sud, Hospices Civils de Lyon, Pierre-B&#xe9;nite, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benzerdjeb</LastName><ForeName>Nazim</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pathology, Institut de Pathologie Multisite, CHU Sud, Hospices Civils de Lyon, Pierre-B&#xe9;nite, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chou</LastName><ForeName>Shaun</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Tissue Pathology and Diagnostic Oncology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Anatomical Pathology, Pathology Queensland, Princess Alexandra Hospital, Woolloongabba, Qld Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dimnik</LastName><ForeName>Katarina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute of Pathology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dutta</LastName><ForeName>Rimlee</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pathology, All India Institute of Medical Sciences, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gomez</LastName><ForeName>Ricardo Santiago</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Department of Oral and Maxillofacial Pathology, Federal University of Minas Gerais, Faculty of Medical Science of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hernandez-Prera</LastName><ForeName>Juan C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Pathology, Moffitt Cancer Center, Tampa, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamboj</LastName><ForeName>Meenakshi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Histopathology and Cytopathology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agander</LastName><ForeName>Tina Klitm&#xf8;ller</ForeName><Initials>TK</Initials><AffiliationInfo><Affiliation>Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Ankur</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pathology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jenny T H</ForeName><Initials>JTH</Initials><AffiliationInfo><Affiliation>Department of Pathology, Sarawak General Hospital, Kuching, Sarawak, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bell</LastName><ForeName>Diana M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Head and Neck Division of Anatomic Pathology, University of Pittsburgh Medical Center, Presbyterian Hospital, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagao</LastName><ForeName>Toshitaka</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Anatomic Pathology, Tokyo Medical University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakaguro</LastName><ForeName>Masato</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Onyuma</LastName><ForeName>Timothy</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pathology, Kenyatta National Hospital, Nairobi, Kenya.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Ji Hyun</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Pathology, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Jin Woo</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Department of Pathology, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patil</LastName><ForeName>Asawari</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pathology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Podhola</LastName><ForeName>Miroslav</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>The Fingerland Department of Pathology, Charles University Faculty of Medicine in Hradec Kr&#xe1;lov&#xe9; and University Hospital Hradec Kr&#xe1;lov&#xe9;, Hradec Kr&#xe1;lov&#xe9;, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rane</LastName><ForeName>Swapnil</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pathology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rasmussen</LastName><ForeName>Sean A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Pathology, Faculty of Medicine, Dalhousie University, Halifax, NS, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rozko&#x161;</LastName><ForeName>Tom&#xe1;&#x161;</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>The Fingerland Department of Pathology, Charles University Faculty of Medicine in Hradec Kr&#xe1;lov&#xe9; and University Hospital Hradec Kr&#xe1;lov&#xe9;, Hradec Kr&#xe1;lov&#xe9;, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Prarthna</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Pathology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Divakar</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Sir H.N. Reliance Foundation Hospital and Research Centre, Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stefi</LastName><ForeName>Stefi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Tissue Pathology and Diagnostic Oncology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stubsgaard</LastName><ForeName>Antje</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tetzner</LastName><ForeName>Ana Cristina</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Oral and Maxillofacial Pathology, Federal University of Minas Gerais, Faculty of Medical Science of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wenig</LastName><ForeName>Bruce M</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Department of Anatomic Pathology, Moffitt Cancer Center, Tampa, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Westra</LastName><ForeName>William H</ForeName><Initials>WH</Initials><AffiliationInfo><Affiliation>Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wise</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Anatomical Pathology, ACT Pathology, Canberra Health Services, Canberra, ACT, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoon</LastName><ForeName>Sun Och</ForeName><Initials>SO</Initials><AffiliationInfo><Affiliation>Department of Pathology, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea. Electronic address: soyoon@yuhs.ac.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>HN-CLEAR steering committee and clinical advisory group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Oncol</MedlineTA><NlmUniqueID>100957246</NlmUniqueID><ISSNLinking>1470-2045</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009626" MajorTopicYN="Y">Terminology as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077195" MajorTopicYN="Y">Squamous Cell Carcinoma of Head and Neck</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D032921" MajorTopicYN="N">Consensus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006258" MajorTopicYN="Y">Head and Neck Neoplasms</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000079822" MajorTopicYN="Y">Extranodal Extension</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of interests The authors declare no competing interests.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Bishop</LastName><ForeName>Justin A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>UT Southwestern Medical Center, Dallas, TX, USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Hunter</LastName><ForeName>Keith D</ForeName><Initials>KD</Initials><AffiliationInfo><Affiliation>Liverpool Head and Neck Centre, University of Liverpool, Liverpool, UK.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Magliocca</LastName><ForeName>Kelly</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Seethala</LastName><ForeName>Raja R</ForeName><Initials>RR</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Thompson</LastName><ForeName>Lester D R</ForeName><Initials>LDR</Initials><AffiliationInfo><Affiliation>Head and Neck Pathology Consultations, Woodland Hills, California, USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Weinreb</LastName><ForeName>Ilan</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Anatomic Pathology, University Health Network and University of Toronto Laboratory Medicine Program, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Angelos</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Endocrine Surgery, University of Chicago, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Beadle</LastName><ForeName>Beth</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Radiation Oncology, Stanford University, Palo Alto, California, USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Bell</LastName><ForeName>R Bryan</ForeName><Initials>RB</Initials><AffiliationInfo><Affiliation>Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, Oregon, USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Clark</LastName><ForeName>Jonathan R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Head and neck Surgery, Chris O'Brien Lifehouse, Royal Prince Alfred Institute of Academic Surgery, The University of Sydney, Sydney, NSW Australia.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Ferris</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>University of Pittsburgh Medical Center, Head and Neck Surgery, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Ladwa</LastName><ForeName>Rahul</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Medical Oncology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Lewis</LastName><ForeName>James S</ForeName><Initials>JS</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Pathology, Mayo Clinic, Phoenix, Arizona, USA.</Affiliation></AffiliationInfo></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>26</Day><Hour>0</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>26</Day><Hour>0</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>25</Day><Hour>22</Hour><Minute>55</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41449157</ArticleId><ArticleId IdType="doi">10.1016/S1470-2045(25)00535-2</ArticleId><ArticleId IdType="pii">S1470-2045(25)00535-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1001/jama.2025.19634 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41231448</PMID><DateRevised><Year>2025</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Nov</Month><Day>13</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Room-Temperature Water.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1001/jama.2025.19634</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Starks</LastName><ForeName>Philip T</ForeName><Initials>PT</Initials><AffiliationInfo><Affiliation>Biology Department, Tufts University, Medford, Massachusetts.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>11</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><OtherAbstract Type="plain-language-summary" Language="eng"><AbstractText>In this narrative medicine essay, a biology professor details undergoing radiation and chemotherapy to treat tongue cancer and how he manages the pain, especially when he swallows.</AbstractText></OtherAbstract></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>11</Month><Day>13</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>11</Month><Day>13</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>11</Month><Day>13</Day><Hour>11</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41231448</ArticleId><ArticleId IdType="doi">10.1001/jama.2025.19634</ArticleId><ArticleId IdType="pii">2841345</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1001/jamaoncol.2025.4092 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41100106</PMID><DateRevised><Year>2025</Year><Month>10</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2374-2445</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Oct</Month><Day>16</Day></PubDate></JournalIssue><Title>JAMA oncology</Title><ISOAbbreviation>JAMA Oncol</ISOAbbreviation></Journal><ArticleTitle>Unexpected Results of Induction Chemotherapy vs Adjuvant Chemotherapy.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaoncol.2025.4092</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chua</LastName><ForeName>Melvin L K</ForeName><Initials>MLK</Initials><AffiliationInfo><Affiliation>Department of Head and Neck and Thoracic Cancers, Division of Radiation Oncology and Division of Medical Sciences, National Cancer Centre Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Oncology Academic Programme, Duke-NUS Medical School, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Darren W T</ForeName><Initials>DWT</Initials><AffiliationInfo><Affiliation>Department of Head and Neck and Thoracic Cancers, Division of Medical Oncology, National Cancer Centre Singapore, Singapore.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>10</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Oncol</MedlineTA><NlmUniqueID>101652861</NlmUniqueID><ISSNLinking>2374-2437</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>10</Month><Day>16</Day><Hour>12</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>10</Month><Day>16</Day><Hour>12</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>10</Month><Day>16</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41100106</ArticleId><ArticleId IdType="doi">10.1001/jamaoncol.2025.4092</ArticleId><ArticleId IdType="pii">2840005</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1001/jamaoncol.2025.5606 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41481305</PMID><DateRevised><Year>2026</Year><Month>01</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2374-2445</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2026</Year><Month>Jan</Month><Day>02</Day></PubDate></JournalIssue><Title>JAMA oncology</Title><ISOAbbreviation>JAMA Oncol</ISOAbbreviation></Journal><ArticleTitle>Thyroid Nodule Molecular Classifiers-Reclaiming Deliberation in an Era of Automation.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaoncol.2025.5606</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brito</LastName><ForeName>Juan P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Care and AI Laboratory, Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Department of Medicine, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toro-Tobon</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Care and AI Laboratory, Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Department of Medicine, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montori</LastName><ForeName>Victor M</ForeName><Initials>VM</Initials><AffiliationInfo><Affiliation>Care and AI Laboratory, Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Department of Medicine, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2026</Year><Month>01</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Oncol</MedlineTA><NlmUniqueID>101652861</NlmUniqueID><ISSNLinking>2374-2437</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><OtherAbstract Type="plain-language-summary" Language="eng"><AbstractText>This Viewpoint discusses the practice of molecular testing for the classification of thyroid nodules and explores related questions regarding automation, transparency, and clinical reasoning.</AbstractText></OtherAbstract></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2026</Year><Month>1</Month><Day>2</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2026</Year><Month>1</Month><Day>2</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2026</Year><Month>1</Month><Day>2</Day><Hour>11</Hour><Minute>34</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41481305</ArticleId><ArticleId IdType="doi">10.1001/jamaoncol.2025.5606</ArticleId><ArticleId IdType="pii">2843205</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1001/jamaoto.2025.4108 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">41165717</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-619X</ISSN><JournalIssue CitedMedium="Internet"><Volume>151</Volume><Issue>12</Issue><PubDate><Year>2025</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA otolaryngology-- head &amp; neck surgery</Title><ISOAbbreviation>JAMA Otolaryngol Head Neck Surg</ISOAbbreviation></Journal><ArticleTitle>Mind, Machine, and Medicine-Challenges and Opportunities.</ArticleTitle><Pagination><StartPage>1111</StartPage><EndPage>1112</EndPage><MedlinePgn>1111-1112</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaoto.2025.4108</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lydiatt</LastName><ForeName>William Bill M</ForeName><Initials>WBM</Initials><AffiliationInfo><Affiliation>Creighton University, Omaha, Nebraska.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Otolaryngol Head Neck Surg</MedlineTA><NlmUniqueID>101589542</NlmUniqueID><ISSNLinking>2168-6181</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><OtherAbstract Type="plain-language-summary" Language="eng"><AbstractText>This Viewpoint summarizes the presidential address of the president of the American Head and Neck Society.</AbstractText></OtherAbstract></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>10</Month><Day>30</Day><Hour>12</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>10</Month><Day>30</Day><Hour>12</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>10</Month><Day>30</Day><Hour>11</Hour><Minute>34</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41165717</ArticleId><ArticleId IdType="doi">10.1001/jamaoto.2025.4108</ArticleId><ArticleId IdType="pii">2840474</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1001/jamaoto.2025.3563 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">41129177</PMID><DateCompleted><Year>2025</Year><Month>12</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>12</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-619X</ISSN><JournalIssue CitedMedium="Internet"><Volume>151</Volume><Issue>12</Issue><PubDate><Year>2025</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA otolaryngology-- head &amp; neck surgery</Title><ISOAbbreviation>JAMA Otolaryngol Head Neck Surg</ISOAbbreviation></Journal><ArticleTitle>Multiomic Selection of Cancer-Testis Antigens as Precision Immuno-oncologic Targets in Head and Neck Cancer.</ArticleTitle><Pagination><StartPage>1196</StartPage><EndPage>1207</EndPage><MedlinePgn>1196-1207</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaoto.2025.3563</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="UNASSIGNED">Head and neck squamous cell carcinoma (HNSCC) is an aggressive malignant neoplasm with an increasing need for precision therapeutics. Cancer-testis antigens (CTAs) represent promising targets given their aberrant tumor expression and otherwise localized expression to immune-privileged tissues with no (testis-restricted) or minimal (testis-selective) expression in other human body sites. Despite their potential, limited studies rigorously evaluate CTAs as therapeutic targets in HNSCC.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To orthogonally validate and present specific CTAs as potential precision immuno-oncologic targets in both previously untreated (de novo) and recurrent HNSCC tumors.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="UNASSIGNED">This was a cross-sectional study conducting multiomic analyses on a single academic tertiary care center's tumor registry from 2018 to 2023, with validation using publicly available transcriptomic datasets. A total of 33 tumor samples from patients with HNSCC, including both de novo and radiation-recurrent tumors, were analyzed. Data were analyzed from August to December 2024.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="UNASSIGNED">The primary outcome was the identification and rigorous validation of specific CTAs with tumor-specific expression in HNSCC.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">This study analyzed 33 HNSCC institutional tumor specimens, including 25 de novo and 8 radiation-recurrent tumors. Of 33 included patients, 25 (76%) were male, 8 (24%) were female, and the median (range) age was 61 (29-87) years. Tumor subsites included the oral cavity (24 [73%]), larynx (7 [21%]), and oropharynx (2 [6%]). Tumors were primarily T4a (23 [70%]), with nodal involvement in 16 (48%). Initial analysis of bulk RNA-sequenced institutional data and single-cell RNA-sequenced external data identified several CTAs (DKKL1, SPANXB1, SPANXD, and ACTL8) upregulated in recurrent tumors. An expanded reanalysis revealed that CTAs were expressed across HNSCCs, including robust expression not only in radiation-recurrent disease but also in de novo tumors. Immunohistochemistry was performed on ACTL8 to confirm transcriptional level findings at the protein level, which showed moderate focal cytoplasmic staining in tumor tissue. To refine the tumor-specific CTA list, an exclusionary analysis using single-cell RNA-sequenced data from normal oral mucosa was conducted, removing any CTAs with any expression in normal tissue. This resulted in a final list of 23 testis-restricted and 44 testis-selective CTAs specific to HNSCC, of which 14 CTAs overlapped across all transcriptomic datasets. Finally, using CopyKAT, CTAs were specifically enriched in malignant epithelial populations compared with benign populations within the same patients with HNSCC.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="UNASSIGNED">In this study, a set of 23 testis-restricted and 44 testis-selective CTAs were orthogonally validated in multiple tumor datasets. Of these, a core set of 14 CTAs were consistently detected across all datasets. Their tumor specificity and broad expression bolster their potential as promising precision immuno-oncologic targets for future T-cell receptor engineering efforts.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Memon</LastName><ForeName>Abdullah A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology and Communication Sciences, Medical College of Wisconsin, Milwaukee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Awan</LastName><ForeName>Musaddiq J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Espinosa</LastName><ForeName>Oscar Villarreal</ForeName><Initials>OV</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology and Communication Sciences, Medical College of Wisconsin, Milwaukee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuehn</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frei</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foeckler</LastName><ForeName>Jamie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bruening</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology and Communication Sciences, Medical College of Wisconsin, Milwaukee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akakpo</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology and Communication Sciences, Medical College of Wisconsin, Milwaukee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Massey</LastName><ForeName>Becky</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology and Communication Sciences, Medical College of Wisconsin, Milwaukee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stadler</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology and Communication Sciences, Medical College of Wisconsin, Milwaukee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Stuart</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Himburg</LastName><ForeName>Heather A</ForeName><Initials>HA</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zenga</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology and Communication Sciences, Medical College of Wisconsin, Milwaukee.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Otolaryngol Head Neck Surg</MedlineTA><NlmUniqueID>101589542</NlmUniqueID><ISSNLinking>2168-6181</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000951">Antigens, Neoplasm</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006258" MajorTopicYN="Y">Head and Neck Neoplasms</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077195" MajorTopicYN="Y">Squamous Cell Carcinoma of Head and Neck</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000951" MajorTopicYN="Y">Antigens, Neoplasm</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057285" MajorTopicYN="N">Precision Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Awan reported grants from the National Instiuttes of Health and nonfinancial support from Genentech outside the submitted work. Dr Himburg reported grants from the National Institute of Allergy and Infectious Diseases outside the submitted work. Dr Zenga reported grants from the National Institute of Dental and Craniofacial Research during the conduct of the study. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2026</Year><Month>10</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>11</Day><Hour>13</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>10</Month><Day>23</Day><Hour>12</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>10</Month><Day>23</Day><Hour>11</Hour><Minute>34</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41129177</ArticleId><ArticleId IdType="pmc">PMC12550742</ArticleId><ArticleId IdType="doi">10.1001/jamaoto.2025.3563</ArticleId><ArticleId IdType="pii">2840416</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>American Cancer Society . Cancer Statistics Center. Accessed July 12, 2024. https://cancerstatisticscenter.cancer.org.</Citation></Reference><Reference><Citation>Lee NY, Ferris RL, Psyrri A, et al. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 2021;22(4):450-462. doi: 10.1016/S1470-2045(20)30737-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(20)30737-3</ArticleId><ArticleId IdType="pubmed">33794205</ArticleId></ArticleIdList></Reference><Reference><Citation>Rathod S, Livergant J, Klein J, Witterick I, Ringash J. A systematic review of quality of life in head and neck cancer treated with surgery with or without adjuvant treatment. Oral Oncol. 2015;51(10):888-900. doi: 10.1016/j.oraloncology.2015.07.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.oraloncology.2015.07.002</ArticleId><ArticleId IdType="pubmed">26209066</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenthal DI, Mohamed ASR, Garden AS, et al. Final report of a prospective randomized trial to evaluate the dose-response relationship for postoperative radiation therapy and pathologic risk groups in patients with head and neck cancer. Int J Radiat Oncol Biol Phys. 2017;98(5):1002-1011. doi: 10.1016/j.ijrobp.2017.02.218</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijrobp.2017.02.218</ArticleId><ArticleId IdType="pmc">PMC5518636</ArticleId><ArticleId IdType="pubmed">28721881</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbs ZA, Whitehurst AW. Emerging contributions of cancer/testis antigens to neoplastic behaviors. Trends Cancer. 2018;4(10):701-712. doi: 10.1016/j.trecan.2018.08.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trecan.2018.08.005</ArticleId><ArticleId IdType="pmc">PMC6366644</ArticleId><ArticleId IdType="pubmed">30292353</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson AJG, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer. 2005;5(8):615-625. doi: 10.1038/nrc1669</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc1669</ArticleId><ArticleId IdType="pubmed">16034368</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Gu Y, Zhang K, et al. Systematic identification of genes with a cancer-testis expression pattern in 19 cancer types. Nat Commun. 2016;7(1):10499. doi: 10.1038/ncomms10499</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms10499</ArticleId><ArticleId IdType="pmc">PMC4737856</ArticleId><ArticleId IdType="pubmed">26813108</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida LG, Sakabe NJ, deOliveira AR, et al. CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens. Nucleic Acids Res. 2009;37(database issue):D816-D819. doi: 10.1093/nar/gkn673</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkn673</ArticleId><ArticleId IdType="pmc">PMC2686577</ArticleId><ArticleId IdType="pubmed">18838390</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahmoud AM. Cancer testis antigens as immunogenic and oncogenic targets in breast cancer. Immunotherapy. 2018;10(9):769-778. doi: 10.2217/imt-2017-0179</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/imt-2017-0179</ArticleId><ArticleId IdType="pmc">PMC6462849</ArticleId><ArticleId IdType="pubmed">29926750</ArticleId></ArticleIdList></Reference><Reference><Citation>Kono K, Iinuma H, Akutsu Y, et al. Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens. J Transl Med. 2012;10(1):141. doi: 10.1186/1479-5876-10-141</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1479-5876-10-141</ArticleId><ArticleId IdType="pmc">PMC3403921</ArticleId><ArticleId IdType="pubmed">22776426</ArticleId></ArticleIdList></Reference><Reference><Citation>Kono K, Mizukami Y, Daigo Y, et al. Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer. Cancer Sci. 2009;100(8):1502-1509. doi: 10.1111/j.1349-7006.2009.01200.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1349-7006.2009.01200.x</ArticleId><ArticleId IdType="pmc">PMC11158753</ArticleId><ArticleId IdType="pubmed">19459850</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapoport AP, Stadtmauer EA, Binder-Scholl GK, et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med. 2015;21(8):914-921. doi: 10.1038/nm.3910</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.3910</ArticleId><ArticleId IdType="pmc">PMC4529359</ArticleId><ArticleId IdType="pubmed">26193344</ArticleId></ArticleIdList></Reference><Reference><Citation>Slingluff CL, Zarour HM, Tawbi HAH, et al. A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody ipilimumab (IPI) in patients with unresectable or metastatic melanoma. Oncoimmunology. 2021;10(1):1898105. doi: 10.1080/2162402X.2021.1898105</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/2162402X.2021.1898105</ArticleId><ArticleId IdType="pmc">PMC8007150</ArticleId><ArticleId IdType="pubmed">33796406</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews S. FastQC: a quality control tool for high throughput sequence data. Accessed August 1, 2024. https://qubeshub.org/resources/fastqc</Citation></Reference><Reference><Citation>Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30(15):2114-2120. doi: 10.1093/bioinformatics/btu170</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btu170</ArticleId><ArticleId IdType="pmc">PMC4103590</ArticleId><ArticleId IdType="pubmed">24695404</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobin A, Davis CA, Schlesinger F, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15-21. doi: 10.1093/bioinformatics/bts635</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/bts635</ArticleId><ArticleId IdType="pmc">PMC3530905</ArticleId><ArticleId IdType="pubmed">23104886</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30(7):923-930. doi: 10.1093/bioinformatics/btt656</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btt656</ArticleId><ArticleId IdType="pubmed">24227677</ArticleId></ArticleIdList></Reference><Reference><Citation>Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550. doi: 10.1186/s13059-014-0550-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-014-0550-8</ArticleId><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman MJ, Craft B, Hastie M, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38(6):675-678. doi: 10.1038/s41587-020-0546-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-020-0546-8</ArticleId><ArticleId IdType="pmc">PMC7386072</ArticleId><ArticleId IdType="pubmed">32444850</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao R, Bai S, Henderson YC, et al. Delineating copy number and clonal substructure in human tumors from single-cell transcriptomes. Nat Biotechnol. 2021;39(5):599-608. doi: 10.1038/s41587-020-00795-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-020-00795-2</ArticleId><ArticleId IdType="pmc">PMC8122019</ArticleId><ArticleId IdType="pubmed">33462507</ArticleId></ArticleIdList></Reference><Reference><Citation>Bill R, Wirapati P, Messemaker M, et al. <i>CXCL9:SPP1</i> macrophage polarity identifies a network of cellular programs that control human cancers. Science. 2023;381(6657):515-524. doi: 10.1126/science.ade2292
</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.ade2292</ArticleId><ArticleId IdType="pmc">PMC10755760</ArticleId><ArticleId IdType="pubmed">37535729</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams DW, Greenwell-Wild T, Brenchley L, et al. ; NIDCD/NIDCR Genomics and Computational Biology Core . Human oral mucosa cell atlas reveals a stromal-neutrophil axis regulating tissue immunity. Cell. 2021;184(15):4090-4104.e15. doi: 10.1016/j.cell.2021.05.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.05.013</ArticleId><ArticleId IdType="pmc">PMC8359928</ArticleId><ArticleId IdType="pubmed">34129837</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamun&#xe9;r FT, Karia BTR, de Oliveira CZ, Santos CRD, Carvalho AL, Vettore AL. A comprehensive expression analysis of cancer testis antigens in head and neck squamous cell carcinoma revels MAGEA3/6 as a marker for recurrence. Mol Cancer Ther. 2015;14(3):828-834. doi: 10.1158/1535-7163.MCT-14-0796</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1535-7163.MCT-14-0796</ArticleId><ArticleId IdType="pubmed">25564441</ArticleId></ArticleIdList></Reference><Reference><Citation>Figueiredo DLA, Mamede RCM, Proto-Siqueira R, Neder L, Silva WA Jr, Zago MA. Expression of cancer testis antigens in head and neck squamous cell carcinomas. Head Neck. 2006;28(7):614-619. doi: 10.1002/hed.20380</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hed.20380</ArticleId><ArticleId IdType="pubmed">16475205</ArticleId></ArticleIdList></Reference><Reference><Citation>Eura M, Ogi K, Chikamatsu K, et al. Expression of the MAGE gene family in human head-and-neck squamous-cell carcinomas. Int J Cancer. 1995;64(5):304-308. doi: 10.1002/ijc.2910640504</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.2910640504</ArticleId><ArticleId IdType="pubmed">7591301</ArticleId></ArticleIdList></Reference><Reference><Citation>Figueiredo DLA, Mamede RCM, Spagnoli GC, et al. High expression of cancer testis antigens MAGE-A, MAGE-C1/CT7, MAGE-C2/CT10, NY-ESO-1, and gage in advanced squamous cell carcinoma of the larynx. Head Neck. 2011;33(5):702-707. doi: 10.1002/hed.21522</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hed.21522</ArticleId><ArticleId IdType="pubmed">20886663</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung CH, Gillison ML. Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications. Clin Cancer Res. 2009;15(22):6758-6762. doi: 10.1158/1078-0432.CCR-09-0784</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-09-0784</ArticleId><ArticleId IdType="pubmed">19861444</ArticleId></ArticleIdList></Reference><Reference><Citation>Kienstra MA, Neel HB, Strome SE, Roche P. Identification of NY-ESO-1, MAGE-1, and MAGE-3 in head and neck squamous cell carcinoma. Head Neck. 2003;25(6):457-463. doi: 10.1002/hed.10223</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hed.10223</ArticleId><ArticleId IdType="pubmed">12784237</ArticleId></ArticleIdList></Reference><Reference><Citation>Laban S, Giebel G, Kl&#xfc;mper N, et al. MAGE expression in head and neck squamous cell carcinoma primary tumors, lymph node metastases and respective recurrences-implications for immunotherapy. Oncotarget. 2017;8(9):14719-14735. doi: 10.18632/oncotarget.14830</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.14830</ArticleId><ArticleId IdType="pmc">PMC5362438</ArticleId><ArticleId IdType="pubmed">28146422</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D, Wang J, Ding N, et al. MAGE-A1 promotes melanoma proliferation and migration through C-JUN activation. Biochem Biophys Res Commun. 2016;473(4):959-965. doi: 10.1016/j.bbrc.2016.03.161</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2016.03.161</ArticleId><ArticleId IdType="pubmed">27045082</ArticleId></ArticleIdList></Reference><Reference><Citation>Laban S, Atanackovic D, Luetkens T, et al. Simultaneous cytoplasmic and nuclear protein expression of melanoma antigen-A family and NY-ESO-1 cancer-testis antigens represents an independent marker for poor survival in head and neck cancer. Int J Cancer. 2014;135(5):1142-1152. doi: 10.1002/ijc.28752</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.28752</ArticleId><ArticleId IdType="pubmed">24482145</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai JR, Chong IW, Chen YH, et al. Differential expression profile of MAGE family in non-small-cell lung cancer. Lung Cancer. 2007;56(2):185-192. doi: 10.1016/j.lungcan.2006.12.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lungcan.2006.12.004</ArticleId><ArticleId IdType="pubmed">17208331</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee AK, Potts PR. A comprehensive guide to the MAGE family of ubiquitin ligases. J Mol Biol. 2017;429(8):1114-1142. doi: 10.1016/j.jmb.2017.03.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2017.03.005</ArticleId><ArticleId IdType="pmc">PMC5421567</ArticleId><ArticleId IdType="pubmed">28300603</ArticleId></ArticleIdList></Reference><Reference><Citation>Peche LY, Ladelfa MF, Toledo MF, et al. Human MageB2 protein expression enhances E2F transcriptional activity, cell proliferation, and resistance to ribotoxic stress. J Biol Chem. 2015;290(49):29652-29662. doi: 10.1074/jbc.M115.671982</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M115.671982</ArticleId><ArticleId IdType="pmc">PMC4705963</ArticleId><ArticleId IdType="pubmed">26468294</ArticleId></ArticleIdList></Reference><Reference><Citation>Pattani KM, Soudry E, Glazer CA, et al. MAGEB2 is activated by promoter demethylation in head and neck squamous cell carcinoma. PLoS One. 2012;7(9):e45534. doi: 10.1371/journal.pone.0045534</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0045534</ArticleId><ArticleId IdType="pmc">PMC3454438</ArticleId><ArticleId IdType="pubmed">23029077</ArticleId></ArticleIdList></Reference><Reference><Citation>Atanackovic D, Hildebrandt Y, Jadczak A, et al. Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells. Haematologica. 2010;95(5):785-793. doi: 10.3324/haematol.2009.014464</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2009.014464</ArticleId><ArticleId IdType="pmc">PMC2864385</ArticleId><ArticleId IdType="pubmed">20015885</ArticleId></ArticleIdList></Reference><Reference><Citation>Atanackovic D, Blum I, Cao Y, et al. Expression of cancer-testis antigens as possible targets for antigen-specific immunotherapy in head and neck squamous cell carcinoma. Cancer Biol Ther. 2006;5(9):1218-1225. doi: 10.4161/cbt.5.9.3174</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/cbt.5.9.3174</ArticleId><ArticleId IdType="pubmed">16929165</ArticleId></ArticleIdList></Reference><Reference><Citation>Montoro JRDMC, Mamede RCM, Neder Serafini L, et al. Expression of cancer-testis antigens MAGE-A4 and MAGE-C1 in oral squamous cell carcinoma. Head Neck. 2012;34(8):1123-1128. doi: 10.1002/hed.21880</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hed.21880</ArticleId><ArticleId IdType="pubmed">22083937</ArticleId></ArticleIdList></Reference><Reference><Citation>Piotti KC, Scognamiglio T, Chiu R, Chen YT. Expression of cancer/testis (CT) antigens in squamous cell carcinoma of the head and neck: evaluation as markers of squamous dysplasia. Pathol Res Pract. 2013;209(11):721-726. doi: 10.1016/j.prp.2013.08.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.prp.2013.08.004</ArticleId><ArticleId IdType="pubmed">24011616</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazar I, Fabre B, Feng Y, et al. SPANX control of Lamin A/C modulates nuclear architecture and promotes melanoma growth. Mol Cancer Res. 2020;18(10):1560-1573. doi: 10.1158/1541-7786.MCR-20-0291</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1541-7786.MCR-20-0291</ArticleId><ArticleId IdType="pmc">PMC7541784</ArticleId><ArticleId IdType="pubmed">32571981</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, Liu M, Xu S, et al. The clinical significance of Dickkopf Wnt signaling pathway inhibitor gene family in head and neck squamous cell carcinoma. Med Sci Monit. 2020;26:e927368. doi: 10.12659/MSM.927368</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/MSM.927368</ArticleId><ArticleId IdType="pmc">PMC7706141</ArticleId><ArticleId IdType="pubmed">33281184</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishihara M, Kageyama S, Miyahara Y, et al. MAGE-A4, NY-ESO-1 and SAGE mRNA expression rates and co-expression relationships in solid tumours. BMC Cancer. 2020;20(1):606. doi: 10.1186/s12885-020-07098-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12885-020-07098-4</ArticleId><ArticleId IdType="pmc">PMC7325278</ArticleId><ArticleId IdType="pubmed">32600281</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H, Kim Y, Jeoung D. DDX53 promotes cancer stem cell-like properties and autophagy. Mol Cells. 2017;40(1):54-65. doi: 10.14348/molcells.2017.2258</Citation><ArticleIdList><ArticleId IdType="doi">10.14348/molcells.2017.2258</ArticleId><ArticleId IdType="pmc">PMC5303889</ArticleId><ArticleId IdType="pubmed">28152297</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X, Potts PR. CSAG2 is a cancer-specific activator of SIRT1. EMBO Rep. 2020;21(9):e50912. doi: 10.15252/embr.202050912</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embr.202050912</ArticleId><ArticleId IdType="pmc">PMC7507327</ArticleId><ArticleId IdType="pubmed">32761762</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoki N, Mochizuki K, Matsui Y. DNA methylation of the Fthl17 5&#x2032;-upstream region regulates differential Fthl17 expression in lung cancer cells and germline stem cells. PLoS One. 2017;12(2):e0172219. doi: 10.1371/journal.pone.0172219</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0172219</ArticleId><ArticleId IdType="pmc">PMC5312872</ArticleId><ArticleId IdType="pubmed">28207785</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao X, Chen G, Cai H, et al. Aberrantly enhanced melanoma-associated antigen (MAGE)-A3 expression facilitates cervical cancer cell proliferation and metastasis via actuating Wnt signaling pathway. Biomed Pharmacother. 2020;122:109710. doi: 10.1016/j.biopha.2019.109710</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2019.109710</ArticleId><ArticleId IdType="pubmed">31918280</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Wang L, Liu J, et al. Expression and prognostic relevance of MAGE-A3 and MAGE-C2 in non-small cell lung cancer. Oncol Lett. 2017;13(3):1609-1618. doi: 10.3892/ol.2017.5665</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ol.2017.5665</ArticleId><ArticleId IdType="pmc">PMC5403542</ArticleId><ArticleId IdType="pubmed">28454298</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaugler B, Van den Eynde B, van der Bruggen P, et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med. 1994;179(3):921-930. doi: 10.1084/jem.179.3.921</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.179.3.921</ArticleId><ArticleId IdType="pmc">PMC2191409</ArticleId><ArticleId IdType="pubmed">8113684</ArticleId></ArticleIdList></Reference><Reference><Citation>Craig AJ, Garcia-Lezana T, Ruiz de Galarreta M, et al. Transcriptomic characterization of cancer-testis antigens identifies MAGEA3 as a driver of tumor progression in hepatocellular carcinoma. PLoS Genet. 2021;17(6):e1009589. doi: 10.1371/journal.pgen.1009589</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1009589</ArticleId><ArticleId IdType="pmc">PMC8224860</ArticleId><ArticleId IdType="pubmed">34166362</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Y, Mutter-Rottmayer E, Greenwalt AM, et al. A neomorphic cancer cell-specific role of MAGE-A4 in trans-lesion synthesis. Nat Commun. 2016;7(1):12105. doi: 10.1038/ncomms12105</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms12105</ArticleId><ArticleId IdType="pmc">PMC4935975</ArticleId><ArticleId IdType="pubmed">27377895</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwamoto O, Nagao Y, Shichijo S, Eura M, Kameyama T, Itoh K. Detection of MAGE-4 protein in sera of patients with head-and-neck squamous-cell carcinoma. Int J Cancer. 1997;70(3):287-290. doi: 10.1002/(SICI)1097-0215(19970127)70:3&lt;287::AID-IJC7&gt;3.0.CO;2-T</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-0215(19970127)70:3&lt;287::AID-IJC7&gt;3.0.CO;2-T</ArticleId><ArticleId IdType="pubmed">9033629</ArticleId></ArticleIdList></Reference><Reference><Citation>Monji M, Senju S, Nakatsura T, et al. Head and neck cancer antigens recognized by the humoral immune system. Biochem Biophys Res Commun. 2002;294(3):734-741. doi: 10.1016/S0006-291X(02)00543-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-291X(02)00543-0</ArticleId><ArticleId IdType="pubmed">12056832</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhan S, Chuang A, Negi SS, Glazer CA, Califano JA. MAGEA4 induces growth in normal oral keratinocytes by inhibiting growth arrest and apoptosis. Oncol Rep. 2012;28(4):1498-1502. doi: 10.3892/or.2012.1934</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/or.2012.1934</ArticleId><ArticleId IdType="pubmed">22842486</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan SJ, Ren J, Jiang H, et al. MAGEA6 promotes human glioma cell survival via targeting AMPK&#x3b1;1. Cancer Lett. 2018;412:21-29. doi: 10.1016/j.canlet.2017.09.051</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canlet.2017.09.051</ArticleId><ArticleId IdType="pubmed">29024810</ArticleId></ArticleIdList></Reference><Reference><Citation>Picard V, Bergeron A, Larue H, Fradet Y. MAGE-A9 mRNA and protein expression in bladder cancer. Int J Cancer. 2007;120(10):2170-2177. doi: 10.1002/ijc.22282</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.22282</ArticleId><ArticleId IdType="pubmed">17290406</ArticleId></ArticleIdList></Reference><Reference><Citation>Karia BTR, Zamuner FT, Carlin V, de Oliveira CZ, Carvalho AL, Vettore AL. Expression and prognostic relevance of GAGE1 and XAGE1 cancer/testis antigens in head and neck squamous cell carcinoma. Curr Mol Med. 2017;17(10):707-717. doi: 10.2174/1566524018666180322162145</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1566524018666180322162145</ArticleId><ArticleId IdType="pubmed">29577858</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia S, Zhang M, Li Y, Zhang L, Dai W. MAGE-A11 expression predicts patient prognosis in head and neck squamous cell carcinoma. Cancer Manag Res. 2020;12:1427-1435. doi: 10.2147/CMAR.S237867</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CMAR.S237867</ArticleId><ArticleId IdType="pmc">PMC7051897</ArticleId><ArticleId IdType="pubmed">32161495</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartmann S, Zwick L, Maurus K, et al. Melanoma-associated antigen A11 reduces erlotinib and afatinib efficacy in head and neck cancer. J Craniomaxillofac Surg. 2018;46(3):492-497. doi: 10.1016/j.jcms.2017.12.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcms.2017.12.014</ArticleId><ArticleId IdType="pubmed">29311018</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh C, Kim HR, Oh S, et al. Epigenetic upregulation of MAGE-A isoforms promotes breast cancer cell aggressiveness. Cancers (Basel). 2021;13(13):3176. doi: 10.3390/cancers13133176</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers13133176</ArticleId><ArticleId IdType="pmc">PMC8268034</ArticleId><ArticleId IdType="pubmed">34202157</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Q, Sun ML, Liu WS, et al. Upregulated expression of ACTL8 contributes to invasion and metastasis and indicates poor prognosis in colorectal cancer. Onco Targets Ther. 2019;12:1749-1763. doi: 10.2147/OTT.S185858</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OTT.S185858</ArticleId><ArticleId IdType="pmc">PMC6402434</ArticleId><ArticleId IdType="pubmed">30881029</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Chu J, Li J, et al. Cancer/testis antigen-Plac1 promotes invasion and metastasis of breast cancer through Furin/NICD/PTEN signaling pathway. Mol Oncol. 2018;12(8):1233-1248. doi: 10.1002/1878-0261.12311</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1878-0261.12311</ArticleId><ArticleId IdType="pmc">PMC6068355</ArticleId><ArticleId IdType="pubmed">29704427</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi R, Nagato T, Kumai T, et al. Expression of placenta-specific 1 and its potential for eliciting anti-tumor helper T-cell responses in head and neck squamous cell carcinoma. Oncoimmunology. 2020;10(1):1856545. doi: 10.1080/2162402X.2020.1856545</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/2162402X.2020.1856545</ArticleId><ArticleId IdType="pmc">PMC7781841</ArticleId><ArticleId IdType="pubmed">33457076</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen R, Sheng C, Ma R, Zhang L, Yang L, Chen Y. PLAC1 is an independent predictor of poor survival, and promotes cell proliferation and invasion in cervical cancer. Mol Med Rep. 2021;24(5):800. doi: 10.3892/mmr.2021.12440</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2021.12440</ArticleId><ArticleId IdType="pmc">PMC8456314</ArticleId><ArticleId IdType="pubmed">34523695</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan P, Chen Z, Zhong W, et al. BRDT is a novel regulator of eIF4EBP1 in renal cell carcinoma. Oncol Rep. 2020;44(6):2475-2486. doi: 10.3892/or.2020.7796</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/or.2020.7796</ArticleId><ArticleId IdType="pmc">PMC7610328</ArticleId><ArticleId IdType="pubmed">33125143</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Cai S, Wang JM, Huai YY, Lu PH, Chu Q. BRDT promotes ovarian cancer cell growth. Cell Death Dis. 2020;11(11):1021. doi: 10.1038/s41419-020-03225-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-020-03225-y</ArticleId><ArticleId IdType="pmc">PMC7705741</ArticleId><ArticleId IdType="pubmed">33257688</ArticleId></ArticleIdList></Reference><Reference><Citation>Prieto I, Suja JA, Pezzi N, et al. Mammalian STAG3 is a cohesin specific to sister chromatid arms in meiosis I. Nat Cell Biol. 2001;3(8):761-766. doi: 10.1038/35087082</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35087082</ArticleId><ArticleId IdType="pubmed">11483963</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao H, Shao Q, Shao Y. Transcription factor CTCFL promotes cell proliferation, migration, and invasion in gastric cancer via activating DPPA2. Comput Math Methods Med. 2021;2021:9097931. doi: 10.1155/2021/9097931</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/9097931</ArticleId><ArticleId IdType="pmc">PMC8548907</ArticleId><ArticleId IdType="pubmed">34721660</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaczmarek K, Niedzialkowska E, Studencka M, Schulz Y, Grzmil P. Ccdc33, a predominantly testis-expressed gene, encodes a putative peroxisomal protein. Cytogenet Genome Res. 2009;126(3):243-252. doi: 10.1159/000251961</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000251961</ArticleId><ArticleId IdType="pubmed">20068295</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin X, Chen Z, Gao P, et al. TEX15: a DNA repair gene associated with prostate cancer risk in Han Chinese. Prostate. 2017;77(12):1271-1278. doi: 10.1002/pros.23387</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pros.23387</ArticleId><ArticleId IdType="pubmed">28730685</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Xia L, Yao CC, et al. NLRP4 negatively regulates type I interferon response and influences the outcome in anti-programmed cell death protein (PD)-1/PD-ligand 1 therapy. Cancer Sci. 2022;113(3):838-851. doi: 10.1111/cas.15243</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cas.15243</ArticleId><ArticleId IdType="pmc">PMC8898729</ArticleId><ArticleId IdType="pubmed">34927309</ArticleId></ArticleIdList></Reference><Reference><Citation>Holcomb RJ, Oura S, Nozawa K, et al. The testis-specific serine proteases PRSS44, PRSS46, and PRSS54 are dispensable for male mouse fertility. Biol Reprod. 2020;102(1):84-91. doi: 10.1093/biolre/ioz158</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/biolre/ioz158</ArticleId><ArticleId IdType="pmc">PMC7013879</ArticleId><ArticleId IdType="pubmed">31403672</ArticleId></ArticleIdList></Reference><Reference><Citation>Pakasticali N, Chobrutskiy A, Patel DN, et al. Chemical complementarity of breast cancer resident, T-cell receptor CDR3 domains and the cancer antigen, ARMC3, is associated with higher levels of survival and granzyme expression. Cancer Inform. 2023;22:11769351231177269. doi: 10.1177/11769351231177269</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/11769351231177269</ArticleId><ArticleId IdType="pmc">PMC10259117</ArticleId><ArticleId IdType="pubmed">37313373</ArticleId></ArticleIdList></Reference><Reference><Citation>Doghman-Bouguerra M, Finetti P, Durand N, et al. Cancer-testis antigen FATE1 expression in adrenocortical tumors is associated with a pervasive autoimmune response and is a marker of malignancy in adult, but not children, ACC. Cancers (Basel). 2020;12(3):689. doi: 10.3390/cancers12030689</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers12030689</ArticleId><ArticleId IdType="pmc">PMC7140037</ArticleId><ArticleId IdType="pubmed">32183347</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamun&#xe9;r FT, Karia BTR, de Oliveira CZ, Santos CRD, Carvalho AL, Vettore AL. A comprehensive expression analysis of cancer testis antigens in head and neck squamous cell carcinoma revels MAGEA3/6 as a marker for recurrence. Mol Cancer Ther. 2015;14(3):828-834. doi: 10.1158/1535-7163.MCT-14-0796</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1535-7163.MCT-14-0796</ArticleId><ArticleId IdType="pubmed">25564441</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z, Xu C, Pan X, et al. lncRNA DSCR8 mediates miR-137/Cdc42 to regulate gastric cancer cell proliferation, invasion, and cell cycle as a competitive endogenous RNA. Mol Ther Oncolytics. 2021;22:468-482. doi: 10.1016/j.omto.2021.05.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omto.2021.05.010</ArticleId><ArticleId IdType="pmc">PMC8430047</ArticleId><ArticleId IdType="pubmed">34553033</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Zhang L, Luo Q, Liu J, Wang G. MORC protein family-related signature within human disease and cancer. Cell Death Dis. 2021;12(12):1112. doi: 10.1038/s41419-021-04393-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-021-04393-1</ArticleId><ArticleId IdType="pmc">PMC8627505</ArticleId><ArticleId IdType="pubmed">34839357</ArticleId></ArticleIdList></Reference><Reference><Citation>Da Gama Duarte J, Woods K, Quigley LT, et al. Ropporin-1 and 1B are widely expressed in human melanoma and evoke strong humoral immune responses. Cancers (Basel). 2021;13(8):1805. doi: 10.3390/cancers13081805</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers13081805</ArticleId><ArticleId IdType="pmc">PMC8069442</ArticleId><ArticleId IdType="pubmed">33918976</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosoya N, Miyagawa K. Synaptonemal complex proteins modulate the level of genome integrity in cancers. Cancer Sci. 2021;112(3):989-996. doi: 10.1111/cas.14791</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cas.14791</ArticleId><ArticleId IdType="pmc">PMC7935773</ArticleId><ArticleId IdType="pubmed">33382503</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao J, Chen HS. Biological functions of melanoma-associated antigens. World J Gastroenterol. 2004;10(13):1849-1853. doi: 10.3748/wjg.v10.i13.1849</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v10.i13.1849</ArticleId><ArticleId IdType="pmc">PMC4572215</ArticleId><ArticleId IdType="pubmed">15222021</ArticleId></ArticleIdList></Reference><Reference><Citation>Sang M, Wang L, Ding C, et al. Melanoma-associated antigen genes&#x2014;an update. Cancer Lett. 2011;302(2):85-90. doi: 10.1016/j.canlet.2010.10.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canlet.2010.10.021</ArticleId><ArticleId IdType="pubmed">21093980</ArticleId></ArticleIdList></Reference><Reference><Citation>Li B, Zhu J, Meng L. High expression of ACTL8 is poor prognosis and accelerates cell progression in head and neck squamous cell carcinoma. Mol Med Rep. 2019;19(2):877-884. doi: 10.3892/mmr.2018.9716</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2018.9716</ArticleId><ArticleId IdType="pmc">PMC6323208</ArticleId><ArticleId IdType="pubmed">30535476</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam RA, Tien TZ, Joseph CR, et al. Cancer-testis antigens in triple-negative breast cancer: role and potential utility in clinical practice. Cancers (Basel). 2021;13(15):3875. doi: 10.3390/cancers13153875</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers13153875</ArticleId><ArticleId IdType="pmc">PMC8345750</ArticleId><ArticleId IdType="pubmed">34359776</ArticleId></ArticleIdList></Reference><Reference><Citation>Investigator Initiated Phase 1 Study of TBI-1301. ClinicalTrials.gov identifier: NCT02366546. Updated October 24, 2018. Accessed January 22, 2025. https://clinicaltrials.gov/study/NCT02366546</Citation></Reference><Reference><Citation>Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity. ClinicalTrials.gov identifier: NCT02873819. Updated March 8, 2023. Accessed January 22, 2025. https://clinicaltrials.gov/study/NCT02873819</Citation></Reference><Reference><Citation>To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors. ClinicalTrials.gov identifier: NCT03159585. Updated January 22, 2020. Accessed January 22, 2025. https://clinicaltrials.gov/study/NCT03159585</Citation></Reference><Reference><Citation>Hicks SC, Townes FW, Teng M, Irizarry RA. Missing data and technical variability in single-cell RNA-sequencing experiments. Biostatistics. 2018;19(4):562-578. doi: 10.1093/biostatistics/kxx053</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/biostatistics/kxx053</ArticleId><ArticleId IdType="pmc">PMC6215955</ArticleId><ArticleId IdType="pubmed">29121214</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiau CK, Lu L, Kieser R, et al. High throughput single cell long-read sequencing analyses of same-cell genotypes and phenotypes in human tumors. Nat Commun. 2023;14(1):4124. doi: 10.1038/s41467-023-39813-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-39813-7</ArticleId><ArticleId IdType="pmc">PMC10336110</ArticleId><ArticleId IdType="pubmed">37433798</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumari P, Kaur M, Dindhoria K, Ashford B, Amarasinghe SL, Thind AS. Advances in long-read single-cell transcriptomics. Hum Genet. 2024;143(9-10):1005-1020. doi: 10.1007/s00439-024-02678-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00439-024-02678-x</ArticleId><ArticleId IdType="pmc">PMC11485027</ArticleId><ArticleId IdType="pubmed">38787419</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1001/jamaoto.2025.3471 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">41129160</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-619X</ISSN><JournalIssue CitedMedium="Internet"><Volume>151</Volume><Issue>12</Issue><PubDate><Year>2025</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA otolaryngology-- head &amp; neck surgery</Title><ISOAbbreviation>JAMA Otolaryngol Head Neck Surg</ISOAbbreviation></Journal><ArticleTitle>Are We Training Too Many Head and Neck Fellows?</ArticleTitle><Pagination><StartPage>1113</StartPage><EndPage>1114</EndPage><MedlinePgn>1113-1114</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaoto.2025.3471</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lydiatt</LastName><ForeName>William Bill M</ForeName><Initials>WBM</Initials><AffiliationInfo><Affiliation>Clarkson Institute, Omaha, Nebraska.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Head and Neck Surgical Oncology, Nebraska Methodist Hospital, Omaha.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Otolaryngol Head Neck Surg</MedlineTA><NlmUniqueID>101589542</NlmUniqueID><ISSNLinking>2168-6181</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><OtherAbstract Type="plain-language-summary" Language="eng"><AbstractText>This Viewpoint discusses the purpose of head and neck fellowship and what the correct number of practicing head and neck surgeons is.</AbstractText></OtherAbstract></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>10</Month><Day>23</Day><Hour>12</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>10</Month><Day>23</Day><Hour>12</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>10</Month><Day>23</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41129160</ArticleId><ArticleId IdType="doi">10.1001/jamaoto.2025.3471</ArticleId><ArticleId IdType="pii">2840414</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1001/jamaoto.2025.3696 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">41100121</PMID><DateCompleted><Year>2025</Year><Month>12</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>12</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-619X</ISSN><JournalIssue CitedMedium="Internet"><Volume>151</Volume><Issue>12</Issue><PubDate><Year>2025</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA otolaryngology-- head &amp; neck surgery</Title><ISOAbbreviation>JAMA Otolaryngol Head Neck Surg</ISOAbbreviation></Journal><ArticleTitle>Reimbursement for Thyroid Surgery and Potential Solutions.</ArticleTitle><Pagination><StartPage>1208</StartPage><EndPage>1213</EndPage><MedlinePgn>1208-1213</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaoto.2025.3696</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="UNASSIGNED">In 2024, the US Senate Committee on Finance released a white paper outlining future reforms to the Medicare payment models.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To characterize trends in Medicare reimbursement for thyroid surgery and to provide evidence for future discussions on payment reforms.</AbstractText><AbstractText Label="DESIGN AND SETTING" NlmCategory="UNASSIGNED">This retrospective economic evaluation used data on reimbursement for thyroid surgeries from the Centers for Medicare &amp; Medicaid Services' Physician Fee Schedule from 2000 to 2023. Data were analyzed from May to June 2024.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="UNASSIGNED">The main outcomes were reimbursement rates for thyroid surgery and changes in reimbursement over time. Dollar amounts were adjusted to January 2023 US dollars. Annual reimbursement was averaged nationally, and compound annual growth rate and Pearson correlation coefficient were used to characterize trends.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Between 2000 and 2023, Medicare reimbursement for thyroid surgeries decreased 38.7%, from $1517.59 to $929.55, when adjusted for inflation. The reimbursement for total thyroidectomy demonstrated the greatest decline at 47.8%, from $1803.16 to $942.07. Thyroid lobectomy and completion thyroidectomy both had reduced reimbursements at 41.7% (from $1250.38 to $729.02) and 25.5% (from $1499.26 to $1117.54), respectively. The compound annual growth rate for thyroid surgeries as a whole was 0.4% when not adjusted for inflation and -2.1% when adjusted for inflation. There was 0% growth in work relative value units between 2012 and 2023 for all thyroid surgeries.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="UNASSIGNED">This economic evaluation found an almost 40% decrease in the rate of reimbursement for thyroid surgery, with total thyroidectomy having the greatest decrease at 47.8%. These findings provide evidence that current trends are not sustainable. Thyroid surgeons should take a proactive approach to improving reimbursements before these changes impact patient access to thyroid surgery.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brauer</LastName><ForeName>Philip R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Head and Neck Institute, Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Octeau</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Head and Neck Institute, Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wajsberg</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Head and Neck Institute, Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lamarre</LastName><ForeName>Eric D</ForeName><Initials>ED</Initials><AffiliationInfo><Affiliation>Head and Neck Institute, Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ku</LastName><ForeName>Jamie A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Head and Neck Institute, Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skugor</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Endocrinology, Diabetes, and Metabolism, Endocrinology and Metabolism Institute, Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bottalico</LastName><ForeName>Danielle M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Head and Neck Institute, Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silver</LastName><ForeName>Natalie L</ForeName><Initials>NL</Initials><AffiliationInfo><Affiliation>Head and Neck Institute, Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prendes</LastName><ForeName>Brandon L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Head and Neck Institute, Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scharpf</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Head and Neck Institute, Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Otolaryngol Head Neck Surg</MedlineTA><NlmUniqueID>101589542</NlmUniqueID><ISSNLinking>2168-6181</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013965" MajorTopicYN="Y">Thyroidectomy</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006278" MajorTopicYN="Y">Medicare</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012051" MajorTopicYN="Y">Reimbursement Mechanisms</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007349" MajorTopicYN="Y">Insurance, Health, Reimbursement</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Ku reported personal fees from EMD Serono and Medical Microinstruments: MMI Inc outside the submitted work. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2026</Year><Month>10</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>11</Day><Hour>13</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>10</Month><Day>16</Day><Hour>12</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>10</Month><Day>16</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41100121</ArticleId><ArticleId IdType="pmc">PMC12532026</ArticleId><ArticleId IdType="doi">10.1001/jamaoto.2025.3696</ArticleId><ArticleId IdType="pii">2840186</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>About us. Medicare . Accessed January 28, 2025. https://www.medicare.gov/about-us</Citation></Reference><Reference><Citation>NHE fact sheet. Centers for Medicare &amp; Medicaid Services . Accessed January 28, 2025. https://www.cms.gov/data-research/statistics-trends-and-reports/national-health-expenditure-data/nhe-fact-sheet</Citation></Reference><Reference><Citation>Consumer Price Index. US Bureau of Labor Statistics . Accessed February 2, 2024. https://www.bls.gov/cpi/</Citation></Reference><Reference><Citation>Dominguez JL, Ederaine SA, Haglin JM, Aragon Sierra AM, Barrs DM, Lott DG. Medicare reimbursement trends for facility performed otolaryngology procedures: 2000-2019. Laryngoscope. 2021;131(3):496-501. doi: 10.1002/lary.28749</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/lary.28749</ArticleId><ArticleId IdType="pubmed">32619309</ArticleId></ArticleIdList></Reference><Reference><Citation>Quereshy HA, Quinton BA, Cabrera CI, Li S, Tamaki A, Fowler N. Medicare reimbursement trends from 2000 to 2020 in head and neck surgical oncology. Head Neck. 2022;44(7):1616-1622. doi: 10.1002/hed.27064</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hed.27064</ArticleId><ArticleId IdType="pmc">PMC9325383</ArticleId><ArticleId IdType="pubmed">35416360</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolstering chronic care through physician payment: current challenges and policy options in Medicare Part B. Senate Committee on Finance . May 17, 2024. Accessed May 30, 2024, https://www.finance.senate.gov/imo/media/doc/051723_phys_payment_cc_white_paper.pdf</Citation></Reference><Reference><Citation>Cronin KA, Lake AJ, Scott S, et al. Annual Report to the Nation on the Status of Cancer, part I: national cancer statistics. Cancer. 2018;124(13):2785-2800. doi: 10.1002/cncr.31551</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.31551</ArticleId><ArticleId IdType="pmc">PMC6033186</ArticleId><ArticleId IdType="pubmed">29786848</ArticleId></ArticleIdList></Reference><Reference><Citation>Brauer PR, Burkey BB, Reddy CA, Lamarre ED. Risk assessment in thyroid lobectomy and total thyroidectomy using over 100 thousand cases. Ann Otol Rhinol Laryngol. 2021;130(12):1351-1359. doi: 10.1177/00034894211007219</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/00034894211007219</ArticleId><ArticleId IdType="pubmed">33834878</ArticleId></ArticleIdList></Reference><Reference><Citation>Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1-133. doi: 10.1089/thy.2015.0020</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/thy.2015.0020</ArticleId><ArticleId IdType="pmc">PMC4739132</ArticleId><ArticleId IdType="pubmed">26462967</ArticleId></ArticleIdList></Reference><Reference><Citation>Physician Fee Schedule Look-up Tool Overview. Centers for Medicare &amp; Medicaid Services . Accessed January 28, 2025. https://www.cms.gov/medicare/physician-fee-schedule/search/overview</Citation></Reference><Reference><Citation>Brauer PR, Reddy CA, Burkey BB, Lamarre ED. A national comparison of postoperative outcomes in completion thyroidectomy and total thyroidectomy. Otolaryngol Head Neck Surg. 2021;164(3):566-573. doi: 10.1177/0194599820951165</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0194599820951165</ArticleId><ArticleId IdType="pubmed">32838642</ArticleId></ArticleIdList></Reference><Reference><Citation>Locality Key. Centers for Medicare &amp; Medicaid Services . Accessed July 27, 2025. https://www.cms.gov/medicare/payment/fee-schedules/physician-fee-schedule/locality-key</Citation></Reference><Reference><Citation>Sibia US, Millen JC, Klune JR, Bilchik A, Foshag LJ. Analysis of 10-year trends in Medicare Physician Fee Schedule payments in surgery. Surgery. 2024;175(4):920-926. doi: 10.1016/j.surg.2023.12.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.surg.2023.12.012</ArticleId><ArticleId IdType="pubmed">38262816</ArticleId></ArticleIdList></Reference><Reference><Citation>Schartz DA, McCool RR. Trends in Medicare reimbursement for otology procedures from 2000 to 2020. Otol Neurotol. 2021;42(4):505-509. doi: 10.1097/MAO.0000000000003010</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MAO.0000000000003010</ArticleId><ArticleId IdType="pubmed">33351566</ArticleId></ArticleIdList></Reference><Reference><Citation>Torabi SJ, Vasandani S, Patel RA, Peter Manes R, Kuan EC. Understanding the composition of a comprehensive otolaryngologist&#x2019;s practice through Medicare reimbursements. Otolaryngol Head Neck Surg. 2025;172(3):888-896. doi: 10.1002/ohn.1071</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ohn.1071</ArticleId><ArticleId IdType="pmc">PMC11844328</ArticleId><ArticleId IdType="pubmed">39588657</ArticleId></ArticleIdList></Reference><Reference><Citation>Kane CK. Physician practice characteristics in 2024: private practices account for less than half of physicians in most specialties. American Medical Association . Accessed July 19. 2025, https://www.ama-assn.org/system/files/2024-prp-pp-characteristics.pdf</Citation></Reference><Reference><Citation>Baggett SM, Martin KL. Medscape otolaryngologist lifestyle, happiness &amp; burnout report 2022. Medscape . February 18, 2022. Accessed May 5, 2024. https://www.medscape.com/slideshow/2022-lifestyle-otolaryngologist-6014787</Citation></Reference><Reference><Citation>Tsinberg M, Duh QY, Cisco RM, et al. Practice patterns and job satisfaction in fellowship-trained endocrine surgeons. Surgery. 2012;152(6):953-956. doi: 10.1016/j.surg.2012.08.032</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.surg.2012.08.032</ArticleId><ArticleId IdType="pubmed">23102635</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung P, Kozhimannil KB, Casey MM, Moscovice IS. Why are obstetric units in rural hospitals closing their doors? Health Serv Res. 2016;51(4):1546-1560. doi: 10.1111/1475-6773.12441</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1475-6773.12441</ArticleId><ArticleId IdType="pmc">PMC4946037</ArticleId><ArticleId IdType="pubmed">26806952</ArticleId></ArticleIdList></Reference><Reference><Citation>Abouleish AE, Pomerantz P, Peterson MD, et al. Closing the chasm: understanding and addressing the anesthesia workforce supply and demand imbalance. Anesthesiology. 2024;141(2):238-249. doi: 10.1097/ALN.0000000000005052</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ALN.0000000000005052</ArticleId><ArticleId IdType="pubmed">38884582</ArticleId></ArticleIdList></Reference><Reference><Citation>Sickels AD, McElroy K, Robinson J, Chen H, Rose JB. Diminishing returns: an analysis of surgeon compensation in the setting of ever-increasing student debt. J Am Coll Surg. 2025;241(2):262-266. doi: 10.1097/XCS.0000000000001257</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/XCS.0000000000001257</ArticleId><ArticleId IdType="pmc">PMC12152205</ArticleId><ArticleId IdType="pubmed">39660729</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen DW, Ospina NS, Haymart MR. Social determinants of health and disparities in thyroid care. J Clin Endocrinol Metab. 2024;109(3):e1309-e1313. doi: 10.1210/clinem/dgad716</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/clinem/dgad716</ArticleId><ArticleId IdType="pmc">PMC10876391</ArticleId><ArticleId IdType="pubmed">38057150</ArticleId></ArticleIdList></Reference><Reference><Citation>Moon PK, Chakoma T, Ma Y, Megwalu UC. Thyroid cancer incidence, clinical presentation, and survival among Native Hawaiian and Other Pacific Islanders. Otolaryngol Head Neck Surg. 2023;169(1):86-96. doi: 10.1177/01945998221118538</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/01945998221118538</ArticleId><ArticleId IdType="pubmed">35943808</ArticleId></ArticleIdList></Reference><Reference><Citation>Calendar year (CY) 2024.  Medicare Physician Fee Schedule final rule. Centers for Medicare &amp; Medicaid Services . November 2, 2023. Accessed May 8, 2024. https://www.cms.gov/newsroom/fact-sheets/calendar-year-cy-2024-medicare-physician-fee-schedule-final-rule</Citation></Reference><Reference><Citation>Zhang J, Chen Y, Einav L, Levin J, Bhattacharya J. Consolidation of primary care physicians and its impact on healthcare utilization. Health Econ. 2021;30(6):1361-1373. doi: 10.1002/hec.4257</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hec.4257</ArticleId><ArticleId IdType="pubmed">33764640</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs JP, Lahey SJ, Nichols FC, et al. ; Society of Thoracic Surgeons Workforce on Coding and Reimbursement . How is physician work valued? Ann Thorac Surg. 2017;103(2):373-380. doi: 10.1016/j.athoracsur.2016.11.059</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2016.11.059</ArticleId><ArticleId IdType="pubmed">28109347</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz S, Melmed G. How relative value units undervalue the cognitive physician visit: a focus on inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2016;12(4):240-244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4872854</ArticleId><ArticleId IdType="pubmed">27231455</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1001/jamaoto.2025.2410 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">41100109</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-619X</ISSN><JournalIssue CitedMedium="Internet"><Volume>151</Volume><Issue>12</Issue><PubDate><Year>2025</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA otolaryngology-- head &amp; neck surgery</Title><ISOAbbreviation>JAMA Otolaryngol Head Neck Surg</ISOAbbreviation></Journal><ArticleTitle>Contralateral Tonsil in p16-Positive Tonsil Squamous Cell Carcinoma.</ArticleTitle><Pagination><StartPage>1115</StartPage><EndPage>1116</EndPage><MedlinePgn>1115-1116</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaoto.2025.2410</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barrette</LastName><ForeName>Louis-Xavier</ForeName><Initials>LX</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gentile</LastName><ForeName>Michelle</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rajasekaran</LastName><ForeName>Karthik</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Otolaryngol Head Neck Surg</MedlineTA><NlmUniqueID>101589542</NlmUniqueID><ISSNLinking>2168-6181</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><OtherAbstract Type="plain-language-summary" Language="eng"><AbstractText>This Viewpoint examines current surgical guidelines and emerging evidence regarding the optimal treatment of patients with p16-positive oropharyngeal squamous cell carcinoma.</AbstractText></OtherAbstract></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>10</Month><Day>16</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>10</Month><Day>16</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>10</Month><Day>16</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41100109</ArticleId><ArticleId IdType="doi">10.1001/jamaoto.2025.2410</ArticleId><ArticleId IdType="pii">2840185</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1001/jamaoto.2025.2688 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40996774</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-619X</ISSN><JournalIssue CitedMedium="Internet"><Volume>151</Volume><Issue>12</Issue><PubDate><Year>2025</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA otolaryngology-- head &amp; neck surgery</Title><ISOAbbreviation>JAMA Otolaryngol Head Neck Surg</ISOAbbreviation></Journal><ArticleTitle>Improving Palliative Care for Patients With Head and Neck Cancer.</ArticleTitle><Pagination><StartPage>1183</StartPage><EndPage>1185</EndPage><MedlinePgn>1183-1185</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaoto.2025.2688</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gourin</LastName><ForeName>Christine G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins Medical Institutions, Baltimore, Maryland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Oncology, Johns Hopkins Medical Institutions, Baltimore, Maryland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Department of Oncology, Johns Hopkins Medical Institutions, Baltimore, Maryland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gersten</LastName><ForeName>Rebecca A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Otolaryngol Head Neck Surg</MedlineTA><NlmUniqueID>101589542</NlmUniqueID><ISSNLinking>2168-6181</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Otolaryngol Head Neck Surg. 2025 Dec 1;151(12):1175-1183. doi: 10.1001/jamaoto.2025.2687.</RefSource><PMID Version="1">40996731</PMID></CommentsCorrections></CommentsCorrectionsList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>25</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>25</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>25</Day><Hour>11</Hour><Minute>34</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40996774</ArticleId><ArticleId IdType="doi">10.1001/jamaoto.2025.2688</ArticleId><ArticleId IdType="pii">2838819</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1001/jamaoto.2025.2687 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40996731</PMID><DateCompleted><Year>2025</Year><Month>12</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>12</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-619X</ISSN><JournalIssue CitedMedium="Internet"><Volume>151</Volume><Issue>12</Issue><PubDate><Year>2025</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA otolaryngology-- head &amp; neck surgery</Title><ISOAbbreviation>JAMA Otolaryngol Head Neck Surg</ISOAbbreviation></Journal><ArticleTitle>Palliative Care With Tracheostomy or Gastrostomy Tube Use and End-of-Life Quality and Costs Among Patients With Head and Neck Cancer.</ArticleTitle><Pagination><StartPage>1175</StartPage><EndPage>1183</EndPage><MedlinePgn>1175-1183</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaoto.2025.2687</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="UNASSIGNED">Patients with head and neck cancer (HNC) have high utilization rates of tracheostomy or gastrostomy tubes (g-tubes) at the end of life, with accompanying high costs. It is unknown whether the timing of palliative care (PC) initiation may attenuate the cost or be associated with better quality of life during the last year and more home deaths.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To assess the association of palliative care (first exposure) and tracheostomy or g-tube utilization with end-of-life costs among patients with head and neck cancer during the last year of life.</AbstractText><AbstractText Label="DESIGN, SETTING, AND POPULATION" NlmCategory="UNASSIGNED">This was a population-based cohort study of adults diagnosed with HNC between January 1, 2007, and December 31, 2022, who died before October 1, 2023, in Ontario, Canada. Health administrative data were deterministically linked and analyzed at the ICES (formerly Institute for Clinical Evaluative Sciences). Data analysis was conducted from January 2024 to June 2025.</AbstractText><AbstractText Label="EXPOSURES" NlmCategory="UNASSIGNED">Timing of PC, categorized as early (12 to 6 months before death), late (&lt;6 months before death), and none (no PC during last year of life), was combined with tracheostomy tube use (binary) to form a 6-level categorical variable. This procedure was repeated for g-tube.</AbstractText><AbstractText Label="MAIN OUTCOMES" NlmCategory="UNASSIGNED">Mean monthly health care costs in last 6 months of life were estimated using a patient-level case-costing algorithm using 2023 CAD$ (CAD$&#x2009;1.00 = US$&#x2009;0.74) and evaluated by negative binomial regression.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The analysis included 11&#x202f;135 adults who received a diagnosis of HNC from 2007 to 2022 and died before October 1, 2023. They had a mean (SD) age of 68.4 (12.1) years at diagnosis and 8245 were male (74.0%). Nearly 90% received PC: 5866 (52.6%), late PC; 4093 (36.8%), early PC; and 1176 (10.6%) did not receive PC. Regarding tracheostomy/g-tube use in the last year of life, 1293 (11.6%) used a tracheostomy and 1235 (11.1%), a g-tube. Compared to those who did not receive PC nor use a tracheostomy tube, the cost increase on using a tracheostomy tube (rate ratio [RR] 2.93; 95% CI, 2.32-3.71) was higher than using it with early PC (RR, 2.88; 95% CI, 2.63-3.15) but lower than using it with late PC (RR 4.37; 95% CI, 4.00-4.77); results were similar for g-tube use. A large proportion of the cohort had an emergency department visit (9109 [81%]) or a non-PC hospital admission (5419 [48.7%]) in last 6 months of life, with both proportions being the lowest among nonrecipients of PC. Early PC was associated with a 46.8% lower likelihood (odd ratio, 0.53; 95% CI, 0.45-0.63) of experiencing a home death than no PC.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="UNASSIGNED">This cohort study found that receiving a tracheostomy/g-tube in last year of life has pronounced economic implications to the health care system. Early initiation of PC may attenuate this high cost but may not reduce the use of aggressive hospital-based care at the end of life or facilitate home deaths. Team-based early provision of PC for this patient population is required.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Rui</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Departments of Community Health Sciences, Surgery &amp; Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sutradhar</LastName><ForeName>Rinku</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Evaluative Clinical Sciences Platform, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre &amp; University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ICES, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Qing</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>ICES, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villemure-Poliquin</LastName><ForeName>No&#xe9;mie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Evaluative Clinical Sciences Platform, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre &amp; University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ICES, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otolaryngology-Head &amp; Neck Surgery, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Kelvin K W</ForeName><Initials>KKW</Initials><AffiliationInfo><Affiliation>Evaluative Clinical Sciences Platform, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre &amp; University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karam</LastName><ForeName>Irene</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hallet</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Evaluative Clinical Sciences Platform, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre &amp; University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ICES, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eskander</LastName><ForeName>Antoine</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Evaluative Clinical Sciences Platform, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre &amp; University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ICES, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otolaryngology-Head &amp; Neck Surgery, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Otolaryngol Head Neck Surg</MedlineTA><NlmUniqueID>101589542</NlmUniqueID><ISSNLinking>2168-6181</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>JAMA Otolaryngol Head Neck Surg. 2025 Dec 1;151(12):1183-1185. doi: 10.1001/jamaoto.2025.2688.</RefSource><PMID Version="1">40996774</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014139" MajorTopicYN="Y">Tracheostomy</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005774" MajorTopicYN="Y">Gastrostomy</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006258" MajorTopicYN="Y">Head and Neck Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010166" MajorTopicYN="Y">Palliative Care</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013727" MajorTopicYN="Y">Terminal Care</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009864" MajorTopicYN="N" Type="Geographic">Ontario</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017048" MajorTopicYN="Y">Health Care Costs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Karam reported serving on the advisory board of EMD Serono outside the submitted work. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2026</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>11</Day><Hour>13</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>25</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>25</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40996731</ArticleId><ArticleId IdType="pmc">PMC12464848</ArticleId><ArticleId IdType="doi">10.1001/jamaoto.2025.2687</ArticleId><ArticleId IdType="pii">2838814</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Yabroff KR, Warren JL, Brown ML. Costs of cancer care in the USA: a descriptive review. Nat Clin Pract Oncol. 2007;4(11):643-656. doi: 10.1038/ncponc0978</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncponc0978</ArticleId><ArticleId IdType="pubmed">17965642</ArticleId></ArticleIdList></Reference><Reference><Citation>Bekelman JE, Halpern SD, Blankart CR, et al. ; International Consortium for End-of-Life Research (ICELR) . Comparison of site of death, health care utilization, and hospital expenditures for patients dying with cancer in 7 developed countries. JAMA. 2016;315(3):272-283. doi: 10.1001/jama.2015.18603</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2015.18603</ArticleId><ArticleId IdType="pubmed">26784775</ArticleId></ArticleIdList></Reference><Reference><Citation>Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363(8):733-742. doi: 10.1056/NEJMoa1000678</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1000678</ArticleId><ArticleId IdType="pubmed">20818875</ArticleId></ArticleIdList></Reference><Reference><Citation>Bevins J, Bhulani N, Goksu SY, et al. Early palliative care is associated with reduced emergency department utilization in pancreatic cancer. Am J Clin Oncol. 2021;44(5):181-186. doi: 10.1097/COC.0000000000000802</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/COC.0000000000000802</ArticleId><ArticleId IdType="pmc">PMC8062302</ArticleId><ArticleId IdType="pubmed">33710133</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumnui N, Nagaviroj K, Anothaisintawee T. A study of the factors associated with emergency department visits in advanced cancer patients receiving palliative care. BMC Palliat Care. 2022;21(1):197. doi: 10.1186/s12904-022-01098-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12904-022-01098-w</ArticleId><ArticleId IdType="pmc">PMC9664626</ArticleId><ArticleId IdType="pubmed">36376908</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmermann C, Swami N, Krzyzanowska M, et al. Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial. Lancet. 2014;383(9930):1721-1730. doi: 10.1016/S0140-6736(13)62416-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)62416-2</ArticleId><ArticleId IdType="pubmed">24559581</ArticleId></ArticleIdList></Reference><Reference><Citation>Dionne-Odom JN, Azuero A, Lyons KD, et al. Benefits of early versus delayed palliative care to informal family caregivers of patients with advanced cancer: outcomes from the ENABLE III randomized controlled trial. J Clin Oncol. 2015;33(13):1446-1452. doi: 10.1200/JCO.2014.58.7824</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2014.58.7824</ArticleId><ArticleId IdType="pmc">PMC4404423</ArticleId><ArticleId IdType="pubmed">25800762</ArticleId></ArticleIdList></Reference><Reference><Citation>Nottelmann L, Groenvold M, Vejlgaard TB, Petersen MA, Jensen LH. Early, integrated palliative rehabilitation improves quality of life of patients with newly diagnosed advanced cancer: the Pal-Rehab randomized controlled trial. Palliat Med. 2021;35(7):1344-1355. doi: 10.1177/02692163211015574</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/02692163211015574</ArticleId><ArticleId IdType="pubmed">34000886</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Jawahri A, LeBlanc TW, Kavanaugh A, et al. Effectiveness of integrated palliative and oncology care for patients with acute myeloid leukemia: a randomized clinical trial. JAMA Oncol. 2021;7(2):238-245. doi: 10.1001/jamaoncol.2020.6343</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2020.6343</ArticleId><ArticleId IdType="pmc">PMC7747042</ArticleId><ArticleId IdType="pubmed">33331857</ArticleId></ArticleIdList></Reference><Reference><Citation>Steel JL, Geller DA, Kim KH, et al. Web-based collaborative care intervention to manage cancer-related symptoms in the palliative care setting. Cancer. 2016;122(8):1270-1282. doi: 10.1002/cncr.29906</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.29906</ArticleId><ArticleId IdType="pmc">PMC4828258</ArticleId><ArticleId IdType="pubmed">26970434</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan DR, Chan B, Lapidus JA, et al. Association of early palliative care use with survival and place of death among patients with advanced lung cancer receiving care in the Veterans Health Administration. JAMA Oncol. 2019;5(12):1702-1709. doi: 10.1001/jamaoncol.2019.3105</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2019.3105</ArticleId><ArticleId IdType="pmc">PMC6753505</ArticleId><ArticleId IdType="pubmed">31536133</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomes SA, Silva DNM, Sorice F, et al. Outpatient palliative care program: impact on home death rate in Brazil. Cancers (Basel). 2024;16(7):1380. doi: 10.3390/cancers16071380</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers16071380</ArticleId><ArticleId IdType="pmc">PMC11010934</ArticleId><ArticleId IdType="pubmed">38611059</ArticleId></ArticleIdList></Reference><Reference><Citation>Seow H, Barbera LC, McGrail K, et al. Effect of early palliative care on end-of-life health care costs: a population-based, propensity score&#x2013;matched cohort study. JCO Oncol Pract. 2022;18(1):e183-e192. doi: 10.1200/OP.21.00299</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/OP.21.00299</ArticleId><ArticleId IdType="pmc">PMC8758090</ArticleId><ArticleId IdType="pubmed">34388021</ArticleId></ArticleIdList></Reference><Reference><Citation>May P, Garrido MM, Cassel JB, et al. Prospective cohort study of hospital palliative care teams for inpatients with advanced cancer: earlier consultation is associated with larger cost-saving effect. J Clin Oncol. 2015;33(25):2745-2752. doi: 10.1200/JCO.2014.60.2334</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2014.60.2334</ArticleId><ArticleId IdType="pmc">PMC4550689</ArticleId><ArticleId IdType="pubmed">26056178</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner DR, Gillis J, Demers AA, et al. ; Canadian Cancer Statistics Advisory Committee . Projected estimates of cancer in Canada in 2024. CMAJ. 2024;196(18):E615-E623. doi: 10.1503/cmaj.240095</Citation><ArticleIdList><ArticleId IdType="doi">10.1503/cmaj.240095</ArticleId><ArticleId IdType="pmc">PMC11090635</ArticleId><ArticleId IdType="pubmed">38740416</ArticleId></ArticleIdList></Reference><Reference><Citation>Cocks H, Ah-See K, Capel M, Taylor P. Palliative and supportive care in head and neck cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol. 2016;130(S2)(suppl 2):S198-S207. doi: 10.1017/S0022215116000633</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0022215116000633</ArticleId><ArticleId IdType="pmc">PMC4873917</ArticleId><ArticleId IdType="pubmed">27841131</ArticleId></ArticleIdList></Reference><Reference><Citation>Irish J, Kim J, Waldron J, et al. ; Expert Panel on Organizational Guidance for the Care of Patients with Head and Neck Cancer in Ontario . Organizational guidance for the care of patients with head-and-neck cancer in Ontario. Curr Oncol. 2020;27(2):e115-e122. doi: 10.3747/co.27.5873</Citation><ArticleIdList><ArticleId IdType="doi">10.3747/co.27.5873</ArticleId><ArticleId IdType="pmc">PMC7253750</ArticleId><ArticleId IdType="pubmed">32489261</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfister DG, Spencer S, Adelstein D, et al. Head and neck cancers, version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020;18(7):873-898. doi: 10.6004/jnccn.2020.0031</Citation><ArticleIdList><ArticleId IdType="doi">10.6004/jnccn.2020.0031</ArticleId><ArticleId IdType="pubmed">32634781</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders JJ, Temin S, Ghoshal A, et al. Palliative care for patients with cancer: ASCO guideline update. J Clin Oncol. 2024;42(19):2336-2357. doi: 10.1200/JCO.24.00542</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.24.00542</ArticleId><ArticleId IdType="pubmed">38748941</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayland CR, Ho QM, Doughty HC, et al. The palliative care needs and experiences of people with advanced head and neck cancer: a scoping review. Palliat Med. 2021;35(1):27-44. doi: 10.1177/0269216320963892</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0269216320963892</ArticleId><ArticleId IdType="pmc">PMC7797618</ArticleId><ArticleId IdType="pubmed">33084497</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan T, Devaiah AK. Tracheostomy in palliative care. Otolaryngol Clin North Am. 2009;42(1):133-141, x. doi: 10.1016/j.otc.2008.09.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.otc.2008.09.002</ArticleId><ArticleId IdType="pubmed">19134496</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan CX, Gutierrez C, Maw MM, et al. Impact of a palliative care program on tracheostomy utilization in a community hospital. J Palliat Med. 2015;18(12):1070-1073. doi: 10.1089/jpm.2015.0172</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jpm.2015.0172</ArticleId><ArticleId IdType="pubmed">26584021</ArticleId></ArticleIdList></Reference><Reference><Citation>Kersen J, Roach P, Chandarana S, Ronksley P, Sauro K. Exploring transitions in care among patients with head and neck CANCER: a multimethod study. BMC Cancer. 2024;24(1):1108. doi: 10.1186/s12885-024-12862-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12885-024-12862-x</ArticleId><ArticleId IdType="pmc">PMC11378503</ArticleId><ArticleId IdType="pubmed">39237932</ArticleId></ArticleIdList></Reference><Reference><Citation>Ullgren H, Kirkpatrick L, Kilpel&#xe4;inen S, Sharp L. Working in silos? Head &amp; neck cancer patients during and after treatment with or without early palliative care referral. Eur J Oncol Nurs. 2017;26:56-62. doi: 10.1016/j.ejon.2016.12.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejon.2016.12.003</ArticleId><ArticleId IdType="pubmed">28069153</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor N, Christie J, Wakefield D. Head and neck cancer end of life care: complex challenges. BMJ Support Palliat Care. 2022;14(e1):e577-e579. doi: 10.1136/bmjspcare-2022-003644</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjspcare-2022-003644</ArticleId><ArticleId IdType="pubmed">35383046</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe1;nchez-S&#xe1;nchez E, Ruano-&#xc1;lvarez MA, D&#xed;az-Jim&#xe9;nez J, D&#xed;az AJ, Ordonez FJ. Enteral nutrition by nasogastric tube in adult patients under palliative care: a systematic review. Nutrients. 2021;13(5):1562. doi: 10.3390/nu13051562</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu13051562</ArticleId><ArticleId IdType="pmc">PMC8148195</ArticleId><ArticleId IdType="pubmed">34066386</ArticleId></ArticleIdList></Reference><Reference><Citation>Benchimol EI, Smeeth L, Guttmann A, et al. ; RECORD Working Committee . The reporting of studies conducted using observational routinely-collected health data (RECORD) statement. PLoS Med. 2015;12(10):e1001885. doi: 10.1371/journal.pmed.1001885</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1001885</ArticleId><ArticleId IdType="pmc">PMC4595218</ArticleId><ArticleId IdType="pubmed">26440803</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen O, Parkin D, MacLennan R, Muir C, Skeet R, eds. Cancer Registration: Principles and Methods. International Agency for Research on Cancer; 1991. https://publications.iarc.fr/Book-And-Report-Series/Iarc-Scientific-Publications/Cancer-Registration-Principles-And-Methods-1991#</Citation></Reference><Reference><Citation>Robles SC, Marrett LD, Clarke EA, Risch HA. An application of capture-recapture methods to the estimation of completeness of cancer registration. J Clin Epidemiol. 1988;41(5):495-501. doi: 10.1016/0895-4356(88)90052-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0895-4356(88)90052-2</ArticleId><ArticleId IdType="pubmed">3367181</ArticleId></ArticleIdList></Reference><Reference><Citation>Matheson F, Moloney G, van Ingen T. 2021 Ontario Marginalization Index: User Guide. St. Michael&#x2019;s Hospital (Unity Health Toronto). Joint publication with Public Health Ontario; 2023. Accessed August 19, 2023. https://www.publichealthontario.ca/-/media/documents/O/2017/on-marg-userguide.pdf</Citation></Reference><Reference><Citation>Noel CW, Sutradhar R, Zhao H, et al. Patient-reported symptom burden as a predictor of emergency department use and unplanned hospitalization in head and neck cancer: a longitudinal population-based study. J Clin Oncol. 2021;39(6):675-684. doi: 10.1200/JCO.20.01845</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.20.01845</ArticleId><ArticleId IdType="pubmed">33405964</ArticleId></ArticleIdList></Reference><Reference><Citation>Noel CW, Sutradhar R, Chan WC, et al. Gaps in depression symptom management for patients with head and neck cancer. Laryngoscope. 2023;133(10):2638-2646. doi: 10.1002/lary.30595</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/lary.30595</ArticleId><ArticleId IdType="pubmed">36748910</ArticleId></ArticleIdList></Reference><Reference><Citation>Noel CW, Sutradhar R, Li Q, et al. Association of immigration status and Chinese and South Asian ethnicity with incidence of head and neck cancer. JAMA Otolaryngol Head Neck Surg. 2020;146(12):1125-1135. doi: 10.1001/jamaoto.2020.4197</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoto.2020.4197</ArticleId><ArticleId IdType="pmc">PMC7645760</ArticleId><ArticleId IdType="pubmed">33151263</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau J, Scott MM, Everett K, et al. Association between opioid use disorder and palliative care: a cohort study using linked health administrative data in Ontario, Canada. CMAJ. 2024;196(16):E547-E557. doi: 10.1503/cmaj.231419</Citation><ArticleIdList><ArticleId IdType="doi">10.1503/cmaj.231419</ArticleId><ArticleId IdType="pmc">PMC11057880</ArticleId><ArticleId IdType="pubmed">38684285</ArticleId></ArticleIdList></Reference><Reference><Citation>Wodchis WP, Bushmeneva K, Nikitovic M, McKillop I. Guidelines on Person-Level Costing Using Administrative Databases in Ontario. Published online May 2013. Accessed March 26, 2019. https://tspace.library.utoronto.ca/handle/1807/87373</Citation></Reference><Reference><Citation>Canadian Institute for Health Information . Cost of a Standard Hospital Stay: Methodology Notes, October 2024. CIHI; 2024. Accessed May 26, 2025. https://www.cihi.ca/sites/default/files/document/cost-standard-hospital-stay-methodology-notes-en.pdf</Citation></Reference><Reference><Citation>Seung SJ, Hurry M, Hassan S, Walton RN, Evans WK. Cost-of-illness study for non-small-cell lung cancer using real-world data. Curr Oncol. 2019;26(2):102-107. doi: 10.3747/co.26.4555</Citation><ArticleIdList><ArticleId IdType="doi">10.3747/co.26.4555</ArticleId><ArticleId IdType="pmc">PMC6476449</ArticleId><ArticleId IdType="pubmed">31043811</ArticleId></ArticleIdList></Reference><Reference><Citation>Seung SJ, Mittmann N, Ante Z, et al. Evaluating real world health system resource utilization and costs for a risk-based breast cancer screening approach in the Canadian PERSPECTIVE integration and implementation project. Cancers (Basel). 2024;16(18):3189. doi: 10.3390/cancers16183189</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers16183189</ArticleId><ArticleId IdType="pmc">PMC11430316</ArticleId><ArticleId IdType="pubmed">39335160</ArticleId></ArticleIdList></Reference><Reference><Citation>Mittmann N, Seung SJ, Diong C, et al. Using real-world data to determine health system costs of ontario women screened for breast cancer. Curr Oncol. 2022;29(11):8330-8339. doi: 10.3390/curroncol29110657</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/curroncol29110657</ArticleId><ArticleId IdType="pmc">PMC9689006</ArticleId><ArticleId IdType="pubmed">36354717</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurry M, Hassan S, Seung SJ, Walton R, Elnoursi A, McGee J. Real-World Treatment Patterns, Survival, and Costs for Ovarian cancer in canada: a retrospective cohort study using provincial administrative data. JHEOR. Published online December 9, 2021:114-121. doi: 10.36469/jheor.2021.29145</Citation><ArticleIdList><ArticleId IdType="doi">10.36469/jheor.2021.29145</ArticleId></ArticleIdList></Reference><Reference><Citation>Seow H, Sutradhar R, McGrail K, et al. End-of-life cancer care: temporal association between homecare nursing and hospitalizations. J Palliat Med. 2016;19(3):263-270. doi: 10.1089/jpm.2015.0229</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jpm.2015.0229</ArticleId><ArticleId IdType="pubmed">26673031</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly EM, James PD, Murthy S, et al. Health care utilization and costs for patients with end-stage liver disease are significantly higher at the end of life compared to those of other decedents. Clin Gastroenterol Hepatol. 2019;17(11):2339-2346.e1. doi: 10.1016/j.cgh.2019.01.046</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2019.01.046</ArticleId><ArticleId IdType="pubmed">30743007</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosella LC, Kornas K, Negatu E, Zhou L. Variations in all-cause mortality, premature mortality and cause-specific mortality among persons with diabetes in Ontario, Canada. BMJ Open Diabetes Res Care. 2023;11(3):e003378. doi: 10.1136/bmjdrc-2023-003378</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjdrc-2023-003378</ArticleId><ArticleId IdType="pmc">PMC10163552</ArticleId><ArticleId IdType="pubmed">37130629</ArticleId></ArticleIdList></Reference><Reference><Citation>Kralj B. Measuring rurality: RIO2008_BASIC: methodology and results. Published online February 2, 2009. Accessed November 1, 2021. https://content.oma.org/wp-content/uploads/2008rio-fulltechnicalpaper.pdf</Citation></Reference><Reference><Citation>Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8-27. doi: 10.1097/00005650-199801000-00004</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005650-199801000-00004</ArticleId><ArticleId IdType="pubmed">9431328</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministry of Health . Ontario hospitals asked to take a planned approach to ramping down elective surgeries. Ontario Newsroom. March 15, 2020. Accessed August 1, 2022. https://news.ontario.ca/en/statement/56328/ontario-hospitals-asked-to-take-a-planned-approach-to-ramping-down-elective-surgeries</Citation></Reference><Reference><Citation>Bremner KE, Yabroff KR, Coughlan D, et al. Patterns of care and costs for older patients with colorectal cancer at the end of life: descriptive study of the United States and Canada. JCO Oncol Pract. 2020;16(1):e1-e18. doi: 10.1200/JOP.19.00061</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JOP.19.00061</ArticleId><ArticleId IdType="pmc">PMC7051852</ArticleId><ArticleId IdType="pubmed">31647697</ArticleId></ArticleIdList></Reference><Reference><Citation>de Oliveira C, Pataky R, Bremner KE, et al. Phase-specific and lifetime costs of cancer care in Ontario, Canada. BMC Cancer. 2016;16(1):809. doi: 10.1186/s12885-016-2835-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12885-016-2835-7</ArticleId><ArticleId IdType="pmc">PMC5070134</ArticleId><ArticleId IdType="pubmed">27756310</ArticleId></ArticleIdList></Reference><Reference><Citation>Parlow S, Fernando SM, Pugliese M, et al. ; LOTUS-ICU Research Group . Resource utilization and costs associated with cardiogenic shock complicating myocardial infarction: a population-based cohort study. JACC Adv. 2024;3(8):101047. doi: 10.1016/j.jacadv.2024.101047</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacadv.2024.101047</ArticleId><ArticleId IdType="pmc">PMC11268098</ArticleId><ArticleId IdType="pubmed">39050814</ArticleId></ArticleIdList></Reference><Reference><Citation>Caulley L, Lasso A, Zagorski B, et al. The economic burden of management of pituitary adenomas: a propensity-score-matched cost analysis. J Otolaryngol Head Neck Surg. 2025;54:19160216251314793. doi: 10.1177/19160216251314793</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/19160216251314793</ArticleId><ArticleId IdType="pmc">PMC11770705</ArticleId><ArticleId IdType="pubmed">39868520</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregori D, Petrinco M, Bo S, Desideri A, Merletti F, Pagano E. Regression models for analyzing costs and their determinants in health care: an introductory review. Int J Qual Health Care. 2011;23(3):331-341. doi: 10.1093/intqhc/mzr010</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/intqhc/mzr010</ArticleId><ArticleId IdType="pubmed">21504959</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh JC, Urman AR, Besaw RJ, Dodge LE, Lee KA, Buss MK. Different associations between inpatient or outpatient palliative care and end-of-life outcomes for hospitalized patients with cancer. JCO Oncol Pract. 2022;18(4):e516-e524. doi: 10.1200/OP.21.00546</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/OP.21.00546</ArticleId><ArticleId IdType="pmc">PMC9810126</ArticleId><ArticleId IdType="pubmed">34914566</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratnasekera N, Fazelzad R, Bagnarol R, Cunha V, Zimmermann C, Lau J. Palliative care interventions for patients with head and neck cancer: protocol for a scoping review. BMJ Open. 2023;13(11):e078980. doi: 10.1136/bmjopen-2023-078980</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2023-078980</ArticleId><ArticleId IdType="pmc">PMC10685954</ArticleId><ArticleId IdType="pubmed">38011979</ArticleId></ArticleIdList></Reference><Reference><Citation>Patil VM, Singhai P, Noronha V, et al. Effect of early palliative care on quality of life of advanced head and neck cancer patients: a phase III trial. J Natl Cancer Inst. 2021;113(9):1228-1237. doi: 10.1093/jnci/djab020</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnci/djab020</ArticleId><ArticleId IdType="pubmed">33606023</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrell B, Chung V, Hughes MT, et al. A palliative care intervention for patients on phase 1 studies. J Palliat Med. 2021;24(6):846-856. doi: 10.1089/jpm.2020.0597</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jpm.2020.0597</ArticleId><ArticleId IdType="pmc">PMC8147498</ArticleId><ArticleId IdType="pubmed">33103938</ArticleId></ArticleIdList></Reference><Reference><Citation>Greer JA, Moy B, El-Jawahri A, et al. Randomized trial of a palliative care intervention to improve end-of-life care discussions in patients with metastatic breast cancer. J Natl Compr Canc Netw. 2022;20(2):136-143. doi: 10.6004/jnccn.2021.7040</Citation><ArticleIdList><ArticleId IdType="doi">10.6004/jnccn.2021.7040</ArticleId><ArticleId IdType="pmc">PMC8830600</ArticleId><ArticleId IdType="pubmed">35130492</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill AD, Stukel TA, Fu L, et al. Trends in site of death and health care utilization at the end of life: a population-based cohort study. CMAJO. 2019;7(2):e306-e315. doi: 10.9778/cmajo.20180097</Citation><ArticleIdList><ArticleId IdType="doi">10.9778/cmajo.20180097</ArticleId></ArticleIdList></Reference><Reference><Citation>Fereidouni A, Rassouli M, Salesi M, Ashrafizadeh H, Vahedian-Azimi A, Barasteh S. Preferred place of death in adult cancer patients: a systematic review and meta-analysis. Front Psychol. 2021;12:704590. doi: 10.3389/fpsyg.2021.704590</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyg.2021.704590</ArticleId><ArticleId IdType="pmc">PMC8429937</ArticleId><ArticleId IdType="pubmed">34512460</ArticleId></ArticleIdList></Reference><Reference><Citation>Malhotra C, Koh LE, Teo I, Ozdemir S, Chaudhry I, Finkelstein E. A prospective cohort study of stability in preferred place of death among patients with stage iv cancer in Singapore. J Natl Compr Canc Netw. 2021;20(1):20-28. doi: 10.6004/jnccn.2020.7795</Citation><ArticleIdList><ArticleId IdType="doi">10.6004/jnccn.2020.7795</ArticleId><ArticleId IdType="pubmed">34359020</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent D, Peixoto C, Quinn KL, et al. Virtual home-based palliative care during COVID-19: a qualitative exploration of the patient, caregiver, and healthcare provider experience. Palliat Med. 2022;36(9):1374-1388. doi: 10.1177/02692163221116251</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/02692163221116251</ArticleId><ArticleId IdType="pmc">PMC9596681</ArticleId><ArticleId IdType="pubmed">36071621</ArticleId></ArticleIdList></Reference><Reference><Citation>Mittmann N, Cheng SY, Liu N, et al. The generation of two specific cancer costing algorithms using Ontario administrative databases. Curr Oncol. 2019;26(5):e682-e692. doi: 10.3747/co.26.5279</Citation><ArticleIdList><ArticleId IdType="doi">10.3747/co.26.5279</ArticleId><ArticleId IdType="pmc">PMC6821127</ArticleId><ArticleId IdType="pubmed">31708661</ArticleId></ArticleIdList></Reference><Reference><Citation>Arapakis K, French E, Jones J, McCauley J. How should we fund end-of-life care in the US? Lancet Reg Health Am. 2022;15:100359. doi: 10.1016/j.lana.2022.100359</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lana.2022.100359</ArticleId><ArticleId IdType="pmc">PMC9904126</ArticleId><ArticleId IdType="pubmed">36778069</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1001/jamaoto.2025.2824 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40932734</PMID><DateCompleted><Year>2025</Year><Month>12</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>12</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-619X</ISSN><JournalIssue CitedMedium="Internet"><Volume>151</Volume><Issue>12</Issue><PubDate><Year>2025</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA otolaryngology-- head &amp; neck surgery</Title><ISOAbbreviation>JAMA Otolaryngol Head Neck Surg</ISOAbbreviation></Journal><ArticleTitle>Barriers and Timely Postoperative Radiation Therapy in Head and Neck Cancer.</ArticleTitle><Pagination><StartPage>1186</StartPage><EndPage>1195</EndPage><MedlinePgn>1186-1195</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaoto.2025.2824</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="UNASSIGNED">Initiation of postoperative radiation therapy (PORT) within 6 weeks of surgery is associated with improved outcomes among patients with head and neck squamous cell carcinoma. However, the relationship of barriers to care with timely PORT is unknown.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To categorize barriers to timely PORT, evaluate the association of barriers to care with initiation of timely PORT, and describe the primary reason for delay among patients without timely PORT.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="UNASSIGNED">This prospective cohort study at a US academic medical center included adults with head and neck squamous cell carcinoma undergoing curative-intent surgery with an indication for PORT. Patients were recruited for the study from May 19, 2020, to November 6, 2023.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="UNASSIGNED">The primary outcome was initiation of timely PORT, defined as starting radiation therapy within 6 weeks of surgery. Barriers to PORT were prospectively collected via patient self-report and the electronic health record. Among patients who did not start PORT within 6 weeks of surgery, the primary reason for delay was defined as the singular barrier category that most directly led to the delay.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Among 78 patients (mean [SD] age, 61.5 [10.8] years; 54 males [69.2%]), 32 patients (41%) initiated PORT within 6 weeks of surgery, and 46 patients (59%) did not initiate PORT within 6 weeks of surgery. Each additional barrier was associated with a decreased odds of initiating timely PORT (adjusted odds ratio, 0.81 [95% CI, 0.63-1.01]); patients with 5 or more barriers had a 76% reduction in the odds of starting PORT within 6 weeks of surgery relative to those with 0 to 2 barriers (adjusted odds ratio, 0.24 [95 CI%, 0.06-0.84]) on multivariable analysis. When analyzed by barrier category, patients with a perioperative adverse effects-related barrier were less likely to initiate timely PORT than patients without a perioperative adverse effects barrier (adjusted odds ratio, 0.17 [95% CI, 0.04-0.66]) on multivariable analysis. Among patients without timely PORT, the most common primary reason for delay was a barrier related to poor care coordination (19/46 [41.3%]).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="UNASSIGNED">In this prospective cohort study, patients with a greater number of barriers and those with a barrier related to the perioperative adverse effects category were less likely to initiate timely PORT. Among patients without timely PORT, the most common primary reason for delay was a barrier related to poor care coordination. Efforts to improve timely PORT should focus on decreasing the number of barriers, improving surgical quality, and enhancing care coordination.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Megan T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Medical University of South Carolina, Charleston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kistner-Griffin</LastName><ForeName>Emily</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Public Health Sciences, Medical University of South Carolina, Charleston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hollings Cancer Center, Medical University of South Carolina, Charleston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeMass</LastName><ForeName>Reid</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Public Health Sciences, Medical University of South Carolina, Charleston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hollings Cancer Center, Medical University of South Carolina, Charleston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chera</LastName><ForeName>Bhisham S</ForeName><Initials>BS</Initials><AffiliationInfo><Affiliation>Hollings Cancer Center, Medical University of South Carolina, Charleston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiation Oncology, Medical University of South Carolina, Charleston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halbert</LastName><ForeName>Chanita Hughes</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Department of Population and Public Health Sciences, University of Southern California, Los Angeles.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Norris Comprehensive Cancer Center, University of Southern California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sterba</LastName><ForeName>Katherine R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>Department of Public Health Sciences, Medical University of South Carolina, Charleston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hollings Cancer Center, Medical University of South Carolina, Charleston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hill</LastName><ForeName>Elizabeth G</ForeName><Initials>EG</Initials><AffiliationInfo><Affiliation>Department of Public Health Sciences, Medical University of South Carolina, Charleston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hollings Cancer Center, Medical University of South Carolina, Charleston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nussenbaum</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>American Board of Otolaryngology-Head and Neck Surgery, Houston, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alberg</LastName><ForeName>Anthony J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of South Carolina Arnold School of Public Health, Columbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sandulache</LastName><ForeName>Vlad C</ForeName><Initials>VC</Initials><AffiliationInfo><Affiliation>Bobby R. Alford Department of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, Houston, Texas.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ENT Section, Operative CareLine, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hernandez</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Bobby R. Alford Department of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, Houston, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jackson</LastName><ForeName>Ryan S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Robert Ebert and Greg Stubblefield Head and Neck Tumor Center at Siteman, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puram</LastName><ForeName>Sidharth V</ForeName><Initials>SV</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Robert Ebert and Greg Stubblefield Head and Neck Tumor Center at Siteman, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kahmke</LastName><ForeName>Russel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Head and Neck Surgery and Communication Sciences, Duke University, Durham, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Osazuwa-Peters</LastName><ForeName>Nosayaba</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Head and Neck Surgery and Communication Sciences, Duke University, Durham, North Carolina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Population Health Sciences, School of Medicine, Duke University, Durham, North Carolina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Deputy Editor, JAMA Otolaryngology-Head &amp; Neck Surgery.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jackson</LastName><ForeName>Gail</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Head and Neck Cancer Alliance, Charleston, South Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yom</LastName><ForeName>Sue S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, University of California, San Francisco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graboyes</LastName><ForeName>Evan M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Medical University of South Carolina, Charleston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Public Health Sciences, Medical University of South Carolina, Charleston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hollings Cancer Center, Medical University of South Carolina, Charleston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Deputy Editor, JAMA Otolaryngology-Head &amp; Neck Surgery.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K08 CA237858</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA138313</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA282165</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000062</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Otolaryngol Head Neck Surg</MedlineTA><NlmUniqueID>101589542</NlmUniqueID><ISSNLinking>2168-6181</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006258" MajorTopicYN="Y">Head and Neck Neoplasms</DescriptorName><QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077195" MajorTopicYN="Y">Squamous Cell Carcinoma of Head and Neck</DescriptorName><QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061665" MajorTopicYN="Y">Time-to-Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018714" MajorTopicYN="N">Radiotherapy, Adjuvant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006297" MajorTopicYN="Y">Health Services Accessibility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011182" MajorTopicYN="Y">Postoperative Care</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Mr DeMass reported personal fees from MountainPass Technology outside the submitted work. Dr Sandulache reported consulting fees Femtovox consulting outside the submitted work. Dr R. Jackson reported honoraria from Intuitive Surgical outside the submitted work. Dr Osazuwa-Peters reported personal fees from Merck and Navigating Cancer outside the submitted work. Dr Yom reported grants from Bristol Myers Squibb, Merck, Johnson &amp; Johnson, and EMD Serono outside the submitted work. Dr Graboyes reported personal fees from Merck, grants from Stryker, and travel support from Stryker outside the submitted work. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>11</Day><Hour>13</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>11</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>11</Day><Hour>11</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>10</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40932734</ArticleId><ArticleId IdType="mid">NIHMS2110949</ArticleId><ArticleId IdType="pmc">PMC12426859</ArticleId><ArticleId IdType="doi">10.1001/jamaoto.2025.2824</ArticleId><ArticleId IdType="pii">2838772</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Head and Neck Cancers; 2025.</Citation></Reference><Reference><Citation>Graboyes EM, Divi V, Moore BA. Head and neck oncology is on the national quality sidelines no longer&#x2014;put me in, coach. JAMA Otolaryngol Head Neck Surg. 2022;148(8):715&#x2013;716. doi: 10.1001/jamaoto.2022.1389</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoto.2022.1389</ArticleId><ArticleId IdType="pmc">PMC9378525</ArticleId><ArticleId IdType="pubmed">35708673</ArticleId></ArticleIdList></Reference><Reference><Citation>Graboyes EM, Kompelli AR, Neskey DM, et al. Association of treatment delays with survival for patients with head and neck cancer: a systematic review. JAMA Otolaryngol Head Neck Surg. 2019;145(2):166&#x2013;177. doi: 10.1001/jamaoto.2018.2716</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoto.2018.2716</ArticleId><ArticleId IdType="pmc">PMC6494704</ArticleId><ArticleId IdType="pubmed">30383146</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun K, Tan JY, Thomson PJ, Choi SW. Influence of time between surgery and adjuvant radiotherapy on prognosis for patients with head and neck squamous cell carcinoma: A systematic review. Head Neck. 2023;45(8):2108&#x2013;2119. doi: 10.1002/hed.27401</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hed.27401</ArticleId><ArticleId IdType="pubmed">37194205</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemure-Poliquin N, Fu R, Gaebe K, et al. Delayed postoperative radiotherapy in head &amp; neck cancers&#x2014;a systematic review and meta-analysis. Laryngoscope. 2025;135(5):1563&#x2013;1570. doi: 10.1002/lary.31990</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/lary.31990</ArticleId><ArticleId IdType="pmc">PMC11980969</ArticleId><ArticleId IdType="pubmed">39744810</ArticleId></ArticleIdList></Reference><Reference><Citation>Duckett KA, Kassir MF, Nguyen SA, et al. Delays starting postoperative radiotherapy among head and neck cancer patients: a systematic review and meta-analysis. Otolaryngol Head Neck Surg. 2024. doi: 10.1002/ohn.538</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ohn.538</ArticleId></ArticleIdList></Reference><Reference><Citation>Duckett KA, Kassir MF, Nguyen SA, et al. Factors associated with head and neck cancer postoperative radiotherapy delays: a systematic review and meta-analysis. Otolaryngol Head Neck Surg. 2024;171(5):1265&#x2013;1282. doi: 10.1002/ohn.835</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ohn.835</ArticleId><ArticleId IdType="pmc">PMC11499046</ArticleId><ArticleId IdType="pubmed">38842034</ArticleId></ArticleIdList></Reference><Reference><Citation>Ponduri A, Liao DZ, Schlecht NF, et al. Impact of nonadherence to NCCN Adjuvant Radiotherapy Initiation Guidelines in Head and Neck Squamous Cell Carcinoma in an underserved urban population. J Natl Compr Canc Netw. Published online September 22, 2021. doi: 10.6004/jnccn.2021.7007</Citation><ArticleIdList><ArticleId IdType="doi">10.6004/jnccn.2021.7007</ArticleId></ArticleIdList></Reference><Reference><Citation>Divi V, Chen MM, Hara W, et al. Reducing the time from surgery to adjuvant radiation therapy: an institutional quality improvement project. Otolaryngol Head Neck Surg. 2018;159(1):158&#x2013;165. doi: 10.1177/0194599818768254</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0194599818768254</ArticleId><ArticleId IdType="pubmed">29631478</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CW, Dupr&#xe9; S, Marlborough F, et al. Postoperative radiotherapy delay in head and neck cancer patients undergoing major resection and free flap reconstruction. J Plast Reconstr Aesthet Surg. 2022;75(7):2084&#x2013;2089. doi: 10.1016/j.bjps.2022.02.038</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bjps.2022.02.038</ArticleId><ArticleId IdType="pubmed">35351393</ArticleId></ArticleIdList></Reference><Reference><Citation>Voora RS, Stramiello JA, Sumner WA, et al. Quality improvement intervention to reduce time to postoperative radiation in head and neck free flap patients. Head Neck. 2021;43(11):3530&#x2013;3539. doi: 10.1002/hed.26852</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hed.26852</ArticleId><ArticleId IdType="pubmed">34492135</ArticleId></ArticleIdList></Reference><Reference><Citation>Graboyes EM, Halbert CH, Li H, et al. Barriers to the delivery of timely, guideline-adherent adjuvant therapy among patients with head and neck cancer. JCO Oncol Pract. 2020;16(12):e1417&#x2013;e1432. doi: 10.1200/OP.20.00271</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/OP.20.00271</ArticleId><ArticleId IdType="pmc">PMC7735037</ArticleId><ArticleId IdType="pubmed">32853120</ArticleId></ArticleIdList></Reference><Reference><Citation>Gharzai LA, Bromfield J, Kwan M, et al. Implementation mapping to identify strategies to increase timely postoperative radiotherapy initiation for head/neck cancer. Otolaryngol Head Neck Surg. 2025;173(1):288&#x2013;298. doi: 10.1002/ohn.1268</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ohn.1268</ArticleId><ArticleId IdType="pmc">PMC12207378</ArticleId><ArticleId IdType="pubmed">40304500</ArticleId></ArticleIdList></Reference><Reference><Citation>Sykes KJ, Morrow E, Smith JB, et al. What is the hold up?&#x2014;mixed-methods analysis of postoperative radiotherapy delay in head and neck cancer. Head Neck. 2020;42(10):2948&#x2013;2957. doi: 10.1002/hed.26355</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hed.26355</ArticleId><ArticleId IdType="pubmed">33174308</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawaf T, Virgen CG, Renslo B, et al. Association of social-ecological factors with delay in time to initiation of postoperative radiation therapy: a prospective cohort study. JAMA Otolaryngol Head Neck Surg. 2023;149(6):477&#x2013;484. doi: 10.1001/jamaoto.2023.0308</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoto.2023.0308</ArticleId><ArticleId IdType="pmc">PMC10119772</ArticleId><ArticleId IdType="pubmed">37079327</ArticleId></ArticleIdList></Reference><Reference><Citation>Freund KM, Battaglia TA, Calhoun E, et al. ; Patient Navigation Research Program Group. National Cancer Institute Patient Navigation Research Program: methods, protocol, and measures. Cancer. 2008;113(12):3391&#x2013;3399. doi: 10.1002/cncr.23960</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.23960</ArticleId><ArticleId IdType="pmc">PMC2698219</ArticleId><ArticleId IdType="pubmed">18951521</ArticleId></ArticleIdList></Reference><Reference><Citation>Janz TA, Kim J, Hill EG, et al. Association of care processes with timely, equitable postoperative radiotherapy in patients with surgically treated head and neck squamous cell carcinoma. JAMA Otolaryngol Head Neck Surg. 2018;144(12):1105&#x2013;1114. doi: 10.1001/jamaoto.2018.2225</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoto.2018.2225</ArticleId><ArticleId IdType="pmc">PMC6472989</ArticleId><ArticleId IdType="pubmed">30347012</ArticleId></ArticleIdList></Reference><Reference><Citation>Graboyes EM, DeMass R, Sterba KR, et al. Randomized trial of enhanced versus standard navigation to promote timely initiation of adjuvant radiotherapy for head and neck cancer. JCO Oncol Pract. 2025;OP2400901:OP2400901. doi: 10.1200/OP-24-00901</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/OP-24-00901</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullin PA, Lohr KN, Bresnahan BW, McNulty P. Applying cognitive design principles to formatting HRQOL instruments. Qual Life Res. 2000;9(1):13&#x2013;27. doi: 10.1023/A:1008923301313</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1008923301313</ArticleId><ArticleId IdType="pubmed">10981203</ArticleId></ArticleIdList></Reference><Reference><Citation>Graboyes EM, Sterba KR, Li H, et al. Development and evaluation of a navigation-based, multilevel intervention to improve the delivery of timely, guideline-adherent adjuvant therapy for patients with head and neck cancer. JCO Oncol Pract. 2021;17(10):e1512&#x2013;e1523. doi: 10.1200/OP.20.00943</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/OP.20.00943</ArticleId><ArticleId IdType="pmc">PMC8791819</ArticleId><ArticleId IdType="pubmed">33689399</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang GX, Baggett TP, Pandharipande PV, et al. Barriers to lung cancer screening engagement from the patient and provider perspective. Radiology. 2019;290(2):278&#x2013;287. doi: 10.1148/radiol.2018180212</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.2018180212</ArticleId><ArticleId IdType="pubmed">30620258</ArticleId></ArticleIdList></Reference><Reference><Citation>Honein-AbouHaidar GN, Kastner M, Vuong V, et al. Systematic review and meta-study synthesis of qualitative studies evaluating facilitators and barriers to participation in colorectal cancer screening. Cancer Epidemiol Biomarkers Prev. 2016;25(6):907&#x2013;917. doi: 10.1158/1055-9965.EPI-15-0990</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1055-9965.EPI-15-0990</ArticleId><ArticleId IdType="pubmed">27197277</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen Z, Jaca A, Ginindza TG, et al. Barriers to uptake of cervical cancer screening services in low-and-middle-income countries: a systematic review. BMC Womens Health. 2022;22(1):486. doi: 10.1186/s12905-022-02043-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12905-022-02043-y</ArticleId><ArticleId IdType="pmc">PMC9716693</ArticleId><ArticleId IdType="pubmed">36461001</ArticleId></ArticleIdList></Reference><Reference><Citation>Battaglia TA, Gunn CM, Bak SM, et al. Patient navigation to address sociolegal barriers for patients with cancer: A comparative-effectiveness study. Cancer. 2022;128 Suppl 13(Suppl 13):2623&#x2013;2635. doi: 10.1002/cncr.33965</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.33965</ArticleId><ArticleId IdType="pmc">PMC10152516</ArticleId><ArticleId IdType="pubmed">35699610</ArticleId></ArticleIdList></Reference><Reference><Citation>Kibudde S, Namisango E, Nakaganda A, et al. Turnaround time and barriers to treatment of newly diagnosed cancer in Uganda: a mixed-methods longitudinal study. Afr Health Sci. 2022;22(1):327&#x2013;337. doi: 10.4314/ahs.v22i1.40</Citation><ArticleIdList><ArticleId IdType="doi">10.4314/ahs.v22i1.40</ArticleId><ArticleId IdType="pmc">PMC9382503</ArticleId><ArticleId IdType="pubmed">36032470</ArticleId></ArticleIdList></Reference><Reference><Citation>Primeau SW, Freund KM, Ramachandran A, et al. Social service barriers delay care among women with abnormal cancer screening. J Gen Intern Med. 2014;29(1):169&#x2013;175. doi: 10.1007/s11606-013-2615-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11606-013-2615-x</ArticleId><ArticleId IdType="pmc">PMC3889949</ArticleId><ArticleId IdType="pubmed">24197626</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramachandran A, Snyder FR, Katz ML, et al. Barriers to health care contribute to delays in follow-up among women with abnormal cancer screening: data from the Patient Navigation Research Program. Cancer. 2015;121(22):4016&#x2013;4024. doi: 10.1002/cncr.29607</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.29607</ArticleId><ArticleId IdType="pmc">PMC4675460</ArticleId><ArticleId IdType="pubmed">26385420</ArticleId></ArticleIdList></Reference><Reference><Citation>Parke R, Hernandez D, Sabichi AL, et al. Development of a low resource tool for optimizing head and neck cancer treatment delivery within an integrated health care delivery system. J Clin Pathw. 2019;5(8). doi: 10.25270/jcp.2019.10.00098</Citation><ArticleIdList><ArticleId IdType="doi">10.25270/jcp.2019.10.00098</ArticleId></ArticleIdList></Reference><Reference><Citation>Graboyes EM, Cagle JL, Ramadan S, et al. Neighborhood-level disadvantage and delayed adjuvant therapy in head and neck cancer. JAMA Otolaryngol Head Neck Surg. 2024;150(6):472&#x2013;482. doi: 10.1001/jamaoto.2024.0424</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoto.2024.0424</ArticleId><ArticleId IdType="pmc">PMC11046410</ArticleId><ArticleId IdType="pubmed">38662392</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosas Herrera AM, Haskins AD, Hanania AN, et al. Timely delivery of PORT for head and neck squamous cell carcinoma in a county hospital. Laryngoscope Investig Otolaryngol. 2023;9(1):e1211. doi: 10.1002/lio2.1211</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/lio2.1211</ArticleId></ArticleIdList></Reference><Reference><Citation>Graboyes EM, Chappell M, Duckett KA, et al. Patient navigation for timely, guideline-adherent adjuvant therapy for head and neck cancer: a national landscape analysis. J Natl Compr Canc Netw. 2023;21(12):1251&#x2013;1259.e5. doi: 10.6004/jnccn.2023.7061</Citation><ArticleIdList><ArticleId IdType="doi">10.6004/jnccn.2023.7061</ArticleId><ArticleId IdType="pmc">PMC10846494</ArticleId><ArticleId IdType="pubmed">38081134</ArticleId></ArticleIdList></Reference><Reference><Citation>Chollette V, Weaver SJ, Huang G, Tsakraklides S, Tu SP. Identifying cancer care team competencies to improve care coordination in multiteam systems: a modified Delphi study. JCO Oncol Pract. 2020;16 (11):e1324&#x2013;e1331. doi: 10.1200/OP.20.00001</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/OP.20.00001</ArticleId><ArticleId IdType="pmc">PMC7846050</ArticleId><ArticleId IdType="pubmed">32584702</ArticleId></ArticleIdList></Reference><Reference><Citation>Weaver SJ, Jacobsen PB. Cancer care coordination: opportunities for healthcare delivery research. Transl Behav Med. 2018;8(3):503&#x2013;508. doi: 10.1093/tbm/ibx079</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/tbm/ibx079</ArticleId><ArticleId IdType="pmc">PMC6257019</ArticleId><ArticleId IdType="pubmed">29800404</ArticleId></ArticleIdList></Reference><Reference><Citation>Graboyes EM, Yom SS. Treatment delays in oral cavity cancer-time, time, time, see what&#x2019;s become of me. JAMA Otolaryngol Head Neck Surg. 2023;149(11):969&#x2013;970. doi: 10.1001/jamaoto.2023.1942</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoto.2023.1942</ArticleId><ArticleId IdType="pmc">PMC10775417</ArticleId><ArticleId IdType="pubmed">37422843</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatt N, Yang J, DeBaere L, et al. Reducing length of stay in reconstructive head and neck surgery patients: a quality improvement initiative. Otolaryngol Head Neck Surg. 2024;171(6):1938&#x2013;1948. doi: 10.1002/ohn.933</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ohn.933</ArticleId><ArticleId IdType="pubmed">39118499</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortes-Mejia NA, Lillemoe HA, Cata JP. Return to intended oncological therapy: state of the art and perspectives. Curr Oncol Rep. 2024;26(11):1420&#x2013;1430. doi: 10.1007/s11912-024-01594-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11912-024-01594-7</ArticleId><ArticleId IdType="pubmed">39320576</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiong KL, Moreno A, Vu CN, et al. Enhanced recovery after surgery (ERAS) in head and neck oncologic surgery: impact on return to intended oncologic therapy (RIOT) and survival. Oral Oncol. 2022;130:105906. doi: 10.1016/j.oraloncology.2022.105906</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.oraloncology.2022.105906</ArticleId><ArticleId IdType="pubmed">35594776</ArticleId></ArticleIdList></Reference><Reference><Citation>Frenkel CH, Donahue EE, Cochran A, et al. The impact of an enhanced recovery after surgery protocol for major head and neck oncologic surgery on postoperative complications and adjuvant treatment delivery. Head Neck. 2025;47(1):68&#x2013;80. doi: 10.1002/hed.27890</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hed.27890</ArticleId><ArticleId IdType="pubmed">39072915</ArticleId></ArticleIdList></Reference><Reference><Citation>Freund KM, Battaglia TA, Calhoun E, et al. ; Writing Group of the Patient Navigation Research Program. Impact of patient navigation on timely cancer care: the Patient Navigation Research Program. J Natl Cancer Inst. 2014;106(6):dju115. doi: 10.1093/jnci/dju115</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnci/dju115</ArticleId><ArticleId IdType="pmc">PMC4072900</ArticleId><ArticleId IdType="pubmed">24938303</ArticleId></ArticleIdList></Reference><Reference><Citation>Hendren S, Chin N, Fisher S, et al. Patients&#x2019; barriers to receipt of cancer care, and factors associated with needing more assistance from a patient navigator. J Natl Med Assoc. 2011;103(8):701&#x2013;710. doi: 10.1016/S0027-9684(15)30409&#x2013;0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0027-9684</ArticleId><ArticleId IdType="pmc">PMC3713073</ArticleId><ArticleId IdType="pubmed">22046847</ArticleId></ArticleIdList></Reference><Reference><Citation>Vu M, Boyd K, De Marchis EH, et al. Perceived appropriateness of assessing for health-related socioeconomic risks among adult patients with cancer. Cancer Res Commun. 2023;3(4):521&#x2013;531. doi: 10.1158/2767-9764.CRC-22-0283</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2767-9764.CRC-22-0283</ArticleId><ArticleId IdType="pmc">PMC10069714</ArticleId><ArticleId IdType="pubmed">37020993</ArticleId></ArticleIdList></Reference><Reference><Citation>Renslo B, Sawaf T, Virgen CG, et al. Assessing the risk of adjuvant radiotherapy initiation delays with social support surveys. Otolaryngol Head Neck Surg. 2023;169(4):928&#x2013;937. doi: 10.1002/ohn.270</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ohn.270</ArticleId><ArticleId IdType="pmc">PMC10688033</ArticleId><ArticleId IdType="pubmed">36939526</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1001/jamaoto.2025.2649 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40906481</PMID><DateCompleted><Year>2025</Year><Month>12</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>12</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-619X</ISSN><JournalIssue CitedMedium="Internet"><Volume>151</Volume><Issue>12</Issue><PubDate><Year>2025</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA otolaryngology-- head &amp; neck surgery</Title><ISOAbbreviation>JAMA Otolaryngol Head Neck Surg</ISOAbbreviation></Journal><ArticleTitle>Preexisting Psychiatric Risk Factors and Any and Long-Term Opioid Use in Head and Neck Cancer.</ArticleTitle><Pagination><StartPage>1166</StartPage><EndPage>1174</EndPage><MedlinePgn>1166-1174</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaoto.2025.2649</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Head and neck cancer (HNC), one of the most emotionally distressing cancers, carries a significant burden of psychiatric comorbidities. While opioids are commonly prescribed in cancer care, the association between preexisting psychiatric risk factors and prescription opioid use in HNC remains unclear.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To test the hypothesis that preexisting psychiatric risk factors are associated with any opioid prescription and long-term opioid therapy in patients with HNC.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="UNASSIGNED">This retrospective longitudinal cohort study used deidentified data from the Optum electronic health record database, comprising a random sample of 5 million patients across the US between January 2010 and December 2018. Eligible patients were adults diagnosed with HNC. Using a 2-year look-back prior to the index date of HNC diagnosis, patients who used prescription opioids prior to HNC diagnosis were excluded. The data analysis was conducted between July 2022 and July 2023.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="UNASSIGNED">Outcomes of interest were receipt of any prescription opioid within 12 months of index HNC and long-term opioid therapy (LTOT), defined as 10 or more opioid prescriptions within 12 months of index HNC. Psychiatric risk factors included anxiety disorders, depression, smoking/nicotine dependence, substance use disorders, and benzodiazepine prescription. Multivariate logistic regression estimated the odds of opioid use based on preexisting psychiatric factors.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Of 20&#x202f;286 patients with an HNC diagnosis, 11&#x202f;335 met all eligibility criteria. Patients in the analytic cohort had a mean (SD) age of 57.1 (15.5) years, and 55.4% were female. Within 12 months of HNC diagnosis, 23.4% received an opioid prescription, and 4.9% received LTOT. In fully adjusted models, depression (adjusted odds ratio [aOR], 1.21; 95% CI, 1.01-1.45), nicotine dependence (aOR, 1.56; 95% CI, 1.40-1.73), and benzodiazepine comedication (aOR, 1.44; 95% CI, 1.22-1.70) were associated with increased odds of receiving any opioid prescription. Furthermore, male patients had 49% greater odds of receiving opioid prescriptions (aOR, 1.49; 95% CI, 1.36-1.64). Only smoking/nicotine dependence was associated with increased odds of LTOT (aOR, 1.77; 95% CI, 1.21-2.61).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="UNASSIGNED">Preexisting psychiatric comorbidities, especially depression and smoking/nicotine dependence, were associated with increased odds of prescription opioid use and LTOT in patients with HNC in this longitudinal cohort study. Screening for these comorbidities during the management of patients with HNC can be impactful in informing clinical decisions that contribute to safer opioid prescribing.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Osazuwa-Peters</LastName><ForeName>Nosayaba</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Head and Neck Surgery &amp; Communication Sciences, Duke University School of Medicine, Durham, North Carolina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Duke Cancer Institute, Durham, North Carolina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for the Study of Suicide Prevention and Intervention, Duke University School of Medicine, Durham, North Carolina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Deputy Editor, JAMA Otolaryngology-Head &amp; Neck Surgery.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>May Z</ForeName><Initials>MZ</Initials><AffiliationInfo><Affiliation>Duke University School of Medicine, Durham, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kahmke</LastName><ForeName>Russel R</ForeName><Initials>RR</Initials><AffiliationInfo><Affiliation>Department of Head and Neck Surgery &amp; Communication Sciences, Duke University School of Medicine, Durham, North Carolina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Duke Cancer Institute, Durham, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramkumar</LastName><ForeName>Shreya P</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head &amp; Neck Surgery, University of Arizona College of Medicine, Tucson.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bates</LastName><ForeName>Nicole E</ForeName><Initials>NE</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychosocial Oncology, Fred Hutchinson Cancer Center, Seattle, Washington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scherrer</LastName><ForeName>Jeffrey F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Department of Family and Community Medicine, St Louis University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Advanced HEAlth Data (AHEAD Research Institute, St Louis University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Neuroscience, St Louis University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health and Clinical Outcomes Research, St Louis University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Otolaryngol Head Neck Surg</MedlineTA><NlmUniqueID>101589542</NlmUniqueID><ISSNLinking>2168-6181</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000701">Analgesics, Opioid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000701" MajorTopicYN="Y">Analgesics, Opioid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006258" MajorTopicYN="Y">Head and Neck Neoplasms</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="Y">Mental Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Osazuwa-Peters reported grants from the National Institutes of Health (NIH)/National Institute of Dental and Craniofacial Research (K01 DE030916; R01 DE032216) and personal fees from Navigating Cancer and Merck outside the submitted work. Dr Scherrer reported grants from NIH outside the submitted work. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2026</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>11</Day><Hour>13</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>4</Day><Hour>12</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>4</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40906481</ArticleId><ArticleId IdType="pmc">PMC12412040</ArticleId><ArticleId IdType="doi">10.1001/jamaoto.2025.2649</ArticleId><ArticleId IdType="pii">2838194</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol. 2007;18(9):1437-1449. doi: 10.1093/annonc/mdm056</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/annonc/mdm056</ArticleId><ArticleId IdType="pubmed">17355955</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho SF, Rau KM, Shao YY, et al. Patients with head and neck cancer may need more intensive pain management to maintain daily functioning: a multi-center study. Support Care Cancer. 2019;27(5):1663-1672. doi: 10.1007/s00520-018-4404-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00520-018-4404-x</ArticleId><ArticleId IdType="pubmed">30112724</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy RE, Hildebrand CJ. Coordinating pain control in newly diagnosed head/neck cancer: from a case report to a multi-disciplinary approach. J Cancer Res Pract. 2018;5(2):77-80. doi: 10.1016/j.jcrpr.2017.12.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcrpr.2017.12.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Epstein JB, Wilkie DJ, Fischer DJ, Kim YO, Villines D. Neuropathic and nociceptive pain in head and neck cancer patients receiving radiation therapy. Head Neck Oncol. 2009;1:26. doi: 10.1186/1758-3284-1-26</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1758-3284-1-26</ArticleId><ArticleId IdType="pmc">PMC2717963</ArticleId><ArticleId IdType="pubmed">19594943</ArticleId></ArticleIdList></Reference><Reference><Citation>Sethi RKV, Panth N, Puram SV, Varvares MA. Opioid prescription patterns among patients with head and neck cancer. JAMA Otolaryngol Head Neck Surg. 2018;144(4):382-383. doi: 10.1001/jamaoto.2017.3343</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoto.2017.3343</ArticleId><ArticleId IdType="pmc">PMC5876851</ArticleId><ArticleId IdType="pubmed">29522065</ArticleId></ArticleIdList></Reference><Reference><Citation>McDermott JD, Eguchi M, Stokes WA, et al. Short- and long-term opioid use in patients with oral and oropharynx cancer. Otolaryngol Head Neck Surg. 2019;160(3):409-419. doi: 10.1177/0194599818808513</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0194599818808513</ArticleId><ArticleId IdType="pmc">PMC6886698</ArticleId><ArticleId IdType="pubmed">30396321</ArticleId></ArticleIdList></Reference><Reference><Citation>Saraswathula A, Chen MM, Mudumbai SC, Whittemore AS, Divi V. Persistent postoperative opioid use in older head and neck cancer patients. Otolaryngol Head Neck Surg. 2019;160(3):380-387. doi: 10.1177/0194599818778276</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0194599818778276</ArticleId><ArticleId IdType="pubmed">29807503</ArticleId></ArticleIdList></Reference><Reference><Citation>Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain&#x2014;United States, 2016. JAMA. 2016;315(15):1624-1645. doi: 10.1001/jama.2016.1464</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2016.1464</ArticleId><ArticleId IdType="pmc">PMC6390846</ArticleId><ArticleId IdType="pubmed">26977696</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones KF, Fu MR, Merlin JS, et al. Exploring factors associated with long-term opioid therapy in cancer survivors: an integrative review. J Pain Symptom Manage. 2021;61(2):395-415. doi: 10.1016/j.jpainsymman.2020.08.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpainsymman.2020.08.015</ArticleId><ArticleId IdType="pubmed">32822751</ArticleId></ArticleIdList></Reference><Reference><Citation>Balachandra S, Eary RL, Lee R, et al. Substance use and mental health burden in head and neck and other cancer survivors: a National Health Interview Survey analysis. Cancer. 2022;128(1):112-121. doi: 10.1002/cncr.33881</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.33881</ArticleId><ArticleId IdType="pubmed">34499355</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehnert A, Br&#xe4;hler E, Faller H, et al. Four-week prevalence of mental disorders in patients with cancer across major tumor entities. J Clin Oncol. 2014;32(31):3540-3546. doi: 10.1200/JCO.2014.56.0086</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2014.56.0086</ArticleId><ArticleId IdType="pubmed">25287821</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohde RL, Adjei Boakye E, Challapalli SD, et al. Prevalence and sociodemographic factors associated with depression among hospitalized patients with head and neck cancer&#x2014;results from a national study. Psychooncology. 2018;27(12):2809-2814. doi: 10.1002/pon.4893</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pon.4893</ArticleId><ArticleId IdType="pubmed">30225960</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y, Hung CF, Chien CY, et al. Comparison of prevalence and associated factors of depressive disorder between patients with head and neck cancer and those with lung cancer at a tertiary hospital in Taiwan: a cross-sectional study. BMJ Open. 2020;10(6):e037918. doi: 10.1136/bmjopen-2020-037918</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-037918</ArticleId><ArticleId IdType="pmc">PMC7328812</ArticleId><ArticleId IdType="pubmed">32601116</ArticleId></ArticleIdList></Reference><Reference><Citation>Mwobobia J, White MC, Osazuwa-Peters OL, et al. Depression, non-medical pain prescriptions, and suicidal behavior in cancer survivors. J Cancer Surviv. Published January 16, 2025. doi: 10.1007/s11764-024-01740-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11764-024-01740-x</ArticleId><ArticleId IdType="pmc">PMC12217687</ArticleId><ArticleId IdType="pubmed">39821751</ArticleId></ArticleIdList></Reference><Reference><Citation>Osazuwa-Peters N, Simpson MC, Zhao L, et al. Suicide risk among cancer survivors: head and neck versus other cancers. Cancer. 2018;124(20):4072-4079. doi: 10.1002/cncr.31675</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.31675</ArticleId><ArticleId IdType="pubmed">30335190</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan MD, Howe CQ. Opioid therapy for chronic pain in the United States: promises and perils. Pain. 2013;154 Suppl 1:S94-s100. doi: 10.1016/j.pain.2013.09.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pain.2013.09.009</ArticleId><ArticleId IdType="pmc">PMC4204477</ArticleId><ArticleId IdType="pubmed">24036286</ArticleId></ArticleIdList></Reference><Reference><Citation>Ko HC, Mehra MN, Burr AR, et al. Opioid use in patients undergoing treatment for oral cavity cancer. J Pain Manag. 2020;13(2):167-173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8388255</ArticleId><ArticleId IdType="pubmed">34457108</ArticleId></ArticleIdList></Reference><Reference><Citation>Abt NB, Holcomb AJ, Feng AL, et al. Opioid usage and prescribing predictors following transoral robotic surgery for oropharyngeal cancer. Laryngoscope. 2021;131(6):E1888-E1894. doi: 10.1002/lary.29276</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/lary.29276</ArticleId><ArticleId IdType="pubmed">33210756</ArticleId></ArticleIdList></Reference><Reference><Citation>Silver N, Dourado J, Hitchcock K, et al. Chronic opioid use in patients undergoing treatment for oropharyngeal cancer. Laryngoscope. 2019;129(9):2087-2093. doi: 10.1002/lary.27791</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/lary.27791</ArticleId><ArticleId IdType="pubmed">30613983</ArticleId></ArticleIdList></Reference><Reference><Citation>Schumacher LD, Sargi ZB, Masforroll M, et al. Long-term opioid use in curative-intent radiotherapy: one-year outcomes in head/neck cancer patients. Head Neck. 2020;42(4):608-624. doi: 10.1002/hed.26034</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hed.26034</ArticleId><ArticleId IdType="pmc">PMC7703799</ArticleId><ArticleId IdType="pubmed">31785054</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon JH, Hui D, Chisholm G, Bruera E. Predictors of long-term opioid treatment among patients who receive chemoradiation for head and neck cancer. Oncologist. 2013;18(6):768-774. doi: 10.1634/theoncologist.2013-0001</Citation><ArticleIdList><ArticleId IdType="doi">10.1634/theoncologist.2013-0001</ArticleId><ArticleId IdType="pmc">PMC4063405</ArticleId><ArticleId IdType="pubmed">23723332</ArticleId></ArticleIdList></Reference><Reference><Citation>Starr N, Oyler DR, Schadler A, Aouad RK. Chronic opioid use after laryngeal cancer treatment. Head Neck. 2021;43(4):1242-1251. doi: 10.1002/hed.26591</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hed.26591</ArticleId><ArticleId IdType="pubmed">33368718</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang JJ, Rubin SJ, Devaiah AK, Faden DL, Salama AR, Edwards HA. Long-term opioid use in post-surgical management of patients with head and neck cancer. Ann Otol Rhinol Laryngol. 2022;131(8):844-850. doi: 10.1177/00034894211045771</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/00034894211045771</ArticleId><ArticleId IdType="pubmed">34521247</ArticleId></ArticleIdList></Reference><Reference><Citation>Cata JP, Patino M, Gorur A, et al. Persistent and chronic postoperative opioid use in a cohort of patients with oral tongue squamous cell carcinoma. Pain Med. 2020;21(5):1061-1067. doi: 10.1093/pm/pnz242</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/pm/pnz242</ArticleId><ArticleId IdType="pmc">PMC8453604</ArticleId><ArticleId IdType="pubmed">31609416</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry M, Alias A, Frenkiel S, et al. Contribution of psychiatric diagnoses to extent of opioid prescription in the first year post-head and neck cancer diagnosis: a longitudinal study. Psychooncology. 2019;28(1):107-115. doi: 10.1002/pon.4917</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pon.4917</ArticleId><ArticleId IdType="pubmed">30308695</ArticleId></ArticleIdList></Reference><Reference><Citation>Solberg LI, Engebretson KI, Sperl-Hillen JM, Hroscikoski MC, O&#x2019;Connor PJ. Are claims data accurate enough to identify patients for performance measures or quality improvement?&#x2014;the case of diabetes, heart disease, and depression. Am J Med Qual. 2006;21(4):238-245. doi: 10.1177/1062860606288243</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1062860606288243</ArticleId><ArticleId IdType="pubmed">16849780</ArticleId></ArticleIdList></Reference><Reference><Citation>Frayne SM, Miller DR, Sharkansky EJ, et al. Using administrative data to identify mental illness: what approach is best? Am J Med Qual. 2010;25(1):42-50. doi: 10.1177/1062860609346347</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1062860609346347</ArticleId><ArticleId IdType="pubmed">19855046</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermesdorf M, Berger K, Baune BT, Wellmann J, Ruscheweyh R, Wersching H. Pain sensitivity in patients with major depression: differential effect of pain sensitivity measures, somatic cofactors, and disease characteristics. J Pain. 2016;17(5):606-616. doi: 10.1016/j.jpain.2016.01.474</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpain.2016.01.474</ArticleId><ArticleId IdType="pubmed">26867484</ArticleId></ArticleIdList></Reference><Reference><Citation>Laird BJ, Boyd AC, Colvin LA, Fallon MT. Are cancer pain and depression interdependent?&#x2014;a systematic review. Psychooncology. 2009;18(5):459-464. doi: 10.1002/pon.1431</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pon.1431</ArticleId><ArticleId IdType="pubmed">18942659</ArticleId></ArticleIdList></Reference><Reference><Citation>Riva JJ, Noor ST, Wang L, et al. Predictors of prolonged opioid use after initial prescription for acute musculoskeletal injuries in adults: a systematic review and meta-analysis of observational studies. Ann Intern Med. 2020;173(9):721-729. doi: 10.7326/M19-3600</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M19-3600</ArticleId><ArticleId IdType="pubmed">32805130</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Ancoli-Israel S. Sleep disturbances in cancer. Psychiatr Ann. 2008;38(9):627-634. doi: 10.3928/00485713-20080901-01</Citation><ArticleIdList><ArticleId IdType="doi">10.3928/00485713-20080901-01</ArticleId><ArticleId IdType="pmc">PMC3021374</ArticleId><ArticleId IdType="pubmed">21243092</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers AH, Zvolensky MJ, Ditre JW, Buckner JD, Asmundson GJG. Association of opioid misuse with anxiety and depression: a systematic review of the literature. Clin Psychol Rev. 2021;84:101978. doi: 10.1016/j.cpr.2021.101978</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cpr.2021.101978</ArticleId><ArticleId IdType="pubmed">33515811</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith JP, Book SW. Anxiety and Substance Use Disorders: A Review. Psychiatr Times. 2008;25(10):19-23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2904966</ArticleId><ArticleId IdType="pubmed">20640182</ArticleId></ArticleIdList></Reference><Reference><Citation>Osazuwa-Peters N, Adjei Boakye E, Chen BY, Tobo BB, Varvares MA. Association between head and neck squamous cell carcinoma survival, smoking at diagnosis, and marital status. JAMA Otolaryngol Head Neck Surg. 2018;144(1):43-50. doi: 10.1001/jamaoto.2017.1880</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoto.2017.1880</ArticleId><ArticleId IdType="pmc">PMC5833596</ArticleId><ArticleId IdType="pubmed">29121146</ArticleId></ArticleIdList></Reference><Reference><Citation>Caini S, Del Riccio M, Vettori V, et al. Post-diagnosis smoking cessation and survival of patients with head and neck cancer: a systematic review and meta-analysis. Br J Cancer. 2022;127(11):1907-1915. doi: 10.1038/s41416-022-01945-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41416-022-01945-w</ArticleId><ArticleId IdType="pmc">PMC9681856</ArticleId><ArticleId IdType="pubmed">35999273</ArticleId></ArticleIdList></Reference><Reference><Citation>Krutz M, Acharya P, Chissoe G, et al. Tobacco cessation after head and neck cancer diagnosis is an independent predictor of treatment response and long-term survival. Oral Oncol. 2022;134:106072. doi: 10.1016/j.oraloncology.2022.106072</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.oraloncology.2022.106072</ArticleId><ArticleId IdType="pmc">PMC10427030</ArticleId><ArticleId IdType="pubmed">35995005</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JJW, Kunaratnam V, Kim CJH, et al. Cigarette smoking cessation, duration of smoking abstinence, and head and neck squamous cell carcinoma prognosis. Cancer. 2023;129(6):867-877. doi: 10.1002/cncr.34620</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.34620</ArticleId><ArticleId IdType="pubmed">36653915</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Heest T, Rubin N, Khariwala SS. Persistent tobacco use after treatment for head and neck cancer. JAMA Otolaryngol Head Neck Surg. 2022;148(7):597-603. doi: 10.1001/jamaoto.2022.0810</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoto.2022.0810</ArticleId><ArticleId IdType="pmc">PMC9100463</ArticleId><ArticleId IdType="pubmed">35551592</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharp L, Johansson H, Fagerstr&#xf6;m K, Rutqvist LE. Smoking cessation among patients with head and neck cancer: cancer as a &#x2018;teachable moment&#x2019;. Eur J Cancer Care (Engl). 2008;17(2):114-119. doi: 10.1111/j.1365-2354.2007.00815.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2354.2007.00815.x</ArticleId><ArticleId IdType="pubmed">18302647</ArticleId></ArticleIdList></Reference><Reference><Citation>Kriplani A, Lavery JA, Mishra A, et al. Trends in chronic opioid therapy among survivors of head and neck cancer. Head Neck. 2021;43(1):223-228. doi: 10.1002/hed.26478</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hed.26478</ArticleId><ArticleId IdType="pmc">PMC8405132</ArticleId><ArticleId IdType="pubmed">32964530</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen-Smith A, Stewart C, Sesay MM, et al. Chronic pain diagnoses and opioid dispensings among insured individuals with serious mental illness. BMC Psychiatry. 2020;20(1):40. doi: 10.1186/s12888-020-2456-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12888-020-2456-1</ArticleId><ArticleId IdType="pmc">PMC6995196</ArticleId><ArticleId IdType="pubmed">32005200</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawal OD, Gold J, Murthy A, et al. Rate and risk factors associated with prolonged opioid use after surgery: a systematic review and meta-analysis. JAMA Netw Open. 2020;3(6):e207367. doi: 10.1001/jamanetworkopen.2020.7367</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.7367</ArticleId><ArticleId IdType="pmc">PMC7317603</ArticleId><ArticleId IdType="pubmed">32584407</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyu X, Guy GP, Baldwin GT, Losby JL, Bohnert ASB, Goldstick JE. State-to-state variation in opioid dispensing changes following the release of the 2016 CDC guideline for prescribing opioids for chronic pain. JAMA Netw Open. 2023;6(9):e2332507-e2332507. doi: 10.1001/jamanetworkopen.2023.32507</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2023.32507</ArticleId><ArticleId IdType="pmc">PMC10495870</ArticleId><ArticleId IdType="pubmed">37695587</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodin R, Li L, McKendrick K, et al. The 2016 CDC opioid guideline and analgesic prescribing patterns in older adults with cancer. JAMA Netw Open. 2025;8(5):e259043-e259043. doi: 10.1001/jamanetworkopen.2025.9043</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2025.9043</ArticleId><ArticleId IdType="pmc">PMC12059969</ArticleId><ArticleId IdType="pubmed">40332933</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1001/jamaoto.2025.2235 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40810933</PMID><DateCompleted><Year>2025</Year><Month>12</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>12</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-619X</ISSN><JournalIssue CitedMedium="Internet"><Volume>151</Volume><Issue>12</Issue><PubDate><Year>2025</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA otolaryngology-- head &amp; neck surgery</Title><ISOAbbreviation>JAMA Otolaryngol Head Neck Surg</ISOAbbreviation></Journal><ArticleTitle>Unilateral vs Bilateral Transoral Surgery for Tonsillar Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis.</ArticleTitle><Pagination><StartPage>1148</StartPage><EndPage>1156</EndPage><MedlinePgn>1148-1156</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaoto.2025.2235</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="UNASSIGNED">Transoral surgery via a radical tonsillectomy followed by pathology-guided adjuvant therapy is standard of care for tonsillar squamous cell carcinoma (SCCa). There is significant variation in the management of the contralateral tonsil without clinical evidence of disease.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To assess the second primary tumor rates, oncologic survival, functional outcomes, and complications between bilateral and unilateral transoral surgery for tonsillar SCCa.</AbstractText><AbstractText Label="DATA SOURCES" NlmCategory="UNASSIGNED">A search of Embase, Ovid MEDLINE, Scopus, and Cochrane was performed on September 11, 2024.</AbstractText><AbstractText Label="STUDY SELECTION" NlmCategory="UNASSIGNED">Inclusion criteria were studies with more than 10 adults undergoing transoral surgery for unilateral tonsillar SCCa reporting at least 1 primary or secondary outcome. Screening of abstracts and full texts along with data extraction were performed in duplicate.</AbstractText><AbstractText Label="DATA EXTRACTION AND SYNTHESIS" NlmCategory="UNASSIGNED">The Meta-analysis of Observational Studies in Epidemiology (MOOSE) reporting guideline was followed. Data were pooled using a random-effects model.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="UNASSIGNED">The primary outcome measure was the synchronous and metachronous contralateral tonsil second primary tumor rates. Secondary outcome measures were between-group differences in oropharyngeal hemorrhage and gastrostomy tube dependence rates and 2-year and 5-year overall survival (OS) and disease-free survival (DFS).</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Of 136 unique citations identified, 11 studies were included, representing a total of 1486 patients (634 bilateral surgery, 852 unilateral surgery). The synchronous contralateral tonsil second primary tumor rate in the bilateral surgery group was 4.0% (95% CI, 2.0%-5.0%; I2&#x2009;=&#x2009;0.05%). The metachronous contralateral tonsil second primary tumor rate in the unilateral surgery group was 0.1% (95% CI, 0%-1%; I2&#x2009;=&#x2009;0.04%). There were no between-group differences in oropharyngeal bleeding rate (-0.2% [95% CI, -5.6% to 5.3%]) or gastrostomy tube dependence rate (-0.5% [95% CI, -5.2% to 4.3%]). The 2-year and 5-year pooled OS proportion differences between the bilateral surgery and unilateral surgery groups were 3.6% (95% CI, -2.2% to 9.4%) and 5.3% (95% CI, -3.8% to 14.4%), respectively. The 2-year and 5-year pooled DFS proportion differences between the bilateral surgery and unilateral surgery groups were -0.5% (95% CI, -6.5% to 5.4%) and 11.1% (95% CI, 1.6%-20.5%), respectively.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="UNASSIGNED">This systematic review and meta-analysis suggests that omission of contralateral elective extracapsular tonsillectomy in tonsillar SCCa is safe with markedly low metachronous contralateral tonsillar second primary tumor rates and no compromise in survival. The decision to perform a simultaneous contralateral extracapsular tonsillectomy can be addressed via clinician-patient shared decision-making with consideration of its pros and cons.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Peterson</LastName><ForeName>Andrew M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Head and Neck Tumor Center at Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruz</LastName><ForeName>Lucas</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Michael P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Head and Neck Tumor Center at Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bockover</LastName><ForeName>Spencer R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Head and Neck Tumor Center at Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kallogjeri</LastName><ForeName>Dorina</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Statistics Editor, JAMA Otolaryngology-Head &amp; Neck Surgery.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yaeger</LastName><ForeName>Lauren H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Bernard Becker Medical Library, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harbison</LastName><ForeName>Alex</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Head and Neck Tumor Center at Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zolkind</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Head and Neck Tumor Center at Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rich</LastName><ForeName>Jason T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Head and Neck Tumor Center at Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pipkorn</LastName><ForeName>Patrik</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Head and Neck Tumor Center at Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paniello</LastName><ForeName>Randal C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Head and Neck Tumor Center at Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puram</LastName><ForeName>Sidharth V</ForeName><Initials>SV</Initials><AffiliationInfo><Affiliation>Head and Neck Tumor Center at Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jackson</LastName><ForeName>Ryan S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Head and Neck Tumor Center at Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Otolaryngol Head Neck Surg</MedlineTA><NlmUniqueID>101589542</NlmUniqueID><ISSNLinking>2168-6181</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014067" MajorTopicYN="Y">Tonsillar Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014068" MajorTopicYN="Y">Tonsillectomy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002294" MajorTopicYN="Y">Carcinoma, Squamous Cell</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016609" MajorTopicYN="N">Neoplasms, Second Primary</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057605" MajorTopicYN="Y">Natural Orifice Endoscopic Surgery</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Kallogjeri reported receiving personal fees from <i>JAMA Otolaryngology&#x2013;Head &amp; Neck Surgery</i> for serving as statistics editor outside the submitted work. Dr Jackson reported receiving honoraria from Intuitive outside the submitted work. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2026</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>11</Day><Hour>13</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>14</Day><Hour>22</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>14</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40810933</ArticleId><ArticleId IdType="pmc">PMC12355387</ArticleId><ArticleId IdType="doi">10.1001/jamaoto.2025.2235</ArticleId><ArticleId IdType="pii">2837623</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cracchiolo JR, Roman BR, Kutler DI, Kuhel WI, Cohen MA. Adoption of transoral robotic surgery compared with other surgical modalities for treatment of oropharyngeal squamous cell carcinoma. J Surg Oncol. 2016;114(4):405-411. doi: 10.1002/jso.24353</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jso.24353</ArticleId><ArticleId IdType="pmc">PMC5019352</ArticleId><ArticleId IdType="pubmed">27392812</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen MA, Weinstein GS, O&#x2019;Malley BW Jr, Feldman M, Quon H. Transoral robotic surgery and human papillomavirus status: oncologic results. Head Neck. 2011;33(4):573-580. doi: 10.1002/hed.21500</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hed.21500</ArticleId><ArticleId IdType="pubmed">21425382</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore EJ, Olsen SM, Laborde RR, et al. Long-term functional and oncologic results of transoral robotic surgery for oropharyngeal squamous cell carcinoma. Mayo Clin Proc. 2012;87(3):219-225. doi: 10.1016/j.mayocp.2011.10.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2011.10.007</ArticleId><ArticleId IdType="pmc">PMC3538408</ArticleId><ArticleId IdType="pubmed">22386176</ArticleId></ArticleIdList></Reference><Reference><Citation>de Almeida JR, Li R, Magnuson JS, et al. Oncologic outcomes after transoral robotic surgery: a multi-institutional study. JAMA Otolaryngol Head Neck Surg. 2015;141(12):1043-1051. doi: 10.1001/jamaoto.2015.1508</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoto.2015.1508</ArticleId><ArticleId IdType="pmc">PMC5019351</ArticleId><ArticleId IdType="pubmed">26402479</ArticleId></ArticleIdList></Reference><Reference><Citation>Leonhardt FD, Quon H, Abrah&#xe3;o M, O&#x2019;Malley BW Jr, Weinstein GS. Transoral robotic surgery for oropharyngeal carcinoma and its impact on patient-reported quality of life and function. Head Neck. 2012;34(2):146-154. doi: 10.1002/hed.21688</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hed.21688</ArticleId><ArticleId IdType="pubmed">21469248</ArticleId></ArticleIdList></Reference><Reference><Citation>Nichols AC, Theurer J, Prisman E, et al. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. Lancet Oncol. 2019;20(10):1349-1359. doi: 10.1016/S1470-2045(19)30410-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(19)30410-3</ArticleId><ArticleId IdType="pubmed">31416685</ArticleId></ArticleIdList></Reference><Reference><Citation>Nami Saber C, Gr&#xf8;nh&#xf8;j C, Jensen DH, et al. Synchronous, bilateral tonsillar carcinomas: patient characteristics and human papillomavirus genotypes. Oral Oncol. 2017;74:105-110. doi: 10.1016/j.oraloncology.2017.09.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.oraloncology.2017.09.019</ArticleId><ArticleId IdType="pubmed">29103737</ArticleId></ArticleIdList></Reference><Reference><Citation>Dziegielewski PT, Boyce BJ, Old M, et al. Transoral robotic surgery for tonsillar cancer: addressing the contralateral tonsil. Head Neck. 2017;39(11):2224-2231. doi: 10.1002/hed.24887</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hed.24887</ArticleId><ArticleId IdType="pubmed">28782298</ArticleId></ArticleIdList></Reference><Reference><Citation>McQuone SJ, Eisele DW, Lee DJ, Westra WH, Koch WM. Occult tonsillar carcinoma in the unknown primary. Laryngoscope. 1998;108(11, pt 1):1605-1610. doi: 10.1097/00005537-199811000-00004</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005537-199811000-00004</ArticleId><ArticleId IdType="pubmed">9818813</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch WM, Bhatti N, Williams MF, Eisele DW. Oncologic rationale for bilateral tonsillectomy in head and neck squamous cell carcinoma of unknown primary source. Otolaryngol Head Neck Surg. 2001;124(3):331-333. doi: 10.1067/mhn.2001.114309</Citation><ArticleIdList><ArticleId IdType="doi">10.1067/mhn.2001.114309</ArticleId><ArticleId IdType="pubmed">11241001</ArticleId></ArticleIdList></Reference><Reference><Citation>Kothari P, Randhawa PS, Farrell R. Role of tonsillectomy in the search for a squamous cell carcinoma from an unknown primary in the head and neck. Br J Oral Maxillofac Surg. 2008;46(4):283-287. doi: 10.1016/j.bjoms.2007.11.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bjoms.2007.11.017</ArticleId><ArticleId IdType="pubmed">18243447</ArticleId></ArticleIdList></Reference><Reference><Citation>Rokkjaer MS, Klug TE. Prevalence of synchronous bilateral tonsil squamous cell carcinoma: a retrospective study. Clin Otolaryngol. 2018;43(1):1-6. doi: 10.1111/coa.12981</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/coa.12981</ArticleId><ArticleId IdType="pubmed">28891195</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahmood S, Ahmed T, Oladejo O, et al. Incidence of synchronous contralateral tonsillar malignancy in a known case of unilateral tonsillar carcinoma. Eur Arch Otorhinolaryngol. 2022;279(7):3665-3669. doi: 10.1007/s00405-021-07213-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00405-021-07213-6</ArticleId><ArticleId IdType="pubmed">35028695</ArticleId></ArticleIdList></Reference><Reference><Citation>Parhar HS, Shimunov D, Brody RM, et al. Revisiting the recommendation for contralateral tonsillectomy in HPV-associated tonsillar carcinoma. Otolaryngol Head Neck Surg. 2021;164(6):1222-1229. doi: 10.1177/0194599820968800</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0194599820968800</ArticleId><ArticleId IdType="pubmed">33138700</ArticleId></ArticleIdList></Reference><Reference><Citation>McMillan RA, Van Abel KM, Yin LX, et al. Second primary tumors in patients presenting with unilateral HPV-associated tonsillar squamous cell carcinoma. Laryngoscope. 2022;132(2):332-338. doi: 10.1002/lary.29741</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/lary.29741</ArticleId><ArticleId IdType="pubmed">34236086</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim CM, St John MA. Should the contralateral tonsil be removed in cases of HPV-positive squamous cell carcinoma of the tonsil? Laryngoscope. 2019;129(6):1257-1258. doi: 10.1002/lary.27563</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/lary.27563</ArticleId><ArticleId IdType="pubmed">30467851</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting: Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008-2012. doi: 10.1001/jama.283.15.2008</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.283.15.2008</ArticleId><ArticleId IdType="pubmed">10789670</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramer WM, Giustini D, de Jonge GB, Holland L, Bekhuis T. De-duplication of database search results for systematic reviews in EndNote. J Med Libr Assoc. 2016;104(3):240-243. doi: 10.3163/1536-5050.104.3.014</Citation><ArticleIdList><ArticleId IdType="doi">10.3163/1536-5050.104.3.014</ArticleId><ArticleId IdType="pmc">PMC4915647</ArticleId><ArticleId IdType="pubmed">27366130</ArticleId></ArticleIdList></Reference><Reference><Citation>Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73(9):712-716. doi: 10.1046/j.1445-2197.2003.02748.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1445-2197.2003.02748.x</ArticleId><ArticleId IdType="pubmed">12956787</ArticleId></ArticleIdList></Reference><Reference><Citation>Drewry AM, Ablordeppey EA, Murray ET, et al. Antipyretic therapy in critically ill septic patients: a systematic review and meta-analysis. Crit Care Med. 2017;45(5):806-813. doi: 10.1097/CCM.0000000000002285</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000002285</ArticleId><ArticleId IdType="pmc">PMC5389594</ArticleId><ArticleId IdType="pubmed">28221185</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JJ, Peterson AM, Embry TW, et al. Survival outcomes of de novo vs inverted papilloma-associated sinonasal squamous cell carcinoma: a systematic review and meta-analysis. JAMA Otolaryngol Head Neck Surg. 2021;147(4):350-359. doi: 10.1001/jamaoto.2020.5261</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoto.2020.5261</ArticleId><ArticleId IdType="pmc">PMC7844698</ArticleId><ArticleId IdType="pubmed">33507208</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders J, Losavio P, Petruzzelli GJ. Incidence of synchronous bilateral tonsillar carcinoma in a cohort of T1/T2 primary tonsil cancer. Otolaryngol Head Neck Surg. 2013;149(S2):177-P177. doi: 10.1177/0194599813496044a105</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0194599813496044a105</ArticleId></ArticleIdList></Reference><Reference><Citation>Wysocka BA, Ulh&#xf8;i BP, Pedersen U, Grau C. Incidence of synchronous bilateral tonsillar squamous cell carcinoma (abstract EP-1165). Radiother Oncol. 2012;103(S1):S449-S450. doi: 10.1016/S0167-8140(12)71498-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0167-8140(12)71498-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Peterson AM, Bockover SR, Kallogjeri D, et al. Unilateral vs bilateral transoral robotic surgery for HPV-positive tonsillar squamous cell carcinoma. JAMA Otolaryngol Head Neck Surg. Published online July 10, 2025. doi: 10.1001/jamaoto.2025.1833</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoto.2025.1833</ArticleId><ArticleId IdType="pmc">PMC12246949</ArticleId><ArticleId IdType="pubmed">40638110</ArticleId></ArticleIdList></Reference><Reference><Citation>Stepan K, Craig E, Skillington SA, et al. Development of second primary malignancies after transoral surgery in human papilloma virus&#x2013;positive oropharyngeal squamous cell carcinoma. Head Neck. 2022;44(5):1069-1078. doi: 10.1002/hed.27002</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hed.27002</ArticleId><ArticleId IdType="pmc">PMC9112335</ArticleId><ArticleId IdType="pubmed">35175648</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1001/jamaoto.2025.2111 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40742602</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-619X</ISSN><JournalIssue CitedMedium="Internet"><Volume>151</Volume><Issue>12</Issue><PubDate><Year>2025</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA otolaryngology-- head &amp; neck surgery</Title><ISOAbbreviation>JAMA Otolaryngol Head Neck Surg</ISOAbbreviation></Journal><ArticleTitle>Emerging Role of Pathologic Response in Head and Neck Squamous Cell Carcinoma Immunotherapy.</ArticleTitle><Pagination><StartPage>1136</StartPage><EndPage>1137</EndPage><MedlinePgn>1136-1137</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaoto.2025.2111</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dahal</LastName><ForeName>Ashish</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uppaluri</LastName><ForeName>Ravindra</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery/Otolaryngology, Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wise-Draper</LastName><ForeName>Trisha M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Division of Hematology/Oncology, Department of Internal Medicine, University of Cincinnati, Cincinnati, Ohio.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Otolaryngol Head Neck Surg</MedlineTA><NlmUniqueID>101589542</NlmUniqueID><ISSNLinking>2168-6181</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Otolaryngol Head Neck Surg. 2025 Dec 1;151(12):1127-1136. doi: 10.1001/jamaoto.2025.1707.</RefSource><PMID Version="1">40742583</PMID></CommentsCorrections></CommentsCorrectionsList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>31</Day><Hour>12</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>31</Day><Hour>12</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>31</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40742602</ArticleId><ArticleId IdType="doi">10.1001/jamaoto.2025.2111</ArticleId><ArticleId IdType="pii">2837004</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1001/jamaoto.2025.1707 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40742583</PMID><DateCompleted><Year>2025</Year><Month>12</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>12</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-619X</ISSN><JournalIssue CitedMedium="Internet"><Volume>151</Volume><Issue>12</Issue><PubDate><Year>2025</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA otolaryngology-- head &amp; neck surgery</Title><ISOAbbreviation>JAMA Otolaryngol Head Neck Surg</ISOAbbreviation></Journal><ArticleTitle>Pathologic Treatment Effect and Survival in HPV-Negative HNSCC Following Neoadjuvant Nivolumab.</ArticleTitle><Pagination><StartPage>1127</StartPage><EndPage>1136</EndPage><MedlinePgn>1127-1136</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e251707</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaoto.2025.1707</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="UNASSIGNED">Neoadjuvant immunotherapy shows promise in the treatment of head and neck squamous cell carcinoma (HNSCC). Pathologic treatment effect (pTE) is one way to assess response to treatment; however, the association of this response with survival outcomes is not yet clear. The current study sought to determine whether treatment response to neoadjuvant nivolumab, as measured by pTE, correlates with survival outcomes.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To determine whether patients with HNSCC with pathologic response to neoadjuvant nivolumab have improved survival outcomes.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="UNASSIGNED">A cohort study performing a pooled analysis of 2 multi-institutional neoadjuvant clinical trials (NCT03238365, NCT03854032) enrolling patients from July 2017 to January 2022, was performed. Patients with resectable HNSCC enrolled in 1 of 2 clinical trials and treated with neoadjuvant immunotherapy and surgical resection were included in the analysis. Patients were followed up for a median (range) of 36 (4-72) months. Analysis took place on April 15, 2024.</AbstractText><AbstractText Label="INTERVENTION" NlmCategory="UNASSIGNED">Patients were treated with neoadjuvant nivolumab with or without the addition of immunomodulating medications (tadalafil or indoleamine 2,3 dioxygenase inhibitor).</AbstractText><AbstractText Label="MAIN OUTCOME AND MEASURE" NlmCategory="UNASSIGNED">Pooled analysis was performed to plot Kaplan-Meier 3-year survival outcomes for pTE responders and low or nonresponders. A pTE response threshold was determined using recursive partitioning analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Seventy-nine patients were included in the analysis, of whom 40 (51%) had human papillomavirus (HPV)-negative disease. Recursive partitioning analysis identified a pTE threshold of 57%, which was used to define pathologic responders vs low or nonresponders. Pathologic responders with HPV-negative disease had significantly improved disease-free survival (100% for responders vs 66.8% for low or nonresponders; 95% CI, 46.1%-80.6%) and overall survival (100% for responders vs 73.3% for low or nonresponders; 95% CI, 53.4%-85.7%). In patients with HPV-positive disease, disease-free survival was high for both responders (90%; 95% CI, 47.3%-98.5%) and low or nonresponders (92.4%; 95% CI, 72.8%-98.1%).</AbstractText><AbstractText Label="CONCLUSION AND RELEVANCE" NlmCategory="UNASSIGNED">This cohort study found that patients with HPV-negative disease who are deemed pathologic responders (pTE &gt;57%) to neoadjuvant nivolumab may have improved survival outcomes compared with those who are low or nonresponders. Not only does this suggest a role for using pathologic response as a surrogate marker, but it further highlights the neoadjuvant strategy in HNSCC as associated with improved survival.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moroco</LastName><ForeName>Annie E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nunes</LastName><ForeName>Kathryn</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alnemri</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bridgham</LastName><ForeName>Kelly</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Llerena</LastName><ForeName>Pablo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tuluc</LastName><ForeName>Madalina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology, Thomas Jefferson University, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gargano</LastName><ForeName>Stacey</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pathology, Thomas Jefferson University, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhan</LastName><ForeName>Tingting</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thal</LastName><ForeName>Arielle G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cognetti</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Curry</LastName><ForeName>Joseph M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Jennifer M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luginbuhl</LastName><ForeName>Adam J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Otolaryngol Head Neck Surg</MedlineTA><NlmUniqueID>101589542</NlmUniqueID><ISSNLinking>2168-6181</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000074322">Antineoplastic Agents, Immunological</NameOfSubstance></Chemical><Chemical><RegistryNumber>31YO63LBSN</RegistryNumber><NameOfSubstance UI="D000077594">Nivolumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>JAMA Otolaryngol Head Neck Surg. 2025 Dec 1;151(12):1136-1137. doi: 10.1001/jamaoto.2025.2111.</RefSource><PMID Version="1">40742602</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000074322" MajorTopicYN="Y">Antineoplastic Agents, Immunological</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006258" MajorTopicYN="Y">Head and Neck Neoplasms</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020360" MajorTopicYN="Y">Neoadjuvant Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077594" MajorTopicYN="Y">Nivolumab</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077195" MajorTopicYN="Y">Squamous Cell Carcinoma of Head and Neck</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> None reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2026</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>11</Day><Hour>13</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>31</Day><Hour>12</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>31</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40742583</ArticleId><ArticleId IdType="pmc">PMC12551806</ArticleId><ArticleId IdType="doi">10.1001/jamaoto.2025.1707</ArticleId><ArticleId IdType="pii">2837002</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Du E, Mazul AL, Farquhar D, et al. Long-term survival in head and neck cancer: impact of site, stage, smoking, and human papillomavirus status. Laryngoscope. 2019;129(11):2506-2513. doi: 10.1002/lary.27807</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/lary.27807</ArticleId><ArticleId IdType="pmc">PMC6907689</ArticleId><ArticleId IdType="pubmed">30637762</ArticleId></ArticleIdList></Reference><Reference><Citation>Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24-35. doi: 10.1056/NEJMoa0912217</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0912217</ArticleId><ArticleId IdType="pmc">PMC2943767</ArticleId><ArticleId IdType="pubmed">20530316</ArticleId></ArticleIdList></Reference><Reference><Citation>Roden DF, Hobelmann K, Vimawala S, et al. Evaluating the impact of smoking on disease-specific survival outcomes in patients with human papillomavirus-associated oropharyngeal cancer treated with transoral robotic surgery. Cancer. 2020;126(9):1873-1887. doi: 10.1002/cncr.32739</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.32739</ArticleId><ArticleId IdType="pubmed">32032441</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernier J, Domenge C, Ozsahin M, et al. ; European Organization for Research and Treatment of Cancer Trial 22931 . Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350(19):1945-1952. doi: 10.1056/NEJMoa032641</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa032641</ArticleId><ArticleId IdType="pubmed">15128894</ArticleId></ArticleIdList></Reference><Reference><Citation>Tasoulas J, Lenze NR, Farquhar D, et al. The addition of chemotherapy to adjuvant radiation is associated with inferior survival outcomes in intermediate-risk HPV-negative HNSCC. Cancer Med. 2021;10(10):3231-3239. doi: 10.1002/cam4.3883</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cam4.3883</ArticleId><ArticleId IdType="pmc">PMC8124130</ArticleId><ArticleId IdType="pubmed">33934525</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrington K, Temam S, Mehanna H, et al. Postoperative adjuvant lapatinib and concurrent chemoradiotherapy followed by maintenance lapatinib monotherapy in high-risk patients with resected squamous cell carcinoma of the head and neck: a phase III, randomized, double-blind, placebo-controlled study. J Clin Oncol. 2015;33(35):4202-4209. doi: 10.1200/JCO.2015.61.4370</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2015.61.4370</ArticleId><ArticleId IdType="pubmed">26527790</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper JS, Pajak TF, Forastiere AA, et al. ; Radiation Therapy Oncology Group 9501/Intergroup . Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350(19):1937-1944. doi: 10.1056/NEJMoa032646</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa032646</ArticleId><ArticleId IdType="pubmed">15128893</ArticleId></ArticleIdList></Reference><Reference><Citation>Burtness B, Harrington KJ, Greil R, et al. ; KEYNOTE-048 Investigators . Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394(10212):1915-1928. doi: 10.1016/S0140-6736(19)32591-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)32591-7</ArticleId><ArticleId IdType="pubmed">31679945</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856-1867. doi: 10.1056/NEJMoa1602252</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1602252</ArticleId><ArticleId IdType="pmc">PMC5564292</ArticleId><ArticleId IdType="pubmed">27718784</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen EEW, Souli&#xe8;res D, Le Tourneau C, et al. ; KEYNOTE-040 investigators . Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2019;393(10167):156-167. doi: 10.1016/S0140-6736(18)31999-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)31999-8</ArticleId><ArticleId IdType="pubmed">30509740</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee NY, Ferris RL, Psyrri A, et al. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 2021;22(4):450-462. doi: 10.1016/S1470-2045(20)30737-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(20)30737-3</ArticleId><ArticleId IdType="pubmed">33794205</ArticleId></ArticleIdList></Reference><Reference><Citation>Machiels JP, Tao Y, Licitra L, et al. ; KEYNOTE-412 Investigators . Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2024;25(5):572-587. doi: 10.1016/S1470-2045(24)00100-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(24)00100-1</ArticleId><ArticleId IdType="pubmed">38561010</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong DJ, Fayette J, Guo Y, et al. Abstract CT123: IMvoke010: randomized phase III study of atezolizumab as adjuvant monotherapy after definitive therapy of squamous cell carcinoma of the head and neck (SCCHN). Cancer Res. 2019;79(13)(suppl):CT123. doi: 10.1158/1538-7445.AM2019-CT123</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1538-7445.AM2019-CT123</ArticleId></ArticleIdList></Reference><Reference><Citation>Uppaluri R. Neoadjuvant and Adjuvant Pembrolizumab Plus Standard of Care in Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma: Phase 3 KEYNOTE-689 Study. Presented at: American Association for Cancer Research Annual Meeting; April 27, 2025; Chicago, IL.</Citation></Reference><Reference><Citation>Cottrell TR, Thompson ED, Forde PM, et al. Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). Ann Oncol. 2018;29(8):1853-1860. doi: 10.1093/annonc/mdy218</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/annonc/mdy218</ArticleId><ArticleId IdType="pmc">PMC6096736</ArticleId><ArticleId IdType="pubmed">29982279</ArticleId></ArticleIdList></Reference><Reference><Citation>Saddawi-Konefka R, Simon AB, Sumner W, Sharabi A, Mell LK, Cohen EEW. Defining the role of immunotherapy in the curative treatment of locoregionally advanced head and neck cancer: promises, challenges, and opportunities. Front Oncol. 2021;11:738626. doi: 10.3389/fonc.2021.738626</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2021.738626</ArticleId><ArticleId IdType="pmc">PMC8490924</ArticleId><ArticleId IdType="pubmed">34621678</ArticleId></ArticleIdList></Reference><Reference><Citation>Uppaluri R, Campbell KM, Egloff AM, et al. Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus-unrelated head and neck cancer: a multicenter, phase II trial. Clin Cancer Res. 2020;26(19):5140-5152. doi: 10.1158/1078-0432.CCR-20-1695</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-20-1695</ArticleId><ArticleId IdType="pmc">PMC7547532</ArticleId><ArticleId IdType="pubmed">32665297</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferris RL, Spanos WC, Leidner R, et al. Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial. J Immunother Cancer. 2021;9(6):e002568. doi: 10.1136/jitc-2021-002568</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jitc-2021-002568</ArticleId><ArticleId IdType="pmc">PMC8183204</ArticleId><ArticleId IdType="pubmed">34083421</ArticleId></ArticleIdList></Reference><Reference><Citation>Luginbuhl AJ, Johnson JM, Harshyne LA, et al. Tadalafil enhances immune signatures in response to neoadjuvant nivolumab in resectable head and neck squamous cell carcinoma. Clin Cancer Res. 2022;28(5):915-927. doi: 10.1158/1078-0432.CCR-21-1816</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-21-1816</ArticleId><ArticleId IdType="pmc">PMC8898272</ArticleId><ArticleId IdType="pubmed">34911681</ArticleId></ArticleIdList></Reference><Reference><Citation>Wise-Draper TM, Gulati S, Palackdharry S, et al. Phase II clinical trial of neoadjuvant and adjuvant pembrolizumab in resectable local-regionally advanced head and neck squamous cell carcinoma. Clin Cancer Res. 2022;28(7):1345-1352. doi: 10.1158/1078-0432.CCR-21-3351</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-21-3351</ArticleId><ArticleId IdType="pmc">PMC8976828</ArticleId><ArticleId IdType="pubmed">35338369</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmid P, Cortes J, Pusztai L, et al. ; KEYNOTE-522 Investigators . Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810-821. doi: 10.1056/NEJMoa1910549</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1910549</ArticleId><ArticleId IdType="pubmed">32101663</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmid P, Cortes J, Dent R, et al. ; KEYNOTE-522 Investigators . Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022;386(6):556-567. doi: 10.1056/NEJMoa2112651</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2112651</ArticleId><ArticleId IdType="pubmed">35139274</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei C, Sun H, Hu J, Ma Z, Cao B. Association of pathological response with long-term survival outcomes after neoadjuvant immunotherapy: A meta-analysis. Int Immunopharmacol. 2024;133:112078. doi: 10.1016/j.intimp.2024.112078</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2024.112078</ArticleId><ArticleId IdType="pubmed">38685176</ArticleId></ArticleIdList></Reference><Reference><Citation>Mastrolonardo EV, Nunes KL, Llerena P, et al. Response-adaptive surgical timing in neoadjuvant immunotherapy demonstrates enhanced pathologic treatment response in head and neck squamous cell carcinoma. Clin Cancer Res. 2025;31(3):515-528. doi: 10.1158/1078-0432.CCR-24-0037</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-24-0037</ArticleId><ArticleId IdType="pmc">PMC11973698</ArticleId><ArticleId IdType="pubmed">39585339</ArticleId></ArticleIdList></Reference><Reference><Citation>Breiman L, Friedman J, Olshen RA, Stone CJ. Classification and Regression Trees. Chapman and Hall/CRC; 2017, doi: 10.1201/9781315139470.</Citation><ArticleIdList><ArticleId IdType="doi">10.1201/9781315139470</ArticleId></ArticleIdList></Reference><Reference><Citation>Therneau T, Atkinson B. rpart: Recursive Partitioning and Regression Trees. Accessed April 15, 2025. https://CRAN.R-project.org/package=rpart</Citation></Reference><Reference><Citation>R Core Team . R: A Language and Environment for Statistical Computing. Published online 2023. Accessed April 15, 2025. https://www.R-project.org/</Citation></Reference><Reference><Citation>Alnemri AE, Tekumalla S, Moroco AE, et al. Predictive capacity of immune-related adverse events and cytokine profiling in neoadjuvant immune checkpoint inhibitor trials for head and neck squamous cell carcinoma. Cancer Med. 2024;13(11):e7370. doi: 10.1002/cam4.7370</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cam4.7370</ArticleId><ArticleId IdType="pmc">PMC11157197</ArticleId><ArticleId IdType="pubmed">38847087</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips R, Alnemri A, Amin D, et al. Effect of preoperative programmed death-1 or programmed death ligand-1 immune check point inhibition on complications after surgery for primary head and neck cancer. Cancer. 2024;130(6):863-875. doi: 10.1002/cncr.35045</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.35045</ArticleId><ArticleId IdType="pubmed">37788128</ArticleId></ArticleIdList></Reference><Reference><Citation>Licitra L, Perrone F, Bossi P, et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol. 2006;24(36):5630-5636. doi: 10.1200/JCO.2005.04.6136</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2005.04.6136</ArticleId><ArticleId IdType="pubmed">17179101</ArticleId></ArticleIdList></Reference><Reference><Citation>Blank CU, Lucas MW, Scolyer RA, et al. Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma. N Engl J Med. 2024;391(18):1696-1708. Published online June 2, 2024. doi: 10.1056/NEJMoa2402604</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2402604</ArticleId><ArticleId IdType="pubmed">38828984</ArticleId></ArticleIdList></Reference><Reference><Citation>Deutsch JS, Cimino-Mathews A, Thompson E, et al. Association between pathologic response and survival after neoadjuvant therapy in lung cancer. Nat Med. 2024;30(1):218-228. doi: 10.1038/s41591-023-02660-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-023-02660-6</ArticleId><ArticleId IdType="pmc">PMC10803255</ArticleId><ArticleId IdType="pubmed">37903504</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellmann MD, Chaft JE, William WN Jr, et al. ; University of Texas MD Anderson Lung Cancer Collaborative Group . Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol. 2014;15(1):e42-e50. doi: 10.1016/S1470-2045(13)70334-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(13)70334-6</ArticleId><ArticleId IdType="pmc">PMC4734624</ArticleId><ArticleId IdType="pubmed">24384493</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164-172. doi: 10.1016/S0140-6736(13)62422-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)62422-8</ArticleId><ArticleId IdType="pubmed">24529560</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Shan F, Wang Y, et al. Correlation of pathological complete response with survival after neoadjuvant chemotherapy in gastric or gastroesophageal junction cancer treated with radical surgery: A meta-analysis. PLoS One. 2018;13(1):e0189294. doi: 10.1371/journal.pone.0189294</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0189294</ArticleId><ArticleId IdType="pmc">PMC5784899</ArticleId><ArticleId IdType="pubmed">29370182</ArticleId></ArticleIdList></Reference><Reference><Citation>Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25(28):4414-4422. doi: 10.1200/JCO.2007.10.6823</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2007.10.6823</ArticleId><ArticleId IdType="pubmed">17785706</ArticleId></ArticleIdList></Reference><Reference><Citation>Rozeman EA, Menzies AM, van Akkooi ACJ, et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol. 2019;20(7):948-960. doi: 10.1016/S1470-2045(19)30151-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(19)30151-2</ArticleId><ArticleId IdType="pubmed">31160251</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang AC, Orlowski RJ, Xu X, et al. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat Med. 2019;25(3):454-461. doi: 10.1038/s41591-019-0357-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0357-y</ArticleId><ArticleId IdType="pmc">PMC6699626</ArticleId><ArticleId IdType="pubmed">30804515</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharon CE, Tortorello GN, Ma KL, et al. Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III/IV cutaneous melanoma. Ann Oncol. 2023;34(9):806-812. doi: 10.1016/j.annonc.2023.06.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annonc.2023.06.006</ArticleId><ArticleId IdType="pmc">PMC11232562</ArticleId><ArticleId IdType="pubmed">37414215</ArticleId></ArticleIdList></Reference><Reference><Citation>Rawson RV, Adhikari C, Bierman C, et al. Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma. Ann Oncol. 2021;32(6):766-777. doi: 10.1016/j.annonc.2021.03.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annonc.2021.03.006</ArticleId><ArticleId IdType="pubmed">33744385</ArticleId></ArticleIdList></Reference><Reference><Citation>Reijers ILM, Menzies AM, van Akkooi ACJ, et al. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nat Med. 2022;28(6):1178-1188. doi: 10.1038/s41591-022-01851-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01851-x</ArticleId><ArticleId IdType="pubmed">35661157</ArticleId></ArticleIdList></Reference><Reference><Citation>Forde PM, Chaft JE, Smith KN, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med. 2018;378(21):1976-1986. doi: 10.1056/NEJMoa1716078</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1716078</ArticleId><ArticleId IdType="pmc">PMC6223617</ArticleId><ArticleId IdType="pubmed">29658848</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrarotto R, Bell D, Rubin ML, et al. Impact of neoadjuvant durvalumab with or without tremelimumab on CD8+ tumor lymphocyte density, safety, and efficacy in patients with oropharynx cancer: CIAO trial results. Clin Cancer Res. 2020;26(13):3211-3219. doi: 10.1158/1078-0432.CCR-19-3977</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-19-3977</ArticleId><ArticleId IdType="pmc">PMC8362306</ArticleId><ArticleId IdType="pubmed">32269052</ArticleId></ArticleIdList></Reference><Reference><Citation>de Scordilli M, Michelotti A, Bertoli E, De Carlo E, Del Conte A, Bearz A. Targeted therapy and immunotherapy in early-stage non-small cell lung cancer: current evidence and ongoing trials. Int J Mol Sci. 2022;23(13):7222. doi: 10.3390/ijms23137222</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23137222</ArticleId><ArticleId IdType="pmc">PMC9266864</ArticleId><ArticleId IdType="pubmed">35806230</ArticleId></ArticleIdList></Reference><Reference><Citation>Merlino DJ, Johnson JM, Tuluc M, et al. Discordant responses between primary head and neck tumors and nodal metastases treated with neoadjuvant nivolumab: correlation of radiographic and pathologic treatment effect. Front Oncol. 2020;10:566315. doi: 10.3389/fonc.2020.566315</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2020.566315</ArticleId><ArticleId IdType="pmc">PMC7738605</ArticleId><ArticleId IdType="pubmed">33344227</ArticleId></ArticleIdList></Reference><Reference><Citation>Saddawi-Konefka R, Schokrpur S, Gutkind JS. Let it be: Preserving tumor-draining lymph nodes in the era of immuno-oncology. Cancer Cell. 2024;42(6):930-933. doi: 10.1016/j.ccell.2024.05.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2024.05.015</ArticleId><ArticleId IdType="pubmed">38861928</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, O&#x2019;Donnell JS, Yan J, et al. Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome. Oncoimmunology. 2019;8(5):e1581530. doi: 10.1080/2162402X.2019.1581530</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/2162402X.2019.1581530</ArticleId><ArticleId IdType="pmc">PMC6492961</ArticleId><ArticleId IdType="pubmed">31069141</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein JE, Soni A, Danilova L, et al. Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response. Ann Oncol. 2019;30(4):589-596. doi: 10.1093/annonc/mdz019</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/annonc/mdz019</ArticleId><ArticleId IdType="pmc">PMC6503625</ArticleId><ArticleId IdType="pubmed">30689736</ArticleId></ArticleIdList></Reference><Reference><Citation>Leidner R, Crittenden M, Young K, et al. Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma. J Immunother Cancer. 2021;9(5):e002485. doi: 10.1136/jitc-2021-002485</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jitc-2021-002485</ArticleId><ArticleId IdType="pmc">PMC8108690</ArticleId><ArticleId IdType="pubmed">33963014</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1001/jamaoto.2025.1976 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40674044</PMID><DateCompleted><Year>2025</Year><Month>12</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>12</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-619X</ISSN><JournalIssue CitedMedium="Internet"><Volume>151</Volume><Issue>12</Issue><PubDate><Year>2025</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA otolaryngology-- head &amp; neck surgery</Title><ISOAbbreviation>JAMA Otolaryngol Head Neck Surg</ISOAbbreviation></Journal><ArticleTitle>Patients With Head and Neck Cancer and High Health Care Costs: A Population-Based Study.</ArticleTitle><Pagination><StartPage>1138</StartPage><EndPage>1147</EndPage><MedlinePgn>1138-1147</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaoto.2025.1976</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="UNASSIGNED">The care for a small subset of patients is responsible for a disproportionately large share of health care expenditures. Head and neck cancer is associated with significant health care costs due to complex treatment regimens and long-term sequelae. Given this high baseline cost, identifying patients with high care costs within a population with cancer might help inform interventions to optimize resource allocation.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To characterize patients with head and neck cancer with the highest health care costs during the first year after diagnosis.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="UNASSIGNED">A population-based, retrospective cohort study was conducted using administrative data from the Institute for Clinical and Evaluative Sciences in Ontario, Canada, and included adults diagnosed with head and neck cancer between January 2007 and October 2020 (identified from the provincial cancer registry) with a full 1.5-year follow-up from the date of diagnosis to the date of death or October 31, 2021. The total 1-year health care costs were estimated using a patient-level algorithm and were collected in 2020 Canadian dollar values. The main analyses were performed in April 2023 and a sensitivity analysis was performed in April 2025.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="UNASSIGNED">High health care costs (&gt;75th percentile) during the first year after a head and neck cancer diagnosis. Predictors of high health care costs were identified using a multivariable logistic regression model.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The cohort included 13&#x202f;795 patients (mean age, 63.2 [SD, 11.7] years and 3452 [25.0%] were female), 3448 (25%) of whom had high health care costs. Cancer stage was the strongest predictor of high health care costs. Compared with patients with stage I cancer, those with stage II cancer had 2-fold greater odds for high health care costs (odds ratio [OR], 3.14 [95% CI, 2.56-3.84]), those with stage III cancer had 5-fold greater odds for high health care costs (OR, 6.08 [95% CI, 4.99-7.41]), and those with stage IV cancer had 8-fold greater odds for high health care costs (OR, 8.94 [95% CI, 7.43-10.80]). Receiving multiple treatment modalities also was associated with greater odds for high-cost care.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="UNASSIGNED">This cohort study found that more advanced disease stage and receiving multiple treatment modalities were the strongest predictors of high-cost care among patients diagnosed with head and neck cancer. Prioritizing research and implementation of screening programs, earlier cancer diagnoses, and effective treatment deescalation strategies might mitigate a significant portion of these high costs.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Villemure-Poliquin</LastName><ForeName>No&#xe9;mie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Institute of Health Policy, Management, and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Rui</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Health Policy, Management, and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departments of Community Health Sciences, Surgery, and Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Qing</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ayoo</LastName><ForeName>Kennedy</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Vascular Surgery, Peter Munk Cardiac Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Kelvin K W</ForeName><Initials>KKW</Initials><AffiliationInfo><Affiliation>Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sunnybrook Research Institute, Sunnybrook Health Sciences Centre and the University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Oncology, Odette Cancer Centre and the University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karam</LastName><ForeName>Irene</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sunnybrook Research Institute, Sunnybrook Health Sciences Centre and the University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiation Oncology, Odette Cancer Centre and the University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wright</LastName><ForeName>Frances C</ForeName><Initials>FC</Initials><AffiliationInfo><Affiliation>Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sunnybrook Research Institute, Sunnybrook Health Sciences Centre and the University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Surgical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coburn</LastName><ForeName>Natalie G</ForeName><Initials>NG</Initials><AffiliationInfo><Affiliation>Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sunnybrook Research Institute, Sunnybrook Health Sciences Centre and the University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Surgical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hallet</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Surgical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eskander</LastName><ForeName>Antoine</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Health Policy, Management, and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sunnybrook Research Institute, Sunnybrook Health Sciences Centre and the University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Otolaryngol Head Neck Surg</MedlineTA><NlmUniqueID>101589542</NlmUniqueID><ISSNLinking>2168-6181</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006258" MajorTopicYN="Y">Head and Neck Neoplasms</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017048" MajorTopicYN="Y">Health Care Costs</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009864" MajorTopicYN="N" Type="Geographic">Ontario</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Karam reported receiving personal fees from EMD Serono and receiving nonfinancial support from Elekta. Dr Wright reported receiving personal fees from Cancer Care Ontario. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2026</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>11</Day><Hour>13</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>17</Day><Hour>12</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>17</Day><Hour>11</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40674044</ArticleId><ArticleId IdType="pmc">PMC12272356</ArticleId><ArticleId IdType="doi">10.1001/jamaoto.2025.1976</ArticleId><ArticleId IdType="pii">2836569</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Muratov S, Lee J, Holbrook A, et al. Incremental healthcare utilisation and costs among new senior high-cost users in Ontario, Canada: a retrospective matched cohort study. BMJ Open. 2019;9(10):e028637. doi: 10.1136/bmjopen-2018-028637</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2018-028637</ArticleId><ArticleId IdType="pmc">PMC6830474</ArticleId><ArticleId IdType="pubmed">31662356</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosella LC, Fitzpatrick T, Wodchis WP, Calzavara A, Manson H, Goel V. High-cost health care users in Ontario, Canada: demographic, socio-economic, and health status characteristics. BMC Health Serv Res. 2014;14:532. doi: 10.1186/s12913-014-0532-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12913-014-0532-2</ArticleId><ArticleId IdType="pmc">PMC4221677</ArticleId><ArticleId IdType="pubmed">25359294</ArticleId></ArticleIdList></Reference><Reference><Citation>Wodchis WP, Austin PC, Henry DA. A 3-year study of high-cost users of health care. CMAJ. 2016;188(3):182-188. doi: 10.1503/cmaj.150064</Citation><ArticleIdList><ArticleId IdType="doi">10.1503/cmaj.150064</ArticleId><ArticleId IdType="pmc">PMC4754179</ArticleId><ArticleId IdType="pubmed">26755672</ArticleId></ArticleIdList></Reference><Reference><Citation>Barsouk A, Aluru JS, Rawla P, Saginala K, Barsouk A. Epidemiology, risk factors, and prevention of head and neck squamous cell carcinoma. Med Sci (Basel). 2023;11(2):42. doi: 10.3390/medsci11020042</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medsci11020042</ArticleId><ArticleId IdType="pmc">PMC10304137</ArticleId><ArticleId IdType="pubmed">37367741</ArticleId></ArticleIdList></Reference><Reference><Citation>Marur S, Forastiere AA. Head and neck squamous cell carcinoma: update on epidemiology, diagnosis, and treatment. Mayo Clin Proc. 2016;91(3):386-396. doi: 10.1016/j.mayocp.2015.12.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2015.12.017</ArticleId><ArticleId IdType="pubmed">26944243</ArticleId></ArticleIdList></Reference><Reference><Citation>Wissinger E, Griebsch I, Lungershausen J, Foster T, Pashos CL. The economic burden of head and neck cancer: a systematic literature review. Pharmacoeconomics. 2014;32(9):865-882. doi: 10.1007/s40273-014-0169-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40273-014-0169-3</ArticleId><ArticleId IdType="pmc">PMC4153967</ArticleId><ArticleId IdType="pubmed">24842794</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rooij JAF, Roubos J, Vrancken Peeters NJMC, Rijken BFM, Corten EML, Mureau MAM. Long-term patient-reported outcomes after reconstructive surgery for head and neck cancer: a systematic review. Head Neck. 2023;45(9):2469-2477. doi: 10.1002/hed.27450</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hed.27450</ArticleId><ArticleId IdType="pubmed">37401563</ArticleId></ArticleIdList></Reference><Reference><Citation>Riechelmann H, Dejaco D, Steinbichler TB, et al. Functional outcomes in head and neck cancer patients. Cancers (Basel). 2022;14(9):2135. doi: 10.3390/cancers14092135</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers14092135</ArticleId><ArticleId IdType="pmc">PMC9099625</ArticleId><ArticleId IdType="pubmed">35565265</ArticleId></ArticleIdList></Reference><Reference><Citation>Massa ST, Chidambaram S, Luong P, Graboyes EM, Mazul AL. Quantifying total and out-of-pocket costs associated with head and neck cancer survivorship. JAMA Otolaryngol Head Neck Surg. 2022;148(12):1111-1119. doi: 10.1001/jamaoto.2022.3269</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoto.2022.3269</ArticleId><ArticleId IdType="pmc">PMC9585466</ArticleId><ArticleId IdType="pubmed">36264567</ArticleId></ArticleIdList></Reference><Reference><Citation>Ontario Ministry of Health . Ontario Healthcare Insurance Plan schedule of benefits: physician services under the Health Insurance Act. Published February 14, 2025. Accessed June 16, 2025. https://www.ontario.ca/files/2025-03/moh-schedule-benefit-2025-03-19.pdf</Citation></Reference><Reference><Citation>Eskander A, Goldstein DP, Irish JC. Health services research and regionalization of care&#x2014;from policy to practice: the Ontario experience in head and neck cancer. Curr Oncol Rep. 2016;18(3):19. doi: 10.1007/s11912-016-0500-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11912-016-0500-6</ArticleId><ArticleId IdType="pubmed">26869188</ArticleId></ArticleIdList></Reference><Reference><Citation>Eskander A, Irish J, Gullane P, et al. Overview of surgery for oral cavity cancer in Ontario. Head Neck. 2016;38(7):1113-1118. doi: 10.1002/hed.24141</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hed.24141</ArticleId><ArticleId IdType="pubmed">26040567</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Care Ontario . New Drug Funding Program. Accessed June 16, 2025. https://www.cancercareontario.ca/en/Funding/New_Drug_Funding_Program</Citation></Reference><Reference><Citation>Benchimol EI, Smeeth L, Guttmann A, et al. ; RECORD Working Committee . The Reporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement. PLoS Med. 2015;12(10):e1001885. doi: 10.1371/journal.pmed.1001885</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1001885</ArticleId><ArticleId IdType="pmc">PMC4595218</ArticleId><ArticleId IdType="pubmed">26440803</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen OM, Storm HH. Cancer registration: principles and methods: reporting of results. IARC Sci Publ. 1991;(95):108-125.</Citation><ArticleIdList><ArticleId IdType="pubmed">1894317</ArticleId></ArticleIdList></Reference><Reference><Citation>Robles SC, Marrett LD, Clarke EA, Risch HA. An application of capture-recapture methods to the estimation of completeness of cancer registration. J Clin Epidemiol. 1988;41(5):495-501. doi: 10.1016/0895-4356(88)90052-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0895-4356(88)90052-2</ArticleId><ArticleId IdType="pubmed">3367181</ArticleId></ArticleIdList></Reference><Reference><Citation>Matheson FI; Ontario Agency for Health Protection and Promotion (Public Health Ontario) . 2016 Ontario Marginalization Index: User Guide. Unity Health Toronto; 2022.</Citation></Reference><Reference><Citation>Steele LS, Durbin A, Sibley LM, Glazier R. Inclusion of persons with mental illness in patient-centred medical homes: cross-sectional findings from Ontario, Canada. Open Med. 2013;7(1):e9-e20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3654503</ArticleId><ArticleId IdType="pubmed">23687535</ArticleId></ArticleIdList></Reference><Reference><Citation>Bremner KE, Yabroff KR, Coughlan D, et al. Patterns of care and costs for older patients with colorectal cancer at the end of life: descriptive study of the United States and Canada. JCO Oncol Pract. 2020;16(1):e1-e18. doi: 10.1200/JOP.19.00061</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JOP.19.00061</ArticleId><ArticleId IdType="pmc">PMC7051852</ArticleId><ArticleId IdType="pubmed">31647697</ArticleId></ArticleIdList></Reference><Reference><Citation>Seung SJ, Hurry M, Hassan S, Walton RN, Evans WK. Cost-of-illness study for non-small-cell lung cancer using real-world data. Curr Oncol. 2019;26(2):102-107. doi: 10.3747/co.26.4555</Citation><ArticleIdList><ArticleId IdType="doi">10.3747/co.26.4555</ArticleId><ArticleId IdType="pmc">PMC6476449</ArticleId><ArticleId IdType="pubmed">31043811</ArticleId></ArticleIdList></Reference><Reference><Citation>Wodchis WP, Bushmeneva K, Nikitovic M, McKillop I. Guidelines on person-level costing using administrative databases in Ontario. Published May 2013. Accessed June 16, 2025. https://hspn.ca/wp-content/uploads/2019/09/Guidelines_on_PersonLevel_Costing_May_2013.pdf
</Citation></Reference><Reference><Citation>Madawaska Valley Current . Ontario hospitals asked to take a planned approach to ramping down elective surgeries. Published March 16, 2020. Accessed June 6, 2025. https://madvalleycurrent.com/2020/03/16/ontario-hospitals-planned-approach-ramping-down-elective-surgeries/</Citation></Reference><Reference><Citation>du Plessis V, Beshiri R, Bollman RD, Clemenson H. Definitions of rural. Published November 2001. Accessed June 6, 2025. https://www150.statcan.gc.ca/n1/en/pub/21-006-x/21-006-x2001003-eng.pdf?st=wI_saK4L</Citation></Reference><Reference><Citation>Sutradhar R, Gu S, Glazier RH, Paszat LF; Investigators of the Ontario Cancer Screening Research Network . The association between visiting a primary care provider and uptake of periodic mammograms as women get older. J Med Screen. 2016;23(2):83-88. doi: 10.1177/0969141315600004</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0969141315600004</ArticleId><ArticleId IdType="pubmed">26355038</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggarwal M, Williams AP. Tinkering at the margins: evaluating the pace and direction of primary care reform in Ontario, Canada. BMC Fam Pract. 2019;20(1):128. doi: 10.1186/s12875-019-1014-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12875-019-1014-8</ArticleId><ArticleId IdType="pmc">PMC6739997</ArticleId><ArticleId IdType="pubmed">31510942</ArticleId></ArticleIdList></Reference><Reference><Citation>Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8-27. doi: 10.1097/00005650-199801000-00004</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005650-199801000-00004</ArticleId><ArticleId IdType="pubmed">9431328</ArticleId></ArticleIdList></Reference><Reference><Citation>Noel CW, Sutradhar R, Chan WC, et al. Gaps in depression symptom management for patients with head and neck cancer. Laryngoscope. 2023;133(10):2638-2646. doi: 10.1002/lary.30595</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/lary.30595</ArticleId><ArticleId IdType="pubmed">36748910</ArticleId></ArticleIdList></Reference><Reference><Citation>Noel CW, Sutradhar R, Zhao H, et al. Patient-reported symptom burden as a predictor of emergency department use and unplanned hospitalization in head and neck cancer: a longitudinal population-based study. J Clin Oncol. 2021;39(6):675-684. doi: 10.1200/JCO.20.01845</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.20.01845</ArticleId><ArticleId IdType="pubmed">33405964</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simul Comput. 2009;38(6):1228-1234. doi: 10.1080/03610910902859574</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/03610910902859574</ArticleId></ArticleIdList></Reference><Reference><Citation>Rais S, Nazerian A, Ardal S, Chechulin Y, Bains N, Malikov K. High-cost users of Ontario&#x2019;s healthcare services. Healthc Policy. 2013;9(1):44-51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3999548</ArticleId><ArticleId IdType="pubmed">23968673</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang K, Menzin J, Earle CC, Jacobson J, Hsu MA. The economic cost of squamous cell cancer of the head and neck: findings from linked SEER-Medicare data. Arch Otolaryngol Head Neck Surg. 2004;130(11):1269-1275. doi: 10.1001/archotol.130.11.1269</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archotol.130.11.1269</ArticleId><ArticleId IdType="pubmed">15545580</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsen ML, Belsky MA, Scheff N, et al. Late and long-term treatment-related effects and survivorship for head and neck cancer patients. Curr Treat Options Oncol. 2020;21(12):92. doi: 10.1007/s11864-020-00797-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11864-020-00797-x</ArticleId><ArticleId IdType="pubmed">33009956</ArticleId></ArticleIdList></Reference><Reference><Citation>Nocon CC, Kennedy A, Jaffe J, Pruitt J, Kuchta K, Bhayani MK. Costs associated with imaging surveillance after treatment for head and neck cancer. JAMA Otolaryngol Head Neck Surg. 2021;147(7):632-637. doi: 10.1001/jamaoto.2021.0835</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoto.2021.0835</ArticleId><ArticleId IdType="pmc">PMC8120445</ArticleId><ArticleId IdType="pubmed">33983375</ArticleId></ArticleIdList></Reference><Reference><Citation>Ribeiro-Rotta RF, Rosa EA, Milani V, et al. The cost of oral cancer: a systematic review. PLoS One. 2022;17(4):e0266346. doi: 10.1371/journal.pone.0266346</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0266346</ArticleId><ArticleId IdType="pmc">PMC9022815</ArticleId><ArticleId IdType="pubmed">35446870</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehanna H, Paleri V, West CM, Nutting C. Head and neck cancer, part 1: epidemiology, presentation, and prevention. BMJ. 2010;341:c4684. doi: 10.1136/bmj.c4684</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.c4684</ArticleId><ArticleId IdType="pubmed">20855405</ArticleId></ArticleIdList></Reference><Reference><Citation>Gogarty DS, Shuman A, O&#x2019;Sullivan EM, et al. Conceiving a national head and neck cancer screening programme. J Laryngol Otol. 2016;130(1):8-14. doi: 10.1017/S0022215115003084</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0022215115003084</ArticleId><ArticleId IdType="pubmed">26585180</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow LQM. Head and neck cancer. N Engl J Med. 2020;382(1):60-72. doi: 10.1056/NEJMra1715715</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1715715</ArticleId><ArticleId IdType="pubmed">31893516</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson-Harvey A, Yetukuri M, Hansen AR, et al. Rising incidence of late-stage head and neck cancer in the United States. Cancer. 2020;126(5):1090-1101. doi: 10.1002/cncr.32583</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.32583</ArticleId><ArticleId IdType="pubmed">31722124</ArticleId></ArticleIdList></Reference><Reference><Citation>Raymond E, Thieblemont C, Alran S, Faivre S. Impact of the COVID-19 outbreak on the management of patients with cancer. Target Oncol. 2020;15(3):249-259. doi: 10.1007/s11523-020-00721-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11523-020-00721-1</ArticleId><ArticleId IdType="pmc">PMC7243433</ArticleId><ArticleId IdType="pubmed">32445083</ArticleId></ArticleIdList></Reference><Reference><Citation>Tartarone A, Lerose R. COVID-19 and cancer care: what do international guidelines say? Med Oncol. 2020;37(9):80. doi: 10.1007/s12032-020-01406-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12032-020-01406-5</ArticleId><ArticleId IdType="pmc">PMC7410959</ArticleId><ArticleId IdType="pubmed">32767203</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick T, Rosella LC, Calzavara A, et al. Looking beyond income and education: socioeconomic status gradients among future high-cost users of health care. Am J Prev Med. 2015;49(2):161-171. doi: 10.1016/j.amepre.2015.02.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amepre.2015.02.018</ArticleId><ArticleId IdType="pubmed">25960393</ArticleId></ArticleIdList></Reference><Reference><Citation>Wick J, Campbell DJT, McAlister FA, et al. Identifying subgroups of adult high-cost health care users: a retrospective analysis. CMAJ Open. 2022;10(2):E390-E399. doi: 10.9778/cmajo.20210265</Citation><ArticleIdList><ArticleId IdType="doi">10.9778/cmajo.20210265</ArticleId><ArticleId IdType="pmc">PMC9022936</ArticleId><ArticleId IdType="pubmed">35440486</ArticleId></ArticleIdList></Reference><Reference><Citation>Noel CW, Sutradhar R, Gotlib Conn L, et al. Development and validation of a machine learning algorithm predicting emergency department use and unplanned hospitalization in patients with head and neck cancer. JAMA Otolaryngol Head Neck Surg. 2022;148(8):764-772. doi: 10.1001/jamaoto.2022.1629</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoto.2022.1629</ArticleId><ArticleId IdType="pmc">PMC9247860</ArticleId><ArticleId IdType="pubmed">35771564</ArticleId></ArticleIdList></Reference><Reference><Citation>Alterio D, Marvaso G, Ferrari A, Volpe S, Orecchia R, Jereczek-Fossa BA. Modern radiotherapy for head and neck cancer. Semin Oncol. 2019;46(3):233-245. doi: 10.1053/j.seminoncol.2019.07.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.seminoncol.2019.07.002</ArticleId><ArticleId IdType="pubmed">31378376</ArticleId></ArticleIdList></Reference><Reference><Citation>Fasano M, Corte CMD, Liello RD, et al. Immunotherapy for head and neck cancer: present and future. Crit Rev Oncol Hematol. 2022;174:103679. doi: 10.1016/j.critrevonc.2022.103679</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.critrevonc.2022.103679</ArticleId><ArticleId IdType="pubmed">35395371</ArticleId></ArticleIdList></Reference><Reference><Citation>Tateya I, Shiotani A, Satou Y, et al. Transoral surgery for laryngo-pharyngeal cancer&#x2014;the paradigm shift of the head and cancer treatment. Auris Nasus Larynx. 2016;43(1):21-32. doi: 10.1016/j.anl.2015.06.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.anl.2015.06.013</ArticleId><ArticleId IdType="pubmed">26298233</ArticleId></ArticleIdList></Reference><Reference><Citation>Lingen MW, Kalmar JR, Karrison T, Speight PM. Critical evaluation of diagnostic aids for the detection of oral cancer. Oral Oncol. 2008;44(1):10-22. doi: 10.1016/j.oraloncology.2007.06.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.oraloncology.2007.06.011</ArticleId><ArticleId IdType="pmc">PMC2424250</ArticleId><ArticleId IdType="pubmed">17825602</ArticleId></ArticleIdList></Reference><Reference><Citation>Mali SB. Molecular screening of head neck cancer. Oral Oncol. 2023;144:106481. doi: 10.1016/j.oraloncology.2023.106481</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.oraloncology.2023.106481</ArticleId><ArticleId IdType="pubmed">37399708</ArticleId></ArticleIdList></Reference><Reference><Citation>Sykes EA, Weisbrod N, Rival E, Haque A, Fu R, Eskander A. Methods, detection rates, and survival outcomes of screening for head and neck cancers: a systematic review. JAMA Otolaryngol Head Neck Surg. 2023;149(11):1047-1056. doi: 10.1001/jamaoto.2023.3010</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoto.2023.3010</ArticleId><ArticleId IdType="pubmed">37796524</ArticleId></ArticleIdList></Reference><Reference><Citation>Sankaranarayanan R, Ramadas K, Thara S, et al. Long term effect of visual screening on oral cancer incidence and mortality in a randomized trial in Kerala, India. Oral Oncol. 2013;49(4):314-321. doi: 10.1016/j.oraloncology.2012.11.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.oraloncology.2012.11.004</ArticleId><ArticleId IdType="pubmed">23265945</ArticleId></ArticleIdList></Reference><Reference><Citation>Sankaranarayanan R, Ramadas K, Thomas G, et al. ; Trivandrum Oral Cancer Screening Study Group . Effect of screening on oral cancer mortality in Kerala, India: a cluster-randomised controlled trial. Lancet. 2005;365(9475):1927-1933. doi: 10.1016/S0140-6736(05)66658-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(05)66658-5</ArticleId><ArticleId IdType="pubmed">15936419</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan MN, Hueniken K, Manojlovic-Kolarski M, et al. Out-of-pocket costs associated with head and neck cancer treatment. Cancer Rep (Hoboken). 2022;5(7):e1528. doi: 10.1002/cnr2.1528</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cnr2.1528</ArticleId><ArticleId IdType="pmc">PMC9327650</ArticleId><ArticleId IdType="pubmed">34428351</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosella LC, Kornas K, Sarkar J, Fransoo R. External validation of a population-based prediction model for high healthcare resource use in adults. Healthcare (Basel). 2020;8(4):537. doi: 10.3390/healthcare8040537</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/healthcare8040537</ArticleId><ArticleId IdType="pmc">PMC7761789</ArticleId><ArticleId IdType="pubmed">33291559</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1001/jamaoto.2025.1833 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40638110</PMID><DateCompleted><Year>2025</Year><Month>12</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>12</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-619X</ISSN><JournalIssue CitedMedium="Internet"><Volume>151</Volume><Issue>12</Issue><PubDate><Year>2025</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA otolaryngology-- head &amp; neck surgery</Title><ISOAbbreviation>JAMA Otolaryngol Head Neck Surg</ISOAbbreviation></Journal><ArticleTitle>Unilateral vs Bilateral Transoral Robotic Surgery for HPV-Positive Tonsillar Squamous Cell Carcinoma.</ArticleTitle><Pagination><StartPage>1157</StartPage><EndPage>1165</EndPage><MedlinePgn>1157-1165</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaoto.2025.1833</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="UNASSIGNED">The palatine tonsil is the most common subsite of human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (SCC). There is debate on how to manage the contralateral clinically uninvolved tonsil in patients undergoing a primary surgical approach via transoral robotic surgery (TORS).</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To assess postoperative complications, functional outcomes, contralateral tonsil second primary rates, and survival in patients undergoing unilateral vs bilateral TORS with pathology-guided adjuvant treatment.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="UNASSIGNED">A retrospective cohort study was carried out in a quaternary care academic medical center. All consecutive unilateral tonsillar patients with SCC undergoing TORS as primary treatment from June 2016 to July 2023 were included. Analysis was conducted between October 1, 2024, and January 1, 2025.</AbstractText><AbstractText Label="EXPOSURE" NlmCategory="UNASSIGNED">Unilateral TORS (ipsilateral radical tonsillectomy) vs bilateral TORS (ipsilateral radical tonsillectomy and contralateral extracapsular tonsillectomy).</AbstractText><AbstractText Label="MAIN OUTCOMES" NlmCategory="UNASSIGNED">The primary outcome measure was rate of postoperative oropharyngeal hemorrhage. Secondary outcome measures included postoperative emergency department (ED) visit/hospitalization rate, time to nasogastric tube (NGT) removal, rate of discharge with an NGT tube, G-tube dependence rates, second primary rates in the contralateral tonsil, length of stay, and 2-year and 5-year disease-free survival (DFS) and overall survival (OS).</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total of 158 (106 unilateral, 52 bilateral TORS) patients with HPV-associated tonsillar SCC were evaluated, including 18 women and 139 men with a mean (SD) age of 60 (10) years. There were clinically meaningful differences in oropharyngeal hemorrhage rates (7% vs 15%; percent difference, -7.8; 95% CI, -18.8% to 3.2%), 30-day ED visit/hospitalization rates (9% vs 21%; percent difference, -11.7%; 95% CI, -24.1 to 0.7), and median length of stay (2 vs 3 days) for unilateral and bilateral TORS, respectively. Swallowing outcomes, DFS, and OS were not significantly different between the 2 groups. A total of 3 patients (1.9%) had a second primary tumor in the contralateral tonsil, including 2 metachronous primary tumors in the unilateral group (1.8%) and 1 synchronous primary tumor incidentally removed at the time of surgery in the bilateral group (1.9%).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="UNASSIGNED">This cohort study found that omission of contralateral elective extracapsular tonsillectomy in HPV-positive SCC was safe and associated with a trend toward lower posttonsillectomy hemorrhage, postoperative ED visits for pain control, and hospital length of stay without compromising survival. Prophylactically resecting the contralateral tonsil may add patient harm without any clear benefits.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Peterson</LastName><ForeName>Andrew M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Head and Neck Tumor Center at Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bockover</LastName><ForeName>Spencer R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Head and Neck Tumor Center at Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kallogjeri</LastName><ForeName>Dorina</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Statistics Editor, JAMA Otolaryngology-Head &amp; Neck Surgery.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Katherine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Head and Neck Tumor Center at Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Emory University School of Medicine, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tharakan</LastName><ForeName>Theresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Head and Neck Tumor Center at Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harbison</LastName><ForeName>R Alex</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Head and Neck Tumor Center at Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zolkind</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Head and Neck Tumor Center at Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rich</LastName><ForeName>Jason T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Head and Neck Tumor Center at Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pipkorn</LastName><ForeName>Patrik</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Head and Neck Tumor Center at Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paniello</LastName><ForeName>Randal C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Head and Neck Tumor Center at Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puram</LastName><ForeName>Sidharth V</ForeName><Initials>SV</Initials><AffiliationInfo><Affiliation>Head and Neck Tumor Center at Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jackson</LastName><ForeName>Ryan S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Head and Neck Tumor Center at Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Otolaryngol Head Neck Surg</MedlineTA><NlmUniqueID>101589542</NlmUniqueID><ISSNLinking>2168-6181</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>JAMA Otolaryngol Head Neck Surg. 2025 Oct;151(10):1012. doi: 10.1001/jamaoto.2025.2804.</RefSource><PMID Version="1">40810992</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065287" MajorTopicYN="Y">Robotic Surgical Procedures</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014067" MajorTopicYN="Y">Tonsillar Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014068" MajorTopicYN="Y">Tonsillectomy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002294" MajorTopicYN="Y">Carcinoma, Squamous Cell</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D030361" MajorTopicYN="Y">Papillomavirus Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057605" MajorTopicYN="N">Natural Orifice Endoscopic Surgery</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> None reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2026</Year><Month>7</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>11</Day><Hour>13</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>10</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>10</Day><Hour>11</Hour><Minute>34</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40638110</ArticleId><ArticleId IdType="pmc">PMC12246949</ArticleId><ArticleId IdType="doi">10.1001/jamaoto.2025.1833</ArticleId><ArticleId IdType="pii">2836483</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Faraji F, Rettig EM, Tsai HL, et al. The prevalence of human papillomavirus in oropharyngeal cancer is increasing regardless of sex or race, and the influence of sex and race on survival is modified by human papillomavirus tumor status. Cancer. 2019;125(5):761-769. doi: 10.1002/cncr.31841</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.31841</ArticleId><ArticleId IdType="pubmed">30521092</ArticleId></ArticleIdList></Reference><Reference><Citation>Wittekindt C, Wagner S, Bushnak A, et al. Increasing incidence rates of oropharyngeal squamous cell carcinoma in Germany and significance of disease burden attributed to human papillomavirus. Cancer Prev Res (Phila). 2019;12(6):375-382. doi: 10.1158/1940-6207.CAPR-19-0098</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1940-6207.CAPR-19-0098</ArticleId><ArticleId IdType="pubmed">31003993</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillison ML, Chaturvedi AK, Anderson WF, Fakhry C. Epidemiology of human papillomavirus-positive head and neck squamous cell carcinoma. J Clin Oncol. 2015;33(29):3235-3242. doi: 10.1200/JCO.2015.61.6995</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2015.61.6995</ArticleId><ArticleId IdType="pmc">PMC4979086</ArticleId><ArticleId IdType="pubmed">26351338</ArticleId></ArticleIdList></Reference><Reference><Citation>Strober W, Shishido S, Wood B, et al. Two for the price of one: prevalence, demographics and treatment implications of multiple HPV mediated head and neck cancers. Oral Oncol. 2020;100:104475. doi: 10.1016/j.oraloncology.2019.104475</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.oraloncology.2019.104475</ArticleId><ArticleId IdType="pmc">PMC7017724</ArticleId><ArticleId IdType="pubmed">31765835</ArticleId></ArticleIdList></Reference><Reference><Citation>Meccariello G, Bianchi G, Calpona S, et al. Trans oral robotic surgery versus definitive chemoradiotherapy for oropharyngeal cancer: 10-year institutional experience. Oral Oncol. 2020;110:104889. doi: 10.1016/j.oraloncology.2020.104889</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.oraloncology.2020.104889</ArticleId><ArticleId IdType="pubmed">32653838</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha P, Karadaghy OA, Doering MM, Tuuli MG, Jackson RS, Haughey BH. Survival for HPV-positive oropharyngeal squamous cell carcinoma with surgical versus non-surgical treatment approach: a systematic review and meta-analysis. Oral Oncol. 2018;86:121-131. doi: 10.1016/j.oraloncology.2018.09.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.oraloncology.2018.09.018</ArticleId><ArticleId IdType="pubmed">30409292</ArticleId></ArticleIdList></Reference><Reference><Citation>Cracchiolo JR, Roman BR, Kutler DI, Kuhel WI, Cohen MA. Adoption of transoral robotic surgery compared with other surgical modalities for treatment of oropharyngeal squamous cell carcinoma. J Surg Oncol. 2016;114(4):405-411. doi: 10.1002/jso.24353</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jso.24353</ArticleId><ArticleId IdType="pmc">PMC5019352</ArticleId><ArticleId IdType="pubmed">27392812</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen MA, Weinstein GS, O&#x2019;Malley BW Jr, Feldman M, Quon H. Transoral robotic surgery and human papillomavirus status: oncologic results. Head Neck. 2011;33(4):573-580. doi: 10.1002/hed.21500</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hed.21500</ArticleId><ArticleId IdType="pubmed">21425382</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore EJ, Olsen SM, Laborde RR, et al. Long-term functional and oncologic results of transoral robotic surgery for oropharyngeal squamous cell carcinoma. Mayo Clin Proc. 2012;87(3):219-225. doi: 10.1016/j.mayocp.2011.10.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2011.10.007</ArticleId><ArticleId IdType="pmc">PMC3538408</ArticleId><ArticleId IdType="pubmed">22386176</ArticleId></ArticleIdList></Reference><Reference><Citation>de Almeida JR, Li R, Magnuson JS, et al. Oncologic outcomes after transoral robotic surgery: a multi-institutional study. JAMA Otolaryngol Head Neck Surg. 2015;141(12):1043-1051. doi: 10.1001/jamaoto.2015.1508</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoto.2015.1508</ArticleId><ArticleId IdType="pmc">PMC5019351</ArticleId><ArticleId IdType="pubmed">26402479</ArticleId></ArticleIdList></Reference><Reference><Citation>Leonhardt FD, Quon H, Abrah&#xe3;o M, O&#x2019;Malley BW Jr, Weinstein GS. Transoral robotic surgery for oropharyngeal carcinoma and its impact on patient-reported quality of life and function. Head Neck. 2012;34(2):146-154. doi: 10.1002/hed.21688</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hed.21688</ArticleId><ArticleId IdType="pubmed">21469248</ArticleId></ArticleIdList></Reference><Reference><Citation>Nichols AC, Theurer J, Prisman E, et al. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. Lancet Oncol. 2019;20(10):1349-1359. doi: 10.1016/S1470-2045(19)30410-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(19)30410-3</ArticleId><ArticleId IdType="pubmed">31416685</ArticleId></ArticleIdList></Reference><Reference><Citation>Dziegielewski PT, Boyce BJ, Old M, et al. Transoral robotic surgery for tonsillar cancer: addressing the contralateral tonsil. Head Neck. 2017;39(11):2224-2231. doi: 10.1002/hed.24887</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hed.24887</ArticleId><ArticleId IdType="pubmed">28782298</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim CM, St John MA. Should the contralateral tonsil be removed in cases of HPV-positive squamous cell carcinoma of the tonsil? Laryngoscope. 2019;129(6):1257-1258. doi: 10.1002/lary.27563</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/lary.27563</ArticleId><ArticleId IdType="pubmed">30467851</ArticleId></ArticleIdList></Reference><Reference><Citation>Bollig CA, Lee DS, Mazul AL, et al. Systematic review of second primary oropharyngeal cancers in patients with p16+ oropharyngeal cancer. Otolaryngol Head Neck Surg. 2021;164(4):733-740. doi: 10.1177/0194599820951175</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0194599820951175</ArticleId><ArticleId IdType="pubmed">32928026</ArticleId></ArticleIdList></Reference><Reference><Citation>Stepan K, Craig E, Skillington SA, et al. Development of second primary malignancies after transoral surgery in human papilloma virus-positive oropharyngeal squamous cell carcinoma. Head Neck. 2022;44(5):1069-1078. doi: 10.1002/hed.27002</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hed.27002</ArticleId><ArticleId IdType="pmc">PMC9112335</ArticleId><ArticleId IdType="pubmed">35175648</ArticleId></ArticleIdList></Reference><Reference><Citation>Parhar HS, Shimunov D, Brody RM, et al. Revisiting the recommendation for contralateral tonsillectomy in HPV-associated tonsillar carcinoma. Otolaryngol Head Neck Surg. 2021;164(6):1222-1229. doi: 10.1177/0194599820968800</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0194599820968800</ArticleId><ArticleId IdType="pubmed">33138700</ArticleId></ArticleIdList></Reference><Reference><Citation>McMillan RA, Van Abel KM, Yin LX, et al. Second primary tumors in patients presenting with unilateral HPV-associated tonsillar squamous cell carcinoma. Laryngoscope. 2022;132(2):332-338. doi: 10.1002/lary.29741</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/lary.29741</ArticleId><ArticleId IdType="pubmed">34236086</ArticleId></ArticleIdList></Reference><Reference><Citation>von Elm E, Altman DG, Egger M, Pocock SJ, G&#xf8;tzsche PC, Vandenbroucke JP; STROBE Initiative . Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335(7624):806-808. doi: 10.1136/bmj.39335.541782.AD</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.39335.541782.AD</ArticleId><ArticleId IdType="pmc">PMC2034723</ArticleId><ArticleId IdType="pubmed">17947786</ArticleId></ArticleIdList></Reference><Reference><Citation>Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more &#x201c;personalized&#x201d; approach to cancer staging. CA Cancer J Clin. 2017;67(2):93-99. doi: 10.3322/caac.21388</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21388</ArticleId><ArticleId IdType="pubmed">28094848</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee DS, Mahal RS, Tharakan T, et al. Hearing outcomes in a deintensification trial of adjuvant therapy for HPV-related oropharyngeal squamous cell carcinoma. Otolaryngol Head Neck Surg. 2023;168(5):1089-1096. doi: 10.1002/ohn.182</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ohn.182</ArticleId><ArticleId IdType="pubmed">36939390</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr, Edward L. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004;291(20):2441-2447. doi: 10.1001/jama.291.20.2441</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.291.20.2441</ArticleId><ArticleId IdType="pubmed">15161894</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollei TR, Hinni ML, Moore EJ, et al. Analysis of postoperative bleeding and risk factors in transoral surgery of the oropharynx. JAMA Otolaryngol Head Neck Surg. 2013;139(11):1212-1218. doi: 10.1001/jamaoto.2013.5097</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoto.2013.5097</ArticleId><ArticleId IdType="pubmed">24113922</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen AY, Frankowski R, Bishop-Leone J, et al. The development and validation of a dysphagia-specific quality-of-life questionnaire for patients with head and neck cancer: the M. D. Anderson dysphagia inventory. Arch Otolaryngol Head Neck Surg. 2001;127(7):870-876.</Citation><ArticleIdList><ArticleId IdType="pubmed">11448365</ArticleId></ArticleIdList></Reference><Reference><Citation>Binenbaum Y, Amit M, Billan S, Cohen JT, Gil Z. Minimal clinically important differences in quality of life scores of oral cavity and oropharynx cancer patients. Ann Surg Oncol. 2014;21(8):2773-2781. doi: 10.1245/s10434-014-3656-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1245/s10434-014-3656-z</ArticleId><ArticleId IdType="pubmed">24710774</ArticleId></ArticleIdList></Reference><Reference><Citation>Rokkjaer MS, Klug TE. Prevalence of synchronous bilateral tonsil squamous cell carcinoma: a retrospective study. Clin Otolaryngol. 2018;43(1):1-6. doi: 10.1111/coa.12981</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/coa.12981</ArticleId><ArticleId IdType="pubmed">28891195</ArticleId></ArticleIdList></Reference><Reference><Citation>McQuone SJ, Eisele DW, Lee DJ, Westra WH, Koch WM. Occult tonsillar carcinoma in the unknown primary. Laryngoscope. 1998;108(11 Pt 1):1605-1610. doi: 10.1097/00005537-199811000-00004</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005537-199811000-00004</ArticleId><ArticleId IdType="pubmed">9818813</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch WM, Bhatti N, Williams MF, Eisele DW. Oncologic rationale for bilateral tonsillectomy in head and neck squamous cell carcinoma of unknown primary source. Otolaryngol Head Neck Surg. 2001;124(3):331-333. doi: 10.1067/mhn.2001.114309</Citation><ArticleIdList><ArticleId IdType="doi">10.1067/mhn.2001.114309</ArticleId><ArticleId IdType="pubmed">11241001</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazak I, Haisch A, Jovanovic S. Bilateral synchronous tonsillar carcinoma in cervical cancer of unknown primary site (CUPS). Eur Arch Otorhinolaryngol. 2003;260(9):490-493. doi: 10.1007/s00405-003-0590-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00405-003-0590-2</ArticleId><ArticleId IdType="pubmed">12739031</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozakiewicz J, Dec M, Miszczyk L, Urba&#x144;czyk H. [The rare case of simultaneous bilateral cancer of tonsilla palatina with large metastases to lymphoid glands of the neck]. Otolaryngol Pol. 2007;61(4):501-504. doi: 10.1016/S0030-6657(07)70470-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0030-6657(07)70470-5</ArticleId><ArticleId IdType="pubmed">18260240</ArticleId></ArticleIdList></Reference><Reference><Citation>Kothari P, Randhawa PS, Farrell R. Role of tonsillectomy in the search for a squamous cell carcinoma from an unknown primary in the head and neck. Br J Oral Maxillofac Surg. 2008;46(4):283-287. doi: 10.1016/j.bjoms.2007.11.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bjoms.2007.11.017</ArticleId><ArticleId IdType="pubmed">18243447</ArticleId></ArticleIdList></Reference><Reference><Citation>McGovern SL, Williams MD, Weber RS, et al. Three synchronous HPV-associated squamous cell carcinomas of Waldeyer&#x2019;s ring: case report and comparison with Slaughter&#x2019;s model of field cancerization. Head Neck. 2010;32(8):1118-1124. doi: 10.1002/hed.21171</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hed.21171</ArticleId><ArticleId IdType="pubmed">19572386</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith RO, Pokala K, Medina JE, Krempl GA. Tonsillar carcinoma in the contralateral tonsil. Laryngoscope. 2010;120(suppl 4):S176. doi: 10.1002/lary.21640</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/lary.21640</ArticleId><ArticleId IdType="pubmed">21225774</ArticleId></ArticleIdList></Reference><Reference><Citation>Mannina EM, Pejavar SM, Glastonbury CM, van Zante A, Wang SJ, Yom SS. Diagnosis of bilateral tonsil cancers via staging PET/CT: case report and review. Int J Otolaryngol. 2011;2011:928240. doi: 10.1155/2011/928240</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2011/928240</ArticleId><ArticleId IdType="pmc">PMC3139134</ArticleId><ArticleId IdType="pubmed">21785599</ArticleId></ArticleIdList></Reference><Reference><Citation>Joseph AW, Ogawa T, Bishop JA, et al. Molecular etiology of second primary tumors in contralateral tonsils of human papillomavirus-associated index tonsillar carcinomas. Oral Oncol. 2013;49(3):244-248. doi: 10.1016/j.oraloncology.2012.09.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.oraloncology.2012.09.009</ArticleId><ArticleId IdType="pmc">PMC3548989</ArticleId><ArticleId IdType="pubmed">23062994</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakahara S, Yasui T, Takenaka Y, et al. Synchronous bilateral tonsillar carcinomas associated with human papillomavirus. Auris Nasus Larynx. 2014;41(1):109-112. doi: 10.1016/j.anl.2013.05.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.anl.2013.05.006</ArticleId><ArticleId IdType="pubmed">23871190</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasband-Lindquist A, Shnayder Y, O&#x2019;Neil M. Synchronous bilateral tonsillar squamous cell carcinoma related to human papillomavirus: two case reports and a brief review of the literature. Ear Nose Throat J. 2016;95(4-5):E30-E34.</Citation><ArticleIdList><ArticleId IdType="pubmed">27140027</ArticleId></ArticleIdList></Reference><Reference><Citation>Theodoraki MN, Veit JA, Hoffmann TK, Greve J. Synchronous bilateral tonsil carcinoma: case presentation and review of the literature. Infect Agent Cancer. 2017;12:38. doi: 10.1186/s13027-017-0146-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13027-017-0146-5</ArticleId><ArticleId IdType="pmc">PMC5485684</ArticleId><ArticleId IdType="pubmed">28670333</ArticleId></ArticleIdList></Reference><Reference><Citation>Topf MC, Vo A, Tassone P, et al. Unplanned readmission following transoral robotic surgery. Oral Oncol. 2017;75:127-132. doi: 10.1016/j.oraloncology.2017.11.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.oraloncology.2017.11.009</ArticleId><ArticleId IdType="pubmed">29224809</ArticleId></ArticleIdList></Reference><Reference><Citation>Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304(9):967-975. doi: 10.1001/jama.2010.1237</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2010.1237</ArticleId><ArticleId IdType="pmc">PMC2948529</ArticleId><ArticleId IdType="pubmed">20810374</ArticleId></ArticleIdList></Reference><Reference><Citation>Meijers-Heijboer H, van Geel B, van Putten WL, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2001;345(3):159-164. doi: 10.1056/NEJM200107193450301</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200107193450301</ArticleId><ArticleId IdType="pubmed">11463009</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1001/jamaoto.2025.1612 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40367056</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-619X</ISSN><JournalIssue CitedMedium="Internet"><Volume>151</Volume><Issue>12</Issue><PubDate><Year>2025</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA otolaryngology-- head &amp; neck surgery</Title><ISOAbbreviation>JAMA Otolaryngol Head Neck Surg</ISOAbbreviation></Journal><ArticleTitle>Considerations and Cautions in Postoperative HPV Circulating Tumor DNA Kinetics.</ArticleTitle><Pagination><StartPage>1124</StartPage><EndPage>1126</EndPage><MedlinePgn>1124-1126</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaoto.2025.1612</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Heft Neal</LastName><ForeName>Molly E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, University of Michigan, Ann Arbor.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bakst</LastName><ForeName>Richard L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chai</LastName><ForeName>Raymond L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, New York.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Otolaryngol Head Neck Surg</MedlineTA><NlmUniqueID>101589542</NlmUniqueID><ISSNLinking>2168-6181</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Otolaryngol Head Neck Surg. 2025 Dec 1;151(12):1117-1124. doi: 10.1001/jamaoto.2025.1606.</RefSource><PMID Version="1">40367049</PMID></CommentsCorrections></CommentsCorrectionsList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>14</Day><Hour>19</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>14</Day><Hour>19</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>14</Day><Hour>13</Hour><Minute>34</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40367056</ArticleId><ArticleId IdType="doi">10.1001/jamaoto.2025.1612</ArticleId><ArticleId IdType="pii">2834216</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1001/jamaoto.2025.1606 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40367049</PMID><DateCompleted><Year>2025</Year><Month>12</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>12</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-619X</ISSN><JournalIssue CitedMedium="Internet"><Volume>151</Volume><Issue>12</Issue><PubDate><Year>2025</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA otolaryngology-- head &amp; neck surgery</Title><ISOAbbreviation>JAMA Otolaryngol Head Neck Surg</ISOAbbreviation></Journal><ArticleTitle>Postoperative ctHPVDNA Kinetics in Patients With HPV-Related Oropharyngeal Cancer.</ArticleTitle><Pagination><StartPage>1117</StartPage><EndPage>1124</EndPage><MedlinePgn>1117-1124</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaoto.2025.1606</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="UNASSIGNED">Circulating tumor human papillomavirus DNA (ctHPVDNA) is an important biomarker for the presence of HPV-associated oropharyngeal squamous cell carcinoma (OPSCC), but little is known about early postoperative kinetics of ctHPVDNA clearance.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To investigate early postoperative kinetics of ctHPVDNA in patients with HPV-associated OPSCC.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="UNASSIGNED">This prospective cohort study was conducted at a single tertiary care center from January 4, 2020, to January 26, 2023. Patients with newly diagnosed HPV-associated OPSCC undergoing surgical management were enrolled. HPV status was defined as positive if findings of p16 immunohistochemistry and/or HPV DNA in situ hybridization and/or E6/E7 RNA in situ hybridization were positive. Exclusion criteria included history of prior head and neck cancer and metastatic disease at presentation. Data were analyzed from September 1, 2024, to April 25, 2025.</AbstractText><AbstractText Label="EXPOSURES" NlmCategory="UNASSIGNED">Transoral robotic surgery with concurrent neck dissection.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="UNASSIGNED">Blood was drawn prior to surgery (pretreatment), 1 to 2 days after surgery (postoperative days 1 to 2), and approximately 2 weeks after surgery (postoperative week 2; range, 8 to 20 days). ctHPVDNA was quantified by a tumor tissue-modified viral (TTMV) HPV DNA test. Correlations were tested between the pretreatment and postoperative day 1 to 2 TTMV HPV DNA levels using Gaussian regression. Concordance between detectability at postoperative day 1 to 2 and postoperative week 2 was explored using negative predictive value and positive predictive value.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Of 57 included patients with detectable pretreatment TTMV HPV DNA, 51 (89%) were male, and the median (IQR) age was 59 (54-66) years. A total of 35 patients (61%) had blood draws at all 3 time points; 16 (28%) had detectable TTMV HPV DNA on postoperative day 1 to 2. Pretreatment and postoperative day 1 to 2 TTMV HPV DNA levels had a medium positive linear correlation (r&#x2009;=&#x2009;0.31; 95% CI, 0.04-0.54). Undetectable TTMV HPV DNA on postoperative day 1 to 2 blood draw had a negative predictive value of 0.95 (95% CI, 0.74-1.00) for an undetectable level on postoperative week 2 blood draw, but a detectable level on postoperative day 1 to 2 blood draw only had a positive predictive value of 0.19 (95% CI, 0.04-0.46). Of the 16 patients with detectable TTMV HPV DNA pretreatment and at postoperative day 1 to 2, only 3 (19%) continued to have detectable TTMV HPV DNA at postoperative week 2. One patient had undetectable levels at postoperative day 1 to 2 and detectable levels at postoperative week 2.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="UNASSIGNED">In this study, ctHPVDNA detectability early after surgery did not predict detectability at 2 weeks after surgery. ctHPVDNA clearance early after surgery could predict a negative test at 2 weeks. A negative blood draw finding on postoperative day 1 may be used to omit a postoperative blood draw at 2 weeks for minimal residual disease detection in future clinical trials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Linda X</ForeName><Initials>LX</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head &amp; Neck Surgery, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hidalgo</LastName><ForeName>Cecelia M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head &amp; Neck Surgery, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bogan</LastName><ForeName>Aaron W</ForeName><Initials>AW</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Scottsdale, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hunter</LastName><ForeName>Danielle E</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head &amp; Neck Surgery, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bartemes</LastName><ForeName>Kathleen R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head &amp; Neck Surgery, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tasche</LastName><ForeName>Kendall K</ForeName><Initials>KK</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head &amp; Neck Surgery, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Eric J</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head &amp; Neck Surgery, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>Daniel L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head &amp; Neck Surgery, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Daniel J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neben-Wittich</LastName><ForeName>Michelle A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lester</LastName><ForeName>Scott C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>Katharine A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGarrah</LastName><ForeName>Patrick W</ForeName><Initials>PW</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fuentes Bayne</LastName><ForeName>Harry E</ForeName><Initials>HE</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Routman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Abel</LastName><ForeName>Kathryn M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head &amp; Neck Surgery, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Otolaryngol Head Neck Surg</MedlineTA><NlmUniqueID>101589542</NlmUniqueID><ISSNLinking>2168-6181</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004279">DNA, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000074141">Circulating Tumor DNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>JAMA Otolaryngol Head Neck Surg. 2025 Dec 1;151(12):1124-1126. doi: 10.1001/jamaoto.2025.1612.</RefSource><PMID Version="1">40367056</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009959" MajorTopicYN="Y">Oropharyngeal Neoplasms</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030361" MajorTopicYN="Y">Papillomavirus Infections</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004279" MajorTopicYN="Y">DNA, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000074141" MajorTopicYN="Y">Circulating Tumor DNA</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011184" MajorTopicYN="N">Postoperative Period</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D027383" MajorTopicYN="Y">Papillomaviridae</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065287" MajorTopicYN="N">Robotic Surgical Procedures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Yin reported nonfinancial support from Naveris during the conduct of the study. Dr Routman reported nonfinancial support from Naveris during the conduct of the study; support from the Paul Calabresi Program in Clinical/Translational Research at the Mayo Clinic Comprehensive Cancer Center; serving on the advisory board for Adela outside the submitted work; and had a patent for DNA methylation licensed to Exact Sciences. Dr Van Abel reported serving as a consultant for Intuitive Surgical and a patent pending from Exact Sciences outside the submitted work. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2026</Year><Month>5</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>11</Day><Hour>13</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>14</Day><Hour>19</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>14</Day><Hour>13</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40367049</ArticleId><ArticleId IdType="pmc">PMC12079564</ArticleId><ArticleId IdType="doi">10.1001/jamaoto.2025.1606</ArticleId><ArticleId IdType="pii">2834215</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chera BS, Kumar S, Shen C, et al. Plasma circulating tumor HPV DNA for the surveillance of cancer recurrence in HPV-associated oropharyngeal cancer. J Clin Oncol. 2020;38(10):1050-1058. doi: 10.1200/JCO.19.02444</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.19.02444</ArticleId><ArticleId IdType="pmc">PMC7106982</ArticleId><ArticleId IdType="pubmed">32017652</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, Tong Y, Wu J, Xu X. Clinical applications and utility of ctDNA in cervical cancer and its precursor lesions: from screening to predictive biomarker. Cancer Cell Int. 2023;23(1):329. doi: 10.1186/s12935-023-03132-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12935-023-03132-0</ArticleId><ArticleId IdType="pmc">PMC10726499</ArticleId><ArticleId IdType="pubmed">38110977</ArticleId></ArticleIdList></Reference><Reference><Citation>Batool S, Sethi RKV, Wang A, et al. Circulating tumor-tissue modified HPV DNA testing in the clinical evaluation of patients at risk for HPV-positive oropharynx cancer: the IDEA-HPV study. Oral Oncol. 2023;147:106584. doi: 10.1016/j.oraloncology.2023.106584</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.oraloncology.2023.106584</ArticleId><ArticleId IdType="pubmed">37837735</ArticleId></ArticleIdList></Reference><Reference><Citation>Han K, Zou J, Zhao Z, et al. Clinical validation of human papilloma virus circulating tumor DNA for early detection of residual disease after chemoradiation in cervical cancer. J Clin Oncol. 2024;42(4):431-440. doi: 10.1200/JCO.23.00954</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.23.00954</ArticleId><ArticleId IdType="pmc">PMC10824379</ArticleId><ArticleId IdType="pubmed">37972346</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikh AR, Van Seventer EE, Siravegna G, et al. Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer. Clin Cancer Res. 2021;27(20):5586-5594. doi: 10.1158/1078-0432.CCR-21-0410</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-21-0410</ArticleId><ArticleId IdType="pmc">PMC8530842</ArticleId><ArticleId IdType="pubmed">33926918</ArticleId></ArticleIdList></Reference><Reference><Citation>Huttinger ZM, Gogineni E, Baliga S, et al. Circulating tumor DNA determines induction chemotherapy response in HPV associated oropharyngeal squamous cell carcinoma: a pilot study. Oral Oncol. 2025;161:107179. doi: 10.1016/j.oraloncology.2025.107179</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.oraloncology.2025.107179</ArticleId><ArticleId IdType="pubmed">39827592</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrier ST, Tsering T, Sadeghi N, Zeitouni A, Burnier JV. Blood and saliva-derived ctDNA is a marker of residual disease after treatment and correlates with recurrence in human papillomavirus-associated head and neck cancer. Cancer Med. 2023;12(15):15777-15787. doi: 10.1002/cam4.6191</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cam4.6191</ArticleId><ArticleId IdType="pmc">PMC10469655</ArticleId><ArticleId IdType="pubmed">37526056</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferris RL, Flamand Y, Weinstein GS, et al. Phase II randomized trial of transoral surgery and low-dose intensity modulated radiation therapy in resectable p16+ locally advanced oropharynx cancer: an ECOG-ACRIN Cancer Research Group Trial (E3311). J Clin Oncol. 2022;40(2):138-149. doi: 10.1200/JCO.21.01752</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.21.01752</ArticleId><ArticleId IdType="pmc">PMC8718241</ArticleId><ArticleId IdType="pubmed">34699271</ArticleId></ArticleIdList></Reference><Reference><Citation>Campo F, Paolini F, Terrenato I, et al. Circulating HPVDNA in patients undergoing transoral robotic surgery for oropharyngeal cancer: liquid biopsy could identify molecular residual disease. Eur Arch Otorhinolaryngol. Published online January 25, 2025. doi: 10.1007/s00405-025-09218-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00405-025-09218-x</ArticleId><ArticleId IdType="pubmed">39863814</ArticleId></ArticleIdList></Reference><Reference><Citation>Naegele S, Das D, Hirayama S, et al. Circulating tumor HPV DNA in patients with stage I and II HPV-associated head and neck cancer after surgery. JAMA Otolaryngol Head Neck Surg. 2024;150(6):521-523. doi: 10.1001/jamaoto.2024.0740</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoto.2024.0740</ArticleId><ArticleId IdType="pmc">PMC11046405</ArticleId><ArticleId IdType="pubmed">38662357</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Boyle CJ, Siravegna G, Varmeh S, et al. Cell-free human papillomavirus DNA kinetics after surgery for human papillomavirus-associated oropharyngeal cancer. Cancer. 2022;128(11):2193-2204. doi: 10.1002/cncr.34109</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.34109</ArticleId><ArticleId IdType="pmc">PMC10032347</ArticleId><ArticleId IdType="pubmed">35139236</ArticleId></ArticleIdList></Reference><Reference><Citation>Routman DM, Kumar S, Chera BS, et al. Detectable postoperative circulating tumor human papillomavirus DNA and association with recurrence in patients with HPV-associated oropharyngeal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2022;113(3):530-538. doi: 10.1016/j.ijrobp.2022.02.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijrobp.2022.02.012</ArticleId><ArticleId IdType="pubmed">35157995</ArticleId></ArticleIdList></Reference><Reference><Citation>Amin MB, Edge SB, Greene FL, et al. , eds. AJCC Cancer Staging Manual. 8th ed. Springer; 2018.</Citation></Reference><Reference><Citation>Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Lawrence Erlbaum Associates; 1988.</Citation></Reference><Reference><Citation>Bonett DG. Point-biserial correlation: interval estimation, hypothesis testing, meta-analysis, and sample size determination. Br J Math Stat Psychol. 2020;73(suppl 1):113-144. doi: 10.1111/bmsp.12189</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bmsp.12189</ArticleId><ArticleId IdType="pubmed">31565811</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma DM, Price K, Moore EJ, et al. MC1675, a phase III evaluation of de-escalated adjuvant radiation therapy (DART) vs. standard adjuvant treatment for human papillomavirus associated oropharyngeal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2021;111(5):1324. doi: 10.1016/j.ijrobp.2021.09.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijrobp.2021.09.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Seo S, Rooper L, Seiwert TY, Fakhry C. Spontaneous regression of an human papillomavirus-positive oropharyngeal squamous cell carcinoma. Head Neck. 2023;45(1):E1-E4. doi: 10.1002/hed.27226</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hed.27226</ArticleId><ArticleId IdType="pubmed">36256583</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartemes KR, Moore RM, Novotny BC, et al. Increased interaction between B cells and CD3+ T cells in non-progressors with human papillomavirus-associated oropharyngeal squamous cell carcinoma. Clin Cancer Res. February 18, 2025. doi: 10.1158/1078-0432.CCR-24-2425</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-24-2425</ArticleId><ArticleId IdType="pubmed">39964349</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakkireddy SR, Jang I, Kim M, et al. Integrative analysis of H&amp;E and IHC identifies prognostic immune subtypes in HPV related oropharyngeal cancer. Commun Med (Lond). 2024;4(1):190. doi: 10.1038/s43856-024-00604-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s43856-024-00604-w</ArticleId><ArticleId IdType="pmc">PMC11450009</ArticleId><ArticleId IdType="pubmed">39363031</ArticleId></ArticleIdList></Reference><Reference><Citation>Challis GB, Stam HJ. The spontaneous regression of cancer. a review of cases from 1900 to 1987. Acta Oncol. 1990;29(5):545-550. doi: 10.3109/02841869009090048</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/02841869009090048</ArticleId><ArticleId IdType="pubmed">2206563</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson JC, Scholes DG, Carpenter EL, Aggarwal C. Molecular response assessment using circulating tumor DNA (ctDNA) in advanced solid tumors. Br J Cancer. 2023;129(12):1893-1902. doi: 10.1038/s41416-023-02445-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41416-023-02445-1</ArticleId><ArticleId IdType="pmc">PMC10703899</ArticleId><ArticleId IdType="pubmed">37789101</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirayama S, Al-Inaya Y, Aye L, et al. Prospective validation of ctHPVDNA for detection of minimal residual disease and prediction of recurrence in patients with HPV-associated head and neck cancer treated with surgery. J Clin Oncol. 2024;42(16)(suppl):6010. doi: 10.1200/JCO.2024.42.16_suppl.6010</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2024.42.16_suppl.6010</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Cohen M, Hatzoglou V, et al. Early disease recurrence following post-operative HPV ctDNA directed active surveillance in oropharyngeal carcinoma&#x2014;outcomes of a prospective pilot study. Int J Radiat Oncol Biol Phys. 2024;118(5):e91. doi: 10.1016/j.ijrobp.2024.02.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijrobp.2024.02.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee NY, Morris LGT, Diehn M. Assessing the evidence for circulating tumor HPV DNA in patients with oropharyngeal cancer. JAMA Oncol. 2024;10(8):1021-1022. doi: 10.1001/jamaoncol.2024.1821</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2024.1821</ArticleId><ArticleId IdType="pubmed">38935364</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1001/jamaoto.2025.4777 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41481310</PMID><DateRevised><Year>2026</Year><Month>01</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2168-619X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2026</Year><Month>Jan</Month><Day>02</Day></PubDate></JournalIssue><Title>JAMA otolaryngology-- head &amp; neck surgery</Title><ISOAbbreviation>JAMA Otolaryngol Head Neck Surg</ISOAbbreviation></Journal><ArticleTitle>A Patient With Recurrent Pleomorphic Adenomas.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaoto.2025.4777</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Freeley</LastName><ForeName>Justis J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Uniformed Services University of the Health Sciences, Bethesda, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Alex W</ForeName><Initials>AW</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology Head and Neck Surgery, Walter Reed National Military Medical Center, Bethesda, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Judd</LastName><ForeName>Nancy</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Kaiser Permanente Midatlantic Permanente Medical Group, McLean, Virginia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2026</Year><Month>01</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Otolaryngol Head Neck Surg</MedlineTA><NlmUniqueID>101589542</NlmUniqueID><ISSNLinking>2168-6181</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><OtherAbstract Type="plain-language-summary" Language="eng"><AbstractText>A 31-year-old female presented with a progressively enlarging left submandibular mass and history of pleomorphic adenoma of the left submandibular gland. What is your diagnosis?</AbstractText></OtherAbstract></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2026</Year><Month>1</Month><Day>2</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2026</Year><Month>1</Month><Day>2</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2026</Year><Month>1</Month><Day>2</Day><Hour>11</Hour><Minute>34</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41481310</ArticleId><ArticleId IdType="doi">10.1001/jamaoto.2025.4777</ArticleId><ArticleId IdType="pii">2843112</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1001/jamaoto.2025.4766 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41481330</PMID><DateRevised><Year>2026</Year><Month>01</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2168-619X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2026</Year><Month>Jan</Month><Day>02</Day></PubDate></JournalIssue><Title>JAMA otolaryngology-- head &amp; neck surgery</Title><ISOAbbreviation>JAMA Otolaryngol Head Neck Surg</ISOAbbreviation></Journal><ArticleTitle>Clinical Trial Termination or Withdrawal in Head and Neck Squamous Cell Carcinoma.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e254766</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaoto.2025.4766</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="UNASSIGNED">Innovative clinical trials (CTs) are needed to address the rising incidence of head and neck squamous cell carcinoma (HNSCC). Despite adequate trial initiation, HNSCC CTs experience high failure rates, and the factors driving these trends remain unclear.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To assess the characteristics associated with failure (termination or withdrawal) in CTs for the treatment of HNSCC.</AbstractText><AbstractText Label="DESIGN AND SETTING" NlmCategory="UNASSIGNED">HNSCC CTs were identified on ClinicalTrials.gov from January 1, 2000, to December 31, 2024, and trial failures were defined as early termination or withdrawal. Trial characteristics were compared between failed CTs and completed CT controls. Data were analyzed from June to August 2025.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="UNASSIGNED">The primary outcome was trial failure. The association between failure and CT characteristics, including phase, enrollment, funding source, intervention type, and age-eligibility criteria, was analyzed using descriptive statistics and multivariable regression models.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total of 692 matched trials were analyzed, including 346 trial failures and 346 completed control trials. The overall leading reasons for failure were strategic decisions (defined as nonscientific, sponsor-driven choices; 102 trials [29.5%]) and poor recruitment (90 trials [26.0%]). The reasons for failure varied by trial characteristics. Strategic decisions were the predominant reason for failure in phase 1 trials, industry-sponsored trials, and immunotherapy and targeted therapy trials. In contrast, poor recruitment was a more common reason in later-phase trials, non-industry-sponsored trials, and trials investigating chemotherapy, radiation, chemoradiation, combination treatments, and supportive care. Temporal analysis revealed a growing failure rate among CTs since 2000. Increased log-transformed actual enrollment safeguarded against trial failure, whereas industry funding was an independent risk factor.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="UNASSIGNED">In this study, HNSCC CTs were terminated early or withdrawn for a variety of reasons, most commonly due to strategic decisions or poor recruitment. Careful attention to trial characteristics associated with early failure is needed to overcome new barriers to drug development and adapt trial design to common reasons for failure.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Janice J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Medical Scientist Training Program, University of Miami Miller School of Medicine, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reznik</LastName><ForeName>Alex S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Medical Scientist Training Program, University of Miami Miller School of Medicine, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sonis</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Oral Medicine and Dentistry, Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Oral Medicine and Oral Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomodels LLC, Waltham, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Primary Endpoint Solutions, Waltham, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franzmann</LastName><ForeName>Elizabeth J</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, University of Miami Miller School of Medicine, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villa</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Oral Medicine, Oral Oncology, and Dentistry, Miami Cancer Institute, Baptist Health South Florida, Miami, Florida.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Orofacial Sciences, University of California, San Francisco.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2026</Year><Month>01</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Otolaryngol Head Neck Surg</MedlineTA><NlmUniqueID>101589542</NlmUniqueID><ISSNLinking>2168-6181</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Sonis reported owning stock in InnoPath Therapeutics outside the submitted work. Dr Franzmann reported grants from Delta Dental; nonfinancial support from Aveta Biomics; owning stock in Vigilant Laboratories; and is CEO of Vigilant Laboratories outside the submitted work; and had a patent for early detection test for cancer licensed to Vigilant Laboratories. Dr Villa reported grants from Merck, Lipella, Mureva, and MeiraGtx as well as personal fees from Primary Endpoint Solutions, WSK Medical, Lipella, Amgen, and K Pharmaceuticals outside the submitted work. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2027</Year><Month>1</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2026</Year><Month>1</Month><Day>2</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2026</Year><Month>1</Month><Day>2</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2026</Year><Month>1</Month><Day>2</Day><Hour>11</Hour><Minute>37</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41481330</ArticleId><ArticleId IdType="pmc">PMC12761761</ArticleId><ArticleId IdType="doi">10.1001/jamaoto.2025.4766</ArticleId><ArticleId IdType="pii">2843111</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gormley M, Creaney G, Schache A, Ingarfield K, Conway DI. Reviewing the epidemiology of head and neck cancer: definitions, trends and risk factors. Br Dent J. 2022;233(9):780-786. doi: 10.1038/s41415-022-5166-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41415-022-5166-x</ArticleId><ArticleId IdType="pmc">PMC9652141</ArticleId><ArticleId IdType="pubmed">36369568</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson LB, Reznik AS, Villa A. Update on oral and oropharyngeal cancers: a guide for oral health care providers. J Dent Hyg. 2024;98(2):39-46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC12547668</ArticleId><ArticleId IdType="pubmed">38649286</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020;6(1):92. doi: 10.1038/s41572-020-00224-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41572-020-00224-3</ArticleId><ArticleId IdType="pmc">PMC7944998</ArticleId><ArticleId IdType="pubmed">33243986</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10-45. doi: 10.3322/caac.21871</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21871</ArticleId><ArticleId IdType="pmc">PMC11745215</ArticleId><ArticleId IdType="pubmed">39817679</ArticleId></ArticleIdList></Reference><Reference><Citation>Devaiah A, Murchison C. Characteristics of NIH- and industry-sponsored head and neck cancer clinical trials. Laryngoscope. 2016;126(9):E300-E303. doi: 10.1002/lary.25942</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/lary.25942</ArticleId><ArticleId IdType="pubmed">27010965</ArticleId></ArticleIdList></Reference><Reference><Citation>Glehan A, Kumaresan T, Ramsey T, Kumaresan J, Gildener-Leapman N. Geospatial mapping of head and neck cancer research: assessing access, disparities, and characteristics of head and neck cancer clinical trials across the United States. Am J Clin Oncol. 2025;48(4):180-184. doi: 10.1097/COC.0000000000001160</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/COC.0000000000001160</ArticleId><ArticleId IdType="pubmed">39610060</ArticleId></ArticleIdList></Reference><Reference><Citation>Muralidhar V, Giacalone NJ, Milani N, et al. Head and neck cancer clinical research on ClinicalTrials.gov: an opportunity for radiation oncologists. Adv Radiat Oncol. 2020;6(3):100608. doi: 10.1016/j.adro.2020.10.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.adro.2020.10.021</ArticleId><ArticleId IdType="pmc">PMC7966829</ArticleId><ArticleId IdType="pubmed">33748541</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaanders JHAM, van den Bosch S, Kleijnen J. Comparison of patients with head and neck cancer in randomized clinical trials and clinical practice: a systematic review. JAMA Otolaryngol Head Neck Surg. 2022;148(7):670-676. doi: 10.1001/jamaoto.2022.0890</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoto.2022.0890</ArticleId><ArticleId IdType="pubmed">35587353</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson AL, Fladie I, Anderson JM, Lewis DM, Mons BR, Vassar M. Rates of discontinuation and nonpublication of head and neck cancer randomized clinical trials. JAMA Otolaryngol Head Neck Surg. 2020;146(2):176-182. doi: 10.1001/jamaoto.2019.3967</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoto.2019.3967</ArticleId><ArticleId IdType="pmc">PMC6990718</ArticleId><ArticleId IdType="pubmed">31876933</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur G, Hutchison I, Mehanna H, Williamson P, Shaw R, Tudur Smith C. Barriers to recruitment for surgical trials in head and neck oncology: a survey of trial investigators. BMJ Open. 2013;3(4):e002625. doi: 10.1136/bmjopen-2013-002625</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2013-002625</ArticleId><ArticleId IdType="pmc">PMC3641444</ArticleId><ArticleId IdType="pubmed">23585392</ArticleId></ArticleIdList></Reference><Reference><Citation>Caruana DL, Nam-Woo Kim D, Galivanche AR, et al. Analysis of the frequency, characteristics, and reasons for termination of spine-related clinical trials. Clin Spine Surg. 2022;35(7):E596-E600. doi: 10.1097/BSD.0000000000001323</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BSD.0000000000001323</ArticleId><ArticleId IdType="pubmed">35351841</ArticleId></ArticleIdList></Reference><Reference><Citation>Roddick AJ, Chan FTS, Stefaniak JD, Zheng SL. Discontinuation and non-publication of clinical trials in cardiovascular medicine. Int J Cardiol. 2017;244:309-315. doi: 10.1016/j.ijcard.2017.06.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2017.06.020</ArticleId><ArticleId IdType="pubmed">28622947</ArticleId></ArticleIdList></Reference><Reference><Citation>Reznik A, Sonis S, Villa A. Characterization of terminated and withdrawn clinical trials for the treatment and prevention of oral mucositis. J Clin Transl Sci. 2025;9(1):e86. doi: 10.1017/cts.2025.65</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/cts.2025.65</ArticleId><ArticleId IdType="pmc">PMC12083202</ArticleId><ArticleId IdType="pubmed">40384757</ArticleId></ArticleIdList></Reference><Reference><Citation>Rees CA, Pica N, Monuteaux MC, Bourgeois FT. Noncompletion and nonpublication of trials studying rare diseases: a cross-sectional analysis. PLoS Med. 2019;16(11):e1002966. doi: 10.1371/journal.pmed.1002966</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1002966</ArticleId><ArticleId IdType="pmc">PMC6871779</ArticleId><ArticleId IdType="pubmed">31751330</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasenda B, von Elm E, You J, et al. Prevalence, characteristics, and publication of discontinued randomized trials. JAMA. 2014;311(10):1045-1051. doi: 10.1001/jama.2014.1361</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2014.1361</ArticleId><ArticleId IdType="pubmed">24618966</ArticleId></ArticleIdList></Reference><Reference><Citation>Takebe T, Imai R, Ono S. The current status of drug discovery and development as originated in United States academia: the influence of industrial and academic collaboration on drug discovery and development. Clin Transl Sci. 2018;11(6):597-606. doi: 10.1111/cts.12577</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cts.12577</ArticleId><ArticleId IdType="pmc">PMC6226120</ArticleId><ArticleId IdType="pubmed">29940695</ArticleId></ArticleIdList></Reference><Reference><Citation>Prayle AP, Hurley MN, Smyth AR. Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: cross sectional study. BMJ. 2012;344:d7373. doi: 10.1136/bmj.d7373</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.d7373</ArticleId><ArticleId IdType="pubmed">22214756</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross JS, Tse T, Zarin DA, Xu H, Zhou L, Krumholz HM. Publication of NIH funded trials registered in ClinicalTrials.gov: cross sectional analysis. BMJ. 2012;344:d7292. doi: 10.1136/bmj.d7292</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.d7292</ArticleId><ArticleId IdType="pmc">PMC3623605</ArticleId><ArticleId IdType="pubmed">22214755</ArticleId></ArticleIdList></Reference><Reference><Citation>Elkin ME, Zhu X. Predictive modeling of clinical trial terminations using feature engineering and embedding learning. Sci Rep. 2021;11(1):3446. doi: 10.1038/s41598-021-82840-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-82840-x</ArticleId><ArticleId IdType="pmc">PMC7876037</ArticleId><ArticleId IdType="pubmed">33568706</ArticleId></ArticleIdList></Reference><Reference><Citation>Haddad RI, Chan AT, Vermorken JB. Barriers to clinical trial recruitment in head and neck cancer. Oral Oncol. 2015;51(3):203-211. doi: 10.1016/j.oraloncology.2014.12.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.oraloncology.2014.12.007</ArticleId><ArticleId IdType="pubmed">25593017</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsiouris A, Mayer A, Wiltink J, Ruckes C, Beutel ME, Zwerenz R. Recruitment of patients with cancer for a clinical trial evaluating a web-based psycho-oncological intervention: secondary analysis of a diversified recruitment strategy in a randomized controlled trial. JMIR Cancer. 2023;9:e42123. doi: 10.2196/42123</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/42123</ArticleId><ArticleId IdType="pmc">PMC10714264</ArticleId><ArticleId IdType="pubmed">38010774</ArticleId></ArticleIdList></Reference><Reference><Citation>de Leeuw J, Prins JB, Teerenstra S, Merkx MA, Marres HA, van Achterberg T. Nurse-led follow-up care for head and neck cancer patients: a quasi-experimental prospective trial. Support Care Cancer. 2013;21(2):537-547. doi: 10.1007/s00520-012-1553-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00520-012-1553-1</ArticleId><ArticleId IdType="pubmed">22864472</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvey RD, Bruinooge SS, Chen L, et al. Impact of broadening trial eligibility criteria for patients with advanced non-small cell lung cancer: real-world analysis of select ASCO-<i>Friends</i> recommendations. Clin Cancer Res. 2021;27(9):2430-2434. doi: 10.1158/1078-0432.CCR-20-3857
</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-20-3857</ArticleId><ArticleId IdType="pubmed">33563634</ArticleId></ArticleIdList></Reference><Reference><Citation>Karim S, Xu Y, Kong S, Abdel-Rahman O, Quan ML, Cheung WY. Generalisability of common oncology clinical trial eligibility criteria in the real world. Clin Oncol (R Coll Radiol). 2019;31(9):e160-e166. doi: 10.1016/j.clon.2019.05.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clon.2019.05.003</ArticleId><ArticleId IdType="pubmed">31133363</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim ES, Bruinooge SS, Roberts S, et al. Broadening eligibility criteria to make clinical trials more representative: American Society of Clinical Oncology and Friends of Cancer Research joint research statement. J Clin Oncol. 2017;35(33):3737-3744. doi: 10.1200/JCO.2017.73.7916</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2017.73.7916</ArticleId><ArticleId IdType="pmc">PMC5692724</ArticleId><ArticleId IdType="pubmed">28968170</ArticleId></ArticleIdList></Reference><Reference><Citation>Unger JM, Xiao H, Vaidya R, LeBlanc M. Patient enrollment to industry-sponsored versus federally-sponsored cancer clinical trials. J Clin Oncol. 2024;42(33):3917-3925. doi: 10.1200/JCO.24.00843</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.24.00843</ArticleId><ArticleId IdType="pmc">PMC11575909</ArticleId><ArticleId IdType="pubmed">39331494</ArticleId></ArticleIdList></Reference><Reference><Citation>DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&amp;D costs. J Health Econ. 2016;47:20-33. doi: 10.1016/j.jhealeco.2016.01.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhealeco.2016.01.012</ArticleId><ArticleId IdType="pubmed">26928437</ArticleId></ArticleIdList></Reference><Reference><Citation>Wouters OJ, McKee M, Luyten J. Estimated research and development investment needed to bring a new medicine to market, 2009-2018. JAMA. 2020;323(9):844-853. doi: 10.1001/jama.2020.1166</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.1166</ArticleId><ArticleId IdType="pmc">PMC7054832</ArticleId><ArticleId IdType="pubmed">32125404</ArticleId></ArticleIdList></Reference><Reference><Citation>Upadhaya S, Yu JX, Oliva C, Hooton M, Hodge J, Hubbard-Lucey VM. Impact of COVID-19 on oncology clinical trials. Nat Rev Drug Discov. 2020;19(6):376-377. doi: 10.1038/d41573-020-00093-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41573-020-00093-1</ArticleId><ArticleId IdType="pubmed">32424343</ArticleId></ArticleIdList></Reference><Reference><Citation>Asaad M, Habibullah NK, Butler CE. The impact of COVID-19 on clinical trials. Ann Surg. 2020;272(3):e222-e223. doi: 10.1097/SLA.0000000000004113</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0000000000004113</ArticleId><ArticleId IdType="pmc">PMC7467053</ArticleId><ArticleId IdType="pubmed">32541234</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Di J, Daizadeh N, et al. Decentralized clinical trials in the era of real-world evidence: a statistical perspective. Clin Transl Sci. 2025;18(2):e70117. doi: 10.1111/cts.70117</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cts.70117</ArticleId><ArticleId IdType="pmc">PMC11839390</ArticleId><ArticleId IdType="pubmed">39972404</ArticleId></ArticleIdList></Reference><Reference><Citation>Underhill C, Freeman J, Dixon J, et al. Decentralized clinical trials as a new paradigm of trial delivery to improve equity of access. JAMA Oncol. 2024;10(4):526-530. doi: 10.1001/jamaoncol.2023.6565</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2023.6565</ArticleId><ArticleId IdType="pubmed">38358756</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatt DL, Mehta C. Adaptive designs for clinical trials. N Engl J Med. 2016;375(1):65-74. doi: 10.1056/NEJMra1510061</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1510061</ArticleId><ArticleId IdType="pubmed">27406349</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1001/jamaoto.2025.4838 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41481329</PMID><DateRevised><Year>2026</Year><Month>01</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2168-619X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2026</Year><Month>Jan</Month><Day>02</Day></PubDate></JournalIssue><Title>JAMA otolaryngology-- head &amp; neck surgery</Title><ISOAbbreviation>JAMA Otolaryngol Head Neck Surg</ISOAbbreviation></Journal><ArticleTitle>Individualized Prognostic Counseling for Decision-Making in Head and Neck Cancer: A Nonrandomized Clinical Trial.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e254838</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaoto.2025.4838</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="UNASSIGNED">Managing head and neck squamous cell carcinoma (HNSCC) involves complex decision-making, requiring a balance between optimizing prognosis and preserving quality of life. However, the role of individualized prognostic counseling in the decision-making process is not well known.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To assess the association of individualized prognostic counseling with the decision-making process in patients with primary HNSCC.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="UNASSIGNED">This prospective nonrandomized clinical trial with sequential cohorts was conducted at an academic tertiary referral center. Patients with newly diagnosed primary HNSCC who were eligible for curative treatment were enrolled between January 2014 and August 2018 (cohort 1; standard) and between October 2019 and January 2022 (cohort 2; intervention). Data were analyzed between January and August 2023.</AbstractText><AbstractText Label="INTERVENTION" NlmCategory="UNASSIGNED">Cohort 1 received standard counseling from the treating physician, while cohort 2 received additional individualized prognostic counseling through an online prognostic model. Both cohorts were divided into small laryngeal squamous cell carcinoma (SLSCC) and other HNSCC groups.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="UNASSIGNED">The primary outcome was decisional conflict, measured using the Decisional Conflict Scale. Secondary outcomes included perceived role in decision-making (Control Preferences Scale), decisional regret, treatment choice, and quality of life.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total of 458 patients were enrolled (258 in cohort 1 and 200 in cohort 2; mean [SD] age, 66.1 [8.8] years; 79% [362 of 458] men). Decisional conflict was lower following individualized prognostic counseling for both SLSCC (Cohen d&#x2009;=&#x2009;0.19; 95% CI, -0.10 to 0.49) and other HNSCC groups (Cohen d&#x2009;=&#x2009;0.34; 95% CI, 0.10-0.58). Among patients with other HNSCC, the largest and most precise effect sizes were seen in the informed, values clarity, and support subscales of the Decisional Conflict Scale. Decisional regret was lower at 3 to 6 months after individualized counseling (cohort 2 median, 5 [IQR. 0-20] and cohort 1 median, 20 [IQR, 1-29]; rank-biserial r&#x2009;=&#x2009;0.15 for SLSCC; cohort 2 median, 10 [IQR. 0-20] and cohort 1 median, 20 [IQR, 10-25]; rank-biserial r&#x2009;=&#x2009;0.29 for other HNSCC), indicating small to moderate improvements. These differences were minimal at 12 months. An association between individualized counseling and more active or shared decision-making roles was observed in the other HNSCC group (Cramer V&#x2009;=&#x2009;0.21). No relevant differences in quality-of-life outcomes were identified.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="UNASSIGNED">This nonrandomized clinical trial found that individualized prognostic counseling with an online prognostic model was associated with improvements in decisional conflict and decisional regret and promoted a more active and shared decision-making role among patients with head and neck cancer. The findings suggest integrating individualized prognostic information into routine consultations may enhance patient engagement, strengthen shared decision-making, and reduce uncertainty in complex treatment choices.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="UNASSIGNED">Dutch Trial Register: NTR4106.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dorr</LastName><ForeName>Maarten C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology and Head and Neck Surgery, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoesseini</LastName><ForeName>Arta</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology and Head and Neck Surgery, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sewnaik</LastName><ForeName>Aniel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology and Head and Neck Surgery, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dronkers</LastName><ForeName>Emilie A C</ForeName><Initials>EAC</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology and Head and Neck Surgery, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baatenburg de Jong</LastName><ForeName>Robert J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology and Head and Neck Surgery, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Offerman</LastName><ForeName>Marinella P J</ForeName><Initials>MPJ</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology and Head and Neck Surgery, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2026</Year><Month>01</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Otolaryngol Head Neck Surg</MedlineTA><NlmUniqueID>101589542</NlmUniqueID><ISSNLinking>2168-6181</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement><b>Conflict of Interest Disclosures:</b> All authors report receiving a grant from Zorginstituut Nederland for the conduct of the study. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2027</Year><Month>1</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2026</Year><Month>1</Month><Day>2</Day><Hour>13</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2026</Year><Month>1</Month><Day>2</Day><Hour>13</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2026</Year><Month>1</Month><Day>2</Day><Hour>11</Hour><Minute>37</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41481329</ArticleId><ArticleId IdType="pmc">PMC12761760</ArticleId><ArticleId IdType="doi">10.1001/jamaoto.2025.4838</ArticleId><ArticleId IdType="pii">2843110</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Davies L, Rhodes LA, Grossman DC, Rosenberg MC, Stevens DP. Decision making in head and neck cancer care. Laryngoscope. 2010;120(12):2434-2445. doi: 10.1002/lary.21036</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/lary.21036</ArticleId><ArticleId IdType="pubmed">21089143</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoesseini A, Dorr MC, Dronkers EAC, de Jong RJB, Sewnaik A, Offerman MPJ. Decisional conflict in patients with head and neck cancer. JAMA Otolaryngol Head Neck Surg. 2023;149(2):160-167. doi: 10.1001/jamaoto.2022.4269</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoto.2022.4269</ArticleId><ArticleId IdType="pmc">PMC9912128</ArticleId><ArticleId IdType="pubmed">36547952</ArticleId></ArticleIdList></Reference><Reference><Citation>Elwyn G, Laitner S, Coulter A, Walker E, Watson P, Thomson R. Implementing shared decision making in the NHS. BMJ. 2010;341:c5146. doi: 10.1136/bmj.c5146</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.c5146</ArticleId><ArticleId IdType="pubmed">20947577</ArticleId></ArticleIdList></Reference><Reference><Citation>Forner D, Noel CW, Shuman AG, et al. Shared decision-making in head and neck surgery: a review. JAMA Otolaryngol Head Neck Surg. 2020;146(9):839-844. doi: 10.1001/jamaoto.2020.1601</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoto.2020.1601</ArticleId><ArticleId IdType="pubmed">32701131</ArticleId></ArticleIdList></Reference><Reference><Citation>Garvelink MM, Boland L, Klein K, et al. Decisional Conflict Scale findings among patients and surrogates making health decisions: part II of an anniversary review. Med Decis Making. 2019;39(4):315-326. doi: 10.1177/0272989X19851346</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0272989X19851346</ArticleId><ArticleId IdType="pubmed">31142205</ArticleId></ArticleIdList></Reference><Reference><Citation>Pieterse AH, Baas-Thijssen MC, Marijnen CA, Stiggelbout AM. Clinician and cancer patient views on patient participation in treatment decision-making: a quantitative and qualitative exploration. Br J Cancer. 2008;99(6):875-882. doi: 10.1038/sj.bjc.6604611</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bjc.6604611</ArticleId><ArticleId IdType="pmc">PMC2538766</ArticleId><ArticleId IdType="pubmed">18781148</ArticleId></ArticleIdList></Reference><Reference><Citation>Steyerberg EW. Clinical Prediction Models: A Practical Approach to Development, Validation, and Updating. Springer; 2009. doi: 10.1007/978-0-387-77244-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-0-387-77244-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Steyerberg EW, Moons KGM, van der Windt DA, et al. ; PROGRESS Group . Prognosis Research Strategy (PROGRESS) 3: prognostic model research. PLoS Med. 2013;10(2):e1001381-e1001381. doi: 10.1371/journal.pmed.1001381</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1001381</ArticleId><ArticleId IdType="pmc">PMC3564751</ArticleId><ArticleId IdType="pubmed">23393430</ArticleId></ArticleIdList></Reference><Reference><Citation>Moons KG, Kengne AP, Grobbee DE, et al. Risk prediction models: II. External validation, model updating, and impact assessment. Heart. 2012;98(9):691-698. doi: 10.1136/heartjnl-2011-301247</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2011-301247</ArticleId><ArticleId IdType="pubmed">22397946</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagarde SM, Franssen SJ, van Werven JR, et al. Patient preferences for the disclosure of prognosis after esophagectomy for cancer with curative intent. Ann Surg Oncol. 2008;15(11):3289-3298. doi: 10.1245/s10434-008-0068-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1245/s10434-008-0068-y</ArticleId><ArticleId IdType="pubmed">18670823</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorr MC, Hoesseini A, Sewnaik A, Hardillo JA, Baatenburg de Jong RJ, Offerman MPJ. Impact of a prognostic model for overall survival on the decision-making process in a head and neck cancer multidisciplinary consultation meeting. Head Neck. 2022;44(11):2481-2490. doi: 10.1002/hed.27163</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hed.27163</ArticleId><ArticleId IdType="pmc">PMC9796582</ArticleId><ArticleId IdType="pubmed">35906922</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Schroeff MP, van Schie K, Langeveld TP, Looman C, Baatenburg de Jong RJ. Model-assisted predictions on prognosis in HNSCC: do we learn? Eur Arch Otorhinolaryngol. 2010;267(9):1445-1448. doi: 10.1007/s00405-010-1251-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00405-010-1251-x</ArticleId><ArticleId IdType="pmc">PMC2908455</ArticleId><ArticleId IdType="pubmed">20401488</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoesseini A, Offerman MPJ, van de Wall-Neecke BJ, Sewnaik A, Wieringa MH, Baatenburg de Jong RJ. Physicians&#x2019; clinical prediction of survival in head and neck cancer patients in the palliative phase. BMC Palliat Care. 2020;19(1):176-176. doi: 10.1186/s12904-020-00682-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12904-020-00682-2</ArticleId><ArticleId IdType="pmc">PMC7687732</ArticleId><ArticleId IdType="pubmed">33234115</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoesseini A, van Leeuwen N, Sewnaik A, et al. Key aspects of prognostic model development and interpretation from a clinical perspective. JAMA Otolaryngol Head Neck Surg. 2022;148(2):180-186. doi: 10.1001/jamaoto.2021.3505</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoto.2021.3505</ArticleId><ArticleId IdType="pubmed">34882175</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoesseini A, Dronkers EAC, Sewnaik A, Hardillo JAU, Baatenburg de Jong RJ, Offerman MPJ. Head and neck cancer patients&#x2019; preferences for individualized prognostic information: a focus group study. BMC Cancer. 2020;20(1):399. doi: 10.1186/s12885-020-6554-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12885-020-6554-8</ArticleId><ArticleId IdType="pmc">PMC7203788</ArticleId><ArticleId IdType="pubmed">32380962</ArticleId></ArticleIdList></Reference><Reference><Citation>Dronkers EAC, Hoesseini A, de Boer MF, Offerman MPJ. Communication of prognosis in head and neck cancer patients; a descriptive qualitative analysis. Oral Oncol. 2018;84:76-81. doi: 10.1016/j.oraloncology.2018.07.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.oraloncology.2018.07.014</ArticleId><ArticleId IdType="pubmed">30115480</ArticleId></ArticleIdList></Reference><Reference><Citation>Palaz&#xf3;n-Bru A, Mares-Garc&#xed;a E, L&#xf3;pez-Bru D, et al. A critical appraisal of the clinical applicability and risk of bias of the predictive models for mortality and recurrence in patients with oropharyngeal cancer: Systematic review. Head Neck. 2020;42(4):763-773. doi: 10.1002/hed.26025</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hed.26025</ArticleId><ArticleId IdType="pubmed">31762119</ArticleId></ArticleIdList></Reference><Reference><Citation>Palaz&#xf3;n-Bru A, Mares-Garc&#xed;a E, L&#xf3;pez-Bru D, Mares-Arambul E, Gil-Guill&#xe9;n VF, Carbonell-Torregrosa M&#xc1;. A systematic review of predictive models for recurrence and mortality in patients with tongue cancer. Eur J Cancer Care (Engl). 2019;28(6):e13157. doi: 10.1111/ecc.13157</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ecc.13157</ArticleId><ArticleId IdType="pubmed">31441567</ArticleId></ArticleIdList></Reference><Reference><Citation>Erasmus MC. OncologIQ. Accessed XXX. https://www.oncologiq.nl/#!/.</Citation></Reference><Reference><Citation>Datema FR, Ferrier MB, van der Schroeff MP, Baatenburg de Jong RJ. Impact of comorbidity on short-term mortality and overall survival of head and neck cancer patients. Head Neck. 2010;32(6):728-736. doi: 10.1002/hed.21245</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hed.21245</ArticleId><ArticleId IdType="pubmed">19827120</ArticleId></ArticleIdList></Reference><Reference><Citation>Datema FR, Ferrier MB, Vergouwe Y, et al. Update and external validation of a head and neck cancer prognostic model. Head Neck. 2013;35(9):1232-1237. doi: 10.1002/hed.23117</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hed.23117</ArticleId><ArticleId IdType="pubmed">22847987</ArticleId></ArticleIdList></Reference><Reference><Citation>Baatenburg de Jong RJ, Hermans J, Molenaar J, Briaire JJ, le Cessie S. Prediction of survival in patients with head and neck cancer. Head Neck. 2001;23(9):718-724. doi: 10.1002/hed.1102</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hed.1102</ArticleId><ArticleId IdType="pubmed">11505480</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoesseini A, van Leeuwen N, Offerman MPJ, et al. Predicting survival in head and neck cancer: External validation and update of the prognostic model OncologIQ in 2189 patients. Head Neck. 2021;43(8):2445-2456. doi: 10.1002/hed.26716</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hed.26716</ArticleId><ArticleId IdType="pmc">PMC8359959</ArticleId><ArticleId IdType="pubmed">33960553</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Schroeff MP, Steyerberg EW, Wieringa MH, Langeveld TP, Molenaar J, Baatenburg de Jong RJ. Prognosis: a variable parameter: dynamic prognostic modeling in head and neck squamous cell carcinoma. Head Neck. 2012;34(1):34-41. doi: 10.1002/hed.21693</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hed.21693</ArticleId><ArticleId IdType="pubmed">21322079</ArticleId></ArticleIdList></Reference><Reference><Citation>World Medical Association . World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-2194. doi: 10.1001/jama.2013.281053</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2013.281053</ArticleId><ArticleId IdType="pubmed">24141714</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira N, Netto E, Fonseca L, et al. Surgery versus radiotherapy: long term outcomes of T1 glottic cancer. Rep Pract Oncol Radiother. 2020;25(6):860-866. doi: 10.1016/j.rpor.2020.08.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rpor.2020.08.007</ArticleId><ArticleId IdType="pmc">PMC7498863</ArticleId><ArticleId IdType="pubmed">32982591</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdurehim Y, Hua Z, Yasin Y, Xukurhan A, Imam I, Yuqin F. Transoral laser surgery versus radiotherapy: systematic review and meta-analysis for treatment options of T1a glottic cancer. Head Neck. 2012;34(1):23-33. doi: 10.1002/hed.21686</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hed.21686</ArticleId><ArticleId IdType="pubmed">21374753</ArticleId></ArticleIdList></Reference><Reference><Citation>Greulich MT, Parker NP, Lee P, Merati AL, Misono S. Voice outcomes following radiation versus laser microsurgery for T1 glottic carcinoma: systematic review and meta-analysis. Otolaryngol Head Neck Surg. 2015;152(5):811-819. doi: 10.1177/0194599815577103</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0194599815577103</ArticleId><ArticleId IdType="pmc">PMC5560897</ArticleId><ArticleId IdType="pubmed">25837666</ArticleId></ArticleIdList></Reference><Reference><Citation>Guimar&#xe3;es AV, Dedivitis RA, Matos LL, Aires FT, Cernea CR. Comparison between transoral laser surgery and radiotherapy in the treatment of early glottic cancer: a systematic review and meta-analysis. Sci Rep. 2018;8(1):11900. doi: 10.1038/s41598-018-30218-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-30218-x</ArticleId><ArticleId IdType="pmc">PMC6085327</ArticleId><ArticleId IdType="pubmed">30093659</ArticleId></ArticleIdList></Reference><Reference><Citation>Spielmann PM, Majumdar S, Morton RP. Quality of life and functional outcomes in the management of early glottic carcinoma: a systematic review of studies comparing radiotherapy and transoral laser microsurgery. Clin Otolaryngol. 2010;35(5):373-382. doi: 10.1111/j.1749-4486.2010.02191.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-4486.2010.02191.x</ArticleId><ArticleId IdType="pubmed">21108747</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorr MC, Andrinopoulou ER, Sewnaik A, et al. Individualized dynamic prediction model for patient-reported voice quality in early-stage glottic cancer. Otolaryngol Head Neck Surg. 2024;170(1):169-178. doi: 10.1002/ohn.479</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ohn.479</ArticleId><ArticleId IdType="pubmed">37573487</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorr MC, Sewnaik A, Andrinopoulou E, et al. Longitudinal patient-reported voice quality in early-stage glottic cancer. Otolaryngol Head Neck Surg. 2023;168(6):1463-1471. doi: 10.1002/ohn.263</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ohn.263</ArticleId><ArticleId IdType="pubmed">36939474</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;connor AM. User Manual&#x2014;Decisional Conflict Scale. 1993. Updated 2010. Ottawa Hospital Research Institute; 2014.</Citation></Reference><Reference><Citation>Thompson-Leduc P, Turcotte S, Labrecque M, L&#xe9;gar&#xe9; F. Prevalence of clinically significant decisional conflict: an analysis of five studies on decision-making in primary care. BMJ Open. 2016;6(6):e011490. doi: 10.1136/bmjopen-2016-011490</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2016-011490</ArticleId><ArticleId IdType="pmc">PMC4932317</ArticleId><ArticleId IdType="pubmed">27354076</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor BA, Hart RD, Rigby MH, Trites J, Taylor SM, Hong P. Decisional conflict in patients considering diagnostic thyroidectomy with indeterminate fine needle aspirate cytopathology. J Otolaryngol Head Neck Surg. 2016;45:16. Published online February 27, 2016. doi: 10.1186/s40463-016-0130-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40463-016-0130-x</ArticleId><ArticleId IdType="pmc">PMC4769510</ArticleId><ArticleId IdType="pubmed">26921257</ArticleId></ArticleIdList></Reference><Reference><Citation>Degner LF, Sloan JA, Venkatesh P. The control preferences scale. Can J Nurs Res. 1997;29(3):21-43.</Citation><ArticleIdList><ArticleId IdType="pubmed">9505581</ArticleId></ArticleIdList></Reference><Reference><Citation>Brehaut JC, O&#x2019;Connor AM, Wood TJ, et al. Validation of a decision regret scale. Med Decis Making. 2003;23(4):281-292. doi: 10.1177/0272989X03256005</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0272989X03256005</ArticleId><ArticleId IdType="pubmed">12926578</ArticleId></ArticleIdList></Reference><Reference><Citation>Belafsky PC, Mouadeb DA, Rees CJ, et al. Validity and reliability of the Eating Assessment Tool (EAT-10). Ann Otol Rhinol Laryngol. 2008;117(12):919-924. doi: 10.1177/000348940811701210</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/000348940811701210</ArticleId><ArticleId IdType="pubmed">19140539</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobson BH, Johnson A, Grywalski C, et al. The Voice Handicap Index (VHI) development and validation. Am J Speech Lang Pathol. 1997;6(3):66-70. doi: 10.1044/1058-0360.0603.66</Citation><ArticleIdList><ArticleId IdType="doi">10.1044/1058-0360.0603.66</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res. 2002;52(2):69-77. doi: 10.1016/S0022-3999(01)00296-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-3999(01)00296-3</ArticleId><ArticleId IdType="pubmed">11832252</ArticleId></ArticleIdList></Reference><Reference><Citation>Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983;67(6):361-370. doi: 10.1111/j.1600-0447.1983.tb09716.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0447.1983.tb09716.x</ArticleId><ArticleId IdType="pubmed">6880820</ArticleId></ArticleIdList></Reference><Reference><Citation>Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365-376. doi: 10.1093/jnci/85.5.365</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnci/85.5.365</ArticleId><ArticleId IdType="pubmed">8433390</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks R. EuroQol: the current state of play. Health Policy. 1996;37(1):53-72. doi: 10.1016/0168-8510(96)00822-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0168-8510(96)00822-6</ArticleId><ArticleId IdType="pubmed">10158943</ArticleId></ArticleIdList></Reference><Reference><Citation>EuroQol Group . EuroQol&#x2013;a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199-208. doi: 10.1016/0168-8510(90)90421-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0168-8510(90)90421-9</ArticleId><ArticleId IdType="pubmed">10109801</ArticleId></ArticleIdList></Reference><Reference><Citation>Flynn KE, Weinfurt KP, Seils DM, et al. Decisional conflict among patients who accept or decline participation in phase I oncology studies. J Empir Res Hum Res Ethics. 2008;3(3):69-77. doi: 10.1525/jer.2008.3.3.69</Citation><ArticleIdList><ArticleId IdType="doi">10.1525/jer.2008.3.3.69</ArticleId><ArticleId IdType="pmc">PMC2613310</ArticleId><ArticleId IdType="pubmed">19122780</ArticleId></ArticleIdList></Reference><Reference><Citation>IBM SPSS Statistics for Windows, Version 28.0. IBM Corp; 2021.</Citation></Reference><Reference><Citation>Scott NW, Fayers PM, Aaronson NK, et al. ; EORTC Quality of Life Group . Reference Values EORTC QLQ-C30. July 2008. Accessed November 7, 2025. https://www.eortc.org/app/uploads/sites/2/2018/02/reference_values_manual2008.pdf</Citation></Reference><Reference><Citation>Sun Q. <i>Predicting Downstream Effects of High Decisional Conflict: Meta-analyses of the Decisional Conflict Scale</i>. Dissertation. University of Ottawa; 2005.</Citation></Reference><Reference><Citation>Gattellari M, Ward JE. Will men attribute fault to their GP for adverse effects arising from controversial screening tests? An Australian study using scenarios about PSA screening. J Med Screen. 2004;11(4):165-169. doi: 10.1258/0969141042467386</Citation><ArticleIdList><ArticleId IdType="doi">10.1258/0969141042467386</ArticleId><ArticleId IdType="pubmed">15563771</ArticleId></ArticleIdList></Reference><Reference><Citation>Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363(8):733-742. doi: 10.1056/NEJMoa1000678</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1000678</ArticleId><ArticleId IdType="pubmed">20818875</ArticleId></ArticleIdList></Reference><Reference><Citation>Back AL, Arnold RM. Discussing prognosis: &#x201c;How much do you want to know?&#x201d; Talking to patients who do not want information or who are ambivalent. J Clin Oncol. 2006;24(25):4214-4217. doi: 10.1200/JCO.2006.06.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2006.06.008</ArticleId><ArticleId IdType="pubmed">16943540</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoesseini A, Sewnaik A, van den Besselaar BN, et al. Prognostic model for overall survival of head and neck cancer patients in the palliative phase. BMC Palliat Care. 2024;23(1):54. doi: 10.1186/s12904-023-01325-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12904-023-01325-y</ArticleId><ArticleId IdType="pmc">PMC10893612</ArticleId><ArticleId IdType="pubmed">38395897</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarney R, Warner J, Iliffe S, van Haselen R, Griffin M, Fisher P. The Hawthorne effect: a randomised, controlled trial. BMC Med Res Methodol. 2007;7(1):30. doi: 10.1186/1471-2288-7-30</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2288-7-30</ArticleId><ArticleId IdType="pmc">PMC1936999</ArticleId><ArticleId IdType="pubmed">17608932</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1001/jamaoto.2025.4670 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41452620</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2168-619X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Dec</Month><Day>26</Day></PubDate></JournalIssue><Title>JAMA otolaryngology-- head &amp; neck surgery</Title><ISOAbbreviation>JAMA Otolaryngol Head Neck Surg</ISOAbbreviation></Journal><ArticleTitle>Patient-Reported Outcomes Across Treatment Strategies in Papillary Thyroid Microcarcinoma: A Meta-Analysis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e254670</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaoto.2025.4670</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="UNASSIGNED">Given the favorable prognosis of papillary thyroid microcarcinoma (PTMC), treatment decisions increasingly rely on patient-reported outcomes (PROs), such as health-related quality of life (HRQOL). Comparative HRQOL data between active surveillance, thermal ablation, and surgery remain limited.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To compare HRQOL among adults with PTMC undergoing active surveillance, thermal ablation, or surgery to inform shared decision-making.</AbstractText><AbstractText Label="DATA SOURCES" NlmCategory="UNASSIGNED">Embase, MEDLINE via Ovid, Web of Science Core Collection, Cochrane Central Register of Controlled Trials, and the top 100 references of Google Scholar were searched from inception to June 17, 2025.</AbstractText><AbstractText Label="STUDY SELECTION" NlmCategory="UNASSIGNED">Eligible studies included adult patients with PTMC and compared at least 2 relevant interventions while reporting PROs. Studies restricted to noncomparative designs or non-PTMC populations were excluded. Two reviewers independently screened titles, abstracts, and full texts, resolving discrepancies with a third reviewer.</AbstractText><AbstractText Label="DATA EXTRACTION AND SYNTHESIS" NlmCategory="UNASSIGNED">This systematic review followed PRISMA 2020 and PRISMA-S guidelines; the meta-analysis adhered to MOOSE guidelines. Data were extracted by 1 reviewer and independently verified by a second. Study quality was assessed using established critical appraisal checklists. Random-effects models were applied to obtain mean differences with 95% CIs.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="UNASSIGNED">The primary outcome was domain-specific HRQOL (eg, voice problems, neuromuscular symptoms, psychological distress), as measured using the Thyroid Cancer Quality of Life (THYCA-QOL), Korean Thyroid-specific Quality of Life (KT-QOL), and other validated instruments.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Of 988 retrieved records, 13 studies comprising 5793 patients were included: 2356 underwent active surveillance, 242 received thermal ablation (211 radiofrequency, 31 laser), and 3195 underwent surgery (2350 lobectomy, 833 total thyroidectomy, 12 unspecified). Active surveillance was consistently associated with better PROs compared with surgery across thyroid-specific domains, including neuromuscular symptoms, voice problems, concentration issues, psychological distress, sympathetic complaints, feelings of being chilly, and scar-related concerns. Generic instruments (eg, 36-item Short Form Health Survey, version 2) supported these findings. Low-certainty evidence indicated that thermal ablation was associated with better HRQOL than surgery after 3 to 6 months, although these differences diminished by 12 months. Across studies, heterogeneity arose from differences in treatment strategies and comparators, outcome instruments and duration of follow-up.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="UNASSIGNED">This systematic review and meta-analysis found that patients whose PTMC was managed with active surveillance reported equal or better HRQOL than those undergoing surgery. These findings support the importance of incorporating PROs into shared decision-making for low-risk thyroid cancer.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van Dijk</LastName><ForeName>Sam P J</ForeName><Initials>SPJ</Initials><AffiliationInfo><Affiliation>Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgical Oncology and Gastrointestinal Surgery, Academic Center for Thyroid Disease, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blanco</LastName><ForeName>Matthew M K</ForeName><Initials>MMK</Initials><AffiliationInfo><Affiliation>Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McMullin</LastName><ForeName>Jessica Liu</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Utah, Salt Lake City.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gazelle</LastName><ForeName>G Scott</ForeName><Initials>GS</Initials><AffiliationInfo><Affiliation>MGH Institute for Technology Assessment, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jalali</LastName><ForeName>Mohammad S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>MGH Institute for Technology Assessment, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sloan School of Management, Massachusetts Institute of Technology, Cambridge.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chhatwal</LastName><ForeName>Jagpreet</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>MGH Institute for Technology Assessment, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gartland</LastName><ForeName>Rajshri M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Husson</LastName><ForeName>Olga</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Surgical Oncology and Gastrointestinal Surgery, Academic Center for Thyroid Disease, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Oncology, Netherlands Cancer Institute-Antoni Van Leeuwenhoek, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Public Health, Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Yinin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Surgical Oncology, Department of Surgery, University of Maryland Baltimore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swan</LastName><ForeName>J Shannon</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>MGH Institute for Technology Assessment, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Ginhoven</LastName><ForeName>Tessa M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Department of Surgical Oncology and Gastrointestinal Surgery, Academic Center for Thyroid Disease, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cunningham</LastName><ForeName>Carrie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MGH Institute for Technology Assessment, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Otolaryngol Head Neck Surg</MedlineTA><NlmUniqueID>101589542</NlmUniqueID><ISSNLinking>2168-6181</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Cunningham reported receiving personal fees for consulting from Intuitive Robotics and 3M outside the submitted work. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2026</Year><Month>12</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>26</Day><Hour>13</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>26</Day><Hour>13</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>26</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41452620</ArticleId><ArticleId IdType="pmc">PMC12743308</ArticleId><ArticleId IdType="doi">10.1001/jamaoto.2025.4670</ArticleId><ArticleId IdType="pii">2842670</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg. 2014;140(4):317-322. doi: 10.1001/jamaoto.2014.1</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoto.2014.1</ArticleId><ArticleId IdType="pubmed">24557566</ArticleId></ArticleIdList></Reference><Reference><Citation>Leenhardt L, Grosclaude P, Ch&#xe9;ri&#xe9;-Challine L; Thyroid Cancer Committee . Increased incidence of thyroid carcinoma in France: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee. Thyroid. 2004;14(12):1056-1060. doi: 10.1089/thy.2004.14.1056</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/thy.2004.14.1056</ArticleId><ArticleId IdType="pubmed">15650358</ArticleId></ArticleIdList></Reference><Reference><Citation>Lon&#x10d;ar I, van Dijk SPJ, Metman MJH, et al. Active surveillance for papillary thyroid microcarcinoma in a population with restrictive diagnostic workup strategies. Thyroid. 2021;31(8):1219-1225. doi: 10.1089/thy.2020.0845</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/thy.2020.0845</ArticleId><ArticleId IdType="pubmed">33430696</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccarella S, Franceschi S, Bray F, Wild CP, Plummer M, Dal Maso L. Worldwide thyroid-cancer epidemic? The increasing impact of overdiagnosis. N Engl J Med. 2016;375(7):614-617. doi: 10.1056/NEJMp1604412</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp1604412</ArticleId><ArticleId IdType="pubmed">27532827</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang F, Zhong Q, Huang Z, Lian M, Fang J. Survival in papillary thyroid microcarcinoma: a comparative analysis between the 7th and 8th versions of the AJCC/UICC Staging System based on the SEER database. Front Endocrinol (Lausanne). 2019;10:10. doi: 10.3389/fendo.2019.00010</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2019.00010</ArticleId><ArticleId IdType="pmc">PMC6354565</ArticleId><ArticleId IdType="pubmed">30733707</ArticleId></ArticleIdList></Reference><Reference><Citation>Applewhite MK, James BC, Kaplan SP, et al. Quality of life in thyroid cancer is similar to that of other cancers with worse survival. World J Surg. 2016;40(3):551-561. doi: 10.1007/s00268-015-3300-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00268-015-3300-5</ArticleId><ArticleId IdType="pubmed">26546191</ArticleId></ArticleIdList></Reference><Reference><Citation>McIntyre C, Jacques T, Palazzo F, Farnell K, Tolley N. Quality of life in differentiated thyroid cancer. Int J Surg. 2018;50:133-136. doi: 10.1016/j.ijsu.2017.12.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijsu.2017.12.014</ArticleId><ArticleId IdType="pubmed">29288117</ArticleId></ArticleIdList></Reference><Reference><Citation>Frey S, Figueres L, Pattou F, et al. ; Qol-Hypopara Study Group . Impact of permanent post-thyroidectomy hypoparathyroidism on self-evaluation of quality of life and voice: results from the National QoL-Hypopara Study. Ann Surg. 2021;274(5):851-858. doi: 10.1097/SLA.0000000000005129</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0000000000005129</ArticleId><ArticleId IdType="pubmed">34353986</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim BH, Ryu SR, Lee JW, et al. Longitudinal changes in quality of life before and after thyroidectomy in patients with differentiated thyroid cancer. J Clin Endocrinol Metab. 2024;109(6):1505-1516. doi: 10.1210/clinem/dgad748</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/clinem/dgad748</ArticleId><ArticleId IdType="pubmed">38141213</ArticleId></ArticleIdList></Reference><Reference><Citation>Durante C, Heged&#xfc;s L, Czarniecka A, et al. 2023 European Thyroid Association Clinical Practice Guidelines for thyroid nodule management. Eur Thyroid J. 2023;12(5):e230067. doi: 10.1530/ETJ-23-0067</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/ETJ-23-0067</ArticleId><ArticleId IdType="pmc">PMC10448590</ArticleId><ArticleId IdType="pubmed">37358008</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringel MD, Sosa JA, Baloch Z, et al. 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer. Thyroid. 2025;35(8):841-985. doi: 10.1177/10507256251363120</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/10507256251363120</ArticleId><ArticleId IdType="pubmed">40844370</ArticleId></ArticleIdList></Reference><Reference><Citation>van Dijk SPJ, Coerts HI, Gunput STG, et al. Assessment of radiofrequency ablation for papillary microcarcinoma of the thyroid: a systematic review and meta-analysis. JAMA Otolaryngol Head Neck Surg. 2022;148(4):317-325. doi: 10.1001/jamaoto.2021.4381</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoto.2021.4381</ArticleId><ArticleId IdType="pmc">PMC8832309</ArticleId><ArticleId IdType="pubmed">35142816</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramer WM, de Jonge GB, Rethlefsen ML, Mast F, Kleijnen J. A systematic approach to searching: an efficient and complete method to develop literature searches. J Med Libr Assoc. 2018;106(4):531-541. doi: 10.5195/jmla.2018.283</Citation><ArticleIdList><ArticleId IdType="doi">10.5195/jmla.2018.283</ArticleId><ArticleId IdType="pmc">PMC6148622</ArticleId><ArticleId IdType="pubmed">30271302</ArticleId></ArticleIdList></Reference><Reference><Citation>Moola SMZ, Tufanaru C, Aromataris E, et al. Systematic reviews of etiology and risk. In: Aromataris E, Munn Z, eds. JBI Manual for Evidence Synthesis. JBI; 2020:255-279.</Citation></Reference><Reference><Citation>Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135. doi: 10.1186/1471-2288-14-135</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2288-14-135</ArticleId><ArticleId IdType="pmc">PMC4383202</ArticleId><ArticleId IdType="pubmed">25524443</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G, Li R, Zhong J, et al. A multicenter cohort study of thyroidectomy-related decision regret in patients with low-risk papillary thyroid microcarcinoma. Nat Commun. 2025;16(1):2317. doi: 10.1038/s41467-025-57627-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-025-57627-7</ArticleId><ArticleId IdType="pmc">PMC11890561</ArticleId><ArticleId IdType="pubmed">40057484</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong W, Zhang R, Zhang S, Zhai Y, Zheng C, Zhang D. Comparison between thermal ablation and surgery in low risk papillary thyroid carcinoma: a prospective study. Front Endocrinol (Lausanne). 2024;15:1398208. doi: 10.3389/fendo.2024.1398208</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2024.1398208</ArticleId><ArticleId IdType="pmc">PMC11324463</ArticleId><ArticleId IdType="pubmed">39149120</ArticleId></ArticleIdList></Reference><Reference><Citation>Song Q, Gao H, Ren L, et al. Radiofrequency ablation versus total thyroidectomy in patients with papillary thyroid microcarcinoma located in the isthmus: a retrospective cohort study. Int J Hyperthermia. 2021;38(1):708-714. doi: 10.1080/02656736.2021.1916625</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/02656736.2021.1916625</ArticleId><ArticleId IdType="pubmed">33899651</ArticleId></ArticleIdList></Reference><Reference><Citation>Furuya-Kanamori L, Barendregt JJ, Doi SAR. A new improved graphical and quantitative method for detecting bias in meta-analysis. Int J Evid Based Healthc. 2018;16(4):195-203. doi: 10.1097/XEB.0000000000000141</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/XEB.0000000000000141</ArticleId><ArticleId IdType="pubmed">29621038</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeon MJ, Lee YM, Sung TY, et al. Quality of life in patients with papillary thyroid microcarcinoma managed by active surveillance or lobectomy: a cross-sectional study. Thyroid. 2019;29(7):956-962. doi: 10.1089/thy.2018.0711</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/thy.2018.0711</ArticleId><ArticleId IdType="pubmed">31038017</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazusaka H, Sugitani I, Toda K, et al. Patient-reported outcomes in patients with low-risk papillary thyroid carcinoma: cross-sectional study to compare active surveillance and immediate surgery. World J Surg. 2023;47(5):1190-1198. doi: 10.1007/s00268-022-06786-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00268-022-06786-5</ArticleId><ArticleId IdType="pubmed">36282283</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim MJ, Won H, Kim WB, et al. Comparison of patient-reported outcomes between active surveillance and immediate lobectomy in patients with low-risk papillary thyroid microcarcinoma: initial findings from the KoMPASS cohort. Thyroid. 2024;34(11):1371-1378. doi: 10.1089/thy.2024.0264</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/thy.2024.0264</ArticleId><ArticleId IdType="pubmed">39287055</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong SH, Ryu J, Kim MJ, et al. Longitudinal assessment of quality of life according to treatment options in low-risk papillary thyroid microcarcinoma patients: active surveillance or immediate surgery (interim analysis of MAeSTro). Thyroid. 2019;29(8):1089-1096. doi: 10.1089/thy.2018.0624</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/thy.2018.0624</ArticleId><ArticleId IdType="pubmed">31161898</ArticleId></ArticleIdList></Reference><Reference><Citation>Lan Y, Cao L, Song Q, et al. The quality of life in papillary thyroid microcarcinoma patients undergoing lobectomy or total thyroidectomy: a cross-sectional study. Cancer Med. 2021;10(6):1989-2002. doi: 10.1002/cam4.3747</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cam4.3747</ArticleId><ArticleId IdType="pmc">PMC7957180</ArticleId><ArticleId IdType="pubmed">33638269</ArticleId></ArticleIdList></Reference><Reference><Citation>Lan Y, Luo Y, Zhang M, et al. Quality of life in papillary thyroid microcarcinoma patients undergoing radiofrequency ablation or surgery: a comparative study. Front Endocrinol (Lausanne). 2020;11:249. doi: 10.3389/fendo.2020.00249</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2020.00249</ArticleId><ArticleId IdType="pmc">PMC7242647</ArticleId><ArticleId IdType="pubmed">32499754</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C, Zhao H, Xia Y, et al. Active surveillance versus immediate surgery: a comparison of clinical and quality of life outcomes among patients with highly suspicious thyroid nodules 1 cm or smaller in China. Eur J Surg Oncol. 2023;49(9):106917. doi: 10.1016/j.ejso.2023.04.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejso.2023.04.016</ArticleId><ArticleId IdType="pubmed">37137793</ArticleId></ArticleIdList></Reference><Reference><Citation>Moon JH, Ryu CH, Cho SW, et al. Effect of initial treatment choice on 2-year quality of life in patients with low-risk papillary thyroid microcarcinoma. J Clin Endocrinol Metab. 2021;106(3):724-735. doi: 10.1210/clinem/dgaa889</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/clinem/dgaa889</ArticleId><ArticleId IdType="pubmed">33248442</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura T, Miyauchi A, Ito Y, et al. Quality of life in patients with low-risk papillary thyroid microcarcinoma: active surveillance versus immediate surgery. Endocr Pract. 2020;26(12):1451-1457. doi: 10.4158/EP-2020-0201</Citation><ArticleIdList><ArticleId IdType="doi">10.4158/EP-2020-0201</ArticleId><ArticleId IdType="pubmed">33471737</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida Y, Horiuchi K, Okamoto T. Patients&#x2019; view on the management of papillary thyroid microcarcinoma: active surveillance or surgery. Thyroid. 2020;30(5):681-687. doi: 10.1089/thy.2019.0420</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/thy.2019.0420</ArticleId><ArticleId IdType="pmc">PMC7232659</ArticleId><ArticleId IdType="pubmed">31910100</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho AS, Kim S, Zalt C, et al. Expanded parameters in active surveillance for low-risk papillary thyroid carcinoma: a nonrandomized controlled trial. JAMA Oncol. 2022;8(11):1588-1596. doi: 10.1001/jamaoncol.2022.3875</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2022.3875</ArticleId><ArticleId IdType="pmc">PMC9478884</ArticleId><ArticleId IdType="pubmed">36107411</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamdy FC, Donovan JL, Lane JA, et al. ; ProtecT Study Group . 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med. 2016;375(15):1415-1424. doi: 10.1056/NEJMoa1606220</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1606220</ArticleId><ArticleId IdType="pubmed">27626136</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito Y, Miyauchi A, Kihara M, Fukushima M, Higashiyama T, Miya A. Overall survival of papillary thyroid carcinoma patients: a single-institution long-term follow-up of 5897 patients. World J Surg. 2018;42(3):615-622. doi: 10.1007/s00268-018-4479-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00268-018-4479-z</ArticleId><ArticleId IdType="pmc">PMC5801380</ArticleId><ArticleId IdType="pubmed">29349484</ArticleId></ArticleIdList></Reference><Reference><Citation>Donovan JL, Hamdy FC, Lane JA, et al. Patient-reported outcomes 12 years after localized prostate cancer treatment. NEJM Evid. 2023;2(4):a2300018. Published online March 11, 2023. doi: 10.1056/EVIDoa2300018</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/EVIDoa2300018</ArticleId><ArticleId IdType="pubmed">38320051</ArticleId></ArticleIdList></Reference><Reference><Citation>Partridge AH, Hyslop T, Rosenberg SM, et al. ; COMET Study Consortium . Patient-reported outcomes for low-risk ductal carcinoma in situ: a secondary analysis of the COMET randomized clinical trial. JAMA Oncol. 2025;11(3):300-309. doi: 10.1001/jamaoncol.2024.6556</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2024.6556</ArticleId><ArticleId IdType="pmc">PMC11908405</ArticleId><ArticleId IdType="pubmed">39665588</ArticleId></ArticleIdList></Reference><Reference><Citation>Cocks K, King MT, Velikova G, Martyn St-James M, Fayers PM, Brown JM. Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. J Clin Oncol. 2011;29(1):89-96. doi: 10.1200/JCO.2010.28.0107</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2010.28.0107</ArticleId><ArticleId IdType="pubmed">21098316</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunningham CE. Thyroid Nodule Treatment Optimization: A Personalized Approach. National Institutes of Health; 2019.</Citation></Reference><Reference><Citation>Pilz MJ, Seyringer S, Singer S, et al. ; EORTC Quality of Life Group . The cancer-specific health economic measure QLU-C10D is valid and responsive for assessing health utility in patients with thyroid cancer. Thyroid. 2024;34(11):1356-1370. doi: 10.1089/thy.2024.0396</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/thy.2024.0396</ArticleId><ArticleId IdType="pubmed">39475110</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Yan L, Xiao J, et al. Long-term outcomes and risk factors of radiofrequency ablation for T1N0M0 papillary thyroid carcinoma. JAMA Surg. 2024;159(1):51-58. doi: 10.1001/jamasurg.2023.5202</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamasurg.2023.5202</ArticleId><ArticleId IdType="pmc">PMC10600723</ArticleId><ArticleId IdType="pubmed">37878294</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen CB, Saucke MC, Pitt SC. Active surveillance for thyroid cancer: a qualitative study of barriers and facilitators to implementation. BMC Cancer. 2021;21(1):471. doi: 10.1186/s12885-021-08230-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12885-021-08230-8</ArticleId><ArticleId IdType="pmc">PMC8080390</ArticleId><ArticleId IdType="pubmed">33910527</ArticleId></ArticleIdList></Reference><Reference><Citation>Pusztaszeri MP, Tamilia M, Payne RJ. Active surveillance for low-risk small papillary thyroid cancer in North American countries: past, present and future (bridging the gap between North American and Asian practices). Gland Surg. 2020;9(5):1685-1697. doi: 10.21037/gs-20-389</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/gs-20-389</ArticleId><ArticleId IdType="pmc">PMC7667052</ArticleId><ArticleId IdType="pubmed">33224846</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70158 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41474089</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Dec</Month><Day>31</Day></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Postoperative Antithrombotic Strategies in Head and Neck Free Flap Reconstruction: A Systematic Review and Network Meta-Analysis.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70158</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The role of postoperative antithrombotic therapy in microvascular free flap reconstruction remains controversial, with no consensus on the optimal regimen.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A systematic review and arm-based Bayesian network meta-analysis was conducted searching PubMed, Scopus, and Google Scholar databases. Aspirin (ASA), dextran, low-molecular-weight heparin (LMWH), intravenous or subcutaneous unfractionated heparin (IV UFH, SC UFH), prostaglandin E1 (PGE1) were compared with no prophylaxis. Primary outcomes were total and partial flap loss, vascular complications, hematoma, and reoperation.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Fifty-four studies (17&#x2009;773 patients) were included. IV UFH significantly increased hematoma risk (OR 4.18, 95% CI 1.36-13.22) and LMWH modestly raised reoperation rates (OR 2.25, 95% CI 1.00-5.01). No regimen consistently reduced flap loss or thrombosis compared with no prophylaxis.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Antithrombotic agents showed limited benefit in reducing flap-related complications. These findings support individualized prophylaxis and highlight the need for prospective studies to inform evidence-based guidelines.</AbstractText><CopyrightInformation>&#xa9; 2025 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Uralov</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0009-0009-1979-0624</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Virgilio</LastName><ForeName>Armando</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of 'Organi di Senso', University "Sapienza", Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Canali</LastName><ForeName>Luca</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-9957-149X</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Humanitas University, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Otorhinolaryngology Unit, IRCCS Humanitas Research Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pace</LastName><ForeName>Gian Marco</ForeName><Initials>GM</Initials><Identifier Source="ORCID">0000-0002-8378-4028</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Humanitas University, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Otorhinolaryngology Unit, IRCCS Humanitas Research Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alamoudi</LastName><ForeName>Uthman</ForeName><Initials>U</Initials><Identifier Source="ORCID">0000-0002-1585-5357</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, AdventHealth Orlando, Orlando, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Magnuson</LastName><ForeName>J Scott</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, AdventHealth Orlando, Orlando, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spriano</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Humanitas University, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Otorhinolaryngology Unit, IRCCS Humanitas Research Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costantino</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5551-7785</Identifier><AffiliationInfo><Affiliation>Otorhinolaryngology Unit, IRCCS Humanitas Research Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">aspirin</Keyword><Keyword MajorTopicYN="N">free tissue flaps</Keyword><Keyword MajorTopicYN="N">head and neck cancer</Keyword><Keyword MajorTopicYN="N">heparin</Keyword><Keyword MajorTopicYN="N">postoperative complications</Keyword><Keyword MajorTopicYN="N">thrombosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>12</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>12</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>31</Day><Hour>12</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>31</Day><Hour>12</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>31</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41474089</ArticleId><ArticleId IdType="doi">10.1002/hed.70158</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>C. Copelli, K. Tewfik, L. Cassano, et&#xa0;al., &#x201c;Management of Free Flap Failure in Head and Neck Surgery,&#x201d; Acta Otorhinolaryngologica Italica 37, no. 5 (2017): 387&#x2013;392, https://doi.org/10.14639/0392&#x2010;100X&#x2010;1376.</Citation></Reference><Reference><Citation>K. E. Blackwell, &#x201c;Unsurpassed Reliability of Free Flaps for Head and Neck Reconstruction,&#x201d; Archives of Otolaryngology &#x2013; Head &amp; Neck Surgery 125, no. 3 (1999): 295, https://doi.org/10.1001/archotol.125.3.295.</Citation></Reference><Reference><Citation>D. Novakovic, R. S. Patel, D. P. Goldstein, and P. J. Gullane, &#x201c;Salvage of Failed Free Flaps Used in Head and Neck Reconstruction,&#x201d; Head &amp; Neck Oncology 1, no. 1 (2009): 33, https://doi.org/10.1186/1758&#x2010;3284&#x2010;1&#x2010;33.</Citation></Reference><Reference><Citation>S. K. Odorico, K. Reuter Mu&#xf1;oz, P. J Nicksic, et&#xa0;al., &#x201c;Surgical and Demographic Predictors of Free Flap Salvage After Takeback: A Systematic Review,&#x201d; Microsurgery 43, no. 1 (2023): 78&#x2013;88, https://doi.org/10.1002/micr.30921.</Citation></Reference><Reference><Citation>E. Saldanha, D. G. Patel, S. M. Desai, et&#xa0;al., &#x201c;Comparison of Functional and Survival Outcomes in Pedicled and Microsurgical Flap Reconstruction for Near&#x2010;Total and Total Glossectomies,&#x201d; Annals of Maxillofacial Surgery 12, no. 1 (2022): 54&#x2013;59, https://doi.org/10.4103/ams.ams_178_21.</Citation></Reference><Reference><Citation>S. S. Kroll, M. J. Miller, G. P. Reece, et&#xa0;al., &#x201c;Anticoagulants and Hematomas in Free Flap Surgery,&#x201d; Plastic and Reconstructive Surgery 96, no. 3 (1995): 643&#x2013;647, https://doi.org/10.1097/00006534&#x2010;199509000&#x2010;00017.</Citation></Reference><Reference><Citation>R. K. Khouri, B. C. Cooley, A. R. Kunselman, et&#xa0;al., &#x201c;A Prospective Study of Microvascular Free&#x2010;Flap Surgery and Outcome,&#x201d; Plastic and Reconstructive Surgery 102, no. 3 (1998): 711&#x2013;721, https://doi.org/10.1097/00006534&#x2010;199809010&#x2010;00015.</Citation></Reference><Reference><Citation>A. Glicksman, M. Ferder, P. Casale, J. Posner, R. Kim, and B. Strauch, &#x201c;1457&#x2009;Years of Microsurgical Experience,&#x201d; Plastic and Reconstructive Surgery 100, no. 2 (1997): 355&#x2013;363, https://doi.org/10.1097/00006534&#x2010;199708000&#x2010;00012.</Citation></Reference><Reference><Citation>J. H. Spiegel and J. K. Polat, &#x201c;Microvascular Flap Reconstruction by Otolaryngologists: Prevalence, Postoperative Care, and Monitoring Techniques,&#x201d; Laryngoscope 117, no. 3 (2007): 485&#x2013;490, https://doi.org/10.1097/MLG.0b013e31802d6e66.</Citation></Reference><Reference><Citation>M. T. Brands, S. C. Van Den Bosch, F. J. Dieleman, S. J. Berg&#xe9;, and M. A. W. Merkx, &#x201c;Prevention of Thrombosis After Microvascular Tissue Transfer in the Head and Neck. A Review of the Literature and the State of Affairs in Dutch Head and Neck Cancer Centers,&#x201d; International Journal of Oral and Maxillofacial Surgery 39, no. 2 (2010): 101&#x2013;106, https://doi.org/10.1016/j.ijom.2009.11.020.</Citation></Reference><Reference><Citation>L. Salemark, &#x201c;International Survey of Current Microvascular Practices in Free Tissue Transfer and Replantation Surgery,&#x201d; Microsurgery 12, no. 4 (1991): 308&#x2013;311, https://doi.org/10.1002/micr.1920120415.</Citation></Reference><Reference><Citation>R. Philips, K. A. Best, A. Agarwal, et&#xa0;al., &#x201c;A Survey of Microvascular Technique Preferences Among American Head Neck Society Members,&#x201d; Laryngoscope 134, no. 3 (2024): 1265&#x2013;1277, https://doi.org/10.1002/lary.30995.</Citation></Reference><Reference><Citation>K. T. Lee and G. H. Mun, &#x201c;The Efficacy of Postoperative Antithrombotics in Free Flap Surgery: A Systematic Review and Meta&#x2010;Analysis,&#x201d; Plastic and Reconstructive Surgery 135, no. 4 (2015): 1124&#x2013;1139, https://doi.org/10.1097/PRS.0000000000001100.</Citation></Reference><Reference><Citation>S. A. Khan and R. K. Tayeb, &#x201c;Postoperative Outcomes of Aspirin in Microvascular Free Tissue Transfer Surgery&#x2014;A Systematic Review and Meta&#x2010;Analysis,&#x201d; JPRAS Open 39 (2024): 49&#x2013;59, https://doi.org/10.1016/j.jpra.2023.11.003.</Citation></Reference><Reference><Citation>B. M. Barton, C. A. Riley, J. C. Fitzpatrick, C. P. Hasney, B. A. Moore, and E. D. McCoul, &#x201c;Postoperative Anticoagulation After Free Flap Reconstruction for Head and Neck Cancer: A Systematic Review,&#x201d; Laryngoscope 128, no. 2 (2018): 412&#x2013;421, https://doi.org/10.1002/lary.26703.</Citation></Reference><Reference><Citation>J. Liu, Q. Shi, S. Yang, B. Liu, B. Guo, and J. Xu, &#x201c;Does Postoperative Anticoagulation Therapy Lead to a Higher Success Rate for Microvascular Free&#x2010;Tissue Transfer in the Head and Neck? A Systematic Review and Meta&#x2010;Analysis,&#x201d; Journal of Reconstructive Microsurgery 34, no. 2 (2018): 87&#x2013;94, https://doi.org/10.1055/s&#x2010;0037&#x2010;1606346.</Citation></Reference><Reference><Citation>B. E. S. Dawoud, S. Kent, O. Tabbenor, G. Markose, K. Java, and P. Kyzas, &#x201c;Does Anticoagulation Improve Outcomes of Microvascular Free Flap Reconstruction Following Head and Neck Surgery: A Systematic Review and Meta&#x2010;Analysis,&#x201d; British Journal of Oral and Maxillofacial Surgery 60, no. 10 (2022): 1292&#x2013;1302, https://doi.org/10.1016/j.bjoms.2022.07.016.</Citation></Reference><Reference><Citation>V. S. Kotamarti, E. Shiah, K. M. Rezak, A. Patel, and J. A. Ricci, &#x201c;Does Anticoagulation Improve Flap Outcomes in Hypercoagulable Patients? A Systematic Review,&#x201d; Journal of Reconstructive Microsurgery 36 (2020): 204&#x2013;212, https://doi.org/10.1055/s&#x2010;0039&#x2010;3400531.</Citation></Reference><Reference><Citation>Y. E. Lin and M. C. Chen, &#x201c;Dextran&#x2010;40 Reduces Partial Flap Failure: A Systematic Review and Meta&#x2010;Analysis for Antithrombotics After Free Flaps,&#x201d; Plastic and Reconstructive Surgery &#x2010; Global Open 12, no. 5 (2024): e5812, https://doi.org/10.1097/GOX.0000000000005812.</Citation></Reference><Reference><Citation>B. Hutton, G. Salanti, D. M. Caldwell, et&#xa0;al., &#x201c;The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta&#x2010;Analyses of Health Care Interventions: Checklist and Explanations,&#x201d; Annals of Internal Medicine 162, no. 11 (2015): 777&#x2013;784.</Citation></Reference><Reference><Citation>A. M. Methley, S. Campbell, C. Chew&#x2010;Graham, R. McNally, and S. Cheraghi&#x2010;Sohi, &#x201c;PICO, PICOS and SPIDER: A Comparison Study of Specificity and Sensitivity in Three Search Tools for Qualitative Systematic Reviews,&#x201d; BMC Health Services Research 14, no. 1 (2014): 579, https://doi.org/10.1186/s12913&#x2010;014&#x2010;0579&#x2010;0.</Citation></Reference><Reference><Citation>National Institute for Health and Care Excellence, &#x201c;Methods for the Development of NICE Public Health Guidance,&#x201d; London: National Institute for Health and Care Excellence (NICE). 2012.</Citation></Reference><Reference><Citation>S. McGrath, X. Zhao, Z. Z. Qin, R. Steele, and A. Benedetti, &#x201c;One&#x2010;Sample Aggregate Data Meta&#x2010;Analysis of Medians,&#x201d; Statistics in Medicine 38, no. 6 (2019): 969&#x2013;984, https://doi.org/10.1002/sim.8013.</Citation></Reference><Reference><Citation>W. G. Cochran, &#x201c;The Combination of Estimates From Different Experiments,&#x201d; Biometrics 10, no. 1 (1954): 101&#x2013;129, https://doi.org/10.2307/3001666.</Citation></Reference><Reference><Citation>D. Jackson, I. R. White, and R. D. Riley, &#x201c;Quantifying the Impact of Between&#x2010;Study Heterogeneity in Multivariate Meta&#x2010;Analyses,&#x201d; Statistics in Medicine 31, no. 29 (2012): 3805&#x2013;3820, https://doi.org/10.1002/sim.5453.</Citation></Reference><Reference><Citation>A. A. Veroniki, D. Jackson, W. Viechtbauer, et&#xa0;al., &#x201c;Methods to Estimate the Between&#x2010;Studyvariance and Its Uncertainty Inmeta&#x2010; Analysis,&#x201d; Research Synthesis Methods 7, no. 1 (2016): 55&#x2013;79.</Citation></Reference><Reference><Citation>A. Costantino, B. M. Festa, F. Ferreli, et&#xa0;al., &#x201c;Circumferential Pharyngeal Reconstruction After Total Laryngopharyngectomy: A Systematic Review and Network Meta&#x2010;Analysis,&#x201d; Oral Oncology 127 (2022): 105809, https://doi.org/10.1016/j.oraloncology.2022.105809.</Citation></Reference><Reference><Citation>M. K. Cowles and B. P. Carlin, &#x201c;Markov Chain Monte Carlo Convergence Diagnostics: A Comparative Review,&#x201d; Journal of the American Statistical Association 91, no. 434 (1996): 883&#x2013;904.</Citation></Reference><Reference><Citation>G. Biondi&#x2010;Zoccai, Network Meta&#x2010;Analysis: Evidence Synthesis With Mixed Treatment Comparison (Nova Sci Publ Inc, 2014).</Citation></Reference><Reference><Citation>K. Bhatnagar, H. Smith, F. Taghizadeh, et&#xa0;al., &#x201c;The Impact of Lovenox Prophylaxis and Other Anticoagulants on Microvascular Free Flap Outcomes,&#x201d; Otolaryngology and Head and Neck Surgery 172, no. 5 (2025): 1579&#x2013;1584, https://doi.org/10.1002/ohn.1160.</Citation></Reference><Reference><Citation>T. Bondi, N. Walhin, G. Henry, N. Benmoussa&#x2010;Rebibo, N. Leymarie, and J. F. Honart, &#x201c;Intraoral Anastomosis Technique as Part of the Reconstruction Strategy Following Resection of Intermediate and Low&#x2010;Grade Head and Neck Cancer,&#x201d; Journal of Stomatology, Oral and Maxillofacial Surgery 126, no. 5 (2025): 102282, https://doi.org/10.1016/j.jormas.2025.102282.</Citation></Reference><Reference><Citation>J. Fenske, P. Lampert, C. Steffen, et&#xa0;al., &#x201c;Microvascular Free Flaps in Head and Neck Reconstruction: An Analysis of Outcomes in Elderly Patients,&#x201d; Clinical Oral Investigations 29, no. 4 (2025): 190, https://doi.org/10.1007/s00784&#x2010;025&#x2010;06262&#x2010;z.</Citation></Reference><Reference><Citation>A. Galazka, K. Stawarz, K. Bienkowska&#x2010;Pluta, M. Paszkowska, and M. Misiak&#x2010;Galazka, &#x201c;Optimizing Wound Healing in Radial Forearm Donor Sites: A Comparative Study of Ulnar&#x2010;Based Flap and Split&#x2010;Thickness Skin Grafting,&#x201d; Biomedicine 13, no. 5 (2025): 1131, https://doi.org/10.3390/biomedicines13051131.</Citation></Reference><Reference><Citation>G. A. Longfellow, M. Matthews, G. Adams, E. H. Benaim, T. Hackman, and C. B. Sullivan, &#x201c;Head and Neck Free&#x2010;Flap Reconstruction in Patients With Pre&#x2010;Existing Coagulopathies: A Case Series,&#x201d; Ear, Nose, &amp; Throat Journal (2025): 01455613251356340, https://doi.org/10.1177/01455613251356340.</Citation></Reference><Reference><Citation>S. Mouzannar, A. Jalaeefar, M. Shirkhoda, et&#xa0;al., &#x201c;The Role of Anticoagulation Regimen on Flap Outcome in Microvascular Head&#xa0;and Neck Reconstruction,&#x201d; Journal of Oral and Maxillofacial Surgery 83, no. 4 (2025): 467&#x2013;475, https://doi.org/10.1016/j.joms.2024.12.011.</Citation></Reference><Reference><Citation>L. Zuo, Z. Jiang, J. Liu, H. Tian, S. Gao, and W. Huang, &#x201c;A Trilobed Radial Forearm Free Flap: A Novel Approach to Oral Cavity Reconstruction,&#x201d; Head &amp; Neck 47, no. 5 (2025): 1372&#x2013;1378, https://doi.org/10.1002/hed.28046.</Citation></Reference><Reference><Citation>J. Cevik, D. P. Newland, E. Cheong, et&#xa0;al., &#x201c;Unfractionated Heparin Administered Every 8 h Outperforms 12 Hourly Administration for Venous Thromboembolism Prophylaxis in Reconstructive Head and Neck Tumor Patients: A 12 Year Retrospective Cohort Study,&#x201d; Microsurgery 44, no. 8 (2024): e31248, https://doi.org/10.1002/micr.31248.</Citation></Reference><Reference><Citation>M. Cherubino, M. Turri&#x2010;Zanoni, M. Maruccia, et&#xa0;al., &#x201c;Advanced Reconstructive Techniques Following Orbital Exenteration: The Role of LCFA Free Flaps,&#x201d; Journal of Plastic, Reconstructive &amp; Aesthetic Surgery 101 (2025): 23&#x2013;32, https://doi.org/10.1016/j.bjps.2024.11.030.</Citation></Reference><Reference><Citation>S. Farsi, M. Held, M. Brannon, et&#xa0;al., &#x201c;The Microvascular Anastomotic Coupler for Venous Anastomosis in Head and Neck Reconstruction: An Institutional Experience,&#x201d; Cureus 16, no. 7 (2024): e64467, https://doi.org/10.7759/cureus.64467.</Citation></Reference><Reference><Citation>H. Gun&#xe9;, J. Sj&#xf6;vall, M. Becker, et&#xa0;al., &#x201c;Evaluating the Efficacy and Complications of the Scapular Osseous Free Flap for Head and Neck Reconstruction: Results From a Population&#x2010;Based Cohort,&#x201d; JPRAS Open 42 (2024): 296&#x2013;305, https://doi.org/10.1016/j.jpra.2024.09.020.</Citation></Reference><Reference><Citation>K. Kohyama, T. Ishihara, H. Okuda, et&#xa0;al., &#x201c;Factors Affecting the Patency of the Internal Jugular Vein After Neck Dissection for Malignant Hypopharyngeal Tumors&#x2014;Significance of Free Jejunal Flap Transfer Using the Internal Jugular Vein as the Recipient Vein,&#x201d; Journal of Plastic, Reconstructive &amp; Aesthetic Surgery 103 (2025): 248&#x2013;255, https://doi.org/10.1016/j.bjps.2025.01.091.</Citation></Reference><Reference><Citation>K. Liu, L. Lu, Y. Zhi, et&#xa0;al., &#x201c;Effect of Low Molecular Weight Heparin Calcium on Prevention of Lower Limb Deep Venous Thrombosis in Oral Cancer Patients With Anterolateral Thigh Flap Reconstruction,&#x201d; Head &amp; Neck 47, no. 2 (2025): 713&#x2013;719, https://doi.org/10.1002/hed.27947.</Citation></Reference><Reference><Citation>M. A. Maier, P. A. Palines, R. F. Guidry, and M. W. Stalder, &#x201c;Use of Flow&#x2010;Through Free Flaps in Head and Neck Reconstruction,&#x201d; Plastic and Reconstructive Surgery &#x2010; Global Open 12, no. 3 (2024): e5588, https://doi.org/10.1097/GOX.0000000000005588.</Citation></Reference><Reference><Citation>R. Saadoun, D. T. Guerrero, F. B. Bengur, et&#xa0;al., &#x201c;Hypothermia During Microsurgical Head and Neck Reconstruction and Incidence of Venous Thromboembolism,&#x201d; JAMA Otolaryngology. Head &amp; Neck Surgery 151, no. 2 (2025): 121&#x2013;127, https://doi.org/10.1001/jamaoto.2024.3964.</Citation></Reference><Reference><Citation>G. G. &#xdc;st&#xfc;n, G. O. Kaplan, G. Sert, and H. Uzun, &#x201c;Flap Loss in Head and Neck Reconstruction: Is There a Singular Cause for Failure?,&#x201d; Journal of Plastic, Reconstructive &amp; Aesthetic Surgery 91 (2024): 353&#x2013;359, https://doi.org/10.1016/j.bjps.2024.02.050.</Citation></Reference><Reference><Citation>F. D. Grill, L. Pilstl, L. M. Ritschl, et&#xa0;al., &#x201c;Perioperative Anticoagulation in Head and Neck Free Flap Reconstructions: Experience of an Anticoagulative Scheme and Its Modification,&#x201d; Microsurgery 44, no. 1 (2024): e31096, https://doi.org/10.1002/micr.31096.</Citation></Reference><Reference><Citation>J. L. Bishop, M. Vasudev, N. Garcia, et&#xa0;al., &#x201c;Effect of Perioperative Antithrombotics on Head and Neck Microvascular Free Flap Survival After Anastomotic Revision,&#x201d; Otolaryngology and Head and Neck Surgery 168, no. 6 (2023): 1353&#x2013;1361, https://doi.org/10.1002/ohn.295.</Citation></Reference><Reference><Citation>C. M. Bowe, J. Twigg, A. M. Salker, S. Doumas, and M. W. Ho, &#x201c;Outcomes of Anastomotic Venous Flow Couplers in Head and Neck Free Flap Reconstruction &#x2013; Five&#x2010;Year Experience in a Single Centre,&#x201d; British Journal of Oral and Maxillofacial Surgery 60, no. 6 (2022): 847&#x2013;851, https://doi.org/10.1016/j.bjoms.2022.01.002.</Citation></Reference><Reference><Citation>R. Rothweiler, V. Gerlach, P. Voss, et&#xa0;al., &#x201c;Aspirin, Heparin and Ischemia Time in Microvascular Free Flap Surgery &#x2010; Their Influence and an Optimal Anticoagulation Protocol,&#x201d; Journal of Stomatology, Oral and Maxillofacial Surgery 123, no. 5 (2022): e556&#x2013;e562, https://doi.org/10.1016/j.jormas.2022.03.001.</Citation></Reference><Reference><Citation>K. Sag&#xfc;illo, F. P&#xe9;rez&#x2010;Flecha, F. Almeida, M. Pic&#xf3;n, and J. Acero, &#x201c;Bemiparin vs Enoxaparin in the Prevention of Thrombosis in Microvascular Head and Neck Reconstruction,&#x201d; Journal of Plastic, Reconstructive &amp; Aesthetic Surgery 75, no. 8 (2022): 2831&#x2013;2870, https://doi.org/10.1016/j.bjps.2022.06.041.</Citation></Reference><Reference><Citation>K. Wu, Z. Gong, H. Wu, Y. Mao, and S. Zhang, &#x201c;Evaluating the Role of Low Molecular Heparin to Prevent Anterolateral Thigh Flap Compromise in 2460 Head and Neck Defect Cases,&#x201d; Journal of Oral and Maxillofacial Surgery 80, no. 5 (2022): 944&#x2013;948, https://doi.org/10.1016/j.joms.2022.01.005.</Citation></Reference><Reference><Citation>D. Filipan, E. Dediol, I. Blivajs, and M. Milic, &#x201c;The Effects of Dextran on Postoperative Thrombosis and Hemodilution in Microvascular Head and Neck Reconstruction,&#x201d; Annals of Plastic Surgery 85, no. 1 (2020): 38&#x2013;42, https://doi.org/10.1097/SAP.0000000000002148.</Citation></Reference><Reference><Citation>M. Sievert, M. Goncalves, R. Tamse, et&#xa0;al., &#x201c;Postoperative Management of Antithrombotic Medication in Microvascular Head and Neck Reconstruction: A Comparative Analysis of Unfractionated and Low&#x2010;Molecular&#x2010;Weight Heparin,&#x201d; European Archives of Oto&#x2010;Rhino&#x2010;Laryngology 278, no. 5 (2021): 1567&#x2013;1575, https://doi.org/10.1007/s00405&#x2010;020&#x2010;06219&#x2010;w.</Citation></Reference><Reference><Citation>U. Kisser, C. Adderson&#x2010;Kisser, P. Baumeister, and M. Reiter, &#x201c;Influence of Coupler Size on Revision Rate and Timing of Revision After Free Flap Tissue Transfer in the Head and Neck,&#x201d; European Archives of Oto&#x2010;Rhino&#x2010;Laryngology 275, no. 1 (2018): 199&#x2013;206, https://doi.org/10.1007/s00405&#x2010;017&#x2010;4804&#x2010;4.</Citation></Reference><Reference><Citation>W. Zhou, W. B. Zhang, Y. Yu, et&#xa0;al., &#x201c;Are Antithrombotic Agents Necessary for Head and Neck Microvascular Surgery?,&#x201d; International Journal of Oral and Maxillofacial Surgery 48, no. 7 (2019): 869&#x2013;874, https://doi.org/10.1016/j.ijom.2018.10.022.</Citation></Reference><Reference><Citation>W. Zhou, W. B. Zhang, Y. Yu, et&#xa0;al., &#x201c;Risk Factors for Free Flap Failure: A Retrospective Analysis of 881 Free Flaps for Head and Neck Defect Reconstruction,&#x201d; International Journal of Oral and Maxillofacial Surgery 46, no. 8 (2017): 941&#x2013;945, https://doi.org/10.1016/j.ijom.2017.03.023.</Citation></Reference><Reference><Citation>T. Numajiri, Y. Sowa, K. Nishino, et&#xa0;al., &#x201c;Use of Systemic Low&#x2010;Dose Unfractionated Heparin in Microvascular Head and Neck Reconstruction: Influence in Free&#x2010;Flap Outcomes,&#x201d; Journal of Plastic Surgery and Hand Surgery 50, no. 3 (2016): 135&#x2013;141, https://doi.org/10.3109/2000656X.2015.1125359.</Citation></Reference><Reference><Citation>K. A. Eley, R. J. Parker, and S. R. Watt&#x2010;Smith, &#x201c;Low Molecular Weight Heparin in Patients Undergoing Free Tissue Transfer Following Head and Neck Ablative Surgery: Review of Efficacy and Associated Complications,&#x201d; British Journal of Oral and Maxillofacial Surgery 51, no. 7 (2013): 610&#x2013;614, https://doi.org/10.1016/j.bjoms.2013.01.017.</Citation></Reference><Reference><Citation>Z. Han, J. Li, H. Li, M. Su, and L. Qin, &#x201c;Single Versus Dual Venous Anastomoses of the Free Fibula Osteocutaneous Flap in Mandibular Reconstruction: A Retrospective Study,&#x201d; Microsurgery 33, no. 8 (2013): 652&#x2013;655, https://doi.org/10.1002/micr.22176.</Citation></Reference><Reference><Citation>K. Jayaprasad, J. Mathew, K. Thankappan, et&#xa0;al., &#x201c;Safety and Efficacy of Low Molecular Weight Dextran (Dextran 40) in Head and Neck Free Flap Reconstruction,&#x201d; Journal of Reconstructive Microsurgery 29, no. 7 (2013): 443&#x2013;448, https://doi.org/10.1055/s&#x2010;0033&#x2010;1343950.</Citation></Reference><Reference><Citation>P. Kessler, L. Poort, R. B&#xf6;ckmann, and B. Lethaus, &#x201c;Definition of Quality Indicators in Microsurgery in Head and Neck Reconstruction Based on a 5&#x2010;Year Follow&#x2010;Up Without a Loss,&#x201d; Journal of Cranio&#x2010;Maxillofacial Surgery 41, no. 1 (2013): 2&#x2013;6, https://doi.org/10.1016/j.jcms.2012.05.004.</Citation></Reference><Reference><Citation>J. G. Lighthall, R. Cain, T. A. Ghanem, and M. K. Wax, &#x201c;Effect of Postoperative Aspirin on Outcomes in Microvascular Free Tissue Transfer Surgery,&#x201d; Otolaryngology&#x2010;Head and Neck Surgery 148, no. 1 (2013): 40&#x2013;46, https://doi.org/10.1177/0194599812463320.</Citation></Reference><Reference><Citation>T. K. Blackburn, K. R. Java, D. Lowe, J. S. Brown, and S. N. Rogers, &#x201c;Safety of a Regimen for Thromboprophylaxis in Head and Neck Cancer Microvascular Reconstructive Surgery: Non&#x2010;Concurrent Cohort Study,&#x201d; British Journal of Oral and Maxillofacial Surgery 50, no. 3 (2012): 227&#x2013;232, https://doi.org/10.1016/j.bjoms.2011.03.265.</Citation></Reference><Reference><Citation>M. Okochi, M. Okazaki, and H. Asato, &#x201c;Oral Antithrombotic Treatment and Postoperative Thrombotic Complications After Head and Neck Reconstruction Using Free Flaps,&#x201d; Journal of Plastic Surgery and Hand Surgery 46, no. 3&#x2013;4 (2012): 163&#x2013;166, https://doi.org/10.3109/2000656X.2012.697374.</Citation></Reference><Reference><Citation>M. Reiter, M. Kapsreiter, C. S. Betz, and U. Harr&#xe9;us, &#x201c;Perioperative Management of Antithrombotic Medication in Head and Neck Reconstruction&#x2014;A Retrospective Analysis of 137 Patients,&#x201d; American Journal of Otolaryngology 33, no. 6 (2012): 693&#x2013;696, https://doi.org/10.1016/j.amjoto.2012.05.008.</Citation></Reference><Reference><Citation>F. M. G. Riva, Y. Chen, N. Tan, et&#xa0;al., &#x201c;The Outcome of Prostaglandin&#x2010;E1 and Dextran&#x2010;40 Compared to no Antithrombotic Therapy in Head and Neck Free Tissue Transfer: Analysis of 1,351 Cases in a Single Center,&#x201d; Microsurgery 32, no. 5 (2012): 339&#x2013;343, https://doi.org/10.1002/micr.21958.</Citation></Reference><Reference><Citation>T. Y. Wang, J. M. Serletti, A. Cuker, et&#xa0;al., &#x201c;Free Tissue Transfer in the Hypercoagulable Patient: A Review of 58 Flaps,&#x201d; Plastic and Reconstructive Surgery 129, no. 2 (2012): 443&#x2013;453, https://doi.org/10.1097/PRS.0b013e31823aec4d.</Citation></Reference><Reference><Citation>Y. H. Joo, D. I. Sun, J. O. Park, K. J. Cho, and M. S. Kim, &#x201c;Risk Factors of Free Flap Compromise in 247 Cases of Microvascular Head and Neck Reconstruction: A Single Surgeon's Experience,&#x201d; European Archives of Oto&#x2010;Rhino&#x2010;Laryngology 267, no. 10 (2010): 1629&#x2013;1633, https://doi.org/10.1007/s00405&#x2010;010&#x2010;1268&#x2010;1.</Citation></Reference><Reference><Citation>C. Ayala and K. E. Blackwell, &#x201c;Protein C Deficiency in Microvascular Head and Neck Reconstruction,&#x201d; Laryngoscope 109, no. 2 (1999): 259&#x2013;265, https://doi.org/10.1097/00005537&#x2010;199902000&#x2010;00016.</Citation></Reference><Reference><Citation>N. Chernichenko, D. A. Ross, J. Shin, J. Y. Chow, C. T. Sasaki, and S. Ariyan, &#x201c;Arterial Coupling for Microvascular Free Tissue Transfer,&#x201d; Otolaryngology&#x2010;Head and Neck Surgery 138, no. 5 (2008): 614&#x2013;618, https://doi.org/10.1016/j.otohns.2007.12.029.</Citation></Reference><Reference><Citation>T. Fukuiwa, K. Nishimoto, T. Hayashi, and Y. Kurono, &#x201c;Venous Thrombosis After Microvascular Free&#x2010;Tissue Transfer in Head and Neck Cancer Reconstruction,&#x201d; Auris, Nasus, Larynx 35, no. 3 (2008): 390&#x2013;396, https://doi.org/10.1016/j.anl.2007.10.005.</Citation></Reference><Reference><Citation>L. Guo, N. F. Ferraro, B. L. Padwa, L. B. Kaban, and J. Upton, &#x201c;Vascularized Fibular Graft for Pediatric Mandibular Reconstruction,&#x201d; Plastic and Reconstructive Surgery 121, no. 6 (2008): 2095&#x2013;2105, https://doi.org/10.1097/PRS.0b013e3181712399.</Citation></Reference><Reference><Citation>Y. Liu, X. Jiang, J. Huang, et&#xa0;al., &#x201c;Reliability of the Superficial Venous Drainage of the Radial Forearm Free Flaps in Oral and Maxillofacial Reconstruction,&#x201d; Microsurgery 28, no. 4 (2008): 243&#x2013;247, https://doi.org/10.1002/micr.20489.</Citation></Reference><Reference><Citation>A. Eckardt, A. Meyer, U. Laas, and J. E. Hausamen, &#x201c;Reconstruction of Defects in the Head and Neck With Free Flaps: 20&#x2009;Years Experience,&#x201d; British Journal of Oral and Maxillofacial Surgery 45, no. 1 (2007): 11&#x2013;15, https://doi.org/10.1016/j.bjoms.2005.12.012.</Citation></Reference><Reference><Citation>P. Pohlenz, M. Blessmann, M. Heiland, F. Blake, R. Schmelzle, and L. Li, &#x201c;Postoperative Complications in 202 Cases of Microvascular Head and Neck Reconstruction,&#x201d; Journal of Cranio&#x2010;Maxillofacial Surgery 35, no. 6&#x2013;7 (2007): 311&#x2013;315, https://doi.org/10.1016/j.jcms.2007.05.001.</Citation></Reference><Reference><Citation>M. Nakamizo, K. Yokoshima, and T. Yagi, &#x201c;Use of Free Flaps for Reconstruction in Head and Neck Surgery: A Retrospective Study of 182 Cases,&#x201d; Auris, Nasus, Larynx 31, no. 3 (2004): 269&#x2013;273, https://doi.org/10.1016/j.anl.2004.03.003.</Citation></Reference><Reference><Citation>E. Rosenthal, W. Carroll, M. Dobbs, J. Scott Magnuson, M. Wax, and G. Peters, &#x201c;Simplifying Head and Neck Microvascular Reconstruction,&#x201d; Head &amp; Neck 26, no. 11 (2004): 930&#x2013;936, https://doi.org/10.1002/hed.20076.</Citation></Reference><Reference><Citation>J. D. Suh, J. A. Sercarz, E. Abemayor, et&#xa0;al., &#x201c;Analysis of Outcome and Complications in 400 Cases of Microvascular Head and Neck Reconstruction,&#x201d; Archives of Otolaryngology &#x2013; Head &amp; Neck Surgery 130, no. 8 (2004): 962&#x2013;966, https://doi.org/10.1001/archotol.130.8.962.</Citation></Reference><Reference><Citation>T. B. Sun, S. H. Chien, J. T. Lee, L. F. Cheng, L. P. Hsu, and P. R. Chen, &#x201c;Is Dextran Infusion as an Antithrombotic Agent Necessary in Microvascular Reconstruction of the Upper Aerodigestive Tract?,&#x201d; Journal of Reconstructive Microsurgery 19, no. 7 (2003): 463&#x2013;466, https://doi.org/10.1055/s&#x2010;2003&#x2010;44634.</Citation></Reference><Reference><Citation>J. J. Disa, V. P. Polvora, A. L. Pusic, B. Singh, and P. G. Cordeiro, &#x201c;Dextran&#x2010;Related Complications in Head and Neck Microsurgery: Do the Benefits Outweigh the Risks? A Prospective Randomized Analysis: Plastic and Reconstructive Surgery,&#x201d; Plastic and Reconstructive Surgery 112, no. 6 (2003): 1534&#x2013;1539, https://doi.org/10.1097/01.PRS.0000083378.58757.54.</Citation></Reference><Reference><Citation>A. A. Chalian, T. D. Anderson, G. S. Weinstein, and R. S. Weber, &#x201c;Internal Jugular Vein Versus External Jugular Vein Anastamosis: Implications for Successful Free Tissue Transfer,&#x201d; Head &amp; Neck 23, no. 6 (2001): 475&#x2013;478, https://doi.org/10.1002/hed.1062.</Citation></Reference><Reference><Citation>K. Ueda, K. Harii, T. Nakatsuka, H. Asato, and A. Yamada, &#x201c;Comparison of End&#x2010;To&#x2010;End and End&#x2010;To&#x2010;Side Venous Anastomosis in Free&#x2010;Tissue Transfer Following Resection of Head and Neck Tumors,&#x201d; Microsurgery 17, no. 3 (1996): 146&#x2013;149, https://doi.org/10.1002/(SICI)1098&#x2010;2752(1996)17:3&lt;146::AID&#x2010;MICR9&gt;3.0.CO;2&#x2010;K.</Citation></Reference><Reference><Citation>C. K. Hardin, W. C. Kirk, and W. C. Pederson, &#x201c;Osmotic Complications of Low&#x2010;Molecular&#x2010;Weight Dextran Therapy in Free Flap Surgery,&#x201d; Microsurgery 13, no. 1 (1992): 36&#x2013;38, https://doi.org/10.1002/micr.1920130109.</Citation></Reference><Reference><Citation>A. Costantino, D. Uralov, B. M. Festa, et&#xa0;al., &#x201c;Microvascular Coupling in Venous Anastomoses for Head and Neck Reconstruction: A Systematic Review and Meta&#x2010;Analysis,&#x201d; Otolaryngology and Head and Neck Surgery 172, no. 5 (2025): 1548&#x2013;1559, https://doi.org/10.1002/ohn.1167.</Citation></Reference><Reference><Citation>K. D. Hein, M. E. Wechsler, R. M. Schwartzstein, and D. J. Morris, &#x201c;The Adult Respiratory Distress Syndrome After Dextran Infusion as an Antithrombotic Agent in Free TRAM Flap Breast Reconstruction,&#x201d; Plastic and Reconstructive Surgery 103, no. 6 (1999): 1706&#x2013;1708, https://doi.org/10.1097/00006534&#x2010;199905000&#x2010;00022.</Citation></Reference><Reference><Citation>C. E. Zinderman, L. Landow, and R. P. Wise, &#x201c;Anaphylactoid Reactions to Dextran 40 and 70: Reports to the United States Food and Drug Administration, 1969 to 2004,&#x201d; Journal of Vascular Surgery 43, no. 5 (2006): 1004&#x2013;1009, https://doi.org/10.1016/j.jvs.2006.01.006.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70143 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41467388</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Dec</Month><Day>30</Day></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>KUSCC-192: A Novel Tonsillar Squamous Cell Carcinoma Cell Line With Mixed (Episomal and Integrated)-Typed Human Papillomavirus From a Korean Patient With Tonsil Cancer.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70143</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Human papillomavirus-positive (HPV+) head and neck squamous cell carcinoma (HNSCC) generally has a better prognosis, but some cases are aggressive with poor outcomes. This study established KUSCC-192, a de novo HPV+ tonsillar cancer cell line, and evaluated its tumorigenicity.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">The HPV status in KUSCC-192 was assessed using RT-qPCR, RT-PCR, and FISH. Aggressive characteristics were compared with other HPV+ cell lines and HPV- cell lines.</AbstractText><AbstractText Label="RESULT" NlmCategory="RESULTS">KUSCC-192 exhibited a mixed type with a predominantly diffused FISH pattern and a few dotted signals and lower E2 gene expression. These findings, combined with its aggressive features, suggest that the mixed type may contribute to the poor prognosis observed in 2%-30% of HPV+ HNSCC cases.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">KUSCC-192 is a valuable model to study aggressive HPV+ cancer behaviors. Further research is needed to explore the clinical significance of mixed-type HPV integration in HNSCC.</AbstractText><CopyrightInformation>&#xa9; 2025 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jae Hyeok</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology-Head and Neck Surgery, Research Institute of Medical Science, Konkuk University School of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moon</LastName><ForeName>Jung Hwa</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology-Head and Neck Surgery, Research Institute of Medical Science, Konkuk University School of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Cha Yeon</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology-Head and Neck Surgery, Research Institute of Medical Science, Konkuk University School of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeong</LastName><ForeName>Hee Na</ForeName><Initials>HN</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology-Head and Neck Surgery, Research Institute of Medical Science, Konkuk University School of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Young Chang</ForeName><Initials>YC</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology-Head and Neck Surgery, Research Institute of Medical Science, Konkuk University School of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>National Research Foundation</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">episomal HPV</Keyword><Keyword MajorTopicYN="N">head and neck cancer</Keyword><Keyword MajorTopicYN="N">human papillomavirus (HPV)</Keyword><Keyword MajorTopicYN="N">integrated HPV</Keyword><Keyword MajorTopicYN="N">physical status of HPV</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>10</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>12</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>30</Day><Hour>7</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>30</Day><Hour>7</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>30</Day><Hour>5</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41467388</ArticleId><ArticleId IdType="doi">10.1002/hed.70143</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>F. S. T. Greaney&#x2010;Davies, J. M. Risk, M. Robinson, T. Liloglou, R. J. Shaw, and A. G. Schache, &#x201c;Essential Characterisation of Human Papillomavirus Positive Head and Neck Cancer Cell Lines,&#x201d; Oral Oncology 103 (2020): 104613, https://doi.org/10.1016/j.oraloncology.2020.104613.</Citation></Reference><Reference><Citation>C. C. Ragin, S. C. Reshmi, and S. M. Gollin, &#x201c;Mapping and Analysis of HPV16 Integration Sites in a Head and Neck Cancer Cell Line,&#x201d; International Journal of Cancer 110 (2004): 701&#x2013;709, https://doi.org/10.1002/ijc.20193.</Citation></Reference><Reference><Citation>B. Labarge, M. Hennessy, L. Zhang, et&#xa0;al., &#x201c;Human Papillomavirus Integration Strictly Correlates With Global Genome Instability in Head and Neck Cancer,&#x201d; Molecular Cancer Research 20 (2022): 1420&#x2013;1428, https://doi.org/10.1158/1541&#x2010;7786.MCR&#x2010;21&#x2010;0831.</Citation></Reference><Reference><Citation>Y. X. Lim, M. L. Mierzwa, M. A. Sartor, and N. J. D'Silva, &#x201c;Clinical, Morphologic and Molecular Heterogeneity of HPV&#x2010;Associated Oropharyngeal Cancer,&#x201d; Oncogene 42 (2023): 2939&#x2013;2955, https://doi.org/10.1038/s41388&#x2010;023&#x2010;02819&#x2010;y.</Citation></Reference><Reference><Citation>S. Syrjanen, &#x201c;HPV Infections and Tonsillar Carcinoma,&#x201d; Journal of Clinical Pathology 57 (2004): 449&#x2013;455, https://doi.org/10.1136/jcp.2003.008656.</Citation></Reference><Reference><Citation>H. M. Walline, C. M. Goudsmit, J. B. McHugh, et&#xa0;al., &#x201c;Integration of High&#x2010;Risk Human Papillomavirus Into Cellular Cancer&#x2010;Related Genes in Head and Neck Cancer Cell Lines,&#x201d; Head &amp; Neck 39 (2017): 840&#x2013;852, https://doi.org/10.1002/hed.24729.</Citation></Reference><Reference><Citation>C. Pan, N. Issaeva, and W. G. Yarbrough, &#x201c;HPV&#x2010;Driven Oropharyngeal Cancer: Current Knowledge of Molecular Biology and Mechanisms of Carcinogenesis,&#x201d; Cancers Head Neck 3 (2018): 12, https://doi.org/10.1186/s41199&#x2010;018&#x2010;0039&#x2010;3.</Citation></Reference><Reference><Citation>T. P. Schrank, S. Kim, H. Rehmani, et&#xa0;al., &#x201c;Direct Comparison of HPV16 Viral Genomic Integration, Copy Loss, and Structural Variants in Oropharyngeal and Uterine Cervical Cancers Reveal Distinct Relationships to E2 Disruption and Somatic Alteration,&#x201d; Cancers (Basel) 14 (2022): 4488, https://doi.org/10.3390/cancers14184488.</Citation></Reference><Reference><Citation>L. M. Pinatti, H. N. Sinha, C. V. Brummel, et&#xa0;al., &#x201c;Association of Human Papillomavirus Integration With Better Patient Outcomes in Oropharyngeal Squamous Cell Carcinoma,&#x201d; Head &amp; Neck 43 (2021): 544&#x2013;557, https://doi.org/10.1002/hed.26501.</Citation></Reference><Reference><Citation>A. L. Tang, S. J. Hauff, J. H. Owen, et&#xa0;al., &#x201c;UM&#x2010;SCC&#x2010;104: A New Human Papillomavirus&#x2010;16&#x2010;Positive Cancer Stem Cell&#x2010;Containing Head and Neck Squamous Cell Carcinoma Cell Line,&#x201d; Head &amp; Neck 34 (2012): 1480&#x2013;1491, https://doi.org/10.1002/hed.21962.</Citation></Reference><Reference><Citation>C. Bodelon, M. E. Untereiner, M. J. Machiela, S. Vinokurova, and N. Wentzensen, &#x201c;Genomic Characterization of Viral Integration Sites in HPV&#x2010;Related Cancers,&#x201d; International Journal of Cancer 139 (2016): 2001&#x2013;2011, https://doi.org/10.1002/ijc.30243.</Citation></Reference><Reference><Citation>N. C. Olthof, C. U. Huebbers, J. Kolligs, et&#xa0;al., &#x201c;Viral Load, Gene Expression and Mapping of Viral Integration Sites in HPV16&#x2010;Associated HNSCC Cell Lines,&#x201d; International Journal of Cancer 136 (2015): E207&#x2013;E218, https://doi.org/10.1002/ijc.29112.</Citation></Reference><Reference><Citation>J. S. Park, E. S. Hwang, S. N. Park, et&#xa0;al., &#x201c;Physical Status and Expression of HPV Genes in Cervical Cancers,&#x201d; Gynecologic Oncology 65 (1997): 121&#x2013;129, https://doi.org/10.1006/gyno.1996.4596.</Citation></Reference><Reference><Citation>R. Senapati, N. N. Senapati, and B. Dwibedi, &#x201c;Molecular Mechanisms of HPV Mediated Neoplastic Progression,&#x201d; Infectious Agents and Cancer 11 (2016): 59, https://doi.org/10.1186/s13027&#x2010;016&#x2010;0107&#x2010;4.</Citation></Reference><Reference><Citation>W. Li, S. Tian, P. Wang, et&#xa0;al., &#x201c;The Characteristics of HPV Integration in Cervical Intraepithelial Cells,&#x201d; Journal of Cancer 10 (2019): 2783&#x2013;2787, https://doi.org/10.7150/jca.31450.</Citation></Reference><Reference><Citation>D. E. Symer, K. Akagi, H. M. Geiger, et&#xa0;al., &#x201c;Diverse Tumorigenic Consequences of Human Papillomavirus Integration in Primary Oropharyngeal Cancers,&#x201d; Genome Research 32 (2022): 55&#x2013;70, https://doi.org/10.1101/gr.275911.121.</Citation></Reference><Reference><Citation>H. Balaji, I. Demers, N. Wuerdemann, et&#xa0;al., &#x201c;Causes and Consequences of HPV Integration in Head and Neck Squamous Cell Carcinomas: State of the Art,&#x201d; Cancers (Basel) 13 (2021): 4089, https://doi.org/10.3390/cancers13164089.</Citation></Reference><Reference><Citation>M. H. Karbalaie Niya, H. Keyvani, F. Safarnezhad Tameshkel, et&#xa0;al., &#x201c;Human Papillomavirus Type 16 Integration Analysis by Real&#x2010;Time PCR Assay in Associated Cancers,&#x201d; Translational Oncology 11 (2018): 593&#x2013;598, https://doi.org/10.1016/j.tranon.2018.02.017.</Citation></Reference><Reference><Citation>J. Mainguene, S. Vacher, M. Kamal, et&#xa0;al., &#x201c;Human Papilloma Virus Integration Sites and Genomic Signatures in Head and Neck Squamous Cell Carcinoma,&#x201d; Molecular Oncology 16 (2022): 3001&#x2013;3016, https://doi.org/10.1002/1878&#x2010;0261.13219.</Citation></Reference><Reference><Citation>S. Y. Park, J. J. Lee, Y. J. Lee, et&#xa0;al., &#x201c;Molecular Signature of HPV&#x2010;Positive Head and Neck Squamous Cell Carcinoma Reveals Potential Therapeutic Targets,&#x201d; Genomics 111 (2019): 1853&#x2013;1861, https://doi.org/10.1016/j.ygeno.2018.12.008.</Citation></Reference><Reference><Citation>A. A. McBride and E. A. White, &#x201c;HPV Integration Can Drive the Formation of Virus&#x2010;Host Extrachromosomal DNA in Tumors,&#x201d; Cancer Discovery 13 (2023): 814&#x2013;816.</Citation></Reference><Reference><Citation>J. K. Lee, S. C. Lim, H. D. Kim, et&#xa0;al., &#x201c;KITENIN Represents a More Aggressive Phenotype in a Murine Model of Oral Cavity Squamous Carcinoma,&#x201d; Otolaryngology and Head and Neck Surgery 142 (2010): 747&#x2013;752.e741&#x2013;742, https://doi.org/10.1016/j.otohns.2009.12.032.</Citation></Reference><Reference><Citation>X. Zhang, Y. Liu, M. Z. Gilcrease, et&#xa0;al., &#x201c;A Lymph Node Metastatic Mouse Model Reveals Alterations of Metastasis&#x2010;Related Gene Expression in Metastatic Human Oral Carcinoma Sublines Selected From a Poorly Metastatic Parental Cell Line,&#x201d; Cancer 95 (2002): 1663&#x2013;1672, https://doi.org/10.1002/cncr.10837.</Citation></Reference><Reference><Citation>K. Akagi, J. Li, T. R. Broutian, et&#xa0;al., &#x201c;Genome&#x2010;Wide Analysis of HPV Integration in Human Cancers Reveals Recurrent, Focal Genomic Instability,&#x201d; Genome Research 24 (2014): 185&#x2013;199, https://doi.org/10.1101/gr.164806.113.</Citation></Reference><Reference><Citation>B. Pokryvkova, M. Salakova, J. Smahelova, et&#xa0;al., &#x201c;Detailed Characteristics of Tonsillar Tumors With Extrachromosomal or Integrated Form of Human Papillomavirus,&#x201d; Viruses 12 (2019): 42, https://doi.org/10.3390/v12010042.</Citation></Reference><Reference><Citation>M. P. Canadas, L. Darwich, G. Sirera, et&#xa0;al., &#x201c;New Molecular Method for the Detection of Human Papillomavirus Type 16 Integration,&#x201d; Clinical Microbiology and Infection 16 (2010): 836&#x2013;842, https://doi.org/10.1111/j.1469&#x2010;0691.2009.02964.x.</Citation></Reference><Reference><Citation>L. M. Rooper, M. Gandhi, J. A. Bishop, and W. H. Westra, &#x201c;RNA In&#x2010;Situ Hybridization Is a Practical and Effective Method for Determining HPV Status of Oropharyngeal Squamous Cell Carcinoma Including Discordant Cases That Are p16 Positive by Immunohistochemistry but HPV Negative by DNA In&#x2010;Situ Hybridization,&#x201d; Oral Oncology 55 (2016): 11&#x2013;16, https://doi.org/10.1016/j.oraloncology.2016.02.008.</Citation></Reference><Reference><Citation>L. Satgunaseelan, D. Strbenac, S. Tadi, et&#xa0;al., &#x201c;Viral Integration Plays a Minor Role in the Development and Prognostication of Oral Squamous Cell Carcinoma,&#x201d; Cancers (Basel) 14 (2022): 5213, https://doi.org/10.3390/cancers14215213.</Citation></Reference><Reference><Citation>K. Lai, M. Killingsworth, S. Matthews, et&#xa0;al., &#x201c;Differences in Survival Outcome Between Oropharyngeal and Oral Cavity Squamous Cell Carcinoma in Relation to HPV Status,&#x201d; Journal of Oral Pathology &amp; Medicine 46 (2017): 574&#x2013;582, https://doi.org/10.1111/jop.12535.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70152 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41467362</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Dec</Month><Day>30</Day></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Association Between Elective Nodal Irradiation and Oncologic Outcomes in Node-Negative Olfactory Neuroblastoma and Sinonasal Squamous Cell Carcinoma: A Propensity-Score Matched Analysis.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70152</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The association between elective nodal irradiation (ENI) and oncological outcomes in clinically node-negative (cN0) sinonasal squamous cell carcinoma (SCC) and olfactory neuroblastoma (ONB) treated with postoperative chemoradiotherapy remains unclear.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We retrospectively analyzed cN0 sinonasal SCC and ONB patients receiving postoperative chemoradiotherapy at a single institution. Propensity score matching was performed to minimize confounding. Survival outcomes were assessed using Kaplan-Meier estimates, and logistic regression identified factors associated with specific failure patterns.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 62 eligible patients (36 SCC, 26 ONB; median follow-up 44&#x2009;months), ENI was associated with a lower nodal recurrence rate (4.8% vs. 34.1%; OR 0.10, p&#x2009;=&#x2009;0.030) but not with overall or recurrence-free survival (p&#x2009;&gt;&#x2009;0.05). Perineural invasion was independently associated with worse recurrence-free survival. The association between ENI and reduced nodal recurrence appeared more pronounced in ONB.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Despite the small sample size, ENI was associated with reduced nodal recurrence but not with improved survival in cN0 sinonasal SCC and ONB.</AbstractText><CopyrightInformation>&#xa9; 2025 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Shuo-Fu</ForeName><Initials>SF</Initials><AffiliationInfo><Affiliation>Department of Heavy Particles &amp; Radiation Oncology, Taipei Veterans General Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Yu-Wen</ForeName><Initials>YW</Initials><AffiliationInfo><Affiliation>Department of Heavy Particles &amp; Radiation Oncology, Taipei Veterans General Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yeh</LastName><ForeName>Chien-Fu</ForeName><Initials>CF</Initials><AffiliationInfo><Affiliation>School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otorhinolaryngology-Head and Neck Surgery, Taipei Veterans General Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chou</LastName><ForeName>Cheng-Wai</ForeName><Initials>CW</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology-Head and Neck Surgery, Taipei Veterans General Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lan</LastName><ForeName>Ming-Ying</ForeName><Initials>MY</Initials><AffiliationInfo><Affiliation>School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otorhinolaryngology-Head and Neck Surgery, Taipei Veterans General Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chao</LastName><ForeName>Yun-Ting</ForeName><Initials>YT</Initials><AffiliationInfo><Affiliation>School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otorhinolaryngology-Head and Neck Surgery, Taipei Veterans General Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuo</LastName><ForeName>Ying-Ju</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shiau</LastName><ForeName>Cheng-Ying</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>Department of Heavy Particles &amp; Radiation Oncology, Taipei Veterans General Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Pin-I</ForeName><Initials>PI</Initials><AffiliationInfo><Affiliation>Department of Heavy Particles &amp; Radiation Oncology, Taipei Veterans General Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">concurrent chemoradiotherapy</Keyword><Keyword MajorTopicYN="N">elective nodal irradiation</Keyword><Keyword MajorTopicYN="N">intensity&#x2010;modulated radiotherapy</Keyword><Keyword MajorTopicYN="N">olfactory neuroblastoma</Keyword><Keyword MajorTopicYN="N">sinonasal malignancy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>11</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>7</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>12</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>30</Day><Hour>7</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>30</Day><Hour>7</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>30</Day><Hour>5</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41467362</ArticleId><ArticleId IdType="doi">10.1002/hed.70152</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>R. L. Siegel, A. N. Giaquinto, and A. Jemal, &#x201c;Cancer Statistics, 2024,&#x201d; CA: A Cancer Journal for Clinicians 74 (2024): 12&#x2013;49.</Citation></Reference><Reference><Citation>D. R. Youlden, S. M. Cramb, S. Peters, et&#xa0;al., &#x201c;International Comparisons of the Incidence and Mortality of Sinonasal Cancer,&#x201d; Cancer Epidemiology 37 (2013): 770&#x2013;779.</Citation></Reference><Reference><Citation>R. Thawani, M. S. Kim, A. Arastu, et&#xa0;al., &#x201c;The Contemporary Management of Cancers of the Sinonasal Tract in Adults,&#x201d; CA: A Cancer Journal for Clinicians 73 (2023): 72&#x2013;112.</Citation></Reference><Reference><Citation>C. Demiroz, O. Gutfeld, M. Aboziada, D. Brown, L. J. Marentette, and A. Eisbruch, &#x201c;Esthesioneuroblastoma: Is There a Need for Elective Neck Treatment?,&#x201d; International Journal of Radiation Oncology, Biology, Physics 81 (2011): e255&#x2013;e261.</Citation></Reference><Reference><Citation>Q. Liu, Y. Qu, K. Wang, et&#xa0;al., &#x201c;Lymph Node Metastasis Spread Patterns and the Effectiveness of Prophylactic Neck Irradiation in Sinonasal Squamous Cell Carcinoma (SNSCC),&#x201d; Frontiers in Oncology 12 (2022): 793351.</Citation></Reference><Reference><Citation>A. Kazemian, B. Farazmand, M. Taherioun, et&#xa0;al., &#x201c;The Role of Histology on the Outcome of Sinonasal Carcinomas Treated With Radiotherapy: A Single Institution Experience,&#x201d; Radiation Oncology Journal 42 (2024): 116&#x2013;123.</Citation></Reference><Reference><Citation>J. Thariat, F. Carsuzaa, P. Y. Marcy, B. Verillaud, L. de Gabory, and F. R. Ferrand, &#x201c;Precision Postoperative Radiotherapy in Sinonasal Carcinomas After Endonasal Endoscopic Surgery,&#x201d; Cancers 13 (2021): 4802.</Citation></Reference><Reference><Citation>M. Ferrari, S. Taboni, A. L. C. Carobbio, et&#xa0;al., &#x201c;Sinonasal Squamous Cell Carcinoma, a Narrative Reappraisal of the Current Evidence,&#x201d; Cancers 13 (2021): 2835.</Citation></Reference><Reference><Citation>L. Wang, J. Wang, T. Wang, Y. Li, and X. Song, &#x201c;The Role of Elective Nodal Irradiation in Treating Clinically Node&#x2010;Negative Sinonasal Squamous Cell Carcinoma,&#x201d; International Journal of Radiation Oncology, Biology, Physics 120 (2024): 1058&#x2013;1065.</Citation></Reference><Reference><Citation>M. Tomasoni, E. Marazzi, V. Rampinelli, et&#xa0;al., &#x201c;Lymph Node Metastasis From Olfactory Neuroblastoma at Presentation and as Disease Relapse: A Systematic Review and Proportion Meta&#x2010;Analysis of Prevalence Data and Variables Influencing Regional Control,&#x201d; Head &amp; Neck 45 (2023): 1486&#x2013;1496.</Citation></Reference><Reference><Citation>X. Song, J. Wang, S. Wang, L. Yan, and Y. Li, &#x201c;Prognostic Factors and Outcomes of Multimodality Treatment in Olfactory Neuroblastoma,&#x201d; Oral Oncology 103 (2020): 104618.</Citation></Reference><Reference><Citation>O. K. Noh, S.&#x2010;w. Lee, S. M. Yoon, et&#xa0;al., &#x201c;Radiotherapy for Esthesioneuroblastoma: Is Elective Nodal Irradiation Warranted in the Multimodality Treatment Approach?,&#x201d; International Journal of Radiation Oncology, Biology, Physics 79 (2011): 443&#x2013;449.</Citation></Reference><Reference><Citation>D. Huang, P. Xia, P. Akazawa, et&#xa0;al., &#x201c;Comparison of Treatment Plans Using Intensity&#x2010;Modulated Radiotherapy and Three&#x2010;Dimensional Conformal Radiotherapy for Paranasal Sinus Carcinoma,&#x201d; International Journal of Radiation Oncology, Biology, Physics 56 (2003): 158&#x2013;168.</Citation></Reference><Reference><Citation>A. Al&#x2010;Mamgani, D. Monserez, P. van Rooij, G. M. Verduijn, J. A. Hardillo, and P. C. Levendag, &#x201c;Highly&#x2010;Conformal Intensity&#x2010;Modulated Radiotherapy Reduced Toxicity Without Jeopardizing Outcome in Patients With Paranasal Sinus Cancer Treated by Surgery and Radiotherapy or (Chemo) Radiation,&#x201d; Oral Oncology 48 (2012): 905&#x2013;911.</Citation></Reference><Reference><Citation>K. C. Chao, G. Ozyigit, B. N. Tran, M. Cengiz, J. F. Dempsey, and D. A. Low, &#x201c;Patterns of Failure in Patients Receiving Definitive and Postoperative IMRT for Head&#x2010;And&#x2010;Neck Cancer,&#x201d; International Journal of Radiation Oncology, Biology, Physics 55 (2003): 312&#x2013;321.</Citation></Reference><Reference><Citation>W. H. Lee, S. H. Choi, S.&#x2010;H. Kim, E. C. Choi, C. G. Lee, and K. C. Keum, &#x201c;Elective Neck Treatment in Clinically Node&#x2010;Negative Paranasal Sinus Carcinomas: Impact on Treatment Outcome,&#x201d; Radiation Oncology Journal 36 (2018): 304&#x2013;316.</Citation></Reference><Reference><Citation>E. J. Patel, M. P. Strohl, S. S. Yom, and I. El&#x2010;Sayed, &#x201c;Elective Management of the N0 Neck in Maxillary Sinus Squamous Cell Carcinoma,&#x201d; Head &amp; Neck 46 (2024): 171&#x2013;176.</Citation></Reference><Reference><Citation>J. Wang, Q. Fang, X. Zhang, L. Dai, and R. Luo, &#x201c;Role of Elective Neck Dissection in cT2N0 Maxillary Sinus Squamous Cell Carcinoma,&#x201d; Scientific Reports 14 (2024): 16230.</Citation></Reference><Reference><Citation>M. Howell, B. Branstetter, and C. Snyderman, &#x201c;Patterns of Regional Spread for Esthesioneuroblastoma,&#x201d; American Journal of Neuroradiology 32 (2011): 929&#x2013;933.</Citation></Reference><Reference><Citation>A. R. Wolfe, D. Blakaj, N. London, et&#xa0;al., &#x201c;Clinical Outcomes and Multidisciplinary Patterns of Failure for Olfactory Neuroblastoma: The Ohio State Experience,&#x201d; Journal of Neurological Surgery Part B: Skull Base 81 (2020): 287&#x2013;294.</Citation></Reference><Reference><Citation>A. D. Arosio, D. P. Bernasconi, M. G. Valsecchi, et&#xa0;al., &#x201c;Patterns of Recurrences in Sinonasal Cancers Undergoing an Endoscopic Surgery&#x2010;Based Treatment: Results of the MUSES* on 940 Patients:* MUlti&#x2010;Institutional Collaborative Study on Endoscopically Treated Sinonasal Cancers,&#x201d; Oral Oncology 134 (2022): 106123.</Citation></Reference><Reference><Citation>L. Schmitd, C. Scanlon, and N. D'silva, &#x201c;Perineural Invasion in Head and Neck Cancer,&#x201d; Journal of Dental Research 97 (2018): 742&#x2013;750.</Citation></Reference><Reference><Citation>A. S. Abdelmeguid, D. Bell, D. Roberts, et&#xa0;al., &#x201c;Long&#x2010;Term Outcomes of Olfactory Neuroblastoma: MD A Nderson C Ancer C Enter Experience and Review of the Literature,&#x201d; Laryngoscope 132 (2022): 290&#x2013;297.</Citation></Reference><Reference><Citation>A. Katano, M. Minamitani, S. Ohira, and H. Yamashita, &#x201c;Failure Patterns of Recurrence in Patients With Localized Esthesioneuroblastoma Following Surgery and Adjuvant Radiotherapy Without Elective Nodal Irradiation,&#x201d; Cureus 15 (2023): e46523.</Citation></Reference><Reference><Citation>V. Askoxylakis, P. Hegenbarth, C. Timke, et&#xa0;al., &#x201c;Intensity Modulated Radiation Therapy (IMRT) for Sinonasal Tumors: A Single Center Long&#x2010;Term Clinical Analysis,&#x201d; Radiation Oncology 11 (2016): 1&#x2013;9.</Citation></Reference><Reference><Citation>C.&#x2010;W. Chou, M.&#x2010;Y. Lan, Y.&#x2010;J. Kuo, and C.&#x2010;F. Yeh, &#x201c;Perineural Invasion Is a Poor Prognostic Factor for Sinonasal Squamous Cell Carcinoma,&#x201d; Oral Oncology 150 (2024): 106698.</Citation></Reference><Reference><Citation>Y. Toyomasu, Y. Demizu, Y. Matsuo, et&#xa0;al., &#x201c;Outcomes of Patients With Sinonasal Squamous Cell Carcinoma Treated With Particle Therapy Using Protons or Carbon Ions,&#x201d; International Journal of Radiation Oncology, Biology, Physics 101 (2018): 1096&#x2013;1103.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70148 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41466514</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Dec</Month><Day>30</Day></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Biopsy for Suspicious Oral Lesions: A Review From the American Head and Neck Society-Cancer Prevention Service.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70148</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Oral cancer is often preceded by a precursor lesion. This presents an opportunity for early diagnosis and intervention. Method of biopsy and interpretation are not well standardized and novel methods of analysis are now being investigated.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a narrative review of PubMed/MEDLINE (last search August 31, 2025), focusing on adult oral precancerous lesions evaluated in outpatient settings.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Incisional punch biopsy is reproducible and often provides the diagnostic information needed. However, scalpel biopsy should be considered when initial biopsy is equivocal, depth of invasion is desired, or to minimize sampling bias. Limited studies show improved sensitivity of combining saliva and plasma sampling. Targeted fluorescent imaging may aid in future biopsy site selection. AI has shown encouraging results in both automated detection of dysplasia and prediction of malignant progression, achieving performance comparable to clinically validated grading systems.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This update serves to further inform biopsy of oral suspicious lesions and provide a framework for future investigation.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). Head &amp; Neck published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gates</LastName><ForeName>James Christopher</ForeName><Initials>JC</Initials><Identifier Source="ORCID">0000-0002-7491-8995</Identifier><AffiliationInfo><Affiliation>Department of Oral and Maxillofacial Surgery, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edwards</LastName><ForeName>Heather</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villa</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-1966-6000</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Director of Oral Oncology, Baptist Health, Miami, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Purdy</LastName><ForeName>Nick</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology, Geisinger Health System, Danville, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Troka</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Varela</LastName><ForeName>Peter</ForeName><Initials>P</Initials><Identifier Source="ORCID">0009-0002-8737-5464</Identifier><AffiliationInfo><Affiliation>University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Self</LastName><ForeName>Quinn</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology, University of Vermont, Burlington, Vermont, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yingci</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-9242-0808</Identifier><AffiliationInfo><Affiliation>Department of Diagnostic Sciences, Rutgers School of Dental Medicine, Newark, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dundar</LastName><ForeName>Yusuf</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology, Texas Tech University, Lubbock, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brooks</LastName><ForeName>Patricia Joyce</ForeName><Initials>PJ</Initials><Identifier Source="ORCID">0000-0001-9256-6236</Identifier><AffiliationInfo><Affiliation>Princess Margaret Cancer Centre, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adilbay</LastName><ForeName>Dauren</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology, Medical University of South Carolina, Charleston, South Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Birkeland</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology, UC Davis, Sacramento, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cramer</LastName><ForeName>John</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-6869-8554</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology, Wayne State University, Detroit, Michigan, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>12</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>11</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>12</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>30</Day><Hour>7</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>30</Day><Hour>7</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>30</Day><Hour>3</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41466514</ArticleId><ArticleId IdType="doi">10.1002/hed.70148</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>F. Bray, M. Laversanne, H. Sung, et&#xa0;al., &#x201c;Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,&#x201d; CA: A Cancer Journal for Clinicians 74, no. 3 (2024): 229&#x2013;263.</Citation></Reference><Reference><Citation>M. C. van Harten, F. J. P. Hoebers, K. W. Kross, E. D. van Werkhoven, M. W. M. van den Brekel, and B. A. C. van Dijk, &#x201c;Determinants of Treatment Waiting Times for Head and Neck Cancer in The Netherlands and Their Relation to Survival,&#x201d; Oral Oncology 51, no. 3 (2015): 272&#x2013;278.</Citation></Reference><Reference><Citation>A. C. Birkeland, D. Kademani, M. G. Moore, and E. A. Blair, &#x201c;Practice Patterns for Initial Management of Oral Leukoplakia Amongst Otolaryngologists and Oral and Maxillofacial Surgeons,&#x201d; Oral Oncology 139 (2023): 106341.</Citation></Reference><Reference><Citation>S. Rezende Oliveira, T. Fernandes Ara&#xfa;jo Almeida, T. Aparecida da Silva, R. Alves Mesquita, and L. Guimar&#xe3;es Abreu, &#x201c;Comparison of Tissue Artifacts in Punch and Scalpel Biopsies of Oral and Maxillofacial Lesions: A Systematic Review and Meta&#x2010;Analysis,&#x201d; Journal of Stomatology Oral and Maxillofacial Surgery 121, no. 6 (2020): 704&#x2013;712.</Citation></Reference><Reference><Citation>M. W. Lingen, E. Abt, N. Agrawal, et&#xa0;al., &#x201c;Evidence&#x2010;Based Clinical Practice Guideline for the Evaluation of Potentially Malignant Disorders in the Oral Cavity: A Report of the American Dental Association,&#x201d; Journal of the American Dental Association (1939) 148, no. 10 (2017): 712&#x2013;727.e10.</Citation></Reference><Reference><Citation>V. G. A. Suter, H. J. Altermatt, and M. M. Bornstein, &#x201c;A Randomized Controlled Trial Comparing Surgical Excisional Biopsies Using CO,&#x201d; International Journal of Oral and Maxillofacial Surgery 49, no. 1 (2020): 99&#x2013;106.</Citation></Reference><Reference><Citation>I. Moule, P. A. Parsons, and G. H. Irvine, &#x201c;Avoiding Artefacts in Oral Biopsies: The Punch Biopsy Versus the Incisional Biopsy,&#x201d; British Journal of Oral &amp; Maxillofacial Surgery 33, no. 4 (1995): 244&#x2013;247.</Citation></Reference><Reference><Citation>S. Chen, M. Forman, P. M. Sadow, and M. August, &#x201c;The Diagnostic Accuracy of Incisional Biopsy in the Oral Cavity,&#x201d; Journal of Oral and Maxillofacial Surgery 74, no. 5 (2016): 959&#x2013;964.</Citation></Reference><Reference><Citation>R. Navone, M. Pentenero, I. Rostan, et&#xa0;al., &#x201c;Oral Potentially Malignant Lesions: First&#x2010;Level Micro&#x2010;Histological Diagnosis From Tissue Fragments Sampled in Liquid&#x2010;Based Diagnostic Cytology,&#x201d; Journal of Oral Pathology &amp; Medicine 37, no. 6 (2008): 358&#x2013;363.</Citation></Reference><Reference><Citation>S. L. Avon and H. B. Klieb, &#x201c;Oral Soft&#x2010;Tissue Biopsy: An Overview,&#x201d; Journal of the Canadian Dental Association 78 (2012): c75.</Citation></Reference><Reference><Citation>A. F. Schemel, R. E. Manosalva, D. Pataroque, et&#xa0;al., &#x201c;Shortcomings of Excisional Biopsy in Early&#x2010;Stage Oral Cavity Carcinoma,&#x201d; Oral Oncology 157 (2024): 106909.</Citation></Reference><Reference><Citation>T. Walsh, R. Macey, A. R. Kerr, M. W. Lingen, G. R. Ogden, and S. Warnakulasuriya, &#x201c;Diagnostic Tests for Oral Cancer and Potentially Malignant Disorders in Patients Presenting With Clinically Evident Lesions,&#x201d; Cochrane Database of Systematic Reviews 7, no. 7 (2021): CD010276.</Citation></Reference><Reference><Citation>M. Idrees, C. S. Farah, P. Sloan, and O. Kujan, &#x201c;Oral Brush Biopsy Using Liquid&#x2010;Based Cytology Is a Reliable Tool for Oral Cancer Screening: A Cost&#x2010;Utility Analysis: Oral Brush Biopsy for Oral Cancer Screening,&#x201d; Cancer Cytopathology 130, no. 9 (2022): 740&#x2013;748.</Citation></Reference><Reference><Citation>F. W. Neumann, H. Neumann, S. Spieth, and T. W. Remmerbach, &#x201c;Retrospective Evaluation of the Oral Brush Biopsy in Daily Dental Routine&#x2014;An Effective Way of Early Cancer Detection,&#x201d; Clinical Oral Investigations 26, no. 11 (2022): 6653&#x2013;6659.</Citation></Reference><Reference><Citation>E. Velleuer, R. Dietrich, N. Pomjanski, et&#xa0;al., &#x201c;Diagnostic Accuracy of Brush Biopsy&#x2010;Based Cytology for the Early Detection of Oral Cancer and Precursors in Fanconi Anemia,&#x201d; Cancer Cytopathology 128, no. 6 (2020): 403&#x2013;413.</Citation></Reference><Reference><Citation>R. Mehrotra, S. Mishra, and M. Singh, &#x201c;The Efficacy of Oral Brush Biopsy With Computer&#x2010;Assisted Analysis in Identifying Precancerous and Cancerous Lesions,&#x201d; Head &amp; Neck Oncology 3 (2011): 39.</Citation></Reference><Reference><Citation>A. R. Thierry, S. el Messaoudi, P. B. Gahan, P. Anker, and M. Stroun, &#x201c;Origins, Structures, and Functions of Circulating DNA in Oncology,&#x201d; Cancer Metastasis Reviews 35, no. 3 (2016): 347&#x2013;376.</Citation></Reference><Reference><Citation>M. G. Krebs, R. L. Metcalf, L. Carter, G. Brady, F. H. Blackhall, and C. Dive, &#x201c;Molecular Analysis of Circulating Tumour Cells&#x2010;Biology and Biomarkers,&#x201d; Nature Reviews. Clinical Oncology 11, no. 3 (2014): 129&#x2013;144.</Citation></Reference><Reference><Citation>L. Penny, S. C. Main, S. D. de Michino, and S. V. Bratman, &#x201c;Chromatin&#x2010; and Nucleosome&#x2010;Associated Features in Liquid Biopsy: Implications for Cancer Biomarker Discovery,&#x201d; Biochemistry and Cell Biology 102, no. 4 (2024): 291&#x2013;298.</Citation></Reference><Reference><Citation>Y. Lu, Z. Zheng, Y. Yuan, et&#xa0;al., &#x201c;The Emerging Role of Exosomes in Oral Squamous Cell Carcinoma,&#x201d; Frontiers in Cell and Development Biology 9 (2021): 628103.</Citation></Reference><Reference><Citation>L. Barroso, P. Veiga, J. B. Melo, I. M. Carreira, and I. P. Ribeiro, &#x201c;Molecular and Genetic Pathogenesis of Oral Cancer: A Basis for Customized Diagnosis and Treatment,&#x201d; Biology&#x2010;Basel 14, no. 7 (2025): 842.</Citation></Reference><Reference><Citation>Y. Wang, S. Springer, C. L. Mulvey, et&#xa0;al., &#x201c;Detection of Somatic Mutations and HPV in the Saliva and Plasma of Patients With Head and Neck Squamous Cell Carcinomas,&#x201d; Science Translational Medicine 7, no. 293 (2015): 293ra104.</Citation></Reference><Reference><Citation>S. Flach, K. Howarth, S. Hackinger, et&#xa0;al., &#x201c;Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)&#x2014;A Personalised Circulating Tumour DNA Analysis in Head and Neck Squamous Cell Carcinoma,&#x201d; British Journal of Cancer 126, no. 8 (2022): 1186&#x2013;1195.</Citation></Reference><Reference><Citation>E. Sanz&#x2010;Garcia, J. Zou, L. Avery, et&#xa0;al., &#x201c;Multimodal Detection of Molecular Residual Disease in High&#x2010;Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck,&#x201d; Cell Death and Differentiation 31, no. 4 (2024): 460&#x2013;468.</Citation></Reference><Reference><Citation>N. Honor&#xe9;, C. van Marcke, R. Galot, et&#xa0;al., &#x201c;Tumor&#x2010;Agnostic Plasma Assay for Circulating Tumor DNA Detects Minimal Residual Disease and Predicts Outcome in Locally Advanced Squamous Cell Carcinoma of the Head and Neck,&#x201d; Annals of Oncology 34, no. 12 (2023): 1175&#x2013;1186.</Citation></Reference><Reference><Citation>A. Shanmugam, A. K. Hariharan, R. Hasina, et&#xa0;al., &#x201c;Ultrasensitive Detection of Tumor&#x2010;Specific Mutations in Saliva of Patients With Oral Cavity Squamous Cell Carcinoma,&#x201d; Cancer 127, no. 10 (2021): 1576&#x2013;1589.</Citation></Reference><Reference><Citation>P. A. Jones, &#x201c;Functions of DNA Methylation: Islands, Start Sites, Gene Bodies and Beyond,&#x201d; Nature Reviews. Genetics 13, no. 7 (2012): 484&#x2013;492.</Citation></Reference><Reference><Citation>J. M. Burgener, J. Zou, Z. Zhao, et&#xa0;al., &#x201c;Tumor&#x2010;Na&#xef;ve Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma,&#x201d; Clinical Cancer Research 27, no. 15 (2021): 4230&#x2013;4244.</Citation></Reference><Reference><Citation>G. Liu, S. H. Huang, L. Ailles, et&#xa0;al., &#x201c;Clinical Validation of a Tissue&#x2010;Agnostic Genome&#x2010;Wide Methylome Enrichment Molecular Residual Disease Assay for Head and Neck Malignancies,&#x201d; Annals of Oncology 36, no. 1 (2025): 108&#x2013;117.</Citation></Reference><Reference><Citation>T. Y. Seiwert, C. C. Foster, E. A. Blair, et&#xa0;al., &#x201c;OPTIMA: A Phase II Dose and Volume de&#x2010;Escalation Trial for Human Papillomavirus&#x2010;Positive Oropharyngeal Cancer,&#x201d; Annals of Oncology 30, no. 10 (2019): 1673.</Citation></Reference><Reference><Citation>Y. Coll, A. Geddes, and E. Thomson, &#x201c;The Light at the End of the Tunnel? Can Light&#x2010;Based Tests Increase the Accuracy of Our Diagnoses of Pre&#x2010;Cancerous/Cancerous Lesions?,&#x201d; Evidence&#x2010;Based Dentistry 23, no. 1 (2022): 16&#x2013;17.</Citation></Reference><Reference><Citation>C. S. Farah, L. McIntosh, A. Georgiou, and M. J. McCullough, &#x201c;Efficacy of Tissue Autofluorescence Imaging (VELScope) in the Visualization of Oral Mucosal Lesions,&#x201d; Head &amp; Neck 34, no. 6 (2012): 856&#x2013;862.</Citation></Reference><Reference><Citation>P. de Dem&#xe9;trio Souza Fran&#xe7;a, S. Kossatz, C. Brand, et&#xa0;al., &#x201c;A Phase I Study of a PARP1&#x2010;Targeted Topical Fluorophore for the Detection of Oral Cancer,&#x201d; European Journal of Nuclear Medicine and Molecular Imaging 48, no. 11 (2021): 3618&#x2013;3630.</Citation></Reference><Reference><Citation>H. H&#xf6;tzinger, H. H. Barth, and G. Ries, &#x201c;Recurrent Ameloblastoma of the Upper Jaw&#x2014;Diagnosis,&#x201d; Morphology and Medicine 3, no. 2 (1983): 89&#x2013;96.</Citation></Reference><Reference><Citation>H. Hijioka, T. Setoguchi, A. Miyawaki, et&#xa0;al., &#x201c;Upregulation of Notch Pathway Molecules in Oral Squamous Cell Carcinoma,&#x201d; International Journal of Oncology 36, no. 4 (2010): 817&#x2013;822.</Citation></Reference><Reference><Citation>L. J. Wils, J. B. Poell, A. Brink, et&#xa0;al., &#x201c;Elucidating the Genetic Landscape of Oral Leukoplakia to Predict Malignant Transformation,&#x201d; Clinical Cancer Research 29, no. 3 (2023): 602&#x2013;613.</Citation></Reference><Reference><Citation>P. Saintigny, W. N. William, Jr., J. P. Foy, et&#xa0;al., &#x201c;Met Receptor Tyrosine Kinase and Chemoprevention of Oral Cancer,&#x201d; Journal of the National Cancer Institute 110, no. 3 (2018): 250&#x2013;257.</Citation></Reference><Reference><Citation>S. van Keulen, N. S. van den Berg, N. Nishio, et&#xa0;al., &#x201c;Rapid, Non&#x2010;Invasive Fluorescence Margin Assessment: Optical Specimen Mapping in Oral Squamous Cell Carcinoma,&#x201d; Oral Oncology 88 (2019): 58&#x2013;65.</Citation></Reference><Reference><Citation>J. G. de Wit, J. Vonk, F. J. Voskuil, et&#xa0;al., &#x201c;EGFR&#x2010;Targeted Fluorescence Molecular Imaging for Intraoperative Margin Assessment in Oral Cancer Patients: A Phase II Trial,&#x201d; Nature Communications 14, no. 1 (2023): 4952.</Citation></Reference><Reference><Citation>C. T. Viet, X. Zhang, K. Xu, et&#xa0;al., &#x201c;Brush Swab as a Noninvasive Surrogate for Tissue Biopsies in Epigenomic Profiling of Oral Cancer,&#x201d; Biomarker Research 9, no. 1 (2021): 90.</Citation></Reference><Reference><Citation>M. C. Liu, G. R. Oxnard, E. A. Klein, et&#xa0;al., &#x201c;Sensitive and Specific Multi&#x2010;Cancer Detection and Localization Using Methylation Signatures in Cell&#x2010;Free DNA,&#x201d; Annals of Oncology 31, no. 6 (2020): 745&#x2013;759.</Citation></Reference><Reference><Citation>V. Mishra, A. Singh, X. Chen, et&#xa0;al., &#x201c;Application of Liquid Biopsy as Multi&#x2010;Functional Biomarkers in Head and Neck Cancer,&#x201d; British Journal of Cancer 126, no. 3 (2022): 361&#x2013;370.</Citation></Reference><Reference><Citation>B. Ilhan, P. Guneri, and P. Wilder&#x2010;Smith, &#x201c;The Contribution of Artificial Intelligence to Reducing the Diagnostic Delay in Oral Cancer,&#x201d; Oral Oncology 116 (2021): 105254.</Citation></Reference><Reference><Citation>J. S. Kim, B. G. Kim, and S. H. Hwang, &#x201c;Efficacy of Artificial Intelligence&#x2010;Assisted Discrimination of Oral Cancerous Lesions From Normal Mucosa Based on the Oral Mucosal Image: A Systematic Review and Meta&#x2010;Analysis,&#x201d; Cancers (Basel) 14, no. 14 (2022): 3499.</Citation></Reference><Reference><Citation>W. E. Board, Head and Neck Tumours (WHO Classification of Tumours Series), vol. 9, 5th ed. (International Agency for Research on Cancer, 2022).</Citation></Reference><Reference><Citation>T. Saito, C. Sugiura, A. Hirai, et&#xa0;al., &#x201c;Development of Squamous Cell Carcinoma From Pre&#x2010;Existent Oral Leukoplakia: With Respect to Treatment Modality,&#x201d; International Journal of Oral and Maxillofacial Surgery 30, no. 1 (2001): 49&#x2013;53.</Citation></Reference><Reference><Citation>H. M. Mehanna, T. Rattay, J. Smith, and C. C. McConkey, &#x201c;Treatment and Follow&#x2010;Up of Oral Dysplasia &#x2010; a Systematic Review and Meta&#x2010;Analysis,&#x201d; Head &amp; Neck 31, no. 12 (2009): 1600&#x2013;1609.</Citation></Reference><Reference><Citation>D. J. Fischer, J. B. Epstein, T. H. Morton, Jr., and S. M. Schwartz, &#x201c;Interobserver Reliability in the Histopathologic Diagnosis of Oral Pre&#x2010;Malignant and Malignant Lesions,&#x201d; Journal of Oral Pathology &amp; Medicine 33, no. 2 (2004): 65&#x2013;70.</Citation></Reference><Reference><Citation>M. Sperandio, S. Warnakulasuriya, A. B. Soares, et&#xa0;al., &#x201c;Oral Epithelial Dysplasia Grading: Comparing the Binary System to the Traditional 3&#x2010;Tier System, an Actuarial Study With Malignant Transformation as Outcome,&#x201d; Journal of Oral Pathology &amp; Medicine 52 (2022): 418&#x2013;425.</Citation></Reference><Reference><Citation>M. Hadilou, N. Mahdavi, E. Keykha, A. Ghofrani, E. Tahmasebi, and M. Arabfard, &#x201c;Artificial Intelligence Based Vision Transformer Application for Grading Histopathological Images of Oral Epithelial Dysplasia: A Step Towards AI&#x2010;Driven Diagnosis,&#x201d; BMC Cancer 25, no. 1 (2025): 780.</Citation></Reference><Reference><Citation>Y. Liu, E. Bilodeau, B. Pollack, and K. Batmanghelich, &#x201c;Automated Detection of Premalignant Oral Lesions on Whole Slide Images Using Convolutional Neural Networks,&#x201d; Oral Oncology 134 (2022): 106109.</Citation></Reference><Reference><Citation>A. J. Shephard, H. Mahmood, S. E. A. Raza, et&#xa0;al., &#x201c;Development and Validation of an Artificial Intelligence&#x2010;Based Pipeline for Predicting Oral Epithelial Dysplasia Malignant Transformation,&#x201d; Commun Med (Lond) 5, no. 1 (2025): 186.</Citation></Reference><Reference><Citation>A. Ferrer&#x2010;Sanchez, J. Bagan, J. Vila&#x2010;Franc&#xe9;s, R. Magdalena&#x2010;Benedito, and L. Bagan&#x2010;Debon, &#x201c;Prediction of the Risk of Cancer and the Grade of Dysplasia in Leukoplakia Lesions Using Deep Learning,&#x201d; Oral Oncology 132 (2022): 105967.</Citation></Reference><Reference><Citation>H. Mahmood, A. Shephard, P. Hankinson, et&#xa0;al., &#x201c;Development and Validation of a Multivariable Model for Prediction of Malignant Transformation and Recurrence of Oral Epithelial Dysplasia,&#x201d; British Journal of Cancer 129, no. 10 (2023): 1599&#x2013;1607.</Citation></Reference><Reference><Citation>T. D. Maxime Oquab, T. Moutakanni, H. Vo, et&#xa0;al., &#x201c;DINOv2: Learning Robust Visual Features Without Supervision,&#x201d; in Computer Vision and Pattern Recognition (Microtome Publishing, 2023).</Citation></Reference><Reference><Citation>S. Takahashi, Y. Sakaguchi, N. Kouno, et&#xa0;al., &#x201c;Comparison of Vision Transformers and Convolutional Neural Networks in Medical Image Analysis: A Systematic Review,&#x201d; Journal of Medical Systems 48, no. 1 (2024): 84.</Citation></Reference><Reference><Citation>M. Gadermayr and M. Tschuchnig, &#x201c;Multiple Instance Learning for Digital Pathology: A Review of the State&#x2010;Of&#x2010;The&#x2010;Art, Limitations &amp; Future Potential,&#x201d; Computerized Medical Imaging and Graphics 112 (2024): 102337.</Citation></Reference><Reference><Citation>J. Li, Y. F. Zhou, M. J. Zhang, et&#xa0;al., &#x201c;Next&#x2010;Generation AI Framework for Comprehensive Oral Leukoplakia Evaluation and Management,&#x201d; npj Digital Medicine 8, no. 1 (2025): 513.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70147 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41451817</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Dec</Month><Day>26</Day></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Efficacy of Multimodal Work-Up of Head and Neck Squamous Cell Carcinoma Lymph Node Metastasis of Unknown Primary.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70147</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Head and neck squamous cell carcinoma (HNSCC) often presents with cervical lymph node metastasis, with 1%-4% of cases presenting as cancer of unknown primary (CUP). CUP poses diagnostic and therapeutic challenges and is linked to poorer survival outcomes. Its incidence is expected to rise with the increasing prevalence of HPV-positive HNSCC. This study evaluated the use of MRI, <sup>18</sup>F-FDG PET, examination under anesthesia (EUA), and TORS-assisted tonsillectomy and tongue base mucosectomy (TORS-TE/TBM) in the work-up of CUP.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This single-center retrospective study included 79 patients with cytologically confirmed CUP (years 2019-2024). HPV-positive (n&#x2009;=&#x2009;51) and HPV-negative (n&#x2009;=&#x2009;28) cases were evaluated separately. Primary tumor detection rates for MRI, <sup>18</sup>F-FDG PET and EUA were calculated. For HPV-positive tumors TORS-TE/TBM was additionally evaluated for primary tumor detection.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In HPV-positive cases MRI and <sup>18</sup>F-FDG PET had detection rates of 45% individually (respectively) and 53% combined. Of detected cases, 37% were identified by a single modality. Post-hoc image review increased the detection rate to 63%. Subsequent imaging-guided EUA had a detection rate of 68%. When TORS-TE/TBM was performed after negative EUA, tumor detection occurred in 50% of cases. Multimodal work-up resulted in an over-all detection rate of 75%. In contrast, HPV-negative cases had a lower over-all multimodal detection rate of 39%.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">MRI and <sup>18</sup>F-FDG PET each play a pivotal and complimentary role for the detection of primary tumors in HNSCC CUP. Image-guided EUA and, in selected cases, TORS-TE/TBM further improve detection. A multimodal approach including expert imaging interpretation is recommended for optimal tumor identification and treatment planning.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). Head &amp; Neck published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jansen</LastName><ForeName>Robin W</ForeName><Initials>RW</Initials><Identifier Source="ORCID">0000-0003-0347-1919</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam UMC, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martens</LastName><ForeName>Roland M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam UMC, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdulrahman</LastName><ForeName>Obaida</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam UMC, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peferoen</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam UMC, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leemans</LastName><ForeName>C Ren&#xe9;</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam UMC, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zwezerijnen</LastName><ForeName>Gerben J C</ForeName><Initials>GJC</Initials><AffiliationInfo><Affiliation>Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam UMC, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hendrickx</LastName><ForeName>Jan-Jaap</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam UMC, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Graaf</LastName><ForeName>Pim</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam UMC, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">18F&#x2010;FDG PET</Keyword><Keyword MajorTopicYN="N">EUA</Keyword><Keyword MajorTopicYN="N">MRI</Keyword><Keyword MajorTopicYN="N">head &amp; neck carcinoma unknown primary</Keyword><Keyword MajorTopicYN="N">head and neck squamous cell carcinoma</Keyword><Keyword MajorTopicYN="N">trans&#x2010;oral surgical techniques</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>12</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>26</Day><Hour>13</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>26</Day><Hour>13</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>26</Day><Hour>6</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41451817</ArticleId><ArticleId IdType="doi">10.1002/hed.70147</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>A. Barsouk, J. S. Aluru, P. Rawla, K. Saginala, and A. Barsouk, &#x201c;Epidemiology, Risk Factors, and Prevention of Head and Neck Squamous Cell Carcinoma,&#x201d; Medical Science 11 (2023): 42.</Citation></Reference><Reference><Citation>K. Motz, J. R. Qualliotine, E. Rettig, J. D. Richmon, D. W. Eisele, and C. Fakhry, &#x201c;Changes in Unknown Primary Squamous Cell Carcinoma of the Head and Neck at Initial Presentation in the Era of Human Papillomavirus,&#x201d; JAMA Otolaryngology. Head &amp; Neck Surgery 142 (2016): 223&#x2013;228.</Citation></Reference><Reference><Citation>T. J. Galloway and J. A. Ridge, &#x201c;Management of Squamous Cancer Metastatic to Cervical Nodes With an Unknown Primary Site,&#x201d; Journal of Clinical Oncology 33 (2015): 3328&#x2013;3337.</Citation></Reference><Reference><Citation>F. dos Santos Menezes, G. A. Fernandes, J. L. F. Antunes, L. L. Villa, and T. N. Toporcov, &#x201c;Global Incidence Trends in Head and Neck Cancer for HPV&#x2010;Related And&#x2010;Unrelated Subsites: A Systematic Review of Population&#x2010;Based Studies,&#x201d; Oral Oncology 115 (2021): 105177.</Citation></Reference><Reference><Citation>E. Rassy, P. Nicolai, and N. Pavlidis, &#x201c;Comprehensive Management of HPV&#x2010;Related Squamous Cell Carcinoma of the Head and Neck of Unknown Primary,&#x201d; Head &amp; Neck 41 (2019): 3700&#x2013;3711.</Citation></Reference><Reference><Citation>M. H. H. Larsen, H. I. Channir, and C. von Buchwald, &#x201c;Human Papillomavirus and Squamous Cell Carcinoma of Unknown Primary in the Head and Neck Region: A Comprehensive Review on Clinical Implications,&#x201d; Viruses 13 (2021): 1297.</Citation></Reference><Reference><Citation>C. Demiroz, J. M. Vainshtein, G. V. Koukourakis, et&#xa0;al., &#x201c;Head and Neck Squamous Cell Carcinoma of Unknown Primary: Neck Dissection and Radiotherapy or Definitive Radiotherapy,&#x201d; Head &amp; Neck 36 (2014): 1589&#x2013;1595.</Citation></Reference><Reference><Citation>R. M. Martens, R. Stappen, T. Koopman, et&#xa0;al., &#x201c;The Additional Value of Ultrafast DCE&#x2010;MRI to DWI&#x2010;MRI and 18F&#x2010;FDG&#x2010;PET to Detect Occult Primary Head and Neck Squamous Cell Carcinoma,&#x201d; Cancers 12 (2020): 2826.</Citation></Reference><Reference><Citation>E. Maghami, N. Ismaila, A. Alvarez, et&#xa0;al., &#x201c;Diagnosis and Management of Squamous Cell Carcinoma of Unknown Primary in the Head and Neck: ASCO Guideline,&#x201d; Journal of Clinical Oncology 38 (2020): 2570&#x2013;2596.</Citation></Reference><Reference><Citation>L. M. Keller, T. J. Galloway, T. Holdbrook, et&#xa0;al., &#x201c;p16 Status, Pathologic and Clinical Characteristics, Biomolecular Signature, and Long&#x2010;Term Outcomes in Head and Neck Squamous Cell Carcinomas of Unknown Primary,&#x201d; Head &amp; Neck 36 (2014): 1677&#x2013;1684.</Citation></Reference><Reference><Citation>L. Schroeder, M. Pring, K. Ingarfield, et&#xa0;al., &#x201c;HPV Driven Squamous Cell Head and Neck Cancer of Unknown Primary Is Likely to Be HPV Driven Squamous Cell Oropharyngeal Cancer,&#x201d; Oral Oncology 107 (2020): 104721.</Citation></Reference><Reference><Citation>M. Filauro, A. Paderno, P. Perotti, et&#xa0;al., &#x201c;Role of Narrow&#x2010;Band Imaging in Detection of Head and Neck Unknown Primary Squamous Cell Carcinoma,&#x201d; Laryngoscope 128 (2018): 2060&#x2013;2066.</Citation></Reference><Reference><Citation>M. A. Pynnonen, M. B. Gillespie, B. Roman, et&#xa0;al., &#x201c;Clinical Practice Guideline: Evaluation of the Neck Mass in Adults,&#x201d; Otolaryngology and Head and Neck Surgery 157 (2017): S1&#x2013;S30.</Citation></Reference><Reference><Citation>F. J. Civantos, J. B. Vermorken, J. P. Shah, et&#xa0;al., &#x201c;Metastatic Squamous Cell Carcinoma to the Cervical Lymph Nodes From an Unknown Primary Cancer: Management in the HPV Era,&#x201d; Frontiers in Oncology 10 (2020): 593164.</Citation></Reference><Reference><Citation>R. D. Chernock and J. S. Lewis, &#x201c;Approach to Metastatic Carcinoma of Unknown Primary in the Head and Neck: Squamous Cell Carcinoma and Beyond,&#x201d; Head and Neck Pathology 9 (2015): 6&#x2013;15.</Citation></Reference><Reference><Citation>J. F. Ryan, K. M. Motz, L. M. Rooper, et&#xa0;al., &#x201c;The Impact of a Stepwise Approach to Primary Tumor Detection in Squamous Cell Carcinoma of the Neck With Unknown Primary,&#x201d; Laryngoscope 129 (2019): 1610&#x2013;1616.</Citation></Reference><Reference><Citation>P. Golusinski, P. Di Maio, B. Pehlivan, et&#xa0;al., &#x201c;Evidence for the Approach to the Diagnostic Evaluation of Squamous Cell Carcinoma Occult Primary Tumors of the Head and Neck,&#x201d; Oral Oncology 88 (2019): 145&#x2013;152.</Citation></Reference><Reference><Citation>C. K. Sudoko, M. A. Polacco, B. J. Gosselin, and J. A. Paydarfar, &#x201c;Diagnostic Value of Lingual Tonsillectomy in Unknown Primary Head and Neck Carcinoma Identification After a Negative Clinical Workup and Positron Emission Tomography&#x2010;Computed Tomography,&#x201d; Frontiers in Oncology 8 (2018): 118.</Citation></Reference><Reference><Citation>S. van Weert, J. A. Rijken, F. Plantone, et&#xa0;al., &#x201c;A Systematic Review on Transoral Robotic Surgery (TORS) for Carcinoma of Unknown Primary Origin: Has Tongue Base Mucosectomy Become Indispensable?,&#x201d; Clinical Otolaryngology 45 (2020): 732&#x2013;738.</Citation></Reference><Reference><Citation>A. De Virgilio, A. Costantino, D. Rizzo, et&#xa0;al., &#x201c;Do We Have Enough Evidence to Specifically Recommend Transoral Robotic Surgery in HPV&#x2010;Driven Oropharyngeal Cancer? A Systematic Review,&#x201d; Pathogens 12 (2023): 160.</Citation></Reference><Reference><Citation>K. K. Gupta, H. Khan, Z. Mughal, M. De, N. Sharma, and G. Garas, &#x201c;Primary Tumour Detection in Carcinoma of Unknown Primary With Transoral Robotic Surgery (TORS) Tongue Base Mucosectomy: A Meta&#x2010;Analysis,&#x201d; Annals of Surgical Oncology 31 (2024): 6065&#x2013;6076.</Citation></Reference><Reference><Citation>M. Lanzer, S. Bachna&#x2010;Rotter, M. Graupp, et&#xa0;al., &#x201c;Unknown Primary of the Head and Neck: A Long&#x2010;Term Follow&#x2010;Up,&#x201d; Journal of Cranio&#x2010;Maxillofacial Surgery 43 (2015): 574&#x2013;579.</Citation></Reference><Reference><Citation>G. Madani, Z. Arain, and Z. Awad, &#x201c;The Radiological Unknown Primary of the Head and Neck: Recommendations for Imaging Strategies Based on a Systematic Review,&#x201d; Clinical Otolaryngology 49 (2024): 16&#x2013;28.</Citation></Reference><Reference><Citation>J. C. Hardman, J. Constable, A. Williamson, et&#xa0;al., &#x201c;Investigations for Suspected Head and Neck Squamous Cell Carcinoma of Unknown Primary (HNSCCUP): A National Cohort Study,&#x201d; Clinical Otolaryngology 50 (2025): 462&#x2013;473.</Citation></Reference><Reference><Citation>J. R. Lee, J. S. Kim, J. L. Roh, et&#xa0;al., &#x201c;Detection of Occult Primary Tumors in Patients With Cervical Metastases of Unknown Primary Tumors: Comparison of (18)F FDG PET/CT With Contrast&#x2010;Enhanced CT or CT/MR Imaging&#x2010;Prospective Study,&#x201d; Radiology 274 (2015): 764&#x2013;771.</Citation></Reference><Reference><Citation>M. Godeny, Z. Lengyel, G. Polony, et&#xa0;al., &#x201c;Impact of 3T Multiparametric MRI and FDG&#x2010;PET&#x2010;CT in the Evaluation of Occult Primary Cancer With Cervical Node Metastasis,&#x201d; Cancer Imaging 16 (2016): 38.</Citation></Reference><Reference><Citation>D. P. Noij, R. M. Martens, B. Zwezerijnen, et&#xa0;al., &#x201c;Diagnostic Value of Diffusion&#x2010;Weighted Imaging and 18F&#x2010;FDG&#x2010;PET/CT for the Detection of Unknown Primary Head and Neck Cancer in Patients Presenting With Cervical Metastasis,&#x201d; European Journal of Radiology 107 (2018): 20&#x2013;25.</Citation></Reference><Reference><Citation>S. Van Weert, J.&#x2010;J. Hendrickx, and C. R. Leemans, &#x201c;Carcinoma of Unknown Primary: Diagnostics and the Potential of Transoral Surgery,&#x201d; in Critical Issues in Head and Neck Oncology: Key Concepts From the Eighth THNO Meeting (Springer International Publishing, 2023), 179&#x2013;197.</Citation></Reference><Reference><Citation>M. W. Chan, E. Yu, E. Bartlett, et&#xa0;al., &#x201c;Morphologic and Topographic Radiologic Features of Human Papillomavirus&#x2010;Related and &#x2010;Unrelated Oropharyngeal Carcinoma,&#x201d; Head &amp; Neck 39 (2017): 1524&#x2013;1534.</Citation></Reference><Reference><Citation>M. Ravanelli, A. Grammatica, E. Tononcelli, et&#xa0;al., &#x201c;Correlation Between Human Papillomavirus Status and Quantitative MR Imaging Parameters Including Diffusion&#x2010;Weighted Imaging and Texture Features in Oropharyngeal Carcinoma,&#x201d; AJNR. American Journal of Neuroradiology 39 (2018): 1878&#x2013;1883.</Citation></Reference><Reference><Citation>A. K. Tahari, K. C. Alluri, H. Quon, W. Koch, R. L. Wahl, and R. M. Subramaniam, &#x201c;FDG PET/CT Imaging of Oropharyngeal Squamous Cell Carcinoma: Characteristics of Human Papillomavirus&#x2010;Positive and &#x2010;Negative Tumors,&#x201d; Clinical Nuclear Medicine 39 (2014): 225&#x2013;231.</Citation></Reference><Reference><Citation>M. S. Hofman and R. J. Hicks, &#x201c;How We Read Oncologic FDG PET/CT,&#x201d; Cancer Imaging 16 (2016): 1&#x2013;14.</Citation></Reference><Reference><Citation>M. Albertson, S. Chandra, Z. Sayed, and C. Johnson, &#x201c;PET/CT Evaluation of Head and Neck Cancer of Unknown Primary,&#x201d; in Seminars in Ultrasound, CT and MRI, vol. 40 (Elsevier, 2019), 414&#x2013;423.</Citation></Reference><Reference><Citation>M. Faisal, N.&#x2010;S. Le, S. Grasl, et&#xa0;al., &#x201c;Carcinoma of Unknown Primary (CUP) Versus CUP Turned to Primary Carcinoma of the Head and Neck&#x2014;An Analysis of Diagnostic Methods and the Impact of Primary Tumor on Clinical Outcome,&#x201d; Diagnostics 12 (2022): 894.</Citation></Reference><Reference><Citation>M. Y. Lee, N. Fowler, D. Adelstein, S. Koyfman, B. Prendes, and B. B. Burkey, &#x201c;Detection and Oncologic Outcomes of Head and Neck Squamous Cell Carcinoma of Unknown Primary Origin,&#x201d; Anticancer Research 40 (2020): 4207&#x2013;4214.</Citation></Reference><Reference><Citation>M. W. Kubik, H. I. Channir, N. Rubek, et&#xa0;al., &#x201c;TORS Base&#x2010;Of&#x2010;Tongue Mucosectomy in Human Papilloma Virus&#x2010;Negative Carcinoma of Unknown Primary,&#x201d; Laryngoscope 131 (2021): 78&#x2013;81.</Citation></Reference><Reference><Citation>D. Wang, T. Zou, T. Gao, et&#xa0;al., &#x201c;Diagnosis and Prognosis of Different Methods of Tongue Base Mucosectomy for Occult Head and Neck Cancer: A Systematic Review and Meta&#x2010;Analysis,&#x201d; Medicine 103 (2024): e40250.</Citation></Reference><Reference><Citation>F. A. van der Scheer, F. Jansen, S. E. J. Eerenstein, et&#xa0;al., &#x201c;Swallowing Outcomes After Transoral Robotic Surgery and Adjuvant Treatment in Unknown Primary,&#x201d; Oral Diseases 30 (2024): 4830&#x2013;4837.</Citation></Reference><Reference><Citation>S. Farooq, S. Khandavilli, J. Dretzke, et&#xa0;al., &#x201c;Transoral Tongue Base Mucosectomy for the Identification of the Primary Site in the Work&#x2010;Up of Cancers of Unknown Origin: Systematic Review and Meta&#x2010;Analysis,&#x201d; Oral Oncology 91 (2019): 97&#x2013;106.</Citation></Reference><Reference><Citation>S. Winter, E. Ofo, D. Meikle, et&#xa0;al., &#x201c;Trans&#x2010;Oral Robotic Assisted Tongue Base Mucosectomy for Investigation of Cancer of Unknown Primary in the Head and Neck Region. The UK Experience,&#x201d; Clinical Otolaryngology 42 (2017): 1247&#x2013;1251.</Citation></Reference><Reference><Citation>S. A. Patel, A. Parvathaneni, U. Parvathaneni, et&#xa0;al., &#x201c;Post&#x2010;Operative Therapy Following Transoral Robotic Surgery for Unknown Primary Cancers of the Head and Neck,&#x201d; Oral Oncology 72 (2017): 150&#x2013;156.</Citation></Reference><Reference><Citation>H. I. Channir, N. Rubek, H. U. Nielsen, et&#xa0;al., &#x201c;Transoral Robotic Surgery for the Management of Head and Neck Squamous Cell Carcinoma of Unknown Primary,&#x201d; Acta Oto&#x2010;Laryngologica 135 (2015): 1051&#x2013;1057.</Citation></Reference><Reference><Citation>C. M. Yver, D. Shimunov, G. S. Weinstein, et&#xa0;al., &#x201c;Oncologic and Survival Outcomes for Resectable Locally&#x2010;Advanced HPV&#x2010;Related Oropharyngeal Cancer Treated With Transoral Robotic Surgery,&#x201d; Oral Oncology 118 (2021): 105307.</Citation></Reference><Reference><Citation>F. C. A. Xavier, J. C. Silva, C. O. Rodini, and M. Rodrigues, &#x201c;Mechanisms of Immune Evasion by Head and Neck Cancer Stem Cells,&#x201d; Frontiers in Oral Health 3 (2022): 957310.</Citation></Reference><Reference><Citation>K. L. Kostecki, M. Iida, B. E. Crossman, et&#xa0;al., &#x201c;Immune Escape Strategies in Head and Neck Cancer: Evade, Resist, Inhibit, Recruit,&#x201d; Cancers 16 (2024): 312.</Citation></Reference><Reference><Citation>T. Muijlwijk, D. Nijenhuis, S. H. Ganzevles, et&#xa0;al., &#x201c;Comparative Analysis of Immune Infiltrates in Head and Neck Cancers Across Anatomical Sites,&#x201d; Journal for Immunotherapy of Cancer 12 (2024): e007573.</Citation></Reference><Reference><Citation>F. Bochen, H. Adisurya, S. Wemmert, et&#xa0;al., &#x201c;Effect of 3q Oncogenes SEC62 and SOX2 on Lymphatic Metastasis and Clinical Outcome of Head and Neck Squamous Cell Carcinomas,&#x201d; Oncotarget 8 (2017): 4922&#x2013;4934.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70140 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41450282</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Dec</Month><Day>26</Day></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Survival Impact of Immunotherapy in Advanced Head and Neck Squamous Cell Carcinoma: A National Cancer Database Analysis.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70140</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">We evaluated the association between immunotherapy (IO) and overall survival (OS) in advanced head and neck squamous cell carcinoma (HNSCC) and examined outcomes by IO timing.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Retrospective cohort study of national NCDB 2004-2022 United States adults with Stages III-IVB HNSCC. Exposure was any IO. The primary outcome was OS from diagnosis; analyses used multivariable Cox models, 24-month landmarking, and propensity methods.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 221&#x2009;116 patients (mean age: 62), 10&#x2009;023 (4.5%) received IO. Median follow-up 37 months. IO was associated with lower mortality (HR: 0.91; 95% CI: 0.89-0.94). Landmark analysis showed benefit 0-24 months (HR: 0.76; 0.74-0.79) that reversed thereafter (HR: 1.09; 1.04-1.14). By intent, median OS was 53.2 months (neoadjuvant), 50.1 months (adjuvant), 16.5 months (later-line), versus 60.7 months without IO. Propensity analyses attenuated effects (HR: ~1.00).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In real-world advanced HNSCC, IO confers modest early benefit with varied long-term results; outcomes vary by timing. Prospective biomarker-stratified trials are needed.</AbstractText><CopyrightInformation>&#xa9; 2025 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vuppala</LastName><ForeName>Rohan</ForeName><Initials>R</Initials><Identifier Source="ORCID">0009-0002-3320-7684</Identifier><AffiliationInfo><Affiliation>Medical College of Georgia, Augusta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Long</LastName><ForeName>Sallie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Medical College of Georgia, Augusta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharbel</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Medical College of Georgia, Augusta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weir</LastName><ForeName>Forest</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Medical College of Georgia, Augusta, Georgia, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">National Cancer Database</Keyword><Keyword MajorTopicYN="N">head and neck squamous cell carcinoma</Keyword><Keyword MajorTopicYN="N">immune checkpoint inhibitors</Keyword><Keyword MajorTopicYN="N">landmark analysis</Keyword><Keyword MajorTopicYN="N">overall survival</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>12</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>12</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>26</Day><Hour>7</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>26</Day><Hour>7</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>26</Day><Hour>4</Hour><Minute>24</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41450282</ArticleId><ArticleId IdType="doi">10.1002/hed.70140</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>F. Bray, M. Laversanne, H. Sung, et&#xa0;al., &#x201c;Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,&#x201d; CA: A Cancer Journal for Clinicians 74, no. 3 (2024): 229&#x2013;263, https://doi.org/10.3322/caac.21834.</Citation></Reference><Reference><Citation>D. E. Johnson, B. Burtness, C. R. Leemans, V. W. Y. Lui, J. E. Bauman, and J. R. Grandis, &#x201c;Head and Neck Squamous Cell Carcinoma,&#x201d; Nature Reviews Disease Primers 6, no. 1 (2020): 92, https://doi.org/10.1038/s41572&#x2010;020&#x2010;00224&#x2010;3.</Citation></Reference><Reference><Citation>R. L. Siegel, K. D. Miller, and A. Jemal, &#x201c;Cancer Statistics, 2020,&#x201d; CA: A Cancer Journal for Clinicians 70, no. 1 (2020): 7&#x2013;30, https://doi.org/10.3322/caac.21590.</Citation></Reference><Reference><Citation>S. P. Ramkumar, A. Bhardwaj, A. Patel, et&#xa0;al., &#x201c;Differences in Receipt of Immunotherapy Treatment Among Patients With Head and Neck Cancer,&#x201d; JAMA Otolaryngology. Head &amp; Neck Surgery 149, no. 10 (2023): 912&#x2013;918, https://doi.org/10.1001/jamaoto.2023.2420.</Citation></Reference><Reference><Citation>N. Osazuwa&#x2010;Peters, K. M. Christopher, A. S. Hussaini, A. Behera, R. J. Walker, and M. A. Varvares, &#x201c;Predictors of Stage at Presentation and Outcomes of Head and Neck Cancers in a University Hospital Setting,&#x201d; Head &amp; Neck 38, no. 1 (2016): E1826&#x2013;E1832, https://doi.org/10.1002/hed.24327.</Citation></Reference><Reference><Citation>D. B. Taylor, O. L. Osazuwa&#x2010;Peters, S. I. Okafor, et&#xa0;al., &#x201c;Differential Outcomes Among Survivors of Head and Neck Cancer Belonging to Racial and Ethnic Minority Groups,&#x201d; JAMA Otolaryngology. Head &amp; Neck Surgery 148, no. 2 (2022): 119&#x2013;127, https://doi.org/10.1001/jamaoto.2021.3425.</Citation></Reference><Reference><Citation>M. Guller, D. J. Cooper, H. Alkhatib, et&#xa0;al., &#x201c;Impact of Comorbidities on Outcomes in Patients With Advanced Head and Neck Cancer Undergoing Immunotherapy,&#x201d; Head &amp; Neck 45, no. 11 (2023): 2789&#x2013;2797, https://doi.org/10.1002/hed.27502.</Citation></Reference><Reference><Citation>J. R. Wang, S. Habbous, O. Espin&#x2010;Garcia, et&#xa0;al., &#x201c;Comorbidity and Performance Status as Independent Prognostic Factors in Patients With Head and Neck Squamous Cell Carcinoma,&#x201d; Head &amp; Neck 38, no. 5 (2016): 736&#x2013;742, https://doi.org/10.1002/hed.23947.</Citation></Reference><Reference><Citation>S. K. Gadkaree, J. C. McCarty, J. Siu, et&#xa0;al., &#x201c;Variation in the Geographic Distribution of the Otolaryngology Workforce: A National Geospatial Analysis,&#x201d; Otolaryngology 162, no. 5 (2020): 649&#x2013;657, https://doi.org/10.1177/0194599820908860.</Citation></Reference><Reference><Citation>F. Dayyani, C. J. Etzel, M. Liu, C. H. Ho, S. M. Lippman, and A. S. Tsao, &#x201c;Meta&#x2010;Analysis of the Impact of Human Papillomavirus (HPV) on Cancer Risk and Overall Survival in Head and Neck Squamous Cell Carcinomas (HNSCC),&#x201d; Head &amp; Neck Oncology 2 (2010): 15, https://doi.org/10.1186/1758&#x2010;3284&#x2010;2&#x2010;15.</Citation></Reference><Reference><Citation>A. K. Chaturvedi, E. A. Engels, R. M. Pfeiffer, et&#xa0;al., &#x201c;Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States,&#x201d; Journal of Clinical Oncology 29, no. 32 (2011): 4294&#x2013;4301, https://doi.org/10.1200/JCO.2011.36.4596.</Citation></Reference><Reference><Citation>S. Marur, G. D'Souza, W. H. Westra, and A. A. Forastiere, &#x201c;HPV&#x2010;Associated Head and Neck Cancer: A Virus&#x2010;Related Cancer Epidemic&#x2014;A Review of Epidemiology, Biology, Virus Detection and Issues in Management,&#x201d; Lancet Oncology 11, no. 8 (2010): 781&#x2013;789, https://doi.org/10.1016/S1470&#x2010;2045(10)70017&#x2010;6.</Citation></Reference><Reference><Citation>M. L. Gillison, &#x201c;Human Papillomavirus&#x2010;Associated Head and Neck Cancer Is a Distinct Epidemiologic, Clinical, and Molecular Entity,&#x201d; Seminars in Oncology 31, no. 6 (2004): 744&#x2013;754, https://doi.org/10.1053/j.seminoncol.2004.09.011.</Citation></Reference><Reference><Citation>K. K. Ang, J. Harris, R. Wheeler, et&#xa0;al., &#x201c;Human Papillomavirus and Survival of Patients With Oropharyngeal Cancer,&#x201d; New England Journal of Medicine 363, no. 1 (2010): 24&#x2013;35, https://doi.org/10.1056/NEJMoa0912217.</Citation></Reference><Reference><Citation>C. R. Leemans, P. J. F. Snijders, and R. H. Brakenhoff, &#x201c;The Molecular Landscape of Head and Neck Cancer,&#x201d; Nature Reviews Cancer 18, no. 5 (2018): 269&#x2013;282, https://doi.org/10.1038/nrc.2018.11.</Citation></Reference><Reference><Citation>R. L. Ferris, G. Blumenschein, J. Fayette, et&#xa0;al., &#x201c;Nivolumab for Recurrent Squamous&#x2010;Cell Carcinoma of the Head and Neck,&#x201d; New England Journal of Medicine 375, no. 19 (2016): 1856&#x2013;1867, https://doi.org/10.1056/NEJMoa1602252.</Citation></Reference><Reference><Citation>L. Q. M. Chow, R. Haddad, S. Gupta, et&#xa0;al., &#x201c;Antitumor Activity of Pembrolizumab in Biomarker&#x2010;Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE&#x2010;012 Expansion Cohort,&#x201d; Journal of Clinical Oncology 34, no. 32 (2016): 3838&#x2013;3845, https://doi.org/10.1200/JCO.2016.68.1478.</Citation></Reference><Reference><Citation>B. Burtness, K. J. Harrington, R. Greil, et&#xa0;al., &#x201c;Pembrolizumab Alone or With Chemotherapy Versus Cetuximab With Chemotherapy for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (KEYNOTE&#x2010;048): A Randomised, Open&#x2010;Label, Phase 3 Study,&#x201d; Lancet 394, no. 10212 (2019): 1915&#x2013;1928, https://doi.org/10.1016/S0140&#x2010;6736(19)32591&#x2010;7.</Citation></Reference><Reference><Citation>T. Y. Seiwert, B. Burtness, R. Mehra, et&#xa0;al., &#x201c;Safety and Clinical Activity of Pembrolizumab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (KEYNOTE&#x2010;012): An Open&#x2010;Label, Multicentre, Phase 1b Trial,&#x201d; Lancet Oncology 17, no. 7 (2016): 956&#x2013;965, https://doi.org/10.1016/S1470&#x2010;2045(16)30066&#x2010;3.</Citation></Reference><Reference><Citation>H. Shibata, S. Saito, and R. Uppaluri, &#x201c;Immunotherapy for Head and Neck Cancer: A Paradigm Shift From Induction Chemotherapy to Neoadjuvant Immunotherapy,&#x201d; Frontiers in Oncology 11 (2021): 727433, https://doi.org/10.3389/fonc.2021.727433.</Citation></Reference><Reference><Citation>J. Raphael, L. Richard, M. Lam, et&#xa0;al., &#x201c;Utilization of Immunotherapy in Patients With Cancer Treated in Routine Care Settings: A Population&#x2010;Based Study Using Health Administrative Data,&#x201d; Oncologist 27, no. 8 (2022): 675&#x2013;684, https://doi.org/10.1093/oncolo/oyac085.</Citation></Reference><Reference><Citation>C. M. Black, G. J. Hanna, L. Wang, et&#xa0;al., &#x201c;Real&#x2010;World Treatment Patterns and Outcomes Among Individuals Receiving First&#x2010;Line Pembrolizumab Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma,&#x201d; Frontiers in Oncology 13 (2023): 1160144, https://doi.org/10.3389/fonc.2023.1160144.</Citation></Reference><Reference><Citation>R. Uppaluri, R. I. Haddad, Y. Tao, et&#xa0;al., &#x201c;Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer,&#x201d; New England Journal of Medicine 393, no. 1 (2025): 37&#x2013;50, https://doi.org/10.1056/NEJMoa2415434.</Citation></Reference><Reference><Citation>J. Bourhis, A. Auperin, C. Borel, et&#xa0;al., &#x201c;NIVOPOSTOP (GORTEC 2018&#x2010;01): A Phase III Randomized Trial of Adjuvant Nivolumab Added to Radio&#x2010;Chemotherapy in Patients With Resected Head and Neck Squamous Cell Carcinoma at High Risk of Relapse,&#x201d; Journal of Clinical Oncology 43 (2025): LBA2, https://doi.org/10.1200/JCO.2025.43.17_suppl.LBA2.</Citation></Reference><Reference><Citation>ACS, &#x201c;National Cancer Database,&#x201d; accessed May 18, 2025, https://www.facs.org/quality&#x2010;programs/cancer&#x2010;programs/national&#x2010;cancer&#x2010;database/.</Citation></Reference><Reference><Citation>T. A. Janz, E. M. Graboyes, S. A. Nguyen, et&#xa0;al., &#x201c;A Comparison of the NCDB and SEER Database for Research Involving Head and Neck Cancer,&#x201d; Otolaryngology &#x2013; Head and Neck Surgery 160, no. 2 (2019): 284&#x2013;294, https://doi.org/10.1177/0194599818792205.</Citation></Reference><Reference><Citation>E. von Elm, D. G. Altman, M. Egger, S. J. Pocock, P. C. G&#xf8;tzsche, and J. P. Vandenbroucke, &#x201c;The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies,&#x201d; Lancet 370, no. 9596 (2007): 1453&#x2013;1457, https://doi.org/10.1016/S0140&#x2010;6736(07)61602&#x2010;X.</Citation></Reference><Reference><Citation>A. Mohamed, B. Twardy, M. A. Zordok, et&#xa0;al., &#x201c;Concurrent Chemoradiotherapy With Weekly Versus Triweekly Cisplatin in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Comparative Analysis,&#x201d; Head &amp; Neck 41, no. 5 (2019): 1490&#x2013;1498, https://doi.org/10.1002/hed.25379.</Citation></Reference><Reference><Citation>M. Yao, C. Woods, P. Lavertu, et&#xa0;al., &#x201c;Phase II Study of Erlotinib and Docetaxel With Concurrent Intensity&#x2010;Modulated Radiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma,&#x201d; Head &amp; Neck 38, no. 1 (2016): E1770&#x2013;E1776, https://doi.org/10.1002/hed.24313.</Citation></Reference><Reference><Citation>A. M. Bur, J. A. Brant, C. L. Mulvey, et&#xa0;al., &#x201c;Association of Clinical Risk Factors and Postoperative Complications With Unplanned Hospital Readmission After Head and Neck Cancer Surgery,&#x201d; JAMA Otolaryngology. Head &amp; Neck Surgery 142, no. 12 (2016): 1184&#x2013;1190, https://doi.org/10.1001/jamaoto.2016.2807.</Citation></Reference><Reference><Citation>G. Omura, M. Ando, Y. Saito, K. Kobayashi, T. Yamasoba, and T. Asakage, &#x201c;Comorbidity as Predictor Poor Prognosis for Patients With Advanced Head and Neck Cancer Treated With Major Surgery,&#x201d; Head &amp; Neck 38, no. 3 (2016): 364&#x2013;369, https://doi.org/10.1002/hed.23897.</Citation></Reference><Reference><Citation>S. S. Vasudevan, I. A. Alvarez, C. A. O. Nathan, and J. Pang, &#x201c;Early Death in T3&#x2010;T4 Head and Neck Cancer: NCDB Comparison of Surgical vs. Non&#x2010;Surgical Approaches,&#x201d; Head &amp; Neck 47 (2025): 2058&#x2013;2068, https://doi.org/10.1002/hed.28193.</Citation></Reference><Reference><Citation>J. S. Brady, A. Norouzi, N. Konuthula, et&#xa0;al., &#x201c;Examining the Impact of Race and Sex on the Incidence of Positive Surgical Margins in Oral Cavity Squamous Cell Carcinoma,&#x201d; Head &amp; Neck 47, no. 5 (2025): 1512&#x2013;1519, https://doi.org/10.1002/hed.28075.</Citation></Reference><Reference><Citation>J. M. Moskovitz, J. Moy, T. Y. Seiwert, and R. L. Ferris, &#x201c;Immunotherapy for Head and Neck Squamous Cell Carcinoma: A Review of Current and Emerging Therapeutic Options,&#x201d; Oncologist 22, no. 6 (2017): 680&#x2013;693, https://doi.org/10.1634/theoncologist.2016&#x2010;0318.</Citation></Reference><Reference><Citation>A. E. Golfinos&#x2010;Owens, T. Lozar, P. Khatri, et&#xa0;al., &#x201c;Integrated Single&#x2010;Cell and Spatial Analysis Identifies Context&#x2010;Dependent Myeloid&#x2010;T Cell Interactions in Head and Neck Cancer Immune Checkpoint Blockade Response,&#x201d; preprint, bioRxiv, March 28, https://doi.org/10.1101/2025.03.24.644582.</Citation></Reference><Reference><Citation>P. Zolkind and R. Uppaluri, &#x201c;Checkpoint Immunotherapy in Head and Neck Cancers,&#x201d; Cancer Metastasis Reviews 36, no. 3 (2017): 475&#x2013;489, https://doi.org/10.1007/s10555&#x2010;017&#x2010;9694&#x2010;9.</Citation></Reference><Reference><Citation>E. Ward, A. Jemal, V. Cokkinides, et&#xa0;al., &#x201c;Cancer Disparities by Race/Ethnicity and Socioeconomic Status,&#x201d; CA: A Cancer Journal for Clinicians 54, no. 2 (2004): 78&#x2013;93, https://doi.org/10.3322/canjclin.54.2.78.</Citation></Reference><Reference><Citation>N. Gavrielatou, S. Doumas, P. Economopoulou, P. G. Foukas, and A. Psyrri, &#x201c;Biomarkers for Immunotherapy Response in Head and Neck Cancer,&#x201d; Cancer Treatment Reviews 84 (2020): 101977, https://doi.org/10.1016/j.ctrv.2020.101977.</Citation></Reference><Reference><Citation>B. R. Heath, N. L. Michmerhuizen, C. R. Donnelly, et&#xa0;al., &#x201c;Head and Neck Cancer Immunotherapy Beyond the Checkpoint Blockade,&#x201d; Journal of Dental Research 98, no. 10 (2019): 1073&#x2013;1080, https://doi.org/10.1177/0022034519864112.</Citation></Reference><Reference><Citation>A. Desilets and D. Souli&#xe8;res, &#x201c;Safety Evaluation of Pembrolizumab for Treating Recurrent Head and Neck Squamous Cell Carcinoma,&#x201d; Expert Opinion on Drug Safety 19, no. 8 (2020): 927&#x2013;934, https://doi.org/10.1080/14740338.2020.1775811.</Citation></Reference><Reference><Citation>D. Pereira, D. Martins, and F. Mendes, &#x201c;Immunotherapy in Head and Neck Cancer When, How, and Why?,&#x201d; Biomedicine 10, no. 9 (2022): 2151, https://doi.org/10.3390/biomedicines10092151.</Citation></Reference><Reference><Citation>R. Uppaluri, K. M. Campbell, A. M. Egloff, et&#xa0;al., &#x201c;Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus&#x2010;Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial,&#x201d; Clinical Cancer Research 26, no. 19 (2020): 5140&#x2013;5152, https://doi.org/10.1158/1078&#x2010;0432.CCR&#x2010;20&#x2010;1695.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70146 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41450235</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Dec</Month><Day>26</Day></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Targeted Radionuclide Therapy With <sup>131</sup>I-Labeled Anti-PD-L1 Antibody Suppresses Pharyngeal Squamous Cell Carcinoma in the Animal Model.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70146</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Pharyngeal squamous cell carcinoma (PSCC) is an aggressive subtype of head and neck squamous cell carcinoma (HNSCC) with poor prognosis and low survival rates. Immune checkpoint inhibitors (ICIs) show promise, but less than 20% of HNSCC patients respond positively. Targeted radionuclide therapy (TRT) combines radionuclides with monoclonal antibodies to target tumor cells. This study created a reliable animal model of PSCC for evaluating the therapeutic efficacy of <sup>131</sup>I-aPD-L1.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Nude mice were subcutaneously implanted with FaDu cells-a human PSCC cell line characterized by high PD-L1 expression. The synthesis of <sup>131</sup>I-aPD-L1 was optimized by varying labeling conditions, achieving a labeling efficiency of over 90%. Mice were divided into experimental and control groups; the experimental group received a single intravenous injection of 500&#x2009;&#x3bc;Ci <sup>131</sup>I-aPD-L1. Accumulation of <sup>131</sup>I-aPD-L1 in tumor tissues was confirmed by animal single-photon emission computed tomography (SPECT). Tumor volume and mouse body weight were measured every 3&#x2009;days for 30&#x2009;days. At the end of the study, tumor tissues were stained for histological examination and immunohistochemical analysis of Bcl-2 and Caspase-3 expression levels. Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay was also performed on tumor tissues.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">SPECT verified a significant accumulation of <sup>131</sup>I in FaDu tumor tissue. The experimental group exhibited significantly slower tumor volume increase compared to the control group (t&#x2009;=&#x2009;2.37, p&#x2009;&lt;&#x2009;0.05). Additionally, a significant reduction in body weight was observed in the <sup>131</sup>I-aPD-L1 group compared to the control group (t&#x2009;=&#x2009;5.624, p&#x2009;&lt;&#x2009;0.01). HE staining showed extensive tumor necrosis in the experimental group. Immunohistochemical analysis revealed negative Bcl-2 expression and higher caspase-3 expression in the experimental group, indicating enhanced apoptosis and necrosis in tumor cells. Furthermore, TUNEL assay further confirmed that <sup>131</sup>I exerted cytotoxic effects by inducing DNA fragmentation.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Collectively, our findings demonstrate the promising therapeutic potential of <sup>131</sup>I-aPD-L1 for PSCC, particularly in patients with drug resistance or recurrent head and neck tumors. However, the use of nude mice may have impacted the full therapeutic efficacy and synergistic potential observed with immunotherapy. Future studies should utilize immunocompetent models to better assess the probe's therapeutic impact and to explore its synergistic effects with immunotherapy and reduce the dose of <sup>131</sup>I to mitigate its toxic effects.</AbstractText><CopyrightInformation>&#xa9; 2025 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Ming</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-1066-3532</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jing</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-9761-9915</Identifier><AffiliationInfo><Affiliation>Department of Nuclear Medicine, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tu</LastName><ForeName>Liangqian</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Handan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Jinghong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pathology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pang</LastName><ForeName>Xiaoxi</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0002-1303-5224</Identifier><AffiliationInfo><Affiliation>Department of Nuclear Medicine, The Second Hospital of Anhui Medical University, Hefei, Anhui Province, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>LY23H130002</GrantID><Agency>Zhejiang Provincial Natural Science Foundation of China</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">131I&#x2010;labeled anti&#x2010;PD&#x2010;L1 antibody (131I&#x2010;aPD&#x2010;L1)</Keyword><Keyword MajorTopicYN="N">Bcl&#x2010;2</Keyword><Keyword MajorTopicYN="N">animal model</Keyword><Keyword MajorTopicYN="N">apoptosis</Keyword><Keyword MajorTopicYN="N">caspase&#x2010;3</Keyword><Keyword MajorTopicYN="N">necrosis</Keyword><Keyword MajorTopicYN="N">pharyngeal squamous cell carcinoma (PSCC)</Keyword><Keyword MajorTopicYN="N">targeted radionuclide therapy (TRT)</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>11</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>12</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>26</Day><Hour>7</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>26</Day><Hour>7</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>26</Day><Hour>4</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41450235</ArticleId><ArticleId IdType="doi">10.1002/hed.70146</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>P. Sabljak, P. Pesko, D. Stojakov, et&#xa0;al., &#x201c;Micrometastasis of Hypopharyngeal Cancer,&#x201d; Langenbeck's Archives of Surgery 399, no. 6 (2014): 765&#x2013;771.</Citation></Reference><Reference><Citation>K. Sato, A. Kubota, M. Furukawa, et&#xa0;al., &#x201c;Definitive Radiotherapy for Early&#x2010;Stage Hypopharyngeal Squamous Cell Carcinoma,&#x201d; European Archives of Oto&#x2010;Rhino&#x2010;Laryngology 272, no. 8 (2015): 2001&#x2013;2006.</Citation></Reference><Reference><Citation>A. Habib, &#x201c;Management of Advanced Hypopharyngeal Carcinoma: Systematic Review of Survival Following Surgical and Non&#x2010;Surgical Treatments,&#x201d; Journal of Laryngology and Otology 132, no. 5 (2018): 385&#x2013;400.</Citation></Reference><Reference><Citation>J. R. Newman, T. M. Connolly, E. A. Illing, M. L. Kilgore, J. L. Locher, and W. R. Carroll, &#x201c;Survival Trends in Hypopharyngeal Cancer: A Population&#x2010;Based Review,&#x201d; Laryngoscope 125, no. 3 (2015): 624&#x2013;629.</Citation></Reference><Reference><Citation>N. Gavrielatou, I. Vathiotis, T. N. Aung, et&#xa0;al., &#x201c;Digital Spatial Profiling Links Beta&#x2010;2&#x2010;Microglobulin Expression With Immune Checkpoint Blockade Outcomes in Head and Neck Squamous Cell Carcinoma,&#x201d; Cancer Research Communications 3, no. 4 (2023): 558&#x2013;563.</Citation></Reference><Reference><Citation>M. Yi, X. Zheng, M. Niu, S. Zhu, H. Ge, and K. Wu, &#x201c;Combination Strategies With PD&#x2010;1/PD&#x2010;L1 Blockade: Current Advances and Future Directions,&#x201d; Molecular Cancer 21 (2022): 28, https://doi.org/10.1186/s12943&#x2010;021&#x2010;01489&#x2010;2.</Citation></Reference><Reference><Citation>T. Y. Seiwert, B. Burtness, R. Mehra, et&#xa0;al., &#x201c;Safety and Clinical Activity of Pembrolizumab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (KEYNOTE&#x2010;012): An Open&#x2010;Label, Multicentre, Phase 1b Trial,&#x201d; Lancet Oncology 17, no. 7 (2016): 956&#x2013;965.</Citation></Reference><Reference><Citation>A. T. Ruffin, H. Li, L. Vujanovic, D. P. Zandberg, R. L. Ferris, and T. C. Bruno, &#x201c;Improving Head and Neck Cancer Therapies by Immunomodulation of the Tumour Microenvironment,&#x201d; Nature Reviews. Cancer 23, no. 3 (2023): 173&#x2013;188.</Citation></Reference><Reference><Citation>J. M. Johnson, B. Burtness, R. Mehra, et&#xa0;al., &#x201c;Nivolumab and Ipilimumab in Combination With Radiotherapy in Patients With High&#x2010;Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck,&#x201d; Journal for Immunotherapy of Cancer 11, no. 8 (2023): e007141, https://doi.org/10.1136/jitc&#x2010;2023&#x2010;007141.</Citation></Reference><Reference><Citation>J. Shen, K. Feng, J. Yu, et&#xa0;al., &#x201c;Responsive and Traceless Assembly of Iron Nanoparticles and 131I Labeled Radiopharmaceuticals for Ferroptosis Enhanced Radio&#x2010;Immunotherapy,&#x201d; Biomaterials 313 (2025): 122795, https://doi.org/10.1016/j.biomaterials.</Citation></Reference><Reference><Citation>C. Jiang, Q. Tian, X. Xu, et&#xa0;al., &#x201c;Enhanced Antitumor Immune Responses via a New Agent [131I]&#x2010;Labeled Dual&#x2010;Target Immunosuppressant,&#x201d; European Journal of Nuclear Medicine and Molecular Imaging 50, no. 2 (2023): 275&#x2013;286.</Citation></Reference><Reference><Citation>Z. Kong, Z. Li, X. Y. Cui, et&#xa0;al., &#x201c;CTR&#x2010;FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma,&#x201d; Cancer Discovery 15, no. 2 (2025): 316&#x2013;328.</Citation></Reference><Reference><Citation>H. Chen, L. Zhao, K. Fu, et&#xa0;al., &#x201c;Integrin &#x3b1;v&#x3b2;3&#x2010;Targeted Radionuclide Therapy Combined With Immune Checkpoint Blockade Immunotherapy Synergistically Enhances Anti&#x2010;Tumor Efficacy,&#x201d; Theranostics 9, no. 25 (2019): 7948&#x2013;7960, https://doi.org/10.7150/thno.39203.</Citation></Reference><Reference><Citation>Y. J. Lee, N. S. van den Berg, H. Duan, et&#xa0;al., &#x201c;89Zr&#x2010;Panitumumab Combined With 18F&#x2010;FDG PET Improves Detection and Staging of Head and Neck Squamous Cell Carcinoma,&#x201d; Clinical Cancer Research 28, no. 20 (2022): 4425&#x2013;4434.</Citation></Reference><Reference><Citation>X. Pang, M. Liu, R. Wang, X. Liao, P. Yan, and C. Zhang, &#x201c;Radioimmunoimaging and Targeting Treatment in an Immunocompetent Murine Model of Triple&#x2010;Negative Breast Cancer Using Radiolabeled Anti&#x2010;Programmed Death&#x2010;Ligand 1 Monoclonal Antibody,&#x201d; Journal of Labelled Compounds &amp; Radiopharmaceuticals 61, no. 10 (2018): 876&#x2013;886.</Citation></Reference><Reference><Citation>J. A. Bonner, P. M. Harari, J. Giralt, et&#xa0;al., &#x201c;Radiotherapy Plus Cetuximab for Squamous&#x2010;Cell Carcinoma of the Head and Neck,&#x201d; New England Journal of Medicine 354, no. 6 (2006): 567&#x2013;578.</Citation></Reference><Reference><Citation>K. L. Meadows and H. I. Hurwitz, &#x201c;Anti&#x2010;VEGF Therapies in the Clinic,&#x201d; Cold Spring Harbor Perspectives in Medicine 2, no. 10 (2012): a006577, https://doi.org/10.1101/cshperspect.a006577.</Citation></Reference><Reference><Citation>R. Saddawi&#x2010;Konefka, S. Schokrpur, A. J. Lui, and J. S. Gutkind, &#x201c;HER2 and HER3 as Therapeutic Targets in Head and Neck Cancer,&#x201d; Cancer Journal 28, no. 5 (2022): 339, https://doi.org/10.1097/PPO.0000000000000622.</Citation></Reference><Reference><Citation>B. Sobol, O. Azzam&#x2010;Nieto, E. L. Eberlein, et&#xa0;al., &#x201c;Specific Targeting of Antiapoptotic Bcl&#x2010;2 Proteins as a Radiosensitizing Approach in Solid Tumors,&#x201d; International Journal of Molecular Sciences 23, no. 14 (2022): 7850, https://doi.org/10.3390/ijms23147850.</Citation></Reference><Reference><Citation>P. F. Liu, Y. C. Hu, B. H. Kang, et&#xa0;al., &#x201c;Expression Levels of Cleaved Caspase&#x2010;3 and Caspase&#x2010;3 in Tumorigenesis and Prognosis of Oral Tongue Squamous Cell Carcinoma,&#x201d; PLoS One 12, no. 7 (2017): e0180620, https://doi.org/10.1371/journal.pone.0180620.</Citation></Reference><Reference><Citation>S. Pattingre and B. Levine, &#x201c;Bcl&#x2010;2 Inhibition of Autophagy: A New Route to Cancer?,&#x201d; Cancer Research 66, no. 6 (2006): 2885&#x2013;2888.</Citation></Reference><Reference><Citation>J. Drost and H. Clevers, &#x201c;Organoids in Cancer Research,&#x201d; Nature Reviews. Cancer 18, no. 7 (2018): 407&#x2013;418.</Citation></Reference><Reference><Citation>I. Tinhofer, D. Braunholz, and K. Klinghammer, &#x201c;Preclinical Models of Head and Neck Squamous Cell Carcinoma for a Basic Understanding of Cancer Biology and Its Translation Into Efficient Therapies,&#x201d; Cancers Head Neck 5 (2020): 9, https://doi.org/10.1186/s41199&#x2010;020&#x2010;00056&#x2010;4.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70149 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41439423</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Dec</Month><Day>24</Day></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Selection of an Endoscopic Endonasal or Transoral Approach to the Infratemporal Fossa.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70149</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Both endonasal and transoral approaches can provide minimally invasive access to the infratemporal fossa (ITF); however, the appropriate indications for each corridor have not been sufficiently defined. This study aimed to explore the indication for selection of an endonasal or a transoral approach to the ITF.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Cadaveric dissection was performed on 6 specimens, one side for an endonasal approach and the contralateral side for a transoral approach. A complementary subdivision of the ITF into four quadrants (A-D) based on the crossing line at the lower border of the lateral pterygoid plate was established. Thirty-one patients who underwent endoscopic endonasal (Group 1) or transoral approach (Group 2) to remove tumors in the ITF were retrospectively reviewed. Related indices for each surgical approach were compared.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">On cadaveric dissection, both the endonasal and the transoral approaches can provide access to the ITF. In Group 1, 26 patients underwent an endonasal approach, and the main tumor body was located at quadrant A. While patients in Group 2 performed a transoral resection, the tumor was mainly located in quadrant D. No significant difference for indices (e.g., operation length, morbidity) between groups (all p&#x2009;&gt;&#x2009;0.05), and no recurrence was detected.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The endonasal and transoral corridors are suitable for management of lesions at the medial and lateral or inferolateral aspects of the ITF, respectively. The relative tumor location to the lateral pterygoid plate may constitute an anatomic division tool to determine surgical approach selection.</AbstractText><CopyrightInformation>&#xa9; 2025 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Weiwei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Henan Provincial People's Hospital, Zhengzhou, Henan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kou</LastName><ForeName>Xiujuan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>London</LastName><ForeName>Nyall R</ForeName><Initials>NR</Initials><Suffix>Jr</Suffix><Identifier Source="ORCID">0000-0002-2902-4407</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xiaohong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Lifeng</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-0114-7608</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>PX2024008</GrantID><Agency>Beijing Municipal Administration of Hospitals Incubating Program</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">endonasal</Keyword><Keyword MajorTopicYN="N">infratemporal fossa</Keyword><Keyword MajorTopicYN="N">resection</Keyword><Keyword MajorTopicYN="N">transoral</Keyword><Keyword MajorTopicYN="N">tumor</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>12</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>24</Day><Hour>12</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>24</Day><Hour>12</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41439423</ArticleId><ArticleId IdType="doi">10.1002/hed.70149</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>L. Li, N. R. London, Jr., D. M. Prevedello, and R. L. Carrau, &#x201c;Anatomy Based Corridors to the Infratemporal Fossa: Implications for Endoscopic Approaches,&#x201d; Head and Neck 42 (2020): 846&#x2013;853.</Citation></Reference><Reference><Citation>L. Li, N. R. London, D. M. Prevedello, and R. L. Carrau, &#x201c;Endonasal Access to Lower Cranial Nerves: From Foramina to Upper Parapharyngeal Space,&#x201d; Head and Neck 43 (2021): 3225&#x2013;3233.</Citation></Reference><Reference><Citation>L. Li, S. Zhao, J. Kang, and X. Chen, &#x201c;Internal Maxillary Artery Pretreatment Is Valuable for Bleeding Control for Endonasal Infratemporal Fossa Surgery,&#x201d; Clinical Otolaryngology 50 (2024): 177&#x2013;183.</Citation></Reference><Reference><Citation>M. V. Dimitrijevi&#x107;, J. P. Sopta, N. R. Todorovi&#x107;, and L. Simi&#x107;, &#x201c;Infratemporal Fossa Chondroblastoma,&#x201d; Journal of Craniofacial Surgery 33 (2022): e449&#x2013;e452.</Citation></Reference><Reference><Citation>S. M. Kim, S. H. Paek, and J. H. Lee, &#x201c;Infratemporal Fossa Approach: The Modified Zygomatico&#x2010;Transmandibular Approach,&#x201d; Maxillofacial Plastic and Reconstructive Surgery 41 (2019): 3.</Citation></Reference><Reference><Citation>O. I. Mansour, R. L. Carrau, C. H. Snyderman, and A. B. Kassam, &#x201c;Preauricular Infratemporal Fossa Surgical Approach: Modifications of the Technique and Surgical Indications,&#x201d; Skull Base 14 (2004): 143&#x2013;151.</Citation></Reference><Reference><Citation>U. Fisch, P. Fagan, and A. Valavanis, &#x201c;The Infratemporal Fossa Approach for the Lateral Skull Base,&#x201d; Otolaryngologic Clinics of North America 17 (1984): 513&#x2013;552.</Citation></Reference><Reference><Citation>J. Liu, C. D. Pinheiro&#x2010;Neto, D. Yang, et&#xa0;al., &#x201c;Comparison of Endoscopic Endonasal Approach and Lateral Microsurgical Infratemporal Fossa Approach to the Jugular Foramen: An Anatomical Study,&#x201d; Journal of Neurological Surgery, Part B: Skull Base 83 (2022): e474&#x2013;e483.</Citation></Reference><Reference><Citation>E. W. Wang, A. M. Zanation, P. A. Gardner, et&#xa0;al., &#x201c;ICAR: Endoscopic Skull&#x2010;Base Surgery,&#x201d; International Forum of Allergy and Rhinology 9 (2019): S145&#x2010;s365.</Citation></Reference><Reference><Citation>R. G. Campbell, &#x201c;Robotic Surgery of the Anterior Skull Base,&#x201d; International Forum of Allergy and Rhinology 9 (2019): 1508&#x2013;1514.</Citation></Reference><Reference><Citation>L. Li, N. R. London, Jr., D. M. Prevedello, and R. L. Carrau, &#x201c;Endoscopic Endonasal Approach to the Pterygopalatine Fossa and Infratemporal Fossa: Comparison of the Prelacrimal and Denker's Corridors,&#x201d; American Journal of Rhinology and Allergy 36 (2022): 599&#x2013;606.</Citation></Reference><Reference><Citation>L. Li, N. R. London, Jr., D. M. Prevedello, and R. L. Carrau, &#x201c;Endonasal Endoscopic Transpterygoid Approach to the Upper Parapharyngeal Space,&#x201d; Head and Neck 42 (2020): 2734&#x2013;2740.</Citation></Reference><Reference><Citation>H. S. Patwa, J. C. Yanez&#x2010;Siller, M. Gomez Galarce, B. A. Otto, D. M. Prevedello, and R. L. Carrau, &#x201c;Analysis of the Far&#x2010;Medial Transoral Endoscopic Approach to the Infratemporal Fossa,&#x201d; Laryngoscope 128 (2018): 2273&#x2013;2281.</Citation></Reference><Reference><Citation>W. W. Cai, Y. Zou, Z. Kang, J. G. Liang, H. Y. He, and Q. T. Yang, &#x201c;Endoscopic Anatomical Study of the Trans&#x2010;Lateral Molar Approach to the Infratemporal Fossa,&#x201d; European Archives of Oto&#x2010;Rhino&#x2010;Laryngology 276 (2019): 1783&#x2013;1791.</Citation></Reference><Reference><Citation>L. Li, N. R. London, Jr., D. M. Prevedello, and R. L. Carrau, &#x201c;Anatomical Variations and Relationships of the Infratemporal Fossa: Foundation of a Novel Endonasal Approach to the Foramen Ovale,&#x201d; Journal of Neurological Surgery, Part B: Skull Base 82 (2021): 668&#x2013;674.</Citation></Reference><Reference><Citation>E. Agosti, A. Y. Alexander, G. Choby, M. Peris&#x2010;Celda, and C. D. Pinheiro&#x2010;Neto, &#x201c;Combined Endoscopic Endonasal Transpterygoid and Sublabial Transmaxillary Approaches for a Large Infratemporal Fossa Trigeminal Schwannoma,&#x201d; Acta Neurochirurgica 164 (2022): 2525&#x2013;2531.</Citation></Reference><Reference><Citation>S. M. Hosseini, A. Razfar, R. L. Carrau, et&#xa0;al., &#x201c;Endonasal Transpterygoid Approach to the Infratemporal Fossa: Correlation of Endoscopic and Multiplanar CT Anatomy,&#x201d; Head and Neck 34 (2012): 313&#x2013;320.</Citation></Reference><Reference><Citation>S. Mao, R. Tang, Y. Gu, B. Chen, and W. Zhang, &#x201c;Endoscopic Endonasal Combined Transoral Medial Approach to the Nasopharynx, Parapharyngeal Space, and Jugular Foramen,&#x201d; Head and Neck 46 (2024): 485&#x2013;491.</Citation></Reference><Reference><Citation>P. Battaglia, M. Turri&#x2010;Zanoni, I. Dallan, et&#xa0;al., &#x201c;Endoscopic Endonasal Transpterygoid Transmaxillary Approach to the Infratemporal and Upper Parapharyngeal Tumors,&#x201d; Otolaryngology and Head and Neck Surgery 150 (2014): 696&#x2013;702.</Citation></Reference><Reference><Citation>Z. Chi, C. Zhang, and W. Wang, &#x201c;Granulomatous Mucormycosis of the Temporal Bone Extending Into Temporomandibular Joint and Infratemporal Fossa: A Case Report,&#x201d; Ear, Nose, and Throat Journal 102 (2023): Np534&#x2013;np537.</Citation></Reference><Reference><Citation>X. Liu, S. Wan, A. Abdelrehem, M. Chen, and C. Yang, &#x201c;Benign Temporomandibular Joint Tumours With Extension to Infratemporal Fossa and Skull Base: Condyle Preserving Approach,&#x201d; International Journal of Oral and Maxillofacial Surgery 49 (2020): 867&#x2013;873.</Citation></Reference><Reference><Citation>R. Rodriguez Rubio, O. Kola, A. Tayebi Meybodi, et&#xa0;al., &#x201c;Minimally Invasive Exposure of the Maxillary Artery at the Anteromedial Infratemporal Fossa,&#x201d; Operative Neurosurgery 16 (2019): 79&#x2013;85.</Citation></Reference><Reference><Citation>L. Chang, Y. Zixiang, F. Zheming, et&#xa0;al., &#x201c;Management of Pterygoid Venous Plexus Hemorrhage During Resection of a Large Juvenile Nasopharyngeal Angiofibroma: A Review of 27 Cases,&#x201d; Ear, Nose, and Throat Journal 92 (2013): 204&#x2013;208.</Citation></Reference><Reference><Citation>G. Bozkurt, M. Turri&#x2010;Zanoni, F. Russo, H. A. Elhassan, P. Castelnuovo, and P. Battaglia, &#x201c;Ultrasonic Scalpel&#x2010;Assisted Endoscopic Endonasal Surgery of Infratemporal Fossa: Our First Impressions,&#x201d; World Neurosurgery 123 (2019): 23&#x2013;28.</Citation></Reference><Reference><Citation>A. Guha, L. Hart, H. Polachova, M. Chovanec, and P. Schalek, &#x201c;Partial Maxillectomy for Ameloblastoma of the Maxilla With Infratemporal Fossa Involvement: A Combined Endoscopic Endonasal and Transoral Approach,&#x201d; Journal of Stomatology Oral and Maxillofacial Surgery 119 (2018): 212&#x2013;215.</Citation></Reference><Reference><Citation>R. M. Soriano, J. M. R. Barbero, G. Pradilla, and O. A. Henriquez, &#x201c;Combined Endoscopic Endonasal and Transoral Approach to Transpatial Lesion Involving the Infratemporal Fossa and Masticator Space: A Case Study and Literature Review,&#x201d; Neurocirug&#xed;a (Asturias, Spain) 34 (2023): 87&#x2013;92.</Citation></Reference><Reference><Citation>P. J. Bradley, &#x201c;Infratemporal Fossa Surgical Approaches to Primary/Recurrent Malignancies of Salivary Origin: Paradigm Surgical Shift, Patient Selection, and Oncologic Outcomes,&#x201d; Current Opinion in Otolaryngology and Head and Neck Surgery 28 (2020): 79&#x2013;89.</Citation></Reference><Reference><Citation>P. J. Hunt, M. Amit, K. E. Kabotyanski, et&#xa0;al., &#x201c;Predictors of Postoperative Performance Status After Surgical Management of Infratemporal Fossa Malignancies,&#x201d; Neurosurgery Review 46 (2023): 157.</Citation></Reference><Reference><Citation>F. Mancini, A. Marini, R. Paracino, G. Consorti, M. Iacoangeli, and M. Dobran, &#x201c;Fronto&#x2010;Orbito&#x2010;Zygomatic (FOZ) Approach for Infratemporal Fossa Lesions Extending to Middle Cranial Fossa: Our Experience and Review of Literature,&#x201d; Neurologia i Neurochirurgia Polska 56 (2022): 178&#x2013;186.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70112 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41431870</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Dec</Month><Day>23</Day></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Evaluation of the Clinical Effects of Intraoperative Facial Nerve Repair and Reconstruction for Parotid Malignant Tumors.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70112</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate facial nerve reconstruction's impact on quality of life (QoL) and clinical outcomes in radical parotid malignancy surgery.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients were stratified into the Preservation Group, Reconstruction Group, and Disconnection Group, retrospectively analyzed objective measures (from medical records and operative reports) and subjective measures (using the Sunnybrook Facial Grading System [SFGS] and Facial Clinimetric Evaluation [FaCE] scale) across the three patient groups.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">No significant differences in recurrence or mortality were observed between Reconstruction and Disconnection groups (p&#x2009;&gt;&#x2009;0.05). Facial nerve reconstruction significantly improves outcomes in patients with high-risk parotid malignancies (p&#x2009;&lt;&#x2009;0.05), despite higher-risk profiles in the reconstruction cohort. This improvement remained stable over time, showing no significant decline (p&#x2009;&gt;&#x2009;0.05). Venous nerve conduit trap yielded superior facial nerve function and QoL versus end-to-end repair (p&#x2009;&lt;&#x2009;0.05).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Facial nerve reconstruction effectively improves outcomes in parotid malignancy surgery. Venous nerve conduit trap application is better than end-to-end repair.</AbstractText><CopyrightInformation>&#xa9; 2025 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>He</LastName><ForeName>Zi-Ao</ForeName><Initials>ZA</Initials><AffiliationInfo><Affiliation>Department of Head and Neck Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Oral and Maxillofacial Surgery, School of Stomatology, Guizhou Medical University, Guiyang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Nan</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-5555-552X</Identifier><AffiliationInfo><Affiliation>Department of Head and Neck Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Oral and Maxillofacial Surgery, School of Stomatology, Guizhou Medical University, Guiyang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Hong-Qiang</ForeName><Initials>HQ</Initials><AffiliationInfo><Affiliation>Department of Head and Neck Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Long-Yue</ForeName><Initials>LY</Initials><AffiliationInfo><Affiliation>Department of Head and Neck Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Si-Cheng</ForeName><Initials>SC</Initials><Identifier Source="ORCID">0000-0003-0046-3382</Identifier><AffiliationInfo><Affiliation>Department of Head and Neck Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Head and Neck Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yu-Pei</ForeName><Initials>YP</Initials><AffiliationInfo><Affiliation>Department of Head and Neck Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Head and Neck Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Lin-Jie</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Department of Head and Neck Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shui</LastName><ForeName>Chun-Yan</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>Department of Head and Neck Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Guo-Wei</ForeName><Initials>GW</Initials><AffiliationInfo><Affiliation>Department of Oral and Maxillofacial Surgery, School of Stomatology, Guizhou Medical University, Guiyang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Rong-Hao</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>Department of Head and Neck Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Chao</ForeName><Initials>C</Initials><Identifier Source="ORCID">0009-0003-4876-320X</Identifier><AffiliationInfo><Affiliation>Department of Head and Neck Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Oral and Maxillofacial Surgery, School of Stomatology, Guizhou Medical University, Guiyang, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2024YFHZ0215</GrantID><Agency>Regional Innovation Cooperation Project of the Sichuan Provincial Department of Science and Technology</Agency><Country/></Grant><Grant><GrantID>2023GPWKP001</GrantID><Agency>Sichuan Provincial Key Clinical Specialty Construction Project</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">facial nerve</Keyword><Keyword MajorTopicYN="N">parotid tumor</Keyword><Keyword MajorTopicYN="N">quality of life</Keyword><Keyword MajorTopicYN="N">repair and reconstruction</Keyword><Keyword MajorTopicYN="N">total parotidectomy</Keyword><Keyword MajorTopicYN="N">venous nerve conduit</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>11</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>23</Day><Hour>7</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>23</Day><Hour>7</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>23</Day><Hour>4</Hour><Minute>45</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41431870</ArticleId><ArticleId IdType="doi">10.1002/hed.70112</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>J. Huang, Y. C. Fung, W. S. Pang, et&#xa0;al., &#x201c;Disease Distribution and Temporal Trends of Salivary Gland Cancer: A Global Population&#x2010;Based Study,&#x201d; Clinical and Translational Medicine 14, no. 5 (2024): e1667, https://doi.org/10.1002/ctm2.1667.</Citation></Reference><Reference><Citation>C. van Herpen, V. Vander Poorten, A. Skalova, et&#xa0;al., &#x201c;Salivary Gland Cancer: ESMO&#x2010;European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for Diagnosis, Treatment and Follow&#x2010;Up,&#x201d; ESMO Open 7, no. 6 (2022): 100602, https://doi.org/10.1016/j.esmoop.2022.100602.</Citation></Reference><Reference><Citation>I. Alsanie, S. Rajab, H. Cottom, et&#xa0;al., &#x201c;Distribution and Frequency of Salivary Gland Tumours: An International Multicenter Study,&#x201d; Head and Neck Pathology 16, no. 4 (2022): 1043&#x2013;1054, https://doi.org/10.1007/s12105&#x2010;022&#x2010;01459&#x2010;0.</Citation></Reference><Reference><Citation>D. R. Gnepp, Diagnostic Surgical Pathology of the Head and Neck, 2d ed. (Scitech Book News, 2009), 33.3.</Citation></Reference><Reference><Citation>K. C. C. Choy, M. M. Bundele, E. W. Fu, et&#xa0;al., &#x201c;Risk Stratification of Parotid Neoplasms Based on Intraoperative Frozen Section and Preoperative Fine Needle Aspiration Cytology,&#x201d; European Archives of Oto&#x2010;Rhino&#x2010;Laryngology 279, no. 4 (2022): 2117&#x2013;2131, https://doi.org/10.1007/s00405&#x2010;021&#x2010;07015&#x2010;w.</Citation></Reference><Reference><Citation>J. D. Spiro and R. H. Spiro, &#x201c;Cancer of the Parotid Gland: Role of 7th Nerve Preservation,&#x201d; World Journal of Surgery 27, no. 7 (2003): 863&#x2013;867, https://doi.org/10.1007/s00268&#x2010;003&#x2010;7112&#x2010;7.</Citation></Reference><Reference><Citation>O. Guntinas&#x2010;Lichius, C. E. Silver, J. Thielker, et&#xa0;al., &#x201c;Management of the Facial Nerve in Parotid Cancer: Preservation or Resection and Reconstruction,&#x201d; European Archives of Oto&#x2010;Rhino&#x2010;Laryngology 275, no. 11 (2018): 2615&#x2013;2626, https://doi.org/10.1007/s00405&#x2010;018&#x2010;5154&#x2010;6.</Citation></Reference><Reference><Citation>H. U. Rashid, I. U. Rehman, M. Rashid, S. Yousaf, N. Khan, and A. Aqsa, &#x201c;Results of Immediate Facial Nerve Reconstruction in Patients Undergoing Parotid Tumour Resection,&#x201d; Journal of Ayub Medical College, Abbottabad 31, no. 3 (2019): 340&#x2013;345.</Citation></Reference><Reference><Citation>A. Giotta Lucifero, S. Luzzi, J. Rabski, D. Meredith, P. A. D. S. Kadri, and O. Al&#x2010;Mefty, &#x201c;Surgical Management of Symptomatic Hemangioma of the Geniculate Ganglion: Fascicular&#x2010;Sparing Resection or Grafting?,&#x201d; Neurosurgical Review 46, no. 1 (2023): 1120, https://doi.org/10.1007/s10143&#x2010;023&#x2010;02029&#x2010;w.</Citation></Reference><Reference><Citation>Y. Ning, W. Wang, Y. Cai, et&#xa0;al., &#x201c;The Application of Venous Nerve Conduit Trap in the Immediate Repair and Reconstruction of Facial Nerve in Parotid Gland Tumor: An Attempt of a New Technique,&#x201d; European Archives of Oto&#x2010;Rhino&#x2010;Laryngology 278, no. 12 (2021): 4967&#x2013;4976, https://doi.org/10.1007/s00405&#x2010;021&#x2010;06732&#x2010;6.</Citation></Reference><Reference><Citation>A. P. Gatti, M. T. Ribeiro, and F. C. Hojaij, &#x201c;Psychosocial Impact of Facial Paralysis Following Neck Dissection: A Literature Review,&#x201d; Cureus 16, no. 10 (2024): e72104, https://doi.org/10.7759/cureus.72104.</Citation></Reference><Reference><Citation>F. T. Kayhan, D. Zurakowski, and S. D. Rauch, &#x201c;Toronto Facial Grading System: Interobserver Reliability,&#x201d; Otolaryngology and Head and Neck Surgery 122, no. 2 (2000): 212&#x2013;215, https://doi.org/10.1016/S0194&#x2010;5998(00)70241&#x2010;5.</Citation></Reference><Reference><Citation>B. G. Ross, G. Fradet, and J. M. Nedzelski, &#x201c;Development of a Sensitive Clinical Facial Grading System,&#x201d; Otolaryngology &#x2013; Head and Neck Surgery 114, no. 3 (1996): 380&#x2013;386, https://doi.org/10.1016/S0194&#x2010;59989670206&#x2010;1.</Citation></Reference><Reference><Citation>J. B. Kahn, R. E. Gliklich, K. P. Boyev, et&#xa0;al., &#x201c;Validation of a Patientgraded Instrument for Facial Nerve Paralysis: The FaCE Scale,&#x201d; Laryngoscope 111 (2001): 387&#x2013;398.</Citation></Reference><Reference><Citation>R. W. Lindsay, P. Bhama, J. Weinberg, and T. A. Hadlock, &#x201c;The Success of Free Graci&#x2010;Lis Muscle Transfer to Restore Smile in Patients With Nonflaccid Facial Paralysis,&#x201d; Annals of Plastic Surgery 73 (2014): 177&#x2013;182.</Citation></Reference><Reference><Citation>S.&#x2010;Y. Lee, J. Seong, and Y. H. Kim, &#x201c;Clinical Implication of Facial Nerve Decompression in Complete Bell's Palsy: A Systematic Review and Meta&#x2010;Analysis,&#x201d; Clinical and Experimental Otorhinolaryngology 12, no. 4 (2019): 348&#x2013;359, https://doi.org/10.21053/ceo.2019.00535.</Citation></Reference><Reference><Citation>W. Li, L. Yang, M. Chen, M. M. Zhang, and Y. K. Zhang, &#x201c;Immediate Reconstruction of Facial Nerve Defect Using Cable Grafting of the Greater Auricualr Nerve After Parotid Cancer Resection,&#x201d; Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi = Journal of Clinical Otorhinolaryngology Head and Neck Surgery 31, no. 16 (2017): 1254&#x2013;1258, https://doi.org/10.13201/j.issn.1001&#x2010;1781.2017.16.009.</Citation></Reference><Reference><Citation>F. Zumbusch, P. Schlattmann, and O. Guntinas&#x2010;Lichius, &#x201c;Facial Nerve Reconstruction for Flaccid Facial Paralysis: A Systematic Review and Meta&#x2010;Analysis,&#x201d; Frontiers in Surgery 11 (2024): 1440953, https://doi.org/10.3389/fsurg.2024.1440953.</Citation></Reference><Reference><Citation>F. Biglioli, V. Colombo, D. Rabbiosi, et&#xa0;al., &#x201c;Masseteric&#x2010;Facial Nerve Neurorrhaphy: Results of a Case Series,&#x201d; Journal of Neurosurgery 126, no. 1 (2017): 312&#x2013;318, https://doi.org/10.3171/2015.12.JNS14601.</Citation></Reference><Reference><Citation>C. E. Steuer, G. J. Hanna, K. Viswanathan, et&#xa0;al., &#x201c;The Evolving Landscape of Salivary Gland Tumors,&#x201d; CA: A Cancer Journal for Clinicians 73, no. 6 (2023): 597&#x2013;619, https://doi.org/10.3322/caac.21807.</Citation></Reference><Reference><Citation>A. Mentula, M. Uimonen, A. Lindford, S. Suominen, J. P. Repo, and T. Yl&#xe4;&#x2010;Kotola, &#x201c;Translation and Validation of a Finnish Version of the Facial Clinimetric Evaluation (FaCE) Scale,&#x201d; Journal of Plastic Surgery and Hand Surgery 58 (2023): 33&#x2013;39, https://doi.org/10.2340/jphs.v58.6533.</Citation></Reference><Reference><Citation>J. Xu, S. E. Varitimidis, K. J. Fisher, M. M. Tomaino, and D. G. Sotereanos, &#x201c;The Effect of Wrapping Scarred Nerves with Autogenous Vein Graft to Treat Recurrent Chronic Nerve Compression,&#x201d; Journal of Hand Surgery 25, no. 1 (2000): 93&#x2013;103, https://doi.org/10.1053/jhsu.2000.jhsu025a0093.</Citation></Reference><Reference><Citation>R. Ramos&#x2010;Z&#xfa;&#xf1;iga, I. Segura&#x2010;Duran, R. E. Gonz&#xe1;lez&#x2010;Casta&#xf1;eda, and J. A. Gonz&#xe1;lez Rios, &#x201c;The Challenges of the Bioactive Scaffolds in Nervous System: From Their Molecular Conformation to Their Therapeutic Efficiency,&#x201d; Neurology Perspectives 2 (2022): S3.</Citation></Reference><Reference><Citation>A. Q. Lam, T. P. C. Tran, D. V. Tran, H. X. Tran, A. J. Fox, and L. V. Tran, &#x201c;Rehabilitation Surgery for Peripheral Facial Nerve Injury After Facial Trauma,&#x201d; International Archives of Otorhinolaryngology 28, no. 3 (2024): e509&#x2013;e516, https://doi.org/10.1055/s&#x2010;0044&#x2010;1782199.</Citation></Reference><Reference><Citation>D. J. Carey, M. S. Todd, and C. M. Rafferty, &#x201c;Schwann Cell Myelination: Induction by Exogenous Basement Membrane&#x2010;Like Extracellular Matrix,&#x201d; Journal of Cell Biology 102, no. 6 (1986): 2254&#x2013;2263, https://doi.org/10.1083/jcb.102.6.2254.</Citation></Reference><Reference><Citation>Z. Zhu, S. Li, C. Ma, et&#xa0;al., &#x201c;African Swine Fever Virus E184L Protein Interacts With Innate Immune Adaptor STING to Block IFN Production for Viral Replication and Pathogenesis,&#x201d; Journal of Immunology 210, no. 4 (2023): 442&#x2013;458, https://doi.org/10.4049/jimmunol.2200357.</Citation></Reference><Reference><Citation>S. Ramachandran and R. Midha, &#x201c;Recent Advances in Nerve Repair,&#x201d; Neurology India 67, no. Supplement (2019): S106&#x2013;S114, https://doi.org/10.4103/0028&#x2010;3886.250702.</Citation></Reference><Reference><Citation>B. M. Erovic, M. D. Shah, G. Bruch, et&#xa0;al., &#x201c;Outcome Analysis of 215 Patients With Parotid Gland Tumors: A Retrospective Cohort Analysis,&#x201d; Journal of Otolaryngology 44 (2015): 43, https://doi.org/10.1186/s40463&#x2010;015&#x2010;0097&#x2010;z.</Citation></Reference><Reference><Citation>V. Sopik and S. A. Narod, &#x201c;The Relationship Between Tumour Size, Nodal Status and Distant Metastases: On the Origins of Breast Cancer,&#x201d; Breast Cancer Research and Treatment 170, no. 3 (2018): 647&#x2013;656, https://doi.org/10.1007/s10549&#x2010;018&#x2010;4796&#x2010;9.</Citation></Reference><Reference><Citation>X. Hui, G. Zhou, Y. Zheng, Y. Wang, and Q. Guo, &#x201c;Development and Validation of a Tumor Size&#x2010;Stratified Prognostic Nomogram for Patients With Gastric Signet Ring Cell Carcinoma,&#x201d; Updates in Surgery 76, no. 8 (2024): 2813&#x2013;2824, https://doi.org/10.1007/s13304&#x2010;024&#x2010;02020&#x2010;0.</Citation></Reference><Reference><Citation>S. Y. Choi, E. Lee, E. Kim, et&#xa0;al., &#x201c;Clinical Outcomes of Bulky Parotid Gland Cancers: Need for Self&#x2010;Examination and Screening Program for Early Diagnosis of Parotid Tumors,&#x201d; BMC Cancer 21, no. 1 (2021): 1178, https://doi.org/10.1186/s12885&#x2010;021&#x2010;07902&#x2010;9.</Citation></Reference><Reference><Citation>F. Xu, X. Feng, F. Zhao, et&#xa0;al., &#x201c;Competing&#x2010;Risks Nomograms for Predicting Cause&#x2010;Specific Mortality in Parotid&#x2010;Gland Carcinoma: A Population&#x2010; Based Analysis,&#x201d; Cancer Medicine 10, no. 11 (2021): 3756&#x2013;3769, https://doi.org/10.1002/cam4.3919.</Citation></Reference><Reference><Citation>X. Han, C. Yang, X. Tan, and Y. Li, &#x201c;The 8th AJCC Classification Is Inferior to a New Neck Stage Based on Intraparotid Lymph Node in Parotid Gland Cancer,&#x201d; BMC Oral Health 24, no. 1 (2024): 1590, https://doi.org/10.1186/s12903&#x2010;024&#x2010;04346&#x2010;y.</Citation></Reference><Reference><Citation>A. T. Anastasio, A. N. Baumann, M. E. Callaghan, et&#xa0;al., &#x201c;The Impact of Surgeon Experience on Surgical Parameters and Complication Rates for the Surgical Management of Adult Spinal Deformities: A Systematic Review and Meta&#x2010;Analysis,&#x201d; Prosthesis 6, no. 3 (2024): 582&#x2013;595, https://doi.org/10.3390/prosthesis6030041.</Citation></Reference><Reference><Citation>J. Huang, N. A. Shlobin, M. DeCuypere, and S. K. Lam, &#x201c;Deep Learning for Outcome Prediction in Neurosurgery: A Systematic Review of Design, Reporting, and Reproducibility,&#x201d; Neurosurgery 90, no. 1 (2022): 16&#x2013;38, https://doi.org/10.1227/NEU.0000000000001736.</Citation></Reference><Reference><Citation>S. Clark, L. Boyle, P. Matthews, P. Schweder, C. Deng, and D. Campbell, &#x201c;Development and Validation of a Multivariate Prediction Model of Perioperative Mortality in Neurosurgery: The New Zealand Neurosurgical Risk Tool (NZRISK&#x2010;NEURO),&#x201d; Neurosurgery 87, no. 3 (2020): E313&#x2013;E320, https://doi.org/10.1093/neuros/nyaa144.</Citation></Reference><Reference><Citation>A. K. Rock, D. T. Woodrum, and M. S. Avidan, &#x201c;Safety Outcomes Following Spine and Cranial Neurosurgery: Evidence From the National Surgical Quality Improvement Program,&#x201d; Journal of Neurosurgical Anesthesiology 30, no. 4 (2018): 328&#x2013;336, https://doi.org/10.1097/ANA.000000000000047.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70145 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41424359</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Dec</Month><Day>22</Day></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Greater Attention to Gingival Cancer and Floor of Mouth Cancer: Based on a Retrospective Analysis of Oral Cancer Across Different Subsites.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70145</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The gingiva and floor of the mouth are distinct subsites, and oral squamous cell carcinoma (OSCC) originating in these locations warrants further indepth understanding.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This study enrolled patients with OSCC from 2000 to 2020, and analyzed the clinicopathological characteristics. Kaplan-Meier analysis compared overall survival (OS) and recurrence-free survival (RFS). Univariate analysis and multivariate Cox proportional hazards model examined the risk factors on survival outcomes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 885 OSCC patients were included, with the most common tumor subsites: oral tongue (41.9%), gingiva (31.8%), and floor of mouth (16.0%). Gingival and floor of mouth showed a higher proportion of advanced stage (65.8%, 66.9%) and significantly poorer OS (3-year: 63.0%, 57.0%; 5-year: 49.8%, 37.3%) and RFS (3-year: 59.1%, 61.3%; 5-year: 55.5%, 57.0%). Neoadjuvant chemotherapy was associated with significantly reduced mortality in gingival cancer (HR&#x2009;=&#x2009;0.598), while tobacco exposure (HR&#x2009;=&#x2009;1.952) was associated with a significant increase in mortality in floor of mouth cancer.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Gingival cancer and floor of mouth cancer have a worse prognosis, and thus require greater attention throughout the entire management process.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). Head &amp; Neck published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Hao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Head and Neck Oncology, Tianjin Medical University Cancer Institute &amp; Hospital, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Basic and Translational Medicine on Head &amp; Neck Cancer, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Head and Neck Oncology, Tianjin Medical University Cancer Institute &amp; Hospital, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Basic and Translational Medicine on Head &amp; Neck Cancer, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Yansheng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Head and Neck Oncology, Tianjin Medical University Cancer Institute &amp; Hospital, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Basic and Translational Medicine on Head &amp; Neck Cancer, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-0956-0293</Identifier><AffiliationInfo><Affiliation>Department of Head and Neck Oncology, Tianjin Medical University Cancer Institute &amp; Hospital, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Basic and Translational Medicine on Head &amp; Neck Cancer, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xinhua</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0003-2360-7553</Identifier><AffiliationInfo><Affiliation>Department of Head and Neck Oncology, Tianjin Medical University Cancer Institute &amp; Hospital, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Basic and Translational Medicine on Head &amp; Neck Cancer, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Weifeng</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Head and Neck Oncology, Tianjin Medical University Cancer Institute &amp; Hospital, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Basic and Translational Medicine on Head &amp; Neck Cancer, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Shaoshi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Head and Neck Oncology, Tianjin Medical University Cancer Institute &amp; Hospital, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Basic and Translational Medicine on Head &amp; Neck Cancer, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Ailin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Head and Neck Oncology, Tianjin Medical University Cancer Institute &amp; Hospital, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Basic and Translational Medicine on Head &amp; Neck Cancer, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Head and Neck Oncology, Tianjin Medical University Cancer Institute &amp; Hospital, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Basic and Translational Medicine on Head &amp; Neck Cancer, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Ruoyu</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Head and Neck Oncology, Tianjin Medical University Cancer Institute &amp; Hospital, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Basic and Translational Medicine on Head &amp; Neck Cancer, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jing</LastName><ForeName>Chao</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Head and Neck Oncology, Tianjin Medical University Cancer Institute &amp; Hospital, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Basic and Translational Medicine on Head &amp; Neck Cancer, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xudong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Head and Neck Oncology, Tianjin Medical University Cancer Institute &amp; Hospital, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Basic and Translational Medicine on Head &amp; Neck Cancer, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duan</LastName><ForeName>Yuansheng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Head and Neck Oncology, Tianjin Medical University Cancer Institute &amp; Hospital, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Basic and Translational Medicine on Head &amp; Neck Cancer, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>7-2-8</GrantID><Agency>Peak Discipline Support Program of the 14th Five-Year Plan of Tianjin Medical University Cancer Institute &amp; Hospital</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">floor&#x2010;of&#x2010;mouth</Keyword><Keyword MajorTopicYN="N">gingival</Keyword><Keyword MajorTopicYN="N">oral squamous cell carcinoma</Keyword><Keyword MajorTopicYN="N">prognosis</Keyword><Keyword MajorTopicYN="N">risk factor</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>11</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>12</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>22</Day><Hour>5</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41424359</ArticleId><ArticleId IdType="doi">10.1002/hed.70145</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>W. Cao, K. Qin, F. Li, and W. Chen, &#x201c;Socioeconomic Inequalities in Cancer Incidence and Mortality: An Analysis of GLOBOCAN 2022,&#x201d; Chinese Medical Journal 137 (2024): 1407&#x2013;1413.</Citation></Reference><Reference><Citation>P. Tandon, A. Dadhich, H. Saluja, S. Bawane, and S. Sachdeva, &#x201c;The Prevalence of Squamous Cell Carcinoma in Different Sites of Oral Cavity at Our Rural Health Care Centre in Loni, Maharashtra&#x2014;A Retrospective 10&#x2010;Year Study,&#x201d; Contemporary Oncology (Poznan, Poland) 21 (2017): 178&#x2013;183.</Citation></Reference><Reference><Citation>S. He, C. Xia, H. Li, et&#xa0;al., &#x201c;Cancer Profiles in China and Comparisons With the USA: A Comprehensive Analysis in the Incidence, Mortality, Survival, Staging, and Attribution to Risk Factors,&#x201d; Science China. Life Sciences 67 (2024): 122&#x2013;131.</Citation></Reference><Reference><Citation>L. Xie, C. M. Huang, Y. L. Song, Z. Shao, and Z. J. Shang, &#x201c;Incidence Trends and Projections of Lip and Oral Cavity Cancer in China 1990&#x2010;2021: An Age&#x2010;Period&#x2010;Cohort and Decomposition Analysis,&#x201d; BMC Oral Health 25 (2025): 406.</Citation></Reference><Reference><Citation>C. Kirsch, &#x201c;Oral Cavity Cancer,&#x201d; Topics in Magnetic Resonance Imaging 18 (2007): 269&#x2013;280.</Citation></Reference><Reference><Citation>S. L. Zhang, J. W. Tian, J. Jia, and Z. L. Yu, &#x201c;A New Approach: Cervical Approach for Marginal Resection of the Posterior Mandible,&#x201d; Journal of Stomatology Oral and Maxillofacial Surgery 126 (2025): 102046.</Citation></Reference><Reference><Citation>S. J. La'porte, J. K. Juttla, and R. K. Lingam, &#x201c;Imaging the Floor of the Mouth and the Sublingual Space,&#x201d; Radiographics 31 (2011): 1215&#x2013;1230.</Citation></Reference><Reference><Citation>A. Grammatica, C. Piazza, M. Ferrari, et&#xa0;al., &#x201c;Step&#x2010;By&#x2010;Step Cadaver Dissection and Surgical Technique for Compartmental Tongue and Floor of Mouth Resection,&#x201d; Frontiers in Oncology 11 (2021): 613945.</Citation></Reference><Reference><Citation>A. Miranda&#x2010;Filho and F. Bray, &#x201c;Global Patterns and Trends in Cancers of the Lip, Tongue and Mouth,&#x201d; Oral Oncology 102 (2020): 104551.</Citation></Reference><Reference><Citation>Z. Farhood, M. Simpson, G. M. Ward, R. J. Walker, and N. Osazuwa&#x2010;Peters, &#x201c;Does Anatomic Subsite Influence Oral Cavity Cancer Mortality? A SEER Database Analysis,&#x201d; Laryngoscope 129 (2019): 1400&#x2013;1406.</Citation></Reference><Reference><Citation>M. M. Justesen, H. Stampe, K. K. Jakobsen, et&#xa0;al., &#x201c;Impact of Tumor Subsite on Survival Outcomes in Oral Squamous Cell Carcinoma: A Retrospective Cohort Study From 2000 to 2019,&#x201d; Oral Oncology 149 (2024): 106684.</Citation></Reference><Reference><Citation>S. Warnakulasuriya and A. M. Filho, &#x201c;Oral Cancer in the South and South&#x2010;East Asia Region, 2022: Incidence and Mortality,&#x201d; Oral Diseases 31 (2025): 1398&#x2013;1405.</Citation></Reference><Reference><Citation>B. V. Sundermann, L. Uhlmann, J. Hoffmann, K. Freier, and O. C. Thiele, &#x201c;The Localization and Risk Factors of Squamous Cell Carcinoma in the Oral Cavity: A Retrospective Study of 1501 Cases,&#x201d; Journal of Cranio&#x2010;Maxillo&#x2010;Facial Surgery 46 (2018): 177&#x2013;182.</Citation></Reference><Reference><Citation>Y. Li, J. Tian, Y. You, et&#xa0;al., &#x201c;Global Variations and Socioeconomic Inequalities in Lifetime Risk of Lip, Oral Cavity, and Pharyngeal Cancer: A Population&#x2010;Based Systematic Analysis of GLOBOCAN 2022,&#x201d; International Journal of Surgery 111 (2025): 3698&#x2013;3709.</Citation></Reference><Reference><Citation>B. A. van Dijk, M. T. Brands, S. M. Geurts, M. A. Merkx, and J. L. Roodenburg, &#x201c;Trends in Oral Cavity Cancer Incidence, Mortality, Survival and Treatment in The Netherlands,&#x201d; International Journal of Cancer 139 (2016): 574&#x2013;583.</Citation></Reference><Reference><Citation>J. Qiu, H. Wen, J. Bai, and C. Yu, &#x201c;The Mortality of Oral Cancer Attributable to Tobacco in China, the US, and India,&#x201d; Journal of Cancer Research and Clinical Oncology 149 (2023): 16741&#x2013;16752.</Citation></Reference><Reference><Citation>Y. Hu, R. Zhong, H. Li, and Y. Zou, &#x201c;Effects of Betel Quid, Smoking and Alcohol on Oral Cancer Risk: A Case&#x2010;Control Study in Hunan Province, China,&#x201d; Substance Use &amp; Misuse 55 (2020): 1501&#x2013;1508.</Citation></Reference><Reference><Citation>W. W. Su, C. W. Su, D. C. Chang, et&#xa0;al., &#x201c;Impact of Varying Anatomic Sites on Advanced Stage and Survival of Oral Cancer: 9&#x2010;Year Prospective Cohort of 27&#x2009;717 Cases,&#x201d; Head &amp; Neck 41 (2019): 1475&#x2013;1483.</Citation></Reference><Reference><Citation>X. X. Bai, J. Zhang, and L. Wei, &#x201c;Analysis of Primary Oral and Oropharyngeal Squamous Cell Carcinoma in Inhabitants of Beijing, China&#x2014;A 10&#x2010;Year Continuous Single&#x2010;Center Study,&#x201d; BMC Oral Health 20 (2020): 208.</Citation></Reference><Reference><Citation>S. Yoshida, T. Shimo, Y. Murase, et&#xa0;al., &#x201c;The Prognostic Implications of Bone Invasion in Gingival Squamous Cell Carcinoma,&#x201d; Anticancer Research 38 (2018): 955&#x2013;962.</Citation></Reference><Reference><Citation>E. Chimenos K&#xfc;stner, F. Finestres Zubeldia, and P. Huguet Redecilla, &#x201c;Gingival Squamous Cell Carcinoma: A Clinical Case and Differential Diagnosis,&#x201d; Medicina Oral 6 (2001): 335&#x2013;341.</Citation></Reference><Reference><Citation>J. Seoane, P. I. Varela&#x2010;Centelles, T. F. Walsh, J. L. Lopez&#x2010;Cedrun, and I. Vazquez, &#x201c;Gingival Squamous Cell Carcinoma: Diagnostic Delay or Rapid Invasion?,&#x201d; Journal of Periodontology 77 (2006): 1229&#x2013;1233.</Citation></Reference><Reference><Citation>Y. Smail, M. Troizier&#x2010;Cheyne, C. M. Lutz, and A. L. Ejeil, &#x201c;Clinico&#x2010;Pathological Specificities of Gingival Carcinoma Among 32 Patients With Oral Cancer: A Cross Sectional Retrospective and Observational Study,&#x201d; BMC Oral Health 24 (2024): 1317.</Citation></Reference><Reference><Citation>R. Eloranta, S. T. Vil&#xe9;n, A. Kein&#xe4;nen, et&#xa0;al., &#x201c;Oral Squamous Cell Carcinoma: Effect of Tobacco and Alcohol on Cancer Location,&#x201d; Tobacco Induced Diseases 22 (2024): 1&#x2013;9.</Citation></Reference><Reference><Citation>T. D. Ellington, S. J. Henley, V. Senkomago, et&#xa0;al., &#x201c;Trends in Incidence of Cancers of the Oral Cavity and Pharynx&#x2014;United States 2007&#x2010;2016,&#x201d; MMWR. Morbidity and Mortality Weekly Report 69 (2020): 433&#x2013;438.</Citation></Reference><Reference><Citation>P. B. Sehgal, H. Yuan, and S. V. DiSenso&#x2010;Browne, &#x201c;Temperature and WNK&#x2010;SPAK/OSR1 Kinases Dynamically Regulate Antiviral Human GFP&#x2010;MxA Biomolecular Condensates in Oral Cancer Cells,&#x201d; Cells 14 (2025): 947.</Citation></Reference><Reference><Citation>India Project Team of the International Cancer Genome Consortium, &#x201c;Mutational Landscape of Gingivo&#x2010;Buccal Oral Squamous Cell Carcinoma Reveals New Recurrently&#x2010;Mutated Genes and Molecular Subgroups,&#x201d; Nature Communications 4 (2013): 2873.</Citation></Reference><Reference><Citation>A. Sami, I. Elimairi, C. A. Ryan, C. Stanton, D. Patangia, and R. P. Ross, &#x201c;Altered Oral Microbiome in Sudanese Toombak Smokeless Tobacco Users Carries a Newly Emerging Risk of Squamous Cell Carcinoma Development and Progression,&#x201d; Scientific Reports 13 (2023): 6645.</Citation></Reference><Reference><Citation>J. Eichberger, F. Weber, G. Spanier, et&#xa0;al., &#x201c;Loss of MMP&#x2010;27 Predicts Mandibular Bone Invasion in Oral Squamous Cell Carcinoma,&#x201d; Cancers (Basel) 14 (2022): 4044.</Citation></Reference><Reference><Citation>L. Boldrup, P. J. Coates, G. Laurell, and K. Nylander, &#x201c;Differences in p63 Expression in SCCHN Tumours of Different Sub&#x2010;Sites Within the Oral Cavity,&#x201d; Oral Oncology 47 (2011): 861&#x2013;865.</Citation></Reference><Reference><Citation>V. M. Patil, K. Prabhash, V. Noronha, et&#xa0;al., &#x201c;Neoadjuvant Chemotherapy Followed by Surgery in Very Locally Advanced Technically Unresectable Oral Cavity Cancers,&#x201d; Oral Oncology 50 (2014): 1000&#x2013;1004.</Citation></Reference><Reference><Citation>J. Y. Fu, X. H. Yue, M. J. Dong, J. Li, and C. P. Zhang, &#x201c;Assessment of Neoadjuvant Chemotherapy With Docetaxel, Cisplatin, and Fluorouracil in Patients With Oral Cavity Cancer,&#x201d; Cancer Medicine 12 (2023): 2417&#x2013;2426.</Citation></Reference><Reference><Citation>V. Noronha, A. Dhanawat, V. M. Patil, et&#xa0;al., &#x201c;Long&#x2010;Term Outcomes of Neo&#x2010;Adjuvant Chemotherapy on Borderline Resectable Oral Cavity Cancers: Real&#x2010;World Data of 3266 Patients and Implications for Clinical Practice,&#x201d; Oral Oncology 148 (2024): 106633.</Citation></Reference><Reference><Citation>A. Joshi, V. M. Patil, V. Noronha, et&#xa0;al., &#x201c;Is There a Role of Induction Chemotherapy Followed by Resection in T4b Oral Cavity Cancers?,&#x201d; Indian Journal of Cancer 50 (2013): 349&#x2013;355.</Citation></Reference><Reference><Citation>P. Bossi, S. Lo Vullo, M. Guzzo, et&#xa0;al., &#x201c;Preoperative Chemotherapy in Advanced Resectable OCSCC: Long&#x2010;Term Results of a Randomized Phase III Trial,&#x201d; Annals of Oncology 25 (2014): 462&#x2013;466.</Citation></Reference><Reference><Citation>F. Perrone, P. Bossi, B. Cortelazzi, et&#xa0;al., &#x201c;TP53 Mutations and Pathologic Complete Response to Neoadjuvant Cisplatin and Fluorouracil Chemotherapy in Resected Oral Cavity Squamous Cell Carcinoma,&#x201d; Journal of Clinical Oncology 28 (2010): 761&#x2013;766.</Citation></Reference><Reference><Citation>E. A. Mroz and J. W. Rocco, &#x201c;Functional p53 Status as a Biomarker for Chemotherapy Response in Oral&#x2010;Cavity Cancer,&#x201d; Journal of Clinical Oncology 28 (2010): 715&#x2013;717.</Citation></Reference><Reference><Citation>B. Ravishankar, B. V. Madhavi, A. Kalagara, et&#xa0;al., &#x201c;Clinical and Pathological Correlation of P(53) Expression in Oral Cancers,&#x201d; Pathology, Research and Practice 253 (2024): 155071.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70136 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41420436</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Dec</Month><Day>20</Day></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Feasibility and Adherence to Home-Based Intensive Treatment Programs for Chronic Radiation-Associated Dysphagia in Head and Neck Cancer Survivors-The HIT-CRAD Trial.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70136</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The HIT-CRAD trial (ISRCTN57028065) is the first to combine home-based non-invasive brain stimulation with high-volume strength and skill training over 8&#x2009;weeks in patients with chronic radiation-associated dysphagia (CRAD) following primary (chemo)radiotherapy for head and neck cancer.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Fifty-four patients were randomized into three groups. Group 1 performed 8&#x2009;weeks of strength training. Groups 2 and 3 combined 4&#x2009;weeks of strength training with 4&#x2009;weeks of skill training. Group 3 received high-definition transcranial direct current stimulation (HD-tDCS) during training. Group 2 received sham HD-tDCS.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall adherence and exercise adherence remained above 75% across all groups. Home-based HD-tDCS proved safe and feasible, with mild to moderate side effects (tingling, itching, or burning). Median exercise performance levels for strength training exercises ranged from 94% to 100%.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study confirms the feasibility of high-volume strength and skill training with HD-tDCS in patients with C-RAD. Proactive adherence-supporting factors facilitate high adherence in this population. Both real and sham HD-tDCS proved safe, feasible, and well tolerated.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">International Standard Randomized Controlled Trials Number (ISRCTN) registry ID ISRCTN57028065.</AbstractText><CopyrightInformation>&#xa9; 2025 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Massonet</LastName><ForeName>Hanne</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-6331-9738</Identifier><AffiliationInfo><Affiliation>Department of Neurosciences, Research Group Experimental Oto-Rhino-Laryngology, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Translational Neurosciences, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department Ear Nose Throat and Head and Neck Surgery, Swallow Clinic, University Hospitals Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goeleven</LastName><ForeName>Ann</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Research Group Experimental Oto-Rhino-Laryngology, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department Ear Nose Throat and Head and Neck Surgery, Swallow Clinic, University Hospitals Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nuyts</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-5540-4796</Identifier><AffiliationInfo><Affiliation>Department of Oncology, University Hospitals Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Oncology, Laboratory of Experimental Radiotherapy, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vergauwen</LastName><ForeName>Alice</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0005-0173-5804</Identifier><AffiliationInfo><Affiliation>Department of Translational Neurosciences, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otolaryngology and Head and Neck Surgery, Rehabilitation Center for Communication Disorders, Antwerp University Hospital, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baudelet</LastName><ForeName>Margot</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Head and Neck Surgery, Ghent University Hospital, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duprez</LastName><ForeName>Fr&#xe9;deric</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-7633-1960</Identifier><AffiliationInfo><Affiliation>Department of Head and Neck Surgery, Ghent University Hospital, Ghent, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Human Structure and Repair, Ghent University, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tomassen</LastName><ForeName>Peter</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-0698-6574</Identifier><AffiliationInfo><Affiliation>Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van den Steen</LastName><ForeName>Leen</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Translational Neurosciences, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otolaryngology and Head and Neck Surgery, Rehabilitation Center for Communication Disorders, Antwerp University Hospital, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Nuffelen</LastName><ForeName>Gwen</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-6934-4168</Identifier><AffiliationInfo><Affiliation>Department of Translational Neurosciences, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otolaryngology and Head and Neck Surgery, Rehabilitation Center for Communication Disorders, Antwerp University Hospital, Antwerp, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Head and Neck Surgery, Ghent University Hospital, Ghent, Belgium.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>KotK_KUL/2019/11813/1</GrantID><Agency>Kom op tegen Kanker (Stand Up to Cancer), the Flemish Cancer Society</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">McNeill dysphagia therapy program (MDTP)</Keyword><Keyword MajorTopicYN="N">chin tuck against resistance (CTAR)</Keyword><Keyword MajorTopicYN="N">dysphagia</Keyword><Keyword MajorTopicYN="N">expiratory muscle strength training (EMST)</Keyword><Keyword MajorTopicYN="N">head and neck</Keyword><Keyword MajorTopicYN="N">high&#x2010;definition transcranial direct current stimulation (HD&#x2010;tDCS)</Keyword><Keyword MajorTopicYN="N">non&#x2010;invasive brain stimulation</Keyword><Keyword MajorTopicYN="N">swallowing</Keyword><Keyword MajorTopicYN="N">swallowing exercises</Keyword><Keyword MajorTopicYN="N">tongue strengthening exercises</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>10</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>12</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>20</Day><Hour>6</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>20</Day><Hour>6</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>20</Day><Hour>4</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41420436</ArticleId><ArticleId IdType="doi">10.1002/hed.70136</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>L. R. Wall, E. C. Ward, B. Cartmill, and A. J. Hill, &#x201c;Physiological Changes to the Swallowing Mechanism Following (Chemo)radiotherapy for Head and Neck Cancer: A Systematic Review,&#x201d; Dysphagia 28 (2013): 481&#x2013;493, https://doi.org/10.1007/S00455&#x2010;013&#x2010;9491&#x2010;8.</Citation></Reference><Reference><Citation>H. M. Starmer, D. Tippett, K. Webster, et&#xa0;al., &#x201c;Swallowing Outcomes in Patients With Oropharyngeal Cancer Undergoing Organ&#x2010; Preservation Treatment,&#x201d; Head &amp; Neck 36 (2014): 1392&#x2013;1397, https://doi.org/10.1002/hed.23465.</Citation></Reference><Reference><Citation>N. P. Nguyen, S. Sallah, U. Karlsson, and J. E. Antoine, &#x201c;Combined Chemotherapy and Radiation Therapy for Head and Neck Malignancies: Quality of Life Issues,&#x201d; Cancer 94 (2002): 1131&#x2013;1141, https://doi.org/10.1002/cncr.10257.</Citation></Reference><Reference><Citation>S. J. Lovell, H. B. Wong, K. S. Loh, R. Y. S. Ngo, and J. A. Wilson, &#x201c;Impact of Dysphagia on Quality&#x2010;Of&#x2010;Life in Nasopharyngeal Carcinoma,&#x201d; Head &amp; Neck 27 (2005): 864&#x2013;872, https://doi.org/10.1002/HED.20250.</Citation></Reference><Reference><Citation>K. Grisar, R. Dok, J. Schoenaers, et&#xa0;al., &#x201c;Differences in Human Papillomavirus&#x2010;Positive and &#x2010;Negative Head and Neck Cancers in Belgium: An 8&#x2010;Year Retrospective, Comparative Study,&#x201d; Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology 121 (2016): 456&#x2013;460, https://doi.org/10.1016/j.oooo.2015.10.035.</Citation></Reference><Reference><Citation>C. Nutting, L. Finneran, J. Roe, et&#xa0;al., &#x201c;Dysphagia&#x2010;Optimised Intensity&#x2010;Modulated Radiotherapy Versus Standard Intensity&#x2010;Modulated Radiotherapy in Patients With Head and Neck Cancer (DARS): A Phase 3, Multicentre, Randomised, Controlled Trial,&#x201d; Lancet Oncology 24 (2023): 868&#x2013;880, https://doi.org/10.1016/S1470&#x2010;2045(23)00265&#x2010;6.</Citation></Reference><Reference><Citation>S. S. Batth, J. J. Caudell, and A. M. Chen, &#x201c;Practical Considerations in Reducing Swallowing Dysfunction Following Concurrent Chemoradiotherapy With Intensity&#x2010;Modulated Radiotherapy for Head and Neck Cancer,&#x201d; Head &amp; Neck 36 (2014): 291&#x2013;298, https://doi.org/10.1002/hed.23246.</Citation></Reference><Reference><Citation>A. Perry, S. H. Lee, S. Cotton, and C. Kennedy, &#x201c;Therapeutic Exercises for Affecting Post&#x2010;Treatment Swallowing in People Treated for Advanced&#x2010;Stage Head and Neck Cancers,&#x201d; Cochrane Database of Systematic Reviews 2016 (2016): CD011112, https://doi.org/10.1002/14651858.CD011112.pub2.</Citation></Reference><Reference><Citation>B. M. Ebersole, H. McMillan, and K. Hutcheson, &#x201c;Evaluation and Management of Speech and Swallowing Issues in RFS,&#x201d; Current Physical Medicine and Rehabilitation Reports 11 (2023): 93&#x2013;104, https://doi.org/10.1007/s40141&#x2010;023&#x2010;00388&#x2010;5.</Citation></Reference><Reference><Citation>H. Massonet, A. Goeleven, L. Van den Steen, et&#xa0;al., &#x201c;Home&#x2010;Based Intensive Treatment of Chronic Radiation&#x2010;Associated Dysphagia in Head and Neck Cancer Survivors (HIT&#x2010;CRAD Trial),&#x201d; Trials 23 (2022): 893, https://doi.org/10.1186/s13063&#x2010;022&#x2010;06832&#x2010;6.</Citation></Reference><Reference><Citation>J. Room, E. Hannink, H. Dawes, and K. Barker, &#x201c;What Interventions Are Used to Improve Exercise Adherence in Older People and What Behavioural Techniques Are They Based on? A Systematic Review,&#x201d; BMJ Open 7 (2017): e019221, https://doi.org/10.1136/bmjopen&#x2010;2017&#x2010;019221.</Citation></Reference><Reference><Citation>I. C. Cnossen, C. F. van Uden&#x2010;Kraan, R. N. P. M. Rinkel, et&#xa0;al., &#x201c;Multimodal Guided Self&#x2010;Help Exercise Program to Prevent Speech, Swallowing, and Shoulder Problems Among Head and Neck Cancer Patients: A Feasibility Study,&#x201d; Journal of Medical Internet Research 16 (2014): e74, https://doi.org/10.2196/jmir.2990.</Citation></Reference><Reference><Citation>S. A. C. Kraaijenga, L. van der Molen, M. M. Stuiver, et&#xa0;al., &#x201c;Efficacy of a Novel Swallowing Exercise Program for Chronic Dysphagia in Long&#x2010;Term Head and Neck Cancer Survivors,&#x201d; Head &amp; Neck 39 (2017): 1943&#x2013;1961, https://doi.org/10.1002/HED.24710.</Citation></Reference><Reference><Citation>J. Zhu, X. Wang, S. Chen, et&#xa0;al., &#x201c;Improving Compliance With Swallowing Exercise to Decrease Radiotherapy&#x2010;Related Dysphagia in Patients With Head and Neck Cancer,&#x201d; Asia&#x2010;Pacific Journal of Oncology Nursing 10 (2023): 100169, https://doi.org/10.1016/j.apjon.2022.100169.</Citation></Reference><Reference><Citation>M. Wells and E. King, &#x201c;Patient Adherence to Swallowing Exercises in Head and Neck Cancer,&#x201d; Current Opinion in Otolaryngology &amp; Head and Neck Surgery 25 (2017): 175&#x2013;181, https://doi.org/10.1097/MOO.0000000000000356.</Citation></Reference><Reference><Citation>L. Van Der Molen, M. A. Van Rossum, L. M. Burkhead, L. E. Smeele, C. R. N. Rasch, and F. J. M. Hilgers, &#x201c;A Randomized Preventive Rehabilitation Trial in Advanced Head and Neck Cancer Patients Treated With Chemoradiotherapy: Feasibility, Compliance, and Short&#x2010;Term Effects,&#x201d; Dysphagia 26 (2011): 155&#x2013;170, https://doi.org/10.1007/s00455&#x2010;010&#x2010;9288&#x2010;y.</Citation></Reference><Reference><Citation>E. Sabat&#xe9;, Adherence to Long&#x2010;Term Therapies: Evidence for Action (World Health Organisation, 2003).</Citation></Reference><Reference><Citation>E. M. Sluijs, G. J. Kok, and J. van der Zee, &#x201c;Correlates of Exercise Compliance in Physical Therapy,&#x201d; Physical Therapy 73 (1993): 771&#x2013;782, https://doi.org/10.1093/ptj/73.11.771.</Citation></Reference><Reference><Citation>K. Peek, R. Sanson&#x2010;Fisher, L. Mackenzie, and M. Carey, &#x201c;Interventions to Aid Patient Adherence to Physiotherapist Prescribed Self&#x2010;Management Strategies: A Systematic Review,&#x201d; Physiotherapy 102 (2016): 127&#x2013;135, https://doi.org/10.1016/J.PHYSIO.2015.10.003.</Citation></Reference><Reference><Citation>R. Govender, C. H. Smith, S. A. Taylor, D. Grey, J. Wardle, and B. Gardner, &#x201c;Identification of Behaviour Change Components in Swallowing Interventions for Head and Neck Cancer Patients: Protocol for a Systematic Review,&#x201d; Systematic Reviews 4 (2015): 89, https://doi.org/10.1186/s13643&#x2010;015&#x2010;0077&#x2010;4.</Citation></Reference><Reference><Citation>B. N. Krekeler, C. K. Broadfoot, S. Johnson, N. P. Connor, and N. Rogus&#x2010;Pulia, &#x201c;Patient Adherence to Dysphagia Recommendations: A Systematic Review,&#x201d; Dysphagia 33 (2018): 173&#x2013;184, https://doi.org/10.1007/S00455&#x2010;017&#x2010;9852&#x2010;9.</Citation></Reference><Reference><Citation>R. Govender, C. E. Wood, S. A. Taylor, C. H. Smith, H. Barratt, and B. Gardner, &#x201c;Patient Experiences of Swallowing Exercises After Head and Neck Cancer: A Qualitative Study Examining Barriers and Facilitators Using Behaviour Change Theory,&#x201d; Dysphagia 32 (2017): 559&#x2013;569, https://doi.org/10.1007/S00455&#x2010;017&#x2010;9799&#x2010;X.</Citation></Reference><Reference><Citation>R. Govender, C. H. Smith, S. A. Taylor, H. Barratt, and B. Gardner, &#x201c;Swallowing Interventions for the Treatment of Dysphagia After&#xa0;Head and Neck Cancer: A Systematic Review of Behavioural Strategies Used to Promote Patient Adherence to Swallowing Exercises,&#x201d; BMC Cancer 17 (2017): 43, https://doi.org/10.1186/s12885&#x2010;016&#x2010;2990&#x2010;x.</Citation></Reference><Reference><Citation>G. D. Carnaby&#x2010;Mann and M. A. Crary, &#x201c;McNeill Dysphagia Therapy Program: A Case&#x2010;Control Study,&#x201d; Archives of Physical Medicine and Rehabilitation 91 (2010): 743&#x2013;749, https://doi.org/10.1016/J.APMR.2010.01.013.</Citation></Reference><Reference><Citation>L. Van den Steen, M. Baudelet, P. Tomassen, K. Bonte, M. De Bodt, and G. Van Nuffelen, &#x201c;Effect of Tongue&#x2010;Strengthening Exercises on Tongue Strength and Swallowing&#x2010;Related Parameters in Chronic Radiation&#x2010;Associated Dysphagia,&#x201d; Head &amp; Neck 42 (2020): 2298&#x2013;2307, https://doi.org/10.1002/hed.26179.</Citation></Reference><Reference><Citation>K. A. Hutcheson, M. P. Barrow, E. K. Plowman, et&#xa0;al., &#x201c;Expiratory Muscle Strength Training for Radiation&#x2010;Associated Aspiration After Head and Neck Cancer: A Case Series,&#x201d; Laryngoscope 128 (2018): 1044&#x2013;1051, https://doi.org/10.1002/LARY.26845.</Citation></Reference><Reference><Citation>M. L. Huckabee, R. Flynn, and M. Mills, &#x201c;Expanding Rehabilitation Options for Dysphagia: Skill&#x2010;Based Swallowing Training,&#x201d; Dysphagia 38 (2023): 756&#x2013;767, https://doi.org/10.1007/S00455&#x2010;022&#x2010;10516&#x2010;3.</Citation></Reference><Reference><Citation>A. S&#xe1;nchez&#x2010;Kuhn, C. P&#xe9;rez&#x2010;Fern&#xe1;ndez, R. C&#xe1;novas, P. Flores, and F. S&#xe1;nchez&#x2010;Santed, &#x201c;Transcranial Direct Current Stimulation as a Motor Neurorehabilitation Tool: An Empirical Review,&#x201d; Biomedical Engineering Online 16 (2017): 76, https://doi.org/10.1186/s12938&#x2010;017&#x2010;0361&#x2010;8.</Citation></Reference><Reference><Citation>S. H. Doeltgen, L. Rigney, C. Cock, and T. Omari, &#x201c;Effects of Cortical Anodal Transcranial Direct Current Stimulation on Swallowing Biomechanics,&#x201d; Neurogastroenterology and Motility 30 (2018): e13434, https://doi.org/10.1111/nmo.13434.</Citation></Reference><Reference><Citation>I. Cheng, A. Sasegbon, and S. Hamdy, &#x201c;Effects of Neurostimulation on Poststroke Dysphagia: A Synthesis of Current Evidence From Randomized Controlled Trials,&#x201d; Neuromodulation: Technology at the Neural Interface 24 (2021): 1388&#x2013;1401, https://doi.org/10.1111/ner.13327.</Citation></Reference><Reference><Citation>J. Reckow, A. Rahman&#x2010;Filipiak, S. Garcia, et&#xa0;al., &#x201c;Tolerability and Blinding of 4x1 High&#x2010;Definition Transcranial Direct Current Stimulation (HD&#x2010;tDCS) at Two and Three Milliamps,&#x201d; Brain Stimulation 11 (2018): 991&#x2013;997, https://doi.org/10.1016/J.BRS.2018.04.022.</Citation></Reference><Reference><Citation>C. El Jamal, A. Harrie, A. Rahman&#x2010;Filipiak, et&#xa0;al., &#x201c;Tolerability and Blinding of High&#x2010;Definition Transcranial Direct Current Stimulation Among Older Adults at Intensities of up to 4 mA per Electrode,&#x201d; Brain Stimulation 16 (2023): 1328&#x2013;1335, https://doi.org/10.1016/J.BRS.2023.08.025.</Citation></Reference><Reference><Citation>B. de Souza Moura, X. S. Hu, M. F. DosSantos, and A. F. DaSilva, &#x201c;Study Protocol of tDCS Based Pain Modulation in Head and Neck Cancer Patients Under Chemoradiation Therapy Condition: An fNIRS&#x2010;EEG Study,&#x201d; Frontiers in Molecular Neuroscience 15 (2022): 859988, https://doi.org/10.3389/FNMOL.2022.859988.</Citation></Reference><Reference><Citation>X.&#x2010;S. Hu, C. A. Fisher, S. M. Munz, et&#xa0;al., &#x201c;Feasibility of Non&#x2010;Invasive Brain Modulation for Management of Pain Related to Chemoradiotherapy in Patients With Advanced Head and Neck Cancer,&#x201d; Frontiers in Human Neuroscience 10 (2016): 466, https://doi.org/10.3389/fnhum.2016.00466.</Citation></Reference><Reference><Citation>P. C. Belafsky, D. A. Mouadeb, C. J. Rees, et&#xa0;al., &#x201c;Validity and Reliability of the Eating Assessment Tool (EAT&#x2010;10),&#x201d; Annals of Otology, Rhinology and Laryngology 117 (2008): 919&#x2013;924, https://doi.org/10.1177/000348940811701210.</Citation></Reference><Reference><Citation>M. A. Crary, G. D. Carnaby Mann, and M. E. Groher, &#x201c;Initial Psychometric Assessment of a Functional Oral Intake Scale for Dysphagia in Stroke Patients,&#x201d; Archives of Physical Medicine and Rehabilitation 86 (2005): 1516&#x2013;1520, https://doi.org/10.1016/j.apmr.2004.11.049.</Citation></Reference><Reference><Citation>O. Lerner, J. Friedman, and S. Frenkel&#x2010;Toledo, &#x201c;The Effect of High&#x2010;Definition Transcranial Direct Current Stimulation Intensity on Motor Performance in Healthy Adults: A Randomized Controlled Trial,&#x201d; Journal of Neuroengineering and Rehabilitation 18 (2021): 103, https://doi.org/10.1186/S12984&#x2010;021&#x2010;00899&#x2010;Z.</Citation></Reference><Reference><Citation>S. Jefferson, S. Mistry, S. Singh, J. Rothwell, and S. Hamdy, &#x201c;Characterizing the Application of Transcranial Direct Current Stimulation in Human Pharyngeal Motor Cortex,&#x201d; American Journal of Physiology. Gastrointestinal and Liver Physiology 297 (2009): G1035&#x2013;G1040, https://doi.org/10.1152/ajpgi.00294.2009.</Citation></Reference><Reference><Citation>M. Baudelet, F. Duprez, L. Van den Steen, et&#xa0;al., &#x201c;Increasing Adherence to Prophylactic Swallowing Exercises During Head and Neck Radiotherapy: The Multicenter, Randomized Controlled PRESTO&#x2010;Trial,&#x201d; Dysphagia 38 (2023): 886&#x2013;895, https://doi.org/10.1007/S00455&#x2010;022&#x2010;10513&#x2010;6.</Citation></Reference><Reference><Citation>L. R. Wall, E. C. Ward, B. Cartmill, A. J. Hill, and S. V. Porceddu, &#x201c;Adherence to a Prophylactic Swallowing Therapy Program During (Chemo) Radiotherapy: Impact of Service&#x2010;Delivery Model and Patient Factors,&#x201d; Dysphagia 32 (2017): 279&#x2013;292, https://doi.org/10.1007/S00455&#x2010;016&#x2010;9757&#x2010;Z.</Citation></Reference><Reference><Citation>N. Stinckens, A. Ulburghs, and L. Claes, &#x201c;De werkalliantie als sleutelelement in het therapiegebeuren Meting met behulp van de WAV&#x2010;12, de Nederlandstalige verkorte versie van de Working Alliance Inventory,&#x201d; Klinische Psychologie 39 (2009): 44&#x2013;60.</Citation></Reference><Reference><Citation>A. R. Brunoni, J. Amadera, B. Berbel, M. S. Volz, B. G. Rizzerio, and F. Fregni, &#x201c;A Systematic Review on Reporting and Assessment of Adverse Effects Associated With Transcranial Direct Current Stimulation,&#x201d; International Journal of Neuropsychopharmacology 14 (2011): 1133&#x2013;1145, https://doi.org/10.1017/S1461145710001690.</Citation></Reference><Reference><Citation>A. J. A. M. Thissen, F. van Bergen, J. F. M. de Jonghe, R. P. C. Kessels, and P. L. J. Dautzenberg, &#x201c;Bruikbaarheid en validiteit van de Nederlandse versie van de Montreal Cognitive Assessment (MoCA&#x2010;D) bij het diagnosticeren van Mild Cognitive Impairment,&#x201d; Tijdschrift voor Gerontologie en Geriatrie 41 (2010): 231&#x2013;240, https://doi.org/10.1007/s12439&#x2010;010&#x2010;0218&#x2010;0.</Citation></Reference><Reference><Citation>M. Sekhon, M. Cartwright, and J. J. Francis, &#x201c;Acceptability of Healthcare Interventions: An Overview of Reviews and Development of a Theoretical Framework,&#x201d; BMC Health Services Research 17 (2017): 88, https://doi.org/10.1186/s12913&#x2010;017&#x2010;2031&#x2010;8.</Citation></Reference><Reference><Citation>G. Constantinescu, J. Rieger, H. Seikaly, and D. Eurich, &#x201c;Adherence to Home&#x2010;Based Swallowing Therapy Using a Mobile System in Head and Neck Cancer Survivors,&#x201d; American Journal of Speech&#x2010;Language Pathology 30 (2021): 2465&#x2013;2475, https://doi.org/10.1044/2021_AJSLP&#x2010;21&#x2010;00026.</Citation></Reference><Reference><Citation>K. Petersson, C. Finizia, N. Pauli, H. Dotevall, and L. Tuomi, &#x201c;A Randomized Controlled Study Evaluating the Head&#x2010;Lift Exercise in Head and Neck Cancer Patients With Radiation&#x2010;Induced Dysphagia: Effect on Swallowing Function and Health&#x2010;Related Quality of Life Over 12 Months,&#x201d; European Archives of Oto&#x2010;Rhino&#x2010;Laryngology 280 (2023): 5445&#x2013;5457, https://doi.org/10.1007/s00405&#x2010;023&#x2010;08183&#x2010;7.</Citation></Reference><Reference><Citation>E. H. Shinn, K. Basen&#x2010;Engquist, G. Baum, et&#xa0;al., &#x201c;Adherence to Preventive Exercises and Self&#x2010;Reported Swallowing Outcomes in Post&#x2010;Radiation Head and Neck Cancer Patients,&#x201d; Head &amp; Neck 35 (2013): 1707&#x2013;1712, https://doi.org/10.1002/HED.23255.</Citation></Reference><Reference><Citation>G. P. Krisciunas, K. Castellano, T. M. McCulloch, et&#xa0;al., &#x201c;Impact of Compliance on Dysphagia Rehabilitation in Head and Neck Cancer Patients: Results From a Multi&#x2010;Center Clinical Trial,&#x201d; Dysphagia 32 (2017): 327&#x2013;336, https://doi.org/10.1007/s00455&#x2010;016&#x2010;9760&#x2010;4.</Citation></Reference><Reference><Citation>M. Checklin, J. Bain, L. Bath, and K. Lethbridge, &#x201c;Patients' Perspectives on What Makes a Better Care Experience While Undergoing Treatment for Oropharyngeal Dysphagia Secondary to Head and Neck Cancer,&#x201d; Dysphagia 35 (2020): 702&#x2013;716, https://doi.org/10.1007/S00455&#x2010;019&#x2010;10077&#x2010;Y.</Citation></Reference><Reference><Citation>A. Antal, I. Alekseichuk, M. Bikson, et&#xa0;al., &#x201c;Low Intensity Transcranial Electric Stimulation: Safety, Ethical, Legal Regulatory and Application Guidelines,&#x201d; Clinical Neurophysiology 128 (2017): 1774&#x2013;1809, https://doi.org/10.1016/j.clinph.2017.06.001.</Citation></Reference><Reference><Citation>M. Velez, L. H. Lugo&#x2010;Agudelo, D. F. Pati&#xf1;o Lugo, et&#xa0;al., &#x201c;Factors That Influence the Provision of Home&#x2010;Based Rehabilitation Services for People Needing Rehabilitation: A Qualitative Evidence Synthesis,&#x201d; Cochrane Database of Systematic Reviews 2023, no. 2 (2023): CD014823, https://doi.org/10.1002/14651858.CD014823.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70132 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41403153</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Dec</Month><Day>16</Day></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Neutrophil to Lymphocyte and Lymphocyte to Monocyte Ratios Predict Improved Survival and Response to Induction Chemotherapy in Locally Advanced Squamous Cell Carcinoma of the Larynx.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70132</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">University of Michigan Cancer Center (UMCC) protocol 9520 treated stage III/IV locally advanced squamous cell carcinoma of the larynx (LASCCL) with cisplatin and 5-fluorouracil to select for definitive therapy based on response. Studies have shown that neutrophil-lymphocyte ratio (NLR) and lymphocyte-monocyte ratio (LMR) are potential prognostic markers in p16-negative LASCCL. This study analyzes the predictive value of NLR and LMR.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Samples from 193 LASCCL patients treated with chemotherapy were reviewed. Response to induction chemotherapy was tested with logistic regression. Optimal cut-points were determined by Youden's index. Survival was tested with Cox proportional hazards models.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">LMR had a positive association, NLR had a negative association with response to chemotherapy (p&#x2009;=&#x2009;0.004;0.07). Response was higher in patients with LMR &#x2265;&#x2009;2.8 (p&#x2009;=&#x2009;0.0007) and NLR &#x2264;&#x2009;2.8 (p&#x2009;=&#x2009;0.04). Overall and disease-specific survival improved with LMR &#x2265;&#x2009;2.8 (p&#x2009;=&#x2009;0.0002;0.004) and NLR &#x2264;&#x2009;2.8 (p&#x2009;=&#x2009;0.10;0.03).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Low NLR and high LMR were associated with favorable responses to chemotherapy and survival in LASCCL.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). Head &amp; Neck published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Risch</LastName><ForeName>Zachary</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Hematology/Oncology, Ohio State University, Columbus, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bellile</LastName><ForeName>Emily</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Cancer Data Science, Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bughrara</LastName><ForeName>Moneb S</ForeName><Initials>MS</Initials><Identifier Source="ORCID">0000-0002-1100-6518</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swiecicki</LastName><ForeName>Paul L</ForeName><Initials>PL</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casper</LastName><ForeName>Keith</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malloy</LastName><ForeName>Kelly</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hogikyan</LastName><ForeName>Norman</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spector</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shuman</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stucken</LastName><ForeName>Chaz</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chinn</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chepeha</LastName><ForeName>Douglas C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jolly</LastName><ForeName>Shruti</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mierzwa</LastName><ForeName>Michelle</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bradford</LastName><ForeName>Carol</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Ohio State University, Columbus, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eisbruch</LastName><ForeName>Avraham</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carey</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prince</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolf</LastName><ForeName>Gregory T</ForeName><Initials>GT</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Worden</LastName><ForeName>Francis P</ForeName><Initials>FP</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30CA046592</GrantID><Agency>National Cancer Institute of the National Institutes of Health under the University of Michigan Comprehensive Cancer Center Core Grant</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">induction chemotherapy</Keyword><Keyword MajorTopicYN="N">lymphocyte/monocyte</Keyword><Keyword MajorTopicYN="N">neutrophil/lymphocyte ratio</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>8</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>11</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>17</Day><Hour>2</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41403153</ArticleId><ArticleId IdType="doi">10.1002/hed.70132</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>R. L. Siegel, T. B. Kratzer, A. N. Giaquinto, H. Sung, and A. Jemal, &#x201c;Cancer Statistics, 2025,&#x201d; CA: A Cancer Journal for Clinicians 75, no. 1 (2025): 10&#x2013;45, https://doi.org/10.3322/caac.21871.</Citation></Reference><Reference><Citation>J. P. Shah, &#x201c;Epidermoid Carcinoma of the Supraglottic Larynx. Role of Neck Dissection in Initial Surgical Treatment,&#x201d; American Journal of Surgery 128, no. 4 (1974): 494&#x2013;499, https://doi.org/10.1016/0002&#x2010;9610(74)90262&#x2010;1.</Citation></Reference><Reference><Citation>N. V. Hawkins, &#x201c;The Treatment of Glottic Carcinoma: An Analysis of 800 Cases,&#x201d; Laryngoscope 85 (1975): 1485&#x2013;1493, https://doi.org/10.1288/00005537&#x2010;197509000&#x2010;00009.</Citation></Reference><Reference><Citation>R. H. Jesse, &#x201c;The Evaluation of Treatment of Patients With Extensive Squamous Cancer of the Vocal Cords,&#x201d; Laryngoscope 85 (1975): 1424&#x2013;1429, https://doi.org/10.1288/00005537&#x2010;197509000&#x2010;00002.</Citation></Reference><Reference><Citation>A. R. Harwood and E. Rawlinson, &#x201c;The Quality of Life of Patients Following Treatment for Laryngeal Cancer,&#x201d; International Journal of Radiation Oncology, Biology, Physics 7 (1983): 335&#x2013;338, https://doi.org/10.1016/0360&#x2010;3016(83)90292&#x2010;4.</Citation></Reference><Reference><Citation>B. J. Mcneil, R. Weichselbaum, and S. G. Pauker, &#x201c;Speech and Survival,&#x201d; New England Journal of Medicine 305, no. 17 (1981): 982&#x2013;987, https://doi.org/10.1056/nejm198110223051704.</Citation></Reference><Reference><Citation>G. T. Wolf, S. G. Fisher, W. K. Hong, et&#xa0;al., &#x201c;Induction Chemotherapy Plus Radiation Compared With Surgery Plus Radiation in Patients With Advanced Laryngeal Cancer,&#x201d; New England Journal of Medicine 324, no. 24 (1991): 1685&#x2013;1690, https://doi.org/10.1056/nejm199106133242402.</Citation></Reference><Reference><Citation>A. A. Forastiere, H. Goepfert, M. Maor, et&#xa0;al., &#x201c;Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer,&#x201d; New England Journal of Medicine 349, no. 22 (2003): 2091&#x2013;2098, https://doi.org/10.1056/nejmoa031317.</Citation></Reference><Reference><Citation>D. A. Silverman, S. V. Puram, J. W. Rocco, M. O. Old, and S. Y. Kang, &#x201c;Salvage Laryngectomy Following Organ&#x2010;Preservation Therapy: An Evidence&#x2010;Based Review,&#x201d; Oral Oncology 88 (2019): 137&#x2013;144, https://doi.org/10.1016/j.oraloncology.2018.11.022.</Citation></Reference><Reference><Citation>S. Urba, G. Wolf, A. Eisbruch, et&#xa0;al., &#x201c;Single&#x2010;Cycle Induction Chemotherapy Selects Patients With Advanced Laryngeal Cancer for Combined Chemoradiation: A New Treatment Paradigm,&#x201d; Journal of Clinical Oncology 24, no. 4 (2006): 593&#x2013;598, https://doi.org/10.1200/jco.2005.01.2047.</Citation></Reference><Reference><Citation>K. Fung, T. H. Lyden, J. Lee, et&#xa0;al., &#x201c;Voice and Swallowing Outcomes of an Organ&#x2010;Preservation Trial for Advanced Laryngeal Cancer,&#x201d; International Journal of Radiation Oncology, Biology, Physics 63, no. 5 (2005): 1395&#x2013;1399, https://doi.org/10.1016/j.ijrobp.2005.05.004.</Citation></Reference><Reference><Citation>G. T. Wolf, E. Bellile, A. Eisbruch, et&#xa0;al., &#x201c;Survival Rates Using Individualized Bioselection Treatment Methods in Patients With Advanced Laryngeal Cancer,&#x201d; JAMA Otolaryngology. Head &amp; Neck Surgery 143, no. 4 (2017): 355, https://doi.org/10.1001/jamaoto.2016.3669.</Citation></Reference><Reference><Citation>N. A. Dewyer, G. T. Wolf, E. Light, et&#xa0;al., &#x201c;Circulating CD4&#x2010;Positive Lymphocyte Levels as Predictor of Response to Induction Chemotherapy in Patients With Advanced Laryngeal Cancer,&#x201d; Head &amp; Neck 36, no. 1 (2014): 9&#x2013;14, https://doi.org/10.1002/hed.23263.</Citation></Reference><Reference><Citation>F. De Felice, M. Tombolini, G. Abate, et&#xa0;al., &#x201c;Prognostic Significance of the Neutrophil/Lymphocyte Ratio in Patients With Non&#x2010;Human Papilloma Virus&#x2010;Related Oropharyngeal Cancer: A Retrospective Cohort Study,&#x201d; Oncology 96, no. 1 (2019): 8&#x2013;13, https://doi.org/10.1159/000492389.</Citation></Reference><Reference><Citation>J. Yang, C. Y. Hsueh, W. Cao, and L. Zhou, &#x201c;Pretreatment Lymphocyte&#x2010;To&#x2010;Monocyte Ratio as an Independent Prognostic Factor for Hypopharyngeal Squamous Cell Carcinoma,&#x201d; Acta Oto&#x2010;Laryngologica 138, no. 8 (2018): 734&#x2013;740, https://doi.org/10.1080/00016489.2018.1449965.</Citation></Reference><Reference><Citation>J.&#x2010;K. Cho, M. W. Kim, I. S. Choi, et&#xa0;al., &#x201c;Optimal Cutoff of Pretreatment Neutrophil&#x2010;To&#x2010;Lymphocyte Ratio in Head and Neck Cancer Patients: A Meta&#x2010;Analysis and Validation Study,&#x201d; BMC Cancer 18, no. 1 (2018): 969, https://doi.org/10.1186/s12885&#x2010;018&#x2010;4876&#x2010;6.</Citation></Reference><Reference><Citation>T. F. Nishijima, H. B. Muss, S. S. Shachar, K. Tamura, and Y. Takamatsu, &#x201c;Prognostic Value of Lymphocyte&#x2010;To&#x2010;Monocyte Ratio in Patients With Solid Tumors: A Systematic Review and Meta&#x2010;Analysis,&#x201d; Cancer Treatment Reviews 41, no. 10 (2015): 971&#x2013;978, https://doi.org/10.1016/j.ctrv.2015.10.003.</Citation></Reference><Reference><Citation>P. Gorphe, S. Bouhir, G. C. T. E. Garcia, et&#xa0;al., &#x201c;Anemia and Neutrophil&#x2010;To&#x2010;Lymphocyte Ratio in Laryngeal Cancer Treated With Induction Chemotherapy,&#x201d; Laryngoscope 130, no. 4 (2020): E144&#x2013;E150, https://doi.org/10.1002/lary.28021.</Citation></Reference><Reference><Citation>Y. C. Zeng, F. Chi, R. Xing, et&#xa0;al., &#x201c;Pre&#x2010;Treatment Neutrophil&#x2010;To&#x2010;Lymphocyte Ratio Predicts Prognosis in Patients With Locoregionally Advanced Laryngeal Carcinoma Treated With Chemoradiotherapy,&#x201d; Japanese Journal of Clinical Oncology 46, no. 2 (2016): 126&#x2013;131, https://doi.org/10.1093/jjco/hyv175.</Citation></Reference><Reference><Citation>F. Pag&#xe8;s, A. Kirilovsky, B. Mlecnik, et&#xa0;al., &#x201c;In Situ Cytotoxic and Memory T Cells Predict Outcome in Patients With Early&#x2010;Stage Colorectal Cancer,&#x201d; Journal of Clinical Oncology 27, no. 35 (2009): 5944&#x2013;5951, https://doi.org/10.1200/jco.2008.19.6147.</Citation></Reference><Reference><Citation>R. Hoesli, A. C. Birkeland, A. J. Rosko, et&#xa0;al., &#x201c;Proportion of CD4 and CD8 Tumor Infiltrating Lymphocytes Predicts Survival in Persistent/Recurrent Laryngeal Squamous Cell Carcinoma,&#x201d; Oral Oncology 77 (2018): 83&#x2013;89, https://doi.org/10.1016/j.oraloncology.2017.12.003.</Citation></Reference><Reference><Citation>P. Balermpas, Y. Michel, J. Wagenblast, et&#xa0;al., &#x201c;Tumour&#x2010;Infiltrating Lymphocytes Predict Response to Definitive Chemoradiotherapy in Head and Neck Cancer,&#x201d; British Journal of Cancer 110, no. 2 (2014): 501&#x2013;509, https://doi.org/10.1038/bjc.2013.640.</Citation></Reference><Reference><Citation>Y. Zhu, M. Li, C. Bo, et&#xa0;al., &#x201c;Prognostic Significance of the Lymphocyte&#x2010;To&#x2010;Monocyte Ratio and the Tumor&#x2010;Infiltrating Lymphocyte to Tumor&#x2010;Associated Macrophage Ratio in Patients With Stage T3N0M0 Esophageal Squamous Cell Carcinoma,&#x201d; Cancer Immunology, Immunotherapy 66, no. 3 (2017): 343&#x2013;354, https://doi.org/10.1007/s00262&#x2010;016&#x2010;1931&#x2010;5.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.28248 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40657847</PMID><DateCompleted><Year>2025</Year><Month>12</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>12</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><Volume>48</Volume><Issue>1</Issue><PubDate><Year>2026</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Traumatic Intrathyroidal Hematoma: Case Report and Review of Literature.</ArticleTitle><Pagination><StartPage>E10</StartPage><EndPage>E13</EndPage><MedlinePgn>E10-E13</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.28248</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Traumatic expanding intrathyroidal hematoma is rare and can be clinically obscured, leading to delayed diagnosis and potential airway compromise. Identification and prompt intervention are paramount to survival.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patient presented to the emergency department as a modified trauma without signs of respiratory distress or enlarging neck circumference. Comprehensive trauma imaging identified the thyroid pathology prompting otolaryngology involvement.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Rapid operating room arrangement allowed for prevention of airway compromise, straight forward intubation, and resolution of thyroid pathology prior to clinical decompensation.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We present an unusual case of traumatic thyroid hematoma in which the bleeding source was contained within the thyroid capsule; intubation and surgical intervention resolved the airway and thyroid pathology. Trauma-indicated imaging allowed for identification in a clinically obscured pathology.</AbstractText><CopyrightInformation>&#xa9; 2025 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Terry</LastName><ForeName>Morgan</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-7546-1472</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology, Oregon Health &amp; Science University, Portland, Oregon, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Araujo</LastName><ForeName>Ana</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-6331-2317</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology, Oregon Health &amp; Science University, Portland, Oregon, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trott</LastName><ForeName>Skylar</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-0628-6882</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology, Oregon Health &amp; Science University, Portland, Oregon, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wax</LastName><ForeName>Mark K</ForeName><Initials>MK</Initials><Identifier Source="ORCID">0000-0003-0250-8636</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology, Oregon Health &amp; Science University, Portland, Oregon, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006406" MajorTopicYN="Y">Hematoma</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014057" MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013961" MajorTopicYN="Y">Thyroid Gland</DescriptorName><QualifierName UI="Q000293" MajorTopicYN="N">injuries</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013959" MajorTopicYN="Y">Thyroid Diseases</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">neck hematoma</Keyword><Keyword MajorTopicYN="N">thyroid rupture</Keyword><Keyword MajorTopicYN="N">trauma</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>2</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>14</Day><Hour>12</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>14</Day><Hour>8</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40657847</ArticleId><ArticleId IdType="doi">10.1002/hed.28248</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>J. Ahrens, B. J&#xfc;ttner, S. Heidt, D. Scheinichen, and M. Przemeck, &#x201c;Thyroid Gland Rupture: A Rare Case of Respiratory Distress,&#x201d; Journal of Emergency Medicine 43, no. 1 (2012): 41&#x2013;43, https://doi.org/10.1016/j.jemermed.2009.05.010.</Citation></Reference><Reference><Citation>K. Hoetzenecker, M. T&#xf6;pker, W. Klepetko, and H. J. Ankersmit, &#x201c;Spontaneous Rupture of the Inferior Thyroid Artery Resulting in Mediastinal Hematoma,&#x201d; Interactive Cardiovascular and Thoracic Surgery 11, no. 2 (2010): 209&#x2013;210, https://doi.org/10.1510/icvts.2010.232553.</Citation></Reference><Reference><Citation>M. Stenner, V. Helmstaedter, E. Spuentrup, G. Quante, and K. B. Huettenbrink, &#x201c;Cervical Hemorrhage due to Spontaneous Rupture of the Superior Thyroid Artery: Case Report and Review of the Literature,&#x201d; Head &amp; Neck 32, no. 9 (2010): 1277&#x2013;1281, https://doi.org/10.1002/hed.21213.</Citation></Reference><Reference><Citation>L. B. Chartier and J. P. Turner, &#x201c;Delayed Intrathyroidal Hematoma Causing Respiratory Distress After a Seemingly Benign Fall: A Case Report,&#x201d; International Journal of Emergency Medicine 3, no. 4 (2010): 431&#x2013;433, https://doi.org/10.1007/s12245&#x2010;010&#x2010;0196&#x2010;6.</Citation></Reference><Reference><Citation>J. Lemke, M. N. Schreiber, D. Henne&#x2010;Bruns, G. Cammerer, and A. Hillenbrand, &#x201c;Thyroid Gland Hemorrhage After Blunt Neck Trauma: Case Report and Review of the Literature,&#x201d; BMC Surgery 17, no. 1 (2017): 115, https://doi.org/10.1186/s12893&#x2010;017&#x2010;0322&#x2010;y.</Citation></Reference><Reference><Citation>C. Stylianou, I. Gogoulis, V. Karapepera, K. Chaidas, and M. Karanikas, &#x201c;Successful Conservative Management of Thyroid Rupture and Haematoma Following Blunt Cervical Trauma: A Case Report,&#x201d; Cureus 17, no. 2 (2025): e78368, https://doi.org/10.7759/cureus.78368.</Citation></Reference><Reference><Citation>A. S. Alayaaf and Y. S. Kim, &#x201c;Thyroid Gland Injury After Blunt Neck Trauma: A Case Report,&#x201d; Ulusal Travma ve Acil Cerrahi Dergisi 29, no. 7 (2023): 834&#x2013;836, https://doi.org/10.14744/tjtes.2023.77567.</Citation></Reference><Reference><Citation>M. S. Shenoy, V. Mathew, I. Mathews, N. George, and G. Joseph, &#x201c;Isolated Cricoid Fracture and Thyroid Hematoma in Blunt Injury of the Neck,&#x201d; Indian Journal of Otolaryngology and Head &amp; Neck Surgery 74, no. Suppl 3 (2022): 5028&#x2013;5032, https://doi.org/10.1007/s12070&#x2010;021&#x2010;02659&#x2010;w.</Citation></Reference><Reference><Citation>S. S. Huang and W. C. Lien, &#x201c;Successful Nonoperative Management of a Traumatic Bilateral Thyroid Hemorrhage Following Blunt Neck Trauma,&#x201d; Journal of Emergencies, Trauma, and Shock 15, no. 4 (2022): 186&#x2013;187, https://doi.org/10.4103/jets.jets_157_21.</Citation></Reference><Reference><Citation>I. Al&#x2010;Njadat, M. Obeidat, W. El&#x2010;Sukkar, and M. Al&#x2010;Swalgh, &#x201c;Isolated Thyroid Hematoma After Blunt Neck Trauma Presented With Aphonia,&#x201d; Medical Journal Armed Forces India 76, no. 4 (2020): 456&#x2013;458, https://doi.org/10.1016/j.mjafi.2019.02.001.</Citation></Reference><Reference><Citation>C. T. Nguyen and J. Bunevich, &#x201c;Hemorrhagic Thyroid Nodule Resulting in Expanding Neck Hematoma Following Blunt Cervical Trauma,&#x201d; Ear, Nose &amp; Throat Journal 98, no. 4 (2019): 195&#x2013;196, https://doi.org/10.1177/0145561318823396.</Citation></Reference><Reference><Citation>H. P. Tam, C. F. Hsieh, C. M. Chao, and C. C. Lai, &#x201c;Blunt Neck Trauma Causing Thyroid Hemorrhage,&#x201d; American Journal of the Medical Sciences 351, no. 6 (2016): e9, https://doi.org/10.1016/j.amjms.2016.01.029.</Citation></Reference><Reference><Citation>H. Hara, Y. Hirose, and H. Yamashita, &#x201c;Thyroid Gland Rupture Caused by Blunt Trauma to the Neck,&#x201d; BMC Research Notes 9 (2016): 114, https://doi.org/10.1186/s13104&#x2010;016&#x2010;1932&#x2010;7.</Citation></Reference><Reference><Citation>R. Ved, N. Patel, and M. Stechman, &#x201c;Surgical Management of Life&#x2010;Threatening Thyroid Haematoma Following Occult Blunt Neck Trauma,&#x201d; Case Reports in Endocrinology 2016 (2016): 4307695, https://doi.org/10.1155/2016/4307695.</Citation></Reference><Reference><Citation>K. Tsukahara, K. Sato, T. Yumoto, et&#xa0;al., &#x201c;Soft Tissue Hematoma of the Neck Due to Thyroid Rupture With Unusual Mechanism,&#x201d; International Journal of Surgery Case Reports 26 (2016): 217&#x2013;220, https://doi.org/10.1016/j.ijscr.2016.08.002.</Citation></Reference><Reference><Citation>J. H. Shin, Y. B. Ji, J. H. Jeong, S. H. Lee, and K. Tae, &#x201c;Two Cases of Thyroid Rupture After Blunt Cervical Trauma,&#x201d; Ear, Nose &amp; Throat Journal 94, no. 7 (2015): E21&#x2013;E23, https://doi.org/10.1177/014556131509400718.</Citation></Reference><Reference><Citation>S. Arana&#x2010;Garza, M. Juarez&#x2010;Parra, J. Monterrubio&#x2010;Rodr&#xed;guez, et&#xa0;al., &#x201c;Thyroid Gland Rupture After Blunt Neck Trauma: A Case Report and Review of the Literature,&#x201d; International Journal of Surgery Case Reports 12 (2015): 44&#x2013;47, https://doi.org/10.1016/j.ijscr.2015.04.020.</Citation></Reference><Reference><Citation>Y. L. Sow, N. A. Aziz, and K. L. Ng, &#x201c;Thyroid Rupture Secondary to Blunt Neck Trauma,&#x201d; American Journal of Emergency Medicine 31, no. 4 (2013): 760.e3&#x2013;760.e5, https://doi.org/10.1016/j.ajem.2012.12.005.</Citation></Reference><Reference><Citation>G. Donatini, &#x201c;Persistent Dyspnea Following Thyroid Hematoma After Neck Blunt Trauma,&#x201d; Updates in Surgery 64, no. 1 (2012): 69&#x2013;71, https://doi.org/10.1007/s13304&#x2010;011&#x2010;0076&#x2010;5.</Citation></Reference><Reference><Citation>C. M. Rivera&#x2010;Serrano, B. J. Park, and R. L. Ferris, &#x201c;Traumatic Thyroid Hematoma Associated With Thyroid Carcinoma,&#x201d; Ear, Nose &amp; Throat Journal 91, no. 9 (2012): E25&#x2013;E26.</Citation></Reference><Reference><Citation>E. E. Schipper, D. R. Kool, T. Wobbes, and L. M. Geeraedts, Jr., &#x201c;Management of Thyroid Gland Hemorrhage After Blunt Trauma: A Case Report and Review of the Literature,&#x201d; European Journal of Trauma and Emergency Surgery 35, no. 6 (2009): 587&#x2013;590, https://doi.org/10.1007/s00068&#x2010;008&#x2010;8226&#x2010;2.</Citation></Reference><Reference><Citation>B. Saylam, B. Com&#xe7;ali, M. V. Ozer, and F. Coskun, &#x201c;Thyroid Gland Hematoma After Blunt Neck Trauma,&#x201d; Western Journal of Emergency Medicine 10, no. 4 (2009): 247&#x2013;249.</Citation></Reference><Reference><Citation>H. Stunell, J. O'Brien, W. Benfayed, and W. C. Torreggiani, &#x201c;Thyroid Gland Rupture After Blunt Cervical Trauma,&#x201d; Journal of Ultrasound in Medicine 26, no. 7 (2007): 992, https://doi.org/10.7863/jum.2007.26.7.992.</Citation></Reference><Reference><Citation>Y. Oka, J. Nishijima, T. Azuma, et&#xa0;al., &#x201c;Blunt Thyroid Trauma With Acute Hemorrhage and Respiratory Distress,&#x201d; Journal of Emergency Medicine 32, no. 4 (2007): 381&#x2013;385, https://doi.org/10.1016/j.jemermed.2006.08.019.</Citation></Reference><Reference><Citation>C. H. Park, K. K. Oh, E. K. Kim, M. J. Kim, J. Jeong, and E. J. Son, &#x201c;Thyroid Gland Rupture After Blunt Cervical Trauma,&#x201d; Journal of Ultrasound in Medicine 25, no. 7 (2006): 943&#x2013;946, https://doi.org/10.7863/jum.2006.25.7.943.</Citation></Reference><Reference><Citation>D. Pop, N. Venissac, F. Leo, B. S. Karimdjee, F. Tiger, and J. Mouroux, &#x201c;Traumatic Rupture of Retrosternal Goiter: A Rare Case of Acute Superior Mediastinal Syndrome,&#x201d; Journal of Thoracic and Cardiovascular Surgery 129, no. 2 (2005): 460&#x2013;461, https://doi.org/10.1016/j.jtcvs.2004.06.032.</Citation></Reference><Reference><Citation>C. Weeks, F. D. Moore, Jr., S. J. Ferzoco, and J. Gates, &#x201c;Blunt Trauma to the Thyroid: A Case Report,&#x201d; American Surgeon 71, no. 6 (2005): 518&#x2013;521.</Citation></Reference><Reference><Citation>N. Hirshoren, E. Hocwald, and R. Eliashar, &#x201c;Isolated Traumatic Thyroid Hemorrhage Secondary to Air Bag Deployment,&#x201d; Otolaryngology&#x2013;Head and Neck Surgery 130, no. 6 (2004): 791&#x2013;793, https://doi.org/10.1016/j.otohns.2003.08.021.</Citation></Reference><Reference><Citation>F. J. P&#xe9;rez Font&#xe1;n, M. Santos Hern&#xe1;ndez, S. Pombo V&#xe1;zquez, and N. M. Lago, &#x201c;Thyroid Gland Rupture After Blunt Neck Trauma: Sonographic and Computed Tomographic Findings,&#x201d; Journal of Ultrasound in Medicine 20, no. 11 (2001): 1249&#x2013;1251, https://doi.org/10.7863/jum.2001.20.11.1249.</Citation></Reference><Reference><Citation>K. C. Hsieh, F. F. Chou, and C. H. Lee, &#x201c;Nonsurgical Treatment of Thyroid Injury After Blunt Cervical Trauma,&#x201d; American Journal of Emergency Medicine 18, no. 6 (2000): 739&#x2013;741.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.28231 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40621801</PMID><DateCompleted><Year>2025</Year><Month>12</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>12</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><Volume>48</Volume><Issue>1</Issue><PubDate><Year>2026</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Magnifying Glass on Sinonasal NUT Carcinoma Heterogeneity via Spatial Transcriptomics.</ArticleTitle><Pagination><StartPage>E1</StartPage><EndPage>E9</EndPage><MedlinePgn>E1-E9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.28231</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Nuclear protein in testis (NUT) carcinomas (NCs) are rare, clinically aggressive tumors with characteristic translocation involving NUTM1 and BRD4 genes. While NCs are generally characterized by undifferentiated basaloid cells with focal/abrupt squamous differentiation, tumoral heterogeneity remains unexplored. This may have therapeutic implications as NC frequently develops drug resistance and metastasis. Spatial transcriptomics (ST) sequencing technology emerged as an approach to elucidate tumoral heterogeneity by integrating cellular transcriptome and spatial distributions within tissues, providing insights into the interactions among different cell types and overall tissue genomic architecture.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Three cases of sinonasal NC with formalin-fixed paraffin embedded tissue formed the study material. A representative region of each NC was subjected to 10X Genomics Visium Spatial Gene Expression analysis. Resulting data were analyzed in 10X Genomics Loupe Browser.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">All cases demonstrated statistically distinct (graph-neural network based) transcriptomic clusters. These clusters were correlated with histologic characteristics by parsing all spots by region types based on tissue distribution including tumor, limited stroma, and normal epithelium. Cluster constitution and transcriptomic pattern were consistent with the morphologic features of each tissue region. NC#3 had a relatively low number of tumor clusters in comparison to NC#1 and NC#2.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Spatial transcriptomic profiling corresponds to histopathologic features in NC and yet highlights cell type diversity across tumors and in the case of NC#2, within a given tumor. Behavioral correlates are speculative, but NC#3 for which the patient had a rapidly lethal outcome showed a preponderance of neural gene expression which may be of interest in tumor cell progression/evolution.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). Head &amp; Neck published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bell</LastName><ForeName>Diana</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-3531-8241</Identifier><AffiliationInfo><Affiliation>Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, Skull Base at University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choby</LastName><ForeName>Garret</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-3745-2727</Identifier><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, Skull Base at University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Afkhami</LastName><ForeName>Michelle</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-5830-6158</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Division of Molecular Pathology, City of Hope Comprehensive Cancer Center, Duarte, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maghami</LastName><ForeName>Ellie</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Surgery Head and Neck, City of Hope Comprehensive Cancer Center, Duarte, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrarotto</LastName><ForeName>Renata</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-3561-215X</Identifier><AffiliationInfo><Affiliation>Department of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snyderman</LastName><ForeName>Carl</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, Skull Base at University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, Skull Base at University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanna</LastName><ForeName>Ehab</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Head and Neck Surgery, MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seethala</LastName><ForeName>Raja</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, Skull Base at University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000630260">NUTM1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015513">Oncogene Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="Y">Transcriptome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009687" MajorTopicYN="Y">Nuclear Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002277" MajorTopicYN="Y">Carcinoma</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009363" MajorTopicYN="Y">Neoplasm Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010255" MajorTopicYN="Y">Paranasal Sinus Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015513" MajorTopicYN="Y">Oncogene Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008444" MajorTopicYN="Y">Maxillary Sinus Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">NUT carcinoma</Keyword><Keyword MajorTopicYN="N">PRAME</Keyword><Keyword MajorTopicYN="N">spatial transcriptomics</Keyword><Keyword MajorTopicYN="N">tumoral heterogeneity</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>7</Day><Hour>12</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>12</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40621801</ArticleId><ArticleId IdType="pmc">PMC12703572</ArticleId><ArticleId IdType="doi">10.1002/hed.28231</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>French C., &#x201c;NUT Midline Carcinoma,&#x201d; Nature Reviews. Cancer 14, no. 3 (2014): 149&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">25688404</ArticleId></ArticleIdList></Reference><Reference><Citation>French C. A., &#x201c;NUT Carcinoma: Clinicopathologic Features, Pathogenesis, and Treatment,&#x201d; Pathology International 68, no. 11 (2018): 583&#x2013;595.</Citation><ArticleIdList><ArticleId IdType="pubmed">30362654</ArticleId></ArticleIdList></Reference><Reference><Citation>French C. A., Ramirez C. L., Kolmakova J., et&#xa0;al., &#x201c;BRD&#x2010;NUT Oncoproteins: A Family of Closely Related Nuclear Proteins That Block Epithelial Differentiation and Maintain the Growth of Carcinoma Cells,&#x201d; Oncogene 27, no. 15 (2008): 2237&#x2013;2242.</Citation><ArticleIdList><ArticleId IdType="pubmed">17934517</ArticleId></ArticleIdList></Reference><Reference><Citation>Abreu R. F., Oliveira T. B., Hertzler H., et&#xa0;al., &#x201c;NUT Carcinoma, an Under&#x2010;Recognized Malignancy: A Clinicopathologic and Molecular Series of 6 Cases Showing a Subset of Patients With Better Prognosis and a Rare ZNF532::NUTM1 Fusion,&#x201d; Human Pathology 126 (2022): 87&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">35623465</ArticleId></ArticleIdList></Reference><Reference><Citation>French C. A., Cheng M. L., Hanna G. J., et&#xa0;al., &#x201c;Report of the First International Symposium on NUT Carcinoma,&#x201d; Clinical Cancer Research 28, no. 12 (2022): 2493&#x2013;2505.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9197941</ArticleId><ArticleId IdType="pubmed">35417004</ArticleId></ArticleIdList></Reference><Reference><Citation>French C. A., Rahman S., Walsh E. M., et&#xa0;al., &#x201c;NSD3&#x2010;NUT Fusion Oncoprotein in NUT Midline Carcinoma: Implications for a Novel Oncogenic Mechanism,&#x201d; Cancer Discovery 4, no. 8 (2014): 928&#x2013;941.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4125436</ArticleId><ArticleId IdType="pubmed">24875858</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauer U. M., Hinterleitner M., Horger M., Ohnesorge P. V., and Zender L., &#x201c;NUT Carcinoma&#x2014;An Underdiagnosed Malignancy,&#x201d; Frontiers in Oncology 12 (2022): 914031.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9360329</ArticleId><ArticleId IdType="pubmed">35957893</ArticleId></ArticleIdList></Reference><Reference><Citation>Haack H., Johnson L. A., Fry C. J., et&#xa0;al., &#x201c;Diagnosis of NUT Midline Carcinoma Using a NUT&#x2010;Specific Monoclonal Antibody,&#x201d; American Journal of Surgical Pathology 33, no. 7 (2009): 984&#x2013;991.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2783402</ArticleId><ArticleId IdType="pubmed">19363441</ArticleId></ArticleIdList></Reference><Reference><Citation>Simons S. A., Bridge J. A., and Leon M. E., &#x201c;Sinonasal Small Round Blue Cell Tumors: An Approach to Diagnosis,&#x201d; Seminars in Diagnostic Pathology 33, no. 2 (2016): 91&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">26585346</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell D., &#x201c;Top IHC/ISH Hacks for and Molecular Surrogates of Poorly Differentiated Sinonasal Small Round Cell Tumors,&#x201d; Head and Neck Pathology 18, no. 1 (2024): 2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10844182</ArticleId><ArticleId IdType="pubmed">38315310</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao A., Barkley D., Franca G. S., and Yanai I., &#x201c;Exploring Tissue Architecture Using Spatial Transcriptomics,&#x201d; Nature 596, no. 7871 (2021): 211&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8475179</ArticleId><ArticleId IdType="pubmed">34381231</ArticleId></ArticleIdList></Reference><Reference><Citation>Stahl P. L., Salmen F., Vickovic S., et&#xa0;al., &#x201c;Visualization and Analysis of Gene Expression in Tissue Sections by Spatial Transcriptomics,&#x201d; Science 353, no. 6294 (2016): 78&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">27365449</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams C. G., Lee H. J., Asatsuma T., Vento&#x2010;Tormo R., and Haque A., &#x201c;An Introduction to Spatial Transcriptomics for Biomedical Research,&#x201d; Genome Medicine 14, no. 1 (2022): 68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9238181</ArticleId><ArticleId IdType="pubmed">35761361</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassiouni R., Gibbs L. D., Craig D. W., Carpten J. D., and McEachron T. A., &#x201c;Applicability of Spatial Transcriptional Profiling to Cancer Research,&#x201d; Molecular Cell 81, no. 8 (2021): 1631&#x2013;1639.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8052283</ArticleId><ArticleId IdType="pubmed">33826920</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassiouni R., Idowu M. O., Gibbs L. D., et&#xa0;al., &#x201c;Spatial Transcriptomic Analysis of a Diverse Patient Cohort Reveals a Conserved Architecture in Triple&#x2010;Negative Breast Cancer,&#x201d; Cancer Research 83, no. 1 (2023): 34&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9812886</ArticleId><ArticleId IdType="pubmed">36283023</ArticleId></ArticleIdList></Reference><Reference><Citation>Song J., Lamstein J., Ramaswamy V. G., et&#xa0;al., &#x201c;Enhancing Spatial Transcriptomics Analysis by Integrating Image&#x2010;Aware Deep Learning Methods,&#x201d; Pacific Symposium on Biocomputing 29 (2024): 450&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pubmed">38160299</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y. and Cohen R., &#x201c;Weighted False Discovery Rate Controlling Procedures for Clinical Trials,&#x201d; Biostatistics 18, no. 1 (2017): 91&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5255051</ArticleId><ArticleId IdType="pubmed">27445132</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang W. and Yu W., &#x201c;Controlling the Joint Local False Discovery Rate Is More Powerful Than Meta&#x2010;Analysis Methods in Joint Analysis of Summary Statistics From Multiple Genome&#x2010;Wide Association Studies,&#x201d; Bioinformatics 33, no. 4 (2017): 500&#x2013;507.</Citation><ArticleIdList><ArticleId IdType="pubmed">28011772</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez Navarro J., Lundeberg J., and Stahl P. L., &#x201c;ST Viewer: A Tool for Analysis and Visualization of Spatial Transcriptomics Datasets,&#x201d; Bioinformatics 35, no. 6 (2019): 1058&#x2013;1060.</Citation><ArticleIdList><ArticleId IdType="pubmed">30875427</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas J., Adegboyega P., Iloabachie K., Mooring J. W., and Lian T., &#x201c;Sinonasal Teratocarcinosarcoma With Yolk Sac Elements: A Neoplasm of Somatic or Germ Cell Origin?,&#x201d; Annals of Diagnostic Pathology 15, no. 2 (2011): 135&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">20952296</ArticleId></ArticleIdList></Reference><Reference><Citation>Agaimy A., Haller F., Renner A., Niedermeyer J., Hartmann A., and French C. A., &#x201c;Misleading Germ Cell Phenotype in Pulmonary NUT Carcinoma Harboring the ZNF532&#x2010;NUTM1 Fusion,&#x201d; American Journal of Surgical Pathology 46, no. 2 (2022): 281&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8741879</ArticleId><ArticleId IdType="pubmed">34232599</ArticleId></ArticleIdList></Reference><Reference><Citation>Balachandran S. and Narendran A., &#x201c;The Developmental Origins of Cancer: A Review of the Genes Expressed in Embryonic Cells With Implications for Tumorigenesis,&#x201d; Genes (Basel) 14, no. 3 (2023): 604.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10048275</ArticleId><ArticleId IdType="pubmed">36980876</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyer L. A., Lee T. I., Cole M. F., et&#xa0;al., &#x201c;Core Transcriptional Regulatory Circuitry in Human Embryonic Stem Cells,&#x201d; Cell 122, no. 6 (2005): 947&#x2013;956.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3006442</ArticleId><ArticleId IdType="pubmed">16153702</ArticleId></ArticleIdList></Reference><Reference><Citation>Gangemi R. M., Griffero F., Marubbi D., et&#xa0;al., &#x201c;SOX2 Silencing in Glioblastoma Tumor&#x2010;Initiating Cells Causes Stop of Proliferation and Loss of Tumorigenicity,&#x201d; Stem Cells 27, no. 1 (2009): 40&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">18948646</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R., Liu W., Helfer C. M., et&#xa0;al., &#x201c;Activation of SOX2 Expression by BRD4&#x2010;NUT Oncogenic Fusion Drives Neoplastic Transformation in NUT Midline Carcinoma,&#x201d; Cancer Research 74, no. 12 (2014): 3332&#x2013;3343.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4097982</ArticleId><ArticleId IdType="pubmed">24736545</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez&#x2010;Marquez R., Llorente J. L., Rodrigo J. P., et&#xa0;al., &#x201c;SOX2 Expression in Hypopharyngeal, Laryngeal, and Sinonasal Squamous Cell Carcinoma,&#x201d; Human Pathology 45, no. 4 (2014): 851&#x2013;857.</Citation><ArticleIdList><ArticleId IdType="pubmed">24656096</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorna D. and Paluszczak J., &#x201c;Targeting Cancer Stem Cells as a Strategy for Reducing Chemotherapy Resistance in Head and Neck Cancers,&#x201d; Journal of Cancer Research and Clinical Oncology 149, no. 14 (2023): 13417&#x2013;13435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10587253</ArticleId><ArticleId IdType="pubmed">37453969</ArticleId></ArticleIdList></Reference><Reference><Citation>Huser L., Novak D., Umansky V., Altevogt P., and Utikal J., &#x201c;Targeting SOX2 in Anticancer Therapy,&#x201d; Expert Opinion on Therapeutic Targets 22, no. 12 (2018): 983&#x2013;991.</Citation><ArticleIdList><ArticleId IdType="pubmed">30366514</ArticleId></ArticleIdList></Reference><Reference><Citation>Leis O., Eguiara A., Lopez&#x2010;Arribillaga E., et&#xa0;al., &#x201c;Sox2 Expression in Breast Tumours and Activation in Breast Cancer Stem Cells,&#x201d; Oncogene 31, no. 11 (2012): 1354&#x2013;1365.</Citation><ArticleIdList><ArticleId IdType="pubmed">21822303</ArticleId></ArticleIdList></Reference><Reference><Citation>Finn O. J., &#x201c;Human Tumor Antigens Yesterday, Today, and Tomorrow,&#x201d; Cancer Immunology Research 5, no. 5 (2017): 347&#x2013;354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5490447</ArticleId><ArticleId IdType="pubmed">28465452</ArticleId></ArticleIdList></Reference><Reference><Citation>Finn O. J., &#x201c;A Believer's Overview of Cancer Immunosurveillance and Immunotherapy,&#x201d; Journal of Immunology 200, no. 2 (2018): 385&#x2013;391.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5763509</ArticleId><ArticleId IdType="pubmed">29311379</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y., Zou R., Wang J., Wang Z. W., and Zhu X., &#x201c;The Role of the Cancer Testis Antigen PRAME in Tumorigenesis and Immunotherapy in Human Cancer,&#x201d; Cell Proliferation 53, no. 3 (2020): e12770.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7106952</ArticleId><ArticleId IdType="pubmed">32022332</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell D., Bell A., Ferrarotto R., et&#xa0;al., &#x201c;High&#x2010;Grade Sinonasal Carcinomas and Surveillance of Differential Expression in Immune Related Transcriptome,&#x201d; Annals of Diagnostic Pathology 49 (2020): 151622.</Citation><ArticleIdList><ArticleId IdType="pubmed">32927372</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen J. L., Peterson S. K., Yu S., et&#xa0;al., &#x201c;PRAME Epitopes Are T&#x2010;Cell Immunovulnerabilities in BRD4::NUTM1 Initiated NUT Carcinoma,&#x201d; bioRxiv, 2025.</Citation></Reference><Reference><Citation>Grayson A. R., Walsh E. M., Cameron M. J., et&#xa0;al., &#x201c;MYC, a Downstream Target of BRD&#x2010;NUT, Is Necessary and Sufficient for the Blockade of Differentiation in NUT Midline Carcinoma,&#x201d; Oncogene 33, no. 13 (2014): 1736&#x2013;1742.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3942361</ArticleId><ArticleId IdType="pubmed">23604113</ArticleId></ArticleIdList></Reference><Reference><Citation>Chau N. G., Ma C., Danga K., et&#xa0;al., &#x201c;An Anatomical Site and Genetic&#x2010;Based Prognostic Model for Patients With Nuclear Protein in Testis (NUT) Midline Carcinoma: Analysis of 124 Patients,&#x201d; JNCI Cancer Spectrum 4, no. 2 (2020): pkz094.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7165803</ArticleId><ArticleId IdType="pubmed">32328562</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng D., Elnegiry A. A., Luo C., et&#xa0;al., &#x201c;Brd4::Nutm1 Fusion Gene Initiates NUT Carcinoma In&#xa0;Vivo,&#x201d; Life Science Alliance 7, no. 7 (2024): e202402602.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11082452</ArticleId><ArticleId IdType="pubmed">38724194</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao J., Li C., Cui Z., et&#xa0;al., &#x201c;Spatial Transcriptomics: A Powerful Tool in Disease Understanding and Drug Discovery,&#x201d; Theranostics 14, no. 7 (2024): 2946&#x2013;2968.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11103497</ArticleId><ArticleId IdType="pubmed">38773973</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Chen D., Song D., et&#xa0;al., &#x201c;Clinical and Translational Values of Spatial Transcriptomics,&#x201d; Signal Transduction and Targeted Therapy 7, no. 1 (2022): 111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8972902</ArticleId><ArticleId IdType="pubmed">35365599</ArticleId></ArticleIdList></Reference><Reference><Citation>Berglund E., Maaskola J., Schultz N., et&#xa0;al., &#x201c;Spatial Maps of Prostate Cancer Transcriptomes Reveal an Unexplored Landscape of Heterogeneity,&#x201d; Nature Communications 9, no. 1 (2018): 2419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6010471</ArticleId><ArticleId IdType="pubmed">29925878</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao E., Stone M. R., Ren X., et&#xa0;al., &#x201c;Spatial Transcriptomics at Subspot Resolution With BayesSpace,&#x201d; Nature Biotechnology 39, no. 11 (2021): 1375&#x2013;1384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8763026</ArticleId><ArticleId IdType="pubmed">34083791</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji A. L., Rubin A. J., Thrane K., et&#xa0;al., &#x201c;Multimodal Analysis of Composition and Spatial Architecture in Human Squamous Cell Carcinoma,&#x201d; Cell 182, no. 6 (2020): 1661&#x2013;1662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7505493</ArticleId><ArticleId IdType="pubmed">32946785</ArticleId></ArticleIdList></Reference><Reference><Citation>Thrane K., Eriksson H., Maaskola J., Hansson J., and Lundeberg J., &#x201c;Spatially Resolved Transcriptomics Enables Dissection of Genetic Heterogeneity in Stage III Cutaneous Malignant Melanoma,&#x201d; Cancer Research 78, no. 20 (2018): 5970&#x2013;5979.</Citation><ArticleIdList><ArticleId IdType="pubmed">30154148</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70100 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">41261839</PMID><DateCompleted><Year>2025</Year><Month>12</Month><Day>15</Day></DateCompleted><DateRevised><Year>2026</Year><Month>01</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><Volume>48</Volume><Issue>1</Issue><PubDate><Year>2026</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Non-Pharmacological Interventions for Improving Xerostomia Among Patients With Head and Neck Cancer: A Systematic Review and Network Meta-Analysis.</ArticleTitle><Pagination><StartPage>302</StartPage><EndPage>316</EndPage><MedlinePgn>302-316</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70100</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Xerostomia is highly prevalent among patients with head and neck cancer (HNC). This review aimed to compare the effectiveness of non-pharmacological interventions (NPIs) for xerostomia among patients with HNC.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We systematically searched nine databases (inception-October 2024) for RCTs assessing the effects of NPIs on xerostomia (self-reported xerostomia, incidence, stimulated/unstimulated salivary flow).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Forty-six trials (3802 patients) identified 10 arms: multimodal NPIs, herbal medicine, acupuncture, exercise, oral care, devices, health education, supplements, and active/passive controls. At post-intervention, multimodal NPIs (the majority being herbal medicine combined with other therapies) ranked first for self-reported xerostomia, incidence, and unstimulated flow versus other interventions. Herbal medicine ranked second for self-reported and incidence of xerostomia and first for stimulated flow. Though lower-ranked, acupuncture significantly improved all outcomes versus passive controls. Sensitivity analyses showed enhanced acupuncture efficacy with high-dose radiotherapy.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Multimodal NPIs, herbal medicine, and acupuncture are promising for improving xerostomia among patients with HNC.</AbstractText><CopyrightInformation>&#xa9; 2025 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Xueyan</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0002-7510-7545</Identifier><AffiliationInfo><Affiliation>Li Ka Shing Faculty of Medicine, School of Nursing, The University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Lizhen</ForeName><Initials>L</Initials><Identifier Source="ORCID">0009-0002-5424-3705</Identifier><AffiliationInfo><Affiliation>Li Ka Shing Faculty of Medicine, School of Nursing, The University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>Mu-Hsing</ForeName><Initials>MH</Initials><Identifier Source="ORCID">0000-0002-9443-4082</Identifier><AffiliationInfo><Affiliation>Li Ka Shing Faculty of Medicine, School of Nursing, The University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Shing Fung</ForeName><Initials>SF</Initials><Identifier Source="ORCID">0000-0003-4696-9434</Identifier><AffiliationInfo><Affiliation>Department of Radiation Oncology, National University Cancer Institute, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>Frederick K</ForeName><Initials>FK</Initials><Identifier Source="ORCID">0000-0001-7190-9025</Identifier><AffiliationInfo><Affiliation>School of Health and Wellbeing, University of Glasgow, Scotland, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yeung</LastName><ForeName>Wing-Fai</ForeName><Initials>WF</Initials><Identifier Source="ORCID">0000-0002-7980-3126</Identifier><AffiliationInfo><Affiliation>School of Nursing, The Hong Kong Polytechnic University, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Chia-Chin</ForeName><Initials>CC</Initials><Identifier Source="ORCID">0000-0001-9551-0991</Identifier><AffiliationInfo><Affiliation>Li Ka Shing Faculty of Medicine, School of Nursing, The University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheung</LastName><ForeName>Denise Shuk Ting</ForeName><Initials>DST</Initials><Identifier Source="ORCID">0000-0002-8741-9271</Identifier><AffiliationInfo><Affiliation>Li Ka Shing Faculty of Medicine, School of Nursing, The University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D000099094">Network Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>11</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014987" MajorTopicYN="Y">Xerostomia</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006258" MajorTopicYN="Y">Head and Neck Neoplasms</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015670" MajorTopicYN="N">Acupuncture Therapy</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">head and neck cancer</Keyword><Keyword MajorTopicYN="N">network meta&#x2010;analysis</Keyword><Keyword MajorTopicYN="N">non&#x2010;pharmacological interventions</Keyword><Keyword MajorTopicYN="N">systematic review</Keyword><Keyword MajorTopicYN="N">xerostomia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>10</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>11</Month><Day>20</Day><Hour>2</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41261839</ArticleId><ArticleId IdType="doi">10.1002/hed.70100</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>S. Mercadante, F. Aielli, C. Adile, et&#xa0;al., &#x201c;Prevalence of Oral Mucositis, Dry Mouth, and Dysphagia in Advanced Cancer Patients,&#x201d; Support Care Cancer 23, no. 11 (2015): 3249&#x2013;3255.</Citation></Reference><Reference><Citation>B. Garcia&#x2010;Chias, E. Figuero, B. Castelo&#x2010;Fernandez, et&#xa0;al., &#x201c;Prevalence of Oral Side Effects of Chemotherapy and Its Relationship With Periodontal Risk: A Cross Sectional Study,&#x201d; Support Care Cancer 27, no. 9 (2019): 3479&#x2013;3490.</Citation></Reference><Reference><Citation>R. Pinna, G. Campus, E. Cumbo, et&#xa0;al., &#x201c;Xerostomia Induced by Radiotherapy: An Overview of the Physiopathology, Clinical Evidence, and Management of the Oral Damage,&#x201d; Therapeutics and Clinical Risk Management 11 (2015): 171&#x2013;188.</Citation></Reference><Reference><Citation>S. A. Bhide, A. B. Miah, K. J. Harrington, K. L. Newbold, and C. M. Nutting, &#x201c;Radiation&#x2010;Induced Xerostomia: Pathophysiology, Prevention and Treatment,&#x201d; Clinical Oncology (Royal College of Radiologists) 21, no. 10 (2009): 737&#x2013;744.</Citation></Reference><Reference><Citation>M. S. Chambers, A. S. Garden, M. S. Kies, and J. W. Martin, &#x201c;Radiation&#x2010;Induced Xerostomia in Patients With Head and Neck Cancer: Pathogenesis, Impact on Quality of Life, and Management,&#x201d; Head &amp; Neck 26, no. 9 (2004): 796&#x2013;807.</Citation></Reference><Reference><Citation>D. Moral Nakamura, H. da Graca Pinto, C. Baena Elchin, et&#xa0;al., &#x201c;Efficacy of Bethanechol Chloride in the Treatment of Radiation&#x2010;Induced Xerostomia in Patients With Head and Neck Cancer: A Systematic Review and Meta&#x2010;Analysis,&#x201d; Radiotherapy and Oncology 186 (2023): 109715.</Citation></Reference><Reference><Citation>C. Q. Cheng, H. Xu, L. Liu, et&#xa0;al., &#x201c;Efficacy and Safety of Pilocarpine for Radiation&#x2010;Induced Xerostomia in Patients With Head and Neck Cancer: A Systematic Review and Meta&#x2010;Analysis,&#x201d; Journal of the American Dental Association (1939) 147, no. 4 (2016): 236&#x2013;243.</Citation></Reference><Reference><Citation>W. F. Yang, G. Q. Liao, S. G. Hakim, D. Q. Ouyang, J. Ringash, and Y. X. Su, &#x201c;Is Pilocarpine Effective in Preventing Radiation&#x2010;Induced Xerostomia? A Systematic Review and Meta&#x2010;Analysis,&#x201d; International Journal of Radiation Oncology, Biology, Physics 94, no. 3 (2016): 503&#x2013;511.</Citation></Reference><Reference><Citation>P. Riley, A. M. Glenny, F. Hua, and H. V. Worthington, &#x201c;Pharmacological Interventions for Preventing Dry Mouth and Salivary Gland Dysfunction Following Radiotherapy,&#x201d; Cochrane Database of Systematic Reviews 7, no. 7 (2017): CD012744.</Citation></Reference><Reference><Citation>S. T. Kahn and P. A. Johnstone, &#x201c;Management of Xerostomia Related to Radiotherapy for Head and Neck Cancer,&#x201d; Oncology (Williston Park, N.Y.) 19, no. 14 (2005): 1827&#x2013;1832 discussion 1832&#x2013;4, 1837&#x2013;9.</Citation></Reference><Reference><Citation>C. O. Nathan, A. A. Asarkar, P. Entezami, et&#xa0;al., &#x201c;Current Management of Xerostomia in Head and Neck Cancer Patients,&#x201d; American Journal of Otolaryngology 44, no. 4 (2023): 103867.</Citation></Reference><Reference><Citation>X. Ni, T. Tian, D. Chen, et&#xa0;al., &#x201c;Acupuncture for Radiation&#x2010;Induced Xerostomia in Cancer Patients: A Systematic Review and Meta&#x2010;Analysis,&#x201d; Integrative Cancer Therapies 19 (2020): 1534735420980825.</Citation></Reference><Reference><Citation>V. Mercadante, A. Al Hamad, G. Lodi, et&#xa0;al., &#x201c;Interventions for the Management of Radiotherapy&#x2010;Induced Xerostomia and Hyposalivation: A Systematic Review and Meta&#x2010;Analysis,&#x201d; Oral Oncology 66 (2017): 64&#x2013;74.</Citation></Reference><Reference><Citation>L. Zhuang, Z. Yang, X. Zeng, et&#xa0;al., &#x201c;The Preventive and Therapeutic Effect of Acupuncture for Radiation&#x2010;Induced Xerostomia in Patients With Head and Neck Cancer: A Systematic Review,&#x201d; Integrative Cancer Therapies 12, no. 3 (2013): 197&#x2013;205.</Citation></Reference><Reference><Citation>W. Gu, H. Dong, Y. Yuan, et&#xa0;al., &#x201c;Is Acupuncture an Effective Treatment for Radiation&#x2010;Induced Xerostomia of Patients With Head and Neck Cancer? A Systematic Review and Meta&#x2010;Analysis,&#x201d; Journal of Integrated Complementary Medicine 31, no. 5 (2024): 431&#x2013;444, https://doi.org/10.1089/jicm.2023.0781.</Citation></Reference><Reference><Citation>S. Hahnel, M. Behr, G. Handel, and R. B&#xfc;rgers, &#x201c;Saliva Substitutes for the Treatment of Radiation&#x2010;Induced Xerostomia&#x2014;A Review,&#x201d; Support Care Cancer 17, no. 11 (2009): 1331&#x2013;1343.</Citation></Reference><Reference><Citation>O. Apperley, N. Medlicott, A. Rich, S. Hanning, and M. L. Huckabee, &#x201c;A Clinical Trial of a Novel Emulsion for Potential Use as a Saliva Substitute in Patients With Radiation&#x2010;Induced Xerostomia,&#x201d; Journal of Oral Rehabilitation 44, no. 11 (2017): 889&#x2013;895.</Citation></Reference><Reference><Citation>B. Park, H. Noh, and D. J. Choi, &#x201c;Herbal Medicine for Xerostomia in Cancer Patients: A Systematic Review of Randomized Controlled Trials,&#x201d; Integrative Cancer Therapies 17, no. 2 (2018): 179&#x2013;191.</Citation></Reference><Reference><Citation>G. Sivaramakrishnan and K. Sridharan, &#x201c;Electrical Nerve Stimulation for Xerostomia: A Meta&#x2010;Analysis of Randomised Controlled Trials,&#x201d; Journal of Traditional and Complementary Medicine 7, no. 4 (2017): 409&#x2013;413.</Citation></Reference><Reference><Citation>S. Furness, H. V. Worthington, G. Bryan, et&#xa0;al., &#x201c;Interventions for the Management of Dry Mouth: Topical Therapies,&#x201d; Cochrane Database of Systematic Reviews 12 (2011): CD008934, https://doi.org/10.1002/14651858.CD008934.pub2.</Citation></Reference><Reference><Citation>S. Furness, G. Bryan, R. McMillan, et&#xa0;al., &#x201c;Interventions for the Management of Dry Mouth: Non&#x2010;Pharmacological Interventions,&#x201d; Cochrane Database System Review 2013, no. 9 (2013): CD009603.</Citation></Reference><Reference><Citation>J. D. Cox, J. Stetz, and T. F. Pajak, &#x201c;Toxicity Criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC),&#x201d; International Journal of Radiation Oncology, Biology, Physics 31, no. 5 (1995): 1341&#x2013;1346.</Citation></Reference><Reference><Citation>SERVICES. USDOHAH, &#x201c;Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0,&#x201d; https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf.</Citation></Reference><Reference><Citation>K. F. Ho, D. J. Farnell, J. A. Routledge, et&#xa0;al., &#x201c;Comparison of Patient&#x2010;Reported Late Treatment Toxicity (LENT&#x2010;SOMA) With Quality of Life (EORTC QLQ&#x2010;C30 and QLQ&#x2010;H&amp;N35) Assessment After Head and Neck Radiotherapy,&#x201d; Radiotherapy and Oncology 97, no. 2 (2010): 270&#x2013;275.</Citation></Reference><Reference><Citation>J. P. T. Higgins, S. Eldridge, and T. Li, &#x201c;Chapter&#xa0;23: Including Variants on Randomized Trials,&#x201d; in Cochrane Handbook for Systematic Reviews of Intervention, ed. J. P. T. Higgins , J. Thomas , J. Chandler , et&#xa0;al. (Cochrane, 2024).</Citation></Reference><Reference><Citation>J. A. C. Sterne, J. Savovic, M. J. Page, et&#xa0;al., &#x201c;RoB 2: A Revised Tool for Assessing Risk of Bias in Randomised Trials,&#x201d; BMJ 366 (2019): l4898.</Citation></Reference><Reference><Citation>C. C. Serdar, M. Cihan, D. Yucel, et&#xa0;al., &#x201c;Sample Size, Power and Effect Size Revisited: Simplified and Practical Approaches in Pre&#x2010;Clinical, Clinical and Laboratory Studies,&#x201d; Biochem Med (Zagreb) 31, no. 1 (2021): 010502.</Citation></Reference><Reference><Citation>J. P. T. Higgins, T. Li, and J. J. Deeks, &#x201c;Chapter&#xa0;6: Choosing Effect Measures and Computing Estimates of Effect,&#x201d; in Cochrane Handbook for Systematic Reviews of Intervention, ed. J. P. T. Higgins , J. Thomas , J. Chandler , et&#xa0;al. (Cochrane, 2024).</Citation></Reference><Reference><Citation>J. J. Deeks, J. P. T. Higgins, D. G. Altman, J. E. McKenzie, and A. A. Veroniki, &#x201c;Chapter&#xa0;10: Analysing Data and Undertaking Meta&#x2010;Analyses,&#x201d; In Cochrane Handbook for Systematic Reviews of Interventions version 6.5, ed. J. P. T. Higgins , J. Thomas , J. Chandler , et&#xa0;al. (Cochrane, 2024).</Citation></Reference><Reference><Citation>O. Efthimiou, G. Rucker, G. Schwarzer, et&#xa0;al., &#x201c;Network Meta&#x2010;Analysis of Rare Events Using the Mantel&#x2010;Haenszel Method,&#x201d; Statistics in Medicine 38, no. 16 (2019): 2992&#x2013;3012.</Citation></Reference><Reference><Citation>G. Salanti, &#x201c;Indirect and Mixed&#x2010;Treatment Comparison, Network, or Multiple&#x2010;Treatments Meta&#x2010;Analysis: Many Names, Many Benefits, Many Concerns for the Next Generation Evidence Synthesis Tool,&#x201d; Research Synthesis Methods 3, no. 2 (2012): 80&#x2013;97.</Citation></Reference><Reference><Citation>M. J. Page, J. P. T. Higgins, and J. A. C. Sterne, &#x201c;Assessing Risk of Bias due to Missing Results in a Synthesis,&#x201d; in Cochrane Handbook for Systematic Reviews of Intervention, ed. J. P. T. Higgins , J. Thomas , J. Chandler , et&#xa0;al. (Cochrane, 2023).</Citation></Reference><Reference><Citation>J. Konig, U. Krahn, and H. Binder, &#x201c;Visualizing the Flow of Evidence in Network Meta&#x2010;Analysis and Characterizing Mixed Treatment Comparisons,&#x201d; Statistics in Medicine 32, no. 30 (2013): 5414&#x2013;5429.</Citation></Reference><Reference><Citation>J. L. Brozek, E. A. Akl, P. Alonso&#x2010;Coello, et&#xa0;al., &#x201c;Grading Quality of Evidence and Strength of Recommendations in Clinical Practice Guidelines. Part 1 of 3. An Overview of the GRADE Approach and Grading Quality of Evidence About Interventions,&#x201d; Allergy 64, no. 5 (2009): 669&#x2013;677.</Citation></Reference><Reference><Citation>M. J. Page, M. K. JE, P. M. Bossuyt, et&#xa0;al., &#x201c;The PRISMA 2020 Statement: An Updated Guideline For Reporting Systematic Reviews,&#x201d; BMJ 372 (2021): N71, https://doi.org/10.1136/bmj.n71.</Citation></Reference><Reference><Citation>H. You and Y. Chen, &#x201c;Observation on Treating Xerostomia After Radiotherapy of Nasopharyngeal Carcinoma by Clicking Teeth, Swallow Plus Touying Zhuaqi,&#x201d; Chinese Journal of Clinical Medicine 10, no. 4 (2018): 53&#x2013;54.</Citation></Reference><Reference><Citation>L. Cohen, S. C. Danhauer, M. K. Garcia, et&#xa0;al., &#x201c;Acupuncture for Chronic Radiation&#x2010;Induced Xerostomia in Head and Neck Cancer: A Multicenter Randomized Clinical Trial,&#x201d; JAMA Network Open 7, no. 5 (2024): e2410421.</Citation></Reference><Reference><Citation>M. K. Garcia, Z. Meng, D. I. Rosenthal, et&#xa0;al., &#x201c;Effect of True and Sham Acupuncture on Radiation&#x2010;Induced Xerostomia Among Patients With Head and Neck Cancer: A Randomized Clinical Trial,&#x201d; JAMA Network Open 2, no. 12 (2019): e1916910.</Citation></Reference><Reference><Citation>M. K. Chung, d. H. Kim, Y. C. Ahn, J. Y. Choi, E. H. Kim, and Y. I. Son, &#x201c;Randomized Trial of Vitamin C/E Complex for Prevention of Radiation&#x2010;Induced Xerostomia in Patients With Head and Neck Cancer,&#x201d; Otolaryngology and Head and Neck Surgery 155, no. 3 (2016): 423&#x2013;430.</Citation></Reference><Reference><Citation>C. Rupe, A. Basco, G. Gioco, et&#xa0;al., &#x201c;Sodium&#x2010;Hyaluronate Mouthwash on Radiotherapy&#x2010;Induced Xerostomia: A Randomised Clinical Trial,&#x201d; Support Care Cancer 31, no. 12 (2023): 644.</Citation></Reference><Reference><Citation>N. Jiang, Y. Zhao, M. Stensson, and J. M&#xe5;rtensson, &#x201c;Effects of an Integrated Supportive Program on Xerostomia and Saliva Characteristics in Patients With Head and Neck Cancer Radiated With a Low Dose to the Major Salivary Glands: A Randomized Controlled Trial,&#x201d; BMC Oral Health 22, no. 1 (2022): 199.</Citation></Reference><Reference><Citation>Z. Meng, M. Kay Garcia, C. Hu, et&#xa0;al., &#x201c;Sham&#x2010;Controlled, Randomised, Feasibility Trial of Acupuncture for Prevention of Radiation&#x2010;Induced Xerostomia Among Patients With Nasopharyngeal Carcinoma,&#x201d; European Journal of Cancer 48, no. 11 (2012): 1692&#x2013;1699.</Citation></Reference><Reference><Citation>A. Charalambous, E. Lambrinou, N. Katodritis, et&#xa0;al., &#x201c;The Effectiveness of Thyme Honey for the Management of Treatment&#x2010;Induced Xerostomia in Head and Neck Cancer Patients: A Feasibility Randomized Control Trial,&#x201d; European Journal of Oncology Nursing 27 (2017): 1&#x2013;8.</Citation></Reference><Reference><Citation>D. Marimuthu, K. M. Han, M. S. F. Mohamad, and M. Azman, &#x201c;Saliva Substitute Mouthwash in Nasopharyngeal Cancer Survivors With Xerostomia: A Randomized Controlled Trial,&#x201d; Clinical Oral Investigations 25, no. 5 (2021): 3105&#x2013;3115.</Citation></Reference><Reference><Citation>P. Mall, P. Chand, B. P. Singh, J. Rao, R. Siddarth, and K. Srivastava, &#x201c;Effectiveness of Positioning Stents in Radiation&#x2010;Induced Xerostomia in Patients With Tongue Carcinoma: A Randomized Controlled Trial,&#x201d; International Journal of Prosthodontics 29, no. 5 (2016): 455&#x2013;460.</Citation></Reference><Reference><Citation>T. Zhou, &#x201c;Clinical Effect of Sangshen Soup on Prevention and Treatment of Radiation&#x2010;Induced Xerostomia,&#x201d; Pharmacology and Clinics of Chinese Materia Medica 37, no. 5 (2021): 181&#x2013;185.</Citation></Reference><Reference><Citation>H. Guo, X. You, M. Wei, T. Si, and Y. Shi, &#x201c;Efficacy Observation of Obtaining Yin From Yang Method in the Treatment of Xerostomia After Radiotherapy in Patients With Nasaopharyngeal Carcinoma,&#x201d; Journal of Nanjing University of Traditional Chinese Medicine 34, no. 1 (2018): 63&#x2013;65.</Citation></Reference><Reference><Citation>C. Fang, P. Xiao, S. Zhong, et&#xa0;al., &#x201c;Clinical Observation of Yinlian Gargle in the Prevention and Treatment of Acute Radiation&#x2010;Induced Oropharyngeal Mucositis After Nasopharyngeal Carcinoma Radiotherapy,&#x201d; Traditional Chinese Drug Research and Clinical Pharmacology 35, no. 1 (2024): 141&#x2013;147.</Citation></Reference><Reference><Citation>C. Paterson, M. C. Thomson, B. Caldwell, et&#xa0;al., &#x201c;Radiotherapy&#x2010;Induced Xerostomia: A Randomised, Double&#x2010;Blind, Controlled Trial of Visco&#x2010;Ease Oral Spray Compared With Placebo in Patients With Cancer of the Head and Neck,&#x201d; British Journal of Oral &amp; Maxillofacial Surgery 57, no. 10 (2019): 1119&#x2013;1125.</Citation></Reference><Reference><Citation>F. P. Braga, C. A. Lemos Junior, F. A. Alves, et&#xa0;al., &#x201c;Acupuncture for the Prevention of Radiation&#x2010;Induced Xerostomia in Patients With Head and Neck Cancer,&#x201d; Brazilian Oral Research 25, no. 2 (2011): 180&#x2013;185.</Citation></Reference><Reference><Citation>C. Wang, P. Wang, H. Ouyang, et&#xa0;al., &#x201c;Efficacy of Traditional Chinese Medicine in Treatment and Prophylaxis of Radiation&#x2010;Induced Oral Mucositis in Patients Receiving Radiotherapy: A Randomized Controlled Trial,&#x201d; Integrative Cancer Therapies 17, no. 2 (2018): 444&#x2013;450.</Citation></Reference><Reference><Citation>A. J. Iovoli, A. Ostrowski, C. I. Rivers, et&#xa0;al., &#x201c;Two&#x2010; Versus Four&#x2010;Times Weekly Acupuncture&#x2010;Like Transcutaneous Electrical Nerve Stimulation for Treatment of Radiation&#x2010;Induced Xerostomia: A Pilot Study,&#x201d; Journal of Alternative and Complementary Medicine 26, no. 4 (2020): 323&#x2013;328.</Citation></Reference><Reference><Citation>S. B. Shinde, A. A. Vaidya, P. P. Jain, A. Gudur, S. K. Patil, and R. Shinde, &#x201c;Effect of Oral Somatosensory Training on Oral Somatosensory Dysfunction in Head and Neck Cancer Survivors,&#x201d; Asian Pacific Journal of Cancer Prevention 25, no. 10 (2024): 3707&#x2013;3716.</Citation></Reference><Reference><Citation>R. Simcock, L. Fallowfield, K. Monson, et&#xa0;al., &#x201c;ARIX: A Randomised Trial of Acupuncture v Oral Care Sessions in Patients With Chronic Xerostomia Following Treatment of Head and Neck Cancer,&#x201d; Annals of Oncology 24, no. 3 (2013): 776&#x2013;783.</Citation></Reference><Reference><Citation>L. van der Molen, M. A. van Rossum, C. R. Rasch, L. E. Smeele, and F. J. Hilgers, &#x201c;Two&#x2010;Year Results of a Prospective Preventive Swallowing Rehabilitation Trial in Patients Treated With Chemoradiation for Advanced Head and Neck Cancer,&#x201d; European Archives of Oto&#x2010;Rhino&#x2010;Laryngology 271, no. 5 (2014): 1257&#x2013;1270.</Citation></Reference><Reference><Citation>Q. Hu and D. Zhao, &#x201c;Effects of Resistance Exercise on Complications, Cancer&#x2010;Related Fatigue and Quality of Life in Nasopharyngeal Carcinoma Patients Undergoing Chemoradiotherapy: A Randomised Controlled Trial,&#x201d; European Journal of Cancer Care 30, no. 1 (2021): e13355.</Citation></Reference><Reference><Citation>M. Zeng, Q. Chen, Z. Liu, and H. Cheng, &#x201c;Clinical Observation of Shennong Baijie Decoction in Prevention and Treatment of Radioactive Dry Mouth Disease,&#x201d; Hainan Medical Journal 25, no. 14 (2014): 2069&#x2013;2071, https://doi.org/10.3969/j.issn.1003&#x2010;6350.2014.14.0803.</Citation></Reference><Reference><Citation>Z. Meng, M. K. Garcia, C. Hu, et&#xa0;al., &#x201c;Randomized Controlled Trial of Acupuncture for Prevention of Radiation&#x2010;Induced Xerostomia Among Patients With Nasopharyngeal Carcinoma,&#x201d; Cancer 118, no. 13 (2012): 3337&#x2013;3344.</Citation></Reference><Reference><Citation>L. Wen, X. Chen, Y. Cui, M. Zhang, and X. Bai, &#x201c;Effects of Baduanjin Exercise in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy: A Randomized Controlled Trial,&#x201d; Support Care Cancer 31, no. 1 (2022): 79.</Citation></Reference><Reference><Citation>C. K. Saniya, M. V. Rao, R. Patil, S. Choudhary, O. P. Singh, and K. S. Dhiman, &#x201c;Evaluating Ayurvedic Mouthwash and Soda&#x2010;Salt Mouthwash for Oral Mucositis in Head and Neck Cancer: A Randomized Controlled Trial,&#x201d; Journal of Ayurveda and Integrative Medicine 14, no. 6 (2023): 100829.</Citation></Reference><Reference><Citation>J. Buntzel, D. Riesenbeck, M. Glatzel, et&#xa0;al., &#x201c;Limited Effects of Selenium Substitution in the Prevention of Radiation&#x2010;Associated Toxicities. Results of a Randomized Study in Head and Neck Cancer Patients,&#x201d; Anticancer Research 30, no. 5 (2010): 1829&#x2013;1832.</Citation></Reference><Reference><Citation>X. Zhang, H. Shan, L. Xi, and S. Ji, &#x201c;Application of Chewing Exercise Combined With Acupoint Massage in Radiation Therapy for Nasopharyngeal Carcinoma in Patients With Radiation Induced Xerostomia,&#x201d; Nursing Practice and Research 20, no. 22 (2023): 3394&#x2013;3399, https://doi.org/10.3969/j.issn.1672&#x2010;9676.2023.22.014.</Citation></Reference><Reference><Citation>D. Huang, H. Huang, and Y. Lu, &#x201c;Clinical Observation of Sarcandra Glabra Combined Chemoradiotherapy for Treating Patients With Local Advanced Nasopharyngeal Carcinoma,&#x201d; Chinese Journal of Integrated Traditional and Western Medicine 33, no. 4 (2013): 456&#x2013;458.</Citation></Reference><Reference><Citation>J. Huang, X. Zhang, X. Guan, and W. Peng, &#x201c;Study on the Protective Effect of Qinghou Wumei Ice Cubes on Radiation Damage of Oral Mucosa During Radiotherapy of Nasopharyngeal Carcinoma,&#x201d; Chinese General Practice Nursing 16, no. 24 (2018): 2991&#x2013;2993.</Citation></Reference><Reference><Citation>X. Xie, S. Qiu, and P. Chen, &#x201c;Dark Plum Aerosol in Patients With Radiation&#x2010;Induced Xerostomia Based on Theory of Sour&#x2010;Sweet Herbs Nourishing Yin: A Randomized Clinical Trial,&#x201d; Liaoning Journal of Traditional Chinese Medicine 43, no. 10 (2016): 2140&#x2013;2143.</Citation></Reference><Reference><Citation>X. Chen, L. Yang, X. Chen, et&#xa0;al., &#x201c;Effects of Phyllanthifructus Spray Intervention on Radiation&#x2010;Induced Xerostomia in Patients With Nasopharyngeal Carcinoma,&#x201d; Journal of Nursing Science 39, no. 18 (2024): 53&#x2013;56.</Citation></Reference><Reference><Citation>P. Huang, L. Li, and Y. Xu, &#x201c;Observation on Effect of Mouthwash by Traditional Chinese Medicine of Detoxification Decoctionfor Sore Healing on Relieving Xerostomia for Patients With Nasopharyngeal Cancinoma Undergoing Radiotherapy,&#x201d; Nursing and Rehabilitation Journal 22, no. 5 (2023): 13&#x2013;17.</Citation></Reference><Reference><Citation>J. Wang, J. Zhang, and X. Li, &#x201c;Efficacy of Jiaweizengye Decoction for the Treatment of Xerostomia After Radiotherapy in Patients With Nasopharyngeal Carcinoma,&#x201d; China Health Standard Management 6, no. 31 (2015): 123&#x2013;125.</Citation></Reference><Reference><Citation>C. Zhang, C. Zeng, Z. Huang, C. Li, X. Wu, and X. Zhang, &#x201c;Clinical Observation Treatment of Xerostomia After Radiotherapy of Nasopharyngeal Carcinoma With Chinese Drugs,&#x201d; Chinese Journal of Clinical Oncology and Rehabilitation 18, no. 4 (2011): 374&#x2013;376.</Citation></Reference><Reference><Citation>Y. Zhang and M. Zhang, &#x201c;Observation on the Therapeutic Effect of Jiawei Zengye Decoction in Treating Xerostomia After Radiotherapy for Nasopharyngeal Carcinoma,&#x201d; Modern Journal of Integrated Traditional Chinese and Western Medicine 24, no. 3 (2015): 308&#x2013;309, https://doi.org/10.3969/j.issn.1008&#x2010;8849.2015.03.033.</Citation></Reference><Reference><Citation>S. Feng, Z. Ke, and X. Lun, &#x201c;Observation on the Therapeutic Effect of Traditional Chinese Medicine in Treating Xerostomia After Radiotherapy of Nasopharyngeal Carcinoma,&#x201d; Current Journal of Clinical Rational Drug Use 14, no. 8 (2021): 141&#x2013;142.</Citation></Reference><Reference><Citation>X. Wang, C. Fu, X. Zhang, et&#xa0;al., &#x201c;Clinical Observation of Huanglianshengdi Decoction in Prevention and Treatment of Radiation&#x2010;Induced Salivary Gland Dysfunction,&#x201d; Chinese Clinical Oncology 16, no. 7 (2011): 597&#x2013;601.</Citation></Reference><Reference><Citation>X. Ma, X. Zhang, Y. Zhi, W. Dong, and S. Liu, &#x201c;Clinical Observation on Qingfei Yangwei Recipe for Preventing and Treating Acute Radiation Stomatitis and Xerostomia,&#x201d; Chinese Journal of Information on Traditional Chinese Medicine 19, no. 4 (2012): 65&#x2013;66.</Citation></Reference><Reference><Citation>R. Di, G. Li, Y. Zhao, and X. Li, &#x201c;Effect of Smart&#x2010;Phone Application on Complications of Chemoradiotherapy and Quality of Life in Patients With Nasopharyngeal Carcinoma,&#x201d; Journal of Otorhinolaryngology Head and Neck Surgery (China) 2017, no. 3 (2017): 215&#x2013;222.</Citation></Reference><Reference><Citation>X. Wu, Q. Yang, L. Jiang, X. Chen, W. Yang, and X. Liu, &#x201c;Vitamin C and Kangfuxin Liquid Alleviate Radiation&#x2010;Induced Oral Mucosal Injury in Patients With Neck and Head Cancer Under Radiotherapy,&#x201d; Journal of Practical Oncology 29, no. 5 (2014): 466&#x2013;469.</Citation></Reference><Reference><Citation>A. Eisbruch, N. Rhodus, D. Rosenthal, et&#xa0;al., &#x201c;How Should We Measure and Report Radiotherapy&#x2010;Induced Xerostomia?,&#x201d; Seminars in Radiation Oncology 13, no. 3 (2003): 226&#x2013;234.</Citation></Reference><Reference><Citation>T. Nishioka, H. Shirato, T. Arimoto, et&#xa0;al., &#x201c;Reduction of Radiation&#x2010;Induced Xerostomia in Nasopharyngeal Carcinoma Using CT Simulation With Laser Patient Marking and Three&#x2010;Field Irradiation Technique,&#x201d; International Journal of Radiation Oncology, Biology, Physics 38, no. 4 (1997): 705&#x2013;712.</Citation></Reference><Reference><Citation>E. Dalbem Paim, M. Costa Batista Berbert, V. Gonzales Zanella, V. Beatris Martins, and F. Edler Macagnan, &#x201c;Effects of Transcutaneous Electrical Nerve Stimulation on the Salivary Flow of Patients With Hyposalivation Induced by Radiotherapy in the Head and Neck Region&#x2014;A Randomised Clinical Trial,&#x201d; Journal of Oral Rehabilitation 46, no. 12 (2019): 1142&#x2013;1150.</Citation></Reference><Reference><Citation>L. P. Porangaba, F. de Melo Garcia, A. Rabelo, et&#xa0;al., &#x201c;Randomized Double&#x2010;Blind Placebo&#x2010;Controlled Study of Salivary Substitute With Enzymatic System for Xerostomia in Patients Irradiated in Head and Neck Region,&#x201d; Current Oncology 31, no. 2 (2024): 1102&#x2013;1112.</Citation></Reference><Reference><Citation>H. Liu, X. Wang, W. Liu, G. He, X. Liang, and Y. Bian, &#x201c;Effectiveness and Safety of Traditional Chinese Medicine in Treatment of Primary Sjogren's Syndrome Patients: A Meta&#x2010;Analysis,&#x201d; Combinatorial Chemistry &amp; High Throughput Screening 26, no. 14 (2023): 2554&#x2013;2571.</Citation></Reference><Reference><Citation>M. Murakami, M. X. Wei, W. Ding, and Q. D. Zhang, &#x201c;Effects of Chinese Herbs on Salivary Fluid Secretion by Isolated and Perfused Rat Submandibular Glands,&#x201d; World Journal of Gastroenterology 15, no. 31 (2009): 3908&#x2013;3915.</Citation></Reference><Reference><Citation>Y. Wang, T. Yan, J. Shen, H. Guo, and X. Xiang, &#x201c;Preventive Effect of Ophiopogon japonicus Polysaccharides on an Autoallergic Mouse Model for Sjogren's Syndrome by Regulating the Th1/Th2 Cytokine Imbalance,&#x201d; Journal of Ethnopharmacology 114, no. 2 (2007): 246&#x2013;253.</Citation></Reference><Reference><Citation>E. Ben&#x2010;Arye, N. Samuels, L. H. Goldstein, et&#xa0;al., &#x201c;Potential Risks Associated With Traditional Herbal Medicine Use in Cancer Care: A Study of Middle Eastern Oncology Health Care Professionals,&#x201d; Cancer 122, no. 4 (2016): 598&#x2013;610.</Citation></Reference><Reference><Citation>P. S. Fasinu, P. J. Bouic, and B. Rosenkranz, &#x201c;An Overview of the Evidence and Mechanisms of Herb&#x2010;Drug Interactions,&#x201d; Frontiers in Pharmacology 3 (2012): 69.</Citation></Reference><Reference><Citation>J. B. Asiimwe, P. B. Nagendrappa, E. C. Atukunda, et&#xa0;al., &#x201c;Prevalence of the Use of Herbal Medicines Among Patients With Cancer: A Systematic Review and Meta&#x2010;Analysis,&#x201d; Evidence&#x2010;based Complementary and Alternative Medicine 2021 (2021): 9963038.</Citation></Reference><Reference><Citation>S. Thillaivanan and K. Samraj, &#x201c;Challenges, Constraints and Opportunities in Herbal Medicines&#x2014;A Review,&#x201d; International Journal of Herbal Medicine 2, no. 1 (2014): 21&#x2013;24.</Citation></Reference><Reference><Citation>X. W. Zhang, W. B. Hou, F. L. Pu, et&#xa0;al., &#x201c;Acupuncture for Cancer&#x2010;Related Conditions: An Overview of Systematic Reviews,&#x201d; Phytomedicine 106 (2022): 154430.</Citation></Reference><Reference><Citation>D. S. T. Cheung, X. Xu, R. Smith, et&#xa0;al., &#x201c;Invasive or Noninvasive? A Systematic Review and Network Meta&#x2010;Analysis of Acupuncture and Acupressure to Treat Sleep Disturbance in Cancer Patients,&#x201d; Worldviews on Evidence&#x2010;Based Nursing 20, no. 3 (2023): 202&#x2013;211.</Citation></Reference><Reference><Citation>D. S. T. Cheung, W. F. Yeung, P. H. Chau, et&#xa0;al., &#x201c;Patient&#x2010;Centred, Self&#x2010;Administered Acupressure for Chinese Advanced Cancer Patients Experiencing Fatigue and Co&#x2010;Occurring Symptoms: A Pilot Randomised Controlled Trial,&#x201d; European Journal of Cancer Care (Engl) 31, no. 5 (2022): e13314.</Citation></Reference><Reference><Citation>M. Blom, T. Lundeberg, I. Dawidson, et&#xa0;al., &#x201c;Effects on Local Blood Flux of Acupuncture Stimulation Used to Treat Xerostomia in Patients Suffering From Sjogren's Syndrome,&#x201d; Journal of Oral Rehabilitation 20, no. 5 (1993): 541&#x2013;548.</Citation></Reference><Reference><Citation>I. Dawidson, B. Angmar&#x2010;Mansson, M. Blom, et&#xa0;al., &#x201c;The Influence of Sensory Stimulation (Acupuncture) on the Release of Neuropeptides in the Saliva of Healthy Subjects,&#x201d; Life Sciences 63, no. 8 (1998): 659&#x2013;674.</Citation></Reference><Reference><Citation>D. S. T. Cheung, A. Tiwari, W. Yeung, et&#xa0;al., &#x201c;Self&#x2010;Administered Acupressure for Caregivers of Older Family Members: A Randomized Controlled Trial,&#x201d; Journal of the American Geriatrics Society 68, no. 6 (2020): 1193&#x2013;1201. Portico, https://doi.org/10.1111/jgs.16357.</Citation></Reference><Reference><Citation>W. F. Yeung, S. C. Chen, D. S. T. Cheung, et&#xa0;al., &#x201c;Self&#x2010;Administered Acupressure for Probable Knee Osteoarthritis in Middle&#x2010;Aged and Older Adults,&#x201d; JAMA Network Open 7, no. 4 (2024): e245830, https://doi.org/10.1001/jamanetworkopen.2024.5830.</Citation></Reference><Reference><Citation>D. S. T. Cheung, X. Xu, R. Smith, et&#xa0;al., &#x201c;Invasive or Noninvasive? A Systematic Review and Network Meta&#x2010;Analysis of Acupuncture and Acupressure to Treat Sleep Disturbance in Cancer Patients,&#x201d; Worldviews on Evidence&#x2010;Based Nursing 20, no. 3 (2022): 202&#x2013;211. Portico, https://doi.org/10.1111/wvn.12617.</Citation></Reference><Reference><Citation>L. See, M. Mohammadi, P. P. Han, R. Mulligan, and R. Enciso, &#x201c;Efficacy of Saliva Substitutes and Stimulants in the Treatment of Dry Mouth,&#x201d; Special Care in Dentistry 39, no. 3 (2019): 287&#x2013;297. Portico. https://doi.org/10.1111/scd.12370.</Citation></Reference><Reference><Citation>M. Dodds, S. Roland, M. Edgar, and M. Thornhill, &#x201c;Saliva A Review of Its Role in Maintaining Oral Health and Preventing Dental Disease,&#x201d; BDJ Team 2 (2015): 1&#x2013;8, https://doi.org/10.1038/bdjteam.2015.123.</Citation></Reference><Reference><Citation>V. Mercadante, A. A. Hamad, J. McCaul, et&#xa0;al., &#x201c;Salivary Electrostimulation in the Treatment of Radiation Therapy&#x2010;Induced Xerostomia (LEONIDAS&#x2010;2): A Multicenter, Randomized, Double&#x2010;Masked, Sham&#x2010;Controlled, Phase 3 Trial,&#x201d; International Journal of Radiation Oncology, Biology, Physics 118, no. 1 (2024): 142&#x2013;153, https://doi.org/10.1016/j.ijrobp.2023.03.047.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.28266 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40727977</PMID><DateCompleted><Year>2025</Year><Month>12</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>12</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><Volume>48</Volume><Issue>1</Issue><PubDate><Year>2026</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Prognostic Significance of Solid Subtype of Papillary Thyroid Carcinoma: Analysis of 63 Patients.</ArticleTitle><Pagination><StartPage>5</StartPage><EndPage>12</EndPage><MedlinePgn>5-12</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.28266</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Solid subtype of papillary thyroid carcinoma (SSPTC) is an uncommon subtype of papillary thyroid cancer (PTC) and its prognostic significance is still controversial. The aim of this review is to present the clinicopathological features of SSPTC and compare its clinical behavior with classical PTC (cPTC).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We retrospectively analyzed patients who underwent thyroidectomy for SSPTC and compared the clinicopathological findings and clinical outcomes with those of patients with cPTC.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 4937 patients treated for PTC, 63 (1.3%) were diagnosed with SSPTC, of which 76.2% were female, with a median age of 40&#x2009;years, 3.2% had prior cervical irradiation, and the median diameter of the tumor was 15&#x2009;mm. Compared to cPTCs, SSPTCs were larger (median tumor diameter: 15 vs. 9&#x2009;mm), more symptomatic (non-incidentally discovered) and were associated with an elevated risk for multifocality, extrathyroidal extension, lympho-vascular invasion, lymph node metastasis, extra-nodal extension, and distant metastasis. After a mean follow-up of 58.5&#x2009;months, rates of biochemical incomplete response to treatment and structural recurrence were higher when compared to those of cPTC. None of the patients who demonstrated an excellent response to treatment presented cancer recurrence during follow-up. Distant metastasis occurred in 3 patients (4.8%). There were no cancer-related deaths.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">SSPTC is an aggressive histological subtype of PTC associated with adverse prognostic features, including larger tumor size, multifocality, and extrathyroidal extension, which correlate with a higher risk of cancer recurrence and therefore should be considered for accurate risk stratification, comprehensive management, and close follow-up.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). Head &amp; Neck published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ywata de Carvalho</LastName><ForeName>Andre</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-3630-8990</Identifier><AffiliationInfo><Affiliation>Head and Neck Surgery and Otorhinolaryngology Department, A. C. Camargo Cancer Center, Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costa</LastName><ForeName>Felipe D' Almeida</ForeName><Initials>FA</Initials><AffiliationInfo><Affiliation>Pathology Department, A. C. Camargo Cancer Center, Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vartanian</LastName><ForeName>Jose Guilherme</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Head and Neck Surgery and Otorhinolaryngology Department, A. C. Camargo Cancer Center, Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kowalski</LastName><ForeName>Luiz Paulo</ForeName><Initials>LP</Initials><Identifier Source="ORCID">0000-0002-0481-156X</Identifier><AffiliationInfo><Affiliation>Head and Neck Surgery and Otorhinolaryngology Department, A. C. Camargo Cancer Center, Sao Paulo, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Head and Neck Surgery Department, University of Sao Paulo, Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013964" MajorTopicYN="Y">Thyroid Neoplasms</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013965" MajorTopicYN="N">Thyroidectomy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077273" MajorTopicYN="N">Thyroid Cancer, Papillary</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002291" MajorTopicYN="Y">Carcinoma, Papillary</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002277" MajorTopicYN="Y">Carcinoma</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009361" MajorTopicYN="N">Neoplasm Invasiveness</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008207" MajorTopicYN="N">Lymphatic Metastasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">aggressive variant</Keyword><Keyword MajorTopicYN="N">papillary carcinoma</Keyword><Keyword MajorTopicYN="N">recurrence</Keyword><Keyword MajorTopicYN="N">solid subtype</Keyword><Keyword MajorTopicYN="N">solid trabecular variant</Keyword><Keyword MajorTopicYN="N">thyroid</Keyword></KeywordList><CoiStatement>The authors have nothing to report. The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>29</Day><Hour>12</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>29</Day><Hour>6</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>12</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40727977</ArticleId><ArticleId IdType="pmc">PMC12703567</ArticleId><ArticleId IdType="doi">10.1002/hed.28266</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wiltshire J. J., Drake T. M., Uttley L., and Balasubramanian S. P., &#x201c;Systematic Review of Trends in the Incidence Rates of Thyroid Cancer,&#x201d; Thyroid 26 (2016): 1541&#x2013;1552, 10.1089/thy.2016.0100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/thy.2016.0100</ArticleId><ArticleId IdType="pubmed">27571228</ArticleId></ArticleIdList></Reference><Reference><Citation>Hundahl S. A., Fleming I. D., Fremgen A. M., et&#xa0;al., &#x201c;A National Cancer Data Base Report on 53,856 Cases of Thyroid Carcinoma Treated in the U.S., 1985&#x2010;1995,&#x201d; Cancer 83, no. 12 (1998): 2638&#x2013;2648, 10.1002/(sici)1097-0142(19981215)83:12&lt;2638::aid-cncr31&gt;3.0.co;2-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(sici)1097-0142(19981215)83:12&lt;2638::aid-cncr31&gt;3.0.co;2-1</ArticleId><ArticleId IdType="pubmed">9874472</ArticleId></ArticleIdList></Reference><Reference><Citation>Grogan R. H., Kaplan S. P., Cao H., et&#xa0;al., &#x201c;A Study of Recurrence and Death From Papillary Thyroid Cancer With 27&#x2009;Years of Median Follow&#x2010;Up,&#x201d; Surgery 154 (2013): 1436&#x2013;1446, discussion 1446&#x2010;1447, 10.1016/j.surg.2013.07.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.surg.2013.07.008</ArticleId><ArticleId IdType="pubmed">24075674</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim H., Devesa S. S., Sosa J. A., Check D., and Kitahara C. M., &#x201c;Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974&#x2010;2013,&#x201d; Journal of the American Medical Association 317, no. 13 (2017): 1338&#x2013;1348.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8216772</ArticleId><ArticleId IdType="pubmed">28362912</ArticleId></ArticleIdList></Reference><Reference><Citation>Haugen B. R., Alexander E. K., Bible K. C., et&#xa0;al., &#x201c;2015 American Thyroid Association Management Guidelines for Adult Patients With Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer,&#x201d; Thyroid 26 (2016): 1&#x2013;133, 10.1089/thy.2015.0020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/thy.2015.0020</ArticleId><ArticleId IdType="pmc">PMC4739132</ArticleId><ArticleId IdType="pubmed">26462967</ArticleId></ArticleIdList></Reference><Reference><Citation>
WHO Classification of Tumors Editorial Board
, Endocrine and Neuroendocrine Tumors (International Agency for Research on Cancer, 2022), https://tumourclassification.iarc.who.int/chapters/36.</Citation></Reference><Reference><Citation>Pizzimenti C., Fiorentino V., Ieni A., et&#xa0;al., &#x201c;Aggressive Variants of Follicular Cell&#x2010;Derived Thyroid Carcinoma: An Overview,&#x201d; Endocrine 78, no. 1 (2022): 1&#x2013;12, 10.1007/s12020-022-03146-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12020-022-03146-0</ArticleId><ArticleId IdType="pubmed">35864338</ArticleId></ArticleIdList></Reference><Reference><Citation>Carcangiu M. L., Zampi G., Pupi A., Castagnoli A., and Rosai J., &#x201c;Papillary Carcinoma of the Thyroid. A Clinicopathologic Study of 241 Cases Treated at the University of Florence, Italy,&#x201d; Cancer 55, no. 4 (1985): 805&#x2013;828, 10.1002/1097-0142(19850215)55:4&lt;805::aid-cncr2820550419&gt;3.0.co;2-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1097-0142(19850215)55:4&lt;805::aid-cncr2820550419&gt;3.0.co;2-z</ArticleId><ArticleId IdType="pubmed">3967175</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam A. K., Lo C., and Lam K. S., &#x201c;Papillary Carcinoma of Thyroid: A 30&#x2010;Yr Clinicopathological Review of the Histological Variants,&#x201d; Endocrine Pathology 16, no. 4 (2005): 323&#x2013;330, 10.1385/ep:16:4:323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1385/ep:16:4:323</ArticleId><ArticleId IdType="pubmed">16627919</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikiforov Y. E., Erickson L. A., Nikiforova M. N., Caudill C. M., and Lloyd R. V., &#x201c;Solid Variant of Papillary Thyroid Carcinoma: Incidence, Clinical&#x2010;Pathologic Characteristics, Molecular Analysis, and Biologic Behavior,&#x201d; American Journal of Surgical Pathology 25, no. 12 (2001): 1478&#x2013;1484, 10.1097/00000478-200112000-00002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000478-200112000-00002</ArticleId><ArticleId IdType="pubmed">11717536</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikiforov Y. and Gnepp D. R., &#x201c;Pediatric Thyroid Cancer After the Chernobyl Disaster: Pathomorphologic Study of 84 Cases (1991&#x2013;1992) From the Republic of Belarus,&#x201d; Cancer 74, no. 2 (1994): 748&#x2013;766, 10.1002/1097-0142(19940715)74:2&lt;748::aid-cncr2820740231&gt;3.0.co;2-h.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1097-0142(19940715)74:2&lt;748::aid-cncr2820740231&gt;3.0.co;2-h</ArticleId><ArticleId IdType="pubmed">8033057</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizukami Y., Noguchi M., Michigishi T., et&#xa0;al., &#x201c;Papillary Thyroid Carcinoma in Kanazawa, Japan: Prognostic Significance of Histological Subtypes,&#x201d; Histopathology 20, no. 3 (1992): 243&#x2013;250, 10.1111/j.1365-2559.1992.tb00963.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2559.1992.tb00963.x</ArticleId><ArticleId IdType="pubmed">1563711</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang H., Kim S. M., Chun K. W., et&#xa0;al., &#x201c;Clinicopathologic Features of Solid Variant Papillary Thyroid Cancer,&#x201d; ANZ Journal of Surgery 84, no. 5 (2014): 380&#x2013;382, 10.1111/ans.12307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ans.12307</ArticleId><ArticleId IdType="pubmed">23826897</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohashi R., &#x201c;Solid Variant of Papillary Thyroid Carcinoma: An Underrecognized Entity,&#x201d; Endocrine Journal 67, no. 3 (2020): 241&#x2013;248, 10.1507/endocrj.EJ19-0414.</Citation><ArticleIdList><ArticleId IdType="doi">10.1507/endocrj.EJ19-0414</ArticleId><ArticleId IdType="pubmed">31983699</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung C. K., Bychkov A., and Kakudo K., &#x201c;Update From the 2022 World Health Organization Classification of Thyroid Tumors: A Standardized Diagnostic Approach,&#x201d; Endocrinology and Metabolism (Seoul) 37, no. 5 (2022): 703&#x2013;718, 10.3803/EnM.2022.1553.</Citation><ArticleIdList><ArticleId IdType="doi">10.3803/EnM.2022.1553</ArticleId><ArticleId IdType="pmc">PMC9633223</ArticleId><ArticleId IdType="pubmed">36193717</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuttle R. M., Tala H., Shah J., et&#xa0;al., &#x201c;Estimating Risk of Recurrence in Differentiated Thyroid Cancer After Total Thyroidectomy and Radioactive Iodine Remnant Ablation: Using Response to Therapy Variables to Modify the Initial Risk Estimates Predicted by the New American Thyroid Association Staging System,&#x201d; Thyroid 20 (2010): 1341&#x2013;1349.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4845674</ArticleId><ArticleId IdType="pubmed">21034228</ArticleId></ArticleIdList></Reference><Reference><Citation>Coca&#x2010;Pelaz A., Shah J. P., Hernandez&#x2010;Prera J. C., et&#xa0;al., &#x201c;Papillary Thyroid Cancer&#x2010;Aggressive Variants and Impact on Management: A Narrative Review,&#x201d; Advances in Therapy 37, no. 7 (2020): 3112&#x2013;3128, 10.1007/s12325-020-01391-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12325-020-01391-1</ArticleId><ArticleId IdType="pmc">PMC7467416</ArticleId><ArticleId IdType="pubmed">32488657</ArticleId></ArticleIdList></Reference><Reference><Citation>Vural &#xc7;., Kiraz U., Turan G., &#xd6;zkara S. K., S&#xf6;zen M., and &#xc7;etinarslan B., &#x201c;Solid Variant of Papillary Thyroid Carcinoma: An Analysis of 28 Cases With Current Literature,&#x201d; Annals of Diagnostic Pathology 52 (2021): 151737, 10.1016/j.anndiagpath.2021.151737.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.anndiagpath.2021.151737</ArticleId><ArticleId IdType="pubmed">33838489</ArticleId></ArticleIdList></Reference><Reference><Citation>Vuong H. G., Odate T., Duong U. N. P., et&#xa0;al., &#x201c;Prognostic Importance of Solid Variant Papillary Thyroid Carcinoma: A Systematic Review and Meta&#x2010;Analysis,&#x201d; Head and Neck 40, no. 7 (2018): 1588&#x2013;1597, 10.1002/hed.25123.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hed.25123</ArticleId><ArticleId IdType="pubmed">29509280</ArticleId></ArticleIdList></Reference><Reference><Citation>Webb R. C., Howard R. S., Stojadinovic A., et&#xa0;al., &#x201c;The Utility of Serum Thyroglobulin Measurement at the Time of Remnant Ablation for Predicting Disease&#x2010;Free Status in Patients With Differentiated Thyroid Cancer: A Meta&#x2010;Analysis Involving 3947 Patients,&#x201d; Journal of Clinical Endocrinology and Metabolism 97, no. 8 (2012): 2754&#x2013;2763, 10.1210/jc.2012-1533.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2012-1533</ArticleId><ArticleId IdType="pubmed">22639291</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibrahimpasic T., Nixon I. J., Palmer F. L., et&#xa0;al., &#x201c;Undetectable Thyroglobulin After Total Thyroidectomy in Patients With Low&#x2010; and Intermediate&#x2010;Risk Papillary Thyroid Cancer&#x2014;Is There a Need for Radioactive Iodine Therapy?,&#x201d; Surgery 152, no. 6 (2012): 1096&#x2013;1105, 10.1016/j.surg.2012.08.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.surg.2012.08.034</ArticleId><ArticleId IdType="pubmed">23158181</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian T., Xu Y., Zhang X., and Liu B., &#x201c;Prognostic Implications of Preablation Stimulated Tg: A Retrospective Analysis of 2500 Thyroid Cancer Patients,&#x201d; Journal of Clinical Endocrinology and Metabolism 106, no. 11 (2021): e4688&#x2013;e4697, 10.1210/clinem/dgab445.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/clinem/dgab445</ArticleId><ArticleId IdType="pubmed">34143886</ArticleId></ArticleIdList></Reference><Reference><Citation>Ywata de Carvalho A., Kohler H. F., Ywata de Carvalho C. C. G., et&#xa0;al., &#x201c;Predictors of Recurrence After Total Thyroidectomy in 1,611 Patients With Papillary Thyroid Carcinoma: Postoperative Stimulated Serum Thyroglobulin and ATA Initial and Dynamic Risk Assessment,&#x201d; Archives of Endocrinology and Metabolism 68 (2024): e220506, 10.20945/2359-4292-2022-0506.</Citation><ArticleIdList><ArticleId IdType="doi">10.20945/2359-4292-2022-0506</ArticleId><ArticleId IdType="pmc">PMC11081051</ArticleId><ArticleId IdType="pubmed">38578436</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad M. L., Vyas M., Horne M. J., et&#xa0;al., &#x201c;NTRK Fusion Oncogenes in Pediatric Papillary Thyroid Carcinoma in Northeast United States,&#x201d; Cancer 122, no. 7 (2016): 1097&#x2013;1107, 10.1002/cncr.29887.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.29887</ArticleId><ArticleId IdType="pubmed">26784937</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70001 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40785350</PMID><DateCompleted><Year>2025</Year><Month>12</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>12</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><Volume>48</Volume><Issue>1</Issue><PubDate><Year>2026</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>A New Orthotopic Mouse Model of Laryngeal Squamous Cell Carcinoma.</ArticleTitle><Pagination><StartPage>106</StartPage><EndPage>113</EndPage><MedlinePgn>106-113</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70001</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The aim of this study is to establish a novel and reproducible orthotopic mouse model, aiming to facilitate research related to laryngeal cancer.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Implantation of mouse squamous cell carcinoma cell line, Meer-LUC, into the larynx of C57BL/6 mice (n&#x2009;=&#x2009;16). Tumor growth and survival were observed using magnetic resonance imaging and optical in&#xa0;vivo three-dimensional imaging. Laryngeal and cervical lymph node specimens were obtained for HE staining and evaluation. Single-cell sequencing was performed on laryngeal cancer patients, orthotopic mouse models, and subcutaneous tumor models to investigate the immune microenvironment of laryngeal cancer.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We successfully established 15 cases of in&#xa0;situ laryngeal cancer mouse models. Tumors maintained steady growth at each observation time point, and histopathological evaluation confirmed the successful construction of the model. Single-cell sequencing results suggest that the orthotopic model better simulates the immune microenvironment alterations of real laryngeal cancer.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We have developed a novel and reproducible orthotopic mouse model, which more faithfully mimics the immune system response of the human body and better simulates the biological evolution process of tumors. This model provides an essential animal research framework for investigating the molecular mechanisms underlying the occurrence and development of laryngeal cancer.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). Head &amp; Neck published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Junrong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology Head and Neck Surgery, Harbin Medical University Cancer Hospital, Harbin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Ming</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology Head and Neck Surgery, Harbin Medical University Cancer Hospital, Harbin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology Head and Neck Surgery, Harbin Medical University Cancer Hospital, Harbin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xueying</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Otolaryngology Major Disease Research Key Laboratory of Hunan Province, Changsha, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Research Center for Laryngopharyngeal and Voice Disorders in Hunan, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Xianguang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology Head and Neck Surgery, Harbin Medical University Cancer Hospital, Harbin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Lunhua</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology Head and Neck Surgery, Harbin Medical University Cancer Hospital, Harbin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jianfeng</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Animal Experimental Center, Harbin Medical University, Harbin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Hongxue</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-1831-2737</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Harbin Medical University Cancer Hospital, Harbin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Xionghui</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology Head and Neck Surgery, Harbin Medical University Cancer Hospital, Harbin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Erliang</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Harbin Medical University Cancer Hospital, Harbin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miao</LastName><ForeName>Susheng</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology Head and Neck Surgery, Harbin Medical University Cancer Hospital, Harbin, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>82473419</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>PDYS2024-09</GrantID><Agency>Harbin Medical University Cancer Hospital Climbing Plan Project</Agency><Country/></Grant><Grant><GrantID>07000044</GrantID><Agency>Natural Science Foundation of Heilongjiang Province, China</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007822" MajorTopicYN="Y">Laryngeal Neoplasms</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002294" MajorTopicYN="Y">Carcinoma, Squamous Cell</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009368" MajorTopicYN="N">Neoplasm Transplantation</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">immune microenvironment</Keyword><Keyword MajorTopicYN="N">laryngeal squamous cell carcinoma</Keyword><Keyword MajorTopicYN="N">orthotopic mouse model</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>11</Day><Hour>3</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>12</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40785350</ArticleId><ArticleId IdType="pmc">PMC12703556</ArticleId><ArticleId IdType="doi">10.1002/hed.70001</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Siegel R. L., Miller K. D., Wagle N. S., and Jemal A., &#x201c;Cancer Statistics, 2023,&#x201d; CA: A Cancer Journal for Clinicians 73, no. 1 (2023): 17&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">36633525</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J., Chan S. C., Ko S., et&#xa0;al., &#x201c;Updated Disease Distributions, Risk Factors, and Trends of Laryngeal Cancer: A Global Analysis of Cancer Registries,&#x201d; International Journal of Surgery 110, no. 2 (2024): 810&#x2013;819.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10871644</ArticleId><ArticleId IdType="pubmed">38000050</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Credico G., Polesel J., Dal Maso L., et&#xa0;al., &#x201c;Alcohol Drinking and Head and Neck Cancer Risk: The Joint Effect of Intensity and Duration,&#x201d; British Journal of Cancer 123, no. 9 (2020): 1456&#x2013;1463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7592048</ArticleId><ArticleId IdType="pubmed">32830199</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang C. P., La Vecchia C., Serraino D., et&#xa0;al., &#x201c;Dietary Glycaemic Index, Glycaemic Load and Head and Neck Cancer Risk: A Pooled Analysis in an International Consortium,&#x201d; British Journal of Cancer 122, no. 6 (2020): 745&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7078183</ArticleId><ArticleId IdType="pubmed">31929514</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffman R. M., &#x201c;Orthotopic Metastatic Mouse Models for Anticancer Drug Discovery and Evaluation: A Bridge to the Clinic,&#x201d; Investigational New Drugs 17, no. 4 (1999): 343&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pubmed">10759402</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen J. T., Gil Z., Binenbaum Y., Na&#x2019;ara S., and Amit M., &#x201c;An Orthotopic Mouse Model of Laryngeal Squamous Cell Carcinoma,&#x201d; Annals of Otology, Rhinology and Laryngology 124, no. 2 (2015): 143&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">25204712</ArticleId></ArticleIdList></Reference><Reference><Citation>Bray F., Laversanne M., Sung H., et&#xa0;al., &#x201c;Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,&#x201d; CA: A Cancer Journal for Clinicians 74 (2024): 229&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">38572751</ArticleId></ArticleIdList></Reference><Reference><Citation>Steuer C. E., El&#x2010;Deiry M., Parks J. R., et&#xa0;al., &#x201c;An Update on Larynx Cancer,&#x201d; CA: A Cancer Journal for Clinicians 67, no. 1 (2017): 31&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">27898173</ArticleId></ArticleIdList></Reference><Reference><Citation>Richmond A. and Su Y., &#x201c;Mouse Xenograft Models vs GEM Models for Human Cancer Therapeutics,&#x201d; Disease Models &amp; Mechanisms 1, no. 2&#x2013;3 (2008): 78&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2562196</ArticleId><ArticleId IdType="pubmed">19048064</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70013 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40785626</PMID><DateCompleted><Year>2025</Year><Month>12</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>12</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><Volume>48</Volume><Issue>1</Issue><PubDate><Year>2026</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Oncological Impact of Surgical Margin Status After Transoral Laser Microsurgery for Early Glottic Cancer.</ArticleTitle><Pagination><StartPage>99</StartPage><EndPage>105</EndPage><MedlinePgn>99-105</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70013</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Transoral laser microsurgery is a well-established treatment for early glottic cancer. However, managing patients with close/positive margins remains debated. This study analyzes the relationship between resection margins and oncologic outcomes.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients with early glottic cancer who underwent transoral laser microsurgery were included. We compared clinical characteristics, recurrence-free survival, laryngeal preservation, and disease-specific survival between negative and close/positive margin groups.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 107 patients, 49 (45.8%) had close/positive margins. The recurrence-free survival rate was significantly lower in the close/positive margin group. Anterior commissure involvement was a significant risk factor for recurrence. The median recurrence time for the close/positive margin group was 18.5&#x2009;months, similar to the negative margin group. Laryngeal preservation and disease-specific survival were similar between groups with &gt;&#x2009;95%.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Patients with close/positive margins in early glottic cancer showed similar disease-specific survival and laryngeal preservation rates as negative margins; despite lower recurrence-free survival, suggesting a follow-up approach is sufficient.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). Head &amp; Neck published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hatomi</LastName><ForeName>Sae</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Keio University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tomisato</LastName><ForeName>Shuta</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Keio University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kasahara</LastName><ForeName>Ken</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-7120-069X</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Keio University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ozawa</LastName><ForeName>Hiroyuki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Keio University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kono</LastName><ForeName>Takeyuki</ForeName><Initials>T</Initials><Identifier Source="ORCID">0009-0008-5792-3072</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Keio University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007822" MajorTopicYN="Y">Laryngeal Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008866" MajorTopicYN="Y">Microsurgery</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072662" MajorTopicYN="Y">Margins of Excision</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053685" MajorTopicYN="Y">Laser Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005931" MajorTopicYN="Y">Glottis</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002294" MajorTopicYN="Y">Carcinoma, Squamous Cell</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">glottic cancer</Keyword><Keyword MajorTopicYN="N">prognosis</Keyword><Keyword MajorTopicYN="N">recurrence</Keyword><Keyword MajorTopicYN="N">surgical margin</Keyword><Keyword MajorTopicYN="N">transoral laser microsurgery</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>11</Day><Hour>5</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>12</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40785626</ArticleId><ArticleId IdType="pmc">PMC12703568</ArticleId><ArticleId IdType="doi">10.1002/hed.70013</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Peretti G., Piazza C., Cocco D., et&#xa0;al., &#x201c;Transoral Co(2) Laser Treatment for T(Is)&#x2010;T(3) Glottic Cancer: The University of Brescia Experience on 595 Patients,&#x201d; Head and Neck 32, no. 8 (2010): 977&#x2013;983, 10.1002/hed.21278.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hed.21278</ArticleId><ArticleId IdType="pubmed">19902535</ArticleId></ArticleIdList></Reference><Reference><Citation>Ansarin M., Cattaneo A., De Benedetto L., et&#xa0;al., &#x201c;Retrospective Analysis of Factors Influencing Oncologic Outcome in 590 Patients With Early&#x2010;Intermediate Glottic Cancer Treated by Transoral Laser Microsurgery,&#x201d; Head &amp; Neck 39, no. 1 (2017): 71&#x2013;81, 10.1002/hed.24534.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hed.24534</ArticleId><ArticleId IdType="pubmed">27453475</ArticleId></ArticleIdList></Reference><Reference><Citation>Piazza C., Paderno A., Del Bon F., et&#xa0;al., &#x201c;Long&#x2010;term Oncologic Outcomes of 1188 Tis&#x2010;T2 Glottic Cancers Treated by Transoral Laser Microsurgery,&#x201d; Otolaryngology and Head and Neck Surgery 165, no. 2 (2021): 321&#x2013;328, 10.1177/0194599820983727.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0194599820983727</ArticleId><ArticleId IdType="pubmed">33400625</ArticleId></ArticleIdList></Reference><Reference><Citation>Peretti G., Piazza C., Mora F., Garofolo S., and Guastini L., &#x201c;Reasonable Limits for Transoral Laser Microsurgery in Laryngeal Cancer,&#x201d; Current Opinion in Otolaryngology &amp; Head and Neck Surgery 24, no. 2 (2016): 135&#x2013;139, 10.1097/MOO.0000000000000240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MOO.0000000000000240</ArticleId><ArticleId IdType="pubmed">26963672</ArticleId></ArticleIdList></Reference><Reference><Citation>Cosway B., Drinnan M., and Paleri V., &#x201c;Narrow Band Imaging for The Diagnosis of Head and Neck Squamous Cell Carcinoma: A Systematic Review,&#x201d; Head &amp; Neck 38, no. Suppl 1 (2016): E2358&#x2013;E2367, 10.1002/hed.24300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hed.24300</ArticleId><ArticleId IdType="pubmed">26891200</ArticleId></ArticleIdList></Reference><Reference><Citation>Campo F., D'Aguanno V., Greco A., Ralli M., and de Vincentiis M., &#x201c;The Prognostic Value of Adding Narrow&#x2010;Band Imaging in Transoral Laser Microsurgery for Early Glottic Cancer: A Review,&#x201d; Lasers in Surgery and Medicine 52, no. 4 (2020): 301&#x2013;306, 10.1002/lsm.23142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/lsm.23142</ArticleId><ArticleId IdType="pubmed">31338852</ArticleId></ArticleIdList></Reference><Reference><Citation>Zwakenberg M. A., Westra J. M., Halmos G. B., Wedman J., van der Laan B., and Plaat B. E. C., &#x201c;Narrow&#x2010;Band Imaging in Transoral Laser Surgery for Early Glottic Cancer: A Randomized Controlled Trial,&#x201d; Otolaryngology and Head and Neck Surgery 169, no. Sep (2023): 606&#x2013;614, 10.1002/ohn.307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ohn.307</ArticleId><ArticleId IdType="pubmed">36821814</ArticleId></ArticleIdList></Reference><Reference><Citation>Kono T., Saito K., Yabe H., Uno K., and Ogawa K., &#x201c;Comparative Multidimensional Assessment of Laryngeal Function and Quality of Life After Radiotherapy and Laser Surgery for Early Glottic Cancer,&#x201d; Head &amp; Neck 38, no. 7 (2016): 1085&#x2013;1090, 10.1002/hed.24412.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hed.24412</ArticleId><ArticleId IdType="pubmed">26969802</ArticleId></ArticleIdList></Reference><Reference><Citation>Remacle M., Van Haverbeke C., Eckel H., et&#xa0;al., &#x201c;Proposal for Revision of the European Laryngological Society Classification of Endoscopic Cordectomies,&#x201d; European Archives of Oto&#x2010;Rhino&#x2010;Laryngology 264, no. 5 (2007): 499&#x2013;504, 10.1007/s00405-007-0279-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00405-007-0279-z</ArticleId><ArticleId IdType="pubmed">17377801</ArticleId></ArticleIdList></Reference><Reference><Citation>Roman B. R., Goldenberg D., Givi B., and Education Committee of American H, Neck, S , &#x201c;AHNS Series&#x2014;Do you know your Guidelines? Guideline Recommended Follow&#x2010;Up and Surveillance of Head and Neck Cancer Survivors,&#x201d; Head &amp; Neck 38, no. 2 (2016): 168&#x2013;174, 10.1002/hed.24100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hed.24100</ArticleId><ArticleId IdType="pubmed">25916656</ArticleId></ArticleIdList></Reference><Reference><Citation>Canis M., Ihler F., Martin A., Matthias C., and Steiner W., &#x201c;Transoral Laser Microsurgery for T1a Glottic Cancer: Review of 404 Cases,&#x201d; Head &amp; Neck 37, no. 6 (2015): 889&#x2013;895, 10.1002/hed.23688.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hed.23688</ArticleId><ArticleId IdType="pubmed">24623709</ArticleId></ArticleIdList></Reference><Reference><Citation>Hans S., Crevier&#x2010;Buchman L., Circiu M., et&#xa0;al., &#x201c;Oncological and Surgical Outcomes of Patients Treated by Transoral CO(2) Laser Cordectomy for Early&#x2010;Stage Glottic Squamous Cell Carcinoma: A Retrospective Chart Review,&#x201d; Ear, Nose, &amp; Throat Journal 100, no. 1_suppl (2021): 33S&#x2013;37S, 10.1177/0145561320911486.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0145561320911486</ArticleId><ArticleId IdType="pubmed">32204623</ArticleId></ArticleIdList></Reference><Reference><Citation>Day A. T., Sinha P., Nussenbaum B., Kallogjeri D., and Haughey B. H., &#x201c;Management of Primary T1&#x2010;T4 Glottic Squamous Cell Carcinoma by Transoral Laser Microsurgery,&#x201d; Laryngoscope 127, no. 3 (2017): 597&#x2013;604, 10.1002/lary.26207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/lary.26207</ArticleId><ArticleId IdType="pubmed">27578610</ArticleId></ArticleIdList></Reference><Reference><Citation>Breda E., Catarino R., and Monteiro E., &#x201c;Transoral Laser Microsurgery for Laryngeal Carcinoma: Survival Analysis in a Hospital&#x2010;Based Population,&#x201d; Head &amp; Neck 37, no. 8 (2015): 1181&#x2013;1186, 10.1002/hed.23728.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hed.23728</ArticleId><ArticleId IdType="pubmed">24798054</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H. S., Chun B. G., Kim S. W., et&#xa0;al., &#x201c;Transoral Laser Microsurgery for Early Glottic Cancer as One&#x2010;Stage Single&#x2010;Modality Therapy,&#x201d; Laryngoscope 123, no. 11 (2013): 2670&#x2013;2674, 10.1002/lary.24080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/lary.24080</ArticleId><ArticleId IdType="pubmed">23553229</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigston E., de Mones E., Babin E., et&#xa0;al., &#x201c;Early&#x2010;Stage Glottic Cancer: Oncological Results and Margins in Laser Cordectomy,&#x201d; Archives of Otolaryngology &#x2013; Head &amp; Neck Surgery 132, no. 2 (2006): 147&#x2013;152, 10.1001/archotol.132.2.147.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archotol.132.2.147</ArticleId><ArticleId IdType="pubmed">16490871</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertino G., Degiorgi G., Tinelli C., Cacciola S., Occhini A., and Benazzo M., &#x201c;Co(2) Laser Cordectomy for T1&#x2010;T2 Glottic Cancer: Oncological and Functional Long&#x2010;Term Results,&#x201d; European Archives of Oto&#x2010;Rhino&#x2010;Laryngology 272, no. Sep (2015): 2389&#x2013;2395, 10.1007/s00405-015-3629-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00405-015-3629-2</ArticleId><ArticleId IdType="pubmed">25895574</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandstorp&#x2010;Boesen J., Sorum Falk R., Boysen M., and Brondbo K., &#x201c;Impact of Stage, Management and Recurrence on Survival Rates in Laryngeal Cancer,&#x201d; PLoS One 12, no. 7 (2017): e0179371, 10.1371/journal.pone.0179371.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0179371</ArticleId><ArticleId IdType="pmc">PMC5510803</ArticleId><ArticleId IdType="pubmed">28708883</ArticleId></ArticleIdList></Reference><Reference><Citation>Pakkanen P., Ilmarinen T., Halme E., et&#xa0;al., &#x201c;T1 Glottic Laryngeal Cancer: the Role of Routine Follow&#x2010;Up Visits in Detecting Local Recurrence,&#x201d; European Archives of Oto&#x2010;Rhino&#x2010;Laryngology 278, no. 12 (2021): 4863&#x2013;4869, 10.1007/s00405-021-06983-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00405-021-06983-3</ArticleId><ArticleId IdType="pmc">PMC8553688</ArticleId><ArticleId IdType="pubmed">34357460</ArticleId></ArticleIdList></Reference><Reference><Citation>Ansarin M., Santoro L., Cattaneo A., et&#xa0;al., &#x201c;Laser Surgery for Early Glottic Cancer: Impact of Margin Status on Local Control and Organ Preservation,&#x201d; Archives Of Otolaryngology&#x2014;Head &amp; Neck Surgery 135, no. 4 (2009): 385&#x2013;390, 10.1001/archoto.2009.10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archoto.2009.10</ArticleId><ArticleId IdType="pubmed">19380362</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallet P., Rumeau C., Nguyen D. T., Teixeira P. A., Baumann C., and Toussaint B., &#x201c;&#x201c;Watchful Observation&#x201d; Follow&#x2010;Up Scheme After Endoscopic Co(2) Laser Treatment for Small Glottic Carcinomas: A Retrospective Study Of 93 Cases,&#x201d; Clinical Otolaryngology 42, no. 6 (2017): 1193&#x2013;1199, 10.1111/coa.12863.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/coa.12863</ArticleId><ArticleId IdType="pubmed">28296244</ArticleId></ArticleIdList></Reference><Reference><Citation>Charbonnier Q., Thisse A. S., Sleghem L., et&#xa0;al., &#x201c;Oncologic Outcomes of Patients With Positive Margins After Laser Cordectomy for T1 and T2 Glottic Squamous Cell Carcinoma,&#x201d; Head &amp; Neck 38, no. 12 (2016): 1804&#x2013;1809, 10.1002/hed.24518.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hed.24518</ArticleId><ArticleId IdType="pubmed">27248845</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiz I., Mazzola F., Fiz F., et&#xa0;al., &#x201c;Impact of Close and Positive Margins in Transoral Laser Microsurgery for Tis&#x2010;T2 Glottic Cancer,&#x201d; Frontiers in Oncology 7 (2017): 245, 10.3389/fonc.2017.00245.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2017.00245</ArticleId><ArticleId IdType="pmc">PMC5650697</ArticleId><ArticleId IdType="pubmed">29085805</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariani C., Carta F., Bontempi M., et&#xa0;al., &#x201c;Management and Oncologic Outcomes of Close and Positive Margins after Transoral CO(2) Laser Microsurgery for Early Glottic Carcinoma,&#x201d; Cancers 15, no. 5 (2023): 1490, 10.3390/cancers15051490.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers15051490</ArticleId><ArticleId IdType="pmc">PMC10000552</ArticleId><ArticleId IdType="pubmed">36900281</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariani C., Carta F., Tatti M., Marrosu V., Gerosa C., and Puxeddu R., &#x201c;Shrinkage of Specimens after Co(2) Laser Cordectomy: An Objective Intraoperative Evaluation,&#x201d; European Archives of Oto&#x2010;Rhino&#x2010;Laryngology 278, no. 5 (2021): 1515&#x2013;1521, 10.1007/s00405-021-06625-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00405-021-06625-8</ArticleId><ArticleId IdType="pubmed">33515084</ArticleId></ArticleIdList></Reference><Reference><Citation>Jumaily M., Faraji F., Osazuwa&#x2010;Peters N., Walker R. J., and Ward G. M., &#x201c;Prognostic Significance of Surgical Margins after Transoral Laser Microsurgery for Early&#x2010;Stage Glottic Squamous Cell Carcinoma,&#x201d; Oral Oncology 97 (2019): 105&#x2013;111, 10.1016/j.oraloncology.2019.08.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.oraloncology.2019.08.005</ArticleId><ArticleId IdType="pubmed">31473467</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiz I., Koelmel J. C., and Sittel C., &#x201c;Nature and Role of Surgical Margins in Transoral Laser Microsurgery for Early and Intermediate Glottic Cancer,&#x201d; Current Opinion in Otolaryngology &amp; Head and Neck Surgery 26, no. 2 (2018): 78&#x2013;83, 10.1097/MOO.0000000000000446.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MOO.0000000000000446</ArticleId><ArticleId IdType="pubmed">29373328</ArticleId></ArticleIdList></Reference><Reference><Citation>Meulemans J., Bijnens J., Delaere P., and Vander Poorten V., &#x201c;Up&#x2010;Front and Salvage Transoral Laser Microsurgery for Early Glottic Squamous Cell Carcinoma: A Single Centre Retrospective Case Series,&#x201d; Frontiers in Oncology 8 (2018): 186, 10.3389/fonc.2018.00186.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2018.00186</ArticleId><ArticleId IdType="pmc">PMC5985398</ArticleId><ArticleId IdType="pubmed">29892574</ArticleId></ArticleIdList></Reference><Reference><Citation>Piazza C., Paderno A., Grazioli P., et&#xa0;al., &#x201c;Laryngeal Exposure and Margin Status in Glottic Cancer Treated by Transoral Laser Microsurgery,&#x201d; Laryngoscope 128, no. 5 (2018): 1146&#x2013;1151, 10.1002/lary.26861.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/lary.26861</ArticleId><ArticleId IdType="pubmed">28895157</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan U., MacKay C., Rigby M., Trites J., Corsten M., and Taylor S. M., &#x201c;Management of Positive Resection Margins Following Transoral Laser Microsurgery for Glottic Cancer,&#x201d; Laryngoscope Investigative Otolaryngology 8, no. 6 (2023): 1579&#x2013;1583, 10.1002/lio2.1184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/lio2.1184</ArticleId><ArticleId IdType="pmc">PMC10731511</ArticleId><ArticleId IdType="pubmed">38130264</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann C., Hans S., Sadoughi B., and Brasnu D., &#x201c;Identifying Outcome Predictors of Transoral Laser Cordectomy for Early Glottic Cancer,&#x201d; Head &amp; Neck 38, no. Suppl 1 (2016): E406&#x2013;E411, 10.1002/hed.24007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hed.24007</ArticleId><ArticleId IdType="pubmed">25641197</ArticleId></ArticleIdList></Reference><Reference><Citation>Simo R., Bradley P., Chevalier D., et&#xa0;al., &#x201c;European Laryngological Society: Els Recommendations for the Follow&#x2010;Up of Patients Treated for Laryngeal Cancer,&#x201d; European Archives of Oto&#x2010;Rhino&#x2010;Laryngology 271, no. 9 (2014): 2469&#x2013;2479, 10.1007/s00405-014-2966-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00405-014-2966-x</ArticleId><ArticleId IdType="pubmed">24609733</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernal&#x2010;Sprekelsen M., Blanch J. L., Caballero&#x2010;Borrego M., and Vilaseca I., &#x201c;The Learning Curve in Transoral Laser Microsurgery for Malignant Tumors of The Larynx and Hypopharynx: Parameters for a Levelled Surgical Approach,&#x201d; European Archives of Oto&#x2010;Rhino&#x2010;Laryngology 270, no. 2 (2013): 623&#x2013;628, 10.1007/s00405-012-2181-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00405-012-2181-6</ArticleId><ArticleId IdType="pubmed">22996081</ArticleId></ArticleIdList></Reference><Reference><Citation>Milovanovic J., Jotic A., Djukic V., et&#xa0;al., &#x201c;Oncological and Functional Outcome After Surgical Treatment of Early Glottic Carcinoma Without Anterior Commissure Involvement,&#x201d; BioMed Research International 2014 (2014): 464781, 10.1155/2014/464781.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2014/464781</ArticleId><ArticleId IdType="pmc">PMC4060788</ArticleId><ArticleId IdType="pubmed">24991554</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodel R. M., Steiner W., Muller R. M., Kron M., and Matthias C., &#x201c;Endoscopic Laser Surgery of Early Glottic Cancer: Involvement of the Anterior Commissure,&#x201d; Head and Neck 31, no. 5 (2009): 583&#x2013;592, 10.1002/hed.20993.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hed.20993</ArticleId><ArticleId IdType="pubmed">19132720</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann C., Cornu N., Hans S., Sadoughi B., Badoual C., and Brasnu D., &#x201c;Early Glottic Cancer Involving the Anterior Commissure Treated by Transoral Laser Cordectomy,&#x201d; Laryngoscope 126, no. 8 (2016): 1817&#x2013;1822, 10.1002/lary.25757.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/lary.25757</ArticleId><ArticleId IdType="pubmed">26597482</ArticleId></ArticleIdList></Reference><Reference><Citation>Hakeem A. H., Tubachi J., and Pradhan S. A., &#x201c;Significance of Anterior Commissure Involvement in Early Glottic Squamous Cell Carcinoma Treated With Trans&#x2010;Oral CO2 Laser Microsurgery,&#x201d; Laryngoscope 123, no. 8 (2013): 1912&#x2013;1917, 10.1002/lary.24012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/lary.24012</ArticleId><ArticleId IdType="pubmed">23606304</ArticleId></ArticleIdList></Reference><Reference><Citation>Rucci L., Gammarota L., and Borghi Cirri M. B., &#x201c;Carcinoma of the Anterior Commissure of the Larynx: I. Embryological and Anatomic Considerations,&#x201d; Annals of Otology, Rhinology, and Laryngology 105, no. 4 (1996): 303&#x2013;308, 10.1177/000348949610500412.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/000348949610500412</ArticleId><ArticleId IdType="pubmed">8604894</ArticleId></ArticleIdList></Reference><Reference><Citation>Carta F., Bandino F., Olla A. M., Chuchueva N., Gerosa C., and Puxeddu R., &#x201c;Prognostic Value of Age, Subglottic, and Anterior Commissure Involvement for Early Glottic Carcinoma Treated with CO(2) Laser Transoral Microsurgery: A Retrospective, Single&#x2010;Center Cohort Study of 261 Patients,&#x201d; European Archives of Oto&#x2010;Rhino&#x2010;Laryngology 275, no. 5 (2018): 1199&#x2013;1210, 10.1007/s00405-018-4890-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00405-018-4890-y</ArticleId><ArticleId IdType="pubmed">29442166</ArticleId></ArticleIdList></Reference><Reference><Citation>Alkan U., Nachalon Y., Shkedy Y., Yaniv D., Shvero J., and Popovtzer A., &#x201c;T1 Squamous Cell Carcinoma of the Glottis with Anterior Commissure Involvement: Radiotherapy Versus Transoral Laser Microsurgery,&#x201d; Head &amp; Neck 39, no. 6 (2017): 1101&#x2013;1105, 10.1002/hed.24723.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hed.24723</ArticleId><ArticleId IdType="pubmed">28371063</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70015 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40799173</PMID><DateCompleted><Year>2025</Year><Month>12</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>12</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><Volume>48</Volume><Issue>1</Issue><PubDate><Year>2026</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Fuel for Recovery: Predicting G-Tube Dependence in HPV-Negative Operable HNSCC.</ArticleTitle><Pagination><StartPage>114</StartPage><EndPage>124</EndPage><MedlinePgn>114-124</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70015</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">HPV-negative head and neck squamous cell carcinoma (HNSCC) patients can face prolonged gastrostomy tube (g-tube) dependence, affecting quality of life and delaying treatment. Existing models lack key health metrics like sarcopenia; this study develops a risk model to enhance preoperative assessment.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This study analyzed 265 HNSCC patients. Sarcopenia was assessed via cervical paraspinal skeletal muscle mass (C3) on CT scans. Patients requiring g-tube support&#x2009;&gt;&#x2009;28&#x2009;days were identified. Risk models were developed and compared to the PEG Score. A 50-patient validation cohort assessed model performance.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Key predictors included male sex, sarcopenia, prior radiotherapy, and adjuvant therapy. Logistic regression (LR) model had the highest AUC (0.78); followed by Recursive Partitioning analysis (RPA) model (0.76), both outperforming the PEG Score (0.67). RPA model maintained superior accuracy in validation (AUC&#x2009;=&#x2009;0.79).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">RPA model outperformed PEG Score, offering a more precise risk tool for preoperative planning and early intervention.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). Head &amp; Neck published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McNicoll</LastName><ForeName>Marie-Michelle</ForeName><Initials>MM</Initials><Identifier Source="ORCID">0009-0004-2369-8680</Identifier><AffiliationInfo><Affiliation>Undergraduate Medical Education, McGill University, Montr&#xe9;al, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mlynarek</LastName><ForeName>Alex M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, McGill University, Montr&#xe9;al, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richardson</LastName><ForeName>Keith</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, McGill University, Montr&#xe9;al, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hier</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, McGill University, Montr&#xe9;al, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sadeghi</LastName><ForeName>Nader</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-3218-2668</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, McGill University, Montr&#xe9;al, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casola</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Clinical Nutrition-Jewish General Hospital, McGill University, Montr&#xe9;al, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bouganim</LastName><ForeName>Nathaniel</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Gerald Bronfman Department of Oncology, McGill University, Montr&#xe9;al, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Esfahani</LastName><ForeName>Khashayar</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Gerald Bronfman Department of Oncology, McGill University, Montr&#xe9;al, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsien</LastName><ForeName>Christina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Gerald Bronfman Department of Oncology, McGill University, Montr&#xe9;al, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shenouda</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Gerald Bronfman Department of Oncology, McGill University, Montr&#xe9;al, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sultanem</LastName><ForeName>Khalil</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Gerald Bronfman Department of Oncology, McGill University, Montr&#xe9;al, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mascarella</LastName><ForeName>Marco A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0002-8880-805X</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, McGill University, Montr&#xe9;al, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Research Program of the Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Clinical Epidemiology, Lady Davis Institute of the Jewish General Hospital, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005774" MajorTopicYN="Y">Gastrostomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055948" MajorTopicYN="Y">Sarcopenia</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006258" MajorTopicYN="Y">Head and Neck Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077195" MajorTopicYN="Y">Squamous Cell Carcinoma of Head and Neck</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014057" MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004750" MajorTopicYN="Y">Enteral Nutrition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HNSCC</Keyword><Keyword MajorTopicYN="N">PEG dependence</Keyword><Keyword MajorTopicYN="N">head and neck cancer</Keyword><Keyword MajorTopicYN="N">risk stratification</Keyword><Keyword MajorTopicYN="N">sarcopenia</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>13</Day><Hour>5</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>12</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40799173</ArticleId><ArticleId IdType="pmc">PMC12703559</ArticleId><ArticleId IdType="doi">10.1002/hed.70015</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bray F., Laversanne M., Sung H., et&#xa0;al., &#x201c;Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,&#x201d; CA: A Cancer Journal for Clinicians 74, no. 3 (2024): 229&#x2013;263, 10.3322/caac.21834.</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21834</ArticleId><ArticleId IdType="pubmed">38572751</ArticleId></ArticleIdList></Reference><Reference><Citation>Yalamanchi P., Peddireddy N. S., McMichael B., et&#xa0;al., &#x201c;Team&#x2010;Based Surgical Approach to Head and Neck Microvascular Free Flap Reconstruction,&#x201d; JAMA Otolaryngology. Head &amp; Neck Surgery 149, no. 11 (2023): 1021&#x2013;1026, 10.1001/jamaoto.2023.3028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoto.2023.3028</ArticleId><ArticleId IdType="pmc">PMC10557027</ArticleId><ArticleId IdType="pubmed">37796525</ArticleId></ArticleIdList></Reference><Reference><Citation>Pohlenz P., Klatt J., Sch&#xf6;n G., Blessmann M., Li L., and Schmelzle R., &#x201c;Microvascular Free Flaps in Head and Neck Surgery: Complications and Outcome of 1000 Flaps,&#x201d; International Journal of Oral and Maxillofacial Surgery 41, no. 6 (2012): 739&#x2013;743, 10.1016/j.ijom.2012.02.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijom.2012.02.012</ArticleId><ArticleId IdType="pubmed">22424757</ArticleId></ArticleIdList></Reference><Reference><Citation>Urken M. L., Weinberg H., Buchbinder D., et&#xa0;al., &#x201c;Microvascular Free Flaps in Head and Neck Reconstruction. Report of 200 Cases and Review of Complications,&#x201d; Archives of Otolaryngology&#x2014;Head &amp; Neck Surgery 120, no. 6 (1994): 633&#x2013;640, 10.1001/archotol.1994.01880300047007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archotol.1994.01880300047007</ArticleId><ArticleId IdType="pubmed">8198786</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart T., Copeland&#x2010;Halperin L. R., Demsas F., et&#xa0;al., &#x201c;Predictors of Gastrostomy Tube Placement in Patients With Head and Neck Cancer Undergoing Resection and Flap&#x2010;Based Reconstruction: Systematic Review and Meta&#x2010;Analysis,&#x201d; Journal of Plastic, Reconstructive &amp; Aesthetic Surgery 79 (2023): 1&#x2013;10, 10.1016/j.bjps.2022.08.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bjps.2022.08.040</ArticleId><ArticleId IdType="pubmed">36780787</ArticleId></ArticleIdList></Reference><Reference><Citation>Zafereo M. E., Weber R. S., Lewin J. S., Roberts D. B., and Hanasono M. M., &#x201c;Complications and Functional Outcomes Following Complex Oropharyngeal Reconstruction,&#x201d; Head &amp; Neck 32, no. 8 (2010): 1003&#x2013;1011, 10.1002/hed.21290.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hed.21290</ArticleId><ArticleId IdType="pubmed">19953614</ArticleId></ArticleIdList></Reference><Reference><Citation>Dragan T., Duprez F., Van Gossum A., et&#xa0;al., &#x201c;Prophylactic Gastrostomy in Locally Advanced Head and Neck Cancer: Results of a National Survey Among Radiation Oncologists,&#x201d; BMC Cancer 21, no. 1 (2021): 656, 10.1186/s12885-021-08348-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12885-021-08348-9</ArticleId><ArticleId IdType="pmc">PMC8171041</ArticleId><ArticleId IdType="pubmed">34078309</ArticleId></ArticleIdList></Reference><Reference><Citation>Sampieri C., Costantino A., Giordano G. G., et&#xa0;al., &#x201c;Predicting the Need for Prophylactic Gastrostomy in Major Head and Neck Cancer Surgery: The PEG Score,&#x201d; Head and Neck 45, no. 12 (2023): 3042&#x2013;3052, 10.1002/hed.27532.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hed.27532</ArticleId><ArticleId IdType="pubmed">37789705</ArticleId></ArticleIdList></Reference><Reference><Citation>Moln&#xe1;r K., Hietanen S., Liisanantti J., Koivunen P., and Lahtinen S., &#x201c;Quality of Life After Free Flap Reconstruction for the Cancer of the Head and Neck: Comparison Between Five&#x2010;Year Survivors and Non&#x2010;Survivors,&#x201d; Oral Oncology 128 (2022): 105855, 10.1016/j.oraloncology.2022.105855.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.oraloncology.2022.105855</ArticleId><ArticleId IdType="pubmed">35405465</ArticleId></ArticleIdList></Reference><Reference><Citation>Walston J. D., &#x201c;Sarcopenia in Older Adults,&#x201d; Current Opinion in Rheumatology 24, no. 6 (2012): 623&#x2013;627, 10.1097/BOR.0b013e328358d59b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0b013e328358d59b</ArticleId><ArticleId IdType="pmc">PMC4066461</ArticleId><ArticleId IdType="pubmed">22955023</ArticleId></ArticleIdList></Reference><Reference><Citation>Anjanappa M., Corden M., Green A., et&#xa0;al., &#x201c;Sarcopenia in Cancer: Risking More Than Muscle Loss,&#x201d; Technical Innovations &amp; Patient Support in Radiation Oncology 16 (2020): 50&#x2013;57, 10.1016/j.tipsro.2020.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tipsro.2020.10.001</ArticleId><ArticleId IdType="pmc">PMC7769854</ArticleId><ArticleId IdType="pubmed">33385074</ArticleId></ArticleIdList></Reference><Reference><Citation>Bj&#xf6;rkman M., Jyv&#xe4;korpi S. K., Strandberg T. E., Pitk&#xe4;l&#xe4; K. H., and Tilvis R. S., &#x201c;Sarcopenia Indicators as Predictors of Functional Decline and Need for Care Among Older People,&#x201d; Journal of Nutrition, Health &amp; Aging 23, no. 10 (2019): 916&#x2013;922, 10.1007/s12603-019-1280-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12603-019-1280-0</ArticleId><ArticleId IdType="pmc">PMC12280617</ArticleId><ArticleId IdType="pubmed">31781719</ArticleId></ArticleIdList></Reference><Reference><Citation>Vangelov B., Bauer J., Moses D., and Smee R., &#x201c;The Effectiveness of Skeletal Muscle Evaluation at the Third Cervical Vertebral Level for Computed Tomography&#x2010;Defined Sarcopenia Assessment in Patients With Head and Neck Cancer,&#x201d; Head &amp; Neck 44, no. 5 (2022): 1047&#x2013;1056, 10.1002/hed.27000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hed.27000</ArticleId><ArticleId IdType="pmc">PMC9305498</ArticleId><ArticleId IdType="pubmed">35138008</ArticleId></ArticleIdList></Reference><Reference><Citation>Bril S. I., Wendrich A. W., Swartz J. E., et&#xa0;al., &#x201c;Interobserver Agreement of Skeletal Muscle Mass Measurement on Head and Neck CT Imaging at the Level of the Third Cervical Vertebra,&#x201d; European Archives of Oto&#x2010;Rhino&#x2010;Laryngology 276, no. 4 (2019): 1175&#x2013;1182, 10.1007/s00405-019-05307-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00405-019-05307-w</ArticleId><ArticleId IdType="pmc">PMC6426814</ArticleId><ArticleId IdType="pubmed">30689037</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura M., Imaoka M., Sakai K., et&#xa0;al., &#x201c;Complement Component C3 Is Associated With Body Composition Parameters and Sarcopenia in Community&#x2010;Dwelling Older Adults: A Cross&#x2010;Sectional Study in Japan,&#x201d; BMC Geriatrics 24, no. 1 (2024): 102, 10.1186/s12877-024-04720-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12877-024-04720-z</ArticleId><ArticleId IdType="pmc">PMC10821262</ArticleId><ArticleId IdType="pubmed">38279167</ArticleId></ArticleIdList></Reference><Reference><Citation>Vangelov B., Bauer J., Moses D., and Smee R., &#x201c;A Prediction Model for Skeletal Muscle Evaluation and Computed Tomography&#x2010;Defined Sarcopenia Diagnosis in a Predominantly Overweight Cohort of Patients With Head and Neck Cancer,&#x201d; European Archives of Oto&#x2010;Rhino&#x2010;Laryngology 280, no. 1 (2023): 321&#x2013;328, 10.1007/s00405-022-07545-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00405-022-07545-x</ArticleId><ArticleId IdType="pmc">PMC9813227</ArticleId><ArticleId IdType="pubmed">35835910</ArticleId></ArticleIdList></Reference><Reference><Citation>Swartz J. E., Pothen A. J., Wegner I., et&#xa0;al., &#x201c;Feasibility of Using Head and Neck CT Imaging to Assess Skeletal Muscle Mass in Head and Neck Cancer Patients,&#x201d; Oral Oncology 62 (2016): 28&#x2013;33, 10.1016/j.oraloncology.2016.09.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.oraloncology.2016.09.006</ArticleId><ArticleId IdType="pubmed">27865369</ArticleId></ArticleIdList></Reference><Reference><Citation>Ajemian M. S., Nirmul G. B., Anderson M. T., Zirlen D. M., and Kwasnik E. M., &#x201c;Routine Fiberoptic Endoscopic Evaluation of Swallowing Following Prolonged Intubation: Implications for Management,&#x201d; Archives of Surgery 136, no. 4 (2001): 434&#x2013;437, 10.1001/archsurg.136.4.434.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archsurg.136.4.434</ArticleId><ArticleId IdType="pubmed">11296115</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapuy C. I., Annino D. J., Snavely A., et&#xa0;al., &#x201c;Swallowing Function Following Post Chemoradiotherapy Neck Dissection&#x2014;Review of Findings and Analysis of Contributing Factors,&#x201d; Otolaryngology&#x2010;Head and Neck Surgery 145, no. 3 (2011): 428&#x2013;434, 10.1177/0194599811403075.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0194599811403075</ArticleId><ArticleId IdType="pmc">PMC3434459</ArticleId><ArticleId IdType="pubmed">21493276</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong X. and Zimmers T. A., &#x201c;Sex Differences in Cancer Cachexia,&#x201d; Current Osteoporosis Reports 18, no. 6 (2020): 646&#x2013;654, 10.1007/s11914-020-00628-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11914-020-00628-w</ArticleId><ArticleId IdType="pmc">PMC7732790</ArticleId><ArticleId IdType="pubmed">33044689</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabrera A. R., Deaver J. W., Lim S., et&#xa0;al., &#x201c;Females Display Relatively Preserved Muscle Quality Compared With Males During the Onset and Early Stages of C26&#x2010;Induced Cancer Cachexia,&#x201d; Journal of Applied Physiology 135, no. 3 (2023): 655&#x2013;672, 10.1152/japplphysiol.00196.2023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/japplphysiol.00196.2023</ArticleId><ArticleId IdType="pmc">PMC10642509</ArticleId><ArticleId IdType="pubmed">37535708</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70025 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40878744</PMID><DateCompleted><Year>2025</Year><Month>12</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>12</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><Volume>48</Volume><Issue>1</Issue><PubDate><Year>2026</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Tongue Surface Electromyography Detects Reduced Motor Unit Recruitment in Oropharyngeal Cancer Survivors With Hypoglossal Neuropathy.</ArticleTitle><Pagination><StartPage>195</StartPage><EndPage>205</EndPage><MedlinePgn>195-205</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70025</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">This proof-of-concept case-control study examined the feasibility of tongue high-density surface electromyography (HDS-EMG) to detect hypoglossal neuropathy.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We analyzed tongue HDS-EMG for N&#x2009;=&#x2009;2 participants. Subjects were graded through clinical tongue functional measures and gold-standard needle EMG. We collected HDS-EMG in three tongue tasks: relaxation, protrusion, and isometric maximum effort. The HDS-EMG was decomposed into motor unit spike train estimates.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Muscle relaxation HDS-EMG contained spikes consistent with fasciculation potential morphology. During tongue protrusion, a case of confirmed CN XII neuropathy exhibited an elevated motor unit (MU) discharge rate and fewer MUs (45.71&#x2009;peaks/s, 3 estimated MUs) compared to the control (11.63&#x2009;peaks/s, 11 estimated MUs). During isometric contraction, the case exhibited an average discharge rate of 3.96&#x2009;peaks/s on 3&#x2009;MU estimates, whereas the control had a discharge rate of 2.58&#x2009;peaks/s on 5 MU estimates.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Non-invasive tongue HDS-EMG appears to show potential sensitivity for detecting reduced MU recruitment in hypoglossal neuropathy.</AbstractText><CopyrightInformation>&#xa9; 2025 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hansen</LastName><ForeName>Nathan J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Department of Electrical and Computer Engineering, The University of Utah, Salt Lake City, Utah, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hutcheson</LastName><ForeName>Katherine A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Department of Head and Neck Surgery, Division of Surgery, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Radiation Oncology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McMillan</LastName><ForeName>Holly</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Head and Neck Surgery, Division of Surgery, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Shitong</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-5122-7497</Identifier><AffiliationInfo><Affiliation>Department of Head and Neck Surgery, Division of Surgery, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vidad</LastName><ForeName>Katelyn</ForeName><Initials>K</Initials><Identifier Source="ORCID">0009-0000-8197-5886</Identifier><AffiliationInfo><Affiliation>Department of Head and Neck Surgery, Division of Surgery, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barbon</LastName><ForeName>Carly E</ForeName><Initials>CE</Initials><Identifier Source="ORCID">0000-0001-8971-6870</Identifier><AffiliationInfo><Affiliation>Department of Head and Neck Surgery, Division of Surgery, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woodman</LastName><ForeName>Karin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>Nicolaas C</ForeName><Initials>NC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Baylor College of Medicine, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanchez</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Electrical and Computer Engineering, The University of Illinois Chicago, Chicago, Illinois, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Richard and Loan Hill Department of Biomedical Engineering, The University of Illinois Chicago, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>OPC&#x2010;SURVIVOR Program Working Group</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2139322</GrantID><Agency>National Science Foundation</Agency><Country/></Grant><Grant><GrantID>2529648</GrantID><Agency>National Science Foundation</Agency><Country/></Grant><Grant><GrantID>2534572</GrantID><Agency>National Science Foundation</Agency><Country/></Grant><Grant><GrantID>1R21CA273984-01A1</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1P01CA285249-01A1</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R21CA289101-01A1</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R01CA271223</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R21MD018488-01A1</GrantID><Acronym>MD</Acronym><Agency>NIMHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>Charles and Daneen Stiefel MD Anderson Oropharynx Program</Agency><Country/></Grant><Grant><GrantID>1R21CA273984-01A1</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1P01CA285249-01A1</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R21CA289101-01A1</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R01CA271223</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R21MD018488-01A1</GrantID><Acronym>MD</Acronym><Agency>NIMHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1609-36195</GrantID><Acronym>PCORI</Acronym><Agency>Patient-Centered Outcomes Research Institute</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004576" MajorTopicYN="Y">Electromyography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014059" MajorTopicYN="Y">Tongue</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000294" MajorTopicYN="N">innervation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020437" MajorTopicYN="Y">Hypoglossal Nerve Diseases</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009959" MajorTopicYN="Y">Oropharyngeal Neoplasms</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011999" MajorTopicYN="Y">Recruitment, Neurophysiological</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005240" MajorTopicYN="N">Feasibility Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017741" MajorTopicYN="N">Survivors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cranial nerve XII neuropathy</Keyword><Keyword MajorTopicYN="N">electromyography</Keyword><Keyword MajorTopicYN="N">head and neck cancer survivors</Keyword><Keyword MajorTopicYN="N">motor unit decomposition</Keyword><Keyword MajorTopicYN="N">radiation therapy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>29</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>29</Day><Hour>5</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40878744</ArticleId><ArticleId IdType="doi">10.1002/hed.70025</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>P. Aggarwal, R. P. Goepfert, A. S. Garden, et&#xa0;al., &#x201c;Risk and Clinical Risk Factors Associated With Late Lower Cranial Neuropathy in Long&#x2010;Term Oropharyngeal Squamous Cell Carcinoma Survivors,&#x201d; JAMA Otolaryngology. Head and Neck Surgery 147 (2021): 469&#x2013;478.</Citation></Reference><Reference><Citation>P. Aggarwal, J. S. Zaveri, R. P. Goepfert, et&#xa0;al., &#x201c;Symptom Burden Associated With Late Lower Cranial Neuropathy in Long&#x2010;Term Oropharyngeal Cancer Survivors,&#x201d; JAMA Otolaryngology. Head and Neck Surgery 144, no. 11 (2018): 1066&#x2013;1076.</Citation></Reference><Reference><Citation>P. Aggarwal, J. S. Zaveri, R. P. Goepfert, et&#xa0;al., &#x201c;Swallowing&#x2010;Related Outcomes Associated With Late Lower Cranial Neuropathy in Long&#x2010;Term Oropharyngeal Cancer Survivors: Cross&#x2010;Sectional Survey Analysis,&#x201d; Head and Neck 41, no. 11 (2019): 3880&#x2013;3894.</Citation></Reference><Reference><Citation>P. Aggarwal, J. Zaveri, R. P. Goepfert, et&#xa0;al., &#x201c;Functional Burden Associated With Late Lower Cranial Neuropathy in Long&#x2010;Term Oropharyngeal Cancer Survivors Treated With Definitive Radiation Therapy,&#x201d; International Journal of Radiation Oncology, Biology, Physics 102, no. 3 (2018): e408.</Citation></Reference><Reference><Citation>B. Xu, I. J. Boero, L. Hwang, et&#xa0;al., &#x201c;Aspiration Pneumonia After Concurrent Chemoradiotherapy for Head and Neck Cancer,&#x201d; Cancer 121, no. 8 (2015): 1303&#x2013;1311.</Citation></Reference><Reference><Citation>A. M. Stino and B. E. Smith, &#x201c;Electrophysiology of Cranial Nerve Testing: Spinal Accessory and Hypoglossal Nerves,&#x201d; Journal of Clinical Neurophysiology 35, no. 1 (2018): 59&#x2013;64.</Citation></Reference><Reference><Citation>J. R. Daube and D. I. Rubin, &#x201c;Needle Electromyography,&#x201d; Muscle and Nerve 39, no. 2 (2009): 244&#x2013;270.</Citation></Reference><Reference><Citation>Y. Liu, Y. T. Chen, C. Zhang, P. Zhou, S. Li, and Y. Zhang, &#x201c;Motor Unit Number Estimation in Spastic Biceps Brachii Muscles of Chronic Stroke Survivors Before and After BoNT Injection,&#x201d; IEEE Transactions on Biomedical Engineering 70, no. 3 (2023): 1045&#x2013;1052.</Citation></Reference><Reference><Citation>G. Averta, F. Barontini, V. Catrambone, et&#xa0;al., &#x201c;U&#x2010;Limb: A Multi&#x2010;Modal, Multi&#x2010;Center Database on Arm Motion Control in Healthy and Post&#x2010;Stroke Conditions,&#x201d; GigaScience 10, no. 6 (2021): 1&#x2013;17.</Citation></Reference><Reference><Citation>E. St&#xe5;lberg, H. van Dijk, B. Falck, et&#xa0;al., &#x201c;Standards for Quantification of EMG and Neurography,&#x201d; Clinical Neurophysiology 130, no. 9 (2019): 1688&#x2013;1729.</Citation></Reference><Reference><Citation>N. van Beek, D. F. Stegeman, J. C. van den Noort, D. Veeger, and H. Maas, &#x201c;Activity Patterns of Extrinsic Finger Flexors and Extensors During Movements of Instructed and Non&#x2010;Instructed Fingers,&#x201d; Journal of Electromyography and Kinesiology 38 (2018): 187&#x2013;196.</Citation></Reference><Reference><Citation>R. S. Howard and N. M. F. Murray, &#x201c;Surface EMG in the Recording of Fasciculations,&#x201d; Muscle and Nerve 15, no. 11 (1992): 1240&#x2013;1245.</Citation></Reference><Reference><Citation>J. E. Ting, A. Del Vecchio, D. Sarma, et&#xa0;al., &#x201c;Sensing and Decoding the Neural Drive to Paralyzed Muscles During Attempted Movements of a Person With Tetraplegia Using a Sleeve Array,&#x201d; Journal of Neurophysiology 126, no. 6 (2021): 2104&#x2013;2118.</Citation></Reference><Reference><Citation>O. W. Samuel, H. Zhou, X. Li, et&#xa0;al., &#x201c;Pattern Recognition of Electromyography Signals Based on Novel Time Domain Features for Amputees' Limb Motion Classification,&#x201d; Computers and Electrical Engineering 67 (2018): 646&#x2013;655.</Citation></Reference><Reference><Citation>L. J. Hargrove, G. Li, K. B. Englehart, and B. S. Hudgins, &#x201c;Principal Components Analysis Preprocessing for Improved Classification Accuracies in Pattern&#x2010;Recognition&#x2010;Based Myoelectric Control,&#x201d; IEEE Transactions on Bio&#x2010;Medical Engineering 56, no. 5 (2009): 1407&#x2013;1414.</Citation></Reference><Reference><Citation>G. Ornelas, H. Bueno Garcia, D. J. Bracken, K. Linnemeyer&#x2010;Risser, T. P. Coleman, and P. A. Weissbrod, &#x201c;Differentiation of Bolus Texture During Deglutition via High&#x2010;Density Surface Electromyography: A Pilot Study,&#x201d; Laryngoscope 133, no. 10 (2023): 2695&#x2013;2703.</Citation></Reference><Reference><Citation>N. J. Hansen, K. Woodman, S. Buoy, et&#xa0;al., &#x201c;Tongue Electrical Impedance Myography Correlates With Functional, Neurophysiologic, and Clinical Outcome Measures in Long&#x2010;Term Oropharyngeal Cancer Survivors With and Without Hypoglossal Neuropathy: An Exploratory Study,&#x201d; Head and Neck 46, no. 3 (2024): 581&#x2013;591.</Citation></Reference><Reference><Citation>B. Sanchez and S. B. Rutkove, &#x201c;Electrical Impedance Myography and Its Applications in Neuromuscular Disorders,&#x201d; Neurotherapeutics 14 (2016): 107&#x2013;118.</Citation></Reference><Reference><Citation>S. B. Rutkove and B. Sanchez, &#x201c;Electrical Impedance Methods in Neuromuscular Assessment: An Overview,&#x201d; Cold Spring Harbor Perspectives in Medicine (2019): a034405.</Citation></Reference><Reference><Citation>D. I. Rosenthal, T. R. Mendoza, M. S. Chambers, et&#xa0;al., &#x201c;The M. D. Anderson Symptom Inventory&#x2013;Head and Neck Module, a Patient&#x2010;Reported Outcome Instrument, Accurately Predicts the Severity of Radiation&#x2010;Induced Mucositis,&#x201d; International Journal of Radiation Oncology Biology Physics 72, no. 5 (2008): 1355&#x2013;1361.</Citation></Reference><Reference><Citation>H. P. van der Laan, H. P. Bijl, R. J. H. M. Steenbakkers, et&#xa0;al., &#x201c;Acute Symptoms During the Course of Head and Neck Radiotherapy or Chemoradiation Are Strong Predictors of Late Dysphagia,&#x201d; Radiotherapy and Oncology 115, no. 1 (2015): 56&#x2013;62.</Citation></Reference><Reference><Citation>A. Y. Chen, R. Frankowski, J. Bishop&#x2010;Leone, et&#xa0;al., &#x201c;The Development and Validation of a Dysphagia&#x2010;Specific Quality&#x2010;Of&#x2010;Life Questionnaire for Patients With Head and Neck Cancer: The M. D. Anderson Dysphagia Inventory,&#x201d; Archives of Otolaryngology&#x2014;Head and Neck Surgery 127, no. 7 (2001): 870&#x2013;876.</Citation></Reference><Reference><Citation>M. A. List, C. Ritter&#x2010;Sterr, and S. B. Lansky, &#x201c;A Performance Status Scale for Head and Neck Cancer Patients,&#x201d; Cancer 66, no. 3 (1990): 564&#x2013;569.</Citation></Reference><Reference><Citation>K. A. Hutcheson, M. P. Barrow, D. A. Barringer, et&#xa0;al., &#x201c;Dynamic Imaging Grade of Swallowing Toxicity (DIGEST): Scale Development and Validation,&#x201d; Cancer 123 (2017): 62&#x2013;70.</Citation></Reference><Reference><Citation>J. C. Rosenbek, J. A. Robbins, E. B. Roecker, J. L. Coyle, and J. L. Wood, &#x201c;A Penetration&#x2010;Aspiration Scale,&#x201d; Dysphagia 11, no. 2 (1996): 93&#x2013;98.</Citation></Reference><Reference><Citation>R. P. Goepfert, J. S. Lewin, M. P. Barrow, et&#xa0;al., &#x201c;Grading Dysphagia as a Toxicity of Head and Neck Cancer: Differences in Severity Classification Based on MBS DIGEST and Clinical CTCAE Grades,&#x201d; Dysphagia 33, no. 2 (2018): 185&#x2013;191.</Citation></Reference><Reference><Citation>B. Martin&#x2010;Harris, M. B. Brodsky, Y. Michel, et&#xa0;al., &#x201c;MBS Measurement Tool for Swallow Impairment&#x2014;MBSImp: Establishing a Standard,&#x201d; Dysphagia 23, no. 4 (2008): 392&#x2013;405.</Citation></Reference><Reference><Citation>C. L. Lazarus, H. Husaini, A. S. Jacobson, et&#xa0;al., &#x201c;Development of a New Lingual Range&#x2010;Of&#x2010;Motion Assessment Scale: Normative Data in Surgically Treated Oral Cancer Patients,&#x201d; Dysphagia 29, no. 4 (2014): 489&#x2013;499.</Citation></Reference><Reference><Citation>R. Franciotti, E. Di Maria, M. D'Attilio, G. Aprile, F. G. Cosentino, and V. Perrotti, &#x201c;Quantitative Measurement of Swallowing Performance Using Iowa Oral Performance Instrument: A Systematic Review and Meta&#x2010;Analysis,&#x201d; Biomedicine 10, no. 9 (2022): 2319.</Citation></Reference><Reference><Citation>C. L. Lazarus, J. A. Logemann, B. R. Pauloski, et&#xa0;al., &#x201c;Swallowing and Tongue Function Following Treatment for Oral and Oropharyngeal Cancer,&#x201d; Journal of Speech, Language, and Hearing Research 43, no. 4 (2000): 1011&#x2013;1023.</Citation></Reference><Reference><Citation>C. Bischoff, E. St&#xe5;lberg, B. Falck, and K. E. Eeg&#x2010;Olofsson, &#x201c;Reference Values of Motor Unit Action Potentials Obtained With Multi&#x2010;MUAP Analysis,&#x201d; Muscle and Nerve 17, no. 8 (1994): 842&#x2013;851.</Citation></Reference><Reference><Citation>D. I. Rubin, &#x201c;Needle Electromyography: Basic Concepts and Patterns of Abnormalities,&#x201d; Neurologic Clinics 30, no. 2 (2012): 429&#x2013;456.</Citation></Reference><Reference><Citation>D. I. Rubin, &#x201c;Chapter&#xa0;17&#x2014;Normal and Abnormal Spontaneous Activity,&#x201d; in Handbook of Clinical Neurology, vol. 160, ed. K. H. Levin and P. Chauvel (Elsevier, 2019), 257&#x2013;279.</Citation></Reference><Reference><Citation>R. W. Graham, &#x201c;The Fundamentals of Electromyography,&#x201d; Practical Neurology 12, no. 3 (2012): 187.</Citation></Reference><Reference><Citation>A. A. Leis, Atlas of Nerve Conduction Studies and Electromyography, 2nd ed. (Oxford University Press, 2013).</Citation></Reference><Reference><Citation>D. Stegeman and H. Hermens, &#x201c;Standards for Surface Electromyography: The European Project Surface EMG for non&#x2010;Invasive Assessment of Muscles (SENIAM), 108&#x2013;112,&#x201d; 2007.</Citation></Reference><Reference><Citation>S. Avrillon, F. Hug, S. N. Baker, C. Gibbs, and D. Farina, &#x201c;Tutorial on MUedit: An Open&#x2010;Source Software for Identifying and Analysing the Discharge Timing of Motor Units From Electromyographic Signals,&#x201d; Journal of Electromyography and Kinesiology 77 (2024): 102886.</Citation></Reference><Reference><Citation>X. Luo, H. V. Gutierrez Pulido, S. B. Rutkove, and B. Sanchez, &#x201c;In Vivo Muscle Conduction Study of the Tongue Using a Multi&#x2010;Electrode Tongue Depressor,&#x201d; Clinical Neurophysiology 132, no. 2 (2021): 683&#x2013;687.</Citation></Reference><Reference><Citation>J.&#x2010;Y. Hogrel, &#x201c;Clinical Applications of Surface Electromyography in Neuromuscular Disorders,&#x201d; Neurophysiologie Clinique/Clinical Neurophysiology 35, no. 2 (2005): 59&#x2013;71.</Citation></Reference><Reference><Citation>G. Drost, D. F. Stegeman, B. G. M. van Engelen, and M. J. Zwarts, &#x201c;Clinical Applications of High&#x2010;Density Surface EMG: A Systematic Review,&#x201d; Journal of Electromyography and Kinesiology 16, no. 6 (2006): 586&#x2013;602.</Citation></Reference><Reference><Citation>D. I. Rubin, &#x201c;Chapter&#xa0;16&#x2014;Needle Electromyography: Basic Concepts,&#x201d; in Handbook of Clinical Neurology, vol. 160, ed. K. H. Levin and P. Chauvel (Elsevier, 2019), 243&#x2013;256.</Citation></Reference><Reference><Citation>K. J. Gilmore, E. A. Kirk, T. J. Doherty, K. Kimpinski, and C. L. Rice, &#x201c;Abnormal Motor Unit Firing Rates in Chronic Inflammatory Demyelinating Polyneuropathy,&#x201d; Journal of the Neurological Sciences 414 (2020): 116859.</Citation></Reference><Reference><Citation>E. F. Bailey, A. D. Rice, and A. J. Fuglevand, &#x201c;Firing Patterns of Human Genioglossus Motor Units During Voluntary Tongue Movement,&#x201d; Journal of Neurophysiology 97, no. 1 (2007): 933&#x2013;936.</Citation></Reference><Reference><Citation>E. F. Bailey, &#x201c;Activities of Human Genioglossus Motor Units,&#x201d; Respiratory Physiology and Neurobiology 179, no. 1 (2011): 14&#x2013;22.</Citation></Reference><Reference><Citation>T. Lulic&#x2010;Kuryllo and J. G. Inglis, &#x201c;Sex Differences in Motor Unit Behaviour: A Review,&#x201d; Journal of Electromyography and Kinesiology 66 (2022): 102689.</Citation></Reference><Reference><Citation>P. Bonato, P. Boissy, U. D. Croce, and S. H. Roy, &#x201c;Changes in the Surface EMG Signal and the Biomechanics of Motion During a Repetitive Lifting Task,&#x201d; IEEE Transactions on Neural Systems and Rehabilitation Engineering 10, no. 1 (2002): 38&#x2013;47.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70027 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40891104</PMID><DateCompleted><Year>2025</Year><Month>12</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>12</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><Volume>48</Volume><Issue>1</Issue><PubDate><Year>2026</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Management of Retropharyngeal Lymph Node Metastases in Thyroid Cancer.</ArticleTitle><Pagination><StartPage>237</StartPage><EndPage>245</EndPage><MedlinePgn>237-245</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70027</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Retropharyngeal lymph node (RPLN) metastases in thyroid cancer are rare, with optimal management underreported.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Retrospective study of consecutive thyroid cancer patients with RPLN metastases treated at MD Anderson Cancer Center between 2000 and 2024.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">One hundred and sixty-seven patients (75% differentiated, 21% medullary, 4% poorly differentiated thyroid cancer) were divided into three groups: active surveillance (AS) (13%), surgery (56%), and nonsurgical treatment (31%). In the AS group (median follow-up 2.3&#x2009;years), RPLN metastases grew a median 3% (range: 0-56) or 0.02&#x2009;cm (range: 0-0.7) per year. Surgical therapy included transcervical (73%), transoral robotic (14%), transoral (12%), and transmandibular (1%) approaches. Median RPLN metastasis size was 1.7&#x2009;cm (interquartile range: 1.3-2.2) at surgery. Three months post-operatively, 11% had dysphagia and 1% had velopharyngeal insufficiency. Nonsurgical treatments included radioactive iodine (10%), radiation therapy (11%), and systemic targeted therapy (79%).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">RPLN metastases grow slowly, and those &#x2265;&#x2009;1&#x2009;cm typically undergo surgical resection without significant long-term morbidity.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). Head &amp; Neck published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fournier</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Head &amp; Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bandi</LastName><ForeName>Ashwini Venkata</ForeName><Initials>AV</Initials><AffiliationInfo><Affiliation>Department of Head &amp; Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamidi</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-1528-9885</Identifier><AffiliationInfo><Affiliation>Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iyer</LastName><ForeName>Priyanka</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Busaidy</LastName><ForeName>Naifa L</ForeName><Initials>NL</Initials><AffiliationInfo><Affiliation>Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cabanillas</LastName><ForeName>Maria E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dadu</LastName><ForeName>Ramona</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Mimi I</ForeName><Initials>MI</Initials><Identifier Source="ORCID">0000-0003-0355-030X</Identifier><AffiliationInfo><Affiliation>Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waguespack</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials><Identifier Source="ORCID">0000-0003-0280-0100</Identifier><AffiliationInfo><Affiliation>Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basmaci</LastName><ForeName>Ugur Nur</ForeName><Initials>UN</Initials><AffiliationInfo><Affiliation>Department of Head &amp; Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Michelle D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Department of Anatomical Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mansour</LastName><ForeName>Mena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Anatomical Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monroe</LastName><ForeName>Maria Gule</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Department of Neuroradiology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gross</LastName><ForeName>Neil D</ForeName><Initials>ND</Initials><AffiliationInfo><Affiliation>Department of Head &amp; Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goepfert</LastName><ForeName>Ryan P</ForeName><Initials>RP</Initials><AffiliationInfo><Affiliation>Department of Head &amp; Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perrier</LastName><ForeName>Nancy D</ForeName><Initials>ND</Initials><AffiliationInfo><Affiliation>Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banuchi</LastName><ForeName>Victoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Head &amp; Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jennifer R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Head &amp; Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maniakas</LastName><ForeName>Anastasios</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4354-2841</Identifier><AffiliationInfo><Affiliation>Department of Head &amp; Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zafereo</LastName><ForeName>Mark E</ForeName><Initials>ME</Initials><Identifier Source="ORCID">0000-0001-7918-9739</Identifier><AffiliationInfo><Affiliation>Department of Head &amp; Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013964" MajorTopicYN="Y">Thyroid Neoplasms</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008207" MajorTopicYN="N">Lymphatic Metastasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013965" MajorTopicYN="N">Thyroidectomy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008198" MajorTopicYN="N">Lymph Nodes</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">medullary</Keyword><Keyword MajorTopicYN="N">papillary</Keyword><Keyword MajorTopicYN="N">retropharyngeal lymph node metastases</Keyword><Keyword MajorTopicYN="N">surgery</Keyword><Keyword MajorTopicYN="N">thyroid cancer</Keyword></KeywordList><CoiStatement>N.L.B. reports research funding from Eisai and personal consulting fees from Eisai and Eli Lilly. M.E.C. has received consulting fees from Bayer, Exelixis, Lilly, Novartis, and research funding from Merck, Genentech, Eisai, Exelixis. R.D. reports grants from Exelixis, Eisai, Merck, and AstraZeneca, personal fees from Bayer and Exelixis. M.I.H. reports research funding from Lilly and personal fees from Crispr therapeutics. S.G.W. reports personal fees from Bayer and consulting fees from Camurus. M.D.W. reports grants from Bayer and speaker fees from Springer Health. M.G.M. reports grants from Bayer pharmaceuticals for an educational grant and salary support from Siemens as part of an institutional development deal. A.M. reports research funding from Jazz Pharmaceuticals and Thryv Therapeutics Inc. M.E.Z. reports research funding from Merck, Eli Lilly, and Exelixis. The other authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>2</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>2</Day><Hour>2</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>12</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40891104</ArticleId><ArticleId IdType="pmc">PMC12703554</ArticleId><ArticleId IdType="doi">10.1002/hed.70027</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Flint P. W., Haughey B. H., Lund V. J., et&#xa0;al., Cummings Otolaryngology (Elsevier, 2020).</Citation></Reference><Reference><Citation>Coskun H. H., Ferlito A., Medina J. E., et&#xa0;al., &#x201c;Retropharyngeal Lymph Node Metastases in Head and Neck Malignancies,&#x201d; Head &amp; Neck 33, no. 10 (October 2011): 1520&#x2013;1529, 10.1002/hed.21526.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hed.21526</ArticleId><ArticleId IdType="pubmed">20737485</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross N. D., Ellingson T. W., Wax M. K., Cohen J. I., and Andersen P. E., &#x201c;Impact of Retropharyngeal Lymph Node Metastasis in Head and Neck Squamous Cell Carcinoma,&#x201d; Archives of Otolaryngology&#x2014;Head &amp; Neck Surgery 130, no. 2 (2004): 169&#x2013;173, 10.1001/archotol.130.2.169.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archotol.130.2.169</ArticleId><ArticleId IdType="pubmed">14967745</ArticleId></ArticleIdList></Reference><Reference><Citation>Mnatsakanian A., Minutello K., Black A. C., and Bordoni B., Anatomy, Head and Neck, Retropharyngeal Space (StatPearls. StatPearls Publishing Copyright 2025, StatPearls Publishing LLC, 2025).</Citation><ArticleIdList><ArticleId IdType="pubmed">30725729</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan X. B., Huang S. T., Qu S., Chen K. H., Jiang Y. M., and Zhu X. D., &#x201c;Retropharyngeal Lymph Node Metastasis on N Stage of Nasopharyngeal Carcinoma,&#x201d; PLoS One 16, no. 6 (2021): e0253424, 10.1371/journal.pone.0253424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0253424</ArticleId><ArticleId IdType="pmc">PMC8211178</ArticleId><ArticleId IdType="pubmed">34138943</ArticleId></ArticleIdList></Reference><Reference><Citation>Tirelli G., Gardenal N., Zanelli E., et&#xa0;al., &#x201c;Prevalence and Prognostic Impact of Retropharyngeal Lymph Nodes Metastases in Oropharyngeal Squamous Cell Carcinoma: Meta&#x2010;Analysis of Published Literature,&#x201d; Head &amp; Neck 44, no. 10 (October 2022): 2265&#x2013;2276, 10.1002/hed.27166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hed.27166</ArticleId><ArticleId IdType="pmc">PMC9540534</ArticleId><ArticleId IdType="pubmed">35913029</ArticleId></ArticleIdList></Reference><Reference><Citation>An C., Sun Y., Miao S., et&#xa0;al., &#x201c;Retropharyngeal Lymph Node Metastasis Diagnosed by Magnetic Resonance Imaging in Hypopharyngeal Carcinoma: A Retrospective Analysis From Chinese Multi&#x2010;Center Data,&#x201d; Frontiers in Oncology 11 (2021): 649540, 10.3389/fonc.2021.649540.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2021.649540</ArticleId><ArticleId IdType="pmc">PMC8226130</ArticleId><ArticleId IdType="pubmed">34178636</ArticleId></ArticleIdList></Reference><Reference><Citation>Harada R., Isobe K., Watanabe M., et&#xa0;al., &#x201c;The Incidence and Significance of Retropharyngeal Lymph Node Metastases in Hypopharyngeal Cancer,&#x201d; Japanese Journal of Clinical Oncology 42, no. 9 (September 2012): 794&#x2013;799, 10.1093/jjco/hys106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jjco/hys106</ArticleId><ArticleId IdType="pubmed">22782965</ArticleId></ArticleIdList></Reference><Reference><Citation>Du C., Ying H., Zhang Y., Huang Y., Zhai R., and Hu C., &#x201c;Treatment for Retropharyngeal Metastatic Undifferentiated Squamous Cell Carcinoma From an Unknown Primary Site: Results of a Prospective Study With Irradiation to Nasopharyngeal Mucosa Plus Bilateral Neck,&#x201d; Oncotarget 8, no. 26 (June 2017): 42372&#x2013;42381, 10.18632/oncotarget.16344.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.16344</ArticleId><ArticleId IdType="pmc">PMC5522073</ArticleId><ArticleId IdType="pubmed">28418897</ArticleId></ArticleIdList></Reference><Reference><Citation>Harries V., McGill M., Tuttle R. M., et&#xa0;al., &#x201c;Management of Retropharyngeal Lymph Node Metastases in Differentiated Thyroid Carcinoma,&#x201d; Thyroid 30, no. 5 (May 2020): 688&#x2013;695, 10.1089/thy.2019.0359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/thy.2019.0359</ArticleId><ArticleId IdType="pmc">PMC7232633</ArticleId><ArticleId IdType="pubmed">31910129</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandler M. L., Xing M. H., Levy J. C., et&#xa0;al., &#x201c;Metastatic Thyroid Carcinoma to the Parapharyngeal and Retropharyngeal Spaces: Systematic Review With Seven Newly Reported Cases Describing an Uncommon Presentation of a Common Disease,&#x201d; Head &amp; Neck 43, no. 4 (April 2021): 1331&#x2013;1344, 10.1002/hed.26572.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hed.26572</ArticleId><ArticleId IdType="pubmed">33295689</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranganath R., Dhillon V. K., Shaear M., Rooper L., Russell J. O., and Tufano R. P., &#x201c;Unusual Locations for Differentiated Thyroid Cancer Nodal Metastasis,&#x201d; World Journal of Otorhinolaryngology&#x2010;Head and Neck Surgery 6, no. 3 (September 2020): 176&#x2013;181, 10.1016/j.wjorl.2020.01.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.wjorl.2020.01.011</ArticleId><ArticleId IdType="pmc">PMC7548392</ArticleId><ArticleId IdType="pubmed">33073213</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartl D. M., Leboulleux S., V&#xe9;layoudom&#x2010;C&#xe9;phise F. L., Mirghani H., D&#xe9;andr&#xe9;is D., and Schlumberger M., &#x201c;Management of Retropharyngeal Node Metastases From Thyroid Carcinoma,&#x201d; World Journal of Surgery 39, no. 5 (May 2015): 1274&#x2013;1281, 10.1007/s00268-015-2947-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00268-015-2947-2</ArticleId><ArticleId IdType="pubmed">25585526</ArticleId></ArticleIdList></Reference><Reference><Citation>Togashi T., Sugitani I., Toda K., Kawabata K., and Takahashi S., &#x201c;Surgical Management of Retropharyngeal Nodes Metastases From Papillary Thyroid Carcinoma,&#x201d; World Journal of Surgery 38, no. 11 (November 2014): 2831&#x2013;2837, 10.1007/s00268-014-2707-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00268-014-2707-8</ArticleId><ArticleId IdType="pubmed">25104545</ArticleId></ArticleIdList></Reference><Reference><Citation>
&#x201c;Cancer Stat Facts: Thyroid Cancer (SEER Database),&#x201d;
https://seer.cancer.gov/statfacts/html/thyro.html.</Citation></Reference><Reference><Citation>Zhang G. Y., Liu L. Z., Wei W. H., Deng Y. M., Li Y. Z., and Liu X. W., &#x201c;Radiologic Criteria of Retropharyngeal Lymph Node Metastasis in Nasopharyngeal Carcinoma Treated With Radiation Therapy,&#x201d; Radiology 255, no. 2 (May 2010): 605&#x2013;612, 10.1148/radiol.10090289.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.10090289</ArticleId><ArticleId IdType="pubmed">20413770</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogura I., Kaneda T., Kato M., Mori S., Motohashi J., and Lee K., &#x201c;MR Study of Lateral Retropharyngeal Lymph Nodes at Different Ages,&#x201d; Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology 98, no. 3 (2004): 355&#x2013;358, 10.1016/j.tripleo.2004.06.067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tripleo.2004.06.067</ArticleId><ArticleId IdType="pubmed">15356476</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J. J., He L. J., Luo G. Y., et&#xa0;al., &#x201c;Fine&#x2010;Needle Aspiration of a Retropharyngeal Lymph Node Guided by Endoscopic Ultrasonography,&#x201d; Endoscopy 47, no. Suppl 1 UCTN (2015): E449&#x2013;E450, 10.1055/s-0034-1392652.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0034-1392652</ArticleId><ArticleId IdType="pubmed">26465178</ArticleId></ArticleIdList></Reference><Reference><Citation>He L. J., Xie C., Li Y., et&#xa0;al., &#x201c;Ultrasound&#x2010;Guided Fine Needle Aspiration of Retropharyngeal Lymph Nodes After Radiotherapy for Nasopharyngeal Carcinoma: A Novel Technique for Accurate Diagnosis,&#x201d; Cancer Communications (London) 38, no. 1 (2018): 20, 10.1186/s40880-018-0286-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40880-018-0286-z</ArticleId><ArticleId IdType="pmc">PMC5993149</ArticleId><ArticleId IdType="pubmed">29764509</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran J. and Zafereo M., &#x201c;Parapharyngeal Dissection for Papillary Thyroid Cancer,&#x201d; VideoEndocrinology 6, no. 1 (2019): ve.2018.0141, 10.1089/ve.2018.0141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ve.2018.0141</ArticleId><ArticleId IdType="pmc">PMC6961789</ArticleId><ArticleId IdType="pubmed">32025530</ArticleId></ArticleIdList></Reference><Reference><Citation>Goepfert R. P., Liu C., and Ryan W. R., &#x201c;Trans&#x2010;Oral Robotic Surgery and Surgeon&#x2010;Performed Trans&#x2010;Oral Ultrasound for Intraoperative Location and Excision of an Isolated Retropharyngeal Lymph Node Metastasis of Papillary Thyroid Carcinoma,&#x201d; American Journal of Otolaryngology 36, no. 5 (2015): 710&#x2013;714, 10.1016/j.amjoto.2015.04.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjoto.2015.04.011</ArticleId><ArticleId IdType="pubmed">25964171</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70003 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40762035</PMID><DateCompleted><Year>2025</Year><Month>12</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>12</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><Volume>48</Volume><Issue>1</Issue><PubDate><Year>2026</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Application of a Saliva-Based Liquid Biopsy for the Detection of HPV in Patients With Oral Cavity Squamous Cell Carcinoma (OCSCC).</ArticleTitle><Pagination><StartPage>56</StartPage><EndPage>63</EndPage><MedlinePgn>56-63</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70003</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Human papilloma virus (HPV) is a DNA virus capable of infecting mucous membranes. In most cases, the infection is cleared by the immune system, but a prolonged exposure to HPV can progress to cancer. 40%-60% of head and neck squamous cell carcinomas (HNSCC) are linked to HPV, which is considered a risk factor especially among young people in industrialized countries. HNSCC are not identified early due to their slow growth and their locations not being easy to see. Despite the prognostic value of HPV, the use of HPV-DNA as a diagnostic marker is not fully developed. HPV-DNA can be detected in saliva specimens of patients with HPV-driven cancers. Considering this, we employed saliva samples to optimize a non-invasive RT-PCR assay for HPV infection and prove the hypothesis that the presence of HPV DNA represents a risk factor for Oral Cavity Squamous Cell Carcinoma (OCSCC). The potential of this work is to highlight how an HPV screening program based on salivary testing can be useful for early cancer detection and patient monitoring.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this retrospective study, 127 patients and 93 control samples were tested for the presence of HPV in self-collected saliva specimens. Viral DNA was extracted from saliva using an automated instrument. A multiplex RT-PCR was employed for the detection of the (28 most frequent HPV Types). Patients' demographics were collected in a clinical database. Statistics were performed by STATA16, and significance was set at p&#x2009;&lt;&#x2009;0.05.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Most patients had a diagnosis of OCSCC (49.1%), 38%-9% of which involved the tongue. 9.6% resulted positive for HPV DNA in saliva, specifically for high-risk subtypes (42.9% type 58; 28.6% types 45, 59, 39 and 9.6% type 16, 18). HPV+patients were compared to those who were found negative. HPV infection was related to the TNM stage, especially with pT2N1 (p&#x2009;&#x2264;&#x2009;0.002) and with primary vs. relapsed tumors (p&#x2009;=&#x2009;0.004). Independent of site, the assay reached a sensitivity of 91.7%, a specificity of 100%, and an agreement of 98.5%, compared to the oropharyngeal swab (Cohen's Kappa&#x2009;=&#x2009;0.947; n&#x2009;=&#x2009;65). Test PPV was 100% (95% CI 71.5-100), while NPV was 98.1% (95% CI 90.1-100).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our findings indicate that salivary HPV testing is a non-invasive and convenient test that could become part of routine clinical management for HPV infection of the oral cavity. This test represents an ideal mode of screening of asymptomatic individuals and a long-term monitoring tool for HPV-driven cancer patients.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). Head &amp; Neck published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bulfoni</LastName><ForeName>Michela</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2646-4228</Identifier><AffiliationInfo><Affiliation>Department of Medicine, University of Udine, Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tel</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Udine, Udine, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Head and Neck and Neuroscience, Academic Hospital of Udine, Clinic of Maxillofacial Surgery, Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krpan</LastName><ForeName>Beatrice</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Friuli Centrale Healthcare University Hospital (ASUFC), Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marcon</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Friuli Centrale Healthcare University Hospital (ASUFC), Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Martino</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Udine, Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vesca</LastName><ForeName>Giorgia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Udine, Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lombardo</LastName><ForeName>Cinzia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Friuli Centrale Healthcare University Hospital (ASUFC), Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marzinotto</LastName><ForeName>Stefania</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Friuli Centrale Healthcare University Hospital (ASUFC), Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nencioni</LastName><ForeName>Emanuele</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Biofarma Group Srl, Mereto di Tomba, Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sembronio</LastName><ForeName>Salvatore</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Head and Neck and Neuroscience, Academic Hospital of Udine, Clinic of Maxillofacial Surgery, Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pipan</LastName><ForeName>Corrado</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Udine, Udine, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Public Health Laboratory, Friuli Centrale Healthcare University Hospital (ASUFC), Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robiony</LastName><ForeName>Massimo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Udine, Udine, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Head and Neck and Neuroscience, Academic Hospital of Udine, Clinic of Maxillofacial Surgery, Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Curcio</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Udine, Udine, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Friuli Centrale Healthcare University Hospital (ASUFC), Udine, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004279">DNA, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012463" MajorTopicYN="Y">Saliva</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073890" MajorTopicYN="N">Liquid Biopsy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002294" MajorTopicYN="Y">Carcinoma, Squamous Cell</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D030361" MajorTopicYN="Y">Papillomavirus Infections</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009062" MajorTopicYN="Y">Mouth Neoplasms</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004279" MajorTopicYN="N">DNA, Viral</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D027383" MajorTopicYN="Y">Papillomaviridae</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077195" MajorTopicYN="N">Squamous Cell Carcinoma of Head and Neck</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055088" MajorTopicYN="N">Early Detection of Cancer</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">human papilloma virus (HPV)</Keyword><Keyword MajorTopicYN="N">molecular biology</Keyword><Keyword MajorTopicYN="N">oral cavity squamous cell carcinoma (OCSCC)</Keyword><Keyword MajorTopicYN="N">saliva</Keyword><Keyword MajorTopicYN="N">screening test</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>5</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>5</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>12</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40762035</ArticleId><ArticleId IdType="pmc">PMC12703555</ArticleId><ArticleId IdType="doi">10.1002/hed.70003</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chaturvedi A. K., Graubard B. I., Broutian T., et&#xa0;al., &#x201c;Prevalence of Oral HPV Infection in Unvaccinated Men and Women in the United States, 2009&#x2013;2016,&#x201d; JAMA 322 (2019): 977&#x2013;979.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6737522</ArticleId><ArticleId IdType="pubmed">31503300</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghantous Y. and Abu Elnaaj I., &#x201c;Global Incidence and Risk Factors of Oral Cancer,&#x201d; Harefuah 156 (2017): 645&#x2013;649.</Citation><ArticleIdList><ArticleId IdType="pubmed">29072384</ArticleId></ArticleIdList></Reference><Reference><Citation>Katabi N. and Lewis J. S., &#x201c;Update From the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: What Is New in the 2017 WHO Blue Book for Tumors and Tumor&#x2010;Like Lesions of the Neck and Lymph Nodes,&#x201d; Head and Neck Pathology 11 (2017): 48&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5340737</ArticleId><ArticleId IdType="pubmed">28247228</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulte D. and Brenner H., &#x201c;Changes in Survival in Head and Neck Cancers in the Late 20th and Early 21st Century: A Period Analysis,&#x201d; Oncologist 15 (2010): 994&#x2013;1001.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3228039</ArticleId><ArticleId IdType="pubmed">20798198</ArticleId></ArticleIdList></Reference><Reference><Citation>De Abreu P. M., C&#xf3; A. C. G., Azevedo P. L., et&#xa0;al., &#x201c;Frequency of HPV in Oral Cavity Squamous Cell Carcinoma,&#x201d; BMC Cancer 18 (2018): 324.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5870524</ArticleId><ArticleId IdType="pubmed">29580212</ArticleId></ArticleIdList></Reference><Reference><Citation>Chattopadhyay A., Weatherspoon D., and Pinto A., &#x201c;Human Papillomavirus and Oral Cancer: A Primer for Dental Public Health Professionals,&#x201d; Community Dental Health 32 (2015): 117&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pubmed">26263606</ArticleId></ArticleIdList></Reference><Reference><Citation>Kole&#x15b;nik M., St&#x119;pie&#x144; E., and Polz&#x2010;Dacewicz M., &#x201c;Prevalence of Human Papillomavirus (HPV) in the Oral Cavity of a Healthy Population in South&#x2010;Eastern Poland,&#x201d; International Journal of Environmental Research and Public Health 19 (2022): 7213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9223096</ArticleId><ArticleId IdType="pubmed">35742462</ArticleId></ArticleIdList></Reference><Reference><Citation>Brouwer A. F., Campredon L. P., Walline H. M., et&#xa0;al., &#x201c;Prevalence and Determinants of Oral and Cervicogenital HPV Infection: Baseline Analysis of the Michigan HPV and Oropharyngeal Cancer (MHOC) Cohort Study,&#x201d; PLoS One 17 (2022): e0268104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9109914</ArticleId><ArticleId IdType="pubmed">35576195</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamani M., Gr&#xf8;nh&#xf8;j C., Jensen D. H., et&#xa0;al., &#x201c;The Current Epidemic of HPV&#x2010;Associated Oropharyngeal Cancer: An 18&#x2010;Year Danish Population&#x2010;Based Study With 2,169 Patients,&#x201d; European Journal of Cancer 134 (2020): 52&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">32460181</ArticleId></ArticleIdList></Reference><Reference><Citation>Katirachi S. K., Gr&#xf8;nlund M. P., Jakobsen K. K., Gr&#xf8;nh&#xf8;j C., and von Buchwald C., &#x201c;The Prevalence of HPV in Oral Cavity Squamous Cell Carcinoma,&#x201d; Viruses 15 (2023): 451.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9964223</ArticleId><ArticleId IdType="pubmed">36851665</ArticleId></ArticleIdList></Reference><Reference><Citation>Jamieson L. M., Garvey G., Hedges J., et&#xa0;al., &#x201c;Cohort Profile: Indigenous Human Papillomavirus and Oropharyngeal Squamous Cell Carcinoma Study &#x2010; a Prospective Longitudinal Cohort,&#x201d; BMJ Open 11 (2021): e046928.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8183277</ArticleId><ArticleId IdType="pubmed">34083343</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimolbutr K., Poomsawat S., Na&#x2010;ek N., Warnakulasuriya S., and Buajeeb W., &#x201c;Prevalence of Human Papillomavirus in Oral Cancer in Asia: A Systematic Review and Meta&#x2010;Analysis,&#x201d; Oral Diseases 31 (2024): odi.14979, 10.1111/odi.14979.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/odi.14979</ArticleId><ArticleId IdType="pubmed">38716741</ArticleId></ArticleIdList></Reference><Reference><Citation>Gr&#xf8;nh&#xf8;j C., Jensen D. H., Dehlendorff C., et&#xa0;al., &#x201c;Development and External Validation of Nomograms in Oropharyngeal Cancer Patients With Known HPV&#x2010;DNA Status: A European Multicentre Study (OroGrams),&#x201d; British Journal of Cancer 118 (2018): 1672&#x2013;1681.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6008433</ArticleId><ArticleId IdType="pubmed">29795309</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirghani H., Casiraghi O., Amen F., et&#xa0;al., &#x201c;Diagnosis of HPV&#x2010;Driven Head and Neck Cancer With a Single Test in Routine Clinical Practice,&#x201d; Modern Pathology 28 (2015): 1518&#x2013;1527.</Citation><ArticleIdList><ArticleId IdType="pubmed">26403782</ArticleId></ArticleIdList></Reference><Reference><Citation>Lechner M., Breeze C. E., O'Mahony J. F., and Masterson L., &#x201c;Early Detection of HPV&#x2010;Associated Oropharyngeal Cancer,&#x201d; Lancet 393 (2019): 2123.</Citation><ArticleIdList><ArticleId IdType="pubmed">31226048</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka H., Suzuki M., Takemoto N., et&#xa0;al., &#x201c;Performance of Oral HPV DNA, Oral HPV mRNA and Circulating Tumor HPV DNA in the Detection of HPV&#x2010;Related Oropharyngeal Cancer and Cancer of Unknown Primary,&#x201d; International Journal of Cancer 150 (2022): 174&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9290341</ArticleId><ArticleId IdType="pubmed">34486724</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin&#x2010;Gomez L., Fulp W. J., Schell M. J., et&#xa0;al., &#x201c;Oral Gargle&#x2010;Tumor Biopsy Human Papillomavirus (HPV) Agreement and Associated Factors Among Oropharyngeal Squamous Cell Carcinoma (OPSCC) Cases,&#x201d; Oral Oncology 92 (2019): 85&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6736648</ArticleId><ArticleId IdType="pubmed">31010629</ArticleId></ArticleIdList></Reference><Reference><Citation>Irfan M., Delgado R. Z. R., and Frias&#x2010;Lopez J., &#x201c;The Oral Microbiome and Cancer,&#x201d; Frontiers in Immunology 11 (2020): 591088.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7645040</ArticleId><ArticleId IdType="pubmed">33193429</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahlstrom K. R., Sikora A. G., Liu Y., et&#xa0;al., &#x201c;Characterization of the Oral Microbiota Among Middle&#x2010;Aged Men With and Without Human Papillomavirus Infection,&#x201d; Oral Oncology 142 (2023): 106401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10330617</ArticleId><ArticleId IdType="pubmed">37178654</ArticleId></ArticleIdList></Reference><Reference><Citation>Wensel C. R., Pluznick J. L., Salzberg S. L., and Sears C. L., &#x201c;Next&#x2010;Generation Sequencing: Insights to Advance Clinical Investigations of the Microbiome,&#x201d; Journal of Clinical Investigation 132 (2022): e154944.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8970668</ArticleId><ArticleId IdType="pubmed">35362479</ArticleId></ArticleIdList></Reference><Reference><Citation>Aulakh S. S., Silverman D. A., Young K., Dennis S. K., and Birkeland A. C., &#x201c;The Promise of Circulating Tumor DNA in Head and Neck Cancer,&#x201d; Cancers 14 (2022): 2968.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9221491</ArticleId><ArticleId IdType="pubmed">35740633</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbella S., Veronesi P., Galimberti V., Weinstein R., Del Fabbro M., and Francetti L., &#x201c;Is Periodontitis a Risk Indicator for Cancer? A Meta&#x2010;Analysis,&#x201d; PLoS One 13 (2018): e0195683.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5903629</ArticleId><ArticleId IdType="pubmed">29664916</ArticleId></ArticleIdList></Reference><Reference><Citation>Schache A. G., Liloglou T., Risk J. M., et&#xa0;al., &#x201c;Evaluation of Human Papilloma Virus Diagnostic Testing in Oropharyngeal Squamous Cell Carcinoma: Sensitivity, Specificity, and Prognostic Discrimination,&#x201d; Clinical Cancer Research 17 (2011): 6262&#x2013;6271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3188400</ArticleId><ArticleId IdType="pubmed">21969383</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustin J. G., Lepine C., Morini A., et&#xa0;al., &#x201c;HPV Detection in Head and Neck Squamous Cell Carcinomas: What Is the Issue?,&#x201d; Frontiers in Oncology 10 (2020): 1751.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7523032</ArticleId><ArticleId IdType="pubmed">33042820</ArticleId></ArticleIdList></Reference><Reference><Citation>Venuti A. and Paolini F., &#x201c;HPV Detection Methods in Head and Neck Cancer,&#x201d; Head and Neck Pathology 6, no. Suppl 1 (2012): S63&#x2013;S74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3394157</ArticleId><ArticleId IdType="pubmed">22782225</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran N. H., Sais D., and Tran N., &#x201c;Advances in Human Papillomavirus Detection and Molecular Understanding in Head and Neck Cancers: Implications for Clinical Management,&#x201d; Journal of Medical Virology 96 (2024): e29746.</Citation><ArticleIdList><ArticleId IdType="pubmed">38884391</ArticleId></ArticleIdList></Reference><Reference><Citation>Wasserman J. K., Rourke R., Purgina B., et&#xa0;al., &#x201c;HPV DNA in Saliva From Patients With SCC of the Head and Neck Is Specific for p16&#x2010;Positive Oropharyngeal Tumours,&#x201d; Journal of Otolaryngology &#x2010; Head &amp; Neck Surgery 46 (2017): 3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5217573</ArticleId><ArticleId IdType="pubmed">28061890</ArticleId></ArticleIdList></Reference><Reference><Citation>Panzarella V., Butt&#xe0; M., Buttacavoli F., et&#xa0;al., &#x201c;Human Papilloma Virus (HPV) Detection in Oral Rinse vs. Oral Sponge: A Preliminary Accuracy Report in Oral Cancer Patients,&#x201d; Cancers 16 (2024): 3256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11475542</ArticleId><ArticleId IdType="pubmed">39409878</ArticleId></ArticleIdList></Reference><Reference><Citation>Izumchenko E., Mishra V., Wing C., et&#xa0;al., &#x201c;Saliva&#x2010;Based Detection of Oral HPV and Oral Cancer,&#x201d; JCO 42 (2024): 6057.</Citation></Reference><Reference><Citation>Lechner M., Liu J., Masterson L., and Fenton T. R., &#x201c;HPV&#x2010;Associated Oropharyngeal Cancer: Epidemiology, Molecular Biology and Clinical Management,&#x201d; Nature Reviews. Clinical Oncology 19 (2022): 306&#x2013;327.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8805140</ArticleId><ArticleId IdType="pubmed">35105976</ArticleId></ArticleIdList></Reference><Reference><Citation>Arenz A., Patze J., Kornmann E., et&#xa0;al., &#x201c;HPV&#x2010;Negative and HPV&#x2010;Positive HNSCC Cell Lines Show Similar Numerical but Different Structural Chromosomal Aberrations,&#x201d; Head &amp; Neck 41 (2019): 3869&#x2013;3879.</Citation><ArticleIdList><ArticleId IdType="pubmed">31441163</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong X., Xiong J., Gong Y., et&#xa0;al., &#x201c;Deciphering the Role of HPV&#x2010;Mediated Metabolic Regulation in Shaping the Tumor Microenvironment and Its Implications for Immunotherapy in HNSCC,&#x201d; Frontiers in Immunology 14 (2023): 1275270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10590915</ArticleId><ArticleId IdType="pubmed">37876923</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulfoni M., Sozio E., Marcon B., et&#xa0;al., &#x201c;Validation of a Saliva&#x2010;Based Test for the Molecular Diagnosis of SARS&#x2010;CoV&#x2010;2 Infection,&#x201d; Disease Markers 2022 (2022): 6478434, 10.1155/2022/6478434.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2022/6478434</ArticleId><ArticleId IdType="pmc">PMC8759915</ArticleId><ArticleId IdType="pubmed">35035611</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70135 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41392798</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Dec</Month><Day>15</Day></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>The Prognostic Value of Worst Pattern of Invasion-5 on Low-Risk and Early-Stage Oral Tongue Cancer.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70135</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">To evaluate the prognostic value of the worst pattern of invasion-5 (WPOI-5) for patients with pathologically early-stage and low-risk oral tongue squamous cell carcinoma (OTSCC).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 224 patients treated between 2005 and 2016 were analyzed. WPOI-5 was defined as tumor satellites &#x2265;&#x2009;1&#x2009;mm from the main tumor or nearest satellite. Its prognostic impact on cancer-specific survival (CSS) and locoregional recurrence-free survival (LRRFS) was assessed, and a WPOI-5-based nomogram was developed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients with WPOI-5 had significantly worse 5-year CSS and LRRFS (both p&#x2009;&lt;&#x2009;0.001). In Cox analysis, WPOI-5 independently predicted poorer CSS (HR 6.908, p&#x2009;=&#x2009;0.006) and LRRFS (HR 14.910, p&#x2009;&lt;&#x2009;0.001). Adding WPOI-5 improved the nomogram's 5-year LRRFS AUC from 0.789 to 0.842.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">WPOI-5 is an adverse prognostic factor in pathologically early-stage, low-risk OTSCC and may justify trials of adjuvant therapy in these patients.</AbstractText><CopyrightInformation>&#xa9; 2025 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Ming-Hsien</ForeName><Initials>MH</Initials><Identifier Source="ORCID">0000-0002-6877-1579</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Chang Gung University College of Medicine, Taoyuan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, College of Medicine, National Sun Yat-Sen University, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Hui-Shan</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>Department of Pathology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chou</LastName><ForeName>Chih-Chi</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Department of Pathology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chuang</LastName><ForeName>Hui-Ching</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Chang Gung University College of Medicine, Taoyuan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, College of Medicine, National Sun Yat-Sen University, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Yu-Tsai</ForeName><Initials>YT</Initials><Identifier Source="ORCID">0000-0002-7311-8638</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Chang Gung University College of Medicine, Taoyuan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, College of Medicine, National Sun Yat-Sen University, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Hui</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-7952-7160</Identifier><AffiliationInfo><Affiliation>Doctoral Program of Clinical and Experimental Medicine, National Sun Yat-Sen University, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chien</LastName><ForeName>Chih-Yen</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Doctoral Program of Clinical and Experimental Medicine, National Sun Yat-Sen University, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Fu-Min</ForeName><Initials>FM</Initials><AffiliationInfo><Affiliation>School of Medicine, Chang Gung University College of Medicine, Taoyuan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, College of Medicine, National Sun Yat-Sen University, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiation Oncology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>CMRPG8N0151</GrantID><Agency>Kaohsiung Chang Gung Memorial Hospital, Taiwan</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">WPOI&#x2010;5</Keyword><Keyword MajorTopicYN="N">early&#x2010;stage oral tongue cancer</Keyword><Keyword MajorTopicYN="N">nomogram</Keyword><Keyword MajorTopicYN="N">prognosis</Keyword><Keyword MajorTopicYN="N">tumor satellite</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>11</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>11</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>12</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>15</Day><Hour>4</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41392798</ArticleId><ArticleId IdType="doi">10.1002/hed.70135</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>J. R. Jhuang, S. Y. Su, C. J. Chiang, et&#xa0;al., &#x201c;Forecast of Peak Attainment and Imminent Decline After 2017 of Oral Cancer Incidence in Men in Taiwan,&#x201d; Scientific Reports 12, no. 1 (2022): 5726.</Citation></Reference><Reference><Citation>T. A. Iseli, M. J. Lin, A. Tsui, A. Guiney, D. Wiesenfeld, and C. E. Iseli, &#x201c;Are Wider Surgical Margins Needed for Early Oral Tongue Cancer?,&#x201d; Journal of Laryngology and Otology 126, no. 3 (2012): 289&#x2013;294.</Citation></Reference><Reference><Citation>R. Padma, A. Kalaivani, S. Sundaresan, and P. Sathish, &#x201c;The Relationship Between Histological Differentiation and Disease Recurrence of Primary Oral Squamous Cell Carcinoma,&#x201d; Journal of Oral and Maxillofacial Pathology 21, no. 3 (2017): 461.</Citation></Reference><Reference><Citation>M. Faisal, M. Abu Bakar, A. Sarwar, et&#xa0;al., &#x201c;Depth of Invasion (DOI) as a Predictor of Cervical Nodal Metastasis and Local Recurrence in Early Stage Squamous Cell Carcinoma of Oral Tongue (ESSCOT),&#x201d; PLoS One 13, no. 8 (2018): e0202632.</Citation></Reference><Reference><Citation>X. Yang, X. Tian, K. Wu, et&#xa0;al., &#x201c;Prognostic Impact of Perineural Invasion in Early Stage Oral Tongue Squamous Cell Carcinoma: Results From a Prospective Randomized Trial,&#x201d; Surgical Oncology 27, no. 2 (2018): 123&#x2013;128.</Citation></Reference><Reference><Citation>A. R. Larson, J. Kemmer, E. Formeister, et&#xa0;al., &#x201c;Beyond Depth of Invasion: Adverse Pathologic Tumor Features in Early Oral Tongue Squamous Cell Carcinoma,&#x201d; Laryngoscope 130, no. 7 (2020): 1715&#x2013;1720.</Citation></Reference><Reference><Citation>M. Mascitti, L. Togni, V. C. A. Caponio, et&#xa0;al., &#x201c;Lymphovascular Invasion as a Prognostic Tool for Oral Squamous Cell Carcinoma: A Comprehensive Review,&#x201d; International Journal of Oral and Maxillofacial Surgery 51, no. 1 (2022): 1&#x2013;9.</Citation></Reference><Reference><Citation>M. H. Tsai, H. S. Huang, H. C. Chuang, et&#xa0;al., &#x201c;Patients of Stage I Oral Cancer With Pathologically Low&#x2010;Risk Feature Managed by Primary Tumor Resection Alone: Impact of Depth of Invasion and a Nomogram Analysis,&#x201d; Laryngoscope Investigative Otolaryngology 7, no. 4 (2022): 1025&#x2013;1032.</Citation></Reference><Reference><Citation>P. W. Hsiao, Y. T. Lin, H. C. Chuang, et&#xa0;al., &#x201c;Impact of Depth of Invasion in Node&#x2010;Negative Oral Tongue Cancer Treated With Surgery Alone,&#x201d; Kaohsiung Journal of Medical Sciences (2025): e70102.</Citation></Reference><Reference><Citation>G. Warburton, N. G. Nikitakis, P. Roberson, et&#xa0;al., &#x201c;Histopathological and Lymphangiogenic Parameters in Relation to Lymph Node Metastasis in Early Stage Oral Squamous Cell Carcinoma,&#x201d; Journal of Oral and Maxillofacial Surgery 65, no. 3 (2007): 475&#x2013;484.</Citation></Reference><Reference><Citation>L. M. Marinelli, K. Chatzopoulos, J. P. Marinelli, et&#xa0;al., &#x201c;Clinicopathologic Predictors of Survival in Buccal Squamous Cell Carcinoma,&#x201d; Journal of Oral Pathology &amp; Medicine 49, no. 9 (2020): 857&#x2013;864.</Citation></Reference><Reference><Citation>A. Mishra, A. Das, I. Dhal, et&#xa0;al., &#x201c;Worst Pattern of Invasion in Oral Squamous Cell Carcinoma Is an Independent Prognostic Factor,&#x201d; Journal of Oral Biology and Craniofacial Research 12, no. 6 (2022): 771&#x2013;776.</Citation></Reference><Reference><Citation>M. Brandwein&#x2010;Gensler, M. S. Teixeira, C. M. Lewis, et&#xa0;al., &#x201c;Oral Squamous Cell Carcinoma: Histologic Risk Assessment, but Not Margin Status, Is Strongly Predictive of Local Disease&#x2010;Free and Overall Survival,&#x201d; American Journal of Surgical Pathology 29, no. 2 (2005): 167&#x2013;178.</Citation></Reference><Reference><Citation>A. Almangush, I. O. Bello, H. Keski&#x2010;Santti, et&#xa0;al., &#x201c;Depth of Invasion, Tumor Budding, and Worst Pattern of Invasion: Prognostic Indicators in Early&#x2010;Stage Oral Tongue Cancer,&#x201d; Head &amp; Neck 36 (2014): 811&#x2013;818.</Citation></Reference><Reference><Citation>A. Almangush, I. O. Bello, R. D. Coletta, et&#xa0;al., &#x201c;For Early&#x2010;Stage Oral Tongue Cancer, Depth of Invasion and Worst Pattern of Invasion Are the Strongest Pathological Predictors for Locoregional Recurrence and Mortality,&#x201d; Virchows Archiv 467 (2015): 39&#x2013;46.</Citation></Reference><Reference><Citation>M. B. Amin, F. L. Greene, S. B. Edge, et&#xa0;al., &#x201c;The Eighth Edition AJCC Cancer Staging Manual: Continuing to Build a Bridge From a Population&#x2010;Based to a More &#x201c;Personalized&#x201d; Approach to Cancer Staging,&#x201d; CA: A Cancer Journal for Clinicians 67, no. 2 (2017): 93&#x2013;99.</Citation></Reference><Reference><Citation>E. von Elm, D. G. Altman, M. Egger, S. J. Pocock, P. C. G&#xf8;tzsche, and J. P. Vandenbroucke, &#x201c;The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies,&#x201d; Journal of Clinical Epidemiology 61, no. 4 (2008): 344&#x2013;349.</Citation></Reference><Reference><Citation>Y. Li, S. Bai, W. Carroll, et&#xa0;al., &#x201c;Validation of the Risk Model: High&#x2010;Risk Classification and Tumor Pattern of Invasion Predict Outcome for Patients With Low&#x2010;Stage Oral Cavity Squamous Cell Carcinoma,&#x201d; Head and Neck Pathology 7, no. 3 (2013): 211&#x2013;223.</Citation></Reference><Reference><Citation>N. Sinha, M. H. Rigby, M. L. McNeil, et&#xa0;al., &#x201c;The Histologic Risk Model Is a Useful and Inexpensive Tool to Assess Risk of Recurrence and Death in Stage I or II Squamous Cell Carcinoma of Tongue and Floor of Mouth,&#x201d; Modern Pathology 31, no. 5 (2018): 772&#x2013;779.</Citation></Reference><Reference><Citation>T. L. Yang, J. Y. Ko, and Y. L. Chang, &#x201c;Involved Margin of Tongue Cancer: The Impact of Tumor Satellites on Prognosis,&#x201d; Head &amp; Neck 30, no. 7 (2008): 845&#x2013;851.</Citation></Reference><Reference><Citation>E. Yosefof, S. Tzelnick, L. Wallach, et&#xa0;al., &#x201c;Tumor Satellites Are Associated With Poor Outcome in Patients With Oral Cancer,&#x201d; Laryngoscope 133, no. 2 (2023): 336&#x2013;343.</Citation></Reference><Reference><Citation>Y. Pu, L. Ding, Y. Wang, et&#xa0;al., &#x201c;Biopsy Pattern of Invasion Type to Determine the Surgical Approach in Early&#x2010;Stage Oral Squamous Cell Carcinoma,&#x201d; Virchows Archiv 479, no. 1 (2021): 109&#x2013;119.</Citation></Reference><Reference><Citation>S. Shimizu, A. Miyazaki, T. Sonoda, et&#xa0;al., &#x201c;Tumor Budding Is an Independent Prognostic Marker in Early Stage Oral Squamous Cell Carcinoma: With Special Reference to the Mode of Invasion and Worst Pattern of Invasion,&#x201d; PLoS One 13, no. 4 (2018): e0195451.</Citation></Reference><Reference><Citation>K. Wu, J. Wei, Z. Liu, et&#xa0;al., &#x201c;Can Pattern and Depth of Invasion Predict Lymph Node Relapse and Prognosis in Tongue Squamous Cell Carcinoma,&#x201d; BMC Cancer 19, no. 1 (2019): 714.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70138 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41392779</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Dec</Month><Day>15</Day></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Nomogram for Predicting Osteoradionecrosis After Fibula Free Flap for Mandibular Reconstruction.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70138</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Osteoradionecrosis (ORN) is a severe complication following radiotherapy (RT), particularly after mandibular reconstruction with a fibula free flap. Risk prediction remains challenging due to limited data.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a multicenter retrospective study including 294 patients who underwent fibula free flap reconstruction and adjuvant RT. A predictive nomogram for ORN was developed using logistic regression with stepwise backward selection, validated via 10-fold cross-validation.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">ORN occurred in 9.9% of patients. Eight variables were retained in the final model, which demonstrated excellent discrimination (AUC&#x2009;=&#x2009;0.94) and good calibration (mean absolute error&#x2009;=&#x2009;0.017). The optimal threshold for classification was 0.30, with the model achieving a sensitivity of 1.0, specificity of 0.80, and an overall accuracy of 0.82.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This is the first nomogram developed to predict ORN following fibula free flap mandibular reconstruction. It provides a personalized risk estimate, supporting individualized clinical decision-making and improved pre- and postoperative planning. Prospective validation is warranted.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). Head &amp; Neck published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Costantino</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5551-7785</Identifier><AffiliationInfo><Affiliation>Otorhinolaryngology Unit, IRCCS Humanitas Research Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Festa</LastName><ForeName>Bianca</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-8785-9277</Identifier><AffiliationInfo><Affiliation>Otorhinolaryngology Unit, IRCCS Humanitas Research Hospital, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Humanitas University, Rozzano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marchi</LastName><ForeName>Filippo</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-7997-964X</Identifier><AffiliationInfo><Affiliation>Unit of Otorhinolaryngology-Head and Neck Surgery, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgical Sciences and Integrated Diagnostics (DISC), University of Genoa, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsao</LastName><ForeName>Chung-Kan</ForeName><Initials>CK</Initials><Identifier Source="ORCID">0000-0003-3995-5894</Identifier><AffiliationInfo><Affiliation>Department of Plastic and Reconstructive Surgery, Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Taoyuan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Tissue Engineering, Chang Gung Memorial Hospital, Taoyuan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pellini</LastName><ForeName>Raul</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology-Head and Neck Surgery, IRCCS Regina Elena National Cancer Institute, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gazzini</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology Head and Neck Surgery, Hospital of Bolzano (SABES-ASDAA), Bolzano, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Teaching Hospital of the Paracelsus Medical Private University (PMU), Bolzano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dzi&#x119;gielewski</LastName><ForeName>Peter T</ForeName><Initials>PT</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology, University of Florida, Gainesville, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ciniglio</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, Head and Neck Surgery, USL Toscana Centro, SOC otorinolarigoiatria 1, Prato, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mazzola</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-1533-8832</Identifier><AffiliationInfo><Affiliation>Department of Otorhinolaryngology-Head and Neck Surgery, IRCCS Regina Elena National Cancer Institute, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calabrese</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology Head and Neck Surgery, Hospital of Bolzano (SABES-ASDAA), Bolzano, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Teaching Hospital of the Paracelsus Medical Private University (PMU), Bolzano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarno</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, Head and Neck Surgery, USL Toscana Centro, SOC otorinolarigoiatria 1, Prato, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parrinello</LastName><ForeName>Giampiero</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Unit of Otorhinolaryngology-Head and Neck Surgery, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chow</LastName><ForeName>Linda</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Albert Einstein College of Medicine, Bronx, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jyh-Kwei</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Department of Oral and Maxillofacial Surgery, Chang Gung Memorial Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peretti</LastName><ForeName>Giorgio</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Unit of Otorhinolaryngology-Head and Neck Surgery, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgical Sciences and Integrated Diagnostics (DISC), University of Genoa, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Virgilio</LastName><ForeName>Armando</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Organs of Sense, 'Sapienza' University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">complications</Keyword><Keyword MajorTopicYN="N">head and neck cancer</Keyword><Keyword MajorTopicYN="N">head and neck squamous cell carcinoma</Keyword><Keyword MajorTopicYN="N">mandible</Keyword><Keyword MajorTopicYN="N">radiotherapy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>12</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>15</Day><Hour>4</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41392779</ArticleId><ArticleId IdType="doi">10.1002/hed.70138</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>C. Madrid, M. Abarca, and K. Bouferrache, &#x201c;Osteoradionecrosis: An Update,&#x201d; Oral Oncology 46, no. 6 (2010): 471&#x2013;474, https://doi.org/10.1016/j.oraloncology.2010.03.017.</Citation></Reference><Reference><Citation>K. O'Dell and U. Sinha, &#x201c;Osteoradionecrosis,&#x201d; Oral and Maxillofacial Surgery Clinics of North America 23, no. 3 (2011): 455&#x2013;464, https://doi.org/10.1016/j.coms.2011.04.011.</Citation></Reference><Reference><Citation>R. E. Marx, &#x201c;Osteoradionecrosis: A New Concept of Its Pathophysiology,&#x201d; Journal of Oral and Maxillofacial Surgery 41, no. 5 (1983): 283&#x2013;288, https://doi.org/10.1016/0278&#x2010;2391(83)90294&#x2010;x.</Citation></Reference><Reference><Citation>T. Kuhnt, A. Stang, A. Wienke, D. Vordermark, R. Schweyen, and J. Hey, &#x201c;Potential Risk Factors for Jaw Osteoradionecrosis After Radiotherapy for Head and Neck Cancer,&#x201d; Radiation Oncology 11 (2016): 101, https://doi.org/10.1186/s13014&#x2010;016&#x2010;0679&#x2010;6.</Citation></Reference><Reference><Citation>T. Reuther, T. Schuster, U. Mende, and A. K&#xfc;bler, &#x201c;Osteoradionecrosis of the Jaws as a Side Effect of Radiotherapy of Head and Neck Tumour Patients&#x2014;A Report of a Thirty Year Retrospective Review,&#x201d; International Journal of Oral and Maxillofacial Surgery 32, no. 3 (2003): 289&#x2013;295, https://doi.org/10.1054/ijom.2002.0332.</Citation></Reference><Reference><Citation>J. Dhanda, D. Pasquier, L. Newman, and R. Shaw, &#x201c;Current Concepts in Osteoradionecrosis After Head and Neck Radiotherapy,&#x201d; Clinical Oncology 28, no. 7 (2016): 459&#x2013;466, https://doi.org/10.1016/j.clon.2016.03.002.</Citation></Reference><Reference><Citation>K. I. Notani, Y. Yamazaki, H. Kitada, et&#xa0;al., &#x201c;Management of Mandibular Osteoradionecrosis Corresponding to the Severity of Osteoradionecrosis and the Method of Radiotherapy,&#x201d; Head &amp; Neck 25, no. 3 (2003): 181&#x2013;186, https://doi.org/10.1002/hed.10171.</Citation></Reference><Reference><Citation>S. Aarup&#x2010;Kristensen, C. Hansen, L. Forner, C. Brink, J. Eriksen, and J. Johansen, &#x201c;Osteoradionecrosis of the Mandible After Radiotherapy for Head and Neck Cancer: Risk Factors and Dose&#x2010;Volume Correlations,&#x201d; Acta Oncologica 58, no. 10 (2019): 1373&#x2013;1377, https://doi.org/10.1080/0284186X.2019.1643037.</Citation></Reference><Reference><Citation>L. Renda, T. Y. Tsai, J. J. Huang, et&#xa0;al., &#x201c;A Nomogram to Predict Osteoradionecrosis in Oral Cancer After Marginal Mandibulectomy and Radiotherapy,&#x201d; Laryngoscope 130, no. 1 (2020): 101&#x2013;107, https://doi.org/10.1002/lary.27870.</Citation></Reference><Reference><Citation>P. T. Dziegielewski, S. Bernard, W. M. Mendenhall, et&#xa0;al., &#x201c;Osteoradionecrosis in Osseous Free Flap Reconstruction: Risk Factors and Treatment,&#x201d; Head &amp; Neck 42, no. 8 (2020): 1928&#x2013;1938, https://doi.org/10.1002/hed.26118.</Citation></Reference><Reference><Citation>S. S. Wu, H. Hong, M. Fritz, et&#xa0;al., &#x201c;Rates of Osteoradionecrosis in Resected Oral Cavity Cancer Reconstructed With Free Tissue Transfer in the Intensity&#x2010;Modulated Radiotherapy Era,&#x201d; Head &amp; Neck 45, no. 4 (2023): 890&#x2013;899, https://doi.org/10.1002/hed.27310.</Citation></Reference><Reference><Citation>K. Y. Wang, W. C. Liu, C. F. Chen, L. W. Chen, H. C. Chen, and K. C. Yang, &#x201c;Osteomyocutaneous Free Fibula Flap Prevents Osteoradionecrosis and Osteomyelitis in Head and Neck Cancer Reconstruction,&#x201d; Journal of Reconstructive Microsurgery 37, no. 6 (2021): 524&#x2013;529, https://doi.org/10.1055/s&#x2010;0040&#x2010;1722647.</Citation></Reference><Reference><Citation>E. von Elm, D. G. Altman, M. Egger, S. J. Pocock, P. C. G&#xf8;tzsche, and J. P. Vandenbroucke, &#x201c;The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies,&#x201d; Lancet 370, no. 9596 (2007): 1453&#x2013;1457, https://doi.org/10.1016/S0140&#x2010;6736(07)61602&#x2010;X.</Citation></Reference><Reference><Citation>S. N. Rogers, A. Aziz, D. Lowe, and D. J. Husband, &#x201c;Feasibility Study of the Retrospective Use of the Adult Comorbidity Evaluation Index (ACE&#x2010;27) in Patients With Cancer of the Head and Neck Who Had Radiotherapy,&#x201d; British Journal of Oral &amp; Maxillofacial Surgery 44, no. 4 (2006): 283&#x2013;288, https://doi.org/10.1016/j.bjoms.2005.06.025.</Citation></Reference><Reference><Citation>M. B. Amin, F. L. Greene, S. B. Edge, et&#xa0;al., &#x201c;The Eighth Edition AJCC Cancer Staging Manual: Continuing to Build a Bridge From a Population&#x2010;Based to a More &#x201c;Personalized&#x201d; Approach to Cancer Staging,&#x201d; CA: A Cancer Journal for Clinicians 67, no. 2 (2017): 93&#x2013;99, https://doi.org/10.3322/caac.21388.</Citation></Reference><Reference><Citation>S. Derksen and H. J. Keselman, &#x201c;Backward, Forward and Stepwise Automated Subset Selection Algorithms: Frequency of Obtaining Authentic and Noise Variables,&#x201d; British Journal of Mathematical and Statistical Psychology 45, no. 2 (1992): 265&#x2013;282, https://doi.org/10.1111/j.2044&#x2010;8317.1992.tb00992.x.</Citation></Reference><Reference><Citation>T. W. Arnold, &#x201c;Uninformative Parameters and Model Selection Using Akaike's Information Criterion,&#x201d; Journal of Wildlife Management 74, no. 6 (2010): 1175&#x2013;1178, https://doi.org/10.1111/j.1937&#x2010;2817.2010.tb01236.x.</Citation></Reference><Reference><Citation>J. D. Rodriguez, A. Perez, and J. A. Lozano, &#x201c;Sensitivity Analysis of k&#x2010;Fold Cross Validation in Prediction Error Estimation,&#x201d; IEEE Transactions on Pattern Analysis and Machine Intelligence 32, no. 3 (2010): 569&#x2013;575, https://doi.org/10.1109/TPAMI.2009.187.</Citation></Reference><Reference><Citation>N. V. Chawla, K. W. Bowyer, L. O. Hall, and W. P. Kegelmeyer, &#x201c;SMOTE: Synthetic Minority Over&#x2010;Sampling Technique,&#x201d; Journal of Artificial Intelligence Research 16 (2002): 321&#x2013;357, https://doi.org/10.1613/jair.953.</Citation></Reference><Reference><Citation>W. J. Youden, &#x201c;Index for Rating Diagnostic Tests,&#x201d; Cancer 3, no. 1 (1950): 32&#x2013;35, https://doi.org/10.1002/1097&#x2010;0142(1950)3:1&lt;32::aid&#x2010;cncr2820030106&gt;3.0.co;2&#x2010;3.</Citation></Reference><Reference><Citation>R Core Team, R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, 2024), https://www.R&#x2010;project.org/.</Citation></Reference><Reference><Citation>N. F. Al Deek and F. C. Wei, &#x201c;The Osteosarcoradionecrosis as an Unfavorable Result Following Head and Neck Tumor Ablation and Microsurgical Reconstruction,&#x201d; Clinics in Plastic Surgery 43, no. 4 (2016): 753&#x2013;759, https://doi.org/10.1016/j.cps.2016.05.009.</Citation></Reference><Reference><Citation>A. B. Robey, M. L. Spann, T. M. McAuliff, J. L. Meza, R. R. Hollins, and P. J. Johnson, &#x201c;Comparison of Miniplates and Reconstruction Plates in Fibular Flap Reconstruction of the Mandible,&#x201d; Plastic and Reconstructive Surgery 122, no. 6 (2008): 1733&#x2013;1738, https://doi.org/10.1097/PRS.0b013e31818a9ac5.</Citation></Reference><Reference><Citation>S. M. Park, J. W. Lee, and G. Noh, &#x201c;Which Plate Results in Better Stability After Segmental Mandibular Resection and Fibula Free Flap Reconstruction? Biomechanical Analysis,&#x201d; Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology 126, no. 5 (2018): 380&#x2013;389, https://doi.org/10.1016/j.oooo.2018.05.048.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70137 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41388740</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Dec</Month><Day>12</Day></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Rates of ICU Delirium After Microvascular Free Tissue Transfer Reconstruction of the Oral Cavity and Oropharynx.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70137</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Microvascular free tissue transfer (MFTT) is the standard in the reconstruction of major head and neck defects, but involves extended hospital stays and an increased risk of post-operative delirium (POD). What risk factors increase the risk of POD in patients undergoing MFTT, and subsequent complications?</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Retrospective cohort study of 168 patients undergoing MFTT following ablation of oral cavity or oropharyngeal cancer. Patient demographic data, operative data, post-operative ventilatory support needs, post-operative complications, and post-operative sedation and analgesic needs were collected, and the association with POD was evaluated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">POD was significantly associated with opioid (p&#x2009;=&#x2009;0.0018) and sedation requirements (p&#x2009;&lt;&#x2009;0.001), postoperative return to the OR (p&#x2009;=&#x2009;0.002) and medical complications (p&#x2009;=&#x2009;0.033). There was no association with the rate of MFTT failure (p&#x2009;&gt;&#x2009;0.05).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In MFTT patients, opioid and sedative administration are potentially modifiable factors that may be able to reduce POD incidence and optimize the postoperative course of patients undergoing MFTT.</AbstractText><CopyrightInformation>&#xa9; 2025 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nesmith</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>University of California, San Francisco, School of Medicine, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fakurnejad</LastName><ForeName>Shayan</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-7332-6998</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology - Head and Neck Surgery, Division of Head and Neck Surgical Oncology, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gillard</LastName><ForeName>Danielle</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-9360-3235</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology - Head and Neck Surgery, Division of Head and Neck Surgical Oncology, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wai</LastName><ForeName>Katherine</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-8180-4542</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology - Head and Neck Surgery, Division of Head and Neck Surgical Oncology, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Mary Jue</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology - Head and Neck Surgery, Division of Head and Neck Surgical Oncology, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Likhterov</LastName><ForeName>Ilya</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology - Head and Neck Surgery, Division of Head and Neck Surgical Oncology, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>George</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology - Head and Neck Surgery, Division of Head and Neck Surgical Oncology, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology - Head and Neck Surgery, Division of Head and Neck Surgical Oncology, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El-Sayed</LastName><ForeName>Ivan</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0001-8121-3726</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology - Head and Neck Surgery, Division of Head and Neck Surgical Oncology, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ha</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-0306-6147</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology - Head and Neck Surgery, Division of Head and Neck Surgical Oncology, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology - Head and Neck Surgery, Division of Facial Plastics and Reconstructive Surgery, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seth</LastName><ForeName>Rahul</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology - Head and Neck Surgery, Division of Facial Plastics and Reconstructive Surgery, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knott</LastName><ForeName>P Daniel</ForeName><Initials>PD</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology - Head and Neck Surgery, Division of Facial Plastics and Reconstructive Surgery, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heaton</LastName><ForeName>Chase</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-4296-8944</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology - Head and Neck Surgery, Division of Head and Neck Surgical Oncology, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>San Francisco VA Medical Center, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>12</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>13</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>13</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>13</Day><Hour>2</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41388740</ArticleId><ArticleId IdType="doi">10.1002/hed.70137</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>J. Densky, A. Eskander, S. Kang, et&#xa0;al., &#x201c;Risk Factors Associated With Postoperative Delirium in Patients Undergoing Head and Neck Free Flap Reconstruction,&#x201d; JAMA Otolaryngology. Head &amp; Neck Surgery 145, no. 3 (2019): 216&#x2013;221.</Citation></Reference><Reference><Citation>E. L. Whitlock, A. Vannucci, and M. S. Avidan, &#x201c;Postoperative delirium,&#x201d; Minerva Anestesiologica 77, no. 4 (2011): 448&#x2013;456.</Citation></Reference><Reference><Citation>E. E. Vasilevskis, J. H. Han, C. G. Hughes, and E. W. Ely, &#x201c;Epidemiology and Risk Factors for Delirium Across Hospital Settings,&#x201d; Best Practice &amp; Research. Clinical Anaesthesiology 26, no. 3 (2012): 277&#x2013;287.</Citation></Reference><Reference><Citation>A. Kolk, C. Schwarzer, K. D. Wolff, F. Grill, and J. Weingart, &#x201c;Factors Associated With Postoperative Delirium in Patients Undergoing Complex Head and Neck Flap Surgery,&#x201d; Journal of Oral and Maxillofacial Surgery 80, no. 2 (2022): 372&#x2013;379.e5.</Citation></Reference><Reference><Citation>T. Makiguchi, S. Yokoo, and J. Kurihara, &#x201c;Risk Factors for Postoperative Delirium in Patients Undergoing Free Flap Reconstruction for Oral Cancer,&#x201d; International Journal of Oral and Maxillofacial Surgery 47, no. 8 (2018): 998&#x2013;1002.</Citation></Reference><Reference><Citation>M. Shiiba, M. Takei, M. Nakatsuru, et&#xa0;al., &#x201c;Clinical Observations of Postoperative Delirium After Surgery for Oral Carcinoma,&#x201d; International Journal of Oral and Maxillofacial Surgery 38, no. 6 (2009): 661&#x2013;665.</Citation></Reference><Reference><Citation>S. G. Wang, U. J. Lee, E. K. Goh, and K. M. Chon, &#x201c;Factors Associated With Postoperative Delirium After Major Head and Neck Surgery,&#x201d; Annals of Otology, Rhinology and Laryngology 113, no. 1 (2004): 48&#x2013;51.</Citation></Reference><Reference><Citation>H. G. Weed, C. V. Lutman, D. C. Young, and D. E. Schuller, &#x201c;Preoperative Identification of Patients at Risk for Delirium After Major Head and Neck Cancer Surgery,&#x201d; Laryngoscope 105, no. 10 (1995): 1066&#x2013;1068.</Citation></Reference><Reference><Citation>K. Yamagata, K. Onizawa, H. Yusa, T. Wakatsuki, T. Yanagawa, and H. Yoshida, &#x201c;Risk Factors for Postoperative Delirium in Patients Undergoing Head and Neck Cancer Surgery,&#x201d; International Journal of Oral and Maxillofacial Surgery 34, no. 1 (2005): 33&#x2013;36.</Citation></Reference><Reference><Citation>B. A. Khan, A. J. Perkins, S. Gao, et&#xa0;al., &#x201c;The Confusion Assessment Method for the ICU&#x2010;7 Delirium Severity Scale: A Novel Delirium Severity Instrument for Use in the ICU,&#x201d; Critical Care Medicine 45, no. 5 (2017): 851&#x2013;857.</Citation></Reference><Reference><Citation>E. Card, P. Pandharipande, C. Tomes, et&#xa0;al., &#x201c;Emergence From General Anaesthesia and Evolution of Delirium Signs in the Post&#x2010;Anaesthesia Care Unit,&#x201d; British Journal of Anaesthesia 115, no. 3 (2015): 411&#x2013;417.</Citation></Reference><Reference><Citation>J. M. Leung, L. P. Sands, E. Lim, T. L. Tsai, and S. Kinjo, &#x201c;Does Preoperative Risk for Delirium Moderate the Effects of Postoperative Pain and Opiate Use on Postoperative Delirium?,&#x201d; American Journal of Geriatric Psychiatry 21, no. 10 (2013): 946&#x2013;956.</Citation></Reference><Reference><Citation>E. P. Lynch, M. A. Lazor, J. E. Gellis, J. Orav, L. Goldman, and E. R. Marcantonio, &#x201c;The Impact of Postoperative Pain on the Development of Postoperative Delirium,&#x201d; Anesthesia and Analgesia 86, no. 4 (1998): 781&#x2013;785.</Citation></Reference><Reference><Citation>Z. Jin, J. Hu, and D. Ma, &#x201c;Postoperative Delirium: Perioperative Assessment, Risk Reduction, and Management,&#x201d; British Journal of Anaesthesia 125, no. 4 (2020): 492&#x2013;504.</Citation></Reference><Reference><Citation>A. Hinther, S. C. Nakoneshny, S. P. Chandarana, T. Wayne Matthews, and J. C. Dort, &#x201c;Efficacy of Postoperative Pain Management in Head and Neck Cancer Patients,&#x201d; Journal of Otolaryngology &#x2010; Head &amp; Neck Surgery 47, no. 1 (2018): 29.</Citation></Reference><Reference><Citation>M. Haefeli and A. Elfering, &#x201c;Pain assessment,&#x201d; European Spine Journal 15, no. S1 (2006): S17&#x2013;S24.</Citation></Reference><Reference><Citation>M. Sommer, J. W. J. M. Geurts, B. Stessel, et&#xa0;al., &#x201c;Prevalence and Predictors of Postoperative Pain After Ear, Nose, and Throat Surgery,&#x201d; Archives of Otolaryngology &#x2013; Head &amp; Neck Surgery 135, no. 2 (2009): 124&#x2013;130.</Citation></Reference><Reference><Citation>A. M. Lukasiewicz, R. A. Grant, B. A. Basques, M. L. Webb, A. M. Samuel, and J. N. Grauer, &#x201c;Patient Factors Associated With 30&#x2010;Day Morbidity, Mortality, and Length of Stay After Surgery for Subdural Hematoma: A Study of the American College of Surgeons National Surgical Quality Improvement Program,&#x201d; Journal of Neurosurgery 124, no. 3 (2016): 760&#x2013;766.</Citation></Reference><Reference><Citation>M. S. Haynes, K. D. Alder, C. Toombs, I. C. Amakiri, L. E. Rubin, and J. N. Grauer, &#x201c;Predictors and Sequelae of Postoperative Delirium in a Geriatric Patient Population With Hip Fracture,&#x201d; Journal of the American Academy of Orthopaedic Surgeons Global Research and Reviews 5, no. 5 (2021): e20,&#xa0;https://doi.org/10.5435/JAAOSGlobal&#x2010;D&#x2010;20&#x2010;00221.</Citation></Reference><Reference><Citation>M. Meyer, J. G&#xf6;tz, L. Parik, et&#xa0;al., &#x201c;Postoperative Delirium Is a Risk Factor for Complications and Poor Outcome After Total Hip and Knee Arthroplasty,&#x201d; Acta Orthopaedica 92, no. 6 (2021): 695&#x2013;700.</Citation></Reference><Reference><Citation>E. A. Park and M. Y. Kim, &#x201c;Postoperative Delirium Is Associated With Negative Outcomes and Long&#x2010;Term Mortality in Elderly Koreans: A Retrospective Observational Study,&#x201d; Medicina (Kaunas, Lithuania) 55, no. 10 (2019): 618,&#xa0;https://doi.org/10.3390/medicina55100618.</Citation></Reference><Reference><Citation>J. H. Spiegel and J. K. Polat, &#x201c;Microvascular Flap Reconstruction by Otolaryngologists: Prevalence, Postoperative Care, and Monitoring Techniques,&#x201d; Laryngoscope 117, no. 3 (2007): 485&#x2013;490.</Citation></Reference><Reference><Citation>H. Arshad, H. G. Ozer, A. Thatcher, et&#xa0;al., &#x201c;Intensive Care Unit Versus Non&#x2010;Intensive Care Unit Postoperative Management of Head and Neck Free Flaps: Comparative Effectiveness and Cost Comparisons: Postoperative Management of Head and Neck Free Flaps,&#x201d; Head &amp; Neck 36, no. 4 (2014): 536&#x2013;539.</Citation></Reference><Reference><Citation>M. A. Mashrah, T. Aldhohrah, A. Abdelrehem, et&#xa0;al., &#x201c;Postoperative Care in ICU Versus Non&#x2010;ICU After Head and Neck Free&#x2010;Flap Surgery: A Systematic Review and Meta&#x2010;Analysis,&#x201d; BMJ Open 12, no. 1 (2022): e053667.</Citation></Reference><Reference><Citation>A. Allak, T. N. Nguyen, D. C. Shonka, Jr., J. F. Reibel, P. A. Levine, and M. J. Jameson, &#x201c;Immediate Postoperative Extubation in Patients Undergoing Free Tissue Transfer: Immediate Extubation After Free Flap Surgery,&#x201d; Laryngoscope 121, no. 4 (2011): 763&#x2013;768.</Citation></Reference><Reference><Citation>M. C. Large, C. Reichard, J. T. B. Williams, et&#xa0;al., &#x201c;Incidence, Risk Factors, and Complications of Postoperative Delirium in Elderly Patients Undergoing Radical Cystectomy,&#x201d; Urology 81, no. 1 (2013): 123&#x2013;128.</Citation></Reference><Reference><Citation>N. R. Sangal, K. Nishimori, E. Zhao, S. H. Siddiqui, S. Baredes, and R. Chan Woo Park, &#x201c;Understanding Risk Factors Associated With Unplanned Reoperation in Major Head and Neck Surgery,&#x201d; JAMA Otolaryngology. Head &amp; Neck Surgery 144, no. 11 (2018): 1044&#x2013;1051.</Citation></Reference><Reference><Citation>E. H. Zhao, K. Nishimori, J. Brady, et&#xa0;al., &#x201c;Analysis of Risk Factors for Unplanned Reoperation Following Free Flap Surgery of the Head and Neck,&#x201d; Laryngoscope 128, no. 12 (2018): 2790&#x2013;2795.</Citation></Reference><Reference><Citation>N. Choi, S. I. Park, H. Kim, I. Sohn, and H. S. Jeong, &#x201c;The Impact of Unplanned Reoperations in Head and Neck Cancer Surgery on Survival,&#x201d; Oral Oncology 83 (2018): 38&#x2013;45.</Citation></Reference><Reference><Citation>P. K. Yu, R. K. V. Sethi, V. Rathi, et&#xa0;al., &#x201c;Postoperative Care in an Intermediate&#x2010;Level Medical Unit After Head and Neck Microvascular Free Flap Reconstruction,&#x201d; Laryngoscope Investigative Otolaryngology 4, no. 1 (2019): 39&#x2013;42.</Citation></Reference><Reference><Citation>C. Corbitt, R. J. Skoracki, P. Yu, and M. M. Hanasono, &#x201c;Free Flap Failure in Head and Neck Reconstruction,&#x201d; Head &amp; Neck 36, no. 10 (2014): 1440&#x2013;1445.</Citation></Reference><Reference><Citation>K. Y. Wang, Y. S. Lin, L. W. Chen, K. C. Yang, W. C. Huang, and W. C. Liu, &#x201c;Risk of Free Flap Failure in Head and Neck Reconstruction: Analysis of 21,548 Cases From A Nationwide Database,&#x201d; Annals of Plastic Surgery 84, no. 1S Suppl 1 (2020): S3&#x2013;S6.</Citation></Reference><Reference><Citation>W. Zhou, W. B. Zhang, Y. Yu, et&#xa0;al., &#x201c;Risk Factors for Free Flap Failure: A Retrospective Analysis of 881 Free Flaps for Head and Neck Defect Reconstruction,&#x201d; International Journal of Oral and Maxillofacial Surgery 46, no. 8 (2017): 941&#x2013;945.</Citation></Reference><Reference><Citation>M. Daabiss, &#x201c;American Society of Anaesthesiologists Physical Status Classification,&#x201d; Indian Journal of Anaesthesia 55, no. 2 (2011): 111&#x2013;115.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70131 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41386690</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Dec</Month><Day>12</Day></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Application of Acellular Dermal Matrix With or Without Flap Repair in Postoperative Defect Repair of Hypopharyngeal Carcinoma.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70131</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The reconstruction of hypopharyngeal tumor defect after tumorectomy is essential. Artificial materials play an important role in the case of extensive defects and a relative lack of healthy tissue. This study aims to investigate the role of acellular dermal matrix (ADM) in repairing defects following hypopharyngeal carcinoma resection.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A retrospective analysis was conducted on 280 patients with hypopharyngeal carcinoma. 143 patients accepted ADM-assisted reconstruction while 137 patients didn't. Data on postoperative deglutition function, respiratory function, and complications were collected and analyzed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">No immune rejection response was observed. In partial laryngectomy, ADM significantly induces the time for hospitalization, decannulation, and oral food intake compared to the control group (p&#x2009;&lt;&#x2009;0.05). In total laryngectomy, ADM has advantages in terms of the number of individuals with good deglutition function (p&#x2009;&lt;&#x2009;0.05). There is no significant difference in pharyngocutaneous fistula.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">ADM is a promising biomaterial for reconstruction in hypopharyngeal carcinoma. It offers advantages such as a high success rate, good graft survival, accessibility, minimal immunogenicity, and simplified surgical procedures.</AbstractText><CopyrightInformation>&#xa9; 2025 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Zhiyan</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0009-0005-2417-5002</Identifier><AffiliationInfo><Affiliation>ENT Institute and Department of Otorhinolaryngology, Eye &amp; ENT Hospital, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>ENT Institute and Department of Otorhinolaryngology, Eye &amp; ENT Hospital, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-9715-7236</Identifier><AffiliationInfo><Affiliation>ENT Institute and Department of Otorhinolaryngology, Eye &amp; ENT Hospital, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yimiao</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>ENT Institute and Department of Otorhinolaryngology, Eye &amp; ENT Hospital, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Siyi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>ENT Institute and Department of Otorhinolaryngology, Eye &amp; ENT Hospital, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Shuaichi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>ENT Institute and Department of Otorhinolaryngology, Eye &amp; ENT Hospital, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pang</LastName><ForeName>Kexin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>ENT Institute and Department of Otorhinolaryngology, Eye &amp; ENT Hospital, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Chen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>ENT Institute and Department of Otorhinolaryngology, Eye &amp; ENT Hospital, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoang</LastName><ForeName>Harry</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Otorhinolaryngology and Head &amp; Neck Surgery, Department of Clinical Neurosciences, Geneva University Hospitals, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shu</LastName><ForeName>Min</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>ENT Institute and Department of Otorhinolaryngology, Eye &amp; ENT Hospital, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>ENT Institute and Department of Otorhinolaryngology, Eye &amp; ENT Hospital, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>ENT Institute and Department of Otorhinolaryngology, Eye &amp; ENT Hospital, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Haitao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>ENT Institute and Department of Otorhinolaryngology, Eye &amp; ENT Hospital, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Peijie</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>ENT Institute and Department of Otorhinolaryngology, Eye &amp; ENT Hospital, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>81870710</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>202340219</GrantID><Agency>Project of Shanghai Municipal Health Commission</Agency><Country/></Grant><Grant><GrantID>2024DR033</GrantID><Agency>China University Industry-Academia-Research Innovation Fund</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">acellular dermal matrix</Keyword><Keyword MajorTopicYN="N">artificial biological material</Keyword><Keyword MajorTopicYN="N">flap</Keyword><Keyword MajorTopicYN="N">hypopharyngeal carcinoma</Keyword><Keyword MajorTopicYN="N">reconstruction</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>11</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>9</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>13</Day><Hour>0</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>13</Day><Hour>0</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>12</Day><Hour>20</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41386690</ArticleId><ArticleId IdType="doi">10.1002/hed.70131</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>J. P. Machiels, C. REN&#xe9; LEEMANS, W. Golusinski, C. Grau, L. Licitra, and V. Gregoire, &#x201c;Squamous Cell Carcinoma of the Oral Cavity, Larynx, Oropharynx and Hypopharynx: EHNS&#x2010;ESMO&#x2010;ESTRO Clinical Practice Guidelines for Diagnosis, Treatment and Follow&#x2010;Up,&#x201d; Annals of Oncology 31, no. 11 (2020): 1462&#x2013;1475.</Citation></Reference><Reference><Citation>Y. H. Hua, Q. Y. Hu, Y. F. Piao, et&#xa0;al., &#x201c;Effect of Number and Ratio of Positive Lymph Nodes in Hypopharyngeal Cancer,&#x201d; Head &amp; Neck 37, no. 1 (2015): 111&#x2013;116.</Citation></Reference><Reference><Citation>G. C. Spyropoulou, P. Y. Lin, C. Y. Chien, et&#xa0;al., &#x201c;Reconstruction of the Hypopharynx With the Anterolateral Thigh Flap: Defect Classification, Method, Tips, and Outcomes,&#x201d; Plastic and Reconstructive Surgery 127, no. 1 (2011): 161&#x2013;172.</Citation></Reference><Reference><Citation>C. A. Righini, G. Bettega, T. Lequeux, P. Chaffanjeon, J. Lebeau, and E. Reyt, &#x201c;Use of Tubed Gastro&#x2010;Omental Free Flap for Hypopharynx and Cervical Esophagus Reconstruction After Total Laryngo&#x2010;Pharyngectomy,&#x201d; European Archives of Oto&#x2010;Rhino&#x2010;Laryngology 262, no. 5 (2005): 362&#x2013;367.</Citation></Reference><Reference><Citation>L. Li, L. Fan, Z. Jiang, et&#xa0;al., &#x201c;Pedicled Flaps Reconstruction of Hypopharynx and Laryngeal Defects: Successful Preservation of Laryngeal Function in Patients With Advanced Hypopharyngeal Cancer,&#x201d; Head &amp; Neck 46, no. 5 (2024): 49&#x2013;56.</Citation></Reference><Reference><Citation>N. M. Haney, M. M. Huang, J. L. Liu, D. J. Hawksworth, and A. L. Burnett, &#x201c;Acellular Dermal Matrix Tissues in Genitourinary Reconstructive Surgery: A Review of the Literature and Case Discussions,&#x201d; Sexual Medicine Reviews 9, no. 3 (2021): 488&#x2013;497.</Citation></Reference><Reference><Citation>M. I. Du Plessis, P. S. Cottler, and C. A. Campbell, &#x201c;Acellular Dermal Matrix Favorably Modulates the Healing Response After Surgery,&#x201d; Plastic and Reconstructive Surgery 150, no. 2 (2022): 290e&#x2013;299e.</Citation></Reference><Reference><Citation>M. Gierek, W. &#x141;abu&#x15b;, D. Kitala, et&#xa0;al., &#x201c;Human Acellular Dermal Matrix in Reconstructive Surgery&#x2010;A Review,&#x201d; Biomedicine 10, no. 11 (2022): 2870.</Citation></Reference><Reference><Citation>R. S. Kirsner, G. Bohn, V. R. Driver, et&#xa0;al., &#x201c;Human Acellular Dermal Wound Matrix: Evidence and Experience,&#x201d; International Wound Journal 12, no. 6 (2015): 646&#x2013;654.</Citation></Reference><Reference><Citation>A. Hui, P. Hong, and M. Bezuhly, &#x201c;Use of Acellular Dermal Matrices in Laryngotracheal and Pharyngeal Reconstruction: Systematic Review,&#x201d; Journal of Laryngology and Otology 131, no. 7 (2017): 585&#x2013;592.</Citation></Reference><Reference><Citation>J. W. Refos, B. I. Witte, C. J. De Goede, et&#xa0;al., &#x201c;Shoulder Morbidity After Pectoralis Major Flap Reconstruction,&#x201d; Head &amp; Neck 38, no. 8 (2016): 1221&#x2013;1228.</Citation></Reference><Reference><Citation>J. Y. W. Chan, R. C. L. Chan, V. L. Y. Chow, et&#xa0;al., &#x201c;Transoral Robotic Total Laryngopharyngectomy and Free Jejunal Flap Reconstruction for Hypopharyngeal Cancer [J],&#x201d; Oral Oncology 72 (2017): 194&#x2013;196.</Citation></Reference><Reference><Citation>Y. Heng, D. Zhang, X. Zhu, et&#xa0;al., &#x201c;Hypopharynx Reconstruction for Primary Hypopharyngeal Carcinoma: A Retrospective Study and Literature Review [J],&#x201d; Translational Cancer Research 10, no. 7 (2021): 3236&#x2013;3247.</Citation></Reference><Reference><Citation>Y. Zhou, Z. Zhang, H. Chen, et&#xa0;al., &#x201c;Application of Acellular Dermal Matrix to Reconstruct the Defects After Hypopharyngeal Carcinoma Resection [J],&#x201d; American Journal of Otolaryngology 42, no. 2 (2021): 102847.</Citation></Reference><Reference><Citation>U. K. Sinha, K. E. Chang, and C. W. Shih, &#x201c;Reconstruction of Pharyngeal Defects Using AlloDerm and Sternocleidomastoid Muscle Flap [J],&#x201d; Laryngoscope 111, no. 11 Pt 1 (2001): 1910&#x2013;1916.</Citation></Reference><Reference><Citation>J. He, Y. Tian, P. Wu, et&#xa0;al., &#x201c;Heterogeneous Bovine Acellular Dermal Matrix for Mucosal Repair in Reconstructive Surgery for Laryngeal and Hypopharyngeal Carcinoma [J],&#x201d; Oncology Research and Treatment 38, no. 6 (2015): 282&#x2013;284.</Citation></Reference><Reference><Citation>J. Zang, S. Feng, H. Yang, et&#xa0;al., &#x201c;Comparison of Xenogeneic Acellular Dermal Matrix and Skin Grafts in Reconstruction of Postoperative Defects of Hypopharyngeal Cancer: A Retrospective Cohort Study [J],&#x201d; Medicine 99, no. 9 (2020): e19361.</Citation></Reference><Reference><Citation>J. W. Liang, Z. D. Li, S. C. Li, et&#xa0;al., &#x201c;Pharyngocutaneous Fistula After Total Laryngectomy: A Systematic Review and Meta&#x2010;Analysis of Risk Factors [J],&#x201d; Auris, Nasus, Larynx 42, no. 5 (2015): 353&#x2013;359.</Citation></Reference><Reference><Citation>M. Wang, Y. Xun, K. Wang, et&#xa0;al., &#x201c;Risk Factors of Pharyngocutaneous Fistula After Total Laryngectomy: A Systematic Review and Meta&#x2010;Analysis [J],&#x201d; European Archives of Oto&#x2010;Rhino&#x2010;Laryngology 277, no. 2 (2020): 585&#x2013;599.</Citation></Reference><Reference><Citation>Y. Heng, C. Xu, H. Lin, et&#xa0;al., &#x201c;Recurrence Risk Stratification and Treatment Strategies of Patients With Stage IVa&#x2010;b Hypopharyngeal Squamous Cell Carcinoma [J],&#x201d; Head &amp; Neck 44, no. 9 (2022): 2030&#x2013;2039.</Citation></Reference><Reference><Citation>R. Israeli and R. S. Feingold, &#x201c;Acellular Dermal Matrix in Breast Reconstruction in the Setting of Radiotherapy,&#x201d; Aesthetic Surgery Journal 31, no. 7 (2011): 51s&#x2013;64s.</Citation></Reference><Reference><Citation>M. G. Dubin, M. Feldman, H. Z. Ibrahim, et&#xa0;al., &#x201c;Allograft Dermal Implant (AlloDerm) in a Previously Irradiated Field,&#x201d; Laryngoscope 110, no. 6 (2000): 934&#x2013;937.</Citation></Reference><Reference><Citation>H. Z. Ibrahim, T. J. Kwiatkowski, K. T. Montone, et&#xa0;al., &#x201c;Effects of External Beam Radiation on the Allograft Dermal Implant,&#x201d; Otolaryngology and Head and Neck Surgery 122, no. 2 (2000): 189&#x2013;194.</Citation></Reference><Reference><Citation>L. Zhang, J. P. Cheng, W. C. Zhang, W. Li, and M. Anniko, &#x201c;Reconstruction of Defects Following Surgery for Hypopharyngeal Carcinoma Using Artificial Biological Material,&#x201d; Acta Oto&#x2010;Laryngologica 130, no. 11 (2010): 1293&#x2013;1299.</Citation></Reference><Reference><Citation>D. Yin, Q. Tang, S. Wang, et&#xa0;al., &#x201c;Xenogeneic Acellular Dermal Matrix in Combination With Pectoralis Major Myocutaneous Flap Reconstructs Hypopharynx and Cervical Esophagus,&#x201d; European Archives of Oto&#x2010;Rhino&#x2010;Laryngology 272, no. 11 (2015): 3457&#x2013;3461.</Citation></Reference><Reference><Citation>N. Kadapa, K. Mangale, P. Watve, L. M. C. Rao S, A. K. Raju, and T. Subramanyeshwar Rao, &#x201c;Postcricoid Carcinoma: Is Organ Preservation Justified in T3?,&#x201d; Laryngoscope 125, no. 2 (2015): 356&#x2013;359.</Citation></Reference><Reference><Citation>R. De Bree, C. R. Leemans, C. E. Silver, et&#xa0;al., &#x201c;Paratracheal Lymph Node Dissection in Cancer of the Larynx, Hypopharynx, and Cervical Esophagus: The Need for Guidelines,&#x201d; Head &amp; Neck 33, no. 6 (2011): 912&#x2013;916.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70128 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41386731</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Dec</Month><Day>12</Day></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Intraoperat&#x131;ve Nerve Mon&#x131;tor&#x131;ng Dur&#x131;ng Thyro&#x131;dectomy Can Reduce the Injury to the External Branch of the Super&#x131;or Laryngeal Nerve Dur&#x131;ng Super&#x131;or Thyro&#x131;d Pole D&#x131;ssect&#x131;on: A Prospective Randomized Study.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70128</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The primary aim of this study was to characterize the prevalence of external branch of the superior laryngeal nerve (EBSLN) injury with and without the use of intraoperative neuromonitoring (IONM) and identify factors associated with injury.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients referred to our clinic for thyroidectomy between June 2015 and June 2016 were prospectively randomized into two groups (single-blinded): in Group 1, IONM was used during upper pole dissection only for the management of the recurrent laryngeal nerve (RLN); in Group 2, IONM was used for both RLN and EBSLN management. After thyroidectomy completion in all patients, cricothyroid muscle (CTM) EMG was performed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">EBSLN injury was significantly higher in Group 1 (15.4 vs. 2.1% of NAR, p&#x2009;&lt;&#x2009;0.001). EBSLN injury was detected in 23 (9.4%) of 245 Friedman type 1, in 7 (18.9%) of 37 Friedman type 2, and in 3 (3.2%) of 94 Friedman type 3 nerves.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">EBSLN injury is often a transection injury associated with permanent EBSLN dysfunction. Use of IONM facilitates the prevention of EBSLN injury.</AbstractText><CopyrightInformation>&#xa9; 2025 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Aygun</LastName><ForeName>Nurcihan</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-7353-8245</Identifier><AffiliationInfo><Affiliation>Department of General Surgery, Division of Endocrine Surgery, University of Health Sciences, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Russell</LastName><ForeName>Marika D</ForeName><Initials>MD</Initials><Identifier Source="ORCID">0000-0001-5436-3649</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Division of Thyroid and Parathyroid Endocrine Surgery, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kartal</LastName><ForeName>Kinyas</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Yeditepe University Kozyatag&#x131; Hospital, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Isgor</LastName><ForeName>Adnan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Sisli Memorial Hospital, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Randolph</LastName><ForeName>Gregory W</ForeName><Initials>GW</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Division of Thyroid and Parathyroid Endocrine Surgery, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uludag</LastName><ForeName>Mehmet</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Division of Endocrine Surgery, University of Health Sciences, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cricothyroid muscle</Keyword><Keyword MajorTopicYN="N">external branch of the superior laryngeal nerve</Keyword><Keyword MajorTopicYN="N">intraoperative nerve monitoring</Keyword><Keyword MajorTopicYN="N">superior thyroid pole dissection</Keyword><Keyword MajorTopicYN="N">thyroidectomy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>10</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>13</Day><Hour>0</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>13</Day><Hour>0</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>12</Day><Hour>20</Hour><Minute>26</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41386731</ArticleId><ArticleId IdType="doi">10.1002/hed.70128</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>G. Grover, G. P. Sadler, and R. Mihai, &#x201c;Morbidity After Thyroid Surgery: Patient Perspective,&#x201d; Laryngoscope 123 (2013): 2319&#x2013;2323.</Citation></Reference><Reference><Citation>I. C. Nam and Y. H. Park, &#x201c;Pharyngolaryngeal Symptoms Associated With Thyroid Disease,&#x201d; Current Opinion in Otolaryngology &amp; Head and Neck Surgery 25, no. 6 (2017): 469&#x2013;474, https://doi.org/10.1097/MOO.0000000000000404.</Citation></Reference><Reference><Citation>J. P. Jeannon, A. A. Orabi, G. A. Bruch, H. A. Abdalsalam, and R. Simo, &#x201c;Diagnosis of Recurrent Laryngeal Nerve Palsy After Thyroidectomy: A Systematic Review,&#x201d; International Journal of Clinical Practice 63, no. 4 (2009): 624&#x2013;629, https://doi.org/10.1111/j.1742&#x2010;1241.2008.01875.x.</Citation></Reference><Reference><Citation>S. Jansson, L. E. Tisell, I. Hagne, et&#xa0;al., &#x201c;Partial Superior Laryngeal Nerve (SLN) Lesions Before and After Thyroid Surgery,&#x201d; World Journal of Surgery 12 (1988): 522&#x2013;527.</Citation></Reference><Reference><Citation>M. Barczynski, G. W. Randolph, C. R. Cernea, et&#xa0;al., &#x201c;External Branch of the Superior Laryngeal Nerve Monitoring During Thyroid and Parathyroid Surgery: International Neural Monitoring Study Group Standards Guideline Statement,&#x201d; Laryngoscope 123, no. 4 (2013): 1&#x2013;14.</Citation></Reference><Reference><Citation>R. Bellantone, M. Boscherini, C. P. Lombardi, et&#xa0;al., &#x201c;Is the Identification of the External Branch of the Superior Laryngeal Nerve Mandatory in Thyroid Operation? Results of a Prospective Randomized Study,&#x201d; Surgery 130 (2001): 1055&#x2013;1059.</Citation></Reference><Reference><Citation>S. Lennquist, C. Cahlin, and S. Smeds, &#x201c;The Superior Laryngeal Nerve in Thyroid Surgery,&#x201d; Surgery 102 (1987): 999&#x2013;1008.</Citation></Reference><Reference><Citation>A. Ritter, I. Ganly, R. J. Wong, et&#xa0;al., &#x201c;Intraoperative Nerve Monitoring Is Used Routinely by a Significant Majority of Head and Neck Surgeons in Thyroid Surgery and Impacts on Extent of Surgery&#x2010;Survey of the American Head and Neck Society,&#x201d; Head &amp; Neck 42, no. 8 (2020): 1757&#x2013;1764, https://doi.org/10.1002/hed.26093.</Citation></Reference><Reference><Citation>M. Barczy&#x144;ski, G. W. Randolph, C. Cernea, and International Neural Monitoring Study Group in Thyroid and Parathyroid Surgery, &#x201c;International Survey on the Identification and Neural Monitoring of the EBSLN During Thyroidectomy,&#x201d; Laryngoscope 126, no. 1 (2016): 285&#x2013;291.</Citation></Reference><Reference><Citation>M. Naytah, I. Ibrahim, and S. da Silva, &#x201c;Importance of Incorporating Intraoperative Neuromonitoring of the External Branch of the Superior Laryngeal Nerve in Thyroidectomy: A Review and Meta&#x2010;Analysis Study,&#x201d; Head &amp; Neck 41, no. 6 (2019): 2034&#x2013;2041.</Citation></Reference><Reference><Citation>M. Uludag, N. Aygun, K. Kartal, E. Besler, and A. Isgor, &#x201c;Is Intraoperative Neural Monitoring Necessary for Exploration of the Superior Laryngeal Nerve?,&#x201d; Surgery 161, no. 4 (2017): 1129&#x2013;1138.</Citation></Reference><Reference><Citation>M. Uludag, N. Aygun, K. Kartal, et&#xa0;al., &#x201c;Contribution of Intraoperative Neural Monitoring to Preservation of the External Branch of the Superior Laryngeal Nerve: A Randomized Prospective Clinical Trial Langenbecks Arch Surg,&#x201d; Langenbeck's Archives of Surgery 402, no. 6 (2017): 965&#x2013;976.</Citation></Reference><Reference><Citation>M. Uludag, N. Aygun, and A. Isgor, &#x201c;Motor Function of the Recurrent Laryngeal Nerve: Sometimes Motor Fibers Are Also Located in the Posterior Branch,&#x201d; Surgery 160 (2016): 153&#x2013;160.</Citation></Reference><Reference><Citation>K. Kartal, N. Aygun, M. F. Celayir, et&#xa0;al., &#x201c;Intraoperative Neuromonitoring in Thyroid Surgery: An Efficient Tool to Avoid Bilateral Vocal Cord Palsy,&#x201d; Ear, Nose, &amp; Throat Journal 100, no. 5 (2021): 694&#x2013;699, https://doi.org/10.1177/0145561320906325.</Citation></Reference><Reference><Citation>C. Martin&#x2010;Oviedo, E. Maranillo, A. Lowy&#x2010;Benoliel, et&#xa0;al., &#x201c;Functional Role of Human Laryngeal Nerve Connections,&#x201d; Laryngoscope 21 (2011): 2338&#x2013;2343, https://doi.org/10.1002/lary.22340.</Citation></Reference><Reference><Citation>M. Uludag, N. Aygun, and A. Isgor, &#x201c;Innervation of the Human Cricopharyngeal Muscle by the Recurrent Laryngeal Nerve and External Branch of the Superior Laryngeal Nerve,&#x201d; Langenbeck's Archives of Surgery 402, no. 4 (2017): 683&#x2013;690, https://doi.org/10.1007/s00423&#x2010;016&#x2010;1376&#x2010;5.</Citation></Reference><Reference><Citation>R. Schneider, G. W. Randolph, G. Dionigi, et&#xa0;al., &#x201c;International Neural Monitoring Study Group Guideline 2018 Part I: Staging Bilateral Thyroid Surgery With Monitoring Loss of Signal,&#x201d; Laryngoscope 128, no. 3 (2018): 1&#x2013;17, https://doi.org/10.1002/lary.27359.</Citation></Reference><Reference><Citation>M. Friedman, P. LoSavio, and H. Ibrahim, &#x201c;Superior Laryngeal Nerve Identification and Preservation in Thyroidectomy,&#x201d; Archives of Otolaryngology &#x2013; Head &amp; Neck Surgery 128 (2002): 296&#x2013;303.</Citation></Reference><Reference><Citation>A. Sanabria, A. Ramirez, L. P. Kowalski, et&#xa0;al., &#x201c;Neuromonitoring in Thyroidectomy: A Meta&#x2010;Analysis of Effectiveness From Randomized Controlled Trials,&#x201d; European Archives of Oto&#x2010;Rhino&#x2010;Laryngology 270 (2013): 2175&#x2013;2189.</Citation></Reference><Reference><Citation>B. Selvan, S. Babu, M. J. Paul, D. Abraham, P. Samuel, and A. Nair, &#x201c;Mapping the Compound Muscle Action Potentials of Cricothyroid Muscle Using Electromyography in Thyroid Operations: A Novel Method to Clinically Type the External Branch of the Superior Laryngeal Nerve,&#x201d; Annals of Surgery 250 (2009): 293&#x2013;300.</Citation></Reference><Reference><Citation>G. Dionigi, H. Y. Kim, G. W. Randolph, et&#xa0;al., &#x201c;Prospective Validation Study of Cernea Classification for Predicting EMG Alterations of the External Branch of the Superior Laryngeal Nerve,&#x201d; Surgery Today 46 (2016): 785&#x2013;791.</Citation></Reference><Reference><Citation>H. Masuoka, A. Miyauchi, T. Higashiyama, et&#xa0;al., &#x201c;Prospective Randomized Study on Injury of the External Branch of the Superior Laryngeal Nerve During Thyroidectomy Comparing Intraoperative Nerve Monitoring and a Conventional Technique,&#x201d; Head &amp; Neck 37 (2015): 1456&#x2013;1460.</Citation></Reference><Reference><Citation>M. Barczy&#x144;ski, A. Konturek, M. Stopa, A. Honowska, and W. Nowak, &#x201c;Randomized Controlled Trial of Visualization Versus Neuromonitoring of the External Branch of the Superior Laryngeal Nerve During Thyroidectomy,&#x201d; World Journal of Surgery 36 (2012): 1340&#x2013;1347.</Citation></Reference><Reference><Citation>A. R. Glover, O. Norl&#xe9;n, J. S. Gundara, M. Morris, and S. B. Sidhu, &#x201c;Use of the Nerve Integrity Monitor During Thyroid Surgery Aids Identification of the External Branch of the Superior Laryngeal Nerve,&#x201d; Annals of Surgical Oncology 22 (2015): 1768&#x2013;1773.</Citation></Reference><Reference><Citation>L. M. Hurtado&#x2010;L&#xf3;pez, P. I. D&#xed;az&#x2010;Hern&#xe1;ndez, E. Basurto&#x2010;Kuba, F. R. Zald&#xed;var&#x2010;Ram&#xed;rez, and A. Pulido&#x2010;Cejudo, &#x201c;Efficacy of Intraoperative Neuro&#x2010;Monitoring to Localize the External Branch of the Superior Laryngeal Nerve,&#x201d; Thyroid 26 (2016): 174&#x2013;178.</Citation></Reference><Reference><Citation>A. F. Engelsman, S. Warhurst, S. Fraser, D. Novakovic, and S. B. Sidhu, &#x201c;Influence of Neural Monitoring During Thyroid Surgery on Nerve Integrity and Postoperative Vocal Function,&#x201d; BJS Open 2, no. 3 (2018): 135&#x2013;141.</Citation></Reference><Reference><Citation>J. Lee, S. Fraser, A. Glover, and S. Sidhu, &#x201c;Prospective e Valuation of the Utility of Routine Neuromonitoring for an Established Thyroid Surgical Practice,&#x201d; ANZ Journal of Surgery 87, no. 10 (2017): 138&#x2013;142.</Citation></Reference><Reference><Citation>L. M. Hurtado&#x2010;L&#xf3;pez, M. I. Pacheco&#x2010;Alvarez, M. L. Montes&#x2010;Castillo, F. R. Zald&#xed;var&#x2010;Ram&#xed;rez, and A. Pulido&#x2010;Cejudo, &#x201c;Importance of the Intraoperative Identification of the External Branch of the Superiorlaryngeal Nerve During Thyroidectomy: Electromyographic Evaluation,&#x201d; Thyroid 15 (2005): 449&#x2013;454.</Citation></Reference><Reference><Citation>C. R. Cernea, A. R. Ferraz, J. Furlani, et&#xa0;al., &#x201c;Identification of the External Branch of the Superior Laryngeal Nerve During Thyroidectomy,&#x201d; American Journal of Surgery 164, no. 6 (1992): 634&#x2013;639.</Citation></Reference><Reference><Citation>I. Cheruiyot, V. Kipkorir, B. M. Henry, et&#xa0;al., &#x201c;Surgical Anatomy of the External Branch of the Superior Laryngeal Nerve: A Systematic Review and Meta&#x2010;Analysis,&#x201d; Langenbeck's Archives of Surgery 403, no. 7 (2018): 811&#x2013;823.</Citation></Reference><Reference><Citation>C. J. De Luca, M. Kuznetsov, L. D. Gilmore, and S. H. Roy, &#x201c;Inter&#x2010;Electrode Spacing of Surface EMG Sensors: Reduction of Crosstalk Contamination During Voluntary Contractions,&#x201d; Journal of Biomechanics 45 (2012): 555&#x2013;561.</Citation></Reference><Reference><Citation>N. Ayg&#xfc;n, M. Uluda&#x11f;, and A. &#x130;&#x15f;g&#xf6;r, &#x201c;Contribution of Intraoperative Neuromonitoring to the Identification of the External Branch of Superior Laryngeal Nerve,&#x201d; Turkish Journal of Surgery 33, no. 3 (2017): 169&#x2013;174.</Citation></Reference><Reference><Citation>A. S. Potenza, V. J. F. Araujo Filho, and C. R. Cernea, &#x201c;Injury of the External Branch of the Superior Laryngeal Nerve in Thyroid Surgery,&#x201d; Gland Surgery 6, no. 5 (2017): 552&#x2013;562.</Citation></Reference><Reference><Citation>M. K. Applewhite, M. G. White, B. C. James, et&#xa0;al., &#x201c;Ultrasonic, Bipolar, and Integrated Energy Devices: Comparing Heat Spread in Collateral Tissues,&#x201d; Journal of Surgical Research 207 (2017): 249&#x2013;254.</Citation></Reference><Reference><Citation>C. W. Wu, G. Dionigi, H. Sun, et&#xa0;al., &#x201c;Intraoperative Neuromonitoring for the Early Detection and Prevention of RLN Traction Injury in Thyroid Surgery,&#x201d; Surgery 155, no. 2 (2014): 329&#x2013;339.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70125 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41386708</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Dec</Month><Day>12</Day></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Medial Sural Artery Perforator Flap Radiographic Vascular Characteristics.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70125</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Medial sural artery perforator (MSAP) flaps are favored in head and neck reconstruction for skin paddle pliability, pedicle length, and low donor site morbidity. We sought to characterize MSA vascular branching patterns based on the Dusseldorp et&#xa0;al. classification system using pre-operative lower extremity computed tomography angiogram (CTA).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a retrospective review of 153 scans from 78 patients who underwent CTA prior to head and neck reconstruction at our institution. Primary data points included MSA branching pattern, branch dominance, and vessel depth.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The type IIa branching type was most prevalent and the MSA lateral branch most frequently dominant, and they were significantly related to one another. There was no significant difference in depth between branching patterns.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Lower extremity CTA provides valuable insight to vascular anatomy for MSAP flap harvest. The type IIa and IIb types may be associated with lateral and medial MSA dominance, respectively.</AbstractText><CopyrightInformation>&#xa9; 2025 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cirelli</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials><Suffix>Jr</Suffix><Identifier Source="ORCID">0009-0007-4561-8049</Identifier><AffiliationInfo><Affiliation>Mayo Clinic Alix School of Medicine, Mayo Clinic, Phoenix, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hintze</LastName><ForeName>Justin M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology - Head &amp; Neck Surgery, Mayo Clinic Arizona, Phoenix, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cave</LastName><ForeName>Taylor B</ForeName><Initials>TB</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology - Head &amp; Neck Surgery, Mayo Clinic Arizona, Phoenix, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>ALNafisee</LastName><ForeName>Daniah</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Plastic &amp; Reconstructive Surgery, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rath</LastName><ForeName>Tanya J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Department of Radiology, Mayo Clinic Arizona, Phoenix, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Brent A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology - Head &amp; Neck Surgery, Mayo Clinic Arizona, Phoenix, Arizona, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">computerized tomography (CT) imaging</Keyword><Keyword MajorTopicYN="N">free flap reconstruction</Keyword><Keyword MajorTopicYN="N">maximum intensity projection (MIP) imaging</Keyword><Keyword MajorTopicYN="N">medial sural artery</Keyword><Keyword MajorTopicYN="N">perforator</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>10</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>11</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>13</Day><Hour>0</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>13</Day><Hour>0</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>12</Day><Hour>20</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41386708</ArticleId><ArticleId IdType="doi">10.1002/hed.70125</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>G. I. Taylor and K. R. Daniel, &#x201c;The Anatomy of Several Free Flap Donor Sites,&#x201d; Plastic and Reconstructive Surgery 56 (1975): 243&#x2013;253.</Citation></Reference><Reference><Citation>W. J. Montegut, R. J. Allen, W. J. Montegut, and R. J. Allen, &#x201c;Sural Artery Perforator Flap as an Alternative for the Gastrocnemius Myocutaneous Flap,&#x201d; Proceedings from the 90th Annual Scientific Assembly of the Southern Medical Association (1996).</Citation></Reference><Reference><Citation>G. G. Hallock, &#x201c;Anatomic Basis of the Gastrocnemius Perforator&#x2010;Based Flap,&#x201d; Annals of Plastic Surgery 47, no. 5 (2001): 517&#x2013;522.</Citation></Reference><Reference><Citation>P. C. Cavadas, J. R. Sanz&#x2010;Gim&#xe9;nez&#x2010;Rico, A. la Gutierrez&#x2010;De C&#xe1;mara, A. Navarro&#x2010;Monzon&#xed;s, S. Soler&#x2010;Nomdedeu, and F. Mart&#xed;nez&#x2010;Soriano, &#x201c;The Medial Sural Artery Perforator Free Flap,&#x201d; Plastic and Reconstructive Surgery 108, no. 6 (2001): 1609&#x2013;1615.</Citation></Reference><Reference><Citation>S. J. Mathes and F. Nahai, &#x201c;Classification of the Vascular Anatomy of Muscles: Experimental and Clinical Correlation,&#x201d; Plastic and Reconstructive Surgery 67, no. 2 (1981): 177&#x2013;187.</Citation></Reference><Reference><Citation>X. Wang, J. Mei, J. Pan, H. Chen, W. Zhang, and M. Tang, &#x201c;Reconstruction of Distal Limb Defects With the Free Medial Sural Artery Perforator Flap,&#x201d; Plastic and Reconstructive Surgery 131, no. 1 (2013): 95&#x2013;105, https://doi.org/10.1097/PRS.0b013e3182729e3c.</Citation></Reference><Reference><Citation>D. A. Daar, S. A. Abdou, J. M. Cohen, S. C. Wilson, and J. P. Levine, &#x201c;Is the Medial Sural Artery Perforator Flap a New Workhorse Flap? A Systematic Review and Meta&#x2010;Analysis,&#x201d; Plastic and Reconstructive Surgery 143 (2019): 393e&#x2013;403e, https://doi.org/10.1097/PRS.0000000000005204.</Citation></Reference><Reference><Citation>J. R. Dusseldorp, Q. J. Pham, Q. Ngo, M. Gianoutsos, and P. Moradi, &#x201c;Vascular Anatomy of the Medial Sural Artery Perforator Flap: A New Classification System of Intra&#x2010;Muscular Branching Patterns,&#x201d; Journal of Plastic, Reconstructive &amp; Aesthetic Surgery 67, no. 9 (2014): 1267&#x2013;1275, https://doi.org/10.1016/j.bjps.2014.05.016.</Citation></Reference><Reference><Citation>X. Sui, U. Z. Khan, L. Qing, F. Yu, P. Wu, and J. Tang, &#x201c;The Free Chimeric Medial Sural Artery Perforator Flap for Individualised and Three&#x2010;Dimensional Reconstruction of Complex Soft&#x2010;Tissue Defects in Extremities,&#x201d; International Wound Journal 20, no. 7 (2023): 2679&#x2013;2687, https://doi.org/10.1111/iwj.14142.</Citation></Reference><Reference><Citation>C. H. Lee, N. J. T. Chang, J. C. Hsiao, Y.&#x2010;Y. Chu, C.&#x2010;H. Lin, and H.&#x2010;K. Kao, &#x201c;Extended Use of Chimeric Medial Sural Artery Perforator Flap for 3&#x2010;Dimensional Defect Reconstruction,&#x201d; Annals of Plastic Surgery 82, no. 1S Suppl 1 (2019): S86&#x2013;S94, https://doi.org/10.1097/SAP.0000000000001697.</Citation></Reference><Reference><Citation>M. J. M. Ng, C. S. L. Goh, N. C. Tan, D. H. Song, and A. S. H. Ooi, &#x201c;A Head&#x2010;To&#x2010;Head Comparison of the Medial Sural Artery Perforator Versus Radial Forearm Flap for Tongue Reconstruction,&#x201d; Journal of Reconstructive Microsurgery 37, no. 5 (2021): 445&#x2013;452, https://doi.org/10.1055/s&#x2010;0040&#x2010;1718551.</Citation></Reference><Reference><Citation>N. F. A. L. Deek, J. C. Hsiao, N. T. Do, et&#xa0;al., &#x201c;The Medial Sural Artery Perforator Flap: Lessons Learned From 200 Consecutive Cases,&#x201d; Plastic and Reconstructive Surgery 146 (2020): 630E&#x2013;641E, https://doi.org/10.1097/PRS.0000000000007282.</Citation></Reference><Reference><Citation>Y. He, S. F. Jin, Z. Y. Zhang, S. Q. Feng, C. P. Zhang, and Y. X. Zhang, &#x201c;A Prospective Study of Medial Sural Artery Perforator Flap With Computed Tomographic Angiography&#x2010;Aided Design in Tongue Reconstruction,&#x201d; Journal of Oral and Maxillofacial Surgery 72, no. 11 (2014): 2351&#x2013;2365, https://doi.org/10.1016/j.joms.2014.05.019.</Citation></Reference><Reference><Citation>G. Agrawal, A. Gupta, V. Chaudhary, F. Qureshi, A. Choraria, and H. Dubey, &#x201c;Medial Sural Artery Perforator Flap for Head and Neck Reconstruction,&#x201d; Annals of Maxillofacial Surgery 8, no. 1 (2018): 61&#x2013;65, https://doi.org/10.4103/ams.ams_137_17.</Citation></Reference><Reference><Citation>A. Gulati, P. Patel, N. Maini, et&#xa0;al., &#x201c;Medial Sural Artery Perforator Flap&#x2014;Indications, Tips and Pitfalls,&#x201d; Frontiers of Oral and Maxillofacial Medicine 3 (2021): 1&#x2013;7, https://doi.org/10.21037/fomm&#x2010;2021&#x2010;01.</Citation></Reference><Reference><Citation>Y. Al Omran, E. Evans, C. Jordan, et&#xa0;al., &#x201c;The Medial Sural Artery Perforator Flap Versus Other Free Flaps in Head and Neck Reconstruction: A Systematic Review,&#x201d; Archives of Plastic Surgery 50, no. 3 (2022): 264&#x2013;273, https://doi.org/10.1055/a&#x2010;2059&#x2010;4009.</Citation></Reference><Reference><Citation>H. K. Kao, K. P. Chang, F. C. Wei, and M. H. Cheng, &#x201c;Comparison of the Medial Sural Artery Perforator Flap With the Radial Forearm Flap for Head and Neck Reconstructions,&#x201d; Plastic and Reconstructive Surgery 124, no. 4 (2009): 1125&#x2013;1132, https://doi.org/10.1097/PRS.0b013e3181b457cf.</Citation></Reference><Reference><Citation>X. Song, H. Wu, W. Zhang, et&#xa0;al., &#x201c;Medial Sural Artery Perforator Flap for Postsurgical Reconstruction of Head and Neck Cancer,&#x201d; Journal of Reconstructive Microsurgery 4 (2015): 319&#x2013;326, https://doi.org/10.1055/s&#x2010;0035&#x2010;1544180.</Citation></Reference><Reference><Citation>W. Zhao, Z. Li, L. Wu, H. Zhu, J. Liu, and H. Wang, &#x201c;Medial Sural Artery Perforator Flap Aided by Ultrasonic Perforator Localization for Reconstruction After Oral Carcinoma Resection,&#x201d; Journal of Oral and Maxillofacial Surgery 74, no. 5 (2016): 1063&#x2013;1071, https://doi.org/10.1016/j.joms.2015.11.011.</Citation></Reference><Reference><Citation>H. M. Titus, S. R. Sreedevi, S. C. Parameswaran, and L. Malathi, &#x201c;A Cadaveric Study on Perforator Anatomy of the Medial Sural Artery Perforator Flap,&#x201d; Indian Journal of Plastic Surgery 2 (2024): 140&#x2013;146, https://doi.org/10.1055/s&#x2010;0044&#x2010;1782201.</Citation></Reference><Reference><Citation>G. Sampieri, J. Tran, A. L. Feng, A. Agur, and J. Davies, &#x201c;Characterization of the MSAP Flap in Head and Neck Surgical Oncology: A 3D Cadaveric Study,&#x201d; Laryngoscope 134 (2024): 4298&#x2013;4303, https://doi.org/10.1002/lary.31532.</Citation></Reference><Reference><Citation>L. M. Basnet, S. K. Ghosh, S. Shrestha, and S. Dhungel, &#x201c;Anatomical Study of Medial Sural Artery and Its Perforators in Nepalese: An Aid to Reconstructive Surgery,&#x201d; Surgical and Radiologic Anatomy 40, no. 8 (2018): 935&#x2013;941, https://doi.org/10.1007/s00276&#x2010;017&#x2010;1956&#x2010;2.</Citation></Reference><Reference><Citation>G. G. Hallock, &#x201c;The Medial Sural Artery Perforator Flap: A Historical Trek From Ignominious to Workhorse,&#x201d; Archives of Plastic Surgery 2 (2022): 240&#x2013;252, https://doi.org/10.1055/s&#x2010;0042&#x2010;1744425.</Citation></Reference><Reference><Citation>A. Cina, M. Salgarello, L. Barone&#x2010;Adesi, P. Rinaldi, and L. Bonomo, &#x201c;Planning Breast Reconstruction With Deep Inferior Epigastric Artery Perforating Vessels: Multidetector CT Angiography Versus Color Doppler US,&#x201d; Radiology 255, no. 3 (2010): 979&#x2013;987, https://doi.org/10.1148/radiol.10091166.</Citation></Reference><Reference><Citation>S. Feng, P. Min, L. Grassetti, et&#xa0;al., &#x201c;A Prospective Head&#x2010;To&#x2010;Head Comparison of Color Doppler Ultrasound and Computed Tomographic Angiography in the Preoperative Planning of Lower Extremity Perforator Flaps,&#x201d; Plastic and Reconstructive Surgery 137, no. 1 (2016): 335&#x2013;347, https://doi.org/10.1097/PRS.0000000000001895.</Citation></Reference><Reference><Citation>M. Prokop, H. O. Shin, A. Schanz, and C. Schaefer&#x2010;Prokop, &#x201c;Use of Maximum Intensity Projections in CT Angiography: A Basic Review,&#x201d; Radiographics 17 (1997): 433&#x2013;451.</Citation></Reference><Reference><Citation>T. Hauck, A. Arkudas, R. E. Horch, et&#xa0;al., &#x201c;The Third Dimension in Perforator Mapping&#x2014;Comparison of Cinematic Rendering and Maximum Intensity Projection in Abdominal&#x2010;Based Autologous Breast Reconstruction,&#x201d; Journal of Plastic, Reconstructive and Aesthetic Surgery 75, no. 2 (2022): 536&#x2013;543, https://doi.org/10.1016/j.bjps.2021.09.011.</Citation></Reference><Reference><Citation>E. K. Fishman, D. R. Ney, D. G. Heath, F. M. Corl, K. M. Horton, and P. T. Johnson, &#x201c;Volume Rendering Versus Maximum Intensity Projection in CT Angiography: What Works Best, When, and Why,&#x201d; Radiographics 26, no. 3 (2006): 905&#x2013;922, https://doi.org/10.1148/rg.263055186.</Citation></Reference><Reference><Citation>M. Z. Wong, C. H. Wong, B. K. Tan, K. Y. Chew, and S. C. Tay, &#x201c;Surgical Anatomy of the Medial Sural Artery Perforator Flap,&#x201d; Journal of Reconstructive Microsurgery 28, no. 8 (2012): 555, https://doi.org/10.1055/s&#x2010;0032&#x2010;1315778.</Citation></Reference><Reference><Citation>A. Thione, L. Valdatta, M. Buoro, S. Tuinder, C. Mortarino, and R. Putz, &#x201c;The Medial Sural Artery Perforators: Anatomic Basis for a Surgical Plan,&#x201d; Annals of Plastic Surgery 53, no. 3 (2004): 250&#x2013;255, https://doi.org/10.1097/01.sap.0000116242.26334.b5.</Citation></Reference><Reference><Citation>J. M. Smit, A. Dimopoulou, A. G. Liss, et&#xa0;al., &#x201c;Preoperative CT Angiography Reduces Surgery Time in Perforator Flap Reconstruction,&#x201d; Journal of Plastic, Reconstructive and Aesthetic Surgery 62, no. 9 (2009): 1112&#x2013;1117, https://doi.org/10.1016/j.bjps.2007.12.090.</Citation></Reference><Reference><Citation>D. L. Lam, L. M. Mitsumori, P. C. Neligan, B. H. Warren, W. P. Shuman, and T. J. Dubinsky, &#x201c;Pre&#x2010;Operative CT Angiography and Three&#x2010;Dimensional Image Post Processing for Deep Inferior Epigastric Perforator Flap Breast Reconstructive Surgery,&#x201d; British Journal of Radiology 85, no. 1020 (2012): e1293&#x2013;e1297, https://doi.org/10.1259/bjr/30590223.</Citation></Reference><Reference><Citation>M. Knitschke, A. K. Baumgart, C. B&#xe4;cker, et&#xa0;al., &#x201c;Computed Tomography Angiography (CTA) Before Reconstructive Jaw Surgery Using Fibula Free Flap: Retrospective Analysis of Vascular Architecture,&#x201d; Diagnostics 11, no. 10 (2021): 1865, https://doi.org/10.3390/diagnostics11101865.</Citation></Reference><Reference><Citation>S. Perandini, N. Faccioli, A. Zaccarella, T. Re, and R. Mucelli, &#x201c;The Diagnostic Contribution of CT Volumetric Rendering Techniques in Routine Practice,&#x201d; Indian Journal of Radiology And Imaging 20, no. 2 (2010): 92&#x2013;97, https://doi.org/10.4103/0971&#x2010;3026.63043.</Citation></Reference><Reference><Citation>M. M. Chen, F. V. Coakley, A. Kaimal, and R. K. Laros, &#x201c;Guidelines for Computed Tomography and Magnetic Resonance Imaging Use During Pregnancy and Lactation,&#x201d; Vol 112 2008, http://www.acr.org/.</Citation></Reference><Reference><Citation>A. K. Nehra, K. Rajendran, F. I. Baffour, et&#xa0;al., &#x201c;Seeing More With Less: Clinical Benefits of Photon&#x2010;Counting Detector CT,&#x201d; Radiographics 43, no. 5 (2023): e220158, https://doi.org/10.1148/rg.220158.</Citation></Reference><Reference><Citation>E. C. Harvey, M. Feng, X. Ji, et&#xa0;al., &#x201c;Impacts of Photon Counting CT to Maximum Intensity Projection (MIP) Images of Cerebral CT Angiography: Theoretical and Experimental Studies,&#x201d; Physics in Medicine and Biology 64, no. 18 (2019): 185015, https://doi.org/10.1088/1361&#x2010;6560/ab32fe.</Citation></Reference><Reference><Citation>D. Aks&#xf6;yler, Y. Yal&#xe7;in, G. Durak, M. S. &#xc7;akir, L. Losco, and E. Kozano&#x11f;lu, &#x201c;The Effect of Leg Dominance in Patients on Perforator&#x2010;Based Flaps Elevated From the Lower Extremities,&#x201d; Microsurgery 44, no. 8 (2024): e31251, https://doi.org/10.1002/micr.31251.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70133 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41386691</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Dec</Month><Day>12</Day></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Chloride Intracellular Channel 2 Can Function as a Malignant Factor in Head and Neck Squamous Cell Carcinoma.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70133</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The association of chloride intracellular channel 2 (CLIC2) with tumors has remained unclear. However, recently, CLIC2 was found to exhibit antitumor properties in some tumors. In this study, we aimed to evaluate the clinical relevance of CLIC2 expression in head and neck squamous cell carcinoma (HNSCC) to determine whether it exerts antitumor effects similar to those in brain tumors and to explore its potential as a novel therapeutic target in HNSCC.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We explored the significance of CLIC in HNSCC using cell biological analyses and investigated the gene expression profile of the CLIC2 forced-expressed HNSCC cell line. CLIC2 expression in human HNSCC was examined histopathologically.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Forced expression of CLIC2 in HNSCC cells was accompanied by increased cell proliferation, resistance against natural killer cells, and expression of tumor-promoting genes in addition to increased tumorigenicity upon xenografting in a mouse model. CLIC2 expression was observed in several human cases of HNSCC.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">CLIC2 may act potentially as a novel risk factor for HNSCC.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). Head &amp; Neck published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hosokawa</LastName><ForeName>Yuki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medicine, Ehime University, Matsuyama, Ehime, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyoshi</LastName><ForeName>Shoko</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Molecular and Cellular Physiology, Graduate School of Medicine, Ehime University, Matsuyama, Ehime, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hayashi</LastName><ForeName>Yuji</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, Head and Neck Surgery, Ehime Prefectural Central Hospital, Matsuyama, Ehime, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Irifune</LastName><ForeName>Yuki</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-2962-9019</Identifier><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medicine, Ehime University, Matsuyama, Ehime, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Eriko</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medicine, Ehime University, Matsuyama, Ehime, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitani</LastName><ForeName>Sohei</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medicine, Ehime University, Matsuyama, Ehime, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choudhury</LastName><ForeName>Mohammed</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-2658-5487</Identifier><AffiliationInfo><Affiliation>Department of Molecular and Cellular Physiology, Graduate School of Medicine, Ehime University, Matsuyama, Ehime, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology and Perioperative Medicine, Graduate School of Medicine, Ehime University, Matsuyama, Ehime, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yano</LastName><ForeName>Hajime</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-1615-7526</Identifier><AffiliationInfo><Affiliation>Department of Molecular and Cellular Physiology, Graduate School of Medicine, Ehime University, Matsuyama, Ehime, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanaka</LastName><ForeName>Junya</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Molecular and Cellular Physiology, Graduate School of Medicine, Ehime University, Matsuyama, Ehime, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology and Perioperative Medicine, Graduate School of Medicine, Ehime University, Matsuyama, Ehime, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hato</LastName><ForeName>Naohito</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medicine, Ehime University, Matsuyama, Ehime, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>23K08988</GrantID><Agency>Japan society for the promotion of science</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">chloride intracellular channel 2 (CLIC2)</Keyword><Keyword MajorTopicYN="N">head and neck squamous cell carcinoma (HNSCC)</Keyword><Keyword MajorTopicYN="N">malignant potential</Keyword><Keyword MajorTopicYN="N">risk factor</Keyword><Keyword MajorTopicYN="N">therapeutic target</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>11</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>13</Day><Hour>0</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>13</Day><Hour>0</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>12</Day><Hour>20</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41386691</ArticleId><ArticleId IdType="doi">10.1002/hed.70133</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>M. Tahara, D. W. T. Lim, B. Keam, et&#xa0;al., &#x201c;Management Approaches for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Anti&#x2010;PD&#x2010;1/PD&#x2010;L1 Immunotherapy,&#x201d; Cancer Treatment Reviews 136 (2025): 102938.</Citation></Reference><Reference><Citation>J. Ringash, &#x201c;Survivorship and Quality of Life in Head and Neck Cancer,&#x201d; Journal of Clinical Oncology 33, no. 29 (2015): 3322&#x2013;3327.</Citation></Reference><Reference><Citation>P. P. Naik, D. N. Das, and P. K. Panda, &#x201c;Implications of Cancer Stem Cells in Developing Therapeutic Resistance in Oral Cancer,&#x201d; Oral Oncology 62 (2016): 122&#x2013;135.</Citation></Reference><Reference><Citation>F. Bray, M. Laversanne, H. Sung, et&#xa0;al., &#x201c;Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,&#x201d; CA: A Cancer Journal for Clinicians 74, no. 3 (2024): 229&#x2013;263.</Citation></Reference><Reference><Citation>C. W. Wang, P. K. Biswas, A. Islam, M. K. Chen, and P. J. Chueh, &#x201c;The Use of Immune Regulation in Treating Head and Neck Squamous Cell Carcinoma (HNSCC),&#x201d; Cells 13, no. 5 (2024): 413.</Citation></Reference><Reference><Citation>A. A. Osman, E. Arslan, M. Bartels, et&#xa0;al., &#x201c;Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma,&#x201d; Clinical Cancer Research 29, no. 7 (2023): 1344&#x2013;1359.</Citation></Reference><Reference><Citation>A. Bhatia and B. Burtness, &#x201c;Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update,&#x201d; Drugs 83, no. 3 (2023): 217&#x2013;248.</Citation></Reference><Reference><Citation>Cancer Genome Atlas Network, &#x201c;Comprehensive Genomic Characterization of Head and Neck Squamous Cell Carcinomas,&#x201d; Nature 517, no. 7536 (2015): 576&#x2013;582.</Citation></Reference><Reference><Citation>M. Kuroki, R. Iinuma, H. Okuda, et&#xa0;al., &#x201c;Comprehensive Genome Profile Testing in Head and Neck Cancer,&#x201d; Auris, Nasus, Larynx 50, no. 6 (2023): 952&#x2013;959.</Citation></Reference><Reference><Citation>J. C. Edwards and C. R. Kahl, &#x201c;Chloride Channels of Intracellular Membranes,&#x201d; FEBS Letters 584, no. 10 (2010): 2102&#x2013;2111.</Citation></Reference><Reference><Citation>E. Argenzio and W. H. Moolenaar, &#x201c;Emerging Biological Roles of Cl&#x2212; Intracellular Channel Proteins,&#x201d; Journal of Cell Science 129, no. 22 (2016): 4165&#x2013;4174.</Citation></Reference><Reference><Citation>S. G. Rao, N. J. Patel, H. Singh, et&#xa0;al., &#x201c;Intracellular Chloride Channels: Novel Biomarkers in Diseases,&#x201d; Frontiers in Physiology 11 (2020): 96.</Citation></Reference><Reference><Citation>P. G. Board, M. Coggan, S. Watson, P. W. Gage, and A. F. Dulhunty, &#x201c;CLIC&#x2010;2 Modulates Cardiac Ryanodine Receptor Ca2+ Release Channels,&#x201d; International Journal of Biochemistry &amp; Cell Biology 36, no. 8 (2004): 1599&#x2013;1612.</Citation></Reference><Reference><Citation>K. S. Hsu, W. Otsu, Y. Li, and H. C. Wang, &#x201c;CLIC4 Regulates Late Endosomal Trafficking and Matrix Degradation Activity of MMP14 at Focal Adhesions in RPE Cells,&#x201d; Scientific Reports 9, no. 1 (2019): 12247.</Citation></Reference><Reference><Citation>A. Shukla, M. Malik, C. Cataisson, et&#xa0;al., &#x201c;TGF&#x2010;&#x3b2; Signalling Is Regulated by Schnurri&#x2010;2 Dependent Nuclear Translocation of CLIC4 and Consequent Stabilization of Phospho Smad2&#x2013;3,&#x201d; Nature Cell Biology 11, no. 6 (2009): 777&#x2013;784.</Citation></Reference><Reference><Citation>S. Ozaki, K. Mikami, T. Kunieda, and J. Tanaka, &#x201c;Chloride Intracellular Channel Proteins (CLICs) and Malignant Tumor Progression: A Focus on the Preventive Role of CLIC2 in Invasion and Metastasis,&#x201d; Cancers 14, no. 19 (2022): 4890.</Citation></Reference><Reference><Citation>Y. Ueno, S. Ozaki, A. Umakoshi, et&#xa0;al., &#x201c;Chloride Intracellular Channel Protein 2 in Cancer and Non&#x2010;Cancer Human Tissues: Relationship With Tight Junctions,&#x201d; Tissue Barriers 7, no. 1 (2019): 1593775.</Citation></Reference><Reference><Citation>L. Zhu, Q. Chen, L. Zhang, and S. Hu, &#x201c;CLIC4 Regulates Radioresistance of Nasopharyngeal Carcinoma by iNOS After &#x3b3;&#x2010;Rays but Not Carbon Ions Irradiation,&#x201d; American Journal of Cancer Research 10, no. 5 (2020): 1400&#x2013;1415.</Citation></Reference><Reference><Citation>V. C. Sanchez, H. H. Yang, A. Craig&#x2010;Lucas, et&#xa0;al., &#x201c;Host CLIC4 Expression in the Tumor Microenvironment Is Essential for Breast Cancer Metastatic Competence,&#x201d; PLoS Genetics 18, no. 6 (2022): e1010271.</Citation></Reference><Reference><Citation>K. S. Parthasarathi, S. Mandal, S. Singh, et&#xa0;al., &#x201c;In Silico Analysis of Ion Channels and Their Correlation With Epithelial to Mesenchymal Transition in Breast Cancer,&#x201d; Cancers 14, no. 6 (2022): 1444.</Citation></Reference><Reference><Citation>C. T. Choy, C. H. Wong, S. L. Chan, et&#xa0;al., &#x201c;Embedding of Genes Using Cancer Gene Expression Data: Biological Relevance and Potential Application on Biomarker Discovery,&#x201d; Frontiers in Genetics 9, no. 4 (2019): 682.</Citation></Reference><Reference><Citation>S. Ozaki, A. Umakoshi, H. Yano, et&#xa0;al., &#x201c;Chloride Intracellular Channel Protein 2 Is Secreted and Inhibits MMP14 Activity, While Preventing Tumor Cell Invasion and Metastasis,&#x201d; Neoplasia 23, no. 8 (2021): 754&#x2013;765.</Citation></Reference><Reference><Citation>M. Egeblad and Z. Werb, &#x201c;New Functions for the Matrix Metalloproteinases in Cancer Progression,&#x201d; Nature Reviews. Cancer 2, no. 3 (2002): 161&#x2013;174.</Citation></Reference><Reference><Citation>M. Liu, L. Huang, Y. Liu, et&#xa0;al., &#x201c;Identification of the MMP Family as Therapeutic Targets and Prognostic Biomarkers in the Microenvironment of Head and Neck Squamous Cell Carcinoma,&#x201d; Journal of Translational Medicine 21 (2023): 208.</Citation></Reference><Reference><Citation>S. Wiegand, A. A. D&#xfc;nne, H. H. M&#xfc;ller, et&#xa0;al., &#x201c;Metaanalysis of the Significance of Matrix Metalloproteinases for Lymph Node Disease in Patients With Head and Neck Squamous Cell Carcinoma,&#x201d; Cancer 104 (2005): 94&#x2013;100.</Citation></Reference><Reference><Citation>Y. Hayashi, S. Miyoshi, I. Watanabe, et&#xa0;al., &#x201c;Simultaneous Disturbance of NHE1 and LOXL2 Decreases Tumorigenicity of Head and Neck Squamous Cell Carcinoma,&#x201d; Auris, Nasus, Larynx 51 (2024): 472&#x2013;480.</Citation></Reference><Reference><Citation>A. E. Mayorca&#x2010;Guiliani, H. Yano, K. I. Nakashiro, H. Hamakawa, and J. Tanaka, &#x201c;Premetastatic Vasculogenesis in Oral Squamous Cell Carcinoma Xenograft&#x2010;Draining Lymph Nodes,&#x201d; Oral Oncology 48 (2012): 663&#x2013;670.</Citation></Reference><Reference><Citation>T. Kaminota, H. Yano, K. Shiota, et&#xa0;al., &#x201c;Elevated Na+/H+ Exchanger&#x2010;1 Expression Enhances the Metastatic Collective Migration of Head and Neck Squamous Cell Carcinoma Cells,&#x201d; Biochemical and Biophysical Research Communications 486 (2017): 101&#x2013;107.</Citation></Reference><Reference><Citation>Y. Ishii, A. Yamaizumi, A. Kawakami, et&#xa0;al., &#x201c;Anti&#x2010;Inflammatory Effects of Noradrenaline on LPS&#x2010;Treated Microglial Cells: Suppression of NFkappaB Nuclear Translocation and Subsequent STAT1 Phosphorylation,&#x201d; Neurochemistry International 90 (2015): 56&#x2013;66.</Citation></Reference><Reference><Citation>K. Kobayashi, H. Yano, A. Umakoshi, et&#xa0;al., &#x201c;A Truncated Form of CD200 (CD200S) Expressed on Glioma Cells Prolonged Survival in a Rat Glioma Model by Induction of a Dendritic Cell&#x2010;Like Phenotype in Tumor&#x2010;Associated Macrophages,&#x201d; Neoplasia 18 (2016): 229&#x2013;241.</Citation></Reference><Reference><Citation>X. Li, Y. Wang, M. Ren, et&#xa0;al., &#x201c;The Role of Chloride Intracellular Channel 4 in Tumors,&#x201d; Cancer Cell International 25, no. 1 (2025): 118.</Citation></Reference><Reference><Citation>T. Sanada, A. Islam, T. Kaminota, et&#xa0;al., &#x201c;Elevated Exosomal Lysyl Oxidase Like 2 Is a Potential Biomarker for Head and Neck Squamous Cell Carcinoma,&#x201d; Laryngoscope 130, no. 5 (2020): E327&#x2013;E334.</Citation></Reference><Reference><Citation>K. E. Huntington, A. Louie, L. Zhou, A. A. Seyhan, A. W. Maxwell, and W. S. el&#x2010;Deiry, &#x201c;Colorectal Cancer Extracellular Acidosis Decreases Immune Cell Killing and Is Partially Ameliorated by pH&#x2010;Modulating Agents That Modify Tumor Cell Cytokine Profiles,&#x201d; American Journal of Cancer Research 12, no. 1 (2022): 138&#x2013;151.</Citation></Reference><Reference><Citation>S. Liu, L. Liu, W. Ye, et&#xa0;al., &#x201c;High Vimentin Expression Associated With Lymph Node Metastasis and Predicated a Poor Prognosis in Oral Squamous Cell Carcinoma,&#x201d; Scientific Reports 6 (2016): 38834.</Citation></Reference><Reference><Citation>X. Hu, Y. Liu, Z. Bing, Q. Ye, and C. Li, &#x201c;High Moesin Expression Is a Predictor of Poor Prognosis of Breast Cancer: Evidence From a Systematic Review With Meta&#x2010;Analysis,&#x201d; Frontiers in Oncology 11 (2021): 650488.</Citation></Reference><Reference><Citation>K. Chen, J. Yong, R. Zauner, et&#xa0;al., &#x201c;Chondroitin Sulfate Proteoglycan 4 as a Marker for Aggressive Squamous Cell Carcinoma,&#x201d; Cancers 14, no. 22 (2022): 5564.</Citation></Reference><Reference><Citation>K. V. Gopalakrishnan, B. Kannan, C. Pandi, V. P. Jayaseelan, and P. Arumugam, &#x201c;Prognostic and Clinicopathological Significance of MRC2 Expression in Head and Neck Squamous Cell Carcinoma,&#x201d; Journal of Stomatology, Oral and Maxillofacial Surgery 124, no. 6S (2023): 101617.</Citation></Reference><Reference><Citation>D. L. Elion and R. S. Cook, &#x201c;Harnessing RIG&#x2010;I and Intrinsic Immunity in the Tumor Microenvironment for Therapeutic Cancer Treatment,&#x201d; Oncotarget 9, no. 48 (2018): 29007&#x2013;29017.</Citation></Reference><Reference><Citation>A. Botticelli, A. Cirillo, L. Strigari, et&#xa0;al., &#x201c;Anti&#x2010;PD&#x2010;1 and Anti&#x2010;PD&#x2010;L1 in Head and Neck Cancer: A Network Meta&#x2010;Analysis,&#x201d; Frontiers in Immunology 12 (2021): 705096.</Citation></Reference><Reference><Citation>M. Oliva, A. Spreafico, M. Taberna, et&#xa0;al., &#x201c;Immune Biomarkers of Response to Immune&#x2010;Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma,&#x201d; Annals of Oncology 30, no. 1 (2019): 57&#x2013;67.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70117 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41367328</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Dec</Month><Day>10</Day></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Risk of Occult Contralateral Neck Metastasis in Early-Stage HPV-Related Lateralized Cancer of the Base of the Tongue.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70117</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">(1) To determine the incidence of occult contralateral cervical lymph node metastasis in patients with early-stage HPV-associated base-of-tongue (BOT) oropharyngeal squamous cell carcinoma (OPSCC) treated with primary surgery; and (2) to compare survival and recurrence in patients who did and did not undergo contralateral neck treatment.</AbstractText><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Contralateral neck management in patients with early-stage HPV+ OPSCC of the BOT treated surgically remains controversial. Despite lacking data, most patients receive surgery and/or radiation to the contralateral neck based on historical incidence of occult lymph node metastasis in OPSCC.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A retrospective chart review of patients with AJCC 7th edition pT1-2, pN0-1 HPV+ BOT OPSCC undergoing transoral robotic BOT resection and ipsilateral neck dissection with adjuvant treatment was conducted. The incidence of occult contralateral nodal metastasis was assessed. Overall and disease-free survival were compared between patients who did and did not undergo contralateral neck treatment.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 106 patients meeting inclusion criteria, 46 (43.3%) did not undergo treatment of the contralateral neck with radiation or lymphadenectomy, whereas 29 (27.4%) received radiation alone to the contralateral neck, and 31 (29.2%) underwent elective contralateral neck dissection without identification of occult metastasis in any case. Overall survival (HR: 0.95, 95% CI: 0.23-4.00) and disease-free survival (HR: 1.43, CI: 0.55-3.71) did not significantly differ between patients who did and did not receive treatment to the contralateral neck.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Risk of occult contralateral cervical lymph node metastasis in patients with early-stage HPV-associated BOT OPSCC treated with primary surgery was low, prompting consideration of forgoing contralateral neck treatment in these patients.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). Head &amp; Neck published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Halle</LastName><ForeName>Tyler R</ForeName><Initials>TR</Initials><Identifier Source="ORCID">0000-0003-4054-1154</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology, Emory University, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Austin C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology-Head &amp; Neck Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naik</LastName><ForeName>Anusha G</ForeName><Initials>AG</Initials><Identifier Source="ORCID">0000-0003-0070-8239</Identifier><AffiliationInfo><Affiliation>Department of Otorhinolaryngology-Head &amp; Neck Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weinstein</LastName><ForeName>Gregory S</ForeName><Initials>GS</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology-Head &amp; Neck Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jake J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head &amp; Neck Surgery, Stanford Medicine, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gobillot</LastName><ForeName>Theodore A</ForeName><Initials>TA</Initials><Identifier Source="ORCID">0000-0002-4313-3204</Identifier><AffiliationInfo><Affiliation>Department of Otorhinolaryngology-Head &amp; Neck Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaye</LastName><ForeName>Erin R</ForeName><Initials>ER</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology, University of Miami, Miami, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brody</LastName><ForeName>Robert M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology, Emory University, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otorhinolaryngology-Head &amp; Neck Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basu</LastName><ForeName>Devraj</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology-Head &amp; Neck Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Malley</LastName><ForeName>Bert W</ForeName><Initials>BW</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Otolaryngology, University of Maryland, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farwell</LastName><ForeName>D Gregory</ForeName><Initials>DG</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology-Head &amp; Neck Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cannady</LastName><ForeName>Steven B</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology-Head &amp; Neck Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lukens</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gentile</LastName><ForeName>Michelle</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Newman</LastName><ForeName>Jason G</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology, Medical Univesity of South Carolina, Charleston, South Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chalian</LastName><ForeName>Ara A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology-Head &amp; Neck Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rasskeh</LastName><ForeName>Christopher H</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology-Head &amp; Neck Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rajasekaran</LastName><ForeName>Karthik</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-2148-1643</Identifier><AffiliationInfo><Affiliation>Department of Otorhinolaryngology-Head &amp; Neck Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leonard Davis Institute of Health Economics, University of Pennsylvania, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HPV&#x2010;related oropharyngeal squamous cell carcinoma</Keyword><Keyword MajorTopicYN="N">base&#x2010;of&#x2010;tongue</Keyword><Keyword MajorTopicYN="N">cervical lymph node metastasis</Keyword><Keyword MajorTopicYN="N">transoral robotic surgery</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>10</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>10</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>10</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>10</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>10</Day><Hour>4</Hour><Minute>24</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41367328</ArticleId><ArticleId IdType="doi">10.1002/hed.70117</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>A. K. Chaturvedi, E. A. Engels, R. M. Pfeiffer, et&#xa0;al., &#x201c;Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States,&#x201d; Journal of Clinical Oncology 29 (2011): 4294&#x2013;4301.</Citation></Reference><Reference><Citation>M. E. Sabatini and S. Chiocca, &#x201c;Human Papillomavirus as a Driver of Head and Neck Cancers,&#x201d; British Journal of Cancer 122, no. 3 (2020): 306&#x2013;314, https://doi.org/10.1038/S41416&#x2010;019&#x2010;0602&#x2010;7.</Citation></Reference><Reference><Citation>E. A. Van Dyne, S. J. Henley, M. Saraiya, C. C. Thomas, L. E. Markowitz, and V. B. Benard, &#x201c;Trends in Human Papillomavirus&#x2010;Associated Cancers&#x2013;United States, 1999&#x2013;2015,&#x201d; MMWR. Morbidity and Mortality Weekly Report 67, no. 33 (2018): 918&#x2013;924, https://doi.org/10.15585/mmwr.mm6733a2.</Citation></Reference><Reference><Citation>E. E. Vokes, N. Agrawal, and T. Y. Seiwert, &#x201c;HPV&#x2010;Associated Head and Neck Cancer,&#x201d; Journal of the National Cancer Institute 107, no. 12 (2015): djv344, https://doi.org/10.1093/jnci/djv344.</Citation></Reference><Reference><Citation>L. Licitra, F. Perrone, P. Bossi, et&#xa0;al., &#x201c;High&#x2010;Risk Human Papillomavirus Affects Prognosis in Patients With Surgically Treated Oropharyngeal Squamous Cell Carcinoma,&#x201d; Journal of Clinical Oncology 24, no. 36 (2006): 5630&#x2013;5636, https://doi.org/10.1200/JCO.2005.04.6136.</Citation></Reference><Reference><Citation>A. C. Nichols, J. Theurer, E. Prisman, et&#xa0;al., &#x201c;Randomized Trial of Radiotherapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma: Long&#x2010;Term Results of the ORATOR Trial,&#x201d; Journal of Clinical Oncology 40, no. 8 (2022): 866&#x2013;875, https://doi.org/10.1200/JCO.21.01961.</Citation></Reference><Reference><Citation>S. A. Koyfman, N. Ismaila, D. Crook, et&#xa0;al., &#x201c;Management of the Neck in Squamous Cell Carcinoma of the Oral Cavity and Oropharynx: ASCO Clinical Practice Guideline,&#x201d; Journal of Clinical Oncology 37, no. 20 (2019): 1753&#x2013;1774, https://doi.org/10.1200/JCO.18.01921.</Citation></Reference><Reference><Citation>D. J. Sher, D. J. Adelstein, G. K. Bajaj, et&#xa0;al., &#x201c;Radiation Therapy for Oropharyngeal Squamous Cell Carcinoma: Executive Summary of an ASTRO Evidence&#x2010;Based Clinical Practice Guideline,&#x201d; Practical Radiation Oncology 7, no. 4 (2017): 246&#x2013;253, https://doi.org/10.1016/j.prro.2017.02.002.</Citation></Reference><Reference><Citation>National Comprehensive Cancer Network, Head and Neck Cancers (Version 2.2022) (2022), https://www.nccn.org/professionals/physician_gls/pdf/head&#x2010;and&#x2010;neck.pdf.</Citation></Reference><Reference><Citation>J. A. Contreras, C. Spencer, T. DeWees, et&#xa0;al., &#x201c;Eliminating Postoperative Radiation to the Pathologically Node&#x2010;Negative Neck: Long&#x2010;Term Results of a Prospective Phase II Study,&#x201d; Journal of Clinical Oncology 37, no. 28 (2019): 2548&#x2013;2555, https://doi.org/10.1200/JCO.19.00186.</Citation></Reference><Reference><Citation>A. S. Last, P. Pipkorn, S. Chen, et&#xa0;al., &#x201c;Risk and Rate of Occult Contralateral Nodal Disease in Surgically Treated Patients With Human Papillomavirus&#x2010;Related Squamous Cell Carcinoma of the Base of the Tongue,&#x201d; JAMA Otolaryngology. Head &amp; Neck Surgery 146, no. 1 (2020): 50&#x2013;56, https://doi.org/10.1001/jamaoto.2019.3277.</Citation></Reference><Reference><Citation>A. W. Smith, M. Gallitto, E. J. Lehrer, et&#xa0;al., &#x201c;Redefining Risk of Contralateral Cervical Nodal Disease in Early Stage Oropharyngeal Cancer in the Human Papillomavirus Era,&#x201d; Head &amp; Neck 43, no. 5 (2021): 1409&#x2013;1414, https://doi.org/10.1002/hed.26607.</Citation></Reference><Reference><Citation>S. B. Edge and C. C. Compton, &#x201c;The American Joint Committee on Cancer: The 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM,&#x201d; Annals of Surgical Oncology 17, no. 6 (2010): 1471&#x2013;1474, https://doi.org/10.1245/S10434&#x2010;010&#x2010;0985&#x2010;4.</Citation></Reference><Reference><Citation>Y. Zhang, X. Su, Y. Qiao, S. Huang, and Y. Kou, &#x201c;Occult Lymph Node Metastasis in the Contralateral Neck of Oropharyngeal Squamous Cell Carcinoma: A Meta&#x2010;Analysis and Literature Review,&#x201d; European Archives of Oto&#x2010;Rhino&#x2010;Laryngology 279, no. 4 (2022): 2157&#x2013;2166, https://doi.org/10.1007/s00405&#x2010;021&#x2010;07230&#x2010;5.</Citation></Reference><Reference><Citation>A. G. Tritter, V. Mehta, M. Samuelson, et&#xa0;al., &#x201c;Incidence of Contralateral&#x2010;Bilateral Nodes in the Human Papillomavirus Era,&#x201d; Laryngoscope 127, no. 6 (2017): 1328&#x2013;1333, https://doi.org/10.1002/lary.26439.</Citation></Reference><Reference><Citation>M. G. Kato, M. A. Ellis, S. A. Nguyen, and T. A. Day, &#x201c;Predictors of Contralateral&#x2010;Bilateral Nodal Disease in Oropharyngeal Cancer: A National Cancer Data Base Study,&#x201d; Head &amp; Neck 40, no. 2 (2018): 338&#x2013;348, https://doi.org/10.1002/hed.24964.</Citation></Reference><Reference><Citation>C. P. McMullen, J. Garneau, E. Weimar, et&#xa0;al., &#x201c;Occult Contralateral Nodal Disease in Oropharyngeal Squamous Cell Carcinoma Patients Undergoing Primary TORS With Bilateral Neck Dissection,&#x201d; Oral Oncology 93 (2019): 96&#x2013;100, https://doi.org/10.1016/j.oraloncology.2019.04.017.</Citation></Reference><Reference><Citation>H. S. Huang, M. H. Tsai, H. C. Chuang, et&#xa0;al., &#x201c;Prediction of Occult Contralateral Nodal Metastasis in Surgical Treated p16 Negative Oropharyngeal Squamous Cell Carcinoma,&#x201d; Cancer Management and Research 14 (2022): 3151&#x2013;3158, https://doi.org/10.2147/CMAR.S382394.</Citation></Reference><Reference><Citation>A. J. Sood, W. McIlwain, B. O'Connell, S. Nguyen, J. J. Houlton, and T. Day, &#x201c;The Association Between T&#x2010;Stage and Clinical Nodal Metastasis in HPV&#x2010;Positive Oropharyngeal Cancer,&#x201d; American Journal of Otolaryngology 35, no. 4 (2014): 463&#x2013;468, https://doi.org/10.1016/j.amjoto.2013.12.008.</Citation></Reference><Reference><Citation>A. Sahovaler, J. J. W. Lee, W. Xu, et&#xa0;al., &#x201c;Contralateral Nodal Failures in Oropharyngeal Cancers After TORS and Unilateral Neck Management: A Retrospective Study,&#x201d; Journal of Otolaryngology &#x2010; Head &amp; Neck Surgery 50, no. 1 (2021): 71, https://doi.org/10.1186/s40463&#x2010;021&#x2010;00551&#x2010;9.</Citation></Reference><Reference><Citation>R. M. Carey, D. Shimunov, G. S. Weinstein, et&#xa0;al., &#x201c;Increased Rate of Recurrence and High Rate of Salvage in Patients With Human Papillomavirus&#x2010;Associated Oropharyngeal Squamous Cell Carcinoma With Adverse Features Treated With Primary Surgery Without Recommended Adjuvant Therapy,&#x201d; Head &amp; Neck 43, no. 4 (2021): 1128&#x2013;1141, https://doi.org/10.1002/hed.26578.</Citation></Reference><Reference><Citation>R. M. Carey, R. M. Brody, D. Shimunov, et&#xa0;al., &#x201c;Locoregional Recurrence in p16&#x2010;Positive Oropharyngeal Squamous Cell Carcinoma After TORS,&#x201d; Laryngoscope 131, no. 12 (2021): E2865&#x2013;E2873, https://doi.org/10.1002/lary.29659.</Citation></Reference><Reference><Citation>I. Berania, A. Hosni, C. M. Thomas, et&#xa0;al., &#x201c;Evaluating Contralateral Neck Failure in Patients With Lateralized OPSCC Treated With Transoral Robotic Surgery and Neck Management Based on Pre&#x2010;Operative SPECT&#x2010;CT Lymphatic Mapping,&#x201d; Journal of Otolaryngology &#x2010; Head &amp; Neck Surgery 51, no. 1 (2022): 47, https://doi.org/10.1186/s40463&#x2010;022&#x2010;00563&#x2010;z.</Citation></Reference><Reference><Citation>C. T. Haring, C. Brummel, C. Bhambhani, et&#xa0;al., &#x201c;Implementation of Human Papillomavirus Circulating Tumor DNA to Identify Recurrence During Treatment de&#x2010;Escalation,&#x201d; Oral Oncology 121 (2021): 105332, https://doi.org/10.1016/j.oraloncology.2021.105332.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70126 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41367329</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Dec</Month><Day>10</Day></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Malignant Craniofacial Perivascular Epithelioid Cell Tumor: A Review of Literature With a Rare Presentation.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70126</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Perivascular epithelioid cell tumors (PEComas) are rare mesenchymal neoplasms with smooth muscle and melanocytic differentiation, typically occurring in genitourinary or abdominopelvic sites. While multiple anatomic sites have been reported, craniofacial involvement is exceptionally rare.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We report the first documented case of a probable high-grade malignant PEComa of the sinonasal tract with anterior skull base and orbital extension. The patient was a 42-year-old woman with a germline RB1 mutation, prior radiotherapy for bilateral retinoblastoma as an infant, and a history of left-sided sinonasal leiomyosarcoma treated with surgical resection and anthracycline chemotherapy. She represented six years later with new contralateral epistaxis and a friable right-sided nasal mass. Upon endoscopy and imaging, a locally aggressive lesion was confirmed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Histopathology showed a highly proliferative tumor with immunohistochemistry positive for HMB45, melan-A, SMA, caldesmon, and TFE3, with absent desmin and MITF. The lesion was most in keeping with a malignant PEComa. The tumor was resected via a combined transcranial, transcaruncular, and endoscopic endonasal approach, achieving clear margins. This case shows unusually rapid progression, likely influenced by prior radiation and germline RB1 gene mutation. Our literature review identified 41 previously reported primary craniofacial PEComas, consisting of 51% sinonasal, 37% orbital, and 10% skull base. Nearly all cases were benign and treated with surgical resection.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This report highlights a rare, malignant craniofacial PEComa with extensive invasion into the orbit and skull base, expanding the known clinical and molecular spectrum of these tumors.</AbstractText><CopyrightInformation>&#xa9; 2025 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Paris</LastName><ForeName>Jai</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-0178-6706</Identifier><AffiliationInfo><Affiliation>Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, South Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdullah</LastName><ForeName>Almater</ForeName><Initials>A</Initials><Suffix>1st</Suffix><AffiliationInfo><Affiliation>Research Excellence Center in Ophthalmology and Visual Sciences, Department of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ang</LastName><ForeName>Terence</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, South Australia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>South Australian Institute of Ophthalmology, Royal Adelaide Hospital, Adelaide, South Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shepard</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinpath Laboratory, Mile End, South Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selva</LastName><ForeName>Dinesh</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, South Australia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>South Australian Institute of Ophthalmology, Royal Adelaide Hospital, Adelaide, South Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Psaltis</LastName><ForeName>Alkis J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, South Australia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otolaryngology, Head and Neck Surgery, The Queen Elizabeth Hospital, Woodville South, South Australia, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">PEComa</Keyword><Keyword MajorTopicYN="N">Sinonasal</Keyword><Keyword MajorTopicYN="N">craniofacial</Keyword><Keyword MajorTopicYN="N">malignant</Keyword><Keyword MajorTopicYN="N">orbit</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>8</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>10</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>10</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>10</Day><Hour>4</Hour><Minute>24</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41367329</ArticleId><ArticleId IdType="doi">10.1002/hed.70126</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>F. Bonetti, M. Pea, G. Martignoni, and G. Zamboni, &#x201c;PEC and Sugar,&#x201d; American Journal of Surgical Pathology 16, no. 3 (1992): 307&#x2013;308, https://doi.org/10.1097/00000478&#x2010;199203000&#x2010;00013.</Citation></Reference><Reference><Citation>K. Thway and C. Fisher, &#x201c;PEComa: Morphology and Genetics of a Complex Tumor Family,&#x201d; Annals of Diagnostic Pathology 19, no. 5 (2015): 359&#x2013;368, https://doi.org/10.1016/j.anndiagpath.2015.06.003.</Citation></Reference><Reference><Citation>S. M. Moudouni, M. Tligui, M. Sibony, et&#xa0;al., &#x201c;Malignant Epithelioid Renal Angiomyolipoma Involving the Inferior Vena Cava in a Patient With Tuberous Sclerosis,&#x201d; Urologia Internationalis 80, no. 1 (2008): 102&#x2013;104, https://doi.org/10.1159/000111739.</Citation></Reference><Reference><Citation>J. S. Bleeker, J. F. Quevedo, and A. L. Folpe, &#x201c;&#x201c;Malignant&#x201d; Perivascular Epithelioid Cell Neoplasm: Risk Stratification and Treatment Strategies,&#x201d; Sarcoma 2012 (2012): 541626, https://doi.org/10.1155/2012/541626.</Citation></Reference><Reference><Citation>A. Agaimy, M. Michal, A. Abdelsatir, et&#xa0;al., &#x201c;TFE3 &#x2010;Rearranged Head and Neck Neoplasms: Twenty&#x2010;Two Cases Spanning the Morphologic Continuum Between Alveolar Soft Part Sarcoma and PEComa and Highlighting Genotypic Diversity,&#x201d; American Journal of Surgical Pathology 49, no. 2 (2025): 104&#x2013;112, https://doi.org/10.1097/pas.0000000000002334.</Citation></Reference><Reference><Citation>A. Kinzel, M. McArthur, L. M. Gettle, E. Felker, and M. Patel, &#x201c;PEComas: A Review of Imaging and Clinical Features,&#x201d; Clinical Imaging 116 (2024): 110332, https://doi.org/10.1016/j.clinimag.2024.110332.</Citation></Reference><Reference><Citation>A. L. Folpe, T. Mentzel, H. A. Lehr, C. Fisher, B. L. Balzer, and S. W. Weiss, &#x201c;Perivascular Epithelioid Cell Neoplasms of Soft Tissue and Gynecologic Origin: A Clinicopathologic Study of 26 Cases and Review of the Literature,&#x201d; American Journal of Surgical Pathology 29, no. 12 (2005): 1558&#x2013;1575, https://doi.org/10.1097/01.pas.0000173232.22117.37.</Citation></Reference><Reference><Citation>Y. Takahashi, A. Yoshida, S. Yoshimoto, et&#xa0;al., &#x201c;TFE3&#x2010;Rearranged Perivascular Epithelioid Cell Tumors of the Head and Neck With Rare Fusion Partners: Clues to the Differential Diagnosis Between Benign and Malignant Tumors,&#x201d; Diagnostic Pathology 20, no. 1 (2025): 7, https://doi.org/10.1186/s13000&#x2010;025&#x2010;01602&#x2010;9.</Citation></Reference><Reference><Citation>A. Gadducci and G. F. Zannoni, &#x201c;Perivascular Epithelioid Cell Tumors (PEComa) of the Female Genital Tract: A Challenging Question for Gynaecologic Oncologist and Pathologist,&#x201d; Gynecologic Oncology Reports 33 (2020): 100603, https://doi.org/10.1016/j.gore.2020.100603.</Citation></Reference><Reference><Citation>A. Afrogheh, J. Schneider, A. F. Bezuidenhout, and J. Hille, &#x201c;PEComa of the Nose: Report of a Case With Immunohistochemical and Ultrustructural Studies and a Review of the Literature,&#x201d; Head and Neck Pathology 8, no. 1 (2014): 122&#x2013;126, https://doi.org/10.1007/s12105&#x2010;013&#x2010;0470&#x2010;z.</Citation></Reference><Reference><Citation>M. S. Alam, B. Mukherjee, S. Krishnakumar, and J. Biswas, &#x201c;Malignant Perivascular Epithelioid Cell Tumor of the Orbit: Report of a Case and Review of Literature,&#x201d; Indian Journal of Ophthalmology 65, no. 9 (2017): 889&#x2013;891, https://doi.org/10.4103/ijo.IJO_331_17.</Citation></Reference><Reference><Citation>N. L. Lehman, &#x201c;Malignant PEComa of the Skull Base,&#x201d; American Journal of Surgical Pathology 28, no. 9 (2004): 1230&#x2013;1232, https://doi.org/10.1097/01.pas.0000128668.34934.81.</Citation></Reference><Reference><Citation>A. Bandhlish, E. Leon Barnes, J. T. Rabban, and J. B. McHugh, &#x201c;Perivascular Epithelioid Cell Tumors (PEComas) of the Head and Neck: Report of Three Cases and Review of the Literature,&#x201d; Head and Neck Pathology 5, no. 3 (2011): 233&#x2013;240, https://doi.org/10.1007/s12105&#x2010;011&#x2010;0268&#x2010;9.</Citation></Reference><Reference><Citation>S. H. Aljneibi, A. A. Aldhanhani, K. Abuhaleeqa, and F. Pichi, &#x201c;Orbital Perivascular Epithelioid Cell Tumor in a Case of Tuberous Sclerosis,&#x201d; Case Reports in Ophthalmology 14, no. 1 (2023): 282&#x2013;287, https://doi.org/10.1159/000530036.</Citation></Reference><Reference><Citation>H. B. Armah and A. V. Parwani, &#x201c;Malignant Perivascular Epithelioid Cell Tumor (PEComa) of the Uterus With Late Renal and Pulmonary Metastases: A Case Report With Review of the Literature,&#x201d; Diagnostic Pathology 2 (2007): 45, https://doi.org/10.1186/1746&#x2010;1596&#x2010;2&#x2010;45.</Citation></Reference><Reference><Citation>J. Lasota, L. D. R. Thompson, M. Ch&#x142;opek, A. Kowalik, and M. Miettinen, &#x201c;Unusual PEComa With PRCC :: TFE3 Fusion Mimicking Sinonasal Tract Melanoma,&#x201d; Applied Immunohistochemistry &amp; Molecular Morphology 32, no. 7 (2024): 322&#x2013;325, https://doi.org/10.1097/pai.0000000000001211.</Citation></Reference><Reference><Citation>B. Leavers, P. Earls, and R. Harvey, &#x201c;Sinonasal Perivascular Epithelioid Cell Tumor: Benign or Malignant Neoplasm?,&#x201d; American Journal of Rhinology &amp; Allergy 26, no. 3 (2012): 213&#x2013;217, https://doi.org/10.2500/ajra.2012.26.3760.</Citation></Reference><Reference><Citation>F. L&#xf3;pez, J. P. Rodrigo, A. Cardesa, et&#xa0;al., &#x201c;Update on Primary Head and Neck Mucosal Melanoma,&#x201d; Head &amp; Neck 38, no. 1 (2016): 147&#x2013;155, https://doi.org/10.1002/hed.23872.</Citation></Reference><Reference><Citation>C. A. Ortega, M. N. Stevens, J. S. Lewis, and M. C. Topf, &#x201c;Nasal Mucosal Desmoplastic Melanoma: A Case Report With Review of the Literature,&#x201d; Head and Neck Pathology 16, no. 3 (2022): 942&#x2013;946, https://doi.org/10.1007/s12105&#x2010;022&#x2010;01429&#x2010;6.</Citation></Reference><Reference><Citation>K. Blessing, D. S. Sanders, and J. J. Grant, &#x201c;Comparison of Immunohistochemical Staining of the Novel Antibody Melan&#x2010;A With S100 Protein and HMB&#x2010;45 in Malignant Melanoma and Melanoma Variants,&#x201d; Histopathology 32, no. 2 (1998): 139&#x2013;146, https://doi.org/10.1046/j.1365&#x2010;2559.1998.00312.x.</Citation></Reference><Reference><Citation>H. Tang, Y. He, Y. Chen, et&#xa0;al., &#x201c;Sinonasal Mucosal Melanoma With Smooth Muscle Differentiation: A Potential Pathological Diagnostic Pitfall,&#x201d; Diagnostic Pathology 17, no. 1 (2022): 95, https://doi.org/10.1186/s13000&#x2010;022&#x2010;01280&#x2010;x.</Citation></Reference><Reference><Citation>J. A. Bennett, Z. Ordulu, A. Pinto, et&#xa0;al., &#x201c;Uterine PEComas: Correlation Between Melanocytic Marker Expression and TSC Alterations/TFE3 Fusions,&#x201d; Modern Pathology 35, no. 4 (2022): 515&#x2013;523, https://doi.org/10.1038/s41379&#x2010;021&#x2010;00855&#x2010;1.</Citation></Reference><Reference><Citation>S. Akumalla, R. Madison, D. I. Lin, et&#xa0;al., &#x201c;Characterization of Clinical Cases of Malignant PEComa via Comprehensive Genomic Profiling of DNA and RNA,&#x201d; Oncology 98, no. 12 (2020): 905&#x2013;912, https://doi.org/10.1159/000510241.</Citation></Reference><Reference><Citation>D. Rojanaporn, T. Boontawon, T. Chareonsirisuthigul, et&#xa0;al., &#x201c;Spectrum of Germline RB1 Mutations and Clinical Manifestations in Retinoblastoma Patients From Thailand,&#x201d; Molecular Vision 24 (2018): 778&#x2013;788.</Citation></Reference><Reference><Citation>R. A. Kleinerman, S. J. Schonfeld, and M. A. Tucker, &#x201c;Sarcomas in Hereditary Retinoblastoma,&#x201d; Clinical Sarcoma Research 2, no. 1 (2012): 15, https://doi.org/10.1186/2045&#x2010;3329&#x2010;2&#x2010;15.</Citation></Reference><Reference><Citation>T. Marees, A. C. Moll, S. M. Imhof, M. R. de Boer, P. J. Ringens, and F. E. van Leeuwen, &#x201c;Risk of Second Malignancies in Survivors of Retinoblastoma: More Than 40&#x2009;Years of Follow&#x2010;Up,&#x201d; Journal of the National Cancer Institute 100, no. 24 (2008): 1771&#x2013;1779, https://doi.org/10.1093/jnci/djn394.</Citation></Reference><Reference><Citation>L. Venkatraman, J. R. Goepel, K. Steele, S. P. Dobbs, R. W. Lyness, and W. G. McCluggage, &#x201c;Soft Tissue, Pelvic, and Urinary Bladder Leiomyosarcoma as Second Neoplasm Following Hereditary Retinoblastoma,&#x201d; Journal of Clinical Pathology 56, no. 3 (2003): 233&#x2013;236, https://doi.org/10.1136/jcp.56.3.233.</Citation></Reference><Reference><Citation>S. S. Sam, B. Stewart, E. Nasri, M. E. Leon, and E. Martinez Duarte, &#x201c;Leiomyosarcoma of the Nasal Cavity and Paranasal Sinuses: A Case Report and Comprehensive Review of the Literature,&#x201d; Head and Neck Pathology 16, no. 3 (2022): 918&#x2013;927, https://doi.org/10.1007/s12105&#x2010;022&#x2010;01427&#x2010;8.</Citation></Reference><Reference><Citation>S. A. Newman, J. Yoo, N. Jones, N. Beasley, and P. Gullane, &#x201c;Radiation&#x2010;Induced Leiomyosarcoma of the Ethmoid Sinus,&#x201d; Skull Base 13, no. 3 (2003): 179&#x2013;182, https://doi.org/10.1055/s&#x2010;2003&#x2010;43329.</Citation></Reference><Reference><Citation>Z. Chen, X. Zheng, and Q. Lin, &#x201c;A Case Report and Literature Review: Leiomyosarcoma or Perivascular Epithelioid Cell Neoplasm?,&#x201d; Frontiers in Oncology 14 (2024): 1499403, https://doi.org/10.3389/fonc.2024.1499403.</Citation></Reference><Reference><Citation>W. J. Anderson, F. Dong, C. D. M. Fletcher, M. S. Hirsch, and M. R. Nucci, &#x201c;A Clinicopathologic and Molecular Characterization of Uterine Sarcomas Classified as Malignant PEComa,&#x201d; American Journal of Surgical Pathology 47, no. 5 (2023): 535&#x2013;546, https://doi.org/10.1097/pas.0000000000002028.</Citation></Reference><Reference><Citation>L. Katsakhyan, M. Shahi, H. C. Eugene, et&#xa0;al., &#x201c;Uterine Leiomyosarcoma Associated With Perivascular Epithelioid Cell Tumor: A Phenomenon of Differentiation/Dedifferentiation and Evidence Suggesting Cell&#x2010;Of&#x2010;Origin,&#x201d; American Journal of Surgical Pathology 48, no. 6 (2024): 761&#x2013;772, https://doi.org/10.1097/pas.0000000000002208.</Citation></Reference><Reference><Citation>X. Dong, Y. Chen, J. Pan, et&#xa0;al., &#x201c;Clinicopathological Features and Prognosis of TFE3&#x2010;Positive Renal Cell Carcinoma,&#x201d; Frontiers in Oncology 12 (2022): 1017425, https://doi.org/10.3389/fonc.2022.1017425.</Citation></Reference><Reference><Citation>Y. Liu, Q. Zheng, C. Wang, et&#xa0;al., &#x201c;Granular Cell Tumors Overexpress TFE3 Without Gene Rearrangement: Evaluation of Immunohistochemistry and Break&#x2010;Apart FISH in 45 Cases,&#x201d; Oncology Letters 18, no. 6 (2019): 6355&#x2013;6360, https://doi.org/10.3892/ol.2019.10995.</Citation></Reference><Reference><Citation>K. Tsuji, Y. Ishikawa, and T. Imamura, &#x201c;Technique for Differentiating Alveolar Soft Part Sarcoma From Other Tumors in Paraffin&#x2010;Embedded Tissue: Comparison of Immunohistochemistry for TFE3 and CD147 and of Reverse Transcription Polymerase Chain Reaction for ASPSCR1&#x2010;TFE3 Fusion Transcript,&#x201d; Human Pathology 43, no. 3 (2012): 356&#x2013;363, https://doi.org/10.1016/j.humpath.2011.05.004.</Citation></Reference><Reference><Citation>P. Argani, S. Aulmann, P. B. Illei, et&#xa0;al., &#x201c;A Distinctive Subset of PEComas Harbors TFE3 Gene Fusions,&#x201d; American Journal of Surgical Pathology 34, no. 10 (2010): 1395&#x2013;1406, https://doi.org/10.1097/PAS.0b013e3181f17ac0.</Citation></Reference><Reference><Citation>A. Varan, T. Bayhan, H. Kiratli, et&#xa0;al., &#x201c;An Orbital Perivascular Epithelioid Cell Tumor in a 7&#x2010;Year&#x2010;Old Boy: Case Report and Review of the Literature,&#x201d; Journal of AAPOS 21, no. 4 (2017): 325&#x2013;328.e1, https://doi.org/10.1016/j.jaapos.2017.05.022.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70130 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41364079</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Dec</Month><Day>09</Day></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Quantifying Neck Disability After Neck Dissection in HNSCC-A Prospective Study of Patient-Reported and Objective Functional Outcomes.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70130</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Neck dissection, a cornerstone of head and neck squamous cell carcinoma (HNSCC) treatment, is associated with significant postoperative neck disability. This study prospectively evaluates the trajectory of patient-reported and objective functional outcomes to quantify disability and identify key predictors.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A prospective cohort of 178 patients undergoing neck dissection for HNSCC was assessed preoperatively and at 3, 6, and 12&#x2009;months postoperatively. The primary outcome was the change in the Neck Disability Index (NDI). Secondary outcomes included neck pain (Visual Analog Scale, VAS), patient-specific function (Patient-Specific Functional Scale, PSFS), cervical range of motion (CROM), manual muscle testing (MMT), and spinal accessory nerve (SAN) function.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">At 12&#x2009;months, functional outcomes failed to return to preoperative baselines. A significant proportion of patients had severe neck disability (NDI&#x2009;&gt;&#x2009;25, 22.7%) or poor objective neck mobility (CROM&#x2009;&lt;&#x2009;70% normative, 26.7%). Radical neck dissection (RND vs. MRND/SND: OR&#x2009;=&#x2009;2.10, 95% CI: 1.02-4.32), dissection involving levels IV/V (OR&#x2009;=&#x2009;2.45, 95% CI: 1.11-5.39), and administration of chemotherapy (OR&#x2009;=&#x2009;2.18, 95% CI: 1.02-4.66) were independent predictors of severe disability. The upper trapezius was the most affected muscle, with SAN function remaining impaired in 42% of patients at 12&#x2009;months. Strong correlations were observed between subjective disability and objective measures like CROM (r&#x2009;=&#x2009;-0.72, p&#x2009;&lt;&#x2009;0.001) and trapezius strength (r&#x2009;=&#x2009;-0.65, p&#x2009;&lt;&#x2009;0.001).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Neck dissection results in persistent disability strongly linked to surgical extent and chemotherapy. The concordance between patient-reported and objective measures underscores the need for integrated assessment and the development of tailored, multidisciplinary rehabilitation to mitigate long-term morbidity.</AbstractText><CopyrightInformation>&#xa9; 2025 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Hongli</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Rehabilitation, The Fifth Clinical Medical College of Henan University of Chinese Medicine (Zhengzhou People's Hospital), Zhengzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Fujiang</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Rehabilitation, The 3rd Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gu</LastName><ForeName>Minjie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Rehabilitation, The 3rd Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wan</LastName><ForeName>Quanqing</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Rehabilitation, The 3rd Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Rubao</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Rehabilitation, The 3rd Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duan</LastName><ForeName>Lingling</ForeName><Initials>L</Initials><Identifier Source="ORCID">0009-0000-1501-9319</Identifier><AffiliationInfo><Affiliation>Department of Rehabilitation, The 2nd Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Mingbo</ForeName><Initials>M</Initials><Identifier Source="ORCID">0009-0002-5151-1786</Identifier><AffiliationInfo><Affiliation>Department of Rehabilitation, The Fifth Clinical Medical College of Henan University of Chinese Medicine (Zhengzhou People's Hospital), Zhengzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2019SJMZY03-01</GrantID><Agency>Provincial-Level Famous TCM Physician Quanqing Wan Studio Construction Project</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">head and neck squamous cell carcinoma</Keyword><Keyword MajorTopicYN="N">neck dissection</Keyword><Keyword MajorTopicYN="N">patient reported outcome measures</Keyword><Keyword MajorTopicYN="N">quality of life</Keyword><Keyword MajorTopicYN="N">spinal accessory nerve</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>11</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>11</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>9</Day><Hour>13</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>9</Day><Hour>13</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>9</Day><Hour>10</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41364079</ArticleId><ArticleId IdType="doi">10.1002/hed.70130</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>M. Pandey, S. Karthikeyan, D. Joshi, M. Kumar, and M. Shukla, &#x201c;Results of a Randomized Controlled Trial of Level IIb Preserving Neck Dissection in Clinically Node&#x2010;Negative Squamous Carcinoma of the Oral Cavity,&#x201d; World Journal of Surgical Oncology 16 (2018): 219.</Citation></Reference><Reference><Citation>K. J. Taylor, C. D. Amdal, K. Bjordal, et&#xa0;al., &#x201c;Long&#x2010;Term Health&#x2010;Related Quality of Life in Head and Neck Cancer Survivors: A Large Multinational Study,&#x201d; International Journal of Cancer 154 (2024): 1772&#x2013;1785.</Citation></Reference><Reference><Citation>M. K. Ghiam, K. Mannion, M. S. Dietrich, K. L. Stevens, J. Gilbert, and B. A. Murphy, &#x201c;Assessment of Musculoskeletal Impairment in Head and Neck Cancer Patients,&#x201d; Supportive Care in Cancer 25 (2017): 2085&#x2013;2092.</Citation></Reference><Reference><Citation>S. Spalthoff, R. Zimmerer, P. Jehn, N. C. Gellrich, J. Handschel, and G. Kr&#xfc;skemper, &#x201c;Neck Dissection's Burden on the Patient: Functional and Psychosocial Aspects in 1,652 Patients With Oral Squamous Cell Carcinomas,&#x201d; Journal of Oral and Maxillofacial Surgery 75 (2017): 839&#x2013;849.</Citation></Reference><Reference><Citation>G. Crile, III, &#x201c;On the Technique of Operations Upon the Head and Neck,&#x201d; Annals of Surgery 44 (1906): 842&#x2013;850.</Citation></Reference><Reference><Citation>B. Celik, H. Coskun, F. F. Kumas, et&#xa0;al., &#x201c;Accessory Nerve Function After Level 2b&#x2010;Preserving Selective Neck Dissection,&#x201d; Head &amp; Neck 31 (2009): 1496&#x2013;1501.</Citation></Reference><Reference><Citation>K. Murer, G. F. Huber, S. R. Haile, and S. J. Stoeckli, &#x201c;Comparison of Morbidity Between Sentinel Node Biopsy and Elective Neck Dissection for Treatment of the n0 Neck in Patients With Oral Squamous Cell Carcinoma,&#x201d; Head &amp; Neck 33 (2011): 1260&#x2013;1264.</Citation></Reference><Reference><Citation>G. van Hinte, J. G. H. Wetzels, M. A. W. Merkx, A. F. J. de Haan, R. Koole, and C. M. Speksnijder, &#x201c;Factors Influencing Neck and Shoulder Function After Oral Oncology Treatment: A Five&#x2010;Year Prospective Cohort Study in 113 Patients,&#x201d; Supportive Care in Cancer 27 (2019): 2553&#x2013;2560.</Citation></Reference><Reference><Citation>J. A. Cleland, J. M. Fritz, J. M. Whitman, and J. A. Palmer, &#x201c;The Reliability and Construct Validity of the Neck Disability Index and Patient Specific Functional Scale in Patients With Cervical Radiculopathy,&#x201d; Spine (Phila Pa 1976) 31 (2006): 598&#x2013;602.</Citation></Reference><Reference><Citation>Z. Bai, T. Shu, J. Lu, and W. Niu, &#x201c;Measurement Properties of the Functional Rating Index: A Systematic Review and Meta&#x2010;Analysis,&#x201d; Spine (Phila Pa 1976) 43 (2018): E1340&#x2013;E1349.</Citation></Reference><Reference><Citation>R. Pellini, G. Mercante, C. Marchese, et&#xa0;al., &#x201c;Predictive Factors for Postoperative Wound Complications After Neck Dissection,&#x201d; Acta Otorhinolaryngologica Italica 33 (2013): 16&#x2013;22.</Citation></Reference><Reference><Citation>A. Sakai, T. Nonaka, H. Furuya, et&#xa0;al., &#x201c;Shoulder Function After Neck Dissection With Level IIb Preservation: A Prospective Observational Study,&#x201d; Acta Oto&#x2010;Laryngologica 143 (2023): 814&#x2013;822.</Citation></Reference><Reference><Citation>C. M. Speksnijder, A. van der Bilt, M. Slappendel, A. de Wijer, M. A. Merkx, and R. Koole, &#x201c;Neck and Shoulder Function in Patients Treated for Oral Malignancies: A 1&#x2010;Year Prospective Cohort Study,&#x201d; Head &amp; Neck 35 (2013): 1303&#x2013;1313.</Citation></Reference><Reference><Citation>E. M. Gane, Z. A. Michaleff, M. A. Cottrell, et&#xa0;al., &#x201c;Prevalence, Incidence, and Risk Factors for Shoulder and Neck Dysfunction After Neck Dissection: A Systematic Review,&#x201d; European Journal of Surgical Oncology 43 (2017): 1199&#x2013;1218.</Citation></Reference><Reference><Citation>E. M. Gane, S. P. O'Leary, A. L. Hatton, B. J. Panizza, and S. M. McPhail, &#x201c;Neck and Upper Limb Dysfunction in Patients Following Neck Dissection: Looking Beyond the Shoulder,&#x201d; Otolaryngology and Head and Neck Surgery 157 (2017): 631&#x2013;640.</Citation></Reference><Reference><Citation>Y. H. Chen, W. A. Liang, C. Y. Hsu, et&#xa0;al., &#x201c;Functional Outcomes and Quality of Life After a 6&#x2010;Month Early Intervention Program for Oral Cancer Survivors: A Single&#x2010;Arm Clinical Trial,&#x201d; PeerJ 6 (2018): e4419.</Citation></Reference><Reference><Citation>E. M. Gane, S. M. McPhail, A. L. Hatton, B. J. Panizza, and S. P. O'Leary, &#x201c;The Relationship Between Physical Impairments, Quality of Life and Disability of the Neck and Upper Limb in Patients Following Neck Dissection,&#x201d; Journal of Cancer Survivorship 12 (2018): 619&#x2013;631.</Citation></Reference><Reference><Citation>E. M. Gane, S. M. McPhail, A. L. Hatton, B. J. Panizza, and S. P. O'Leary, &#x201c;Neck and Shoulder Motor Function Following Neck Dissection: A Comparison With Healthy Control Subjects,&#x201d; Otolaryngology and Head and Neck Surgery 160 (2019): 1009&#x2013;1018.</Citation></Reference><Reference><Citation>Y. H. Chen, C. R. Lin, W. A. Liang, and C. Y. Huang, &#x201c;Motor Control Integrated Into Muscle Strengthening Exercises Has More Effects on Scapular Muscle Activities and Joint Range of Motion Before Initiation of Radiotherapy in Oral Cancer Survivors With Neck Dissection: A Randomized Controlled Trial,&#x201d; PLoS One 15 (2020): e0237133.</Citation></Reference><Reference><Citation>M. Conley, J. Brooks, D. Oladokun, R. Dawson, and J. Moor, &#x201c;Motor and Sensory Complications Following Neck Dissection: A Prospective Telephone&#x2010;Interview Study,&#x201d; Journal of Laryngology and Otology 139 (2025): 663&#x2013;670.</Citation></Reference><Reference><Citation>Y. Li, W. Du, X. Zhang, et&#xa0;al., &#x201c;Impact of Cervical Osteoarthritis on Quality of Life After Free Flap Reconstruction in Head and Neck Cancer,&#x201d; Frontiers in Oncology 15 (2025): 1630458.</Citation></Reference><Reference><Citation>Z. Balogun, L. A. Gardiner, J. Li, E. A. Moroni, M. Rosenzweig, and M. L. Nilsen, &#x201c;Neighborhood Deprivation and Symptoms, Psychological Distress, and Quality of Life Among Head and Neck Cancer Survivors,&#x201d; JAMA Otolaryngology. Head &amp; Neck Surgery 150 (2024): 295&#x2013;302.</Citation></Reference><Reference><Citation>S. Crimi, S. Battaglia, C. Maugeri, et&#xa0;al., &#x201c;Does Age Affect the Rate of Spinal Nerve Injury After Selective Neck Dissection? Age as a Prognostic Factor of Spinal Nerve Injury After Selective Neck Dissection,&#x201d; Journal of Personalized Medicine 13 (2023): 1082.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70096 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41358506</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Dec</Month><Day>08</Day></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Appraisal of Radiologic Size Criteria for Malignant Lymph Nodes in Parotid Region in Nasopharyngeal Carcinoma: Implication for Parotid-Sparing IMRT.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70096</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">We evaluate the appropriateness of current radiology size criteria (short axial diameter, SAD &#x2265;&#x2009;10&#x2009;mm) for malignant nodes in the parotid region (PLN), and appreciate the clinical implications of the Node-Reporting-and-Data-System (Node-RADS) in nasopharyngeal carcinoma (NPC).</AbstractText><AbstractText Label="METHODS AND MATERIAL" NlmCategory="METHODS">NPC patients who received curative IMRT were included. Pre-treatment MRI was reviewed by two radiologists to record the presence/absence, size, and configuration of PLN, and calculated Node-RADS score. Malignant PLN was defined as either fine-needle aspiration (FNA) positive or the occurrence of subsequent out-field in&#xa0;situ PLN failure following parotid-sparing IMRT.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Pre-treatment PLN was identified in 74 (11.8%) of 627 consecutive patients. SAD PLNs were 5-6&#x2009;mm (n&#x2009;=&#x2009;53, 72%), 6-8&#x2009;mm (n&#x2009;=&#x2009;15, 20%), 8-10&#x2009;mm (n&#x2009;=&#x2009;4, 5%), and&#x2009;&#x2265;&#x2009;10&#x2009;mm (2, 3%), respectively. FNAs were positive in 6 patients (2 each in SAD 6-8&#x2009;mm, 8-10&#x2009;mm, and&#x2009;&#x2265;&#x2009;10&#x2009;mm). Out-field in&#xa0;situ PLN failure occurred in 6 patients: 1 with SAD 5-6&#x2009;mm, 3 with SAD 6-8&#x2009;mm, and 2 with SAD 8-10&#x2009;mm. The risk of PLN being malignant was 1.9% (1/53), 33.3% (5/15), 100% (4/4), and 100% (2/2) in SAD 5-6&#x2009;mm, 6-8&#x2009;mm, 8-10&#x2009;mm, and&#x2009;&#x2265;&#x2009;10&#x2009;mm subsets, respectively. Malignant PLN with Node-RADS score &#x2265;&#x2009;4 were 10% (1/10), 45.5% (5/11), and 100% (4/4) in SAD 5-6&#x2009;mm, 6-8&#x2009;mm, 8-10&#x2009;mm subsets, respectively.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Current radiologic size criteria of &#x2265;&#x2009;10&#x2009;mm for positive PLN should be reduced to &#x2265;&#x2009;8&#x2009;mm. Node-RADS score of 4-5, which includes adverse morphological nodal features, could improve the specificity of identifying malignant PLNs in the 6-8&#x2009;mm subset.</AbstractText><CopyrightInformation>&#xa9; 2025 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Qiaojuan</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0002-4091-8014</Identifier><AffiliationInfo><Affiliation>Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fujian Key Laboratory of Translational Cancer Medicine, Fuzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Xiaojing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Zhiwei</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xinlan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Lisha</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Caizhu</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zong</LastName><ForeName>Jingfeng</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Hanchuan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Yahan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Ziyi</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Youping</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Radiology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Jianji</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fujian Key Laboratory of Translational Cancer Medicine, Fuzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Shao Hui</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Princess Margaret Cancer Centre/University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Shaojun</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-7164-9761</Identifier><AffiliationInfo><Affiliation>Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fujian Key Laboratory of Translational Cancer Medicine, Fuzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">diagnostic criteria</Keyword><Keyword MajorTopicYN="N">intensity modulated radiotherapy</Keyword><Keyword MajorTopicYN="N">nasopharyngeal carcinoma</Keyword><Keyword MajorTopicYN="N">node reporting and data system</Keyword><Keyword MajorTopicYN="N">parotid lymph nodes</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>10</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>8</Day><Hour>13</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>8</Day><Hour>13</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>8</Day><Hour>7</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41358506</ArticleId><ArticleId IdType="doi">10.1002/hed.70096</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>L. Lin, Y. Lu, X. J. Wang, et&#xa0;al., &#x201c;Delineation of Neck Clinical Target Volume Specific to Nasopharyngeal Carcinoma Based on Lymph Node Distribution and the International Consensus Guidelines,&#x201d; International Journal of Radiation Oncology, Biology, Physics 100, no. 4 (2018): 891&#x2013;902.</Citation></Reference><Reference><Citation>X. Wang, C. Hu, H. Ying, et&#xa0;al., &#x201c;Patterns of Lymph Node Metastasis From Nasopharyngeal Carcinoma Based on the 2013 Updated Consensus Guidelines for Neck Node Levels,&#x201d; Radiotherapy and Oncology 115, no. 1 (2015): 41&#x2013;45.</Citation></Reference><Reference><Citation>A. W. Lee, W. T. Ng, J. J. Pan, et&#xa0;al., &#x201c;International Guideline for the Delineation of the Clinical Target Volumes (CTV) for Nasopharyngeal Carcinoma,&#x201d; Radiotherapy and Oncology 126, no. 1 (2018): 25&#x2013;36.</Citation></Reference><Reference><Citation>N. Lee, J. Harris, A. S. Garden, et&#xa0;al., &#x201c;Intensity&#x2010;Modulated Radiation Therapy With or Without Chemotherapy for Nasopharyngeal Carcinoma: Radiation Therapy Oncology Group Phase II Trial 0225,&#x201d; Journal of Clinical Oncology 27, no. 22 (2009): 3684&#x2013;3690.</Citation></Reference><Reference><Citation>N. Y. Lee, Q. Zhang, D. G. Pfister, et&#xa0;al., &#x201c;Addition of Bevacizumab to Standard Chemoradiation for Locoregionally Advanced Nasopharyngeal Carcinoma (RTOG 0615): A Phase 2 Multi&#x2010;Institutional Trial,&#x201d; Lancet Oncology 13, no. 2 (2012): 172&#x2013;180.</Citation></Reference><Reference><Citation>M. W. van den Brekel, H. V. Stel, J. A. Castelijns, et&#xa0;al., &#x201c;Cervical Lymph Node Metastasis: Assessment of Radiologic Criteria,&#x201d; Radiology 177, no. 2 (1990): 379&#x2013;384.</Citation></Reference><Reference><Citation>D. M. Cannon and N. Y. Lee, &#x201c;Recurrence in Region of Spared Parotid Gland After Definitive Intensity&#x2010;Modulated Radiotherapy for Head and Neck Cancer,&#x201d; International Journal of Radiation Oncology, Biology, Physics 70, no. 3 (2008): 660&#x2013;665.</Citation></Reference><Reference><Citation>C. N. Cao, J. W. Luo, L. Gao, G. Z. Xu, S. Y. Li, and J. P. Xiao, &#x201c;Recurrence of Nasopharyngeal Carcinoma in the Parotid Region After Definitive Intensity&#x2010;Modulated Radiotherapy,&#x201d; Journal of Oral and Maxillofacial Surgery 71, no. 11 (2013): 1993&#x2013;1997.</Citation></Reference><Reference><Citation>D. S. Lin, Y. M. Jen, J. C. Lee, S. C. Liu, and Y. S. Lin, &#x201c;Recurrence of Nasopharyngeal Carcinoma in the Parotid Region After Parotid&#x2010;Gland&#x2010;Sparing Radiotherapy,&#x201d; Journal of the Formosan Medical Association 110, no. 10 (2011): 655&#x2013;660.</Citation></Reference><Reference><Citation>J. Li, P. Venigalla, J. E. Leeman, et&#xa0;al., &#x201c;Patterns of Nodal Failure After Intensity Modulated Radiotherapy for Nasopharyngeal Carcinoma,&#x201d; Laryngoscope 127, no. 2 (2017): 377&#x2013;382.</Citation></Reference><Reference><Citation>Y. Xu, M. Zhang, Q. Yue, et&#xa0;al., &#x201c;Analysis of Rare Periparotid Recurrence After Parotid Gland&#x2010;Sparing Intensity&#x2010;Modulated Radiotherapy for Nasopharyngeal Carcinoma,&#x201d; Cancer Radioth&#xe9;rapie 20, no. 5 (2016): 377&#x2013;383.</Citation></Reference><Reference><Citation>Q. Guo, T. Lu, W. Huang, et&#xa0;al., &#x201c;Selectively Sparing of the Supraclavicular Area During Intensity&#x2010;Modulated Radiotherapy in Nasopharyngeal Carcinoma: A Double&#x2010;Center Observation Study,&#x201d; Radiotherapy and Oncology 192 (2024): 110086.</Citation></Reference><Reference><Citation>X. Xiao, Y. Wu, Y. Chen, et&#xa0;al., &#x201c;Patterns and Prognosis of Regional Recurrence in Nasopharyngeal Carcinoma After Intensity&#x2010;Modulated Radiotherapy,&#x201d; Cancer Medicine 12, no. 2 (2023): 1399&#x2013;1408.</Citation></Reference><Reference><Citation>J. J. Pan, W. T. Ng, J. F. Zong, et&#xa0;al., &#x201c;Proposal for the 8th Edition of the AJCC/UICC Staging System for Nasopharyngeal Cancer in the Era of Intensity&#x2010;Modulated Radiotherapy,&#x201d; Cancer 122, no. 4 (2016): 546&#x2013;558.</Citation></Reference><Reference><Citation>H. Peng, L. Chen, L. L. Tang, et&#xa0;al., &#x201c;Significant Value of 18F&#x2010;FDG&#x2010;PET/CT in Diagnosing Small Cervical Lymph Node Metastases in Patients With Nasopharyngeal Carcinoma Treated With Intensity&#x2010;Modulated Radiotherapy,&#x201d; Chinese Journal of Cancer 36, no. 1 (2017): 95.</Citation></Reference><Reference><Citation>F. H. J. Elsholtz, P. Asbach, M. Haas, et&#xa0;al., &#x201c;Introducing the Node Reporting and Data System 1.0 (Node&#x2010;RADS): A Concept for Standardized Assessment of Lymph Nodes in Cancer,&#x201d; European Radiology 31, no. 8 (2021): 6116&#x2013;6124.</Citation></Reference><Reference><Citation>Q. Y. H. Ai, T. Y. So, K. F. Hung, and A. D. King, &#x201c;Normal Size of Benign Upper Neck Nodes on MRI: Parotid, Submandibular, Occipital, Facial, Retroauricular and Level IIb Nodal Groups,&#x201d; Cancer Imaging 22, no. 1 (2022): 66.</Citation></Reference><Reference><Citation>V. Gr&#xe9;goire, K. Ang, W. Budach, et&#xa0;al., &#x201c;Delineation of the Neck Node Levels for Head and Neck Tumors: A 2013 Update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG Consensus Guidelines,&#x201d; Radiotherapy and Oncology 110, no. 1 (2014): 172&#x2013;181.</Citation></Reference><Reference><Citation>Q. Guo, Y. Zheng, J. Lin, et&#xa0;al., &#x201c;Modified Reduced&#x2010;Volume Intensity&#x2010;Modulated Radiation Therapy in Non&#x2010;Metastatic Nasopharyngeal Carcinoma: A Prospective Observation Series,&#x201d; Radiotherapy and Oncology 156 (2021): 251&#x2013;257.</Citation></Reference><Reference><Citation>H. z. Wang, C. n. Cao, J. w. Luo, et&#xa0;al., &#x201c;High&#x2010;Risk Factors of Parotid Lymph Node Metastasis in Nasopharyngeal Carcinoma: A Case&#x2010;Control Study,&#x201d; Radiation Oncology 11, no. 1 (2016): 113.</Citation></Reference><Reference><Citation>Y. Zhang, Z. C. Zhang, W. F. Li, X. Liu, Q. Liu, and J. Ma, &#x201c;Prognosis and Staging of Parotid Lymph Node Metastasis in Nasopharyngeal Carcinoma: An Analysis in 10,126 Patients,&#x201d; Oral Oncology 95 (2019): 150&#x2013;156.</Citation></Reference><Reference><Citation>Y. Xu, M. Zhang, Y. Xiao, et&#xa0;al., &#x201c;Parotid Area Lymph Node Metastases From Preliminarily Diagnosed Patients With Nasopharyngeal Carcinoma: Report on Tumor Characteristics and Oncologic Outcomes,&#x201d; Oncotarget 7, no. 15 (2016): 19654&#x2013;19665.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70124 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41355498</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Dec</Month><Day>08</Day></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Minimizing Chemoradiation Using a Surgical Algorithm for HPV-Associated Cancer of Unknown Primary.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70124</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The majority of lesions originally diagnosed as cancer of unknown primary (CUP) are eventually identified as HPV-associated oropharyngeal squamous cell carcinoma. Accurate primary tumor localization can facilitate targeted treatment or reduce adjuvant therapy.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This retrospective study examined patients who underwent transoral robotic surgery (TORS) for CUP from 2019 to 2022 at a tertiary care center. We analyzed the primary tumor identification rate, recurrence rate, and need for adjuvant therapy.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 48 patients with HPV-associated CUP underwent TORS, achieving an 87.5% identification rate (42/48). A total of 39.5% (19/48) avoided direct radiation to the primary site, and 20.8% (10/48) received no radiation. No patients had local recurrence, though three experienced regional or distant recurrence.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">A primary surgical approach to HPV-associated CUP of the head and neck should be considered in every patient with CUP. When combined with a robust frozen section pathology protocol helping to guide intraoperative decision-making and margin revision, and a multidisciplinary approach to adjuvant therapy, precise tumor localization can help appropriately direct adjuvant therapy.</AbstractText><CopyrightInformation>&#xa9; 2025 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Daoud</LastName><ForeName>Georges E</ForeName><Initials>GE</Initials><Identifier Source="ORCID">0000-0003-3354-957X</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burnham</LastName><ForeName>Andre J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Emory University School of Medicine, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vettikattu</LastName><ForeName>Nikhil T</ForeName><Initials>NT</Initials><AffiliationInfo><Affiliation>Emory University School of Medicine, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmitt</LastName><ForeName>Nicole C</ForeName><Initials>NC</Initials><Identifier Source="ORCID">0000-0002-0571-3531</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Emory University School of Medicine, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boyce</LastName><ForeName>Brian J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Emory University School of Medicine, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gross</LastName><ForeName>Jennifer H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Emory University School of Medicine, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baddour</LastName><ForeName>Harry M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Emory University School of Medicine, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El-Deiry</LastName><ForeName>Mark W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Emory University School of Medicine, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steuer</LastName><ForeName>Conor E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Hematology Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saba</LastName><ForeName>Nabil F</ForeName><Initials>NF</Initials><Identifier Source="ORCID">0000-0003-4972-1477</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Hematology Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bates</LastName><ForeName>James E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stokes</LastName><ForeName>William A</ForeName><Initials>WA</Initials><Identifier Source="ORCID">0000-0002-1616-7046</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Magliocca</LastName><ForeName>Kelly R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>Department of Oral and Maxillofacial Pathology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Mihir R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Emory University School of Medicine, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaka</LastName><ForeName>Azeem S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Emory University School of Medicine, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cancer of unknown primary</Keyword><Keyword MajorTopicYN="N">human papilloma virus</Keyword><Keyword MajorTopicYN="N">oropharyngeal squamous cell carcinoma</Keyword><Keyword MajorTopicYN="N">transoral robotic surgery</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>11</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>8</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>8</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>8</Day><Hour>4</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41355498</ArticleId><ArticleId IdType="doi">10.1002/hed.70124</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>W. R. McIlwain, A. J. Sood, S. A. Nguyen, and T. A. Day, &#x201c;Initial Symptoms in Patients With HPV&#x2010;Positive and HPV&#x2010;Negative Oropharyngeal Cancer,&#x201d; JAMA Otolaryngology. Head &amp; Neck Surgery 140, no. 5 (2014): 441&#x2013;447, https://doi.org/10.1001/jamaoto.2014.141.</Citation></Reference><Reference><Citation>P. Golusinski, P. Di Maio, B. Pehlivan, et&#xa0;al., &#x201c;Evidence for the Approach to the Diagnostic Evaluation of Squamous Cell Carcinoma Occult Primary Tumors of the Head and Neck,&#x201d; Oral Oncology 88 (2019): 145&#x2013;152, https://doi.org/10.1016/j.oraloncology.2018.11.020.</Citation></Reference><Reference><Citation>L. J. Schipper, K. G. Samsom, P. Snaebjornsson, et&#xa0;al., &#x201c;Complete Genomic Characterization in Patients With Cancer of Unknown Primary Origin in Routine Diagnostics,&#x201d; ESMO Open 7, no. 6 (2022): 100611, https://doi.org/10.1016/j.esmoop.2022.100611.</Citation></Reference><Reference><Citation>M. A. Cummings, S. J. Ma, P. Van Der Sloot, M. T. Milano, D. P. Singh, and A. K. Singh, &#x201c;Squamous Cell Carcinoma of the Head and Neck With Unknown Primary: Trends and Outcomes From a Hospital&#x2010;Based Registry,&#x201d; Annals of Translational Medicine 9, no. 4 (2021): 284, https://doi.org/10.21037/atm&#x2010;20&#x2010;4631.</Citation></Reference><Reference><Citation>T. Tham, S. Ahn, D. Frank, D. Kraus, and P. Costantino, &#x201c;Anatomical Subsite Modifies Survival in Oropharyngeal Squamous Cell Carcinoma: National Cancer Database Study,&#x201d; Head &amp; Neck 42, no. 3 (2020): 434&#x2013;445, https://doi.org/10.1002/hed.26019.</Citation></Reference><Reference><Citation>A. F. Carlander, K. K. Jakobsen, S. K. Bendtsen, et&#xa0;al., &#x201c;A Contemporary Systematic Review on Repartition of HPV&#x2010;Positivity in Oropharyngeal Cancer Worldwide,&#x201d; Viruses 13, no. 7 (2021): 1326, https://doi.org/10.3390/v13071326.</Citation></Reference><Reference><Citation>P. C. Desai, M. V. Jaglal, P. Gopal, et&#xa0;al., &#x201c;Human Papillomavirus in Metastatic Squamous Carcinoma From Unknown Primaries in the Head and Neck: A Retrospective 7 Year Study,&#x201d; Experimental and Molecular Pathology 87, no. 2 (2009): 94&#x2013;98, https://doi.org/10.1016/j.yexmp.2009.04.003.</Citation></Reference><Reference><Citation>D. H. Jensen, N. Hedback, L. Specht, et&#xa0;al., &#x201c;Human Papillomavirus in Head and Neck Squamous Cell Carcinoma of Unknown Primary Is a Common Event and a Strong Predictor of Survival,&#x201d; PLoS One 9, no. 11 (2014): e110456, https://doi.org/10.1371/journal.pone.0110456.</Citation></Reference><Reference><Citation>A. M. Compton, T. Moore&#x2010;Medlin, L. Herman&#x2010;Ferdinandez, et&#xa0;al., &#x201c;Human Papillomavirus in Metastatic Lymph Nodes From Unknown Primary Head and Neck Squamous Cell Carcinoma,&#x201d; Otolaryngology and Head and Neck Surgery 145, no. 1 (2011): 51&#x2013;57, https://doi.org/10.1177/0194599811400385.</Citation></Reference><Reference><Citation>S. Tribius, A. S. Hoffmann, S. Bastrop, et&#xa0;al., &#x201c;HPV Status in Patients With Head and Neck of Carcinoma of Unknown Primary Site: HPV, Tobacco Smoking, and Outcome,&#x201d; Oral Oncology 48, no. 11 (2012): 1178&#x2013;1184, https://doi.org/10.1016/j.oraloncology.2012.05.022.</Citation></Reference><Reference><Citation>K. Kobayashi, Y. Saito, G. Omura, et&#xa0;al., &#x201c;Clinical Features of Human Papilloma Virus&#x2010;Related Head and Neck Squamous Cell Carcinoma of an Unknown Primary Site,&#x201d; ORL 76, no. 3 (2014): 137&#x2013;146, https://doi.org/10.1159/000363190.</Citation></Reference><Reference><Citation>P. Zengel, G. Assmann, M. Mollenhauer, et&#xa0;al., &#x201c;Cancer of Unknown Primary Originating From Oropharyngeal Carcinomas Are Strongly Correlated to HPV Positivity,&#x201d; Virchows Archiv 461, no. 3 (2012): 283&#x2013;290, https://doi.org/10.1007/s00428&#x2010;012&#x2010;1290&#x2010;3.</Citation></Reference><Reference><Citation>K. Durmus, S. V. Rangarajan, M. O. Old, A. Agrawal, T. N. Teknos, and E. Ozer, &#x201c;Transoral Robotic Approach to Carcinoma of Unknown Primary,&#x201d; Head &amp; Neck 36, no. 6 (2014): 848&#x2013;852, https://doi.org/10.1002/hed.23385.</Citation></Reference><Reference><Citation>A. Al&#x2010;Lami, C. Gao, M. Saddiq, et&#xa0;al., &#x201c;Reducing the Unknowns: A Systematic Review &amp; Meta&#x2010;Analysis of the Effectiveness of Trans&#x2010;Oral Surgical Techniques in Identifying Head and Neck Primary Cancer in Carcinoma Unknown Primary,&#x201d; Oral Oncology 126 (2022): 105748, https://doi.org/10.1016/j.oraloncology.2022.105748.</Citation></Reference><Reference><Citation>R. M. Ferrandino, S. Chen, C. Kappauf, et&#xa0;al., &#x201c;Performance of Liquid Biopsy for Diagnosis and Surveillance of Human Papillomavirus&#x2010;Associated Oropharyngeal Cancer,&#x201d; JAMA Otolaryngology. Head &amp; Neck Surgery 149, no. 11 (2023): 971&#x2013;977, https://doi.org/10.1001/jamaoto.2023.1937.</Citation></Reference><Reference><Citation>B. S. Chera, S. Kumar, B. T. Beaty, et&#xa0;al., &#x201c;Rapid Clearance Profile of Plasma Circulating Tumor HPV Type 16 DNA During Chemoradiotherapy Correlates With Disease Control in HPV&#x2010;Associated Oropharyngeal Cancer,&#x201d; Clinical Cancer Research 25, no. 15 (2019): 4682&#x2013;4690, https://doi.org/10.1158/1078&#x2010;0432.CCR&#x2010;19&#x2010;0211.</Citation></Reference><Reference><Citation>K. K. Jensen, C. Gr&#xf8;nh&#xf8;j, D. H. Jensen, and C. von Buchwald, &#x201c;Circulating Human Papillomavirus DNA as a Surveillance Tool in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta&#x2010;Analysis,&#x201d; Clinical Otolaryngology 43, no. 5 (2018): 1242&#x2013;1249, https://doi.org/10.1111/coa.13136.</Citation></Reference><Reference><Citation>G. J. Hanna, J. G. Supplee, Y. Kuang, et&#xa0;al., &#x201c;Plasma HPV Cell&#x2010;Free DNA Monitoring in Advanced HPV&#x2010;Associated Oropharyngeal Cancer,&#x201d; Annals of Oncology 29, no. 9 (2018): 1980&#x2013;1986, https://doi.org/10.1093/annonc/mdy251.</Citation></Reference><Reference><Citation>M. Egyud, P. Sridhar, A. Devaiah, et&#xa0;al., &#x201c;Plasma Circulating Tumor DNA as a Potential Tool for Disease Monitoring in Head and Neck Cancer,&#x201d; Head &amp; Neck 41, no. 5 (2019): 1351&#x2013;1358, https://doi.org/10.1002/hed.25563.</Citation></Reference><Reference><Citation>M. Kubik, R. Mandal, W. Albergotti, U. Duvvuri, R. L. Ferris, and S. Kim, &#x201c;Effect of Transcervical Arterial Ligation on the Severity of Postoperative Hemorrhage After Transoral Robotic Surgery,&#x201d; Head &amp; Neck 39, no. 8 (2017): 1510&#x2013;1515, https://doi.org/10.1002/hed.24677.</Citation></Reference><Reference><Citation>M. B. Amin, S. B. Edge, F. L. Greene, et&#xa0;al., AJCC Cancer Staging Manual, 8th ed. (Springer, 2017).</Citation></Reference><Reference><Citation>S. Swisher&#x2010;McClure, J. N. Lukens, C. Aggarwal, et&#xa0;al., &#x201c;A Phase 2 Trial of Alternative Volumes of Oropharyngeal Irradiation for De&#x2010;Intensification (AVOID): Omission of the Resected Primary Tumor Bed After Transoral Robotic Surgery for Human Papilloma Virus&#x2010;Related Squamous Cell Carcinoma of the Oropharynx,&#x201d; International Journal of Radiation Oncology, Biology, Physics 106, no. 4 (2020): 725&#x2013;732, https://doi.org/10.1016/j.ijrobp.2019.11.021.</Citation></Reference><Reference><Citation>V. R. Dhere, C. E. Escott, S. Tian, et&#xa0;al., &#x201c;The Omission of Intentional Primary Site Radiation Following Transoral Robotic Surgery in 59 Patients: No Local&#x2010;Regional Failures,&#x201d; Head &amp; Neck 44, no. 2 (2022): 382&#x2013;390, https://doi.org/10.1002/hed.26928.</Citation></Reference><Reference><Citation>M. Filauro, A. Paderno, P. Perotti, et&#xa0;al., &#x201c;Role of Narrow&#x2010;Band Imaging in Detection of Head and Neck Unknown Primary Squamous Cell Carcinoma,&#x201d; Laryngoscope 128, no. 9 (2018): 2060&#x2013;2066, https://doi.org/10.1002/lary.27098.</Citation></Reference><Reference><Citation>C. Fakhry, N. Agrawal, J. Califano, et&#xa0;al., &#x201c;The Use of Ultrasound in the Search for the Primary Site of Unknown Primary Head and Neck Squamous Cell Cancers,&#x201d; Oral Oncology 50, no. 7 (2014): 640&#x2013;645, https://doi.org/10.1016/j.oraloncology.2014.03.015.</Citation></Reference><Reference><Citation>W. K. Mydlarz, J. Liu, R. Blanco, and C. Fakhry, &#x201c;Transcervical Ultrasound Identifies Primary Tumor Site of Unknown Primary Head and Neck Squamous Cell Carcinoma,&#x201d; Otolaryngology and Head and Neck Surgery 151, no. 6 (2014): 1090&#x2013;1092, https://doi.org/10.1177/0194599814549181.</Citation></Reference><Reference><Citation>C. M. Bowe and M. Garg, &#x201c;The Role of Non&#x2010;Oropharyngeal Biopsies in Head and Neck Squamous Cell Carcinoma of Unknown Primary: A Systematic Review,&#x201d; Clinical Otolaryngology 49 (2024): 531&#x2013;537, https://doi.org/10.1111/coa.14157.</Citation></Reference><Reference><Citation>J. Ren, W. Yang, J. Su, et&#xa0;al., &#x201c;Human Papillomavirus and p16 Immunostaining, Prevalence and Prognosis of Squamous Carcinoma of Unknown Primary in the Head and Neck Region,&#x201d; International Journal of Cancer 145, no. 6 (2019): 1465&#x2013;1474, https://doi.org/10.1002/ijc.32164.</Citation></Reference><Reference><Citation>T. Hutchens, W. Thorstad, X. Wang, et&#xa0;al., &#x201c;Head and Neck Squamous Cell Carcinomas of Unknown Primary: Can Ancillary Studies Help Identify More Primary Tumor Sites?,&#x201d; Experimental and Molecular Pathology 138 (2024): 104915, https://doi.org/10.1016/j.yexmp.2024.104915.</Citation></Reference><Reference><Citation>V. Ruhlmann, M. Ruhlmann, A. Bellendorf, et&#xa0;al., &#x201c;Hybrid Imaging for Detection of Carcinoma of Unknown Primary: A Preliminary Comparison Trial of Whole&#x2010;Body PET/MRI Versus PET/CT,&#x201d; European Journal of Radiology 85, no. 11 (2016): 1941&#x2013;1947, https://doi.org/10.1016/j.ejrad.2016.08.020.</Citation></Reference><Reference><Citation>J. D. Waltonen, E. Ozer, N. C. Hall, D. E. Schuller, and A. Agrawal, &#x201c;Metastatic Carcinoma of the Neck of Unknown Primary Origin: Evolution and Efficacy of the Modern Workup,&#x201d; Archives of Otolaryngology &#x2013; Head &amp; Neck Surgery 135, no. 10 (2009): 1024&#x2013;1029, https://doi.org/10.1001/archoto.2009.145.</Citation></Reference><Reference><Citation>M. Cianchetti, A. A. Mancuso, R. J. Amdur, et&#xa0;al., &#x201c;Diagnostic Evaluation of Squamous Cell Carcinoma Metastatic to Cervical Lymph Nodes From an Unknown Head and Neck Primary Site,&#x201d; Laryngoscope 119, no. 12 (2009): 2348&#x2013;2354, https://doi.org/10.1002/lary.20638.</Citation></Reference><Reference><Citation>M. Pinkiewicz, K. Dorobisz, and T. Zato&#x144;ski, &#x201c;A Systematic Review of Cancer of Unknown Primary in the Head and Neck Region,&#x201d; Cancer Management and Research 13 (2021): 7235&#x2013;7241, https://doi.org/10.2147/CMAR.S319179.</Citation></Reference><Reference><Citation>M. Geltzeiler, S. Doerfler, M. Turner, et&#xa0;al., &#x201c;Transoral Robotic Surgery for Management of Cervical Unknown Primary Squamous Cell Carcinoma: Updates on Efficacy, Surgical Technique and Margin Status,&#x201d; Oral Oncology 66 (2017): 9&#x2013;13, https://doi.org/10.1016/j.oraloncology.2016.12.033.</Citation></Reference><Reference><Citation>K. M. Hatten, B. W. O'Malley, A. M. Bur, et&#xa0;al., &#x201c;Transoral Robotic Surgery&#x2010;Assisted Endoscopy With Primary Site Detection and Treatment in Occult Mucosal Primaries,&#x201d; JAMA Otolaryngology. Head &amp; Neck Surgery 143, no. 3 (2017): 267&#x2013;273, https://doi.org/10.1001/jamaoto.2016.3419.</Citation></Reference><Reference><Citation>R. L. Ferris, Y. Flamand, G. S. Weinstein, et&#xa0;al., &#x201c;Phase II Randomized Trial of Transoral Surgery and Low&#x2010;Dose Intensity Modulated Radiation Therapy in Resectable&#xa0;p16+ Locally Advanced Oropharynx Cancer: An ECOG&#x2010;ACRIN Cancer Research Group Trial (E3311),&#x201d; Journal of Clinical Oncology 40, no. 2 (2022): 138&#x2013;149, https://doi.org/10.1200/JCO.21.01752.</Citation></Reference><Reference><Citation>B. A. Miles, M. R. Posner, V. Gupta, et&#xa0;al., &#x201c;De&#x2010;Escalated Adjuvant Therapy After Transoral Robotic Surgery for Human Papillomavirus&#x2010;Related Oropharyngeal Carcinoma: The Sinai Robotic Surgery (SIRS) Trial,&#x201d; Oncologist 26, no. 6 (2021): 504&#x2013;513, https://doi.org/10.1002/onco.13742.</Citation></Reference><Reference><Citation>A. Beddok, A. Vela, V. Calugaru, et&#xa0;al., &#x201c;Proton Therapy for Head and Neck Squamous Cell Carcinomas: A Review of the Physical and Clinical Challenges,&#x201d; Radiotherapy and Oncology 147 (2020): 30&#x2013;39, https://doi.org/10.1016/j.radonc.2020.03.006.</Citation></Reference><Reference><Citation>S. Nuyts, H. Bollen, S. P. Ng, et&#xa0;al., &#x201c;Proton Therapy for Squamous Cell Carcinoma of the Head and Neck: Early Clinical Experience and Current Challenges,&#x201d; Cancers 14, no. 11 (2022): 2587, https://doi.org/10.3390/cancers14112587.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70122 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41346079</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Dec</Month><Day>04</Day></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Disparities in Proton Radiation Utilization for HPV-Associated Oropharyngeal Cancer Following TORS.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70122</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Racial, socioeconomic, and geographic disparities in receipt of proton radiation have been reported. Whether disparities exist for oropharyngeal squamous cell carcinoma (OPSCC) is not well studied.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients with HPV-associated OPSCC treated with transoral robotic surgery (TORS) and adjuvant radiation from 2016 to 2023 were reviewed. Demographics, disease characteristics, treatment details, and socioeconomic variables were collected.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 116 patients, 102 (87.9%) were male, 105 (90.5%) White, with a median age of 59.7&#x2009;years. Fifty (43.1%) received proton radiation. Age, gender, race, tumor subsite, tumor and nodal staging, insurance, employment, and distance from our institution were not significantly associated with proton radiation, while higher median income was (p&#x2009;=&#x2009;0.04).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">While higher median income was significantly associated with proton radiation, other traditionally described disparities were not apparent for HPV-associated OPSCC treated with TORS. Although this cohort included predominantly privately insured White males, access to adjuvant proton therapy seemed to be equitably available across demographics.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). Head &amp; Neck published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tong</LastName><ForeName>Jane Y</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology-Head and Neck Surgery, School of Medicine, University of Maryland, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bzhilyanskaya</LastName><ForeName>Vera</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-7886-4613</Identifier><AffiliationInfo><Affiliation>Department of Otorhinolaryngology-Head and Neck Surgery, School of Medicine, University of Maryland, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molitoris</LastName><ForeName>Jason K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, School of Medicine, University of Maryland, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferris</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0003-0402-4707</Identifier><AffiliationInfo><Affiliation>Department of Radiation Oncology, School of Medicine, University of Maryland, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hatten</LastName><ForeName>Kyle M</ForeName><Initials>KM</Initials><Identifier Source="ORCID">0000-0003-3980-296X</Identifier><AffiliationInfo><Affiliation>Department of Otorhinolaryngology-Head and Neck Surgery, School of Medicine, University of Maryland, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HPV</Keyword><Keyword MajorTopicYN="N">TORS</Keyword><Keyword MajorTopicYN="N">disparities</Keyword><Keyword MajorTopicYN="N">oropharyngeal cancer</Keyword><Keyword MajorTopicYN="N">proton radiation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>9</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>11</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>5</Day><Hour>6</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>5</Day><Hour>6</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>5</Day><Hour>1</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41346079</ArticleId><ArticleId IdType="doi">10.1002/hed.70122</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>G. Anderson, M. Ebadi, K. Vo, J. Novak, A. Govindarajan, and A. Amini, &#x201c;An Updated Review on Head and Neck Cancer Treatment With Radiation Therapy,&#x201d; Cancers 13, no. 19 (2021): 4912, https://doi.org/10.3390/cancers13194912.</Citation></Reference><Reference><Citation>S. I. Gutiontov, E. J. Shin, B. Lok, N. Y. Lee, and R. Cabanillas, &#x201c;Intensity&#x2010;Modulated Radiation Therapy (IMRT) for Head and Neck Surgeons,&#x201d; Head and Neck 38, no. 1 (2016): E2368&#x2013;E2373, https://doi.org/10.1002/hed.24338.</Citation></Reference><Reference><Citation>B. O'Sullivan, R. B. Rumble, and P. Warde, &#x201c;Intensity&#x2010;Modulated Radiotherapy in the Treatment of Head and Neck Cancer,&#x201d; Clinical Oncology 24, no. 7 (2012): 474&#x2013;487, https://doi.org/10.1016/j.clon.2012.05.006.</Citation></Reference><Reference><Citation>W. M. Mendenhall, J. J. Beitler, N. F. Saba, et&#xa0;al., &#x201c;Proton Beam Radiation Therapy for Oropharyngeal Squamous Cell Carcinoma,&#x201d; International Journal of Particle Therapy 9, no. 4 (2023): 243&#x2013;252, https://doi.org/10.14338/IJPT&#x2010;22&#x2010;00030.1.</Citation></Reference><Reference><Citation>Z. Chen, M. M. Dominello, M. C. Joiner, and J. W. Burmeister, &#x201c;Proton Versus Photon Radiation Therapy: A Clinical Review,&#x201d; Frontiers in Oncology 13 (2023): 1133909, https://doi.org/10.3389/fonc.2023.1133909.</Citation></Reference><Reference><Citation>J. Y. Tong, V. Bzhilyanskaya, M. J. Ferris, J. K. Molitoris, and K. M. Hatten, &#x201c;Adjuvant Proton Radiation Following Transoral Robotic Surgery for HPV&#x2010;Positive Oropharyngeal Squamous Cell Carcinoma,&#x201d; Otolaryngology&#x2014;Head and Neck Surgery 172, no. 4 (2025): 1309&#x2013;1317, https://doi.org/10.1002/ohn.1150.</Citation></Reference><Reference><Citation>F. Tommasino and M. Durante, &#x201c;Proton Radiobiology,&#x201d; Cancers 7, no. 1 (2015): 353&#x2013;381, https://doi.org/10.3390/cancers7010353.</Citation></Reference><Reference><Citation>T. W. H. Meijer, D. Scandurra, and J. A. Langendijk, &#x201c;Reduced Radiation&#x2010;Induced Toxicity by Using Proton Therapy for the Treatment of Oropharyngeal Cancer,&#x201d; British Journal of Radiology 93, no. 1107 (2020): 20190955, https://doi.org/10.1259/bjr.20190955.</Citation></Reference><Reference><Citation>P. Blanchard, A. S. Garden, G. B. Gunn, et&#xa0;al., &#x201c;Intensity&#x2010;Modulated Proton Beam Therapy (IMPT) Versus Intensity&#x2010;Modulated Photon Therapy (IMRT) for Patients With Oropharynx Cancer &#x2010; A Case Matched Analysis,&#x201d; Radiotherapy and Oncology 120, no. 1 (2016): 48&#x2013;55, https://doi.org/10.1016/j.radonc.2016.05.022.</Citation></Reference><Reference><Citation>H. G. Yoon, Y. C. Ahn, D. Oh, et&#xa0;al., &#x201c;Early Clinical Outcomes of Intensity Modulated Radiation Therapy/Intensity Modulated Proton Therapy Combination in Comparison With Intensity Modulated Radiation Therapy Alone in Oropharynx Cancer Patients,&#x201d; Cancers 13, no. 7 (2021): 1549, https://doi.org/10.3390/cancers13071549.</Citation></Reference><Reference><Citation>S. J. Frank, P. Busse, D. I. Rosenthal, et&#xa0;al., &#x201c;Phase III Randomized Trial of Intensity&#x2010;Modulated Proton Therapy (IMPT) Versus Intensity&#x2010;Modulated Photon Therapy (IMRT) for the Treatment of Head and Neck Oropharyngeal Carcinoma (OPC),&#x201d; Journal of Clinical Oncology 42, no. 16 (2024): 6006, https://doi.org/10.1200/JCO.2024.42.16_suppl.6006.</Citation></Reference><Reference><Citation>C. J. Shen, C. Hu, M. M. Ladra, A. K. Narang, C. E. Pollack, and S. A. Terezakis, &#x201c;Socioeconomic Factors Affect the Selection of Proton Radiation Therapy for Children,&#x201d; Cancer 123, no. 20 (2017): 4048&#x2013;4056, https://doi.org/10.1002/cncr.30849.</Citation></Reference><Reference><Citation>C. G. Washington and C. Deville, &#x201c;Health Disparities and Inequities in the Utilization of Proton Therapy for Prostate Cancer,&#x201d; Cancers 16, no. 22 (2024): 3837, https://doi.org/10.3390/cancers16223837.</Citation></Reference><Reference><Citation>C. R. Weil, F. H. Lew, V. M. Williams, L. M. Burt, R. P. Ermoian, and M. M. Poppe, &#x201c;Patterns of Care and Utilization Disparities in Proton Radiation Therapy for Pediatric Central Nervous System Malignancies,&#x201d; Advances in Radiation Oncology 7, no. 6 (2022): 100868, https://doi.org/10.1016/j.adro.2021.100868.</Citation></Reference><Reference><Citation>N. S. McCall, Y. Liu, J. Janopaul&#x2010;Naylor, et&#xa0;al., &#x201c;Standard but Not Equal: Disparities in Advanced Radiotherapy Techniques for Head and Neck Cancer in the United States,&#x201d; International Journal of Radiation Oncology, Biology, Physics 112, no. 5 (2022): e11&#x2013;e12, https://doi.org/10.1016/j.ijrobp.2021.12.030.</Citation></Reference><Reference><Citation>A. Lee, J. Kang, Y. Yu, et&#xa0;al., &#x201c;Trends and Disparities of Proton Therapy Use Among Patients With Head and Neck Cancer: Analysis From the National Cancer Database (2005&#x2010;14),&#x201d; International Journal of Particle Therapy 5, no. 4 (2019): 1&#x2013;10, https://doi.org/10.14338/IJPT&#x2010;19&#x2010;00051.1.</Citation></Reference><Reference><Citation>M. W. McDonald, J. E. Bates, N. S. McCall, et&#xa0;al., &#x201c;Insurance Authorization and Access to Proton Therapy for Patients With Head and Neck Cancers,&#x201d; International Journal of Radiation Oncology, Biology, Physics 116, no. 2 (2023): 404&#x2013;412, https://doi.org/10.1016/j.ijrobp.2023.02.033.</Citation></Reference><Reference><Citation>P. B. Romesser, O. Cahlon, E. D. Scher, et&#xa0;al., &#x201c;Proton Beam Reirradiation for Recurrent Head and Neck Cancer: Multi&#x2010;Institutional Report on Feasibility and Early Outcomes,&#x201d; International Journal of Radiation Oncology, Biology, Physics 95, no. 1 (2016): 386&#x2013;395, https://doi.org/10.1016/j.ijrobp.2016.02.036.</Citation></Reference><Reference><Citation>P. B. Romesser, O. Cahlon, E. Scher, et&#xa0;al., &#x201c;Proton Beam Radiation Therapy Results in Significantly Reduced Toxicity Compared With Intensity&#x2010;Modulated Radiation Therapy for Head and Neck Tumors That Require Ipsilateral Radiation,&#x201d; Radiotherapy and Oncology 118, no. 2 (2016): 286&#x2013;292, https://doi.org/10.1016/j.radonc.2015.12.008.</Citation></Reference><Reference><Citation>N. Y. Lee, N. S. Kalman, D. J. Ma, et&#xa0;al., &#x201c;A Phase II Randomized Study of Proton vs. Intensity&#x2010;Modulated Radiation Therapy in the Treatment of Unilateral Head and Neck Cancer,&#x201d; International Journal of Radiation Oncology, Biology, Physics 123, no. 1 (2025): S105, https://doi.org/10.1016/j.ijrobp.2025.06.1152.</Citation></Reference><Reference><Citation>S. Sharma, O. Zhou, R. Thompson, et&#xa0;al., &#x201c;Quality of Life of Postoperative Photon Versus Proton Radiation Therapy for Oropharynx Cancer,&#x201d; International Journal of Particle Therapy 5, no. 2 (2018): 11&#x2013;17, https://doi.org/10.14338/IJPT&#x2010;18&#x2010;00032.1.</Citation></Reference><Reference><Citation>T. T. Sio, H. K. Lin, Q. Shi, et&#xa0;al., &#x201c;Intensity Modulated Proton Therapy Versus Intensity Modulated Photon Radiation Therapy for Oropharyngeal Cancer: First Comparative Results of Patient&#x2010;Reported Outcomes,&#x201d; International Journal of Radiation Oncology, Biology, Physics 95, no. 4 (2016): 1107&#x2013;1114, https://doi.org/10.1016/j.ijrobp.2016.02.044.</Citation></Reference><Reference><Citation>N. B. Amin, K. M. Bridgham, J. P. Brown, et&#xa0;al., &#x201c;Regionalization of Head and Neck Oncology Tumor Boards: Perspectives of Collaborating Physicians,&#x201d; OTO Open 7, no. 1 (2023): e18, https://doi.org/10.1002/oto2.18.</Citation></Reference><Reference><Citation>J. A. Thompson, J. E. Lubek, N. Amin, et&#xa0;al., &#x201c;Impact of the Novel Coronavirus 2019 (COVID&#x2010;19) Pandemic on Head and Neck Cancer Care,&#x201d; Otolaryngology&#x2010;Head and Neck Surgery 166, no. 1 (2022): 93&#x2013;100, https://doi.org/10.1177/01945998211004544.</Citation></Reference><Reference><Citation>M. M. Chen, U. C. Megwalu, J. Liew, D. Sirjani, E. L. Rosenthal, and V. Divi, &#x201c;Regionalization of Head and Neck Cancer Surgery May Fragment Care and Impact Overall Survival,&#x201d; Laryngoscope 129, no. 6 (2019): 1413&#x2013;1419, https://doi.org/10.1002/lary.27440.</Citation></Reference><Reference><Citation>N. Y. Yu, T. T. Sio, P. Mohindra, et&#xa0;al., &#x201c;The Insurance Approval Process for Proton Beam Therapy Must Change: Prior Authorization Is Crippling Access to Appropriate Health Care,&#x201d; International Journal of Radiation Oncology, Biology, Physics 104, no. 4 (2019): 737&#x2013;739, https://doi.org/10.1016/j.ijrobp.2019.04.007.</Citation></Reference><Reference><Citation>J. Remick, A. M. Chhabra, S. M. Bentzen, et&#xa0;al., &#x201c;The Downstream &#x201c;Halo&#x201d; Effect of a Proton Therapy Center on an Academic Medical Center,&#x201d; International Journal of Radiation Oncology, Biology, Physics 102, no. 3 (2018): e427&#x2013;e428, https://doi.org/10.1016/j.ijrobp.2018.07.1246.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70098 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41342092</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Dec</Month><Day>04</Day></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Obstructive Sleep Apnea in Head and Neck Cancer Patients After Primary Treatment: A Review Focused on Oropharyngeal Cancer.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70098</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Obstructive sleep apnea (OSA) is a disorder with significant health implications. Variations in upper airway anatomy and pharyngeal tone are factors that predispose patients to OSA. Oropharyngeal cancer (OPC) may increase the risk of OSA due to treatment-induced changes in the upper airway. This scoping review aims to assess the prevalence of OSA in OPC patients post-treatment.</AbstractText><AbstractText Label="DATA SOURCES" NlmCategory="METHODS">A search was conducted across multiple databases, including PubMed, Embase, and Cochrane Library, to identify studies reporting the prevalence of OSA in OPC patients post-treatment (including surgery, radiation, and/or chemoradiation).</AbstractText><AbstractText Label="REVIEW METHODS" NlmCategory="METHODS">Studies were screened for eligibility by two reviewers. Inclusion criteria required studies to use standardized diagnostic criteria for OSA and provide prevalence data specifically for post-treatment OPC patients.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The search identified 788 studies: 30 underwent full-text review, and 13 studies with 373 head and neck cancer (HNC) patients met inclusion criteria. The majority of studies did not disaggregate data for OPC from other subsites; one study provided sufficient data on OSA prevalence in OPC patients post-treatment. Five studies reported AHI changes pre- and post-treatment with a mean change of 5.4 events/h with only 2 studies reporting significant changes in OSA rates. Sleep-related symptoms were captured in 11 studies with 2 comparing pre- and post-treatment.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Despite the growing recognition of OSA as a potential comorbidity in cancer survivors, the literature does not adequately address the prevalence of OSA in OPC patients post-treatment. This highlights the need for future studies targeting OSA prevalence in this population using standardized diagnostic methods and reporting criteria.</AbstractText><CopyrightInformation>&#xa9; 2025 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Nina</ForeName><Initials>N</Initials><Identifier Source="ORCID">0009-0001-1143-1290</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Kennedy</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Jolie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-0853-2779</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ha</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-0306-6147</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Likhterov</LastName><ForeName>Ilya</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0003-4234-4306</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">obstructive sleep apnea</Keyword><Keyword MajorTopicYN="N">oropharyngeal cancer</Keyword><Keyword MajorTopicYN="N">prevalence</Keyword><Keyword MajorTopicYN="N">primary treatment</Keyword><Keyword MajorTopicYN="N">scoping review</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>10</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>4</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>4</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>4</Day><Hour>5</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41342092</ArticleId><ArticleId IdType="doi">10.1002/hed.70098</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>R. N. Aurora, N. A. Collop, O. Jacobowitz, S. M. Thomas, S. F. Quan, and A. J. Aronsky, &#x201c;Quality Measures for the Care of Adult Patients With Obstructive Sleep Apnea,&#x201d; Journal of Clinical Sleep Medicine 11, no. 3 (2015): 357&#x2013;383.</Citation></Reference><Reference><Citation>H. Damgacioglu, K. Sonawane, Y. Zhu, et&#xa0;al., &#x201c;Oropharyngeal Cancer Incidence and Mortality Trends in All 50 States in the US, 2001&#x2013;2017,&#x201d; JAMA Otolaryngology. Head &amp; Neck Surgery 148, no. 2 (2022): 155&#x2013;165.</Citation></Reference><Reference><Citation>Y. Cao, P. Ning, Q. Li, and S. Wu, &#x201c;Cancer and Obstructive Sleep Apnea: An Updated Meta&#x2010;Analysis,&#x201d; Medicine 101, no. 10 (2022): e28930.</Citation></Reference><Reference><Citation>D. Moher, A. Liberati, J. Tetzlaff, D. G. Altman, and PRISMA Group*, &#x201c;Preferred Reporting Items for Systematic Reviews and Meta&#x2010;Analyses: The PRISMA Statement,&#x201d; Annals of Internal Medicine 151, no. 4 (2009): 264&#x2013;269.</Citation></Reference><Reference><Citation>W. S. Richardson, M. C. Wilson, J. Nishikawa, and R. S. Hayward, &#x201c;The Well&#x2010;Built Clinical Question: A Key to Evidence&#x2010;Based Decisions,&#x201d; ACP Journal Club 123, no. 3 (1995): A12&#x2013;A13.</Citation></Reference><Reference><Citation>P. Huyett, S. Kim, J. T. Johnson, and R. J. Soose, &#x201c;Obstructive Sleep Apnea in the Irradiated Head and Neck Cancer Patient,&#x201d; Laryngoscope 127, no. 11 (2017): 2673&#x2013;2677.</Citation></Reference><Reference><Citation>R. T. Karsten, J. A. Rijken, I. Toprak, et&#xa0;al., &#x201c;Prevalence of Obstructive Sleep Apnea After Treatment for Advanced T&#x2010;Stage Head and Neck Cancer,&#x201d; European Archives of Oto&#x2010;Rhino&#x2010;Laryngology 281, no. 4 (2024): 1941&#x2013;1952.</Citation></Reference><Reference><Citation>A. Steffen, H. Graefe, E. Gehrking, I. R. K&#xf6;nig, and B. Wollenberg, &#x201c;Sleep Apnoea in Patients After Treatment of Head Neck Cancer,&#x201d; Acta Oto&#x2010;Laryngologica 129, no. 11 (2009): 1300&#x2013;1305.</Citation></Reference><Reference><Citation>S. A. Faiz, D. Balachandran, A. C. Hessel, et&#xa0;al., &#x201c;Sleep&#x2010;Related Breathing Disorders in Patients With Tumors in the Head and Neck Region,&#x201d; Oncologist 19, no. 11 (2014): 1200&#x2013;1206.</Citation></Reference><Reference><Citation>W. Qian, J. Haight, I. Poon, D. Enepekides, and K. M. Higgins, &#x201c;Sleep Apnea in Patients With Oral Cavity and Oropharyngeal Cancer After Surgery and Chemoradiation Therapy,&#x201d; Otolaryngology and Head and Neck Surgery 143, no. 2 (2010): 248&#x2013;252.</Citation></Reference><Reference><Citation>W. Nesse, A. Hoekema, B. Stegenga, J. H. van der Hoeven, L. G. de Bont, and J. L. Roodenburg, &#x201c;Prevalence of Obstructive Sleep Apnoea Following Head and Neck Cancer Treatment: A Cross&#x2010;Sectional Study,&#x201d; Oral Oncology 42, no. 1 (2006): 107&#x2013;113.</Citation></Reference><Reference><Citation>M. Friedman, R. Landsberg, S. Pryor, Z. Syed, H. Ibrahim, and D. D. Caldarelli, &#x201c;The Occurrence of Sleep&#x2010;Disordered Breathing Among Patients With Head and Neck Cancer,&#x201d; Laryngoscope 111, no. 11 (2001): 1917&#x2013;1919.</Citation></Reference><Reference><Citation>A. Inoshita, N. Sata, S. Ohba, et&#xa0;al., &#x201c;Impact of Radiotherapy for Head and Neck Cancer on Obstructive Sleep Apnea: A Prospective Study,&#x201d; Annals of Palliative Medicine 11, no. 8 (2022): 2631640.</Citation></Reference><Reference><Citation>T. Huppertz, V. Horstmann, C. Scharnow, et&#xa0;al., &#x201c;OSA in Patients With Head and Neck Cancer Is Associated With Cancer Size and Oncologic Outcome,&#x201d; European Archives of Oto&#x2010;Rhino&#x2010;Laryngology 278 (2021): 2485&#x2013;2491.</Citation></Reference><Reference><Citation>F. H. Liao, C. C. Chang, Y. C. Lu, C. Y. Lin, and W. S. Lai, &#x201c;Impact of Free Flap Reconstruction on Obstructive Sleep Apnea in Patients With Oral and Oropharyngeal Cancer,&#x201d; Asia&#x2010;Pacific Journal of Oncology Nursing 9, no. 10 (2022): 100136.</Citation></Reference><Reference><Citation>F. Carsuzaa, E. Chary, J. Thariat, X. Dufour, and V. Favier, &#x201c;Obstructive Sleep Apnea Syndrome: A Frequent and Difficult&#x2010;to&#x2010;Detect Complication of Radiotherapy for Oropharyngeal Cancers,&#x201d; Radiotherapy and Oncology 192 (2024): 110109.</Citation></Reference><Reference><Citation>O. Gil, B. Fenske, T. Bremert, et&#xa0;al., &#x201c;POTT&#x2010;Study&#x2013;Prevalence of OSA in HNSCC Patients Before and After Treatment,&#x201d; Medicina 60, no. 2 (2024): 310.</Citation></Reference><Reference><Citation>F. Yoshikawa, N. Nozaki&#x2010;Taguchi, A. Yamamoto, et&#xa0;al., &#x201c;Preoperative Sleep&#x2010;Disordered Breathing and Craniofacial Abnormalities Are Risk Factors for Postoperative Sleep&#x2010;Disordered Breathing in Patients Undergoing Skin&#x2010;Flap Oropharyngeal Reconstruction Surgery for Oral Cavity Cancer: A Prospective Case&#x2010;Control Study,&#x201d; Sleep and Breathing 28, no. 2 (2024): 797&#x2013;806.</Citation></Reference><Reference><Citation>W. Lydiatt, S. Patel, J. Ridge, B. O'Sullivan, and J. Shah, &#x201c;Part II. Head and Neck. Chapter&#xa0;5. Staging Head and Neck Cancers,&#x201d; in AJCC Cancer Staging Manual, 8th ed., ed. D. B. Amid (Springer, 2017).</Citation></Reference><Reference><Citation>M. W. Johns, &#x201c;A New Method for Measuring Daytime Sleepiness: The Epworth Sleepiness Scale,&#x201d; Sleep 14, no. 6 (1991): 540&#x2013;545.</Citation></Reference><Reference><Citation>M. D. S. Silva, D. Poyares, L. O. Silva, et&#xa0;al., &#x201c;Associations of the Severity of Obstructive Sleep Apnea With Age&#x2010;Related Comorbidities: A Population&#x2010;Based Study,&#x201d; Frontiers in Neurology 13 (2022): 802554.</Citation></Reference><Reference><Citation>A. Loth, J. Michel, R. Giorgi, et&#xa0;al., &#x201c;Prevalence of Obstructive Sleep Apnoea Syndrome Following Oropharyngeal Cancer Treatment: A Prospective Cohort Study,&#x201d; Clinical Otolaryngology 42, no. 6 (2017): 1281&#x2013;1288.</Citation></Reference><Reference><Citation>Z. Zhang, J. C. Brown, B. W. O'Malley, et&#xa0;al., &#x201c;Post&#x2010;Treatment Weight Change in Oral Cavity and Oropharyngeal Squamous Cell Carcinoma,&#x201d; Supportive Care in Cancer 24 (2016): 2333&#x2013;2340.</Citation></Reference><Reference><Citation>J. P. Machiels, C. R. Leemans, W. Golusinski, C. Grau, L. Licitra, and V. Gregoire, &#x201c;Squamous Cell Carcinoma of the Oral Cavity, Larynx, Oropharynx and Hypopharynx: EHNS&#x2013;ESMO&#x2013;ESTRO Clinical Practice Guidelines for Diagnosis, Treatment and Follow&#x2010;Up,&#x201d; Annals of Oncology 31, no. 11 (2020): 1462&#x2013;1475.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70107 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41340588</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Dec</Month><Day>04</Day></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Longitudinal Patterns of Radiation-Associated Dysphagia in Patients With Head and Neck Cancer: A Systematic Review.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70107</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate the diagnostic profile of early (i.e., &lt;&#x2009;6&#x2009;months of treatment) and late (i.e., &#x2265;&#x2009;6 months of treatment) radiation-associated dysphagia (RAD) in patients with head and neck cancer.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">The literature was queried from inception to July 19, 2024. Outcomes included patient-reported outcome measures, aspiration prevalence, pharyngoesophageal stricture rate, and gastric tube presence. Data were collected at various time points from baseline up to 24&#x2009;months post-treatment; longer-term data beyond 24&#x2009;months was descriptively summarized. Meta-analysis of continuous measures (mean) and proportions (%) with 95% confidence intervals (CI) was performed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 2881 abstracts identified, 99 studies (N&#x2009;=&#x2009;15&#x2009;578 patients) were included. Mean age was 58.4&#x2009;years; 78.9% of patients were male. M.D. Anderson Dysphagia Inventory composite scores were 71.2 (CI: 66.8-75.6) at 3&#x2009;months and 82.8 (CI: 79.2-86.3) at 24&#x2009;months, signifying improvement in swallowing-related quality of life. Aspiration prevalence was 28.4% (CI: 11.6-49.1) at 3&#x2009;months and 8.8% (CI: 0.13-28.7) at 24&#x2009;months. Stricture rate was 21.2% (CI: 9.7-15.2) at 6&#x2009;months and 9.1% [CI: 3.0-17.9] at 24&#x2009;months. Gastric tube presence declined from baseline (44.5% [CI: 36.8-52.4]) to 6&#x2009;months (12.3% [CI: 9.7-16.6]) and fluctuated from 1 to 10&#x2009;years post-treatment (range: 4.14% [CI: 2.7-5.9] to 9.17% [CI: 5.5-14.2]).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">RAD severity peaks within 3&#x2009;months post-treatment, with improvement by 6&#x2009;months. However, even at 2&#x2009;years post-treatment, a substantial number of patients continue to experience clinically significant dysphagia. These findings highlight the persistent burden of RAD, underscoring the need for proactive longer-term dysphagia evaluation and management in this population.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). Head &amp; Neck published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Anuja H</ForeName><Initials>AH</Initials><Identifier Source="ORCID">0009-0004-9839-4374</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology - Head and Neck Surgery, Medical University of South Carolina, Charleston, South Carolina, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Georgetown University School of Medicine, Washington, DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Megan T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology - Head and Neck Surgery, Medical University of South Carolina, Charleston, South Carolina, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Penn State College of Medicine, Hershey, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Shaun A</ForeName><Initials>SA</Initials><Identifier Source="ORCID">0000-0003-0664-4571</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology - Head and Neck Surgery, Medical University of South Carolina, Charleston, South Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pelic</LastName><ForeName>Justin C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology - Head and Neck Surgery, Medical University of South Carolina, Charleston, South Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davidson</LastName><ForeName>Kate</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology - Head and Neck Surgery, Medical University of South Carolina, Charleston, South Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Rourke</LastName><ForeName>Ashli K</ForeName><Initials>AK</Initials><Identifier Source="ORCID">0000-0002-1293-501X</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology - Head and Neck Surgery, Medical University of South Carolina, Charleston, South Carolina, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">chemoradiation</Keyword><Keyword MajorTopicYN="N">deglutition</Keyword><Keyword MajorTopicYN="N">dysphagia</Keyword><Keyword MajorTopicYN="N">head and neck cancer</Keyword><Keyword MajorTopicYN="N">swallowing</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>11</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>4</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>4</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>4</Day><Hour>4</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41340588</ArticleId><ArticleId IdType="doi">10.1002/hed.70107</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>D. G. Pfister, S. Spencer, D. Adelstein, et&#xa0;al., &#x201c;Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology,&#x201d; Journal of the National Comprehensive Cancer Network 18, no. 7 (2020): 873&#x2013;898, https://doi.org/10.6004/jnccn.2020.0031.</Citation></Reference><Reference><Citation>K. A. Hutcheson, Z. Nurgalieva, H. Zhao, et&#xa0;al., &#x201c;Two&#x2010;Year Prevalence of Dysphagia and Related Outcomes in Head and Neck Cancer Survivors: An Updated SEER&#x2010;Medicare Analysis,&#x201d; Head &amp; Neck 41, no. 2 (2019): 479&#x2013;487, https://doi.org/10.1002/hed.25412.</Citation></Reference><Reference><Citation>Dysphagia Section, Oral Care Study Group, Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO), et&#xa0;al., &#x201c;Swallowing Dysfunction in Cancer Patients,&#x201d; Supportive Care in Cancer 20, no. 3 (2012): 433&#x2013;443, https://doi.org/10.1007/s00520&#x2010;011&#x2010;1342&#x2010;2.</Citation></Reference><Reference><Citation>M. A. Kuhn, M. B. Gillespie, S. L. Ishman, et&#xa0;al., &#x201c;Expert Consensus Statement: Management of Dysphagia in Head and Neck Cancer Patients,&#x201d; Otolaryngology&#x2010;Head and Neck Surgery 168, no. 4 (2023): 571&#x2013;592, https://doi.org/10.1002/ohn.302.</Citation></Reference><Reference><Citation>L. Evangelista, N. Nativ&#x2010;Zeltzer, A. Bewley, et&#xa0;al., &#x201c;Functional Laryngectomy and Quality of Life in Survivors of Head and Neck Cancer With Intractable Aspiration,&#x201d; JAMA Otolaryngology. Head &amp; Neck Surgery 150, no. 4 (2024): 335&#x2013;341, https://doi.org/10.1001/jamaoto.2024.0049.</Citation></Reference><Reference><Citation>M. d. C. M. F. Gomes, P. M. d. V. Ferreira, A. C. S. M. Almeida, et&#xa0;al., &#x201c;Dysphagia, Nutritional Status, and Quality of Life in Patients With Head and Neck Cancer Undergoing Radiotherapy Alone or Combined With Chemotherapy: An Observational Study,&#x201d; BMC Cancer 25, no. 1 (2025): 416, https://doi.org/10.1186/s12885&#x2010;025&#x2010;13695&#x2010;y.</Citation></Reference><Reference><Citation>K. A. Hutcheson, M. K. Bhayani, B. M. Beadle, et&#xa0;al., &#x201c;Eat and Exercise During Radiotherapy or Chemoradiotherapy for Pharyngeal Cancers: Use It or Lose It,&#x201d; JAMA Otolaryngology. Head &amp; Neck Surgery 139, no. 11 (2013): 1127&#x2013;1134, https://doi.org/10.1001/jamaoto.2013.4715.</Citation></Reference><Reference><Citation>S. L. Crowder, N. Najam, K. P. Sarma, B. H. Fiese, and A. E. Arthur, &#x201c;Head and Neck Cancer Survivors' Experiences With Chronic Nutrition Impact Symptom Burden After Radiation: A Qualitative Study,&#x201d; Journal of the Academy of Nutrition and Dietetics 120, no. 10 (2020): 1643&#x2013;1653, https://doi.org/10.1016/j.jand.2020.04.016.</Citation></Reference><Reference><Citation>N. P. Nguyen, C. Frank, C. C. Moltz, et&#xa0;al., &#x201c;Impact of Dysphagia on Quality of Life After Treatment of Head&#x2010;And&#x2010;Neck Cancer,&#x201d; International Journal of Radiation Oncology, Biology, Physics 61, no. 3 (2005): 772&#x2013;778, https://doi.org/10.1016/j.ijrobp.2004.06.017.</Citation></Reference><Reference><Citation>E. M. Miller, R. K. Walters, S. A. Nguyen, J. L. Harper, B. Depaoli, and A. K. O'Rourke, &#x201c;Time to Onset of Dysphagia Following Head and Neck Radiation,&#x201d; Dysphagia 40, no. 4 (2024): 841&#x2013;850, https://doi.org/10.1007/s00455&#x2010;024&#x2010;10782&#x2010;3.</Citation></Reference><Reference><Citation>H. P. van der Laan, H. P. Bijl, R. J. H. M. Steenbakkers, et&#xa0;al., &#x201c;Acute Symptoms During the Course of Head and Neck Radiotherapy or Chemoradiation Are Strong Predictors of Late Dysphagia,&#x201d; Radiotherapy and Oncology 115, no. 1 (2015): 56&#x2013;62, https://doi.org/10.1016/j.radonc.2015.01.019.</Citation></Reference><Reference><Citation>B. A. Murphy and J. Gilbert, &#x201c;Dysphagia in Head and Neck Cancer Patients Treated With Radiation: Assessment, Sequelae, and Rehabilitation,&#x201d; Seminars in Radiation Oncology 19, no. 1 (2009): 35&#x2013;42, https://doi.org/10.1016/j.semradonc.2008.09.007.</Citation></Reference><Reference><Citation>H. R. Withers, H. D. Thames, B. L. Flow, K. A. Mason, and D. H. Hussey, &#x201c;The Relationship of Acute to Late Skin Injury in 2 and 5 Fraction/Week Gamma&#x2010;Ray Therapy,&#x201d; International Journal of Radiation Oncology, Biology, Physics 4, no. 7&#x2013;8 (1978): 595&#x2013;601, https://doi.org/10.1016/0360&#x2010;3016(78)90180&#x2010;3.</Citation></Reference><Reference><Citation>L. A. Gharzai, P. Li, M. J. Schipper, et&#xa0;al., &#x201c;Characterization of Very Late Dysphagia After Chemoradiation for Oropharyngeal Squamous Cell Carcinoma,&#x201d; Oral Oncology 111 (2020): 104853, https://doi.org/10.1016/j.oraloncology.2020.104853.</Citation></Reference><Reference><Citation>N. E. Schaen&#x2010;Heacock, C. A. Jones, and T. M. McCulloch, &#x201c;Pharyngeal Swallowing Pressures in Patients With Radiation&#x2010;Associated Dysphagia,&#x201d; Dysphagia 36, no. 2 (2021): 242&#x2013;249, https://doi.org/10.1007/s00455&#x2010;020&#x2010;10128&#x2010;9.</Citation></Reference><Reference><Citation>H. R. Mortensen, K. Jensen, K. Aksgl&#xe6;de, M. Behrens, and C. Grau, &#x201c;Late Dysphagia After IMRT for Head and Neck Cancer and Correlation With Dose&#x2010;Volume Parameters,&#x201d; Radiotherapy and Oncology 107, no. 3 (2013): 288&#x2013;294, https://doi.org/10.1016/j.radonc.2013.06.001.</Citation></Reference><Reference><Citation>S. N. King, N. E. Dunlap, P. A. Tennant, and T. Pitts, &#x201c;Pathophysiology of Radiation&#x2010;Induced Dysphagia in Head and Neck Cancer,&#x201d; Dysphagia 31, no. 3 (2016): 339&#x2013;351, https://doi.org/10.1007/s00455&#x2010;016&#x2010;9710&#x2010;1.</Citation></Reference><Reference><Citation>P. Dirix, S. Abbeel, B. Vanstraelen, R. Hermans, and S. Nuyts, &#x201c;Dysphagia After Chemoradiotherapy for Head&#x2010;And&#x2010;Neck Squamous Cell Carcinoma: Dose&#x2010;Effect Relationships for the Swallowing Structures,&#x201d; International Journal of Radiation Oncology, Biology, Physics 75, no. 2 (2009): 385&#x2013;392, https://doi.org/10.1016/j.ijrobp.2008.11.041.</Citation></Reference><Reference><Citation>M. J. Page, J. E. McKenzie, P. M. Bossuyt, et&#xa0;al., &#x201c;The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews,&#x201d; BMJ (Clinical Research Ed.) 372 (2021): n71, https://doi.org/10.1136/bmj.n71.</Citation></Reference><Reference><Citation>A. Y. Chen, R. Frankowski, J. Bishop&#x2010;Leone, et&#xa0;al., &#x201c;The Development and Validation of a Dysphagia&#x2010;Specific Quality&#x2010;of&#x2010;Life Questionnaire for Patients With Head and Neck Cancer: The M. D. Anderson Dysphagia Inventory,&#x201d; Archives of Otolaryngology &#x2013; Head &amp; Neck Surgery 127, no. 7 (2001): 870&#x2013;876.</Citation></Reference><Reference><Citation>K. Bjordal, E. Hammerlid, M. Ahlner&#x2010;Elmqvist, et&#xa0;al., &#x201c;Quality of Life in Head and Neck Cancer Patients: Validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire&#x2010;H&amp;N35,&#x201d; Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 17, no. 3 (1999): 1008&#x2013;1019, https://doi.org/10.1200/JCO.1999.17.3.1008.</Citation></Reference><Reference><Citation>L. Thomas, T. M. Jones, S. Tandon, C. Katre, D. Lowe, and S. N. Rogers, &#x201c;An Evaluation of the University of Washington Quality of Life Swallowing Domain Following Oropharyngeal Cancer,&#x201d; European Archives of Oto&#x2010;Rhino&#x2010;Laryngology 265, no. Suppl 1 (2008): S29&#x2013;S37, https://doi.org/10.1007/s00405&#x2010;007&#x2010;0470&#x2010;2.</Citation></Reference><Reference><Citation>B. Martin&#x2010;Harris, M. B. Brodsky, Y. Michel, et&#xa0;al., &#x201c;MBS Measurement Tool for Swallow Impairment&#x2013;MBSImp: Establishing a Standard,&#x201d; Dysphagia 23, no. 4 (2008): 392&#x2013;405, https://doi.org/10.1007/s00455&#x2010;008&#x2010;9185&#x2010;9.</Citation></Reference><Reference><Citation>J. C. Borders and D. Brates, &#x201c;Use of the Penetration&#x2010;Aspiration Scale in Dysphagia Research: A Systematic Review,&#x201d; Dysphagia 35, no. 4 (2020): 583&#x2013;597, https://doi.org/10.1007/s00455&#x2010;019&#x2010;10064&#x2010;3.</Citation></Reference><Reference><Citation>K. A. Hutcheson, M. P. Barrow, D. A. Barringer, et&#xa0;al., &#x201c;Dynamic Imaging Grade of Swallowing Toxicity (DIGEST): Scale Development and Validation,&#x201d; Cancer 123, no. 1 (2017): 62&#x2013;70, https://doi.org/10.1002/cncr.30283.</Citation></Reference><Reference><Citation>A. Villa, M. Vollemans, A. De Moraes, and S. Sonis, &#x201c;Concordance of the WHO, RTOG, and CTCAE v4.0 Grading Scales for the Evaluation of Oral Mucositis Associated With Chemoradiation Therapy for the Treatment of Oral and Oropharyngeal Cancers,&#x201d; Supportive Care in Cancer 29, no. 10 (2021): 6061&#x2013;6068, https://doi.org/10.1007/s00520&#x2010;021&#x2010;06177&#x2010;x.</Citation></Reference><Reference><Citation>M. A. List, L. L. D'Antonio, D. F. Cella, et&#xa0;al., &#x201c;The Performance Status Scale for Head and Neck Cancer Patients and the Functional Assessment of Cancer Therapy&#x2010;Head and Neck Scale. A Study of Utility and Validity,&#x201d; Cancer 77, no. 11 (1996): 2294&#x2013;2301, https://doi.org/10.1002/(SICI)1097&#x2010;0142(19960601)77:11%3C2294::AID&#x2010;CNCR17%3E3.0.CO;2&#x2010;S.</Citation></Reference><Reference><Citation>J. Howick, The Oxford Levels of Evidence 2 (Oxford Centre for Evidence&#x2010;Based Medicine, 2011).</Citation></Reference><Reference><Citation>J. A. C. Sterne, J. Savovi&#x107;, M. J. Page, et&#xa0;al., &#x201c;RoB 2: A Revised Tool for Assessing Risk of Bias in Randomised Trials,&#x201d; BMJ (Clinical Research Ed.) 366 (2019): l4898, https://doi.org/10.1136/bmj.l4898.</Citation></Reference><Reference><Citation>J. A. Sterne, M. A. Hern&#xe1;n, B. C. Reeves, et&#xa0;al., &#x201c;ROBINS&#x2010;I: A Tool for Assessing Risk of Bias in Non&#x2010;Randomised Studies of Interventions,&#x201d; BMJ (Clinical Research Ed.) 355 (2016): i4919, https://doi.org/10.1136/bmj.i4919.</Citation></Reference><Reference><Citation>T. H. Barker, S. Hasanoff, E. Aromataris, et&#xa0;al., &#x201c;The Revised JBI Critical Appraisal Tool for the Assessment of Risk of Bias for Cohort Studies,&#x201d; JBI Evidence Synthesis 23 (2024): 441&#x2013;453, https://doi.org/10.11124/JBIES&#x2010;24&#x2010;00103.</Citation></Reference><Reference><Citation>Z. Munn, T. H. Barker, S. Moola, et&#xa0;al., &#x201c;Methodological Quality of Case Series Studies: An Introduction to the JBI Critical Appraisal Tool,&#x201d; JBI Evidence Synthesis 18, no. 10 (2020): 2127&#x2013;2133, https://doi.org/10.11124/JBISRIR&#x2010;D&#x2010;19&#x2010;00099.</Citation></Reference><Reference><Citation>M. Borenstein, Introduction to Meta&#x2010;Analysis (John Wiley &amp; Sons, Ltd, 2009).</Citation></Reference><Reference><Citation>M. Borenstein, L. V. Hedges, J. P. T. Higgins, and H. R. Rothstein, eds., &#x201c;Fixed&#x2010;Effect Model,&#x201d; in Introduction to Meta&#x2010;Analysis (John Wiley &amp; Sons, Ltd, 2009), 63&#x2013;67, https://doi.org/10.1002/9780470743386.ch11.</Citation></Reference><Reference><Citation>J. P. T. Higgins, S. G. Thompson, J. J. Deeks, and D. G. Altman, &#x201c;Measuring Inconsistency in Meta&#x2010;Analyses,&#x201d; BMJ 327, no. 7414 (2003): 557&#x2013;560, https://doi.org/10.1136/bmj.327.7414.557.</Citation></Reference><Reference><Citation>J. A. Sterne and M. Egger, &#x201c;Funnel Plots for Detecting Bias in Meta&#x2010;Analysis: Guidelines on Choice of Axis,&#x201d; Journal of Clinical Epidemiology 54, no. 10 (2001): 1046&#x2013;1055, https://doi.org/10.1016/s0895&#x2010;4356(01)00377&#x2010;8.</Citation></Reference><Reference><Citation>A. H. Ackerstaff, A. J. M. Balm, C. R. N. Rasch, et&#xa0;al., &#x201c;First&#x2010;Year Quality of Life Assessment of an Intra&#x2010;Arterial (RADPLAT) Versus Intravenous Chemoradiation Phase III Trial,&#x201d; Head &amp; Neck 31, no. 1 (2009): 77&#x2013;84, https://doi.org/10.1002/hed.20937.</Citation></Reference><Reference><Citation>J. Agarwal, D. Dutta, V. Palwe, et&#xa0;al., &#x201c;Prospective Subjective Evaluation of Swallowing Function and Dietary Pattern in Head and Neck Cancers Treated With Concomitant Chemo&#x2010;Radiation,&#x201d; Journal of Cancer Research and Therapeutics 6, no. 1 (2010): 15&#x2013;21, https://doi.org/10.4103/0973&#x2010;1482.63563.</Citation></Reference><Reference><Citation>L. M. Akst, J. Chan, P. Elson, J. Saxton, M. Strome, and D. Adelstein, &#x201c;Functional Outcomes Following Chemoradiotherapy for Head and Neck Cancer,&#x201d; Otolaryngology and Head and Neck Surgery 131, no. 6 (2004): 950&#x2013;957, https://doi.org/10.1016/j.otohns.2004.05.020.</Citation></Reference><Reference><Citation>A. Al&#x2010;Mamgani, P. Van Rooij, L. Tans, D. N. Teguh, and P. C. Levendag, &#x201c;Toxicity and Outcome of Intensity&#x2010;Modulated Radiotherapy Versus 3&#x2010;Dimensional Conformal Radiotherapy for Oropharyngeal Cancer: A Matched&#x2010;Pair Analysis,&#x201d; Technology in Cancer Research &amp; Treatment 12, no. 2 (2013): 123&#x2013;130, https://doi.org/10.7785/tcrt.2012.500305.</Citation></Reference><Reference><Citation>A. Al&#x2010;Mamgani, R. Kessels, A. Navran, et&#xa0;al., &#x201c;Reduction of GTV to High&#x2010;Risk CTV Radiation Margin in Head and Neck Squamous Cell Carcinoma Significantly Reduced Acute and Late Radiation&#x2010;Related Toxicity With Comparable Outcomes,&#x201d; Radiotherapy and Oncology 162 (2021): 170&#x2013;177, https://doi.org/10.1016/j.radonc.2021.07.016.</Citation></Reference><Reference><Citation>A. Al&#x2010;Mamgani, R. Kessels, T. Janssen, et&#xa0;al., &#x201c;The Dosimetric and Clinical Advantages of the GTV&#x2010;CTV&#x2010;PTV Margins Reduction by 6&#x2009;Mm in Head and Neck Squamous Cell Carcinoma: Significant Acute and Late Toxicity Reduction,&#x201d; Radiotherapy and Oncology 168 (2022): 16&#x2013;22, https://doi.org/10.1016/j.radonc.2022.01.013.</Citation></Reference><Reference><Citation>M. O. F. Al&#x2010;Othman, R. J. Amdur, C. G. Morris, R. W. Hinerman, and W. M. Mendenhall, &#x201c;Does Feeding Tube Placement Predict for Long&#x2010;Term Swallowing Disability After Radiotherapy for Head and Neck Cancer?,&#x201d; Head &amp; Neck 25, no. 9 (2003): 741&#x2013;747, https://doi.org/10.1002/hed.10279.</Citation></Reference><Reference><Citation>C. E. A. Barbon, C. M. K. Yao, C. B. Peterson, et&#xa0;al., &#x201c;Swallowing After Primary TORS and Unilateral or Bilateral Radiation for Low&#x2010; to Intermediate&#x2010;Risk Tonsil Cancer,&#x201d; Otolaryngology&#x2010;Head and Neck Surgery 167, no. 3 (2022): 484&#x2013;493, https://doi.org/10.1177/01945998211059967.</Citation></Reference><Reference><Citation>M. K. Barnhart, R. A. Robinson, V. A. Simms, et&#xa0;al., &#x201c;Treatment Toxicities and Their Impact on Oral Intake Following Non&#x2010;Surgical Management for Head and Neck Cancer: A 3&#x2010;Year Longitudinal Study,&#x201d; Supportive Care in Cancer 26, no. 7 (2018): 2341&#x2013;2351, https://doi.org/10.1007/s00520&#x2010;018&#x2010;4076&#x2010;6.</Citation></Reference><Reference><Citation>A. M. Baschnagel, S. Yadav, O. Marina, et&#xa0;al., &#x201c;Toxicities and Costs of Placing Prophylactic and Reactive Percutaneous Gastrostomy Tubes in Patients With Locally Advanced Head and Neck Cancers Treated With Chemoradiotherapy,&#x201d; Head &amp; Neck 36, no. 8 (2014): 1155&#x2013;1161, https://doi.org/10.1002/hed.23426.</Citation></Reference><Reference><Citation>A. Ba&#x15f;tu&#x11f; Dumbak, F. Esen Ayd&#x131;nl&#x131;, G. Yaz&#x131;c&#x131;, et&#xa0;al., &#x201c;Investigation of the Effect of Radiotherapy Dose on Chewing and Swallowing Structures in Head and Neck Cancer Patients Treated With Concomitant Chemoradiotherapy,&#x201d; Dysphagia 37, no. 6 (2022): 1400&#x2013;1413, https://doi.org/10.1007/s00455&#x2010;021&#x2010;10398&#x2010;x.</Citation></Reference><Reference><Citation>S. Batham, S. Gupta, A. Ghosh, et&#xa0;al., &#x201c;Comparative Study of Dysphagia&#x2010;Optimized Intensity Modulated Radiotherapy (Do&#x2010;IMRT) and Standard Intensity Modulated Radiotherapy (S&#x2010;IMRT) and Its Clinical Correlation in Head and Neck Cancer Patients,&#x201d; Asian Pacific Journal of Cancer Prevention 24, no. 11 (2023): 3697&#x2013;3704, https://doi.org/10.31557/APJCP.2023.24.11.3697.</Citation></Reference><Reference><Citation>M. K. Bhayani, K. A. Hutcheson, D. A. Barringer, et&#xa0;al., &#x201c;Gastrostomy Tube Placement in Patients With Oropharyngeal Carcinoma Treated With Radiotherapy or Chemoradiotherapy: Factors Affecting Placement and Dependence,&#x201d; Head &amp; Neck 35, no. 11 (2013): 1634&#x2013;1640, https://doi.org/10.1002/hed.23200.</Citation></Reference><Reference><Citation>T. Bird, F. De Felice, A. Michaelidou, et&#xa0;al., &#x201c;Outcomes of Intensity&#x2010;Modulated Radiotherapy as Primary Treatment for Oropharyngeal Squamous Cell Carcinoma&#x2013;A European Singleinstitution Analysis,&#x201d; Clinical Otolaryngology 42, no. 1 (2017): 115&#x2013;122, https://doi.org/10.1111/coa.12674.</Citation></Reference><Reference><Citation>J. A. Bonner, J. Giralt, P. M. Harari, et&#xa0;al., &#x201c;Association of Human Papillomavirus and p16 Status With Mucositis and Dysphagia for Head and Neck Cancer Patients Treated With Radiotherapy With or Without Cetuximab: Assessment From a Phase 3 Registration Trial,&#x201d; European Journal of Cancer 64 (2016): 1&#x2013;11, https://doi.org/10.1016/j.ejca.2016.05.008.</Citation></Reference><Reference><Citation>A. Bottomley, G. Tridello, C. Coens, et&#xa0;al., &#x201c;An International Phase 3 Trial in Head and Neck Cancer: Quality of Life and Symptom Results,&#x201d; Cancer 120, no. 3 (2014): 390&#x2013;398, https://doi.org/10.1002/cncr.28392.</Citation></Reference><Reference><Citation>B. Cartmill, P. Cornwell, E. Ward, W. Davidson, and S. Porceddu, &#x201c;A Prospective Investigation of Swallowing, Nutrition, and Patient&#x2010;Rated Functional Impact Following Altered Fractionation Radiotherapy With Concomitant Boost for Oropharyngeal Cancer,&#x201d; Dysphagia 27, no. 1 (2012): 32&#x2013;45, https://doi.org/10.1007/s00455&#x2010;011&#x2010;9333&#x2010;5.</Citation></Reference><Reference><Citation>J. J. Caudell, P. E. Schaner, R. F. Meredith, et&#xa0;al., &#x201c;Factors Associated With Long&#x2010;Term Dysphagia After Definitive Radiotherapy for Locally Advanced Head&#x2010;and&#x2010;Neck Cancer,&#x201d; International Journal of Radiation Oncology, Biology, Physics 73, no. 2 (2009): 410&#x2013;415, https://doi.org/10.1016/j.ijrobp.2008.04.048.</Citation></Reference><Reference><Citation>Y. C. Chang, S. Y. Chen, L. L. Ting, S. S. F. Peng, T. C. Wang, and T. G. Wang, &#x201c;A 2&#x2010;Year Follow&#x2010;Up of Swallowing Function After Radiation Therapy in Patients With Nasopharyngeal Carcinoma,&#x201d; Archives of Physical Medicine and Rehabilitation 92, no. 11 (2011): 1814&#x2013;1819, https://doi.org/10.1016/j.apmr.2011.06.008.</Citation></Reference><Reference><Citation>E. Charters, H. Bogaardt, J. Clark, et&#xa0;al., &#x201c;Functional Swallowing Outcomes Related to Radiation Exposure to Dysphagia and Aspiration&#x2010;Related Structures in Patients With Head and Neck Cancer Undergoing Definitive and Postoperative Intensity&#x2010;Modulated Radiotherapy,&#x201d; Head &amp; Neck 44, no. 2 (2022): 399&#x2013;411, https://doi.org/10.1002/hed.26936.</Citation></Reference><Reference><Citation>A. M. Chen, C. Felix, P. C. Wang, et&#xa0;al., &#x201c;Reduced&#x2010;Dose Radiotherapy for Human Papillomavirus&#x2010;Associated Squamous&#x2010;Cell Carcinoma of the Oropharynx: A Single&#x2010;Arm, Phase 2 Study,&#x201d; Lancet Oncology 18, no. 6 (2017): 803&#x2013;811, https://doi.org/10.1016/S1470&#x2010;2045(17)30246&#x2010;2.</Citation></Reference><Reference><Citation>M. E. M. C. Christianen, I. M. Verdonck&#x2010;de Leeuw, P. Doornaert, et&#xa0;al., &#x201c;Patterns of Long&#x2010;Term Swallowing Dysfunction After Definitive Radiotherapy or Chemoradiation,&#x201d; Radiotherapy and Oncology 117, no. 1 (2015): 139&#x2013;144, https://doi.org/10.1016/j.radonc.2015.07.042.</Citation></Reference><Reference><Citation>P. D. de Veij Mestdagh, I. Walraven, W. V. Vogel, et&#xa0;al., &#x201c;SPECT/CT&#x2010;Guided Elective Nodal Irradiation for Head and Neck Cancer Is Oncologically Safe and Less Toxic: A Potentially Practice&#x2010;Changing Approach,&#x201d; Radiotherapy and Oncology 147 (2020): 56&#x2013;63, https://doi.org/10.1016/j.radonc.2020.03.012.</Citation></Reference><Reference><Citation>K. Dornfeld, J. R. Simmons, L. Karnell, et&#xa0;al., &#x201c;Radiation Doses to Structures Within and Adjacent to the Larynx Are Correlated With Long&#x2010;Term Diet&#x2010; and Speech&#x2010;Related Quality of Life,&#x201d; International Journal of Radiation Oncology, Biology, Physics 68, no. 3 (2007): 750&#x2013;757, https://doi.org/10.1016/j.ijrobp.2007.01.047.</Citation></Reference><Reference><Citation>T. Dragan, S. Beauvois, M. Moreau, et&#xa0;al., &#x201c;Clinical Outcome and Toxicity After Simultaneous Integrated Boost IMRT in Head and Neck Squamous Cell Cancer Patients,&#x201d; Oral Oncology 98 (2019): 132&#x2013;140, https://doi.org/10.1016/j.oraloncology.2019.09.012.</Citation></Reference><Reference><Citation>C. M. L. Driessen, J. M. M. Groenewoud, J. P. de Boer, et&#xa0;al., &#x201c;Quality of Life of Patients With Locally Advanced Head and Neck Cancer Treated With Induction Chemotherapy Followed by Cisplatin&#x2010;Containing Chemoradiotherapy in the Dutch CONDOR Study: A Randomized Controlled Trial,&#x201d; Supportive Care in Cancer 26, no. 4 (2018): 1233&#x2013;1242, https://doi.org/10.1007/s00520&#x2010;017&#x2010;3946&#x2010;7.</Citation></Reference><Reference><Citation>A. Eisbruch, T. Lyden, C. R. Bradford, et&#xa0;al., &#x201c;Objective Assessment of Swallowing Dysfunction and Aspiration After Radiation Concurrent With Chemotherapy for Head&#x2010;And&#x2010;Neck Cancer,&#x201d; International Journal of Radiation Oncology, Biology, Physics 53, no. 1 (2002): 23&#x2013;28, https://doi.org/10.1016/S0360&#x2010;3016(02)02712&#x2010;8.</Citation></Reference><Reference><Citation>E. Y. Erkal, D. Cano&#x11f;lu, A. Kaya, et&#xa0;al., &#x201c;Assessment of Early and Late Dysphagia Using Videofluoroscopy and Quality of Life Questionnaires in Patients With Head and Neck Cancer Treated With Radiation Therapy,&#x201d; Radiation Oncology 9 (2014): 137, https://doi.org/10.1186/1748&#x2010;717X&#x2010;9&#x2010;137.</Citation></Reference><Reference><Citation>F. M. Fang, W. L. Tsai, C. Y. Chien, et&#xa0;al., &#x201c;Changing Quality of Life in Patients With Advanced Head and Neck Cancer After Primary Radiotherapy or Chemoradiation,&#x201d; Oncology 68, no. 4&#x2013;6 (2005): 405&#x2013;413, https://doi.org/10.1159/000086982.</Citation></Reference><Reference><Citation>F. Y. Feng, H. M. Kim, T. H. Lyden, et&#xa0;al., &#x201c;Intensity&#x2010;Modulated Chemoradiotherapy Aiming to Reduce Dysphagia in Patients With Oropharyngeal Cancer: Clinical and Functional Results,&#x201d; Journal of Clinical Oncology 28, no. 16 (2010): 2732&#x2013;2738, https://doi.org/10.1200/JCO.2009.24.6199.</Citation></Reference><Reference><Citation>C. Franzese, A. Fogliata, E. Clerici, et&#xa0;al., &#x201c;Toxicity Profile and Early Clinical Outcome for Advanced Head and Neck Cancer Patients Treated With Simultaneous Integrated Boost and Volumetric Modulated Arc Therapy,&#x201d; Radiation Oncology 10, no. 1 (2015): 224, https://doi.org/10.1186/s13014&#x2010;015&#x2010;0535&#x2010;0.</Citation></Reference><Reference><Citation>J. Frowen, S. Cotton, J. Corry, and A. Perry, &#x201c;Impact of Demographics, Tumor Characteristics, and Treatment Factors on Swallowing After (Chemo)radiotherapy for Head and Neck Cancer,&#x201d; Head &amp; Neck 32, no. 4 (2010): 513&#x2013;528, https://doi.org/10.1002/hed.21218.</Citation></Reference><Reference><Citation>A. Gawryszuk, H. P. Bijl, A. van der Schaaf, et&#xa0;al., &#x201c;Relationship Between Videofluoroscopic and Subjective (Physician&#x2010; and Patient&#x2010; Rated) Assessment of Late Swallowing Dysfunction After (Chemo) Radiation: Results of a Prospective Observational Study,&#x201d; Radiotherapy and Oncology 164 (2021): 253&#x2013;260, https://doi.org/10.1016/j.radonc.2021.09.017.</Citation></Reference><Reference><Citation>R. P. Goepfert, J. S. Lewin, M. P. Barrow, et&#xa0;al., &#x201c;Predicting Two&#x2010;Year Longitudinal MD Anderson Dysphagia Inventory Outcomes After Intensity Modulated Radiotherapy for Locoregionally Advanced Oropharyngeal Carcinoma,&#x201d; Laryngoscope 127, no. 4 (2017): 842&#x2013;848, https://doi.org/10.1002/lary.26153.</Citation></Reference><Reference><Citation>S. R. Grant, K. A. Hutcheson, R. Ye, et&#xa0;al., &#x201c;Prospective Longitudinal Patient&#x2010;Reported Outcomes of Swallowing Following Intensity Modulated Proton Therapy for Oropharyngeal Cancer,&#x201d; Radiotherapy and Oncology 148 (2020): 133&#x2013;139, https://doi.org/10.1016/j.radonc.2020.04.021.</Citation></Reference><Reference><Citation>E. Greco, J. Ringash, G. Tomlinson, et&#xa0;al., &#x201c;Presence and Duration of Feeding Tube in a 5&#x2010;Year Cohort of Patients With Head and Neck Cancer Treated With Curative Intensity&#x2010;Modulated Radiation Therapy,&#x201d; Head &amp; Neck 43, no. 5 (2021): 1610&#x2013;1620, https://doi.org/10.1002/hed.26638.</Citation></Reference><Reference><Citation>G. Z. Guo, K. R. Sutherland, C. Myers, P. Lambert, S. K. Loewen, and H. C. Quon, &#x201c;Prospective Swallowing Outcomes After IMRT for Oropharyngeal Cancer: Dosimetric Correlations in a Population&#x2010;Based Cohort,&#x201d; Oral Oncology 61 (2016): 135&#x2013;141, https://doi.org/10.1016/j.oraloncology.2016.08.021.</Citation></Reference><Reference><Citation>J. V. Hegde, N. Shaverdian, M. E. Daly, et&#xa0;al., &#x201c;Patient&#x2010;Reported Quality&#x2010;of&#x2010;Life Outcomes After de&#x2010;Escalated Chemoradiation for Human Papillomavirus&#x2010;Positive Oropharyngeal Carcinoma: Findings From a Phase 2 Trial,&#x201d; Cancer 124, no. 3 (2018): 521&#x2013;529, https://doi.org/10.1002/cncr.30954.</Citation></Reference><Reference><Citation>M. Hemmati, C. Barbon, A. S. R. Mohamed, et&#xa0;al., &#x201c;Optimized Decision Support for Selection of Transoral Robotic Surgery or (Chemo)radiation Therapy Based on Posttreatment Swallowing Toxicity,&#x201d; Cancer Medicine 12, no. 4 (2023): 5088&#x2013;5098, https://doi.org/10.1002/cam4.5253.</Citation></Reference><Reference><Citation>A. Homma, H. Hatakeyama, T. Mizumachi, et&#xa0;al., &#x201c;A Retrospective Study of G&#x2010;Tube Use in Japanese Patients Treated With Concurrent Chemoradiotherapy for Hypopharyngeal Cancer,&#x201d; PLoS One 11, no. 8 (2016): e0161734, https://doi.org/10.1371/journal.pone.0161734.</Citation></Reference><Reference><Citation>Q. Hu and B. Xie, &#x201c;Effect of Maitake D&#x2010;Fraction in Advanced Laryngeal and Pharyngeal Cancers During Concurrent Chemoradiotherapy: A Randomized Clinical Trial,&#x201d; Acta Biochimica Polonica 69, no. 3 (2022): 625&#x2013;632, https://doi.org/10.18388/abp.2020_5996.</Citation></Reference><Reference><Citation>R. T. Hughes, B. J. Levine, N. May, et&#xa0;al., &#x201c;Survival and Swallowing Function After Primary Radiotherapy Versus Transoral Robotic Surgery for Human Papillomavirus&#x2010;Associated Oropharyngeal Squamous Cell Carcinoma,&#x201d; Journal for Oto&#x2010;Rhino&#x2010;Laryngology and Its Related Specialties 85, no. 5 (2023): 284&#x2013;293, https://doi.org/10.1159/000531995.</Citation></Reference><Reference><Citation>K. U. Hunter, M. Schipper, F. Y. Feng, et&#xa0;al., &#x201c;Toxicities Affecting Quality of Life After Chemo&#x2010;IMRT of Oropharyngeal Cancer: Prospective Study of Patient&#x2010;Reported, Observer&#x2010;Rated, and Objective Outcomes,&#x201d; International Journal of Radiation Oncology, Biology, Physics 85, no. 4 (2013): 935&#x2013;940, https://doi.org/10.1016/j.ijrobp.2012.08.030.</Citation></Reference><Reference><Citation>C. Jeans, B. Brown, E. C. Ward, et&#xa0;al., &#x201c;A Prospective, Longitudinal and Exploratory Study of Head and Neck Lymphoedema and Dysphagia Following Chemoradiotherapy for Head and Neck Cancer,&#x201d; Dysphagia 38, no. 4 (2023): 1059&#x2013;1071, https://doi.org/10.1007/s00455&#x2010;022&#x2010;10526&#x2010;1.</Citation></Reference><Reference><Citation>A. Jegannathen, K. Mais, A. Sykes, et&#xa0;al., &#x201c;Synchronous Chemoradiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Using Capecitabine: A Single&#x2010;Centre, Open&#x2010;Label, Single&#x2010;Group Phase II Study,&#x201d; Clinical Oncology 23, no. 2 (2011): 149&#x2013;158, https://doi.org/10.1016/j.clon.2010.09.010.</Citation></Reference><Reference><Citation>N. Jovanovic, C. Dreyer, S. Hawkins, et&#xa0;al., &#x201c;The Natural History of Weight and Swallowing Outcomes in Oropharyngeal Cancer Patients Following Radiation or Concurrent Chemoradiation Therapy,&#x201d; Supportive Care in Cancer 29, no. 3 (2021): 1597&#x2013;1607, https://doi.org/10.1007/s00520&#x2010;020&#x2010;05628&#x2010;1.</Citation></Reference><Reference><Citation>S. Keereweer, J. D. F. Kerrebijn, A. Al&#x2010;Mamgani, A. Sewnaik, R. J. B. de Jong, and E. van Meerten, &#x201c;Chemoradiation for Advanced Hypopharyngeal Carcinoma: A Retrospective Study on Efficacy, Morbidity and Quality of Life,&#x201d; European Archives of Oto&#x2010;Rhino&#x2010;Laryngology 269, no. 3 (2012): 939&#x2013;946, https://doi.org/10.1007/s00405&#x2010;011&#x2010;1694&#x2010;8.</Citation></Reference><Reference><Citation>M. S. Kies, F. C. Holsinger, J. J. Lee, et&#xa0;al., &#x201c;Induction Chemotherapy and Cetuximab for Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Results From a Phase II Prospective Trial,&#x201d; Journal of Clinical Oncology 28, no. 1 (2010): 8&#x2013;14, https://doi.org/10.1200/JCO.2009.23.0425.</Citation></Reference><Reference><Citation>T. Kitabatake, K. Takayama, T. Tominaga, et&#xa0;al., &#x201c;Treatment Outcomes of Proton Beam Therapy Combined With Retrograde Intra&#x2010;Arterial Infusion Chemotherapy for Locally Advanced Oral Cancer in the Elderly,&#x201d; International Journal of Oral and Maxillofacial Surgery 51, no. 10 (2022): 1264&#x2013;1272, https://doi.org/10.1016/j.ijom.2022.01.014.</Citation></Reference><Reference><Citation>T. Kotz, A. D. Federman, J. Kao, et&#xa0;al., &#x201c;Prophylactic Swallowing Exercises in Patients With Head and Neck Cancer Undergoing Chemoradiation: A Randomized Trial,&#x201d; Archives of Otolaryngology &#x2013; Head &amp; Neck Surgery 138, no. 4 (2012): 376&#x2013;382, https://doi.org/10.1001/archoto.2012.187.</Citation></Reference><Reference><Citation>S. A. C. Kraaijenga, L. van der Molen, I. Jacobi, O. Hamming&#x2010;Vrieze, F. J. M. Hilgers, and M. W. M. van den Brekel, &#x201c;Prospective Clinical Study on Long&#x2010;Term Swallowing Function and Voice Quality in Advanced Head and Neck Cancer Patients Treated With Concurrent Chemoradiotherapy and Preventive Swallowing Exercises,&#x201d; European Archives of Oto&#x2010;Rhino&#x2010;Laryngology 272, no. 11 (2015): 3521&#x2013;3531, https://doi.org/10.1007/s00405&#x2010;014&#x2010;3379&#x2010;6.</Citation></Reference><Reference><Citation>S. A. C. Kraaijenga, I. M. Oskam, L. van der Molen, O. Hamming&#x2010;Vrieze, F. J. M. Hilgers, and M. W. M. van den Brekel, &#x201c;Evaluation of Long Term (10&#x2010;Years+) Dysphagia and Trismus in Patients Treated With Concurrent Chemo&#x2010;Radiotherapy for Advanced Head and Neck Cancer,&#x201d; Oral Oncology 51, no. 8 (2015): 787&#x2013;794, https://doi.org/10.1016/j.oraloncology.2015.05.003.</Citation></Reference><Reference><Citation>H. J. Lee, D. H. Han, J. H. Kim, and H. G. Wu, &#x201c;The Effect of Comprehensive Oral Care Program on Oral Health and Quality of Life in Patients Undergoing Radiotherapy for Head and Neck Cancer: A Quasi&#x2010;Experimental Case&#x2010;Control Study,&#x201d; Medicine (Baltimore) 100, no. 16 (2021): e25540, https://doi.org/10.1097/MD.0000000000025540.</Citation></Reference><Reference><Citation>S. L. Lewis, R. Brody, R. Touger&#x2013;Decker, J. S. Parrott, and J. Epstein, &#x201c;Feeding Tube Use in Patients With Head and Neck Cancer,&#x201d; Head and Neck 36, no. 12 (2014): 1789&#x2013;1795, https://doi.org/10.1002/hed.23538.</Citation></Reference><Reference><Citation>J. A. Logemann, B. R. Pauloski, A. W. Rademaker, et&#xa0;al., &#x201c;Swallowing Disorders in the First Year After Radiation and Chemoradiation,&#x201d; Head &amp; Neck 30, no. 2 (2008): 148&#x2013;158, https://doi.org/10.1002/hed.20672.</Citation></Reference><Reference><Citation>R. J. Maggiore, E. K. Curran, M. E. Witt, D. J. Haraf, E. E. Vokes, and E. E. W. Cohen, &#x201c;Survival and Selected Outcomes of Older Adults With Locally Advanced Head/Neck Cancer Treated With Chemoradiation Therapy,&#x201d; Journal of Geriatric Oncology 4, no. 4 (2013): 327&#x2013;333, https://doi.org/10.1016/j.jgo.2013.05.003.</Citation></Reference><Reference><Citation>S. M. McBride, R. J. Parambi, J. W. Jang, T. Goldsmith, P. M. Busse, and A. W. Chan, &#x201c;Intensity&#x2010;Modulated Versus Conventional Radiation Therapy for Oropharyngeal Carcinoma: Long&#x2010;Term Dysphagia and Tumor Control Outcomes,&#x201d; Head and Neck 36, no. 4 (2014): 492&#x2013;498, https://doi.org/10.1002/hed.23319.</Citation></Reference><Reference><Citation>B. P. Messing, E. C. Ward, C. L. Lazarus, et&#xa0;al., &#x201c;Prophylactic Swallow Therapy for Patients With Head and Neck Cancer Undergoing Chemoradiotherapy: A Randomized Trial,&#x201d; Dysphagia 32, no. 4 (2017): 487&#x2013;500, https://doi.org/10.1007/s00455&#x2010;017&#x2010;9790&#x2010;6.</Citation></Reference><Reference><Citation>A. B. Miah, S. A. Bhide, M. T. Guerrero&#x2010;Urbano, et&#xa0;al., &#x201c;Dose&#x2010;Escalated Intensity&#x2010;Modulated Radiotherapy Is Feasible and May Improve Locoregional Control and Laryngeal Preservation in Laryngo&#x2010;Hypopharyngeal Cancers,&#x201d; International Journal of Radiation Oncology, Biology, Physics 82, no. 2 (2012): 539&#x2013;547, https://doi.org/10.1016/j.ijrobp.2010.09.055.</Citation></Reference><Reference><Citation>M. L. Mierzwa, L. A. Gharzai, P. Li, et&#xa0;al., &#x201c;Early MRI Blood Volume Changes in Constrictor Muscles Correlate With Postradiation Dysphagia,&#x201d; International Journal of Radiation Oncology, Biology, Physics 110, no. 2 (2021): 566&#x2013;573, https://doi.org/10.1016/j.ijrobp.2020.12.018.</Citation></Reference><Reference><Citation>G. Mok, I. Gauthier, H. Jiang, et&#xa0;al., &#x201c;Outcomes of Intensity&#x2010;Modulated Radiotherapy Versus Conventional Radiotherapy for Hypopharyngeal Cancer,&#x201d; Head &amp; Neck 37, no. 5 (2015): 655&#x2013;661, https://doi.org/10.1002/hed.23649.</Citation></Reference><Reference><Citation>H. R. Mortensen, K. Jensen, K. Aksgl&#xe6;de, K. Lambertsen, E. Eriksen, and C. Grau, &#x201c;Prophylactic Swallowing Exercises in Head and Neck Cancer Radiotherapy,&#x201d; Dysphagia 30, no. 3 (2015): 304&#x2013;314, https://doi.org/10.1007/s00455&#x2010;015&#x2010;9600&#x2010;y.</Citation></Reference><Reference><Citation>S. Murono, A. Tsuji, K. Endo, S. Kondo, N. Wakisaka, and T. Yoshizaki, &#x201c;Factors Associated With Gastrostomy Tube Dependence After Concurrent Chemoradiotherapy for Hypopharyngeal Cancer,&#x201d; Supportive Care in Cancer 23, no. 2 (2015): 457&#x2013;462, https://doi.org/10.1007/s00520&#x2010;014&#x2010;2388&#x2010;8.</Citation></Reference><Reference><Citation>M. Naik, M. C. Ward, T. J. Bledsoe, et&#xa0;al., &#x201c;It Is Not Just IMRT: Human Papillomavirus Related Oropharynx Squamous Cell Carcinoma Is Associated With Better Swallowing Outcomes After Definitive Chemoradiotherapy,&#x201d; Oral Oncology 51, no. 8 (2015): 800&#x2013;804, https://doi.org/10.1016/j.oraloncology.2015.04.008.</Citation></Reference><Reference><Citation>D. Nevens, A. Goeleven, F. Duprez, et&#xa0;al., &#x201c;Correlation of Patient&#x2010; and Physician&#x2010;Scored Dysphagia With Videofluoroscopies in Patients Treated With Radiotherapy for Head and Neck Cancer,&#x201d; Dysphagia 33, no. 5 (2018): 684&#x2013;690, https://doi.org/10.1007/s00455&#x2010;018&#x2010;9888&#x2010;5.</Citation></Reference><Reference><Citation>A. C. Nichols, J. Theurer, E. Prisman, et&#xa0;al., &#x201c;Randomized Trial of Radiotherapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma: Long&#x2010;Term Results of the ORATOR Trial,&#x201d; Journal of Clinical Oncology 40, no. 8 (2022): 866&#x2013;875, https://doi.org/10.1200/JCO.21.01961.</Citation></Reference><Reference><Citation>C. Nutting, L. Finneran, J. Roe, et&#xa0;al., &#x201c;Dysphagia&#x2010;Optimised Intensity&#x2010;Modulated Radiotherapy Versus Standard Intensity&#x2010;Modulated Radiotherapy in Patients With Head and Neck Cancer (DARS): A Phase 3, Multicentre, Randomised, Controlled Trial,&#x201d; Lancet Oncology 24, no. 8 (2023): 868&#x2013;880, https://doi.org/10.1016/S1470&#x2010;2045(23)00265&#x2010;6.</Citation></Reference><Reference><Citation>J. M. Patterson, E. McColl, P. N. Carding, and J. A. Wilson, &#x201c;Swallowing Beyond Six Years Post (Chemo)radiotherapy for Head and Neck Cancer; a Cohort Study,&#x201d; Oral Oncology 83 (2018): 53&#x2013;58, https://doi.org/10.1016/j.oraloncology.2018.06.003.</Citation></Reference><Reference><Citation>B. R. Pauloski, A. W. Rademaker, J. A. Logemann, et&#xa0;al., &#x201c;Relationship Between Swallow Motility Disorders on Videofluorography and Oral Intake in Patients Treated for Head and Neck Cancer With Radiotherapy With or Without Chemotherapy,&#x201d; Head &amp; Neck 28, no. 12 (2006): 1069&#x2013;1076, https://doi.org/10.1002/hed.20459.</Citation></Reference><Reference><Citation>B. R. Pauloski, A. W. Rademaker, J. A. Logemann, M. Discekici&#x2013;Harris, and B. B. Mittal, &#x201c;Comparison of Swallowing Function After Intensity&#x2010;Modulated Radiation Therapy and Conventional Radiotherapy for Head and Neck Cancer,&#x201d; Head and Neck 37, no. 11 (2015): 1575&#x2013;1582, https://doi.org/10.1002/hed.23796.</Citation></Reference><Reference><Citation>S. Pohar, M. Demarcantonio, P. Whiting, E. Crandley, J. Wadsworth, and D. Karakla, &#x201c;Percutaneous Endoscopic Gastrostomy Tube Dependence Following Chemoradiation in Head and Neck Cancer Patients,&#x201d; Laryngoscope 125, no. 6 (2015): 1366&#x2013;1371, https://doi.org/10.1002/lary.25117.</Citation></Reference><Reference><Citation>J. Ringash, J. N. Waldron, L. L. Siu, et&#xa0;al., &#x201c;Quality of Life and Swallowing With Standard Chemoradiotherapy Versus Accelerated Radiotherapy and Panitumumab in Locoregionally Advanced Carcinoma of the Head and Neck: A Phase III Randomised Trial From the Canadian Cancer Trials Group (HN.6),&#x201d; European Journal of Cancer 72 (2017): 192&#x2013;199, https://doi.org/10.1016/j.ejca.2016.11.008.</Citation></Reference><Reference><Citation>J. W. G. Roe, M. J. Drinnan, P. N. Carding, K. J. Harrington, and C. M. Nutting, &#x201c;Patient&#x2010;Reported Outcomes Following Parotid&#x2010;Sparing Intensity&#x2010;Modulated Radiotherapy for Head and Neck Cancer. How Important Is Dysphagia?,&#x201d; Oral Oncology 50, no. 12 (2014): 1182&#x2013;1187, https://doi.org/10.1016/j.oraloncology.2014.09.009.</Citation></Reference><Reference><Citation>J. W. G. Roe, P. N. Carding, M. J. Drinnan, K. J. Harrington, and C. M. Nutting, &#x201c;Swallowing Performance and Tube Feeding Status in Patients Treated With Parotid&#x2010;Sparing Intensity&#x2010;Modulated Radiotherapy for Head and Neck Cancer,&#x201d; Head and Neck 38, no. S1 (2016): E1436&#x2013;E1444, https://doi.org/10.1002/hed.24255.</Citation></Reference><Reference><Citation>M. Saks&#xf8;, E. Andersen, J. Bentzen, et&#xa0;al., &#x201c;A Prospective, Multicenter DAHANCA Study of Hyperfractionated, Accelerated Radiotherapy for Head and Neck Squamous Cell Carcinoma,&#x201d; Acta Oncologica 58, no. 10 (2019): 1495&#x2013;1501, https://doi.org/10.1080/0284186X.2019.1658897.</Citation></Reference><Reference><Citation>D. L. Schwartz, K. Hutcheson, D. Barringer, et&#xa0;al., &#x201c;Candidate Dosimetric Predictors of Long&#x2010;Term Swallowing Dysfunction After Oropharyngeal Intensity&#x2010;Modulated Radiotherapy,&#x201d; International Journal of Radiation Oncology 78, no. 5 (2010): 1356&#x2013;1365, https://doi.org/10.1016/j.ijrobp.2009.10.002.</Citation></Reference><Reference><Citation>S. I. Scott, A. Kathrine &#xd8;. Madsen, N. Rubek, et&#xa0;al., &#x201c;Long&#x2010;Term Quality of Life &amp; Functional Outcomes After Treatment of Oropharyngeal Cancer,&#x201d; Cancer Medicine 10, no. 2 (2021): 483&#x2013;495, https://doi.org/10.1002/cam4.3599.</Citation></Reference><Reference><Citation>J. Setton, N. Y. Lee, N. Riaz, et&#xa0;al., &#x201c;A Multi&#x2010;Institution Pooled Analysis of Gastrostomy Tube Dependence in Patients With Oropharyngeal Cancer Treated With Definitive Intensity&#x2010;Modulated Radiotherapy,&#x201d; Cancer 121, no. 2 (2015): 294&#x2013;301, https://doi.org/10.1002/cncr.29022.</Citation></Reference><Reference><Citation>A. Sharma, S. Patel, F. M. Baik, et&#xa0;al., &#x201c;Survival and Gastrostomy Prevalence in Patients With Oropharyngeal Cancer Treated With Transoral Robotic Surgery vs Chemoradiotherapy,&#x201d; JAMA Otolaryngology. Head &amp; Neck Surgery 142, no. 7 (2016): 691&#x2013;697, https://doi.org/10.1001/jamaoto.2016.1106.</Citation></Reference><Reference><Citation>S. G. Shiley, C. A. Hargunani, J. M. Skoner, J. M. Holland, and M. K. Wax, &#x201c;Swallowing Function After Chemoradiation for Advanced Stage Oropharyngeal Cancer,&#x201d; Otolaryngology&#x2010;Head and Neck Surgery 134, no. 3 (2006): 455&#x2013;459, https://doi.org/10.1016/j.otohns.2005.10.054.</Citation></Reference><Reference><Citation>R. V. Smith, T. Kotz, J. J. Beitler, and S. Wadler, &#x201c;Long&#x2010;Term Swallowing Problems After Organ Preservation Therapy With Concomitant Radiation Therapy and Intravenous Hydroxyurea: Initial Results,&#x201d; Archives of Otolaryngology &#x2013; Head &amp; Neck Surgery 126, no. 3 (2000): 384&#x2013;389, https://doi.org/10.1001/archotol.126.3.384.</Citation></Reference><Reference><Citation>W. Sumner, X. Ray, L. Sutton, et&#xa0;al., &#x201c;Gene Alterations as Predictors of Radiation&#x2010;Induced Toxicity in Head and Neck Squamous Cell Carcinoma,&#x201d; Journal of Translational Medicine 19, no. 1 (2021): 212, https://doi.org/10.1186/s12967&#x2010;021&#x2010;02876&#x2010;5.</Citation></Reference><Reference><Citation>L. L. Tang, C. L. Huang, N. Zhang, et&#xa0;al., &#x201c;Elective Upper&#x2010;Neck Versus Whole&#x2010;Neck Irradiation of the Uninvolved Neck in Patients With Nasopharyngeal Carcinoma: An Open&#x2010;Label, Non&#x2010;Inferiority, Multicentre, Randomised Phase 3 Trial,&#x201d; Lancet Oncology 23, no. 4 (2022): 479&#x2013;490, https://doi.org/10.1016/S1470&#x2010;2045(22)00058&#x2010;4.</Citation></Reference><Reference><Citation>D. C. Tippett and K. T. Webster, &#x201c;Rehabilitation Needs of Patients With Oropharyngeal Cancer,&#x201d; Otolaryngologic Clinics of North America 45, no. 4 (2012): 863&#x2013;878, https://doi.org/10.1016/j.otc.2012.05.005.</Citation></Reference><Reference><Citation>M. T. Truong, R. Lee, N. Saito, et&#xa0;al., &#x201c;Correlating Computed Tomography Perfusion Changes in the Pharyngeal Constrictor Muscles During Head&#x2010;and&#x2010;Neck Radiotherapy to Dysphagia Outcome,&#x201d; International Journal of Radiation Oncology 82, no. 2 (2012): e119&#x2013;e127, https://doi.org/10.1016/j.ijrobp.2011.04.058.</Citation></Reference><Reference><Citation>J. K. L. Tuan, T. C. Ha, W. S. Ong, et&#xa0;al., &#x201c;Late Toxicities After Conventional Radiation Therapy Alone for Nasopharyngeal Carcinoma,&#x201d; Radiotherapy and Oncology 104, no. 3 (2012): 305&#x2013;311, https://doi.org/10.1016/j.radonc.2011.12.028.</Citation></Reference><Reference><Citation>S. Ursino, E. Calistri, F. De Felice, et&#xa0;al., &#x201c;Patient&#x2010;Reported Outcomes After Swallowing (SWOARs)&#x2010;Sparing IMRT in Head and Neck Cancers: Primary Results From a Prospective Study Endorsed by the Head and Neck Study Group (HNSG) of the Italian Association of Radiotherapy and Clinical Oncology (AIRO),&#x201d; Dysphagia 38, no. 1 (2023): 159&#x2013;170, https://doi.org/10.1007/s00455&#x2010;022&#x2010;10434&#x2010;4.</Citation></Reference><Reference><Citation>S. Ursino, P. Cocuzza, V. Seccia, et&#xa0;al., &#x201c;Pattern of Dysphagia After Swallowing&#x2010;Sparing Intensity&#x2010;Modulated Radiotherapy (IMRT) of Head and Neck Cancers: Results of a Mono&#x2010;Institutional Prospective Study,&#x201d; Strahlentherapie Und Onkologie 194, no. 12 (2018): 1114&#x2013;1123, https://doi.org/10.1007/s00066&#x2010;018&#x2010;1328&#x2010;9.</Citation></Reference><Reference><Citation>J. M. Vainshtein, D. H. Moon, F. Y. Feng, D. B. Chepeha, A. Eisbruch, and M. H. Stenmark, &#x201c;Long&#x2010;Term Quality of Life After Swallowing and Salivary&#x2010;Sparing Chemo&#x2013;Intensity Modulated Radiation Therapy in Survivors of Human Papillomavirus&#x2013;Related Oropharyngeal Cancer,&#x201d; International Journal of Radiation Oncology, Biology, Physics 91, no. 5 (2015): 925&#x2013;933, https://doi.org/10.1016/j.ijrobp.2014.12.045.</Citation></Reference><Reference><Citation>G. B. van den Broek, A. J. M. Balm, M. W. M. van den Brekel, M. Hauptmann, J. H. Schornagel, and C. R. N. Rasch, &#x201c;Relationship Between Clinical Factors and the Incidence of Toxicity After Intra&#x2010;Arterial Chemoradiation for Head and Neck Cancer,&#x201d; Radiotherapy and Oncology 81, no. 2 (2006): 143&#x2013;150, https://doi.org/10.1016/j.radonc.2006.09.002.</Citation></Reference><Reference><Citation>D. Van Gestel, D. Van den Weyngaert, G. De Kerf, et&#xa0;al., &#x201c;Helical Tomotherapy in Head and Neck Cancer: A European Single&#x2010;Center Experience,&#x201d; Oncologist 20, no. 3 (2015): 279&#x2013;290, https://doi.org/10.1634/theoncologist.2014&#x2010;0337.</Citation></Reference><Reference><Citation>I. M. Verdonck&#x2010;de Leeuw, L. M. Buffart, M. W. Heymans, et&#xa0;al., &#x201c;The Course of Health&#x2010;Related Quality of Life in Head and Neck Cancer Patients Treated With Chemoradiation: A Prospective Cohort Study,&#x201d; Radiotherapy and Oncology 110, no. 3 (2014): 422&#x2013;428, https://doi.org/10.1016/j.radonc.2014.01.002.</Citation></Reference><Reference><Citation>G. Vlacich, D. E. Spratt, R. Diaz, et&#xa0;al., &#x201c;Dose to the Inferior Pharyngeal Constrictor Predicts Prolonged Gastrostomy Tube Dependence With Concurrent Intensity&#x2010;Modulated Radiation Therapy and Chemotherapy for Locally&#x2010;Advanced Head and Neck Cancer,&#x201d; Radiotherapy and Oncology 110, no. 3 (2014): 435&#x2013;440, https://doi.org/10.1016/j.radonc.2013.12.007.</Citation></Reference><Reference><Citation>M. J. Ward, T. Mellows, S. Harris, et&#xa0;al., &#x201c;Staging and Treatment of Oropharyngeal Cancer in the Human Papillomavirus Era,&#x201d; Head &amp; Neck 37, no. 7 (2015): 1002&#x2013;1013, https://doi.org/10.1002/hed.23697.</Citation></Reference><Reference><Citation>J. A. Wilson, P. N. Carding, and J. M. Patterson, &#x201c;Dysphagia After Nonsurgical Head and Neck Cancer Treatment,&#x201d; Otolaryngology&#x2010;Head and Neck Surgery 145, no. 5 (2011): 767&#x2013;771, https://doi.org/10.1177/0194599811414506.</Citation></Reference><Reference><Citation>E. Xinou, I. Chryssogonidis, A. Kalogera&#x2010;Fountzila, D. Panagiotopoulou&#x2010;Mpoukla, and A. Printza, &#x201c;Longitudinal Evaluation of Swallowing With Videofluoroscopy in Patients With Locally Advanced Head and Neck Cancer After Chemoradiation,&#x201d; Dysphagia 33, no. 5 (2018): 691&#x2013;706, https://doi.org/10.1007/s00455&#x2010;018&#x2010;9889&#x2010;4.</Citation></Reference><Reference><Citation>T. Xu, C. Shen, X. Zhou, et&#xa0;al., &#x201c;Selective Treatment Deintensification by Reducing Radiation Dose and Omitting Concurrent Chemotherapy Based on Response to Induction Chemotherapy in Human Papillomavirus&#x2010;Associated Oropharyngeal Squamous Cell Carcinoma: A Single&#x2010;Arm, Phase 2 Trial (IChoice&#x2010;01),&#x201d; International Journal of Radiation Oncology 118, no. 1 (2024): 169&#x2013;178, https://doi.org/10.1016/j.ijrobp.2023.07.037.</Citation></Reference><Reference><Citation>S. S. Yom, P. Torres&#x2010;Saavedra, J. J. Caudell, et&#xa0;al., &#x201c;Reduced&#x2010;Dose Radiation Therapy for HPV&#x2010;Associated Oropharyngeal Carcinoma (NRG Oncology HN002),&#x201d; Journal of Clinical Oncology 39, no. 9 (2021): 956&#x2013;965, https://doi.org/10.1200/JCO.20.03128.</Citation></Reference><Reference><Citation>J. A. Vermaire, C. P. J. Raaijmakers, E. M. Monninkhof, et&#xa0;al., &#x201c;The Course of Swallowing Problems in the First 2&#x2009;Years After Diagnosis of Head and Neck Cancer,&#x201d; Supportive Care in Cancer 30, no. 11 (2022): 9527&#x2013;9538, https://doi.org/10.1007/s00520&#x2010;022&#x2010;07322&#x2010;w.</Citation></Reference><Reference><Citation>T. T. M. Huynh, E. Dale, R. S. Falk, et&#xa0;al., &#x201c;Radiation&#x2010;Induced Long&#x2010;Term Dysphagia in Survivors of Head and Neck Cancer and Association With Dose&#x2010;Volume Parameters,&#x201d; Radiotherapy and Oncology 190 (2024): 110044, https://doi.org/10.1016/j.radonc.2023.110044.</Citation></Reference><Reference><Citation>N. Jiang, L. J. Zhang, L. Y. Li, Y. Zhao, and D. W. Eisele, &#x201c;Risk Factors for Late Dysphagia After (Chemo)radiotherapy for Head and Neck Cancer: A Systematic Methodological Review,&#x201d; Head &amp; Neck 38, no. 5 (2016): 792&#x2013;800, https://doi.org/10.1002/hed.23963.</Citation></Reference><Reference><Citation>E. E. W. Cohen, S. J. LaMonte, N. L. Erb, et&#xa0;al., &#x201c;American Cancer Society Head and Neck Cancer Survivorship Care Guideline,&#x201d; CA: A Cancer Journal for Clinicians 66, no. 3 (2016): 203&#x2013;239, https://doi.org/10.3322/caac.21343.</Citation></Reference><Reference><Citation>R. Martino, M. I. Fitch, C. D. Fuller, et&#xa0;al., &#x201c;The PRO&#x2010;ACTIVE Trial Protocol: A Randomized Study Comparing the Effectiveness of PROphylACTic Swallow InterVEntion for Patients Receiving Radiotherapy for Head and Neck Cancer,&#x201d; BMC Cancer 21, no. 1 (2021): 1100, https://doi.org/10.1186/s12885&#x2010;021&#x2010;08826&#x2010;0.</Citation></Reference><Reference><Citation>E. Greco, T. Simic, J. Ringash, G. Tomlinson, Y. Inamoto, and R. Martino, &#x201c;Dysphagia Treatment for Patients With Head and Neck Cancer Undergoing Radiation Therapy: A Meta&#x2010;Analysis Review,&#x201d; International Journal of Radiation Oncology, Biology, Physics 101, no. 2 (2018): 421&#x2013;444, https://doi.org/10.1016/j.ijrobp.2018.01.097.</Citation></Reference><Reference><Citation>L. Dixon, S. Ramasamy, K. Cardale, et&#xa0;al., &#x201c;Long Term Patient Reported Swallowing Function Following Chemoradiotherapy for Oropharyngeal Carcinoma,&#x201d; Radiotherapy and Oncology 128, no. 3 (2018): 452&#x2013;458, https://doi.org/10.1016/j.radonc.2018.06.014.</Citation></Reference><Reference><Citation>Y. A. Tsou, N. H. Meng, W. D. Chang, and C. H. Hua, &#x201c;Does Swallow Rehabilitation Improve Recovery of Swallow Function After Treatment for Advanced Head and Neck Cancer,&#x201d; Scientific Reports 15, no. 1 (2025): 8300, https://doi.org/10.1038/s41598&#x2010;025&#x2010;87877&#x2010;w.</Citation></Reference><Reference><Citation>M. Baudelet, L. Van den Steen, F. Duprez, et&#xa0;al., &#x201c;Prophylactic Swallowing Therapy During Head&#x2010;and&#x2010;Neck Cancer Radiotherapy: Effect of Service&#x2010;Delivery Mode and Overall Adherence Level on Swallowing Function and Muscle Strength&#x2010;The PRESTO Trial,&#x201d; Dysphagia 39, no. 2 (2024): 267&#x2013;281, https://doi.org/10.1007/s00455&#x2010;023&#x2010;10609&#x2010;7.</Citation></Reference><Reference><Citation>C. E. A. Barbon, C. B. Peterson, A. C. Moreno, et&#xa0;al., &#x201c;Adhering to Eat and Exercise Status During Radiotherapy for Oropharyngeal Cancer for Prevention and Mitigation of Radiotherapy&#x2010;Associated Dysphagia,&#x201d; JAMA Otolaryngology. Head &amp; Neck Surgery 148, no. 10 (2022): 956&#x2013;964, https://doi.org/10.1001/jamaoto.2022.2313.</Citation></Reference><Reference><Citation>H. M. Starmer, &#x201c;Dysphagia in Head and Neck Cancer,&#x201d; Current Opinion in Otolaryngology &amp; Head and Neck Surgery 22, no. 3 (2014): 195&#x2013;200, https://doi.org/10.1097/MOO.0000000000000044.</Citation></Reference><Reference><Citation>A. A. Forastiere, N. Ismaila, J. S. Lewin, et&#xa0;al., &#x201c;Use of Larynx&#x2010;Preservation Strategies in the Treatment of Laryngeal Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update,&#x201d; Journal of Clinical Oncology 36, no. 11 (2018): 1143&#x2013;1169, https://doi.org/10.1200/JCO.2017.75.7385.</Citation></Reference><Reference><Citation>R. M. Bhethanabotla, A. Gulati, I. K. Khalsa, et&#xa0;al., &#x201c;Swallowing Function Outcomes in Head and Neck Cancer Survivors Followed by a Long&#x2010;Term Dysphagia Surveillance Protocol,&#x201d; Head and Neck 47 (2025): 2650&#x2013;2660, https://doi.org/10.1002/hed.28166.</Citation></Reference><Reference><Citation>M. G. A. van den Berg, H. R&#xfc;tten, E. L. Rasmussen&#x2010;Conrad, et&#xa0;al., &#x201c;Nutritional Status, Food Intake, and Dysphagia in Long&#x2010;Term Survivors With Head and Neck Cancer Treated With Chemoradiotherapy: A Cross&#x2010;Sectional Study,&#x201d; Head &amp; Neck 36, no. 1 (2014): 60&#x2013;65, https://doi.org/10.1002/hed.23265.</Citation></Reference><Reference><Citation>R. J. Harley, J. T. Johnson, M. L. Nilsen, and M. C. Munin, &#x201c;Electromyography Findings in Radiation&#x2010;Induced Unilateral Tongue Immobility,&#x201d; Head &amp; Neck 46, no. 6 (2024): 1304&#x2013;1309, https://doi.org/10.1002/hed.27692.</Citation></Reference><Reference><Citation>Y. Dong, J. A. Ridge, B. Ebersole, et&#xa0;al., &#x201c;Incidence and Outcomes of Radiation&#x2010;Induced Late Cranial Neuropathy in 10&#x2010;Year Survivors of Head and Neck Cancer,&#x201d; Oral Oncology 95 (2019): 59&#x2013;64, https://doi.org/10.1016/j.oraloncology.2019.05.014.</Citation></Reference><Reference><Citation>L. R. Wall, E. C. Ward, B. Cartmill, and A. J. Hill, &#x201c;Physiological Changes to the Swallowing Mechanism Following (Chemo)radiotherapy for Head and Neck Cancer: A Systematic Review,&#x201d; Dysphagia 28, no. 4 (2013): 481&#x2013;493, https://doi.org/10.1007/s00455&#x2010;013&#x2010;9491&#x2010;8.</Citation></Reference><Reference><Citation>I. Porto de Toledo, L. L. Q. Pantoja, K. F. Luchesi, D. X. Assad, G. De Luca Canto, and E. N. S. Guerra, &#x201c;Deglutition Disorders as a Consequence of Head and Neck Cancer Therapies: A Systematic Review and Meta&#x2010;Analysis,&#x201d; Supportive Care in Cancer 27, no. 10 (2019): 3681&#x2013;3700, https://doi.org/10.1007/s00520&#x2010;019&#x2010;04920&#x2010;z.</Citation></Reference><Reference><Citation>S. McClelland, J. Z. Andrews, H. Chaudhry, S. Teckie, and A. Goenka, &#x201c;Prophylactic Versus Reactive Gastrostomy Tube Placement in Advanced Head and Neck Cancer Treated With Definitive Chemoradiotherapy: A Systematic Review,&#x201d; Oral Oncology 87 (2018): 77&#x2013;81, https://doi.org/10.1016/j.oraloncology.2018.10.028.</Citation></Reference><Reference><Citation>M. Itkin, M. H. DeLegge, J. C. Fang, et&#xa0;al., &#x201c;Multidisciplinary Practical Guidelines for Gastrointestinal Access for Enteral Nutrition and Decompression From the Society of Interventional Radiology and American Gastroenterological Association (AGA) Institute, With Endorsement by Canadian Interventional Radiological Association (CIRA) and Cardiovascular and Interventional Radiological Society of Europe (CIRSE),&#x201d; Journal of Vascular and Interventional Radiology 22, no. 8 (2011): 1089&#x2013;1106, https://doi.org/10.1016/j.jvir.2011.04.006.</Citation></Reference><Reference><Citation>S. A. McClave, J. K. DiBaise, G. E. Mullin, and R. G. Martindale, &#x201c;ACG Clinical Guideline: Nutrition Therapy in the Adult Hospitalized Patient,&#x201d; American Journal of Gastroenterology 111, no. 3 (2016): 315&#x2013;334, quiz 335, https://doi.org/10.1038/ajg.2016.28.</Citation></Reference><Reference><Citation>C. Y. Hsu, J. N. Lai, W. M. Kung, et&#xa0;al., &#x201c;Nationwide Prevalence and Outcomes of Long&#x2010;Term Nasogastric Tube Placement in Adults,&#x201d; Nutrients 14, no. 9 (2022): 1748, https://doi.org/10.3390/nu14091748.</Citation></Reference><Reference><Citation>M. A. Yantis, R. Velander, and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N), &#x201c;Untangling Enteral Nutrition Guidelines,&#x201d; Nursing (London) 41, no. 9 (2011): 32&#x2013;38, https://doi.org/10.1097/01.NURSE.0000403379.78665.7f.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70121 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41334671</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Dec</Month><Day>03</Day></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Hypofractionated Spot Scanning Proton Therapy for Head and Neck Mucosal Melanoma: A Retrospective Analysis With Quality-of-Life Outcome.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70121</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate clinical outcomes and quality of life (QOL) following hypofractionated spot-scanning proton therapy (SSPT) for head and neck malignant mucosal melanoma (HNMM).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This retrospective study included 39 patients treated with SSPT (60-64&#x2009;Gy[RBE] in 15-16 fractions) between 2013 and 2023. Endpoints included overall survival (OS), local control (LC), progression-free survival (PFS), toxicities, and QOL.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Most tumors were located in the sinonasal cavity (n&#x2009;=&#x2009;32). Surgery was performed in 8 patients; 19 received immune checkpoint inhibitors post-SSPT. The 3-year OS, LC, and PFS were 50%, 83%, and 30%, respectively. Larger tumor volumes (&#x2265;&#x2009;20&#x2009;cm<sup>3</sup>) were linked to worse PFS. Grade 3 mucositis occurred in 13%. Late toxicities included sinus disorder, osteonecrosis, and blindness (3%-5%). QOL was largely preserved, with notable declines in pain, swallowing, and mouth opening.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">SSPT provides favorable LC with acceptable toxicity. Effective systemic therapies are needed to improve long-term outcomes.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). Head &amp; Neck published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nakajima</LastName><ForeName>Koichiro</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-2306-7836</Identifier><AffiliationInfo><Affiliation>Department of Radiation Oncology, Nagoya Proton Therapy Center, Nagoya City University West Medical Center, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwata</LastName><ForeName>Hiromitsu</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-9809-9800</Identifier><AffiliationInfo><Affiliation>Department of Radiation Oncology, Nagoya Proton Therapy Center, Nagoya City University West Medical Center, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takano</LastName><ForeName>Gaku</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, Nagoya City University West Medical Center, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kojima</LastName><ForeName>Daiki</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Oral and Maxillofacial Surgery, Nagoya City University West Medical Center, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hattori</LastName><ForeName>Yukiko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Nagoya Proton Therapy Center, Nagoya City University West Medical Center, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsuzuki</LastName><ForeName>Yusuke</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0009-0000-2335-3309</Identifier><AffiliationInfo><Affiliation>Department of Radiation Oncology, Nagoya Proton Therapy Center, Nagoya City University West Medical Center, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sudo</LastName><ForeName>Shuou</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Nagoya Proton Therapy Center, Nagoya City University West Medical Center, Nagoya, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hayashi</LastName><ForeName>Kensuke</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Proton Therapy Technology, Nagoya Proton Therapy Center, Nagoya City West Medical Center, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toshito</LastName><ForeName>Toshiyuki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Proton Therapy Physics, Nagoya Proton Therapy Center, Nagoya City West Medical Center, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fukano</LastName><ForeName>Hideo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Oral and Maxillofacial Surgery, Nagoya City University West Medical Center, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ogino</LastName><ForeName>Hiroyuki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Nagoya Proton Therapy Center, Nagoya City University West Medical Center, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hiwatashi</LastName><ForeName>Akio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Radiology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>24K18835</GrantID><Agency>Japan Society for the Promotion of Science</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">head and neck</Keyword><Keyword MajorTopicYN="N">melanoma</Keyword><Keyword MajorTopicYN="N">proton therapy</Keyword><Keyword MajorTopicYN="N">quality of life</Keyword><Keyword MajorTopicYN="N">spot scanning</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>11</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>3</Day><Hour>14</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>3</Day><Hour>14</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41334671</ArticleId><ArticleId IdType="doi">10.1002/hed.70121</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>P. A. Ascierto, R. Accorona, G. Botti, et&#xa0;al., &#x201c;Mucosal Melanoma of the Head and Neck,&#x201d; Critical Reviews in Oncology/Hematology 112 (2017): 136&#x2013;152.</Citation></Reference><Reference><Citation>F. L&#xf3;pez, J. P. Rodrigo, A. Cardesa, et&#xa0;al., &#x201c;Update on Primary Head and Neck Mucosal Melanoma,&#x201d; Head &amp; Neck 38 (2016): 147&#x2013;155.</Citation></Reference><Reference><Citation>M. A. Moreno, D. B. Roberts, M. E. Kupferman, et&#xa0;al., &#x201c;Mucosal Melanoma of the Nose and Paranasal Sinuses, a Contemporary Experience From the M. D. Anderson Cancer Center,&#x201d; Cancer 116 (2010): 2215&#x2013;2223.</Citation></Reference><Reference><Citation>S. P. Lee, K. T. Shimizu, L. M. Tran, et&#xa0;al., &#x201c;Mucosal Melanoma of the Head and Neck: The Impact of Local Control on Survival: The Impact of Local Control on Survival,&#x201d; Laryngoscope 104 (1994): 121&#x2013;126.</Citation></Reference><Reference><Citation>M. C. Grant&#x2010;Freemantle, B. Lane O'Neill, and A. J. P. Clover, &#x201c;The Effectiveness of Radiotherapy in the Treatment of Head and Neck Mucosal Melanoma: Systematic Review and Meta&#x2010;Analysis,&#x201d; Head &amp; Neck 43 (2021): 323&#x2013;333.</Citation></Reference><Reference><Citation>M. Koto, Y. Demizu, J.&#x2010;I. Saitoh, et&#xa0;al., &#x201c;Multicenter Study of Carbon&#x2010;Ion Radiation Therapy for Mucosal Melanoma of the Head and Neck: Subanalysis of the Japan Carbon&#x2010;Ion Radiation Oncology Study Group (J&#x2010;CROS) Study (1402 HN),&#x201d; International Journal of Radiation Oncology, Biology, Physics 97 (2017): 1054&#x2013;1060.</Citation></Reference><Reference><Citation>Y. Takayasu, N. Kubo, M. Shino, et&#xa0;al., &#x201c;Carbon&#x2010;Ion Radiotherapy Combined With Chemotherapy for Head and Neck Mucosal Melanoma: Prospective Observational Study,&#x201d; Cancer Medicine 8 (2019): 7227&#x2013;7235.</Citation></Reference><Reference><Citation>S. Ronchi, A. Cicchetti, M. Bonora, et&#xa0;al., &#x201c;Curative Carbon Ion Radiotherapy in a Head and Neck Mucosal Melanoma Series: Facing the Future Within Multidisciplinarity,&#x201d; Radiotherapy and Oncology 190 (2024): 110003.</Citation></Reference><Reference><Citation>H. Fuji, S. Yoshikawa, M. Kasami, et&#xa0;al., &#x201c;High&#x2010;Dose Proton Beam Therapy for Sinonasal Mucosal Malignant Melanoma,&#x201d; Radiation Oncology 9 (2014): 162.</Citation></Reference><Reference><Citation>S. Zenda, T. Akimoto, M. Mizumoto, et&#xa0;al., &#x201c;Phase II Study of Proton Beam Therapy as a Nonsurgical Approach for Mucosal Melanoma of the Nasal Cavity or Para&#x2010;Nasal Sinuses,&#x201d; Radiotherapy and Oncology 118 (2016): 267&#x2013;271.</Citation></Reference><Reference><Citation>Y. Demizu, O. Fujii, K. Terashima, et&#xa0;al., &#x201c;Particle Therapy for Mucosal Melanoma of the Head and Neck. A Single&#x2010;Institution Retrospective Comparison of Proton and Carbon Ion Therapy,&#x201d; Strahlentherapie und Onkologie 190 (2014): 186&#x2013;191.</Citation></Reference><Reference><Citation>M. Koto, H. Ikawa, T. Inaniwa, et&#xa0;al., &#x201c;Dose&#x2010;Averaged LET Optimized Carbon&#x2010;Ion Radiotherapy for Head and Neck Cancers,&#x201d; Radiotherapy and Oncology 194 (2024): 110180.</Citation></Reference><Reference><Citation>Particle Therapy Co&#x2010;Operative Group, Facilities in Operation, 2025, https://ptcog.site/index.php/facilities&#x2010;in&#x2010;operation&#x2010;public.</Citation></Reference><Reference><Citation>P. C. Park, X. R. Zhu, A. K. Lee, et&#xa0;al., &#x201c;A Beam&#x2010;Specific Planning Target Volume (PTV) Design for Proton Therapy to Account for Setup and Range Uncertainties,&#x201d; International Journal of Radiation Oncology, Biology, Physics 82 (2012): e329&#x2013;e336.</Citation></Reference><Reference><Citation>D. Pflugfelder, J. J. Wilkens, and U. Oelfke, &#x201c;Worst Case Optimization: A Method to Account for Uncertainties in the Optimization of Intensity Modulated Proton Therapy,&#x201d; Physics in Medicine and Biology 53 (2008): 1689&#x2013;1700.</Citation></Reference><Reference><Citation>H. Iwata, H. Ogino, S. Hashimoto, et&#xa0;al., &#x201c;Spot Scanning and Passive Scattering Proton Therapy: Relative Biological Effectiveness and Oxygen Enhancement Ratio in Cultured Cells,&#x201d; International Journal of Radiation Oncology, Biology, Physics 95 (2016): 95&#x2013;102.</Citation></Reference><Reference><Citation>T. Toshito, C. Omachi, Y. Kibe, et&#xa0;al., &#x201c;A Proton Therapy System in Nagoya Proton Therapy Center,&#x201d; Australasian Physical &amp; Engineering Sciences in Medicine 39 (2016): 645&#x2013;654.</Citation></Reference><Reference><Citation>K. Nakajima, H. Iwata, Y. Hattori, et&#xa0;al., &#x201c;Spot Scanning Proton Therapy for Sinonasal Malignant Tumors,&#x201d; International Journal of Particle Therapy 8 (2021): 189&#x2013;199.</Citation></Reference><Reference><Citation>K. Yasui, T. Toshito, C. Omachi, et&#xa0;al., &#x201c;Evaluation of Dosimetric Advantages of Using Patient&#x2010;Specific Aperture System With Intensity&#x2010;Modulated Proton Therapy for the Shallow Depth Tumor,&#x201d; Journal of Applied Clinical Medical Physics 19 (2018): 132&#x2013;137.</Citation></Reference><Reference><Citation>N. K. Aaronson, S. Ahmedzai, B. Bergman, et&#xa0;al., &#x201c;The European Organization for Research and Treatment of Cancer QLQ&#x2010;C30: A Quality&#x2010;Of&#x2010;Life Instrument for Use in International Clinical Trials in Oncology,&#x201d; Journal of the National Cancer Institute 85 (1993): 365&#x2013;376.</Citation></Reference><Reference><Citation>M. Cengiz, E. Ozyar, M. Esassolak, et&#xa0;al., &#x201c;Assessment of Quality of Life of Nasopharyngeal Carcinoma Patients With EORTC QLQ&#x2010;C30 and H&amp;N&#x2010;35 Modules,&#x201d; International Journal of Radiation Oncology, Biology, Physics 63 (2005): 1347&#x2013;1353.</Citation></Reference><Reference><Citation>D. Osoba, G. Rodrigues, J. Myles, B. Zee, and J. Pater, &#x201c;Interpreting the Significance of Changes in Health&#x2010;Related Quality&#x2010;Of&#x2010;Life Scores,&#x201d; Journal of Clinical Oncology 16 (1998): 139&#x2013;144.</Citation></Reference><Reference><Citation>Y. Kanda, &#x201c;Investigation of the Freely Available Easy&#x2010;To&#x2010;Use Software &#x2018;EZR&#x2019; for Medical Statistics,&#x201d; Bone Marrow Transplantation 48 (2012): 452&#x2013;458.</Citation></Reference><Reference><Citation>M. Q. Schmidt, J. David, E. J. Yoshida, et&#xa0;al., &#x201c;Predictors of Survival in Head and Neck Mucosal Melanoma,&#x201d; Oral Oncology 73 (2017): 36&#x2013;42.</Citation></Reference><Reference><Citation>A. Moya&#x2010;Plana, A. Aup&#xe9;rin, R. Obongo, et&#xa0;al., &#x201c;Oncologic Outcomes, Prognostic Factor Analysis and Therapeutic Algorithm Evaluation of Head and Neck Mucosal Melanomas in France,&#x201d; European Journal of Cancer 123 (2019): 1&#x2013;10.</Citation></Reference><Reference><Citation>K. Naganawa, M. Koto, R. Takagi, et&#xa0;al., &#x201c;Long&#x2010;Term Outcomes After Carbon&#x2010;Ion Radiotherapy for Oral Mucosal Malignant Melanoma,&#x201d; Journal of Radiation Research 58 (2017): 517&#x2013;522.</Citation></Reference><Reference><Citation>N. Penel, Y. Mallet, X. Mirabel, J. T. van, and J. L. Lefebvre, &#x201c;Primary Mucosal Melanoma of Head and Neck: Prognostic Value of Clear Margins,&#x201d; Laryngoscope 116 (2006): 993&#x2013;995.</Citation></Reference><Reference><Citation>S. J. Frank, P. Busse, D. I. Rosenthal, et&#xa0;al., &#x201c;Phase III Randomized Trial of Intensity&#x2010;Modulated Proton Therapy (IMPT) Versus Intensity&#x2010;Modulated Photon Therapy (IMRT) for the Treatment of Head and Neck Oropharyngeal Carcinoma (OPC),&#x201d; Journal of Clinical Oncology 42 (2024): 6006&#x2013;6006.</Citation></Reference><Reference><Citation>H. Iwata, T. Toshito, K. Hayashi, et&#xa0;al., &#x201c;Proton Therapy for Non&#x2010;Squamous Cell Carcinoma of the Head and Neck: Planning Comparison and Toxicity,&#x201d; Journal of Radiation Research 60 (2019): 612&#x2013;621.</Citation></Reference><Reference><Citation>W. Tinganelli and M. Durante, &#x201c;Carbon Ion Radiobiology,&#x201d; Cancers 12 (2020): 3022.</Citation></Reference><Reference><Citation>C. Robert, J. Schachter, G. V. Long, et&#xa0;al., &#x201c;Pembrolizumab Versus Ipilimumab in Advanced Melanoma,&#x201d; New England Journal of Medicine 372 (2015): 2521&#x2013;2532.</Citation></Reference><Reference><Citation>F. S. Hodi, V. Chiarion&#x2010;Sileni, R. Gonzalez, et&#xa0;al., &#x201c;Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab Alone in Advanced Melanoma (CheckMate 067): 4&#x2010;Year Outcomes of a Multicentre, Randomised, Phase 3 Trial,&#x201d; Lancet Oncology 19 (2018): 1480&#x2013;1492.</Citation></Reference><Reference><Citation>S. J. Antonia, A. Villegas, D. Daniel, et&#xa0;al., &#x201c;Durvalumab After Chemoradiotherapy in Stage III Non&#x2010;Small&#x2010;Cell Lung Cancer,&#x201d; New England Journal of Medicine 377 (2017): 1919&#x2013;1929.</Citation></Reference><Reference><Citation>Y. Umeda, S. Yoshikawa, Y. Kiniwa, et&#xa0;al., &#x201c;Real&#x2010;World Efficacy of Anti&#x2010;PD&#x2010;1 Antibody or Combined Anti&#x2010;PD&#x2010;1 Plus Anti&#x2010;CTLA&#x2010;4 Antibodies, With or Without Radiotherapy, in Advanced Mucosal Melanoma Patients: A Retrospective, Multicenter Study,&#x201d; European Journal of Cancer 157 (2021): 361&#x2013;372, https://doi.org/10.1016/j.ejca.2021.08.034.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70111 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41328503</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Dec</Month><Day>02</Day></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Oral Carcinoma Cuniculatum: A Rare, Clinically Challenging Entity-A Case Report and Updated Systematic Review.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70111</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Oral carcinoma cuniculatum (OCC) is a rare, well-differentiated variant of oral squamous cell carcinoma (SCC) that often mimics benign lesions, resulting in delayed diagnosis. Evidence on its clinical behavior and risk of recurrence remains limited.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We report a representative OCC case and conducted a PRISMA-based systematic review of PubMed, Embase, Cochrane Library, Google Scholar, and Airiti Library, including studies with patient-level data.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Forty-six studies comprising 115 patients were included. The gingiva was the most common primary site. Nodal metastasis was reported in 9.0% (8/89), and the overall recurrence rate was 15.8%, predominantly local. Higher recurrences were found among patients receiving neck dissection or adjuvant therapy, which likely reflected selection bias rather than a treatment effect.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">OCC shows a low nodal metastatic rate and mainly local recurrence. Routine elective neck dissection may not be required in clinically N0 patients, but this hypothesis requires validation in larger, multi-institutional cohorts.</AbstractText><CopyrightInformation>&#xa9; 2025 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Po-Jung</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Department of Medical Education, MacKay Memorial Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ting</LastName><ForeName>Ching-Heng</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Department of Pathology, MacKay Memorial Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, MacKay Medical College, New Taipei City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leu</LastName><ForeName>Yi-Shing</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology and Head &amp; Neck Surgery, Mackay Memorial Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>Nien-Hsuan</ForeName><Initials>NH</Initials><Identifier Source="ORCID">0000-0002-0052-2330</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology and Head &amp; Neck Surgery, Mackay Memorial Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Chien-Fu</ForeName><Initials>CF</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology and Head &amp; Neck Surgery, Mackay Memorial Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">carcinoma cuniculatum</Keyword><Keyword MajorTopicYN="N">oral cavity</Keyword><Keyword MajorTopicYN="N">pathological variants</Keyword><Keyword MajorTopicYN="N">rare entities</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>11</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>11</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>2</Day><Hour>7</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>2</Day><Hour>7</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>2</Day><Hour>4</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41328503</ArticleId><ArticleId IdType="doi">10.1002/hed.70111</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>S. Flieger and T. Owi&#x144;ski, &#x201c;Epithelioma Cuniculatum an Unusual Form of Mouth and Jaw Neoplasm,&#x201d; Czasopismo Stomatologiczne 30, no. 5 (1977): 395&#x2013;401.</Citation></Reference><Reference><Citation>JBI, &#x201c;Checklist for Case Reports,&#x201d; Secondary Checklist for Case Reports 2025, https://jbi.global/critical&#x2010;appraisal&#x2010;tools.</Citation></Reference><Reference><Citation>R. Kuffer, C. Brocheriou, M. Rougier, F. Lesbros, C. Bouton, and C. Marche, &#x201c;Buccopharyngeal Localizations of Carcinoma Cuniculatum. Apropos of 5 Cases,&#x201d; Archives d'Anatomie et de Cytologie Pathologiques 32, no. 3 (1984): 184.</Citation></Reference><Reference><Citation>J. L. Kahn, P. Blez, B. Gasser, M. Weill&#x2010;Bousson, J. M. Vetter, and M. Champy, &#x201c;Carcinoma Cuniculatum. Apropos of 4 Cases With Orofacial Involvement,&#x201d; Revue de Stomatologie et de Chirurgie Maxillo&#x2010;Faciale 92, no. 1 (1991): 27&#x2013;33.</Citation></Reference><Reference><Citation>D. Allon, I. Kaplan, R. Manor, and S. Calderon, &#x201c;Carcinoma Cuniculatum of the Jaw: A Rare Variant of Oral Carcinoma,&#x201d; Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics 94, no. 5 (2002): 601&#x2013;608, https://doi.org/10.1067/moe.2002.126913.</Citation></Reference><Reference><Citation>N. Gassler, B. Helmke, H. G. Schweigert, S. Hassfeld, H. F. Otto, and C. Flechtenmacher, &#x201c;Carcinoma Cuniculatum of the Oral Cavity. A Contribution to the Differential Diagnosis of Potentially Malignant Papillary Lesions of Mouth Mucosa,&#x201d; Pathologe 23, no. 4 (2002): 313&#x2013;317, https://doi.org/10.1007/s00292&#x2010;002&#x2010;0525&#x2010;5.</Citation></Reference><Reference><Citation>J. D. Raguse, H. Menneking, H. J. Scholmann, and J. Bier, &#x201c;Manifestation of Carcinoma Cuniculatum in the Mandible,&#x201d; Oral Oncology Extra 42, no. 4 (2006): 173&#x2013;175.</Citation></Reference><Reference><Citation>A. L. Kruse and K. W. Graetz, &#x201c;Carcinoma Cuniculatum: A Rare Entity in the Oral Cavity,&#x201d; Journal of Craniofacial Surgery 20, no. 4 (2009): 1270&#x2013;1272, https://doi.org/10.1097/SCS.0b013e3181ace06b.</Citation></Reference><Reference><Citation>S. Jalisi, S. Seo, M. Lee, and V. Mardirossian, &#x201c;Carcinoma Cuniculatum of the Oral Cavity: A Histological and Clinical Dilemma,&#x201d; Laryngoscope 119, no. SUPPL. 1 (2009): 8, https://doi.org/10.1002/lary.20037.</Citation></Reference><Reference><Citation>A. Hutton, S. McKaig, P. Bardsley, A. Monaghan, and S. Parmar, &#x201c;Oral Carcinoma Cuniculatum in a Young Child,&#x201d; Journal of Clinical Pediatric Dentistry 35, no. 1 (2010): 89&#x2013;94, https://doi.org/10.17796/jcpd.35.1.9qt8601640386651.</Citation></Reference><Reference><Citation>Y. Pons, S. Kerrary, A. Cox, A. Guerre, C. Bertolus, and F. Gruffaz, &#x201c;Mandibular Cuniculatum Carcinoma: Apropos of 3 Cases and Literature Review,&#x201d; Head &amp; Neck 34, no. 2 (2012): 291&#x2013;295, https://doi.org/10.1002/hed.21493.</Citation></Reference><Reference><Citation>Y. Sun, K. Kuyama, A. Burkhardt, and H. Yamamoto, &#x201c;Clinicopathological Evaluation of Carcinoma Cuniculatum: A Variant of Oral Squamous Cell Carcinoma,&#x201d; Journal of Oral Pathology &amp; Medicine 41, no. 4 (2012): 303&#x2013;308, https://doi.org/10.1111/j.1600&#x2010;0714.2011.01116.x.</Citation></Reference><Reference><Citation>J. Suzuki, S. Hashimoto, K. Watanabe, K. Takahashi, H. Usubuchi, and H. Suzuki, &#x201c;Carcinoma Cuniculatum Mimicking Leukoplakia of the Mandibular Gingiva,&#x201d; Auris Nasus Larynx 39, no. 3 (2012): 321&#x2013;325, https://doi.org/10.1016/j.anl.2011.06.004.</Citation></Reference><Reference><Citation>S. Thavaraj, A. Cobb, N. Kalavrezos, T. Beale, D. M. Walker, and A. Jay, &#x201c;Carcinoma Cuniculatum Arising in the Tongue,&#x201d; Head and Neck Pathology 6, no. 1 (2012): 130&#x2013;134, https://doi.org/10.1007/s12105&#x2010;011&#x2010;0270&#x2010;2.</Citation></Reference><Reference><Citation>F. P. Fonseca, H. A. Pontes, F. S. Pontes, F. S. C. Pontes, P. L. de Carvalho, and M. Sena&#x2010;Filho, &#x201c;Oral Carcinoma Cuniculatum: Two Cases Illustrative of a Diagnostic Challenge,&#x201d; Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology 116, no. 4 (2013): 457&#x2013;463, https://doi.org/10.1016/j.oooo.2013.06.006.</Citation></Reference><Reference><Citation>G. H. Goh, K. Venkateswaran, P. C. Leow, K. S. Loh, T. P. Thamboo, and F. Petersson, &#x201c;Carcinoma Cuniculatum of the Esophagus and Tongue: Report of Two Cases, Including TP53 Mutational Analysis,&#x201d; Head and Neck Pathology 8, no. 3 (2014): 261&#x2013;268, https://doi.org/10.1007/s12105&#x2010;014&#x2010;0522&#x2010;z.</Citation></Reference><Reference><Citation>R. J. Padilla and V. A. Murrah, &#x201c;Carcinoma Cuniculatum of the Oral Mucosa: A Potentially Underdiagnosed Entity in the Absence of Clinical Correlation,&#x201d; Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology 118, no. 6 (2014): 684&#x2013;693, https://doi.org/10.1016/j.oooo.2014.08.011.</Citation></Reference><Reference><Citation>M. C. Shapiro, B. Wong, M. J. O'Brien, and A. Salama, &#x201c;Mandibular Destruction Secondary to Invasion by Carcinoma Cuniculatum,&#x201d; Journal of Oral and Maxillofacial Surgery 73, no. 12 (2015): 2343&#x2013;2351, https://doi.org/10.1016/j.joms.2015.05.034.</Citation></Reference><Reference><Citation>S. Shay, W. Choy, R. E. Christensen, and M. A. St John, &#x201c;Extensive Carcinoma Cuniculatum of the Mandible,&#x201d; American Journal of Otolaryngology 36, no. 3 (2015): 446&#x2013;450, https://doi.org/10.1016/j.amjoto.2015.01.002.</Citation></Reference><Reference><Citation>U. V. Datar, A. Kale, and D. Mane, &#x201c;Oral Carcinoma Cuniculatum: A New Entity in the Clinicopathological Spectrum of Oral Squamous Cell Carcinoma,&#x201d; Journal of Clinical and Diagnostic Research 11, no. 1 (2017): Zd37&#x2013;zd39, https://doi.org/10.7860/jcdr/2017/23437.9226.</Citation></Reference><Reference><Citation>R. S. Prasad, A. Moorthy, A. Bhadranna, and A. Pai, &#x201c;Proliferative Endophytic Lesion of the Maxilla: A Diagnostic Challenge,&#x201d; Journal of Oral and Maxillofacial Pathology 22, no. Suppl 1 (2018): S82&#x2013;s86, https://doi.org/10.4103/jomfp.JOMFP_248_17.</Citation></Reference><Reference><Citation>G. O. Ramos, G. L. Meyer, F. Visioli, M. D. Manoela, and M. G. Oliveira, &#x201c;Carcinoma Cuniculatum in the Tongue of a Patient With Oral Lichen Planus: Unusual Presentation,&#x201d; Indian Journal of Dental Research 29, no. 4 (2018): 525&#x2013;528, https://doi.org/10.4103/ijdr.IJDR_185_16.</Citation></Reference><Reference><Citation>F. Thibouw, H. Anna, J. Levasseur, C. Mondoloni, M. H. Aubriot&#x2010;Lorton, and N. Zwetyenga, &#x201c;Carcinoma Cuniculatum of the Lip: A Case Report,&#x201d; Journal of Stomatology Oral and Maxillofacial Surgery 119, no. 3 (2018): 224&#x2013;228, https://doi.org/10.1016/j.jormas.2018.01.006.</Citation></Reference><Reference><Citation>C. Zhang, Y. Hu, Z. Tian, L. Zhu, C. Zhang, and J. Li, &#x201c;Oral Carcinoma Cuniculatum Presenting With Moth&#x2010;Eaten Destruction of the Mandible,&#x201d; Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology 125, no. 4 (2018): e86&#x2013;e93, https://doi.org/10.1016/j.oooo.2018.01.008.</Citation></Reference><Reference><Citation>A. Ajith, N. Subramaniam, D. Balasubramanian, K. Thankappan, and S. Iyer, &#x201c;Carcinoma Cuniculatum of the Oral Cavity: A Diagnostic Dilemma,&#x201d; Journal of Head &amp; Neck Physicians and Surgeons 6, no. 1 (2018): 54&#x2013;56.</Citation></Reference><Reference><Citation>K. Ben Arfi, A. Marchal, H. Hafian, and C. Boulagnon&#x2010;Rombi, &#x201c;Carcinoma Cuniculatum: An Unusual Oral Tumor,&#x201d; Annales de Pathologie 39, no. 5 (2019): 369&#x2013;373, https://doi.org/10.1016/j.annpat.2019.03.005.</Citation></Reference><Reference><Citation>E. Broly, P. Barth&#xe9;l&#xe9;my, S. Ciftci, C. Borel, M. Broly, and C.&#x2010;I. Gros, &#x201c;Hidden Intra&#x2010;Mandibular Carcinoma Cuniculatum Appearing in a Patient With Metastatic Prostate Cancer: A Case Report,&#x201d; BMC Oral Health 19, no. 1 (2019): 54, https://doi.org/10.1186/s12903&#x2010;019&#x2010;0745&#x2010;1.</Citation></Reference><Reference><Citation>B. Sivapathasundharam, B. Kavitha, and V. M. Padmapriya, &#x201c;Carcinoma Cuniculatum of the Alveolar Mucosa: A Rare Variant of Squamous Cell Carcinoma,&#x201d; Head and Neck Pathology 13, no. 4 (2019): 652&#x2013;655, https://doi.org/10.1007/s12105&#x2010;018&#x2010;0938&#x2010;y.</Citation></Reference><Reference><Citation>A. W. Barrett, M. Garg, D. Armstrong, B. S. Bisase, L. Newman, and P. M. Norris, &#x201c;Cystic Squamous Cell Carcinomas of the Jaws: Twelve Cases Highlighting Histopathological Pitfalls,&#x201d; International Journal of Surgical Pathology 28, no. 6 (2020): 624&#x2013;630, https://doi.org/10.1177/1066896920903388.</Citation></Reference><Reference><Citation>N. V. Lee, E. T. B. Kang, C. Senger, and C. F. Poh, &#x201c;Oral Cancer in a 5&#x2010;Year&#x2010;Old Boy: A Rare Case Report and Review of Literature,&#x201d; Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology 130, no. 1 (2020): e10&#x2013;e19, https://doi.org/10.1016/j.oooo.2019.12.005.</Citation></Reference><Reference><Citation>E. Elangovan, A. Banerjee, and R. B. Abhinandan, &#x201c;Oral Carcinoma Cuniculatum,&#x201d; Journal of Oral and Maxillofacial Pathology 25, no. 1 (2021): 163&#x2013;166, https://doi.org/10.4103/jomfp.JOMFP_272_20.</Citation></Reference><Reference><Citation>M. Janardhanan, S. Rakesh, V. Savithri, T. Aravind, and M. Mohan, &#x201c;Carcinoma Cuniculatum of Mandible Masquerading as Odontogenic Keratocyst: Challenges in the Histopathological Diagnosis,&#x201d; Head and Neck Pathology 15, no. 4 (2021): 1313&#x2013;1321, https://doi.org/10.1007/s12105&#x2010;020&#x2010;01265&#x2010;6.</Citation></Reference><Reference><Citation>D. Jia, Y. Yang, S. Xu, and C. Jiang, &#x201c;Carcinoma Cuniculatum in Maxillary Gingiva Mimicking Verruciform Xanthoma: A Case Report,&#x201d; Translational Cancer Research 10, no. 10 (2021): 4553&#x2013;4559, https://doi.org/10.21037/tcr&#x2010;21&#x2010;552.</Citation></Reference><Reference><Citation>S. Niklander, L. M. Sernuda, and R. Martinez, &#x201c;Unusual Case of Carcinoma Cuniculatum Affecting the Oral Cavity of an 11&#x2010;Year&#x2010;Old Boy,&#x201d; Anais Brasileiros de Dermatologia 96, no. 6 (2021): 799&#x2013;801, https://doi.org/10.1016/j.abd.2020.08.029.</Citation></Reference><Reference><Citation>J. V. Abilasha, P. Thankappan, T. I. Joseph, and D. Angelin, &#x201c;Aggressive Oral Carcinoma Cuniculatum: A Rare Entity,&#x201d; Journal of Cancer Research and Therapeutics 18, no. 1 (2022): 266&#x2013;269, https://doi.org/10.4103/jcrt.JCRT_161_20.</Citation></Reference><Reference><Citation>S. Baz, H. W. Amer, and A. A. Wahed, &#x201c;Oral Carcinoma Cuniculatum: An Unacquainted Entity With Diagnostic Challenges&#x2010;A Case Report,&#x201d; Journal of the Egyptian National Cancer Institute 34, no. 1 (2022): 3, https://doi.org/10.1186/s43046&#x2010;021&#x2010;00101&#x2010;4.</Citation></Reference><Reference><Citation>J. E. Beute, G. T. Seo, L. A. Greenberg, N. Mundi, E. M. Dowling, and A. Matloob, &#x201c;Cuneiform (Cuniculatum) Variant of Oral Squamous Cell Carcinoma Revisited: Presentation of Two Cases and Literature Review of a Rare Entity,&#x201d; Head &amp; Neck 44, no. 4 (2022): E16&#x2013;e24, https://doi.org/10.1002/hed.26984.</Citation></Reference><Reference><Citation>R. Mass&#xe9;, J. Duvernay, S. Korbi, C. Majoufre, and M. Schlund, &#x201c;Mandibular Gingiva Lesion With Osteolysis: A Diagnosis Challenge,&#x201d; Journal of Stomatology Oral and Maxillofacial Surgery 123, no. 4 (2022): e173&#x2013;e175, https://doi.org/10.1016/j.jormas.2022.05.021.</Citation></Reference><Reference><Citation>S. Yadav, M. Bal, S. Rane, N. Mittal, A. Janu, and A. Patil, &#x201c;Carcinoma Cuniculatum of the Oral Cavity: A Series of 6 Cases and Review of Literature,&#x201d; Head and Neck Pathology 16, no. 1 (2022): 213&#x2013;223, https://doi.org/10.1007/s12105&#x2010;021&#x2010;01340&#x2010;6.</Citation></Reference><Reference><Citation>V. J. P. Mokhasanavisu, M. T. Mithi, P. Rathod, V. Bande, and S. J. Pandya, &#x201c;Oral Carcinoma Cuniculatum: A Variant of Squamous Cell Carcinoma With Unique Histological Characteristics and a Diagnostic Challenge,&#x201d; Indian Journal of Otolaryngology and Head &amp; Neck Surgery 75, no. 3 (2023): 2591&#x2013;2594, https://doi.org/10.1007/s12070&#x2010;023&#x2010;03812&#x2010;3.</Citation></Reference><Reference><Citation>A. Muramatsu, H. Hasegawa, K. Kusafuka, and M. Suzuki, &#x201c;Carcinoma Cuniculatum of the Maxilla Arising From Oroantral Fistula: A Report of an Extremely Rare Case,&#x201d; Cureus 15, no. 4 (2023): e37796, https://doi.org/10.7759/cureus.37796.</Citation></Reference><Reference><Citation>M. Nagai, B. Pastwik, A. Aguirre, M. Burke, and J. Campbell, &#x201c;Carcinoma Cuniculatum: A Rare Malignancy With Unique Diagnostic Dilemmas,&#x201d; Cureus 15, no. 4 (2023): e37453, https://doi.org/10.7759/cureus.37453.</Citation></Reference><Reference><Citation>S. Ourania, B. Olga, and K. Vasiliki, &#x201c;Carcinoma Cuniculatum of the Maxilla Mimicking Nonhealing Extraction Sockets at the Right Molar Region&#x2014;An Interesting Case,&#x201d; Eplasty 23 (2023): e23.</Citation></Reference><Reference><Citation>R. Mass&#xe9;, J. Duvernay, S. Korbi, C. Majoufre, and M. Schlund, &#x201c;Oral Carcinoma Cuniculatum, A Rare Variant of Squamous Cell Carcinoma,&#x201d; Journal of Stomatology Oral and Maxillofacial Surgery 125, no. 4 (2024): 101729, https://doi.org/10.1016/j.jormas.2023.101729.</Citation></Reference><Reference><Citation>C. Mourouzis, I. Toursounidis, C. Eftychiadis, and G. Rallis, &#x201c;Management and Treatment of Four Cases of Oral Carcinoma Cuniculatum,&#x201d; Journal of the Korean Association of Oral and Maxillofacial Surgeons 50, no. 1 (2024): 35&#x2013;40, https://doi.org/10.5125/jkaoms.2024.50.1.35.</Citation></Reference><Reference><Citation>D. Pandiar and R. P. Krishnan, &#x201c;Gingival Carcinoma Cuniculatum: A Case Series of Seven Cases With Emphasis on Immunohistochemical and Histochemical Features,&#x201d; Indian Journal of Otolaryngology and Head &amp; Neck Surgery 76, no. 3 (2024): 2930&#x2013;2938, https://doi.org/10.1007/s12070&#x2010;024&#x2010;04559&#x2010;1.</Citation></Reference><Reference><Citation>A. M. Sim&#xf3;n, P. de Leyva, C. C&#xe1;rdenas, N. Vieira, M. Garc&#xed;a, and &#xc1;. Ranz, &#x201c;Carcinoma Cuniculatum, A Rare Variant of Oral Squamous Cell Carcinoma: Presentation of Five Clinical Cases and Review of the Literature,&#x201d; Journal of Oral and Maxillofacial Surgery 23, no. 4 (2024): 972&#x2013;978, https://doi.org/10.1007/s12663&#x2010;024&#x2010;02247&#x2010;9.</Citation></Reference><Reference><Citation>I. Aird, H. D. Johnson, B. Lennox, and A. G. Stansfeld, &#x201c;Epithelioma Cuniculatum a Variety of Squamous Carcinoma Peculiar to the Foot,&#x201d; British Journal of Surgery 42, no. 173 (1954): 245&#x2013;250, https://doi.org/10.1002/bjs.18004217304.</Citation></Reference><Reference><Citation>A. F. Farag, D. A. Abou&#x2010;Alnour, and N. S. Abu&#x2010;Taleb, &#x201c;Oral Carcinoma Cuniculatum, an Unacquainted Variant of Oral Squamous Cell Carcinoma: A Systematic Review,&#x201d; Imaging Science in Dentistry 48, no. 4 (2018): 233&#x2013;244, https://doi.org/10.5624/isd.2018.48.4.233.</Citation></Reference><Reference><Citation>B. Cao, C. Hill, C. Bonaldi, et&#xa0;al., &#x201c;Cancers Attributable to Tobacco Smoking in France in 2015,&#x201d; European Journal of Public Health 28, no. 4 (2018): 707&#x2013;712, https://doi.org/10.1093/eurpub/cky077.</Citation></Reference><Reference><Citation>H. Jawad, S. S. Ashaari, R. O'Shea, D. Callanan, P. Sheahan, and L. Feeley, &#x201c;Prognostic Performance of TNM8 Staging Rules in Oral Cavity Squamous Cell Carcinoma,&#x201d; Oral Oncology 111 (2020): 105021, https://doi.org/10.1016/j.oraloncology.2020.105021.</Citation></Reference><Reference><Citation>P. Li, Q. Fang, Y. Yang, et&#xa0;al., &#x201c;Survival Significance of Number of Positive Lymph Nodes in Oral Squamous Cell Carcinoma Stratified by p16,&#x201d; Frontiers in Oncology 11 (2021): 545433, https://doi.org/10.3389/fonc.2021.545433.</Citation></Reference><Reference><Citation>A. A. Arain, M. S. A. Rajput, S. A. Ansari, et&#xa0;al., &#x201c;Occult Nodal Metastasis in Oral Cavity Cancers,&#x201d; Cureus 12, no. 11 (2020): e11640, https://doi.org/10.7759/cureus.11640.</Citation></Reference><Reference><Citation>D. G. Pfister, NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Head and Neck Cancers (NCCN Guidelines is the National Comprehensive Cancer Network (NCCN), 2025).</Citation></Reference><Reference><Citation>A. K. D'Cruz, R. Vaish, N. Kapre, M. Dandekar, S. Gupta, and R. Hawaldar, &#x201c;Elective Versus Therapeutic Neck Dissection in Node&#x2010;Negative Oral Cancer,&#x201d; New England Journal of Medicine 373, no. 6 (2015): 521&#x2013;529, https://doi.org/10.1056/NEJMoa1506007.</Citation></Reference><Reference><Citation>S. Blatt, M. Kr&#xfc;ger, K. Sagheb, et&#xa0;al., &#x201c;Tumor Recurrence and Follow&#x2010;Up Intervals in Oral Squamous Cell Carcinoma,&#x201d; Journal of Clinical Medicine 11, no. 23 (2022): 7061, https://doi.org/10.3390/jcm11237061.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70119 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41328494</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Dec</Month><Day>02</Day></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Radiotherapy Outcomes and Prognostic Factors in Head and Neck NUT Carcinoma: A Single-Center Cohort Analysis.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70119</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">NUT carcinoma is a rare, aggressive malignancy defined by NUTM1 gene rearrangement, with the head and neck as the second most common site. Its prognosis is poor, and current treatment references other cancers. Although radiotherapy is key in managing head and neck tumors, its efficacy and prognostic factors in head and neck NUT carcinoma are unclear.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We retrospectively analyzed 31 patients with locally advanced or recurrent/metastatic head and neck NUT carcinoma treated with radiotherapy. OS and PFS were estimated by Kaplan-Meier, and prognostic factors were identified using Cox regression.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 31 patients (64.5% male, median age 37), nasal cavity/paranasal sinuses were the most common primary site (51.6%). Most received intensity-modulated radiotherapy with &#x2265;&#x2009;66&#x2009;Gy. Median OS and PFS were 18.73 and 3&#x2009;months, respectively. Nasal cavity/paranasal sinus primaries had the worst prognosis (median OS: 16.7&#x2009;months). Locally advanced cases had significantly better survival than recurrent/metastatic disease (median OS: 30.43 vs. 13.93&#x2009;months; PFS: 5.83 vs. 2.3&#x2009;months). High-dose radiotherapy (&#x2265;&#x2009;66&#x2009;Gy) was associated with improved OS, and R0 resection combined with &#x2265;&#x2009;66&#x2009;Gy achieved median OS of 27.9&#x2009;months. In surgical patients, GTV longest diameter &gt;&#x2009;3.5&#x2009;cm independently predicted worse PFS (HR&#x2009;=&#x2009;5.01, p&#x2009;=&#x2009;0.01). Recurrent/metastatic status was the most critical independent adverse prognostic factor for both PFS (HR&#x2009;=&#x2009;4.56) and OS (HR&#x2009;=&#x2009;10.12). Adjuvant therapy after radiotherapy prolonged PFS, particularly in locally advanced patients. BETi-based regimens before radiotherapy showed potential for improved locoregional and distant control in postoperative recurrence/metastasis.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Prognosis in head and neck NUT carcinoma treated with radiotherapy is affected by disease status, primary site, radiotherapy dose, and adjuvant therapy. Locally advanced patients benefit most from high-dose radiotherapy and adjuvant therapy. GTV &gt;&#x2009;3.5&#x2009;cm identifies high-risk populations requiring intensified treatment, while BETi may improve outcomes in postoperative recurrence/metastasis.</AbstractText><CopyrightInformation>&#xa9; 2025 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Zhuomiao</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0003-2983-5944</Identifier><AffiliationInfo><Affiliation>Clinical Research Center (CRC), Chongqing University Three Gorges Hospital, Chongqing University, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Helei</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Clinical Research Center (CRC), Chongqing University Three Gorges Hospital, Chongqing University, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xin</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0001-8140-0484</Identifier><AffiliationInfo><Affiliation>Medical Pathology Center (MPC), Chongqing University Three Gorges Hospital, Chongqing University, Chongqing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Advanced Interdisciplinary Studies, Chongqing University, Chongqing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CQU-Ferenc Krausz Nobel Laureate Scientific Workstation, Chongqing University Three Gorges Hospital &amp; Academy for Advanced Interdisciplinary Technology, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Cancer Early Detection and Treatment Center (CEDTC), Chongqing University Three Gorges Hospital, Chongqing University, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Fei</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Breast Surgery, Chongqing University Three Gorges Hospital, Chongqing University, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Chao</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Breast Surgery, Chongqing University Three Gorges Hospital, Chongqing University, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Mingzhu</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-6964-7131</Identifier><AffiliationInfo><Affiliation>Clinical Research Center (CRC), Chongqing University Three Gorges Hospital, Chongqing University, Chongqing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Pathology Center (MPC), Chongqing University Three Gorges Hospital, Chongqing University, Chongqing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Advanced Interdisciplinary Studies, Chongqing University, Chongqing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CQU-Ferenc Krausz Nobel Laureate Scientific Workstation, Chongqing University Three Gorges Hospital &amp; Academy for Advanced Interdisciplinary Technology, Chongqing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Early Detection and Treatment Center (CEDTC), Chongqing University Three Gorges Hospital, Chongqing University, Chongqing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Translational Medicine Research Center (TMRC), Chongqing University Three Gorges Hospital, Chongqing University, Chongqing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>CSTB2025TIAD-STX0046</GrantID><Agency>the Science and Technology Innovation Key R&amp;D Program of Chongqing</Agency><Country/></Grant><Grant><GrantID>2023CDJYGRH-YB05</GrantID><Agency>Fundamental Research Funds for the Central Universities</Agency><Country/></Grant><Grant><GrantID>CSTB2023NSCQ-MSX0658</GrantID><Agency>Chongqing Natural Science Foundation</Agency><Country/></Grant><Grant><GrantID>CSTB2024NSCQ-MSX0874</GrantID><Agency>The Natural Science Foundation of Chongqing</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">NUT carcinoma</Keyword><Keyword MajorTopicYN="N">NUTM1</Keyword><Keyword MajorTopicYN="N">cohort</Keyword><Keyword MajorTopicYN="N">radiotherapy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>10</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>10</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>2</Day><Hour>7</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>2</Day><Hour>7</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>2</Day><Hour>4</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41328494</ArticleId><ArticleId IdType="doi">10.1002/hed.70119</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>J. Luo, J. A. Bishop, S. G. DuBois, et&#xa0;al., &#x201c;Hiding in Plain Sight: NUT Carcinoma Is an Unrecognized Subtype of Squamous Cell Carcinoma of the Lungs and Head and Neck,&#x201d; Nature Reviews Clinical Oncology 22, no. 4 (2025): 292&#x2013;306.</Citation></Reference><Reference><Citation>Z. Liang, Y. Tang, C. Li, et&#xa0;al., &#x201c;Oral and Oropharyngeal NUT Carcinoma: A Multicentre Screening Study of Poorly Differentiated Oral Cancer,&#x201d; Histopathology 85, no. 6 (2024): 868&#x2013;878.</Citation></Reference><Reference><Citation>T. Lee, J. Cho, C. H. Baek, et&#xa0;al., &#x201c;Prevalence of NUT Carcinoma in Head and Neck: Analysis of 362 Cases With Literature Review,&#x201d; Head &amp; Neck 42, no. 5 (2020): 924&#x2013;938.</Citation></Reference><Reference><Citation>C. A. French, M. L. Cheng, G. J. Hanna, et&#xa0;al., &#x201c;Report of the First International Symposium on NUT Carcinoma,&#x201d; Clinical Cancer Research 28, no. 12 (2022): 2493&#x2013;2505.</Citation></Reference><Reference><Citation>K. Viswanathan, E. Hahn, S. Dogan, et&#xa0;al., &#x201c;The Histological Spectrum and Immunoprofile of Head and Neck NUT Carcinoma: A Multicentre Series of 30 Cases,&#x201d; Histopathology 85, no. 2 (2024): 317&#x2013;326.</Citation></Reference><Reference><Citation>J. J. Kim, S. A. Walton, N. R. Mahadevan, et&#xa0;al., &#x201c;Molecular Characterization of NUT Carcinoma: A Report From the NUT Carcinoma Registry,&#x201d; Clinical Cancer Research 31 (2025): 3922&#x2013;3931.</Citation></Reference><Reference><Citation>W. Luo, T. M. Stevens, P. Stafford, M. Miettinen, Z. Gatalica, and S. Vranic, &#x201c;NUTM1&#x2010;Rearranged Neoplasms&#x2010;A Heterogeneous Group of Primitive Tumors With Expanding Spectrum of Histology and Molecular Alterations&#x2010;An Updated Review,&#x201d; Current Oncology 28, no. 6 (2021): 4485&#x2013;4503.</Citation></Reference><Reference><Citation>Z. Ye, X. Li, F. Xie, et&#xa0;al., &#x201c;Expert Consensus and Current Landscape of NUT Carcinoma: A Comprehensive Strategy From Diagnosis to Treatment,&#x201d; Tumor Discovery 3, no. 4 (2024): 4904.</Citation></Reference><Reference><Citation>L. Lemelle, T. Flaadt, B. Fresneau, et&#xa0;al., &#x201c;NUT Carcinoma in Children and Adolescents: The Expert European Standard Clinical Practice Harmonized Recommendations,&#x201d; Journal of Pediatric Hematology/Oncology 45, no. 4 (2023): 165&#x2013;173.</Citation></Reference><Reference><Citation>N. G. Chau, S. Hurwitz, C. M. Mitchell, et&#xa0;al., &#x201c;Intensive Treatment and Survival Outcomes in NUT Midline Carcinoma of the Head and Neck,&#x201d; Cancer 122, no. 23 (2016): 3632&#x2013;3640.</Citation></Reference><Reference><Citation>U. Ramesh, K. J. Contrera, N. Shakibai, et&#xa0;al., &#x201c;Sinonasal NUT Carcinoma: A Consecutive Case Series and Systematic Review,&#x201d; Head and Neck 46, no. 1 (2024): 29&#x2013;36.</Citation></Reference><Reference><Citation>S. A. Piha&#x2010;Paul, C. L. Hann, C. A. French, et&#xa0;al., &#x201c;Phase 1 Study of Molibresib (GSK525762), A Bromodomain and Extra&#x2010;Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors,&#x201d; JNCI Cancer Spectrum 4, no. 2 (2020): pkz093.</Citation></Reference><Reference><Citation>J. Lewin, J. C. Soria, A. Stathis, et&#xa0;al., &#x201c;Phase Ib Trial With Birabresib, a Small&#x2010;Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors,&#x201d; Journal of Clinical Oncology 36, no. 30 (2018): 3007&#x2013;3014.</Citation></Reference><Reference><Citation>G. I. Shapiro, P. LoRusso, A. Dowlati, et&#xa0;al., &#x201c;A Phase 1 Study of RO6870810, a Novel Bromodomain and Extra&#x2010;Terminal Protein Inhibitor, in Patients With NUT Carcinoma, Other Solid Tumours, or Diffuse Large B&#x2010;Cell Lymphoma,&#x201d; British Journal of Cancer 124, no. 4 (2021): 744&#x2013;753.</Citation></Reference><Reference><Citation>J. Hilton, M. Cristea, S. Postel&#x2010;Vinay, et&#xa0;al., &#x201c;BMS&#x2010;986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients With Selected Advanced Solid Tumors: Results From a Phase 1/2a Trial,&#x201d; Cancers (Basel) 14, no. 17 (2022): 4079.</Citation></Reference><Reference><Citation>A. Stathis, E. Zucca, M. Bekradda, et&#xa0;al., &#x201c;Clinical Response of Carcinomas Harboring the BRD4&#x2010;NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK&#x2010;8628,&#x201d; Cancer Discovery 6, no. 5 (2016): 492&#x2013;500.</Citation></Reference><Reference><Citation>S. S. Younis, F. A. A. Ghafil, S. Majeed, and N. R. Hadi, &#x201c;NHWD&#x2010;870 Protects the Kidney From Ischemia/Reperfusion Injury by Upregulating the PI3K/AKT Signaling Pathway (Experimental Study),&#x201d; Journal of Medicine and Life 16, no. 6 (2023): 925&#x2013;931.</Citation></Reference><Reference><Citation>Y. Zhang, F. Wu, and N. Yang, &#x201c;NHWD&#x2010;870, a Novel BET Family Bromodomain Inhibitor Targeting BRD4, Proved To Be Effective and Promising for Treatment of Small Cell Lung Cancer,&#x201d; Cancer Research 78 (2018): 1668.</Citation></Reference><Reference><Citation>Z. Ye, X. Li, F. Xie, et&#xa0;al., &#x201c;A Single&#x2010;Cell Sequencing&#x2010;Based Analysis of a 13&#x2010;Year&#x2010;Old With Maxillary Sinus NUT Carcinoma,&#x201d; Oral Oncology 162 (2025): 107185.</Citation></Reference><Reference><Citation>U. M. Lauer, A. Awada, S. Postel&#x2010;Vinay, et&#xa0;al., &#x201c;Final Results From the Phase Ia/Ib Study of the Novel Bromodomain and Extra&#x2010;Terminal Domain Inhibitor, BI 894999, in Patients With Advanced Solid Tumors or Diffuse Large B&#x2010;Cell Lymphoma,&#x201d; ESMO Open 10, no. 5 (2025): 104499.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70120 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41320846</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Nov</Month><Day>30</Day></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Modified Platysma Myocutaneous Flap Reconstruction for Advanced Laryngeal Carcinoma: A Multicenter Retrospective Cohort Study.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70120</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">This study presents a modified platysma myocutaneous flap technique for reconstructing extensive laryngeal defects in patients with advanced-stage transglottic laryngeal carcinoma.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A retrospective cohort analysis was conducted on patients undergoing organ-preserving partial laryngectomy followed by reconstruction using a modified platysma flap. Primary endpoints included decannulation rate and 3-year overall survival. Functional recovery of respiration, swallowing, and phonation was evaluated using validated scales.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Sixty patients (mean age: 62.85&#x2009;&#xb1;&#x2009;6.09&#x2009;years) were enrolled across two centers. The overall decannulation rate was 85.0%, with significantly higher success rates observed in the partial laryngectomy group (p&#x2009;&lt;&#x2009;0.05). The 3-year survival rate was 78.3%. Swallowing and phonatory functions were well preserved, with median scores of 2 and 1, respectively. The technique was associated with a low incidence of flap-related complications (13.3%) and favorable mucosalization outcomes.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The modified platysma flap offers a practical and effective reconstructive strategy for laryngeal defects in advanced carcinoma, achieving satisfactory respiratory decannulation and preservation of laryngeal function with minimal morbidity.</AbstractText><CopyrightInformation>&#xa9; 2025 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Zhen</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology Head and Neck Surgery, Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University, Qingdao, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Pengwei</ForeName><Initials>P</Initials><Identifier Source="ORCID">0009-0006-5861-0348</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology- Head &amp; Neck Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Head and Neck Surgical Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Zheng</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0001-7160-4512</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology- Head &amp; Neck Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Head and Neck Surgical Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jun</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-4800-7749</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology- Head &amp; Neck Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Head and Neck Surgical Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Xinliang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology Head and Neck Surgery, Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University, Qingdao, Shandong, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>11</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">laryngeal cancer</Keyword><Keyword MajorTopicYN="N">platysma myocutaneous flap</Keyword><Keyword MajorTopicYN="N">survival rate</Keyword><Keyword MajorTopicYN="N">swallowing function</Keyword><Keyword MajorTopicYN="N">voice function</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>11</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>1</Day><Hour>6</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>1</Day><Hour>6</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41320846</ArticleId><ArticleId IdType="doi">10.1002/hed.70120</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>J. Huang, S. C. Chan, S. Ko, et&#xa0;al., &#x201c;Updated Disease Distributions, Risk Factors, and Trends of Laryngeal Cancer: A Global Analysis of Cancer Registries,&#x201d; International Journal of Surgery 110 (2024): 810&#x2013;819, https://doi.org/10.1097/js9.0000000000000902.</Citation></Reference><Reference><Citation>R. Nocini, G. Molteni, C. Mattiuzzi, and G. Lippi, &#x201c;Updates on Larynx Cancer Epidemiology,&#x201d; Chinese Journal of Cancer Research 32 (2020): 18&#x2013;25, https://doi.org/10.21147/j.issn.1000&#x2010;9604.2020.01.03.</Citation></Reference><Reference><Citation>C. E. Steuer, M. El&#x2010;Deiry, J. R. Parks, K. A. Higgins, and N. F. Saba, &#x201c;An Update on Larynx Cancer,&#x201d; CA: A Cancer Journal for Clinicians 67 (2017): 31&#x2013;50, https://doi.org/10.3322/caac.21386.</Citation></Reference><Reference><Citation>J. W. Futrell, M. E. Johns, M. T. Edgerton, R. W. Cantrell, and G. S. Fitz&#x2010;Hugh, &#x201c;Platysma Myocutaneous Flap for Intraoral Reconstruction,&#x201d; American Journal of Surgery 136 (1978): 504&#x2013;507, https://doi.org/10.1016/0002&#x2010;9610(78)90270&#x2010;2.</Citation></Reference><Reference><Citation>N. Imanishi, H. Nakajima, K. Kishi, H. Chang, and S. Aiso, &#x201c;Is the Platysma Flap Musculocutaneous? Angiographic Study of the Platysma,&#x201d; Plastic and Reconstructive Surgery 115 (2005): 1018&#x2013;1024, https://doi.org/10.1097/01.prs.0000154211.52778.71.</Citation></Reference><Reference><Citation>W. M. Koch, &#x201c;The Platysma Myocutaneous Flap: Underused Alternative for Head and Neck Reconstruction,&#x201d; Laryngoscope 112 (2002): 1204&#x2013;1208, https://doi.org/10.1097/00005537&#x2010;200207000&#x2010;00012.</Citation></Reference><Reference><Citation>G. Dursun and O. B. Ozgursoy, &#x201c;Laryngeal Reconstruction by Platysma Myofascial Flap After Vertical Partial Laryngectomy,&#x201d; Head &amp; Neck 27 (2005): 762&#x2013;770, https://doi.org/10.1002/hed.20241.</Citation></Reference><Reference><Citation>Q. Cai, F. Liang, X. Huang, P. Han, Y. Pan, and Y. Zheng, &#x201c;Hypopharynx and Larynx Defect Repair After Resection for Pyriform Fossa Cancer With a Platysma Skin Flap,&#x201d; Otolaryngology and Head and Neck Surgery 152 (2015): 374&#x2013;376, https://doi.org/10.1177/0194599814559508.</Citation></Reference><Reference><Citation>L. Chen, R. Chen, Z. Guan, et&#xa0;al., &#x201c;Platysma Skin Flap: Laryngeal Repair Material to Produce Phonatory Flap Vibrational Wave,&#x201d; Head &amp; Neck 42 (2020): 2757&#x2013;2763, https://doi.org/10.1002/hed.26294.</Citation></Reference><Reference><Citation>K. Wu, Z. Gong, H. Wu, Y. Mao, and S. Zhang, &#x201c;Evaluating the Role of Low Molecular Heparin to Prevent Anterolateral Thigh Flap Compromise in 2460 Head and Neck Defect Cases,&#x201d; Journal of Oral and Maxillofacial Surgery 80 (2022): 944&#x2013;948, https://doi.org/10.1016/j.joms.2022.01.005.</Citation></Reference><Reference><Citation>M. S. De Bodt, F. L. Wuyts, P. H. Van de Heyning, and C. Croux, &#x201c;Test&#x2010;Retest Study of the GRBAS Scale: Influence of Experience and Professional Background on Perceptual Rating of Voice Quality,&#x201d; Journal of Voice 11 (1997): 74&#x2013;80, https://doi.org/10.1016/s0892&#x2010;1997(97)80026&#x2010;4.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70106 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41307158</PMID><DateRevised><Year>2025</Year><Month>11</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Nov</Month><Day>27</Day></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Postoperative Adjuvant Therapy in Resectable Advanced Oral Squamous Cell Carcinoma With Intermediate Risk Factors.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70106</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Postoperative adjuvant therapy strategies are generally determined based on pathological risk stratification in oral cancer. However, the efficacy of postoperative adjuvant therapy in patients with intermediate-risk factors for recurrence of oral cancer such as close surgical margins, pT3-T4 classification, pN2-N3 nodal status, perineural invasion, vascular invasion, lymphatic invasion and pattern of invasion remains unclear, and no standardized treatment guidelines or consensus have been established to date. Therefore, this study retrospectively analyzed the clinical significance of risk factors for pathological recurrence in patients with advanced oral cancer and evaluated the impact of postoperative adjuvant therapy on patient prognosis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This retrospective clinical study included 130 patients who underwent initial radical surgical resection for advanced oral squamous cell carcinoma (OSCC) at our institution between January 2010 and December 2023. The postoperative recurrence risk factors included ENE of the cervical lymph nodes, positive surgical margins, close surgical margins, pathological T classification (pT3 or pT4), pathological N classification (pN2 or pN3), metastasis to level IV or V lymph nodes, perineural invasion, vascular invasion, and lymphatic invasion. We analyzed the relationships among the presence of these risk factors, administration of postoperative adjuvant therapy (RT or CRT), occurrence of recurrence or metastasis, and patient prognosis (DFS).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients with lymphatic invasion had a significantly lower survival rate than those without lymphatic invasion (66.7% vs. 82.8%, p&#x2009;&lt;&#x2009;0.05). Although pT4, pN2-N3, perineural invasion-positive and vascular invasion-positive did not reach statistical significance, a trend toward reduced survival was observed in each case. The perineural invasion-positive group had significantly higher recurrence and metastasis rates than the perineural invasion-negative group (51.9% vs. 23.6%, p&#x2009;&lt;&#x2009;0.05). Multivariate analysis using logistic regression also confirmed the presence of perineural invasion as an independent prognostic factor (HR&#x2009;=&#x2009;4.496, p&#x2009;=&#x2009;0.019).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study demonstrated that perineural invasion is a significant risk factor for recurrence and that lymphatic invasion is a poor prognostic factor in oral cancer. Postoperative adjuvant therapy in patients with perineural or lymphatic invasion-positive disease contributed to reduced recurrence rates and prolonged survival. These findings suggest that the pathological evaluation of perineural and lymphatic invasions is an important indicator in determining the appropriateness of postoperative adjuvant therapy.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). Head &amp; Neck published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Koizumi</LastName><ForeName>Koichi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Oral Oncology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Obayashi</LastName><ForeName>Fumitaka</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-6427-6354</Identifier><AffiliationInfo><Affiliation>Department of Oral Oncology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Higaki</LastName><ForeName>Mirai</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Oral Oncology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morishita</LastName><ForeName>Kota</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Oral Oncology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamada</LastName><ForeName>Atsuko</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Oral Oncology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamasaki</LastName><ForeName>Sachiko</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-0390-7014</Identifier><AffiliationInfo><Affiliation>Department of Oral Oncology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ito</LastName><ForeName>Nanako</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-1933-7274</Identifier><AffiliationInfo><Affiliation>Department of Oral Oncology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yanamoto</LastName><ForeName>Souichi</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-2372-8347</Identifier><AffiliationInfo><Affiliation>Department of Oral Oncology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>11</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">chemoradiotherapy (CRT)</Keyword><Keyword MajorTopicYN="N">intermediate risk factor</Keyword><Keyword MajorTopicYN="N">postoperative adjuvant therapy</Keyword><Keyword MajorTopicYN="N">radiotherapy (RT)</Keyword><Keyword MajorTopicYN="N">resectable advanced OSCC</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>11</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>7</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>11</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>11</Month><Day>27</Day><Hour>5</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41307158</ArticleId><ArticleId IdType="doi">10.1002/hed.70106</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>J. S. Cooper, T. F. Pajak, A. A. Forastiere, et&#xa0;al., &#x201c;Postoperative Concurrent Radiotherapy and Chemotherapy for High&#x2010;Risk Squamous&#x2010;Cell Carcinoma of the Head and Neck,&#x201d; New England Journal of Medicine 350 (2004): 1937&#x2013;1944.</Citation></Reference><Reference><Citation>J. P. Pignon, A. le Maitre, E. Maillard, J. Bourhis, and MACH&#x2010;NC Collaborative Group, &#x201c;Meta&#x2010;Analysis of Chemotherapy in Head and Neck Cancer (MACH&#x2010;NC): An Update on 93 Randomised Trials and 17,346 Patients,&#x201d; Radiotherapy and Oncology 92 (2009): 4&#x2013;14.</Citation></Reference><Reference><Citation>C. T. Liao, S. F. Huang, I. H. Chen, et&#xa0;al., &#x201c;Risk Stratification of Patients With Oral Cavity Squamous Cell Carcinoma and Contralateral Neck Recurrence Following Radical Surgery,&#x201d; Annals of Surgical Oncology 16 (2009): 159&#x2013;170.</Citation></Reference><Reference><Citation>S. Yanamoto, S. Yamada, H. Takahashi, et&#xa0;al., &#x201c;Clinicopathological Risk Factors for Local Recurrence in Oral Squamous Cell Carcinoma,&#x201d; International Journal of Oral and Maxillofacial Surgery 41 (2012): 1195&#x2013;1200.</Citation></Reference><Reference><Citation>S. Yanamoto, S. Yamada, H. Takahashi, et&#xa0;al., &#x201c;Predictors of Locoregional Recurrence in T1&#x2010;2N0 Tongue Cancer Patients,&#x201d; Pathology Oncology Research 19 (2013): 795&#x2013;803.</Citation></Reference><Reference><Citation>S. B. Chinn and J. N. Myers, &#x201c;Oral Cavity Carcinoma: Current Management, Controversies, and Future Directions,&#x201d; Journal of Clinical Oncology 33 (2015): 3269&#x2013;3276.</Citation></Reference><Reference><Citation>M. Higaki, K. Koizumi, T. Ando, et&#xa0;al., &#x201c;Extranodal Extension in Oral Squamous Cell Carcinoma: Clinical and Histopathological Analysis,&#x201d; Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology 137 (2024): 632&#x2013;639.</Citation></Reference><Reference><Citation>A. Tarsitano, M. L. Tardio, and C. Marchetti, &#x201c;Impact of Perineural Invasion as Independent Prognostic Factor for Local and Regional Failure in Oral Squamous Cell Carcinoma,&#x201d; Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology 119 (2015): 221&#x2013;228.</Citation></Reference><Reference><Citation>B. K. Varsha, M. B. Radhika, S. Makarla, M. A. Kuriakose, G. S. Kiran, and G. V. Padmalatha, &#x201c;Perineural Invasion in Oral Squamous Cell Carcinoma: Case Series and Review of Literature,&#x201d; Journal of Oral and Maxillofacial Pathology 19 (2015): 335&#x2013;341.</Citation></Reference><Reference><Citation>S. Spoerl, S. Spoerl, S. Reil, et&#xa0;al., &#x201c;Prognostic Value of Perineural Invasion on Survival and Recurrence in Oral Squamous Cell Carcinoma,&#x201d; Diagnostics 12 (2022): 1062.</Citation></Reference><Reference><Citation>N. Binmadi, M. Alsharif, S. Almazrooa, et&#xa0;al., &#x201c;Perineural Invasion Is a Significant Prognostic Factor in Oral Squamous Cell Carcinoma: A Systematic Review and Meta&#x2010;Analysis,&#x201d; Diagnostics 13 (2023): 3339.</Citation></Reference><Reference><Citation>Q. Huang, Y. Huang, C. Chen, et&#xa0;al., &#x201c;Prognostic Impact of Lymphovascular and Perineural Invasion in Squamous Cell Carcinoma of the Tongue,&#x201d; Scientific Reports 13 (2023): 3828.</Citation></Reference><Reference><Citation>Z. Y. Tao, G. Chu, and Y. X. Su, &#x201c;The Prognostic Role of Perineural Invasion for Survival in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta&#x2010;Analysis,&#x201d; Cancers 16 (2024): 2514.</Citation></Reference><Reference><Citation>L. J. Peters, H. Goepfert, K. K. Ang, et&#xa0;al., &#x201c;Evaluation of the Dose for Postoperative Radiation Therapy of Head and Neck Cancer: First Report of a Prospective Randomized Trial,&#x201d; International Journal of Radiation Oncology, Biology, Physics 26 (1993): 3&#x2013;11.</Citation></Reference><Reference><Citation>F. Bekiroglu, N. Ghazali, R. Laycock, C. Katre, D. Lowe, and S. N. Rogers, &#x201c;Adjuvant Radiotherapy and Health&#x2010;Related Quality of Life of Patients at Intermediate Risk of Recurrence Following Primary Surgery for Oral Squamous Cell Carcinoma,&#x201d; Oral Oncology 47 (2011): 967&#x2013;973.</Citation></Reference><Reference><Citation>A. Di Rito, F. Fiorica, R. Carbonara, et&#xa0;al., &#x201c;Adding Concomitant Chemotherapy to Postoperative Radiotherapy in Oral Cavity Carcinoma With Minor Risk Factors: Systematic Review of the Literature and Meta&#x2010;Analysis,&#x201d; Cancers 14 (2022): 3704.</Citation></Reference><Reference><Citation>S. Das, S. Ghosh Laskar, S. V. Kane, and A. K. D'Cruz, &#x201c;Adjuvant Therapy for Intermediate Risk Factors in Oral Cancer: Can We Reach a Consensus?,&#x201d; Oral Oncology 157 (2024): 106972.</Citation></Reference><Reference><Citation>G. Loganadane, B. H. Kann, H. S. Park, et&#xa0;al., &#x201c;Clinical Outcomes of Head and Neck Cancer Patients Who Undergo Resection, but Forgo Adjuvant Therapy,&#x201d; Anticancer Research 39 (2019): 4885&#x2013;4890.</Citation></Reference><Reference><Citation>M. Li, M. Hu, Y. Wang, and X. Yang, &#x201c;Adjuvant Chemoradiotherapy Versus Radiotherapy in Cervical Cancer Patients With Intermediate&#x2010;Risk Factors: A Systematic Review and Meta&#x2010;Analysis,&#x201d; European Journal of Obstetrics, Gynecology, and Reproductive Biology 238 (2019): 1&#x2013;6.</Citation></Reference><Reference><Citation>Q. Guo, R. Wang, D. Jin, et&#xa0;al., &#x201c;Comparison of Adjuvant Chemoradiotherapy Versus Radiotherapy in Early&#x2010;Stage Cervical Cancer Patients With Intermediate&#x2010;Risk Factors: A Systematic Review and Meta&#x2010;Analysis,&#x201d; Taiwanese Journal of Obstetrics &amp; Gynecology 61 (2022): 15&#x2013;23.</Citation></Reference><Reference><Citation>H. Nishimura, T. Amano, Y. Yoneoka, et&#xa0;al., &#x201c;Comparison of Postoperative Adjuvant Platinum&#x2010;Based Chemotherapy and no Further Therapy After Radical Surgery in Intermediate&#x2010;Risk Early&#x2010;Stage Cervical Cancer,&#x201d; Journal of Gynecologic Oncology 36 (2025): e2.</Citation></Reference><Reference><Citation>S. Tam, M. Amit, M. Zafereo, D. Bell, and R. S. Weber, &#x201c;Depth of Invasion as a Predictor of Nodal Disease and Survival in Patients With Oral Tongue Squamous Cell Carcinoma,&#x201d; Head &amp; Neck 41 (2019): 177&#x2013;184.</Citation></Reference><Reference><Citation>A. Ebrahimi, Z. Gil, M. Amit, et&#xa0;al., &#x201c;Depth of Invasion Alone as an Indication for Postoperative Radiotherapy in Small Oral Squamous Cell Carcinomas: An International Collaborative Study,&#x201d; Head &amp; Neck 41 (2019): 1935&#x2013;1942.</Citation></Reference><Reference><Citation>C. G. F. van Lanschot, Y. P. Klazen, M. A. J. de Ridder, et&#xa0;al., &#x201c;Depth of Invasion in Early Stage Oral Cavity Squamous Cell Carcinoma: The Optimal Cut&#x2010;Off Value for Elective Neck Dissection,&#x201d; Oral Oncology 111 (2020): 104940.</Citation></Reference><Reference><Citation>S. Tandon, P. Ahlawat, S. Mahajan, et&#xa0;al., &#x201c;Depth of Invasion as an Independent Indication for Postoperative Radiation Therapy in Oral Tongue Squamous Cell Carcinoma,&#x201d; International Journal of Radiation Oncology, Biology, Physics 123 (2025): S0360&#x2010;3016(25)00361&#x2010;X.</Citation></Reference><Reference><Citation>K. Aivazian, A. Ebrahimi, T. H. Low, et&#xa0;al., &#x201c;Perineural Invasion in Oral Squamous Cell Carcinoma: Quantitative Subcategorisation of Perineural Invasion and Prognostication,&#x201d; Journal of Surgical Oncology 111 (2015): 352&#x2013;358.</Citation></Reference><Reference><Citation>L. B. Schmitd, C. S. Scanlon, and N. J. D'Silva, &#x201c;Perineural Invasion in Head and Neck Cancer,&#x201d; Journal of Dental Research 97 (2018): 742&#x2013;750.</Citation></Reference><Reference><Citation>R. L. Bakst, C. M. Glastonbury, U. Parvathaneni, N. Katabi, K. S. Hu, and S. S. Yom, &#x201c;Perineural Invasion and Perineural Tumor Spread in Head and Neck Cancer,&#x201d; International Journal of Radiation Oncology, Biology, Physics 103 (2019): 1109&#x2013;1124.</Citation></Reference><Reference><Citation>A. A. Alfurhud, &#x201c;Prognosis, Controversies and Assessment of Bone Erosion or Invasion of Oral Squamous Cell Carcinoma,&#x201d; Diagnostics 15 (2025): 104.</Citation></Reference><Reference><Citation>F. Tankere, A. Camproux, B. Barry, C. Guedon, J. Depondt, and P. Gehanno, &#x201c;Prognostic Value of Lymph Node Involvement in Oral Cancers: A Study of 137 Cases,&#x201d; Laryngoscope 110 (2000): 2061&#x2013;2065.</Citation></Reference><Reference><Citation>Z. H. Ren, J. L. Xu, B. Li, T. F. Fan, T. Ji, and C. P. Zhang, &#x201c;Elective Versus Therapeutic Neck Dissection in Node&#x2010;Negative Oral Cancer: Evidence From Five Randomized Controlled Trials,&#x201d; Oral Oncology 51 (2015): 976&#x2013;981.</Citation></Reference><Reference><Citation>L. Verde&#x2010;Sanchez, A. L. Capote, A. Sanz&#x2010;Garcia, P. Brabyn, F. J. Rodriguez&#x2010;Campo, and L. Naval Gias, &#x201c;Prognostic Involvement of Lymph Node Density in Oral Squamous Cell Carcinoma. A New Predictive Model,&#x201d; Journal of Oral and Maxillofacial Surgery 81 (2023): 358&#x2013;369.</Citation></Reference><Reference><Citation>S. Fan, S. Cai, Y. Cheng, Y. Wu, and W. Jiang, &#x201c;Prognostic Value of Positive Lymph Node Ratio in Oral Cavity Squamous Cell Carcinoma After Neoadjuvant Treatment: A Retrospective Real&#x2010;World Study,&#x201d; Scientific Reports 15 (2025): 17785.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70113 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41293826</PMID><DateRevised><Year>2025</Year><Month>11</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Nov</Month><Day>26</Day></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Myopericytoma of the Head and Neck: A Case Series and Literature Review.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70113</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Myopericytoma (MPC) is a rare perivascular tumor with myoid differentiation that poses diagnostic and therapeutic challenges in the head and neck.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We present four cases of oral and sinonasal MPC and conducted a literature review to analyze clinical characteristics, diagnostic approaches, and management.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Sixty-five published cases were identified, yielding a cohort of 69 patients. The oral cavity was the most common site (44.9%) followed by parotid (15.9%), sinonasal (10.1%), neck (10.1%), and other head regions (18.8%). Complete excision was achieved in 95.7% of cases with a 7.2% recurrence rate. Histopathology confirmed MPC in all cases with characteristic perivascular spindle cell proliferation, 95.6% showing positive smooth muscle actin immunostaining.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">MPC must be considered in the differential diagnosis of vascular head and neck lesions. Complete surgical excision with negative margins remains the treatment of choice, with immunohistochemistry essential for accurate diagnosis.</AbstractText><CopyrightInformation>&#xa9; 2025 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Giannaris</LastName><ForeName>Peter S</ForeName><Initials>PS</Initials><Identifier Source="ORCID">0009-0001-4052-9908</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology Head and Neck Surgery, Northwell Health, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mendelsohn</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology, State University of New York-Downstate Health Sciences University, Brooklyn, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kokabee</LastName><ForeName>Mostafa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine Lenox Hill Hospital, Northwell Health, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Shengjie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine Lenox Hill Hospital, Northwell Health, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guerrero</LastName><ForeName>Dominick</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine Lenox Hill Hospital, Northwell Health, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chaskes</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology Head and Neck Surgery, Northwell Health, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fastenberg</LastName><ForeName>Judd</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology Head and Neck Surgery, Northwell Health, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tong</LastName><ForeName>Charles C L</ForeName><Initials>CCL</Initials><Identifier Source="ORCID">0000-0002-4471-5134</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology Head and Neck Surgery, Northwell Health, New York, New York, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>11</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">head and neck vascular neoplasms</Keyword><Keyword MajorTopicYN="N">myopericytoma</Keyword><Keyword MajorTopicYN="N">oral myopericytoma</Keyword><Keyword MajorTopicYN="N">perivascular tumors</Keyword><Keyword MajorTopicYN="N">sinonasal myopericytoma</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>11</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>11</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>11</Month><Day>26</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>11</Month><Day>26</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>11</Month><Day>26</Day><Hour>5</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41293826</ArticleId><ArticleId IdType="doi">10.1002/hed.70113</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>M. E. McMenamin and C. D. M. Fletcher, &#x201c;Malignant Myopericytoma: Expanding the Spectrum of Tumours With Myopericytic Differentiation,&#x201d; Histopathology 41, no. 5 (2002): 450&#x2013;460.</Citation></Reference><Reference><Citation>L. Requena, H. Kutzner, H. H&#xfc;gel, A. R&#xfc;tten, and V. Furio, &#x201c;Cutaneous Adult Myofibroma: A Vascular Neoplasm,&#x201d; Journal of Cutaneous Pathology 23, no. 5 (1996): 445&#x2013;457.</Citation></Reference><Reference><Citation>J. Gibbs, E. Henderson&#x2010;Jackson, and M. M. Bui, &#x201c;Bone and Soft Tissue Pathology: Diagnostic and Prognostic Implications,&#x201d; Surgical Clinics of North America 96, no. 5 (2016): 915&#x2013;962.</Citation></Reference><Reference><Citation>T. Mentzel, A. P. Dei Tos, Z. Sapi, and H. Kutzner, &#x201c;Myopericytoma of Skin and Soft Tissues: Clinicopathologic and Immunohistochemical Study of 54 Cases,&#x201d; American Journal of Surgical Pathology 30, no. 1 (2006): 104&#x2013;113.</Citation></Reference><Reference><Citation>F. Bandi, F. Chu, L. M. Stringa, R. De Berardinis, M. Tagliabue, and G. Pietrobon, &#x201c;Head and Neck Myopericytoma (MPC): A Case Report of Double Synchronous Sinonasal MPC,&#x201d; Annali Italiani di Chirurgia 95, no. 5 (2024): 760&#x2013;766.</Citation></Reference><Reference><Citation>M. B. Chaskes, J. W. Bishop, M. Bobinski, and D. G. Farwell, &#x201c;Myopericytoma of the Neck Originating From the Middle Scalene: A Case Report,&#x201d; Ear, Nose, &amp; Throat Journal 99, no. 7 (2020): NP72&#x2013;NP74.</Citation></Reference><Reference><Citation>N. Agrawal and K. Nag, &#x201c;Myopericytoma of the Thoracic Spine: A Case Report and Review of Literature,&#x201d; Spine Journal: Official Journal of the North American Spine Society 13, no. 11 (2013): e23&#x2013;27.</Citation></Reference><Reference><Citation>T. Sawaf, J. Wasman, and S. E. Mowry, &#x201c;A Rare Case of Myopericytoma in the Mastoid,&#x201d; Otology &amp; Neurotology: Official Publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology 42, no. 9 (2021): e1404&#x2013;e1405.</Citation></Reference><Reference><Citation>Q. Li, H. J. Chen, H. Y. Zhang, X. J. Li, and H. Bu, &#x201c;Myopericytoma in the Right Submandible: A Case Report,&#x201d; Zhonghua Bing Li Xue Za Zhi 34, no. 5 (2005): 318&#x2013;319.</Citation></Reference><Reference><Citation>V. Datta, Y. B. Rawal, H. H. Mincer, and M. K. Anderson, &#x201c;Myopericytoma of the Oral Cavity,&#x201d; Head &amp; Neck 29, no. 6 (2007): 605&#x2013;608.</Citation></Reference><Reference><Citation>F. Ide, K. Obara, H. Yamada, K. Mishima, and I. Saito, &#x201c;Intravascular Myopericytoma of the Oral Mucosa: A Rare Histologic Variant in an Uncommon Location,&#x201d; Virchows Archiv: An International Journal of Pathology 450, no. 4 (2007): 475&#x2013;477.</Citation></Reference><Reference><Citation>A. C. Laga, A. L. Tajirian, M. N. Islam, et&#xa0;al., &#x201c;Myopericytoma: Report of Two Cases Associated With Trauma,&#x201d; Journal of Cutaneous Pathology 35, no. 9 (2008): 866&#x2013;870.</Citation></Reference><Reference><Citation>F. Ide, K. Mishima, H. Yamada, et&#xa0;al., &#x201c;Perivascular Myoid Tumors of the Oral Region: A Clinicopathologic Re&#x2010;Evaluation of 35 Cases,&#x201d; Journal of Oral Pathology &amp; Medicine: Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 37, no. 1 (2008): 43&#x2013;49.</Citation></Reference><Reference><Citation>P. P. L. Lau, O.&#x2010;K. Wong, P. C. W. Lui, et&#xa0;al., &#x201c;Myopericytoma in Patients With AIDS: A New Class of Epstein&#x2010;Barr Virus&#x2010;Associated Tumor,&#x201d; American Journal of Surgical Pathology 33, no. 11 (2009): 1666&#x2013;1672.</Citation></Reference><Reference><Citation>S. Sapelli, M. Ribas, W. D. Martins, L. de Noronha, and A. P. Gomes, &#x201c;Myopericytoma of the Lip: Report of Case,&#x201d; Head and Neck 31, no. 4 (2009): 561&#x2013;564.</Citation></Reference><Reference><Citation>T. Terada, &#x201c;Myopericytoma of Low Grade Malignancy in the Oral Cavity,&#x201d; Rare Tumors 4, no. 1 (2012): 24&#x2013;25.</Citation></Reference><Reference><Citation>S. Akbulut, D. Berk, M. G. Demir, and S. Kayahan, &#x201c;Myopericytoma of the Tongue: A Case Report,&#x201d; Acta Medica (Hradec Kr&#xe1;lov&#xe9;) 56, no. 3 (2013): 124&#x2013;225.</Citation></Reference><Reference><Citation>S. Bansal, R. S. Desai, and S. Shetty, &#x201c;Myopericytoma of Oral Cavity: A Case Report and Review of Literature,&#x201d; International Journal of Oral &amp; Maxillofacial Pathology 4, no. 3 (2013): 31&#x2013;35.</Citation></Reference><Reference><Citation>S. M. Vasenwala, N. Afroz, H. A. Ansari, A. H. Khan, R. Basari, and S. Rehman, &#x201c;Myopericytoma of Lip: A Rare Lesion in an Unusual Location,&#x201d; Indian Journal of Pathology and Microbiology 58, no. 2 (2015): 211&#x2013;213.</Citation></Reference><Reference><Citation>N. K. Mathew, K. Y. Zhang, and M. D. Batstone, &#x201c;Myopericytoma of the Coronoid Process: A Case Report and Review of the Literature,&#x201d; Oral and Maxillofacial Surgery Cases 1, no. 2 (2015): 25&#x2013;28.</Citation></Reference><Reference><Citation>K. V. Alexander Valasidis, A. Kyrgidis, A. Baliaka, and V. Kaloutsi, &#x201c;Myopericytoma of the Maxillofacial Region: A Report of Two Cases,&#x201d; Scientific Pages of Otolaryngology 1, no. 1 (2017): 20&#x2013;24.</Citation></Reference><Reference><Citation>E. Strayer, R. Throndson, C. Clement, and K. McDaniel, &#x201c;Myopericytoma of the Lip: A Case Report of This Rare Lesion,&#x201d; Journal of Oral and Maxillofacial Surgery: Official Journal of the American Association of Oral and Maxillofacial Surgeons 76, no. 7 (2018): 1464&#x2013;1467.</Citation></Reference><Reference><Citation>S. Rubino, R. De Berardinis, D. Colombo, and A. De Padova, &#x201c;Myopericytoma of the Tongue Base: A Case Report,&#x201d; Acta Otorrinolaringol&#xf3;gica Espa&#xf1;ola 69, no. 5 (2018): 304&#x2013;305.</Citation></Reference><Reference><Citation>W.&#x2010;T. Ju, T.&#x2010;C. Zhao, Y. Liu, et&#xa0;al., &#x201c;Clinical and Pathologic Analysis of Myopericytoma in the Oral and Maxillofacial Region,&#x201d; Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology 128, no. 4 (2019): 393&#x2013;399.</Citation></Reference><Reference><Citation>M. Ralli, V. D'Aguanno, L. De Vincentiis, M. de Vincentiis, and A. Corsi, &#x201c;Glomangiopericytoma&#x2010;Type Glomus Tumour/Myopericytoma of the Lip,&#x201d; British Journal of Oral &amp; Maxillofacial Surgery 57, no. 9 (2019): 923&#x2013;925.</Citation></Reference><Reference><Citation>L. K. Y. Almeida, R. O. Jabur, H. A. Silveira, et&#xa0;al., &#x201c;Gingival Ossifying Myopericytoma in a Pediatric Patient: Immunohistochemical Analysis and Literature Review,&#x201d; Oral Oncology 107 (2020): 104826.</Citation></Reference><Reference><Citation>D. P. B. Amy, V. Yaffe, R. Kawar, S. Akrish, and I. A. El&#x2010;Naaj, &#x201c;Oral Myopericytoma: A Rare Pediatric Case Report and a Review of the Literature,&#x201d; BMC Oral Health 21, no. 1 (2021): 176.</Citation></Reference><Reference><Citation>E. Polat and &#x130;. Atak, &#x201c;A Rare Tumor of the Oral Mucosa, Myopericytoma: Case Report,&#x201d; European Annals of Dental Sciences 49, no. 2 (2022): 92&#x2013;95.</Citation></Reference><Reference><Citation>M. W. P. Tan, A. Y. W. Tay, P. Y. Tang, K. Y. Chew, and E. M. N. Yeo, &#x201c;Myopericytoma: A Review of Twenty&#x2010;Three Cases Over Twelve Years and a Case Report of a Rare Neoplasm,&#x201d; American Journal of Dermatopathology 44, no. 9 (2022): 623&#x2013;631.</Citation></Reference><Reference><Citation>O. Hamdy, A. Mahmoud, S. Attia, et&#xa0;al., &#x201c;Myopericytoma of the Mouth Floor: The Diagnostic and Therapeutic Challenge&#x2014;A Case Report and Literature Review,&#x201d; Oral Surgery 17, no. 3 (2024): 264&#x2013;269.</Citation></Reference><Reference><Citation>B. Wei, G. Liu, K. Li, and H. Quan, &#x201c;Pediatric Upper Lip Myopericytoma: A Case Report and Comprehensive Review,&#x201d; BMC Oral Health 24, no. 1 (2024): 478.</Citation></Reference><Reference><Citation>A. S. L. Karczub and D. Thean, &#x201c;Myopericytoma in the Mandible: A Case Report,&#x201d; Heliyon 11, no. 4 (2025): e42811.</Citation></Reference><Reference><Citation>T. Wilson, H. B. Hellquist, S. Ray, and J. Pickles, &#x201c;Intranasal Myopericytoma. A Tumour With Perivascular Myoid Differentiation: The Changing Nomenclature for Haemangiopericytoma,&#x201d; Journal of Laryngology and Otology 121, no. 8 (2007): 786&#x2013;789.</Citation></Reference><Reference><Citation>R. L. Arden, Z. H. Griggs, and E. A. Wey, &#x201c;Asymptomatic Septal Mass,&#x201d; JAMA Otolaryngology. Head &amp; Neck Surgery 144, no. 2 (2018): 169&#x2013;170.</Citation></Reference><Reference><Citation>Z.&#x2010;G. Chu, J.&#x2010;Q. Yu, Z.&#x2010;G. Yang, Z.&#x2010;Y. Zhu, and H.&#x2010;M. Yuan, &#x201c;Myopericytoma Involving the Parotid Gland as Depicted on Multidetector CT,&#x201d; Korean Journal of Radiology 10, no. 4 (2009): 398&#x2013;401.</Citation></Reference><Reference><Citation>L. Xia, Y. Chen, N. Geng, J. Jiang, M. Yang, and W. Zhang, &#x201c;Multifocal Myopericytoma in the Maxillofacial Region: A Case Report,&#x201d; Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics 109, no. 2 (2010): e59&#x2013;e62.</Citation></Reference><Reference><Citation>J. Kuczkowski, R. Rzepko, and E. Szurowska, &#x201c;Myopericytoma of the Parotid Gland&#x2010;A Pathological Conundrum,&#x201d; Journal of Cranio&#x2010;Maxillo&#x2010;Facial Surgery: Official Publication of the European Association for Cranio&#x2010;Maxillo&#x2010;Facial Surgery 38, no. 8 (2010): 595&#x2013;596.</Citation></Reference><Reference><Citation>S. K. Lee and S. Y. Kwon, &#x201c;Imaging Features and Sonographically Guided Core&#x2010;Needle Biopsy of Facial Myopericytoma: A Case Report,&#x201d; Journal of the Korean Society of Radiology 67, no. 4 (2012): 235&#x2013;239.</Citation></Reference><Reference><Citation>S. K. Lee and S. Y. Kwon, &#x201c;Gray&#x2010;Scale and Power Doppler Sonography and CT Findings of Myopericytoma of the Posterior Cervical Space,&#x201d; AJNR. American Journal of Neuroradiology 30, no. 8 (2009): 1604&#x2013;1606.</Citation></Reference><Reference><Citation>Y.&#x2010;I. Jung, Y.&#x2010;K. Chung, and S. Chung, &#x201c;Multiple Myopericytoma of the Face and Parotid Gland,&#x201d; Archives of Plastic Surgery 39, no. 2 (2012): 158&#x2013;161.</Citation></Reference><Reference><Citation>F. Wu, J. Sun, J. Dong, X. Wang, and Q. Gao, &#x201c;Management of Multicentric Myopericytoma in the Maxillofacial Region: A Case Report,&#x201d; Case Reports in Oncology 6, no. 2 (2013): 350&#x2013;355.</Citation></Reference><Reference><Citation>A. S. Bates, P. Craig, and G. J. Knepil, &#x201c;Myopericytoma of the Parotid Region Treated by Extracapsular Dissection,&#x201d; BMJ Case Reports 2014, no. apr09 1 (2014): bcr2013201924.</Citation></Reference><Reference><Citation>Y. Pan, L. Chen, D. Shi, Y. Chen, and R.&#x2010;S. Yu, &#x201c;Imaging Features of Myopericytoma Arising From the Parotid Gland: Report of 2 Cases and Literature Review,&#x201d; Medicine 100, no. 14 (2021): e25471.</Citation></Reference><Reference><Citation>N. J. Roig, M. Wu, O. Hernandez, C. Z. Liu, and T. C. Brandler, &#x201c;Myopericytoma of the Parotid and Molecular Profiling: Report of a Rare Case and Review of the Literature,&#x201d; International Journal of Surgical Pathology 30, no. 5 (2022): 574&#x2013;580.</Citation></Reference><Reference><Citation>V. Maheshwari, K. Alam, A. Jain, and S. C. Sharma, &#x201c;Myopericytoma of Neck Region &#x2010; A Case Report,&#x201d; Indian Journal of Otolaryngology and Head and Neck Surgery: Official Publication of the Association of Otolaryngologists of India 60, no. 2 (2008): 179&#x2013;180.</Citation></Reference><Reference><Citation>T. Terada, &#x201c;Minute Myopericytoma of the Neck: A Case Report With Literature Review and Differential Diagnosis,&#x201d; Pathology Oncology Research: POR 16, no. 4 (2010): 613&#x2013;616.</Citation></Reference><Reference><Citation>B. H. Rho, S. K. Lee, and S. Y. Kwon, &#x201c;Myopericytoma of the Neck: Sonographic Appearance and Sonographically Guided Needle Biopsy,&#x201d; Journal of Clinical Ultrasound: JCU 39, no. 8 (2011): 469&#x2013;472.</Citation></Reference><Reference><Citation>P.&#x2010;C. Hm, H. M. Prado&#x2010;Calleros, D. Galarza&#x2010;Lozano, et&#xa0;al., &#x201c;Myopericytoma Arising Adjacent to the Common Carotid Artery: Case Report and Systematic Review of Deep Located Neck Myopericytomas,&#x201d; Head &amp; Neck 38, no. 9 (2016): E2479&#x2013;E2482.</Citation></Reference><Reference><Citation>Y. B. Lee, K. J. Lee, H. J. Park, and J. Y. Shin, &#x201c;A Case of Glomangiopericytoma&#x2010;Type Myopericytoma on the Nose Tip,&#x201d; Journal of the American Academy of Dermatology 64, no. 2 (2011): 375&#x2013;376.</Citation></Reference><Reference><Citation>N. A. Chotey, T. K. Naidu, V. Naidoo, and J. Naidoo, &#x201c;Myopericytoma of the External Auditory Canal and Tragus,&#x201d; Journal of Laryngology and Otology 127, no. 8 (2013): 805&#x2013;808.</Citation></Reference><Reference><Citation>E. K. Kim, J. H. Lee, S. Y. Kim, and G. M. Kim, &#x201c;Myopericytoma of the Facial Cheek,&#x201d; Annals of Dermatology 25, no. 1 (2013): 122.</Citation></Reference><Reference><Citation>D. Cebeci, &#x15e;. Ya&#x15f;ar, P. G&#xfc;ne&#x15f;, and S. Aytekin, &#x201c;Cutaneous Myopericytoma on the Forehead: A Rare Localization,&#x201d; Indian Journal of Dermatology 65, no. 2 (2020): 169&#x2013;172.</Citation></Reference><Reference><Citation>J. C. Slack, M. L. Hollowell, K. S. Khouri, et&#xa0;al., &#x201c;Expanding the Spectrum of Perioral Myogenic Tumors in Pediatric Patients: An SRF::NCOA2 Fused Perivascular Tumor of the Philtrum,&#x201d; Pediatric and Developmental Pathology 26, no. 1 (2023): 65&#x2013;71.</Citation></Reference><Reference><Citation>K. Watanabe, T. Tajino, M. Sekiguchi, and T. Suzuki, &#x201c;H&#x2010;Caldesmon as a Specific Marker for Smooth Muscle Tumors. Comparison With Other Smooth Muscle Markers in Bone Tumors,&#x201d; American Journal of Clinical Pathology 113, no. 5 (2000): 663&#x2013;668.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70110 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41293786</PMID><DateRevised><Year>2025</Year><Month>11</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Nov</Month><Day>26</Day></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Potential Utility of Micronucleus and Binucleus Frequencies in Malignancy Prediction in Thyroid Nodules.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70110</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate the frequency of micronuclei (MN) and binucleated (BN) cells in thyroid nodules and adjacent normal tissue, and evaluate their correlation with cytological (Bethesda classification) and histopathological diagnoses to assess their potential utility in preoperative malignancy prediction.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This prospective study included 39 patients (16 benign, 19 papillary carcinoma, 4 follicular carcinoma) who underwent thyroidectomy. Tissue samples from both nodular and adjacent normal thyroid regions were collected. MN and BN frequencies were evaluated in 1000 cells per sample using May-Gr&#xfc;nwald and 5% Giemsa staining. Data were analyzed in relation to Bethesda categories and final surgical pathology using mixed-effects models in R 4.4.1. ROC analysis was conducted to assess the diagnostic performance of MN/BN frequency.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">MN and BN frequencies were significantly higher in nodular tissue compared to adjacent normal thyroid tissue (p&#x2009;&lt;&#x2009;0.05). Malignant lesions showed significantly increased MN/BN frequencies compared to benign ones, although no significant difference was observed between papillary and follicular subtypes (p&#x2009;&lt;&#x2009;0.05). MN/BN frequencies were also significantly higher in Bethesda categories III-VI compared to categories I-II (p&#x2009;&lt;&#x2009;0.05). No significant variation was found in normal thyroid tissue across cytological or pathological groups.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">MN and BN cell frequencies were elevated in malignant nodules and higher Bethesda categories, supporting their potential role as adjunctive cytogenetic markers in thyroid nodule assessment. While findings are promising, their diagnostic utility in indeterminate nodules remains unclear. Larger, FNAB-based studies are required to validate their feasibility and clinical relevance in routine preoperative evaluation.</AbstractText><CopyrightInformation>&#xa9; 2025 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alper</LastName><ForeName>Hilmi</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-1188-1814</Identifier><AffiliationInfo><Affiliation>Department of Otorhinolaryngology-Head and Neck Surgery, Faculty of Medicine, Necmettin Erbakan University, Konya, T&#xfc;rkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Somuncu</LastName><ForeName>Makbule Nihan</ForeName><Initials>MN</Initials><Identifier Source="ORCID">0000-0001-6041-457X</Identifier><AffiliationInfo><Affiliation>Department of Genetics, Necmettin Erbakan University, Faculty of Medicine, Konya, T&#xfc;rkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xd6;z&#xe7;elik</LastName><ForeName>Rukiye Erdem</ForeName><Initials>RE</Initials><Identifier Source="ORCID">0000-0001-5087-4652</Identifier><AffiliationInfo><Affiliation>Department of Otorhinolaryngology-Head and Neck Surgery, Faculty of Medicine, Necmettin Erbakan University, Konya, T&#xfc;rkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eravc&#x131;</LastName><ForeName>Fakih Cihat</ForeName><Initials>FC</Initials><Identifier Source="ORCID">0000-0001-9092-7923</Identifier><AffiliationInfo><Affiliation>Department of Otorhinolaryngology-Head and Neck Surgery, Faculty of Medicine, Necmettin Erbakan University, Konya, T&#xfc;rkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zamani</LastName><ForeName>Ay&#x15f;e G&#xfc;l</ForeName><Initials>AG</Initials><Identifier Source="ORCID">0000-0003-0329-9047</Identifier><AffiliationInfo><Affiliation>Department of Genetics, Necmettin Erbakan University, Faculty of Medicine, Konya, T&#xfc;rkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arba&#x11f;</LastName><ForeName>Hamdi</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-6146-8801</Identifier><AffiliationInfo><Affiliation>Department of Otorhinolaryngology-Head and Neck Surgery, Faculty of Medicine, Necmettin Erbakan University, Konya, T&#xfc;rkiye.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>23TU18021</GrantID><Agency>Necmettin Erbakan &#xdc;niversitesi</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>11</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AUS/FLUS</Keyword><Keyword MajorTopicYN="N">FNAB</Keyword><Keyword MajorTopicYN="N">binucleated cell</Keyword><Keyword MajorTopicYN="N">micronucleus</Keyword><Keyword MajorTopicYN="N">thyroid cancer</Keyword><Keyword MajorTopicYN="N">thyroid nodule</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>11</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>11</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>11</Month><Day>26</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>11</Month><Day>26</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>11</Month><Day>26</Day><Hour>4</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41293786</ArticleId><ArticleId IdType="doi">10.1002/hed.70110</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>S. Erkan, H. Yabano&#x11f;lu, T. Avci, et&#xa0;al., &#x201c;The Necessity of Fine&#x2010;Needle Aspiration Biopsy in Surgical Decision&#x2010;Making for Thyroid Nodules Larger Than 3 Cm,&#x201d; Medicine 103 (2024): e40373.</Citation></Reference><Reference><Citation>S. Ali, Z. Baloch, B. Cochand&#x2010;Priollet, F. Schmitt, P. Vielh, and P. VanderLaan, &#x201c;The 2023 Bethesda System for Reporting Thyroid Cytopathology,&#x201d; Journal of the American Society of Cytopathology 12 (2023): 319&#x2013;325.</Citation></Reference><Reference><Citation>S. Kim, J. Roh, J. Baek, S. Hong, Y. Shong, and W. Kim, &#x201c;Risk of Malignancy According to Sub&#x2010;Classification of the Atypia of Undetermined Significance or Follicular Lesion of Undetermined Significance (AUS/FLUS) Category in the Bethesda System for Reporting Thyroid Cytopathology,&#x201d; Cytopathology 28 (2017): 65&#x2013;73.</Citation></Reference><Reference><Citation>F. Zhang and F. Lin, &#x201c;Molecular Testing of Thyroid Nodules. A Review of Current Available Tests for Fine&#x2010;Needle Aspiration,&#x201d; Archives of Pathology &amp; Laboratory Medicine 140 (2016): 1338&#x2013;1344.</Citation></Reference><Reference><Citation>R. Kant, A. Davis, and V. Verma, &#x201c;Thyroid Nodules: Advances in Evaluation and Management,&#x201d; American Family Physician 102 (2020): 298&#x2013;304.</Citation></Reference><Reference><Citation>P. Valderrabano, V. Zota, B. McIver, D. Coppola, and M. Leon, &#x201c;Molecular Assays in Cytopathology for Thyroid Cancer,&#x201d; Cancer Control 22 (2015): 152&#x2013;157.</Citation></Reference><Reference><Citation>M. Fenech, &#x201c;Cytokinesis&#x2010;Block Micronucleus Cytome Assay,&#x201d; Nature Protocols 2 (2007): 1084&#x2013;1104.</Citation></Reference><Reference><Citation>T. Kokenek&#x2010;Unal and I. Coban, &#x201c;Micronuclei and Nuclear Buds: Highlighting Overlooked Indicators of Chromosomal Damage in Thyroid Aspiration Smears,&#x201d; Diagnostic Cytopathology 45 (2017): 673&#x2013;680.</Citation></Reference><Reference><Citation>N. &#xc7;elik, A. Alt&#x131;nbo&#x11f;a, and T. &#xdc;nal, &#x201c;Micronucleus and Nuclear Budding Help to Identify Malignancy in Thyroid Fine Needle Aspiration Cytology,&#x201d; Cytopathology (2025), https://doi.org/10.1111/cyt.13505.</Citation></Reference><Reference><Citation>M. Fenech, M. Kirsch&#x2010;Volders, A. Natarajan, J. Surralles, J. Crott, and J. Parry, &#x201c;Molecular Mechanisms of Micronucleus, Nucleoplasmic Bridge and Nuclear Bud Formation in Mammalian and Human Cells,&#x201d; Mutagenesis 26 (2011): 125&#x2013;132.</Citation></Reference><Reference><Citation>A. Bhatia and Y. Kumar, &#x201c;Cancer Cell Micronucleus: An Update on Clinical and Diagnostic Applications,&#x201d; APMIS: acta pathologica, microbiologica, et immunologica Scandinavica 121 (2013): 569&#x2013;581.</Citation></Reference><Reference><Citation>A. Nersesyan, M. Kundi, M. Fenech, H. Stopper, J. da Silva, and C. Bolognesi, &#x201c;Recommendations and Quality Criteria for Micronucleus Studies With Humans,&#x201d; Mutation Research, Reviews in Mutation Research 789 (2022): 108410.</Citation></Reference><Reference><Citation>S. Bonassi, M. Neri, C. Lando, M. Ceppi, Y. Lin, and W. Chang, &#x201c;Effect of Smoking Habit on the Frequency of Micronuclei in Human Lymphocytes: Results From the Human MicroNucleus Project,&#x201d; Mutation Research 543 (2003): 155&#x2013;166.</Citation></Reference><Reference><Citation>M. Re&#x15f;orlu, Y. Ertekin, &#x15e;. Ertem, and F. Kam&#x131;&#x15f;, &#x201c;The Evaluation of Fine Needle Aspiration Biopsy Results in Differentiating Between Benign and Malignant Thyroid Nodules,&#x201d; Family Practice and Palliative Care 9 (2024): 85&#x2013;89.</Citation></Reference><Reference><Citation>D. S&#x142;owi&#x144;ska&#x2010;Klencka, M. Klencki, J. Duda&#x2010;Szyma&#x144;ska, and B. Popowicz, &#x201c;Optimization of the Management of Category III Thyroid Nodules Using Repeat FNA and TIRADS,&#x201d; Cancers (Basel) 14 (2022): 4489.</Citation></Reference><Reference><Citation>B. Geramizadeh, S. Bos&#x2010;Hagh, and Z. Maleki, &#x201c;Cytomorphologic, Imaging, Molecular Findings, and Outcome in Thyroid Follicular Lesion of Undetermined Significance/Atypical Cell of Undetermined Significance (AUS/FLUS): A Mini&#x2010;Review,&#x201d; Acta Cytologica 63 (2019): 1&#x2013;9.</Citation></Reference><Reference><Citation>M. Kwon, M. L. Leibowitz, and J. H. Lee, &#x201c;Small but Mighty: The Causes and Consequences of Micronucleus Rupture,&#x201d; Experimental &amp; Molecular Medicine 52 (2020): 1777&#x2013;1786, https://doi.org/10.1038/s12276&#x2010;020&#x2010;00529&#x2010;z.</Citation></Reference><Reference><Citation>M. Di Bona and S. F. Bakhoum, &#x201c;Micronuclei and Cancer,&#x201d; Cancer Discovery 14, no. 2 (2024): 214&#x2013;226, https://doi.org/10.1158/2159&#x2010;8290.CD&#x2010;23&#x2010;1073.</Citation></Reference><Reference><Citation>G. Nilsson, &#x201c;Micronuclei Studied in Fine Needle Goitre Aspirates,&#x201d; Acta Pathologica et Microbiologica Scandinavica, Section A 86 (1978): 201&#x2013;204.</Citation></Reference><Reference><Citation>A. Pavlov, I. Aleksandrov, I. Beliakov, and T. Korableva, &#x201c;Morphological Analysis of Genetically Damaged Thyrocytes in Nodular Pathology of the Thyroid Gland,&#x201d; Vestnik Khirurgii Imeni I. I. Grekova 166 (2007): 58&#x2013;61.</Citation></Reference><Reference><Citation>S. Samanta, P. Dey, and R. Nijhawan, &#x201c;The Role of Micronucleus Scoring in Fine Needle Aspirates of Ductal Carcinoma of the Breast,&#x201d; Cytopathology 22 (2011): 111&#x2013;114.</Citation></Reference><Reference><Citation>M. T. Sylvia, L. Baskaran, and R. V. Bhat, &#x201c;Micronucleus Study on Breast Cytology Aspirate Smears and Its Diagnostic Utility,&#x201d; Journal of Cytology 35, no. 1 (2018): 22&#x2013;26, https://doi.org/10.4103/JOC.JOC_160_16.</Citation></Reference><Reference><Citation>J. L. de Geus, L. M. Wambier, M. C. Bortoluzzi, A. D. Loguercio, S. Kossatz, and A. Reis, &#x201c;Does Smoking Habit Increase the Micronuclei Frequency in the Oral Mucosa of Adults Compared to Non&#x2010;Smokers? A Systematic Review and Meta&#x2010;Analysis,&#x201d; Clinical Oral Investigations 22, no. 1 (2018): 81&#x2013;91, https://doi.org/10.1007/s00784&#x2010;017&#x2010;2246&#x2010;4.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70108 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41288069</PMID><DateRevised><Year>2025</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Nov</Month><Day>25</Day></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Neck Spasms After Lateral Neck Dissection: A Survey of Head and Neck Cancer Patients.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70108</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Neck spasms or myoclonus are an underreported sequela of HNC treatment, often described following radiation. The frequency of neck spasm following neck dissection is unknown.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A phone survey was conducted of HNC patients following neck dissection to determine the incidence and severity of neck spasms using the Penn Spasm Frequency Scale and Neck Dissection Impairment Index. Demographic and treatment-related factors were compared between those with and without neck spasms.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">56/136 patients (41.2%) responded with 16 (28.6%) reporting neck spasms. Spasms ranged from mild to severe and were associated with a lower NDII score (85.62 vs. 90.44, p&#x2009;=&#x2009;0.078) Neck spasms occurred irrespective of shoulder dysfunction due to cranial nerve 11 injury and were not associated with any patient or treatment-related factors, including radiation therapy.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Neck spasms occur after neck dissection irrespective of radiation therapy or spinal accessory nerve injury with a negative impact on quality of life.</AbstractText><CopyrightInformation>&#xa9; 2025 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bridgham</LastName><ForeName>Kelly</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-7043-0602</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Thomas Jefferson University Hospital, Philadelphia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duong</LastName><ForeName>Teresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Thomas Jefferson University Hospital, Philadelphia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaki</LastName><ForeName>Praneet</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Thomas Jefferson University Hospital, Philadelphia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allcroft</LastName><ForeName>Tyler</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Thomas Jefferson University Hospital, Philadelphia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Kalena</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Thomas Jefferson University Hospital, Philadelphia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mastrolonardo</LastName><ForeName>Eric</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-2869-8848</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Thomas Jefferson University Hospital, Philadelphia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kenny</LastName><ForeName>Hannah</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Thomas Jefferson University Hospital, Philadelphia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Ravin</LastName><ForeName>Emma</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Thomas Jefferson University Hospital, Philadelphia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thal</LastName><ForeName>Arielle</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-7498-8512</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Thomas Jefferson University Hospital, Philadelphia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Curry</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-9507-4237</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Thomas Jefferson University Hospital, Philadelphia, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>11</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">head and neck cancer</Keyword><Keyword MajorTopicYN="N">myoclonus</Keyword><Keyword MajorTopicYN="N">neck dissection morbidity</Keyword><Keyword MajorTopicYN="N">neck spasms</Keyword><Keyword MajorTopicYN="N">quality of life</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>9</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>11</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>11</Month><Day>25</Day><Hour>13</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>11</Month><Day>25</Day><Hour>13</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>11</Month><Day>25</Day><Hour>6</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41288069</ArticleId><ArticleId IdType="doi">10.1002/hed.70108</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>A. Barsouk, J. S. Aluru, P. Rawla, K. Saginala, and A. Barsouk, &#x201c;Epidemiology, Risk Factors, and Prevention of Head and Neck Squamous Cell Carcinoma,&#x201d; Medical Science 11, no. 2 (2023): 42, https://doi.org/10.3390/medsci11020042.</Citation></Reference><Reference><Citation>S. M. Eickmeyer, C. K. Walczak, K. B. Myers, D. R. Lindstrom, P. Layde, and B. H. Campbell, &#x201c;Quality of Life, Shoulder Range of Motion, and Spinal Accessory Nerve Status in 5&#x2010;Year Survivors of Head and Neck Cancer,&#x201d; PM &amp; R: The Journal of Injury, Function, and Rehabilitation 6, no. 12 (2014): 1073&#x2013;1080, https://doi.org/10.1016/j.pmrj.2014.05.015.</Citation></Reference><Reference><Citation>H. Jeyarajan and S. McCammon, &#x201c;Functional Complications of Neck Dissections,&#x201d; Operative Techniques in Otolaryngology&#x2010;Head and Neck Surgery 35, no. 4 (2024): 368&#x2013;378, https://doi.org/10.1016/j.otot.2024.08.019.</Citation></Reference><Reference><Citation>K. U. Hunter, F. Worden, C. Bradford, et&#xa0;al., &#x201c;Neck Spasm After Chemoradiotherapy for Head and Neck cancer: Natural History and Dosimetric Correlates,&#x201d; Head &amp; Neck 36, no. 2 (2014): 176&#x2013;180, https://doi.org/10.1002/hed.23284.</Citation></Reference><Reference><Citation>D. Gelblum, S. Wolden, K. Schupak, and N. Lee, &#x201c;Neck Spasms as a Late Effect of Intensity Modulated Radiation Therapy (IMRT) for Head and Neck Cancer,&#x201d; International Journal of Radiation Oncology, Biology, Physics 81, no. 2 (2011): S550, https://doi.org/10.1016/j.ijrobp.2011.06.864.</Citation></Reference><Reference><Citation>P. B. Mills, A. P. Vakil, C. Phillips, L. Kei, and B. K. Kwon, &#x201c;Intra&#x2010;Rater and Inter&#x2010;Rater Reliability of the Penn Spasm Frequency Scale in People With Chronic Traumatic Spinal Cord Injury,&#x201d; Spinal Cord 56, no. 6 (2018): 569&#x2013;574, https://doi.org/10.1038/s41393&#x2010;018&#x2010;0063&#x2010;5.</Citation></Reference><Reference><Citation>R. J. Taylor, J. C. Chepeha, T. N. Teknos, et&#xa0;al., &#x201c;Development and Validation of the Neck Dissection Impairment Index,&#x201d; Archives of Otolaryngology &#x2013; Head &amp; Neck Surgery 128, no. 1 (2002): 44&#x2013;49, https://doi.org/10.1001/archotol.128.1.44.</Citation></Reference><Reference><Citation>E. M. Gane, Z. A. Michaleff, M. A. Cottrell, et&#xa0;al., &#x201c;Prevalence, Incidence, and Risk Factors for Shoulder and Neck Dysfunction After Neck Dissection: A Systematic Review,&#x201d; European Journal of Surgical Oncology 43, no. 7 (2017): 1199&#x2013;1218, https://doi.org/10.1016/j.ejso.2016.10.026.</Citation></Reference><Reference><Citation>E. M. Gane, S. M. McPhail, A. L. Hatton, B. J. Panizza, and S. P. O'Leary, &#x201c;The Relationship Between Physical Impairments, Quality of Life and Disability of the Neck and Upper Limb in Patients Following Neck Dissection,&#x201d; Journal of Cancer Survivorship 12, no. 5 (2018): 619&#x2013;631, https://doi.org/10.1007/s11764&#x2010;018&#x2010;0697&#x2010;5.</Citation></Reference><Reference><Citation>L. Zhang, G. Zhou, Z. Qi, et&#xa0;al., &#x201c;Patient&#x2010; and Treatment&#x2010;Related Risk Factors Associated With Neck Muscle Spasm in Nasopharyngeal Carcinoma Patients After Intensity&#x2010;Modulated Radiotherapy,&#x201d; BMC Cancer 17, no. 1 (2017): 788, https://doi.org/10.1186/s12885&#x2010;017&#x2010;3780&#x2010;9.</Citation></Reference><Reference><Citation>B. Lanisnik, M. Zargi, and Z. Rodi, &#x201c;Electrophysiologic Analysis of Injury to Cranial Nerve XI During Neck Dissection,&#x201d; Head &amp; Neck 38, no. S1 (2016): E372&#x2013;E376, https://doi.org/10.1002/hed.24002.</Citation></Reference><Reference><Citation>P. T. Dziegielewski, M. L. McNeely, N. Ashworth, et&#xa0;al., &#x201c;2b or Not 2b? Shoulder Function After Level 2b Neck Dissection: A Double&#x2010;Blind Randomized Controlled Clinical Trial,&#x201d; Cancer 126, no. 7 (2020): 1492&#x2013;1501, https://doi.org/10.1002/cncr.32681.</Citation></Reference><Reference><Citation>S. Akihiro, N. Takuma, F. Hiroyuki, et&#xa0;al., &#x201c;Shoulder Function After Neck Dissection With Level IIb Preservation: A Prospective Observational Study,&#x201d; Acta Oto&#x2010;Laryngologica 143 (2023): 814&#x2013;822, https://doi.org/10.1080/00016489.2023.2261985.</Citation></Reference><Reference><Citation>E. E. W. Cohen, S. J. LaMonte, N. L. Erb, et&#xa0;al., &#x201c;American Cancer Society Head and Neck Cancer Survivorship Care Guideline,&#x201d; CA: a Cancer Journal for Clinicians 66, no. 3 (2016): 203&#x2013;239, https://doi.org/10.3322/caac.21343.</Citation></Reference><Reference><Citation>M. L. McNeely, M. Parliament, K. S. Courneya, et&#xa0;al., &#x201c;A Pilot Study of a Randomized Controlled Trial to Evaluate the Effects of Progressive Resistance Exercise Training on Shoulder Dysfunction Caused by Spinal Accessory Neurapraxia/Neurectomy in Head and Neck Cancer Survivors,&#x201d; Head &amp; Neck 26, no. 6 (2004): 518&#x2013;530, https://doi.org/10.1002/hed.20010.</Citation></Reference><Reference><Citation>M. L. McNeely, M. B. Parliament, H. Seikaly, et&#xa0;al., &#x201c;Effect of Exercise on Upper Extremity Pain and Dysfunction in Head and Neck Cancer Survivors,&#x201d; Cancer 113, no. 1 (2008): 214&#x2013;222, https://doi.org/10.1002/cncr.23536.</Citation></Reference><Reference><Citation>A. P. Carvalho, F. M. Vital, and B. G. Soares, &#x201c;Exercise Interventions for Shoulder Dysfunction in Patients Treated for Head and Neck Cancer,&#x201d; Cochrane Database of Systematic Reviews 2012, no. 4 (2012): CD008693, https://doi.org/10.1002/14651858.CD008693.pub2.</Citation></Reference><Reference><Citation>M. D. Stubblefield, A. Levine, C. M. Custodio, and T. Fitzpatrick, &#x201c;The Role of Botulinum Toxin Type A in the Radiation Fibrosis Syndrome: A Preliminary Report,&#x201d; Archives of Physical Medicine and Rehabilitation 89, no. 3 (2008): 417&#x2013;421, https://doi.org/10.1016/j.apmr.2007.11.022.</Citation></Reference><Reference><Citation>C. Bach, I. Wagner, X. Lachiver, B. Baujat, and F. Chabolle, &#x201c;Botulinum Toxin in the Treatment of Post&#x2010;Radiosurgical Neck Contracture in Head and Neck Cancer: A Novel Approach,&#x201d; European Annals of Otorhinolaryngology, Head and Neck Diseases 129, no. 1 (2012): 6&#x2013;10, https://doi.org/10.1016/j.anorl.2011.07.002.</Citation></Reference><Reference><Citation>C. Wittekindt, W. Liu, S. F. Preuss, and O. Guntinas&#x2010;Lichius, &#x201c;Botulinum Toxin A for Neuropathic Pain After Neck Dissection: A Dose&#x2010;Finding Study,&#x201d; Laryngoscope 116, no. 7 (2006): 1168&#x2013;1171, https://doi.org/10.1097/01.mlg.0000217797.05523.75.</Citation></Reference><Reference><Citation>J. Costa, F. B. Rodrigues, G. S. Duarte, et&#xa0;al., &#x201c;Botulinum Toxin Type A Therapy for Cervical Dystonia,&#x201d; Cochrane Database of Systematic Reviews 2020, no. 11 (2020): CD003633, https://doi.org/10.1002/14651858.cd003633.pub4.</Citation></Reference><Reference><Citation>M. Petracca, M. R. Lo Monaco, T. Ialongo, et&#xa0;al., &#x201c;Efficacy and Safety of Long&#x2010;Term Botulinum Toxin Treatment for Acquired Cervical Dystonia: A 25&#x2010;Year Follow&#x2010;Up,&#x201d; Journal of Neurology 270, no. 1 (2023): 340&#x2013;347, https://doi.org/10.1007/s00415&#x2010;022&#x2010;11343&#x2010;0.</Citation></Reference><Reference><Citation>M. S. David, H. Mark, J. A. Eric, et&#xa0;al., &#x201c;Practice Guideline Update Summary: Botulinum Neurotoxin for the Treatment of Blepharospasm, Cervical Dystonia, Adult Spasticity, and Headache,&#x201d; Neurology 86, no. 19 (2016): 1818&#x2013;1826, https://doi.org/10.1212/wnl.0000000000002560.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70109 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41287947</PMID><DateRevised><Year>2025</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Nov</Month><Day>25</Day></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>The Anti-Thyroglobulin Antibody Trajectory and Risk of Structural Recurrence in Patients With Papillary Thyroid Cancer.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70109</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">To explore the relationship between anti-thyroglobulin antibody (TgAb) trajectories and recurrence risk in papillary thyroid cancer (PTC) patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This multiple-center, retrospective cohort included 4161 patients who had no evidence of structural disease and a stimulated thyroglobulin (s-Tg) of &#x2264;&#x2009;10&#x2009;ng/mL at the initial radioiodine (RAI) treatment. Among 3660 patients who had repeated TgAb measurements (before RAI treatment, 1, 6, or 12 months after treatment) and available response assessments, latent class models were used to identify TgAb trajectories. Associations of trajectories with the risk of recurrence were estimated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Four distinct TgAb trajectories were identified. Compared with patients belonging to the consistently negative trajectory, patients with the other three trajectories had higher risks of recurrence (medium-level descent: odds ratio&#x2009;=&#x2009;3.46 [95% CI&#x2009;=&#x2009;1.56-6.90], high-level descent: 8.04 [1.26-28.78], persistently increasing: 12.11 [5.73-23.75]).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">TgAb trajectories within 1 year after RAI treatment are associated with the risk of recurrence in PTC patients with a s-Tg&#x2009;&#x2264;&#x2009;10&#x2009;ng/mL.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">Registered at www.chictr.org.cn (identifier: ChiCTR2300075574).</AbstractText><CopyrightInformation>&#xa9; 2025 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Hongxi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Tian</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Qianrui</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Rong</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-5191-9004</Identifier><AffiliationInfo><Affiliation>Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>82402390</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>2025ZNSFSC1757</GrantID><Agency>Science and Technology Department of Sichuan Province</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>11</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antithyroglobulin antibodies</Keyword><Keyword MajorTopicYN="N">latent class model</Keyword><Keyword MajorTopicYN="N">papillary thyroid cancerthyroglobulin</Keyword><Keyword MajorTopicYN="N">treatment response</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>11</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>11</Month><Day>25</Day><Hour>6</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>11</Month><Day>25</Day><Hour>6</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>11</Month><Day>25</Day><Hour>5</Hour><Minute>10</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41287947</ArticleId><ArticleId IdType="doi">10.1002/hed.70109</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>H. Sung, J. Ferlay, R. L. Siegel, et&#xa0;al., &#x201c;Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,&#x201d; CA: A Cancer Journal for Clinicians 71, no. 3 (2021): 209&#x2013;249.</Citation></Reference><Reference><Citation>D. W. Chen, B. H. H. Lang, D. S. A. McLeod, K. Newbold, and M. R. Haymart, &#x201c;Thyroid Cancer,&#x201d; Lancet 401, no. 10387 (2023): 1531&#x2013;1544.</Citation></Reference><Reference><Citation>B. R. Haugen, E. K. Alexander, K. C. Bible, et&#xa0;al., &#x201c;2015 American Thyroid Association Management Guidelines for Adult Patients With Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer,&#x201d; Thyroid 26, no. 1 (2016): 1&#x2013;133.</Citation></Reference><Reference><Citation>I. Petrovic, J. LoPresti, S. Fatemi, A. Gianoukakis, K. Burman, and C. J. Gomez&#x2010;Lima, &#x201c;Influence of Thyroglobulin (Tg) Autoantibodies on Tg Levels Measured by Different Methodologies: (IMA, LC&#x2010;MS/MS and RIA),&#x201d; Journal of Clinical Endocrinology and Metabolism 109, no. 12 (2024): 3254&#x2013;3263.</Citation></Reference><Reference><Citation>E. S. Kim, D. J. Lim, K. H. Baek, et&#xa0;al., &#x201c;Thyroglobulin Antibody Is Associated With Increased Cancer Risk in Thyroid Nodules,&#x201d; Thyroid 20, no. 8 (2010): 885&#x2013;891.</Citation></Reference><Reference><Citation>K. Jo and D. J. Lim, &#x201c;Clinical Implications of Anti&#x2010;Thyroglobulin Antibody Measurement Before Surgery in Thyroid Cancer,&#x201d; Korean Journal of Internal Medicine 33, no. 6 (2018): 1050&#x2013;1057.</Citation></Reference><Reference><Citation>C. A. Spencer, M. Takeuchi, M. Kazarosyan, et&#xa0;al., &#x201c;Serum Thyroglobulin Autoantibodies: Prevalence, Influence on Serum Thyroglobulin Measurement, and Prognostic Significance in Patients With Differentiated Thyroid Carcinoma,&#x201d; Journal of Clinical Endocrinology and Metabolism 83, no. 4 (1998): 1121&#x2013;1127.</Citation></Reference><Reference><Citation>S. Deza, J. Maroto, O. Tellechea, et&#xa0;al., &#x201c;Clinical Implications of Changing Thyroglobulin and Antithyroglobulin Antibodies Analytical Methods in the Follow&#x2010;Up of Patients With Differentiated Thyroid Carcinoma,&#x201d; Clinica Chimica Acta 548 (2023): 117502.</Citation></Reference><Reference><Citation>Z. J. O. Lee, G. D. Eslick, and S. Edirimanne, &#x201c;Investigating Antithyroglobulin Antibody as a Prognostic Marker for Differentiated Thyroid Cancer: A Meta&#x2010;Analysis and Systematic Review,&#x201d; Thyroid 30, no. 11 (2020): 1601&#x2013;1612.</Citation></Reference><Reference><Citation>F. Vaisman, D. Momesso, D. A. Bulzico, et&#xa0;al., &#x201c;Spontaneous Remission in Thyroid Cancer Patients After Biochemical Incomplete Response to Initial Therapy,&#x201d; Clinical Endocrinology 77, no. 1 (2012): 132&#x2013;138.</Citation></Reference><Reference><Citation>K. Bech, U. Feldt&#x2010;Rasmussen, H. Bliddal, J. Date, and M. Blichert&#x2010;Toft, &#x201c;The Acute Changes in Thyroid Stimulating Immunoglobulins, Thyroglobulin and Thyroglobulin Antibodies Following Subtotal Thyroidectomy,&#x201d; Clinical Endocrinology 16, no. 3 (1982): 235&#x2013;242.</Citation></Reference><Reference><Citation>Q. Liu, M. Yin, and G. Li, &#x201c;Antithyroglobulin Antibody Variation During Follow&#x2010;Up Has a Good Prognostic Value for Preoperative Antithyroglobulin Antibody&#x2010;Positive Differentiated Thyroid Cancer Patients: A Retrospective Study in Southwest China,&#x201d; Front Endocrinol (Lausanne) 12 (2021): 774275.</Citation></Reference><Reference><Citation>Y. Zhao, Z. Mu, D. Liang, et&#xa0;al., &#x201c;Prognostic Value of Postoperative Anti&#x2010;Thyroglobulin Antibody in Patients With Differentiated Thyroid Cancer,&#x201d; Front Endocrinol (Lausanne) 15 (2024): 1354426.</Citation></Reference><Reference><Citation>P. Trimboli, V. Zilioli, M. Imperiali, and L. Giovanella, &#x201c;Thyroglobulin Autoantibodies Before Radioiodine Ablation Predict Differentiated Thyroid Cancer Outcome,&#x201d; Clinical Chemistry and Laboratory Medicine 55, no. 12 (2017): 1995&#x2013;2001.</Citation></Reference><Reference><Citation>Y. Tsushima, A. Miyauchi, Y. Ito, et&#xa0;al., &#x201c;Prognostic Significance of Changes in Serum Thyroglobulin Antibody Levels of Pre&#x2010; and Post&#x2010;Total Thyroidectomy in Thyroglobulin Antibody&#x2010;Positive Papillary Thyroid Carcinoma Patients,&#x201d; Endocrine Journal 60, no. 7 (2013): 871&#x2013;876.</Citation></Reference><Reference><Citation>O. Yamada, A. Miyauchi, Y. Ito, et&#xa0;al., &#x201c;Changes in Serum Thyroglobulin Antibody Levels as a Dynamic Prognostic Factor for Early&#x2010;Phase Recurrence of Thyroglobulin Antibody&#x2010;Positive Papillary Thyroid Carcinoma After Total Thyroidectomy,&#x201d; Endocrine Journal 61, no. 10 (2014): 961&#x2013;965.</Citation></Reference><Reference><Citation>H. Anderson, K. H. Lim, S. Gull, R. Oprean, K. Spence, and T. Cvasciuc, &#x201c;Predicting Clinical Outcomes of Patients With Serum Thyroglobulin Antibodies After Thyroidectomy for Differentiated Thyroid Cancer: A Retrospective Study From a UK Regional Center,&#x201d; Minerva Endocrinol (Torino) 49, no. 1 (2024): 60&#x2013;68.</Citation></Reference><Reference><Citation>H. Ge, W. Chen, Z. Lin, Y. Li, and S. Chen, &#x201c;Analysis of the Prognostic Value of Thyroglobulin Antibody Change Trends During Follow&#x2010;Up After (131)I Treatment in Patients With Differentiated Thyroid Carcinoma,&#x201d; Frontiers in Oncology 15 (2025): 1496594.</Citation></Reference><Reference><Citation>M. Herle, N. Micali, M. Abdulkadir, et&#xa0;al., &#x201c;Identifying Typical Trajectories in Longitudinal Data: Modelling Strategies and Interpretations,&#x201d; European Journal of Epidemiology 35, no. 3 (2020): 205&#x2013;222.</Citation></Reference><Reference><Citation>C. An, R. Wei, W. Yao, et&#xa0;al., &#x201c;Association of Serum AFP Trajectories and Hepatocellular Carcinoma Outcomes After Hepatic Arterial Infusion Chemotherapy: A Longitudinal, Multicenter Study,&#x201d; Cancer Medicine 13, no. 11 (2024): e7319.</Citation></Reference><Reference><Citation>H. Y. Yang, S. C. Shun, Y. H. Lee, et&#xa0;al., &#x201c;Trajectories of Perioperative Nutritional Status in Patients With Pancreatic Tumor After Surgery in Six Months,&#x201d; European Journal of Oncology Nursing 72 (2024): 102687.</Citation></Reference><Reference><Citation>Y. Liu, S. Dai, Z. Liu, et&#xa0;al., &#x201c;Serum Tumor Markers and Outcomes in Lung Cancer Patients With Brain Metastases: A Retrospective Longitudinal Cohort Study,&#x201d; Translational Lung Cancer Research 13, no. 9 (2024): 2282&#x2013;2295.</Citation></Reference><Reference><Citation>S. F. Kuo, T. C. Chao, H. Y. Chang, et&#xa0;al., &#x201c;Prognosis of Papillary Thyroid Cancers With Positive Serum Thyroglobulin Antibody After Total Thyroidectomy,&#x201d; Asian Journal of Surgery 40, no. 3 (2017): 186&#x2013;192.</Citation></Reference><Reference><Citation>M. Sanjari, M. Ordooei, L. Amirkhosravi, A. Naghibzadeh&#x2010;Tahami, and S. Nazemi, &#x201c;The Effect of Positive Thyroglobulin Antibodies on the Prognosis and Treatment Response in Patients With Papillary Thyroid Carcinoma,&#x201d; Heliyon 10, no. 4 (2024): e26092.</Citation></Reference><Reference><Citation>H. Y. Nam, J. C. Paeng, J. K. Chung, et&#xa0;al., &#x201c;Monitoring Differentiated Thyroid Cancer Patients With Negative Serum Thyroglobulin. Diagnostic Implication of TSH&#x2010;Stimulated Antithyroglobulin Antibody,&#x201d; Nuklearmedizin 53, no. 2 (2014): 32&#x2013;38.</Citation></Reference><Reference><Citation>N. Han, C. Lu, J. Li, et&#xa0;al., &#x201c;Stimulated Thyroglobulin and Pre&#x2010;Ablation Antithyroglobulin Antibody Products Can Predict the Response to Radioiodine Therapy of TgAb&#x2010;Positive Differentiated Thyroid Cancer Patients: A Retrospective Study,&#x201d; Front Endocrinol (Lausanne) 14 (2023): 1222470.</Citation></Reference><Reference><Citation>C. Xi, G. Q. Zhang, H. J. Song, et&#xa0;al., &#x201c;Change in Antithyroglobulin Antibody Levels Is a Good Predictor of Responses to Therapy in Antithyroglobulin Antibody&#x2010;Positive Pediatric Papillary Thyroid Carcinoma Patients,&#x201d; International Journal of Endocrinology 2022 (2022): 7173919.</Citation></Reference><Reference><Citation>A. Donnici, M. Mirabelli, S. Giuliano, et&#xa0;al., &#x201c;Coexistence of Hashimoto's Thyroiditis in Differentiated Thyroid Cancer: Post&#x2010;Operative Monitoring of Anti&#x2010;Thyroglobulin Antibodies and Assessment of Treatment Response,&#x201d; Diagnostics (Basel) 14, no. 2 (2024): 166.</Citation></Reference><Reference><Citation>H. Wang, C. Zhang, Q. Li, et&#xa0;al., &#x201c;Development and Validation of Prediction Models for Papillary Thyroid Cancer Structural Recurrence Using Machine Learning Approaches,&#x201d; BMC Cancer 24, no. 1 (2024): 427.</Citation></Reference><Reference><Citation>H. Wang, Q. Li, T. Tian, B. Liu, and R. Tian, &#x201c;Improving the Risk Prediction of the 2015 ATA Recurrence Risk Stratification in Papillary Thyroid Cancer,&#x201d; Journal of Clinical Endocrinology and Metabolism 110, no. 2 (2025): 534&#x2013;541.</Citation></Reference><Reference><Citation>H. Wang, T. Tian, and R. Tian, &#x201c;Supplementary Materials for the Anti&#x2010;Thyroglobulin Antibody Trajectory and Risk of Structural Recurrence in Patients With Papillary Thyroid Cancer,&#x201d; https://doi.org/10.6084/m9.figshare.28150910.v1. 2025.</Citation></Reference><Reference><Citation>A. Piccardo, G. Siri, S. Raffa, et&#xa0;al., &#x201c;How to Better Stratify the Risk of Differentiated Thyroid Carcinomas: The Key Role of Radioactive Iodine Therapy, Age, and Gender,&#x201d; European Journal of Nuclear Medicine and Molecular Imaging 48, no. 3 (2021): 822&#x2013;830.</Citation></Reference><Reference><Citation>K. R. Joseph, S. Edirimanne, and G. D. Eslick, &#x201c;Multifocality as a Prognostic Factor in Thyroid Cancer: A Meta&#x2010;Analysis,&#x201d; International Journal of Surgery 50 (2018): 121&#x2013;125.</Citation></Reference><Reference><Citation>L. M. Youngwirth, M. A. Adam, R. P. Scheri, S. A. Roman, and J. A. Sosa, &#x201c;Extrathyroidal Extension Is Associated With Compromised Survival in Patients With Thyroid Cancer,&#x201d; Thyroid 27, no. 5 (2017): 626&#x2013;631.</Citation></Reference><Reference><Citation>C. Qin, S. Cai, M. Yin, et&#xa0;al., &#x201c;Association of Lymph Nodes Positive Rate With the Risk of Recurrence in Patients With Stage T1 Papillary Thyroid Cancer,&#x201d; Journal of the Endocrine Society 8, no. 8 (2024): bvae131.</Citation></Reference><Reference><Citation>N. Chidambaranathan, S. Thiagarajan, B. Gurukeerthi, et&#xa0;al., &#x201c;The Significance of the Presence of Extranodal Extension in the Metastatic Node of Differentiated Thyroid Cancer: A Proposal for Modification in the American Thyroid Association (ATA) Risk Stratification,&#x201d; European Archives of Oto&#x2010;Rhino&#x2010;Laryngology 281, no. 4 (2024): 1923&#x2013;1931.</Citation></Reference><Reference><Citation>M. B. Amin, S. B. Edge, F. Greene, et&#xa0;al., AJCC Cancer Staging Manual, 8th ed. (Springer, 2017).</Citation></Reference><Reference><Citation>C. Proust&#x2010;Lima, V. Philipps, and B. Liquet, &#x201c;Estimation of Extended Mixed Models Using Latent Classes and Latent Processes: The R Package Lcmm,&#x201d; Journal of Statistical Software 78, no. 2 (2017): 1&#x2013;56.</Citation></Reference><Reference><Citation>E. Song, J. Ahn, H. S. Oh, et&#xa0;al., &#x201c;Time Trends of Thyroglobulin Antibody in Ablated Papillary Thyroid Carcinoma Patients: Can We Predict the Rate of Negative Conversion?,&#x201d; Oral Oncology 91 (2019): 29&#x2013;34.</Citation></Reference><Reference><Citation>F. Bueno, M. G. G. Falcone, M. A. Penaloza, E. Abelleira, and F. Pitoia, &#x201c;Dynamics of Serum Antithyroglobulin Antibodies in Patients With Differentiated Thyroid Cancer,&#x201d; Endocrine 67, no. 2 (2020): 387&#x2013;396.</Citation></Reference><Reference><Citation>K. Jo, M. H. Kim, J. Ha, et&#xa0;al., &#x201c;Prognostic Value of Preoperative Anti&#x2010;Thyroglobulin Antibody in Differentiated Thyroid Cancer,&#x201d; Clinical Endocrinology 87, no. 3 (2017): 292&#x2013;299.</Citation></Reference><Reference><Citation>A. Ernaga&#x2010;Lorea, M. C. Hernandez&#x2010;Morhain, E. Anda&#x2010;Apinaniz, et&#xa0;al., &#x201c;Prognostic Value of Change in Anti&#x2010;Thyroglobulin Antibodies After Thyroidectomy in Patients With Papillary Thyroid Carcinoma,&#x201d; Clinical &amp; Translational Oncology 20, no. 6 (2018): 740&#x2013;744.</Citation></Reference><Reference><Citation>C. Durante, S. Tognini, T. Montesano, et&#xa0;al., &#x201c;Clinical Aggressiveness and Long&#x2010;Term Outcome in Patients With Papillary Thyroid Cancer and Circulating Anti&#x2010;Thyroglobulin Autoantibodies,&#x201d; Thyroid 24, no. 7 (2014): 1139&#x2013;1145.</Citation></Reference><Reference><Citation>W. G. Kim, J. H. Yoon, W. B. Kim, et&#xa0;al., &#x201c;Change of Serum Antithyroglobulin Antibody Levels Is Useful for Prediction of Clinical Recurrence in Thyroglobulin&#x2010;Negative Patients With Differentiated Thyroid Carcinoma,&#x201d; Journal of Clinical Endocrinology and Metabolism 93, no. 12 (2008): 4683&#x2013;4689.</Citation></Reference><Reference><Citation>G. A. Lupoli, O. E. Okosieme, C. Evans, et&#xa0;al., &#x201c;Prognostic Significance of Thyroglobulin Antibody Epitopes in Differentiated Thyroid Cancer,&#x201d; Journal of Clinical Endocrinology and Metabolism 100, no. 1 (2015): 100&#x2013;108.</Citation></Reference><Reference><Citation>F. Ragusa, P. Fallahi, G. Elia, et&#xa0;al., &#x201c;Hashimotos' Thyroiditis: Epidemiology, Pathogenesis, Clinic and Therapy,&#x201d; Best Practice &amp; Research. Clinical Endocrinology &amp; Metabolism 33, no. 6 (2019): 101367.</Citation></Reference><Reference><Citation>S. Xu, H. Huang, J. Qian, et&#xa0;al., &#x201c;Prevalence of Hashimoto Thyroiditis in Adults With Papillary Thyroid Cancer and Its Association With Cancer Recurrence and Outcomes,&#x201d; JAMA Network Open 4, no. 7 (2021): e2118526.</Citation></Reference><Reference><Citation>X. Hu, Y. Wang, E. Liu, et&#xa0;al., &#x201c;Causality of Hashimoto's Thyroiditis to Thyroid Cancer: A 2&#x2010;S Mendelian Randomization Study,&#x201d; Endocrine Practice 30, no. 12 (2024): 1158&#x2013;1165.</Citation></Reference><Reference><Citation>Z. F. Xu, H. Ge, N. Tang, Z. E. Qin, and H. L. Tan, &#x201c;Prevalence of Hashimoto's Thyroiditis in Papillary Thyroid Cancer and Its Association With Aggressive Characteristics,&#x201d; Gland Surgery 14, no. 3 (2025): 451&#x2013;461.</Citation></Reference><Reference><Citation>A. Murari, E. Peluso, F. Cianfrani, P. Gaudio, and M. Lungaroni, &#x201c;On the Use of Entropy to Improve Model Selection Criteria,&#x201d; Entropy (Basel) 21, no. 4 (2019): 394.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70105 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41287448</PMID><DateRevised><Year>2025</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Nov</Month><Day>24</Day></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Preoperative Anxiety and Depression Symptoms Stratifying Based on Gender Differences Influence Outcome of Oral Squamous Cell Carcinoma.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70105</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The objective of this study is to investigate the impact of preoperative anxiety symptoms (AS) and depression symptoms (DS) on clinical outcomes and time to treatment initiation (TTI) of oral squamous cell carcinoma (OSCC).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Seven hundred and twenty-five OSCC patients were included. Kaplan-Meier and Cox models analyzed hazard ratio (HR) for survival, while accelerated failure time models estimated time ratio (TR) for TTI.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Females showed higher prevalence and severity of AS (p&#x2009;=&#x2009;0.014) and DS (p&#x2009;=&#x2009;0.002). Mild AS (HR: 2.132, 95% CI: 1.091-4.165; p&#x2009;=&#x2009;0.027) and DS (HR: 2.061, 95% CI: 1.052-4.038; p&#x2009;=&#x2009;0.035) increased mortality risk in females. Mild DS prolonged TTI in females (TR: 1.450, 95% CI: 1.001-2.099; p&#x2009;=&#x2009;0.049). Males with mild DS (TR: 0.718, 95% CI: 0.549-0.940; p&#x2009;=&#x2009;0.016) or moderate-severe AS (TR: 0.562, 95% CI: 0.382-0.826; p&#x2009;=&#x2009;0.003) had reduced TTI.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Psychological distress impacts survival and TTI differently by gender.</AbstractText><CopyrightInformation>&#xa9; 2025 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Lirui</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-5061-8405</Identifier><AffiliationInfo><Affiliation>Department of Oral and Maxillofacial-Head and Neck Oncology, Beijing Stomatological Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Chang</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of General Dentistry and Integrated Emergency Dental Care, Beijing Stomatological Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Qiaoshi</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Oral and Maxillofacial-Head and Neck Oncology, Beijing Stomatological Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Chong</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-5804-9750</Identifier><AffiliationInfo><Affiliation>Department of Oral and Maxillofacial-Head and Neck Oncology, Beijing Stomatological Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Bo</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-1040-1540</Identifier><AffiliationInfo><Affiliation>Department of Oral and Maxillofacial-Head and Neck Oncology, Beijing Stomatological Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Huan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Oral and Maxillofacial-Head and Neck Oncology, Beijing Stomatological Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Hao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Outpatient Department of Oral and Maxillofacial Surgery, Beijing Stomatological Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Zhien</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0003-1952-6734</Identifier><AffiliationInfo><Affiliation>Department of Oral and Maxillofacial-Head and Neck Oncology, Beijing Stomatological Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Z221100007422046</GrantID><Agency>Beijing Municipal Science and Technology Commission</Agency><Country/></Grant><Grant><GrantID>7252058</GrantID><Agency>Beijing Municipal Natural Science Foundation</Agency><Country/></Grant><Grant><GrantID>20230484404</GrantID><Agency>Beijing Nova Program</Agency><Country/></Grant><Grant><GrantID>YGLX202338</GrantID><Agency>Beijing Hospitals Authority Clinical Medicine Development of Special Funding Support</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>11</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Hospital Anxiety and Depression Scale</Keyword><Keyword MajorTopicYN="N">anxiety symptoms</Keyword><Keyword MajorTopicYN="N">depression symptoms</Keyword><Keyword MajorTopicYN="N">oral squamous cell carcinoma</Keyword><Keyword MajorTopicYN="N">time to treatment initiation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>11</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>11</Month><Day>25</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>11</Month><Day>25</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>11</Month><Day>25</Day><Hour>4</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41287448</ArticleId><ArticleId IdType="doi">10.1002/hed.70105</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>B. Li, Z. Zhao, Y. Huang, et&#xa0;al., &#x201c;The Application of Adjuvant Radiotherapy in pN1 OSCC Patients Without Adverse Pathologic Features,&#x201d; Oral Diseases 31, no. 8 (2025): 2466&#x2013;2473.</Citation></Reference><Reference><Citation>Q. Li, X. Liu, D. Wang, et&#xa0;al., &#x201c;Prognostic Value of Tertiary Lymphoid Structure and Tumour Infiltrating Lymphocytes in Oral Squamous Cell Carcinoma,&#x201d; International Journal of Oral Science 12, no. 1 (2020): 24.</Citation></Reference><Reference><Citation>Q. Xu, L. Zhang, B. Li, et&#xa0;al., &#x201c;The Significance of Elective Neck Dissection for Patients With T2N0M0 OSCC at Different Ages,&#x201d; Oral Diseases 30, no. 4 (2023): 2219&#x2013;2228.</Citation></Reference><Reference><Citation>D. Lu, T. M. Andersson, K. Fall, et&#xa0;al., &#x201c;Clinical Diagnosis of Mental Disorders Immediately Before and After Cancer Diagnosis: A Nationwide Matched Cohort Study in Sweden,&#x201d; JAMA Oncology 2, no. 9 (2016): 1188&#x2013;1196.</Citation></Reference><Reference><Citation>L. Zhang, Q. Xu, H. Liu, et&#xa0;al., &#x201c;The Application of Salvage Surgery Improves the Quality of Life and Overall Survival of Extensively Recurrent Head and Neck Cancer After Multiple Operation Plus Radiotherapy,&#x201d; Frontiers in Oncology 12 (2022): 1017630.</Citation></Reference><Reference><Citation>G. J. F. Kemps, I. Krebbers, W. Pilz, S. Vanbelle, and L. W. J. Baijens, &#x201c;Affective Symptoms and Swallow&#x2010;Specific Quality of Life in Total Laryngectomy Patients,&#x201d; Head &amp; Neck 42, no. 11 (2020): 3179&#x2013;3187.</Citation></Reference><Reference><Citation>P. Jim&#xe9;nez&#x2010;Labaig, C. Aymerich, A. Rullan, et&#xa0;al., &#x201c;Prevalence of Depressive and Anxiety Symptoms in Patients With Head and Neck Cancer Undergoing Radiotherapy: A Systematic Review and Meta&#x2010;Analysis of Longitudinal Studies,&#x201d; Radiotherapy and Oncology 202 (2025): 110649.</Citation></Reference><Reference><Citation>F. E. van Beek, F. Jansen, L. Mak, et&#xa0;al., &#x201c;The Course of Symptoms of Anxiety and Depression From Time of Diagnosis up to 2&#x2009;Years Follow&#x2010;Up in Head and Neck Cancer Patients Treated With Primary (Chemo)radiation,&#x201d; Oral Oncology 102 (2020): 104576.</Citation></Reference><Reference><Citation>C. E. Low, C. E. Yau, R. Y. Tan, et&#xa0;al., &#x201c;Association of Depression With All&#x2010;Cause and Cancer&#x2010;Specific Mortality in Older Adults With Cancer: Systematic Review, Meta&#x2010;Analysis, and Meta&#x2010;Regression,&#x201d; Journal of Geriatric Oncology 15, no. 4 (2024): 101700.</Citation></Reference><Reference><Citation>Y. H. Wang, J. Q. Li, J. F. Shi, et&#xa0;al., &#x201c;Depression and Anxiety in Relation to Cancer Incidence and Mortality: A Systematic Review and Meta&#x2010;Analysis of Cohort Studies,&#x201d; Molecular Psychiatry 25, no. 7 (2020): 1487&#x2013;1499.</Citation></Reference><Reference><Citation>Y. Zeng, C. H. Hu, Y. Z. Li, et&#xa0;al., &#x201c;Association Between Pretreatment Emotional Distress and Immune Checkpoint Inhibitor Response in Non&#x2010;Small&#x2010;Cell Lung Cancer,&#x201d; Nature Medicine 30, no. 6 (2024): 1680&#x2013;1688.</Citation></Reference><Reference><Citation>Y. Qi, X. Hu, Y. Yao, and C. Li, &#x201c;Digital Barrier and Depressive Disorders in Older Chinese Adults: Policy Implications,&#x201d; Innovation Medicine 3, no. 2 (2025): 100127.</Citation></Reference><Reference><Citation>R. L. Venchiarutti, R. Kapoor, J. R. Clark, C. E. Palme, and J. M. Young, &#x201c;Interventions to Reduce Times to Diagnosis and Treatment of Head and Neck Cancer: A Systematic Review and Narrative Synthesis,&#x201d; Head &amp; Neck 45, no. 6 (2023): 1333&#x2013;1358.</Citation></Reference><Reference><Citation>J. Gigliotti, S. Madathil, and N. Makhoul, &#x201c;Delays in Oral Cavity Cancer,&#x201d; International Journal of Oral and Maxillofacial Surgery 48, no. 9 (2019): 1131&#x2013;1137.</Citation></Reference><Reference><Citation>H. W. Schutte, F. Heutink, D. J. Wellenstein, et&#xa0;al., &#x201c;Impact of Time to Diagnosis and Treatment in Head and Neck Cancer: A Systematic Review,&#x201d; Otolaryngology&#x2010;Head and Neck Surgery 162, no. 4 (2020): 446&#x2013;457.</Citation></Reference><Reference><Citation>C. J. Rygalski, S. Zhao, A. Eskander, et&#xa0;al., &#x201c;Time to Surgery and Survival in Head and Neck Cancer,&#x201d; Annals of Surgical Oncology 28, no. 2 (2020): 877&#x2013;885.</Citation></Reference><Reference><Citation>A. L. Fenech, G. M. Humphris, J. P. Laurenceau, et&#xa0;al., &#x201c;Anxiety, Depression, and Fear of Cancer Recurrence in Head and Neck Cancer,&#x201d; Health Psychology 43, no. 11 (2024): 803&#x2013;812.</Citation></Reference><Reference><Citation>Z. Balogun, L. A. Gardiner, J. Li, E. A. Moroni, M. Rosenzweig, and M. L. Nilsen, &#x201c;Neighborhood Deprivation and Symptoms, Psychological Distress, and Quality of Life Among Head and Neck Cancer Survivors,&#x201d; JAMA Otolaryngology. Head &amp; Neck Surgery 150, no. 4 (2024): 295.</Citation></Reference><Reference><Citation>A. Hinz, P. Y. Herzberg, F. Lordick, et&#xa0;al., &#x201c;Age and Gender Differences in Anxiety and Depression in Cancer Patients Compared With the General Population,&#x201d; European Journal of Cancer Care 28, no. 5 (2019): e13129.</Citation></Reference><Reference><Citation>N. C. Donner and C. A. Lowry, &#x201c;Sex Differences in Anxiety and Emotional Behavior,&#x201d; Pfl&#xfc;gers Archiv &#x2013; European Journal of Physiology 465, no. 5 (2013): 601&#x2013;626.</Citation></Reference><Reference><Citation>N. C. Jacobson and M. G. Newman, &#x201c;Anxiety and Depression as Bidirectional Risk Factors for One Another: A Meta&#x2010;Analysis of Longitudinal Studies,&#x201d; Psychological Bulletin 143, no. 11 (2017): 1155&#x2013;1200.</Citation></Reference><Reference><Citation>H. Liu, L. Peng, L. Zhang, et&#xa0;al., &#x201c;Predictive Value of Three Comorbidity Indices for Survival Endpoints in Oral Squamous Cell Carcinoma,&#x201d; Oral Oncology 167 (2025): 107443.</Citation></Reference><Reference><Citation>Q. Xu, C. Wang, B. Li, et&#xa0;al., &#x201c;The Impact of Age on Oral Squamous Cell Carcinoma: A Longitudinal Cohort Study of 2,782 Patients,&#x201d; Oral Diseases 25, no. 3 (2019): 730&#x2013;741.</Citation></Reference><Reference><Citation>C. Wang, Y. Pan, Q. Xu, et&#xa0;al., &#x201c;Relationship Between Body Mass Index and Outcomes for Patients With Oral Squamous Cell Carcinoma,&#x201d; Oral Diseases 25, no. 1 (2019): 87&#x2013;96.</Citation></Reference><Reference><Citation>L. Xiong, H. Yu, W. Wei, et&#xa0;al., &#x201c;Chemotherapy for Primary Cancer Can Reduce the Risk of Head and Neck Second Primary Malignancy: A Propensity&#x2010;Matched Analysis,&#x201d; Clinical Oral Investigations 27, no. 2 (2023): 571&#x2013;580.</Citation></Reference><Reference><Citation>Y. Oikawa, S. Suzuki, H. Igarashi, et&#xa0;al., &#x201c;Prognostic Impact of Age and Treatment Strategies in Elderly Patients With Oral Squamous Cell Carcinoma: An 11&#x2010;Year Retrospective Analysis,&#x201d; Head &amp; Neck (2025).</Citation></Reference><Reference><Citation>C. T. Murphy, T. J. Galloway, E. A. Handorf, et&#xa0;al., &#x201c;Increasing Time to Treatment Initiation for Head and Neck Cancer: An Analysis of the National Cancer Database,&#x201d; Cancer 121, no. 8 (2015): 1204&#x2013;1213.</Citation></Reference><Reference><Citation>S. Zaveri, D. Nevid, M. Ru, et&#xa0;al., &#x201c;Racial Disparities in Time to Treatment Persist in the Setting of a Comprehensive Breast Center,&#x201d; Annals of Surgical Oncology 29, no. 11 (2022): 6692&#x2013;6703.</Citation></Reference><Reference><Citation>P. Jimenez&#x2010;Labaig, C. Aymerich, I. Brana, et&#xa0;al., &#x201c;A Comprehensive Examination of Mental Health in Patients With Head and Neck Cancer: Systematic Review and Meta&#x2010;Analysis,&#x201d; JNCI Cancer Spectrum 8, no. 3 (2024): pkae031.</Citation></Reference><Reference><Citation>V. Budach and I. Tinhofer, &#x201c;Novel Prognostic Clinical Factors and Biomarkers for Outcome Prediction in Head and Neck Cancer: A Systematic Review,&#x201d; Lancet Oncology 20, no. 6 (2019): e313&#x2013;e326.</Citation></Reference><Reference><Citation>M. Dionisi&#x2010;Vici, M. Fantoni, R. Botto, et&#xa0;al., &#x201c;Distress, Anxiety, Depression and Unmet Needs in Thyroid Cancer Survivors: A Longitudinal Study,&#x201d; Endocrine 74, no. 3 (2021): 603&#x2013;610.</Citation></Reference><Reference><Citation>H. Fu, D. Zhao, L. Sun, Y. Huang, and X. Ma, &#x201c;Identification of Autophagy&#x2010;Related Biomarker and Analysis of Immune Infiltrates in Oral Carcinoma,&#x201d; Journal of Clinical Laboratory Analysis 36, no. 5 (2022): e24417.</Citation></Reference><Reference><Citation>L. Boguszewicz, A. Heyda, M. Ciszek, et&#xa0;al., &#x201c;Metabolite Biomarkers of Prolonged and Intensified Pain and Distress in Head and Neck Cancer Patients Undergoing Radio&#x2010; or Chemoradiotherapy by Means of NMR&#x2010;Based Metabolomics&#x2014;A Preliminary Study,&#x201d; Metabolites 14, no. 1 (2024): 60.</Citation></Reference><Reference><Citation>H. Houston, I. Beck, C. Albert, et&#xa0;al., &#x201c;Anxiety Symptoms Predict Head and Neck Cancer Survival: Exploring Mediation by Systemic Inflammation and Tumor Response to Treatment,&#x201d; Psycho&#x2010;Oncology 33, no. 7 (2024): e6375.</Citation></Reference><Reference><Citation>E. Cash, C. Albert, I. Palmer, et&#xa0;al., &#x201c;Depressive Symptoms, Systemic Inflammation, and Survival Among Patients With Head and Neck Cancer,&#x201d; JAMA Otolaryngology. Head &amp; Neck Surgery 150, no. 5 (2024): 405&#x2013;413.</Citation></Reference><Reference><Citation>L. Dinapoli, N. Dinapoli, E. Marconi, et&#xa0;al., &#x201c;Gender Role in Radiotherapy: Psychosocial Differences Between Males and Females During Cancer Care: Single&#x2010;Centre Report on Adult and Paediatric Oncological Patients,&#x201d; Strahlentherapie und Onkologie (2025), https://doi.org/10.1007/s00066&#x2010;025&#x2010;02379&#x2010;y.</Citation></Reference><Reference><Citation>P. Jehn, S. S. Linsen, A. N. Zeller, et&#xa0;al., &#x201c;Gender&#x2010;Specific Differences Concerning Psychosocial Aspects and Functional Impairments That Influence Quality of Life in Oral Cancer Treatment,&#x201d; Supportive Care in Cancer 30, no. 6 (2022): 4905&#x2013;4915.</Citation></Reference><Reference><Citation>Y. Min, Z. Liu, R. Huang, et&#xa0;al., &#x201c;Survival Outcomes Following Treatment Delays Among Patients With Early&#x2010;Stage Female Cancers: A Nationwide Study,&#x201d; Journal of Translational Medicine 20, no. 1 (2022): 560.</Citation></Reference><Reference><Citation>E. L. Zeilinger, C. Oppenauer, M. Knefel, et&#xa0;al., &#x201c;Prevalence of Anxiety and Depression in People With Different Types of Cancer or Haematologic Malignancies: A Cross&#x2010;Sectional Study,&#x201d; Epidemiology and Psychiatric Sciences 31 (2022): 31.</Citation></Reference><Reference><Citation>D. A. Bangasser and A. Cuarenta, &#x201c;Sex Differences in Anxiety and Depression: Circuits and Mechanisms,&#x201d; Nature Reviews. Neuroscience 22, no. 11 (2021): 674&#x2013;684.</Citation></Reference><Reference><Citation>E. S. Williams, C. E. Manning, A. L. Eagle, et&#xa0;al., &#x201c;Androgen&#x2010;Dependent Excitability of Mouse Ventral Hippocampal Afferents to Nucleus Accumbens Underlies Sex&#x2010;Specific Susceptibility to Stress,&#x201d; Biological Psychiatry 87, no. 6 (2020): 492&#x2013;501.</Citation></Reference><Reference><Citation>N. Zhang, S. Zhao, Y. Ma, et&#xa0;al., &#x201c;Hyperexcitation of ovBNST CRF Neurons During Stress Contributes to Female&#x2010;Biased Expression of Anxiety&#x2010;Like Avoidance Behaviors,&#x201d; Science Advances 10, no. 19 (2024): eadk7636.</Citation></Reference><Reference><Citation>M. B. Howren, A. J. Christensen, L. H. Karnell, and G. F. Funk, &#x201c;Psychological Factors Associated With Head and Neck Cancer Treatment and Survivorship: Evidence and Opportunities for Behavioral Medicine,&#x201d; Journal of Consulting and Clinical Psychology 81, no. 2 (2013): 299&#x2013;317.</Citation></Reference><Reference><Citation>W. K. So, R. J. Chan, D. N. Chan, et&#xa0;al., &#x201c;Quality&#x2010;of&#x2010;Life Among Head and Neck Cancer Survivors at One Year After Treatment &#x2013; A Systematic Review,&#x201d; European Journal of Cancer 48, no. 15 (2012): 2391&#x2013;2408.</Citation></Reference><Reference><Citation>L. H. A. Korsten, F. Jansen, B. J. F. de Haan, et&#xa0;al., &#x201c;Factors Associated With Depression Over Time in Head and Neck Cancer Patients: A Systematic Review,&#x201d; Psycho&#x2010;Oncology 28, no. 6 (2019): 1159&#x2013;1183.</Citation></Reference><Reference><Citation>S. C. Oancea and V. K. Cheruvu, &#x201c;Psychological Distress Among Adult Cancer Survivors: Importance of Survivorship Care Plan,&#x201d; Supportive Care in Cancer 24, no. 11 (2016): 4523&#x2013;4531.</Citation></Reference><Reference><Citation>C. Shunmuga Sundaram, H. M. Dhillon, P. N. Butow, P. Sundaresan, and C. Rutherford, &#x201c;A Systematic Review of Body Image Measures for People Diagnosed With Head and Neck Cancer (HNC),&#x201d; Supportive Care in Cancer 27, no. 10 (2019): 3657&#x2013;3666.</Citation></Reference><Reference><Citation>Z. A. K. Frosch, L. M. Jacobs, C. S. O'Brien, et&#xa0;al., &#x201c;&#x2018;Cancer's a Demon&#x2019;: A Qualitative Study of Fear and Multilevel Factors Contributing to Cancer Treatment Delays,&#x201d; Supportive Care in Cancer 32, no. 1 (2023): 13.</Citation></Reference><Reference><Citation>H. L. Peng, Y. H. Chen, H. Y. Lee, et&#xa0;al., &#x201c;Factors Associated With Shame and Stigma Among Head and Neck Cancer Patients: A Cross&#x2010;Sectional Study,&#x201d; Supportive Care in Cancer 32, no. 6 (2024): 357.</Citation></Reference><Reference><Citation>A. Ivanova, R. Rodr&#xed;guez&#x2010;Cano, I. L. Kvalem, D. Harcourt, C. E. Kiserud, and C. D. Amdal, &#x201c;Body Image Concerns in Long&#x2010;Term Head and Neck Cancer Survivors: Prevalence and Role of Clinical Factors and Patient&#x2010;Reported Late Effects,&#x201d; Journal of Cancer Survivorship 17, no. 2 (2023): 526&#x2013;534.</Citation></Reference><Reference><Citation>C. Chen, J. Cao, L. Wang, R. Zhang, H. Li, and J. Peng, &#x201c;Body Image and Its Associated Factors Among Chinese Head and Neck Cancer Patients Undergoing Surgical Treatment: A Cross&#x2010;Sectional Survey,&#x201d; Supportive Care in Cancer 28, no. 3 (2020): 1233&#x2013;1239.</Citation></Reference><Reference><Citation>H. G&#xf6;tze, M. Friedrich, S. Taubenheim, A. Dietz, F. Lordick, and A. Mehnert, &#x201c;Depression and Anxiety in Long&#x2010;Term Survivors 5 and 10&#x2009;Years After Cancer Diagnosis,&#x201d; Supportive Care in Cancer 28, no. 1 (2020): 211&#x2013;220.</Citation></Reference><Reference><Citation>B. L. Andersen, C. Lacchetti, K. Ashing, et&#xa0;al., &#x201c;Management of Anxiety and Depression in Adult Survivors of Cancer: ASCO Guideline Update,&#x201d; Journal of Clinical Oncology 41, no. 18 (2023): 3426&#x2013;3453.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70102 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41273066</PMID><DateRevised><Year>2025</Year><Month>11</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Nov</Month><Day>21</Day></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Tracheostomy in Flap-Based Head and Neck Cancer Surgery: A Meta-Analysis of Indications and Adverse Outcomes.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70102</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Tracheostomy is frequently performed during flap-based reconstruction for head and neck cancer, but predictive factors and complications are not well established.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A systematic review and meta-analysis was conducted per PRISMA guidelines. Studies of adult patients undergoing free or pedicled flap reconstruction were included. Pooled tracheostomy rates, predictors, and complications were analyzed using random-effects models. Heterogeneity was assessed with the I<sup>2</sup> statistic.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Twenty-six studies (27&#x2009;029 patients) were included. The pooled tracheostomy rate was 54.6%, decreasing to 42.4% when routine tracheostomy studies were excluded. Advanced tumor stage, oropharyngeal site, bilateral neck dissection, prior radiotherapy, and smoking predicted tracheostomy. Flap type was not significantly associated. The overall complication rate was 16.3%, including airway issues (2.6%). No significant change in tracheostomy rates was observed over 30&#x2009;years.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Tracheostomy use is influenced by tumor, surgical, and patient factors. Selective tracheostomy and validated risk tools may improve outcomes. Further prospective studies are needed.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). Head &amp; Neck published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chowdhury</LastName><ForeName>Raisa</ForeName><Initials>R</Initials><Identifier Source="ORCID">0009-0000-5433-5808</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine and Health Sciences, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tran</LastName><ForeName>Khanh Linh</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Division of Otolaryngology, Department of Surgery, University of British Columbia, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Otolaryngology - Head and Neck Surgery, Vancouver General Hospital, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karimi</LastName><ForeName>Naser</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kahlon</LastName><ForeName>Jhorrit</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Royal College of Surgeons in Ireland, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>K&#xfc;rten</LastName><ForeName>Cornelius</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Otolaryngology, Department of Surgery, University of British Columbia, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Otolaryngology - Head and Neck Surgery, Vancouver General Hospital, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turkdogan</LastName><ForeName>Sena</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Otolaryngology, Department of Surgery, University of British Columbia, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Otolaryngology - Head and Neck Surgery, Vancouver General Hospital, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prisman</LastName><ForeName>Eitan</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-7201-6181</Identifier><AffiliationInfo><Affiliation>Division of Otolaryngology, Department of Surgery, University of British Columbia, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Otolaryngology - Head and Neck Surgery, Vancouver General Hospital, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>11</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">airway</Keyword><Keyword MajorTopicYN="N">flaps</Keyword><Keyword MajorTopicYN="N">head and neck</Keyword><Keyword MajorTopicYN="N">operative</Keyword><Keyword MajorTopicYN="N">oral cancer</Keyword><Keyword MajorTopicYN="N">tracheostomy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>10</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>7</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>11</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>11</Month><Day>22</Day><Hour>3</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41273066</ArticleId><ArticleId IdType="doi">10.1002/hed.70102</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>J. Thariat, F. Carsuzaa, A. Beddok, et&#xa0;al., &#x201c;Reconstructive Flap Surgery in Head and Neck Cancer Patients: An Interdisciplinary View of the Challenges Encountered by Radiation Oncologists in Postoperative Radiotherapy,&#x201d; Frontiers in Oncology 14 (2024): 1379861, https://doi.org/10.3389/fonc.2024.1379861.</Citation></Reference><Reference><Citation>N. H. Cheung and L. M. Napolitano, &#x201c;Tracheostomy: Epidemiology, Indications, Timing, Technique, and Outcomes,&#x201d; Respiratory Care 59, no. 6 (2014): 895&#x2013;919, https://doi.org/10.4187/respcare.02971.</Citation></Reference><Reference><Citation>M. Marsh, S. Elliott, R. Anand, and P. Brennan, &#x201c;Early Postoperative Care for Free Flap Head &amp; Neck Reconstructive Surgery&#x2014;A National Survey of Practice,&#x201d; British Journal of Oral and Maxillofacial Surgery 47, no. 3 (2008): 182&#x2013;185, https://doi.org/10.1016/j.bjoms.2008.06.004.</Citation></Reference><Reference><Citation>C. Meerwein, T. P&#xe9;zier, B. Beck&#x2010;Schimmer, S. Schmid, and G. Huber, &#x201c;Airway Management in Head and Neck Cancer Patients Undergoing Microvascular Free Tissue Transfer: Delayed Extubation as an Alternative to Routine Tracheotomy,&#x201d; Schweizerische Medizinische Wochenschrift 144 (2014): w13941, https://doi.org/10.4414/smw.2014.13941.</Citation></Reference><Reference><Citation>R. Dawson, D. Phung, J. Every, et&#xa0;al., &#x201c;Tracheostomy in Free&#x2010;Flap Reconstruction of the Oral Cavity: Can It Be Avoided? A Cohort Study of 187 Patients,&#x201d; ANZ Journal of Surgery 91, no. 6 (2021): 1246&#x2013;1250, https://doi.org/10.1111/ans.16762.</Citation></Reference><Reference><Citation>M. Cameron, A. Corner, A. Diba, and M. Hankins, &#x201c;Development of a Tracheostomy Scoring System to Guide Airway Management After Major Head and Neck Surgery,&#x201d; International Journal of Oral and Maxillofacial Surgery 38, no. 8 (2009): 846&#x2013;849, https://doi.org/10.1016/j.ijom.2009.03.713.</Citation></Reference><Reference><Citation>M. K. Abril, D. M. Berkowitz, Y. Chen, L. A. Waller, G. S. Martin, and J. A. Kempker, &#x201c;The Epidemiology of Adult Tracheostomy in the United States 2002&#x2013;2017: A Serial Cross&#x2010;Sectional Study,&#x201d; Critical Care Explorations 3, no. 9 (2021): e0523, https://doi.org/10.1097/cce.0000000000000523.</Citation></Reference><Reference><Citation>P. Tugwell and D. Tovey, &#x201c;PRISMA 2020,&#x201d; Journal of Clinical Epidemiology 134 (2021): A5&#x2013;A6, https://doi.org/10.1016/j.jclinepi.2021.04.008.</Citation></Reference><Reference><Citation>S. Sideri, S. N. Papageorgiou, and T. Eliades, &#x201c;Registration in the International Prospective Register of Systematic Reviews (PROSPERO) of Systematic Review Protocols Was Associated With Increased Review Quality,&#x201d; Journal of Clinical Epidemiology 100 (2018): 103&#x2013;110, https://doi.org/10.1016/j.jclinepi.2018.01.003.</Citation></Reference><Reference><Citation>J. Babineau, &#x201c;Product Review: Covidence (Systematic Review Software),&#x201d; Journal of the Canadian Health Libraries Association/Journal De L'association des Biblioth&#xe8;ques De La Sant&#xe9; Du Canada 35, no. 2 (2014): 68, https://doi.org/10.5596/c14&#x2010;016.</Citation></Reference><Reference><Citation>E. Flemyng, T. H. Moore, I. Boutron, et&#xa0;al., &#x201c;Using Risk of Bias 2 to Assess Results From Randomised Controlled Trials: Guidance From Cochrane,&#x201d; BMJ Evidence&#x2010;Based Medicine 28, no. 4 (2023): 260&#x2013;266, https://doi.org/10.1136/bmjebm&#x2010;2022&#x2010;112102.</Citation></Reference><Reference><Citation>Z. Munn, E. Aromataris, C. Tufanaru, et&#xa0;al., &#x201c;The Development of Software to Support Multiple Systematic Review Types,&#x201d; International Journal of Evidence&#x2010;Based Healthcare 17, no. 1 (2018): 36&#x2013;43, https://doi.org/10.1097/xeb.0000000000000152.</Citation></Reference><Reference><Citation>M. Borenstein, L. V. Hedges, J. P. T. Higgins, and H. R. Rothstein, &#x201c;A Basic Introduction to Fixed&#x2010;Effect and Random&#x2010;Effects Models for Meta&#x2010;Analysis,&#x201d; Research Synthesis Methods 1, no. 2 (2010): 97&#x2013;111, https://doi.org/10.1002/jrsm.12.</Citation></Reference><Reference><Citation>F. Schoonjans, A. Zalata, C. E. Depuydt, and F. H. Comhaire, &#x201c;MedCalc: A New Computer Program for Medical Statistics,&#x201d; Computer Methods and Programs in Biomedicine 48, no. 3 (1995): 257&#x2013;262, https://doi.org/10.1016/0169&#x2010;2607(95)01703&#x2010;8.</Citation></Reference><Reference><Citation>Y. Leiser, M. Barak, Y. Ghantous, N. Yehudai, and I. A. El&#x2010;Naaj, &#x201c;Indications for Elective Tracheostomy in Reconstructive Surgery in Patients With Oral Cancer,&#x201d; Journal of Craniofacial Surgery 28, no. 1 (2016): e18&#x2013;e22, https://doi.org/10.1097/scs.0000000000003168.</Citation></Reference><Reference><Citation>T. Cai, W. Zhang, Y. Yu, et&#xa0;al., &#x201c;Scoring System for Selective Tracheostomy in Head and Neck Surgery With Free Flap Reconstruction,&#x201d; Head &amp; Neck 42, no. 3 (2020): 476&#x2013;484, https://doi.org/10.1002/hed.26028.</Citation></Reference><Reference><Citation>A. Adhikari, A. Noor, M. Mair, et&#xa0;al., &#x201c;Comparison of Postoperative Complications in Early Versus Delayed Tracheostomy Decannulation in Patients Undergoing Oral Cancer Surgery With Microvascular Reconstruction,&#x201d; British Journal of Oral and Maxillofacial Surgery 61, no. 1 (2023): 101&#x2013;106, https://doi.org/10.1016/j.bjoms.2022.11.285.</Citation></Reference><Reference><Citation>B. Castling, M. Telfer, and B. Avery, &#x201c;Complications of Tracheostomy in Major Head and Neck Cancer Surgery; a Retrospective Study of 60 Consecutive Cases,&#x201d; British Journal of Oral and Maxillofacial Surgery 32, no. 1 (1994): 3&#x2013;5, https://doi.org/10.1016/0266&#x2010;4356(94)90162&#x2010;7.</Citation></Reference><Reference><Citation>X. Chen, Y. Chen, S. Gokavarapu, Q. Shen, and T. Ji, &#x201c;Free Flap Reconstruction for Patients Aged 85&#x2009;Years and Over With Head and Neck Cancer: Clinical Considerations for Comprehensive Care,&#x201d; British Journal of Oral and Maxillofacial Surgery 55, no. 8 (2017): 793&#x2013;797, https://doi.org/10.1016/j.bjoms.2017.07.003.</Citation></Reference><Reference><Citation>K. P. Davis, A. Kompelli, J. R. Gardner, et&#xa0;al., &#x201c;Postoperative and 1&#x2010;Year Functional Outcomes After Free Flap Surgery Among Patients 80&#x2009;Years or Older,&#x201d; Otolaryngology 167, no. 1 (2022): 41&#x2013;47, https://doi.org/10.1177/01945998221083592.</Citation></Reference><Reference><Citation>E. Esteller, A. Ag&#xfc;ero, M. Martel, M. L&#xf3;pez, M. Quer, and X. Le&#xf3;n, &#x201c;Stomal Recurrence in Head and Neck Cancer Patients With Temporary Tracheostomy,&#x201d; Auris Nasus Larynx 41, no. 5 (2014): 467&#x2013;470, https://doi.org/10.1016/j.anl.2014.02.003.</Citation></Reference><Reference><Citation>K. Gupta, D. Mandlik, D. Patel, et&#xa0;al., &#x201c;Clinical Assessment Scoring System for Tracheostomy (CASST) Criterion: Objective Criteria to Predict Pre&#x2010;Operatively the Need for a Tracheostomy in Head and Neck Malignancies,&#x201d; Journal of Cranio&#x2010;Maxillofacial Surgery 44, no. 9 (2016): 1310&#x2013;1313, https://doi.org/10.1016/j.jcms.2016.07.008.</Citation></Reference><Reference><Citation>W. Halfpenny and M. McGurk, &#x201c;Analysis of Tracheostomy&#x2010;Associated Morbidity After Operations for Head and Neck Cancer,&#x201d; British Journal of Oral and Maxillofacial Surgery 38, no. 5 (2000): 509&#x2013;512, https://doi.org/10.1054/bjom.2000.0310.</Citation></Reference><Reference><Citation>B. Kruse&#x2010;L&#xf6;sler, E. Langer, A. Reich, U. Joos, and J. Kleinheinz, &#x201c;Score System for Elective Tracheotomy in Major Head and Neck Tumour Surgery,&#x201d; Acta Anaesthesiologica Scandinavica 49, no. 5 (2005): 654&#x2013;659, https://doi.org/10.1111/j.1399&#x2010;6576.2005.00655.x.</Citation></Reference><Reference><Citation>H. J. Lee, Y. Park, R. Kim, S. Kang, and I. Nam, &#x201c;Feasibility of Percutaneous Dilatational Tracheotomy in Head and Neck Cancer Surgery: A Preliminary Study,&#x201d; International Surgery 106, no. 1 (2022): 27&#x2013;31, https://doi.org/10.9738/intsurg&#x2010;d&#x2010;21&#x2010;00015.1.</Citation></Reference><Reference><Citation>O. Madgar, N. Livneh, A. Dobriyan, E. Dagan, and E. E. Alon, &#x201c;Airway Management Following Head and Neck Microvascular Reconstruction: Is Tracheostomy Mandatory?,&#x201d; Brazilian Journal of Otorhinolaryngology 88 (2022): S44&#x2013;S49, https://doi.org/10.1016/j.bjorl.2021.07.007.</Citation></Reference><Reference><Citation>C. Malata, I. Foo, K. Simpson, and A. Batchelor, &#x201c;An Audit of Bjork Flap Tracheostomies in Head and Neck Plastic Surgery,&#x201d; British Journal of Oral and Maxillofacial Surgery 34, no. 1 (1996): 42&#x2013;46, https://doi.org/10.1016/s0266&#x2010;4356(96)90134&#x2010;5.</Citation></Reference><Reference><Citation>J. McDevitt, M. De Camargo Cancela, M. Kelly, H. Comber, and L. Sharp, &#x201c;Tracheostomy and Infection Prolong Length of Stay in Hospital After Surgery for Head and Neck Cancer: A Population Based Study,&#x201d; Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology 121, no. 1 (2016): 22&#x2013;28.e1, https://doi.org/10.1016/j.oooo.2015.08.004.</Citation></Reference><Reference><Citation>J. Meier, M. Wunschel, A. Angermann, et&#xa0;al., &#x201c;Influence of Early Elective Tracheostomy on the Incidence of Postoperative Complications in Patients Undergoing Head and Neck Surgery,&#x201d; BMC Anesthesiology 19, no. 1 (2019): 43, https://doi.org/10.1186/s12871&#x2010;019&#x2010;0715&#x2010;9.</Citation></Reference><Reference><Citation>H. Mohamedbhai, S. Ali, I. Dimasi, and N. Kalavrezos, &#x201c;TRACHY Score: A Simple and Effective Guide to Management of the Airway in Head and Neck Cancer,&#x201d; British Journal of Oral and Maxillofacial Surgery 56, no. 8 (2018): 709&#x2013;714, https://doi.org/10.1016/j.bjoms.2018.07.015.</Citation></Reference><Reference><Citation>R. Nagarkar, G. Kokane, A. Wagh, et&#xa0;al., &#x201c;Airway Management Techniques in Head and Neck Cancer Surgeries: A Retrospective Analysis,&#x201d; Oral and Maxillofacial Surgery 23, no. 3 (2019): 311&#x2013;315, https://doi.org/10.1007/s10006&#x2010;019&#x2010;00782&#x2010;1.</Citation></Reference><Reference><Citation>A. Siddiqui, S. Dogar, S. Lal, S. Akhtar, and F. Khan, &#x201c;Airway Management and Postoperative Length of Hospital Stay in Patients Undergoing Head and Neck Cancer Surgery,&#x201d; Journal of Anaesthesiology Clinical Pharmacology 32, no. 1 (2016): 49&#x2013;53, https://doi.org/10.4103/0970&#x2010;9185.173341.</Citation></Reference><Reference><Citation>P. Tassone, M. Wieser, A. Givens, et&#xa0;al., &#x201c;Factors Leading to Gastrostomy Tube and Tracheostomy Requirements in Patients Treated Initially With Radiotherapy and Salvaged With Surgery and Free Flap Reconstruction,&#x201d; Laryngoscope 133, no. 9 (2022): 2141&#x2013;2147, https://doi.org/10.1002/lary.30514.</Citation></Reference><Reference><Citation>S. Xu, K. Wang, K. Liu, et&#xa0;al., &#x201c;Predictive Nomogram for the Necessity of Tracheotomy During Oral and Oropharyngeal Cancer Surgery,&#x201d; Laryngoscope 131, no. 5 (2021): 1489&#x2013;1495, https://doi.org/10.1002/lary.29121.</Citation></Reference><Reference><Citation>A. J. Holcomb, A. White, E. Rossman, et&#xa0;al., &#x201c;Tracheostomy Avoidance in Flap Reconstruction of the Upper Aerodigestive Tract Is Safe in Selected Patients,&#x201d; Otolaryngology 172 (2025): 100&#x2013;109, https://doi.org/10.1002/ohn.963.</Citation></Reference><Reference><Citation>A. Abdelrahman, N. Turton, M. R. Idle, P. Praveen, T. Martin, and S. Parmar, &#x201c;Percutaneous Tracheostomy in Head and Neck Oncology Surgery: How COVID&#x2010;19 Changed Our Practice,&#x201d; Advances in Oral and Maxillofacial Surgery 10 (2023): 100422, https://doi.org/10.1016/j.adoms.2023.100422.</Citation></Reference><Reference><Citation>A. Gupta, T. A. Poorna, and V. N. Khismatrao, &#x201c;Can Prophylactic Tracheostomy Be Avoided in Advanced Oral Cancer Surgery for Airway Management? An Experience and Guidelines From a Tertiary Care Facility,&#x201d; Journal of Maxillofacial and Oral Surgery 23, no. 4 (2024): 918&#x2013;922, https://doi.org/10.1007/s12663&#x2010;024&#x2010;02237&#x2010;x.</Citation></Reference><Reference><Citation>K. Fang, C. Kang, L. Lee, et&#xa0;al., &#x201c;Prognostic Impact of Elective Tracheotomy in Resected Oral Cavity Squamous Cell Carcinoma: A Nationwide Cohort Study,&#x201d; Cancer Medicine 13, no. 12 (2024): e7213, https://doi.org/10.1002/cam4.7213.</Citation></Reference><Reference><Citation>Y. Kim, J. Yang, Y. Ma, et&#xa0;al., &#x201c;Efficacy of Tracheostomy for Respiratory Management in Patients With Advanced Oral Cancer,&#x201d; Maxillofacial Plastic and Reconstructive Surgery 46, no. 1 (2024): 28, https://doi.org/10.1186/s40902&#x2010;024&#x2010;00439&#x2010;4.</Citation></Reference><Reference><Citation>J. D. Cramer, S. Samant, E. Greenbaum, and U. A. Patel, &#x201c;Association of Airway Complications With Free Tissue Transfer to the Upper Aerodigestive Tract With or Without Tracheotomy,&#x201d; JAMA Otolaryngology. Head &amp; Neck Surgery 142, no. 12 (2016): 1177&#x2013;1183, https://doi.org/10.1001/jamaoto.2016.2002.</Citation></Reference><Reference><Citation>N. R. Haddaway, M. J. Page, C. C. Pritchard, and L. A. McGuinness, &#x201c;PRISMA2020: An R Package and Shiny App for Producing PRISMA 2020&#x2010;Compliant Flow Diagrams, With Interactivity for Optimised Digital Transparency and Open Synthesis,&#x201d; Campbell Systematic Reviews 18, no. 2 (2022): e1230, https://doi.org/10.1002/cl2.1230.</Citation></Reference><Reference><Citation>A. Stang, &#x201c;Critical Evaluation of the Newcastle&#x2010;Ottawa Scale for the Assessment of the Quality of Nonrandomized Studies in Meta&#x2010;Analyses,&#x201d; European Journal of Epidemiology 25, no. 9 (2010): 603&#x2013;605, https://doi.org/10.1007/s10654&#x2010;010&#x2010;9491&#x2010;z.</Citation></Reference><Reference><Citation>J. Lau, J. P. A. Ioannidis, N. Terrin, C. H. Schmid, and I. Olkin, &#x201c;The Case of the Misleading Funnel Plot,&#x201d; BMJ 333, no. 7568 (2006): 597&#x2013;600, https://doi.org/10.1136/bmj.333.7568.597.</Citation></Reference><Reference><Citation>F. Eissner, G. Haymerle, and M. Brunner, &#x201c;Risk Factors for Acute Unplanned Tracheostomy During Panendoscopy in HNSCC Patients,&#x201d; PLoS One 13, no. 12 (2018): e0207171, https://doi.org/10.1371/journal.pone.0207171.</Citation></Reference><Reference><Citation>H. Gong, J. Wu, J. Sun, et&#xa0;al., &#x201c;Preoperative Tracheotomy in the Treatment of Upper Airway Obstruction of Patients With Advanced Stage Supraglottic Carcinoma,&#x201d; American Journal of Otolaryngology 43, no. 3 (2022): 103381, https://doi.org/10.1016/j.amjoto.2022.103381.</Citation></Reference><Reference><Citation>M. E. H. Neal, R. W. Gao, J. R. Brennan, et&#xa0;al., &#x201c;Functional Outcomes and Tracheostomy Dependence Following Salvage Oropharyngeal Surgery,&#x201d; Oral Oncology 113 (2020): 105034, https://doi.org/10.1016/j.oraloncology.2020.105034.</Citation></Reference><Reference><Citation>R. A. Dedivitis, A. V. Guimar&#xe3;es, E. G. Pfuetzenreiter, Jr., and M. a. F. De Castro, &#x201c;Complica&#xe7;&#xf5;es dos esvaziamentos cervicais,&#x201d; Brazilian Journal of Otorhinolaryngology 77, no. 1 (2011): 65&#x2013;69, https://doi.org/10.1590/s1808&#x2010;86942011000100011.</Citation></Reference><Reference><Citation>A. Mijiti, N. Kuerbantayi, Z. Q. Zhang, M. Y. Su, X. H. Zhang, and M. Huojia, &#x201c;Influence of Preoperative Radiotherapy on Head and Neck Free&#x2010;Flap Reconstruction: Systematic Review and Meta&#x2010;Analysis,&#x201d; Head &amp; Neck 42, no. 8 (2020): 2165&#x2013;2180, https://doi.org/10.1002/hed.26136.</Citation></Reference><Reference><Citation>S. D. Agustina, M. D. Wibowo, and D. H. Susilo, &#x201c;Analysis of the Performance of the TRACHY Score as a Predictive Factor for Determining the Need for Elective Tracheostomy in Patients With Head and Neck Malignancies Undergoing Extensive Excision and Reconstruction Surgery at Dr. Soetomo General Regional,&#x201d; Edelweiss Applied Science and Technology 9 (2025): 457&#x2013;466, https://doi.org/10.55214/25768484.v9i2.4511.</Citation></Reference><Reference><Citation>M. G. Moore, A. D. Bhrany, D. O. Francis, B. Yueh, and N. D. Futran, &#x201c;Use of Nasotracheal Intubation in Patients Receiving Oral Cavity Free Flap Reconstruction,&#x201d; Head and Neck 32, no. 8 (2009): 1056&#x2013;1061, https://doi.org/10.1002/hed.21291.</Citation></Reference><Reference><Citation>J. Gigliotti, G. Cheung, O. Suhaym, R. V. Agnihotram, M. El&#x2010;Hakim, and N. Makhoul, &#x201c;Nasotracheal Intubation: The Preferred Airway in Oral Cavity Microvascular Reconstructive Surgery?,&#x201d; Journal of Oral and Maxillofacial Surgery 76, no. 10 (2018): 2231&#x2013;2240, https://doi.org/10.1016/j.joms.2018.04.005.</Citation></Reference><Reference><Citation>A. Ferro, S. Kotecha, G. Auzinger, E. Yeung, and K. Fan, &#x201c;Systematic Review and Meta&#x2010;Analysis of Tracheostomy Outcomes in COVID&#x2010;19 Patients,&#x201d; British Journal of Oral &amp; Maxillofacial Surgery 59, no. 9 (2021): 1013&#x2013;1023, https://doi.org/10.1016/j.bjoms.2021.05.011.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70104 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41261809</PMID><DateRevised><Year>2025</Year><Month>11</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Nov</Month><Day>19</Day></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Fully COVID-19 Vaccinated Status Enhanced the Efficacy of Immune Checkpoint Inhibitors in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70104</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Little is known regarding the interaction between vaccination and immunotherapy in cancer patients. Herein, we conducted a retrospective study to evaluate the impact of coronavirus disease 2019 (COVID-19) vaccinated status on survival in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with immune checkpoint inhibitors (ICI).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients who were treated with ICI for their R/M HNSCC were reviewed retrospectively. Patients who received at least one shot of the vaccine against COVID-19 were recruited into our study. Patients were stratified into fully vaccinated (FV) and partially vaccinated (PV) according to their vaccination status. Kaplan-Meier curves were estimated for progression-free survival (PFS) and overall survival (OS).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 127 patients were enrolled in our study for oncologic outcomes evaluation, including 70 FV and 57 PV. For the total population, the median PFS was 4.6&#x2009;months and OS was 23.7&#x2009;months. After stratifying according to COVID-19 vaccination status, the median PFS was 6.2&#x2009;months in FV and 3.1&#x2009;months in PV (p&#x2009;=&#x2009;0.010). The median OS was 32.5&#x2009;months in FV and 10.3&#x2009;months in PV (p&#x2009;&lt;&#x2009;0.001). After the last dose of vaccination, the median neutrophil-lymphocyte ratio and platelet-lymphocyte ratio were significantly lower in FV than in PV (p&#x2009;&lt;&#x2009;0.001). No new safety issues were found in our patient cohort and were insignificant between the FV and PV groups.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">R/M HNSCC patients with FV had significantly lower NLR and PLR, and had better survival when treated with ICI without increasing treatment toxicity.</AbstractText><CopyrightInformation>&#xa9; 2025 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Chien-Chung</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology, E-Da Hospital, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Medicine, I-Shou University, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Chih-Chun</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology, E-Da Hospital, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Medicine, I-Shou University, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Chuan-Chien</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology, E-Da Hospital, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Medicine, I-Shou University, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hwang</LastName><ForeName>Tzer-Zen</ForeName><Initials>TZ</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology, E-Da Hospital, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Medicine, I-Shou University, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lien</LastName><ForeName>Ching-Feng</ForeName><Initials>CF</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology, E-Da Hospital, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Medicine, I-Shou University, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shih</LastName><ForeName>Yu-Chen</ForeName><Initials>YC</Initials><AffiliationInfo><Affiliation>College of Medicine, I-Shou University, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otolaryngology, E-Da Cancer Hospital, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yeh</LastName><ForeName>Shyh-An</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>College of Medicine, I-Shou University, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiation Oncology, E-Da Hospital, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsieh</LastName><ForeName>Meng-Che</ForeName><Initials>MC</Initials><Identifier Source="ORCID">0000-0002-1626-3396</Identifier><AffiliationInfo><Affiliation>College of Medicine, I-Shou University, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Hematology-Oncology, E-Da Cancer Hospital, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>11</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID&#x2010;19</Keyword><Keyword MajorTopicYN="N">immune checkpoint inhibitors</Keyword><Keyword MajorTopicYN="N">recurrent or metastatic head and neck squamous cell carcinoma</Keyword><Keyword MajorTopicYN="N">survival</Keyword><Keyword MajorTopicYN="N">vaccinated status</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>11</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>7</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>11</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>11</Month><Day>20</Day><Hour>1</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41261809</ArticleId><ArticleId IdType="doi">10.1002/hed.70104</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>R. L. Siegel, K. D. Miller, and A. Jemal, &#x201c;Cancer Statistics,&#x201d; CA: a Cancer Journal for Clinicians 69 (2019): 7&#x2013;34.</Citation></Reference><Reference><Citation>S. Marur and A. A. Forastiere, &#x201c;Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment,&#x201d; Mayo Clinic Proceedings 91 (2016): 386&#x2013;396.</Citation></Reference><Reference><Citation>J. B. Vermorken, R. Mesia, F. Rivera, et&#xa0;al., &#x201c;Platinum&#x2010;Based Chemotherapy Plus Cetuximab in Head and Neck Cancer,&#x201d; New England Journal of Medicine 11 (2008): 1116&#x2013;1127.</Citation></Reference><Reference><Citation>S. Trivedi, L. Sun, and C. Aggarwal, &#x201c;Immunotherapy for Head and Neck Cancer,&#x201d; Hematology/Oncology Clinics of North America 35 (2021): 1021&#x2013;1037.</Citation></Reference><Reference><Citation>E. E. W. Cohen, D. Souli&#xe8;res, C. Le Tourneau, et&#xa0;al., &#x201c;Pembrolizumab Versus Methotrexate, Docetaxel, or Cetuximab for Recurrent or Metastatic Head&#x2010;And&#x2010;Neck Squamous Cell Carcinoma (KEYNOTE&#x2010;040): A Randomised, Open&#x2010;Label, Phase 3 Study,&#x201d; Lancet 393 (2019): 156&#x2013;167.</Citation></Reference><Reference><Citation>R. L. Ferris, G. Blumenschein, Jr., J. Fayette, et&#xa0;al., &#x201c;Nivolumab for Recurrent Squamous&#x2010;Cell Carcinoma of the Head and Neck,&#x201d; New England Journal of Medicine 375 (2016): 1856&#x2013;1867.</Citation></Reference><Reference><Citation>B. Burtness, K. J. Harrington, R. Greil, et&#xa0;al., &#x201c;Pembrolizumab Alone or With Chemotherapy Versus Cetuximab With Chemotherapy for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (KEYNOTE&#x2010;048): A Randomised, Open&#x2010;Label, Phase 3 Study,&#x201d; Lancet 394 (2019): 1915&#x2013;1928.</Citation></Reference><Reference><Citation>M. Negahdaripour, &#x201c;The Battle Against COVID&#x2010;19: Where Do we Stand Now?,&#x201d; Iranian Journal of Medical Sciences 45 (2020): 30476.</Citation></Reference><Reference><Citation>A. Mandal, P. Singh, A. Samaddar, et&#xa0;al., &#x201c;Vaccination of Cancer Patients Against COVID&#x2010;19: Towards the End of a Dilemma,&#x201d; Medical Oncology 38 (2021): 92.</Citation></Reference><Reference><Citation>A. Thakkar, J. D. Gonzalez&#x2010;Lugo, N. Goradia, et&#xa0;al., &#x201c;Seroconversion Rates Following COVID&#x2010;19 Vaccination Among Patients With Cancer,&#x201d; Cancer Cell 39 (2021): 1081&#x2013;1090.</Citation></Reference><Reference><Citation>M. Negahdaripour, M. Shafiekhani, S. M. I. Moezzi, et&#xa0;al., &#x201c;Administration of COVID&#x2010;19 Vaccines in Immunocompromised Patients,&#x201d; International Immunopharmacology 99 (2021): 108021.</Citation></Reference><Reference><Citation>C. Kumarasamy, V. Tiwary, K. Sunil, et&#xa0;al., &#x201c;Prognostic Utility of Platelet&#x2010;Lymphocyte Ratio, Neutrophil&#x2010;Lymphocyte Ratio and Monocyte&#x2010;Lymphocyte Ratio in Head and Neck Cancers: A Detailed PRISMA Compliant Systematic Review and Meta&#x2010;Analysis,&#x201d; Cancers (Basel) 13 (2021): 4166.</Citation></Reference><Reference><Citation>J. Zhou, S. Wei, X. Guo, et&#xa0;al., &#x201c;Correlation Between Preoperative Peripheral Blood NLR, PLR, LMR and Prognosis of Patients With Head and Neck Squamous Cell Carcinoma,&#x201d; BMC Cancer 23 (2023): 1247.</Citation></Reference><Reference><Citation>Y. Lei, C. Cao, R. Tang, and Y. Liu, &#x201c;Peripheral Blood Inflammatory Biomarkers Neutrophil/ Lymphocyte Ratio, Platelet/Lymphocyte Ratio and Systemic Immune&#x2010;Inflammation Index/Albumin Ratio Predict Prognosis and Efficacy in Non&#x2010;Small Cell Lung Cancer Patients Receiving Immunotherapy and Opioids,&#x201d; BMC Cancer 25 (2025): 664.</Citation></Reference><Reference><Citation>S. Liao, H. Sun, H. Lu, et&#xa0;al., &#x201c;Neutrophil&#x2010;To&#x2010;Lymphocyte Ratio&#x2010;Based Prognostic Score Can Predict Outcomes in Patients With Advanced Non&#x2010;Small Cell Lung Cancer Treated With Immunotherapy Plus Chemotherapy,&#x201d; BMC Cancer 25 (2025): 697.</Citation></Reference><Reference><Citation>M. Deng, Y. Qing, D. Qiu, Y. Sheng, J. Zhou, and L. Sun, &#x201c;The Prognostic Value of Pretreatment Neutrophil&#x2010;Lymphocyte Ratio and Platelet&#x2010;Lymphocyte Ratio in Patients With Esophageal Cancer Undergoing Immunotherapy: A Systematic Review and Meta&#x2010;Analysis,&#x201d; Frontiers in Oncology 15 (2025): 1536920.</Citation></Reference><Reference><Citation>Y. Ou, S. Liang, Q. Gao, et&#xa0;al., &#x201c;Prognostic Value of Inflammatory Markers NLR, PLR, LMR, dNLR, ANC in Melanoma Patients Treated With Immune Checkpoint Inhibitors: A Meta&#x2010;Analysis and Systematic Review,&#x201d; Frontiers in Immunology 15 (2024): 1482746.</Citation></Reference><Reference><Citation>S. Tran, T. H. Truong, and A. Narendran, &#x201c;Evaluation of COVID&#x2010;19 Vaccine Response in Patients With Cancer: An Interim Analysis,&#x201d; European Journal of Cancer 159 (2021): 259&#x2013;274.</Citation></Reference><Reference><Citation>M. Bersanelli, D. Giannarelli, U. De Giorgi, et&#xa0;al., &#x201c;Symptomatic COVID&#x2010;19 in Advanced&#x2010;Cancer Patients Treated With Immune&#x2010;Checkpoint Inhibitors: Prospective Analysis From a Multicentre Observational Trial by FICOG,&#x201d; Therapeutic Advances in Medical Oncology 12 (2020): 1&#x2013;12.</Citation></Reference><Reference><Citation>B. Luo, J. Li, X. Hou, et&#xa0;al., &#x201c;Indications for and Contraindications of Immune Checkpoint Inhibitors in Cancer Patients With COVID&#x2010;19 Vaccination,&#x201d; Future Oncology 26 (2021): 3477&#x2013;3484.</Citation></Reference><Reference><Citation>S. F. Oosting, A. A. M. van der Veldt, C. H. GeurtsvanKessel, et&#xa0;al., &#x201c;mRNA&#x2010;1273 COVID&#x2010;19 Vaccination in Patients Receiving Chemotherapy, Immunotherapy, or Chemoimmunotherapy for Solid Tumours: A Prospective, Multicentre, Non&#x2010;Inferiority Trial,&#x201d; Lancet Oncology 22 (2021): 1681&#x2013;1691.</Citation></Reference><Reference><Citation>A. J. Grippin, C. Marconi, S. Copling, et&#xa0;al., &#x201c;SARS&#x2010;CoV&#x2010;2 mRNA Vaccines Sensitize Tumours to Immune Checkpoint Blockade,&#x201d; Nature 647 (2025): 488&#x2013;497.</Citation></Reference><Reference><Citation>H. B. C. L&#xe4;ubli, L. Kaufmann, M. Stanczak, et&#xa0;al., &#x201c;Influenza Vaccination of Cancer Patients During PD&#x2010;1 Blockade Induces Serological Protection but May Raise the Risk for Immune&#x2010;Related Adverse Events,&#x201d; Journal for Immunotherapy of Cancer 6 (2018): 40.</Citation></Reference><Reference><Citation>T. Gambichler, J. S. C. Reuther, and J. C. Becker, &#x201c;On the Use of Immune Checkpoint Inhibitors in Patients With Viral Infections Including COVID&#x2010;19,&#x201d; Journal for Immunotherapy of Cancer 4 (2020): 1.</Citation></Reference><Reference><Citation>F. Spagnolo, A. Boutros, E. Croce, et&#xa0;al., &#x201c;Influenza Vaccination in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Systematic Review,&#x201d; European Journal of Clinical Investigation 51 (2021): e13604.</Citation></Reference><Reference><Citation>T. Gambichler, J. Reuther, C. H. Scheel, and J. C. Becker, &#x201c;On the Use of Immune Checkpoint Inhibitors in Patients With Viral Infections Including COVID&#x2010;19,&#x201d; Journal for Immunotherapy of Cancer 8 (2020): e001145.</Citation></Reference><Reference><Citation>A. J. Widman, B. Cohen, V. Park, T. McClure, J. Wolchok, and M. Kamboj, &#x201c;Immune&#x2010;Related Adverse Events Among COVID&#x2010;19&#x2013;Vaccinated Patients With Cancer Receiving Immune Checkpoint Blockade,&#x201d; Journal of the National Comprehensive Cancer Network 20 (2022): 1134&#x2013;1138.</Citation></Reference><Reference><Citation>S. B. Strobel, D. Machiraju, K. A. K&#xe4;lber, and J. C. Hassel, &#x201c;Immune&#x2010;Related Adverse Events of COVID&#x2010;19 Vaccination in Skin Cancer Patients Receiving Immune&#x2010;Checkpoint Inhibitor Treatment,&#x201d; Cancer Immunology, Immunotherapy 71 (2022): 2051&#x2013;2056.</Citation></Reference><Reference><Citation>B. Luo, J. H. X. Li, Q. Yang, et&#xa0;al., &#x201c;Indications for and Contraindications of Immune Checkpoint Inhibitors in Cancer Patients With COVID&#x2010;19 Vaccination,&#x201d; Future Oncology 17 (2021): 3477&#x2013;3484.</Citation></Reference><Reference><Citation>P. F. Wang, Y. Chen, S. Y. Song, et&#xa0;al., &#x201c;Immune&#x2010;Related Adverse Events Associated With Anti&#x2010;PD&#x2010;1/PD&#x2010;L1 Treatment for Malignancies: A Meta&#x2010;Analysis,&#x201d; Frontiers in Pharmacology 8 (2017): 730.</Citation></Reference><Reference><Citation>Y. Qian, Z. Zhu, Y. Y. Mo, and Z. Zhang, &#x201c;COVID&#x2010;19 Vaccination Is Associated With Enhanced Efficacy of Anti&#x2010;PD&#x2010;(L) 1 Immunotherapy in Advanced NSCLC Patients: A Real&#x2010;World Study,&#x201d; Infectious Agent Cancer 18 (2023): 50.</Citation></Reference><Reference><Citation>M. C. Garassino and A. Ribas, &#x201c;At the Crossroads: COVID&#x2010;19 and Immune&#x2010;Checkpoint Blockade for Cancer,&#x201d; Cancer Immunology Research 3 (2021): 261&#x2013;264.</Citation></Reference><Reference><Citation>S. Ehmsen, A. Asmussen, S. S. Jeppesen, et&#xa0;al., &#x201c;Antibody and T Cell Immune Responses Following mRNA COVID&#x2010;19 Vaccination in Patients With Cancer,&#x201d; Cancer Cell 39 (2021): 1034&#x2013;1036.</Citation></Reference><Reference><Citation>R. Gutzmer, F. M&#xfc;ller, D. Schr&#xf6;der, et&#xa0;al., &#x201c;Immunogenicity of COVID&#x2010;19 Vaccination in Melanoma Patients Under Immune Checkpoint Blockade,&#x201d; Oncology 100 (2022): 392&#x2013;398.</Citation></Reference><Reference><Citation>J. Kattan, C. Kattan, and T. Assi, &#x201c;Do Checkpoint Inhibitors Compromise the Cancer Patients' Immunity and Increase the Vulnerability to COVID&#x2010;19 Infection?,&#x201d; Immunotherapy 12 (2020): 351&#x2013;354.</Citation></Reference><Reference><Citation>A. Fendler, E. G. E. de Vries, C. H. Geurtsvan Kessel, et&#xa0;al., &#x201c;COVID&#x2010;19 Vaccines in Patients With Cancer: Immunogenicity, Efficacy and Safety,&#x201d; Nature Reviews Clinical Oncology 19 (2022): 385&#x2013;401.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70097 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41257353</PMID><DateRevised><Year>2025</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Nov</Month><Day>19</Day></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Transoral Robotic Surgery (TORS) for Head and Neck Cancer in the Elderly Population: Functional Outcomes, Survival, and Complications.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70097</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To compare functional and oncologic outcomes in elderly (&#x2265;&#x2009;70&#x2009;years) and nonelderly (&lt;&#x2009;70&#x2009;years) patients after transoral robotic surgery (TORS).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A retrospective chart review was conducted on 114 patients who underwent TORS for head and neck squamous cell carcinoma between 2012 and 2022. Patient and tumor characteristics, perioperative details, complications, and survival parameters were analyzed. Swallowing function was assessed using the Functional Outcome Swallowing Scale (FOSS).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 114 patients, 37 (32.5%) were elderly, and 77 (67.5%) were nonelderly. Elderly patients had higher comorbidity scores (p&#x2009;&lt;&#x2009;0.001). Oropharyngeal and oral cavity primaries were more common in the nonelderly group, whereas laryngeal primaries predominated in elderly patients (p&#x2009;&lt;&#x2009;0.01). Complication rates were higher in nonelderly (37.6%) than in elderly (18.9%) patients, though not statistically significant (p&#x2009;=&#x2009;0.07). In elderly patients, FOSS scores showed no significant change preoperatively, postoperatively (&lt;&#x2009;3&#x2009;months), or at the last follow-up (median 36&#x2009;months). The nonelderly group experienced worse early postoperative FOSS scores compared to baseline but showed significant improvement, returning to preoperative levels by the last follow-up. Nonelderly patients had better FOSS scores at last follow-up compared to elderly patients (p&#x2009;=&#x2009;0.014). Overall and recurrence-free survival outcomes were better in the nonelderly group, but disease-specific survival rates were comparable.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Despite higher comorbidity rates in the elderly, TORS demonstrated favorable complication rates in the elderly population. Swallowing function returned to baseline after 3 months in both groups. TORS appears safe for elderly patients with comparable oncologic outcomes.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). Head &amp; Neck published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pamuk</LastName><ForeName>Erim</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-8813-0357</Identifier><AffiliationInfo><Affiliation>Service d'Oto-Rhino-Laryngologie-Chirurgie Cervico-Faciale, Centre Hospitalier Universitaire Vaudois (CHUV), Universit&#xe9; de Lausanne (UNIL), Lausanne, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beharry</LastName><ForeName>Avinash</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-7694-1312</Identifier><AffiliationInfo><Affiliation>Service d'Oto-Rhino-Laryngologie-Chirurgie Cervico-Faciale, Centre Hospitalier Universitaire Vaudois (CHUV), Universit&#xe9; de Lausanne (UNIL), Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lambercy</LastName><ForeName>Karma</ForeName><Initials>K</Initials><Identifier Source="ORCID">0009-0000-3323-7440</Identifier><AffiliationInfo><Affiliation>Service d'Oto-Rhino-Laryngologie-Chirurgie Cervico-Faciale, Centre Hospitalier Universitaire Vaudois (CHUV), Universit&#xe9; de Lausanne (UNIL), Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dalla-Vale</LastName><ForeName>Margaux</ForeName><Initials>M</Initials><Identifier Source="ORCID">0009-0004-8443-905X</Identifier><AffiliationInfo><Affiliation>Service d'Oto-Rhino-Laryngologie-Chirurgie Cervico-Faciale, Centre Hospitalier Universitaire Vaudois (CHUV), Universit&#xe9; de Lausanne (UNIL), Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wahler</LastName><ForeName>Nina</ForeName><Initials>N</Initials><Identifier Source="ORCID">0009-0003-5024-4492</Identifier><AffiliationInfo><Affiliation>Service d'Oto-Rhino-Laryngologie-Chirurgie Cervico-Faciale, Centre Hospitalier Universitaire Vaudois (CHUV), Universit&#xe9; de Lausanne (UNIL), Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ho&#x15f;al</LastName><ForeName>&#x15e;efik</ForeName><Initials>&#x15e;</Initials><Identifier Source="ORCID">0009-0005-1452-2226</Identifier><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, Faculty of Medicine, At&#x131;l&#x131;m University, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simon</LastName><ForeName>Christian</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-4156-9143</Identifier><AffiliationInfo><Affiliation>Service d'Oto-Rhino-Laryngologie-Chirurgie Cervico-Faciale, Centre Hospitalier Universitaire Vaudois (CHUV), Universit&#xe9; de Lausanne (UNIL), Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>11</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">TORS</Keyword><Keyword MajorTopicYN="N">age</Keyword><Keyword MajorTopicYN="N">complications</Keyword><Keyword MajorTopicYN="N">elderly</Keyword><Keyword MajorTopicYN="N">functional outcome</Keyword><Keyword MajorTopicYN="N">head and neck carcinoma</Keyword><Keyword MajorTopicYN="N">nonelderly</Keyword><Keyword MajorTopicYN="N">survival</Keyword><Keyword MajorTopicYN="N">swallowing</Keyword><Keyword MajorTopicYN="N">transoral robotic surgery</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>10</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>11</Month><Day>19</Day><Hour>12</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>11</Month><Day>19</Day><Hour>12</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41257353</ArticleId><ArticleId IdType="doi">10.1002/hed.70097</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>J. R. de Almeida, R. Li, J. S. Magnuson, et&#xa0;al., &#x201c;Oncologic Outcomes After Transoral Robotic Surgery: A Multi&#x2010;Institutional Study,&#x201d; JAMA Otolaryngology. Head &amp; Neck Surgery 141, no. 12 (2015): 1043&#x2013;1051.</Citation></Reference><Reference><Citation>G. S. Weinstein, B. W. O'Malley, Jr., J. S. Magnuson, et&#xa0;al., &#x201c;Transoral Robotic Surgery: A Multicenter Study to Assess Feasibility, Safety, and Surgical Margins,&#x201d; Laryngoscope 122, no. 8 (2012): 1701&#x2013;1707.</Citation></Reference><Reference><Citation>R. Philips, M. C. Topf, M. B. Crawley, et&#xa0;al., &#x201c;Functional and Survival Outcomes in Elderly Patients Undergoing Transoral Robotic Surgery,&#x201d; Oral Oncology 111 (2020): 104954.</Citation></Reference><Reference><Citation>W. K. Mydlarz, J. Y. Chan, and J. D. Richmon, &#x201c;The Role of Surgery for HPV&#x2010;Associated Head and Neck Cancer,&#x201d; Oral Oncology 51, no. 4 (2015): 305&#x2013;313.</Citation></Reference><Reference><Citation>A. De Virgilio, O. Iocca, L. Malvezzi, et&#xa0;al., &#x201c;The Emerging Role of Robotic Surgery Among Minimally Invasive Surgical Approaches in the Treatment of Hypopharyngeal Carcinoma: Systematic Review and Meta&#x2010;Analysis,&#x201d; Journal of Clinical Medicine 8, no. 2 (2019): 256.</Citation></Reference><Reference><Citation>W. Golusinski and E. Golusinska&#x2010;Kardach, &#x201c;Current Role of Surgery in the Management of Oropharyngeal Cancer,&#x201d; Frontiers in Oncology 9 (2019): 388.</Citation></Reference><Reference><Citation>Z. S. Zumsteg, G. Cook&#x2010;Wiens, E. Yoshida, et&#xa0;al., &#x201c;Incidence of Oropharyngeal Cancer Among Elderly Patients in the United States,&#x201d; JAMA Oncology 2, no. 12 (2016): 1617&#x2013;1623.</Citation></Reference><Reference><Citation>H. S. Parhar, D. Shimunov, J. G. Newman, et&#xa0;al., &#x201c;Oncologic Outcomes Following Transoral Robotic Surgery for Human Papillomavirus&#x2010;Associated Oropharyngeal Carcinoma in Older Patients,&#x201d; JAMA Otolaryngology. Head &amp; Neck Surgery 146, no. 12 (2020): 1167&#x2013;1175.</Citation></Reference><Reference><Citation>A. Costantino, B. Haughey, U. Alamoudi, M. Biskup, and J. S. Magnuson, &#x201c;Safety and Postoperative Outcomes of Transoral Surgery for Oropharyngeal Carcinoma in Older Adults,&#x201d; JAMA Otolaryngology. Head &amp; Neck Surgery 150, no. 10 (2024): 879&#x2013;886.</Citation></Reference><Reference><Citation>F. Caparrotti, B. O'Sullivan, S. V. Bratman, et&#xa0;al., &#x201c;Exploring the Impact of Human Papillomavirus Status, Comorbidity, Polypharmacy, and Treatment Intensity on Outcome of Elderly Oropharyngeal Cancer Patients Treated With Radiation Therapy With or Without Chemotherapy,&#x201d; International Journal of Radiation Oncology, Biology, Physics 98, no. 4 (2017): 858&#x2013;867.</Citation></Reference><Reference><Citation>P. A. Clavien, J. Barkun, M. L. de Oliveira, et&#xa0;al., &#x201c;The Clavien&#x2010;Dindo Classification of Surgical Complications: Five&#x2010;Year Experience,&#x201d; Annals of Surgery 250, no. 2 (2009): 187&#x2013;196.</Citation></Reference><Reference><Citation>A. Hay, J. Migliacci, D. Karassawa Zanoni, et&#xa0;al., &#x201c;Complications Following Transoral Robotic Surgery (TORS): A Detailed Institutional Review of Complications,&#x201d; Oral Oncology 67 (2017): 160&#x2013;166.</Citation></Reference><Reference><Citation>J. E. Tota, A. F. Best, Z. S. Zumsteg, M. L. Gillison, P. S. Rosenberg, and A. K. Chaturvedi, &#x201c;Evolution of the Oropharynx Cancer Epidemic in the United States: Moderation of Increasing Incidence in Younger Individuals and Shift in the Burden to Older Individuals,&#x201d; Journal of Clinical Oncology 37, no. 18 (2019): 1538&#x2013;1546.</Citation></Reference><Reference><Citation>M. J. Windon, G. D'Souza, E. M. Rettig, et&#xa0;al., &#x201c;Increasing Prevalence of Human Papillomavirus&#x2010;Positive Oropharyngeal Cancers Among Older Adults,&#x201d; Cancer 124, no. 14 (2018): 2993&#x2013;2999.</Citation></Reference><Reference><Citation>B. Lacas, A. Carmel, C. Landais, et&#xa0;al., &#x201c;Meta&#x2010;Analysis of Chemotherapy in Head and Neck Cancer (MACH&#x2010;NC): An Update on 107 Randomized Trials and 19,805 Patients, on Behalf of MACH&#x2010;NC Group,&#x201d; Radiotherapy and Oncology 156 (2021): 281&#x2013;293.</Citation></Reference><Reference><Citation>K. A. Hutcheson, F. C. Holsinger, M. E. Kupferman, and J. S. Lewin, &#x201c;Functional Outcomes After TORS for Oropharyngeal Cancer: A Systematic Review,&#x201d; European Archives of Oto&#x2010;Rhino&#x2010;Laryngology 272, no. 2 (2015): 463&#x2013;471.</Citation></Reference><Reference><Citation>P. Guarino, F. Chiari, S. Cordeschi, et&#xa0;al., &#x201c;A Comprehensive Systematic Review on Functional Results, Speech and Swallowing Outcomes After Trans&#x2010;Oral Robotic Surgery for Oropharyngeal Squamous Cell Cancer,&#x201d; Journal of Clinical Medicine 13, no. 20 (2024): 6039.</Citation></Reference><Reference><Citation>P. T. Dziegielewski, S. Y. Kang, and E. Ozer, &#x201c;Transoral Robotic Surgery (TORS) for Laryngeal and Hypopharyngeal Cancers,&#x201d; Journal of Surgical Oncology 112, no. 7 (2015): 702&#x2013;706.</Citation></Reference><Reference><Citation>E. J. Moore, K. D. Olsen, and J. L. Kasperbauer, &#x201c;Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma: A Prospective Study of Feasibility and Functional Outcomes,&#x201d; Laryngoscope 119, no. 11 (2009): 2156&#x2013;2164.</Citation></Reference><Reference><Citation>S. M. Olsen, E. J. Moore, C. A. Koch, D. L. Price, J. L. Kasperbauer, and K. D. Olsen, &#x201c;Transoral Robotic Surgery for Supraglottic Squamous Cell Carcinoma,&#x201d; American Journal of Otolaryngology 33, no. 4 (2012): 379&#x2013;384.</Citation></Reference><Reference><Citation>R. T. Hughes, B. J. Levine, N. May, et&#xa0;al., &#x201c;Survival and Swallowing Function After Primary Radiotherapy Versus Transoral Robotic Surgery for Human Papillomavirus&#x2010;Associated Oropharyngeal Squamous Cell Carcinoma,&#x201d; ORL: Journal for Otorhinolaryngology and Its Related Specialties 85, no. 5 (2023): 284&#x2013;293.</Citation></Reference><Reference><Citation>K. A. Hutcheson, C. L. Warneke, C. M. K. L. Yao, et&#xa0;al., &#x201c;Dysphagia After Primary Transoral Robotic Surgery With Neck Dissection vs Nonsurgical Therapy in Patients With Low&#x2010; to Intermediate&#x2010;Risk Oropharyngeal Cancer,&#x201d; JAMA Otolaryngology. Head &amp; Neck Surgery 145, no. 11 (2019): 1053&#x2013;1063.</Citation></Reference><Reference><Citation>A. C. Nichols, J. Theurer, E. Prisman, et&#xa0;al., &#x201c;Radiotherapy Versus Transoral Robotic Surgery and Neck Dissection for Oropharyngeal Squamous Cell Carcinoma (ORATOR): An Open&#x2010;Label, Phase 2, Randomised Trial,&#x201d; Lancet Oncology 20, no. 10 (2019): 1349&#x2013;1359.</Citation></Reference><Reference><Citation>J. H. Gross, M. Townsend, H. Y. Hong, et&#xa0;al., &#x201c;Predictors of Swallow Function After Transoral Surgery for Locally Advanced Oropharyngeal Cancer,&#x201d; Laryngoscope 130, no. 1 (2020): 94&#x2013;100.</Citation></Reference><Reference><Citation>C. Fogg, S. D. S. Fraser, P. Roderick, et&#xa0;al., &#x201c;The Dynamics of Frailty Development and Progression in Older Adults in Primary Care in England (2006&#x2010;2017): A Retrospective Cohort Profile,&#x201d; BMC Geriatrics 22, no. 1 (2022): 30.</Citation></Reference><Reference><Citation>M. T. Turner, J. Chung, S. Noorkbash, et&#xa0;al., &#x201c;Complications Following Salvage Transoral Robotic Surgery With and Without Reconstruction: A Systematic Review of the Literature,&#x201d; Oral Oncology 145 (2023): 106467.</Citation></Reference><Reference><Citation>J. D. Phillips, C. S. Kim, E. W. Fonkalsrud, H. Zeng, and H. Dindar, &#x201c;Effects of Chronic Corticosteroids and Vitamin A on the Healing of Intestinal Anastomoses,&#x201d; American Journal of Surgery 163, no. 1 (1992): 71&#x2013;77.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70101 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41257342</PMID><DateRevised><Year>2025</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Nov</Month><Day>19</Day></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Geriatric Nutritional Risk Index Predicts Treatment Intolerance and Survival in Head and Neck Cancer.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70101</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Malnutrition is associated with worse outcomes in head and neck cancer (HNC). The geriatric nutritional risk index (GNRI) may predict postoperative morbidity and survival, but its role remains underexplored.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">An ambispective study of patients undergoing HNC surgery at two academic centers (2015-2024) was performed. Preoperative GNRI was categorized into moderate-to-high risk (&lt;&#x2009;92), low risk (92-98), and no risk (&gt;&#x2009;98). Outcomes included 90-day mortality, treatment intolerance, overall survival, and disease-free survival. Analyses were performed using multivariable logistic and Cox regression adjusted for age, Charlson Comorbidity Index (CCI), tumor stage, primary tumor site, and percutaneous endoscopic gastrostomy (PEG) status. Patients with prior head and neck cancer or prior radiation were excluded.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 312 treatment-na&#xef;ve surgical patients, 13% were moderate-to-high GNRI risk and 8% low risk. Moderate-to-high GNRI risk had higher major adverse events (57% vs. 36% in no-risk), greater treatment intolerance (61% vs. 41%), and a trend toward higher 90-day mortality (11% vs. 4%). On multivariable models adjusted for tumor site and pathologic stage, moderate-to-high GNRI risk was associated with higher odds of 90-day mortality (OR 2.99, 95% CI 1.01-9.31; p&#x2009;=&#x2009;0.048) and treatment intolerance (OR 2.35, 95% CI 1.21-4.56; p&#x2009;=&#x2009;0.012). Cox regression showed shorter overall (HR 2.28, 95% CI 1.44-3.62; p&#x2009;&lt;&#x2009;0.001) and disease-free survival (HR 1.87, 95% CI 1.20-2.91; p&#x2009;=&#x2009;0.005).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The GNRI predicted treatment intolerance and poorer survival in patients with operable HNC.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). Head &amp; Neck published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chowdhury</LastName><ForeName>Raisa</ForeName><Initials>R</Initials><Identifier Source="ORCID">0009-0000-5433-5808</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine and Health Sciences, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mlynarek</LastName><ForeName>Alex M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richardson</LastName><ForeName>Keith</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sadeghi</LastName><ForeName>Nader</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-3218-2668</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hier</LastName><ForeName>Michael P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wurzba</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Esfahani</LastName><ForeName>Khashayar</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bouganim</LastName><ForeName>Nathaniel</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sultanem</LastName><ForeName>Khalil</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shenouda</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsien</LastName><ForeName>Christina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mascarella</LastName><ForeName>Marco A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0002-8880-805X</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>11</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">geriatric nutritional risk index</Keyword><Keyword MajorTopicYN="N">head and neck cancer</Keyword><Keyword MajorTopicYN="N">nutritional risk assessment</Keyword><Keyword MajorTopicYN="N">postoperative complications</Keyword><Keyword MajorTopicYN="N">surgical outcomes</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>10</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>7</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>11</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>11</Month><Day>19</Day><Hour>5</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41257342</ArticleId><ArticleId IdType="doi">10.1002/hed.70101</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>T. Brown, A. Edwards, A. Pashley, et&#xa0;al., &#x201c;Nutritional Status and Post&#x2010;Operative Complications in Patients Undergoing Surgery for Advanced Pharyngeal or Laryngeal Cancer,&#x201d; European Archives of Oto&#x2010;Rhino&#x2010;Laryngology 280, no. 12 (2023): 5531&#x2013;5538, https://doi.org/10.1007/s00405&#x2010;023&#x2010;08139&#x2010;x.</Citation></Reference><Reference><Citation>C. Caburet, N. Farigon, A. Mulliez, et&#xa0;al., &#x201c;Impact of Nutritional Status at the Outset of Assessment on Postoperative Complications in Head and Neck Cancer,&#x201d; European Annals of Otorhinolaryngology, Head and Neck Diseases 137, no. 5 (2020): 393&#x2013;398, https://doi.org/10.1016/j.anorl.2019.12.005.</Citation></Reference><Reference><Citation>M. D. Fahmy, B. L. Hechler, E. R. Carlson, A. J. Gross, and R. E. Heidel, &#x201c;Preoperative Serum Albumin Predicts Wound Dehiscence but not Infection After Surgery for Oral Squamous Cell Carcinoma,&#x201d; Journal of Oral and Maxillofacial Surgery 79, no. 6 (2021): 1355&#x2013;1363, https://doi.org/10.1016/j.joms.2020.12.021.</Citation></Reference><Reference><Citation>J. Oh, A. Liu, E. Tran, et&#xa0;al., &#x201c;Association Between Nutritional Risk Index and Outcomes for Head and Neck Cancer Patients Receiving Concurrent Chemo&#x2010;Radiotherapy,&#x201d; Head &amp; Neck 42, no. 9 (2020): 2560&#x2013;2570, https://doi.org/10.1002/hed.26315.</Citation></Reference><Reference><Citation>M. H. Tsai, H. C. Chuang, Y. T. Lin, et&#xa0;al., &#x201c;Clinical Impact of Albumin in Advanced Head and Neck Cancer Patients With Free Flap Reconstruction&#x2014;A Retrospective Study,&#x201d; PeerJ 6 (2018): e4490, https://doi.org/10.7717/peerj.4490.</Citation></Reference><Reference><Citation>M. Nakayama, K. Ohnishi, M. Adachi, et&#xa0;al., &#x201c;Efficacy of the Pretreatment Geriatric Nutritional Risk Index for Predicting Severe Adverse Events in Patients With Head and Neck Cancer Treated With Chemoradiotherapy,&#x201d; Auris, Nasus, Larynx 49, no. 2 (2022): 279&#x2013;285, https://doi.org/10.1016/j.anl.2021.08.009.</Citation></Reference><Reference><Citation>Y. T. Tsai, L. T. Kuo, Y. T. Wang, et&#xa0;al., &#x201c;Prognostic Utility of the Geriatric Nutritional Risk Index for Head and Neck Cancer: Systematic Review and Meta&#x2010;Analysis,&#x201d; Head &amp; Neck 46, no. 8 (2024): 2086&#x2013;2097, https://doi.org/10.1002/hed.27842.</Citation></Reference><Reference><Citation>C. Y. Yiu, C. C. Liu, J. Y. Wu, et&#xa0;al., &#x201c;Efficacy of the Geriatric Nutritional Risk Index for Predicting Overall Survival in Patients With Head and Neck Cancer: A Meta&#x2010;Analysis,&#x201d; Nutrients 15, no. 20 (2023): 4348, https://doi.org/10.3390/nu15204348.</Citation></Reference><Reference><Citation>O. Bouillanne, G. Morineau, C. Dupont, et&#xa0;al., &#x201c;Geriatric Nutritional Risk Index: A New Index for Evaluating At&#x2010;Risk Elderly Medical Patients,&#x201d; American Journal of Clinical Nutrition 82, no. 4 (2005): 777&#x2013;783, https://doi.org/10.1093/ajcn/82.4.777.</Citation></Reference><Reference><Citation>D. Danan, D. C. Shonka, Jr., Y. Selman, Z. Chow, M. E. Smolkin, and M. J. Jameson, &#x201c;Prognostic Value of Albumin in Patients With Head and Neck Cancer,&#x201d; Laryngoscope 126, no. 7 (2016): 1567&#x2013;1571, https://doi.org/10.1002/lary.25877.</Citation></Reference><Reference><Citation>N. Miyamoto, Y. Takenaka, T. Sudo, et&#xa0;al., &#x201c;Prognostic Significance of Nutritional Indices in Patients With Head and Neck Squamous Cell Carcinoma Treated With Immune Checkpoint Inhibitors,&#x201d; Acta Oto&#x2010;Laryngologica 143, no. 10 (2023): 925&#x2013;930, https://doi.org/10.1080/00016489.2023.2288910.</Citation></Reference><Reference><Citation>M. Haas, A. Lein, T. Fuereder, et&#xa0;al., &#x201c;The Geriatric Nutritional Risk Index (GNRI) as a Prognostic Biomarker for Immune Checkpoint Inhibitor Response in Recurrent and/or Metastatic Head and Neck Cancer,&#x201d; Nutrients 15, no. 4 (2023): 880, https://doi.org/10.3390/nu15040880.</Citation></Reference><Reference><Citation>GlobalSurg Collaborative and NIHR Global Health Unit on Global Surgery, &#x201c;Impact of Malnutrition on Early Outcomes After Cancer Surgery: An International, Multicentre, Prospective Cohort Study,&#x201d; Lancet Global Health 11 (2023): e341&#x2013;e349, https://doi.org/10.1016/s2214&#x2010;109x(22)00550&#x2010;2.</Citation></Reference><Reference><Citation>V. Budach and I. Tinhofer, &#x201c;Novel Prognostic Clinical Factors and Biomarkers for Outcome Prediction in Head and Neck Cancer: A Systematic Review,&#x201d; Lancet Oncology 20, no. 6 (2019): e313&#x2013;e326, https://doi.org/10.1016/s1470&#x2010;2045(19)30177&#x2010;9.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70049 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41257300</PMID><DateRevised><Year>2025</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Nov</Month><Day>19</Day></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Sclerotic Head and Neck Paragangliomas: An Unfavorable Indicator Associated With Surgical Outcomes.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70049</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">This retrospective case-control study investigated surgical outcomes of head and neck paragangliomas (HNPGLs) with varying degrees of sclerosis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Data from 95 patients who underwent HNPGL surgery over 20&#x2009;years were analyzed. Based on histology, tumors were classified as having non-significant (&lt;&#x2009;30%) or significant (&#x2265;&#x2009;30%) sclerosis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Seventy patients had non-significant sclerosis and 25 had significant sclerosis. The significant sclerosis group was younger (39 vs. 44&#x2009;years, p&#x2009;=&#x2009;0.026), had more multiple tumors (48% vs. 12.9%, p&#x2009;=&#x2009;0.001), higher nerve injury rates (p&#x2009;=&#x2009;0.021), and more vascular injuries (20.8% vs. 4.17%, p&#x2009;=&#x2009;0.022). Multivariate analysis identified tumor volume (OR&#x2009;=&#x2009;1.014, p&#x2009;=&#x2009;0.005) and sclerosis degree (OR&#x2009;=&#x2009;0.276, p&#x2009;=&#x2009;0.013) as independent risk factors for severe complications involving both nerve and vascular injury.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Sclerotic HNPGLs are associated with earlier onset, multiple tumors, and increased risk of intraoperative complications, suggesting unfavorable surgical outcomes.</AbstractText><CopyrightInformation>&#xa9; 2025 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Chenliang</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-4157-5268</Identifier><AffiliationInfo><Affiliation>Department of Vascular Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Dingfang</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Pathology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Yaru</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Yiming</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Zhigang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piao</LastName><ForeName>Yingshi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pathology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Zhengya</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xiaohong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>DFL20220201</GrantID><Agency>Beijing Hospital Management Center "Ascending the Peak" Talent Training Program</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>11</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">head and neck paragangliomas</Keyword><Keyword MajorTopicYN="N">sclerosis</Keyword><Keyword MajorTopicYN="N">surgical outcomes</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>9</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>11</Month><Day>19</Day><Hour>5</Hour><Minute>38</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41257300</ArticleId><ArticleId IdType="doi">10.1002/hed.70049</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>L. Sandow, R. Thawani, M. S. Kim, and M. C. Heinrich, &#x201c;Paraganglioma of the Head and Neck: A Review,&#x201d; Endocrine Practice 29, no. 2 (2023): 141&#x2013;147.</Citation></Reference><Reference><Citation>S. Richter, G. Constantinescu, G. Fancello, C. T. Paties, R. Mariani&#x2010;Costantini, and M. Sanna, &#x201c;Head and Neck Paragangliomas: Recent Advances in Translational and Clinical Research and Guidelines for Patient Care,&#x201d; Best Practice &amp; Research. Clinical Endocrinology &amp; Metabolism 38, no. 6 (2024): 101951.</Citation></Reference><Reference><Citation>D. Ta&#xef;eb, G. B. Wanna, M. Ahmad, et&#xa0;al., &#x201c;Clinical Consensus Guideline on the Management of Phaeochromocytoma and Paraganglioma in Patients Harbouring Germline SDHD Pathogenic Variants,&#x201d; Lancet Diabetes and Endocrinology 11, no. 5 (2023): 345&#x2013;361.</Citation></Reference><Reference><Citation>I. Jochmanova and K. Pacak, &#x201c;Genomic Landscape of Pheochromocytoma and Paraganglioma,&#x201d; Trends Cancer 4, no. 1 (2018): 6&#x2013;9.</Citation></Reference><Reference><Citation>J. A. Plaza, P. E. Wakely, C. Moran, C. D. M. Fletcher, and S. Suster, &#x201c;Sclerosing Paraganglioma: Report of 19 Cases of an Unusual Variant of Neuroendocrine Tumor That May be Mistaken for an Aggressive Malignant Neoplasm,&#x201d; American Journal of Surgical Pathology 30, no. 1 (2006): 7&#x2013;12.</Citation></Reference><Reference><Citation>S. Javidiparsijani, A. Brickman, D. M. Lin, et&#xa0;al., &#x201c;Is Regional Lymph Node Metastasis of Head and Neck Paraganglioma a Sign of Aggressive Clinical Behavior: A Clinical/Pathologic Review,&#x201d; Ear, Nose, &amp; Throat Journal 100, no. 6 (2021): 447&#x2013;453.</Citation></Reference><Reference><Citation>H. Tang, X. Jiang, S. Xue, W. Fu, X. Tang, and D. Guo, &#x201c;Long&#x2010;Term Surgical Outcomes of Carotid Body Tumors With Pathological Fibrosis: A Cohort Study,&#x201d; Frontiers in Oncology 11 (2021): 684600.</Citation></Reference><Reference><Citation>G. Y. Kim, P. F. Lawrence, R. S. Moridzadeh, et&#xa0;al., &#x201c;New Predictors of Complications in Carotid Body Tumor Resection,&#x201d; Journal of Vascular Surgery 65, no. 6 (2017): 1673&#x2013;1679.</Citation></Reference><Reference><Citation>G. Gu, X. Wu, L. Ji, et&#xa0;al., &#x201c;Proposed Modification to the Shamblin's Classification of Carotid Body Tumors: A Single&#x2010;Center Retrospective Experience of 116 Tumors,&#x201d; EJSO 47, no. 8 (2021): 1953&#x2013;1960.</Citation></Reference><Reference><Citation>O. Mete, S. L. Asa, A. J. Gill, N. Kimura, R. R. De Krijger, and A. Tischler, &#x201c;Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas,&#x201d; Endocrine Pathology 33, no. 1 (2022): 90&#x2013;114.</Citation></Reference><Reference><Citation>C. Bima, F. Bioletto, C. Lopez, M. Bollati, S. Arata, and M. Procopio, &#x201c;Clinical and Pathological Tools for Predicting Recurrence and/or Metastasis in Patients With Pheochromocytoma and Paraganglioma,&#x201d; Biomedicine 10, no. 8 (2022): 1813.</Citation></Reference><Reference><Citation>M. Parasiliti&#x2010;Caprino, B. Lucatello, C. Lopez, et&#xa0;al., &#x201c;Predictors of Recurrence of Pheochromocytoma and Paraganglioma: A Multicenter Study in Piedmont, Italy,&#x201d; Hypertension Research 43, no. 6 (2020): 500&#x2013;510.</Citation></Reference><Reference><Citation>D. F. Davidoff, R. De Abreu Lourenco, V. H. M. Tsang, D. E. Benn, and R. J. Clifton&#x2010;Bligh, &#x201c;Outcomes of SDHB Pathogenic Variant Carriers: A Systematic Review and Meta&#x2010;Analysis,&#x201d; Journal of Clinical Endocrinology and Metabolism 109, no. 9 (2024): 2400&#x2013;2410.</Citation></Reference><Reference><Citation>D. Ta&#xef;eb, S. N&#xf6;lting, N. D. Perrier, et&#xa0;al., &#x201c;Management of Phaeochromocytoma and Paraganglioma in Patients With Germline SDHB Pathogenic Variants: An International Expert Consensus Statement,&#x201d; Nature Reviews. Endocrinology 20, no. 3 (2024): 168&#x2013;184.</Citation></Reference><Reference><Citation>H. Lee, S. Jeong, Y. Yu, et&#xa0;al., &#x201c;Risk of Metastatic Pheochromocytoma and Paraganglioma in SDHx Mutation Carriers: A Systematic Review and Updated Meta&#x2010;Analysis,&#x201d; Journal of Medical Genetics 57, no. 4 (2020): 217&#x2013;225.</Citation></Reference><Reference><Citation>G. Eisenhofer, J. W. M. Lenders, G. Siegert, et&#xa0;al., &#x201c;Plasma Methoxytyramine: A Novel Biomarker of Metastatic Pheochromocytoma and Paraganglioma in Relation to Established Risk Factors of Tumour Size, Location and SDHB Mutation Status,&#x201d; European Journal of Cancer 48, no. 11 (2012): 1739&#x2013;1749.</Citation></Reference><Reference><Citation>N. Kimura, R. Takayanagi, N. Takizawa, et&#xa0;al., &#x201c;Pathological Grading for Predicting Metastasis in Phaeochromocytoma and Paraganglioma,&#x201d; Endocrine&#x2010;Related Cancer 21, no. 3 (2014): 405&#x2013;414.</Citation></Reference><Reference><Citation>H. Wachtel, T. Hutchens, E. Baraban, et&#xa0;al., &#x201c;Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma: A Comparison of PASS and GAPP Scoring Systems,&#x201d; Journal of Clinical Endocrinology and Metabolism 105, no. 12 (2020): e4661&#x2013;e4670.</Citation></Reference><Reference><Citation>C. Pamporaki, A. M. A. Berends, A. Filippatos, et&#xa0;al., &#x201c;Prediction of Metastatic Pheochromocytoma and Paraganglioma: A Machine Learning Modelling Study Using Data From a Cross&#x2010;Sectional Cohort,&#x201d; Lancet Digit Health 5, no. 9 (2023): e551&#x2013;e559.</Citation></Reference><Reference><Citation>L. Fishbein, J. Del Rivero, T. Else, J. R. Howe, S. L. Asa, and D. L. Cohen, &#x201c;The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma,&#x201d; Pancreas 50, no. 4 (2021): 469&#x2013;493.</Citation></Reference><Reference><Citation>A. Pucci, A. Bacca, I. Barravecchia, I. Di Stefano, B. Belgio, and D. Lorenzini, &#x201c;Sclerosing Paragangliomas: Correlations of Histological Features With Patients' Genotype and Vesicular Monoamine Transporter Expression,&#x201d; Head and Neck Pathology 16, no. 4 (2022): 998&#x2013;1011.</Citation></Reference><Reference><Citation>B. Calsina, E. Pi&#xf1;eiro&#x2010;Y&#xe1;&#xf1;ez, &#xc1;. M. Mart&#xed;nez&#x2010;Montes, et&#xa0;al., &#x201c;Genomic and Immune Landscape of Metastatic Pheochromocytoma and Paraganglioma,&#x201d; Nature Communications 14, no. 1 (2023): 1122.</Citation></Reference><Reference><Citation>O. Uher, K. Hadrava Vanova, D. Ta&#xef;eb, et&#xa0;al., &#x201c;The Immune Landscape of Pheochromocytoma and Paraganglioma: Current Advances and Perspectives,&#x201d; Endocrine Reviews 45, no. 4 (2024): 521&#x2013;552.</Citation></Reference><Reference><Citation>A. Bagaev, N. Kotlov, K. Nomie, et&#xa0;al., &#x201c;Conserved Pan&#x2010;Cancer Microenvironment Subtypes Predict Response to Immunotherapy,&#x201d; Cancer Cell 39, no. 6 (2021): 845&#x2013;865.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70090 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41261786</PMID><DateRevised><Year>2025</Year><Month>11</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Nov</Month><Day>19</Day></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Dental Rehabilitation After Bone Mandibular Reconstruction for Head and Neck Cancer: A GETTEC Multicenter Study.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70090</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The microvascular bone free flap (MBFF) is the preferred reconstruction after mandibular resection as it facilitates secondary dental rehabilitation.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this multicenter study, patients were included if treated between January 2017 and January 2022 for head and neck cancer with MBFF reconstruction.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 487 identified patients, 104 patients were included. Median follow-up was 49&#x2009;months. 61 patients (59%) had no dental rehabilitation. Of the 43 rehabilitated patients, 81% had a conventional prosthesis and 19% an implant-supported prosthesis. Neither the number of osteotomies, nor the complexity of the reconstruction, nor the radiotherapy, were statistically associated with dental rehabilitation. Only the absence of a dental specialist in the center (p&#x2009;=&#x2009;0.04) and a number of one or fewer native mandibular teeth (p&#x2009;=&#x2009;0.05) were significantly associated with no dental rehabilitation in multivariate analysis.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The rate of dental rehabilitation is still insufficient. The presence of a dental specialist is essential.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). Head &amp; Neck published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lise-Marie</LastName><ForeName>Roussel</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-7831-1912</Identifier><AffiliationInfo><Affiliation>Department of Oto-Rhino-Laryngology, Head and Neck Surgery, Centre Henri Becquerel, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roxane</LastName><ForeName>Elaldi</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Oto-Rhino-Laryngology, Head and Neck Surgery, Institut Universitaire de la Face et du Cou, Nice, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marine</LastName><ForeName>Anquetil</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Maxillo-Facial Surgery, CHU de Nantes, Nantes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Emilie</LastName><ForeName>L&#xe9;v&#xea;que</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Clinical Research Unit, Centre Henri Becquerel, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Emmanuel</LastName><ForeName>Babin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Oto-Rhino-Laryngology, Head and Neck Surgery, CHU de Caen, Caen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alexandre</LastName><ForeName>Bozec</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Oto-Rhino-Laryngology, Head and Neck Surgery, Institut Universitaire de la Face et du Cou, Nice, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Audrey</LastName><ForeName>Lasne Cardon</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Department of Oto-Rhino-Laryngology, Head and Neck Surgery, Centre Fran&#xe7;ois Baclesse, Caen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alexandre</LastName><ForeName>Boulay</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Oto-Rhino-Laryngology, Head and Neck Surgery, CHU de Caen, Caen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maud</LastName><ForeName>Le Guyader</ForeName><Initials>LG</Initials><AffiliationInfo><Affiliation>Department of Radiotherapy, Institut Universitaire de la Face et du Cou, Nice, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xe9;bastien</LastName><ForeName>Thureau</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Radiotherapy, Centre Henri Becquerel, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Esteban</LastName><ForeName>Brenet</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Oto-Rhino-Laryngology, Head and Neck Surgery, Robert Debr&#xe9; University Hospital, Reims, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Florian</LastName><ForeName>Clatot</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>11</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">dental implants</Keyword><Keyword MajorTopicYN="N">dental restoration repair</Keyword><Keyword MajorTopicYN="N">free tissue flaps</Keyword><Keyword MajorTopicYN="N">head and neck neoplasms</Keyword><Keyword MajorTopicYN="N">hospice care</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>10</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>10</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>11</Month><Day>20</Day><Hour>1</Hour><Minute>46</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41261786</ArticleId><ArticleId IdType="doi">10.1002/hed.70090</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, &#x201c;Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,&#x201d; CA: A Cancer Journal for Clinicians 68 (2018): 394&#x2013;424, https://doi.org/10.3322/caac.21492.</Citation></Reference><Reference><Citation>A. L. Mazul, S. Chidambaram, J. P. Zevallos, and S. T. Massa, &#x201c;Disparities in Head and Neck Cancer Incidence and Trends by Race/Ethnicity and Sex,&#x201d; Head &amp; Neck 45 (2023): 75&#x2013;84, https://doi.org/10.1002/hed.27209.</Citation></Reference><Reference><Citation>D.&#x2010;N. Lu, W.&#x2010;C. Zhang, Y.&#x2010;Z. Lin, et&#xa0;al., &#x201c;The Incidence Trends of Oral Cancers Worldwide From 1988 to 2012 and the Prediction up to 2030,&#x201d; Head &amp; Neck 45 (2023): 2394&#x2013;2412, https://doi.org/10.1002/hed.27443.</Citation></Reference><Reference><Citation>C.&#x2010;H. Wong and F.&#x2010;C. Wei, &#x201c;Microsurgical Free Flap in Head and Neck Reconstruction,&#x201d; Head &amp; Neck 32 (2010): 1236&#x2013;1245, https://doi.org/10.1002/hed.21284.</Citation></Reference><Reference><Citation>M. Ragbir, J. S. Brown, and H. Mehanna, &#x201c;Reconstructive Considerations in Head and Neck Surgical Oncology: United Kingdom National Multidisciplinary Guidelines,&#x201d; Journal of Laryngology and Otology 130 (2016): S191&#x2013;S197, https://doi.org/10.1017/S0022215116000621.</Citation></Reference><Reference><Citation>K. H. Teoh, J. M. Huryn, S. Patel, et&#xa0;al., &#x201c;Implant Prosthodontic Rehabilitation of Fibula Free&#x2010;Flap Reconstructed Mandibles: A Memorial Sloan&#x2010;Kettering Cancer Center Review of Prognostic Factors and Implant Outcomes,&#x201d; International Journal of Oral &amp; Maxillofacial Implants 20 (2005): 738&#x2013;746.</Citation></Reference><Reference><Citation>R. J. Shaw, A. F. Sutton, J. I. Cawood, et&#xa0;al., &#x201c;Oral Rehabilitation After Treatment for Head and Neck Malignancy,&#x201d; Head &amp; Neck 27 (2005): 459&#x2013;470, https://doi.org/10.1002/hed.20176.</Citation></Reference><Reference><Citation>J. N. Lodders, F. K. J. Leusink, A. Ridwan&#x2010;Pramana, et&#xa0;al., &#x201c;Long&#x2010;Term Outcomes of Implant&#x2010;Based Dental Rehabilitation in Head and Neck Cancer Patients After Reconstruction With the Free Vascularized Fibula Flap,&#x201d; Journal of Cranio&#x2010;Maxillofacial Surgery 49 (2021): 845&#x2013;854, https://doi.org/10.1016/j.jcms.2021.03.002.</Citation></Reference><Reference><Citation>S. Ch'ng, R. J. Skoracki, J. C. Selber, et&#xa0;al., &#x201c;Osseointegrated Implant&#x2010;Based Dental Rehabilitation in Head and Neck Reconstruction Patients,&#x201d; Head and Neck 38, no. Suppl 1 (2016): E321&#x2013;E327, https://doi.org/10.1002/hed.23993.</Citation></Reference><Reference><Citation>E. de Mon&#xe8;s, S. Vergez, B. Barry, et&#xa0;al., &#x201c;Bilan Initial Des Carcinomes &#xc9;pidermo&#xef;de de la Cavit&#xe9; Buccale, du Larynx et du Pharynx (Nasopharynx Exclu). Partie 3: Bilan G&#xe9;n&#xe9;ral. Recommandations SFORL 2012,&#x201d; Annales Fran&#xe7;aises D'oto&#x2010;Rhino&#x2010;Laryngologie et De Pathologie Cervico&#x2010;Faciale 130 (2013): 169&#x2013;177, https://doi.org/10.1016/j.aforl.2012.10.008.</Citation></Reference><Reference><Citation>C. Butterworth, L. McCaul, and C. Barclay, &#x201c;Restorative Dentistry and Oral Rehabilitation: United Kingdom National Multidisciplinary Guidelines,&#x201d; Journal of Laryngology &amp; Otology 130 (2016): S41&#x2013;S44, https://doi.org/10.1017/S0022215116000414.</Citation></Reference><Reference><Citation>E. E. W. Cohen, S. J. LaMonte, N. L. Erb, et&#xa0;al., &#x201c;American Cancer Society Head and Neck Cancer Survivorship Care Guideline,&#x201d; CA: A Cancer Journal for Clinicians 66 (2016): 203&#x2013;239, https://doi.org/10.3322/caac.21343.</Citation></Reference><Reference><Citation>A. Ali, M. J. Fardy, and D. W. Patton, &#x201c;Maxillectomy&#x2014;To Reconstruct or Obturate? Results of a UK Survey of Oral and Maxillofacial Surgeons,&#x201d; British Journal of Oral and Maxillofacial Surgery 33 (1995): 207&#x2013;210, https://doi.org/10.1016/0266&#x2010;4356(95)90001&#x2010;2.</Citation></Reference><Reference><Citation>J. T. M. van Gemert, R. J. J. van Es, A. J. W. P. Rosenberg, A. van der Bilt, R. Koole, and E. M. Van Cann, &#x201c;Free Vascularized Flaps for Reconstruction of the Mandible: Complications, Success, and Dental Rehabilitation,&#x201d; Journal of Oral and Maxillofacial Surgery 70 (2012): 1692&#x2013;1698, https://doi.org/10.1016/j.joms.2011.08.024.</Citation></Reference><Reference><Citation>K. Zeman&#x2010;Kuhnert, A. J. Gaggl, G. B. Bottini, et&#xa0;al., &#x201c;Long&#x2010;Term Outcomes of Dental Rehabilitation and Quality of Life After Microvascular Alveolar Ridge Reconstruction in Patients With Head and Neck Cancer,&#x201d; Journal of Clinical Medicine 13 (2024): 3110, https://doi.org/10.3390/jcm13113110.</Citation></Reference><Reference><Citation>D. D. Jewer, J. B. Boyd, R. T. Manktelow, et&#xa0;al., &#x201c;Orofacial and Mandibular Reconstruction With the Iliac Crest Free Flap: A Review of 60 Cases and a New Method of Classification,&#x201d; Plastic and Reconstructive Surgery 84 (1989): 391&#x2013;403, Discussion 404&#x2013;405.</Citation></Reference><Reference><Citation>T.&#x2010;T. Nham, C. Koudougou, B. Piot, P. Corre, H. Bertin, and J. Longis, &#x201c;Prosthetic Rehabilitation in Patients With Jaw Reconstruction by Fibula Free Flap: A Systematic Review,&#x201d; Journal of Stomatology, Oral and Maxillofacial Surgery 125 (2024): 101735, https://doi.org/10.1016/j.jormas.2023.101735.</Citation></Reference><Reference><Citation>K. P. Dholam, H. A. Pusalkar, P. S. Yadav, G. A. Quazi, and P. P. Somani, &#x201c;Implant&#x2010;Retained Dental Rehabilitation in Head and Neck Cancer Patients: An Assessment of Success and Failure,&#x201d; Implant Dentistry 22 (2013): 604, https://doi.org/10.1097/ID.0b013e3182a4d7bc.</Citation></Reference><Reference><Citation>A. C. Hundepool, A. G. Dumans, S. O. P. Hofer, et&#xa0;al., &#x201c;Rehabilitation After Mandibular Reconstruction With Fibula Free&#x2010;Flap: Clinical Outcome and Quality of Life Assessment,&#x201d; International Journal of Oral and Maxillofacial Surgery 37 (2008): 1009&#x2013;1013, https://doi.org/10.1016/j.ijom.2008.05.021.</Citation></Reference><Reference><Citation>H. Ma, J. Van Dessel, S. Shujaat, et&#xa0;al., &#x201c;Long&#x2010;Term Survival of Implant&#x2010;Based Oral Rehabilitation Following Maxillofacial Reconstruction With Vascularized Bone Flap,&#x201d; International Journal of Implant Dentistry 8 (2022): 15, https://doi.org/10.1186/s40729&#x2010;022&#x2010;00413&#x2010;7.</Citation></Reference><Reference><Citation>F. Goker, P. Beretta, A. Baj, et&#xa0;al., &#x201c;Oral Rehabilitation of Oncology Patients With Dental Implants After Reconstruction Surgery With Autogenous Flaps,&#x201d; European Review for Medical and Pharmacological Sciences 26 (2022): 51&#x2013;61, https://doi.org/10.26355/eurrev_202212_30795.</Citation></Reference><Reference><Citation>S. Ferrari, C. Copelli, B. Bianchi, et&#xa0;al., &#x201c;Rehabilitation With Endosseous Implants in Fibula Free&#x2010;Flap Mandibular Reconstruction: A Case Series of up to 10&#x2009;Years,&#x201d; Journal of Cranio&#x2010;Maxillofacial Surgery 41 (2013): 172&#x2013;178, https://doi.org/10.1016/j.jcms.2012.07.006.</Citation></Reference><Reference><Citation>W. Fang, Y. Liu, Q. Ma, B.&#x2010;L. Liu, and Y. Zhao, &#x201c;Long&#x2010;Term Results of Mandibular Reconstruction of Continuity Defects With Fibula Free Flap and Implant&#x2010;Borne Dental Rehabilitation,&#x201d; International Journal of Oral &amp; Maxillofacial Implants 30, no. 169 (2015): 169&#x2013;178, https://doi.org/10.11607/jomi.3606.</Citation></Reference><Reference><Citation>&#x201c;Functional and Aesthetic Treatment Outcomes After Immediate Jaw Reconstruction Using a Fibula Flap and Dental Implants,&#x201d; Journal of Cranio&#x2010;Maxillofacial Surgery 47 (2019): 786&#x2013;791, https://doi.org/10.1016/j.jcms.2018.12.017.</Citation></Reference><Reference><Citation>E. Zavattero, G. Ramieri, G. Agr&#xf2;, M. Fasolis, P. Garzino&#x2010;Demo, and C. Borbon, &#x201c;Implant Dental Rehabilitation of Fibula&#x2010;Free Flap Reconstructed Jaws,&#x201d; Journal of Craniofacial Surgery 32 (2021): e134, https://doi.org/10.1097/SCS.0000000000006874.</Citation></Reference><Reference><Citation>H.&#x2010;C. Jacobsen, F. Wahnschaff, T. Trenkle, P. Sieg, and S. G. Hakim, &#x201c;Oral Rehabilitation With Dental Implants and Quality of Life Following Mandibular Reconstruction With Free Fibular Flap,&#x201d; Clinical Oral Investigations 20 (2016): 187&#x2013;192, https://doi.org/10.1007/s00784&#x2010;015&#x2010;1487&#x2010;3.</Citation></Reference><Reference><Citation>L. Zhang, Q. Ding, C. Liu, Y. Sun, Q. Xie, and Y. Zhou, &#x201c;Survival, Function, and Complications of Oral Implants Placed in Bone Flaps in Jaw Rehabilitation: A Systematic Review,&#x201d; International Journal of Prosthodontics 29 (2016): 115&#x2013;125, https://doi.org/10.11607/ijp.4402.</Citation></Reference><Reference><Citation>E. Tahmasebi, E. Keykha, S. Hajisadeghi, et&#xa0;al., &#x201c;Outcomes and Influential Factors in Functional and Dental Rehabilitation Following Microvascular Fibula Flap Reconstruction in the Maxillomandibular Region: A Systematic Review and Meta&#x2010;Analysis,&#x201d; Maxillofacial Plastic and Reconstructive Surgery 45 (2023): 24, https://doi.org/10.1186/s40902&#x2010;023&#x2010;00392&#x2010;8.</Citation></Reference><Reference><Citation>J. Brown, F. Bekiroglu, and R. Shaw, &#x201c;Indications for the Scapular Flap in Reconstructions of the Head and Neck,&#x201d; British Journal of Oral and Maxillofacial Surgery 48 (2010): 331&#x2013;337, https://doi.org/10.1016/j.bjoms.2009.09.013.</Citation></Reference><Reference><Citation>J. M. Blumberg, P. Walker, S. Johnson, et&#xa0;al., &#x201c;Mandibular Reconstruction With the Scapula Tip Free Flap,&#x201d; Head &amp; Neck 41 (2019): 2353&#x2013;2358, https://doi.org/10.1002/hed.25702.</Citation></Reference><Reference><Citation>C. J. Butterworth, &#x201c;Primary vs Secondary Zygomatic Implant Placement in Patients With Head and Neck Cancer&#x2010;A 10&#x2010;Year Prospective Study,&#x201d; Head &amp; Neck 41 (2019): 1687&#x2013;1695, https://doi.org/10.1002/hed.25645.</Citation></Reference><Reference><Citation>L. M. Ritschl, H. Singer, F.&#x2010;C. Clasen, et&#xa0;al., &#x201c;Oral Rehabilitation and Associated Quality of Life Following Mandibular Reconstruction With Free Fibula Flap: A Cross&#x2010;Sectional Study,&#x201d; Frontiers in Oncology 14 (2024): 1371405, https://doi.org/10.3389/fonc.2024.1371405.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70095 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41246979</PMID><DateRevised><Year>2025</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Nov</Month><Day>17</Day></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Computer-Assisted Versus Freehand Surgery in Oncological Margins Control for Oral Squamous Cell Carcinomas: A Retrospective Case-Control Clinical Study.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70095</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Margin control is a crucial prognostic factor in head and neck oncological surgery. This retrospective case-control study aims to assess the superiority of computer-assisted surgery compared to traditional surgery in achieving optimal resection margins in maxillofacial oncologic surgery.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Eighty patients with stage T3 or T4 oral squamous cell carcinoma were included, equally divided into computer-assisted surgery (CAS) and freehand groups. Negative, close, and positive margin rates were compared. Logistic regression with Firth's correction and multivariable Cox models for disease-free survival (DFS) and overall survival (OS) were applied, with tobacco and alcohol included as covariates. Sensitivity analyses used inverse probability of treatment weighting (IPTW)-weighted models.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">CAS was associated with a significantly lower risk of positive margins (OR 0.24; 95% CI: 0.06-0.78; p&#x2009;=&#x2009;0.01), confirmed in the IPTW analysis. DFS was significantly improved with CAS in both multivariable and IPTW Cox models (HR 0.41 and 0.46, respectively), while OS showed no significant benefit. Nodal status emerged as the strongest prognostic factor.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Despite its univocality, the CAS technology seems to offer significant advantages in achieving precise oncological margin control for oral squamous cell carcinomas.</AbstractText><CopyrightInformation>&#xa9; 2025 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Marzi Manfroni</LastName><ForeName>Alice</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0007-7732-1207</Identifier><AffiliationInfo><Affiliation>Oral and Maxillofacial Surgery Unit, IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scaccini</LastName><ForeName>Otto Pietro</ForeName><Initials>OP</Initials><Identifier Source="ORCID">0009-0006-8754-5450</Identifier><AffiliationInfo><Affiliation>Oral and Maxillofacial Surgery Unit, IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ceccariglia</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Oral and Maxillofacial Surgery Unit, IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical and Neuromotor Science Alma Mater Studiorum, University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Querzoli</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Pathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leucci</LastName><ForeName>Anna Caterina</ForeName><Initials>AC</Initials><Identifier Source="ORCID">0000-0003-3562-6524</Identifier><AffiliationInfo><Affiliation>ENT Unit, Bellaria Hospital, Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cercenelli</LastName><ForeName>Laura</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-7818-1356</Identifier><AffiliationInfo><Affiliation>eDIMES Lab - Laboratory of Bioengineering, Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marcelli</LastName><ForeName>Emanuela</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>eDIMES Lab - Laboratory of Bioengineering, Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foschini</LastName><ForeName>Maria Pia</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Unit of Anatomic Pathology, Bellaria Hospital, Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Badiali</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Oral and Maxillofacial Surgery Unit, IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical and Neuromotor Science Alma Mater Studiorum, University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tarsitano</LastName><ForeName>Achille</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-5815-7591</Identifier><AffiliationInfo><Affiliation>Oral and Maxillofacial Surgery Unit, IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical and Neuromotor Science Alma Mater Studiorum, University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>11</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CAD/CAM technology</Keyword><Keyword MajorTopicYN="N">computer&#x2010;assisted surgery</Keyword><Keyword MajorTopicYN="N">cutting guides</Keyword><Keyword MajorTopicYN="N">oral squamous cell carcinoma</Keyword><Keyword MajorTopicYN="N">resection margins</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>10</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>11</Month><Day>17</Day><Hour>17</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>11</Month><Day>17</Day><Hour>17</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>11</Month><Day>17</Day><Hour>7</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41246979</ArticleId><ArticleId IdType="doi">10.1002/hed.70095</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>L. A. Ravasz, P. J. Slootweg, G. J. Hordijk, F. Smit, and I. van der Tweel, &#x201c;The Status of the Resection Margin as a Prognostic Factor in the Treatment of Head and Neck Carcinoma,&#x201d; Journal of Cranio&#x2010;Maxillo&#x2010;Facial Surgery 19, no. 7 (1991): 314&#x2013;318.</Citation></Reference><Reference><Citation>A. Binahmed, R. W. Nason, and A. A. Abdoh, &#x201c;The Clinical Significance of the Positive Surgical Margin in Oral Cancer,&#x201d; Oral Oncology 43, no. 8 (2007): 780&#x2013;784.</Citation></Reference><Reference><Citation>D. N. Sutton, J. S. Brown, S. N. Rogers, E. D. Vaughan, and J. A. Woolgar, &#x201c;The Prognostic Implications of the Surgical Margin in Oral Squamous Cell Carcinoma,&#x201d; International Journal of Oral and Maxillofacial Surgery 32, no. 1 (2003): 30&#x2013;34.</Citation></Reference><Reference><Citation>M. L. Hinni, A. Ferlito, M. S. Brandwein&#x2010;Gensler, et&#xa0;al., &#x201c;Surgical Margins in Head and Neck Cancer: A Contemporary Review,&#x201d; Head &amp; Neck 35, no. 9 (2013): 1362&#x2013;1370.</Citation></Reference><Reference><Citation>J. K. Dillon, C. B. Brown, T. M. McDonald, et&#xa0;al., &#x201c;How Does the Close Surgical Margin Impact Recurrence and Survival When Treating Oral Squamous Cell Carcinoma?,&#x201d; Journal of Oral and Maxillofacial Surgery 73, no. 6 (2015): 1182&#x2013;1188.</Citation></Reference><Reference><Citation>J. Solomon, A. Hinther, T. W. Matthews, et&#xa0;al., &#x201c;The Impact of Close Surgical Margins on Recurrence in Oral Squamous Cell Carcinoma,&#x201d; Journal of Otolaryngology &#x2010; Head &amp; Neck Surgery 50, no. 1 (2021): 9.</Citation></Reference><Reference><Citation>C. R. Anderson, K. Sisson, and M. Moncrieff, &#x201c;A Meta&#x2010;Analysis of Margin Size and Local Recurrence in Oral Squamous Cell Carcinoma,&#x201d; Oral Oncology 51, no. 5 (2015): 464&#x2013;469.</Citation></Reference><Reference><Citation>P. A. Brennan, F. Dylgjeri, R. D. Coletta, G. Arakeri, and A. M. Goodson, &#x201c;Surgical Tumour Margins and Their Significance in Oral Squamous Cell Carcinoma,&#x201d; Journal of Oral Pathology &amp; Medicine 51, no. 4 (2022): 311&#x2013;314.</Citation></Reference><Reference><Citation>G. J. C. van Baar, T. Forouzanfar, N. P. T. J. Liberton, H. A. H. Winters, and F. K. J. Leusink, &#x201c;Accuracy of Computer&#x2010;Assisted Surgery in Mandibular Reconstruction: A Systematic Review,&#x201d; Oral Oncology 84 (2018): 52&#x2013;60.</Citation></Reference><Reference><Citation>M. Rana, H. Essig, A. M. Eckardt, et&#xa0;al., &#x201c;Advances and Innovations in Computer&#x2010;Assisted Head and Neck Oncologic Surgery,&#x201d; Journal of Craniofacial Surgery 23, no. 1 (2012): 272&#x2013;278.</Citation></Reference><Reference><Citation>N. Karnatz, H. L. M&#xf6;llmann, M. Wilkat, A. Parviz, and M. Rana, &#x201c;Advances and Innovations in Ablative Head and Neck Oncologic Surgery Using Mixed Reality Technologies in Personalized Medicine,&#x201d; Journal of Clinical Medicine 11, no. 16 (2022): 4767.</Citation></Reference><Reference><Citation>S. Catanzaro, C. Copelli, A. Manfuso, et&#xa0;al., &#x201c;Intraoperative Navigation in Complex Head and Neck Resections: Indications and Limits,&#x201d; International Journal of Computer Assisted Radiology and Surgery 12, no. 5 (2017): 881&#x2013;887.</Citation></Reference><Reference><Citation>F. Ricotta, L. Cercenelli, S. Battaglia, et&#xa0;al., &#x201c;Navigation&#x2010;Guided Resection of Maxillary Tumors: Can a New Volumetric Virtual Planning Method Improve Outcomes in Terms of Control of Resection Margins?,&#x201d; Journal of Cranio&#x2010;Maxillo&#x2010;Facial Surgery 46, no. 12 (2018): 2240&#x2013;2247.</Citation></Reference><Reference><Citation>A. Tarsitano, F. Ricotta, G. Baldino, et&#xa0;al., &#x201c;Navigation&#x2010;Guided Resection of Maxillary Tumours: The Accuracy of Computer&#x2010;Assisted Surgery in Terms of Control of Resection Margins &#x2010; A Feasibility Study,&#x201d; Journal of Cranio&#x2010;Maxillo&#x2010;Facial Surgery 45, no. 12 (2017): 2109&#x2013;2114.</Citation></Reference><Reference><Citation>M. E. Al&#x2010;Sabahi, O. M. Jamali, M. I. Shindy, et&#xa0;al., &#x201c;Aesthetic Reconstruction of Onco&#x2010;Surgical Mandibular Defects Using Free Fibular Flap With and Without CAD/CAM Customized Osteotomy Guide: A Randomized Controlled Clinical Trial,&#x201d; BMC Cancer 22, no. 1 (2022): 1252.</Citation></Reference><Reference><Citation>A. Tarsitano, L. Ciocca, R. Scotti, and C. Marchetti, &#x201c;Morphological Results of Customized Microvascular Mandibular Reconstruction: A Comparative Study,&#x201d; Journal of Cranio&#x2010;Maxillo&#x2010;Facial Surgery 44, no. 6 (2016): 697&#x2013;702.</Citation></Reference><Reference><Citation>S. Mazzoni, A. Bianchi, G. Schiariti, G. Badiali, and C. Marchetti, &#x201c;Computer&#x2010;Aided Design and Computer&#x2010;Aided Manufacturing Cutting Guides and Customized Titanium Plates Are Useful in Upper Maxilla Waferless Repositioning,&#x201d; Journal of Oral and Maxillofacial Surgery 73, no. 4 (2015): 701&#x2013;707.</Citation></Reference><Reference><Citation>S. C. Nyirjesy, M. Heller, N. von Windheim, et&#xa0;al., &#x201c;The Role of Computer Aided Design/Computer Assisted Manufacturing (CAD/CAM) and 3&#x2010; Dimensional Printing in Head and Neck Oncologic Surgery: A Review and Future Directions,&#x201d; Oral Oncology 132 (2022): 105976.</Citation></Reference><Reference><Citation>F. Ceccariglia, L. Cercenelli, G. Badiali, E. Marcelli, and A. Tarsitano, &#x201c;Application of Augmented Reality to Maxillary Resections: A Three&#x2010;Dimensional Approach to Maxillofacial Oncologic Surgery,&#x201d; Journal of Personalized Medicine 12, no. 12 (2022): 2047.</Citation></Reference><Reference><Citation>N. Yodrabum, J. Tianrungroj, C. Sinmaroeng, K. Rudeejaroonrung, K. Pavavongsak, and C. Puncreobutr, &#x201c;How Is a Cutting Guide With Additional Anatomical References Better in Fibular&#x2010;Free Flap Mandibular Reconstruction? A Technical Strategy,&#x201d; Journal of Craniofacial Surgery 35, no. 1 (2024): 63&#x2013;66.</Citation></Reference><Reference><Citation>T. P. Ter Braak, S. G. B. de Koning, M. J. A. van Alphen, et&#xa0;al., &#x201c;A Surgical Navigated Cutting Guide for Mandibular Osteotomies: Accuracy and Reproducibility of an Image&#x2010;Guided Mandibular Osteotomy,&#x201d; International Journal of Computer Assisted Radiology and Surgery 15, no. 10 (2020): 1719&#x2013;1725.</Citation></Reference><Reference><Citation>T. Numajiri, D. Morita, R. Yamochi, et&#xa0;al., &#x201c;Does an In&#x2010;House Computer&#x2010;Aided Design/Computer&#x2010;Aided Manufacturing Approach Contribute to Accuracy and Time Shortening in Mandibular Reconstruction?,&#x201d; Journal of Craniofacial Surgery 31, no. 7 (2020): 1928&#x2013;1932.</Citation></Reference><Reference><Citation>D. Firth, &#x201c;Bias Reduction of Maximum Likelihood Estimates,&#x201d; Biometrika 80 (1993): 27&#x2013;38.</Citation></Reference><Reference><Citation>G. Heinze and M. Schemper, &#x201c;A Solution to the Problem of Separation in Logistic Regression,&#x201d; Statistics in Medicine 21, no. 16 (2002): 2409&#x2013;2419.</Citation></Reference><Reference><Citation>P. Peduzzi, J. Concato, E. Kemper, T. R. Holford, and A. R. Feinstein, &#x201c;A Simulation Study of the Number of Events per Variable in Logistic Regression Analysis,&#x201d; Journal of Clinical Epidemiology 49, no. 12 (1996): 1373&#x2013;1379.</Citation></Reference><Reference><Citation>M. E. May, E. D. Cash, C. L. Silverman, et&#xa0;al., &#x201c;Prognostic Factors and Selection Criteria in the Retreatment of Head and Neck Cancers,&#x201d; Oral Oncology 88 (2019): 85&#x2013;90.</Citation></Reference><Reference><Citation>F. Chiesa, S. Mauri, N. Tradati, et&#xa0;al., &#x201c;Surfing Prognostic Factors in Head and Neck Cancer at the Millennium,&#x201d; Oral Oncology 35, no. 6 (1999): 590&#x2013;596.</Citation></Reference><Reference><Citation>V. Budach and I. Tinhofer, &#x201c;Novel Prognostic Clinical Factors and Biomarkers for Outcome Prediction in Head and Neck Cancer: A Systematic Review,&#x201d; Lancet Oncology 20, no. 6 (2019): e313&#x2013;e326.</Citation></Reference><Reference><Citation>D. M. Steinbacher, &#x201c;Three&#x2010;Dimensional Analysis and Surgical Planning in Craniomaxillofacial Surgery,&#x201d; Journal of Oral and Maxillofacial Surgery 73, no. 12 Suppl (2015): S40&#x2013;S56.</Citation></Reference><Reference><Citation>A. Wysluch, I. Stricker, F. H&#xf6;lzle, K. D. Wolff, and P. Maurer, &#x201c;Intraoperative Evaluation of Bony Margins With Frozen&#x2010;Section Analysis and Trephine Drill Extraction Technique: A Preliminary Study,&#x201d; Head &amp; Neck 32, no. 11 (2010): 1473&#x2013;1478.</Citation></Reference><Reference><Citation>R. A. Ord and S. Aisner, &#x201c;Accuracy of Frozen Sections in Assessing Margins in Oral Cancer Resection,&#x201d; Journal of Oral and Maxillofacial Surgery 55, no. 7 (1997): 663&#x2013;669.</Citation></Reference><Reference><Citation>A. W. Namin, S. D. Bruggers, B. A. Panuganti, K. M. Christopher, R. J. Walker, and M. A. Varvares, &#x201c;Efficacy of Bone Marrow Cytologic Evaluations in Detecting Occult Cancellous Invasion,&#x201d; Laryngoscope 125, no. 5 (2015): E173&#x2013;E179.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70099 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41243878</PMID><DateRevised><Year>2025</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Nov</Month><Day>17</Day></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Regional Osteocutaneous Submental Island Flap for Premaxillary Reconstruction: A Clinical Experience.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70099</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Reconstruction of premaxillary defects remains a surgical challenge due to the region's functional and aesthetic importance. While prosthetic rehabilitation and osteocutaneous free flaps are commonly used, they can be resource-intensive or unsuitable for some patients. This study reports our experience using the regional osteocutaneous submental island flap (ROC-SIF) for premaxillary reconstruction.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We retrospectively reviewed four patients with premaxillary defects who underwent reconstruction using ROC-SIF between 2017 and 2022. All patients had malignant tumors with no clinical or radiologic evidence of cervical lymph node involvement (N0). Flap harvest technique, intraoperative findings, and postoperative outcomes were analyzed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Defect sizes ranged from 30 to 58&#x2009;mm. ROC-SIF provided adequate soft tissue coverage and bony support for all cases. Functional outcomes, including speech and swallowing, were acceptable. Aesthetic results were satisfactory to both patients and surgeons. No major flap-related complications occurred. Donor site morbidity was minimal. However, the narrow diameter of the bony component limited its suitability for dental implantation.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">ROC-SIF is a reliable, cost-effective option for the reconstruction of small to moderate premaxillary defects, particularly in settings where free flap reconstruction is contraindicated or unavailable. Its straightforward harvest, minimal morbidity, and satisfactory functional and aesthetic outcomes make it a viable alternative in selected patients. Further studies with larger cohorts are warranted to better define its role and limitations in oral cavity reconstruction.</AbstractText><CopyrightInformation>&#xa9; 2025 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Karimi</LastName><ForeName>Ebrahim</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Otorhinolaryngology Research Centre, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mousavi</LastName><ForeName>Pooria</ForeName><Initials>P</Initials><Identifier Source="ORCID">0009-0002-8964-4891</Identifier><AffiliationInfo><Affiliation>Otorhinolaryngology Research Centre, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yousefzadeh</LastName><ForeName>Ali</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Otorhinolaryngology Research Centre, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saeedi</LastName><ForeName>Niloufar</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-0113-5479</Identifier><AffiliationInfo><Affiliation>Otorhinolaryngology Research Centre, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farahbakhsh</LastName><ForeName>Farbood</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Otorhinolaryngology Research Centre, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohebbi</LastName><ForeName>Mahdieh</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Otorhinolaryngology Research Centre, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aghazadeh</LastName><ForeName>Kayvan</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Otorhinolaryngology Research Centre, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heidari</LastName><ForeName>Farrokh</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-6904-5691</Identifier><AffiliationInfo><Affiliation>Otorhinolaryngology Research Centre, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>11</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">oral cavity defects</Keyword><Keyword MajorTopicYN="N">osteocutaneous flap</Keyword><Keyword MajorTopicYN="N">premaxillary reconstruction</Keyword><Keyword MajorTopicYN="N">submental flap</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>7</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>10</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>11</Month><Day>17</Day><Hour>9</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>11</Month><Day>17</Day><Hour>9</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>11</Month><Day>17</Day><Hour>5</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41243878</ArticleId><ArticleId IdType="doi">10.1002/hed.70099</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>A. Rahpeyma and S. Khajehahmadi, &#x201c;Submental Artery Island Flap in Intraoral Reconstruction: A Review,&#x201d; Journal of Cranio&#x2010;Maxillofacial Surgery 42, no. 6 (2014): 983&#x2013;989.</Citation></Reference><Reference><Citation>U. A. Patel, &#x201c;The Submental Flap for Head and Neck Reconstruction: Comparison of Outcomes to the Radial Forearm Free Flap,&#x201d; Laryngoscope 130 (2020): S1&#x2013;S10.</Citation></Reference><Reference><Citation>S. M. Mooney, D. C. Sukato, O. Azoulay, and R. M. Rosenfeld, &#x201c;Systematic Review of Submental Artery Island Flap Versus Free Flap in Head and Neck Reconstruction,&#x201d; American Journal of Otolaryngology 42, no. 6 (2021): 103142.</Citation></Reference><Reference><Citation>W. M. Lydiatt, S. G. Patel, B. O'Sullivan, et&#xa0;al., &#x201c;Head and Neck Cancers&#x2014;Major Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual,&#x201d; CA: A Cancer Journal for Clinicians 67, no. 2 (2017): 122&#x2013;137.</Citation></Reference><Reference><Citation>V. Pistre, P. Pelissier, D. Martin, A. Lim, and J. Baudet, &#x201c;Ten Years of Experience With the Submental Flap,&#x201d; Plastic and Reconstructive Surgery 108, no. 6 (2001): 1576&#x2013;1581.</Citation></Reference><Reference><Citation>S. Merten, R. Jiang, and D. Caminer, &#x201c;The Submental Artery Island Flap for Head and Neck Reconstruction,&#x201d; ANZ Journal of Surgery 72, no. 2 (2002): 121&#x2013;124.</Citation></Reference><Reference><Citation>A. Abouchadi, N. Capon&#x2010;Degardin, P. Paten&#xf4;tre, V. Martinot&#x2010;Duquennoy, and P. Pellerin, &#x201c;The Submental Flap in Facial Reconstruction: Advantages and Limitations,&#x201d; Journal of Oral and Maxillofacial Surgery 65, no. 5 (2007): 863&#x2013;869.</Citation></Reference><Reference><Citation>A. A. Amin, M. A. Sakkary, A. A. Khalil, M. A. Rifaat, and S. B. Zayed, &#x201c;The Submental Flap for Oral Cavity Reconstruction: Extended Indications and Technical Refinements,&#x201d; Head &amp; Neck Oncology 3 (2011): 1&#x2013;7.</Citation></Reference><Reference><Citation>B. Bertrand, C. S. Honeyman, A. Emparanza, et&#xa0;al., &#x201c;Twenty&#x2010;Five Years of Experience With the Submental Flap in Facial Reconstruction: Evolution and Technical Refinements Following 311 Cases in Europe and Africa,&#x201d; Plastic and Reconstructive Surgery 143, no. 6 (2019): 1747&#x2013;1758.</Citation></Reference><Reference><Citation>O. Aladashi, M. Shindy, S. Noaman, A. Alqutaibi, and S. Refahee, &#x201c;Effect of Submental Flap Reconstruction Versus Obturator Rehabilitation After Maxillectomy on Quality of Life: A Randomized Clinical Trial,&#x201d; International Journal of Oral and Maxillofacial Surgery 50, no. 9 (2021): 1156&#x2013;1160.</Citation></Reference><Reference><Citation>A. H. Jahromi, L. J. McClure, S. R. Horen, and P. Konofaos, &#x201c;Comprehensive Review of the Submental Flap in Head and Neck and Facial Reconstruction: What Plastic Surgeons Need to Know,&#x201d; Journal of Craniofacial Surgery 32, no. 7 (2021): 2406&#x2013;2410.</Citation></Reference><Reference><Citation>J. K. Meier, S. Spoerl, G. Spanier, et&#xa0;al., &#x201c;Alternatives to Free Flap Surgery for Maxillofacial Reconstruction: Focus on the Submental Island Flap and the Pectoralis Major Myocutaneous Flap,&#x201d; BMC Oral Health 21 (2021): 1&#x2013;8.</Citation></Reference><Reference><Citation>F. P. Salazar, P. Cariati, A. M. Fernandez, and I. M. Lara, &#x201c;Submental Osteocutaneous Flap for Reconstruction of Maxillary and Mandibular Defects After Tumor Resections,&#x201d; Journal of Craniofacial Surgery 36, no. 7 (2025): e832&#x2013;e835, https://doi.org/10.1097/SCS.0000000000011160.</Citation></Reference><Reference><Citation>X. Zhang and Y. Tao, &#x201c;Submental Flap in Head and Neck Reconstruction: Anatomical Insights, Clinical Advances, and Prospective Innovations,&#x201d; Head and Neck Diseases Conflux 1, no. 1 (2025): 41&#x2013;50.</Citation></Reference><Reference><Citation>C. M. L. Setty, V. Konduru, A. J. Tirkey, M. Agrawal, and P. George, &#x201c;The Submental Flap&#x2013;Outcomes and Oncologic Safety in Head and Neck Reconstruction,&#x201d; Advances in Oral and Maxillofacial Surgery 3 (2021): 100082.</Citation></Reference><Reference><Citation>V. Filomena, M. A. Almero, and E. F. Perep&#xe9;rez, &#x201c;Submental Flap: A Reconstructive Option in Head and Neck Surgery,&#x201d; JPRAS Open 42 (2024): 284&#x2013;291.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70091 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41243802</PMID><DateRevised><Year>2025</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Nov</Month><Day>17</Day></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Microvascular Free Tissue Transfer for Reconstruction of Anterior Skull Base Defects.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70091</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">We present our experience with free flap reconstruction of the anterior skull base (SB), focusing on complex composite defects in patients undergoing multimodality therapy for SB tumors.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Outcomes of patients undergoing anterior SB free flap reconstruction were retrospectively analyzed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Sixty-three free flap reconstructions of the anterior SB were performed. Open maxillectomy (56%) and craniofacial resection (46%) were the most common ablative approaches. The anterolateral thigh (ALT) flap was the most common reconstructive method (84%), including chimeric ALT flaps used in 70% of the patients to reconstruct defects that encompassed more than one subsite. Twenty-one (33%) patients experienced a complication within 30&#x2009;days after reconstruction. There were no cases of surgical mortality.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Microvascular free tissue transfer is an effective reconstructive option for the anterior SB. Chimeric free flaps are often best suited for the reconstruction of the anterior SB due to the flexibility of inset, allowing adjacent areas to be reconstructed without adding undesirable bulk.</AbstractText><CopyrightInformation>&#xa9; 2025 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Townes</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><Identifier Source="ORCID">0009-0000-3407-4719</Identifier><AffiliationInfo><Affiliation>Department of Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Edward I</ForeName><Initials>EI</Initials><Identifier Source="ORCID">0000-0003-1067-9750</Identifier><AffiliationInfo><Affiliation>Department of Plastic Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sewastjanow-Silva</LastName><ForeName>Matheus</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-4804-1891</Identifier><AffiliationInfo><Affiliation>Department of Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Peirong</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Plastic Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanna</LastName><ForeName>Ehab Y</ForeName><Initials>EY</Initials><AffiliationInfo><Affiliation>Department of Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeMonte</LastName><ForeName>Franco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raza</LastName><ForeName>Shaan M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanasono</LastName><ForeName>Matthew M</ForeName><Initials>MM</Initials><Identifier Source="ORCID">0000-0001-5534-5426</Identifier><AffiliationInfo><Affiliation>Department of Plastic Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Shirley Y</ForeName><Initials>SY</Initials><Identifier Source="ORCID">0000-0002-3903-8204</Identifier><AffiliationInfo><Affiliation>Department of Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>11</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">free flap</Keyword><Keyword MajorTopicYN="N">free tissue</Keyword><Keyword MajorTopicYN="N">microvascular</Keyword><Keyword MajorTopicYN="N">reconstruction</Keyword><Keyword MajorTopicYN="N">skull base</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>10</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>10</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>11</Month><Day>17</Day><Hour>9</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>11</Month><Day>17</Day><Hour>9</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>11</Month><Day>17</Day><Hour>5</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41243802</ArticleId><ArticleId IdType="doi">10.1002/hed.70091</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>X. Lim, R. Rajagopal, P. Silva, D. S. Jeyaretna, R. Mykula, and M. Potter, &#x201c;A Systematic Review on Outcomes of Anterior Skull Base Reconstruction,&#x201d; Journal of Plastic, Reconstructive &amp; Aesthetic Surgery 73, no. 11 (2020): 1940&#x2013;1950, https://doi.org/10.1016/j.bjps.2020.05.044.</Citation></Reference><Reference><Citation>G. L. Clayman, F. DeMonte, D. M. Jaffe, et&#xa0;al., &#x201c;Outcome and Complications of Extended Cranial&#x2010;Base Resection Requiring Microvascular Free&#x2010;Tissue Transfer,&#x201d; Archives of Otolaryngology&#x2014;Head &amp; Neck Surgery 121, no. 11 (1995): 1253&#x2013;1257, https://doi.org/10.1001/archotol.1995.01890110031006.</Citation></Reference><Reference><Citation>W. Wang, A. Vincent, M. Sokoya, S. Kohlert, S. Kadakia, and Y. Ducic, &#x201c;Free&#x2010;Flap Reconstruction of Skull Base and Orbital Defects,&#x201d; Seminars in Plastic Surgery 33, no. 1 (2019): 72&#x2013;77, https://doi.org/10.1055/s&#x2010;0039&#x2010;1677881.</Citation></Reference><Reference><Citation>J. D. Vargo, W. Przylecki, P. J. Camarata, and B. T. Andrews, &#x201c;Classification and Microvascular Flap Selection for Anterior Cranial Fossa Reconstruction,&#x201d; Journal of Reconstructive Microsurgery 34, no. 8 (2018): 590&#x2013;600, https://doi.org/10.1055/s&#x2010;0038&#x2010;1649520.</Citation></Reference><Reference><Citation>J. C. Irish, P. J. Gullane, F. Gentili, et&#xa0;al., &#x201c;Tumors of the Skull Base: Outcome and Survival Analysis of 77 Cases,&#x201d; Head &amp; Neck 16, no. 1 (1994): 3&#x2013;10, https://doi.org/10.1002/hed.2880160103.</Citation></Reference><Reference><Citation>D. W. Chang, H. N. Langstein, A. Gupta, et&#xa0;al., &#x201c;Reconstructive Management of Cranial Base Defects After Tumor Ablation,&#x201d; Plastic and Reconstructive Surgery 107, no. 6 (2001): 1346&#x2013;1355, Discussion 1356&#x2013;1357, https://doi.org/10.1097/00006534&#x2010;200105000&#x2010;00003.</Citation></Reference><Reference><Citation>M. M. Hanasono, A. Silva, R. J. Skoracki, et&#xa0;al., &#x201c;Skull Base Reconstruction: An Updated Approach,&#x201d; Plastic and Reconstructive Surgery 128, no. 3 (2011): 675&#x2013;686, https://doi.org/10.1097/PRS.0b013e318221dcef.</Citation></Reference><Reference><Citation>R. P. Dang, A. R. Ettyreddy, Z. Rizvi, et&#xa0;al., &#x201c;Free Flap Reconstruction of the Anterior Skull Base: A Systematic Review,&#x201d; Journal of Neurological Surgery, Part B: Skull Base 83, no. 2 (2021): 125&#x2013;132, https://doi.org/10.1055/s&#x2010;0040&#x2010;1718909.</Citation></Reference><Reference><Citation>P. Yu, &#x201c;Characteristics of the Anterolateral Thigh Flap in a Western Population and Its Application in Head and Neck Reconstruction,&#x201d; Head &amp; Neck 26, no. 9 (2004): 759&#x2013;769, https://doi.org/10.1002/hed.20050.</Citation></Reference><Reference><Citation>M. M. Hanasono, J. M. Sacks, N. Goel, M. Ayad, and R. J. Skoracki, &#x201c;The Anterolateral Thigh Free Flap for Skull Base Reconstruction,&#x201d; Otolaryngology&#x2014;Head and Neck Surgery 140, no. 6 (2009): 855&#x2013;860, https://doi.org/10.1016/j.otohns.2009.02.025.</Citation></Reference><Reference><Citation>B. R. Lawson and M. A. Moreno, &#x201c;Head and Neck Reconstruction With Chimeric Anterolateral Thigh Free Flap: Indications, Outcomes, and Technical Considerations,&#x201d; Otolaryngology&#x2014;Head and Neck Surgery 154, no. 1 (2016): 59&#x2013;65, https://doi.org/10.1177/0194599815606438.</Citation></Reference><Reference><Citation>M. M. Hanasono, R. J. Skoracki, and P. Yu, &#x201c;A Prospective Study of Donor&#x2010;Site Morbidity After Anterolateral Thigh Fasciocutaneous and Myocutaneous Free Flap Harvest in 220 Patients,&#x201d; Plastic and Reconstructive Surgery 125, no. 1 (2010): 209&#x2013;214, https://doi.org/10.1097/PRS.0b013e3181c495ed.</Citation></Reference><Reference><Citation>G. G. Hallock, &#x201c;The Complete Nomenclature for Combined Perforator Flaps,&#x201d; Plastic and Reconstructive Surgery 127, no. 4 (2011): 1720&#x2013;1729, https://doi.org/10.1097/PRS.0b013e31820a662b.</Citation></Reference><Reference><Citation>E. V. Mastrolonardo, S. Sussman, P. Llerena, et&#xa0;al., &#x201c;Flow&#x2010;Through Flaps as a Robust Method for Advanced Free Flap Reconstruction in the Head and Neck: A Multi&#x2010;Institutional Experience,&#x201d; Head and Neck 47, no. 5 (2025): 1462&#x2013;1470, https://doi.org/10.1002/hed.28061.</Citation></Reference><Reference><Citation>M. Yong, Y. Q. Wu, S. Su, et&#xa0;al., &#x201c;The Effect of Prior Radiation on the Success of Ventral Skull Base Reconstruction: A Systematic Review and Meta&#x2010;Analysis,&#x201d; Head and Neck 43, no. 9 (2021): 2795&#x2013;2806, https://doi.org/10.1002/hed.26709.</Citation></Reference><Reference><Citation>D. Yaniv and S. Y. Su, &#x201c;Updates in Management Strategies of Locally Advanced Sinonasal Malignancy,&#x201d; Current Opinion in Otolaryngology &amp; Head and Neck Surgery 31, no. 1 (2023): 39&#x2013;44, https://doi.org/10.1097/MOO.0000000000000866.</Citation></Reference><Reference><Citation>M. Amit, A. S. Abdelmeguid, T. Watcherporn, et&#xa0;al., &#x201c;Induction Chemotherapy Response as a Guide for Treatment Optimization in Sinonasal Undifferentiated Carcinoma,&#x201d; Journal of Clinical Oncology 37, no. 6 (2019): 504&#x2013;512, https://doi.org/10.1200/JCO.18.00353.</Citation></Reference><Reference><Citation>E. C. Kuan, E. W. Wang, N. D. Adappa, et&#xa0;al., &#x201c;International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors,&#x201d; International Forum of Allergy &amp; Rhinology 14, no. 2 (2024): 149&#x2013;608, https://doi.org/10.1002/alr.23262.</Citation></Reference><Reference><Citation>K. L. Kiong, C. M. K. L. Yao, F. Y. Lin, et&#xa0;al., &#x201c;Delay to Surgery After Neoadjuvant Chemotherapy in Head and Neck Squamous Cell Carcinoma Affects Oncologic Outcomes,&#x201d; Cancer 127, no. 12 (2021): 1984&#x2013;1992, https://doi.org/10.1002/cncr.33471.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70076 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41221671</PMID><DateRevised><Year>2025</Year><Month>11</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Nov</Month><Day>12</Day></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Genomic and Immune Correlates of EZH2 Expression and Activity in Olfactory Neuroblastoma.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70076</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Olfactory neuroblastoma (ONB) is a rare sinonasal malignancy with limited therapeutic options in the recurrent/metastatic setting; little is known regarding its responsiveness to immunotherapy. Inhibition of enhancer of zeste homolog 2 (EZH2) has been shown to improve T-cell-mediated killing and susceptibility to immune checkpoint inhibitors in a variety of cancers. We aimed to evaluate the expression and activity of EZH2 in ONB and its association with immune characteristics.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">We studied a cohort of 36 ONB real-world patient samples that underwent molecular profiling at a centralized lab (Caris Life Science). To infer EZH2 methyltransferase activity, we adopted an EZH2 gene repression signature (ERS) score: ONB samples were stratified into ERS-low and ERS-high subgroups, corresponding to high and low inferred EZH2 methyltransferase activity, respectively. Transcriptomic data were utilized to calculate the T-cell-inflamed (TCI) score and mitogen-activated protein kinase (MAPK) pathway activation score (MPAS). Tumor immune microenvironment composition was inferred from tumor-derived bulk RNA sequencing data. We analyzed immunologic differences between ERS-low and ERS-high ONB.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In ERS-high ONB, we observed a higher expression of immune-related genes, a higher proportion of TCI tumors, and an enrichment in inflammatory pathways. ERS-high ONB also displayed increased macrophages, and to a lesser extent, B cells and CD8<sup>+</sup> T cell infiltration in the tumor microenvironment. Also, ERS-high was associated with increased MPAS, potentially identifying ONB with increased susceptibility to MAPK inhibitors. These data were confirmed in an independent validation cohort using a publicly available dataset.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Taken together, our data suggest that low EZH2 activity is associated with a more immunogenic microenvironment, paving the way for potential combinations of EZH2 inhibitors with checkpoint blockade in ONB.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). Head &amp; Neck published by Wiley Periodicals LLC. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xue</LastName><ForeName>Elisabetta</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-1963-9555</Identifier><AffiliationInfo><Affiliation>Center for Immuno-Oncology, CCR, NCI, NIH, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adeyelu</LastName><ForeName>Tolulope</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>CARIS Life Sciences, Phoenix, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krause</LastName><ForeName>Harris</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>CARIS Life Sciences, Phoenix, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elliott</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>CARIS Life Sciences, Phoenix, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mehra</LastName><ForeName>Ranee</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>University of Maryland Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soares</LastName><ForeName>Heloisa</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lou</LastName><ForeName>Emil</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vanderwalde</LastName><ForeName>Ari</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>CARIS Life Sciences, Phoenix, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spetzler</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>CARIS Life Sciences, Phoenix, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bracken-Clarke</LastName><ForeName>Dara</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Center for Immuno-Oncology, CCR, NCI, NIH, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>London</LastName><ForeName>Nyall R</ForeName><Initials>NR</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sinonasal and Skull Base Tumor Section, Surgical Oncology Program, CCR, NCI, NIH, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gulley</LastName><ForeName>James L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Center for Immuno-Oncology, CCR, NCI, NIH, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Floudas</LastName><ForeName>Charalampos S</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Center for Immuno-Oncology, CCR, NCI, NIH, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Intramural Research Program, National Institutes of Health, National Cancer Institute, Center for Cancer Research</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>11</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>10</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>11</Month><Day>12</Day><Hour>6</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>11</Month><Day>12</Day><Hour>6</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>11</Month><Day>12</Day><Hour>5</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41221671</ArticleId><ArticleId IdType="doi">10.1002/hed.70076</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>M. J. Zunitch, A. S. Fisch, B. Lin, et&#xa0;al., &#x201c;Molecular Evidence for Olfactory Neuroblastoma as a Tumor of Malignant Globose Basal Cells,&#x201d; Modern Pathology 36, no. 5 (2023): 100122, https://doi.org/10.1016/j.modpat.2023.100122.</Citation></Reference><Reference><Citation>Y. Yang, Z. Wan, E. Zhang, and Y. Piao, &#x201c;Genomic Profiling and Immune Landscape of Olfactory Neuroblastoma in China,&#x201d; Frontiers in Oncology 13 (2023): 1226494, https://doi.org/10.3389/fonc.2023.1226494.</Citation></Reference><Reference><Citation>Y. Hoshi, T. Enokida, S. Tamura, et&#xa0;al., &#x201c;Efficacy of Anti&#x2010;PD&#x2010;1 Monotherapy for Recurrent or Metastatic Olfactory Neuroblastoma,&#x201d; Frontiers in Oncology 14 (2024): 1379013, https://doi.org/10.3389/fonc.2024.1379013.</Citation></Reference><Reference><Citation>S. Hanaki and M. Shimada, &#x201c;Targeting EZH2 as Cancer Therapy,&#x201d; Journal of Biochemistry 170, no. 1 (2021): 1&#x2013;4, https://doi.org/10.1093/jb/mvab007.</Citation></Reference><Reference><Citation>Y. Liao, C. H. Chen, T. Xiao, et&#xa0;al., &#x201c;Inhibition of EZH2 Transactivation Function Sensitizes Solid Tumors to Genotoxic Stress,&#x201d; Proceedings of the National Academy of Sciences of the United States of America 119, no. 3 (2022): e2105898119, https://doi.org/10.1073/pnas.2105898119.</Citation></Reference><Reference><Citation>R. Duan, W. Du, and W. Guo, &#x201c;EZH2: A Novel Target for Cancer Treatment,&#x201d; Journal of Hematology &amp; Oncology 13, no. 1 (2020): 104, https://doi.org/10.1186/s13045&#x2010;020&#x2010;00937&#x2010;8.</Citation></Reference><Reference><Citation>R. D. Morin, N. A. Johnson, T. M. Severson, et&#xa0;al., &#x201c;Somatic Mutations Altering EZH2 (Tyr641) in Follicular and Diffuse Large B&#x2010;Cell Lymphomas of Germinal&#x2010;Center Origin,&#x201d; Nature Genetics 42, no. 2 (2010): 181&#x2013;185, https://doi.org/10.1038/ng.518.</Citation></Reference><Reference><Citation>K. H. Kim, W. Kim, T. P. Howard, et&#xa0;al., &#x201c;SWI/SNF&#x2010;Mutant Cancers Depend on Catalytic and Non&#x2010;Catalytic Activity of EZH2,&#x201d; Nature Medicine 21, no. 12 (2015): 1491&#x2013;1496, https://doi.org/10.1038/nm.3968.</Citation></Reference><Reference><Citation>C. Lanzi, N. Arrighetti, S. Pasquali, and G. Cassinelli, &#x201c;Targeting EZH2 in SMARCB1&#x2010;Deficient Sarcomas: Advances and Opportunities to Potentiate the Efficacy of EZH2 Inhibitors,&#x201d; Biochemical Pharmacology 215 (2023): 115727, https://doi.org/10.1016/j.bcp.2023.115727.</Citation></Reference><Reference><Citation>M. Gounder, P. Schoffski, R. L. Jones, et&#xa0;al., &#x201c;Tazemetostat in Advanced Epithelioid Sarcoma With Loss of INI1/SMARCB1: An International, Open&#x2010;Label, Phase 2 Basket Study,&#x201d; Lancet Oncology 21, no. 11 (2020): 1423&#x2013;1432, https://doi.org/10.1016/S1470&#x2010;2045(20)30451&#x2010;4.</Citation></Reference><Reference><Citation>B. G. Bitler, K. M. Aird, A. Garipov, et&#xa0;al., &#x201c;Synthetic Lethality by Targeting EZH2 Methyltransferase Activity in ARID1A&#x2010;Mutated Cancers,&#x201d; Nature Medicine 21, no. 3 (2015): 231&#x2013;238, https://doi.org/10.1038/nm.3799.</Citation></Reference><Reference><Citation>G. Xiao, L. L. Jin, C. Q. Liu, et&#xa0;al., &#x201c;EZH2 Negatively Regulates PD&#x2010;L1 Expression in Hepatocellular Carcinoma,&#x201d; Journal for Immunotherapy of Cancer 7, no. 1 (2019): 300, https://doi.org/10.1186/s40425&#x2010;019&#x2010;0784&#x2010;9.</Citation></Reference><Reference><Citation>L. Zhou, T. Mudianto, X. Ma, R. Riley, and R. Uppaluri, &#x201c;Targeting EZH2 Enhances Antigen Presentation, Antitumor Immunity, and Circumvents Anti&#x2010;PD&#x2010;1 Resistance in Head and Neck Cancer,&#x201d; Clinical Cancer Research 26, no. 1 (2020): 290&#x2013;300, https://doi.org/10.1158/1078&#x2010;0432.CCR&#x2010;19&#x2010;1351.</Citation></Reference><Reference><Citation>B. Guo, X. Tan, and H. Cen, &#x201c;EZH2 Is a Negative Prognostic Biomarker Associated With Immunosuppression in Hepatocellular Carcinoma,&#x201d; PLoS One 15, no. 11 (2020): e0242191, https://doi.org/10.1371/journal.pone.0242191.</Citation></Reference><Reference><Citation>V. Gambacorta, S. Beretta, M. Ciccimarra, et&#xa0;al., &#x201c;Integrated Multiomic Profiling Identifies the Epigenetic Regulator PRC2 as a Therapeutic Target to Counteract Leukemia Immune Escape and Relapse,&#x201d; Cancer Discovery 12, no. 6 (2022): 1449&#x2013;1461, https://doi.org/10.1158/2159&#x2010;8290.CD&#x2010;21&#x2010;0980.</Citation></Reference><Reference><Citation>D. Zingg, N. Arenas&#x2010;Ramirez, D. Sahin, et&#xa0;al., &#x201c;The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy,&#x201d; Cell Reports 20, no. 4 (2017): 854&#x2013;867, https://doi.org/10.1016/j.celrep.2017.07.007.</Citation></Reference><Reference><Citation>K. L. Morel, A. V. Sheahan, D. L. Burkhart, et&#xa0;al., &#x201c;EZH2 Inhibition Activates a dsRNA&#x2010;STING&#x2010;Interferon Stress Axis That Potentiates Response to PD&#x2010;1 Checkpoint Blockade in Prostate Cancer,&#x201d; Nature Cancer 2, no. 4 (2021): 444&#x2013;456, https://doi.org/10.1038/s43018&#x2010;021&#x2010;00185&#x2010;w.</Citation></Reference><Reference><Citation>B. J. Goldstein, G. M. Goss, R. Choi, et&#xa0;al., &#x201c;Contribution of Polycomb Group Proteins to Olfactory Basal Stem Cell Self&#x2010;Renewal in a Novel c&#x2010;KIT+ Culture Model and In&#xa0;Vivo,&#x201d; Development 143, no. 23 (2016): 4394&#x2013;4404, https://doi.org/10.1242/dev.142653.</Citation></Reference><Reference><Citation>J. B. Finlay, R. Abi Hachem, D. W. Jang, N. Osazuwa&#x2010;Peters, and B. J. Goldstein, &#x201c;Deconstructing Olfactory Epithelium Developmental Pathways in Olfactory Neuroblastoma,&#x201d; Cancer Research Communications 3, no. 6 (2023): 980&#x2013;990, https://doi.org/10.1158/2767&#x2010;9764.CRC&#x2010;23&#x2010;0013.</Citation></Reference><Reference><Citation>M. Classe, H. Yao, R. Mouawad, et&#xa0;al., &#x201c;Integrated Multi&#x2010;Omic Analysis of Esthesioneuroblastomas Identifies Two Subgroups Linked to Cell Ontogeny,&#x201d; Cell Reports 25, no. 3 (2018): 811&#x2013;821.e5, https://doi.org/10.1016/j.celrep.2018.09.047.</Citation></Reference><Reference><Citation>R. Bao, D. Stapor, and J. J. Luke, &#x201c;Molecular Correlates and Therapeutic Targets in T Cell&#x2010;Inflamed Versus Non&#x2010;T Cell&#x2010;Inflamed Tumors Across Cancer Types,&#x201d; Genome Medicine 12, no. 1 (2020): 90, https://doi.org/10.1186/s13073&#x2010;020&#x2010;00787&#x2010;6.</Citation></Reference><Reference><Citation>M. C. Wagle, D. Kirouac, C. Klijn, et&#xa0;al., &#x201c;A Transcriptional MAPK Pathway Activity Score (MPAS) is a Clinically Relevant Biomarker in Multiple Cancer Types,&#x201d; npj Precision Oncology 2, no. 1 (2018): 7, https://doi.org/10.1038/s41698&#x2010;018&#x2010;0051&#x2010;4.</Citation></Reference><Reference><Citation>F. Finotello, C. Mayer, C. Plattner, et&#xa0;al., &#x201c;Molecular and Pharmacological Modulators of the Tumor Immune Contexture Revealed by Deconvolution of RNA&#x2010;Seq Data,&#x201d; Genome Medicine 11, no. 1 (2019): 34, https://doi.org/10.1186/s13073&#x2010;019&#x2010;0638&#x2010;6.</Citation></Reference><Reference><Citation>J. Yu, J. Yu, D. R. Rhodes, et&#xa0;al., &#x201c;A Polycomb Repression Signature in Metastatic Prostate Cancer Predicts Cancer Outcome,&#x201d; Cancer Research 67, no. 22 (2007): 10657&#x2013;10663, https://doi.org/10.1158/0008&#x2010;5472.CAN&#x2010;07&#x2010;2498.</Citation></Reference><Reference><Citation>B. Muzellec, M. Telenczuk, V. Cabeli, and M. Andreux, &#x201c;PyDESeq2: A Python Package for Bulk RNA&#x2010;Seq Differential Expression Analysis,&#x201d; Bioinformatics 39, no. 9 (2023): btad547, https://doi.org/10.1093/bioinformatics/btad547.</Citation></Reference><Reference><Citation>A. Subramanian, P. Tamayo, V. K. Mootha, et&#xa0;al., &#x201c;Gene Set Enrichment Analysis: A Knowledge&#x2010;Based Approach for Interpreting Genome&#x2010;Wide Expression Profiles,&#x201d; Proceedings of the National Academy of Sciences of the United States of America 102, no. 43 (2005): 15545&#x2013;15550, https://doi.org/10.1073/pnas.0506580102.</Citation></Reference><Reference><Citation>A. Liberzon, C. Birger, H. Thorvaldsdottir, M. Ghandi, J. P. Mesirov, and P. Tamayo, &#x201c;The Molecular Signatures Database (MSigDB) Hallmark Gene Set Collection,&#x201d; Cell Systems 1, no. 6 (2015): 417&#x2013;425, https://doi.org/10.1016/j.cels.2015.12.004.</Citation></Reference><Reference><Citation>M. I. Love, W. Huber, and S. Anders, &#x201c;Moderated Estimation of Fold Change and Dispersion for RNA&#x2010;Seq Data With DESeq2,&#x201d; Genome Biology 15, no. 12 (2014): 550, https://doi.org/10.1186/s13059&#x2010;014&#x2010;0550&#x2010;8.</Citation></Reference><Reference><Citation>P. J. Vlachostergios, &#x201c;Polycomb Repressive Complex 2 Mutations Predict Survival Benefit in Advanced Cancer Patients Treated With Immune Checkpoint Inhibitors,&#x201d; Immuno&#x2010;Oncology and Technology 10 (2021): 100035, https://doi.org/10.1016/j.iotech.2021.100035.</Citation></Reference><Reference><Citation>D. Ennishi, K. Takata, W. Beguelin, et&#xa0;al., &#x201c;Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition,&#x201d; Cancer Discovery 9, no. 4 (2019): 546&#x2013;563, https://doi.org/10.1158/2159&#x2010;8290.CD&#x2010;18&#x2010;1090.</Citation></Reference><Reference><Citation>Y. Isshiki, X. Chen, M. Teater, et&#xa0;al., &#x201c;EZH2 Inhibition Enhances T Cell Immunotherapies by Inducing Lymphoma Immunogenicity and Improving T Cell Function,&#x201d; Cancer Cell Jan 13 43, no. 1 (2025): 49&#x2013;68.e9, https://doi.org/10.1016/j.ccell.2024.11.006.</Citation></Reference><Reference><Citation>J. Shan, W. Jing, Y. Ping, et&#xa0;al., &#x201c;LFA&#x2010;1 Regulated by IL&#x2010;2/STAT5 Pathway Boosts Antitumor Function of Intratumoral CD8(+) T Cells for Improving Anti&#x2010;PD&#x2010;1 Antibody Therapy,&#x201d; Oncoimmunology 13, no. 1 (2024): 2293511, https://doi.org/10.1080/2162402X.2023.2293511.</Citation></Reference><Reference><Citation>A. R. Jung, C. H. Jung, J. K. Noh, Y. C. Lee, and Y. G. Eun, &#x201c;Epithelial&#x2010;Mesenchymal Transition Gene Signature Is Associated With Prognosis and Tumor Microenvironment in Head and Neck Squamous Cell Carcinoma,&#x201d; Scientific Reports 10, no. 1 (2020): 3652, https://doi.org/10.1038/s41598&#x2010;020&#x2010;60707&#x2010;x.</Citation></Reference><Reference><Citation>H. Cardenas, J. Zhao, E. Vieth, K. P. Nephew, and D. Matei, &#x201c;EZH2 Inhibition Promotes Epithelial&#x2010;to&#x2010;Mesenchymal Transition in Ovarian Cancer Cells,&#x201d; Oncotarget 7, no. 51 (2016): 84453&#x2013;84467, https://doi.org/10.18632/oncotarget.11497.</Citation></Reference><Reference><Citation>A. Gallardo, L. L&#xf3;pez&#x2010;Onieva, E. Belmonte&#x2010;Reche, et&#xa0;al., &#x201c;EZH2 Represses Mesenchymal Genes and Upholds the Epithelial State of Breast Carcinoma Cells,&#x201d; Cell Death &amp; Disease 15, no. 8 (2024): 609, https://doi.org/10.1038/s41419&#x2010;024&#x2010;07011&#x2010;y.</Citation></Reference><Reference><Citation>Y. F. Wang, L. Yu, Z. L. Hu, et&#xa0;al., &#x201c;Regulation of CCL2 by EZH2 Affects Tumor&#x2010;Associated Macrophages Polarization and Infiltration in Breast Cancer,&#x201d; Cell Death &amp; Disease 13, no. 8 (2022): 748, https://doi.org/10.1038/s41419&#x2010;022&#x2010;05169&#x2010;x.</Citation></Reference><Reference><Citation>E. Riquelme, C. Behrens, H. Y. Lin, et&#xa0;al., &#x201c;Modulation of EZH2 Expression by MEK&#x2010;ERK or PI3K&#x2010;AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations,&#x201d; Cancer Research 76, no. 3 (2016): 675&#x2013;685, https://doi.org/10.1158/0008&#x2010;5472.CAN&#x2010;15&#x2010;1141.</Citation></Reference><Reference><Citation>P. Jurmeister, S. Gloss, R. Roller, et&#xa0;al., &#x201c;DNA Methylation&#x2010;Based Classification of Sinonasal Tumors,&#x201d; Nature Communications 13, no. 1 (2022): 7148, https://doi.org/10.1038/s41467&#x2010;022&#x2010;34815&#x2010;3.</Citation></Reference><Reference><Citation>L. M. Rooper, A. Agaimy, D. Bell, et&#xa0;al., &#x201c;Recurrent Wnt Pathway and ARID1A Alterations in Sinonasal Olfactory Carcinoma,&#x201d; Modern Pathology 37, no. 5 (2024): 100448, https://doi.org/10.1016/j.modpat.2024.100448.</Citation></Reference><Reference><Citation>Y. Drosos, J. A. Myers, B. Xu, et&#xa0;al., &#x201c;NSD1 Mediates Antagonism Between SWI/SNF and Polycomb Complexes and Is Required for Transcriptional Activation Upon EZH2 Inhibition,&#x201d; Molecular Cell 82, no. 13 (2022): 2472&#x2013;2489.e8, https://doi.org/10.1016/j.molcel.2022.04.015.</Citation></Reference><Reference><Citation>Z. Liu, X. Hu, Q. Wang, et&#xa0;al., &#x201c;Design and Synthesis of EZH2&#x2010;Based PROTACs to Degrade the PRC2 Complex for Targeting the Noncatalytic Activity of EZH2,&#x201d; Journal of Medicinal Chemistry 64, no. 5 (2021): 2829&#x2013;2848, https://doi.org/10.1021/acs.jmedchem.0c02234.</Citation></Reference><Reference><Citation>S. Radko&#x2010;Juettner, H. Yue, J. A. Myers, et&#xa0;al., &#x201c;Targeting DCAF5 Suppresses SMARCB1&#x2010;Mutant Cancer by Stabilizing SWI/SNF,&#x201d; Nature 628, no. 8007 (2024): 442&#x2013;449, https://doi.org/10.1038/s41586&#x2010;024&#x2010;07250&#x2010;1.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70093 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41216777</PMID><DateRevised><Year>2025</Year><Month>11</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Nov</Month><Day>11</Day></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>An Isolated Soft Tissue Ectopic Paraganglioma in the Head and Neck.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70093</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Paragangliomas are rare neuroendocrine tumors derived from autonomic paraganglia of neural crest origin. While typically found at predictable sites in the head and neck, ectopic paragangliomas in unusual locations are exceptionally rare and diagnostically challenging.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We describe a novel presentation of an ectopic paraganglioma found as a discrete soft tissue mass in the neck.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A 45-year-old female with a pathogenic mutation in the SDHB gene was diagnosed with an isolated ectopic paraganglioma in left level III. Intraoperatively, the soft tissue mass was anatomically separate from the carotid sheath and all thyroid and laryngeal neurovascular structures. Histopathology revealed the absence of lymph node architecture, excluding the diagnosis of metastasis.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This case represents a previously unreported location of an ectopic head and neck paraganglioma, unrelated to known neurovascular structures or nodal metastasis, highlighting key diagnostic and management considerations-especially in the context of hereditary disease.</AbstractText><CopyrightInformation>&#xa9; 2025 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sayeed</LastName><ForeName>Salmaan</ForeName><Initials>S</Initials><Identifier Source="ORCID">0009-0009-7344-5784</Identifier><AffiliationInfo><Affiliation>THANC (Thyroid, Head &amp; Neck Cancer) Foundation, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stanisce</LastName><ForeName>Luke</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-9681-6052</Identifier><AffiliationInfo><Affiliation>THANC (Thyroid, Head &amp; Neck Cancer) Foundation, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramirez</LastName><ForeName>Ricardo J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>THANC (Thyroid, Head &amp; Neck Cancer) Foundation, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sohn</LastName><ForeName>Soo Yeon</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khorsandi</LastName><ForeName>Azita</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Urken</LastName><ForeName>Mark L</ForeName><Initials>ML</Initials><Identifier Source="ORCID">0000-0002-6615-9247</Identifier><AffiliationInfo><Affiliation>THANC (Thyroid, Head &amp; Neck Cancer) Foundation, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>11</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ectopic paraganglioma</Keyword><Keyword MajorTopicYN="N">hereditary disease</Keyword><Keyword MajorTopicYN="N">isolated paraganglioma</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>10</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>11</Month><Day>11</Day><Hour>6</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>11</Month><Day>11</Day><Hour>6</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>11</Month><Day>11</Day><Hour>5</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41216777</ArticleId><ArticleId IdType="doi">10.1002/hed.70093</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>P. K. Pellitteri, A. Rinaldo, D. Myssiorek, et&#xa0;al., &#x201c;Paragangliomas of the Head and Neck,&#x201d; Oral Oncology 40, no. 6 (2004): 563&#x2013;575, https://doi.org/10.1016/j.oraloncology.2003.09.004.</Citation></Reference><Reference><Citation>V. Mehta, T. Fischer, G. Levi, B. Wang, and M. L. Urken, &#x201c;Hypopharyngeal Paraganglioma: Case Report and Review of the Literature,&#x201d; Head &amp; Neck 35, no. 7 (2013): E205&#x2013;E208, https://doi.org/10.1002/hed.23002.</Citation></Reference><Reference><Citation>P. M. Konowitz, W. Lawson, M. L. Urken, P. M. Som, B. A. Breakstone, and H. F. Biller, &#x201c;Laryngeal Paraganglioma: Update on Diagnosis and Treatment,&#x201d; Laryngoscope 98, no. 1 (1988): 40&#x2013;49, https://doi.org/10.1288/00005537&#x2010;198801000&#x2010;00010.</Citation></Reference><Reference><Citation>M. Brandwein, G. Levi, P. Som, and M. L. Urken, &#x201c;Paraganglioma of the Inferior Laryngeal Paraganglia: A Case Report,&#x201d; Archives of Otolaryngology 118, no. 9 (1992): 994&#x2013;996, https://doi.org/10.1001/archotol.1992.01880090110029.</Citation></Reference><Reference><Citation>B.&#x2010;H. Yu, W.&#x2010;Q. Sheng, and J. Wang, &#x201c;Primary Paraganglioma of Thyroid Gland: A Clinicopathologic and Immunohistochemical Analysis of Three Cases With a Review of the Literature,&#x201d; Head and Neck Pathology 7, no. 4 (2013): 373&#x2013;380, https://doi.org/10.1007/s12105&#x2010;013&#x2010;0467&#x2010;7.</Citation></Reference><Reference><Citation>J. Yun, D. Kapustin, A. Omorogbe, et&#xa0;al., &#x201c;Report of a Vagal Paraganglioma at the Cervicothoracic Junction,&#x201d; Head &amp; Neck 45, no. 10 (2023): E36&#x2013;E43, https://doi.org/10.1002/hed.27481.</Citation></Reference><Reference><Citation>Y. M. D. Wang, Z. M. D. Liu, C. M. D. Lian, S. P. Wang, and J. P. Wang, &#x201c;An Ectopic Paraganglioma Supplied by the Subclavian Artery in the Right Supraclavicular Fossa,&#x201d; Journal of Vascular Surgery Cases and Innovative Techniques 5, no. 2 (2019): 91&#x2013;94, https://doi.org/10.1016/j.jvscit.2018.09.009.</Citation></Reference><Reference><Citation>O. Mete and B. M. Wenig, &#x201c;Update From the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Overview of the 2022 WHO Classification of Head and Neck Neuroendocrine Neoplasms,&#x201d; Head and Neck Pathology 16, no. 1 (2022): 123&#x2013;142, https://doi.org/10.1007/s12105&#x2010;022&#x2010;01435&#x2010;8.</Citation></Reference><Reference><Citation>J. M. Bilbao, E. Horvath, K. Kovacs, W. Singer, and A. R. Hudson, &#x201c;Intrasellar Paraganglioma Associated With Hypopituitarism,&#x201d; Archives of Pathology &amp; Laboratory Medicine 102, no. 2 (1978): 95&#x2013;98.</Citation></Reference><Reference><Citation>L. V. Lotti, S. Vespa, M. R. Pantalone, et&#xa0;al., &#x201c;A Developmental Perspective on Paragangliar Tumorigenesis,&#x201d; Cancers 11, no. 3 (2019): 273, https://doi.org/10.3390/cancers11030273.</Citation></Reference><Reference><Citation>T. Papp, Z. Ferenczi, M. Petro, Z. Meszar, Z. Kepes, and E. Berenyi, &#x201c;Disorders of Neural Crest Derivates in Oncoradiological Practice,&#x201d; Translational Cancer Research 8, no. 8 (2019): 2916&#x2013;2923, https://doi.org/10.21037/tcr.2019.10.38.</Citation></Reference><Reference><Citation>K.&#x2010;C. Ho, G. Meyer, J. Garancis, and J. Hanna, &#x201c;Chemodectoma Involving the Cavernous Sinus and Semilunar Ganglion,&#x201d; Human Pathology 13, no. 10 (1982): 942&#x2013;943, https://doi.org/10.1016/S0046&#x2010;8177(82)80058&#x2010;0.</Citation></Reference><Reference><Citation>N. Subedi, R. Prestwich, F. Chowdhury, C. Patel, and A. Scarsbrook, &#x201c;Neuroendocrine Tumours of the Head and Neck: Anatomical, Functional and Molecular Imaging and Contemporary Management,&#x201d; Cancer Imaging 13, no. 3 (2013): 407&#x2013;422, https://doi.org/10.1102/1470&#x2010;7330.2013.0034.</Citation></Reference><Reference><Citation>M. R. B. Farr, T. P. C. Martin, A. R. Walsh, and R. M. Irving, &#x201c;A Case of Paraganglioma of the Hypoglossal Nerve,&#x201d; Journal of Laryngology &amp; Otology 124, no. 5 (2010): e3, https://doi.org/10.1017/S0022215110000794.</Citation></Reference><Reference><Citation>D. S. Fink, M. M. Benoit, G. M. Lamuraglia, and D. G. Deschler, &#x201c;Paraganglioma of the Hypoglossal Nerve,&#x201d; Laryngoscope 120, no. S4 (2010): S147, https://doi.org/10.1002/lary.21611.</Citation></Reference><Reference><Citation>L. Sandow, R. Thawani, M. S. Kim, and M. C. Heinrich, &#x201c;Paraganglioma of the Head and Neck: A Review,&#x201d; Endocrine Practice 29, no. 2 (2023): 141&#x2013;147, https://doi.org/10.1016/j.eprac.2022.10.002.</Citation></Reference><Reference><Citation>W. M. Mendenhall, R. J. Amdur, M. Vaysberg, C. M. Mendenhall, and J. W. Werning, &#x201c;Head and Neck Paragangliomas,&#x201d; Head &amp; Neck 33, no. 10 (2011): 1530&#x2013;1534, https://doi.org/10.1002/hed.21524.</Citation></Reference><Reference><Citation>C. Offergeld, C. Brase, S. Yaremchuk, et&#xa0;al., &#x201c;Head and Neck Paragangliomas: Clinical and Molecular Genetic Classification,&#x201d; Clinics (S&#xe3;o Paulo, Brazil) 67, no. suppl 1 (2012): 19&#x2013;28, https://doi.org/10.6061/clinics/2012(Sup01)05.</Citation></Reference><Reference><Citation>F. Schiavi, C. C. Boedeker, B. Bausch, et&#xa0;al., &#x201c;Predictors and Prevalence of Paraganglioma Syndrome Associated With Mutations of the SDHC Gene,&#x201d; JAMA: The Journal of the American Medical Association 294, no. 16 (2005): 2057&#x2013;2063, https://doi.org/10.1001/jama.294.16.2057.</Citation></Reference><Reference><Citation>D. E. Benn, Y. Zhu, K. A. Andrews, et&#xa0;al., &#x201c;Bayesian Approach to Determining Penetrance of Pathogenic SDH Variants,&#x201d; Journal of Medical Genetics 55, no. 11 (2018): 729&#x2013;734, https://doi.org/10.1136/jmedgenet&#x2010;2018&#x2010;105427.</Citation></Reference><Reference><Citation>K. A. Andrews, D. B. Ascher, D. E. V. Pires, et&#xa0;al., &#x201c;Tumour Risks and Genotype&#x2013;Phenotype Correlations Associated With Germline Variants in Succinate Dehydrogenase Subunit Genes SDHB, SDHC and SDHD,&#x201d; Journal of Medical Genetics 55, no. 6 (2018): 384&#x2013;394, https://doi.org/10.1136/jmedgenet&#x2010;2017&#x2010;105127.</Citation></Reference><Reference><Citation>I. Jochmanova, K. I. Wolf, K. S. King, et&#xa0;al., &#x201c;SDHB&#x2010;Related Pheochromocytoma and Paraganglioma Penetrance and Genotype&#x2013;Phenotype Correlations,&#x201d; Journal of Cancer Research and Clinical Oncology 143, no. 8 (2017): 1421&#x2013;1435, https://doi.org/10.1007/s00432&#x2010;017&#x2010;2397&#x2010;3.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70084 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41195582</PMID><DateRevised><Year>2025</Year><Month>11</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Nov</Month><Day>06</Day></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Quality of Life After Surgical Treatment of Head and Neck Paragangliomas.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70084</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Head and neck paragangliomas (HNPGLs) are rare neuroendocrine tumors and often arise in the head and neck. Due to their localization, the tumor and its surgical treatment pose a risk for cranial nerve impairments. Few studies have focused on the health-related quality of life (HRQOL) in patients with HNPGLs and their relation to tumor localization.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In patients (n&#x2009;=&#x2009;125) treated with primary surgery for HNPGLs between 2006 and 2023, clinical data was obtained. Long-term QOL was assessed with the validated German version of the EORTC QLQ-H&amp;N43 with a mean follow-up since surgery of 6.0&#x2009;years.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Most common were carotid body PGLs (n&#x2009;=&#x2009;78; 62.4%) including Shamblin I (n&#x2009;=&#x2009;25), II (n&#x2009;=&#x2009;42) and III (n&#x2009;=&#x2009;9) along jugular (n&#x2009;=&#x2009;31; 24.8%) and vagal (n&#x2009;=&#x2009;10; 8.0%) tumors. In the QLQ-H&amp;N43, the scales fear of progression (41.2), coughing (33.9), neurological problems (22.4), sexuality (21.4), and swallowing (21.2) showed the highest mean scores. Jugular and vagal tumors showed higher symptom levels compared to carotid body tumors, especially Shamblin I.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Surgical treatment of PGLs may lead to significant impairments in physical and psychological domains, especially in larger carotid body, vagal and jugular tumors. Structured pre- and postoperative cranial nerve examinations and interprofessional support should be provided to mitigate postoperative QOL reduction.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). Head &amp; Neck published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sauter</LastName><ForeName>Christina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, Head and Neck Surgery, Heidelberg University Hospital, Heidelberg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, Head and Neck Surgery, Augsburg University Hospital, Augsburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erhart</LastName><ForeName>Philipp</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Vascular and Endovascular Surgery, Heidelberg University Hospital, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>B&#xf6;ckler</LastName><ForeName>Dittmar</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Vascular and Endovascular Surgery, Heidelberg University Hospital, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuler</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, Head and Neck Surgery, Heidelberg University Hospital, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Plinkert</LastName><ForeName>Peter K</ForeName><Initials>PK</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, Head and Neck Surgery, Heidelberg University Hospital, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hohenberger</LastName><ForeName>Ralph</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-6289-296X</Identifier><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, Head and Neck Surgery, Heidelberg University Hospital, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>11</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">head and neck paraganglioma</Keyword><Keyword MajorTopicYN="N">paraganglioma</Keyword><Keyword MajorTopicYN="N">quality of life</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>7</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>11</Month><Day>6</Day><Hour>5</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41195582</ArticleId><ArticleId IdType="doi">10.1002/hed.70084</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>N. D. Cass, M. A. Schopper, J. A. Lubin, L. Fishbein, and S. P. Gubbels, &#x201c;The Changing Paradigm of Head and Neck Paragangliomas: What Every Otolaryngologist Needs to Know,&#x201d; Annals of Otology, Rhinology and Laryngology 129, no. 11 (2020): 1135&#x2013;1143, https://doi.org/10.1177/0003489420931540.</Citation></Reference><Reference><Citation>L. Sandow, R. Thawani, M. S. Kim, and M. C. Heinrich, &#x201c;Paraganglioma of the Head and Neck: A Review,&#x201d; Endocrine Practice 29, no. 2 (2023): 141&#x2013;147, https://doi.org/10.1016/j.eprac.2022.10.002.</Citation></Reference><Reference><Citation>C. Offergeld, C. Brase, S. Yaremchuk, et&#xa0;al., &#x201c;Head and Neck Paragangliomas: Clinical and Molecular Genetic Classification,&#x201d; Clinics (2012): 67, https://doi.org/10.6061/clinics/2012(Sup01)05.</Citation></Reference><Reference><Citation>J. H. Lee, F. Barich, L. H. Karnell, et&#xa0;al., &#x201c;National Cancer Data Base Report on Malignant Paragangliomas of the Head and Neck,&#x201d; Cancer 94, no. 3 (2002): 730&#x2013;737, https://doi.org/10.1002/cncr.10252.</Citation></Reference><Reference><Citation>A. Mediouni, S. Ammari, M. Wassef, et&#xa0;al., &#x201c;Malignant Head/Neck Paragangliomas,&#x201d; Comparative Study. European Annals of Otorhinolaryngology, Head and Neck Diseases 131, no. 3 (2014): 159&#x2013;166, https://doi.org/10.1016/j.anorl.2013.05.003.</Citation></Reference><Reference><Citation>O. Mete, S. L. Asa, A. J. Gill, N. Kimura, R. R. de Krijger, and A. Tischler, &#x201c;Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas,&#x201d; Endocrine Pathology 33 (2022): 90&#x2013;114, https://doi.org/10.1007/s12022&#x2010;022&#x2010;09704&#x2010;6.</Citation></Reference><Reference><Citation>S. Richter, B. Qiu, M. Ghering, et&#xa0;al., &#x201c;Head/Neck Paragangliomas: Focus on Tumor Location, Mutational Status and Plasma Methoxytyramine,&#x201d; Endocrine&#x2010;Related Cancer 29, no. 4 (2022): 213&#x2013;224, https://doi.org/10.1530/ERC&#x2010;21&#x2010;0359.</Citation></Reference><Reference><Citation>G. Rougier, A. Rochand, R. Bourdais, et&#xa0;al., &#x201c;Long&#x2010;Term Outcomes in Head and Neck Paragangliomas Managed With Intensity&#x2010;Modulated Radiotherapy,&#x201d; Laryngoscope 133, no. 3 (2023): 607&#x2013;614, https://doi.org/10.1002/lary.30226.</Citation></Reference><Reference><Citation>B. Havekes, A. A. van der Klaauw, H. C. Hoftijzer, et&#xa0;al., &#x201c;Reduced Quality of Life in Patients With Head&#x2010;And&#x2010;Neck Paragangliomas,&#x201d; European Journal of Endocrinology 158, no. 2 (2008): 247&#x2013;253, https://doi.org/10.1530/EJE&#x2010;07&#x2010;0464.</Citation></Reference><Reference><Citation>C. M. Hoffmann&#x2010;Wieker, A. Rebelo, M. Moll, et&#xa0;al., &#x201c;Association of Tumor Volumetry With Postoperative Outcomes for Cervical Paraganglioma,&#x201d; Diagnostics 13, no. 4 (2023): 744, https://doi.org/10.3390/diagnostics13040744.</Citation></Reference><Reference><Citation>S. Singer, C. D. Amdal, E. Hammerlid, et&#xa0;al., &#x201c;International Validation of the Revised European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module, the EORTC QLQ&#x2010;HN43: Phase IV,&#x201d; Head &amp; Neck 41, no. 6 (2019): 1725&#x2013;1737, https://doi.org/10.1002/hed.25609.</Citation></Reference><Reference><Citation>R. J. Ellis, D. Patel, T. Prodanov, N. Nilubol, K. Pacak, and E. Kebebew, &#x201c;The Presence of SDHB Mutations Should Modify Surgical Indications for Carotid Body Paragangliomas,&#x201d; Annals of Surgery 260, no. 1 (2014): 158&#x2013;162, https://doi.org/10.1097/SLA.0000000000000283.</Citation></Reference><Reference><Citation>S. Batista, L. B. Palavani, F. Fim Andre&#xe3;o, et&#xa0;al., &#x201c;Assessing the Safety and Efficacy of EVOH Pre&#x2010;Embolization in Head and Neck Paraganglioma Tumors: A Comprehensive Analysis of Current Literature,&#x201d; Journal of Clinical Neuroscience 120 (2024): 147&#x2013;153, https://doi.org/10.1016/j.jocn.2024.01.017.</Citation></Reference><Reference><Citation>P. De Marini, M. Greget, E. Boatta, et&#xa0;al., &#x201c;Safety and Technical Efficacy of Pre&#x2010;Operative Embolization of Head and Neck Paragangliomas: A 10&#x2010;Year Mono&#x2010;Centric Experience and Systematic Review: Pre&#x2010;Operative Embolization of Head and Neck Paraganglioma,&#x201d; Clinical Imaging 80 (2021): 292&#x2013;299, https://doi.org/10.1016/j.clinimag.2021.08.014.</Citation></Reference><Reference><Citation>W. M. Mendenhall, C. G. Morris, R. J. Amdur, K. E. Hitchcock, N. L. Silver, and P. T. Dziegielewski, &#x201c;Radiotherapy for Benign Head and Neck Paragangliomas,&#x201d; Head &amp; Neck 41, no. 7 (2019): 2107&#x2013;2110, https://doi.org/10.1002/hed.25664.</Citation></Reference><Reference><Citation>P. Gilbo, C. G. Morris, R. J. Amdur, et&#xa0;al., &#x201c;Radiotherapy for Benign Head and Neck Paragangliomas: A 45&#x2010;Year Experience,&#x201d; Cancer 120, no. 23 (2014): 3738&#x2013;3743, https://doi.org/10.1002/cncr.28923.</Citation></Reference><Reference><Citation>J. K&#xfc;nzel, M. Koch, C. Brase, R. Fietkau, H. Iro, and J. Zenk, &#x201c;Treatment of Cervical Paragangliomas: Is Surgery the Only Way?,&#x201d; American Journal of Otolaryngology &#x2013; Head and Neck Medicine and Surgery 35, no. 2 (2014): 186&#x2013;191, https://doi.org/10.1016/j.amjoto.2013.08.020.</Citation></Reference><Reference><Citation>D. Ta&#xef;eb, A. Kaliski, C. C. Boedeker, et&#xa0;al., &#x201c;Current Approaches and Recent Developments in the Management of Head and Neck Paragangliomas,&#x201d; Endocrine Reviews 35, no. 5 (2014): 795&#x2013;819, https://doi.org/10.1210/er.2014&#x2010;1026.</Citation></Reference><Reference><Citation>A. P. Gimenez&#x2010;Roqueplo, P. L. Dahia, and M. Robledo, &#x201c;An Update on the Genetics of Paraganglioma, Pheochromocytoma, and Associated Hereditary Syndromes,&#x201d; Hormone and Metabolic Research 44, no. 5 (2012): 328&#x2013;333, https://doi.org/10.1055/s&#x2010;0031&#x2010;1301302.</Citation></Reference><Reference><Citation>D. E. Benn, A. P. Gimenez&#x2010;Roqueplo, J. R. Reilly, et&#xa0;al., &#x201c;Clinical Presentation and Penetrance of Pheochromocytoma/Paraganglioma Syndromes,&#x201d; Journal of Clinical Endocrinology and Metabolism 91, no. 3 (2006): 827&#x2013;836, https://doi.org/10.1210/jc.2005&#x2010;1862.</Citation></Reference><Reference><Citation>N. D. Niemeijer, J. A. Rijken, K. Eijkelenkamp, et&#xa0;al., &#x201c;The Phenotype of SDHB Germline Mutation Carriers: A Nationwide Study,&#x201d; European Journal of Endocrinology 177, no. 2 (2017): 115&#x2013;125, https://doi.org/10.1530/EJE&#x2010;17&#x2010;0074.</Citation></Reference><Reference><Citation>J. Schovanek, V. Martucci, R. Wesley, et&#xa0;al., &#x201c;The Size of the Primary Tumor and Age at Initial Diagnosis Are Independent Predictors of the Metastatic Behavior and Survival of Patients With SDHB&#x2010;Related Pheochromocytoma and Paraganglioma: A Retrospective Cohort Study,&#x201d; BMC Cancer 14 (2014): 523, https://doi.org/10.1186/1471&#x2010;2407&#x2010;14&#x2010;523.</Citation></Reference><Reference><Citation>P. Erhart, D. K&#xf6;rfer, C. Hoffmann&#x2010;Wieker, et&#xa0;al., &#x201c;Paragangliome der A. carotis,&#x201d; Gef&#xe4;sschirurgie 27 (2022): 517&#x2013;523, https://doi.org/10.1007/s00772&#x2010;022&#x2010;00919&#x2010;9.</Citation></Reference><Reference><Citation>L. Fishbein, S. Merrill, D. L. Fraker, D. L. Cohen, and K. L. Nathanson, &#x201c;Inherited Mutations in Pheochromocytoma and Paraganglioma: Why All Patients Should Be Offered Genetic Testing,&#x201d; Annals of Surgical Oncology 20 (2013): 1444&#x2013;1450, https://doi.org/10.1245/s10434&#x2010;013&#x2010;2942&#x2010;5.</Citation></Reference><Reference><Citation>S. Singer, J. I. Arraras, I. Baumann, et&#xa0;al., &#x201c;Quality of Life in Patients With Head and Neck Cancer Receiving Targeted or Multimodal Therapy &#x2013; Update of the EORTC QLQ&#x2010;H&amp;N35, Phase i,&#x201d; Head &amp; Neck 35, no. 9 (2013): 1331&#x2013;1338, https://doi.org/10.1002/hed.23127.</Citation></Reference><Reference><Citation>R. Obholzer, P. Patel, S. Mcgowan, B. Grunfeld, M. Sherriff, and M. Gleeson, &#x201c;Quality of Life and Paragangliomas of the,&#x201d; Head and Neck 73 (2012): A399, https://doi.org/10.1055/s&#x2010;0032&#x2010;1314310.</Citation></Reference><Reference><Citation>S. Galland&#x2010;Girodet, J. P. Maire, E. De&#x2010;Mones, et&#xa0;al., &#x201c;The Role of Radiation Therapy in the Management of Head and Neck Paragangliomas: Impact of Quality of Life Versus Treatment Response,&#x201d; Radiotherapy and Oncology 111, no. 3 (2014): 463&#x2013;467, https://doi.org/10.1016/j.radonc.2014.06.002.</Citation></Reference><Reference><Citation>F. Ehret, M. Kufeld, C. F&#xfc;rweger, et&#xa0;al., &#x201c;Single&#x2010;Session Image&#x2010;Guided Robotic Radiosurgery and Quality of Life for glomus Jugulare Tumors,&#x201d; Head &amp; Neck 42 (2020): 2421&#x2013;2430, https://doi.org/10.1002/hed.26231.</Citation></Reference><Reference><Citation>N. S. Patel, M. J. Link, N. M. Tombers, B. E. Pollock, and M. L. Carlson, &#x201c;Quality of Life in Jugular Paraganglioma Following Radiosurgery,&#x201d; Otology &amp; Neurotology 40, no. 6 (2019): 820&#x2013;825, https://doi.org/10.1097/MAO.0000000000002250.</Citation></Reference><Reference><Citation>C. J. M. de Bresser, B. P. M. van Nesselrooij, M. J. C. van Treijen, et&#xa0;al., &#x201c;Head and Neck Paraganglioma (HNPGL) Registry: A Study Protocol for Prospective Data Collection in Patients With Head and Neck Paragangliomas,&#x201d; PLoS One 19 (2024): e0307311, https://doi.org/10.1371/journal.pone.0307311.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1002/hed.70050 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41174874</PMID><DateRevised><Year>2025</Year><Month>11</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Oct</Month><Day>31</Day></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Study on the Ultrasonic Characteristics of the Paraglottic Space at the Glottic Level in Normal Adults.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.70050</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">High-frequency ultrasound was used to observe and measure the width of the normal adult glottal-level paraglottic space (PGS).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">One thousand healthy Han Chinese adults (694 women; 18-79&#x2009;years) were enrolled between October 2023 and April 2024. PGS ultrasound characteristics were observed, and the width was measured at the midpoint of the anterior, middle, and posterior 1/3 points. The data were stratified by age group and sex. Spearman correlation analysis was used to analyze the correlations between PGS width and sex, age, height, weight, BMI, and BSA.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The glottic-level PGS is a triangular hyperechoic structure that is narrow in the front and wide in the back of the parathyroid cartilage section. The PGS width reference ranges (5th and 95th percentiles) were as follows: Male: W<sub>1</sub> (0.45-1.16) mm, W<sub>2</sub> (0.55-1.71) mm, W<sub>3</sub> (1.30-2.35) mm; Female: W<sub>1</sub> (0.55-0.95) mm, W<sub>2</sub> (0.90-1.35) mm, W<sub>3</sub> (1.55-2.00) mm. There were no statistically significant differences in W<sub>1</sub>, W<sub>2</sub>, and W<sub>3</sub> between males and females or between different age groups (all p&#x2009;&gt;&#x2009;0.05).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study summarized normal adult PGS ultrasound characteristics at the glottal level and established references for PGS width, which can provide reference values for clinical practice.</AbstractText><CopyrightInformation>&#xa9; 2025 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiang-Ru</ForeName><Initials>XR</Initials><Identifier Source="ORCID">0009-0007-9774-758X</Identifier><AffiliationInfo><Affiliation>Department of Ultrasound, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Hua</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Ultrasound, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Yue</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Ultrasound, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ultrasound, Xi'an People's Hospital (Xi'an Fourth Hospital), Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Guo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Ultrasound, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiao-Peng</ForeName><Initials>XP</Initials><AffiliationInfo><Affiliation>Department of Ultrasound, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Ultrasound, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>10</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">normal adult</Keyword><Keyword MajorTopicYN="N">paraglottic space</Keyword><Keyword MajorTopicYN="N">ultrasound</Keyword><Keyword MajorTopicYN="N">width</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>9</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>11</Month><Day>1</Day><Hour>6</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>11</Month><Day>1</Day><Hour>6</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>11</Month><Day>1</Day><Hour>2</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41174874</ArticleId><ArticleId IdType="doi">10.1002/hed.70050</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>W. Jiang, B. Geng, X. Zheng, and Q. Xue, &#x201c;A Computational Study of the Influence of Thyroarytenoid and Cricothyroid Muscle Interaction on Vocal Fold Dynamics in an Mri&#x2010;Based Human Laryngeal Model,&#x201d; Biomechanics and Modeling in Mechanobiology 23 (2024): 1801&#x2013;1813.</Citation></Reference><Reference><Citation>L. Wu, H. Zhang, L. Deng, and C. Chen, &#x201c;Usage of Point&#x2010;Of&#x2010;Care Ultrasound to Assess and Predict Glottic Stenosis During Emergency Surgery: A Case Report,&#x201d; Asian Journal of Surgery 46 (2023): 4783&#x2013;4784.</Citation></Reference><Reference><Citation>Z. Ling, G. Hu, Z. Wang, et&#xa0;al., &#x201c;Prognostic Impact of Different Tumor Invasion Patterns in the Surgical Treatment of t3 Glottic Laryngeal Cancer,&#x201d; Journal of Clinical Otorhinolaryngology, Head, and Neck Surgery 37 (2023): 998&#x2013;1004.</Citation></Reference><Reference><Citation>L. Wang, D. Liu, R. Sun, Z. Jiang, and J. Yue, &#x201c;Therapeutic Effect on Pyriform Sinus Carcinoma Resection via Paraglottic Space Approach,&#x201d; Frontiers in Surgery 9 (2022): 1068754.</Citation></Reference><Reference><Citation>M. L. Nilsen, L. Lyu, M. A. Belsky, et&#xa0;al., &#x201c;Impact of Neck Disability on Health&#x2010;Related Quality of Life Among Head and Neck Cancer Survivors,&#x201d; Otolaryngology&#x2010;Head and Neck Surgery 162 (2020): 64&#x2013;72.</Citation></Reference><Reference><Citation>W. Li, D. Wei, Y. Qian, et&#xa0;al., &#x201c;A Novel Surgical Approach for Hypopharyngeal Carcinoma Resection via the Paraglottic Space,&#x201d; BMC Surgery 21 (2021): 230.</Citation></Reference><Reference><Citation>H. Wang, X. Yang, J. Hou, et&#xa0;al., &#x201c;Application of Transcutaneous Laryngeal Ultrasonography in the Diagnosis of Vocal Fold Polyps,&#x201d; Ultrasound in Medicine &amp; Biology 46 (2020): 2293&#x2013;2302.</Citation></Reference><Reference><Citation>D. Ahn, J. H. Kwak, G. J. Lee, and J. H. Sohn, &#x201c;Ultrasonography for Masses of the Pharynx and Larynx and Assessment of Laryngeal Squamous Cell Carcinoma,&#x201d; Auris Nasus Larynx 49 (2022): 868&#x2013;874.</Citation></Reference><Reference><Citation>A. A. Kuprin, Z. E. Komarova, N. N. Vetsheva, E. R. Argunova, N. S. Malyuga, and N. N. Mazur, &#x201c;Polypositional Transcutaneous Ultrasound Assessment of Vocal Folds Mobility. Ultrasonographic Sign of Laryngeal Dysfunction,&#x201d; Vestnik Otorinolaringologii 88 (2023): 25&#x2013;39.</Citation></Reference><Reference><Citation>A. Safia, E. U. Abd, M. Roch, et&#xa0;al., &#x201c;Determinants of Clinical Response to Injection Laryngoplasty in Unilateral Vocal Fold Paralysis: A Systematic Review and Meta&#x2010;Analysis,&#x201d; International Journal of Surgery 110 (2024): 7281&#x2013;7310.</Citation></Reference><Reference><Citation>Y. Lahav, M. Adi, E. Arberboy, D. Halperin, H. Shoffel&#x2010;Havakuk, and O. Cohen, &#x201c;Relations Between Body Mass Index, Laryngeal Fat Pads, and Laryngeal Airway Configuration in Adult Men Population,&#x201d; International Journal of Obesity 45 (2021): 288&#x2013;295.</Citation></Reference><Reference><Citation>K. L. McCullagh, R. N. Shah, and B. Y. Huang, &#x201c;Anatomy of the Larynx and Cervical Trachea,&#x201d; Neuroimaging Clinics of North America 32 (2022): 809&#x2013;829.</Citation></Reference><Reference><Citation>L. Wu and Z. Zhang, &#x201c;Impact of the Paraglottic Space on Voice Production in an Mri&#x2010;Based Vocal Fold Model,&#x201d; Journal of Voice 37 (2023): 633.e15&#x2013;633.e23.</Citation></Reference><Reference><Citation>M. Fermi, M. A. Lo, G. Di Massa, et&#xa0;al., &#x201c;Paraglottic Space Invasion in Glottic Laryngeal Cancer: A Clinical&#x2010;Pathological Study,&#x201d; Laryngoscope 133 (2023): 1184&#x2013;1190.</Citation></Reference><Reference><Citation>M. Becker, Y. Monnier, and C. de Vito, &#x201c;Mr Imaging of Laryngeal and Hypopharyngeal Cancer,&#x201d; Magnetic Resonance Imaging Clinics of North America 30 (2022): 53&#x2013;72.</Citation></Reference><Reference><Citation>H. Saleh, N. Seidel, T. J&#xf6;ns, D. M&#xfc;rbe, and T. Nawka, &#x201c;The Inside&#x2010;Out Surgical Anatomy of the Paraglottic Space a Video&#x2010;Guided Endoscopic Dissection,&#x201d; Laryngoscope Investigative Otolaryngology 8 (2023): 162&#x2013;167.</Citation></Reference><Reference><Citation>M. Ravanelli, P. Rondi, M. Ferrari, et&#xa0;al., &#x201c;Ct and mr Anatomy of the Larynx and Hypopharynx,&#x201d; Neuroradiology 66 (2024): 883&#x2013;896.</Citation></Reference><Reference><Citation>R. Hu, W. Xu, L. Y. Cheng, X. Y. Li, and H. Z. Wang, &#x201c;Long&#x2010;Term Outcomes of Lateral Vocal Fold Autologous Fat Injection for Unilateral Vocal Fold Paralysis,&#x201d; Chinese Journal of Otorhinolaryngology Head and Neck Surgery 58 (2023): 28&#x2013;36.</Citation></Reference><Reference><Citation>H. Umeno, H. I. Tanaka, T. Kurita, R. Mihashi, S. I. Chitose, and K. Sato, &#x201c;Long&#x2010;Term Effects of Fat Injection Laryngoplasty in Relation to the Injected Fat Volume in Patients With Unilateral Vocal Fold Paralysis,&#x201d; Journal of Voice 39 (2025): 512&#x2013;519.</Citation></Reference><Reference><Citation>S. Talugula, A. Mangahas, A. Carlson, and I. A. Husain, &#x201c;Voice Outcomes After Bariatric Surgery: A Systematic Review,&#x201d; Journal of Voice 39 (2025): 1140.e17&#x2013;1140.e26.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/JCO-24-02679 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41435207</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1527-7755</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Dec</Month><Day>23</Day></PubDate></JournalIssue><Title>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</Title><ISOAbbreviation>J Clin Oncol</ISOAbbreviation></Journal><ArticleTitle>Automated Lymph Node and Extranodal Extension Assessment Improves Risk Stratification in Oropharyngeal Carcinoma.</ArticleTitle><Pagination><StartPage>JCO2402679</StartPage><MedlinePgn>JCO2402679</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/JCO-24-02679</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Extranodal extension (ENE) is a biomarker in oropharyngeal carcinoma (OPC) but can only be diagnosed via surgical pathology. We applied an automated artificial intelligence (AI) imaging platform integrating lymph node autosegmentation with ENE prediction to determine the prognostic value of the number of predicted ENE nodes.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">We conducted a multisite, retrospective study of 1,733 OPC patients with pretreatment computed tomography who underwent definitive radiation therapy across three institutions. Malignant lymph nodes were segmented using a validated deep learning auto-segmentation model, and segmented lymph nodes were sequentially processed with a validated ENE prediction model to calculate number of nodes with AI-predicted ENE (AI-ENE) per patient. We evaluated associations of AI-ENE with disease outcomes using site-stratified, multivariable Cox regression, adjusting for human papillomavirus (HPV) status, smoking pack-years, tumor and nodal stage, age, and sex. We evaluated risk-stratification improvement when incorporating AI-ENE into the Radiation Therapy Oncology Group (RTOG)-0129 risk groupings and derived American Joint Committee on Cancer (AJCC) 8th edition staging with Uno C-indices and decision curve analyses.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall, median AI-ENE node number was 1 (range, 0-6). AI-ENE node number was independently associated with poorer distant control (DC; hazard ratio [HR], 1.44 [95% CI, 1.23 to 1.69]; <i>P</i> &lt; .001) and overall survival (OS; HR, 1.30 [95% CI, 1.16 to 1.46]; <i>P</i> &lt; .001). Increasing AI-ENE node number was incrementally associated with worse outcome, particularly DC (<i>P</i> &lt; .001). C-indices improved in the external data set when incorporating AI-ENE into RTOG-0129 groupings (OS: 0.70 <i>v</i> 0.65; DC: 0.65 <i>v</i> 0.57) and AJCC-8 stage (OS: 0.75 <i>v</i> 0.70; DC: 0.72 <i>v</i> 0.67; <i>P</i> &lt; .001 for each). The largest improvements were observed among HPV-negative patients (C-index: +15% for OS, +14% for DC).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Automated, AI-ENE node number is a novel risk factor for OPC that may better inform pretreatment risk stratification and decision-making.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Zezhong</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mojahed-Yazdi</LastName><ForeName>Reza</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zapaishchykova</LastName><ForeName>Anna</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-6860-9160</Identifier><AffiliationInfo><Affiliation>Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tak</LastName><ForeName>Divyanshu</ForeName><Initials>D</Initials><Identifier Source="ORCID">0009-0003-4183-209X</Identifier><AffiliationInfo><Affiliation>Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahootiha</LastName><ForeName>Maryam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pardo</LastName><ForeName>Juan Carlos Climent</ForeName><Initials>JCC</Initials><Identifier Source="ORCID">0009-0007-9110-2043</Identifier><AffiliationInfo><Affiliation>Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zielke</LastName><ForeName>John</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-8655-3508</Identifier><AffiliationInfo><Affiliation>Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zha</LastName><ForeName>Yining</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0009-0000-7653-3223</Identifier><AffiliationInfo><Affiliation>Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guthier</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tishler</LastName><ForeName>Roy B</ForeName><Initials>RB</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Margalit</LastName><ForeName>Danielle N</ForeName><Initials>DN</Initials><Identifier Source="ORCID">0000-0002-8281-0829</Identifier><AffiliationInfo><Affiliation>Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schoenfeld</LastName><ForeName>Jonathan D</ForeName><Initials>JD</Initials><Identifier Source="ORCID">0000-0002-5119-0401</Identifier><AffiliationInfo><Affiliation>Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haddad</LastName><ForeName>Robert I</ForeName><Initials>RI</Initials><Identifier Source="ORCID">0000-0003-1413-0079</Identifier><AffiliationInfo><Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uppaluri</LastName><ForeName>Ravindra</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery/Otolaryngology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haibe-Kains</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Medical Biophysics, University Health Network, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fuller</LastName><ForeName>Clifton D</ForeName><Initials>CD</Initials><Identifier Source="ORCID">0000-0002-5264-3994</Identifier><AffiliationInfo><Affiliation>Division of Radiation Oncology, Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naser</LastName><ForeName>Mohamed</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-1020-4966</Identifier><AffiliationInfo><Affiliation>Division of Radiation Oncology, Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burtness</LastName><ForeName>Barbara A</ForeName><Initials>BA</Initials><Identifier Source="ORCID">0000-0003-4660-1859</Identifier><AffiliationInfo><Affiliation>Department of Medicine and Yale Cancer Center, Yale University School of Medicine and Yale Cancer Center, New Haven, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aerts</LastName><ForeName>Hugo J W L</ForeName><Initials>HJWL</Initials><AffiliationInfo><Affiliation>Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Radiology and Nuclear Medicine, CARIM &amp; GROW, Maastricht University, Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoebers</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kann</LastName><ForeName>Benjamin H</ForeName><Initials>BH</Initials><Identifier Source="ORCID">0000-0002-4313-2754</Identifier><AffiliationInfo><Affiliation>Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Oncol</MedlineTA><NlmUniqueID>8309333</NlmUniqueID><ISSNLinking>0732-183X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>23</Day><Hour>19</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>23</Day><Hour>19</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>23</Day><Hour>16</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41435207</ArticleId><ArticleId IdType="doi">10.1200/JCO-24-02679</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/OP-25-00249 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40249905</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2688-1535</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>12</Issue><PubDate><Year>2025</Year><Month>Dec</Month></PubDate></JournalIssue><Title>JCO oncology practice</Title><ISOAbbreviation>JCO Oncol Pract</ISOAbbreviation></Journal><ArticleTitle>Transoral Robotic Surgery in the Multidisciplinary Care of Patients With Oropharyngeal Squamous Cell Carcinoma: ASCO Guideline Clinical Insights.</ArticleTitle><Pagination><StartPage>1742</StartPage><EndPage>1745</EndPage><MedlinePgn>1742-1745</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/OP-25-00249</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ryan</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-1129-2489</Identifier><AffiliationInfo><Affiliation>Oregon Health &amp; Science University, Portland, OR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ku</LastName><ForeName>Jamie A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Cleveland Clinic, Cleveland, OH.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adkins</LastName><ForeName>Douglas</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-3207-8227</Identifier><AffiliationInfo><Affiliation>Washington University, St Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yom</LastName><ForeName>Sue S</ForeName><Initials>SS</Initials><Identifier Source="ORCID">0000-0002-0779-7476</Identifier><AffiliationInfo><Affiliation>University of California San Francisco, San Francisco, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Starmer</LastName><ForeName>Heather</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-1716-9852</Identifier><AffiliationInfo><Affiliation>Stanford University, Palo Alto, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ismaila</LastName><ForeName>Nofisat</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-2074-1896</Identifier><AffiliationInfo><Affiliation>American Society of Clinical Oncology (ASCO), Alexandria, VA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holsinger</LastName><ForeName>F Christopher</ForeName><Initials>FC</Initials><Identifier Source="ORCID">0000-0002-9594-1414</Identifier><AffiliationInfo><Affiliation>Stanford University, Palo Alto, CA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>04</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Oncol Pract</MedlineTA><NlmUniqueID>101758685</NlmUniqueID><ISSNLinking>2688-1527</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>JCO Oncol Pract. 2025 Dec;21(12):1893. doi: 10.1200/OP-25-00446.</RefSource><PMID Version="1">40446179</PMID></CommentsCorrections></CommentsCorrectionsList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>4</Month><Day>18</Day><Hour>18</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>4</Month><Day>18</Day><Hour>18</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>4</Month><Day>18</Day><Hour>16</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40249905</ArticleId><ArticleId IdType="doi">10.1200/OP-25-00249</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/OP-25-00867 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">41118619</PMID><DateCompleted><Year>2025</Year><Month>12</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>12</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2688-1535</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>12</Issue><PubDate><Year>2025</Year><Month>Dec</Month></PubDate></JournalIssue><Title>JCO oncology practice</Title><ISOAbbreviation>JCO Oncol Pract</ISOAbbreviation></Journal><ArticleTitle>Impact of an Electronic Patient-Reported Outcome-Informed Clinical Decision Support Tool on Clinical Discussions With Head and Neck Cancer Survivors: Findings From the HN-STAR Randomized Controlled Trial (WF-1805CD).</ArticleTitle><Pagination><StartPage>1786</StartPage><EndPage>1799</EndPage><MedlinePgn>1786-1799</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/OP-25-00867</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Post-treatment head and neck cancer (HNC) survivors experience multiple symptoms and behavioral health issues. We developed Head and Neck Survivorship Tool: Assessments and Recommendation (HN-STAR), a clinical decision support tool using electronic patient-reported outcomes (ePROs) to improve follow-up of HNC survivors.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a cluster-randomized controlled trial of oncology practices in the Wake Forest National Cancer Institute Community Oncology Research Program Research Base comparing HN-STAR to usual care (UC) during a routine clinic visit. Eligible survivors completed treatment for HNC &lt; 2 years before. Before the visit, survivors completed ePROs rating the burden of 26 concerns (symptoms and health behaviors). During the visit, HN-STAR presented survivor's concerns and tailored clinician recommendations. After the visit, survivors reported which concerns were discussed. To evaluate differences in concerns discussed in clinic, concerns were characterized as absent or mild versus burdensome, with comparisons between arms for number of concerns discussed, number of burdensome concerns discussed, and proportion of burdensome concerns discussed, assessed by mixed models adjusted for within-practice correlation.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Three hundred forty-nine survivors at 28 practices reported a previsit mean of 7.5 burdensome concerns (standard deviation, 4.6), most commonly xerostomia (70%), taste changes (53%), and neck or shoulder stiffness (48%). In adjusted models, survivors in the HN-STAR arm had more burdensome concerns discussed (4.1 <i>v</i> 3.3 concerns, <i>P</i> = .042) and a greater proportion of burdensome concerns discussed (57% <i>v</i> 44%, <i>P</i> = .015) at the visit than survivors in the UC arm.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In a large, national, diverse, and symptomatic sample of HNC survivors at community oncology practices, using an ePRO-informed clinical decision support tool increased the likelihood that burdensome concerns were discussed in clinic. Alerting providers to burdensome concerns and presenting guideline-concordant management options at the point of care may improve provider-survivor interactions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Salz</LastName><ForeName>Talya</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-4515-6004</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dressler</LastName><ForeName>Emily V</ForeName><Initials>EV</Initials><Identifier Source="ORCID">0000-0002-6054-7839</Identifier><AffiliationInfo><Affiliation>Division of Public Health Sciences, Department of Biostatistics and Data Science, Wake Forest University School of Medicine, Winston-Salem, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kittel</LastName><ForeName>Carol</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-4512-0634</Identifier><AffiliationInfo><Affiliation>Division of Public Health Sciences, Department of Biostatistics and Data Science, Wake Forest University School of Medicine, Winston-Salem, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salner</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-3145-2953</Identifier><AffiliationInfo><Affiliation>Hartford Healthcare Cancer Institute, Hartford Hospital, Hartford, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayer</LastName><ForeName>Deborah K</ForeName><Initials>DK</Initials><Identifier Source="ORCID">0000-0001-7007-4978</Identifier><AffiliationInfo><Affiliation>School of Nursing, University of North Carolina at Chapel Hill, Chapel Hill, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nightingale</LastName><ForeName>Chandylen L</ForeName><Initials>CL</Initials><Identifier Source="ORCID">0000-0002-2275-9849</Identifier><AffiliationInfo><Affiliation>Division of Public Health Sciences, Department of Social Sciences and Health Policy, Wake Forest University School of Medicine, Winston-Salem, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hughes</LastName><ForeName>Ryan T</ForeName><Initials>RT</Initials><Identifier Source="ORCID">0000-0003-1548-9753</Identifier><AffiliationInfo><Affiliation>Department of Radiation Oncology, Wake Forest School of Medicine, Winston-Salem, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kriplani</LastName><ForeName>Anuja</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atkinson</LastName><ForeName>Thomas M</ForeName><Initials>TM</Initials><Identifier Source="ORCID">0000-0002-4965-3913</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patil</LastName><ForeName>Sujata</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-1706-5321</Identifier><AffiliationInfo><Affiliation>Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oeffinger</LastName><ForeName>Kevin C</ForeName><Initials>KC</Initials><Identifier Source="ORCID">0000-0003-0806-7894</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Duke University, Durham, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>Sarah N</ForeName><Initials>SN</Initials><Identifier Source="ORCID">0000-0002-1622-1700</Identifier><AffiliationInfo><Affiliation>Division of Public Health Sciences, Department of Social Sciences and Health Policy, Wake Forest University School of Medicine, Winston-Salem, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asad</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Public Health Sciences, Department of Social Sciences and Health Policy, Wake Forest University School of Medicine, Winston-Salem, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheedy</LastName><ForeName>Jessica</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Public Health Sciences, Department of Social Sciences and Health Policy, Wake Forest University School of Medicine, Winston-Salem, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jinna</LastName><ForeName>Sankeerth</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-8478-5017</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lesser</LastName><ForeName>Glenn</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Medicine, Wake Forest School of Medicine, Winston-Salem, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ostroff</LastName><ForeName>Jamie S</ForeName><Initials>JS</Initials><Identifier Source="ORCID">0000-0003-2671-5680</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weaver</LastName><ForeName>Kathryn E</ForeName><Initials>KE</Initials><Identifier Source="ORCID">0000-0001-9006-4064</Identifier><AffiliationInfo><Affiliation>Division of Public Health Sciences, Department of Social Sciences and Health Policy, Wake Forest University School of Medicine, Winston-Salem, NC.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>10</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Oncol Pract</MedlineTA><NlmUniqueID>101758685</NlmUniqueID><ISSNLinking>2688-1527</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006258" MajorTopicYN="Y">Head and Neck Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071066" MajorTopicYN="Y">Patient Reported Outcome Measures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073116" MajorTopicYN="Y">Cancer Survivors</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020000" MajorTopicYN="Y">Decision Support Systems, Clinical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>12</Day><Hour>3</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>10</Month><Day>21</Day><Hour>18</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>10</Month><Day>21</Day><Hour>16</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41118619</ArticleId><ArticleId IdType="doi">10.1200/OP-25-00867</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/OP-25-00446 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40446179</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2688-1535</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>12</Issue><PubDate><Year>2025</Year><Month>Dec</Month></PubDate></JournalIssue><Title>JCO oncology practice</Title><ISOAbbreviation>JCO Oncol Pract</ISOAbbreviation></Journal><ArticleTitle>Erratum: Transoral Robotic Surgery in the Multidisciplinary Care of Patients With Oropharyngeal Squamous Cell Carcinoma: ASCO Guideline Clinical Insights.</ArticleTitle><Pagination><StartPage>1893</StartPage><MedlinePgn>1893</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/OP-25-00446</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ryan</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Ku</LastName><ForeName>Jamie A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Adkins</LastName><ForeName>Douglas</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Yom</LastName><ForeName>Sue S</ForeName><Initials>SS</Initials></Author><Author ValidYN="Y"><LastName>Starmer</LastName><ForeName>Heather</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Ismaila</LastName><ForeName>Nofisat</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Holsinger</LastName><ForeName>F Christopher</ForeName><Initials>FC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016425">Published Erratum</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Oncol Pract</MedlineTA><NlmUniqueID>101758685</NlmUniqueID><ISSNLinking>2688-1527</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumFor"><RefSource>JCO Oncol Pract. 2025 Dec;21(12):1742-1745. doi: 10.1200/OP-25-00249.</RefSource><PMID Version="1">40249905</PMID></CommentsCorrections></CommentsCorrectionsList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>30</Day><Hour>18</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>30</Day><Hour>18</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>30</Day><Hour>16</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40446179</ArticleId><ArticleId IdType="doi">10.1200/OP-25-00446</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/OP-25-00027 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40454680</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2688-1535</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jun</Month><Day>02</Day></PubDate></JournalIssue><Title>JCO oncology practice</Title><ISOAbbreviation>JCO Oncol Pract</ISOAbbreviation></Journal><ArticleTitle>Adequacy of Immune Checkpoint Inhibitor-Associated Thyroid Function Monitoring After Therapy.</ArticleTitle><Pagination><StartPage>OP2500027</StartPage><MedlinePgn>OP2500027</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/OP-25-00027</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Immune checkpoint inhibitor (ICI)-induced thyroid dysfunction is a common endocrine immune-related adverse event. Although rates during therapy are well documented, data on post-treatment thyroid dysfunction are limited. We hypothesized that post-ICI thyroid dysfunction is under-recognized because of inadequate surveillance.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A retrospective analysis of 3,626 patients treated with ICIs for various malignancies within a single health system was conducted. Clinically acted-upon thyroid dysfunction (diagnosis or thyroid-directed medication) was evaluated before, during, and after ICI therapy, alongside rates of thyroid laboratory surveillance.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Clinically acted-upon thyroid dysfunction occurred in 8.1% (294/3,626) during treatment and 4.4% (159/3,626) after treatment. Among the 1,170 patients with post-ICI thyroid laboratory results and no prior dysfunction, 11.6% (136/1,170) developed post-ICI thyroid dysfunction. However, 48.6%% (1,764/3,626) had no post-ICI thyroid laboratory results. Thirty percent of patients with abnormal thyroid stimulating hormone (TSH) values and no clinically acted-upon thyroid dysfunction before therapy discontinuation subsequently developed clinically acted-upon thyroid dysfunction, and the rate of post-ICI clinically acted-upon thyroid dysfunction was higher in patients who received 9 or less months of ICI therapy.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Post-ICI thyroid dysfunction is frequent, with 11.6% of monitored patients being affected, and patients with abnormal TSH before ICI discontinuation and those who received treatment for 9 months or less may benefit from more stringent post-ICI surveillance.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Velez</LastName><ForeName>Maria A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0001-5197-4719</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Division of Hematology and Oncology, University of California, Los Angeles, Los Angeles, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Elliot S</ForeName><Initials>ES</Initials><Identifier Source="ORCID">0000-0002-0001-1186</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Division of Hematology and Oncology, University of California, Los Angeles, Los Angeles, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Chester A</ForeName><Initials>CA</Initials><Identifier Source="ORCID">0009-0004-3089-9923</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Division of Hematology and Oncology, University of California, Los Angeles, Los Angeles, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lind-Lebuffe</LastName><ForeName>Jackson</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Hematology and Oncology, University of California, Los Angeles, Los Angeles, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Collin</ForeName><Initials>C</Initials><Identifier Source="ORCID">0009-0005-6657-620X</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Division of Hematology and Oncology, University of California, Los Angeles, Los Angeles, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Seung Jun</ForeName><Initials>SJ</Initials><Identifier Source="ORCID">0009-0005-9261-6818</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Division of Hematology and Oncology, University of California, Los Angeles, Los Angeles, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Andy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Hematology and Oncology, University of California, Los Angeles, Los Angeles, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gower</LastName><ForeName>Arjan</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-3361-9286</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Division of Hematology and Oncology, University of California, Los Angeles, Los Angeles, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-4293-4509</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Division of Hematology and Oncology, University of California, Los Angeles, Los Angeles, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rochigneux</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-7932-0530</Identifier><AffiliationInfo><Affiliation>Department of Medical Oncology, Paoli-Calmettes Institute, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grogan</LastName><ForeName>Tristan R</ForeName><Initials>TR</Initials><Identifier Source="ORCID">0000-0001-9471-2938</Identifier><AffiliationInfo><Affiliation>UCLA Department of Medicine Statistics Core, University of California, Los Angeles, Los Angeles, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elashoff</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>UCLA Department of Medicine Statistics Core, University of California, Los Angeles, Los Angeles, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garon</LastName><ForeName>Edward B</ForeName><Initials>EB</Initials><Identifier Source="ORCID">0000-0001-7077-8801</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Division of Hematology and Oncology, University of California, Los Angeles, Los Angeles, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lisberg</LastName><ForeName>Aaron</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-3048-4352</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Division of Hematology and Oncology, University of California, Los Angeles, Los Angeles, CA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 CA276917</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Oncol Pract</MedlineTA><NlmUniqueID>101758685</NlmUniqueID><ISSNLinking>2688-1527</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2026</Year><Month>6</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>2</Day><Hour>12</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>2</Day><Hour>12</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>2</Day><Hour>8</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40454680</ArticleId><ArticleId IdType="mid">NIHMS2079963</ArticleId><ArticleId IdType="pmc">PMC12353488</ArticleId><ArticleId IdType="doi">10.1200/OP-25-00027</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Haratani K, Hayashi H, Chiba Y, et al. : Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non&#x2013;Small-Cell Lung Cancer. JAMA Oncology 4:374&#x2013;378, 2018</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6583041</ArticleId><ArticleId IdType="pubmed">28975219</ArticleId></ArticleIdList></Reference><Reference><Citation>Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al. : Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis. JAMA Oncology 4:173&#x2013;182, 2018</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5838579</ArticleId><ArticleId IdType="pubmed">28973656</ArticleId></ArticleIdList></Reference><Reference><Citation>Lechner MG, Ryder M: Insights into immune checkpoint inhibitor-induced thyroiditis. Nat Rev Endocrinol 17:643&#x2013;644, 2021</Citation><ArticleIdList><ArticleId IdType="pubmed">34471237</ArticleId></ArticleIdList></Reference><Reference><Citation>Raphael J, Richard L, Lam M, et al. : Utilization of Immunotherapy in Patients with Cancer Treated in Routine Care Settings: A Population-Based Study Using Health Administrative Data. Oncologist 27:675&#x2013;684, 2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9355820</ArticleId><ArticleId IdType="pubmed">35552444</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz TU, Zierold S, Sachse MM, et al. : Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients&#x2019; health-related quality of life. European Journal of Cancer 176:88&#x2013;99, 2022</Citation><ArticleIdList><ArticleId IdType="pubmed">36198246</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu D, Yao J, Yuan G, et al. : Immune Checkpoint Inhibitor-related New-onset Thyroid Dysfunction: A Retrospective Analysis Using the US FDA Adverse Event Reporting System. Oncologist 27:e126&#x2013;e132, 2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8895746</ArticleId><ArticleId IdType="pubmed">35641200</ArticleId></ArticleIdList></Reference><Reference><Citation>El Sabbagh R, Azar NS, Eid AA, Azar ST: Thyroid Dysfunctions Due to Immune Checkpoint Inhibitors: A Review. Int J Gen Med 13:1003&#x2013;1009, 2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7650809</ArticleId><ArticleId IdType="pubmed">33177863</ArticleId></ArticleIdList></Reference><Reference><Citation>Iyer PC, Cabanillas ME, Waguespack SG, et al. : Immune-Related Thyroiditis with Immune Checkpoint Inhibitors. Thyroid 28:1243&#x2013;1251, 2018</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6157359</ArticleId><ArticleId IdType="pubmed">30132401</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy OJ, Ali N, Lee R, et al. : Thyroid dysfunction after immune checkpoint inhibitors in a single-centre UK pan-cancer cohort: A retrospective study. European Journal of Cancer 202:113949, 2024</Citation><ArticleIdList><ArticleId IdType="pubmed">38432099</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryder M, Callahan M, Postow MA, et al. : Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocrine-Related Cancer 21:371&#x2013;381, 2014</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4573438</ArticleId><ArticleId IdType="pubmed">24610577</ArticleId></ArticleIdList></Reference><Reference><Citation>Chera A, Stancu AL, Bucur O: Thyroid-related adverse events induced by immune checkpoint inhibitors. Front Endocrinol (Lausanne) 13:1010279, 2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9530140</ArticleId><ArticleId IdType="pubmed">36204105</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghisoni E, Wicky A, Bouchaab H, et al. : Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy. European Journal of Cancer 149:153&#x2013;164, 2021</Citation><ArticleIdList><ArticleId IdType="pubmed">33865201</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou N, Velez MA, Bachrach B, et al. : Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC. Lung Cancer 161:34&#x2013;41, 2021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8923054</ArticleId><ArticleId IdType="pubmed">34507111</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartmann K: Thyroid Disorders in the Oncology Patient. J Adv Pract Oncol 6:99&#x2013;106, 2015</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4601890</ArticleId><ArticleId IdType="pubmed">26649243</ArticleId></ArticleIdList></Reference><Reference><Citation>NCCN Guidelines Version 2.2024 Management of Immune Checkpoint Inhibitor-Related Toxicities, 2024</Citation></Reference><Reference><Citation>Brahmer JR, Abu-Sbeih H, Ascierto PA, et al. : Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. Journal for ImmunoTherapy of Cancer 9:e002435, 2021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8237720</ArticleId><ArticleId IdType="pubmed">34172516</ArticleId></ArticleIdList></Reference><Reference><Citation>Brahmer JR, Lacchetti C, Schneider BJ, et al. : Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36:1714&#x2013;1768, 2018</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6481621</ArticleId><ArticleId IdType="pubmed">29442540</ArticleId></ArticleIdList></Reference><Reference><Citation>Muir CA, Tsang VHM, Menzies AM, Clifton-Bligh RJ: Immune Related Adverse Events of the Thyroid - A Narrative Review. Front Endocrinol (Lausanne) 13:886930, 2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9178092</ArticleId><ArticleId IdType="pubmed">35692394</ArticleId></ArticleIdList></Reference><Reference><Citation>Baraka B, Abosheaishaa H, Nassar M: Immunotherapy-induced thyroid dysfunction: an updated review. The Egyptian Journal of Internal Medicine 35:48, 2023</Citation></Reference><Reference><Citation>Bossi P, Botta L, Bironzo P, et al. : Systematic Review of adverse events reporting in clinical trials leading to approval of targeted therapy and immunotherapy. Future Oncology 15:2543&#x2013;2553, 2019</Citation><ArticleIdList><ArticleId IdType="pubmed">31240949</ArticleId></ArticleIdList></Reference><Reference><Citation>Couey MA, Bell RB, Patel AA, et al. : Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance. Journal for ImmunoTherapy of Cancer 7:165, 2019</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6609357</ArticleId><ArticleId IdType="pubmed">31269983</ArticleId></ArticleIdList></Reference><Reference><Citation>Quan L, Liu J, Wang Y, et al. : Exploring risk factors for endocrine-related immune-related adverse events: Insights from meta-analysis and Mendelian randomization. Hum Vaccin Immunother 20:2410557, 2024</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11469449</ArticleId><ArticleId IdType="pubmed">39377304</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/OP-25-00450 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41343754</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2688-1535</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Dec</Month><Day>04</Day></PubDate></JournalIssue><Title>JCO oncology practice</Title><ISOAbbreviation>JCO Oncol Pract</ISOAbbreviation></Journal><ArticleTitle>Evolving Use of Circulating Tumor DNA for HPV+ Oropharyngeal Carcinoma: Consensus Recommendations From the California Head and Neck Consortium.</ArticleTitle><Pagination><StartPage>OP2500450</StartPage><MedlinePgn>OP2500450</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/OP-25-00450</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Circulating tumor DNA (ctDNA) assays have evolved into transformative tools capable of disrupting current management paradigms, including that of human papillomavirus (HPV)-positive oropharyngeal carcinoma (OPC). Despite readily available assays, guidance on its implementation remains undefined.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A systematic literature review, an expert physician panel, and patient interviews were used to develop consensus items on circulating tumor HPV DNA (ctHPVDNA) use. A hybrid Delphi approach was applied with California Head and Neck Consortium (CHNC) experts to appraise consensus over iterative rounds of feedback. Voting continued until thematic saturation was achieved.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In total, 33 CHNC experts participated, representing various entities (academic medical center, integrated managed care system, county hospital, Veterans Affairs hospital, community cancer center, private practice). Item development led to 32 statements across five domains, which later expanded to 33 items. Thematic saturation was reached after three rounds, with complete participation (33 of 33 votes) achieved in each round. Of these statements, 63.6% (21 of 33) reached strong consensus, 9.1% (3 of 33) reached consensus, 12.1% (4 of 33) was found to have no consensus, and 15.1% (5 of 33) was rejected. Key statements highlighted the strong consensus that ctHPVDNA was a valuable tool appropriate for diagnosis and surveillance settings, but not for screening or treatment modifications in current clinical practice. Despite the promise of this technology, there was strong consensus that randomized clinical trials should be performed to optimize its use in HPV+ OPC in the setting of potential increased costs.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Using currently available evidence and expertise, we establish a pragmatic framework of consensus recommendations for ctHPVDNA use. Such statements of varying strength will help bridge gaps in knowledge and lead to judicious implementation of assays into clinical practice.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>Allen S</ForeName><Initials>AS</Initials><Identifier Source="ORCID">0000-0001-5423-509X</Identifier><AffiliationInfo><Affiliation>Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moyers</LastName><ForeName>Justin T</ForeName><Initials>JT</Initials><Identifier Source="ORCID">0000-0001-5139-1652</Identifier><AffiliationInfo><Affiliation>The Angeles Clinic and Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Attarian</LastName><ForeName>Shirin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Medical Oncology, Department of Medicine, University of California Irvine (UCI), Irvine, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banker</LastName><ForeName>Rupali</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Medical Oncology, Department of Medicine, University of California Irvine (UCI), Irvine, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Birkeland</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, University of California Davis (UCD), Davis, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Michelle M</ForeName><Initials>MM</Initials><Identifier Source="ORCID">0000-0002-6988-5658</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Stanford University School of Medicine, Stanford, CA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>US Department of Veterans Affairs, Veterans Health Administration, Washington, DC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coffey</LastName><ForeName>Charles S</ForeName><Initials>CS</Initials><Identifier Source="ORCID">0000-0002-4513-3400</Identifier><AffiliationInfo><Affiliation>US Department of Veterans Affairs, Veterans Health Administration, Washington, DC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, University of California San Diego (UCSD), San Diego, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Theresa</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-1689-3275</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, University of California San Diego (UCSD), San Diego, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haidar</LastName><ForeName>Yarah</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, University of California Irvine (UCI), Irvine, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harris</LastName><ForeName>Jeremy P</ForeName><Initials>JP</Initials><Identifier Source="ORCID">0000-0001-7603-0263</Identifier><AffiliationInfo><Affiliation>Department of Radiation Oncology, University of California Irvine (UCI), Irvine, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holsinger</LastName><ForeName>F Christopher</ForeName><Initials>FC</Initials><Identifier Source="ORCID">0000-0002-9594-1414</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Stanford University School of Medicine, Stanford, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Inman</LastName><ForeName>Jared</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Loma Linda Medical Center, Loma Linda, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jang</LastName><ForeName>Julie K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kokot</LastName><ForeName>Niels</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-7388-6373</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, University of Southern California (USC), Los Angeles, CA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Los Angeles General Medical Center, Los Angeles, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwon</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-3574-4830</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, University of Southern California (USC), Los Angeles, CA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Los Angeles General Medical Center, Los Angeles, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larson</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-4164-5801</Identifier><AffiliationInfo><Affiliation>Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, Kaiser Permanente Sunset Los Angeles, Los Angeles, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Alice</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, Kaiser Permanente Sunset Los Angeles, Los Angeles, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maghami</LastName><ForeName>Ellie</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, City of Hope National Medical Center, Duarte, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mallen-St Clair</LastName><ForeName>Jon</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-2558-4682</Identifier><AffiliationInfo><Affiliation>Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mendelsohn</LastName><ForeName>Abie</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-8895-0286</Identifier><AffiliationInfo><Affiliation>US Department of Veterans Affairs, Veterans Health Administration, Washington, DC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Los Angeles Center for Ear, Nose, Throat, and Allergy, Los Angeles, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mita</LastName><ForeName>Alain C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Division of Medical Oncology, Department of Medicine, Hoag Family Cancer Institute, Newport Beach, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>William R</ForeName><Initials>WR</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, University of California San Francisco (UCSF), San Francisco, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>St John</LastName><ForeName>Maie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, University of California Los Angeles (UCLA), Los Angeles, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sampath</LastName><ForeName>Sagus</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-5464-7446</Identifier><AffiliationInfo><Affiliation>Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scher</LastName><ForeName>Kevin S</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Division of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sinha</LastName><ForeName>Uttam</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, University of Southern California (USC), Los Angeles, CA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, Los Angeles General Medical Center, Los Angeles, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Liyang</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-4639-3925</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, University of Southern California (USC), Los Angeles, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Jacob</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-8420-366X</Identifier><AffiliationInfo><Affiliation>Division of Medical Oncology, Department of Medicine, University of Southern California (USC), Los Angeles, CA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Medical Oncology, Department of Medicine, Los Angeles General Medical Center, Los Angeles, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tjoa</LastName><ForeName>Tjoson</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, University of California Irvine (UCI), Irvine, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wai</LastName><ForeName>Katherine C</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, University of California San Francisco (UCSF), San Francisco, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walgama</LastName><ForeName>Evan S</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Deborah J</ForeName><Initials>DJ</Initials><Identifier Source="ORCID">0000-0002-7811-7247</Identifier><AffiliationInfo><Affiliation>Division of Hematology/Oncology, Department of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zumsteg</LastName><ForeName>Zachary S</ForeName><Initials>ZS</Initials><Identifier Source="ORCID">0000-0001-7484-3631</Identifier><AffiliationInfo><Affiliation>Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Oncol Pract</MedlineTA><NlmUniqueID>101758685</NlmUniqueID><ISSNLinking>2688-1527</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>4</Day><Hour>19</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>4</Day><Hour>19</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>4</Day><Hour>16</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41343754</ArticleId><ArticleId IdType="doi">10.1200/OP-25-00450</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/OP-25-00440 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41418091</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2688-1535</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Dec</Month><Day>19</Day></PubDate></JournalIssue><Title>JCO oncology practice</Title><ISOAbbreviation>JCO Oncol Pract</ISOAbbreviation></Journal><ArticleTitle>Increasing Access and Quality Care for Immune Checkpoint Inhibitor-Related Thyroid Dysfunction.</ArticleTitle><Pagination><StartPage>OP2500440</StartPage><MedlinePgn>OP2500440</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/OP-25-00440</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The use of immunotherapy for cancer treatment is becoming increasingly prevalent, resulting in a growing number of patients experiencing immune-related adverse events (irAEs). Given the frequency of immunotherapy-related thyroid dysfunction (irTD), there is a growing demand for endocrine consultations, which has led to scheduling delays. This quality improvement project aimed to decrease the time to consultation and normalization of thyroid function tests (TFTs) in patients with irTD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Using the Plan-Do-Study-Act framework, a clinic dedicated to the evaluation and treatment of irTD was created. The immuno-oncology toxicity (IOTOX) clinic is staffed by advanced practice providers (APPs) using standardized algorithms and physician support.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">After implementation, a prospective analysis of 46 patients from the IOTOX clinic was compared with 67 historical control patients seen before implementation. The median consultation wait time improved from 21 to 9 days (<i>P</i> = .01), and the median time to follow-up decreased from 180 to 58 days (<i>P</i> &lt; .001). Notably, the median time to thyroid-stimulating hormone normalization was reduced from 102 to 38 days (<i>P</i> &lt; .001).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These findings suggest that an IOTOX clinic staffed by APPs using standardized algorithms with physician support effectively improved patient access to consultation and expedited the time to normalization of TFTs. This approach can serve as a framework for addressing other irAEs at our institution and has the potential to be implemented or adapted by other institutions to improve the care of patients with irAEs.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brinkman</LastName><ForeName>Anne K</ForeName><Initials>AK</Initials><Identifier Source="ORCID">0009-0008-6969-2101</Identifier><AffiliationInfo><Affiliation>Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salami-Henry</LastName><ForeName>Amori Y</ForeName><Initials>AY</Initials><Identifier Source="ORCID">0009-0003-0756-3439</Identifier><AffiliationInfo><Affiliation>Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aaron-Brija</LastName><ForeName>Lori A</ForeName><Initials>LA</Initials><Identifier Source="ORCID">0009-0008-2347-4328</Identifier><AffiliationInfo><Affiliation>Texas Woman's University, Dallas, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hannah</LastName><ForeName>Faheemah M</ForeName><Initials>FM</Initials><AffiliationInfo><Affiliation>Texas Woman's University, Dallas, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Mimi I</ForeName><Initials>MI</Initials><Identifier Source="ORCID">0000-0003-0355-030X</Identifier><AffiliationInfo><Affiliation>Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hwang</LastName><ForeName>Li-Ling</ForeName><Initials>LL</Initials><AffiliationInfo><Affiliation>Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Rachna P</ForeName><Initials>RP</Initials><AffiliationInfo><Affiliation>Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rollins</LastName><ForeName>Johnny L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sherman</LastName><ForeName>Steven I</ForeName><Initials>SI</Initials><Identifier Source="ORCID">0000-0002-3079-5153</Identifier><AffiliationInfo><Affiliation>Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Jessica K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kikani</LastName><ForeName>Nupur J</ForeName><Initials>NJ</Initials><Identifier Source="ORCID">0000-0003-3790-3927</Identifier><AffiliationInfo><Affiliation>Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weitzman</LastName><ForeName>Steven P</ForeName><Initials>SP</Initials><Identifier Source="ORCID">0000-0002-9045-0202</Identifier><AffiliationInfo><Affiliation>Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Oncol Pract</MedlineTA><NlmUniqueID>101758685</NlmUniqueID><ISSNLinking>2688-1527</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>19</Day><Hour>18</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>19</Day><Hour>18</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>19</Day><Hour>16</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41418091</ArticleId><ArticleId IdType="doi">10.1200/OP-25-00440</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/OP-25-00057 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40712114</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2688-1535</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jul</Month><Day>25</Day></PubDate></JournalIssue><Title>JCO oncology practice</Title><ISOAbbreviation>JCO Oncol Pract</ISOAbbreviation></Journal><ArticleTitle>Impact of Drug Shortages on Cancer Care Delivery Within the National Cancer Institute Community Oncology Research Program.</ArticleTitle><Pagination><StartPage>OP2500057</StartPage><MedlinePgn>OP2500057</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/OP-25-00057</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Drug shortages represent a challenge in oncology care, with potential repercussions including suboptimal treatment options, treatment delays, and medication errors. However, there is scant evidence on how drug shortages interrupt cancer care delivery (CCD) nationally and specifically across National Cancer Institute (NCI) Community Oncology Research Program (NCORP) community oncology practices.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Between December 2020 and July 2024, 96 NCORP community oncology practices were enrolled. NCORP practice study staff completed the Drug Shortage Baseline Survey and Pharmacy Baseline Survey. The primary outcome was proportion of practices seriously affected by drug shortages (ie, encountered CCD problems [change to less effective treatments, adoption of more toxic alternatives, treatment delays, or an increase in medication errors or near misses]) in the past 3 months. Secondary outcomes included CCD problems among practices (eg, ethical dilemmas) and strategies used by practices (eg, use of alternative drugs, stockpiling). Finally, we described differences between seriously affected and nonaffected practices.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Nearly 54% of NCORP practices were seriously affected by drug shortages in the past 3 months, with 23 drugs (including carboplatin [24.7%], leucovorin [22.6%], and cisplatin [19.4%]). Seriously affected practices were more likely to report lack of suitable alternatives (34.7% <i>v</i> 13.6%), substantial resources spent (70.8% <i>v</i> 50.0%), and change to alternative administration (73.5% <i>v</i> 52.3%) and were less likely to hire staff to address shortages (16.3% <i>v</i> 36.4%). Strategies to address shortages included using alternative drugs (91.5%), stockpiling (87.2%), and developing action plans (84.0%). Most (50.5%) practices reported experiencing an ethical dilemma related to a drug shortage.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Drug shortages influenced CCD among NCORP practices. This study underscores the need for robust strategies and policies to mitigate these effects and enhance the resilience of oncology practices.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ghazal</LastName><ForeName>Lauren V</ForeName><Initials>LV</Initials><Identifier Source="ORCID">0000-0001-5768-5571</Identifier><AffiliationInfo><Affiliation>University of Rochester School of Nursing, Rochester, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohile</LastName><ForeName>Supriya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Hematology/Oncology, Department of Medicine, University of Rochester Medical Center, URCC Research Base, Rochester, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loh</LastName><ForeName>Kah Poh</ForeName><Initials>KP</Initials><Identifier Source="ORCID">0000-0002-6978-0418</Identifier><AffiliationInfo><Affiliation>Division of Hematology/Oncology, Department of Medicine, University of Rochester Medical Center, Rochester, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mustian</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>University of Rochester School of Medicine &amp; Dentistry, URCC Research Base, Rochester, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sventek</LastName><ForeName>Grace</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Public Health Sciences, University of Rochester School of Medicine &amp; Dentistry, Rochester, NY.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Economics, University of Rochester School of Medicine &amp; Dentistry, Rochester, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gada</LastName><ForeName>Umang</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>University of Rochester School of Medicine &amp; Dentistry, Rochester, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Chin-Shang</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>University of Rochester School of Medicine &amp; Dentistry, Rochester, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Culakova</LastName><ForeName>Eva</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-9852-6515</Identifier><AffiliationInfo><Affiliation>Department of Surgery, University of Rochester Medical Center, Rochester, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foust</LastName><ForeName>Melyssa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Gibbs Cancer Center &amp; Research Institute, Upstate Carolina NCORP, Greer, SC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hopkins</LastName><ForeName>Judith O</ForeName><Initials>JO</Initials><Identifier Source="ORCID">0000-0002-9829-1242</Identifier><AffiliationInfo><Affiliation>SCOR PI/Novant Health Cancer Institute, Kernersville, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kehn</LastName><ForeName>Heather</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Metro-Minnesota Community Oncology Research Consortium, St Louis Park, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamen</LastName><ForeName>Charles</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-4219-4320</Identifier><AffiliationInfo><Affiliation>University of Rochester School of Medicine &amp; Dentistry, URCC Research Base, Rochester, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>Erin R</ForeName><Initials>ER</Initials><Identifier Source="ORCID">0000-0003-0070-0501</Identifier><AffiliationInfo><Affiliation>University of Utah Health, University of Utah College of Pharmacy, Salt Lake City, UT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hill</LastName><ForeName>Elaine L</ForeName><Initials>EL</Initials><Identifier Source="ORCID">0000-0003-2494-317X</Identifier><AffiliationInfo><Affiliation>Department of Public Health Sciences, University of Rochester School of Medicine &amp; Dentistry, URCC Research Base, Rochester, NY.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Economics, University of Rochester School of Medicine &amp; Dentistry, URCC Research Base, Rochester, NY.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, University of Rochester School of Medicine &amp; Dentistry, URCC Research Base, Rochester, NY.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UG1 CA189961</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Oncol Pract</MedlineTA><NlmUniqueID>101758685</NlmUniqueID><ISSNLinking>2688-1527</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2026</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>18</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>18</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>16</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40712114</ArticleId><ArticleId IdType="mid">NIHMS2091545</ArticleId><ArticleId IdType="pmc">PMC12313152</ArticleId><ArticleId IdType="doi">10.1200/OP-25-00057</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kehl KL, Gray SW, Kim B, et al. : Oncologists&#x2019; experiences with drug shortages. J Oncol Pract 11:e154&#x2013;162, 2015</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4371121</ArticleId><ArticleId IdType="pubmed">25549653</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Food and Drug Administration C for DE and: Drug Shortages [Internet]. FDA, 2024[cited 2024 Jul 22] Available from: https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages</Citation></Reference><Reference><Citation>Fox ER, McLaughlin MM: ASHP guidelines on managing drug product shortages. Am J Health Syst Pharm 75:1742&#x2013;1750, 2018</Citation><ArticleIdList><ArticleId IdType="pubmed">30061155</ArticleId></ArticleIdList></Reference><Reference><Citation>Kantarjian H: Chemotherapy Drug Shortages in the United States Revisited. JOP 10:329&#x2013;331, 2014</Citation><ArticleIdList><ArticleId IdType="pubmed">25232189</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Food and Drug Administration (FDA), Drug Shortages Task Force: Drug Shortages: Root Causes and Potential Solutions [Internet]. 2019.  Available from: http://www.fda.gov/media/131130/download</Citation></Reference><Reference><Citation>Shukar S, Zahoor F, Hayat K, et al. : Drug Shortage: Causes, Impact, and Mitigation Strategies. Frontiers in Pharmacology 12:693426, 2021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8299364</ArticleId><ArticleId IdType="pubmed">34305603</ArticleId></ArticleIdList></Reference><Reference><Citation>American Society of Health-System Pharmacists (ASHP): Current Drug Shortages [Internet]. ASHP- Drug Shortage Bulletin, 2024[cited 2024 Nov 5] Available from: https://www.ashp.org/Drug-Shortages/Current-Shortages</Citation></Reference><Reference><Citation>American Society of Health-System Pharmacists (ASHP): Drug Shortages Statistics [Internet]. National Drug Shortages: January 2001 to September 2024, 2024[cited 2024 Nov 19] Available from: https://www.ashp.org/Drug-Shortages/Shortage-Resources/Drug-Shortages-Statistics</Citation></Reference><Reference><Citation>Callaway Kim K, Rothenberger SD, Tadrous M, et al. : Drug Shortages Prior to and During the COVID-19 Pandemic. JAMA Network Open 7:e244246, 2024</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10998160</ArticleId><ArticleId IdType="pubmed">38578641</ArticleId></ArticleIdList></Reference><Reference><Citation>Darwin R: NCCN Releases Statement Addressing Ongoing Chemotherapy Shortages; Shares Survey Results Finding More than 90% of Cancer Centers are Impacted [Internet]. NCCN, 2023[cited 2024 Oct 30] Available from: https://www.nccn.org/home/news/newsdetails?NewsId=3970</Citation></Reference><Reference><Citation>National Comprehensive Cancer Network, Inc. (NCCN): NCCN Best Practices Committee Drug Shortage Follow-Up Survey Results [Internet], 2023[cited 2025 Mar 10] Available from: https://www.nccn.org/docs/default-source/oncology-policy-program/nccn-drug-shortages-survey-update.pdf?sfvrsn=4916cea8_1</Citation></Reference><Reference><Citation>Goldsack JC, Reilly C, Bush C, et al. : Impact of shortages of injectable oncology drugs on patient care. Am J Health Syst Pharm 71:571&#x2013;578, 2014</Citation><ArticleIdList><ArticleId IdType="pubmed">24644117</ArticleId></ArticleIdList></Reference><Reference><Citation>McBride A, Holle LM, Westendorf C, et al. : National survey on the effect of oncology drug shortages on cancer care. Am J Health Syst Pharm 70:609&#x2013;617, 2013</Citation><ArticleIdList><ArticleId IdType="pubmed">23515514</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang YT, Socal M, Bennett CL: Addressing the Drug-Shortage Crisis in Oncology. JAMA Oncology 10:155&#x2013;156, 2024</Citation><ArticleIdList><ArticleId IdType="pubmed">38175651</ArticleId></ArticleIdList></Reference><Reference><Citation>Tucker EL, Cao Y, Fox ER, et al. : The Drug Shortage Era: A Scoping Review of the Literature 2001&#x2013;2019. Clin Pharmacol Ther 108:1150&#x2013;1155, 2020</Citation><ArticleIdList><ArticleId IdType="pubmed">32521038</ArticleId></ArticleIdList></Reference><Reference><Citation>McBride A, Hudson-DiSalle S, Pilz J, et al. : National Survey on the Effect of Oncology Drug Shortages in Clinical Practice: A Hematology Oncology Pharmacy Association Survey. JCO Oncol Pract 18:e1289&#x2013;e1296, 2022</Citation><ArticleIdList><ArticleId IdType="pubmed">35544740</ArticleId></ArticleIdList></Reference><Reference><Citation>Caulder CR, Mehta B, Bookstaver PB, et al. : Impact of Drug Shortages on Health System Pharmacies in the Southeastern United States. Hospital Pharmacy 50:279, 2015</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4589883</ArticleId><ArticleId IdType="pubmed">26448658</ArticleId></ArticleIdList></Reference><Reference><Citation>Browne C, Ayoub T, Samarasinghe N, et al. : Impact of an Etoposide Chemotherapy Shortage on Patients With Extensive-Stage Small-Cell Lung Cancer: Results of a Natural Experiment. JCO Oncol Pract 0:OP.24.00394, 2024</Citation><ArticleIdList><ArticleId IdType="pubmed">39226485</ArticleId></ArticleIdList></Reference><Reference><Citation>Special Issue: Drug shortages: National Survey Reveals High Level of Frustration, Low Level of Safety | Institute For Safe Medication Practices [Internet], 2018[cited 2024 Mar 19] Available from: https://www.ismp.org/resources/special-issue-drug-shortages-national-survey-reveals-high-level-frustration-low-level</Citation></Reference><Reference><Citation>Tadrous M, Callaway Kim K, Hernandez I, et al. : Differences in Drug Shortages in the US and Canada. JAMA 332:1912&#x2013;1922, 2024</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11528343</ArticleId><ArticleId IdType="pubmed">39480469</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlos RC, Sicks JD, Chang GJ, et al. : Capacity for Cancer Care Delivery Research in NCORP Community Practices: Availability of Radiology and Primary Care Research Partners. J Am Coll Radiol 14:1530&#x2013;1537, 2017</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5880209</ArticleId><ArticleId IdType="pubmed">29055605</ArticleId></ArticleIdList></Reference><Reference><Citation>Nightingale CL, Dressler EVM, McDonald AM, et al. : The 2022 NCI Community Oncology Research Program (NCORP) Landscape Committee Assessment: Methods and participating practice group characteristics. JCO 41:e13517&#x2013;e13517, 2023</Citation></Reference><Reference><Citation>CenterWatch: Oncology | FDA Approved Drugs | CenterWatch [Internet], 2024[cited 2024 Mar 19] Available from: https://www.centerwatch.com/directories/1067-fda-approved-drugs/topic/103-oncology</Citation></Reference><Reference><Citation>University of Utah: Utah Drug Information Service database [Internet]. University of Utah Hospital Drug Information Service, 2021[cited 2024 Oct 30] Available from: https://pharmacyservices.utah.edu/rx-web-links/drug-shortages</Citation></Reference><Reference><Citation>National Comprehensive Cancer Network (NCCN): NCCN Best Practices Committee New Information and Survey Results from June 2024 [Internet], 2024[cited 2025 Mar 23] Available from: https://www.nccn.org/docs/default-source/oncology-policy-program/nccnbestpracticesdrugshortagesurvey.pdf?sfvrsn=b081351e_6</Citation></Reference><Reference><Citation>Santos ES, Oliver TK, Lacchetti C, et al. : Drug Shortages in Oncology: ASCO Clinical Guidance for Alternative Treatments. JCO Oncol Pract 20:19&#x2013;32, 2024</Citation><ArticleIdList><ArticleId IdType="pubmed">37963306</ArticleId></ArticleIdList></Reference><Reference><Citation>Faiman B: Providing Care During Cancer Drug Shortages. J Adv Pract Oncol 14:356&#x2013;357, 2023</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10414530</ArticleId><ArticleId IdType="pubmed">37576367</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson B, Faquin W: Generic cancer drugs are still in short supply. Cancer Cytopathology 132:5&#x2013;6, 2024</Citation><ArticleIdList><ArticleId IdType="pubmed">38163921</ArticleId></ArticleIdList></Reference><Reference><Citation>G Salazar E, Bernhardt MB, Li Y, et al. : The impact of chemotherapy shortages on COG and local clinical trials: a report from the Children&#x2019;s Oncology Group. Pediatr Blood Cancer 62:940&#x2013;944, 2015</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4670038</ArticleId><ArticleId IdType="pubmed">25704486</ArticleId></ArticleIdList></Reference><Reference><Citation>Office of the Assistant Secretary for Planning and Evaluation (ASPE): Policy Considerations to Prevent Drug Shortages and Mitigate Supply Chain Vulnerabilities in the United States [Internet]. Department of Health and Human Services, 2024[cited 2025 Apr 6] Available from: http://aspe.hhs.gov/reports/preventing-shortages-supply-chain-vulnerabilities</Citation></Reference><Reference><Citation>Rep. Jacobs S [D-C-51: H.R.3008 &#x2013; 118th Congress (2023&#x2013;2024): Drug Shortage Prevention Act of 2023 [Internet]. 2023[cited 2025 Apr 6] Available from: https://www.congress.gov/bill/118th-congress/house-bill/3008</Citation></Reference><Reference><Citation>Shuman AG, Fox ER, Unguru Y: COVID-19 and Drug Shortages: A Call to Action. J Manag Care Spec Pharm 26: 10.18553/jmcp.2020.26.8.945, 2020</Citation><ArticleIdList><ArticleId IdType="doi">10.18553/jmcp.2020.26.8.945</ArticleId><ArticleId IdType="pmc">PMC10391236</ArticleId><ArticleId IdType="pubmed">32715960</ArticleId></ArticleIdList></Reference><Reference><Citation>American Society of Clinical Oncology (ASCO): Ethics Principles &amp; Implementation Strategies [Internet]. ASCO, 2023[cited 2024 Oct 31] Available from: https://society.asco.org/practice-patients/practice-support/drug-shortages/ethics-principles-implementation-strategies</Citation></Reference><Reference><Citation>American Society of Clinical Oncology (ASCO): Drug Shortages [Internet]. ASCO Practice Support, 2023[cited 2024 Jul 30] Available from: https://society.asco.org/practice-patients/practice-support/drug-shortages</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/GO-24-00349 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39819125</PMID><DateCompleted><Year>2025</Year><Month>01</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2687-8941</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><PubDate><Year>2025</Year><Month>Jan</Month></PubDate></JournalIssue><Title>JCO global oncology</Title><ISOAbbreviation>JCO Glob Oncol</ISOAbbreviation></Journal><ArticleTitle>Multicentric Cross-Sectional Survey to Assess the Variation of Fractionation Strategies Used in the Management of Head and Neck Cancers in the Asian Region (INNOCENCE-ASIA).</ArticleTitle><Pagination><StartPage>e2400349</StartPage><MedlinePgn>e2400349</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/GO-24-00349</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Head and neck cancers (HNCs) are in general treated with conventional fractionation regimen of 1.8-2 Gy per fraction. Altered fractionation (ALFT) strategies such as hypofractionation radiotherapy (HYPO-RT), accelerated fractionation radiotherapy (AFRT), and hyperfractionation radiotherapy (HFRT) have not been practiced uniformly across centers in different parts of the world. Countries in Asia share common cancer demographics, and we designed this survey for Federation of Asian Radiation Oncology (FARO) member countries to understand the usage and challenges in the delivery of ALFT in HNCs.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">A 21-point electronic survey (Federation of Asian Radiation Oncology Research Network [FERN]-S-005) was designed by the FERN and was circulated through the FARO research secretariat to the FARO council member countries and the responses were collected between August and November 2023.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Twelve of 14 member countries (85.7%) responded to the survey. Twenty-seven responses were received and 78% of the respondents belonged to government/teaching academic institute. 4/27 (14.8%) reported never using HYPO-RT for any of the clinical subsite of HNCs, while the majority (85.2%) used it for glottic cancers and 22% also used it for postoperative setting. Majority (77.7%) used a fractionation schedule with dose per fraction ranging between 2.2 and 2.5 Gy. 6/27 (22.2%) used AFRT for definitive setting and five of these also used concurrent chemoradiotherapy. 4/27 (14.8%) centers reported using HFRT. The most common reason (62.9%) for the limited usage of AFRT/HFRT was reported to be logistical, such as unavailability of machine slots, patient load, and so on.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The result of the survey suggests that among the ALFT strategies for HNCs, HYPO-RT schedules have common interest and feasibility among the FARO member countries and also highlights the challenges in the delivery of AFRT/HFRT in the Asian region.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gandhi</LastName><ForeName>Ajeet Kumar</ForeName><Initials>AK</Initials><Identifier Source="ORCID">0000-0001-5713-0963</Identifier><AffiliationInfo><Affiliation>Department of Radiation Oncology, Dr Ram Manohar Lohia Institute of Medical Sciences, Lucknow, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chopra</LastName><ForeName>Supriya</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-2656-1792</Identifier><AffiliationInfo><Affiliation>Department of Radiation Oncology, Advanced Centre for Treatment Research and Education in Cancer, Tata Memorial Centre, Homi Bhabha National Institute, Navi Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rastogi</LastName><ForeName>Madhup</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-7060-7201</Identifier><AffiliationInfo><Affiliation>Department of Radiation Oncology, Dr Ram Manohar Lohia Institute of Medical Sciences, Lucknow, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mallick</LastName><ForeName>Indranil</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-5567-9204</Identifier><AffiliationInfo><Affiliation>Department of Radiation Oncology, Tata Medical Center, Kolkata, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruz</LastName><ForeName>Misael C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Central Luzon Integrated Oncology Center and Cancer Institute Sacred Heart Medical Center, Pampanga, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yasuda</LastName><ForeName>Koichi</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-6333-3051</Identifier><AffiliationInfo><Affiliation>Department of Radiation Oncology, Hokkaido University Hospital, Sapporo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sum</LastName><ForeName>Ying Ying</ForeName><Initials>YY</Initials><AffiliationInfo><Affiliation>Department of Radiotherapy and Oncology, Penang General Hospital, George Town, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagata</LastName><ForeName>Yasushi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Chugoku Rosai Hospital, Emeritus Professor, Hiroshima University, Kure, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Hong-Gyun</ForeName><Initials>HG</Initials><Identifier Source="ORCID">0000-0002-0167-7991</Identifier><AffiliationInfo><Affiliation>Department of Radiation Oncology, Seoul National University College of Medicine and Seoul National University Hospital, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prajogi</LastName><ForeName>Gregorius B</ForeName><Initials>GB</Initials><Identifier Source="ORCID">0000-0001-9615-3084</Identifier><AffiliationInfo><Affiliation>Department of Radiation Oncology, Faculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo Hospital, Jakarta, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kodrat</LastName><ForeName>Henry</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Faculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo Hospital, Jakarta, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Mingwei</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Peking University First Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nisar</LastName><ForeName>Asif</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0007-6903-1138</Identifier><AffiliationInfo><Affiliation>Clinical and Radiation Oncologist, AECH NORI, Islamabad, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chitapanarux</LastName><ForeName>Imjai</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-8552-0149</Identifier><AffiliationInfo><Affiliation>Department of Radiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>01</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Glob Oncol</MedlineTA><NlmUniqueID>101760170</NlmUniqueID><ISSNLinking>2687-8941</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006258" MajorTopicYN="Y">Head and Neck Neoplasms</DescriptorName><QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019583" MajorTopicYN="Y">Dose Fractionation, Radiation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001208" MajorTopicYN="N" Type="Geographic">Asia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>1</Month><Day>17</Day><Hour>18</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>1</Month><Day>17</Day><Hour>18</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>1</Month><Day>17</Day><Hour>12</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39819125</ArticleId><ArticleId IdType="doi">10.1200/GO-24-00349</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/GO-24-00530 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40014841</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>10</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2687-8941</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><PubDate><Year>2025</Year><Month>Feb</Month></PubDate></JournalIssue><Title>JCO global oncology</Title><ISOAbbreviation>JCO Glob Oncol</ISOAbbreviation></Journal><ArticleTitle>Radiotherapy and Nuclear Medicine Equipment Shortages in Vietnam: A Critical Gap in Cancer Care.</ArticleTitle><Pagination><StartPage>e2400530</StartPage><MedlinePgn>e2400530</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/GO-24-00530</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The aim of this study was to evaluate the current availability and distribution of radiotherapy (RT) and nuclear medicine equipment in Vietnam, focusing on the shortage of linear accelerators (LINACs), positron emission tomography/computed tomography (PET/CT) scanners, and brachytherapy units. The study seeks to quantify these shortages and highlight the implications for cancer treatment access and outcomes.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Data were collected from 50 hospitals across Vietnam that provide RT services or nuclear medicine imaging. The availability of LINACs, PET/CT devices, brachytherapy units, and other essential equipment was assessed, alongside patient loads and machine utilization rates. National data were compared with the standard in developed countries, with a particular focus on the International Atomic Energy Agency's (IAEA) recommendations for RT infrastructure.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Vietnam has a total of 82 LINACs, resulting in a LINAC density of 0.82 per million people, which is far below the standard in developed countries of 4-8 per million. Of the existing LINACs, 43% are outdated and unable to deliver advanced RT techniques such as volumetric modulated arc therapy. Additionally, the country has only 12 PET/CT scanners and three cyclotrons, which limits access to early cancer diagnosis and treatment planning. The central region of Vietnam is particularly underserved, with only 1 PET/CT device and limited access to brachytherapy services. Long wait times for RT-often up to 2 weeks-are common, leading to delayed treatments and reduced treatment efficacy. Patients, particularly those with conditions requiring timely RT after chemotherapy, face increased risks because of these delays.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The shortage of modern RT and nuclear medicine equipment in Vietnam critically limits timely access to cancer treatment, affecting patient outcomes and placing a heavy burden on health care providers. Expanding access to advanced RT technology through government investment, public-private partnerships, and international collaborations with organizations such as the IAEA could alleviate these challenges. Increasing Vietnam's RT capacity is essential for improving cancer care outcomes and managing the rising burden of cancer across the country.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Dang Van</ForeName><Initials>DV</Initials><Identifier Source="ORCID">0000-0002-3370-478X</Identifier><AffiliationInfo><Affiliation>Department of Oncology, Hanoi Medical University, Hanoi, Vietnam.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Head and Neck Radiation Oncology, Vietnam National Cancer Hospital, Hanoi, Vietnam.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pham</LastName><ForeName>Manh Duy</ForeName><Initials>MD</Initials><Identifier Source="ORCID">0000-0003-3356-055X</Identifier><AffiliationInfo><Affiliation>Department of Oncology, Hanoi Medical University, Hanoi, Vietnam.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoang</LastName><ForeName>Thai Huu</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>Department of Radiotherapy and Medical Physics, Nghe An Oncology Hospital, Nghe An Province, Vietnam.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Binh Thanh</ForeName><Initials>BT</Initials><AffiliationInfo><Affiliation>Radiation Therapy Physics Department, Vietnam National Cancer Hospital, Hanoi, Vietnam.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>02</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Glob Oncol</MedlineTA><NlmUniqueID>101760170</NlmUniqueID><ISSNLinking>2687-8941</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D014744" MajorTopicYN="N" Type="Geographic">Vietnam</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName><QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009683" MajorTopicYN="Y">Nuclear Medicine</DescriptorName><QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011878" MajorTopicYN="Y">Radiotherapy</DescriptorName><QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010315" MajorTopicYN="N">Particle Accelerators</DescriptorName><QualifierName UI="Q000600" MajorTopicYN="N">supply &amp; distribution</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072078" MajorTopicYN="N">Positron Emission Tomography Computed Tomography</DescriptorName><QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>2</Month><Day>27</Day><Hour>18</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>2</Month><Day>27</Day><Hour>18</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>2</Month><Day>27</Day><Hour>16</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40014841</ArticleId><ArticleId IdType="doi">10.1200/GO-24-00530</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/GO-24-00409 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40127379</PMID><DateCompleted><Year>2025</Year><Month>03</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2687-8941</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><PubDate><Year>2025</Year><Month>Mar</Month></PubDate></JournalIssue><Title>JCO global oncology</Title><ISOAbbreviation>JCO Glob Oncol</ISOAbbreviation></Journal><ArticleTitle>Overcoming Financial and Access Barriers in Global Cancer Care With Low-Dose Immunotherapy: A Systematic Review.</ArticleTitle><Pagination><StartPage>e2400409</StartPage><MedlinePgn>e2400409</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/GO-24-00409</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Immune checkpoint inhibitors (ICIs) have significantly improved outcomes in various malignancies. However, the high cost of these therapies limits access for much of the global population. This systematic review aims to evaluate the efficacy of low-dose ICIs compared with standard doses in different malignancies, addressing financial and access barriers in global cancer care.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a systematic review of studies comparing the efficacy of low-dose versus standard-dose ICI regimens in advanced solid tumors. A comprehensive search was performed across multiple electronic databases, including retrospective and prospective studies. Excluded were animal studies, editorials, conference papers, book chapters, and other immunotherapy modalities. Outcomes assessed included overall survival (OS), progression-free survival, and objective response rate. Results were summarized descriptively due to study heterogeneity.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">From 1,010 screened articles, four studies with 435 Asian patients were included, covering a variety of solid tumors. All included studies were with a low quality of evidence and a high risk of bias due to retrospective design. Two studies used weight-based dosing (pembrolizumab &lt;2 mg/kg and nivolumab &lt;2.15 mg/kg), showing similar OS to standard dosing in non-small cell lung cancer (NSCLC) and renal cell carcinoma, respectively. Flat dose regimens in two studies (nivolumab 20 mg or 100 mg once every 3 weeks and pembrolizumab 100 mg once every 3 weeks) also demonstrated comparable OS in NSCLC.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Low-dose ICIs may offer equivalent clinical benefits to standard dosing, potentially reducing costs and expanding access in developing countries. Although awaiting more representative randomized clinical trials, weight-based ICI regimens could be a viable alternative in low- and middle-income countries.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hoyek</LastName><ForeName>Celine</ForeName><Initials>C</Initials><Identifier Source="ORCID">0009-0000-7839-6760</Identifier><AffiliationInfo><Affiliation>Department of Hematology and Oncology, Mayo Clinic, Arizona, AZ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng-Lin</LastName><ForeName>Binbin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Hematology and Oncology, Mayo Clinic, Arizona, AZ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bauernfeind</LastName><ForeName>Jennah J</ForeName><Initials>JJ</Initials><Identifier Source="ORCID">0000-0002-3257-9454</Identifier><AffiliationInfo><Affiliation>Department of Hematology and Oncology, Mayo Clinic, Arizona, AZ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Ahmad</LastName><ForeName>Omar Hussain</ForeName><Initials>OH</Initials><AffiliationInfo><Affiliation>Syrian American Medical Society, Syria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bekaii-Saab</LastName><ForeName>Tanios</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-7721-1699</Identifier><AffiliationInfo><Affiliation>Department of Hematology and Oncology, Mayo Clinic, Arizona, AZ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chakrabarti</LastName><ForeName>Sakti</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-1582-098X</Identifier><AffiliationInfo><Affiliation>University Hospital, Seidman Cancer Center, Cleveland, OH.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rashdan</LastName><ForeName>Sawsan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sonbol</LastName><ForeName>Mohamad B</ForeName><Initials>MB</Initials><Identifier Source="ORCID">0000-0002-6931-242X</Identifier><AffiliationInfo><Affiliation>Department of Hematology and Oncology, Mayo Clinic, Arizona, AZ.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>03</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Glob Oncol</MedlineTA><NlmUniqueID>101760170</NlmUniqueID><ISSNLinking>2687-8941</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007167" MajorTopicYN="Y">Immunotherapy</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006297" MajorTopicYN="Y">Health Services Accessibility</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000082082" MajorTopicYN="Y">Immune Checkpoint Inhibitors</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>24</Day><Hour>18</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>24</Day><Hour>18</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>24</Day><Hour>16</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40127379</ArticleId><ArticleId IdType="doi">10.1200/GO-24-00409</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/GO-25-00043 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40440572</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>29</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2687-8941</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><PubDate><Year>2025</Year><Month>May</Month></PubDate></JournalIssue><Title>JCO global oncology</Title><ISOAbbreviation>JCO Glob Oncol</ISOAbbreviation></Journal><ArticleTitle>Genomic Characterization of Papillary Thyroid Cancer Reveals Germline Mutations Associated With Congenital Hypothyroidism.</ArticleTitle><Pagination><StartPage>e2500043</StartPage><MedlinePgn>e2500043</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/GO-25-00043</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Thyroid dyshormonogenesis, a form of congenital hypothyroidism, is characterized by defects in thyroid hormone synthesis genes, affecting both children and adults. However, the potential link between such genetic defects and the development of papillary thyroid cancer (PTC) remains unclear.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted whole-exome sequencing on 100 (N = 100) tumor-normal paired and orphan tumor samples of PTC from Indian patients, characterizing both germline and somatic molecular alterations.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We identified significant germline mutations in the <i>DUOX2</i> gene (approximately 8.8%), commonly associated with congenital hypothyroidism and thyroid dyshormonogenesis, and found these mutations to correlate with poor prognosis in PTC. Additionally, hallmark somatic mutations were detected in genes such as <i>BRAF</i> (35.4%), <i>KRAS</i> (3.8%), <i>HRAS</i> (5.1%), and <i>NRAS</i> (17.7%), which are well-known drivers of PTC. Importantly, we identified a distinct molecular subtype termed independent of BRAF-RAS (iBR), characterized by nonhallmark alterations and associated with a higher recurrence rate and poorer recurrence-free survival in Indian patients with PTC, highlighting the clinical significance of these molecular insights in prognosis and treatment strategies.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our analysis of PTC among Indians revealed novel genetic alterations and molecular subtypes. We identified a germline mutation in the <i>DUOX2</i> gene, associated with congenital hypothyroidism, as a potential risk factor of PTC. Additionally, we characterized distinct molecular subtypes, <i>BRAF-RAS</i> driven and iBR driven, and their clinical implications. These findings provide valuable insights into the genetic landscape of thyroid cancer in Indian patients and offer potential avenues for targeted therapies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Trivedi</LastName><ForeName>Vaishakhi</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Tata Memorial Hospital, Parel, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Homi Bhabha National Institute, Training School Complex, Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kore</LastName><ForeName>Hitesh</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-4118-6855</Identifier><AffiliationInfo><Affiliation>Department of Anatomy and Physiology, The University of Melbourne, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poojary</LastName><ForeName>Disha</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-2927-6679</Identifier><AffiliationInfo><Affiliation>Medical Oncology Molecular Laboratory, Tata Memorial Hospital, Parel, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noronha</LastName><ForeName>Vanita</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-0191-2744</Identifier><AffiliationInfo><Affiliation>Department of Medical Oncology, Tata Memorial Hospital, Parel, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Homi Bhabha National Institute, Training School Complex, Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bal</LastName><ForeName>Munita</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0345-5620</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Tata Memorial Hospital, Parel, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chandrani</LastName><ForeName>Pratik</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-2572-0189</Identifier><AffiliationInfo><Affiliation>Homi Bhabha National Institute, Training School Complex, Mumbai, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Oncology Molecular Laboratory, Tata Memorial Hospital, Parel, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Computational Biology, Bioinformatics and Crosstalk Lab, Advanced Centre for Treatment, Research, and Education in Cancer, Kharghar, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choughule</LastName><ForeName>Anuradha</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-9889-2136</Identifier><AffiliationInfo><Affiliation>Department of Medical Oncology, Tata Memorial Hospital, Parel, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Homi Bhabha National Institute, Training School Complex, Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pange</LastName><ForeName>Priyanka</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Tata Memorial Hospital, Parel, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Vinod</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Tata Memorial Hospital, Parel, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Menon</LastName><ForeName>Nandini</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-4214-5799</Identifier><AffiliationInfo><Affiliation>Department of Medical Oncology, Tata Memorial Hospital, Parel, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patil</LastName><ForeName>Vijay</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-7691-3995</Identifier><AffiliationInfo><Affiliation>Department of Medical Oncology, Tata Memorial Hospital, Parel, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Minit</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0979-9555</Identifier><AffiliationInfo><Affiliation>Department of Medical Oncology, Tata Memorial Hospital, Parel, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chaturvedi</LastName><ForeName>Pankaj</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-3520-1342</Identifier><AffiliationInfo><Affiliation>Homi Bhabha National Institute, Training School Complex, Mumbai, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Head and Neck Oncology, Tata Memorial Centre, Parel, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prabhash</LastName><ForeName>Kumar</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-8858-5004</Identifier><AffiliationInfo><Affiliation>Department of Medical Oncology, Tata Memorial Hospital, Parel, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Homi Bhabha National Institute, Training School Complex, Mumbai, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Oncology Molecular Laboratory, Tata Memorial Hospital, Parel, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dutt</LastName><ForeName>Amit</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Integrated Cancer Genomics Laboratory, Department of Genetics (Biotech Centre), University of Delhi South Campus, New Delhi, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Glob Oncol</MedlineTA><NlmUniqueID>101760170</NlmUniqueID><ISSNLinking>2687-8941</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 1.11.1.-</RegistryNumber><NameOfSubstance UI="D000074623">Dual Oxidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.6.3.1</RegistryNumber><NameOfSubstance UI="C431515">DUOX2 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018095" MajorTopicYN="Y">Germ-Line Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003409" MajorTopicYN="Y">Congenital Hypothyroidism</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077273" MajorTopicYN="Y">Thyroid Cancer, Papillary</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013964" MajorTopicYN="Y">Thyroid Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000074623" MajorTopicYN="N">Dual Oxidases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D023281" MajorTopicYN="N">Genomics</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073359" MajorTopicYN="N">Exome Sequencing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>29</Day><Hour>20</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>29</Day><Hour>20</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>29</Day><Hour>16</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40440572</ArticleId><ArticleId IdType="doi">10.1200/GO-25-00043</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/GO-24-00610 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40674659</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2687-8941</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><PubDate><Year>2025</Year><Month>Jul</Month></PubDate></JournalIssue><Title>JCO global oncology</Title><ISOAbbreviation>JCO Glob Oncol</ISOAbbreviation></Journal><ArticleTitle>Comprehensive Genomic Profiling of Anaplastic Thyroid Cancer Identifies Alterations in <i>THRA</i>, a Potential Modifier of Cellular Plasticity.</ArticleTitle><Pagination><StartPage>e2400610</StartPage><MedlinePgn>e2400610</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/GO-24-00610</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Lineage-specific cellular plasticity is one of the emerging hallmarks of cancer. The undifferentiated state of anaplastic thyroid cancer (ATC) represents an instance of cellular plasticity where lineage-specific molecular markers are underacknowledged. In this study, we identified recurrent mutations in the thyroid hormone receptor &#x3b1; (<i>THRA</i>) gene, which may play a role in lineage-specific cellular plasticity in ATC.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">We performed whole-exome sequencing and targeted sequencing of 68 formalin-fixed paraffin-embedded orphan tumors of ATC from Indian patients.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Our analysis reveals the hallmark mutations in <i>TP53</i> (approximately 42%), <i>BRAF</i> (approximately 10.3%), <i>KRAS</i> (approximately 2.9%), <i>NRAS</i> (29.4%), <i>HRAS</i> (23.5%), <i>NF1</i> (1.5%), <i>AKT1</i> (approximately 2.9%), and <i>PIK3CA</i> (approximately 1.5%) genes. Interestingly, we found significant mutations in <i>THRA</i> (approximately 11%) in our cohort, unlike the White population, which is a substantial gene in the thyroid cell's differentiation process. <i>THRA</i> mutations co-occur with TP53 and other hallmark genes, which suggests a synergetic molecular mechanism in phenotypic change in ATC.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our data reveal the significant association of <i>THRA</i> mutations potentially influencing cellular plasticity in a subset of patients with ATC.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Trivedi</LastName><ForeName>Vaishakhi</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Homi Bhabha National Institute, Training School Complex, Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noronha</LastName><ForeName>Vanita</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-0191-2744</Identifier><AffiliationInfo><Affiliation>Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Homi Bhabha National Institute, Training School Complex, Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bal</LastName><ForeName>Munita</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0345-5620</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Tata Memorial Hospital, Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chandrani</LastName><ForeName>Pratik</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-2572-0189</Identifier><AffiliationInfo><Affiliation>Homi Bhabha National Institute, Training School Complex, Mumbai, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Oncology Molecular Laboratory, Tata Memorial Hospital, Mumbai, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Computational Biology, Bioinformatics and Crosstalk Lab, Advanced Centre for Treatment, Research, and Education in Cancer, Navi Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poojary</LastName><ForeName>Disha</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-2927-6679</Identifier><AffiliationInfo><Affiliation>Medical Oncology Molecular Laboratory, Tata Memorial Hospital, Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saldanha</LastName><ForeName>Elveera</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-4748-8344</Identifier><AffiliationInfo><Affiliation>Homi Bhabha National Institute, Training School Complex, Mumbai, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Oncology Molecular Laboratory, Tata Memorial Hospital, Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choughule</LastName><ForeName>Anuradha</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-9889-2136</Identifier><AffiliationInfo><Affiliation>Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Homi Bhabha National Institute, Training School Complex, Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pange</LastName><ForeName>Priyanka</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Vinod</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Menon</LastName><ForeName>Nandini</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-4214-5799</Identifier><AffiliationInfo><Affiliation>Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patil</LastName><ForeName>Vijay</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-7691-3995</Identifier><AffiliationInfo><Affiliation>Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Minit</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0979-9555</Identifier><AffiliationInfo><Affiliation>Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chaturvedi</LastName><ForeName>Pankaj</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-3520-1342</Identifier><AffiliationInfo><Affiliation>Homi Bhabha National Institute, Training School Complex, Mumbai, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Head and Neck Oncology, Tata Memorial Centre, Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prabhash</LastName><ForeName>Kumar</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-1119-4774</Identifier><AffiliationInfo><Affiliation>Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Homi Bhabha National Institute, Training School Complex, Mumbai, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Oncology Molecular Laboratory, Tata Memorial Hospital, Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dutt</LastName><ForeName>Amit</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-8858-5004</Identifier><AffiliationInfo><Affiliation>Integrated Cancer Genomics Laboratory, Department of Genetics (Biotech Centre), University of Delhi South Campus, New Delhi, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Glob Oncol</MedlineTA><NlmUniqueID>101760170</NlmUniqueID><ISSNLinking>2687-8941</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065646" MajorTopicYN="Y">Thyroid Carcinoma, Anaplastic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013964" MajorTopicYN="Y">Thyroid Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000066670" MajorTopicYN="Y">Cell Plasticity</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073359" MajorTopicYN="N">Exome Sequencing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D023281" MajorTopicYN="N">Genomics</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>17</Day><Hour>18</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>17</Day><Hour>18</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>17</Day><Hour>16</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40674659</ArticleId><ArticleId IdType="doi">10.1200/GO-24-00610</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/GO-25-00119 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40700664</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>23</Day></DateCompleted><DateRevised><Year>2025</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2687-8941</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><PubDate><Year>2025</Year><Month>Jul</Month></PubDate></JournalIssue><Title>JCO global oncology</Title><ISOAbbreviation>JCO Glob Oncol</ISOAbbreviation></Journal><ArticleTitle>Association of Decayed, Missing, Filled Teeth Score With the Risk for Buccal Mucosa Cancer, Stratified on Tobacco and Alcohol Use: A Multicenter Case-Control Study From India.</ArticleTitle><Pagination><StartPage>e2500119</StartPage><MedlinePgn>e2500119</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/GO-25-00119</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Buccal mucosa cancer (BMC), the most prevalent oral cancer (OC) site, is a multifactorial disease. With relatively high prevalence of periodontal diseases because of poor oral hygiene practices, oral health indicators remain an area of exploration in the Indian context for its association with BMC.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 1,673 histologically confirmed cases and 1,601 frequency-matched controls from a hospital-based, multicenter case-control study was analyzed for the risk of BMC because of the oral hygiene indicators-denture use, number of decayed, missing, and filled teeth, and the Decayed, Missing, Filled Teeth (DMFT) score. Logistic regression models, adjusted for potential confounders like age, sex, rural-urban status, education, and tobacco and alcohol use (duration and frequency), were used to estimate odds ratios (ORs) and 95% CI. Analysis was further stratified on tobacco chewing and smoking.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We obtained an increased risk of decayed (OR<sub>&gt;2 decayed teeth</sub>, 1.53; 95% CI, 1.09 to 2.16), missing teeth (OR<sub>&gt;2 missing teeth</sub>, 2.59; 95% CI, 1.99 to 3.37), and high DMFT scores (OR<sub>&gt;3 DMFT score</sub>, 2.07; 95% CI, 1.62 to 2.66). Similar results were observed on the stratified analysis. Protective effect was observed for teeth filling (OR<sub>&gt;2 teeth-fillings</sub>, 0.59; 95% CI, 0.34 to 1.03) and denture use (OR<sub>ever versus never used dentures</sub>, 0.63; 95% CI, 0.47 to 0.85).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our findings suggest that DMFT score is associated with the risk of BMC and should be included in national oral health programs for prevention of OCs, along with other indicators of oral hygiene.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>George</LastName><ForeName>Grace Sarah</ForeName><Initials>GS</Initials><Identifier Source="ORCID">0009-0005-4874-488X</Identifier><AffiliationInfo><Affiliation>Division of Molecular Epidemiology and Population Genomics, Centre for Cancer Epidemiology, Tata Memorial Centre, Navi Mumbai, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Homi Bhabha National Institute (HBNI), Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Arjun</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-8119-8439</Identifier><AffiliationInfo><Affiliation>Homi Bhabha National Institute (HBNI), Mumbai, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Head and Neck Oncology, Tata Memorial Centre, Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moirangthem</LastName><ForeName>Romi</ForeName><Initials>R</Initials><Identifier Source="ORCID">0009-0009-6754-0523</Identifier><AffiliationInfo><Affiliation>Division of Molecular Epidemiology and Population Genomics, Centre for Cancer Epidemiology, Tata Memorial Centre, Navi Mumbai, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Homi Bhabha National Institute (HBNI), Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patil</LastName><ForeName>Aniket</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0002-8238-955X</Identifier><AffiliationInfo><Affiliation>Division of Molecular Epidemiology and Population Genomics, Centre for Cancer Epidemiology, Tata Memorial Centre, Navi Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pullat</LastName><ForeName>Gayathri B</ForeName><Initials>GB</Initials><Identifier Source="ORCID">0009-0008-4601-1465</Identifier><AffiliationInfo><Affiliation>Division of Molecular Epidemiology and Population Genomics, Centre for Cancer Epidemiology, Tata Memorial Centre, Navi Mumbai, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Homi Bhabha National Institute (HBNI), Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sagare</LastName><ForeName>Sakshi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Molecular Epidemiology and Population Genomics, Centre for Cancer Epidemiology, Tata Memorial Centre, Navi Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krishnatreya</LastName><ForeName>Manigreeva</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-9247-4814</Identifier><AffiliationInfo><Affiliation>Dr B. Borooah Cancer Institute-Tata Memorial Centre, Guwahati, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mishra</LastName><ForeName>Aseem</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-7823-5334</Identifier><AffiliationInfo><Affiliation>Homi Bhabha National Institute (HBNI), Mumbai, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mahamana Pandit Madan Mohan Malviya Cancer Centre, Varanasi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sonwane</LastName><ForeName>Rahul</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Centre for Cancer Epidemiology, Tata Memorial Centre, Navi Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hosseini</LastName><ForeName>Bayan</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-2670-9133</Identifier><AffiliationInfo><Affiliation>Environment and Lifestyle Epidemiology Branch, International Agency for Research on Cancer, World Health Organisation, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chaturvedi</LastName><ForeName>Anil</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-2696-8899</Identifier><AffiliationInfo><Affiliation>Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chaturvedi</LastName><ForeName>Pankaj</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-3520-1342</Identifier><AffiliationInfo><Affiliation>Homi Bhabha National Institute (HBNI), Mumbai, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Head and Neck Oncology, Tata Memorial Centre, Mumbai, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dikshit</LastName><ForeName>Rajesh</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Homi Bhabha National Institute (HBNI), Mumbai, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Cancer Epidemiology, Tata Memorial Centre, Navi Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mhatre</LastName><ForeName>Sharayu</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-7072-802X</Identifier><AffiliationInfo><Affiliation>Division of Molecular Epidemiology and Population Genomics, Centre for Cancer Epidemiology, Tata Memorial Centre, Navi Mumbai, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Homi Bhabha National Institute (HBNI), Mumbai, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>001</GrantID><Acronym>WHO_</Acronym><Agency>World Health Organization</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Glob Oncol</MedlineTA><NlmUniqueID>101760170</NlmUniqueID><ISSNLinking>2687-8941</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007194" MajorTopicYN="N" Type="Geographic">India</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009062" MajorTopicYN="Y">Mouth Neoplasms</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000428" MajorTopicYN="Y">Alcohol Drinking</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009061" MajorTopicYN="Y">Mouth Mucosa</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064424" MajorTopicYN="Y">Tobacco Use</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003731" MajorTopicYN="Y">Dental Caries</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009910" MajorTopicYN="N">Oral Hygiene</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>23</Day><Hour>18</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>23</Day><Hour>18</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>23</Day><Hour>16</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40700664</ArticleId><ArticleId IdType="doi">10.1200/GO-25-00119</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/GO-25-00207 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40924971</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2687-8941</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><PubDate><Year>2025</Year><Month>May</Month></PubDate></JournalIssue><Title>JCO global oncology</Title><ISOAbbreviation>JCO Glob Oncol</ISOAbbreviation></Journal><ArticleTitle>Challenges and Opportunities in Head and Neck Cancer Research in Developing Countries: Insights From a Fireside Chat.</ArticleTitle><Pagination><StartPage>e2500207</StartPage><MedlinePgn>e2500207</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/GO-25-00207</ELocationID><Abstract><AbstractText>Head and neck squamous cell carcinoma (HNSCC) represents a significant public health burden in developing countries, where access to early diagnosis, comprehensive care, and research infrastructure is limited. This article synthesizes the insights generated during a Fireside Chat convened by members of the Latin American Cooperative Oncology Group (LACOG)-Head and Neck and the Brazilian Group of Head and Neck Cancer (GBCP), with the participation of international expert Professor Hisham Mehanna. The discussion addressed key challenges and opportunities in clinical and translational research within resource-constrained settings. Major themes included the unmet needs of patients with HNSCC, particularly regarding treatment-related toxicities and the need for biomarker-driven, personalized approaches. Barriers to research in low- and middle-income countries were explored, including patient comorbidities, late-stage presentation, and regulatory hurdles. The group emphasized the importance of pragmatic, context-sensitive research that reflects local disease burden, health care structures, and cultural factors. Capacity building, multidisciplinary teamwork, and integration of translational science into clinical care were highlighted as essential for advancing outcomes. The manuscript also outlines the preparedness of Brazilian centers for early-phase trials, strategies to enhance patient recruitment, and mechanisms to strengthen collaboration among researchers, governmental agencies, and industry. Successful models from LACOG and GBCP were presented to illustrate local leadership in advancing HNSCC research. Ultimately, the authors advocate for a coordinated national research agenda that positions Brazil and similar nations as meaningful contributors to the global head and neck cancer research landscape, fostering innovation while addressing the realities of under-represented populations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chaves</LastName><ForeName>Aline Lauda Freitas</ForeName><Initials>ALF</Initials><Identifier Source="ORCID">0000-0002-6759-9463</Identifier><AffiliationInfo><Affiliation>DOM Oncologia, Divin&#xf3;polis, Grupo Oncocl&#xed;nicas, Belo Horizonte, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kowalski</LastName><ForeName>Luiz Paulo</ForeName><Initials>LP</Initials><Identifier Source="ORCID">0000-0002-0481-156X</Identifier><AffiliationInfo><Affiliation>Instituto do C&#xe2;ncer do Estado de S&#xe3;o Paulo, AC Camargo Cancer Center, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marta</LastName><ForeName>Gustavo Nader</ForeName><Initials>GN</Initials><Identifier Source="ORCID">0000-0002-3298-3684</Identifier><AffiliationInfo><Affiliation>Department of Radiation Oncology, Hospital S&#xed;rio-Liban&#xea;s, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santos-Silva</LastName><ForeName>Alan Roger</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Piracicaba Dental School, State University of Campinas (UNICAMP), Piracicaba, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vieira Muniz</LastName><ForeName>Luciana</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>DOM Oncologia, Divin&#xf3;polis, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mak</LastName><ForeName>Milena Perez</ForeName><Initials>MP</Initials><Identifier Source="ORCID">0000-0001-5876-6533</Identifier><AffiliationInfo><Affiliation>Instituto do C&#xe2;ncer do Estado de S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gossling</LastName><ForeName>Gustavo</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-4361-2889</Identifier><AffiliationInfo><Affiliation>LACOG, Porto Alegre, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guimaraes</LastName><ForeName>V&#xed;tor Souza</ForeName><Initials>VS</Initials><AffiliationInfo><Affiliation>Grupo Oncocl&#xed;nicas, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oliveira de Castro Junior</LastName><ForeName>Dalvaro</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Cl&#xed;nica AMO/DASA, Salvador, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Oliveira</LastName><ForeName>Thiago Bueno</ForeName><Initials>TB</Initials><Identifier Source="ORCID">0000-0002-6472-3596</Identifier><AffiliationInfo><Affiliation>AC Camargo Cancer Center, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lima</LastName><ForeName>Carmen Silvia Passos</ForeName><Initials>CSP</Initials><AffiliationInfo><Affiliation>Universidade Estadual de Campinas, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Traldi Macedo</LastName><ForeName>Ligia</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-0575-586X</Identifier><AffiliationInfo><Affiliation>Universidade Estadual de Campinas, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacinto</LastName><ForeName>Alexandre Arthur</ForeName><Initials>AA</Initials><Identifier Source="ORCID">0000-0002-6353-2202</Identifier><AffiliationInfo><Affiliation>Hospital de C&#xe2;ncer de Barretos, Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harada</LastName><ForeName>Guilherme</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-4012-3251</Identifier><AffiliationInfo><Affiliation>Hospital S&#xed;rio-Liban&#xea;s, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barbosa</LastName><ForeName>Malu Viter da Rosa</ForeName><Initials>MVDR</Initials><Identifier Source="ORCID">0000-0001-9088-2227</Identifier><AffiliationInfo><Affiliation>Grupo Oncocl&#xed;nicas, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santos</LastName><ForeName>Izabella Costa</ForeName><Initials>IC</Initials><Identifier Source="ORCID">0000-0002-6426-2419</Identifier><AffiliationInfo><Affiliation>Instituto Nacional do Cancer, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Batalha Filho</LastName><ForeName>Eronides Salustiano</ForeName><Initials>ES</Initials><Identifier Source="ORCID">0000-0001-5503-3158</Identifier><AffiliationInfo><Affiliation>Hospital S&#xed;rio-Liban&#xea;s, Bras&#xed;lia, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Castro Junior</LastName><ForeName>Gilberto</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-8765-3044</Identifier><AffiliationInfo><Affiliation>Instituto do C&#xe2;ncer do Estado de S&#xe3;o Paulo, Hospital S&#xed;rio-Liban&#xea;s, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Marchi</LastName><ForeName>Pedro Rafael Martins</ForeName><Initials>PRM</Initials><Identifier Source="ORCID">0000-0001-5259-0215</Identifier><AffiliationInfo><Affiliation>Grupo Oncocl&#xed;nicas, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matos</LastName><ForeName>Leandro Luongo</ForeName><Initials>LL</Initials><AffiliationInfo><Affiliation>Instituto do C&#xe2;ncer do Estado de S&#xe3;o Paulo, Faculdade Israelita de Ci&#xea;ncias da Sa&#xfa;de Albert Einstein, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Curado</LastName><ForeName>Maria Paula</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>AC Camargo Cancer Center, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mehanna</LastName><ForeName>Hisham</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-5544-6224</Identifier><AffiliationInfo><Affiliation>University of Birmingham, Birmingham, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>William</LastName><ForeName>William Nassib</ForeName><Initials>WN</Initials><Suffix>Jr</Suffix><Identifier Source="ORCID">0000-0001-5008-8854</Identifier><AffiliationInfo><Affiliation>Grupo Oncocl&#xed;nicas, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Glob Oncol</MedlineTA><NlmUniqueID>101760170</NlmUniqueID><ISSNLinking>2687-8941</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006258" MajorTopicYN="Y">Head and Neck Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003906" MajorTopicYN="N">Developing Countries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077195" MajorTopicYN="Y">Squamous Cell Carcinoma of Head and Neck</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D035843" MajorTopicYN="Y">Biomedical Research</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001938" MajorTopicYN="N" Type="Geographic">Brazil</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057170" MajorTopicYN="N">Translational Research, Biomedical</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>9</Day><Hour>18</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>9</Day><Hour>18</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>9</Day><Hour>16</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40924971</ArticleId><ArticleId IdType="doi">10.1200/GO-25-00207</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/GO-24-00652 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40971755</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>19</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2687-8941</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><PubDate><Year>2025</Year><Month>Sep</Month></PubDate></JournalIssue><Title>JCO global oncology</Title><ISOAbbreviation>JCO Glob Oncol</ISOAbbreviation></Journal><ArticleTitle>Characteristics and Impact of p16 Expression in Patients With Oropharyngeal Squamous Cell Carcinoma in Tanzania.</ArticleTitle><Pagination><StartPage>e2400652</StartPage><MedlinePgn>e2400652</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/GO-24-00652</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Oropharyngeal cancer is on the rise, despite declines in other head and neck cancers. The primary cause of this increase is human papillomavirus (HPV) infection, which accounts for over a quarter of new cancer patients in Tanzania. These cancers are largely preventable through HPV vaccination. HPV-associated oropharyngeal squamous cell carcinoma (OPSCC) is recognized as a distinct molecular and clinical entity, with unique demographics, staging, survival, and prognosis. International guidelines recommend that all staging, prognosis, and treatment decisions for OPSCC occur after determining the p16 expression, a surrogate immunohistochemical marker for HPV infection. However, current Tanzanian guidelines and clinical practice do not incorporate p16 immunohistochemistry (IHC) testing, despite the availability of qualified pathologists and laboratories.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">This retrospective hospital-based cohort study was conducted at the Ocean Road Cancer Institute (ORCI) and Muhimbili National Hospital in Dar es Salaam, Tanzania. A total of 83 patients with OPSCC were included. We assessed the sociodemographic and clinicopathologic profiles and the impact of p16 expression on overall survival (OS) in patients with OPSCC treated at the ORCI.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The prevalence of p16-positive OPSCC was found to be 43.4%. Patients with p16-positive tumors were younger and predominantly male and had a 3-year OS of 36% compared with 16.6% in those with p16-negative tumors.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our findings support the use of p16 IHC as a prognostic biomarker for OPSCC. In addition, the high prevalence of p16-positive OPSCC in our cohort suggests the broader implementation of gender-neutral HPV vaccination across Tanzania.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nnko</LastName><ForeName>Godwin</ForeName><Initials>G</Initials><Identifier Source="ORCID">0009-0001-1882-8282</Identifier><AffiliationInfo><Affiliation>Cancer Care Center, Kilimanjaro Christian Medical Centre, Moshi, Tanzania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Academic, Research, and Consultancy Unit, Ocean Road Cancer Institute, Dar es Salaam, Tanzania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Oncology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Saloni</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-8250-9569</Identifier><AffiliationInfo><Affiliation>Johns Hopkins University School of Medicine, Baltimore, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rugengamanzi</LastName><ForeName>Eulade</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-0385-3706</Identifier><AffiliationInfo><Affiliation>Academic, Research, and Consultancy Unit, Ocean Road Cancer Institute, Dar es Salaam, Tanzania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Oncology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Oncology, the Butaro Cancer Center of Excellence, Butaro, Rwanda.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Division, Medical School, University of Global Health Equity (UGHE), Butaro, Tanzania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramadhani</LastName><ForeName>Shafii S</ForeName><Initials>SS</Initials><Identifier Source="ORCID">0009-0000-3260-1909</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shimbo</LastName><ForeName>Dammy A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Pathology, Muhimbili National Hospital, Dar es Salaam, Tanzania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banzi</LastName><ForeName>Mathias</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-6103-1597</Identifier><AffiliationInfo><Affiliation>Academic, Research, and Consultancy Unit, Ocean Road Cancer Institute, Dar es Salaam, Tanzania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Oncology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Oncology, Mbeya Zonal Referral Hospital, Mbeya, Tanzania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malangwa</LastName><ForeName>Godfrey</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-6885-8404</Identifier><AffiliationInfo><Affiliation>Academic, Research, and Consultancy Unit, Ocean Road Cancer Institute, Dar es Salaam, Tanzania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Oncology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Oncology, Muhimbili National Hospital, Mloganzila, Tanzania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mashashi</LastName><ForeName>Getruda</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Academic, Research, and Consultancy Unit, Ocean Road Cancer Institute, Dar es Salaam, Tanzania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Oncology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Oncology, Bugando Medical Centre, Mwanza, Tanzania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Makupa</LastName><ForeName>Glory</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-0736-892X</Identifier><AffiliationInfo><Affiliation>Cancer Care Center, Kilimanjaro Christian Medical Centre, Moshi, Tanzania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Academic, Research, and Consultancy Unit, Ocean Road Cancer Institute, Dar es Salaam, Tanzania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Oncology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moturi</LastName><ForeName>Milpah</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Academic, Research, and Consultancy Unit, Ocean Road Cancer Institute, Dar es Salaam, Tanzania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Oncology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Oncology, Chuka County Referral Hospital, Chuka, Kenya.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mwakipunda</LastName><ForeName>Leila</ForeName><Initials>L</Initials><Identifier Source="ORCID">0009-0005-4938-373X</Identifier><AffiliationInfo><Affiliation>Cancer Care Center, Kilimanjaro Christian Medical Centre, Moshi, Tanzania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Academic, Research, and Consultancy Unit, Ocean Road Cancer Institute, Dar es Salaam, Tanzania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Oncology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jonathan</LastName><ForeName>Jesse</ForeName><Initials>J</Initials><Identifier Source="ORCID">0009-0003-5961-8323</Identifier><AffiliationInfo><Affiliation>Academic, Research, and Consultancy Unit, Ocean Road Cancer Institute, Dar es Salaam, Tanzania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Oncology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Oncology, Benjamin Mkapa Hospital, Dodoma, Tanzania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramadhani</LastName><ForeName>Aisha</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Academic, Research, and Consultancy Unit, Ocean Road Cancer Institute, Dar es Salaam, Tanzania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Oncology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gisiri</LastName><ForeName>Mwitasrobert</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Academic, Research, and Consultancy Unit, Ocean Road Cancer Institute, Dar es Salaam, Tanzania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Oncology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Oncology, Bugando Medical Centre, Mwanza, Tanzania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Idrissa</LastName><ForeName>Cepheline</ForeName><Initials>C</Initials><Identifier Source="ORCID">0009-0004-1266-5787</Identifier><AffiliationInfo><Affiliation>Academic, Research, and Consultancy Unit, Ocean Road Cancer Institute, Dar es Salaam, Tanzania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Oncology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Oncology, Bugando Medical Centre, Mwanza, Tanzania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mabruk</LastName><ForeName>Nur Antar</ForeName><Initials>NA</Initials><Identifier Source="ORCID">0009-0000-1440-0054</Identifier><AffiliationInfo><Affiliation>Academic, Research, and Consultancy Unit, Ocean Road Cancer Institute, Dar es Salaam, Tanzania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Oncology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karia</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Academic, Research, and Consultancy Unit, Ocean Road Cancer Institute, Dar es Salaam, Tanzania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Oncology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sifueli</LastName><ForeName>Innocent</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Academic, Research, and Consultancy Unit, Ocean Road Cancer Institute, Dar es Salaam, Tanzania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Oncology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chuwa</LastName><ForeName>Harrison</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-7632-9051</Identifier><AffiliationInfo><Affiliation>Department of Oncology, Aga Khan Health Service, Dar es Salaam, Tanzania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Alexis A</ForeName><Initials>AA</Initials><Identifier Source="ORCID">0000-0003-3044-3358</Identifier><AffiliationInfo><Affiliation>Illawarra Cancer Care Centre, Wollongong, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ndumbalo</LastName><ForeName>Jerry</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-4853-5499</Identifier><AffiliationInfo><Affiliation>Academic, Research, and Consultancy Unit, Ocean Road Cancer Institute, Dar es Salaam, Tanzania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Oncology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Glob Oncol</MedlineTA><NlmUniqueID>101760170</NlmUniqueID><ISSNLinking>2687-8941</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019941">Cyclin-Dependent Kinase Inhibitor p16</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000614131">CDKN2A protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013636" MajorTopicYN="N" Type="Geographic">Tanzania</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009959" MajorTopicYN="Y">Oropharyngeal Neoplasms</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019941" MajorTopicYN="Y">Cyclin-Dependent Kinase Inhibitor p16</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030361" MajorTopicYN="N">Papillomavirus Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077195" MajorTopicYN="Y">Squamous Cell Carcinoma of Head and Neck</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002294" MajorTopicYN="Y">Carcinoma, Squamous Cell</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>19</Day><Hour>18</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>19</Day><Hour>18</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>19</Day><Hour>16</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40971755</ArticleId><ArticleId IdType="doi">10.1200/GO-24-00652</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/GO-25-00304 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">41021876</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>29</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2687-8941</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><PubDate><Year>2025</Year><Month>Sep</Month></PubDate></JournalIssue><Title>JCO global oncology</Title><ISOAbbreviation>JCO Glob Oncol</ISOAbbreviation></Journal><ArticleTitle>Knowledge, Attitudes, and Health-Seeking Behavior for Cervical, Breast, and Oral Cancers Among Women in Jashore, Bangladesh: A Cross-Sectional Study.</ArticleTitle><Pagination><StartPage>e2500304</StartPage><MedlinePgn>e2500304</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/GO-25-00304</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">This study aimed to assess cancer-related knowledge, attitudes, screening behaviors, and willingness to engage in community-based screening for cervical, breast, and oral cancers among women in rural Bangladesh, with the goal of informing the design of a scalable, national cancer screening strategy.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A cross-sectional survey was conducted among 1,046 eligible women (age &#x2265; 30 years or married &#x2265; 10 years) in Nawly village, Jashore, Bangladesh. Trained interviewers administered a structured questionnaire assessing sociodemographics, cancer knowledge, attitudes, screening behaviors, and willingness to participate in organized screening. Descriptive statistics and multivariate logistic regression models identified predictors of knowledge, participation, and willingness.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Although 75.4% of women were aware of cervical cancer, only 28.3% correctly identified screening intervals. Awareness of breast and oral cancer screening was lower (11.5% and 6.2%, respectively). Participation in cervical cancer screening was 18.2%, and &lt;1% for breast or oral cancer. However, willingness to participate in future community-based screening was high (&gt;89% across all cancer types). Higher education and income were significantly associated with better knowledge and increased screening participation. Fear and misconceptions were the most common barriers among those unwilling to participate.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Despite limited screening uptake, there is strong community readiness for organized cancer screening. These findings underscore the need for tailored education campaigns and scalable, community-based programs to enhance early cancer detection in low-resource settings such as Bangladesh.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Azim</LastName><ForeName>Md Ragaul</ForeName><Initials>MR</Initials><Identifier Source="ORCID">0000-0001-9958-9414</Identifier><AffiliationInfo><Affiliation>Institute of Health Economics, University of Dhaka, Dhaka, Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Evelyn Yi Ting</ForeName><Initials>EYT</Initials><Identifier Source="ORCID">0000-0002-2569-1261</Identifier><AffiliationInfo><Affiliation>National Cancer Centre Singapore, Singapore City, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rahman</LastName><ForeName>Md Mahfujur</ForeName><Initials>MM</Initials><Identifier Source="ORCID">0000-0002-9396-2692</Identifier><AffiliationInfo><Affiliation>Institute of Health Economics, University of Dhaka, Dhaka, Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Islam</LastName><ForeName>Md Sirajul</ForeName><Initials>MS</Initials><Identifier Source="ORCID">0000-0001-5351-269X</Identifier><AffiliationInfo><Affiliation>Institute of Health Economics, University of Dhaka, Dhaka, Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Talukder</LastName><ForeName>Md Habibullah</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Gonoshasthaya Cancer Hospital, Dhaka, Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woon</LastName><ForeName>Brian Shao Tian</ForeName><Initials>BST</Initials><Identifier Source="ORCID">0009-0005-4847-5114</Identifier><AffiliationInfo><Affiliation>National Cancer Centre Singapore, Singapore City, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joarder</LastName><ForeName>Taufique</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-3299-2628</Identifier><AffiliationInfo><Affiliation>SingHealth Duke-NUS Global Health Institute, Duke-NUS Medical School, Singapore City, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanesvaran</LastName><ForeName>Ravindran</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-2351-881X</Identifier><AffiliationInfo><Affiliation>National Cancer Centre Singapore, Singapore City, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamid</LastName><ForeName>Syed Abdul</ForeName><Initials>SA</Initials><Identifier Source="ORCID">0000-0002-3880-4317</Identifier><AffiliationInfo><Affiliation>Institute of Health Economics, University of Dhaka, Dhaka, Bangladesh.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Glob Oncol</MedlineTA><NlmUniqueID>101760170</NlmUniqueID><ISSNLinking>2687-8941</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001459" MajorTopicYN="N" Type="Geographic">Bangladesh</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007722" MajorTopicYN="Y">Health Knowledge, Attitudes, Practice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="Y">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="Y">Breast Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055088" MajorTopicYN="N">Early Detection of Cancer</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009062" MajorTopicYN="Y">Mouth Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010342" MajorTopicYN="Y">Patient Acceptance of Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>29</Day><Hour>22</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>29</Day><Hour>22</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>29</Day><Hour>16</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41021876</ArticleId><ArticleId IdType="doi">10.1200/GO-25-00304</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/GO-24-00285 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39772800</PMID><DateCompleted><Year>2025</Year><Month>01</Month><Day>08</Day></DateCompleted><DateRevised><Year>2025</Year><Month>01</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2687-8941</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><PubDate><Year>2025</Year><Month>Jan</Month></PubDate></JournalIssue><Title>JCO global oncology</Title><ISOAbbreviation>JCO Glob Oncol</ISOAbbreviation></Journal><ArticleTitle>Changing Landscape of Head and Neck Squamous Cell Carcinoma and Nasopharyngeal Carcinoma Treatment and Survival Trends in Thailand: A 13-Year Multicenter Retrospective Study of Patients.</ArticleTitle><Pagination><StartPage>e2400285</StartPage><MedlinePgn>e2400285</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/GO-24-00285</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The incidence and survival rates of head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal carcinoma (NPC) vary globally, influenced by factors such as ethnicity, lifestyle, and health care systems.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A retrospective analysis was conducted on patients with HNSCC treated between 2008 and 2020 in four major Thai academic cancer centers, using a multidisciplinary multicenter database. The study focused on the evolution of patient characteristics, survival changes, and treatment landscape alterations over time.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 6,319 patients, the most common primary sites were nasopharynx (33%), oral cavity (23%), oropharynx (17%), larynx (15%), and hypopharynx (8%). An increase in human papillomavirus-related oropharyngeal carcinoma was noted, from 13% in 2008 to 42% in 2019-2020. The majority of patients presented with locally advanced (LA) stages (IVa/b: 50%, III: 26%). Chemoradiotherapy (54%) and surgery (24%) were the main treatments, with cisplatin (79%) being most commonly used in chemoradiation. Overall survival (OS) improved annually across all subsites, correlating with an increase in intensity-modulated radiotherapy (IMRT) use, from 25% in 2008 to 90% in 2019-2020. The median follow-up duration was 4.59 years, with a minimum of 2.75 years. Patients treated with IMRT had significantly longer OS compared with those treated with non-IMRT techniques, in both NPC and non-NPC HNSCC (<i>P</i> &lt; .001).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">To our knowledge, this is the largest study in Thailand that demonstrates increasing survival outcomes in patients with HNSCC and NPC, despite commonly presenting with LA stages. The increasing use of IMRT may be contributing to improved survival outcomes in both patients with NPC and non-NPC HNSCC patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ngamphaiboon</LastName><ForeName>Nuttapong</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-6535-6345</Identifier><AffiliationInfo><Affiliation>Division of Medical Oncology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dechaphunkul</LastName><ForeName>Arunee</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Unit of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkla, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vinayanuwattikun</LastName><ForeName>Chanida</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-3622-7752</Identifier><AffiliationInfo><Affiliation>Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Danchaivijitr</LastName><ForeName>Pongwut</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-8230-5232</Identifier><AffiliationInfo><Affiliation>Division of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thamrongjirapat</LastName><ForeName>Thanaporn</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Medical Oncology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prayongrat</LastName><ForeName>Anussara</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Radiation Oncology, Department of Radiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dechaphunkul</LastName><ForeName>Tanadech</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology Head and Neck Surgery, Faculty of Medicine, Prince of Songkla University, Songkla, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiratrachu</LastName><ForeName>Rungarun</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-8683-0755</Identifier><AffiliationInfo><Affiliation>Division of Radiation Oncology, Department of Radiology, Faculty of Medicine, Prince of Songkla University, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pattaranutaporn</LastName><ForeName>Poompis</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-8101-3505</Identifier><AffiliationInfo><Affiliation>Division of Radiation Oncology, Department of Radiology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiarpinitnun</LastName><ForeName>Chuleeporn</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Radiation Oncology, Department of Radiology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Setakornnukul</LastName><ForeName>Jiraporn</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-7201-0377</Identifier><AffiliationInfo><Affiliation>Division of Radiation Oncology, Department of Radiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>01</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Glob Oncol</MedlineTA><NlmUniqueID>101760170</NlmUniqueID><ISSNLinking>2687-8941</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059248" MajorTopicYN="N">Chemoradiotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006258" MajorTopicYN="Y">Head and Neck Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077274" MajorTopicYN="Y">Nasopharyngeal Carcinoma</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009303" MajorTopicYN="Y">Nasopharyngeal Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077195" MajorTopicYN="Y">Squamous Cell Carcinoma of Head and Neck</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013785" MajorTopicYN="N" Type="Geographic">Thailand</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>1</Month><Day>8</Day><Hour>18</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>1</Month><Day>8</Day><Hour>18</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>1</Month><Day>8</Day><Hour>14</Hour><Minute>47</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39772800</ArticleId><ArticleId IdType="doi">10.1200/GO-24-00285</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/GO-25-00037 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40294360</PMID><DateCompleted><Year>2025</Year><Month>04</Month><Day>29</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2687-8941</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><PubDate><Year>2025</Year><Month>Apr</Month></PubDate></JournalIssue><Title>JCO global oncology</Title><ISOAbbreviation>JCO Glob Oncol</ISOAbbreviation></Journal><ArticleTitle>Improving the Sensitivity-Specificity Balance of Human Papillomavirus Testing on Self- and Clinician-Collected Samples in South Africa.</ArticleTitle><Pagination><StartPage>e2500037</StartPage><MedlinePgn>e2500037</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2500037</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1200/GO-25-00037</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Human papillomavirus (HPV) testing on self-collected samples may increase coverage of cervical cancer screening, but previous studies have observed lower specificity of HPV testing in self- versus clinician-collected samples. Here we investigate strategies to improve the sensitivity-specificity balance of a round of HPV testing on self-collected samples.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Women living with and without HIV, age 30-65 years, were recruited in South Africa. Self-collected vaginal samples and clinician-collected cervical samples were tested with Xpert HPV, an assay that detects the 14 high-risk HPV types in five separate channels: (P1) HPV 16; (P2) HPV 18, 45; (P3) HPV 31, 33, 35, 52, 58; (P4) HPV 51, 59; and (P5) HPV 39, 56, 66, 68. All women underwent colposcopy with histology sampling, and diagnosis of cervical intraepithelial neoplasia grade 2 or greater (CIN2+) was determined by adjudicated pathology. The AUC and related performance parameters were calculated using logistic regression with the cycle threshold (Ct) values of the channels as predictors.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">HPV prevalence in women without and with HIV was higher in self-collected (25.1% <i>v</i> 61.5%) than in clinician-collected samples (16.2% <i>v</i> 48.4%). The optimal model to predict CIN2+ used Ct values from the three channels that detect HPV 16, 18, 45, 31, 33, 35, 52, and/or 58. AUC was superior for testing on clinician-collected (0.908) than on self-collected samples (0.878; <i>P</i> = .0261) in women without HIV, as well as for women living with HIV (0.868 <i>v</i> 0.819; clinician <i>v</i> self; <i>P</i> = .0002). Alternate approaches to handling multiple types and sequential testing approaches did not allow self-testing to achieve equivalent performance to testing on clinician-collected samples.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Using more stringent Ct cutoffs on the three channels that detect the eight highest-risk HPV types can improve the sensitivity-specificity balance of a round of screening in both self- and clinician-collected samples. Although performance of HPV testing on self-collected samples is excellent, performance parameters are better on clinician-collected samples.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Houvessou</LastName><ForeName>Gbenankpon M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Gertrude H. Sergievsky Center, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saidu</LastName><ForeName>Rakiya</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department Obstetrics and Gynaecology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department Obstetrics and Gynaecology, Faculty of Health Sciences, South African Medical Research Council Gynaecology Cancer Research Centre, University of Cape Town, Cape Town, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boa</LastName><ForeName>Rosalind</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department Obstetrics and Gynaecology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department Obstetrics and Gynaecology, Faculty of Health Sciences, South African Medical Research Council Gynaecology Cancer Research Centre, University of Cape Town, Cape Town, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mbatani</LastName><ForeName>Nomonde</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-8826-5182</Identifier><AffiliationInfo><Affiliation>Department Obstetrics and Gynaecology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department Obstetrics and Gynaecology, Faculty of Health Sciences, South African Medical Research Council Gynaecology Cancer Research Centre, University of Cape Town, Cape Town, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moodley</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-9398-5202</Identifier><AffiliationInfo><Affiliation>Department Obstetrics and Gynaecology, Faculty of Health Sciences, South African Medical Research Council Gynaecology Cancer Research Centre, University of Cape Town, Cape Town, South Africa.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Health Sciences, Cancer Research Initiative and School of Public Health, University of Cape Town, Cape Town, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuhn</LastName><ForeName>Louise</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-2305-8665</Identifier><AffiliationInfo><Affiliation>Gertrude H. Sergievsky Center, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department Epidemiology, Mailman School of Public Health, Columbia University Irving Medical Center, New York, NY.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>04</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Glob Oncol</MedlineTA><NlmUniqueID>101760170</NlmUniqueID><ISSNLinking>2687-8941</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013019" MajorTopicYN="N" Type="Geographic">South Africa</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030361" MajorTopicYN="Y">Papillomavirus Infections</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="Y">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013048" MajorTopicYN="Y">Specimen Handling</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D027383" MajorTopicYN="Y">Papillomaviridae</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055088" MajorTopicYN="N">Early Detection of Cancer</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002578" MajorTopicYN="Y">Uterine Cervical Dysplasia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014626" MajorTopicYN="N">Vaginal Smears</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094302" MajorTopicYN="N">Human Papillomavirus Viruses</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/go/authors/author-center. Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments). No potential conflicts of interest were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>4</Month><Day>29</Day><Hour>6</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>4</Month><Day>28</Day><Hour>18</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>4</Month><Day>28</Day><Hour>16</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>4</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40294360</ArticleId><ArticleId IdType="pmc">PMC12056977</ArticleId><ArticleId IdType="doi">10.1200/GO-25-00037</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>El-Zein M, Bouten S, Louvanto K, et al. Validation of a new HPV self-sampling device for cervical cancer screening: The Cervical and Self-Sample in Screening (CASSIS) study. Gynecol Oncol. 2018;149:491&#x2013;497.</Citation><ArticleIdList><ArticleId IdType="pubmed">29678360</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbyn M, Smith SB, Temin S, et al. Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: Updated meta-analyses. BMJ. 2018;363:k4823.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6278587</ArticleId><ArticleId IdType="pubmed">30518635</ArticleId></ArticleIdList></Reference><Reference><Citation>Quincy BL, Turbow DJ, Dabinett LN, et al. Diagnostic accuracy of self-collected human papillomavirus specimens as a primary screen for cervical cancer. J Obstet Gynaecol. 2012;32:795&#x2013;799.</Citation><ArticleIdList><ArticleId IdType="pubmed">23075359</ArticleId></ArticleIdList></Reference><Reference><Citation>Kellen E, Benoy I, Vanden Broeck D, et al. A randomized, controlled trial of two strategies of offering the home-based HPV self-sampling test to non- participants in the Flemish cervical cancer screening program. Int J Cancer. 2018;143:861&#x2013;868.</Citation><ArticleIdList><ArticleId IdType="pubmed">29569715</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Gennaro G, Licata F, Trovato A, et al. Does self-sampling for human papilloma virus testing have the potential to increase cervical cancer screening? An updated meta-analysis of observational studies and randomized clinical trials. Front Public Health. 2022;10:1003461.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9773849</ArticleId><ArticleId IdType="pubmed">36568753</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrasquillo O, Seay J, Amofah A, et al. HPV self-sampling for cervical cancer screening among ethnic minority women in South Florida: A randomized trial. J Gen Intern Med. 2018;33:1077&#x2013;1083.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6025679</ArticleId><ArticleId IdType="pubmed">29594933</ArticleId></ArticleIdList></Reference><Reference><Citation>Narvaez L, Viviano M, Dickson C, et al. The acceptability of HPV vaginal self-sampling for cervical cancer screening in Latin America: A systematic review. Public Health Pract (Oxf) 2023;6:100417.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10410574</ArticleId><ArticleId IdType="pubmed">37564780</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanczuk GA, Currie H, Forson W, et al. Self-sampling as the principal modality for population based cervical screening: Five-year follow-up of the PaVDaG study. Int J Cancer. 2022;150:1350&#x2013;1356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9300001</ArticleId><ArticleId IdType="pubmed">34850395</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatzistamatiou K, Vrekoussis T, Tsertanidou A, et al. Acceptability of self-sampling for human papillomavirus-based cervical cancer screening. J Womens Health (Larchmt) 2020;29:1447&#x2013;1456.</Citation><ArticleIdList><ArticleId IdType="pubmed">32757997</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura H, Yeh PT, Oguntade H, et al. HPV self-sampling for cervical cancer screening: A systematic review of values and preferences. BMJ Glob Health. 2021;6:e003743.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8137189</ArticleId><ArticleId IdType="pubmed">34011537</ArticleId></ArticleIdList></Reference><Reference><Citation>Polman NJ, Ebisch RMF, Heideman DAM, et al. Performance of human papillomavirus testing on self-collected versus clinician-collected samples for the detection of cervical intraepithelial neoplasia of grade 2 or worse: A randomised, paired screen-positive, non-inferiority trial. Lancet Oncol. 2019;20:229&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pubmed">30658933</ArticleId></ArticleIdList></Reference><Reference><Citation>Toliman PJ, Kaldor JM, Badman SG, et al. Evaluation of self-collected vaginal specimens for the detection of high-risk human papillomavirus infection and the prediction of high-grade cervical intraepithelial lesions in a high-burden, low-resource setting. Clin Microbiol Infect. 2019;25:496&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">29906593</ArticleId></ArticleIdList></Reference><Reference><Citation>Saville M, Hawkes D, Keung M, et al. Analytical performance of HPV assays on vaginal self-collected vs practitioner-collected cervical samples: The SCoPE study. J Clin Virol. 2020;127:104375.</Citation><ArticleIdList><ArticleId IdType="pubmed">32361328</ArticleId></ArticleIdList></Reference><Reference><Citation>Saidu R, Kuhn L, Tergas A, et al. Performance of Xpert HPV on self-collected vaginal samples for cervical cancer screening among women in South Africa. J Low Genit Tract Dis. 2021;25:15&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7748046</ArticleId><ArticleId IdType="pubmed">33105451</ArticleId></ArticleIdList></Reference><Reference><Citation>Castle PE, Ajeh R, Dzudie A, et al. A comparison of screening tests for detection of high-grade cervical abnormalities in women living with HIV from Cameroon. Infect Agent Cancer. 2020;15:45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7353796</ArticleId><ArticleId IdType="pubmed">32676125</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn L, Saidu R, Boa R, et al. Clinical evaluation of modifications to a human papillomavirus assay to optimise its utility for cervical cancer screening in low-resource settings: A diagnostic accuracy study. Lancet Glob Health. 2020;8:e296&#x2013;e304.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8720235</ArticleId><ArticleId IdType="pubmed">31981559</ArticleId></ArticleIdList></Reference><Reference><Citation>Broquet C, Vassilakos P, Ndam Nsangou FM, et al. Utility of extended HPV genotyping for the triage of self-sampled HPV-positive women in a screen-and-treat strategy for cervical cancer prevention in Cameroon: A prospective study of diagnostic accuracy. BMJ Open. 2022;12:e057234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9791451</ArticleId><ArticleId IdType="pubmed">36549727</ArticleId></ArticleIdList></Reference><Reference><Citation>Botha MH, Van der Merwe FH, Snyman LC, et al. Utility of extended HPV genotyping as primary cervical screen in an unscreened population with high HIV co-infection rate. J Low Genit Tract Dis. 2023;27:212&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">37097217</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson LG, Saidu R, Mbulawa Z, et al. Selecting human papillomavirus genotypes to optimize the performance of screening tests among South African women. Cancer Med. 2020;9:6813&#x2013;6824.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7520316</ArticleId><ArticleId IdType="pubmed">32706163</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahesa C, Thomsen LT, Linde DS, et al. Comparison of human papillomavirus-based cervical cancer screening strategies in Tanzania among women with and without HIV. Int J Cancer. 2023;152:686&#x2013;696.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10087897</ArticleId><ArticleId IdType="pubmed">36093587</ArticleId></ArticleIdList></Reference><Reference><Citation>DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics. 1988;44:837&#x2013;845.</Citation><ArticleIdList><ArticleId IdType="pubmed">3203132</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbyn M, Verdoodt F, Snijders P, et al. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: A meta-analysis. Lancet Oncol. 2014;15:172&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pubmed">24433684</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbyn M, Castle P, Schiffman M, et al. Meta-analysis of agreement/concordance statistics in studies comparing self- vs clinician-collected samples for HPV testing in cervical cancer screening. Int J Cancer. 2022;151:308&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pubmed">35179777</ArticleId></ArticleIdList></Reference><Reference><Citation>Toliman PJ, Kaldor JM, Badman SG, et al. Performance of clinical screening algorithms comprising point-of-care HPV-DNA testing using self-collected vaginal specimens, and visual inspection of the cervix with acetic acid, for the detection of underlying high-grade squamous intraepithelial lesions in Papua New Guinea. Papillomavirus Res. 2018;6:70&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6250751</ArticleId><ArticleId IdType="pubmed">30391365</ArticleId></ArticleIdList></Reference><Reference><Citation>Viviano M, Tran PL, Kenfack B, et al. Self- versus physician-collected samples for the follow-up of human papillomavirus-positive women in sub-Saharan Africa. Int J Womens Health. 2018;10:187&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5903477</ArticleId><ArticleId IdType="pubmed">29692637</ArticleId></ArticleIdList></Reference><Reference><Citation>Catarino R, Vassilakos P, Bilancioni A, et al. Accuracy of self-collected vaginal dry swabs using the Xpert human papillomavirus assay. PLoS One. 2017;12:e0181905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5547698</ArticleId><ArticleId IdType="pubmed">28750015</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan R, Zhao X, Zhang H, et al. Performance of cervical cancer screening and triage strategies among women living with HIV in China. Cancer Med. 2021;10:6078&#x2013;6088.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8419757</ArticleId><ArticleId IdType="pubmed">34342174</ArticleId></ArticleIdList></Reference><Reference><Citation>Song F, Du H, Wang C, et al. The effectiveness of human papillomavirus load, reflected by cycle threshold values, for the triage of HPV-positive self-samples in cervical cancer screening. J Med Screen. 2021;28:318&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">32869705</ArticleId></ArticleIdList></Reference><Reference><Citation>Adcock R, Cuzick J, Hunt W, et al. Role of HPV genotype, multiple infections, and viral load on the risk of high-grade cervical neoplasia. Cancer Epidemiol Biomarkers Prev. 2019;28:1816&#x2013;1824.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8394698</ArticleId><ArticleId IdType="pubmed">31488417</ArticleId></ArticleIdList></Reference><Reference><Citation>IARC https://publications.iarc.fr/Book-And-Report-Series/IarcHandbooks-Of-Cancer-Prevention/Cervical-Cancer-Screening-20222022 Cervical cancer screening IARC handbooks of cancer prevention volume 18.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/GO-24-00451 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40367395</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2687-8941</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><PubDate><Year>2025</Year><Month>Apr</Month></PubDate></JournalIssue><Title>JCO global oncology</Title><ISOAbbreviation>JCO Glob Oncol</ISOAbbreviation></Journal><ArticleTitle>Can Elective Neck Dissection for Oral Cancer Be Planned on the Basis of Depth of Invasion? Retrospective Analysis.</ArticleTitle><Pagination><StartPage>e2400451</StartPage><MedlinePgn>e2400451</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/GO-24-00451</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The literature suggests that elective neck dissection (END) may be avoided in primaries with a depth of invasion (DOI) &lt;3 mm. This study evaluated the accuracy of DOI in predicting nodal metastases (lymph node metastasis [LNM]) in oral squamous cell carcinoma (OSCC).</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">In this retrospective institutional chart review, pathologic N classification (pN) was correlated with DOI using Spearman's rank-order (pN1-3) and point-biserial (pN0 <i>v</i> pN+) correlation statistics. The receiver operating characteristic (ROC) curve was analyzed to determine the accuracy of DOI in predicting LNM. Chi-square statistics were used to measure the association between the DOI groups and pN status (pN0; pN+). Post hoc analysis of variance with Bonferroni statistics was used to compare the three DOI groups.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">DOI failed to demonstrate a strong positive correlation with the pN classification (&#x3c1; = 0.31; <i>P</i> &lt; .001). DOI was not strongly correlated with pN status (<i>r</i><sub>pb</sub> = 0.27; <i>P</i> &lt; .001). ROC curve analysis suggested a poor accuracy of DOI in predicting nodal metastases (AUC = 0.67 [95% CI, 0.6 to 0.73]). A statistically significant difference in LNM (pN+) was found between the DOI &gt;10 mm and DOI &#x2264;10 mm primaries (<i>P</i> &lt; .001 for DOI &#x2264;5 mm; <i>P</i> = .016 for DOI &gt;5 mm and &#x2264;10 mm). However, the sensitivity and specificity achieved by ROC analysis for a DOI cutoff value of 10 mm in the present cohort were 69.3% and 57.9%, respectively.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">DOI is a poor indicator of LNM in OSCC. The decision to perform END should not be based on the tumor DOI.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Majumdar</LastName><ForeName>Kinjal S</ForeName><Initials>KS</Initials><Identifier Source="ORCID">0000-0003-4696-3139</Identifier><AffiliationInfo><Affiliation>Department of Head &amp; Neck Surgery, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otolaryngology-Head &amp; Neck Surgery, All India Institute of Medical Sciences Rishikesh, Rishikesh, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgical Oncology, All India Institute of Medical Sciences Rishikesh, Rishikesh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abhinav</LastName><ForeName>Thaduri</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-3222-8125</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology-Head &amp; Neck Surgery, All India Institute of Medical Sciences Rishikesh, Rishikesh, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgical Oncology, All India Institute of Medical Sciences Rishikesh, Rishikesh, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Consultant Head &amp; Neck Oncologist, Basavatarakam Indo American Cancer Hospital, Hyderabad, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Panuganti</LastName><ForeName>Achyuth</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4490-5536</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology-Head &amp; Neck Surgery, All India Institute of Medical Sciences Rishikesh, Rishikesh, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgical Oncology, All India Institute of Medical Sciences Rishikesh, Rishikesh, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Consultant Head &amp; Neck Oncologist, Apollo Cancer Block, Apollo Hospitals, Jubilee Hills, Hyderabad, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seenivasagam</LastName><ForeName>Rajkumar K</ForeName><Initials>RK</Initials><AffiliationInfo><Affiliation>Department of Surgical Oncology, All India Institute of Medical Sciences Rishikesh, Rishikesh, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgical Oncology, PSG Institute of Medical Sciences &amp; Research, Coimbatore, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malhotra</LastName><ForeName>Manu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head &amp; Neck Surgery, All India Institute of Medical Sciences Rishikesh, Rishikesh, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Glob Oncol</MedlineTA><NlmUniqueID>101760170</NlmUniqueID><ISSNLinking>2687-8941</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009062" MajorTopicYN="Y">Mouth Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D037981" MajorTopicYN="Y">Neck Dissection</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008207" MajorTopicYN="N">Lymphatic Metastasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009361" MajorTopicYN="N">Neoplasm Invasiveness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017558" MajorTopicYN="N">Elective Surgical Procedures</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002294" MajorTopicYN="Y">Carcinoma, Squamous Cell</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>14</Day><Hour>19</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>14</Day><Hour>16</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40367395</ArticleId><ArticleId IdType="doi">10.1200/GO-24-00451</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/GO-25-00045 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40768686</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>06</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2687-8941</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><PubDate><Year>2025</Year><Month>Aug</Month></PubDate></JournalIssue><Title>JCO global oncology</Title><ISOAbbreviation>JCO Glob Oncol</ISOAbbreviation></Journal><ArticleTitle>Head and Neck Cancer in Suriname: An Epidemiologic Review of Clinical and Pathologic Features of Patients Treated Between 2009 and 2021.</ArticleTitle><Pagination><StartPage>e2500045</StartPage><MedlinePgn>e2500045</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/GO-25-00045</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">This study investigates the incidence and clinicopathologic characteristics of head and neck cancer (HNC) in the Surinamese population, with an emphasis on the burden of human papillomavirus (HPV) and Epstein-Barr virus (EBV).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Histologically confirmed HNC diagnosed between 2009 and 2021 were retrospectively collected from the Academic Hospital Paramaribo, the country's diagnostic pathology center. Additional clinical data were acquired from three other hospitals. Incidence rates were expressed as crude rates and age-adjusted World Standardized Rates per 100,000 population. Annual percentage changes (APCs) were calculated with Joinpoint regression software. HPV and EBV status were determined on pretreatment biopsies or resections of 263 patients from whom histopathologic material could be collected.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 364 patients, 279 (76.6%) were male. A substantial increase in HNC incidence was observed (2012-2019: annual percentage change 6.8%). Oral cavity carcinoma was most common in the Hindustani population, nasopharyngeal carcinoma (NPC) in the Maroon and Javanese populations, and laryngeal carcinoma (LC) in the Creole population. Patients with LC were more often smokers, whereas patients with oropharyngeal carcinoma (OPC) more often consumed alcohol. Most patients presented with advanced-stage disease at diagnosis (73.0%). Among 60 OPCs, 21 (35.0%) were HPV positive, and among 47 NPCs 43 (91.4%) were EBV positive.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">An increase in HNC incidence in Suriname has been observed that appears to be unrelated to a rise in OPC and is likely due to better diagnostic modalities and increase in the number of ear, nose, and throat specialists. Ethnic and lifestyle differences are seen in HNC primary tumor sites. The high proportion of advanced-stage disease at diagnosis highlights the urgent need to raise disease awareness and prioritize early detection to improve survival outcomes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bisheshar</LastName><ForeName>Sangeeta K</ForeName><Initials>SK</Initials><Identifier Source="ORCID">0000-0002-9941-0020</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dams</LastName><ForeName>Els T M</ForeName><Initials>ETM</Initials><Identifier Source="ORCID">0000-0001-6036-9692</Identifier><AffiliationInfo><Affiliation>Department of Oncology, Diakonessen Hospital, Paramaribo, Suriname.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Mikel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology, Academic Hospital Paramaribo, Paramaribo, Suriname.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Slagter-Menkema</LastName><ForeName>Lorian</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basdew</LastName><ForeName>Harie</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Radiotherapeutic Center Suriname, Paramaribo, Suriname.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Sluis</LastName><ForeName>Tineke</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohamedradja-Taus</LastName><ForeName>Rabia N</ForeName><Initials>RN</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, Academic Hospital Paramaribo, Paramaribo, Suriname.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ameerali</LastName><ForeName>Dave P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, Academic Hospital Paramaribo, Paramaribo, Suriname.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akrum</LastName><ForeName>Ralph A E</ForeName><Initials>RAE</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, St Vincentius Hospital, Paramaribo, Suriname.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheorajpanday</LastName><ForeName>Surya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, Academic Hospital Paramaribo, Paramaribo, Suriname.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mehilal</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Radiotherapeutic Center Suriname, Paramaribo, Suriname.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Leeuwaarde</LastName><ForeName>Rachel S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Department of Endocrine Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devriese</LastName><ForeName>Lot A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Department of Endocrine Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Dijk</LastName><ForeName>Boukje A C</ForeName><Initials>BAC</Initials><AffiliationInfo><Affiliation>Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Willems</LastName><ForeName>Stefan M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Vegt</LastName><ForeName>Bert</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-2613-1506</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Breimer</LastName><ForeName>Gerben E</ForeName><Initials>GE</Initials><Identifier Source="ORCID">0000-0003-0365-3667</Identifier><AffiliationInfo><Affiliation>Department of Pathology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Glob Oncol</MedlineTA><NlmUniqueID>101760170</NlmUniqueID><ISSNLinking>2687-8941</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013532" MajorTopicYN="N" Type="Geographic">Suriname</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006258" MajorTopicYN="Y">Head and Neck Neoplasms</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004854" MajorTopicYN="N">Herpesvirus 4, Human</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D030361" MajorTopicYN="N">Papillomavirus Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>6</Day><Hour>18</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>6</Day><Hour>18</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>6</Day><Hour>16</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40768686</ArticleId><ArticleId IdType="doi">10.1200/GO-25-00045</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/GO-25-00259 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40971754</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>19</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2687-8941</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><PubDate><Year>2025</Year><Month>Sep</Month></PubDate></JournalIssue><Title>JCO global oncology</Title><ISOAbbreviation>JCO Glob Oncol</ISOAbbreviation></Journal><ArticleTitle>Public Awareness, Knowledge, and Acceptability of Oral Cancer Screening Program in Malaysia.</ArticleTitle><Pagination><StartPage>e2500259</StartPage><MedlinePgn>e2500259</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/GO-25-00259</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Oral cancer (OC) remains a significant public health concern in Malaysia, with high mortality largely because of late-stage diagnosis. Despite the introduction of a national oral cancer screening (OCS) program over 20 years ago, early detection rates remain low. This study aims to evaluate the public awareness, knowledge, and acceptability of the OCS program in Malaysia.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A quantitative field study using a validated questionnaire was performed to assess awareness, knowledge, and acceptability of the OCS program among general public attending selected health clinics. Data collection took place in Samarahan and Kapit Divisions, in the state of Sarawak, Malaysia.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 651 of 655 respondents from the general public attending five selected health clinics in Samarahan and Kapit Divisions during a 1-month period completed the questionnaires, yielding an overall response rate of 99.4%. The mean age of participants was 38 years. More than half (56.8%) were female, and 32.0% worked in the government sector. Equal proportions were of Iban (31.8%) and Malay (31.5%) ethnicity. Three quarters had heard of OC (75.0%); however, less than half had heard of OCS (45.0%). Hence, although 62.4% knew what OC is, a similar proportion (63.4%) did not know of OCS. Age group, location, employment status, and risk habits were among the sociodemographic factors significantly associated with public awareness on OC and OCS; public knowledge on risk habits and prevention of OC; and acceptability of the OCS.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Enhancing public knowledge on OC and improving accessibility to screening especially for high-risk groups are crucial for improving early detection rates and reducing the disease burden in Malaysia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ab Latif</LastName><ForeName>Nur Diana</ForeName><Initials>ND</Initials><Identifier Source="ORCID">0009-0003-2280-0893</Identifier><AffiliationInfo><Affiliation>Oral Health Programme, Ministry of Health Malaysia, Federal Government Administrative Centre, Putrajaya, Malaysia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Community Oral Health and Clinical Prevention, Faculty of Dentistry, University of Malaya, Kuala Lumpur, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dahlui</LastName><ForeName>Maznah</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Social and Preventive Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geraldine Doss</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-2511-7523</Identifier><AffiliationInfo><Affiliation>Department of Community Oral Health and Clinical Prevention, Faculty of Dentistry, University of Malaya, Kuala Lumpur, Malaysia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Glob Oncol</MedlineTA><NlmUniqueID>101760170</NlmUniqueID><ISSNLinking>2687-8941</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009062" MajorTopicYN="Y">Mouth Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008296" MajorTopicYN="N" Type="Geographic">Malaysia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055088" MajorTopicYN="Y">Early Detection of Cancer</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007722" MajorTopicYN="Y">Health Knowledge, Attitudes, Practice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010342" MajorTopicYN="N">Patient Acceptance of Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>19</Day><Hour>18</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>19</Day><Hour>18</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>19</Day><Hour>16</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40971754</ArticleId><ArticleId IdType="doi">10.1200/GO-25-00259</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/GO-25-00032 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40403198</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2687-8941</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><PubDate><Year>2025</Year><Month>May</Month></PubDate></JournalIssue><Title>JCO global oncology</Title><ISOAbbreviation>JCO Glob Oncol</ISOAbbreviation></Journal><ArticleTitle>Triple Oral Metronomic Chemotherapy Versus Chemotherapy of Physician Discretion After Failure of Platinum-Based Therapy in Advanced Head and Neck Cancer: A Phase III Randomized Study (METRO-CHASE Study).</ArticleTitle><Pagination><StartPage>e2500032</StartPage><MedlinePgn>e2500032</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/GO-25-00032</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Platinum-refractory advanced head and neck squamous cell carcinoma (HNSCC) has poor outcomes and limited treatment options, especially in resource-constrained settings. Triple oral metronomic chemotherapy (OMCT), involving low-dose continuous administration of chemotherapeutic agents, has shown promise in phase II studies but lacks evidence from randomized controlled trials. This study evaluated whether triple OMCT improves overall survival (OS) compared with chemotherapy of physician discretion (CPD).</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">In this phase III randomized open-label study, 214 patients with advanced HNSCC who had previous platinum-based chemotherapy were randomly assigned 1:1 to receive either triple OMCT (arm A) with erlotinib, celecoxib, and methotrexate, or CPD (arm B). The primary end point was OS, with secondary end points including progression-free survival (PFS), quality of life (QOL), and safety. Kaplan-Meier and log-rank tests were used for OS and PFS, and Cox-proportional hazard models estimated hazard ratios. QOL was evaluated using European Organisation for Research and Treatment of Cancer QLQ-C30 and FACT H&amp;N.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Median OS was 5 months in arm A and 3.1 months in arm B (hazard ratio [HR], 0.63 [95% CI, 0.47 to 0.83]; <i>P</i> = .00011). Median PFS was 4.8 months in arm A and 2.7 months in arm B (HR, 0.67 [95% CI, 0.52 to 0.87]; <i>P</i> &lt; .0001). Previous treatment was a significant prognostic factor for OS, while age, tumor site, and previous treatment were significant for PFS. Triple OMCT improved global health status, physical functions, fatigue, and insomnia. It was well tolerated, with fewer grade 3 or higher adverse events than CPD (28.0% <i>v</i> 39.3%, <i>P</i> = .03).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Triple OMCT is an effective and safe treatment for advanced HNSCC after platinum-based chemotherapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kapoor</LastName><ForeName>Akhil</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-6006-2631</Identifier><AffiliationInfo><Affiliation>Department of Medical Oncology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Anuj</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-1241-5436</Identifier><AffiliationInfo><Affiliation>Department of Medical Oncology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sansar</LastName><ForeName>Bipinesh</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-7656-8650</Identifier><AffiliationInfo><Affiliation>Department of Medical Oncology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mishra</LastName><ForeName>Bal Krishna</ForeName><Initials>BK</Initials><Identifier Source="ORCID">0009-0007-1838-7097</Identifier><AffiliationInfo><Affiliation>Department of Medical Oncology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Pooja</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-3426-1404</Identifier><AffiliationInfo><Affiliation>Department of Medical Oncology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Arpita</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Upadhyay</LastName><ForeName>Arvind</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kashyap</LastName><ForeName>Lakhan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pal</LastName><ForeName>Ankita</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0005-8287-6640</Identifier><AffiliationInfo><Affiliation>Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Amit</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5920-0048</Identifier><AffiliationInfo><Affiliation>Department of Medical Oncology, Homi Bhabha Cancer Hospital &amp; Research Centre, Muzaffarpur, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nanda</LastName><ForeName>Sambit S</ForeName><Initials>SS</Initials><Identifier Source="ORCID">0000-0002-0801-9262</Identifier><AffiliationInfo><Affiliation>Department of Radiation Oncology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mukherji</LastName><ForeName>Ashutosh</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1273-2439</Identifier><AffiliationInfo><Affiliation>Department of Radiation Oncology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kapoor</LastName><ForeName>Ankita Rungta</ForeName><Initials>AR</Initials><Identifier Source="ORCID">0000-0003-2483-0968</Identifier><AffiliationInfo><Affiliation>Department of Radiation Oncology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pradhan</LastName><ForeName>Satyajit</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mishra</LastName><ForeName>Aseem</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-7823-5334</Identifier><AffiliationInfo><Affiliation>Department of Surgical Oncology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chowdhury</LastName><ForeName>Zachariah</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0002-1766-5012</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patne</LastName><ForeName>Shashikant</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-1275-7444</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dhal</LastName><ForeName>Ipsita</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Pathology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Neha</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-9788-0395</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Institute of Medical Science, BHU, Varanasi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shukla</LastName><ForeName>Shreya</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-7815-9252</Identifier><AffiliationInfo><Affiliation>Department of Radiodiagnosis, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Satyendra Narayan</ForeName><Initials>SN</Initials><Identifier Source="ORCID">0000-0001-5707-4148</Identifier><AffiliationInfo><Affiliation>Department of Radiodiagnosis, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shukla</LastName><ForeName>Varun</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-0312-9139</Identifier><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manikandan</LastName><ForeName>M V</ForeName><Initials>MV</Initials><Identifier Source="ORCID">0000-0002-8918-5384</Identifier><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suresh</LastName><ForeName>Arvind</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banavali</LastName><ForeName>Shripad</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-4069-023X</Identifier><AffiliationInfo><Affiliation>Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dey</LastName><ForeName>Somnath</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-3599-8531</Identifier><AffiliationInfo><Affiliation>Department of Palliative Medicine, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vinayak</LastName><ForeName>Kunal Ranjan</ForeName><Initials>KR</Initials><Identifier Source="ORCID">0009-0008-1114-0566</Identifier><AffiliationInfo><Affiliation>Department of Palliative Medicine, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lakshman</LastName><ForeName>Praveen</ForeName><Initials>P</Initials><Identifier Source="ORCID">0009-0001-1018-497X</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Lokendra</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-7812-2118</Identifier><AffiliationInfo><Affiliation>Department of Dentistry &amp; Prosthodontics, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gavel</LastName><ForeName>Pratibha</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bandekar</LastName><ForeName>Bhavesh P</ForeName><Initials>BP</Initials><AffiliationInfo><Affiliation>Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patil</LastName><ForeName>Vijay</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-7691-3995</Identifier><AffiliationInfo><Affiliation>Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noronha</LastName><ForeName>Vanita</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-0191-2744</Identifier><AffiliationInfo><Affiliation>Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prabhash</LastName><ForeName>Kumar</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-8858-5004</Identifier><AffiliationInfo><Affiliation>Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>CTRI/2021/09/036296</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Glob Oncol</MedlineTA><NlmUniqueID>101760170</NlmUniqueID><ISSNLinking>2687-8941</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>YL5FZ2Y5U1</RegistryNumber><NameOfSubstance UI="D008727">Methotrexate</NameOfSubstance></Chemical><Chemical><RegistryNumber>JCX84Q7J1L</RegistryNumber><NameOfSubstance UI="D000068579">Celecoxib</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059250" MajorTopicYN="N">Administration, Metronomic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006258" MajorTopicYN="Y">Head and Neck Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="Y">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077195" MajorTopicYN="Y">Squamous Cell Carcinoma of Head and Neck</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008727" MajorTopicYN="N">Methotrexate</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068579" MajorTopicYN="N">Celecoxib</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>22</Day><Hour>18</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>22</Day><Hour>18</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>22</Day><Hour>16</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40403198</ArticleId><ArticleId IdType="doi">10.1200/GO-25-00032</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/GO-25-00185 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">41124623</PMID><DateCompleted><Year>2025</Year><Month>10</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>10</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2687-8941</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><PubDate><Year>2025</Year><Month>Oct</Month></PubDate></JournalIssue><Title>JCO global oncology</Title><ISOAbbreviation>JCO Glob Oncol</ISOAbbreviation></Journal><ArticleTitle>Global Burden of Thyroid Cancer in Adults Age 15-49 Years and Its Predictions: Findings From Global Burden of Disease Study 2021.</ArticleTitle><Pagination><StartPage>e2500185</StartPage><MedlinePgn>e2500185</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/GO-25-00185</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">This study used the latest data from the Global Burden of Disease (GBD) 2021 to comprehensively analyze the burden of thyroid cancer in adults age 15-49 years globally.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Data from the GBD 2021 were used. The estimated annual percentage changes (EAPCs) were used to assess the trends in thyroid cancer. Decomposition analysis was used to identify the factors contributing to the observed epidemiological changes in thyroid cancer. Projections of the thyroid cancer burden through 2044 were generated using the Nordpred modeling.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In 2021, there were 96,287.8 thyroid cancer cases in adults globally. From 1990 to 2021, the age-standardized incidence rate (ASIR; EAPC = 1.68; 95% uncertainty interval [UI], 1.56 to 1.81) and the age-standardized disability-adjusted life year (DALY) rate (EAPC = 0.21; 95% UI, 0.18 to 0.23) of thyroid cancer in adults showed an increasing trend, whereas the age-standardized mortality rate (EAPC = -0.03; 95% UI, -0.05 to -0.01) showed a downward trend. Females showed an upward trend only in ASIR, whereas males were on the rise in all trends of age-standardized rates from 1990 to 2021 globally. Decomposition analysis revealed that the population growth was a major contributor to the deaths and DALYs associated with thyroid cancer. By 2044, thyroid cancer incidence, deaths, and DALYs are projected to reach 121,096, 6,293, and 384,836, respectively.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Thyroid cancer, particularly among adults, has emerged as a global health concern. Our findings suggest that targeted strategies and measures are urgently needed for the prevention and management of thyroid cancer in adults, especially among males.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Min</ForeName><Initials>M</Initials><Identifier Source="ORCID">0009-0001-0914-0355</Identifier><AffiliationInfo><Affiliation>Maternal and Child Health Development Research Center, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, Shandong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Public Health, Jiamusi University, Jiamusi, Heilongjiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Min</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Immunoprevention and Administration, Shandong Center for Disease Control and Prevention, Jinan, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Immunization Planning, Binzhou City Center for Disease Control and Prevention, Binzhou, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Meimei</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Maternal and Child Health Development Research Center, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, Shandong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Pathology, School of Basic Medicine, Shandong Second Medical University, Weifang, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jiayi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Maternal and Child Health Development Research Center, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, Shandong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Second Clinical Medicine (Yantai Affiliated Hospital), Binzhou Medical University, Yantai, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jia</LastName><ForeName>Jingjing</ForeName><Initials>J</Initials><Identifier Source="ORCID">0009-0000-9422-6059</Identifier><AffiliationInfo><Affiliation>Maternal and Child Health Development Research Center, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, Shandong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Basic Medical, Jiamusi University, Jiamusi, Heilongjiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Wenjie</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Maternal and Child Health Development Research Center, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, Shandong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Public Health, Jiamusi University, Jiamusi, Heilongjiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Limei</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-7299-3628</Identifier><AffiliationInfo><Affiliation>Maternal and Child Health Development Research Center, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, Shandong, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>10</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Glob Oncol</MedlineTA><NlmUniqueID>101760170</NlmUniqueID><ISSNLinking>2687-8941</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013964" MajorTopicYN="Y">Thyroid Neoplasms</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071219" MajorTopicYN="Y">Global Burden of Disease</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000087509" MajorTopicYN="N">Disability-Adjusted Life Years</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>10</Month><Day>22</Day><Hour>18</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>10</Month><Day>22</Day><Hour>18</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>10</Month><Day>22</Day><Hour>16</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41124623</ArticleId><ArticleId IdType="doi">10.1200/GO-25-00185</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/GO-25-00142 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40532137</PMID><DateCompleted><Year>2025</Year><Month>06</Month><Day>18</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2687-8941</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><PubDate><Year>2025</Year><Month>Jun</Month></PubDate></JournalIssue><Title>JCO global oncology</Title><ISOAbbreviation>JCO Glob Oncol</ISOAbbreviation></Journal><ArticleTitle>Emerging Trends in Point-of-Care Technology Development for Oncology in Low- and Middle-Income Countries.</ArticleTitle><Pagination><StartPage>e2500142</StartPage><MedlinePgn>e2500142</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2500142</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1200/GO-25-00142</ELocationID><Abstract><AbstractText>The growing cancer burden and suboptimal diagnostic capacity in low- and middle-income countries calls for urgent innovation in diagnostic solutions. Point-of-care technologies (POCTs) offer a transformative approach to decentralizing cancer diagnostics by providing rapid, affordable, and scalable testing in resource-constrained settings. Recent advancements, including loop-mediated isothermal amplification and multiplexed lateral flow immunoassay, enable high-sensitivity detection of cancer biomarkers without the need for complex laboratory infrastructure. Additionally, noninvasive imaging tools, such as optical coherence tomography and fluorescence-guided microscopy, offer portable and cost-effective solutions for early cancer detection in settings with limited health care services. These innovations are complemented by the integration of artificial intelligence, which improves diagnostic accuracy and reduces reliance on highly trained personnel. However, significant infrastructure and logistical challenges persist, including resource constraints, unreliable electricity, and insufficient cold-chain logistics, which limit diagnostic precision and accessibility. This review discusses recent advances in POCTs for oncology and examines how public-private partnerships and multisector collaborations can address key implementation barriers. By prioritizing inclusivity, cross-sector collaboration, and targeted investments, POCTs can sustainably narrow global disparities in cancer diagnosis and treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Wenting</ForeName><Initials>W</Initials><Identifier Source="ORCID">0009-0005-2356-5244</Identifier><AffiliationInfo><Affiliation>Meinig School of Biomedical Engineering, Cornell University, Ithaca, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manning</LastName><ForeName>Jason C</ForeName><Initials>JC</Initials><Identifier Source="ORCID">0000-0002-6839-382X</Identifier><AffiliationInfo><Affiliation>Meinig School of Biomedical Engineering, Cornell University, Ithaca, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devaraj</LastName><ForeName>Kirtana</ForeName><Initials>K</Initials><Identifier Source="ORCID">0009-0007-0057-4345</Identifier><AffiliationInfo><Affiliation>Meinig School of Biomedical Engineering, Cornell University, Ithaca, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richards-Kortum</LastName><ForeName>Rebecca R</ForeName><Initials>RR</Initials><Identifier Source="ORCID">0000-0003-2347-9467</Identifier><AffiliationInfo><Affiliation>Department of Bioengineering, Rice University, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McFall</LastName><ForeName>Sally M</ForeName><Initials>SM</Initials><Identifier Source="ORCID">0000-0001-5554-6615</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Engineering, McCormick School of Engineering, Northwestern University, Evanston, IL.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Innovation in Point-of-Care Technologies for HIV/AIDS and Emerging Infectious Diseases at Northwestern (C-THAN), Northwestern University, Evanston, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murphy</LastName><ForeName>Robert L</ForeName><Initials>RL</Initials><Identifier Source="ORCID">0000-0003-3936-2052</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Engineering, McCormick School of Engineering, Northwestern University, Evanston, IL.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Innovation in Point-of-Care Technologies for HIV/AIDS and Emerging Infectious Diseases at Northwestern (C-THAN), Northwestern University, Evanston, IL.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Semeere</LastName><ForeName>Aggrey</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1826-2239</Identifier><AffiliationInfo><Affiliation>Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erickson</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-1624-9711</Identifier><AffiliationInfo><Affiliation>Sibley School of Mechanical and Aerospace Engineering, Cornell University, Ithaca, NY.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Nutritional Sciences, Cornell University, Ithaca, NY.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>PORTENT-Center for Point of Care Technologies for Nutrition, Infection and Cancer for Global Health, Cornell University, Ithaca, NY.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U54 EB027049</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 EB034652</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 EB034654</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Glob Oncol</MedlineTA><NlmUniqueID>101760170</NlmUniqueID><ISSNLinking>2687-8941</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003906" MajorTopicYN="N">Developing Countries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019095" MajorTopicYN="Y">Point-of-Care Systems</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008495" MajorTopicYN="Y">Medical Oncology</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/go/authors/author-center. Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments). 
<b>Sally M. McFall</b>
. <b>Stock and Other Ownership Interests:</b> Nuclein LLC. <b>Consulting or Advisory Role:</b> Nuclein LLC. <b>Research Funding:</b> Nuclein LLC. <b>Patents, Royalties, Other Intellectual Property:</b> Foundational IP for the DASH PCR system licensed to Nuclein, LLC by Northwestern University (Inst). No other potential conflicts of interest were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>18</Day><Hour>18</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>18</Day><Hour>18</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>18</Day><Hour>16</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>6</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40532137</ArticleId><ArticleId IdType="mid">NIHMS2100577</ArticleId><ArticleId IdType="pmc">PMC12312415</ArticleId><ArticleId IdType="doi">10.1200/GO-25-00142</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bray F, Laversanne M, Sung H, et al. : Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229-263, 2024</Citation><ArticleIdList><ArticleId IdType="pubmed">38572751</ArticleId></ArticleIdList></Reference><Reference><Citation>GBD 2019 Demographics Collaborators : Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950&#x2013;2019: A comprehensive demographic analysis for the Global Burden of Disease Study 2019. Lancet 396:1160-1203, 2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7566045</ArticleId><ArticleId IdType="pubmed">33069325</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung H, Ferlay J, Siegel RL, et al. : Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209-249, 2021</Citation><ArticleIdList><ArticleId IdType="pubmed">33538338</ArticleId></ArticleIdList></Reference><Reference><Citation>Brand NR, Qu LG, Chao A, et al. : Delays and barriers to cancer care in low- and middle-income countries: A systematic review. Oncologist 24:e1371-e1380, 2019</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6975966</ArticleId><ArticleId IdType="pubmed">31387949</ArticleId></ArticleIdList></Reference><Reference><Citation>Sankaranarayanan R, Swaminathan R, Brenner H, et al. : Cancer survival in Africa, Asia, and Central America: A population-based study. Lancet Oncol 11:165-173, 2010</Citation><ArticleIdList><ArticleId IdType="pubmed">20005175</ArticleId></ArticleIdList></Reference><Reference><Citation>Drain PK, Hyle EP, Noubary F, et al. : Diagnostic point-of-care tests in resource-limited settings. Lancet Infect Dis 14:239-249, 2014</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4016042</ArticleId><ArticleId IdType="pubmed">24332389</ArticleId></ArticleIdList></Reference><Reference><Citation>Dincer C, Bruch R, Kling A, et al. : Multiplexed point-of-care testing&#x2014;xPOCT. Trends Biotechnol 35:728-742, 2017</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5538621</ArticleId><ArticleId IdType="pubmed">28456344</ArticleId></ArticleIdList></Reference><Reference><Citation>New England BioLabs : Getting started with loop-mediated isothermal amplification. NEBinspired Blog. https://www.neb.com/en-us/nebinspired-blog/getting-started-with-loop-mediated-isothermal-amplification</Citation></Reference><Reference><Citation>Richards-Kortum R, Lorenzoni C, Bagnato VS, et al. : Optical imaging for screening and early cancer diagnosis in low-resource settings. Nat Rev Bioeng 2:25-43, 2024</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11412616</ArticleId><ArticleId IdType="pubmed">39301200</ArticleId></ArticleIdList></Reference><Reference><Citation>Asci Erkocyigit B, Ozufuklar O, Yardim A, et al. : Biomarker detection in early diagnosis of cancer: Recent achievements in point-of-care devices based on paper microfluidics. Biosensors 13:387, 2023</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10046104</ArticleId><ArticleId IdType="pubmed">36979600</ArticleId></ArticleIdList></Reference><Reference><Citation>Moehling TJ, Choi G, Dugan LC, et al. : LAMP diagnostics at the point-of-care: Emerging Trends and perspectives for the developer community. Expert Rev Mol Diagn 21:43-61, 2021</Citation><ArticleIdList><ArticleId IdType="pubmed">33474990</ArticleId></ArticleIdList></Reference><Reference><Citation>Becherer L, Borst N, Bakheit M, et al. : Loop-mediated isothermal amplification (LAMP)&#x2014;Review and classification of methods for sequence-specific detection. Anal Methods 12:717-746, 2020</Citation></Reference><Reference><Citation>Posthuma-Trumpie GA, Korf J, Van Amerongen A: Lateral flow (immuno)assay: Its strengths, weaknesses, opportunities and threats. A literature survey. Anal Bioanal Chem 393:569-582, 2009</Citation><ArticleIdList><ArticleId IdType="pubmed">18696055</ArticleId></ArticleIdList></Reference><Reference><Citation>Parra SG, Rodriguez AM, Cherry KD, et al. : Low-cost, high-resolution imaging for detecting cervical precancer in medically-underserved areas of Texas. Gynecol Oncol 154:558-564, 2019</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6941476</ArticleId><ArticleId IdType="pubmed">31288949</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrin L, Bayarmagnai B, Gligorijevic B: Frontiers in intravital multiphoton microscopy of cancer. Cancer Rep 3:e1192, 2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7197974</ArticleId><ArticleId IdType="pubmed">32368722</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim DH, Kim SW, Hwang SH: Autofluorescence imaging to identify oral malignant or premalignant lesions: Systematic review and meta-analysis. Head Neck 42:3735-3743, 2020</Citation><ArticleIdList><ArticleId IdType="pubmed">32866310</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin L, Wang LV: The emerging role of photoacoustic imaging in clinical oncology. Nat Rev Clin Oncol 19:365-384, 2022</Citation><ArticleIdList><ArticleId IdType="pubmed">35322236</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L, Chen Y, Ling S, et al. : Research progress on the application of optical coherence tomography in the field of oncology. Front Oncol 12:953934, 2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9358962</ArticleId><ArticleId IdType="pubmed">35957903</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunt B, Fregnani JHTG, Brenes D, et al. : Cervical lesion assessment using real-time microendoscopy image analysis in Brazil: The CLARA study. Int J Cancer 149:431-441, 2021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8815862</ArticleId><ArticleId IdType="pubmed">33811763</ArticleId></ArticleIdList></Reference><Reference><Citation>Savage N: How AI is improving cancer diagnostics. Nature 579:S14-S16, 2020</Citation><ArticleIdList><ArticleId IdType="pubmed">32214265</ArticleId></ArticleIdList></Reference><Reference><Citation>Hecht R, Stover J, Bollinger L, et al. : Financing of HIV/AIDS programme scale-up in low-income and middle-income countries, 2009&#x2013;31. Lancet 376:1254-1260, 2010</Citation><ArticleIdList><ArticleId IdType="pubmed">20934597</ArticleId></ArticleIdList></Reference><Reference><Citation>Slingsby B, Kurokawa K: The Global Health Innovative Technology (GHIT) fund: Financing medical innovations for neglected populations. Lancet Glob Health 1:e184-e185, 2013</Citation><ArticleIdList><ArticleId IdType="pubmed">25104343</ArticleId></ArticleIdList></Reference><Reference><Citation>Land KJ, Boeras DI, Chen X-S, et al. : REASSURED diagnostics to inform disease control strategies, strengthen health systems and improve patient outcomes. Nat Microbiol 4:46-54, 2019</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7097043</ArticleId><ArticleId IdType="pubmed">30546093</ArticleId></ArticleIdList></Reference><Reference><Citation>McFall SM, Maiga M, Glucksberg MR, et al. : Supporting diagnosis and management of HIV/AIDS patients through point-of-care technology development. Curr Opin Biomed Eng 11:9-15, 2019</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7448583</ArticleId><ArticleId IdType="pubmed">32864521</ArticleId></ArticleIdList></Reference><Reference><Citation>Kubista M, Andrade JM, Bengtsson M, et al. : The real-time polymerase chain reaction. Mol Aspects Med 27:95-125, 2006</Citation><ArticleIdList><ArticleId IdType="pubmed">16460794</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreitmann L, Miglietta L, Xu K, et al. : Next-generation molecular diagnostics: Leveraging digital technologies to enhance multiplexing in real-time PCR. Trends Analyt Chem 160:116963, 2023</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7614363</ArticleId><ArticleId IdType="pubmed">36968318</ArticleId></ArticleIdList></Reference><Reference><Citation>Kew MC: Hepatocellular carcinoma in developing countries: Prevention, diagnosis and treatment. World J Hepatol 4:99-104, 2012</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3321496</ArticleId><ArticleId IdType="pubmed">22489262</ArticleId></ArticleIdList></Reference><Reference><Citation>Okunade KS: Human papillomavirus and cervical cancer. J Obstet Gynaecol 40:602-608, 2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7062568</ArticleId><ArticleId IdType="pubmed">31500479</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization : Prequalified in vitro diagnostics. https://extranet.who.int/prequal/vitro-diagnostics/prequalified-vitro-diagnostics</Citation></Reference><Reference><Citation>Notomi T: Loop-mediated isothermal amplification of DNA. Nucleic Acids Res 28:63e, 2000</Citation><ArticleIdList><ArticleId IdType="pmc">PMC102748</ArticleId><ArticleId IdType="pubmed">10871386</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi G, Moehling TJ, Meagher RJ: Advances in RT-LAMP for COVID-19 testing and diagnosis. Expert Rev Mol Diagn 23:9-28, 2023</Citation><ArticleIdList><ArticleId IdType="pubmed">36695788</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization : The selection and use of essential in vitro diagnostics: WHO Technical Report Series, No. 1031, 2021. https://www.who.int/publications/i/item/9789240019102</Citation></Reference><Reference><Citation>Adashek JJ, Janku F, Kurzrock R: Signed in blood: Circulating tumor DNA in cancer diagnosis, treatment and screening. Cancers 13:3600, 2021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8306582</ArticleId><ArticleId IdType="pubmed">34298813</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Food and Drug Administration : List of cleared or approved companion diagnostic devices (in vitro and imaging tools). https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools</Citation></Reference><Reference><Citation>Collins FS, Varmus H: A new initiative on precision medicine. N Engl J Med 372:793-795, 2015</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5101938</ArticleId><ArticleId IdType="pubmed">25635347</ArticleId></ArticleIdList></Reference><Reference><Citation>Sajid M, Kawde A-N, Daud M: Designs, formats and applications of lateral flow assay: A literature review. J Saudi Chem Soc 19:689-705, 2015</Citation></Reference><Reference><Citation>Sena-Torralba A, &#xc1;lvarez-Diduk R, Parolo C, et al. : Toward next generation lateral flow assays: Integration of nanomaterials. Chem Rev 122:14881-14910, 2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9523712</ArticleId><ArticleId IdType="pubmed">36067039</ArticleId></ArticleIdList></Reference><Reference><Citation>Koczula K, Gallotta A: Lateral flow assays. Essays Biochem 60:111-120, 2016</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4986465</ArticleId><ArticleId IdType="pubmed">27365041</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Hou F, Ma Y: Simultaneous quantitative detection of multiple tumor markers with a rapid and sensitive multicolor quantum dots based immunochromatographic test strip. Biosens Bioelectron 68:156-162, 2015</Citation><ArticleIdList><ArticleId IdType="pubmed">25562743</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Zhou S-Y, Zhu W, et al. : Highly sensitive lanthanide-doped nanoparticles-based point-of-care diagnosis of human cardiac troponin I. Int J Nanomedicine 17:635-646, 2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8843803</ArticleId><ArticleId IdType="pubmed">35177903</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao X, Cui Y, Levenson RM, et al. : In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol 22:969-976, 2004</Citation><ArticleIdList><ArticleId IdType="pubmed">15258594</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee R, Jaiswal A: Recent advances in nanoparticle-based lateral flow immunoassay as a point-of-care diagnostic tool for infectious agents and diseases. Analyst 143:1970-1996, 2018</Citation><ArticleIdList><ArticleId IdType="pubmed">29645058</ArticleId></ArticleIdList></Reference><Reference><Citation>Rey EG, O&#x2019;Dell D, Mehta S, et al. : Mitigating the hook effect in lateral flow sandwich immunoassays using real-time reaction kinetics. Anal Chem 89:5095-5100, 2017</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5839149</ArticleId><ArticleId IdType="pubmed">28388030</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Z, O&#x2019;Dell D, Srinivasan B, et al. : Rapid diagnostic testing platform for iron and vitamin A deficiency. Proc Natl Acad Sci USA 114:13513-13518, 2017</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5754775</ArticleId><ArticleId IdType="pubmed">29203653</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Zhan L, Qin Z, et al. : Ultrasensitive and highly specific lateral flow assays for point-of-care diagnosis. ACS Nano 15:3593-3611, 2021</Citation><ArticleIdList><ArticleId IdType="pubmed">33607867</ArticleId></ArticleIdList></Reference><Reference><Citation>Mudanyali O, Dimitrov S, Sikora U, et al. : Integrated rapid-diagnostic-test reader platform on a cellphone. Lab Chip 12:2678-2686, 2012</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3390446</ArticleId><ArticleId IdType="pubmed">22596243</ArticleId></ArticleIdList></Reference><Reference><Citation>Schary W, Paskali F, Rentschler S, et al. : Open-source, adaptable, all-in-one smartphone-based system for quantitative analysis of point-of-care diagnostics. Diagnostics 12:589, 2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8947044</ArticleId><ArticleId IdType="pubmed">35328142</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou H, Mitbander R, Tang Y, et al. : Optical imaging technologies for in vivo cancer detection in low-resource settings. Curr Opin Biomed Eng 28:100495, 2023</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10883072</ArticleId><ArticleId IdType="pubmed">38406798</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller J, Lam CT, Dahl D, et al. : Portable pocket colposcopy performs comparably to standard-of-care clinical colposcopy using acetic acid and Lugol&#x2019;s iodine as contrast mediators: An investigational study in Peru. BJOG 125:1321-1329, 2018</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6115285</ArticleId><ArticleId IdType="pubmed">29893472</ArticleId></ArticleIdList></Reference><Reference><Citation>Arens C, Betz C, Kraft M, et al. : Narrow band imaging for early diagnosis of epithelial dysplasia and microinvasive tumors in the upper aerodigestive tract. HNO 65:5-12, 2017. (suppl 1)</Citation><ArticleIdList><ArticleId IdType="pubmed">27878600</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitbander R, Brenes D, Coole JB, et al. : Development and evaluation of an automated multimodal mobile detection of oral cancer imaging system to aid in risk-based management of oral mucosal lesions. Cancer Prev Res (Phila) 18:197-207, 2025</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11959271</ArticleId><ArticleId IdType="pubmed">39817650</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherry KD, Schwarz RA, Yang EC, et al. : Autofluorescence imaging to monitor the progression of oral potentially malignant disorders. Cancer Prev Res (Phila) 12:791-800, 2019</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7319038</ArticleId><ArticleId IdType="pubmed">31451520</ArticleId></ArticleIdList></Reference><Reference><Citation>Poh CF, Anderson DW, Durham JS, et al. : Fluorescence visualization-guided surgery for early-stage oral cancer. JAMA Otolaryngol Head Neck Surg 142:209-216, 2016</Citation><ArticleIdList><ArticleId IdType="pubmed">26769431</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenes DR, Nipper AJ, Tan MT, et al. : Mildly dysplastic oral lesions with optically-detectable abnormalities share genetic similarities with severely dysplastic lesions. Oral Oncol 135:106232, 2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9881670</ArticleId><ArticleId IdType="pubmed">36335817</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Rollins AM, Levenson RM, et al. : An affordable, versatile and high-performance fluorescence microscope using a smartphone. Commun Biol 4:334, 2021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7955119</ArticleId><ArticleId IdType="pubmed">33712728</ArticleId></ArticleIdList></Reference><Reference><Citation>Fereidouni F, Harmany ZT, Tian M, et al. : Microscopy with ultraviolet surface excitation for rapid slide-free histology. Nat Biomed Eng 1:957-966, 2017</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6223324</ArticleId><ArticleId IdType="pubmed">31015706</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin L, Tang Y, Wu Y, et al. : Deep learning extended depth-of-field microscope for fast and slide-free histology. Proc Natl Acad Sci USA 117:33051-33060, 2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7776814</ArticleId><ArticleId IdType="pubmed">33318169</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin L, Tang Y, Coole JB, et al. : DeepDOF-SE: Affordable deep-learning microscopy platform for slide-free histology. Nat Commun 15:2935, 2024</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10997797</ArticleId><ArticleId IdType="pubmed">38580633</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussain I, Boza J, Lukande R, et al. : Automated detection of Kaposi sarcoma-associated herpesvirus-infected cells in immunohistochemical images of skin biopsies. JCO Glob Oncol
10.1200/GO-24-00536</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/GO-24-00536</ArticleId><ArticleId IdType="pmc">PMC12137223</ArticleId><ArticleId IdType="pubmed">40239145</ArticleId></ArticleIdList></Reference><Reference><Citation>Yim J, Chopra R, Spitz T, et al. : Predicting conversion to wet age-related macular degeneration using deep learning. Nat Med 26:892-899, 2020</Citation><ArticleIdList><ArticleId IdType="pubmed">32424211</ArticleId></ArticleIdList></Reference><Reference><Citation>Yala A, Lehman C, Schuster T, et al. : A deep learning mammography-based model for improved breast cancer risk prediction. Radiology 292:60-66, 2019</Citation><ArticleIdList><ArticleId IdType="pubmed">31063083</ArticleId></ArticleIdList></Reference><Reference><Citation>Akingbola A, Adegbesan A, Ojo O, et al. : Artificial intelligence and cancer care in Africa. J Med Surg Public Health 3:100132, 2024</Citation></Reference><Reference><Citation>William W, Ware A, Basaza-Ejiri AH, et al. : Cervical cancer classification from Pap-smears using an enhanced fuzzy C-means algorithm. Inform Med Unlocked 14:23-33, 2019</Citation></Reference><Reference><Citation>Aboelenin NA, Elserafi A, Zaki N, et al. : Assessment of artificial intelligence-aided computed tomography in lung cancer screening. Egypt J Radiol Nucl Med 54:74, 2023</Citation></Reference><Reference><Citation>Mango VL, Olasehinde O, Omisore AD, et al. : The iBreastExam versus clinical breast examination for breast evaluation in high risk and symptomatic Nigerian women: A prospective study. Lancet Glob Health 10:e555-e563, 2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9102465</ArticleId><ArticleId IdType="pubmed">35303464</ArticleId></ArticleIdList></Reference><Reference><Citation>Retamero JA, Gulturk E, Bozkurt A, et al. : Artificial intelligence helps pathologists increase diagnostic accuracy and efficiency in the detection of breast cancer lymph node metastases. Am J Surg Pathol 48:846-854, 2024</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11191045</ArticleId><ArticleId IdType="pubmed">38809272</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan MS, Umer H, Faruqe F: Artificial intelligence for low income countries. Humanit Soc Sci Commun 11:1422, 2024</Citation></Reference><Reference><Citation>Yu L, Zhai X: Use of artificial intelligence to address health disparities in low-and middle-income countries: A thematic analysis of ethical issues. Public Health 234:77-83, 2024</Citation><ArticleIdList><ArticleId IdType="pubmed">38964129</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh H, Sethi S, Raber M, et al. : Errors in cancer diagnosis: Current understanding and future directions. J Clin Oncol 25:5009-5018, 2007</Citation><ArticleIdList><ArticleId IdType="pubmed">17971601</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandhi TK, Kachalia A, Thomas EJ, et al. : Missed and delayed diagnoses in the ambulatory setting: A study of closed malpractice claims. Ann Intern Med 145:488-496, 2006</Citation><ArticleIdList><ArticleId IdType="pubmed">17015866</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorace J, Aberle DR, Elimam D, et al. : Integrating pathology and radiology disciplines: An emerging opportunity? BMC Med 10:100-106, 2012</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3523019</ArticleId><ArticleId IdType="pubmed">22950414</ArticleId></ArticleIdList></Reference><Reference><Citation>Syedmoradi LMLN, Norton ML, Omidfar K: Point-of-care cancer diagnostic devices: From academic research to clinical translation. Talanta 225:122002, 2021</Citation><ArticleIdList><ArticleId IdType="pubmed">33592810</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva MLS: Cancer serum biomarkers based on aberrant post-translational modifications of glycoproteins: Clinical value and discovery strategies. Biochim Biophys Acta 1856:165-177, 2015</Citation><ArticleIdList><ArticleId IdType="pubmed">26232626</ArticleId></ArticleIdList></Reference><Reference><Citation>Cesarman E, Damania B, Krown SE, et al. : Kaposi sarcoma. Nat Rev Dis Primers 5:9, 2019</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6685213</ArticleId><ArticleId IdType="pubmed">30705286</ArticleId></ArticleIdList></Reference><Reference><Citation>McNerney R: Diagnostics for developing countries. Diagnostics 5:200-209, 2015</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4665590</ArticleId><ArticleId IdType="pubmed">26854149</ArticleId></ArticleIdList></Reference><Reference><Citation>Adesina A, Chumba D, Nelson AM, et al. : Improvement of pathology in sub-Saharan Africa. Lancet Oncol 14:e152-e157, 2013</Citation><ArticleIdList><ArticleId IdType="pubmed">23561746</ArticleId></ArticleIdList></Reference><Reference><Citation>Lidenge SJ, Tso FY, Mortazavi Y, et al. : Viral and immunological analytes are poor predictors of the clinical treatment response in Kaposi&#x2019;s sarcoma patients. Cancers 12:1594, 2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7352224</ArticleId><ArticleId IdType="pubmed">32560243</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenorio-Mucha J, Busta-Flores P, Lazo-Porras M, et al. : Facilitators and barriers of the implementation of point-of-care devices for cardiometabolic diseases: A scoping review. BMC Health Serv Res 23:412, 2023</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10144879</ArticleId><ArticleId IdType="pubmed">37118750</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidt B, Siqueira WF, Eersels K, et al. : Point of care diagnostics in resource-limited settings: A review of the present and future of PoC in its most needed environment. Biosensors 10:133, 2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7598644</ArticleId><ArticleId IdType="pubmed">32987809</ArticleId></ArticleIdList></Reference><Reference><Citation>Snodgrass R, Gardner A, Semeere A, et al. : A portable device for nucleic acid quantification powered by sunlight, a flame or electricity. Nat Biomed Eng 2:657-665, 2018</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6425734</ArticleId><ArticleId IdType="pubmed">30906647</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunter BSH, Hindocha S, Lee RW: The role of artificial intelligence in early cancer diagnosis. Cancers 14:1524, 2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8946688</ArticleId><ArticleId IdType="pubmed">35326674</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleming KA, Horton S, Wilson ML, et al. : The Lancet Commission on diagnostics: Transforming access to diagnostics. Lancet 398:1997-2050, 2021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8494468</ArticleId><ArticleId IdType="pubmed">34626542</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Food and Drug Administration : Recommendations for Clinical Laboratory Improvement Amendments of 1988 (CLIA) waiver applications. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-clinical-laboratory-improvement-amendments-1988-clia-waiver-applications</Citation></Reference><Reference><Citation>Perkins J, Chandler C, Kelly A, et al. : The social lives of point-of-care tests in low- and middle-income countries: A meta-ethnography. Health Policy Plan 39:782-798, 2024</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11308614</ArticleId><ArticleId IdType="pubmed">38907518</ArticleId></ArticleIdList></Reference><Reference><Citation>National Cancer Institute, Center for Global Health (CGH) : Affordable Cancer Technologies (ACTs) program. https://www.cancer.gov/about-nci/organization/cgh/global-research-programs/affordable-ca</Citation></Reference><Reference><Citation>National Cancer Institute (NCI) : Low-cost technologies for global cancer diagnosis, treatment, and management. Funding Overview Report, Center for Global Health (CGH), 2014. https://www.cancer.gov/about-nci/organization/cgh/funding/low-cost-technologies-overview.pdf</Citation></Reference><Reference><Citation>National Cancer Institute (NCI) : ACTs transition from validation to build phase. NCI CGH Blog, 2017. https://www.cancer.gov/about-nci/organization/cgh/blog/2017/acts-transition</Citation></Reference><Reference><Citation>National Cancer Institute (NCI) : Strategic plan 2021-2025. Center for Global Health (CGH), National Cancer Institute, 2021. https://www.cancer.gov/about-nci/organization/cgh/about/strategic-plan/cgh-strategic-plan.pdf</Citation></Reference><Reference><Citation>Achenbach CJ, Caputo M, Hawkins C, et al. : Clinical evaluation of the Diagnostic Analyzer for Selective Hybridization (DASH): A point-of-care PCR test for rapid detection of SARS-CoV-2 infection. PLoS One 17:e0270060, 2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9202852</ArticleId><ArticleId IdType="pubmed">35709204</ArticleId></ArticleIdList></Reference><Reference><Citation>Pathania D, Landeros C, Rohrer L, et al. : Point-of-care cervical cancer screening using deep learning-based microholography. Theranostics 9:8438-8447, 2019</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6924258</ArticleId><ArticleId IdType="pubmed">31879529</ArticleId></ArticleIdList></Reference><Reference><Citation>Parra S, Oden M, Schmeler K, et al. : Low-cost instructional apparatus to improve training for cervical cancer screening and prevention. Obstet Gynecol 133:559-567, 2019</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6407823</ArticleId><ArticleId IdType="pubmed">30741811</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiragga AN, Onzia A, Nakate V, et al. : Community pharmacies: Key players in point-of-care diagnostics for STI screening in Africa. PLoS One 19:e0315191, 2024</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11684620</ArticleId><ArticleId IdType="pubmed">39775736</ArticleId></ArticleIdList></Reference><Reference><Citation>Ansu-Mensah M, Kuupiel D, Asiamah EA, et al. : Facilitators and barriers to in vitro diagnostics implementation in resource-limited settings: A scoping review. Afr J Prim Health Care Fam Med 15:e1-e9, 2023</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9982514</ArticleId><ArticleId IdType="pubmed">36861922</ArticleId></ArticleIdList></Reference><Reference><Citation>Shafiee H, Wang S, Inci F, et al. : Emerging technologies for point-of-care management of HIV infection. Annu Rev Med 66:387-405, 2015</Citation><ArticleIdList><ArticleId IdType="pubmed">25423597</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakravarty S, Knorringa P: Enabling inclusive technological change through transformative policies, in Transformative Innovation in Times of Change, Volume 169. 2021</Citation></Reference><Reference><Citation>Soni A, Herbert C, Lin H, et al. : Performance of rapid antigen tests to detect symptomatic and asymptomatic SARS-CoV-2 infection: A prospective cohort study. Ann Intern Med 176:975-982, 2023</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10321467</ArticleId><ArticleId IdType="pubmed">37399548</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization : Global Tuberculosis Report 2024. Geneva, Switzerland, World Health Organization, 2024, p 50</Citation></Reference><Reference><Citation>Marokane P, Ndlovu S, Mahlatsi O, et al. : Anaylsis of Xpert MTB/RIF rejection rates using laboratory data 2011-2015, South Africa, National priority program. Poster: African Society for Laboratory Medicine Annual Conference, Volume 3. 2016</Citation></Reference><Reference><Citation>David A, Singh L, Peloakgosi-Shikwambani K, et al. : Diagnostic accuracy of self-collected tongue swabs for Mycobacterium tuberculosis complex detection in individuals being assessed for TB in South Africa using the Xpert MTB/RIF Ultra assay. Clin Microbiol Infect 31:1040-1045, 2025</Citation><ArticleIdList><ArticleId IdType="pubmed">39884504</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/GO-25-00419 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">41397192</PMID><DateCompleted><Year>2025</Year><Month>12</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>12</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2687-8941</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><PubDate><Year>2025</Year><Month>Dec</Month></PubDate></JournalIssue><Title>JCO global oncology</Title><ISOAbbreviation>JCO Glob Oncol</ISOAbbreviation></Journal><ArticleTitle>National Public Health Policy Blueprint to Expand Equitable Radiation Therapy Access in India: A Scalable Model.</ArticleTitle><Pagination><StartPage>e2500419</StartPage><MedlinePgn>e2500419</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/GO-25-00419</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To propose a comprehensive national policy blueprint to expand equitable radiation therapy (RT) access in India, addressing persistent rural-urban disparities and aligning with global cancer control priorities.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">This expert viewpoint was informed by consultations with oncology practitioners from government and private centers, medical physicists, policy planners, and patient advocates. Drawing on Indian and global precedents, best practices were synthesized to develop a 10-point framework addressing infrastructure, financing, workforce, quality assurance, and governance.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">RT services in India remain highly centralized, with only 120 of 740 districts offering access, disproportionately affecting the 934 million rural population. Key strategies in the proposed blueprint include import duty reform to incentivize rural investment, quality-linked reimbursements under public insurance schemes, bundled workforce incentives, and regionally focused public-private partnerships. Additional measures include phased deployment of indigenous linear accelerators (LINACs), pooled brachytherapy services, mandatory cancer notification, and digital integration through the Ayushman Bharat Digital Mission. Use of artificial intelligence (AI) and remote planning is highlighted as a means to address workforce shortages. The framework is modular and designed for adaptation by other low- and middle-income countries (LMICs).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This 10-point National RT Policy Blueprint provides a scalable pathway to strengthen oncology infrastructure and improve treatment equity in India, with direct relevance for LMICs pursuing universal health coverage and Sustainable Development Goal 3.4. Although promising, some elements such as indigenous LINAC deployment and AI-enabled remote planning are aspirational and contingent on phased implementation, infrastructure readiness, and sustained political commitment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chilukuri</LastName><ForeName>Srinivas</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-0491-7935</Identifier><AffiliationInfo><Affiliation>Department of Radiation Oncology, Apollo Proton Cancer Centre, Chennai, Tamil Nadu, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tike</LastName><ForeName>Pramod</ForeName><Initials>P</Initials><Identifier Source="ORCID">0009-0007-4872-6440</Identifier><AffiliationInfo><Affiliation>Department of Radiation Oncology, Vivekanand Cancer Hospital &amp; Optimus Oncology Advanced Radiotherapy Centre, Latur, Maharashtra, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siddha</LastName><ForeName>Manish</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Jupiter Hospital, Indore, Madhya Pradesh, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sant Tukaram Hospital, Optimus Oncology Advanced Radiotherapy Centre, Akola, Maharashtra, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghadyalpatil</LastName><ForeName>Nikhil</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Apollo Hospitals, Hyderabad, Telangana, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vivekananda Cancer Hospital, Optimus Oncology Advanced Radiotherapy Centre, Latur, Maharashtra, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Panda</LastName><ForeName>Pankaj Kumar</ForeName><Initials>PK</Initials><Identifier Source="ORCID">0000-0003-2804-8033</Identifier><AffiliationInfo><Affiliation>Clinical Trials and Epidemiological Sciences, National Cancer Centre Singapore, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nemade</LastName><ForeName>Bhushan</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Sankalp Hospital &amp; Optimus Oncology, Nashik, Maharashtra, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Khandesh Cancer Centre, Optimus Oncology Advanced Radiotherapy Centre, Dhule, Maharashtra, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Glob Oncol</MedlineTA><NlmUniqueID>101760170</NlmUniqueID><ISSNLinking>2687-8941</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007194" MajorTopicYN="N" Type="Geographic">India</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006291" MajorTopicYN="Y">Health Policy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006297" MajorTopicYN="Y">Health Services Accessibility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName><QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011634" MajorTopicYN="Y">Public Health</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>15</Day><Hour>19</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>15</Day><Hour>19</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>15</Day><Hour>16</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41397192</ArticleId><ArticleId IdType="doi">10.1200/GO-25-00419</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/GO-25-00115 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40700662</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2687-8941</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><PubDate><Year>2025</Year><Month>Jul</Month></PubDate></JournalIssue><Title>JCO global oncology</Title><ISOAbbreviation>JCO Glob Oncol</ISOAbbreviation></Journal><ArticleTitle>Critical Review: Efficacy and Safety of Biosimilar Cetuximab Versus Innovator Cetuximab in Indian Patients With Head and Neck Cancer.</ArticleTitle><Pagination><StartPage>e2500115</StartPage><MedlinePgn>e2500115</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/GO-25-00115</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ramesh</LastName><ForeName>Anita</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0009-5784-0127</Identifier><AffiliationInfo><Affiliation>Anita Ramesh, PhD, DM, MD, DNB, MSc Oncology, MBA, MNAMS, DCH, MBBS, Kauvery Hospital, Chennai, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Glob Oncol</MedlineTA><NlmUniqueID>101760170</NlmUniqueID><ISSNLinking>2687-8941</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>23</Day><Hour>18</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>23</Day><Hour>18</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>23</Day><Hour>16</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40700662</ArticleId><ArticleId IdType="doi">10.1200/GO-25-00115</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/GO-25-00445 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">41124622</PMID><DateRevised><Year>2025</Year><Month>10</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2687-8941</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><PubDate><Year>2025</Year><Month>Oct</Month></PubDate></JournalIssue><Title>JCO global oncology</Title><ISOAbbreviation>JCO Glob Oncol</ISOAbbreviation></Journal><ArticleTitle>Beyond the Numbers: Inflammation as the Missing Link in Decayed, Missing, Filled Teeth-Based Buccal Mucosa Cancer Risk Models.</ArticleTitle><Pagination><StartPage>e2500445</StartPage><MedlinePgn>e2500445</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/GO-25-00445</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Somay</LastName><ForeName>Efsun</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-8251-6913</Identifier><AffiliationInfo><Affiliation>Efsun Somay, DDS, PhD, Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Baskent University, Ankara, Turkey; Erkan Topkan, MD, Department of Radiation Oncology, Faculty of Medicine, Baskent University, Adana, Turkey; and Ugur Selek, MD, Department of Radiation Oncology, Faculty of Medicine, Koc University, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Topkan</LastName><ForeName>Erkan</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-8120-7123</Identifier><AffiliationInfo><Affiliation>Efsun Somay, DDS, PhD, Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Baskent University, Ankara, Turkey; Erkan Topkan, MD, Department of Radiation Oncology, Faculty of Medicine, Baskent University, Adana, Turkey; and Ugur Selek, MD, Department of Radiation Oncology, Faculty of Medicine, Koc University, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selek</LastName><ForeName>Ugur</ForeName><Initials>U</Initials><Identifier Source="ORCID">0000-0001-8087-3140</Identifier><AffiliationInfo><Affiliation>Efsun Somay, DDS, PhD, Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Baskent University, Ankara, Turkey; Erkan Topkan, MD, Department of Radiation Oncology, Faculty of Medicine, Baskent University, Adana, Turkey; and Ugur Selek, MD, Department of Radiation Oncology, Faculty of Medicine, Koc University, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>10</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Glob Oncol</MedlineTA><NlmUniqueID>101760170</NlmUniqueID><ISSNLinking>2687-8941</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>10</Month><Day>22</Day><Hour>18</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>10</Month><Day>22</Day><Hour>18</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>10</Month><Day>22</Day><Hour>16</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41124622</ArticleId><ArticleId IdType="doi">10.1200/GO-25-00445</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/GO-24-00651 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39883899</PMID><DateRevised><Year>2025</Year><Month>03</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2687-8941</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><PubDate><Year>2025</Year><Month>Jan</Month></PubDate></JournalIssue><Title>JCO global oncology</Title><ISOAbbreviation>JCO Glob Oncol</ISOAbbreviation></Journal><ArticleTitle>Erratum: Genetic Signatures: <i>CD44</i> Single-Nucleotide Polymorphisms Affect Cell Surface Expression and Elevate Risk in Head and Neck Squamous Cell Carcinoma.</ArticleTitle><Pagination><StartPage>e2400651</StartPage><MedlinePgn>e2400651</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2400651</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1200/GO-24-00651</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kashif</LastName><ForeName>Muhammad</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Jahan</LastName><ForeName>Shah</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Minhas</LastName><ForeName>Sadia</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Amar</LastName><ForeName>Ali</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Tahir</LastName><ForeName>Romeeza</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Nisar</LastName><ForeName>Haseeb</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Shehzad</LastName><ForeName>Faheem</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Nagi</LastName><ForeName>Abdul Hanan</ForeName><Initials>AH</Initials></Author><Author ValidYN="Y"><LastName>Afzal</LastName><ForeName>Nadeem</ForeName><Initials>N</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016425">Published Erratum</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>01</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Glob Oncol</MedlineTA><NlmUniqueID>101760170</NlmUniqueID><ISSNLinking>2687-8941</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumFor"><RefSource>JCO Glob Oncol. 2024 Oct;10:e2400084. doi: 10.1200/GO.24.00084.</RefSource><PMID Version="1">39481067</PMID></CommentsCorrections></CommentsCorrectionsList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>1</Month><Day>30</Day><Hour>18</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>1</Month><Day>30</Day><Hour>18</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>1</Month><Day>30</Day><Hour>16</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>1</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39883899</ArticleId><ArticleId IdType="pmc">PMC11892602</ArticleId><ArticleId IdType="doi">10.1200/GO-24-00651</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/GO-25-00216 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40700663</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2687-8941</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><PubDate><Year>2025</Year><Month>Jul</Month></PubDate></JournalIssue><Title>JCO global oncology</Title><ISOAbbreviation>JCO Glob Oncol</ISOAbbreviation></Journal><ArticleTitle>Reply to: Critical Review: Efficacy and Safety of Biosimilar Cetuximab Versus Innovator Cetuximab in Indian Patients With Head and Neck Cancer.</ArticleTitle><Pagination><StartPage>e2500216</StartPage><MedlinePgn>e2500216</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/GO-25-00216</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Prabhash</LastName><ForeName>Kumar</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-8858-5004</Identifier><AffiliationInfo><Affiliation>Kumar Prabhash, MD, DM, Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India; Roshan Pawar, MD, Medical Department, Alkem Laboratories Limited, Mumbai, India; and Vijaya Gunjal, MD, DM, Medical Department, Alkem Laboratories Limited, Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pawar</LastName><ForeName>Roshan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Kumar Prabhash, MD, DM, Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India; Roshan Pawar, MD, Medical Department, Alkem Laboratories Limited, Mumbai, India; and Vijaya Gunjal, MD, DM, Medical Department, Alkem Laboratories Limited, Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gunjal</LastName><ForeName>Vijaya</ForeName><Initials>V</Initials><Identifier Source="ORCID">0009-0001-5800-7008</Identifier><AffiliationInfo><Affiliation>Kumar Prabhash, MD, DM, Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India; Roshan Pawar, MD, Medical Department, Alkem Laboratories Limited, Mumbai, India; and Vijaya Gunjal, MD, DM, Medical Department, Alkem Laboratories Limited, Mumbai, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Glob Oncol</MedlineTA><NlmUniqueID>101760170</NlmUniqueID><ISSNLinking>2687-8941</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>23</Day><Hour>18</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>23</Day><Hour>18</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>23</Day><Hour>16</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40700663</ArticleId><ArticleId IdType="doi">10.1200/GO-25-00216</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/GO-25-00487 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">41124627</PMID><DateRevised><Year>2025</Year><Month>10</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2687-8941</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><PubDate><Year>2025</Year><Month>Oct</Month></PubDate></JournalIssue><Title>JCO global oncology</Title><ISOAbbreviation>JCO Glob Oncol</ISOAbbreviation></Journal><ArticleTitle>Reply to: Beyond the Numbers: Inflammation as the Missing Link in Decayed, Missing, Filled Teeth-Based Buccal Mucosa Cancer Risk Models.</ArticleTitle><Pagination><StartPage>e2500487</StartPage><MedlinePgn>e2500487</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/GO-25-00487</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>George</LastName><ForeName>Grace Sarah</ForeName><Initials>GS</Initials><Identifier Source="ORCID">0009-0005-4874-488X</Identifier><AffiliationInfo><Affiliation>Grace Sarah George, MSc and Rajesh Dikshit, PhD, Centre for Cancer Epidemiology, Tata Memorial Centre, Navi Mumbai, India; Anil Chaturvedi, PhD, National Cancer Institute, Rockville, MD; and Pankaj Chaturvedi, MS and Sharayu Mhatre, PhD, Centre for Cancer Epidemiology, Tata Memorial Centre, Navi Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dikshit</LastName><ForeName>Rajesh</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Grace Sarah George, MSc and Rajesh Dikshit, PhD, Centre for Cancer Epidemiology, Tata Memorial Centre, Navi Mumbai, India; Anil Chaturvedi, PhD, National Cancer Institute, Rockville, MD; and Pankaj Chaturvedi, MS and Sharayu Mhatre, PhD, Centre for Cancer Epidemiology, Tata Memorial Centre, Navi Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chaturvedi</LastName><ForeName>Anil</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-2696-8899</Identifier><AffiliationInfo><Affiliation>Grace Sarah George, MSc and Rajesh Dikshit, PhD, Centre for Cancer Epidemiology, Tata Memorial Centre, Navi Mumbai, India; Anil Chaturvedi, PhD, National Cancer Institute, Rockville, MD; and Pankaj Chaturvedi, MS and Sharayu Mhatre, PhD, Centre for Cancer Epidemiology, Tata Memorial Centre, Navi Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chaturvedi</LastName><ForeName>Pankaj</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-3520-1342</Identifier><AffiliationInfo><Affiliation>Grace Sarah George, MSc and Rajesh Dikshit, PhD, Centre for Cancer Epidemiology, Tata Memorial Centre, Navi Mumbai, India; Anil Chaturvedi, PhD, National Cancer Institute, Rockville, MD; and Pankaj Chaturvedi, MS and Sharayu Mhatre, PhD, Centre for Cancer Epidemiology, Tata Memorial Centre, Navi Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mhatre</LastName><ForeName>Sharayu</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-7072-802X</Identifier><AffiliationInfo><Affiliation>Grace Sarah George, MSc and Rajesh Dikshit, PhD, Centre for Cancer Epidemiology, Tata Memorial Centre, Navi Mumbai, India; Anil Chaturvedi, PhD, National Cancer Institute, Rockville, MD; and Pankaj Chaturvedi, MS and Sharayu Mhatre, PhD, Centre for Cancer Epidemiology, Tata Memorial Centre, Navi Mumbai, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>10</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Glob Oncol</MedlineTA><NlmUniqueID>101760170</NlmUniqueID><ISSNLinking>2687-8941</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>10</Month><Day>22</Day><Hour>18</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>10</Month><Day>22</Day><Hour>18</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>10</Month><Day>22</Day><Hour>16</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41124627</ArticleId><ArticleId IdType="doi">10.1200/GO-25-00487</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/CCI-24-00219 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39938017</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2473-4276</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><PubDate><Year>2025</Year><Month>Feb</Month></PubDate></JournalIssue><Title>JCO clinical cancer informatics</Title><ISOAbbreviation>JCO Clin Cancer Inform</ISOAbbreviation></Journal><ArticleTitle>Leveraging Radiotherapy Data for Precision Oncology: Veterans Affairs Granular Radiotherapy Information Database.</ArticleTitle><Pagination><StartPage>e2400219</StartPage><MedlinePgn>e2400219</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2400219</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1200/CCI-24-00219</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Despite the frequency with which patients with cancer receive radiotherapy, integrating radiation oncology data with other aspects of the clinical record remains challenging because of siloed and variable software systems, high data complexity, and inconsistent data encoding. Recognizing these challenges, the Veterans Affairs (VA) National Radiation Oncology Program (NROP) is developing Granular Radiotherapy Information Database (GRID), a platform and pipeline to combine radiotherapy data across the VA with the goal of both better understanding treatment patterns and outcomes and enhancing research and data analysis capabilities.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This study represents a proof-of-principle retrospective cohort analysis and review of select radiation treatment data from the VA Radiation Oncology Quality Surveillance Program (VAROQS) initiative. Key radiation oncology data elements were extracted from Digital Imaging and Communications in Medicine Radiotherapy extension (DICOM-RT) files and combined into a single database using custom scripts. These data were transferred to the VA's Corporate Data Warehouse (CDW) for integration and comparison with the VA Cancer Registry System and tumor sequencing data.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The final cohort includes 1,568 patients, 766 of whom have corresponding DICOM-RT data. All cases were successfully linked to the CDW; 18.8% of VAROQS cases were not reported in the existing VA cancer registry. The VAROQS data contributed accurate radiation treatment details that were often erroneous or missing from the cancer registry record. Tumor sequencing data were available for approximately 5% of VAROQS cases. Finally, we describe a clinical dosimetric analysis leveraging GRID.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">NROP's GRID initiative aims to integrate VA radiotherapy data with other clinical data sets. It is anticipated to generate the single largest collection of radiation oncology-centric data merged with detailed clinical and genomic data, primed for large-scale quality assurance, research reuse, and discovery science.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Katsoulakis</LastName><ForeName>Evangelia</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-3462-6303</Identifier><AffiliationInfo><Affiliation>VA Informatics and Computing Infrastructure (VINCI), VA Salt Lake City Health Care System, Salt Lake City, UT.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiation Oncology, University of South Florida, Tampa, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madison</LastName><ForeName>Cecelia J</ForeName><Initials>CJ</Initials><Identifier Source="ORCID">0000-0002-0261-0414</Identifier><AffiliationInfo><Affiliation>VA Informatics and Computing Infrastructure (VINCI), VA Salt Lake City Health Care System, Salt Lake City, UT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kapoor</LastName><ForeName>Rishabh</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>VA National Radiation Oncology Program, Richmond, VA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Melson</LastName><ForeName>Ryan A</ForeName><Initials>RA</Initials><Identifier Source="ORCID">0000-0002-2230-908X</Identifier><AffiliationInfo><Affiliation>Research and Development Service, VA Portland Healthcare System, Portland, OR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Anthony</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-6781-7873</Identifier><AffiliationInfo><Affiliation>VA Informatics and Computing Infrastructure (VINCI), VA Salt Lake City Health Care System, Salt Lake City, UT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bian</LastName><ForeName>Jiantao</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-5989-5177</Identifier><AffiliationInfo><Affiliation>VA Informatics and Computing Infrastructure (VINCI), VA Salt Lake City Health Care System, Salt Lake City, UT.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hausler</LastName><ForeName>Ryan M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>VA Informatics and Computing Infrastructure (VINCI), VA Salt Lake City Health Care System, Salt Lake City, UT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Danilov</LastName><ForeName>Peter N</ForeName><Initials>PN</Initials><AffiliationInfo><Affiliation>VA Informatics and Computing Infrastructure (VINCI), VA Salt Lake City Health Care System, Salt Lake City, UT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nickols</LastName><ForeName>Nicholas G</ForeName><Initials>NG</Initials><AffiliationInfo><Affiliation>Radiation Oncology Service, VA Greater Los Angeles Healthcare System, Los Angeles, CA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solanki</LastName><ForeName>Abhishek A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Edward Hines Jr VA Hospital, Hines, IL.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stritch School of Medicine, Loyola University Chicago, Maywood, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sleeman</LastName><ForeName>William C</ForeName><Initials>WC</Initials><Suffix>4th</Suffix><Identifier Source="ORCID">0000-0002-8431-8483</Identifier><AffiliationInfo><Affiliation>VA National Radiation Oncology Program, Richmond, VA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palta</LastName><ForeName>Jatinder R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>VA National Radiation Oncology Program, Richmond, VA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DuVall</LastName><ForeName>Scott L</ForeName><Initials>SL</Initials><Identifier Source="ORCID">0000-0002-4898-3865</Identifier><AffiliationInfo><Affiliation>VA Informatics and Computing Infrastructure (VINCI), VA Salt Lake City Health Care System, Salt Lake City, UT.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lynch</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0003-0108-2127</Identifier><AffiliationInfo><Affiliation>VA Informatics and Computing Infrastructure (VINCI), VA Salt Lake City Health Care System, Salt Lake City, UT.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Reid F</ForeName><Initials>RF</Initials><Identifier Source="ORCID">0000-0003-3661-5296</Identifier><AffiliationInfo><Affiliation>VA National Radiation Oncology Program, Richmond, VA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Hospital and Specialty Medicine, VA Portland Healthcare System, Portland, OR.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiation Medicine, Oregon Health &amp; Science University, Portland, OR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kelly</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>VA National Radiation Oncology Program, Richmond, VA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>02</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Clin Cancer Inform</MedlineTA><NlmUniqueID>101708809</NlmUniqueID><ISSNLinking>2473-4276</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057285" MajorTopicYN="Y">Precision Medicine</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018787" MajorTopicYN="Y">Radiation Oncology</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName><QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014493" MajorTopicYN="N">United States Department of Veterans Affairs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="Y">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011878" MajorTopicYN="Y">Radiotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/cci/author-center. Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments). 
<b>Evangelia Katsoulakis</b>
. <b>Stock and Other Ownership Interests:</b> AbbVie, Pfizer, Intuitive Surgical, Bristol Myers Squibb/Pfizer. <b>Research Funding:</b> Advantagene Local Site PI (Inst). 
<b>Cecelia J. Madison</b>
. <b>Stock and Other Ownership Interests:</b> Merck (I). 
<b>Rishabh Kapoor</b>
. <b>Employment:</b> Intelligent Health Solutions LLC. 
<b>Jiantao Bian</b>
. <b>Employment:</b> Verily. 
<b>Peter N. Danilov</b>
. <b>Research Funding:</b> Alnylam (Inst), Astellas Pharma (Inst), AstraZeneca (Inst), Biodesix (Inst), Boehringer Ingelheim (Inst), Celgene (Inst), Lilly (Inst), Genentech (Inst), Gilead Sciences (Inst), GlaxoSmithKline (Inst), Innocrin Pharma (Inst), IQVIA (Inst), Janssen (Inst), Kantar Health (Inst), MDxHealth (Inst), Merck (Inst), Myriad Genetics (Inst), Novartis (Inst), Parexel/Puma Biotechnology (Inst). 
<b>Nicholas G. Nickols</b>
. <b>Consulting or Advisory Role:</b> PrimeFour. <b>Research Funding:</b> Lantheus Medical Imaging (Inst), Janssen Oncology (Inst). 
<b>Jatinder R. Palta</b>
. <b>Consulting or Advisory Role:</b> VA National Radiation Oncology Program (11SPEC22). 
<b>Scott L. DuVall</b>
. <b>Research Funding:</b> AstraZeneca (Inst), Celgene (Inst), Janssen (Inst), Novartis (Inst), Parexel International Corporation (Inst), Alnylam (Inst), Cerner Enviza (Inst), Biodesix (Inst), GlaxoSmithKline (Inst), Moderna Therapeutics (Inst). 
<b>Julie A. Lynch</b>
. <b>Research Funding:</b> AstraZeneca (Inst), Janssen (Inst), Novartis (Inst), Celgene (Inst). 
<b>Reid F. Thompson</b>
. <b>Research Funding:</b> AstraZeneca. No other potential conflicts of interest were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>2</Month><Day>12</Day><Hour>18</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>2</Month><Day>12</Day><Hour>18</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>2</Month><Day>12</Day><Hour>16</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>2</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39938017</ArticleId><ArticleId IdType="pmc">PMC11841735</ArticleId><ArticleId IdType="doi">10.1200/CCI-24-00219</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zullig LL, Jazowski SA, Chawla N, et al. : Summary of Veterans Health Administration cancer data sources. J Registry Manag 51:21-28, 2024</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11178113</ArticleId><ArticleId IdType="pubmed">38881982</ArticleId></ArticleIdList></Reference><Reference><Citation>Delaney GP, Barton MB: Evidence-based estimates of the demand for radiotherapy. Clin Oncol (R Coll Radiol) 27:70-76, 2015</Citation><ArticleIdList><ArticleId IdType="pubmed">25455408</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown JM, Adler JR: Is equipment development stifling innovation in radiation oncology? Int J Radiat Oncol Biol Phys 92:713-714, 2015</Citation><ArticleIdList><ArticleId IdType="pubmed">26104924</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Heerik ASVM, Horeweg N, Nout RA, et al. : PORTEC-4a: International randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer. Int J Gynecol Cancer 30:2002-2007, 2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7788476</ArticleId><ArticleId IdType="pubmed">33046573</ArticleId></ArticleIdList></Reference><Reference><Citation>Solanki AA, Puckett LL, Kujundzic K, et al. : Consensus quality measures and dose constraints for prostate cancer from the Veterans Affairs Radiation Oncology Quality Surveillance Program and American Society for Radiation Oncology expert panel. Pract Radiat Oncol 13:e149-e165, 2023</Citation><ArticleIdList><ArticleId IdType="pubmed">36522277</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J, Venkatesulu BP, Kujundzic K, et al. : Consensus quality measures and dose constraints for rectal cancer from the Veterans Affairs Radiation Oncology Quality Surveillance Program and American Society for Radiation Oncology (ASTRO) expert panel. Pract Radiat Oncol 12:424-436, 2022</Citation><ArticleIdList><ArticleId IdType="pubmed">35907764</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing L, Cotrutz C, Hunjan S, et al. : Inverse planning for functional image-guided intensity-modulated radiation therapy. Phys Med Biol 47:3567-3578, 2002</Citation><ArticleIdList><ArticleId IdType="pubmed">12433120</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J, Puckett LL, Katsoulakis E, et al. : Veterans Affairs Radiation Oncology Quality Surveillance Program and American Society for Radiation Oncology quality measures initiative. Pract Radiat Oncol 12:468-474, 2022</Citation><ArticleIdList><ArticleId IdType="pubmed">35690354</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsoulakis E, Kudner R, Chapman C, et al. : Consensus quality measures and dose constraints for head and neck cancer with an emphasis on oropharyngeal and laryngeal cancer from the Veterans Affairs Radiation Oncology Quality Surveillance Program and American Society for Radiation Oncology expert panel. Pract Radiat Oncol 12:409-423, 2022</Citation><ArticleIdList><ArticleId IdType="pubmed">35667551</ArticleId></ArticleIdList></Reference><Reference><Citation>Puckett LL, Kodali D, Solanki AA, et al. : Consensus quality measures and dose constraints for breast cancer from the Veterans Affairs Radiation Oncology Quality Surveillance Program and American Society for Radiation Oncology expert panel. Pract Radiat Oncol 13:217-230, 2023</Citation><ArticleIdList><ArticleId IdType="pubmed">36115498</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Z, Shu Y, Zhou H, et al. : Radiogenomics helps to achieve personalized therapy by evaluating patient responses to radiation treatment. Carcinogenesis 36:307-317, 2015</Citation><ArticleIdList><ArticleId IdType="pubmed">25604391</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapoor R, Sleeman WC, Ghosh P, et al. : Infrastructure tools to support an effective Radiation Oncology Learning Health System. J Appl Clin Med Phys 24:e14127, 2023</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10562037</ArticleId><ArticleId IdType="pubmed">37624227</ArticleId></ArticleIdList></Reference><Reference><Citation>Bibault J-E, Zapletal E, Rance B, et al. : Labeling for Big Data in radiation oncology: The Radiation Oncology Structures ontology. PLoS One 13:e0191263, 2018</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5774757</ArticleId><ArticleId IdType="pubmed">29351341</ArticleId></ArticleIdList></Reference><Reference><Citation>Bocquet F, Raimbourg J, Bigot F, et al. : Opportunities and obstacles to the development of health data warehouses in hospitals in France: The recent experience of comprehensive cancer centers. Int J Environ Res Public Health 20:1645, 2023</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9861145</ArticleId><ArticleId IdType="pubmed">36674399</ArticleId></ArticleIdList></Reference><Reference><Citation>Syed K, Iv WS, Ivey K, et al. : Integrated natural language processing and machine learning models for standardizing radiotherapy structure names. Healthcare (Basel) 8:120, 2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7348919</ArticleId><ArticleId IdType="pubmed">32365973</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayman JA, Dekker A, Feng M, et al. : Minimum data elements for radiation oncology: An American Society for Radiation Oncology consensus paper. Pract Radiat Oncol 9:395-401, 2019</Citation><ArticleIdList><ArticleId IdType="pubmed">31445187</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapoor R, Sleeman WC, Nalluri JJ, et al. : Automated data abstraction for quality surveillance and outcome assessment in radiation oncology. J Appl Clin Med Phys 22:177-187, 2021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8292697</ArticleId><ArticleId IdType="pubmed">34101349</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayo CS, Kessler ML, Eisbruch A, et al. : The big data effort in radiation oncology: Data mining or data farming? Adv Radiat Oncol 1:260-271, 2016</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5514231</ArticleId><ArticleId IdType="pubmed">28740896</ArticleId></ArticleIdList></Reference><Reference><Citation>Moran JM, Feng M, Benedetti LA, et al. : Development of a model web-based system to support a statewide quality consortium in radiation oncology. Pract Radiat Oncol 7:e205-e213, 2017</Citation><ArticleIdList><ArticleId IdType="pubmed">28196607</ArticleId></ArticleIdList></Reference><Reference><Citation>Matuszak MM, Fuller CD, Yock TI, et al. : Performance/outcomes data and physician process challenges for practical big data efforts in radiation oncology. Med Phys 45:e811-e819, 2018</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6679351</ArticleId><ArticleId IdType="pubmed">30229946</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagan M, Kapoor R, Michalski J, et al. : VA-Radiation Oncology Quality Surveillance Program. Int J Radiat Oncol Biol Phys 106:639-647, 2020</Citation><ArticleIdList><ArticleId IdType="pubmed">31983560</ArticleId></ArticleIdList></Reference><Reference><Citation>Law MYY, Liu B: Informatics in radiology: DICOM-RT and its utilization in radiation therapy. Radiographics 29:655-667, 2009</Citation><ArticleIdList><ArticleId IdType="pubmed">19270073</ArticleId></ArticleIdList></Reference><Reference><Citation>Office of Information and Technology : Oncology (Onc) user manual, 2020. https://www.va.gov/vdl/documents/Clinical/Oncology/onc_2_2_p12_um.pdf</Citation></Reference><Reference><Citation>Poonnen PJ, Duffy JE, Hintze B, et al. : Genomic analysis of metastatic solid tumors in veterans: Findings from the VHA National Precision Oncology Program. JCO Precis Oncol
10.1200/PO.19.00075</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/PO.19.00075</ArticleId><ArticleId IdType="pmc">PMC7446382</ArticleId><ArticleId IdType="pubmed">32914016</ArticleId></ArticleIdList></Reference><Reference><Citation>NAACR: Standards for cancer registries, standard data edits, volume IV, 2024. https://www.naaccr.org/standard-data-edits/</Citation></Reference><Reference><Citation>Mayo CS, Moran JM, Bosch W, et al. : American Association of Physicists in Medicine task group 263: Standardizing nomenclatures in radiation oncology. Int J Radiat Oncol Biol Phys 100:1057-1066, 2018</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7437157</ArticleId><ArticleId IdType="pubmed">29485047</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawell MP, Indelicato DJ, Paulino AC, et al. : An open invitation to join the Pediatric Proton/Photon Consortium Registry to standardize data collection in pediatric radiation oncology. Br J Radiol 93:20190673, 2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7066966</ArticleId><ArticleId IdType="pubmed">31600082</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoppe BS, Nichols RC, Flampouri S, et al. : Chemoradiation with hypofractionated proton therapy in stage II-III non-small cell lung cancer: A Proton Collaborative Group phase 2 trial. Int J Radiat Oncol Biol Phys 113:732-741, 2022</Citation><ArticleIdList><ArticleId IdType="pubmed">35306151</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheehan JP, Kavanagh BD, Asher A, et al. : Inception of a national multidisciplinary registry for stereotactic radiosurgery. J Neurosurg 124:155-162, 2016</Citation><ArticleIdList><ArticleId IdType="pubmed">26252466</ArticleId></ArticleIdList></Reference><Reference><Citation>Jairam V, Park HS: Strengths and limitations of large databases in lung cancer radiation oncology research. Transl Lung Cancer Res 8:S172-S183, 2019. (suppl 2)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6795574</ArticleId><ArticleId IdType="pubmed">31673522</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott JG, Berglund A, Schell MJ, et al. : A genome-based model for adjusting radiotherapy dose (GARD): A retrospective, cohort-based study. Lancet Oncol 18:202-211, 2017</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7771305</ArticleId><ArticleId IdType="pubmed">27993569</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerns SL, Kundu S, Oh JH, et al. : The prediction of radiotherapy toxicity using single nucleotide polymorphism-based models: A step toward prevention. Semin Radiat Oncol 25:281-291, 2015</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4576690</ArticleId><ArticleId IdType="pubmed">26384276</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y-Q, Wang T-M, Yang D-W, et al. : A comprehensive predictive model for radiation-induced brain injury in risk stratification and personalized radiotherapy of nasopharyngeal carcinoma. Radiother Oncol 190:109974, 2024</Citation><ArticleIdList><ArticleId IdType="pubmed">37913956</ArticleId></ArticleIdList></Reference><Reference><Citation>Lococo F, Boldrini L, Diepriye C-D, et al. : Lung cancer multi-omics digital human avatars for integrating precision medicine into clinical practice: The LANTERN study. BMC Cancer 23:540, 2023</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10262371</ArticleId><ArticleId IdType="pubmed">37312079</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaziano JM, Concato J, Brophy M, et al. : Million Veteran Program: A mega-biobank to study genetic influences on health and disease. J Clin Epidemiol 70:214-223, 2016</Citation><ArticleIdList><ArticleId IdType="pubmed">26441289</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiore LD, Rodriguez H, Shriver CD: Collaboration to accelerate proteogenomics cancer care: The Department of Veterans Affairs, Department of Defense, and the National Cancer Institute&#x2019;s Applied Proteogenomics OrganizationaL Learning and Outcomes (APOLLO) Network. Clin Pharmacol Ther 101:619-621, 2017</Citation><ArticleIdList><ArticleId IdType="pubmed">28187513</ArticleId></ArticleIdList></Reference><Reference><Citation>Graff JN, Huang GD: Leveraging Veterans Health Administration clinical and research resources to accelerate discovery and testing in precision oncology. Fed Pract 37:S62-S67, 2020. (suppl 4)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7473727</ArticleId><ArticleId IdType="pubmed">32908354</ArticleId></ArticleIdList></Reference><Reference><Citation>Department of Veterans Affairs : VA/CMS data for research project: VA Information Resource Center, 2024. https://www.virec.research.va.gov/VACMS/About.asp</Citation></Reference><Reference><Citation>Valle LF, Nickols NG, Hausler R, et al. : Actionable genomic alterations in prostate cancer among Black and White United States Veterans. Oncologist 28:e473-e477, 2023</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10243786</ArticleId><ArticleId IdType="pubmed">37084789</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/CCI-24-00177 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39965177</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>08</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2473-4276</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><PubDate><Year>2025</Year><Month>Feb</Month></PubDate></JournalIssue><Title>JCO clinical cancer informatics</Title><ISOAbbreviation>JCO Clin Cancer Inform</ISOAbbreviation></Journal><ArticleTitle>Prognosis of p16 and Human Papillomavirus Discordant Oropharyngeal Cancers and the Exploration of Using Natural Language Processing to Analyze Free-Text Pathology Reports.</ArticleTitle><Pagination><StartPage>e2400177</StartPage><MedlinePgn>e2400177</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/CCI-24-00177</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Treatment deintensification for human papillomavirus-positive (HPV+)-associated oropharyngeal cancer (OPC) has been the catalyst of experts worldwide. In situ hybridization is optimal to identify HPV+ OPC, but immunohistochemistry for its surrogate p16INK4a (p16) is standard-of-care given its availability and sensitivity. HPV testing is not required for clinical management, so treatments are often administered on the basis of p16 status alone. However, the prognosis of p16/HPV discordant tumors is uncertain.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">This cohort study included 727 consecutive patients with OPC with digitized unstructured pathology reports receiving curative radiation therapy at an academic cancer center. Natural language processing (NLP) methods were used to classify biomarker status and compared against manually derived classification. Patients were excluded if either p16 or HPV testing was not performed or equivocal. Primary end points were progression-free survival (PFS), cancer-specific survival (CSS), and overall survival.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">NLP classified p16 and HPV status from a majority (91%) of reports. Accuracy, positive predictive value, sensitivity, and <i>F</i>-score for NLP-derived p16/HPV were 84%/82%, 91%/87%, 90%/89%, and 90%/88%, respectively. Four groups were identified: p16-positive (p16+)/HPV+ (75%), p16+/HPV-negative (HPV-; 13%), p16-negative (p16-)/HPV- (10%), and p16-/HPV+ (2%). There was no statistically significant difference in outcomes between p16+/HPV- and p16-/HPV- patients (5-year PFS 76.1% <i>v</i> 68.9%; <i>P</i> = .12; 5-year CSS 81.5% <i>v</i> 84.9%; <i>P</i> = .22). Number needed to harm calculations estimated one excess cancer-related death for every 10 p16+/HPV- patients, compared with that expected with p16+/HPV+ patients.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">NLP classified head and neck cancer pathology reports with high concordance with gold-standard categorization, but a conspicuous portion of reports could not be interpreted. p16/HPV discordant OPC constitutes a noteworthy minority of patients. The inferior prognosis of p16+/HPV- suggests that p16 alone for prognostication is insufficient-especially when considering treatment de-escalation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shin</LastName><ForeName>Ethan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Geneva School, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Justin</ForeName><Initials>J</Initials><Identifier Source="ORCID">0009-0003-3866-8719</Identifier><AffiliationInfo><Affiliation>SUNY Downstate College of Medicine, Brooklyn, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hung</LastName><ForeName>Tony K W</ForeName><Initials>TKW</Initials><Identifier Source="ORCID">0000-0002-3872-5512</Identifier><AffiliationInfo><Affiliation>Memorial Sloan Kettering Cancer Center, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poon</LastName><ForeName>Chester</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Memorial Sloan Kettering Cancer Center, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riaz</LastName><ForeName>Nadeem</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-9873-5862</Identifier><AffiliationInfo><Affiliation>Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Yao</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-2814-4482</Identifier><AffiliationInfo><Affiliation>Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Jung Julie</ForeName><Initials>JJ</Initials><Identifier Source="ORCID">0000-0001-9773-5481</Identifier><AffiliationInfo><Affiliation>Department of Therapeutic Radiology, Yale University, New Haven, CT.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>02</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Clin Cancer Inform</MedlineTA><NlmUniqueID>101708809</NlmUniqueID><ISSNLinking>2473-4276</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019941">Cyclin-Dependent Kinase Inhibitor p16</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000614131">CDKN2A protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009323" MajorTopicYN="Y">Natural Language Processing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009959" MajorTopicYN="Y">Oropharyngeal Neoplasms</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019941" MajorTopicYN="Y">Cyclin-Dependent Kinase Inhibitor p16</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030361" MajorTopicYN="Y">Papillomavirus Infections</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D027383" MajorTopicYN="N">Papillomaviridae</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094302" MajorTopicYN="N">Human Papillomavirus Viruses</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>2</Month><Day>18</Day><Hour>18</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>2</Month><Day>18</Day><Hour>18</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>2</Month><Day>18</Day><Hour>16</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39965177</ArticleId><ArticleId IdType="doi">10.1200/CCI-24-00177</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/CCI-24-00239 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">41100788</PMID><DateCompleted><Year>2025</Year><Month>10</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>10</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2473-4276</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><PubDate><Year>2025</Year><Month>Oct</Month></PubDate></JournalIssue><Title>JCO clinical cancer informatics</Title><ISOAbbreviation>JCO Clin Cancer Inform</ISOAbbreviation></Journal><ArticleTitle>Using Natural Language Processing to Assess Goals-of-Care Conversations for Patients With Cancer.</ArticleTitle><Pagination><StartPage>e2400239</StartPage><MedlinePgn>e2400239</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/CCI-24-00239</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Goals-of-care (GOC) discussions during advanced serious illness and end-of-life (EOL) care are critical. Institutions are increasingly tracking the frequency and timing of GOC documentation, but large-scale content assessments have been limited. We aimed to use natural language processing (NLP) to assess GOC documentation quality and associations with EOL care for patients with cancer.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This is a retrospective review of patients at a single US center who died with cancer between 2018 and 2022, and had documented GOC notes in the last 12 months of life. Eight GOC components were identified: current understanding of illness, information preferences, prognostic disclosure, goals, fears, acceptable function, trade-offs, and family involvement. NLP software searched for the aggregate presence of these components at the patient level within extracted GOC notes. We evaluated associations between these eight components and receipt of aggressive EOL care (chemotherapy within 14 days of death, no hospice care, or hospice admission &#x2264;3 days of death).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Two thousand thirty-one patients met inclusion criteria. The most common GOC component addressed was family involvement (75.0%) and the least common was fears (21.1%). Only 5.4% had all eight components documented. More comprehensive GOC notes were associated with lower rates of aggressive EOL care; 73.2% received aggressive care when 0/8 components were documented, compared with 56.8% and 50.3% with six or seven components discussed, respectively. In multivariate logistic regression, GOC components documented (&#x2264;6 <i>v</i> &#x2265;7: OR, 2.13; <i>P</i> &lt; .0001) and primary tumor site (lymphoma: OR, 2.86; <i>P</i> &lt; .0001) were independent predictors of aggressive EOL care.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Increasingly comprehensive and higher-quality GOC documentation is associated with a lower likelihood of receiving aggressive EOL care. Opportunities to improve the quality and documentation of GOC conversations may affect EOL care for patients with cancer.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Greene</LastName><ForeName>Melissa K</ForeName><Initials>MK</Initials><Identifier Source="ORCID">0009-0007-6832-5310</Identifier><AffiliationInfo><Affiliation>Duke University School of Medicine, Durham, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Broadwater</LastName><ForeName>Gloria</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Biostatistics Shared Resource, Duke Cancer Institute, Duke University Medical Center, Durham, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niedzwiecki</LastName><ForeName>Donna</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-3566-0450</Identifier><AffiliationInfo><Affiliation>Biostatistics Shared Resource, Duke Cancer Institute, Duke University Medical Center, Durham, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>LeBlanc</LastName><ForeName>Thomas W</ForeName><Initials>TW</Initials><Identifier Source="ORCID">0000-0002-0546-7895</Identifier><AffiliationInfo><Affiliation>Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Cancer Patient Experience Research Program, Duke Cancer Institute, Durham, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Jessica E</ForeName><Initials>JE</Initials><Identifier Source="ORCID">0000-0002-9448-0353</Identifier><AffiliationInfo><Affiliation>Division of General Internal Medicine, Department of Medicine, Duke University School of Medicine, Geriatric Research, Education, and Clinical Center, Durham VA Health System, Durham, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casarett</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Section of Palliative Care, Duke University Department of Medicine, Duke Center for Palliative Care, Duke University Medical Center, Durham, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davidson</LastName><ForeName>Brittany A</ForeName><Initials>BA</Initials><Identifier Source="ORCID">0000-0001-9698-0442</Identifier><AffiliationInfo><Affiliation>Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>10</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Clin Cancer Inform</MedlineTA><NlmUniqueID>101708809</NlmUniqueID><ISSNLinking>2473-4276</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009323" MajorTopicYN="Y">Natural Language Processing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013727" MajorTopicYN="Y">Terminal Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010347" MajorTopicYN="Y">Patient Care Planning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>10</Month><Day>16</Day><Hour>18</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>10</Month><Day>16</Day><Hour>18</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>10</Month><Day>16</Day><Hour>16</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41100788</ArticleId><ArticleId IdType="doi">10.1200/CCI-24-00239</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/CCI-25-00218 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">41150999</PMID><DateCompleted><Year>2025</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2025</Year><Month>10</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2473-4276</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><PubDate><Year>2025</Year><Month>Oct</Month></PubDate></JournalIssue><Title>JCO clinical cancer informatics</Title><ISOAbbreviation>JCO Clin Cancer Inform</ISOAbbreviation></Journal><ArticleTitle>Leveraging Centralized Health System Data Management and Large Language Model-Based Data Preprocessing to Identify Predictors for Radiation Therapy Interruption.</ArticleTitle><Pagination><StartPage>e2500218</StartPage><MedlinePgn>e2500218</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2500218</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1200/CCI-25-00218</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Unplanned treatment interruptions represent an important care quality shortfall for patients undergoing cancer radiotherapy. This study aimed to evaluate use of a centralized electronic health record warehouse and large language model-based data preprocessing to facilitate identification of risk factors for radiation therapy interruptions (RTI).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We analyzed demographic, behavioral, clinical, and neighborhood-level data for 2,130 patients treated with radiotherapy at the University of Tennessee Medical Center in Knoxville. Treatment interruptions were measured as missed days, adjusted for weekends and holidays. Multinomial logistic regression was used to identify factors associated with moderate (2-4 days) and severe (&#x2265;5 days) RTI.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Moderate RTI occurred in 15.8% of patients, while 7.7% experienced severe RTI. Moderate delays were associated with genitourinary cancer (adjusted odds ratio (AOR), 3.81; 95% CI, 1.24 to 11.66), prostate cancer (AOR, 2.44; 95% CI, 1.34 to 4.46), and Medicaid coverage (AOR, 2.22; 95% CI, 1.32 to 3.73). Severe RTI was associated with marital status (AOR for divorced or separated patients, 1.86; 95% CI, 1.18 to 2.94), head and neck cancer (AOR, 2.31; 95% CI, 1.10 to 4.87), gynecologic cancer (AOR, 2.97; 95% CI, 1.30 to 6.79), Medicaid insurance (AOR, 3.43; 95% CI, 1.77 to 6.64), daily dose of &#x2264;225 cGy (AOR, 2.55; 95% CI, 1.21 to 5.37), and a total dose of &#x2265;6,000 cGy (AOR, 2.30; 95% CI, 1.09 to 4.88). Severe interruptions were also significantly associated with high neighborhood social vulnerability (AOR, 2.60; 95% CI, 1.32 to 5.09).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Automated data preprocessing permitted efficient identification of treatment course length, marital status, disease site, Medicaid coverage, and socially vulnerable locations as significant factors associated with RTI. These findings underscore the need for data-driven risk assessment and intervention strategies to maintain cancer treatment quality at scale.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kumsa</LastName><ForeName>Fekede Asefa</ForeName><Initials>FA</Initials><Identifier Source="ORCID">0000-0002-6700-4810</Identifier><AffiliationInfo><Affiliation>Center for Biomedical Informatics, Department of Pediatrics, College of Medicine, University of Tennessee Health Science Center, Memphis, TN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brett</LastName><ForeName>Christopher L</ForeName><Initials>CL</Initials><Identifier Source="ORCID">0000-0003-2958-599X</Identifier><AffiliationInfo><Affiliation>University of Tennessee Graduate School of Medicine, Knoxville, TN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hashtarkhani</LastName><ForeName>Soheil</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-7750-6294</Identifier><AffiliationInfo><Affiliation>Center for Biomedical Informatics, Department of Pediatrics, College of Medicine, University of Tennessee Health Science Center, Memphis, TN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rashid</LastName><ForeName>Rezaur</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-1343-5364</Identifier><AffiliationInfo><Affiliation>Center for Biomedical Informatics, Department of Pediatrics, College of Medicine, University of Tennessee Health Science Center, Memphis, TN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chinthala</LastName><ForeName>Lokesh</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-1258-8353</Identifier><AffiliationInfo><Affiliation>Center for Biomedical Informatics, Department of Pediatrics, College of Medicine, University of Tennessee Health Science Center, Memphis, TN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zink</LastName><ForeName>Janet A</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0002-0261-4917</Identifier><AffiliationInfo><Affiliation>Center for Biomedical Informatics, Department of Pediatrics, College of Medicine, University of Tennessee Health Science Center, Memphis, TN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Robert L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Center for Biomedical Informatics, Department of Pediatrics, College of Medicine, University of Tennessee Health Science Center, Memphis, TN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaban-Nejad</LastName><ForeName>Arash</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-2047-4759</Identifier><AffiliationInfo><Affiliation>Center for Biomedical Informatics, Department of Pediatrics, College of Medicine, University of Tennessee Health Science Center, Memphis, TN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwartz</LastName><ForeName>David L</ForeName><Initials>DL</Initials><Identifier Source="ORCID">0000-0002-7235-5586</Identifier><AffiliationInfo><Affiliation>Department of Radiation Oncology, College of Medicine, University of Tennessee Health Science Center, Memphis, TN.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Preventive Medicine, College of Medicine, University of Tennessee Health Science Center, Memphis, TN.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>10</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Clin Cancer Inform</MedlineTA><NlmUniqueID>101708809</NlmUniqueID><ISSNLinking>2473-4276</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName><QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000079803" MajorTopicYN="Y">Data Management</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013714" MajorTopicYN="N" Type="Geographic">Tennessee</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000098342" MajorTopicYN="N">Large Language Models</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/cci/author-center. Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments). 
<b>Christopher L. Brett</b>
. <b>Stock and Other Ownership Interests:</b> IO Biotech. 
<b>Robert L. Davis</b>
. <b>Patents, Royalties, Other Intellectual Property:</b> I am coowner of 9plus1ai.com. We build AI solutions for early detection of heart disease and maternal health conditions related to pregnancy. 
<b>Arash Shaban-Nejad</b>
. <b>Consulting or Advisory Role:</b> Haleon. <b>Travel, Accommodations, Expenses:</b> Haleon. 
<b>David L. Schwartz</b>
. <b>Research Funding:</b> National Cancer Institute, Elekta (Inst). <b>Travel, Accommodations, Expenses:</b> National Comprehensive Cancer Network. <b>Other Relationship:</b> NRG Cooperative Research Group. No other potential conflicts of interest were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>10</Month><Day>28</Day><Hour>18</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>10</Month><Day>28</Day><Hour>18</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>10</Month><Day>28</Day><Hour>16</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>10</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41150999</ArticleId><ArticleId IdType="pmc">PMC12558007</ArticleId><ArticleId IdType="doi">10.1200/CCI-25-00218</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ohri N, Rapkin BD, Guha C, et al. : Radiation therapy noncompliance and clinical outcomes in an urban academic cancer Center. Int J Radiat Oncol Biol Phys 95:563-570, 2016</Citation><ArticleIdList><ArticleId IdType="pubmed">27020104</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow R, Hasan S, Choi J, et al. : Effect of treatment interruptions on overall survival in patients with triple-negative breast cancer. J Natl Cancer Inst 115:1029-1035, 2023</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10483262</ArticleId><ArticleId IdType="pubmed">37399094</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudat V, Nour A, Hammoud M, et al. : Better compliance with hypofractionation vs. conventional fractionation in adjuvant breast cancer radiotherapy: Results of a single, institutional, retrospective study. Strahlenther Onkol 193:375-384, 2017</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5405099</ArticleId><ArticleId IdType="pubmed">28233048</ArticleId></ArticleIdList></Reference><Reference><Citation>Razmjoo S, Haghi N, Birgani MJT, et al. : Radiotherapy interruption in cancer patients: Rates and causes at Ahvaz Golestan Hospital. Asian Pac J Cancer Care 5:33-36, 2019</Citation></Reference><Reference><Citation>Pozo G, P&#xe9;rez-Escutia MA, Ru&#xed;z A, et al. : Management of interruptions in radiotherapy treatments: Adaptive implementation in high workload sites. Rep Pract Oncol Radiother 24:239-244, 2019</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6395853</ArticleId><ArticleId IdType="pubmed">30858768</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao J-J, Jin Y-N, Wang S-Y, et al. : The detrimental effects of radiotherapy interruption on local control after concurrent chemoradiotherapy for advanced T-stage nasopharyngeal carcinoma: An observational, prospective analysis. BMC Cancer 18:740-747, 2018</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6048841</ArticleId><ArticleId IdType="pubmed">30012115</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaudio E, Ammar N, Gunturkun F, et al. : Defining radiation treatment interruption rates during the COVID-19 pandemic: Findings from an academic center in an underserved urban setting. Int J Radiat Oncol Biol Phys 116:379-393, 2023</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9584778</ArticleId><ArticleId IdType="pubmed">36183931</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarev S, Gupta V, Ghiassi-Nejad Z, et al. : Premature discontinuation of curative radiation therapy: Insights from head and neck irradiation. Adv Radiat Oncol 3:62-69, 2018</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5856974</ArticleId><ArticleId IdType="pubmed">29556582</ArticleId></ArticleIdList></Reference><Reference><Citation>Pepin AN, Zwart A, Danner M, et al. : Treatment interruptions during stereotactic body radiotherapy for prostate cancer. Front Oncol 11:796496, 2021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8807506</ArticleId><ArticleId IdType="pubmed">35127506</ArticleId></ArticleIdList></Reference><Reference><Citation>Waddle MR, Chen RC, Arastu NH, et al. : Unanticipated hospital admissions during or soon after radiation therapy: Incidence and predictive factors. Pract Radiat Oncol 5:e245-e253, 2015</Citation><ArticleIdList><ArticleId IdType="pubmed">25413398</ArticleId></ArticleIdList></Reference><Reference><Citation>Wakefield DV, Carnell M, Dove APH, et al. : Location as destiny: Identifying geospatial disparities in radiation treatment interruption by neighborhood, race, and insurance. Int J Radiat Oncol Biol Phys 107:815-826, 2020</Citation><ArticleIdList><ArticleId IdType="pubmed">32234552</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas K, Martin T, Gao A, et al. : Interruptions of head and neck radiotherapy across insured and indigent patient populations. J Oncol Pract 13:e319-e328, 2017</Citation><ArticleIdList><ArticleId IdType="pubmed">28267393</ArticleId></ArticleIdList></Reference><Reference><Citation>Yarn C, Wakefield DV, Spencer S, et al. : Insurance status and head and neck radiotherapy interruption disparities in the Mid-Southern United States. Head Neck 42:2013-2020, 2020</Citation><ArticleIdList><ArticleId IdType="pubmed">32141652</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutten RJ, Weil CR, Gaffney DK, et al. : Worsening racial disparities in utilization of intensity modulated radiation therapy. Adv Radiat Oncol 7:100887, 2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8960883</ArticleId><ArticleId IdType="pubmed">35360509</ArticleId></ArticleIdList></Reference><Reference><Citation>Flanagan BE, Gregory EW, Hallisey EJ, et al. : A social vulnerability index for disaster management. J Homeland Security Emerg Manag 8:1-22, 2011</Citation></Reference><Reference><Citation>Hashtarkhani S, Rashid R, Brett CL, et al. : Cancer diagnosis categorization in electronic health records using large language models and BioBERT: Model performance evaluation study. JMIR Cancer 10.2196/72005 [epub ahead of print on October 2, 2025]. In press</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/72005</ArticleId><ArticleId IdType="pmc">PMC12490771</ArticleId><ArticleId IdType="pubmed">41037674</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez Ferreira JA, Ja&#xe9;n Olasolo J, Azinovic I, et al. : Effect of radiotherapy delay in overall treatment time on local control and survival in head and neck cancer: Review of the literature. Rep Pract Oncol Radiother 20:328-339, 2015</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4597087</ArticleId><ArticleId IdType="pubmed">26549990</ArticleId></ArticleIdList></Reference><Reference><Citation>Vangeli M: Large language models as advanced data preprocessors transforming unstructured text into fine-tuning datasets. 2014. https://www.diva-portal.org/smash/record.jsf?pid=diva2%3A1879125&amp;dswid=-5089</Citation></Reference><Reference><Citation>Torres-Small S, Davies C, Kumsa FA, et al. : Effects of rurality, socioeconomic status, and race on head and neck squamous cell carcinoma outcomes. Laryngoscope 135:1715-1723, 2025</Citation><ArticleIdList><ArticleId IdType="pubmed">39703100</ArticleId></ArticleIdList></Reference><Reference><Citation>Haggerty JL, Roberge D, L&#xe9;vesque JF, et al. : An exploration of rural-urban differences in healthcare-seeking trajectories: Implications for measures of accessibility. Health Place 28:92-98, 2014</Citation><ArticleIdList><ArticleId IdType="pubmed">24793139</ArticleId></ArticleIdList></Reference><Reference><Citation>Economic Research Service: U.S. Department of Agriculture : Rural-urban&#x2014;Commuting area codes. 2022. https://www.ers.usda.gov/data-products/rural-urban-commuting-area-codes</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/CCI-25-00069 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">41092280</PMID><DateCompleted><Year>2025</Year><Month>10</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2473-4276</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><PubDate><Year>2025</Year><Month>Oct</Month></PubDate></JournalIssue><Title>JCO clinical cancer informatics</Title><ISOAbbreviation>JCO Clin Cancer Inform</ISOAbbreviation></Journal><ArticleTitle>Evaluating Dimensionality Reduction for Patient-Reported Outcome-Based Survival Modeling in Patients With Head and Neck Cancer.</ArticleTitle><Pagination><StartPage>e2500069</StartPage><MedlinePgn>e2500069</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2500069</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1200/CCI-25-00069</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">This study aims to improve survival modeling in head and neck cancer (HNC) by integrating patient-reported outcomes (PROs) using dimensionality reduction techniques. PROs capture symptom severity across the treatment timeline and offer key insights for personalized care. However, their high dimensionality poses challenges such as overfitting and computational complexity. This work focuses on transforming and incorporating PRO data to enhance model performance in HNC.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">We analyzed retrospective data of 923 patients with HNC treated at the University of Texas MD Anderson Cancer Center between 2010 and 2021. Baseline clinical data including demographic, treatment, and disease characteristics were used to build a reference survival model. PRO data, capturing symptom ratings, were integrated using dimensionality reduction techniques: principal component analysis (PCA), autoencoders (AEs), and patient clustering. These reduced representations, combined with clinical data, were input into Cox proportional hazards models to predict overall survival (OS) and progression-free survival (PFS). Model performance was assessed using the concordance index, time-dependent AUC, Brier score for calibration, and hazard ratios for predictor significance.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Cox models incorporating PCA and AE outperformed the clinical-only reference model for both OS and PFS. The PCA-based model achieved the highest C-indices (0.74 for OS and 0.64 for PFS), followed by the AE model (0.73 and 0.63) and the clustering model (0.72 and 0.62). Time-dependent AUCs reinforced these results, with PCA showing the highest average AUC over 36 months. All models were well-calibrated, with low Brier scores. Key predictors included age, disease stage, and tumor subsite.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Dimensionality reduction techniques improve survival prediction in patients with HNC by effectively incorporating PRO data, potentially providing greater insights into more personalized treatment strategies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Anyimadu</LastName><ForeName>Eric Ababio</ForeName><Initials>EA</Initials><Identifier Source="ORCID">0009-0004-3442-2401</Identifier><AffiliationInfo><Affiliation>The University of Iowa, Iowa City, IA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yaohua</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0009-0004-7214-1176</Identifier><AffiliationInfo><Affiliation>The University of Iowa, Iowa City, IA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreno</LastName><ForeName>Amy C</ForeName><Initials>AC</Initials><Identifier Source="ORCID">0000-0001-6762-6807</Identifier><AffiliationInfo><Affiliation>The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fuller</LastName><ForeName>Clifton David</ForeName><Initials>CD</Initials><Identifier Source="ORCID">0000-0002-5264-3994</Identifier><AffiliationInfo><Affiliation>The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xinhua</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>The University of Illinois Chicago, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marai</LastName><ForeName>G Elisabeta</ForeName><Initials>GE</Initials><AffiliationInfo><Affiliation>The University of Illinois Chicago, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Canahuate</LastName><ForeName>Guadalupe M</ForeName><Initials>GM</Initials><Identifier Source="ORCID">0000-0001-5873-5454</Identifier><AffiliationInfo><Affiliation>The University of Iowa, Iowa City, IA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 CA258827</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>10</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Clin Cancer Inform</MedlineTA><NlmUniqueID>101708809</NlmUniqueID><ISSNLinking>2473-4276</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071066" MajorTopicYN="Y">Patient Reported Outcome Measures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006258" MajorTopicYN="Y">Head and Neck Neoplasms</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000098405" MajorTopicYN="N">Dimensionality Reduction</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/cci/author-center. Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments). 
<b>Clifton David Fuller</b>
. <b>Employment:</b> MD Anderson Cancer Center. <b>Honoraria:</b> Elekta, Varian Medical Systems/Siemens Healthineers. <b>Research Funding:</b> Elekta (Inst), RaySearch Laboratories (Inst), Oncospace (Inst). <b>Patents, Royalties, Other Intellectual Property:</b> USPTO 11730561&#x2014;Apparatus and methods for three-dimensional printed oral stents for head and neck radiotherapy [licensed to Kallisio Inc] (Inst). <b>Travel, Accommodations, Expenses:</b> Elekta, Philips Healthcare, Siemens Medical Solutions USA, Inc. <b>Other Relationship:</b> NRG Oncology. <b>Uncompensated Relationships:</b> Philips/Elekta. <b>Open Payments Link:</b>
https://openpaymentsdata.cms.gov/physician/444063. 
<b>G. Elisabeta Marai</b>
. <b>Patents, Royalties, Other Intellectual Property:</b> Patent licensed to C-Motion Inc. No other potential conflicts of interest were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>10</Month><Day>15</Day><Hour>18</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>10</Month><Day>15</Day><Hour>18</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>10</Month><Day>15</Day><Hour>16</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>10</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41092280</ArticleId><ArticleId IdType="pmc">PMC12529990</ArticleId><ArticleId IdType="doi">10.1200/CCI-25-00069</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>National Cancer Institute : Dictionary of cancer terms: Progression-free survival. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/progression-free-survival</Citation></Reference><Reference><Citation>Chow LQM: Head and neck cancer. N Engl J Med 382:60-72, 2020</Citation><ArticleIdList><ArticleId IdType="pubmed">31893516</ArticleId></ArticleIdList></Reference><Reference><Citation>American Association for Cancer Research (AACR) : Head and Neck Cancers, 2024. https://www.aacr.org/patients-caregivers/cancer/head-and-neck-cancers/</Citation></Reference><Reference><Citation>National Cancer Institute : Dictionary of cancer terms: Overall survival. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/overall-survival</Citation></Reference><Reference><Citation>Mohamed AN, Wahid KA, Mohamed ASR, et al. : Progression free survival prediction for head and neck cancer using deep learning based on clinical and PET/CT imaging data, in 3D Head and Neck Tumor Segmentation in PET/CT Challenge. Cham, Switzerland, Springer International, 2021, pp 287-299</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8991450</ArticleId><ArticleId IdType="pubmed">35399868</ArticleId></ArticleIdList></Reference><Reference><Citation>Korn RL, Crowley JJ: Overview: Progression-free survival as an endpoint in clinical trials with solid tumors. Clin Cancer Res 19:2607-2612, 2013</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3654394</ArticleId><ArticleId IdType="pubmed">23669420</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganesan P, Sekaran S, Ramasamy P, et al. : Systematic analysis of chemotherapy, immunotherapy, and combination therapy in Head and Neck Squamous Cell Carcinoma (HNSCC) clinical trials: Focusing on overall survival and progression-free survival outcomes. Oral Oncol Rep 12:100673, 2024</Citation></Reference><Reference><Citation>Anyimadu EA, Wang Y, Floricel C, et al. : Pro-based stratification improves model prediction for toxicity and survival of head and neck cancer patients. IEEE J Biomed Health Inform 29:807-814, 2025</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11970995</ArticleId><ArticleId IdType="pubmed">40030567</ArticleId></ArticleIdList></Reference><Reference><Citation>Canahuate G, Wentzel A, Mohamed ASR, et al. : Spatially-aware clustering improves AJCC-8 risk stratification performance in oropharyngeal carcinomas. Oral Oncol 144:106460, 2023</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10561377</ArticleId><ArticleId IdType="pubmed">37390759</ArticleId></ArticleIdList></Reference><Reference><Citation>Marai GE, Ma C, Burks AT, et al. : Precision risk analysis of cancer therapy with interactive nomograms and survival plots. IEEE Trans Vis Comput Graph 25:1732-1745, 2019</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6148410</ArticleId><ArticleId IdType="pubmed">29994094</ArticleId></ArticleIdList></Reference><Reference><Citation>Dormann CF, Elith J, Bacher S, et al. : Collinearity: A review of methods to deal with it and a simulation study evaluating their performance. Ecography 36:27-46, 2013</Citation></Reference><Reference><Citation>Witten DM, Tibshirani R: Survival analysis with high-dimensional covariates. Stat Methods Med Res 19:29-51, 2010</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4806549</ArticleId><ArticleId IdType="pubmed">19654171</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Yao H, Zhao S: Auto-encoder based dimensionality reduction. Neurocomputing 184:232-242, 2016</Citation></Reference><Reference><Citation>Wang Y, Van Dijk L, Mohamed ASR, et al. : Improving prediction of late symptoms using LSTM and patient-reported outcomes for head and neck cancer patients, in 2023 IEEE 11th International Conference on Healthcare Informatics (ICHI), Houston, TX, IEEE, 2023, pp 292-300</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10853990</ArticleId><ArticleId IdType="pubmed">38343586</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Q, Mendoza TR, Gunn GB, et al. : Using group-based trajectory modeling to examine heterogeneity of symptom burden in patients with head and neck cancer undergoing aggressive non-surgical therapy. Qual Life Res 22:2331-2339, 2013</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3718875</ArticleId><ArticleId IdType="pubmed">23475689</ArticleId></ArticleIdList></Reference><Reference><Citation>Franco EF, Rana P, Cruz A, et al. : Performance comparison of deep learning autoencoders for cancer subtype detection using multi-omics data. Cancers 13:2013, 2021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8122584</ArticleId><ArticleId IdType="pubmed">33921978</ArticleId></ArticleIdList></Reference><Reference><Citation>Anzai Y, Minoshima S, Wolf GT, et al. : Head and neck cancer: Detection of recurrence with three-dimensional principal components analysis at dynamic FDG PET. Radiology 212:285-290, 1999</Citation><ArticleIdList><ArticleId IdType="pubmed">10405755</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrugia M, Yu H, Ma SJ, et al. : A principal component of quality of life measures is associated with survival for head and neck cancer patients treated with radiation therapy. Cancers 13:1155, 2021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7962523</ArticleId><ArticleId IdType="pubmed">33800256</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson LA, Biersack M, Lockwood G, et al. : Use of principal component analysis to evaluate the partial organ tolerance of normal tissues to radiation. Int J Radiat Oncol Biol Phys 62:829-837, 2005</Citation><ArticleIdList><ArticleId IdType="pubmed">15936567</ArticleId></ArticleIdList></Reference><Reference><Citation>Linting M, Meulman JJ, Groenen PJF, et al. : Nonlinear principal components analysis: Introduction and application. Psychol Methods 12:336-358, 2007</Citation><ArticleIdList><ArticleId IdType="pubmed">17784798</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabir MF, Chen T, Ludwig SA: A performance analysis of dimensionality reduction algorithms in machine learning models for cancer prediction. Healthc Anal 3:100125, 2023</Citation></Reference><Reference><Citation>Zhou Z, Wang K, Folkert M, et al. : Multifaceted radiomics for distant metastasis prediction in head &amp; neck cancer. Phys Med Biol 65:155009, 2020</Citation><ArticleIdList><ArticleId IdType="pubmed">32294632</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong N, Gou S, Yang S, et al. : Fully automatic multi-organ segmentation for head and neck cancer radiotherapy using shape representation model constrained fully convolutional neural networks. Med Phys 45:4558-4567, 2018</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6181786</ArticleId><ArticleId IdType="pubmed">30136285</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh D, Singh B: Investigating the impact of data normalization on classification performance. Appl Soft Comput 97:105524, 2020</Citation></Reference><Reference><Citation>Weber GM, Adams WG, Bernstam EV, et al. : Biases introduced by filtering electronic health records for patients with &#x201c;complete data.&#x201d; J Am Med Inform Assoc 24:1134-1141, 2017</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6080680</ArticleId><ArticleId IdType="pubmed">29016972</ArticleId></ArticleIdList></Reference><Reference><Citation>Anyimadu EA, Fuller CD, Zhang X, et al. : Collaborative filtering for the imputation of patient reported outcomes, in Strauss C, Amagasa T, Manco G, et al. (eds): Database and Expert Systems Applications. Lecture Notes in Computer Science, Volume 14910. Cham, Springer, 2024</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11503500</ArticleId><ArticleId IdType="pubmed">39463781</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Canahuate GM, Van Dijk LV, et al. : Predicting late symptoms of head and neck cancer treatment using LSTM and patient reported outcomes, in Proceedings of the 25th International Database Engineering &amp; Applications Symposium (IDEAS '21). New York, NY, Association for Computing Machinery, 2021, pp 273-279</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8982996</ArticleId><ArticleId IdType="pubmed">35392138</ArticleId></ArticleIdList></Reference><Reference><Citation>Salem N, Hussein S: Data dimensional reduction and principal components analysis. Procedia Comput Sci 163:292-299, 2019</Citation></Reference><Reference><Citation>Santurkar S, Tsipras D, Ilyas A, et al. : How does batch normalization help optimization? Adv Neural Inf Process Syst 31, 2018</Citation></Reference><Reference><Citation>Hodson TO: Root-mean-square error (RMSE) or mean absolute error (MAE): When to use them or not. Geosci Model Dev 15:5481-5487, 2022</Citation></Reference><Reference><Citation>Chipman HA, Gu H: Interpretable dimension reduction. J Appl Stat 32:969-987, 2005</Citation></Reference><Reference><Citation>Steck H, Krishnapuram B, Dehing-Oberije C, et al. : On ranking in survival analysis: Bounds on the concordance index. Adv Neural Inf Process Syst 20, 2007</Citation></Reference><Reference><Citation>Pickett KL, Suresh K, Campbell KR, et al. : Random survival forests for dynamic predictions of a time-to-event outcome using a longitudinal biomarker. BMC Med Res Methodol 21:216-14, 2021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8520610</ArticleId><ArticleId IdType="pubmed">34657597</ArticleId></ArticleIdList></Reference><Reference><Citation>Putzel P, Smyth P, Yu J, et al. : Dynamic survival analysis with individualized truncated parametric distributions, in Survival Prediction-Algorithms, Challenges and Applications. Proceedings of Machine Learning Research, 2021, pp 159-170</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8969882</ArticleId><ArticleId IdType="pubmed">35372850</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/CCI-25-00144 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">41118606</PMID><DateCompleted><Year>2025</Year><Month>10</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2473-4276</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><PubDate><Year>2025</Year><Month>Oct</Month></PubDate></JournalIssue><Title>JCO clinical cancer informatics</Title><ISOAbbreviation>JCO Clin Cancer Inform</ISOAbbreviation></Journal><ArticleTitle>Tumor Site-Specific Radiation-Induced Lymphocyte Depletion Models After Fractionated Radiotherapy: Considerations of Model Structure From an Aggregate Data Meta-Analysis.</ArticleTitle><Pagination><StartPage>e2500144</StartPage><MedlinePgn>e2500144</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/CCI-25-00144</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Radiotherapy can have an impact on the immune system through lymphocyte depletion. In particular, it can influence tumor control. Accurately predicting radiation-induced lymphopenia (RIL) is key to optimizing treatment strategies. We aimed to evaluate mathematical model structures capable of capturing the kinetics of lymphocyte concentrations after irradiation, with attention to the saturation effect observed during fractionated radiotherapy.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">A meta-analysis of aggregate data from patients with solid tumor treated with specific radiation doses was conducted. We extracted patient and treatment characteristics, lymphocyte counts, including tumor type/location, radiation modality (X-rays <i>v</i> protons), and baseline counts. Various models-including exponential, extended exponential, exponential-quadratic, and saturation models-were tested for their ability to predict lymphocyte kinetics.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Data from 29 studies covering brain, nasopharyngeal, oropharyngeal, esophageal, non-small cell lung, hepatocarcinoma, cervical, pancreatic, rectal cancers, and soft tissue sarcoma were analyzed. Lymphocyte depletion rates varied, with cervical cancer showing the highest reduction, followed by esophageal, hepatocarcinoma, and others. Lymphocyte recovery post-treatment depended heavily on baseline counts and time since radiotherapy completion. Saturation models best fit most cancer types, but for head and neck/central nervous system cancer without nodal involvement, the exponential-quadratic model performed better, reflecting a unique early lymphocyte increase before RIL.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In conclusion, the choice of lymphocyte depletion model should align with cancer type and location. Standardized prospective studies are needed to refine models and enhance radiotherapy strategies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pham</LastName><ForeName>Thao-Nguyen</ForeName><Initials>TN</Initials><Identifier Source="ORCID">0009-0003-9342-6464</Identifier><AffiliationInfo><Affiliation>Universit&#xe9; de Caen Normandie, CNRS, Normandie Universit&#xe9;, ISTCT UMR6030, GIP CYCERON, Caen, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratoire de Physique Corpusculaire UMR6534 IN2P3/ENSICAEN, France-Normandie Universit&#xe9;, Caen, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiation Oncology, Centre Fran&#xe7;ois Baclesse, Caen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coupey</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Universit&#xe9; de Caen Normandie, CNRS, Normandie Universit&#xe9;, ISTCT UMR6030, GIP CYCERON, Caen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valable</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-0355-0270</Identifier><AffiliationInfo><Affiliation>Universit&#xe9; de Caen Normandie, CNRS, Normandie Universit&#xe9;, ISTCT UMR6030, GIP CYCERON, Caen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thariat</LastName><ForeName>Juliette</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-4755-496X</Identifier><AffiliationInfo><Affiliation>Laboratoire de Physique Corpusculaire UMR6534 IN2P3/ENSICAEN, France-Normandie Universit&#xe9;, Caen, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiation Oncology, Centre Fran&#xe7;ois Baclesse, Caen, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>10</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Clin Cancer Inform</MedlineTA><NlmUniqueID>101708809</NlmUniqueID><ISSNLinking>2473-4276</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName><QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019583" MajorTopicYN="N">Dose Fractionation, Radiation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008231" MajorTopicYN="Y">Lymphopenia</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008214" MajorTopicYN="Y">Lymphocytes</DescriptorName><QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018655" MajorTopicYN="N">Lymphocyte Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011832" MajorTopicYN="Y">Radiation Injuries</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008962" MajorTopicYN="N">Models, Theoretical</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>10</Month><Day>21</Day><Hour>18</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>10</Month><Day>21</Day><Hour>18</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>10</Month><Day>21</Day><Hour>16</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41118606</ArticleId><ArticleId IdType="doi">10.1200/CCI-25-00144</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/CCI-25-00220 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">41237352</PMID><DateCompleted><Year>2025</Year><Month>11</Month><Day>14</Day></DateCompleted><DateRevised><Year>2025</Year><Month>11</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2473-4276</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><PubDate><Year>2025</Year><Month>Nov</Month></PubDate></JournalIssue><Title>JCO clinical cancer informatics</Title><ISOAbbreviation>JCO Clin Cancer Inform</ISOAbbreviation></Journal><ArticleTitle>RadOncRAG: A Novel Retrieval-Augmented Generation Framework Improves Large Language Model Benchmark Performance in Radiation Oncology.</ArticleTitle><Pagination><StartPage>e2500220</StartPage><MedlinePgn>e2500220</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/CCI-25-00220</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Large language models (LLMs) show promise in assisting knowledge-intensive fields such as oncology, where up-to-date information and multidisciplinary expertise are critical. Traditional LLMs risk hallucinations and reliance on static, possibly outdated data that lack domain-specific context. Retrieval-augmented generation (RAG) has emerged as a strategy to address these issues by incorporating domain-specific information from external knowledge repositories.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We evaluated 15 LLMs, including Meta Llama-2/3, generative pretrained transformer (GPT)-3.5/4/4o variants, Claude-3, Gemini-2.0, and DeepSeek-R1. In a zero-shot workflow, each LLM answered 298 scorable questions from the 2021 American College of Radiology in-training examination. We implemented a RAG pipeline (Iridium Model) that transforms user prompts into vector embeddings, queries a specialized radiation oncology database, and merges relevant text with the original prompt to form an augmented query. We compared zero-shot versus RAG-augmented performance.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Larger-parameter LLMs had higher zero-shot accuracy, with six models outscoring graduating residents (<i>P</i> &lt; .01). Top scorers were reasoning models GPT-4o1, o3-mini, and DeepSeek-R1, which achieved 91.6%, 86.6%, and 91.6% without RAG, respectively. Gemini-2.0 improved 6.7% (to 79.2%), Llama-3-70b 8.4% (to 75.8%), and GPT-4o 5.7% (to 85.6%) with RAG. Top scoring reasoning models surpassed graduating resident averages by 17.7%-20% (<i>P</i> &lt; .01), but had no improvement or detriment with RAG. Domain-specific gains occurred in clinical, biology, and physics. Majority voting boosted aggregate accuracy when individual model performance exceeded 50%. RAG workflows and reasoning models incurred higher computational costs.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Radiation-oncology-specific retrieval-augmented generation pipeline enhances nonreasoning LLM performance in radiation oncology by integrating domain-specific evidence, whereas it does not improve performance of reasoning models. These findings demonstrate that RAG can elevate clinical decision support by enabling simpler, cost-effective nonreasoning models to tackle complex tasks through retrieval capabilities-an efficient alternative to extensive model training that also yields citable, evidence-based explanations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thaker</LastName><ForeName>Nikhil Gautam</ForeName><Initials>NG</Initials><Identifier Source="ORCID">0000-0003-3608-0025</Identifier><AffiliationInfo><Affiliation>Capital Health, Pennington, NJ.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bayta Systems, Newtown, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Redjal</LastName><ForeName>Navid</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-0951-2195</Identifier><AffiliationInfo><Affiliation>Capital Health, Pennington, NJ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dicker</LastName><ForeName>Adam</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-0733-3337</Identifier><AffiliationInfo><Affiliation>Thomas Jefferson, Philadelphia, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loaiza-Bonilla</LastName><ForeName>Arturo</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-3655-9602</Identifier><AffiliationInfo><Affiliation>St Luke's University Health Network, Easton, PA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Massive Bio, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Royce</LastName><ForeName>Trevor</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-9879-1290</Identifier><AffiliationInfo><Affiliation>Atrium Health Wake Forest Baptist, Winston Salem, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Subbiah</LastName><ForeName>Vivek</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-6064-6837</Identifier><AffiliationInfo><Affiliation>Sarah Cannon Research Institute, Nashville, TN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deendyal</LastName><ForeName>Vikash</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Capital Health, Pennington, NJ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gabriel</LastName><ForeName>Jonathan R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>University of Arizona, Tucson, AZ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shetty</LastName><ForeName>Neena</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Capital Health, Pennington, NJ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choudhri</LastName><ForeName>Ajay</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Capital Health, Pennington, NJ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thaker</LastName><ForeName>Gautam H</ForeName><Initials>GH</Initials><AffiliationInfo><Affiliation>Bayta Systems, Newtown, PA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>11</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Clin Cancer Inform</MedlineTA><NlmUniqueID>101708809</NlmUniqueID><ISSNLinking>2473-4276</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018787" MajorTopicYN="Y">Radiation Oncology</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019985" MajorTopicYN="Y">Benchmarking</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName><QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016247" MajorTopicYN="Y">Information Storage and Retrieval</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000098342" MajorTopicYN="N">Large Language Models</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>11</Month><Day>14</Day><Hour>18</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>11</Month><Day>14</Day><Hour>18</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>11</Month><Day>14</Day><Hour>16</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41237352</ArticleId><ArticleId IdType="doi">10.1200/CCI-25-00220</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/CCI-25-00108 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">41086385</PMID><DateCompleted><Year>2025</Year><Month>10</Month><Day>14</Day></DateCompleted><DateRevised><Year>2025</Year><Month>10</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2473-4276</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><PubDate><Year>2025</Year><Month>Oct</Month></PubDate></JournalIssue><Title>JCO clinical cancer informatics</Title><ISOAbbreviation>JCO Clin Cancer Inform</ISOAbbreviation></Journal><ArticleTitle>Large Language Models for Translational Cancer Informatics.</ArticleTitle><Pagination><StartPage>e2500108</StartPage><MedlinePgn>e2500108</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/CCI-25-00108</ELocationID><Abstract><AbstractText Label="PURPOSE">Cancer remains a leading cause of death worldwide. The growing volume of high-throughput single-cell and spatial transcriptomic data sets-particularly those related to cancer-offers immense opportunities as well as analytical challenges for effective data analysis and interpretation. Large language models (LLMs), pretrained on vast data sets and capable of various biomedical tasks, offer a promising solution. This review explores the application of LLMs in cancer research from both cellular and pathologic perspectives, aiming to showcase their potential in advancing precision oncology.</AbstractText><AbstractText Label="MATERIALS AND METHODS">We systematically review current LLMs in analyzing single-cell RNA sequencing, spatial transcriptomic, and histology image data, emphasizing their relevance to cancer biology and translational research.</AbstractText><AbstractText Label="RESULTS">A total of 24 LLMs, published or in preprint between 2022 and 2025, were selected for review. In single-cell transcriptomics, LLMs have primarily been used for cell type annotation, batch integration, and drug-response prediction. In spatial transcriptomics, LLMs support multislide and multimodal spatial data integration, gene expression imputation, niche and region label prediction, spatial domain identification, cell-cell communication inference, and marker gene detection. In computational pathology, LLMs have been applied to cancer subtyping, detection of rare malignancies, genomic mutation prediction, image segmentation, as well as cross-modal retrieval. Despite these advances, many models remain underoptimized for cancer-specific applications, highlighting the need for domain-specific fine-tuning and scalable adaptation strategies.</AbstractText><AbstractText Label="CONCLUSION">LLMs have the potential to significantly advance cancer research by providing scalable and effective tools for analyzing and interpreting single-cell, spatial transcriptomic, and pathology data. Future efforts should prioritize tailoring these models to cancer-specific contexts to enhance their utility in uncovering disease mechanisms, identifying biomarkers, and informing therapeutic strategies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Yining</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Health Outcomes and Biomedical Informatics, College of Medicine, University of Florida, Gainesville, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yanfei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Health Outcomes and Biomedical Informatics, College of Medicine, University of Florida, Gainesville, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Guangyu</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-4803-7200</Identifier><AffiliationInfo><Affiliation>Center for Bioinformatics and Computational Biology, Houston Methodist Research Institute, Houston, TX.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Weill Cornell Medicine, Cornell University, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Jing</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-4917-6173</Identifier><AffiliationInfo><Affiliation>Department of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis, IN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Topaloglu</LastName><ForeName>Umit</ForeName><Initials>U</Initials><Identifier Source="ORCID">0000-0002-3241-8773</Identifier><AffiliationInfo><Affiliation>Center for Biomedical Informatics and Information Technology, National Cancer Institute, Rockville MD</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Qianqian</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0002-4455-5302</Identifier><AffiliationInfo><Affiliation>Department of Health Outcomes and Biomedical Informatics, College of Medicine, University of Florida, Gainesville, FL.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>10</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Clin Cancer Inform</MedlineTA><NlmUniqueID>101708809</NlmUniqueID><ISSNLinking>2473-4276</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057170" MajorTopicYN="Y">Translational Research, Biomedical</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059010" MajorTopicYN="N">Single-Cell Analysis</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019295" MajorTopicYN="Y">Computational Biology</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000098342" MajorTopicYN="N">Large Language Models</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>10</Month><Day>14</Day><Hour>18</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>10</Month><Day>14</Day><Hour>18</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>10</Month><Day>14</Day><Hour>16</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41086385</ArticleId><ArticleId IdType="doi">10.1200/CCI-25-00108</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/PO-24-00741 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39869839</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>03</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2473-4284</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><PubDate><Year>2025</Year><Month>Jan</Month></PubDate></JournalIssue><Title>JCO precision oncology</Title><ISOAbbreviation>JCO Precis Oncol</ISOAbbreviation></Journal><ArticleTitle>Correlates of Cetuximab Efficacy in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma Previously Treated With Immunotherapy.</ArticleTitle><Pagination><StartPage>e2400741</StartPage><MedlinePgn>e2400741</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/PO-24-00741</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Immune checkpoint inhibitors (ICIs) are now first-line therapy for most patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC), and cetuximab is most often used as subsequent therapy. However, data describing cetuximab efficacy in the post-ICI setting are limited.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We performed a single-institution retrospective analysis of patients with R/M HNSCC treated with cetuximab, either as monotherapy or in combination with chemotherapy, after receiving an ICI. We extracted objective response rate (ORR), duration of treatment (DOT), and overall survival (OS) and compared them on the basis of patient characteristics. Multivariable models assessed associations between patient and tumor characteristics and outcomes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We identified 70 patients treated with cetuximab after an ICI. The mean age was 67.6 years, with 60% having virus-associated HNSCC. Overall, the ORR was 21.4%, the median DOT was 1.9 months, and the median OS was 6.3 months. Patients receiving cetuximab with chemotherapy had a higher ORR (27.7% <i>v</i> 8.7%) and longer median DOT but similar OS compared with monotherapy. Virus-independent HNSCC had higher ORR (28.6% <i>v</i> 10.7%), longer DOT (3.3 <i>v</i> 1.2 months; hazard ratio [HR], 0.47 [95% CI, 0.25 to 0.90]), and longer OS (8.1 <i>v</i> 4.6 months; HR, 0.40 [95% CI, 0.19 to 0.83]). In multivariable models, virus-independent disease and negative smoking history were associated with improved OS. Concurrent chemotherapy, age, and sex were not associated with differences in OS. When assessing genomic data, <i>TP53</i> mutations were associated with improved DOT (HR, 0.33 [95% CI, 0.15 to 0.70]) and OS (HR, 0.38 [95% CI, 0.17 to 0.86]).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Cetuximab-based therapy shows limited efficacy in R/M HNSCC post-ICI, although outcomes were better in virus-independent HNSCC and nonsmokers. The findings may improve prognostication and patient selection for cetuximab after ICI in R/M HNSCC.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Jong Chul</ForeName><Initials>JC</Initials><Identifier Source="ORCID">0000-0002-1052-0734</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Massachusetts General Hospital, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahn</LastName><ForeName>Jong Seok</ForeName><Initials>JS</Initials><Identifier Source="ORCID">0000-0003-1189-5981</Identifier><AffiliationInfo><Affiliation>Department of Medical Affairs, Lunit, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merkin</LastName><ForeName>Ross</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-3418-2220</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Massachusetts General Hospital, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Manisha</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine, Massachusetts General Hospital, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wirth</LastName><ForeName>Lori</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-2629-2289</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Massachusetts General Hospital, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roberts</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials><Identifier Source="ORCID">0000-0003-0709-2270</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Massachusetts General Hospital, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>01</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Precis Oncol</MedlineTA><NlmUniqueID>101705370</NlmUniqueID><ISSNLinking>2473-4284</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>PQX0D8J21J</RegistryNumber><NameOfSubstance UI="D000068818">Cetuximab</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000074322">Antineoplastic Agents, Immunological</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068818" MajorTopicYN="Y">Cetuximab</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077195" MajorTopicYN="Y">Squamous Cell Carcinoma of Head and Neck</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006258" MajorTopicYN="Y">Head and Neck Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009364" MajorTopicYN="Y">Neoplasm Recurrence, Local</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007167" MajorTopicYN="Y">Immunotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000074322" MajorTopicYN="Y">Antineoplastic Agents, Immunological</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000082082" MajorTopicYN="Y">Immune Checkpoint Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>1</Month><Day>27</Day><Hour>18</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>1</Month><Day>27</Day><Hour>18</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>1</Month><Day>27</Day><Hour>16</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39869839</ArticleId><ArticleId IdType="doi">10.1200/PO-24-00741</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/PO-25-00067 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">40570261</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2473-4284</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><PubDate><Year>2025</Year><Month>Jun</Month></PubDate></JournalIssue><Title>JCO precision oncology</Title><ISOAbbreviation>JCO Precis Oncol</ISOAbbreviation></Journal><ArticleTitle>Circulating Tumor DNA as a Biomarker for Disease Surveillance in Anaplastic Thyroid Cancer.</ArticleTitle><Pagination><StartPage>e2500067</StartPage><MedlinePgn>e2500067</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/PO-25-00067</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Anaplastic thyroid cancer (ATC) is a highly lethal malignancy in which early detection of progression could allow timely treatment modifications and potentially improve outcomes. Novel circulating tumor DNA (ctDNA) assays allow the detection of molecular residual disease. We aimed to investigate the utility of ctDNA as a biomarker in ATC.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Retrospective cohort study of patients with ATC and at least one ctDNA drawn before systemic therapy start (referred to as baseline) between February 2021 and August 2024. ctDNA was correlated with concomitant imaging and/or pathologic results. Patients with &#x2265;1 additional ctDNA on systemic therapy were included in a secondary analysis to evaluate the detection of ctDNA as a molecular evidence of disease recurrence/progression. These patients were divided into two subgroups: recurrence detection after curative-intent therapy (group 1) or treatment response monitoring if known residual disease (group 2).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Forty-five patients met the inclusion criteria. At baseline, ctDNA result correlated with disease status in 93% of patients (75% true positives, 18% true negatives, 7% false negatives [FNs], 0% false positive). Thirty-one patients had &#x2265;1 follow-up ctDNA on systemic therapy, with a total of 130 evaluable results. In group 1(n = 60), ctDNA had 77% sensitivity, 100% specificity, 92% negative predictive value (NPV), and 100% positive predictive value (PPV). In group 2 (n = 70), ctDNA had 78% sensitivity, 100% specificity, 84% NPV, and 100% PPV. Potential reasons for FN ctDNA included low tumor burden, lung-only/brain-only metastatic disease, and heterogeneous molecular profiles in ATC.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">ctDNA is a promising tumor biomarker for disease monitoring in ATC, with a high specificity and PPV. It should be considered in addition to standard-of-care surveillance methods to better inform treatment decision making.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hamidi</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-1528-9885</Identifier><AffiliationInfo><Affiliation>Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dadu</LastName><ForeName>Ramona</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iyer</LastName><ForeName>Priyanka C</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Busaidy</LastName><ForeName>Naifa L</ForeName><Initials>NL</Initials><Identifier Source="ORCID">0000-0002-3808-6378</Identifier><AffiliationInfo><Affiliation>Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maniakas</LastName><ForeName>Anastasios</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4354-2841</Identifier><AffiliationInfo><Affiliation>Department of Head &amp; Neck Surgery, The University of Texas MD Anderson Cancer, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jennifer R</ForeName><Initials>JR</Initials><Identifier Source="ORCID">0000-0002-0807-3832</Identifier><AffiliationInfo><Affiliation>Department of Head &amp; Neck Surgery, The University of Texas MD Anderson Cancer, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banuchi</LastName><ForeName>Victoria E</ForeName><Initials>VE</Initials><AffiliationInfo><Affiliation>Department of Head &amp; Neck Surgery, The University of Texas MD Anderson Cancer, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hosseini</LastName><ForeName>S Mohsen</ForeName><Initials>SM</Initials><Identifier Source="ORCID">0000-0003-3626-9928</Identifier><AffiliationInfo><Affiliation>Department of Anatomical Pathology, The University of Texas MD Anderson Cancer, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Michelle D</ForeName><Initials>MD</Initials><Identifier Source="ORCID">0000-0002-9133-7332</Identifier><AffiliationInfo><Affiliation>Department of Anatomical Pathology, The University of Texas MD Anderson Cancer, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zafereo</LastName><ForeName>Mark E</ForeName><Initials>ME</Initials><Identifier Source="ORCID">0000-0001-7918-9739</Identifier><AffiliationInfo><Affiliation>Department of Head &amp; Neck Surgery, The University of Texas MD Anderson Cancer, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cabanillas</LastName><ForeName>Maria E</ForeName><Initials>ME</Initials><Identifier Source="ORCID">0000-0002-5124-1811</Identifier><AffiliationInfo><Affiliation>Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer, Houston, TX.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Precis Oncol</MedlineTA><NlmUniqueID>101705370</NlmUniqueID><ISSNLinking>2473-4284</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000074141">Circulating Tumor DNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000074141" MajorTopicYN="Y">Circulating Tumor DNA</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055088" MajorTopicYN="N">Early Detection of Cancer</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009364" MajorTopicYN="Y">Neoplasm Recurrence, Local</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065646" MajorTopicYN="Y">Thyroid Carcinoma, Anaplastic</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013964" MajorTopicYN="Y">Thyroid Neoplasms</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>26</Day><Hour>18</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>26</Day><Hour>18</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>26</Day><Hour>16</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40570261</ArticleId><ArticleId IdType="doi">10.1200/PO-25-00067</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/PO-25-00490 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">41166678</PMID><DateCompleted><Year>2025</Year><Month>10</Month><Day>30</Day></DateCompleted><DateRevised><Year>2025</Year><Month>11</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2473-4284</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><PubDate><Year>2025</Year><Month>Oct</Month></PubDate></JournalIssue><Title>JCO precision oncology</Title><ISOAbbreviation>JCO Precis Oncol</ISOAbbreviation></Journal><ArticleTitle>Clinical Utility of Whole-Genome Sequencing to Aid Histologic Diagnosis and to Direct Personalized Medicine in Salivary Gland Cancer.</ArticleTitle><Pagination><StartPage>e2500490</StartPage><MedlinePgn>e2500490</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2500490</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1200/PO-25-00490</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Salivary gland cancers (SGCs) are rare and comprise multiple histologic entities. In the recurrent or metastatic (R/M) setting, there is limited evidence for effective systemic anticancer treatment for most subtypes, affecting prognosis and quality of life. Molecular analysis of SGCs holds promise to more accurately classify SGC subtypes and to determine novel therapeutic targets.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Fifteen patients with R/M SGC underwent tumor biopsy and blood sampling to perform whole-genome sequencing (WGS) of tumor and germline as part of their standard-of-care management. Small somatic mutations, structural alterations, copy number variation, and mutational signatures were processed using WGS pipelines alongside germline testing. Alterations were correlated to clinical features and fed back to clinical team to inform treatment decisions.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">WGS quality control was acceptable in 14 of 15 patients (adenoid cystic carcinoma [AdCC, n = 10], salivary duct carcinoma ex pleomorphic adenoma [n = 1]; clear cell myoepithelial carcinoma [n = 1]; epithelial-myoepithelial carcinoma [n = 1]; and acinic cell carcinoma [n = 1]). Genomic rearrangements/fusions were present in 12 of 14. Rearrangements involving MYB and or NFIB were identified in 8 of 10 patients with AdCC. One patient harbored a clinically actionable <i>FGFR1</i>-<i>pleomorphic adenoma gene 1</i> fusion and responded to fibroblast growth factor receptor-targeted therapy, in addition to enabling histologic reclassification. Other fusions included <i>EWSR1</i>-<i>ATF1</i> and <i>CRTC1</i>-<i>MAML2</i>, which also aided definitive histologic classification. Small somatic alterations were identified in all but one patient. There were no pathogenic germline mutations.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">WGS in SGC is achievable in clinically relevant timeframes, providing genomic information for deeper understanding of disease pathophysiology, to clarify histologic subtype and can identify actionable genomic targets which may not be found through routine sequencing technologies. Further use of WGS has the potential to improve care for patients with SGC.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Church</LastName><ForeName>Matt</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-5825-3241</Identifier><AffiliationInfo><Affiliation>The Christie NHS Foundation Trust, Manchester, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The University of Manchester, Manchester, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burghel</LastName><ForeName>George</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-9360-8194</Identifier><AffiliationInfo><Affiliation>The University of Manchester, Manchester, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Manchester University NHS Foundation Trust, Manchester, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Betts</LastName><ForeName>Guy</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Manchester University NHS Foundation Trust, Manchester, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Churchill</LastName><ForeName>Steven Michael</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>The Christie NHS Foundation Trust, Manchester, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schlecht</LastName><ForeName>Helene Barbara</ForeName><Initials>HB</Initials><AffiliationInfo><Affiliation>Manchester University NHS Foundation Trust, Manchester, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jain</LastName><ForeName>Yatin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>The Christie NHS Foundation Trust, Manchester, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harrington</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-6014-348X</Identifier><AffiliationInfo><Affiliation>Royal Marsden NHS Foundation Trust, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Institute of Cancer Research, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Metcalf</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>The Christie NHS Foundation Trust, Manchester, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The University of Manchester, Manchester, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>10</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Precis Oncol</MedlineTA><NlmUniqueID>101705370</NlmUniqueID><ISSNLinking>2473-4284</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057285" MajorTopicYN="Y">Precision Medicine</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012468" MajorTopicYN="Y">Salivary Gland Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073336" MajorTopicYN="Y">Whole Genome Sequencing</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center. Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>10</Month><Day>30</Day><Hour>18</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>10</Month><Day>30</Day><Hour>18</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>10</Month><Day>30</Day><Hour>16</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>10</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41166678</ArticleId><ArticleId IdType="pmc">PMC12591553</ArticleId><ArticleId IdType="doi">10.1200/PO-25-00490</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ettl T, Schwarz-Furlan S, Gosau M, et al. Salivary gland carcinomas. Oral Maxillofac Surg. 2012;16:267&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pubmed">22842859</ArticleId></ArticleIdList></Reference><Reference><Citation>Sk&#xe1;lov&#xe1; A, Hyrcza MD, Leivo I. Update from the 5th edition of the World Health Organization classification of head and neck tumors: Salivary glands. Head Neck Pathol. 2022;16:40&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9018948</ArticleId><ArticleId IdType="pubmed">35312980</ArticleId></ArticleIdList></Reference><Reference><Citation>Sk&#xe1;lov&#xe1; A, Vanecek T, Sima R, et al. Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: A hitherto undescribed salivary gland tumor entity. Am J Surg Pathol. 2010;34:599&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pubmed">20410810</ArticleId></ArticleIdList></Reference><Reference><Citation>van Herpen C, Vander Poorten V, Skalova A, et al. Salivary gland cancer: ESMO&#x2013;European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up. ESMO Open. 2022;7:100602.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9808465</ArticleId><ArticleId IdType="pubmed">36567082</ArticleId></ArticleIdList></Reference><Reference><Citation>Valstar MH, Van Den Brekel MWM, Smeele LE. Interpretation of treatment outcome in the clinically node-negative neck in primary parotid carcinoma: A systematic review of the literature. Head Neck. 2010;32:1402&#x2013;1411.</Citation><ArticleIdList><ArticleId IdType="pubmed">20029981</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau VH, Aouad R, Farwell DG, et al. Patterns of nodal involvement for clinically N0 salivary gland carcinoma: Refining the role of elective neck irradiation. Head Neck. 2014;36:1435&#x2013;1439.</Citation><ArticleIdList><ArticleId IdType="pubmed">24038533</ArticleId></ArticleIdList></Reference><Reference><Citation>Nam SJ, Roh JL, Cho KJ, et al. Risk factors and survival associated with distant metastasis in patients with carcinoma of the salivary gland. Ann Surg Oncol. 2016;23:4376&#x2013;4383.</Citation><ArticleIdList><ArticleId IdType="pubmed">27338749</ArticleId></ArticleIdList></Reference><Reference><Citation>Girelli L, Locati L, Galeone C, et al. Lung metastasectomy in adenoid cystic cancer: Is it worth it? Oral Oncol. 2017;65:114&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">28341276</ArticleId></ArticleIdList></Reference><Reference><Citation>Laurie SA, Siu LL, Winquist E, et al. A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer: A trial of the NCIC Clinical Trials Group. Cancer. 2010;116:362&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">19924794</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner VP, Bingle CD, Bingle L. MYB-NFIB fusion transcript in adenoid cystic carcinoma: Current state of knowledge and future directions. Crit Rev Oncol Hematol. 2022;176:103745.</Citation><ArticleIdList><ArticleId IdType="pubmed">35738530</ArticleId></ArticleIdList></Reference><Reference><Citation>Le X, Baik C, Bauman J, et al. Larotrectinib treatment for patients with TRK fusion-positive salivary gland cancers. Oncologist. 2022;29:e779&#x2013;e788.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11144979</ArticleId><ArticleId IdType="pubmed">35536733</ArticleId></ArticleIdList></Reference><Reference><Citation>Adashek JJ, Sapkota S, de Castro Luna R, et al. Complete response to alectinib in ALK-fusion metastatic salivary ductal carcinoma. NPJ Precis Oncol. 2023;7:36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10090142</ArticleId><ArticleId IdType="pubmed">37041305</ArticleId></ArticleIdList></Reference><Reference><Citation>Subbiah V, Wolf J, Konda B, et al. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): A phase 1/2, open-label, basket trial. Lancet Oncol. 2022;23:1261&#x2013;1273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11702314</ArticleId><ArticleId IdType="pubmed">36108661</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi H, Tada Y, Saotome T, et al. Phase II trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma. J Clin Oncol. 2019;37:125&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">30452336</ArticleId></ArticleIdList></Reference><Reference><Citation>Fushimi C, Tada Y, Takahashi H, et al. A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma. Ann Oncol. 2018;29:979&#x2013;984.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5913639</ArticleId><ArticleId IdType="pubmed">29211833</ArticleId></ArticleIdList></Reference><Reference><Citation>Laurie SA, Ho AL, Fury MG, et al. Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: A systematic review. Lancet Oncol. 2011;12:815&#x2013;824.</Citation><ArticleIdList><ArticleId IdType="pubmed">21147032</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodon J, Soria JC, Berger R, et al. Genomic and transcriptomic profiling expands precision cancer medicine: The WINTHER trial. Nat Med. 2019;25:751&#x2013;758.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6599610</ArticleId><ArticleId IdType="pubmed">31011205</ArticleId></ArticleIdList></Reference><Reference><Citation>Sosinsky A, Ambrose J, Cross W, et al. Insights for precision oncology from the integration of genomic and clinical data of 13,880 tumors from the 100,000 genomes Cancer Programme. Nat Med. 2024;30:279&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10803271</ArticleId><ArticleId IdType="pubmed">38200255</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagnamenta AT, Yu J, Walker S, et al. The impact of inversions across 33,924 families with rare disease from a national genome sequencing project. Am J Hum Genet. 2024;111:1140&#x2013;1164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11179413</ArticleId><ArticleId IdType="pubmed">38776926</ArticleId></ArticleIdList></Reference><Reference><Citation>Behera S, Catreux S, Rossi M, et al. Comprehensive genome analysis and variant detection at scale using DRAGEN. Nat Biotechnol. 2024;43:1177&#x2013;1191.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC12022141</ArticleId><ArticleId IdType="pubmed">39455800</ArticleId></ArticleIdList></Reference><Reference><Citation>den Dunnen JT, Dalgleish R, Maglott DR, et al. HGVS recommendations for the description of sequence variants: 2016 update. Hum Mutat. 2016;37:564&#x2013;569.</Citation><ArticleIdList><ArticleId IdType="pubmed">26931183</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrett A, Callaway A, Durkie M, et al. Cancer Variant Interpretation Group UK (CanVIG-UK): An exemplar national subspecialty multidisciplinary network. J Med Genet. 2020;57:829&#x2013;834.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7691806</ArticleId><ArticleId IdType="pubmed">32170000</ArticleId></ArticleIdList></Reference><Reference><Citation>Li MM, Datto M, Duncavage EJ, et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: A joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2017;19:4&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5707196</ArticleId><ArticleId IdType="pubmed">27993330</ArticleId></ArticleIdList></Reference><Reference><Citation>NHS England: National Genomic Test Directory. 2018. https://www.england.nhs.uk/publication/national-genomic-test-directories/</Citation></Reference><Reference><Citation>Barwell J, Snape K, Wedderburn S. The new genomic medicine service and implications for patients. Clin Med (Lond) 2019;19:273&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6752257</ArticleId><ArticleId IdType="pubmed">31308102</ArticleId></ArticleIdList></Reference><Reference><Citation>Sondka Z, Bamford S, Cole CG, et al. The COSMIC Cancer Gene Census: Describing genetic dysfunction across all human cancers. Nat Rev Cancer. 2018;18:696&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6450507</ArticleId><ArticleId IdType="pubmed">30293088</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez J, Coll J, Haimel M, et al. HGVA: The human genome variation archive. Nucleic Acids Res. 2017;45:W189&#x2013;W194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5570161</ArticleId><ArticleId IdType="pubmed">28535294</ArticleId></ArticleIdList></Reference><Reference><Citation>Suybeng V, Koeppel F, Harl&#xe9; A, et al. Comparison of pathogenicity prediction tools on somatic variants. J Mol Diagn. 2020;22:1383&#x2013;1392.</Citation><ArticleIdList><ArticleId IdType="pubmed">33011441</ArticleId></ArticleIdList></Reference><Reference><Citation>COSMIC. Signatures of Mutational Processes in Human Cancer. 2015. https://cancer.sanger.ac.uk/signatures/signatures_v2/</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3776390</ArticleId><ArticleId IdType="pubmed">23945592</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4544753</ArticleId><ArticleId IdType="pubmed">25741868</ArticleId></ArticleIdList></Reference><Reference><Citation>Kendre G, Murugesan K, Brummer T, et al. Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma. J Hepatol. 2023;78:614&#x2013;626.</Citation><ArticleIdList><ArticleId IdType="pubmed">36528236</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Zhang Y, Yin L, et al. Fibroblast growth factor receptor fusions in cancer: Opportunities and challenges. J Exp Clin Cancer Res. 2021;40:345.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8564965</ArticleId><ArticleId IdType="pubmed">34732230</ArticleId></ArticleIdList></Reference><Reference><Citation>Persson F, Winnes M, Andr&#xe9;n Y, et al. High-resolution array CGH analysis of salivary gland tumors reveals fusion and amplification of the FGFR1 and PLAG1 genes in ring chromosomes. Oncogene. 2008;27:3072&#x2013;3080.</Citation><ArticleIdList><ArticleId IdType="pubmed">18059337</ArticleId></ArticleIdList></Reference><Reference><Citation>Voz ML, Agten NS, Van de Ven WJM, et al. PLAG1, the main translocation target in pleomorphic adenoma of the salivary glands, is a positive regulator of IGF-II. Cancer Res. 2000;60:106&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pubmed">10646861</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalin MG, Katabi N, Persson M, et al. Multi-dimensional genomic analysis of myoepithelial carcinoma identifies prevalent oncogenic gene fusions. Nat Commun. 2017;8:1197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5662567</ArticleId><ArticleId IdType="pubmed">29084941</ArticleId></ArticleIdList></Reference><Reference><Citation>Subbiah V, Iannotti NO, Gutierrez M, et al. FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies. Ann Oncol. 2022;33:522&#x2013;533.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11961695</ArticleId><ArticleId IdType="pubmed">35176457</ArticleId></ArticleIdList></Reference><Reference><Citation>Meric-Bernstam F, Bahleda R, Hierro C, et al. Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF/FGFR aberrations: A phase I dose-expansion study. Cancer Discov. 2022;12:402&#x2013;415.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9762334</ArticleId><ArticleId IdType="pubmed">34551969</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson EV, Lee JJK, Gulhan DC, et al. Chromosome evolution screens recapitulate tissue-specific tumor aneuploidy patterns. Nat Genet. 2024;56:900&#x2013;912.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11096114</ArticleId><ArticleId IdType="pubmed">38388848</ArticleId></ArticleIdList></Reference><Reference><Citation>V&#xe9;kony H, R&#xf6;ser K, L&#xf6;ning T, et al. Copy number gain at 8q12.1-q22.1 is associated with a malignant tumor phenotype in salivary gland myoepitheliomas. Genes Chromosomes Cancer. 2009;48:202&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">19009612</ArticleId></ArticleIdList></Reference><Reference><Citation>Rod&#xf3;n J, Damian S, Furqan M, et al. Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: Phase 2 FIGHT-207 basket trial. Nat Med. 2024;30:1645&#x2013;1654.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11186762</ArticleId><ArticleId IdType="pubmed">38710951</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitani Y, Liu B, Rao PH, et al. Novel MYBL1 gene rearrangements with recurrent MYBL1-NFIB fusions in salivary adenoid cystic carcinomas lacking t(6;9) translocations. Clin Cancer Res. 2016;22:725&#x2013;733.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4807116</ArticleId><ArticleId IdType="pubmed">26631609</ArticleId></ArticleIdList></Reference><Reference><Citation>Karpinets TV, Mitani Y, Liu B, et al. Whole-genome sequencing of common salivary gland carcinomas: Subtype-restricted and shared genetic alterations. Clin Cancer Res. 2021;27:3960&#x2013;3969.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8598082</ArticleId><ArticleId IdType="pubmed">34011559</ArticleId></ArticleIdList></Reference><Reference><Citation>Rettig EM, Talbot CC, Sausen M, et al. Whole-genome sequencing of salivary gland adenoid cystic carcinoma. Cancer Prev Res. 2016;9:265&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4818686</ArticleId><ArticleId IdType="pubmed">26862087</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y, Song S, Lee M, et al. Integrative genomic analysis of salivary duct carcinoma. Sci Rep. 2020;10:14995.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7490354</ArticleId><ArticleId IdType="pubmed">32929114</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho AS, Kannan K, Roy DM, et al. The mutational landscape of adenoid cystic carcinoma. Nat Genet. 2013;45:791&#x2013;798.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3708595</ArticleId><ArticleId IdType="pubmed">23685749</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho AS, Ochoa A, Jayakumaran G, et al. Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma. J Clin Invest. 2019;129:4276&#x2013;4289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763222</ArticleId><ArticleId IdType="pubmed">31483290</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi K, Saito Y, Kage H, et al. CDK12 alterations and ARID1A mutations are predictors of poor prognosis and therapeutic targets in high-grade salivary gland carcinoma: Analysis of the National Genomic Profiling Database. Jpn J Clin Oncol. 2023;53:798&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pubmed">37357968</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou H, Sun D, Zhang X. The role of MDM2 amplification and overexpression in therapeutic resistance of malignant tumors. Cancer Cell Int. 2019;19:216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6704499</ArticleId><ArticleId IdType="pubmed">31440117</ArticleId></ArticleIdList></Reference><Reference><Citation>West RB, Kong C, Clarke N, et al. MYB expression and translocation in adenoid cystic carcinomas and other salivary gland tumors with clinicopathologic correlation. Am J Surg Pathol. 2011;35:92&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3127258</ArticleId><ArticleId IdType="pubmed">21164292</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu LH, Zhao F, Yang WW, et al. MYB promotes the growth and metastasis of salivary adenoid cystic carcinoma. Int J Oncol. 2019;54:1579&#x2013;1590.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6438425</ArticleId><ArticleId IdType="pubmed">30896785</ArticleId></ArticleIdList></Reference><Reference><Citation>Togashi Y, Dobashi A, Sakata S, et al. MYB and MYBL1 in adenoid cystic carcinoma: Diversity in the mode of genomic rearrangement and transcripts. Mod Pathol. 2018;31:934&#x2013;946.</Citation><ArticleIdList><ArticleId IdType="pubmed">29410490</ArticleId></ArticleIdList></Reference><Reference><Citation>Saade RE, Bell D, Garcia J, et al. Role of CRTC1/MAML2 translocation in the prognosis and clinical outcomes of mucoepidermoid carcinoma. JAMA Otolaryngol Head Neck Surg. 2016;142:234&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pubmed">26796488</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z, Ni W, Li JL, et al. The CRTC1-MAML2 fusion is the major oncogenic driver in mucoepidermoid carcinoma. JCI Insight. 2021;6:e139497.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8119194</ArticleId><ArticleId IdType="pubmed">33830080</ArticleId></ArticleIdList></Reference><Reference><Citation>Thway K, Fisher C. Tumors with EWSR1-CREB1 and EWSR1-ATF1 fusions: The current status. Am J Surg Pathol. 2012;36:e1&#x2013;e11.</Citation><ArticleIdList><ArticleId IdType="pubmed">22510762</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonescu CR, Katabi N, Zhang L, et al. EWSR1-ATF1 fusion is a novel and consistent finding in hyalinizing clear-cell carcinoma of salivary gland. Genes Chromosomes Cancer. 2011;50:559&#x2013;570.</Citation><ArticleIdList><ArticleId IdType="pubmed">21484932</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xf6;ller E, Praz V, Rajendran S, et al. EWSR1-ATF1 dependent 3D connectivity regulates oncogenic and differentiation programs in clear cell sarcoma. Nat Commun. 2022;13:2267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9046276</ArticleId><ArticleId IdType="pubmed">35477713</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilodeau EA, Weinreb I, Antonescu CR, et al. Clear cell odontogenic carcinomas show ewsr1 rearrangements: A novel finding and a biological link to salivary clear cell carcinomas. Am J Surg Pathol. 2013;37:1001&#x2013;1005.</Citation><ArticleIdList><ArticleId IdType="pubmed">23715163</ArticleId></ArticleIdList></Reference><Reference><Citation>Flucke U, Mentzel T, Verdijk MA, et al. EWSR1-ATF1 chimeric transcript in a myoepithelial tumor of soft tissue: A case report. Hum Pathol. 2012;43:764&#x2013;768.</Citation><ArticleIdList><ArticleId IdType="pubmed">22154050</ArticleId></ArticleIdList></Reference><Reference><Citation>LeckeyJr BD, Ivy J, Miguel R-M, et al. EWSR1-ATF1 fusion in a myoepithelial carcinoma of soft tissue with small round cell morphology: A potential diagnostic pitfall. Pediatr Dev Pathol. 2021;24:258&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">33683984</ArticleId></ArticleIdList></Reference><Reference><Citation>Geiger JL, Ismaila N, Beadle B, et al. Management of Salivary Gland Malignancy: ASCO Guideline. J Clin Oncol. 2021;39:1909&#x2013;1941.</Citation><ArticleIdList><ArticleId IdType="pubmed">33900808</ArticleId></ArticleIdList></Reference><Reference><Citation>Magrin L, Fanale D, Brando C, et al. MUTYH-associated tumor syndrome: The other face of MAP. Oncogene. 2022;41:2531&#x2013;2539.</Citation><ArticleIdList><ArticleId IdType="pubmed">35422474</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuiper RP, Nielsen M, Voer RMD, et al. NTHL1 Tumor Syndrome. GeneReviews; 2020.</Citation></Reference><Reference><Citation>Win AK, Reece JC, Dowty JG, et al. Risk of extracolonic cancers for people with biallelic and monoallelic mutations in MUTYH. Int J Cancer. 2016;139(7):1557&#x2013;1563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5094810</ArticleId><ArticleId IdType="pubmed">27194394</ArticleId></ArticleIdList></Reference><Reference><Citation>Na K, Hernandez-Prera JC, Lim JY, et al. Characterization of novel genetic alterations in salivary gland secretory carcinoma. Mod Pathol. 2020;33:541&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7113190</ArticleId><ArticleId IdType="pubmed">31822803</ArticleId></ArticleIdList></Reference><Reference><Citation>Brownlie J, Kulkarni S, Algethami M, et al. Targeting DNA damage repair precision medicine strategies in cancer. Curr Opin Pharmacol. 2023;70:102381.</Citation><ArticleIdList><ArticleId IdType="pubmed">37148685</ArticleId></ArticleIdList></Reference><Reference><Citation>Pruis MA, Groenendijk FH, Badloe KS, et al. Personalised selection of experimental treatment in patients with advanced solid cancer is feasible using whole-genome sequencing. Br J Cancer. 2022;127:776&#x2013;783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9381598</ArticleId><ArticleId IdType="pubmed">35606463</ArticleId></ArticleIdList></Reference><Reference><Citation>Bagger FO, Borgwardt L, Jespersen AS, et al. Whole genome sequencing in clinical practice. BMC Med Genomics. 2024;17:1&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10823711</ArticleId><ArticleId IdType="pubmed">38287327</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison SM, Biesecker LG, Rehm HL. Overview of specifications to the ACMG/AMP variant interpretation guidelines. Curr Protoc Hum Genet. 2019;103:e93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6885382</ArticleId><ArticleId IdType="pubmed">31479589</ArticleId></ArticleIdList></Reference><Reference><Citation>Akhoundova D, Rubin MA. The grand challenge of moving cancer whole-genome sequencing into the clinic. Nat Med. 2024;30:39&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">38200256</ArticleId></ArticleIdList></Reference><Reference><Citation>McLaren W, Gil L, Hunt SE, et al. The Ensembl variant effect predictor. Genome Biol. 2016;17:122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4893825</ArticleId><ArticleId IdType="pubmed">27268795</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng PC, Henikoff S. Predicting deleterious amino acid substitutions. Genome Res. 2001;11:863&#x2013;874.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC311071</ArticleId><ArticleId IdType="pubmed">11337480</ArticleId></ArticleIdList></Reference><Reference><Citation>Rentzsch P, Witten D, Cooper GM, et al. CADD: Predicting the deleteriousness of variants throughout the human genome. Nucleic Acids Res. 2019;47:D886&#x2013;D894.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6323892</ArticleId><ArticleId IdType="pubmed">30371827</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioannidis NM, Rothstein JH, Pejaver V, et al. REVEL: An ensemble method for predicting the pathogenicity of rare missense variants. Am J Hum Genet. 2016;99:877&#x2013;885.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5065685</ArticleId><ArticleId IdType="pubmed">27666373</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/PO.24.00321 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39983078</PMID><DateCompleted><Year>2025</Year><Month>02</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2473-4284</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><PubDate><Year>2025</Year><Month>Jan</Month></PubDate></JournalIssue><Title>JCO precision oncology</Title><ISOAbbreviation>JCO Precis Oncol</ISOAbbreviation></Journal><ArticleTitle><i>NTRK</i> Fusion-Positive Thyroid Carcinoma: From Diagnosis to Targeted Therapy.</ArticleTitle><Pagination><StartPage>e2400321</StartPage><MedlinePgn>e2400321</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2400321</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1200/PO.24.00321</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Neurotrophic tropomyosin receptor kinase (<i>NTRK</i>) fusions may act as an oncogenic driver in thyroid carcinomas. Given their low frequency, clinical, pathological, and molecular data on these patients and their responses to targeted therapies are limited.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This is an observational retrospective study conducted at a single high-volume cancer center in the United States. Data were retrospectively collected from medical records.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We included 65 patients (37 adult, 28 pediatric) with an <i>NTRK</i> fusion-positive thyroid carcinoma (24 <i>NTRK1</i>, 41 <i>NTRK3</i>), of which 54 were papillary thyroid carcinomas (PTC), four poorly differentiated thyroid carcinomas (PDTC), and seven anaplastic thyroid carcinomas (ATC). In PTC, an extensive follicular growth pattern was seen in 22 (41%) patients. In adults, <i>NTRK3</i> fusions were 3 times more frequent (nine <i>NTRK1</i>, 28 <i>NTRK3</i>), whereas in pediatric patients their frequencies were similar (15 <i>NTRK1</i>, 13 <i>NTRK3</i>; <i>P</i> = .021). In patients with PDTC/ATC treated with larotrectinib, we detected four emergent solvent front mutations (three <i>NTRK3</i> G623R, one <i>NTRK1</i> G595R) causing resistance to drug and disease progression. Three of them (two ATC, one PDTC) received second-line selitrectinib on a clinical trial. Partial responses were seen in all three patients, but both patients with ATC progressed within a year.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS"><i>NTRK1</i>/<i>3</i> fusions are seen in PTC, PDTC, and ATC, and a follicular growth pattern was observed in a high proportion of cases. In patients treated with larotrectinib, <i>NTRK</i> solvent front mutations are the main resistance mechanism, frequently occurring in PDTC/ATC. Responses to single-agent TRK inhibitor are short-lived in patients with ATC; thus, these drugs should be used with caution in this population.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Marczyk</LastName><ForeName>Vicente R</ForeName><Initials>VR</Initials><Identifier Source="ORCID">0000-0001-7005-722X</Identifier><AffiliationInfo><Affiliation>Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fazeli</LastName><ForeName>Sasan</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-5181-6013</Identifier><AffiliationInfo><Affiliation>Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dadu</LastName><ForeName>Ramona</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Busaidy</LastName><ForeName>Naifa L</ForeName><Initials>NL</Initials><Identifier Source="ORCID">0000-0002-3808-6378</Identifier><AffiliationInfo><Affiliation>Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iyer</LastName><ForeName>Priyanka</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Mimi I</ForeName><Initials>MI</Initials><Identifier Source="ORCID">0000-0003-0355-030X</Identifier><AffiliationInfo><Affiliation>Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sherman</LastName><ForeName>Steven I</ForeName><Initials>SI</Initials><Identifier Source="ORCID">0000-0002-3079-5153</Identifier><AffiliationInfo><Affiliation>Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamidi</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-1528-9885</Identifier><AffiliationInfo><Affiliation>Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hosseini</LastName><ForeName>Sayed Mohsen</ForeName><Initials>SM</Initials><Identifier Source="ORCID">0000-0003-3626-9928</Identifier><AffiliationInfo><Affiliation>Department of Pathology, The University of Texas MD Anderson Cancer, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Michelle D</ForeName><Initials>MD</Initials><Identifier Source="ORCID">0000-0002-9133-7332</Identifier><AffiliationInfo><Affiliation>Department of Pathology, The University of Texas MD Anderson Cancer, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Salmaan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neuroradiology, The University of Texas MD Anderson Cancer, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Routbort</LastName><ForeName>Mark J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0003-4860-261X</Identifier><AffiliationInfo><Affiliation>Department of Hematopathology, The University of Texas MD Anderson Cancer, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luthra</LastName><ForeName>Raja</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-7133-0221</Identifier><AffiliationInfo><Affiliation>Department of Hematopathology, The University of Texas MD Anderson Cancer, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roy-Chowdhuri</LastName><ForeName>Sinchita</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-9447-7701</Identifier><AffiliationInfo><Affiliation>Department of Pathology, The University of Texas MD Anderson Cancer, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>San Lucas</LastName><ForeName>Francis Anthony</ForeName><Initials>FA</Initials><AffiliationInfo><Affiliation>Clinical Bioinformatics, The University of Texas MD Anderson Cancer, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Keyur P</ForeName><Initials>KP</Initials><Identifier Source="ORCID">0000-0001-5081-2427</Identifier><AffiliationInfo><Affiliation>Department of Hematopathology, The University of Texas MD Anderson Cancer, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>David S</ForeName><Initials>DS</Initials><Identifier Source="ORCID">0000-0001-8721-1609</Identifier><AffiliationInfo><Affiliation>Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zafereo</LastName><ForeName>Mark</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-7918-9739</Identifier><AffiliationInfo><Affiliation>Department of Head &amp; Neck Surgery, The University of Texas MD Anderson Cancer, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jennifer R</ForeName><Initials>JR</Initials><Identifier Source="ORCID">0000-0002-0807-3832</Identifier><AffiliationInfo><Affiliation>Department of Head &amp; Neck Surgery, The University of Texas MD Anderson Cancer, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maniakas</LastName><ForeName>Anastasios</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4354-2841</Identifier><AffiliationInfo><Affiliation>Department of Head &amp; Neck Surgery, The University of Texas MD Anderson Cancer, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waguespack</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials><Identifier Source="ORCID">0000-0003-0280-0100</Identifier><AffiliationInfo><Affiliation>Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cabanillas</LastName><ForeName>Maria E</ForeName><Initials>ME</Initials><Identifier Source="ORCID">0000-0002-5124-1811</Identifier><AffiliationInfo><Affiliation>Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer, Houston, TX.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 CA016672</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>02</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Precis Oncol</MedlineTA><NlmUniqueID>101705370</NlmUniqueID><ISSNLinking>2473-4284</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D020917">Receptor, trkA</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D020812">Receptor, trkC</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000707038">NTRK3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000611485">NTRK1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>PF9462I9HX</RegistryNumber><NameOfSubstance UI="C000609083">larotrectinib</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>JCO Precis Oncol. 2025 Jul;9:e2500552. doi: 10.1200/PO-25-00552.</RefSource><PMID Version="1">40632979</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013964" MajorTopicYN="Y">Thyroid Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020917" MajorTopicYN="Y">Receptor, trkA</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020812" MajorTopicYN="Y">Receptor, trkC</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011720" MajorTopicYN="N">Pyrazoles</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077273" MajorTopicYN="Y">Thyroid Cancer, Papillary</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center. Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments). 
<b>Maria E. Cabanillas</b>
. <b>Honoraria:</b> Boston University, University of Miami. <b>Consulting or Advisory Role:</b> Bayer, Exelixis, Novartis, Thryv. <b>Research Funding:</b> Eisai, Roche/Genentech, Exelixis, Merck. No other potential conflicts of interest were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>2</Month><Day>21</Day><Hour>18</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>2</Month><Day>21</Day><Hour>18</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>2</Month><Day>21</Day><Hour>16</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>2</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39983078</ArticleId><ArticleId IdType="pmc">PMC11867807</ArticleId><ArticleId IdType="doi">10.1200/PO.24.00321</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Baloch ZW, Asa SL, Barletta JA, et al. : Overview of the 2022 WHO Classification of Thyroid Neoplasms. Endocr Pathol 33:27-63, 2022</Citation><ArticleIdList><ArticleId IdType="pubmed">35288841</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal N, Akbani R, Aksoy BA, et al. : Integrated genomic characterization of papillary thyroid carcinoma. Cell 159:676-690, 2014</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4243044</ArticleId><ArticleId IdType="pubmed">25417114</ArticleId></ArticleIdList></Reference><Reference><Citation>Cocco E, Scaltriti M, Drilon A: NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol 15:731-747, 2018</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6419506</ArticleId><ArticleId IdType="pubmed">30333516</ArticleId></ArticleIdList></Reference><Reference><Citation>Haddad R, Elisei R, Hoff AO, et al. : Diagnosis and management of tropomyosin receptor kinase fusion-positive thyroid carcinomas. JAMA Oncol 9:1132-1141, 2023</Citation><ArticleIdList><ArticleId IdType="pubmed">37289450</ArticleId></ArticleIdList></Reference><Reference><Citation>Pekova B, Sykorova V, Mastnikova K, et al. : <i>NTRK</i> fusion genes in thyroid carcinomas: Clinicopathological characteristics and their impacts on prognosis. Cancers (Basel)
13:1932, 2021
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8073383</ArticleId><ArticleId IdType="pubmed">33923728</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Schmitz AA, Kallionp&#xe4;&#xe4; RE, et al. : Neurotrophic-tyrosine receptor kinase gene fusion in papillary thyroid cancer: A clinicogenomic biobank and record linkage study from Finland. Oncotarget 15:106-116, 2024</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10852057</ArticleId><ArticleId IdType="pubmed">38329731</ArticleId></ArticleIdList></Reference><Reference><Citation>Pozdeyev N, Gay LM, Sokol ES, et al. : Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers. Clin Cancer Res 24:3059-3068, 2018</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6030480</ArticleId><ArticleId IdType="pubmed">29615459</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen EY, Goldman DA, Hechtman JF, et al. : TRK fusions are enriched in cancers with uncommon histologies and the absence of canonical driver mutations. Clin Cancer Res 26:1624-1632, 2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7124988</ArticleId><ArticleId IdType="pubmed">31871300</ArticleId></ArticleIdList></Reference><Reference><Citation>Koehler VF, Achterfeld J, Sandner N, et al. : NTRK fusion events and targeted treatment of advanced radioiodine refractory thyroid cancer. J Cancer Res Clin Oncol 149:14035-14043, 2023</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10590332</ArticleId><ArticleId IdType="pubmed">37548775</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu Y-H, Dias-Santagata D, Farahani AA, et al. : Clinicopathologic and molecular characterization of NTRK-rearranged thyroid carcinoma (NRTC). Mod Pathol 33:2186-2197, 2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7584778</ArticleId><ArticleId IdType="pubmed">32457407</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang J, Cai W, Feng D, et al. : Genetic landscape of papillary thyroid carcinoma in the Chinese population. J Pathol 244:215-226, 2018</Citation><ArticleIdList><ArticleId IdType="pubmed">29144541</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatalica Z, Xiu J, Swensen J, et al. : Molecular characterization of cancers with <i>NTRK</i> gene fusions. Mod Pathol
32:147-153, 2019
</Citation><ArticleIdList><ArticleId IdType="pubmed">30171197</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon JP, Linkov I, Rosado A, et al. : <i>NTRK</i> fusion detection across multiple assays and 33,997 cases: Diagnostic implications and pitfalls. Mod Pathol
33:38-46, 2020
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7437403</ArticleId><ArticleId IdType="pubmed">31375766</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu Y-H, Wirth LJ, Farahani AA, et al. : Clinicopathologic features of kinase fusion-related thyroid carcinomas: An integrative analysis with molecular characterization. Mod Pathol 33:2458-2472, 2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7688509</ArticleId><ArticleId IdType="pubmed">32737449</ArticleId></ArticleIdList></Reference><Reference><Citation>Eszlinger M, Stewardson P, McIntyre JB, et al. : Systematic population-based identification of <i>NTRK</i> and <i>RET</i> fusion-positive thyroid cancers. Eur Thyroid J
11:e210061, 2022
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9142806</ArticleId><ArticleId IdType="pubmed">34981751</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y-C, Chen J-Y, Huang C-J, et al. : Detection of <i>NTRK1</i>/<i>3</i> rearrangements in papillary thyroid carcinoma using immunohistochemistry, fluorescent in situ hybridization, and next-generation sequencing. Endocr Pathol
31:348-358, 2020
</Citation><ArticleIdList><ArticleId IdType="pubmed">32880785</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JC, Ashok A, Liu C, et al. : Real-world experience of <i>NTRK</i> fusion&#x2013;positive thyroid cancer. JCO Precis Oncol
10.1200/PO.21.00442</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/PO.21.00442</ArticleId><ArticleId IdType="pmc">PMC8865519</ArticleId><ArticleId IdType="pubmed">35171659</ArticleId></ArticleIdList></Reference><Reference><Citation>Pekova B, Sykorova V, Dvorakova S, et al. : <i>RET</i>, <i>NTRK</i>, <i>ALK</i>, <i>BRAF</i>, and <i>MET</i> fusions in a large cohort of pediatric papillary thyroid carcinomas. Thyroid
30:1771-1780, 2020
</Citation><ArticleIdList><ArticleId IdType="pubmed">32495721</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricarte-Filho JC, Halada S, O&#x2019;Neill A, et al. : The clinical aspect of <i>NTRK</i>-fusions in pediatric papillary thyroid cancer. Cancer Genet
262&#x2013;263:57-63, 2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8931989</ArticleId><ArticleId IdType="pubmed">35092884</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee YA, Lee H, Im S-W, et al. : <i>NTRK</i> and <i>RET</i> fusion&#x2013;directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake. J Clin Invest
131:e144847, 2021
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8439610</ArticleId><ArticleId IdType="pubmed">34237031</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallant J-N, Chen S-C, Ortega CA, et al. : Evaluation of the molecular landscape of pediatric thyroid nodules and use of a multigene genomic classifier in children. JAMA Oncol 8:1323-1327, 2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9185516</ArticleId><ArticleId IdType="pubmed">35679040</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad ML, Vyas M, Horne MJ, et al. : <i>NTRK</i> fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States. Cancer
122:1097-1107, 2016
</Citation><ArticleIdList><ArticleId IdType="pubmed">26784937</ArticleId></ArticleIdList></Reference><Reference><Citation>Nies M, Vassilopoulou-Sellin R, Bassett RL, et al. : Distant metastases from childhood differentiated thyroid carcinoma: Clinical course and mutational landscape. J Clin Endocrinol Metab 106:1683-1697, 2021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7993569</ArticleId><ArticleId IdType="pubmed">33382403</ArticleId></ArticleIdList></Reference><Reference><Citation>Picarsic JL, Buryk MA, Ozolek J, et al. : Molecular characterization of sporadic pediatric thyroid carcinoma with the DNA/RNA ThyroSeq v2 next-generation sequencing assay. Pediatr Dev Pathol 19:115-122, 2016</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5894824</ArticleId><ArticleId IdType="pubmed">26367451</ArticleId></ArticleIdList></Reference><Reference><Citation>Franco AT, Ricarte-Filho JC, Isaza A, et al. : Fusion oncogenes are associated with increased metastatic capacity and persistent disease in pediatric thyroid cancers. J Clin Oncol 40:1081-1090, 2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8966969</ArticleId><ArticleId IdType="pubmed">35015563</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X, Kotch C, Fox E, et al. : NTRK fusions identified in pediatric tumors: The frequency, fusion partners, and clinical outcome. JCO Precis Oncol
10.1200/PO.20.00250</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/PO.20.00250</ArticleId><ArticleId IdType="pmc">PMC8140782</ArticleId><ArticleId IdType="pubmed">34036219</ArticleId></ArticleIdList></Reference><Reference><Citation>Demetri GD, De Braud F, Drilon A, et al. : Updated integrated analysis of the efficacy and safety of entrectinib in patients with <i>NTRK</i> fusion-positive solid tumors. Clin Cancer Res
28:1302-1312, 2022
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9365368</ArticleId><ArticleId IdType="pubmed">35144967</ArticleId></ArticleIdList></Reference><Reference><Citation>Doebele RC, Drilon A, Paz-Ares L, et al. : Entrectinib in patients with advanced or metastatic <i>NTRK</i> fusion-positive solid tumours: Integrated analysis of three phase 1&#x2013;2 trials. Lancet Oncol
21:271-282, 2020
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7461630</ArticleId><ArticleId IdType="pubmed">31838007</ArticleId></ArticleIdList></Reference><Reference><Citation>Drilon A, Laetsch TW, Kummar S, et al. : Efficacy of larotrectinib in TRK fusion&#x2013;positive cancers in adults and children. N Engl J Med 378:731-739, 2018</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5857389</ArticleId><ArticleId IdType="pubmed">29466156</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong DS, DuBois SG, Kummar S, et al. : Larotrectinib in patients with TRK fusion-positive solid tumours: A pooled analysis of three phase 1/2 clinical trials. Lancet Oncol 21:531-540, 2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7497841</ArticleId><ArticleId IdType="pubmed">32105622</ArticleId></ArticleIdList></Reference><Reference><Citation>Waguespack SG, Drilon A, Lin JJ, et al. : Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. Eur J Endocrinol 186:631-643, 2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9066591</ArticleId><ArticleId IdType="pubmed">35333737</ArticleId></ArticleIdList></Reference><Reference><Citation>Sukrithan V, Jain P, Shah MH, et al. : Kinase inhibitors in thyroid cancers. Endocr Oncol 3:e220062, 2023</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10305552</ArticleId><ArticleId IdType="pubmed">37434642</ArticleId></ArticleIdList></Reference><Reference><Citation>Drilon A, Nagasubramanian R, Blake JF, et al. : A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion&#x2013;positive solid tumors. Cancer Discov 7:963-972, 2017</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5581710</ArticleId><ArticleId IdType="pubmed">28578312</ArticleId></ArticleIdList></Reference><Reference><Citation>Drilon A, Ou S-HI, Cho BC, et al. : Repotrectinib (TPX-0005) is a next-generation ROS1/TRK/ALK inhibitor that potently inhibits ROS1/TRK/ALK solvent- front mutations. Cancer Discov 8:1227-1236, 2018</Citation><ArticleIdList><ArticleId IdType="pubmed">30093503</ArticleId></ArticleIdList></Reference><Reference><Citation>Katayama R, Gong B, Togashi N, et al. : The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models. Nat Commun 10:3604, 2019</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6688997</ArticleId><ArticleId IdType="pubmed">31399568</ArticleId></ArticleIdList></Reference><Reference><Citation>Harada G, Drilon A: TRK inhibitor activity and resistance in TRK fusion-positive cancers in adults. Cancer Genet 264&#x2013;265:33-39, 2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9133157</ArticleId><ArticleId IdType="pubmed">35334340</ArticleId></ArticleIdList></Reference><Reference><Citation>Harada G, Choudhury NJ, Schram AM, et al. : Mechanisms of acquired resistance to TRK inhibitors. J Clin Oncol 40:3104, 2022</Citation></Reference><Reference><Citation>Drilon A, Camidge DR, Lin JJ, et al. : Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer. N Engl J Med 390:118-131, 2024</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11702311</ArticleId><ArticleId IdType="pubmed">38197815</ArticleId></ArticleIdList></Reference><Reference><Citation>Besse B, Baik C, Springfeld C, et al. : Repotrectinib in patients with NTRK fusion-positive advanced solid tumors: Update from the registrational phase 2 TRIDENT-1 trial. Mol Cancer Ther 20, 2021. (abstr P02-P01)</Citation></Reference><Reference><Citation>Papadopoulos KP, Borazanci E, Shaw AT, et al. : U.S. Phase I first-in-human study of taletrectinib (DS-6051b/AB-106), a ROS1/TRK inhibitor, in patients with advanced solid tumors. Clin Cancer Res 26:4785-4794, 2020</Citation><ArticleIdList><ArticleId IdType="pubmed">32591465</ArticleId></ArticleIdList></Reference><Reference><Citation>Ou S-HI, Fujiwara Y, Shaw AT, et al. : Efficacy of taletrectinib (AB-106/DS-6051b) in <i>ROS1+</i> NSCLC: An updated pooled analysis of U.S. and Japan phase 1 studies. JTO Clin Res Rep
2:100108, 2021
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8474193</ArticleId><ArticleId IdType="pubmed">34589973</ArticleId></ArticleIdList></Reference><Reference><Citation>Shonka DC Jr, Ho A, Chintakuntlawar AV, et al. : American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment. Head Neck 44:1277-1300, 2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9332138</ArticleId><ArticleId IdType="pubmed">35274388</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/PO-24-00603 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39772833</PMID><DateCompleted><Year>2025</Year><Month>01</Month><Day>08</Day></DateCompleted><DateRevised><Year>2025</Year><Month>01</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2473-4284</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><PubDate><Year>2025</Year><Month>Jan</Month></PubDate></JournalIssue><Title>JCO precision oncology</Title><ISOAbbreviation>JCO Precis Oncol</ISOAbbreviation></Journal><ArticleTitle>Optimizing Radiotherapy Timing for Nasopharyngeal Carcinoma: The Impact of Radiation Scheduling on Survival.</ArticleTitle><Pagination><StartPage>e2400603</StartPage><MedlinePgn>e2400603</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2400603</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1200/PO-24-00603</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Chronoradiobiology has emerged as a potential field of study with therapeutic implications for cancer treatment. We aimed to investigate the association between radiation chronotherapy and the efficacy and toxicity of patients with nasopharyngeal carcinoma (NPC).</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Patients with nonmetastatic NPC treated with intensity-modulated radiotherapy in Fujian Cancer Hospital between January 2017 and December 2019 were included. Propensity score matching (PSM) with 1:1:1 was used to account for selection bias. Cox regression analysis was performed to explore the impact of radiotherapy timing on patient survival. Sensitivity analysis was implemented to determine the size and directional stability.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">One thousand forty patients met study inclusion criteria and 332 patients were included in a PSM cohort. In the unmatched cohort analysis, morning radiotherapy exhibited a significantly superior overall survival (OS) outcome (hazard ratio [HR], 0.60 [95% CI, 0.40 to 0.91], adjusted log-rank <i>P</i> = .028) than the afternoon one. After PSM analysis, it was observed that individuals undergoing radiotherapy in the afternoon group (HR, 5.88 [95% CI, 2.55 to 13.58], adjusted log-rank <i>P</i> = .004) and the night group (HR, 4.81 [95% CI, 1.91 to 12.11], adjusted log-rank <i>P</i> = .018) displayed a tendency toward shorter OS compared with the morning group. No significant differences in acute treatment-related adverse effects were observed among the three groups. Morning radiotherapy demonstrated consistent robustness in the multivariable analysis, thereby establishing an association with higher OS. The directionality of the effect size was consistent across sensitivity analysis.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These results underscore the potential benefits of scheduling radiotherapy in the morning for NPC management, although prospective studies are needed to confirm these findings.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center), Fujian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weng</LastName><ForeName>Youliang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center), Fujian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Zongwei</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center), Fujian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Lishui</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center), Fujian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Siqi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center), Fujian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Yingjie</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Fujian Medical University, Fujian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Haolan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Fujian Medical University, Fujian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Jinghua</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center), Fujian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center), Fujian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiu</LastName><ForeName>Sufang</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-7660-6955</Identifier><AffiliationInfo><Affiliation>Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center), Fujian, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fujian Key Laboratory of Translational Cancer Medicine, Fujian, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fujian Provincial Key Laboratory of Tumor Biotherapy, Fujian, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>01</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Precis Oncol</MedlineTA><NlmUniqueID>101705370</NlmUniqueID><ISSNLinking>2473-4284</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077274" MajorTopicYN="Y">Nasopharyngeal Carcinoma</DescriptorName><QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009303" MajorTopicYN="Y">Nasopharyngeal Neoplasms</DescriptorName><QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050397" MajorTopicYN="Y">Radiotherapy, Intensity-Modulated</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center. Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments). No potential conflicts of interest were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>1</Month><Day>8</Day><Hour>18</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>1</Month><Day>8</Day><Hour>18</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>1</Month><Day>8</Day><Hour>14</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>1</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39772833</ArticleId><ArticleId IdType="pmc">PMC11723500</ArticleId><ArticleId IdType="doi">10.1200/PO-24-00603</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Yip PL, You R, Chen MY, et al. Embracing personalized strategies in radiotherapy for nasopharyngeal carcinoma: Beyond the conventional bounds of fields and borders. Cancers. 2024;16:383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10814653</ArticleId><ArticleId IdType="pubmed">38254872</ArticleId></ArticleIdList></Reference><Reference><Citation>Siak PY, Heng WS, Teoh SSH, et al. Precision medicine in nasopharyngeal carcinoma: Comprehensive review of past, present, and future prospect. J Transl Med. 2023;21:786.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10629096</ArticleId><ArticleId IdType="pubmed">37932756</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee AW, Ng WT, Pan JJ, et al. International guideline on dose prioritization and acceptance criteria in radiation therapy planning for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2019;105:567&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">31276776</ArticleId></ArticleIdList></Reference><Reference><Citation>Shuboni-Mulligan DD, Breton G, Smart D, et al. Radiation chronotherapy-clinical impact of treatment time-of-day: A systematic review. J Neurooncol. 2019;145:415&#x2013;427.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8130840</ArticleId><ArticleId IdType="pubmed">31729636</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim YH, Lazar MA. Transcriptional control of circadian rhythms and metabolism: A matter of time and space. Endocr Rev. 2020;41:707&#x2013;732.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7334005</ArticleId><ArticleId IdType="pubmed">32392281</ArticleId></ArticleIdList></Reference><Reference><Citation>Almaida-Pagan PF, Torrente M, Campos M, et al. Chronodisruption and ambulatory circadian monitoring in cancer patients: Beyond the body clock. Curr Oncol Rep. 2022;24:135&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8857092</ArticleId><ArticleId IdType="pubmed">35061192</ArticleId></ArticleIdList></Reference><Reference><Citation>Albuquerque T, Neves AR, Quintela T, et al. Exploring the link between chronobiology and drug delivery: Effects on cancer therapy. J Mol Med (Berl) 2021;99:1349&#x2013;1371.</Citation><ArticleIdList><ArticleId IdType="pubmed">34213595</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang PX, Jin F, Li ZL, et al. A randomized phase II trial of induction chemotherapy followed by cisplatin chronotherapy versus constant rate delivery combined with radiotherapy. Chronobiol Int. 2018;35:240&#x2013;248.</Citation><ArticleIdList><ArticleId IdType="pubmed">29215933</ArticleId></ArticleIdList></Reference><Reference><Citation>Karabou&#xe9; A, Collon T, Pavese I, et al. Time-dependent efficacy of checkpoint inhibitor nivolumab: Results from a pilot study in patients with metastatic non-small-cell lung cancer. Cancers. 2022;14:896.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8870559</ArticleId><ArticleId IdType="pubmed">35205644</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv J, Liao S, Li B, et al. Scheduling radiotherapy for patients with nasopharyngeal carcinoma in the corresponding time window can reduce radiation-induced oral mucositis: A randomized, prospective study. Cancer Med. 2023;12:16032&#x2013;16040.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10469752</ArticleId><ArticleId IdType="pubmed">37537945</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu F, Farrugia MK, Duncan WD, et al. Daily time of radiation treatment is associated with subsequent oral mucositis severity during radiotherapy in head and neck cancer patients. Cancer Epidemiol Biomarkers Prev. 2020;29:949&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7898770</ArticleId><ArticleId IdType="pubmed">32098893</ArticleId></ArticleIdList></Reference><Reference><Citation>Zieker D, Jenne I, Koenigsrainer I, et al. Circadian expression of clock- and tumor suppressor genes in human oral mucosa. Cell Physiol Biochem. 2010;26:155&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pubmed">20798499</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X, He Z, Jiang X, et al. Development and application of MOSAIQ integration platform based on radiotherapy workflow. Chin J Radiat Oncol. 2017;6:918&#x2013;923.</Citation></Reference><Reference><Citation>Li Y, Weng Y, Huang Z, et al. Prognostic model on overall survival in elderly nasopharyngeal carcinoma patients: A recursive partitioning analysis identifying pre-treatment risk stratification. Radiat Oncol. 2023;18:104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10290415</ArticleId><ArticleId IdType="pubmed">37353800</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Zhang Q, Lu T, et al. Prioritizing sufficient dose to gross tumor volume over normal tissue sparing in intensity-modulated radiotherapy treatment of T4 nasopharyngeal carcinoma. Head Neck. 2023;45:1130&#x2013;1140.</Citation><ArticleIdList><ArticleId IdType="pubmed">36856128</ArticleId></ArticleIdList></Reference><Reference><Citation>Radiation therapy oncology group protocol 02&#x2013;25. http://www.rtog.org/members/protocols/0225/0225.pdf</Citation></Reference><Reference><Citation>Bryer JM, Speerschneider K.Trimatch: An R package for propensity score matching of non-binary treatments The R User conference, useR 2013pp 10-12</Citation></Reference><Reference><Citation>Zstats. www.medsta.cn/software</Citation></Reference><Reference><Citation>Ruiz-Torres DA, Naegele S, Podury A, et al. Immunotherapy time of infusion impacts survival in head and neck cancer: A propensity score matched analysis. Oral Oncol. 2024;151:106761.</Citation><ArticleIdList><ArticleId IdType="pubmed">38507992</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayyar VS, Sukumaran S. Circadian rhythms: Influence on physiology, pharmacology, and therapeutic interventions. J Pharmacokinet Pharmacodyn. 2021;48:321&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8015932</ArticleId><ArticleId IdType="pubmed">33797011</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xe9;vi FA, Okyar A, Hadadi E, et al. Circadian regulation of drug responses: Toward sex-specific and personalized chronotherapy. Annu Rev Pharmacol Toxicol. 2024;64:89&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pubmed">37722720</ArticleId></ArticleIdList></Reference><Reference><Citation>Damato AR, Herzog ED. Circadian clock synchrony and chronotherapy opportunities in cancer treatment. Semin Cell Develop Biol. 2022;126:27&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8810901</ArticleId><ArticleId IdType="pubmed">34362656</ArticleId></ArticleIdList></Reference><Reference><Citation>Mure LS, Le HD, Benegiamo G, et al. Diurnal transcriptome atlas of a primate across major neural and peripheral tissues. Science. 2018;359:eaao0318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5924732</ArticleId><ArticleId IdType="pubmed">29439024</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaue D, McBride WH. Opportunities and challenges of radiotherapy for treating cancer. Nat Rev Clin Oncol. 2015;12:527&#x2013;540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8396062</ArticleId><ArticleId IdType="pubmed">26122185</ArticleId></ArticleIdList></Reference><Reference><Citation>Sancar A, Van Gelder RN. Clocks, cancer, and chronochemotherapy. Science. 2021;371:eabb0738.</Citation><ArticleIdList><ArticleId IdType="pubmed">33384351</ArticleId></ArticleIdList></Reference><Reference><Citation>He H, Lin K, Zou C, et al. Knockdown of annexin A2 enhances radiosensitivity by increasing G2/M-phase arrest, apoptosis and activating the p38 MAPK-HSP27 pathway in nasopharyngeal carcinoma. Front Oncol. 2022;12:769544.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8968728</ArticleId><ArticleId IdType="pubmed">35371986</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson N, Lombardo J, Matlack L, et al. Chronoradiobiology of breast cancer: The time is now to link circadian rhythm and radiation biology. Int J Mol Sci. 2022;23:1331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8836288</ArticleId><ArticleId IdType="pubmed">35163264</ArticleId></ArticleIdList></Reference><Reference><Citation>Dakup PP, Porter KI, Little AA, et al. The circadian clock regulates cisplatin-induced toxicity and tumor regression in melanoma mouse and human models. Oncotarget. 2018;9:14524&#x2013;14538.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5865687</ArticleId><ArticleId IdType="pubmed">29581861</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaddameedhi S, Selby CP, Kaufmann WK, et al. Control of skin cancer by the circadian rhythm. Proc Natl Acad Sci USA. 2011;108:18790&#x2013;18795.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3219110</ArticleId><ArticleId IdType="pubmed">22025708</ArticleId></ArticleIdList></Reference><Reference><Citation>Dakup P, Gaddameedhi S. Impact of the circadian clock on UV-induced DNA damage response and photocarcinogenesis. Photochem Photobiol. 2017;93:296&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5315601</ArticleId><ArticleId IdType="pubmed">27861965</ArticleId></ArticleIdList></Reference><Reference><Citation>Kranjc BS, Prevc A, Niksic ZM, et al. Synergistic effect of cisplatin chemotherapy combined with fractionated radiotherapy regimen in HPV-positive and HPV-negative experimental pharyngeal squamous cell carcinoma. Scientific Rep. 2020;10:1563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6994509</ArticleId><ArticleId IdType="pubmed">32005919</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YP, Ismaila N, Chua MLK, et al. Chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II-IVa nasopharyngeal carcinoma: CSCO and ASCO guideline. J Clin Oncol. 2021;39:840&#x2013;859.</Citation><ArticleIdList><ArticleId IdType="pubmed">33405943</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng XL, Yang JJ, Wang YY, et al. RIP1 promotes proliferation through G2/M checkpoint progression and mediates cisplatin-induced apoptosis and necroptosis in human ovarian cancer cells. Acta Pharmacologica Sin. 2020;41:1223&#x2013;1233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7608477</ArticleId><ArticleId IdType="pubmed">32242118</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian DC, Kleber T, Brammer B, et al. Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): A propensity score-matched analysis of a single-centre, longitudinal study. Lancet Oncol. 2021;22:1777&#x2013;1786.</Citation><ArticleIdList><ArticleId IdType="pubmed">34780711</ArticleId></ArticleIdList></Reference><Reference><Citation>Aiello I, Fedele MLM, Rom&#xe1;n F, et al. Circadian disruption promotes tumor-immune microenvironment remodeling favoring tumor cell proliferation. Sci Adv. 2020;6:eaaz4530.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7556830</ArticleId><ArticleId IdType="pubmed">33055171</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Chen X, Wu L, et al. Impact of the radiotherapy rhythm on prognosis in nasopharyngeal carcinoma. Ann Med. 2024;56:2407061.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11421160</ArticleId><ArticleId IdType="pubmed">39310946</ArticleId></ArticleIdList></Reference><Reference><Citation>Mostafaie N, K&#xe1;llay E, Sauerzapf E, et al. Correlated downregulation of estrogen receptor beta and the circadian clock gene Per1 in human colorectal cancer. Mol Carcinog. 2009;48:642&#x2013;647.</Citation><ArticleIdList><ArticleId IdType="pubmed">19148895</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan S, Rowbottom L, McDonald R, et al. Could time of whole brain radiotherapy delivery impact overall survival in patients with multiple brain metastases? Ann Palliat Med. 2016;5:267&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pubmed">27806623</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailey M, Silver R. Sex differences in circadian timing systems: Implications for disease. Front Neuroendocrinol. 2014;35:111&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4041593</ArticleId><ArticleId IdType="pubmed">24287074</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y, Wang RH. Associations among metabolism, circadian rhythm and age-associated diseases. Aging Dis. 2017;8:314&#x2013;333.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5440111</ArticleId><ArticleId IdType="pubmed">28580187</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu FM, Hou WH, Huang CY, et al. Differences in toxicity and outcome associated with circadian variations between patients undergoing daytime and evening radiotherapy for prostate adenocarcinoma. Chronobiol Int. 2016;33:210&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pubmed">26818960</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/PO.24.00299 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40138600</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>14</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2473-4284</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><PubDate><Year>2025</Year><Month>Mar</Month></PubDate></JournalIssue><Title>JCO precision oncology</Title><ISOAbbreviation>JCO Precis Oncol</ISOAbbreviation></Journal><ArticleTitle>Routine Clinical Liquid Biopsy Testing for Solid Tumors Delivers the Promise of Minimally Invasive Detection of Genomic Variants With a Faster Turnaround Time.</ArticleTitle><Pagination><StartPage>e2400299</StartPage><MedlinePgn>e2400299</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/PO.24.00299</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">A 70-gene liquid biopsy (LB) panel (LBP-70) was implemented at our institution to identify genetic alterations in the plasma of patients with solid tumors. We report the clinical utility of LBP-70 in a retrospective study of 1,243 consecutively tested patients.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Electronic medical records were reviewed for relevant clinicopathologic and radiologic information and preanalytical variables, including circulating cell-free DNA yield. The clinical utility of the LBP-70 assay was evaluated on the basis of its ability to identify major tumor drivers and/or targetable alterations and the concordance of the LBP-70 results with tissue genotyping and radiologic findings.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Positive LB findings were reported in 75% of patients, ranging from 67% to 85% among various tumor types and 60% to 77% in different tumor stages within an average of seven workdays. The mutant allele frequency (AF) ranged from 0.1% to 90%, and 50% of the variants were detected at AF &lt;2%. Overall, LBP-70 provided clinically informative findings in 87% of the patients. In patients with non-small cell lung cancer (NSCLC) and colorectal cancer without tissue specimens, LBP-70 identified informative findings in 74% of patients, including <i>EGFR</i> exon 18-21 mutations in 22% of patients with NSCLC and <i>RAS</i> and/or <i>BRAF</i> V600E mutations in 44% of patients with colorectal cancer. LBP-70 results showed 62% concordance with tissue genotyping and 79% concordance with radiologic findings.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The results of this study demonstrated the clinical utility of LBP-70 in identifying clinically informative findings. LBP-70 is an alternative to tissue-based tumor genotyping and provides a more rapid method for detecting actionable genetic alterations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Peng</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-0899-484X</Identifier><AffiliationInfo><Affiliation>Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Richard Kenneth</ForeName><Initials>RK</Initials><Identifier Source="ORCID">0000-0003-0433-8626</Identifier><AffiliationInfo><Affiliation>Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jelloul</LastName><ForeName>Fatima Zahra</ForeName><Initials>FZ</Initials><Identifier Source="ORCID">0000-0002-3791-3204</Identifier><AffiliationInfo><Affiliation>Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luthra</LastName><ForeName>Rajyalakshmi</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-7133-0221</Identifier><AffiliationInfo><Affiliation>Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Routbort</LastName><ForeName>Mark J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0003-4860-261X</Identifier><AffiliationInfo><Affiliation>Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Hui</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-5847-0561</Identifier><AffiliationInfo><Affiliation>Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loghavi</LastName><ForeName>Sanam</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ok</LastName><ForeName>Chi Young</ForeName><Initials>CY</Initials><Identifier Source="ORCID">0000-0002-6822-7880</Identifier><AffiliationInfo><Affiliation>Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanagal-Shamanna</LastName><ForeName>Rashmi</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-7829-5249</Identifier><AffiliationInfo><Affiliation>Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roy-Chowdhuri</LastName><ForeName>Sinchita</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-9447-7701</Identifier><AffiliationInfo><Affiliation>Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Medeiros</LastName><ForeName>L Jeffrey</ForeName><Initials>LJ</Initials><Identifier Source="ORCID">0000-0001-6577-8006</Identifier><AffiliationInfo><Affiliation>Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Keyur P</ForeName><Initials>KP</Initials><Identifier Source="ORCID">0000-0001-5081-2427</Identifier><AffiliationInfo><Affiliation>Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>03</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Precis Oncol</MedlineTA><NlmUniqueID>101705370</NlmUniqueID><ISSNLinking>2473-4284</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073890" MajorTopicYN="N">Liquid Biopsy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>27</Day><Hour>16</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>27</Day><Hour>16</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>26</Day><Hour>16</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40138600</ArticleId><ArticleId IdType="doi">10.1200/PO.24.00299</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/PO-25-00069 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40403207</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2473-4284</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><PubDate><Year>2025</Year><Month>May</Month></PubDate></JournalIssue><Title>JCO precision oncology</Title><ISOAbbreviation>JCO Precis Oncol</ISOAbbreviation></Journal><ArticleTitle>Palbociclib, a Selective CDK4/6 Inhibitor, Administered Before and After Chemoradiotherapy for Human Papillomavirus-Negative, Locally Advanced Head and Neck Squamous Cell Carcinoma: A Single-Arm, Phase II Trial.</ArticleTitle><Pagination><StartPage>e2500069</StartPage><MedlinePgn>e2500069</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/PO-25-00069</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The primary aim of this single-arm, phase II trial was to determine the objective response rate (ORR) with palbociclib, a selective CDK4/6 inhibitor, administered before chemoradiotherapy (CRT) in patients with human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC).</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Eligibility required untreated stage III-IVB HPV-negative HNSCC. Palbociclib 125 mg once daily was administered on days 1-21 of each 28-day cycle for two cycles before and six cycles after CRT. Pretreatment tumor samples underwent genome sequencing. The primary end point was tumor response to palbociclib given before CRT, assessed by RECIST1.1. A sample of 24 evaluable patients (those with response assessment) yielded an 80% power at a one-sided significance level of 0.05 if the ORR was &#x2265;38% (null ORR 17%). A key secondary end point was relapse.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We enrolled 26 patients with HPV-negative, locally advanced HNSCC. Alterations in <i>CDKN2A</i> were identified in 15 patients (58%), and alterations in <i>CCND1</i> were identified in eight (31%). Twenty-four patients were evaluable for the primary end point, and 25 were evaluable for relapse. The ORR with palbociclib given before CRT was 41.7% (95% CI, 22.1 to 63.4). Response to palbociclib occurred in 10 of 15 patients (66.7%) with versus 0 of 9 (0%) without tumor <i>CDKN2A</i> alterations (<i>P</i> = .002) and in one of six patients (16.7%) with versus nine of 18 (50%) without <i>CCND1</i> alterations (<i>P</i> = .34). The median follow-up was 33.9 months (IQR, 31.3-49.2). Relapse occurred in two of 15 patients (13.3%) with versus seven of 10 (70%) without tumor <i>CDKN2A</i> alterations (<i>P</i> = .009) and in one of seven patients (14.3%) with versus 8 of 18 (44.4%) without <i>CCND1</i> alterations (<i>P</i> = .36).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Palbociclib is an active drug in previously untreated HPV-negative, locally advanced HNSCC. Alterations in <i>CDKN2A</i> were associated with a higher ORR with palbociclib and a lower relapse risk after CRT.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Oppelt</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Division of Medical Oncology, Washington University School of Medicine, St Louis, MO.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alvin J. Siteman Cancer Center, St Louis, MO.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Robert Ebert and Greg Stubblefield Head and Neck Tumor Center at Siteman, St Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ley</LastName><ForeName>Jessica C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Division of Medical Oncology, Washington University School of Medicine, St Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puram</LastName><ForeName>Sidharth V</ForeName><Initials>SV</Initials><Identifier Source="ORCID">0000-0003-3543-889X</Identifier><AffiliationInfo><Affiliation>Alvin J. Siteman Cancer Center, St Louis, MO.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Robert Ebert and Greg Stubblefield Head and Neck Tumor Center at Siteman, St Louis, MO.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otolaryngology, Washington University School of Medicine, St Louis, MO.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics, Washington University School of Medicine, St Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jackson</LastName><ForeName>Ryan S</ForeName><Initials>RS</Initials><Identifier Source="ORCID">0000-0003-4626-2324</Identifier><AffiliationInfo><Affiliation>Alvin J. Siteman Cancer Center, St Louis, MO.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Robert Ebert and Greg Stubblefield Head and Neck Tumor Center at Siteman, St Louis, MO.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otolaryngology, Washington University School of Medicine, St Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paniello</LastName><ForeName>Randall C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Alvin J. Siteman Cancer Center, St Louis, MO.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Robert Ebert and Greg Stubblefield Head and Neck Tumor Center at Siteman, St Louis, MO.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otolaryngology, Washington University School of Medicine, St Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rich</LastName><ForeName>Jason T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Alvin J. Siteman Cancer Center, St Louis, MO.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Robert Ebert and Greg Stubblefield Head and Neck Tumor Center at Siteman, St Louis, MO.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otolaryngology, Washington University School of Medicine, St Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pipkorn</LastName><ForeName>Patrik</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-4118-7743</Identifier><AffiliationInfo><Affiliation>Alvin J. Siteman Cancer Center, St Louis, MO.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Robert Ebert and Greg Stubblefield Head and Neck Tumor Center at Siteman, St Louis, MO.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otolaryngology, Washington University School of Medicine, St Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jingxia</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-9434-7907</Identifier><AffiliationInfo><Affiliation>Division of Public Health Sciences, Washington University School of Medicine, St Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thorstad</LastName><ForeName>Wade L</ForeName><Initials>WL</Initials><Identifier Source="ORCID">0000-0002-2757-0543</Identifier><AffiliationInfo><Affiliation>Alvin J. Siteman Cancer Center, St Louis, MO.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Robert Ebert and Greg Stubblefield Head and Neck Tumor Center at Siteman, St Louis, MO.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiation Oncology, Washington University School of Medicine, St Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adkins</LastName><ForeName>Douglas R</ForeName><Initials>DR</Initials><Identifier Source="ORCID">0000-0003-3207-8227</Identifier><AffiliationInfo><Affiliation>Division of Medical Oncology, Washington University School of Medicine, St Louis, MO.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alvin J. Siteman Cancer Center, St Louis, MO.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Robert Ebert and Greg Stubblefield Head and Neck Tumor Center at Siteman, St Louis, MO.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 CA091842</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Precis Oncol</MedlineTA><NlmUniqueID>101705370</NlmUniqueID><ISSNLinking>2473-4284</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>G9ZF61LE7G</RegistryNumber><NameOfSubstance UI="C500026">palbociclib</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011725">Pyridines</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.22</RegistryNumber><NameOfSubstance UI="D051361">Cyclin-Dependent Kinase 6</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.22</RegistryNumber><NameOfSubstance UI="D051358">Cyclin-Dependent Kinase 4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="Y">Piperazines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011725" MajorTopicYN="Y">Pyridines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077195" MajorTopicYN="Y">Squamous Cell Carcinoma of Head and Neck</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059248" MajorTopicYN="Y">Chemoradiotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006258" MajorTopicYN="Y">Head and Neck Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051361" MajorTopicYN="N">Cyclin-Dependent Kinase 6</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051358" MajorTopicYN="N">Cyclin-Dependent Kinase 4</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D027383" MajorTopicYN="N">Papillomaviridae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="Y">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047428" MajorTopicYN="Y">Protein Kinase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094302" MajorTopicYN="N">Human Papillomavirus Viruses</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>JL, SP, JR, RCP, and PP have no disclosures to report. PO reports research funding from Merck and HiFiBio and travel support from Natco, outside the submitted work. JCL reports travel support from Natco, outside the submitted work. SP reports research funding from Cue Biopharma, outside the submitted work. RJ reports consulting fees from Intuitive, Inc and payment for testimony, outside the submitted work. WT reports other from Elekta, Inc (wife is employee. Radiotherapy hardware and software company. However, the department doesn&#x2019;t use those products). DA reports research funding from Pfizer for the submitted work and consulting or scientific advisory board support from Washington University, Merck, Adlai Nortye, Cue Biopharma, Inhibrx, Exelixis, Immunitas, Kura Oncology, Genmab, Sanofi, Merck KGA, Merus, Boehringer Ingelheim, Coherus Biosciences, Natco Pharma, Purple Biotech, Regeneron, Seagen, and TargImmune Therapeutics, travel support from Natco, leadership role on the NCCN practice guidelines and the Barnes Jewish Hospital Pharmacy and Therapeutics Committee and institutional research support from Eli Lilly, Pfizer, Merck, Celgene/BMS, Novartis, AstraZeneca, Blueprint Medicine, Kura Oncology, Cue Biopharma, Cofactor Genomics, Debiopharm Group, ISA pharmaceuticals, Gilead Sciences, BeiGene, Roche, Vaccinex, Immutep, Hookpia Biotech, Epizyme, Adlai Nortye, BioAtla, Boehringer Ingelheim, Calliditas Therapeutics, Genmab, Natco Pharma, Tizona Therapeutics, Erasca, Alentis, Inhibrx, Seagen, Surface (now Coherus), Takeda, Xilio, Aveo, GSK and J&amp;J outside the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2026</Year><Month>5</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>22</Day><Hour>18</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>22</Day><Hour>18</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>22</Day><Hour>16</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40403207</ArticleId><ArticleId IdType="mid">NIHMS2073265</ArticleId><ArticleId IdType="pmc">PMC12147653</ArticleId><ArticleId IdType="doi">10.1200/PO-25-00069</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Akinyemiju TF, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: A systematic analysis for the global burden of disease study. JAMA Oncol 2018;4(11):1553&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6248091</ArticleId><ArticleId IdType="pubmed">29860482</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen WS, Bindra RS, Mo A, et al. CDKN2A copy number loss is an independent prognostic factor in HPV-negative head and neck squamous cell carcinoma. Front Oncol 2018;8:95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5893829</ArticleId><ArticleId IdType="pubmed">29670856</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee NY, Ferris RL, Psyrri A, et al. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomized, double-blind, placebo-controlled, multicenter, phase 3 trial. Lancet Oncol 2021;22(4):450&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">33794205</ArticleId></ArticleIdList></Reference><Reference><Citation>Ang KK, Zhang Q, Rosenthal DI, et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol 2014;32(27):2940&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4162493</ArticleId><ArticleId IdType="pubmed">25154822</ArticleId></ArticleIdList></Reference><Reference><Citation>Machiels J, Tao Y, Burtness B, et al. Primary results of the phase III KEYNOTE-412 study: Pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC). Ann Oncol 2022;33(suppl_7):S808&#x2013;69.</Citation></Reference><Reference><Citation>Martins RG, Parvathaneni U, Bauman JE, et al. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: A randomized phase II trial. J Clin Oncol 2012;31(11):1415&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">23460709</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong SJ, Torres-Saavedra PA, Saba NF, et al. Radiotherapy plus cisplatin with or without lapatinib for non-human papillomavirus head and neck carcinoma: A phase 2 randomized clinical trial. JAMA Oncol 2023;9(11):1565&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10540060</ArticleId><ArticleId IdType="pubmed">37768670</ArticleId></ArticleIdList></Reference><Reference><Citation>Argiris A, Bauman JE, Ohr J, et al. Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer. Ann Oncol 2016;27:1594&#x2013;1600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6279075</ArticleId><ArticleId IdType="pubmed">27177865</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015;517(7536):576&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4311405</ArticleId><ArticleId IdType="pubmed">25631445</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Chen L, Savage SR, et al. Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma. Cancer Cell 2021;39(3):361&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7946781</ArticleId><ArticleId IdType="pubmed">33417831</ArticleId></ArticleIdList></Reference><Reference><Citation>Ku BM, Yi SY, Koh J, et al. The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma. Oncotarget 2016;7(12):14803&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4924753</ArticleId><ArticleId IdType="pubmed">26909611</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck TN, Georgopoulos R, Shagisultanova EI, et al. EGFR and RB1 as dual biomarkers in HPV-negative head and neck cancer. Mol Cancer Ther 2016;15(10):2486&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5522587</ArticleId><ArticleId IdType="pubmed">27507850</ArticleId></ArticleIdList></Reference><Reference><Citation>Karamboulas C, Bruce JP, Hope AJ, et al. Patient-derived xenografts for prognostication and personalized treatment for head and neck squamous cell carcinoma. Cell Rep 2018;25:1318&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">30380421</ArticleId></ArticleIdList></Reference><Reference><Citation>van Caloen G, Schmitz S, El Baroudi M, et al. Preclinical activity of ribociclib in squamous cell carcinoma of the head and neck. Mol Cancer Ther 2020;19(3):777&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">31924739</ArticleId></ArticleIdList></Reference><Reference><Citation>Zainal NS, Lee BKB, Wong ZW, et al. Effects of palbociclib on oral squamous cell carcinoma and the role of PIK3CA in conferring resistance. Cancer Biol Med 2019;16(2):264&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6713638</ArticleId><ArticleId IdType="pubmed">31516747</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalish LH, Kwong RA, Cole IE, et al. Deregulated Cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines. Clin Cancer Res 2004;10:7764&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">15570011</ArticleId></ArticleIdList></Reference><Reference><Citation>Michel L, Ley J, Wildes TM, et al. Phase I trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma. Oral Oncol 2016;58:41&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5047057</ArticleId><ArticleId IdType="pubmed">27311401</ArticleId></ArticleIdList></Reference><Reference><Citation>Adkins DA, Ley J, Neupane P, et al. Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial. Lancet Oncol 2019;20(9):1295&#x2013;1305.</Citation><ArticleIdList><ArticleId IdType="pubmed">31351869</ArticleId></ArticleIdList></Reference><Reference><Citation>Adkins DR, Lin J-C, Sacco A, et al. Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-na&#xef;ve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trial. Oral Oncol 2021;115:105192.</Citation><ArticleIdList><ArticleId IdType="pubmed">33571736</ArticleId></ArticleIdList></Reference><Reference><Citation>Worden FP, Pisick EB, Rothe M, et al. Palbociclib in patients with head and neck cancer and other tumors with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry study. JCO Precis Oncol 2024;8:e24&#x2013;00477.</Citation><ArticleIdList><ArticleId IdType="pubmed">39413339</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson AM, Rathore R, Redlich NJ, et al. Cisplatin exposure causes c-Myc-dependent resistance to CDK4/6 inhibition in HPV-negative head and neck squamous cell carcinoma. Cell Death Dis 2019;10:867.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6856201</ArticleId><ArticleId IdType="pubmed">31727874</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">19097774</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner NC, Neven P, Loibl S, Andre F. Advances in the treatment of advanced oestrogen-receptor-positive breast cancer. Lancet 2017;389(10087):2403&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">27939057</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Sullivan CC, Clarke R, Goetz MP, Robertson J. Cyclin-dependent kinase 4/6 inhibitors for treatment of hormone receptor-positive, ERBB2-negative breast cancer: A review. JAMA Oncol 2023;9(9):1273&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11385778</ArticleId><ArticleId IdType="pubmed">37382948</ArticleId></ArticleIdList></Reference><Reference><Citation>Forastiere AA, Zhang Q, Weber RS, et al. Long-term results of RTOG 91&#x2013;11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 2013;31(7):845&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3577950</ArticleId><ArticleId IdType="pubmed">23182993</ArticleId></ArticleIdList></Reference><Reference><Citation>Lefebvre JL, Andry G, Chevalier D, et al. Laryngeal preservation with induction chemotherapy for hypopharyngeal squamous cell carcinoma: 10-year results of EORTC trial 24891. Ann Oncol 2012;23(10):2708&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3457747</ArticleId><ArticleId IdType="pubmed">22492697</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen-Tan PF, Zhang Q, Ang KK, et al. Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity. J Clin Oncol 2014;32(34):3858&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4239304</ArticleId><ArticleId IdType="pubmed">25366680</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottgens EL, Bussink J, Leszczynska KB, Peters H, Span PN, Hammond EM. Inhibition of CDK4/CDK6 enhances radiosensitivity of HPV negative head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 2019;105(3):548&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">31271827</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngamphaiboon N, Pattaranutaporn P, Lukerak S, et al. A phase I study of the CDK4/6 inhibitor palbociclib in combination with cetuximab and radiotherapy for locally advanced head and neck squamous cell carcinoma. Clin Cancer Res 2024;30(2):294&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pubmed">37982827</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/PO-24-00760 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40768677</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>06</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2473-4284</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><PubDate><Year>2025</Year><Month>Aug</Month></PubDate></JournalIssue><Title>JCO precision oncology</Title><ISOAbbreviation>JCO Precis Oncol</ISOAbbreviation></Journal><ArticleTitle>Clonal Hematopoiesis Prevalence Years Before a Thyroid Cancer Diagnosis: A Case-Control Study.</ArticleTitle><Pagination><StartPage>e2400760</StartPage><MedlinePgn>e2400760</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/PO-24-00760</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Individuals with thyroid cancer have the highest prevalence of clonal hematopoiesis (CH) among patients with cancer. We sought to determine whether individuals who later develop thyroid cancer more frequently have CH before diagnosis or germline cancer susceptibility than healthy controls.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a retrospective case-control study using subjects enrolled between 2002 and 2015 in a population-based biobank. Cases were healthy at enrollment but subsequently developed an incident thyroid cancer. Controls were healthy age- and race-matched subjects who were never diagnosed with a cancer. To assess baseline CH, whole-exome sequencing (WES) was performed on peripheral blood (PB) DNAs collected at enrollment. To assess CH acquisition over time, we recontacted a subset of cases and controls approximately 20 years after initial sampling for repeat PB WES.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">At enrollment, on average 9 years before a thyroid cancer diagnosis for cases, we identified CH in three of 63 (5%) cases and four of 125 (3%) controls. Adjusting for age, sex, and race, those with CH had a 1.51 odds (0.31-7.33; <i>P</i> = .61) of a thyroid cancer diagnosis versus those without CH at baseline. We detected pathogenic germline cancer susceptibility variants in 11% of cases and 7% of controls (<i>P</i> = .44). Among seven cases and seven controls recontacted, we found incident CH development in three (43%) and two (29%), respectively.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">We found that individuals who later develop early-stage thyroid cancers do not have a significantly higher prevalence of CH years before their diagnosis nor carry germline cancer susceptibility variants more often than those who do not develop thyroid cancer. Larger longitudinal studies are needed to fully elucidate the impact of germline and exposures in CH etiology.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cabral</LastName><ForeName>Paloma L</ForeName><Initials>PL</Initials><Identifier Source="ORCID">0000-0001-7063-5077</Identifier><AffiliationInfo><Affiliation>Department of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aimalla</LastName><ForeName>Nikhila</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Center for Precision Medicine Research, Marshfield Clinic Research Institute, Marshfield Clinic Health System, Marshfield, WI.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shoger</LastName><ForeName>Kyle</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caskey</LastName><ForeName>John R</ForeName><Initials>JR</Initials><Identifier Source="ORCID">0000-0001-5665-524X</Identifier><AffiliationInfo><Affiliation>Department of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zurbriggen</LastName><ForeName>Luke</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Neepa</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Center for Precision Medicine Research, Marshfield Clinic Research Institute, Marshfield Clinic Health System, Marshfield, WI.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basharat</LastName><ForeName>Ahmad</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Precision Medicine Research, Marshfield Clinic Research Institute, Marshfield Clinic Health System, Marshfield, WI.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moat</LastName><ForeName>Luke F</ForeName><Initials>LF</Initials><AffiliationInfo><Affiliation>Center for Precision Medicine Research, Marshfield Clinic Research Institute, Marshfield Clinic Health System, Marshfield, WI.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reinig</LastName><ForeName>Erica</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Wisconsin-Madison, Madison, WI.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Long</LastName><ForeName>Kristin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Endocrine Surgery, Department of Surgery, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pozzo</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Center for Precision Medicine Research, Marshfield Clinic Research Institute, Marshfield Clinic Health System, Marshfield, WI.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kitchner</LastName><ForeName>Terrie</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Center for Precision Medicine Research, Marshfield Clinic Research Institute, Marshfield Clinic Health System, Marshfield, WI.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eickhoff</LastName><ForeName>Jens</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Medical Informatics, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carter</LastName><ForeName>Tonia C</ForeName><Initials>TC</Initials><Identifier Source="ORCID">0000-0002-2107-7838</Identifier><AffiliationInfo><Affiliation>Center for Precision Medicine Research, Marshfield Clinic Research Institute, Marshfield Clinic Health System, Marshfield, WI.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Churpek</LastName><ForeName>Jane E</ForeName><Initials>JE</Initials><Identifier Source="ORCID">0000-0001-7998-5479</Identifier><AffiliationInfo><Affiliation>Department of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Precis Oncol</MedlineTA><NlmUniqueID>101705370</NlmUniqueID><ISSNLinking>2473-4284</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013964" MajorTopicYN="Y">Thyroid Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000082182" MajorTopicYN="Y">Clonal Hematopoiesis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073359" MajorTopicYN="N">Exome Sequencing</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>6</Day><Hour>18</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>6</Day><Hour>18</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>6</Day><Hour>16</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40768677</ArticleId><ArticleId IdType="doi">10.1200/PO-24-00760</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/PO-24-00802 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40700671</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2473-4284</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><PubDate><Year>2025</Year><Month>Jul</Month></PubDate></JournalIssue><Title>JCO precision oncology</Title><ISOAbbreviation>JCO Precis Oncol</ISOAbbreviation></Journal><ArticleTitle>Combination Therapy With Olaparib Plus Lenvatinib in a Patient With <i>BRCA2</i>-Mutated, Radioiodine-Refractory, Metastatic Papillary Thyroid Cancer: A Case Report.</ArticleTitle><Pagination><StartPage>e2400802</StartPage><MedlinePgn>e2400802</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2400802</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1200/PO-24-00802</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Young</LastName><ForeName>Zachary</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0009-0004-9028-6029</Identifier><AffiliationInfo><Affiliation>Masters of Biomedical Sciences Program, Duke University School of Medicine, Durham, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tasoulas</LastName><ForeName>Jason</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-3791-3252</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology/Head and Neck Surgery, University of North Carolina School of Medicine, Chapel Hill, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fajardo</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Oncology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gwynn</LastName><ForeName>Morgan</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-0333-835X</Identifier><AffiliationInfo><Affiliation>Division of Oncology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>Jacqueline</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Steven M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of North Carolina School of Medicine, Chapel Hill, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheth</LastName><ForeName>Siddharth</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-1923-2309</Identifier><AffiliationInfo><Affiliation>Division of Oncology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Precis Oncol</MedlineTA><NlmUniqueID>101705370</NlmUniqueID><ISSNLinking>2473-4284</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center. Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments). 
<b>Siddharth Sheth</b>
. <b>Honoraria:</b> Eisai, InhibRx, Coherus Biosciences. <b>Speakers' Bureau:</b> Exelixis. <b>Research Funding:</b> AstraZeneca (Inst), INOVIO Pharmaceuticals (Inst), Exelixis (Inst), Regeneron (Inst), Merck (Inst). <b>Travel, Accommodations, Expenses:</b> Merus. No other potential conflicts of interest were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>23</Day><Hour>18</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>23</Day><Hour>18</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>23</Day><Hour>16</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40700671</ArticleId><ArticleId IdType="pmc">PMC12309517</ArticleId><ArticleId IdType="doi">10.1200/PO-24-00802</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Boucai L, Zafereo M, Cabanillas ME: Thyroid cancer: A review. JAMA 331:425-435, 2024</Citation><ArticleIdList><ArticleId IdType="pubmed">38319329</ArticleId></ArticleIdList></Reference><Reference><Citation>Haddad RI, Bischoff L, Bernet V, et al. : NCCN clinical practice guidelines in oncology: Thyroid carcinoma. J Natl Compr Cancer Netw 20:925-951, 2022</Citation><ArticleIdList><ArticleId IdType="pubmed">35948029</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlumberger M, Tahara M, Wirth LJ, et al. : Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 372:621-630, 2015</Citation><ArticleIdList><ArticleId IdType="pubmed">25671254</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu JF, Brady MF, Matulonis UA, et al. : Olaparib with or without cediranib versus platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer (NRG-GY004): A randomized, open-label, phase III trial. J Clin Oncol 40:2138-2147, 2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9242406</ArticleId><ArticleId IdType="pubmed">35290101</ArticleId></ArticleIdList></Reference><Reference><Citation>Brose MS, Panaseykin Y, Konda B, et al. : A randomized study of lenvatinib 18 mg vs 24 mg in patients with radioiodine-refractory differentiated thyroid cancer. J Clin Endocrinol Metab 107:776-787, 2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8852210</ArticleId><ArticleId IdType="pubmed">34664662</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang H-J, Chang Y-H, Chen Y-H, et al. : Low dose of lenvatinib treatment for patients of radioiodine-refractory differentiated thyroid carcinoma&#x2013;a real-world experience. Cancer Manag Res 13:7139-7148, 2021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8449554</ArticleId><ArticleId IdType="pubmed">34548818</ArticleId></ArticleIdList></Reference><Reference><Citation>Brose MS, Robinson BG, Sherman SI, et al. : Cabozantinib for previously treated radioiodine&#x2010;refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial. Cancer 128:4203-4212, 2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10092751</ArticleId><ArticleId IdType="pubmed">36259380</ArticleId></ArticleIdList></Reference><Reference><Citation>Busaidy NL, Konda B, Wei L, et al. : Dabrafenib versus dabrafenib+ trametinib in BRAF-mutated radioactive iodine refractory differentiated thyroid cancer: Results of a randomized, phase 2, open-label multicenter trial. Thyroid 32:1184-1192, 2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9595631</ArticleId><ArticleId IdType="pubmed">35658604</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee N, Walker GC: Mechanisms of DNA damage, repair, and mutagenesis. Environ Mol mutagenesis 58:235-263, 2017</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5474181</ArticleId><ArticleId IdType="pubmed">28485537</ArticleId></ArticleIdList></Reference><Reference><Citation>W&#xf3;jcicka A, Czetwerty&#x144;ska M, &#x15a;wierniak M, et al. : Variants in the ATM-CHEK2-BRCA1 axis determine genetic predisposition and clinical presentation of papillary thyroid carcinoma. Genes, chromosomes &amp; cancer 53:516-523, 2014</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4058861</ArticleId><ArticleId IdType="pubmed">24599715</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerbinskaite A, Mukhopadhyay A, Plummer ER, et al. : Defective homologous recombination in human cancers. Cancer Treat Rev 38:89-100, 2012</Citation><ArticleIdList><ArticleId IdType="pubmed">21715099</ArticleId></ArticleIdList></Reference><Reference><Citation>Talens F, Jalving M, Gietema JA, et al. : Therapeutic targeting and patient selection for cancers with homologous recombination defects. Expert Opin Drug Discov 12:565-581, 2017</Citation><ArticleIdList><ArticleId IdType="pubmed">28425306</ArticleId></ArticleIdList></Reference><Reference><Citation>Benafif S, Hall M: An update on PARP inhibitors for the treatment of cancer. OncoTargets Ther 8:519-528, 2015</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4348139</ArticleId><ArticleId IdType="pubmed">25750544</ArticleId></ArticleIdList></Reference><Reference><Citation>ClinVar : [VCV000037957.47]. National Center for Biotechnology Information</Citation></Reference><Reference><Citation>Domansk&#xfd; M, Andrl&#xed;k M, Kurucz S, et al. : Cardiac conduction system as an OAR in radiation therapy: Doses to SA/AV nodes and their reduction. Int J Part Ther 14:100631, 2024</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11471227</ArticleId><ArticleId IdType="pubmed">39399817</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemoine N, Mayall E, Wyllie F, et al. : High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene 4:159-164, 1989</Citation><ArticleIdList><ArticleId IdType="pubmed">2648253</ArticleId></ArticleIdList></Reference><Reference><Citation>Marotta V, Bifulco M, Vitale M: Significance of RAS mutations in thyroid benign nodules and non-medullary thyroid cancer. Cancers 13:3785, 2021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8345070</ArticleId><ArticleId IdType="pubmed">34359686</ArticleId></ArticleIdList></Reference><Reference><Citation>Saha S, Joshi A, Noronha V, et al. : NRAS mutation in differentiated thyroid cancer. Cancer Res Stat Treat 5:722-727, 2022</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/PO-25-00806 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">41370728</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2473-4284</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><PubDate><Year>2025</Year><Month>Dec</Month></PubDate></JournalIssue><Title>JCO precision oncology</Title><ISOAbbreviation>JCO Precis Oncol</ISOAbbreviation></Journal><ArticleTitle>Durable Complete Response of a Delta-Like Ligand 3 Expressing Head and Neck Neuroendocrine Carcinoma to Tarlatamab.</ArticleTitle><Pagination><StartPage>e2500806</StartPage><MedlinePgn>e2500806</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/PO-25-00806</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kirtane</LastName><ForeName>Kedar</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-1302-9577</Identifier><AffiliationInfo><Affiliation>Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puri</LastName><ForeName>Sonam</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-8068-5051</Identifier><AffiliationInfo><Affiliation>Department of Thoracic Oncology, Moffitt Cancer Center, Tampa, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Christine H</ForeName><Initials>CH</Initials><Identifier Source="ORCID">0000-0001-5199-4306</Identifier><AffiliationInfo><Affiliation>Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, FL.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Precis Oncol</MedlineTA><NlmUniqueID>101705370</NlmUniqueID><ISSNLinking>2473-4284</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>10</Day><Hour>19</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>10</Day><Hour>19</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>10</Day><Hour>16</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41370728</ArticleId><ArticleId IdType="doi">10.1200/PO-25-00806</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/PO-25-00552 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40632979</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2473-4284</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><PubDate><Year>2025</Year><Month>Jul</Month></PubDate></JournalIssue><Title>JCO precision oncology</Title><ISOAbbreviation>JCO Precis Oncol</ISOAbbreviation></Journal><ArticleTitle>Erratum: NTRK Fusion-Positive Thyroid Carcinoma: From Diagnosis to Targeted Therapy.</ArticleTitle><Pagination><StartPage>e2500552</StartPage><MedlinePgn>e2500552</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/PO-25-00552</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Marczyk</LastName><ForeName>Vicente R</ForeName><Initials>VR</Initials></Author><Author ValidYN="Y"><LastName>Fazeli</LastName><ForeName>Sasan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Dadu</LastName><ForeName>Ramona</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Busaidy</LastName><ForeName>Naifa L</ForeName><Initials>NL</Initials></Author><Author ValidYN="Y"><LastName>Iyer</LastName><ForeName>Priyanka</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Mimi I</ForeName><Initials>MI</Initials></Author><Author ValidYN="Y"><LastName>Sherman</LastName><ForeName>Steven I</ForeName><Initials>SI</Initials></Author><Author ValidYN="Y"><LastName>Hamidi</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Hosseini</LastName><ForeName>Sayed Mohsen</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Michelle D</ForeName><Initials>MD</Initials></Author><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Salmaan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Routbort</LastName><ForeName>Mark J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Luthra</LastName><ForeName>Raja</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Roy-Chowdhuri</LastName><ForeName>Sinchita</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>San Lucas</LastName><ForeName>Francis Anthony</ForeName><Initials>FA</Initials></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Keyur P</ForeName><Initials>KP</Initials></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>David S</ForeName><Initials>DS</Initials></Author><Author ValidYN="Y"><LastName>Zafereo</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jennifer R</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Maniakas</LastName><ForeName>Anastasios</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Waguespack</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials></Author><Author ValidYN="Y"><LastName>Cabanillas</LastName><ForeName>Maria E</ForeName><Initials>ME</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 CA016672</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016425">Published Erratum</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Precis Oncol</MedlineTA><NlmUniqueID>101705370</NlmUniqueID><ISSNLinking>2473-4284</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumFor"><RefSource>JCO Precis Oncol. 2025 Jan;9:e2400321. doi: 10.1200/PO.24.00321.</RefSource><PMID Version="1">39983078</PMID></CommentsCorrections></CommentsCorrectionsList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>9</Day><Hour>18</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>9</Day><Hour>18</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>9</Day><Hour>16</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40632979</ArticleId><ArticleId IdType="doi">10.1200/PO-25-00552</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/OA-25-00049 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40832450</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2994-9750</ISSN><JournalIssue CitedMedium="Internet"><Volume>2</Volume><Issue>1</Issue><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>JCO oncology advances</Title><ISOAbbreviation>JCO Oncol Adv</ISOAbbreviation></Journal><ArticleTitle>Olaparib, Pembrolizumab, and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase II Trial.</ArticleTitle><Pagination><StartPage>e2500049</StartPage><MedlinePgn>e2500049</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2500049</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1200/OA-25-00049</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Impaired homologous recombination-mediated DNA repair is common in head and neck squamous cell carcinoma (HNSCC) and in preclinical models and sensitizes HNSCC to poly (ADP-ribose) polymerase (PARP) inhibitors and platinum therapy. PARP inhibitors and anti-PD-1 antibodies have synergistic antitumor activity. The primary hypothesis of this phase II trial was that olaparib, a PARP inhibitor, given with pembrolizumab and carboplatin as first-line treatment for biomarker-unselected recurrent or metastatic (RM)-HNSCC, would result in a higher objective response rate (ORR) than that historically reported with fluorouracil, pembrolizumab, and platinum therapy.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients received up to six 21-day cycles of olaparib (200 mg twice daily orally on days 1-10), pembrolizumab, and carboplatin followed by 29 cycles of olaparib (300 mg twice a day on days 1-21) and pembrolizumab. The primary end point was independent radiologist-assessed confirmed objective response per RECIST v1.1. A Simon optimal two-stage design tested the null (H<sub>0</sub>: ORR &#x2264;36%) versus the alternative hypothesis (ORR &#x2265;62%) at a type I error rate of 10% and a power of 90%. H<sub>0</sub> would be rejected if &#x2265;14 responses occurred among 29 patients. Secondary end points included duration of response (DoR), progression-free survival (PFS), and overall survival (OS).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Between July 08, 2021, and October 11, 2023, 30 patients were enrolled. Among the 29 evaluable patients, the ORR was 51.7% (90% CI, 35.2 to 68.0; <i>v</i> H<sub>0</sub>, one-sided <i>P</i> = .04). The median DoR was 14.1 months (IQR, 6.8 to 21.2), and the median PFS and OS were 7.8 (95% CI, 4.1 to 15.4) and 24.5 months (95% CI, 8.8 to 25.3), respectively. The most common study drug-related grade 3 to 4 adverse events included neutropenia (50%) and anemia (23%). Febrile neutropenia and treatment-related deaths did not occur.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Olaparib, pembrolizumab, and carboplatin given as first-line treatment of RM-HNSCC resulted in a higher ORR than that historically reported with fluorouracil, pembrolizumab, and platinum therapy.</AbstractText><CopyrightInformation>&#xa9; 2025 by American Society of Clinical Oncology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Adkins</LastName><ForeName>Douglas</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-3207-8227</Identifier><AffiliationInfo><Affiliation>Alvin J. Siteman Cancer Center, St Louis, MO.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Medical Oncology, Washington University School of Medicine, St Louis, MO.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Robert Ebert and Greg Stubblefield Head and Neck Tumor Center, St Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ley</LastName><ForeName>Jessica C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Division of Medical Oncology, Washington University School of Medicine, St Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jingxia</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-9434-7907</Identifier><AffiliationInfo><Affiliation>Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St Louis, MO.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Biostatistics, Washington University School of Medicine, St Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oppelt</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Alvin J. Siteman Cancer Center, St Louis, MO.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Medical Oncology, Washington University School of Medicine, St Louis, MO.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Robert Ebert and Greg Stubblefield Head and Neck Tumor Center, St Louis, MO.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Oncol Adv</MedlineTA><NlmUniqueID>9918956761606676</NlmUniqueID><ISSNLinking>2994-9750</ISSNLinking></MedlineJournalInfo><CoiStatement>The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to https://ascopubs.org/authors. Douglas Adkins Consulting or Advisory Role: Merck, CUE Biopharma, Exelixis, Immunitas, Kura Oncology, TargImmune Therapeutics, Boehringer Ingelheim, Genmab/Seattle Genetics, Seagen, Adlai Nortye, Inhibrx, Merck KGaA, Merus, Purple Biotech, Regeneron, Sanofi, NATCO Pharma Research Funding: Pfizer (Inst), Lilly (Inst), Merck (Inst), Celgene (Inst), Novartis (Inst), AstraZeneca (Inst), Blueprint Medicines (Inst), Bristol Myers Squibb (Inst), Kura Oncology (Inst), CUE Biopharma (Inst), Cofactor Genomics (Inst), Debiopharm Group (Inst), ISA Pharmaceuticals (Inst), Gilead Sciences (Inst), BeiGene (Inst), Roche (Inst), Vaccinex (Inst), Immutep (Inst), Hookipa Biotech (Inst), Epizyme (Inst), Adlai Nortye (Inst), BioAtla (Inst), Boehringer Ingelheim (Inst), Calliditas Therapeutics (Inst), Genmab (Inst), NATCO Pharma (Inst), Tizona Therapeutics, Inc (Inst), Seagen (Inst), Merus (Inst), InhibRx (Inst), Erasca, Inc (Inst), Alentis Therapeutics (Inst), Coherus Biosciences (Inst), Takeda (Inst), Xilio Therapeutics (Inst), GlaxoSmithKline (Inst), Johnson &amp; Johnson/Janssen (Inst), Rgenta (Inst), AVEO (Inst), Daiichi Sankyo Europe GmbH (Inst), Exelixis (Inst), Tempus (Inst) Travel, Accommodations, Expenses: NATCO Pharma (Inst) Jessica C. Ley Travel, Accommodations, Expenses: NATCO Pharma (Inst) Peter Oppelt Research Funding: Merck (Inst), HiFiBiO Therapeutics (Inst), Enzychem Lifesciences (Inst) No other potential conflicts of interest were reported. Douglas Adkins Consulting or Advisory Role: Merck, CUE Biopharma, Exelixis, Immunitas, Kura Oncology, TargImmune Therapeutics, Boehringer Ingelheim, Genmab/Seattle Genetics, Seagen, Adlai Nortye, Inhibrx, Merck KGaA, Merus, Purple Biotech, Regeneron, Sanofi, NATCO Pharma Research Funding: Pfizer (Inst), Lilly (Inst), Merck (Inst), Celgene (Inst), Novartis (Inst), AstraZeneca (Inst), Blueprint Medicines (Inst), Bristol Myers Squibb (Inst), Kura Oncology (Inst), CUE Biopharma (Inst), Cofactor Genomics (Inst), Debiopharm Group (Inst), ISA Pharmaceuticals (Inst), Gilead Sciences (Inst), BeiGene (Inst), Roche (Inst), Vaccinex (Inst), Immutep (Inst), Hookipa Biotech (Inst), Epizyme (Inst), Adlai Nortye (Inst), BioAtla (Inst), Boehringer Ingelheim (Inst), Calliditas Therapeutics (Inst), Genmab (Inst), NATCO Pharma (Inst), Tizona Therapeutics, Inc (Inst), Seagen (Inst), Merus (Inst), InhibRx (Inst), Erasca, Inc (Inst), Alentis Therapeutics (Inst), Coherus Biosciences (Inst), Takeda (Inst), Xilio Therapeutics (Inst), GlaxoSmithKline (Inst), Johnson &amp; Johnson/Janssen (Inst), Rgenta (Inst), AVEO (Inst), Daiichi Sankyo Europe GmbH (Inst), Exelixis (Inst), Tempus (Inst) Travel, Accommodations, Expenses: NATCO Pharma (Inst) Jessica C. Ley Travel, Accommodations, Expenses: NATCO Pharma (Inst) Peter Oppelt Research Funding: Merck (Inst), HiFiBiO Therapeutics (Inst), Enzychem Lifesciences (Inst) No other potential conflicts of interest were reported. Douglas Adkins Consulting or Advisory Role: Merck, CUE Biopharma, Exelixis, Immunitas, Kura Oncology, TargImmune Therapeutics, Boehringer Ingelheim, Genmab/Seattle Genetics, Seagen, Adlai Nortye, Inhibrx, Merck KGaA, Merus, Purple Biotech, Regeneron, Sanofi, NATCO Pharma Research Funding: Pfizer (Inst), Lilly (Inst), Merck (Inst), Celgene (Inst), Novartis (Inst), AstraZeneca (Inst), Blueprint Medicines (Inst), Bristol Myers Squibb (Inst), Kura Oncology (Inst), CUE Biopharma (Inst), Cofactor Genomics (Inst), Debiopharm Group (Inst), ISA Pharmaceuticals (Inst), Gilead Sciences (Inst), BeiGene (Inst), Roche (Inst), Vaccinex (Inst), Immutep (Inst), Hookipa Biotech (Inst), Epizyme (Inst), Adlai Nortye (Inst), BioAtla (Inst), Boehringer Ingelheim (Inst), Calliditas Therapeutics (Inst), Genmab (Inst), NATCO Pharma (Inst), Tizona Therapeutics, Inc (Inst), Seagen (Inst), Merus (Inst), InhibRx (Inst), Erasca, Inc (Inst), Alentis Therapeutics (Inst), Coherus Biosciences (Inst), Takeda (Inst), Xilio Therapeutics (Inst), GlaxoSmithKline (Inst), Johnson &amp; Johnson/Janssen (Inst), Rgenta (Inst), AVEO (Inst), Daiichi Sankyo Europe GmbH (Inst), Exelixis (Inst), Tempus (Inst) Travel, Accommodations, Expenses: NATCO Pharma (Inst) Jessica C. Ley Travel, Accommodations, Expenses: NATCO Pharma (Inst) Peter Oppelt Research Funding: Merck (Inst), HiFiBiO Therapeutics (Inst), Enzychem Lifesciences (Inst) No other potential conflicts of interest were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>5</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40832450</ArticleId><ArticleId IdType="pmc">PMC12360191</ArticleId><ArticleId IdType="doi">10.1200/OA-25-00049</ArticleId><ArticleId IdType="pii">OA-25-00049</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mody MD, Rocco JW, Yom SS, et al. : Head and neck cancer. Lancet 398:2289-2299, 2021</Citation><ArticleIdList><ArticleId IdType="pubmed">34562395</ArticleId></ArticleIdList></Reference><Reference><Citation>GBD 2016 Disease and Injury Incidence and Prevalence Collaborators, Abajobir AA, Abate KH, et al. : Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet 390:1211-1259, 2017</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5605509</ArticleId><ArticleId IdType="pubmed">28919117</ArticleId></ArticleIdList></Reference><Reference><Citation>Burtness B, Harrington KJ, Greil R, et al. : Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): A randomised, open-label, phase 3 study. Lancet 394:1915-1928, 2019</Citation><ArticleIdList><ArticleId IdType="pubmed">31679945</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs C, Lyman G, Velez-Garc&#xed;a E, et al. : A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 10:257-263, 1992</Citation><ArticleIdList><ArticleId IdType="pubmed">1732427</ArticleId></ArticleIdList></Reference><Reference><Citation>Galluzzi L, Buqu&#xe9; A, Kepp O, et al. : Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell 28:690-714, 2015</Citation><ArticleIdList><ArticleId IdType="pubmed">26678337</ArticleId></ArticleIdList></Reference><Reference><Citation>Wakita D, Iwai T, Harada S, et al. : Cisplatin augments antitumor t-cell responses leading to a potent therapeutic effect in combination with PD-L1 blockade. Anticancer Res 39:1749-1760, 2019</Citation><ArticleIdList><ArticleId IdType="pubmed">30952714</ArticleId></ArticleIdList></Reference><Reference><Citation>Principe DR, Narbutis M, Koch R, et al. : Frequency and prognostic value of mutations associated with the homologous recombination DNA repair pathway in a large pan cancer cohort. Sci Rep 10:20223, 2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7677533</ArticleId><ArticleId IdType="pubmed">33214570</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Genome Atlas Network : Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517:576-582, 2015</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4311405</ArticleId><ArticleId IdType="pubmed">25631445</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung CH, Guthrie VB, Masica DL, et al. : Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing. Ann Oncol 26:1216-1223, 2015</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4516044</ArticleId><ArticleId IdType="pubmed">25712460</ArticleId></ArticleIdList></Reference><Reference><Citation>Seiwert T, Zuo Z, Keck MK, et al. : Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin Cancer Res 21:632-641, 2015</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4305034</ArticleId><ArticleId IdType="pubmed">25056374</ArticleId></ArticleIdList></Reference><Reference><Citation>Marsit CJ, Liu M, Nelson HH, et al. : Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: Implications for treatment and survival. Oncogene 23:1000-1004, 2004</Citation><ArticleIdList><ArticleId IdType="pubmed">14647419</ArticleId></ArticleIdList></Reference><Reference><Citation>Glorieux M, Dok R, Nuyts S: Novel DNA targeted therapies for head and neck cancers: Clinical potential and biomarkers. Oncotarget 8:81662-81678, 2017</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5655317</ArticleId><ArticleId IdType="pubmed">29113422</ArticleId></ArticleIdList></Reference><Reference><Citation>Wurster S, Hennes F, Parplys AC, et al. : PARP1 inhibition radiosensitizes HNSCC cells deficient in homologous recombination by disabling the DNA replication fork elongation response. Oncotarget 7:9732-9741, 2016</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4891080</ArticleId><ArticleId IdType="pubmed">26799421</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendes-Pereira AM, Martin SA, Brough R, et al. : Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 1:315-322, 2009</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3378149</ArticleId><ArticleId IdType="pubmed">20049735</ArticleId></ArticleIdList></Reference><Reference><Citation>Lombardi AJ, Hoskins EE, Foglesong GD, et al. : Acquisition of relative interstrand crosslinker resistance and PARP inhibitor sensitivity in Fanconi anemia head and neck cancers. Clin Cancer Res 21:1962-1972, 2015</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4401632</ArticleId><ArticleId IdType="pubmed">25609062</ArticleId></ArticleIdList></Reference><Reference><Citation>Dok R, Kalev P, Van Limbergen EJ, et al. : p16INK4a impairs homologous recombination-mediated DNA repair in human papillomavirus-positive head and neck tumors. Cancer Res 74:1739-1751, 2014</Citation><ArticleIdList><ArticleId IdType="pubmed">24473065</ArticleId></ArticleIdList></Reference><Reference><Citation>Lechner M, Chakravarthy AR, Walter V, et al. : Frequent HPV-independent p16/INK4A overexpression in head and neck cancer. Oral Oncol 83:32-37, 2018</Citation><ArticleIdList><ArticleId IdType="pubmed">30098776</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen M, Robillard L, Lin KK, et al. : Abstract 1716: The PARP inhibitor rucaparib activates the STING pathway and enhances antitumor responses of immune checkpoint inhibitors in <i>BRCA</i> deficient syngeneic models. Cancer Res
78:1716, 2018.  (suppl 13)</Citation></Reference><Reference><Citation>Huang J, Wang L, Cong Z, et al. : The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1(&#x2212;/&#x2212;) murine model of ovarian cancer. Biochem Biophys Res Commun 463:551-556, 2015</Citation><ArticleIdList><ArticleId IdType="pubmed">26047697</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiao S, Xia W, Yamaguchi H, et al. : PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin Cancer Res 23:3711-3720, 2017</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5511572</ArticleId><ArticleId IdType="pubmed">28167507</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Sun K, Xiao Y, et al. : Abstract 1724: Evaluation of niraparib in combination with anti-PD1/anti-PD-L1 in preclinical models. Cancer Res 78:1724, 2018. (suppl 13)</Citation></Reference><Reference><Citation>Oza AM, Cibula D, Benzaquen AO, et al. : Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: A randomised phase 2 trial. Lancet Oncol 16:87-97, 2015</Citation><ArticleIdList><ArticleId IdType="pubmed">25481791</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonarakis ES, Park SH, Goh JC, et al. : Pembrolizumab plus olaparib for patients with previously treated and biomarker-unselected metastatic castration-resistant prostate cancer: The randomized, open-label, phase III KEYLYNK-010 trial. J Clin Oncol 41:3839-3850, 2023</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10419579</ArticleId><ArticleId IdType="pubmed">37290035</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisenhauer EA, Therasse P, Bogaerts J, et al. : New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009</Citation><ArticleIdList><ArticleId IdType="pubmed">19097774</ArticleId></ArticleIdList></Reference><Reference><Citation>Forastiere AA, Metch B, Schuller DE, et al. : Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: A Southwest Oncology Group study. J Clin Oncol 10:1245-1251, 1992</Citation><ArticleIdList><ArticleId IdType="pubmed">1634913</ArticleId></ArticleIdList></Reference><Reference><Citation>Burtness B, Rischin D, Greil R, et al. : Pembrolizumab alone or with chemotherapy for recurrent/metastatic head and neck squamous cell carcinoma in KEYNOTE-048: Subgroup analysis by programmed death ligand-1 combined positive score. J Clin Oncol 40:2321-2332, 2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9287281</ArticleId><ArticleId IdType="pubmed">35333599</ArticleId></ArticleIdList></Reference><Reference><Citation>Palazzo A, Ciccarese C, Iacovelli R, et al. : Major adverse cardiac events and cardiovascular toxicity with PARP inhibitors-based therapy for solid tumors: A systematic review and safety meta-analysis. ESMO Open 8:101154, 2023</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10163166</ArticleId><ArticleId IdType="pubmed">36893518</ArticleId></ArticleIdList></Reference><Reference><Citation>Moutafi M, Koliou G-A, Papaxoinis G, et al. : Phase II window study of olaparib alone or with cisplatin or durvalumab in operable head and neck cancer. Cancer Res Commun 3:1514-1523, 2023</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10414130</ArticleId><ArticleId IdType="pubmed">37575280</ArticleId></ArticleIdList></Reference><Reference><Citation>Navran A, Al-Mamgani A, Elzinga H, et al. : Phase I feasibility study of olaparib in combination with loco-regional radiotherapy in head and neck squamous cell carcinoma. Clin Transl Radiat Oncol 44:100698, 2024</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10654000</ArticleId><ArticleId IdType="pubmed">38021094</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/OA-25-00021 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40546794</PMID><DateRevised><Year>2025</Year><Month>06</Month><Day>25</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2994-9750</ISSN><JournalIssue CitedMedium="Internet"><Volume>2</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jun</Month></PubDate></JournalIssue><Title>JCO oncology advances</Title><ISOAbbreviation>JCO Oncol Adv</ISOAbbreviation></Journal><ArticleTitle>Impact of the COVID-19 Pandemic Mitigation Strategies on Cancer Treatment Trials: A Meta-Analysis of Industry and National Cancer Institute Studies.</ArticleTitle><Pagination><StartPage>e2500021</StartPage><MedlinePgn>e2500021</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2500021</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1200/OA-25-00021</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The onset of the COVID-19 pandemic in early 2020 disrupted the conduct of cancer clinical trials. In response, federal agencies allowed more flexibility for trial recruitment and patient follow-up. A key question is whether the benefits of adopting these strategies outweigh the potential detriments to quality metrics.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A joint ASCO and Friends of Cancer Research task force invited industry and National Cancer Institute trial sponsors to contribute deidentified trial-level aggregate data on enrollment, major protocol deviations, dropouts, and severe adverse events (Common Terminology Criteria for Adverse Events grade 3-5). These quality metrics were examined as proportions of participants at risk during the pre-COVID-19 (January 2017-February, 2020), initial wave (March-April, 2020), initial recovery (May-December, 2020), and secondary recovery (January 2021-December 2022) periods. Multilevel beta-regression was used, adjusting for phase; study and sponsor were treated as random effects. Indicator variables were used with pre-COVID-19 as the reference.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Ten sponsors contributed 67 analyzable trials with N = 12,000 US-based participants. Enrollment odds decreased 49% in the initial wave (odds ratio [OR], 0.51 [95% CI, 0.30 to 0.86], <i>P</i> = .01) but recovered to pre-COVID-19 levels by 2021-2022 (OR, 1.01 [95% CI, 0.56 to 1.81], <i>P</i> = .97). Major protocol deviations, dropouts, and severe toxicity all had a lower incidence in the initial wave compared with pre-COVID-19; these outcomes were also less frequent (<i>P</i> &lt; .05) in the initial recovery period but returned to pre-COVID-19 levels by 2021-2022.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In this multicollaborator evaluation, large declines in enrollment, major protocol deviations, dropouts, and severe toxicity during the acute phase of the pandemic all returned to pre-COVID-19 levels by 2021-2022. These findings highlight the impact of the temporary disruption to trial conduct during the pandemic's peak, but suggest that pandemic-related procedural flexibility did not result in long-term reduced data quality. Sponsors and regulators should consider broader adaptation of trial flexibilities moving forward.</AbstractText><CopyrightInformation>&#xa9; 2025 by American Society of Clinical Oncology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Unger</LastName><ForeName>Joseph M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0002-5191-0317</Identifier><AffiliationInfo><Affiliation>Fred Hutchinson Cancer Center, Seattle, WA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andrews</LastName><ForeName>Hillary S</ForeName><Initials>HS</Initials><Identifier Source="ORCID">0000-0002-0177-2024</Identifier><AffiliationInfo><Affiliation>Friends of Cancer Research, Washington, DC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levit</LastName><ForeName>Laura A</ForeName><Initials>LA</Initials><Identifier Source="ORCID">0000-0001-9136-4229</Identifier><AffiliationInfo><Affiliation>American Society of Clinical Oncology, Alexandria VA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKelvey</LastName><ForeName>Brittany A</ForeName><Initials>BA</Initials><Identifier Source="ORCID">0000-0001-9239-7153</Identifier><AffiliationInfo><Affiliation>Friends of Cancer Research, Washington, DC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stewart</LastName><ForeName>Mark</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-4847-0736</Identifier><AffiliationInfo><Affiliation>Friends of Cancer Research, Washington, DC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Canin</LastName><ForeName>Beverly</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0001-7864-1121</Identifier><AffiliationInfo><Affiliation>Breast Cancer Options, Kingston, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flaherty</LastName><ForeName>Keith</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-3402-0478</Identifier><AffiliationInfo><Affiliation>Massachusetts General Hospital, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kimball</LastName><ForeName>Denise</ForeName><Initials>D</Initials><Identifier Source="ORCID">0009-0008-7174-9330</Identifier><AffiliationInfo><Affiliation>Johnson &amp; Johnson, New Brunswick, NJ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Therica</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-4086-3076</Identifier><AffiliationInfo><Affiliation>Tisch Cancer Center, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Onitilo</LastName><ForeName>Adedayo</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-9185-0606</Identifier><AffiliationInfo><Affiliation>Marshfield Clinic Health System, Weston, WI.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bruinooge</LastName><ForeName>Suanna</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-9936-2719</Identifier><AffiliationInfo><Affiliation>American Society of Clinical Oncology, Alexandria VA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garrett-Mayer</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-4709-0333</Identifier><AffiliationInfo><Affiliation>American Society of Clinical Oncology, Alexandria VA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schenkel</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-3613-8509</Identifier><AffiliationInfo><Affiliation>Children's National Hospital, Washington, DC.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Oncol Adv</MedlineTA><NlmUniqueID>9918956761606676</NlmUniqueID><ISSNLinking>2994-9750</ISSNLinking></MedlineJournalInfo><CoiStatement>The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to https://ascopubs.org/authors. Joseph M. Unger Consulting or Advisory Role: Loxo/Lilly Keith Flaherty Leadership: Strata Oncology, Kinnate Biopharma, Scorpion Therapeutics, Clovis Oncology, Khora Therapeutics Stock and Other Ownership Interests: Clovis Oncology, Loxo, X4 Pharma, Strata Oncology, PIC Therapeutics, Apricity Health, Oncoceutics, FOGPharma, Tvardi Therapeutics, Kinnate Biopharma, Scorpion Therapeutics, ALX Oncology, xCures, Monopteros Therapeutics, Vibliome Therapeutics, Transcode Therapeutics, Soley Therapeutics, Nextech Invest, Alterome Therapeutics, PreDICTA, Flinr Therapeutics, IntrECate, Tasca Therapeutics Consulting or Advisory Role: Novartis, Tvardi Therapeutics, Takeda, Karkinos Healthcare Denise Kimball Employment: Johnson and Johnson Leadership: Johnson and Johnson Stock and Other Ownership Interests: Johnson and Johnson Innovative Medicine Therica Miller Employment: Mount Sinai Health System Consulting or Advisory Role: Triomics, J&amp;J, Flatiron Health, AOC Oncology Research Funding: J&amp;J Travel, Accommodations, Expenses: American Society of Clinical Oncology Other Relationship: University of Southern California, AOC Oncology, Alliance Foundation Trials, Children's Hospital Los Angeles, George Washington University, Alphasights No other potential conflicts of interest were reported. Therica Miller Employment: Mount Sinai Health System Consulting or Advisory Role: Triomics, J&amp;J, Flatiron Health, AOC Oncology Research Funding: J&amp;J Travel, Accommodations, Expenses: American Society of Clinical Oncology Other Relationship: University of Southern California, AOC Oncology, Alliance Foundation Trials, Children's Hospital Los Angeles, George Washington University, Alphasights No other potential conflicts of interest were reported. Therica Miller Employment: Mount Sinai Health System Consulting or Advisory Role: Triomics, J&amp;J, Flatiron Health, AOC Oncology Research Funding: J&amp;J Travel, Accommodations, Expenses: American Society of Clinical Oncology Other Relationship: University of Southern California, AOC Oncology, Alliance Foundation Trials, Children's Hospital Los Angeles, George Washington University, Alphasights No other potential conflicts of interest were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>4</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>4</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>24</Day><Hour>10</Hour><Minute>57</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>24</Day><Hour>10</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>6</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40546794</ArticleId><ArticleId IdType="pmc">PMC12178165</ArticleId><ArticleId IdType="doi">10.1200/OA-25-00021</ArticleId><ArticleId IdType="pii">OA-25-00021</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Unger JM, Blanke CD, LeBlanc M, et al. : Association of the Coronavirus disease 2019 (COVID-19) outbreak with enrollment in cancer clinical trials. JAMA Netw Open 3:e2010651, 2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7265094</ArticleId><ArticleId IdType="pubmed">32478845</ArticleId></ArticleIdList></Reference><Reference><Citation>Unger JM, Xiao H: The COVID-19 pandemic and new clinical trial activations. Trials 22:260, 2021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8027975</ArticleId><ArticleId IdType="pubmed">33832534</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakouny Z, Labaki C, Bhalla S, et al. : Oncology clinical trial disruption during the COVID-19 pandemic: A COVID-19 and cancer outcomes study. Ann Oncol 33:836-844, 2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9197329</ArticleId><ArticleId IdType="pubmed">35715285</ArticleId></ArticleIdList></Reference><Reference><Citation>National Cancer Institute : Coronavirus guidance, 2022. https://ctep.cancer.gov/investigatorResources/corona_virus_guidance.htm</Citation></Reference><Reference><Citation>US Food and Drug Administration : FDA guidance on conduct of clinical trials of medical products during COVID-19 pandemic, 2020. https://www.fda.gov/regulatory-information/search-fdaguidance-documents/fda-guidance-conduct-clinical-trials-medical-products-during-covid-19-pandemic</Citation></Reference><Reference><Citation>Unger JM, Stires H, Levit LA, et al. : Sponsor perspectives on the impact of the COVID-19 pandemic on interventional cancer clinical trial protocols and data quality. JCO Oncol Pract 19:907-916, 2023</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10615547</ArticleId><ArticleId IdType="pubmed">37643386</ArticleId></ArticleIdList></Reference><Reference><Citation>Unger JM, Xiao H, LeBlanc M, et al. : Cancer clinical trial participation at the 1-year anniversary of the outbreak of the COVID-19 pandemic. JAMA Netw Open 4:e2118433, 2021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8323000</ArticleId><ArticleId IdType="pubmed">34323986</ArticleId></ArticleIdList></Reference><Reference><Citation>Khozin S, Coravos A: Decentralized trials in the age of real-world evidence and inclusivity in clinical investigations. Clin Pharmacol Ther 106:25-27, 2019</Citation><ArticleIdList><ArticleId IdType="pubmed">31013350</ArticleId></ArticleIdList></Reference><Reference><Citation>Sommer C, Zuccolin D, Arnera V, et al. : Building clinical trials around patients: Evaluation and comparison of decentralized and conventional site models in patients with low back pain. Contemp Clin Trials Commun 11:120-126, 2018</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6072894</ArticleId><ArticleId IdType="pubmed">30094387</ArticleId></ArticleIdList></Reference><Reference><Citation>Friends of Cancer Research : Imact of the COVID-19 Pandemic Mitigation Strategies on Cancer Clinical Trials. Preliminary Findings of a Friends of Cancer Research-American Society of Clinical Oncology Study. Friends of Cancer Research Annual Meeting, 2022. https://friendsofcancerresearch.org/wp-content/uploads/Impact_COVID-19_Pandemic_Strategies_Cancer_Clinical_Trials.pdf</Citation></Reference><Reference><Citation>Fleury ME, Farner AM, Unger JM: Association of the COVID-19 outbreak with patient willingness to enroll in cancer clinical trials. JAMA Oncol 7:131-132, 2021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7662493</ArticleId><ArticleId IdType="pubmed">33180102</ArticleId></ArticleIdList></Reference><Reference><Citation>Prindiville SA, Sarosy GA, Loose D, et al. : Patterns of enrollment in cancer treatment trials during the COVID-19 pandemic at National Cancer Institute-designated cancer centers. Cancer J 28:111-117, 2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8969752</ArticleId><ArticleId IdType="pubmed">35333495</ArticleId></ArticleIdList></Reference><Reference><Citation>Upadhaya S, Yu JX, Oliva C, et al. : Impact of COVID-19 on oncology clinical trials. Nat Rev Drug Discov 19:376-377, 2020</Citation><ArticleIdList><ArticleId IdType="pubmed">32424343</ArticleId></ArticleIdList></Reference><Reference><Citation>US Food and Drug Administration : Protocol Deviations for Clinical Investigations of Drugs, Biological Products, and Devices: Guidance for Industry, 2024. https://www.fda.gov/media/184745/download</Citation></Reference><Reference><Citation>National Cancer Institute. Division of Cancer Treatment &amp; Diagnosis : Common Terminology Criteria for Adverse Events (CTCAE). https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention : CDC, Washington state report first COVID-19 death, 2020. https://www.cdc.gov/media/releases/2020/s0229-COVID-19-first-death.html</Citation></Reference><Reference><Citation>Cucinotta D, Vanelli M: WHO declares COVID-19 a pandemic. Acta Biomed 91:157-160, 2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7569573</ArticleId><ArticleId IdType="pubmed">32191675</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad FB, Cisewski JA, Mini&#xf1;o A, et al. : Provisional mortality data&#x2014;United States, 2020. MMWR Morb Mortal Wkly Rep 70:519-522, 2021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8030985</ArticleId><ArticleId IdType="pubmed">33830988</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao H, Vaidya R, Liu F, et al. : Sex, racial, and ethnic representation in COVID-19 clinical trials: A systematic Review and meta-analysis. JAMA Intern Med 183:50-60, 2023</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9857303</ArticleId><ArticleId IdType="pubmed">36469312</ArticleId></ArticleIdList></Reference><Reference><Citation>Smithson M, Verkuilen J: A better lemon squeezer? Maximum-Likelihood regression with beta-distributed dependent variables. Psychol Methods 11:54-71, 2006</Citation><ArticleIdList><ArticleId IdType="pubmed">16594767</ArticleId></ArticleIdList></Reference><Reference><Citation>Cascio WF, Zedeck S: Open a new window in rational research planning: Adjust alpha to maximize statistical power. Personnel Psychol 36:517-526, 1983</Citation></Reference><Reference><Citation>Mathieu JE, Aguinis H, Culpepper SA, et al. : Understanding and estimating the power to detect cross-level interaction effects in multilevel modeling. J Appl Psychol 97:951-966, 2012</Citation><ArticleIdList><ArticleId IdType="pubmed">22582726</ArticleId></ArticleIdList></Reference><Reference><Citation>Dizon DS, Szczepanek CM, Petrylak DP, et al. : National impact of the COVID-19 pandemic on clinical trial staff attrition: Results of the SWOG Cancer Research Network Survey of Oncology Research Professionals. J Clin Oncol 40, 2022. (suppl 16; abstr 11049)</Citation></Reference><Reference><Citation>Huggins A, Husaini M, Wang F, et al. : Care disruption during COVID-19: A national survey of hospital leaders. J Gen Intern Med 38:1232-1238, 2023</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9845025</ArticleId><ArticleId IdType="pubmed">36650332</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun G, Dizon DS, Szczepanek CM, et al. : Crisis of the clinical trials staff attrition after the COVID-19 pandemic. JCO Oncol Pract 19:533-535, 2023</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10424897</ArticleId><ArticleId IdType="pubmed">37285550</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention : Interim Public Health Recommendations for Fully Vaccinated People, 2021. https://stacks.cdc.gov/view/cdc/106177</Citation></Reference><Reference><Citation>Peterson-KFF Health System Tracker : How has healthcare utilization changed since the pandemic?
2023. https://www.healthsystemtracker.org/chart-collection/how-has-healthcare-utilization-changed-since-the-pandemic/</Citation></Reference><Reference><Citation>Daly B, Brawley OW, Gospodarowicz MK, et al. : Remote monitoring and data collection for decentralized clinical trials. JAMA Netw Open 7:e246228, 2024</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11015350</ArticleId><ArticleId IdType="pubmed">38607626</ArticleId></ArticleIdList></Reference><Reference><Citation>US Department of Health and Human Services, Food and Drug Administration : Conducting Clinical Trials With Decentralized Elements: Guidance for Industry, Investigators, and Other Interested Parties. https://www.fda.gov/media/167696/download</Citation></Reference><Reference><Citation>Harvey RD, Miller TM, Hurley PA, et al. : A call to action to advance patient-focused and decentralized clinical trials. Cancer 130:1193-1203, 2024</Citation><ArticleIdList><ArticleId IdType="pubmed">38193828</ArticleId></ArticleIdList></Reference><Reference><Citation>Thota R, Hurley PA, Miller TM, et al. : Improving access to patient-focused, decentralized clinical trials requires streamlined regulatory requirements: An ASCO research statement. J Clin Oncol 42:3986-3995, 2024</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11568957</ArticleId><ArticleId IdType="pubmed">39079075</ArticleId></ArticleIdList></Reference><Reference><Citation>American Society of Clinical Oncology : ASCO Welcomes FDA Efforts to Expand Access to Clinical Trials, Provides Agency with Additional Recommendations. ASCO, 2023. https://society.asco.org/news-initiatives/policy-news-analysis/asco-welcomes-fda-efforts-expand-access-clinical-trials</Citation></Reference><Reference><Citation>National Cancer Institute Clinical Trials and Translational Research Advisory Committee (CTAC) Strategic Planning Working Group : Working Group Report, 2020. https://deainfo.nci.nih.gov/advisory/ctac/1120/SPWGreport.pdf</Citation></Reference><Reference><Citation>Doroshow JH: Adapting NCI&#x2019;s Clinical Trials System to a Changed Clinical Research Environment. National Cancer Advisory Board, 2023. https://deainfo.nci.nih.gov/advisory/ncab/0223/Doroshow.pdf</Citation></Reference><Reference><Citation>US Food and Drug Administration : Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies. Draft Guidance for Industry, 2024. https://www.fda.gov/media/179593/download</Citation></Reference><Reference><Citation>Aburto JM, Tilstra AM, Floridi G, et al. : Significant impacts of the COVID-19 pandemic on race/ethnic differences in US mortality. Proc Natl Acad Sci USA 119:e2205813119, 2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9436308</ArticleId><ArticleId IdType="pubmed">35998219</ArticleId></ArticleIdList></Reference><Reference><Citation>Eberly LA, Kallan MJ, Julien HM, et al. : Patient Characteristics associated with telemedicine access for primary and specialty ambulatory care during the COVID-19 pandemic. JAMA Netw Open 3:e2031640, 2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7772717</ArticleId><ArticleId IdType="pubmed">33372974</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/OA-24-00107 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40487288</PMID><DateRevised><Year>2025</Year><Month>06</Month><Day>11</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2994-9750</ISSN><JournalIssue CitedMedium="Internet"><Volume>2</Volume><Issue>1</Issue><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>JCO oncology advances</Title><ISOAbbreviation>JCO Oncol Adv</ISOAbbreviation></Journal><ArticleTitle>More Frequent than Annual Administration of COVID-19 Vaccination May Be Appropriate for Patients With Cancer.</ArticleTitle><Pagination><StartPage>e2400107</StartPage><MedlinePgn>e2400107</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2400107</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1200/OA-24-00107</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kamboj</LastName><ForeName>Mini</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirkwood</LastName><ForeName>M Kelsey</ForeName><Initials>MK</Initials><Identifier Source="ORCID">0000-0002-6439-4964</Identifier><AffiliationInfo><Affiliation>American Society of Clinical Oncology, Alexandria, VA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bohlke</LastName><ForeName>Kari</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-1529-7903</Identifier><AffiliationInfo><Affiliation>American Society of Clinical Oncology, Alexandria, VA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gralow</LastName><ForeName>Julie R</ForeName><Initials>JR</Initials><Identifier Source="ORCID">0000-0003-3837-9928</Identifier><AffiliationInfo><Affiliation>American Society of Clinical Oncology, Alexandria, VA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garrett-Mayer</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-4709-0333</Identifier><AffiliationInfo><Affiliation>American Society of Clinical Oncology, Alexandria, VA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aggarwal</LastName><ForeName>Charu</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University of Pennsylvania, Philadelphia, PA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Oncol Adv</MedlineTA><NlmUniqueID>9918956761606676</NlmUniqueID><ISSNLinking>2994-9750</ISSNLinking></MedlineJournalInfo><CoiStatement>The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to https://ascopubs.org/authors. Charu Aggarwal Consulting or Advisory Role: AstraZeneca, Daiichi Sankyo/AstraZeneca, Sanofi/Regeneron, Pfizer, Boehringer Ingelheim, Takeda, Arcus Biosciences, Gilead Sciences, Novocure, AbbVie Speakers' Bureau: AstraZeneca (I) Research Funding: Merck Sharp &amp; Dohme (Inst), AstraZeneca/MedImmune (Inst), Daiichi Sankyo/AstraZeneca (Inst), Loxo@Lilly (Inst), Candel Therapeutics (Inst) Mini Kamboj Honoraria: Virginia Commonwealth University Consulting or Advisory Role: Regeneron Uncompensated Relationships: CDC, ASCO No other potential conflicts of interest were reported. Mini Kamboj Honoraria: Virginia Commonwealth University Consulting or Advisory Role: Regeneron Uncompensated Relationships: CDC, ASCO No other potential conflicts of interest were reported. Mini Kamboj Honoraria: Virginia Commonwealth University Consulting or Advisory Role: Regeneron Uncompensated Relationships: CDC, ASCO No other potential conflicts of interest were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>4</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>4</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>9</Day><Hour>12</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>9</Day><Hour>12</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>5</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40487288</ArticleId><ArticleId IdType="pmc">PMC12144529</ArticleId><ArticleId IdType="doi">10.1200/OA-24-00107</ArticleId><ArticleId IdType="pii">OA-24-00107</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kirkwood MK, Aggarwal C, Bruinooge SS, et al. : Differential survival among patients with cancer by COVID-19 vaccination status: An analysis of the ASCO COVID-19 Registry. JCO Oncol Adv 10.1200/OA-24-00034</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/OA-24-00034</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamboj M, Bohlke K, Baptiste DM, et al. : Vaccination of adults with cancer: ASCO guideline. J Clin Oncol 42:1699-1721, 2024</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11095883</ArticleId><ArticleId IdType="pubmed">38498792</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurbegov D, Bruinooge SS, Lei XJ, et al. : Rate of COVID-19 vaccination among patients with cancer who tested positive for severe acute respiratory syndrome-coronavirus 2: Analysis of the American Society of Clinical Oncology Registry. Cancer 129:1752-1762, 2023</Citation><ArticleIdList><ArticleId IdType="pubmed">36920457</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention : Use of COVID-19 Vaccines in the United States. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html</Citation><ArticleIdList><ArticleId IdType="pubmed">34009769</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO : COVID-19 advice for the public: Getting vaccinated. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines/advice</Citation></Reference><Reference><Citation>WHO : WHO SAGE Roadmap for prioritizing uses of COVID-19 vaccines. https://www.who.int/publications/i/item/WHO-2019-nCoV-Vaccines-SAGE-Prioritization-2023.1</Citation></Reference><Reference><Citation>Roper LE, Godfrey M, Link-Gelles R: Use of additional doses of 2024&#x2013;2025 COVID-19 vaccine for adults aged &#x2265;65 years and persons aged &#x2265;6 Months with moderate or severe immunocompromise: Recommendations of the advisory committee on immunization practices&#x2014;United States, 2024. MMWR Morb Mortal Wkly Rep 73:1118-1123, 2024</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/EDBK-25-472460 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40209143</PMID><DateCompleted><Year>2025</Year><Month>04</Month><Day>10</Day></DateCompleted><DateRevised><Year>2025</Year><Month>04</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1548-8756</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><Issue>3</Issue><PubDate><Year>2025</Year><Month>Jun</Month></PubDate></JournalIssue><Title>American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting</Title><ISOAbbreviation>Am Soc Clin Oncol Educ Book</ISOAbbreviation></Journal><ArticleTitle>Updates on Treatments and Management of Nasopharyngeal Carcinoma.</ArticleTitle><Pagination><StartPage>e472460</StartPage><MedlinePgn>e472460</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/EDBK-25-472460</ELocationID><Abstract><AbstractText>Nasopharyngeal carcinoma (NPC) is a unique head and neck cancer, where the endemic subtype is strongly associated with Epstein-Barr virus (EBV) infection, whereas emerging data suggest that a subset of nonendemic NPC may be associated with human papillomavirus (HPV) infection. Nonetheless, treatment advances have been driven by clinical trials conducted in endemic NPC, investigating optimal sequencing of chemotherapy and immune checkpoint inhibitors with radiotherapy for locoregionally advanced disease. The preference for induction chemotherapy (IC) in these patients has also led to evolution in the concept of radiotherapy target delineation. Because of its association with EBV, plasma EBV DNA is an archetypal biomarker for endemic NPC, and it is being explored for precise stratification and treatment individualization in several ongoing trials. In the space of recurrent or metastatic-NPC, with the advent of platinum-doublet chemotherapy and anti-PD-1 antibody as the new standard of care, several trials are investigating new immunotherapeutic combinations, bispecific antibodies, and antibody-drug conjugates that have demonstrated promise in early phase trials. An important advance for NPC in 2025 is the update of the 9th version of the TNM staging system, which has introduced several key changes, including downgrading of the TNM stage groupings for localized disease, and splitting of metastatic NPC into IVA and IVB based on the number of metastatic lesions. These revisions would have implications for the treatment and design of future trials. These advances are also relevant to nonendemic NPC, where evidence is inconclusive whether this disease responds differently to current treatments compared with endemic NPC.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chua</LastName><ForeName>Melvin L K</ForeName><Initials>MLK</Initials><Identifier Source="ORCID">0000-0002-1648-1473</Identifier><AffiliationInfo><Affiliation>Divisions of Radiation Oncology and Medical Sciences, National Cancer Centre Singapore, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Oncology Academic Program, Duke-NUS Medical School, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Radiation Oncology Centre, Chongqing University Cancer Hospital, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Kenneth C W</ForeName><Initials>KCW</Initials><Identifier Source="ORCID">0000-0003-4995-0819</Identifier><AffiliationInfo><Affiliation>State Key Laboratory of Translational Oncology, Department of Clinical Oncology, Sir Y.K. Pao Centre for Cancer, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong SAR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gr&#xe9;goire</LastName><ForeName>Marret</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-4525-7777</Identifier><AffiliationInfo><Affiliation>Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spreafico</LastName><ForeName>Anna</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-3034-3042</Identifier><AffiliationInfo><Affiliation>Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Brigette</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-4802-1102</Identifier><AffiliationInfo><Affiliation>State Key Laboratory of Translational Oncology, Department of Clinical Oncology, Sir Y.K. Pao Centre for Cancer, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong SAR.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Charlie Lee Precision Immuno-Oncology Program, The Chinese University of Hong Kong, Hong Kong SAR.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>04</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am Soc Clin Oncol Educ Book</MedlineTA><NlmUniqueID>101233985</NlmUniqueID><ISSNLinking>1548-8748</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Am Soc Clin Oncol Educ Book. 2025 Jun;45(3):e472460CX1. doi: 10.1200/EDBK-25-472460CX1.</RefSource><PMID Version="1">40300118</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077274" MajorTopicYN="Y">Nasopharyngeal Carcinoma</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009303" MajorTopicYN="Y">Nasopharyngeal Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019468" MajorTopicYN="N">Disease Management</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020031" MajorTopicYN="N">Epstein-Barr Virus Infections</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>4</Month><Day>10</Day><Hour>18</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>4</Month><Day>10</Day><Hour>18</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>4</Month><Day>10</Day><Hour>16</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40209143</ArticleId><ArticleId IdType="doi">10.1200/EDBK-25-472460</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/EDBK-25-481114 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40305739</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>04</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1548-8756</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><Issue>3</Issue><PubDate><Year>2025</Year><Month>Jun</Month></PubDate></JournalIssue><Title>American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting</Title><ISOAbbreviation>Am Soc Clin Oncol Educ Book</ISOAbbreviation></Journal><ArticleTitle>Liquid Biopsy Approaches for Cancer Characterization, Residual Disease Detection, and Therapy Monitoring.</ArticleTitle><Pagination><StartPage>e481114</StartPage><MedlinePgn>e481114</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/EDBK-25-481114</ELocationID><Abstract><AbstractText>Liquid biopsy encompasses a variety of molecular approaches to detect circulating tumor DNA (ctDNA) and has become a powerful tool in the diagnosis and treatment of solid tumors. Current applications include comprehensive genomic profiling for identifying targetable mutations and therapeutic resistance mechanisms, with emerging applications in minimal residual disease detection and treatment response monitoring. Increasingly, the potential for liquid biopsy in guiding treatment decisions is under active investigation through prospective clinical trials using ctDNA-adaptive interventions in patients with early-stage and metastatic cancers. Limitations arise on the basis of the sensitivity and feasibility of individual liquid biopsy assays; nonetheless, emerging technologies set the stage for improving these shortcomings. As the global oncology community continues to ascertain the clinical value of liquid biopsy across the continuum of patient care, this minimally invasive approach heralds a significant advancement in the promise of precision oncology.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Aredo</LastName><ForeName>Jacqueline V</ForeName><Initials>JV</Initials><AffiliationInfo><Affiliation>Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jamali</LastName><ForeName>Amna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Johns Hopkins Molecular Tumor Board, Johns Hopkins School of Medicine, Baltimore, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Jessica</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heater</LastName><ForeName>Natalie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Hematology and Oncology, Department of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wakelee</LastName><ForeName>Heather A</ForeName><Initials>HA</Initials><AffiliationInfo><Affiliation>Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vaklavas</LastName><ForeName>Christos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anagnostou</LastName><ForeName>Valsamo</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Johns Hopkins Molecular Tumor Board, Johns Hopkins School of Medicine, Baltimore, MD.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lung Cancer Precision Medicine Center of Excellence, Johns Hopkins University School of Medicine, Baltimore, MD.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Bloomberg&#x223c;Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Janice</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Hematology and Oncology, Department of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Circulating Tumor Cell (CTC) Core Facility, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>04</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am Soc Clin Oncol Educ Book</MedlineTA><NlmUniqueID>101233985</NlmUniqueID><ISSNLinking>1548-8748</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000074141">Circulating Tumor DNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073890" MajorTopicYN="N">Liquid Biopsy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018365" MajorTopicYN="Y">Neoplasm, Residual</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000074141" MajorTopicYN="Y">Circulating Tumor DNA</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014408" MajorTopicYN="Y">Biomarkers, Tumor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057285" MajorTopicYN="N">Precision Medicine</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>4</Month><Day>30</Day><Hour>18</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>4</Month><Day>30</Day><Hour>16</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40305739</ArticleId><ArticleId IdType="doi">10.1200/EDBK-25-481114</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/EDBK-25-473708 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40435434</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>28</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1548-8756</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><Issue>3</Issue><PubDate><Year>2025</Year><Month>Jun</Month></PubDate></JournalIssue><Title>American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting</Title><ISOAbbreviation>Am Soc Clin Oncol Educ Book</ISOAbbreviation></Journal><ArticleTitle>Emerging Strategies for Drug-Based Cancer Risk Reduction.</ArticleTitle><Pagination><StartPage>e473708</StartPage><MedlinePgn>e473708</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/EDBK-25-473708</ELocationID><Abstract><AbstractText>Chemoprevention has emerged as a promising strategy to reduce cancer incidence by using pharmacologic agents that interrupt the carcinogenesis process. This review discusses emerging insights and recent advancements in chemoprevention, emphasizing novel approaches in several cancer types. Specifically, we examine breast cancer prevention, focusing on optimized endocrine therapy dosing to enhance adherence and minimize adverse effects while maintaining efficacy. Additionally, the potential of glucagon-like peptide-1 receptor agonists to mitigate obesity-related cancer risks is evaluated, highlighting their role in addressing an increasingly prevalent risk factor in the general population. The review further explores strategies targeting colorectal cancer (CRC), specifically in familial adenomatous polyposis, a hereditary CRC syndrome that exemplifies the complex interplay between chemoprevention, genetic risk, and patient management. In prostate cancer, we highlight the evidence supporting the use of 5-alpha reductase inhibitors, detailing their effectiveness in reducing cancer incidence as well as their safety profile. Across these areas, this review underscores the importance of precision medicine, advocating for personalized approaches that balance efficacy, safety, and quality-of-life considerations. Ultimately, advancing chemopreventive strategies through targeted research and clinical trials is essential for reducing cancer burden and improving patient outcomes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Daca-&#xc1;lvarez</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Hospital Cl&#xed;nic Barcelona, Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red en Enfermedades Hep&#xe1;ticas y Digestivas (CIBEREHD), IDIBAPS (Institut d'Investigacions Biom&#xe8;diques August Pi i Sunyer), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brunori</LastName><ForeName>Angelo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Hospital Cl&#xed;nic Barcelona, Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red en Enfermedades Hep&#xe1;ticas y Digestivas (CIBEREHD), IDIBAPS (Institut d'Investigacions Biom&#xe8;diques August Pi i Sunyer), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carbone</LastName><ForeName>Alessio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology and Medicine, Galliera Hospital, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carbonell</LastName><ForeName>Chantelle</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Departments of Oncology and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tangen</LastName><ForeName>Catherine M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>The Fred Hutchinson Cancer Center, Seattle, WA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Unger</LastName><ForeName>Joseph M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>The Fred Hutchinson Cancer Center, Seattle, WA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lucia</LastName><ForeName>M Scott</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>The University of Colorado Health Science Center, Denver, CO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oliva</LastName><ForeName>Martino</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology and Medicine, Galliera Hospital, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Censi</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology and Medicine, Galliera Hospital, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brenner</LastName><ForeName>Darren R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Departments of Oncology and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Ian M</ForeName><Initials>IM</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>CHRISTUS Santa Rosa Health System and The University of Texas Health Science Center at San Antonio, San Antonio, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balaguer</LastName><ForeName>Francesc</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Hospital Cl&#xed;nic Barcelona, Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red en Enfermedades Hep&#xe1;ticas y Digestivas (CIBEREHD), IDIBAPS (Institut d'Investigacions Biom&#xe8;diques August Pi i Sunyer), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Facultat de Medicina i Ci&#xe8;ncies de la Salud, Universitat de Barcelona (UB), Barcelona, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am Soc Clin Oncol Educ Book</MedlineTA><NlmUniqueID>101233985</NlmUniqueID><ISSNLinking>1548-8748</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018890" MajorTopicYN="N">Chemoprevention</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040242" MajorTopicYN="N">Risk Reduction Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>28</Day><Hour>18</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>28</Day><Hour>18</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>28</Day><Hour>16</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40435434</ArticleId><ArticleId IdType="doi">10.1200/EDBK-25-473708</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/EDBK-25-472464 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40489724</PMID><DateCompleted><Year>2025</Year><Month>06</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1548-8756</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><Issue>3</Issue><PubDate><Year>2025</Year><Month>Jun</Month></PubDate></JournalIssue><Title>American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting</Title><ISOAbbreviation>Am Soc Clin Oncol Educ Book</ISOAbbreviation></Journal><ArticleTitle>Artificial Intelligence for Head and Neck Squamous Cell Carcinoma: From Diagnosis to Treatment.</ArticleTitle><Pagination><StartPage>e472464</StartPage><MedlinePgn>e472464</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/EDBK-25-472464</ELocationID><Abstract><AbstractText>Head and neck squamous cell carcinoma (HNSCC) remains a globally prevalent malignancy with high morbidity and mortality. Despite therapeutic advances, patient outcomes are hindered by tumor heterogeneity, treatment-related toxicity, and the limitations of traditional prognostic tools. Artificial intelligence (AI) offers the opportunity to improve personalized HNSCC management by integrating complex radiologic, pathologic, and molecular data into actionable information insights. This review synthesizes recent developments in AI applications across the HNSCC care continuum, from diagnosis through treatment planning, emphasizing their clinical relevance and translational potential. AI has shown promise in enhancing diagnostic accuracy through automated tumor burden assessment, extranodal extension prediction, and endoscopic image analysis. Deep learning applied to radiology and digital pathology enables the extraction of prognostic features that may inform risk stratification and treatment de-escalation, particularly in human papillomavirus-associated oropharyngeal carcinoma. Multimodal AI models that fuse imaging, histopathology, and electronic health records have demonstrated superior performance in predicting survival outcomes compared with unimodal approaches. Additional applications include early toxicity detection during radiotherapy, adaptive treatment planning, and surgical complication forecasting. AI also holds potential in predicting immunotherapy response by identifying imaging and histologic correlates of tumor immunogenicity. Barriers to clinical translation remain, and continued development of explainable models, prospective trials, and seamless integration into clinical workflows will be critical for broad adoption. AI has already begun to affect HNSCC radiotherapy and surgical planning, and with thoughtful implementation, it may enable safer, more personalized care across the HNSCC treatment landscape.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Bolin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Biomedical Engineering, Emory Empathetic AI for Health Institute, Georgia Institute of Technology and Emory University, Atlanta, GA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yadav</LastName><ForeName>Ipsa</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Biomedical Engineering, Emory Empathetic AI for Health Institute, Georgia Institute of Technology and Emory University, Atlanta, GA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Jillian C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Princess Margaret Cancer Centre University Health Network, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madabhushi</LastName><ForeName>Anant</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical Engineering, Emory Empathetic AI for Health Institute, Georgia Institute of Technology and Emory University, Atlanta, GA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kann</LastName><ForeName>Benjamin H</ForeName><Initials>BH</Initials><Identifier Source="ORCID">0000-0002-4313-2754</Identifier><AffiliationInfo><Affiliation>Artificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am Soc Clin Oncol Educ Book</MedlineTA><NlmUniqueID>101233985</NlmUniqueID><ISSNLinking>1548-8748</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001185" MajorTopicYN="Y">Artificial Intelligence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077195" MajorTopicYN="Y">Squamous Cell Carcinoma of Head and Neck</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006258" MajorTopicYN="Y">Head and Neck Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077321" MajorTopicYN="N">Deep Learning</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>9</Day><Hour>18</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>9</Day><Hour>18</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>9</Day><Hour>16</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40489724</ArticleId><ArticleId IdType="doi">10.1200/EDBK-25-472464</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
===== DOI 10.1200/EDBK-25-472460CX1 =====
<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40300118</PMID><DateRevised><Year>2025</Year><Month>04</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1548-8756</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><Issue>3</Issue><PubDate><Year>2025</Year><Month>Jun</Month></PubDate></JournalIssue><Title>American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting</Title><ISOAbbreviation>Am Soc Clin Oncol Educ Book</ISOAbbreviation></Journal><ArticleTitle>Erratum: Updates on Treatments and Management of Nasopharyngeal Carcinoma.</ArticleTitle><Pagination><StartPage>e472460CX1</StartPage><MedlinePgn>e472460CX1</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/EDBK-25-472460CX1</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chua</LastName><ForeName>Melvin L K</ForeName><Initials>MLK</Initials><Identifier Source="ORCID">0000-0002-1648-1473</Identifier></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xin</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Kenneth C W</ForeName><Initials>KCW</Initials><Identifier Source="ORCID">0000-0003-4995-0819</Identifier></Author><Author ValidYN="Y"><LastName>Marret</LastName><ForeName>Gr&#xe9;goire</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-4525-7777</Identifier></Author><Author ValidYN="Y"><LastName>Spreafico</LastName><ForeName>Anna</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-3034-3042</Identifier></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Brigette</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-4802-1102</Identifier></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016425">Published Erratum</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>04</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am Soc Clin Oncol Educ Book</MedlineTA><NlmUniqueID>101233985</NlmUniqueID><ISSNLinking>1548-8748</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumFor"><RefSource>Am Soc Clin Oncol Educ Book. 2025 Jun;45(3):e472460. doi: 10.1200/EDBK-25-472460.</RefSource><PMID Version="1">40209143</PMID></CommentsCorrections></CommentsCorrectionsList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>4</Month><Day>29</Day><Hour>18</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>4</Month><Day>29</Day><Hour>18</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>4</Month><Day>29</Day><Hour>16</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40300118</ArticleId><ArticleId IdType="doi">10.1200/EDBK-25-472460CX1</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>